0000885590-21-000011.txt : 20210224 0000885590-21-000011.hdr.sgml : 20210224 20210224171318 ACCESSION NUMBER: 0000885590-21-000011 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 160 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210224 DATE AS OF CHANGE: 20210224 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bausch Health Companies Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 21674768 BUSINESS ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 FORMER COMPANY: FORMER CONFORMED NAME: Valeant Pharmaceuticals International, Inc. DATE OF NAME CHANGE: 20100928 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 10-K 1 bhc-20201231.htm 10-K bhc-20201231
00008855902020FYfalseus-gaap:AccountingStandardsUpdate201613Memberus-gaap:AccountingStandardsUpdate201616MemberP30DP1YP1Yus-gaap:OtherLiabilitiesP7YP7Y0.5us-gaap:OtherLiabilitiesCurrentus-gaap:OtherLiabilitiesCurrentus-gaap:OtherLiabilitiesNoncurrentus-gaap:OtherLiabilitiesNoncurrent00008855902020-01-012020-12-31iso4217:USD00008855902020-06-30xbrli:shares00008855902021-02-1800008855902019-01-012019-12-3100008855902018-01-012018-12-310000885590us-gaap:RevolvingCreditFacilityMemberbhc:RevolvingCreditFacilityDueJune2023Member2020-12-310000885590us-gaap:LetterOfCreditMemberbhc:RevolvingCreditFacilityDueJune2023Member2020-12-3100008855902020-12-3100008855902019-12-310000885590us-gaap:ProductMember2020-01-012020-12-310000885590us-gaap:ProductMember2019-01-012019-12-310000885590us-gaap:ProductMember2018-01-012018-12-310000885590us-gaap:ProductAndServiceOtherMember2020-01-012020-12-310000885590us-gaap:ProductAndServiceOtherMember2019-01-012019-12-310000885590us-gaap:ProductAndServiceOtherMember2018-01-012018-12-31iso4217:USDxbrli:shares0000885590us-gaap:CommonStockMember2017-12-310000885590us-gaap:AdditionalPaidInCapitalMember2017-12-310000885590us-gaap:RetainedEarningsMember2017-12-310000885590us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-12-310000885590us-gaap:ParentMember2017-12-310000885590us-gaap:NoncontrollingInterestMember2017-12-3100008855902017-12-310000885590us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2017-12-310000885590us-gaap:ParentMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2017-12-310000885590srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2017-12-310000885590us-gaap:CommonStockMember2018-01-012018-12-310000885590us-gaap:AdditionalPaidInCapitalMember2018-01-012018-12-310000885590us-gaap:ParentMember2018-01-012018-12-310000885590us-gaap:NoncontrollingInterestMember2018-01-012018-12-310000885590us-gaap:RetainedEarningsMember2018-01-012018-12-310000885590us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-01-012018-12-310000885590us-gaap:CommonStockMember2018-12-310000885590us-gaap:AdditionalPaidInCapitalMember2018-12-310000885590us-gaap:RetainedEarningsMember2018-12-310000885590us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310000885590us-gaap:ParentMember2018-12-310000885590us-gaap:NoncontrollingInterestMember2018-12-3100008855902018-12-310000885590us-gaap:CommonStockMember2019-01-012019-12-310000885590us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310000885590us-gaap:ParentMember2019-01-012019-12-310000885590us-gaap:NoncontrollingInterestMember2019-01-012019-12-310000885590us-gaap:RetainedEarningsMember2019-01-012019-12-310000885590us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310000885590us-gaap:CommonStockMember2019-12-310000885590us-gaap:AdditionalPaidInCapitalMember2019-12-310000885590us-gaap:RetainedEarningsMember2019-12-310000885590us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000885590us-gaap:ParentMember2019-12-310000885590us-gaap:NoncontrollingInterestMember2019-12-310000885590us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000885590us-gaap:ParentMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000885590srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000885590us-gaap:CommonStockMember2020-01-012020-12-310000885590us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310000885590us-gaap:ParentMember2020-01-012020-12-310000885590us-gaap:NoncontrollingInterestMember2020-01-012020-12-310000885590us-gaap:RetainedEarningsMember2020-01-012020-12-310000885590us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310000885590us-gaap:CommonStockMember2020-12-310000885590us-gaap:AdditionalPaidInCapitalMember2020-12-310000885590us-gaap:RetainedEarningsMember2020-12-310000885590us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000885590us-gaap:ParentMember2020-12-310000885590us-gaap:NoncontrollingInterestMember2020-12-3100008855902017-01-012017-12-31bhc:countrybhc:wholesaler0000885590us-gaap:AccountsReceivableMemberbhc:ThreeLargestUSWholesalerCustomersMemberus-gaap:CreditConcentrationRiskMember2020-01-012020-12-31xbrli:pure0000885590bhc:ArgentinaBrazilEgyptGreeceSerbiaTurkeyUkraineVenezuelaAndVietnamMember2020-12-310000885590bhc:ArgentinaBrazilEgyptGreeceSerbiaTurkeyUkraineVenezuelaAndVietnamMember2019-12-310000885590bhc:ArgentinaBrazilEgyptGreeceSerbiaTurkeyUkraineVenezuelaAndVietnamMember2020-01-012020-12-310000885590srt:MinimumMemberus-gaap:LandImprovementsMember2020-01-012020-12-310000885590us-gaap:LandImprovementsMembersrt:MaximumMember2020-01-012020-12-310000885590us-gaap:BuildingAndBuildingImprovementsMembersrt:MaximumMember2020-01-012020-12-310000885590srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2020-01-012020-12-310000885590us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2020-01-012020-12-310000885590srt:MinimumMemberus-gaap:OtherMachineryAndEquipmentMember2020-01-012020-12-310000885590us-gaap:OtherMachineryAndEquipmentMembersrt:MaximumMember2020-01-012020-12-310000885590us-gaap:EquipmentLeasedToOtherPartyMembersrt:MaximumMember2020-01-012020-12-310000885590us-gaap:LeaseholdsAndLeaseholdImprovementsMembersrt:MaximumMember2020-01-012020-12-310000885590srt:MinimumMemberbhc:ProductBrandsMember2020-01-012020-12-310000885590bhc:ProductBrandsMembersrt:MaximumMember2020-01-012020-12-310000885590us-gaap:TradeNamesMembersrt:MinimumMember2020-01-012020-12-310000885590us-gaap:TradeNamesMembersrt:MaximumMember2020-01-012020-12-310000885590srt:MinimumMemberus-gaap:ContractualRightsMember2020-01-012020-12-310000885590us-gaap:ContractualRightsMembersrt:MaximumMember2020-01-012020-12-310000885590srt:MinimumMemberbhc:PartnerRelationshipsMember2020-01-012020-12-310000885590bhc:PartnerRelationshipsMembersrt:MaximumMember2020-01-012020-12-310000885590srt:MinimumMemberbhc:OutLicensedTechnologyMember2020-01-012020-12-310000885590bhc:OutLicensedTechnologyMembersrt:MaximumMember2020-01-012020-12-310000885590bhc:ReserveForDiscountsAndAllowancesMember2018-12-310000885590bhc:ReserveForCustomerReturnsMember2018-12-310000885590bhc:ReserveForRebatesMember2018-12-310000885590bhc:ReserveForChargebacksMember2018-12-310000885590bhc:ReserveForDistributionFeesMember2018-12-310000885590bhc:ReserveForDiscountsAndAllowancesMember2019-01-012019-12-310000885590bhc:ReserveForCustomerReturnsMember2019-01-012019-12-310000885590bhc:ReserveForRebatesMember2019-01-012019-12-310000885590bhc:ReserveForChargebacksMember2019-01-012019-12-310000885590bhc:ReserveForDistributionFeesMember2019-01-012019-12-310000885590bhc:ReserveForDiscountsAndAllowancesMember2019-12-310000885590bhc:ReserveForCustomerReturnsMember2019-12-310000885590bhc:ReserveForRebatesMember2019-12-310000885590bhc:ReserveForChargebacksMember2019-12-310000885590bhc:ReserveForDistributionFeesMember2019-12-310000885590bhc:ReserveForDiscountsAndAllowancesMember2020-01-012020-12-310000885590bhc:ReserveForCustomerReturnsMember2020-01-012020-12-310000885590bhc:ReserveForRebatesMember2020-01-012020-12-310000885590bhc:ReserveForChargebacksMember2020-01-012020-12-310000885590bhc:ReserveForDistributionFeesMember2020-01-012020-12-310000885590bhc:ReserveForDiscountsAndAllowancesMember2020-12-310000885590bhc:ReserveForCustomerReturnsMember2020-12-310000885590bhc:ReserveForRebatesMember2020-12-310000885590bhc:ReserveForChargebacksMember2020-12-310000885590bhc:ReserveForDistributionFeesMember2020-12-310000885590bhc:ReserveForRebatesAdvertisingCreditsPortionMember2020-12-310000885590bhc:ReserveForRebatesAdvertisingCreditsPortionMember2019-12-310000885590bhc:PriceAppreciationCreditMember2020-01-012020-12-310000885590bhc:PriceAppreciationCreditMember2019-01-012019-12-310000885590srt:MinimumMember2020-01-012020-12-310000885590srt:MaximumMember2020-01-012020-12-310000885590srt:MinimumMember2020-12-310000885590srt:MaximumMember2020-12-3100008855902019-01-010000885590us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-01-010000885590bhc:AccountingStandardsUpdate2016161Member2018-01-010000885590bhc:SynergyPharmaceuticalsInc.Member2019-03-062019-03-060000885590bhc:SynergyPharmaceuticalsInc.Member2019-03-060000885590bhc:SynergyPharmaceuticalsInc.Member2019-03-062019-12-310000885590bhc:SynergyPharmaceuticalsInc.Member2019-01-012019-12-310000885590bhc:MedpharmaPharmaceuticalChemicalIndustriesLLCMember2018-10-160000885590bhc:MedpharmaPharmaceuticalChemicalIndustriesLLCMember2018-10-162018-10-160000885590us-gaap:AdditionalPaidInCapitalMemberbhc:MedpharmaPharmaceuticalChemicalIndustriesLLCMember2018-10-162018-10-16bhc:businessCombination0000885590bhc:AllegroOphthalmicsLLCMember2020-09-212020-09-210000885590bhc:AllegroOphthalmicsLLCMember2020-10-012020-12-310000885590bhc:ACertainInternationalBusinessMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2020-12-310000885590bhc:ACertainInternationalBusinessMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2020-01-012020-12-310000885590bhc:OtherRestructuringIntegrationRelatedOtherCostsMember2020-12-310000885590bhc:OtherRestructuringIntegrationRelatedOtherCostsMember2020-01-012020-12-310000885590bhc:OtherRestructuringIntegrationRelatedOtherCostsMember2019-01-012019-12-310000885590bhc:OtherRestructuringIntegrationRelatedOtherCostsMember2018-01-012018-12-310000885590bhc:SeparationCostsMember2020-01-012020-12-310000885590us-gaap:FairValueMeasurementsRecurringMember2020-12-310000885590us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000885590us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000885590us-gaap:FairValueMeasurementsRecurringMember2019-12-310000885590us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000885590us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000885590us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000885590us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000885590us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000885590us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel3Memberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000885590us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000885590us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000885590us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000885590us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel3Memberus-gaap:NondesignatedMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000885590us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000885590us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000885590us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000885590us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000885590us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000885590us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000885590stpr:NJus-gaap:SettledLitigationMemberbhc:ValeantUSSecuritiesLitigationMember2020-01-012020-12-310000885590us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000885590us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000885590us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-12-310000885590us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-01-012019-12-310000885590us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-12-310000885590us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-01-012019-12-310000885590us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2020-12-310000885590us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2020-01-012020-12-31bhc:rate0000885590us-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Membersrt:MinimumMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000885590us-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembersrt:MaximumMember2020-12-31bhc:number0000885590us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberbhc:MeasurementInputWeightedAverageDiscountRateMember2020-12-310000885590bhc:AccretionForTimeValueOfMoneyMember2020-01-012020-12-310000885590bhc:AccretionForTimeValueOfMoneyMember2019-01-012019-12-310000885590bhc:FairValueAdjustmentsMember2020-01-012020-12-310000885590bhc:FairValueAdjustmentsMember2019-01-012019-12-310000885590us-gaap:FairValueMeasurementsNonrecurringMember2020-12-310000885590us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsNonrecurringMember2020-12-310000885590us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsNonrecurringMember2020-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2020-12-310000885590us-gaap:FairValueMeasurementsNonrecurringMember2019-12-310000885590us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsNonrecurringMember2019-12-310000885590us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsNonrecurringMember2019-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2019-12-31bhc:product0000885590us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberbhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMemberbhc:DiversifiedProductsSegmentMember2019-12-310000885590us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberbhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember2019-07-012019-09-300000885590srt:RestatementAdjustmentMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberbhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember2020-03-310000885590us-gaap:LandMember2020-12-310000885590us-gaap:LandMember2019-12-310000885590us-gaap:BuildingAndBuildingImprovementsMember2020-12-310000885590us-gaap:BuildingAndBuildingImprovementsMember2019-12-310000885590us-gaap:MachineryAndEquipmentMember2020-12-310000885590us-gaap:MachineryAndEquipmentMember2019-12-310000885590bhc:OtherEquipmentAndLeaseholdImprovementMember2020-12-310000885590bhc:OtherEquipmentAndLeaseholdImprovementMember2019-12-310000885590us-gaap:EquipmentLeasedToOtherPartyMember2020-12-310000885590us-gaap:EquipmentLeasedToOtherPartyMember2019-12-310000885590us-gaap:ConstructionInProgressMember2020-12-310000885590us-gaap:ConstructionInProgressMember2019-12-310000885590bhc:ProductBrandsMember2020-01-012020-12-310000885590bhc:ProductBrandsMember2020-12-310000885590bhc:ProductBrandsMember2019-12-310000885590us-gaap:TradeNamesMember2020-01-012020-12-310000885590us-gaap:TradeNamesMember2020-12-310000885590us-gaap:TradeNamesMember2019-12-310000885590us-gaap:ContractualRightsMember2020-01-012020-12-310000885590us-gaap:ContractualRightsMember2020-12-310000885590us-gaap:ContractualRightsMember2019-12-310000885590bhc:PartnerRelationshipsMember2020-01-012020-12-310000885590bhc:PartnerRelationshipsMember2020-12-310000885590bhc:PartnerRelationshipsMember2019-12-310000885590bhc:OutLicensedTechnologyMember2020-01-012020-12-310000885590bhc:OutLicensedTechnologyMember2020-12-310000885590bhc:OutLicensedTechnologyMember2019-12-310000885590bhc:AcquiredInProcessResearchAndDevelopmentMember2020-12-310000885590bhc:AcquiredInProcessResearchAndDevelopmentMember2019-12-310000885590us-gaap:TrademarksMember2020-12-310000885590us-gaap:TrademarksMember2019-12-310000885590bhc:DiscontinuedProductLinesMember2020-01-012020-12-310000885590bhc:AcquiredInProcessResearchAndDevelopmentMember2020-01-012020-12-310000885590bhc:ProductBrandsMember2019-01-012019-12-310000885590us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberbhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember2019-01-012019-12-310000885590us-gaap:ContractualRightsMember2019-01-012019-12-310000885590bhc:AcquiredInProcessResearchAndDevelopmentMember2019-01-012019-12-310000885590bhc:UcerisMember2018-01-012018-12-310000885590bhc:ProductBrandsMember2018-01-012018-12-310000885590bhc:ArestinMember2018-01-012018-12-310000885590us-gaap:ContractualRightsMember2018-01-012018-12-310000885590bhc:AcquiredInProcessResearchAndDevelopmentMember2018-01-012018-12-310000885590us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2018-01-012018-12-310000885590bhc:XifaxanMemberus-gaap:IntangibleAssetsAmortizationPeriodMember2020-01-012020-12-310000885590bhc:XifaxanMemberus-gaap:IntangibleAssetsAmortizationPeriodMember2019-01-012019-12-310000885590bhc:XifaxanMemberus-gaap:IntangibleAssetsAmortizationPeriodMember2018-01-012018-12-310000885590bhc:XifaxanMember2020-12-310000885590bhc:BauschLombInternationalMember2017-12-310000885590bhc:BrandedRXMember2017-12-310000885590bhc:U.S.DiversifiedProductsSegmentMember2017-12-310000885590bhc:BrandedRXMemberbhc:OrthoDermatologicsReportingUnitMember2018-01-012018-12-310000885590bhc:OrthoDermatologicsReportingUnitMember2018-01-012018-12-310000885590bhc:BauschLombInternationalMember2018-01-012018-12-310000885590bhc:BrandedRXMember2018-01-012018-12-310000885590bhc:U.S.DiversifiedProductsSegmentMember2018-01-012018-12-310000885590bhc:SalixSegmentMember2018-01-012018-12-310000885590bhc:OrthoDermatologicsSegmentMember2018-01-012018-12-310000885590bhc:DiversifiedProductsSegmentMember2018-01-012018-12-310000885590bhc:DiversifiedProductsSegmentMemberbhc:DentistryReportingUnitMember2018-01-012018-12-310000885590bhc:DentistryReportingUnitMember2018-01-012018-12-310000885590bhc:BauschLombInternationalMember2018-12-310000885590bhc:BrandedRXMember2018-12-310000885590bhc:U.S.DiversifiedProductsSegmentMember2018-12-310000885590bhc:SalixSegmentMember2018-12-310000885590bhc:OrthoDermatologicsSegmentMember2018-12-310000885590bhc:DiversifiedProductsSegmentMember2018-12-310000885590bhc:SalixSegmentMember2019-01-012019-12-310000885590bhc:BauschLombInternationalMember2019-01-012019-12-310000885590bhc:BauschLombInternationalMember2019-12-310000885590bhc:BrandedRXMember2019-12-310000885590bhc:U.S.DiversifiedProductsSegmentMember2019-12-310000885590bhc:SalixSegmentMember2019-12-310000885590bhc:OrthoDermatologicsSegmentMember2019-12-310000885590bhc:DiversifiedProductsSegmentMember2019-12-310000885590bhc:BauschLombInternationalMember2020-01-012020-12-310000885590bhc:BauschLombInternationalMember2020-12-310000885590bhc:BrandedRXMember2020-12-310000885590bhc:U.S.DiversifiedProductsSegmentMember2020-12-310000885590bhc:SalixSegmentMember2020-12-310000885590bhc:OrthoDermatologicsSegmentMember2020-12-310000885590bhc:DiversifiedProductsSegmentMember2020-12-310000885590bhc:BrandedRxSegmentMemberbhc:SalixReportingUnitMember2018-01-012018-01-010000885590bhc:BrandedRxSegmentMemberbhc:OrthoDermatologicsReportingUnitMember2018-01-012018-01-010000885590bhc:BrandedRxSegmentMemberus-gaap:ScenarioAdjustmentMember2018-03-010000885590bhc:BauschLombInternationalAndU.S.DiversifiedProductsSegmentsMemberus-gaap:ScenarioAdjustmentMember2018-03-310000885590bhc:DentistryReportingUnitMember2018-10-012018-10-010000885590bhc:ReportingUnitsExcludingDentistryMember2018-10-012018-10-010000885590bhc:ReportingUnitsExcludingOrthoDermatologicsAndDentistryMember2018-10-0100008855902019-10-012019-10-0100008855902020-10-012020-12-3100008855902019-10-012019-12-3100008855902020-04-012020-06-3000008855902020-07-012020-09-300000885590bhc:OrthoDermatologicsReportingUnitMember2020-01-012020-03-310000885590bhc:OrthoDermatologicsReportingUnitMember2020-04-012020-06-300000885590bhc:OrthoDermatologicsReportingUnitMember2020-10-010000885590srt:MinimumMemberbhc:OrthoDermatologicsReportingUnitMember2020-10-010000885590bhc:OrthoDermatologicsReportingUnitMembersrt:MaximumMember2020-10-010000885590bhc:OrthoDermatologicsReportingUnitMember2020-10-012020-10-010000885590us-gaap:RevolvingCreditFacilityMemberbhc:RevolvingCreditFacilityDueJune2023Member2019-12-310000885590bhc:TermLoanBFacilityDueJune2025Member2020-12-310000885590bhc:TermLoanBFacilityDueJune2025Member2019-12-310000885590bhc:TermLoanBFacilityDueNovember2025Member2020-12-310000885590bhc:TermLoanBFacilityDueNovember2025Member2019-12-310000885590bhc:SeniorSecuredNotes6.50PercentDueMarch2022Memberus-gaap:SecuredDebtMember2020-12-310000885590bhc:SeniorSecuredNotes6.50PercentDueMarch2022Memberus-gaap:SecuredDebtMember2019-12-310000885590us-gaap:SecuredDebtMemberbhc:SeniorSecuredNotes7.00PercentDueMarch2024Member2020-12-310000885590us-gaap:SecuredDebtMemberbhc:SeniorSecuredNotes7.00PercentDueMarch2024Member2019-12-310000885590us-gaap:SecuredDebtMemberbhc:SeniorSecured5.50NotesDueNovember2025Member2020-12-310000885590us-gaap:SecuredDebtMemberbhc:SeniorSecured5.50NotesDueNovember2025Member2019-12-310000885590bhc:SeniorSecured5.75NotesDueAugust2027Memberus-gaap:SecuredDebtMember2020-12-310000885590bhc:SeniorSecured5.75NotesDueAugust2027Memberus-gaap:SecuredDebtMember2019-12-310000885590bhc:SeniorNotes550DueMarch2023Memberus-gaap:UnsecuredDebtMember2020-12-310000885590bhc:SeniorNotes550DueMarch2023Memberus-gaap:UnsecuredDebtMember2019-12-310000885590bhc:SeniorNotes5875DueMay2023Memberus-gaap:UnsecuredDebtMember2020-12-310000885590bhc:SeniorNotes5875DueMay2023Memberus-gaap:UnsecuredDebtMember2019-12-310000885590us-gaap:UnsecuredDebtMemberbhc:SeniorNotes450DueMay2023Member2020-12-310000885590us-gaap:UnsecuredDebtMemberbhc:SeniorNotes450DueMay2023Member2019-12-310000885590bhc:SeniorNotes6125DueApril2025Memberus-gaap:UnsecuredDebtMember2020-12-310000885590bhc:SeniorNotes6125DueApril2025Memberus-gaap:UnsecuredDebtMember2019-12-310000885590bhc:SeniorNotes900DueDecember2025Memberus-gaap:UnsecuredDebtMember2020-12-310000885590bhc:SeniorNotes900DueDecember2025Memberus-gaap:UnsecuredDebtMember2019-12-310000885590us-gaap:UnsecuredDebtMemberbhc:SeniorNotes925DueApril2026Member2020-12-310000885590us-gaap:UnsecuredDebtMemberbhc:SeniorNotes925DueApril2026Member2019-12-310000885590bhc:SeniorNotes850DueJanuary2027Memberus-gaap:UnsecuredDebtMember2020-12-310000885590bhc:SeniorNotes850DueJanuary2027Memberus-gaap:UnsecuredDebtMember2019-12-310000885590bhc:SeniorNotes700DueJanuary2028Memberus-gaap:UnsecuredDebtMember2020-12-310000885590bhc:SeniorNotes700DueJanuary2028Memberus-gaap:UnsecuredDebtMember2019-12-310000885590bhc:SeniorNotes500DueJanuary2028Memberus-gaap:UnsecuredDebtMember2020-12-310000885590bhc:SeniorNotes500DueJanuary2028Memberus-gaap:UnsecuredDebtMember2019-12-310000885590bhc:SeniorNotes625DueFebruary2029Memberus-gaap:UnsecuredDebtMember2020-12-310000885590bhc:SeniorNotes625DueFebruary2029Memberus-gaap:UnsecuredDebtMember2019-12-310000885590bhc:SeniorNotes500DueFebruary2029Memberus-gaap:UnsecuredDebtMember2020-12-310000885590bhc:SeniorNotes500DueFebruary2029Memberus-gaap:UnsecuredDebtMember2019-12-310000885590bhc:SeniorNotes725DueMay2029Memberus-gaap:UnsecuredDebtMember2020-12-310000885590bhc:SeniorNotes725DueMay2029Memberus-gaap:UnsecuredDebtMember2019-12-310000885590bhc:SeniorNotes525DueJanuary2030Memberus-gaap:UnsecuredDebtMember2020-12-310000885590bhc:SeniorNotes525DueJanuary2030Memberus-gaap:UnsecuredDebtMember2019-12-310000885590bhc:SeniorNotes525DueFebruary2031Memberus-gaap:UnsecuredDebtMember2020-12-310000885590bhc:SeniorNotes525DueFebruary2031Memberus-gaap:UnsecuredDebtMember2019-12-310000885590bhc:OtherLongTermDebtMemberus-gaap:UnsecuredDebtMember2020-12-310000885590bhc:OtherLongTermDebtMemberus-gaap:UnsecuredDebtMember2019-12-310000885590us-gaap:RevolvingCreditFacilityMember2020-12-310000885590us-gaap:RevolvingCreditFacilityMember2018-01-010000885590bhc:SeriesFTrancheBTermLoanFacilityMember2018-01-010000885590us-gaap:RevolvingCreditFacilityMember2018-01-012018-12-310000885590us-gaap:RevolvingCreditFacilityMemberbhc:RevolvingCreditFacilityDueJune2023Member2018-06-010000885590bhc:SeriesFTrancheBTermLoanFacilityMember2018-06-012018-06-010000885590bhc:TermLoanBFacilityDueJune2025Member2018-06-012018-06-010000885590bhc:TermLoanBFacilityDueJune2025Member2018-06-010000885590us-gaap:RevolvingCreditFacilityMemberbhc:RevolvingCreditFacilityDueJune2023Member2018-06-012018-06-010000885590bhc:A5.375SeniorNotesdueMarch2020Memberus-gaap:UnsecuredDebtMember2018-06-012018-06-010000885590bhc:SeniorNotes6.75PercentDueAugust2021Memberus-gaap:UnsecuredDebtMember2018-06-012018-06-010000885590bhc:SeniorNotes6.75PercentDueAugust2021Memberus-gaap:UnsecuredDebtMember2018-06-010000885590bhc:SeniorNotes7.25PercentDueJuly2022Memberus-gaap:UnsecuredDebtMember2018-06-012018-06-010000885590bhc:SeniorNotes7.25PercentDueJuly2022Memberus-gaap:UnsecuredDebtMember2018-06-010000885590bhc:SeniorNotes6.375PercentDueOctober2020Memberus-gaap:UnsecuredDebtMember2018-06-012018-06-010000885590bhc:SeniorNotes6.375PercentDueOctober2020Memberus-gaap:UnsecuredDebtMember2018-06-010000885590bhc:A8.50SeniorNotesDueJanuary2027Memberus-gaap:UnsecuredDebtMember2018-06-012018-06-010000885590bhc:A8.50SeniorNotesDueJanuary2027Memberus-gaap:UnsecuredDebtMember2018-06-0100008855902018-06-0100008855902018-06-012018-06-010000885590bhc:TermLoanBFacilityDueJune2025Member2018-11-272018-11-270000885590bhc:TermLoanBFacilityDueJune2025Member2018-11-270000885590us-gaap:UnsecuredDebtMemberbhc:SeniorNotes7.5July2021Member2018-11-272018-11-270000885590us-gaap:UnsecuredDebtMemberbhc:SeniorNotes7.5July2021Member2018-11-270000885590us-gaap:UnsecuredDebtMemberbhc:SeniorNotes7.5July2021Member2018-12-2700008855902018-11-270000885590us-gaap:RevolvingCreditFacilityMember2019-01-012019-12-310000885590us-gaap:RevolvingCreditFacilityMember2020-01-012020-12-310000885590us-gaap:RevolvingCreditFacilityMemberbhc:TermLoanBFacilityDueJune2025AndNovember2025Member2020-05-262020-05-260000885590us-gaap:EurodollarMemberbhc:SeniorSecuredCreditFacilitiesMember2020-01-012020-12-310000885590us-gaap:EurodollarMemberbhc:SeniorSecuredCreditFacilitiesMembersrt:MinimumMember2020-01-012020-12-310000885590bhc:SeniorSecuredCreditFacilitiesMember2020-01-012020-12-310000885590us-gaap:EurodollarMembersrt:MinimumMemberbhc:RevolvingCreditFacilityDueJune2023Member2020-01-012020-12-310000885590bhc:CanadaBankersAcceptanceRateMemberbhc:RevolvingCreditFacilityDueJune2023Member2020-01-012020-12-310000885590bhc:CanadaBankersAcceptanceRateMembersrt:MinimumMemberbhc:RevolvingCreditFacilityDueJune2023Member2020-01-012020-12-310000885590bhc:SeniorSecuredTermCreditFacilitiesMember2020-01-012020-12-310000885590bhc:BaseRateOrPrimeRateMemberbhc:TermLoanBFacilityDueJune2025Member2020-01-012020-12-310000885590bhc:BaseRateOrPrimeRateMemberbhc:TermLoanBFacilityDueNovember2025Member2020-01-012020-12-310000885590us-gaap:EurodollarMemberbhc:TermLoanBFacilityDueJune2025Member2020-01-012020-12-310000885590us-gaap:EurodollarMemberbhc:TermLoanBFacilityDueNovember2025Member2020-01-012020-12-310000885590bhc:BaseRateOrPrimeRateMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberbhc:RevolvingCreditFacilityDueJune2023Member2020-01-012020-12-310000885590bhc:BaseRateOrPrimeRateMemberus-gaap:RevolvingCreditFacilityMemberbhc:RevolvingCreditFacilityDueJune2023Membersrt:MaximumMember2020-01-012020-12-310000885590us-gaap:RevolvingCreditFacilityMemberus-gaap:EurodollarMembersrt:MinimumMemberbhc:RevolvingCreditFacilityDueJune2023Member2020-01-012020-12-310000885590us-gaap:RevolvingCreditFacilityMemberus-gaap:EurodollarMemberbhc:RevolvingCreditFacilityDueJune2023Membersrt:MaximumMember2020-01-012020-12-310000885590us-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberbhc:RevolvingCreditFacilityDueJune2023Member2020-01-012020-12-310000885590us-gaap:RevolvingCreditFacilityMemberbhc:RevolvingCreditFacilityDueJune2023Membersrt:MaximumMember2020-01-012020-12-310000885590us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredDebtMember2020-12-310000885590us-gaap:RevolvingCreditFacilityMemberus-gaap:UnsecuredDebtMember2020-12-310000885590bhc:SeniorSecuredNotes6.50PercentDueMarch2022Memberus-gaap:SecuredDebtMember2017-03-310000885590us-gaap:SecuredDebtMemberbhc:SeniorSecuredNotes7.00PercentDueMarch2024Member2017-03-310000885590us-gaap:SecuredDebtMemberbhc:SeniorSecured5.50NotesDueNovember2025Member2017-10-170000885590us-gaap:SecuredDebtMemberbhc:SeniorSecured5.50NotesDueNovember2025Member2017-11-210000885590bhc:SeniorSecured5.75NotesDueAugust2027Memberus-gaap:SecuredDebtMember2019-03-080000885590bhc:A8.50SeniorNotesDueJanuary2027Memberus-gaap:UnsecuredDebtMember2020-03-310000885590bhc:A5.875SeniorNotesdueMay2023Memberus-gaap:UnsecuredDebtMember2019-03-082019-03-080000885590bhc:A5.875SeniorNotesdueMay2023Memberus-gaap:UnsecuredDebtMember2019-03-080000885590us-gaap:UnsecuredDebtMemberbhc:SeniorNotes5.625PercentDueDecember2021Member2019-03-082019-03-080000885590us-gaap:UnsecuredDebtMemberbhc:SeniorNotes5.625PercentDueDecember2021Member2019-03-080000885590us-gaap:UnsecuredDebtMemberbhc:A5.50SeniorNotesdueMarch2023Member2019-03-082019-03-080000885590us-gaap:UnsecuredDebtMemberbhc:A5.50SeniorNotesdueMarch2023Member2019-03-080000885590us-gaap:UnsecuredDebtMemberbhc:SeniorNotes5.625PercentDueDecember2021Member2019-04-012019-04-300000885590bhc:SeniorSecuredNotesAndSeniorUnsecuredNotesMember2019-04-3000008855902019-03-082019-03-080000885590bhc:SeniorSecured5.75NotesDueAugust2027Memberus-gaap:SecuredDebtMember2019-03-082019-03-080000885590us-gaap:UnsecuredDebtMember2020-01-012020-12-310000885590us-gaap:UnsecuredDebtMemberbhc:SeniorNotes5.625PercentDueDecember2021Member2013-12-020000885590us-gaap:UnsecuredDebtMemberbhc:SeniorNotes5.625PercentDueDecember2021Member2018-12-012018-12-310000885590us-gaap:UnsecuredDebtMemberbhc:A5.50SeniorNotesdueMarch2023Member2015-01-300000885590us-gaap:UnsecuredDebtMemberbhc:A5.50SeniorNotesdueMarch2023Member2019-05-232019-05-230000885590us-gaap:UnsecuredDebtMemberbhc:A5.50SeniorNotesdueMarch2023Member2020-01-012020-12-310000885590us-gaap:UnsecuredDebtMemberbhc:A5.50SeniorNotesdueMarch2023Member2020-12-012020-12-310000885590bhc:A5.375SeniorNotesdueMarch2020Memberus-gaap:UnsecuredDebtMember2015-03-270000885590bhc:A5.875SeniorNotesdueMay2023Memberus-gaap:UnsecuredDebtMember2015-03-270000885590us-gaap:UnsecuredDebtMemberbhc:SeniorNotes4.502023Member2015-03-270000885590us-gaap:UnsecuredDebtMemberbhc:A6.125SeniorNotesdueApril2025Member2015-03-27iso4217:EUR0000885590bhc:A5.875SeniorNotesdueMay2023Memberus-gaap:UnsecuredDebtMember2019-05-232019-05-230000885590us-gaap:UnsecuredDebtMemberbhc:SeniorUnsecuredNotesDue2023Member2019-10-032019-10-030000885590us-gaap:UnsecuredDebtMemberbhc:SeniorUnsecuredNotesDue2023Member2020-01-160000885590us-gaap:UnsecuredDebtMemberbhc:SeniorUnsecuredNotesDue2023Member2020-01-012020-12-310000885590bhc:A9.00SeniorNotesdueDecember2025Memberus-gaap:UnsecuredDebtMember2017-12-180000885590bhc:A5.375SeniorNotesdueMarch2020Memberus-gaap:UnsecuredDebtMember2017-12-180000885590us-gaap:DebtInstrumentRedemptionPeriodOneMemberbhc:A9.00SeniorNotesdueDecember2025Memberus-gaap:UnsecuredDebtMember2017-12-182017-12-180000885590us-gaap:DebtInstrumentRedemptionPeriodTwoMemberbhc:A9.00SeniorNotesdueDecember2025Memberus-gaap:UnsecuredDebtMember2017-12-182017-12-180000885590bhc:A9.25SeniorNotesDueApril2026Memberus-gaap:UnsecuredDebtMember2018-03-260000885590bhc:A9.25SeniorNotesDueApril2026Memberus-gaap:UnsecuredDebtMember2018-03-262018-03-260000885590bhc:A7.00SeniorUnsecuredNotesDue2028Memberus-gaap:UnsecuredDebtMember2019-05-230000885590bhc:A7.25SeniorUnsecuredNotesDue2029Memberus-gaap:UnsecuredDebtMember2019-05-230000885590us-gaap:UnsecuredDebtMember2019-05-232019-05-230000885590bhc:A7.25SeniorUnsecuredNotesDue2029Memberus-gaap:UnsecuredDebtMember2019-05-232019-05-230000885590bhc:A7.00SeniorUnsecuredNotesDue2028Memberus-gaap:UnsecuredDebtMember2019-05-232019-05-230000885590bhc:A5.00SeniorNotesDueJanuary2028Memberus-gaap:UnsecuredDebtMember2019-12-300000885590us-gaap:UnsecuredDebtMemberbhc:A5.25SeniorNotesDueJanuary2030Member2019-12-300000885590bhc:A5.875SeniorNotesdueMay2023Memberus-gaap:UnsecuredDebtMember2020-01-162020-01-160000885590stpr:NJus-gaap:SettledLitigationMemberbhc:ValeantUSSecuritiesLitigationMember2019-12-162019-12-160000885590bhc:A5.00SeniorNotesDueJanuary2028Memberus-gaap:UnsecuredDebtMember2019-12-302019-12-300000885590us-gaap:UnsecuredDebtMemberbhc:A5.25SeniorNotesDueJanuary2030Member2019-12-302019-12-300000885590bhc:SeniorNotes625DueFebruary2029Memberus-gaap:UnsecuredDebtMember2020-05-260000885590bhc:SeniorSecuredNotes6.50PercentDueMarch2022Memberus-gaap:SecuredDebtMember2020-05-260000885590bhc:TermLoanBFacilityDueJune2025AndNovember2025Member2020-05-262020-05-2600008855902020-05-262020-05-260000885590us-gaap:DebtInstrumentRedemptionPeriodOneMemberbhc:SeniorNotes625DueFebruary2029Memberus-gaap:UnsecuredDebtMember2020-05-262020-05-260000885590us-gaap:DebtInstrumentRedemptionPeriodTwoMemberbhc:SeniorNotes625DueFebruary2029Memberus-gaap:UnsecuredDebtMember2020-05-262020-05-260000885590bhc:SeniorNotes500DueFebruary2029Memberus-gaap:UnsecuredDebtMember2020-12-030000885590bhc:SeniorNotes525DueFebruary2031Memberus-gaap:UnsecuredDebtMember2020-12-030000885590us-gaap:UnsecuredDebtMemberbhc:SeniorNotes4.502023Member2020-12-030000885590bhc:SeniorNotes550DueMarch2023Memberus-gaap:UnsecuredDebtMember2020-12-030000885590bhc:SeniorNotes550DueMarch2023Memberus-gaap:UnsecuredDebtMember2020-12-032020-12-030000885590bhc:SeniorNotes500DueFebruary2029Memberus-gaap:UnsecuredDebtMember2020-12-032020-12-030000885590bhc:SeniorNotes525DueFebruary2031Memberus-gaap:UnsecuredDebtMember2020-12-032020-12-030000885590bhc:SeniorSecuredTermCreditFacilitiesMemberus-gaap:FederalFundsEffectiveSwapRateMember2020-01-012020-12-310000885590us-gaap:PensionPlansDefinedBenefitMember2020-12-31bhc:defined_benefit_plan0000885590us-gaap:PensionPlansDefinedBenefitMembercountry:IE2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMembercountry:IE2014-12-012014-12-310000885590us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-01-012020-12-310000885590us-gaap:PensionPlansDefinedBenefitMembercountry:US2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMembercountry:US2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000885590us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMembercountry:US2020-01-012020-12-310000885590us-gaap:PensionPlansDefinedBenefitMembercountry:US2019-01-012019-12-310000885590us-gaap:PensionPlansDefinedBenefitMembercountry:US2018-01-012018-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2020-01-012020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2019-01-012019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2018-01-012018-12-310000885590us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-01-012019-12-310000885590us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2018-01-012018-12-310000885590us-gaap:PensionPlansDefinedBenefitMembercountry:US2018-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2018-12-310000885590us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2018-12-310000885590country:US2020-12-310000885590us-gaap:ForeignPlanMember2020-12-310000885590country:US2019-12-310000885590us-gaap:ForeignPlanMember2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMembercountry:IE2020-01-012020-12-310000885590us-gaap:PensionPlansDefinedBenefitMembersrt:ScenarioForecastMembercountry:US2021-01-012021-12-310000885590us-gaap:PensionPlansDefinedBenefitMembersrt:ScenarioForecastMembercountry:IE2021-01-012021-12-310000885590us-gaap:CashAndCashEquivalentsMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2020-12-310000885590us-gaap:CashAndCashEquivalentsMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMembercountry:USus-gaap:DefinedBenefitPlanEquitySecuritiesMember2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMembercountry:USus-gaap:DefinedBenefitPlanEquitySecuritiesMember2019-12-310000885590us-gaap:FixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2020-12-310000885590us-gaap:FixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMembercountry:US2019-12-310000885590us-gaap:CashAndCashEquivalentsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2020-12-310000885590us-gaap:CashAndCashEquivalentsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2019-12-310000885590us-gaap:FixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2020-12-310000885590us-gaap:FixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:OtherDebtSecuritiesMember2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:OtherDebtSecuritiesMember2019-12-310000885590us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMembercountry:US2020-12-310000885590us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membercountry:US2020-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2020-12-310000885590us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2020-12-310000885590us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMembercountry:US2019-12-310000885590us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membercountry:US2019-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2019-12-310000885590us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2019-12-310000885590bhc:U.S.BroadMarketMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMembercountry:US2020-12-310000885590bhc:U.S.BroadMarketMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membercountry:US2020-12-310000885590bhc:U.S.BroadMarketMemberus-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2020-12-310000885590bhc:U.S.BroadMarketMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2020-12-310000885590bhc:U.S.BroadMarketMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMembercountry:US2019-12-310000885590bhc:U.S.BroadMarketMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membercountry:US2019-12-310000885590bhc:U.S.BroadMarketMemberus-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2019-12-310000885590bhc:U.S.BroadMarketMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2019-12-310000885590bhc:EmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMembercountry:US2020-12-310000885590bhc:EmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membercountry:US2020-12-310000885590us-gaap:FairValueInputsLevel3Memberbhc:EmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2020-12-310000885590bhc:EmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2020-12-310000885590bhc:EmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMembercountry:US2019-12-310000885590bhc:EmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membercountry:US2019-12-310000885590us-gaap:FairValueInputsLevel3Memberbhc:EmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2019-12-310000885590bhc:EmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberbhc:NonU.S.DevelopedMarketsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMembercountry:US2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberbhc:NonU.S.DevelopedMarketsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membercountry:US2020-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberbhc:NonU.S.DevelopedMarketsMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberbhc:NonU.S.DevelopedMarketsMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberbhc:NonU.S.DevelopedMarketsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMembercountry:US2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberbhc:NonU.S.DevelopedMarketsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membercountry:US2019-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberbhc:NonU.S.DevelopedMarketsMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberbhc:NonU.S.DevelopedMarketsMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2019-12-310000885590bhc:NonU.S.OtherAssetsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMembercountry:US2020-12-310000885590bhc:NonU.S.OtherAssetsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membercountry:US2020-12-310000885590us-gaap:FairValueInputsLevel3Memberbhc:NonU.S.OtherAssetsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2020-12-310000885590bhc:NonU.S.OtherAssetsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2020-12-310000885590bhc:NonU.S.OtherAssetsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMembercountry:US2019-12-310000885590bhc:NonU.S.OtherAssetsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membercountry:US2019-12-310000885590us-gaap:FairValueInputsLevel3Memberbhc:NonU.S.OtherAssetsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2019-12-310000885590bhc:NonU.S.OtherAssetsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberbhc:InvestmentGradeMembercountry:US2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberbhc:InvestmentGradeMembercountry:US2020-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberbhc:InvestmentGradeMembercountry:US2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberbhc:InvestmentGradeMembercountry:US2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberbhc:InvestmentGradeMembercountry:US2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberbhc:InvestmentGradeMembercountry:US2019-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberbhc:InvestmentGradeMembercountry:US2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberbhc:InvestmentGradeMembercountry:US2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMembercountry:US2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membercountry:US2020-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMembercountry:US2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membercountry:US2019-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMembercountry:US2019-12-310000885590us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2020-12-310000885590us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMember2020-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2020-12-310000885590us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2020-12-310000885590us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2019-12-310000885590bhc:EmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2020-12-310000885590bhc:EmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMember2020-12-310000885590us-gaap:FairValueInputsLevel3Memberbhc:EmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2020-12-310000885590bhc:EmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2020-12-310000885590bhc:EmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2019-12-310000885590bhc:EmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:FairValueInputsLevel3Memberbhc:EmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2019-12-310000885590bhc:EmergingMarketsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberbhc:NonU.S.DevelopedMarketsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberbhc:NonU.S.DevelopedMarketsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMember2020-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberbhc:NonU.S.DevelopedMarketsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberbhc:NonU.S.DevelopedMarketsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberbhc:NonU.S.DevelopedMarketsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberbhc:NonU.S.DevelopedMarketsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberbhc:NonU.S.DevelopedMarketsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberbhc:NonU.S.DevelopedMarketsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMemberbhc:InvestmentGradeMember2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberbhc:InvestmentGradeMember2020-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMemberbhc:InvestmentGradeMember2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMemberbhc:InvestmentGradeMember2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMemberbhc:InvestmentGradeMember2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberbhc:InvestmentGradeMember2019-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMemberbhc:InvestmentGradeMember2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMemberbhc:InvestmentGradeMember2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberbhc:GlobalHighYieldMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberbhc:GlobalHighYieldMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMember2020-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberbhc:GlobalHighYieldMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberbhc:GlobalHighYieldMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberbhc:GlobalHighYieldMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberbhc:GlobalHighYieldMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberbhc:GlobalHighYieldMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberbhc:GlobalHighYieldMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMemberus-gaap:USTreasuryAndGovernmentMember2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:USTreasuryAndGovernmentMember2020-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMemberus-gaap:USTreasuryAndGovernmentMember2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMemberus-gaap:USTreasuryAndGovernmentMember2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMemberus-gaap:USTreasuryAndGovernmentMember2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:USTreasuryAndGovernmentMember2019-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMemberus-gaap:USTreasuryAndGovernmentMember2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMemberus-gaap:USTreasuryAndGovernmentMember2019-12-310000885590bhc:OtherAssetsFixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2020-12-310000885590bhc:OtherAssetsFixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMember2020-12-310000885590bhc:OtherAssetsFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2020-12-310000885590bhc:OtherAssetsFixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2020-12-310000885590bhc:OtherAssetsFixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2019-12-310000885590bhc:OtherAssetsFixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMember2019-12-310000885590bhc:OtherAssetsFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2019-12-310000885590bhc:OtherAssetsFixedIncomeSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMember2020-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2020-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignPlanMember2019-12-310000885590us-gaap:PensionPlansDefinedBenefitMembercountry:IE2019-01-012019-12-310000885590bhc:OmnibusIncentivePlan2014Member2014-05-310000885590bhc:OmnibusIncentivePlan2014Member2018-04-302018-04-300000885590bhc:OmnibusIncentivePlan2014Memberbhc:NonemployeeDirectorMember2018-04-302018-04-300000885590bhc:OmnibusIncentivePlan2014Member2020-04-282020-04-280000885590bhc:OmnibusIncentivePlan2014Member2020-12-310000885590us-gaap:EmployeeStockOptionMember2020-01-012020-12-310000885590us-gaap:EmployeeStockOptionMember2019-01-012019-12-310000885590us-gaap:EmployeeStockOptionMember2018-01-012018-12-310000885590us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310000885590us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-12-310000885590us-gaap:RestrictedStockUnitsRSUMember2018-01-012018-12-310000885590us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310000885590us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-12-310000885590us-gaap:ResearchAndDevelopmentExpenseMember2018-01-012018-12-310000885590bhc:SellingGeneralAndAdministrativeExpenseMember2020-01-012020-12-310000885590bhc:SellingGeneralAndAdministrativeExpenseMember2019-01-012019-12-310000885590bhc:SellingGeneralAndAdministrativeExpenseMember2018-01-012018-12-310000885590us-gaap:ShareBasedCompensationAwardTrancheOneMemberus-gaap:EmployeeStockOptionMember2020-01-012020-12-310000885590us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2020-01-012020-12-310000885590us-gaap:ShareBasedCompensationAwardTrancheOneMember2020-01-012020-12-310000885590us-gaap:ShareBasedCompensationAwardTrancheTwoMember2020-01-012020-12-310000885590us-gaap:EmployeeStockOptionMember2019-12-310000885590us-gaap:EmployeeStockOptionMember2020-12-310000885590bhc:TimeBasedRSUMember2019-12-310000885590bhc:TimeBasedRSUMember2020-01-012020-12-310000885590bhc:TimeBasedRSUMember2020-12-310000885590bhc:TimeBasedRSUMember2019-01-012019-12-310000885590bhc:TimeBasedRSUMember2018-01-012018-12-310000885590bhc:PerformanceBasedRestrictedStockUnitsMember2020-01-012020-12-310000885590bhc:PerformanceBasedRestrictedStockUnitsMember2019-01-012019-12-310000885590bhc:PerformanceBasedRestrictedStockUnitsMember2018-01-012018-12-310000885590bhc:PerformanceBasedRestrictedStockUnitsMember2019-12-310000885590bhc:PerformanceBasedRestrictedStockUnitsMember2020-12-310000885590bhc:TSRPerformanceBasedRestrictedStockUnitsMember2020-01-012020-12-310000885590bhc:ROTCPerformanceBasedRestrictedStockUnitsMember2020-01-012020-12-310000885590bhc:PerformanceBasedRestrictedStockUnitsMembersrt:ChiefExecutiveOfficerMember2018-01-012018-12-310000885590us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000885590us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310000885590us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310000885590us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310000885590bhc:SalixLtd.SECInvestigationLitigationMember2018-01-012018-12-310000885590bhc:MilestonePaymentRelatedToCertainProductMember2019-01-012019-12-310000885590us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2019-12-310000885590us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2018-12-310000885590us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2017-12-310000885590us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2020-01-012020-12-310000885590us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2019-01-012019-12-310000885590us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2018-01-012018-12-310000885590us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2020-12-310000885590bhc:ForeignCountryStateAndLocalMember2020-01-012020-12-310000885590bhc:ForeignCountryStateAndLocalMember2019-01-012019-12-310000885590bhc:ForeignCountryStateAndLocalMember2020-12-310000885590bhc:ForeignCountryStateAndLocalMember2019-12-310000885590bhc:ForeignCountryStateAndLocalMemberbhc:PooledScientificResearchAndExperimentalDevelopmentExpendituresMember2020-12-310000885590bhc:ForeignCountryStateAndLocalMemberbhc:PooledScientificResearchAndExperimentalDevelopmentExpendituresMember2019-12-310000885590us-gaap:DomesticCountryMember2020-12-310000885590us-gaap:DomesticCountryMember2019-12-310000885590us-gaap:DomesticCountryMemberus-gaap:RevenueCommissionersIrelandMember2020-12-310000885590us-gaap:ForeignCountryMemberus-gaap:RevenueCommissionersIrelandMember2019-12-31bhc:subsidiary0000885590us-gaap:DomesticCountryMembersrt:MinimumMember2020-01-012020-12-310000885590us-gaap:DomesticCountryMembersrt:MaximumMember2020-01-012020-12-310000885590country:CAsrt:MinimumMember2020-01-012020-12-310000885590country:CAsrt:MaximumMember2020-01-012020-12-310000885590country:DEsrt:MinimumMember2020-01-012020-12-310000885590country:DEsrt:MaximumMember2020-01-012020-12-310000885590srt:MinimumMembercountry:FR2020-01-012020-12-310000885590country:FRsrt:MaximumMember2020-01-012020-12-310000885590srt:MinimumMembercountry:CN2020-01-012020-12-310000885590country:CNsrt:MaximumMember2020-01-012020-12-310000885590srt:MinimumMembercountry:IE2020-01-012020-12-310000885590country:IEsrt:MaximumMember2020-01-012020-12-310000885590country:NLsrt:MaximumMember2020-01-012020-12-310000885590country:NLsrt:MinimumMember2020-01-012020-12-310000885590srt:MinimumMemberus-gaap:AustralianTaxationOfficeMember2020-01-012020-12-310000885590us-gaap:AustralianTaxationOfficeMembersrt:MaximumMember2020-01-012020-12-31iso4217:CAD0000885590us-gaap:ForeignCountryMemberus-gaap:TaxYear2012Memberus-gaap:CanadaRevenueAgencyMember2020-01-012020-12-310000885590us-gaap:TaxYear2013Member2020-01-012020-12-310000885590us-gaap:ForeignCountryMemberus-gaap:CanadaRevenueAgencyMember2020-01-012020-12-310000885590us-gaap:AustralianTaxationOfficeMemberus-gaap:ForeignCountryMember2017-08-082017-08-080000885590us-gaap:StockCompensationPlanMember2020-01-012020-12-310000885590us-gaap:StockCompensationPlanMember2019-01-012019-12-310000885590us-gaap:StockCompensationPlanMember2018-01-012018-12-310000885590bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember2020-01-012020-12-310000885590bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember2019-01-012019-12-310000885590bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember2018-01-012018-12-31bhc:case0000885590stpr:NJus-gaap:UnfavorableRegulatoryActionMemberbhc:ValeantUSSecuritiesLitigationMember2015-10-012015-10-31bhc:group0000885590stpr:NJbhc:ValeantUSSecuritiesLitigationMember2020-01-012020-12-310000885590bhc:CanadianSecuritiesLitigationMembercountry:CA2016-01-012016-12-31bhc:action0000885590bhc:ViolationofCanadianProvincialSecuritiesLegislationMemberbhc:CanadianSecuritiesLitigationMembercountry:CA2020-01-012020-12-310000885590bhc:ViolationofCanadianProvincialSecuritiesLegislationMemberbhc:CanadianSecuritiesLitigationMembercountry:CAus-gaap:SettledLitigationMember2020-08-042020-08-04bhc:entity0000885590bhc:ViolationofCanadianProvincialSecuritiesLegislationMemberbhc:CanadianSecuritiesLitigationMembercountry:CA2019-02-15bhc:insurance_policy_period0000885590bhc:InsuranceCoverageLawsuitMember2017-12-072017-12-070000885590bhc:RICOClassActionsLitigationMemberstpr:NJus-gaap:UnfavorableRegulatoryActionMember2016-05-272016-09-16bhc:shareholder0000885590bhc:DerivativeLawsuitsMember2019-09-130000885590bhc:DerivativeLawsuitsMember2019-09-100000885590bhc:DerivativeLawsuitsMember2020-01-03bhc:healthPlan0000885590bhc:GenericPricingAntitrustLitigationMember2019-07-012019-07-310000885590bhc:GenericPricingAntitrustLitigationMember2020-05-012020-05-310000885590bhc:GlumetzaAntitrustLitigationMember2019-08-012020-07-300000885590bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember2019-08-012020-07-300000885590bhc:PlaintiffsDirectPurchasersMember2019-11-252019-11-250000885590bhc:GlumetzaAntitrustLitigationNonClassComplaintsMemberbhc:PlaintiffsDirectPurchasersMember2019-11-252019-11-250000885590us-gaap:PendingLitigationMemberbhc:GlumetzaAntitrustLitigationMember2020-12-310000885590bhc:SandozLitigationMember2019-09-012019-09-300000885590bhc:SandozLitigationMember2020-02-172020-02-170000885590bhc:PerrigoIsraelPharmaceuticalsLitigationMember2020-08-282020-08-280000885590bhc:PerrigoLitigationMember2020-05-012020-05-010000885590us-gaap:PendingLitigationMemberbhc:ShowertoShowerProductLiabilityLitigationMember2020-12-310000885590bhc:JohnsonJohnsonTalcumPowderLitigationMember2017-03-240000885590bhc:JohnsonJohnsonTalcumPowderLitigationMember2017-03-242017-03-240000885590bhc:JohnsonJohnsonTalcumPowderLitigationNewJerseyDivisionOfTaxationMember2020-12-310000885590bhc:JohnsonJohnsonTalcumPowderLitigationDelawareDivisionOfRevenueMember2020-12-310000885590bhc:JohnsonJohnsonTalcumPowderLitigationNewJerseyDivisionOfTaxationMember2020-01-012020-12-310000885590bhc:JohnsonJohnsonTalcumPowderLitigationMemberstpr:NJ2020-12-310000885590bhc:JohnsonJohnsonTalcumPowderLitigationMemberstpr:OH2020-12-310000885590country:CAbhc:ShowertoShowerProductLiabilityLitigationMember2020-12-310000885590stpr:CA-BCbhc:ShowertoShowerProductLiabilityLitigationMember2020-12-310000885590bhc:ShowertoShowerProductLiabilityLitigationMemberstpr:CA-QC2020-12-310000885590bhc:DoctorsAllergyFormulaLLCLitigationMember2018-04-012018-04-300000885590bhc:LitigationwithFormerSalixCEOMember2019-01-282019-01-280000885590bhc:SECInvestigationLitigationMemberus-gaap:SettledLitigationMember2020-01-012020-12-31bhc:manufacturer0000885590bhc:ContactLensAntitrustClassActionsMemberus-gaap:SettledLitigationMember2016-03-310000885590bhc:ContactLensAntitrustClassActionsMemberus-gaap:SettledLitigationMember2019-08-192019-08-190000885590bhc:MississippiAttorneyGeneralConsumerProtectionActionLitigationMemberus-gaap:SettledLitigationMember2020-01-012020-12-310000885590bhc:InvestigationbytheStateofTexasStatesMedicaidProgramMemberus-gaap:SettledLitigationMember2020-04-012020-04-010000885590bhc:SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member2020-12-310000885590bhc:MitsubishiTanabePharmaCorporationMember2020-12-310000885590bhc:NovaliqGmbHMember2020-12-310000885590bhc:CedarsSinaiMedicalCenterMember2020-12-310000885590bhc:EyenoviaIncMember2020-12-310000885590bhc:AllegroOphthalmicsLLCMember2020-09-012020-09-300000885590us-gaap:OperatingSegmentsMemberbhc:BaushandLombInternationalSegmentMember2020-01-012020-12-310000885590us-gaap:OperatingSegmentsMemberbhc:BaushandLombInternationalSegmentMember2019-01-012019-12-310000885590us-gaap:OperatingSegmentsMemberbhc:BaushandLombInternationalSegmentMember2018-01-012018-12-310000885590us-gaap:OperatingSegmentsMemberbhc:SalixSegmentMember2020-01-012020-12-310000885590us-gaap:OperatingSegmentsMemberbhc:SalixSegmentMember2019-01-012019-12-310000885590us-gaap:OperatingSegmentsMemberbhc:SalixSegmentMember2018-01-012018-12-310000885590us-gaap:OperatingSegmentsMemberbhc:OrthoDermatologicsSegmentMember2020-01-012020-12-310000885590us-gaap:OperatingSegmentsMemberbhc:OrthoDermatologicsSegmentMember2019-01-012019-12-310000885590us-gaap:OperatingSegmentsMemberbhc:OrthoDermatologicsSegmentMember2018-01-012018-12-310000885590bhc:DiversifiedProductsSegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310000885590bhc:DiversifiedProductsSegmentMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310000885590bhc:DiversifiedProductsSegmentMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310000885590us-gaap:OperatingSegmentsMember2020-01-012020-12-310000885590us-gaap:OperatingSegmentsMember2019-01-012019-12-310000885590us-gaap:OperatingSegmentsMember2018-01-012018-12-310000885590us-gaap:CorporateNonSegmentMember2020-01-012020-12-310000885590us-gaap:CorporateNonSegmentMember2019-01-012019-12-310000885590us-gaap:CorporateNonSegmentMember2018-01-012018-12-310000885590bhc:RevenuesNetMemberus-gaap:ProductConcentrationRiskMember2020-01-012020-12-310000885590bhc:RevenuesNetMemberus-gaap:ProductConcentrationRiskMember2019-01-012019-12-310000885590bhc:RevenuesNetMemberus-gaap:ProductConcentrationRiskMember2018-01-012018-12-310000885590bhc:PharmaceuticalProductsMemberbhc:BaushandLombInternationalSegmentMember2020-01-012020-12-310000885590bhc:PharmaceuticalProductsMemberbhc:BaushandLombInternationalSegmentMember2019-01-012019-12-310000885590bhc:PharmaceuticalProductsMemberbhc:BaushandLombInternationalSegmentMember2018-01-012018-12-310000885590bhc:PharmaceuticalProductsMemberbhc:SalixSegmentMember2020-01-012020-12-310000885590bhc:PharmaceuticalProductsMemberbhc:SalixSegmentMember2019-01-012019-12-310000885590bhc:PharmaceuticalProductsMemberbhc:SalixSegmentMember2018-01-012018-12-310000885590bhc:PharmaceuticalProductsMemberbhc:OrthoDermatologicsSegmentMember2020-01-012020-12-310000885590bhc:PharmaceuticalProductsMemberbhc:OrthoDermatologicsSegmentMember2019-01-012019-12-310000885590bhc:PharmaceuticalProductsMemberbhc:OrthoDermatologicsSegmentMember2018-01-012018-12-310000885590bhc:DiversifiedProductsSegmentMemberbhc:PharmaceuticalProductsMember2020-01-012020-12-310000885590bhc:DiversifiedProductsSegmentMemberbhc:PharmaceuticalProductsMember2019-01-012019-12-310000885590bhc:DiversifiedProductsSegmentMemberbhc:PharmaceuticalProductsMember2018-01-012018-12-310000885590bhc:PharmaceuticalProductsMember2020-01-012020-12-310000885590bhc:PharmaceuticalProductsMember2019-01-012019-12-310000885590bhc:PharmaceuticalProductsMember2018-01-012018-12-310000885590bhc:BaushandLombInternationalSegmentMemberbhc:DeviceProductsMember2020-01-012020-12-310000885590bhc:BaushandLombInternationalSegmentMemberbhc:DeviceProductsMember2019-01-012019-12-310000885590bhc:BaushandLombInternationalSegmentMemberbhc:DeviceProductsMember2018-01-012018-12-310000885590bhc:SalixSegmentMemberbhc:DeviceProductsMember2020-01-012020-12-310000885590bhc:SalixSegmentMemberbhc:DeviceProductsMember2019-01-012019-12-310000885590bhc:SalixSegmentMemberbhc:DeviceProductsMember2018-01-012018-12-310000885590bhc:DeviceProductsMemberbhc:OrthoDermatologicsSegmentMember2020-01-012020-12-310000885590bhc:DeviceProductsMemberbhc:OrthoDermatologicsSegmentMember2019-01-012019-12-310000885590bhc:DeviceProductsMemberbhc:OrthoDermatologicsSegmentMember2018-01-012018-12-310000885590bhc:DiversifiedProductsSegmentMemberbhc:DeviceProductsMember2020-01-012020-12-310000885590bhc:DiversifiedProductsSegmentMemberbhc:DeviceProductsMember2019-01-012019-12-310000885590bhc:DiversifiedProductsSegmentMemberbhc:DeviceProductsMember2018-01-012018-12-310000885590bhc:DeviceProductsMember2020-01-012020-12-310000885590bhc:DeviceProductsMember2019-01-012019-12-310000885590bhc:DeviceProductsMember2018-01-012018-12-310000885590bhc:BaushandLombInternationalSegmentMemberbhc:OvertheCounterProductsMember2020-01-012020-12-310000885590bhc:BaushandLombInternationalSegmentMemberbhc:OvertheCounterProductsMember2019-01-012019-12-310000885590bhc:BaushandLombInternationalSegmentMemberbhc:OvertheCounterProductsMember2018-01-012018-12-310000885590bhc:SalixSegmentMemberbhc:OvertheCounterProductsMember2020-01-012020-12-310000885590bhc:SalixSegmentMemberbhc:OvertheCounterProductsMember2019-01-012019-12-310000885590bhc:SalixSegmentMemberbhc:OvertheCounterProductsMember2018-01-012018-12-310000885590bhc:OvertheCounterProductsMemberbhc:OrthoDermatologicsSegmentMember2020-01-012020-12-310000885590bhc:OvertheCounterProductsMemberbhc:OrthoDermatologicsSegmentMember2019-01-012019-12-310000885590bhc:OvertheCounterProductsMemberbhc:OrthoDermatologicsSegmentMember2018-01-012018-12-310000885590bhc:DiversifiedProductsSegmentMemberbhc:OvertheCounterProductsMember2020-01-012020-12-310000885590bhc:DiversifiedProductsSegmentMemberbhc:OvertheCounterProductsMember2019-01-012019-12-310000885590bhc:DiversifiedProductsSegmentMemberbhc:OvertheCounterProductsMember2018-01-012018-12-310000885590bhc:OvertheCounterProductsMember2020-01-012020-12-310000885590bhc:OvertheCounterProductsMember2019-01-012019-12-310000885590bhc:OvertheCounterProductsMember2018-01-012018-12-310000885590bhc:BaushandLombInternationalSegmentMemberbhc:BrandedandOtherGenericProductsMember2020-01-012020-12-310000885590bhc:BaushandLombInternationalSegmentMemberbhc:BrandedandOtherGenericProductsMember2019-01-012019-12-310000885590bhc:BaushandLombInternationalSegmentMemberbhc:BrandedandOtherGenericProductsMember2018-01-012018-12-310000885590bhc:SalixSegmentMemberbhc:BrandedandOtherGenericProductsMember2020-01-012020-12-310000885590bhc:SalixSegmentMemberbhc:BrandedandOtherGenericProductsMember2019-01-012019-12-310000885590bhc:SalixSegmentMemberbhc:BrandedandOtherGenericProductsMember2018-01-012018-12-310000885590bhc:BrandedandOtherGenericProductsMemberbhc:OrthoDermatologicsSegmentMember2020-01-012020-12-310000885590bhc:BrandedandOtherGenericProductsMemberbhc:OrthoDermatologicsSegmentMember2019-01-012019-12-310000885590bhc:BrandedandOtherGenericProductsMemberbhc:OrthoDermatologicsSegmentMember2018-01-012018-12-310000885590bhc:DiversifiedProductsSegmentMemberbhc:BrandedandOtherGenericProductsMember2020-01-012020-12-310000885590bhc:DiversifiedProductsSegmentMemberbhc:BrandedandOtherGenericProductsMember2019-01-012019-12-310000885590bhc:DiversifiedProductsSegmentMemberbhc:BrandedandOtherGenericProductsMember2018-01-012018-12-310000885590bhc:BrandedandOtherGenericProductsMember2020-01-012020-12-310000885590bhc:BrandedandOtherGenericProductsMember2019-01-012019-12-310000885590bhc:BrandedandOtherGenericProductsMember2018-01-012018-12-310000885590bhc:BaushandLombInternationalSegmentMemberbhc:OtherRevenuesMember2020-01-012020-12-310000885590bhc:BaushandLombInternationalSegmentMemberbhc:OtherRevenuesMember2019-01-012019-12-310000885590bhc:BaushandLombInternationalSegmentMemberbhc:OtherRevenuesMember2018-01-012018-12-310000885590bhc:SalixSegmentMemberbhc:OtherRevenuesMember2020-01-012020-12-310000885590bhc:SalixSegmentMemberbhc:OtherRevenuesMember2019-01-012019-12-310000885590bhc:SalixSegmentMemberbhc:OtherRevenuesMember2018-01-012018-12-310000885590bhc:OtherRevenuesMemberbhc:OrthoDermatologicsSegmentMember2020-01-012020-12-310000885590bhc:OtherRevenuesMemberbhc:OrthoDermatologicsSegmentMember2019-01-012019-12-310000885590bhc:OtherRevenuesMemberbhc:OrthoDermatologicsSegmentMember2018-01-012018-12-310000885590bhc:DiversifiedProductsSegmentMemberbhc:OtherRevenuesMember2020-01-012020-12-310000885590bhc:DiversifiedProductsSegmentMemberbhc:OtherRevenuesMember2019-01-012019-12-310000885590bhc:DiversifiedProductsSegmentMemberbhc:OtherRevenuesMember2018-01-012018-12-310000885590bhc:OtherRevenuesMember2020-01-012020-12-310000885590bhc:OtherRevenuesMember2019-01-012019-12-310000885590bhc:OtherRevenuesMember2018-01-012018-12-310000885590bhc:BaushandLombInternationalSegmentMember2020-01-012020-12-310000885590bhc:BaushandLombInternationalSegmentMember2019-01-012019-12-310000885590bhc:BaushandLombInternationalSegmentMember2018-01-012018-12-310000885590bhc:SalixSegmentMember2020-01-012020-12-310000885590bhc:OrthoDermatologicsSegmentMember2020-01-012020-12-310000885590bhc:OrthoDermatologicsSegmentMember2019-01-012019-12-310000885590bhc:DiversifiedProductsSegmentMember2020-01-012020-12-310000885590bhc:DiversifiedProductsSegmentMember2019-01-012019-12-310000885590bhc:UnitedStatesandPuertoRicoMember2020-01-012020-12-310000885590bhc:UnitedStatesandPuertoRicoMember2019-01-012019-12-310000885590bhc:UnitedStatesandPuertoRicoMember2018-01-012018-12-310000885590country:CN2020-01-012020-12-310000885590country:CN2019-01-012019-12-310000885590country:CN2018-01-012018-12-310000885590country:CA2020-01-012020-12-310000885590country:CA2019-01-012019-12-310000885590country:CA2018-01-012018-12-310000885590country:EG2020-01-012020-12-310000885590country:EG2019-01-012019-12-310000885590country:EG2018-01-012018-12-310000885590country:PL2020-01-012020-12-310000885590country:PL2019-01-012019-12-310000885590country:PL2018-01-012018-12-310000885590country:JP2020-01-012020-12-310000885590country:JP2019-01-012019-12-310000885590country:JP2018-01-012018-12-310000885590country:MX2020-01-012020-12-310000885590country:MX2019-01-012019-12-310000885590country:MX2018-01-012018-12-310000885590country:FR2020-01-012020-12-310000885590country:FR2019-01-012019-12-310000885590country:FR2018-01-012018-12-310000885590country:DE2020-01-012020-12-310000885590country:DE2019-01-012019-12-310000885590country:DE2018-01-012018-12-310000885590country:RU2020-01-012020-12-310000885590country:RU2019-01-012019-12-310000885590country:RU2018-01-012018-12-310000885590country:GB2020-01-012020-12-310000885590country:GB2019-01-012019-12-310000885590country:GB2018-01-012018-12-310000885590country:ES2020-01-012020-12-310000885590country:ES2019-01-012019-12-310000885590country:ES2018-01-012018-12-310000885590bhc:OtherCountriesMember2020-01-012020-12-310000885590bhc:OtherCountriesMember2019-01-012019-12-310000885590bhc:OtherCountriesMember2018-01-012018-12-310000885590bhc:UnitedStatesandPuertoRicoMember2020-12-310000885590bhc:UnitedStatesandPuertoRicoMember2019-12-310000885590country:IE2020-12-310000885590country:IE2019-12-310000885590country:CA2020-12-310000885590country:CA2019-12-310000885590country:PL2020-12-310000885590country:PL2019-12-310000885590country:DE2020-12-310000885590country:DE2019-12-310000885590country:MX2020-12-310000885590country:MX2019-12-310000885590country:FR2020-12-310000885590country:FR2019-12-310000885590country:CN2020-12-310000885590country:CN2019-12-310000885590country:RS2020-12-310000885590country:RS2019-12-310000885590country:IT2020-12-310000885590country:IT2019-12-310000885590bhc:OtherCountriesMember2020-12-310000885590bhc:OtherCountriesMember2019-12-310000885590bhc:McKessonCorporationMemberus-gaap:CustomerConcentrationRiskMemberbhc:RevenuesNetMember2020-01-012020-12-310000885590bhc:McKessonCorporationMemberus-gaap:CustomerConcentrationRiskMemberbhc:RevenuesNetMember2019-01-012019-12-310000885590bhc:McKessonCorporationMemberus-gaap:CustomerConcentrationRiskMemberbhc:RevenuesNetMember2018-01-012018-12-310000885590bhc:AmerisourceBergenCorporationMemberus-gaap:CustomerConcentrationRiskMemberbhc:RevenuesNetMember2020-01-012020-12-310000885590bhc:AmerisourceBergenCorporationMemberus-gaap:CustomerConcentrationRiskMemberbhc:RevenuesNetMember2019-01-012019-12-310000885590bhc:AmerisourceBergenCorporationMemberus-gaap:CustomerConcentrationRiskMemberbhc:RevenuesNetMember2018-01-012018-12-310000885590bhc:CardinalHealthIncMemberus-gaap:CustomerConcentrationRiskMemberbhc:RevenuesNetMember2020-01-012020-12-310000885590bhc:CardinalHealthIncMemberus-gaap:CustomerConcentrationRiskMemberbhc:RevenuesNetMember2019-01-012019-12-310000885590bhc:CardinalHealthIncMemberus-gaap:CustomerConcentrationRiskMemberbhc:RevenuesNetMember2018-01-012018-12-3100008855902020-01-012020-03-3100008855902019-01-012019-03-3100008855902019-04-012019-06-3000008855902019-07-012019-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Fiscal Year EndedDecember 31, 2020
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____________ to ____________
Commission File Number: 001-14956
Bausch Health Companies Inc.
(Exact Name of Registrant as Specified in its Charter)
British Columbia,
Canada
98-0448205
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
2150 St. Elzéar Blvd. West, Laval, Québec, Canada H7L 4A8
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (514744-6792
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Shares, No Par ValueBHCNew York Stock Exchange,Toronto Stock Exchange
Securities registered pursuant to section 12(g) of the Act:
None
(Title of class)
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ý    No o
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o    No ý
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý    No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ý    No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
x
Accelerated filer Non-accelerated filer
(Do not check if a smaller
reporting company)
Smaller reporting companyEmerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No 
The aggregate market value of the common shares held by non-affiliates of the registrant as of the last business day of the registrant’s most recently completed second fiscal quarter was $5,664,997,951 based on the last reported sale price on the New York Stock Exchange on June 30, 2020.
The number of outstanding shares of the registrant’s common stock as of February 18, 2021 was 355,619,826.
DOCUMENTS INCORPORATED BY REFERENCE
Part III incorporates certain information by reference from the registrant’s proxy statement for the 2021 Annual Meeting of Shareholders. Such proxy statement will be filed no later than 120 days after the close of the registrant’s fiscal year ended December 31, 2020.


TABLE OF CONTENTS

GENERAL INFORMATION
    Page
PART I
Item 1. Business 
Item 1A. Risk Factors 
Item 1B. Unresolved Staff Comments 
Item 2. Properties 
Item 3. Legal Proceedings 
Item 4. Mine Safety Disclosures 
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 
Item 6.Selected Financial Data
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 
Item 8. Financial Statements and Supplementary Data 
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 
Item 9A. Controls and Procedures 
Item 9B. Other Information 
PART III
Item 10. Directors, Executive Officers and Corporate Governance 
Item 11. Executive Compensation 
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 
Item 13. Certain Relationships and Related Transactions, and Director Independence 
Item 14. Principal Accounting Fees and Services 
PART IV
Item 15. Exhibits and Financial Statement Schedules 
Item 16. Form 10-K Summary
SIGNATURES 
i


Basis of Presentation
General
Except where the context otherwise requires, all references in this Annual Report on Form 10-K (“Form 10-K”) to the “Company”, “we”, “us”, “our” or similar words or phrases are to Bausch Health Companies Inc. and its subsidiaries, taken together. In this Form 10-K, references to “$” or “USD” are to United States dollars, references to “€” are to Euros, and references to “CAD” are to Canadian dollars. Unless otherwise indicated, the statistical and financial data contained in this Form 10-K are presented as of December 31, 2020.
Trademarks
The following words are some of the trademarks in our Company’s trademark portfolio and are the subject of either registration, or application for registration, in one or more of Canada, the United States of America (the “U.S.”) or certain other jurisdictions: AERGEL®, AKREOS®, ALAWAY®, ALREX®, ALTRENO®, AMMONUL®, APLENZIN®, APRISO®, AQUALOX®, ARAZLO®, ARESTIN®, ARTELAC®, ATIVAN®, B & L®, B + L®, BAUSCH & LOMB®, BAUSCH + LOMB®, BAUSCH + LOMB ULTRA®, BAUSCH HEALTH®, BAUSCH HEALTH COMPANIES®, BEDOYECTA®, BENZACLIN®, BEPREVE®, BESIVANCE®, BIOTRUE®, BISOCARD®, BOSTON®, BRYHALI®, BUPAP®, CARAC®, CARDIZEM®, CLEAR + BRILLIANT®, CLINDAGEL®, COLD FX®. COMFORTMOIST®, CRYSTALENS®, CUPRIMINE®, DIASTAT®, DUOBRII®, EDECRIN®, ENVISTA®, ESPAVEN®, FRAXEL®, GLUMETZA®, ISTALOL®, IVEXTERM®, JUBLIA®, LIBRAX®, LOTEMAX®, LUMIFY®, LUXGOOD, LUXSMART, LUZU®, MEDICIS®, MEPHYTON®, MIGRANAL®, MOISTURESEAL®, NEUTRASAL®, NORITATE®, OCUVITE®, ONEXTON®, OPTICALIGN®, ORTHO DERMATOLOGICS®, PRESERVISION®, PROLENSA®, PUREVISION®, RELISTOR®, RENU®, RENU MULTIPLUS®, RETIN-A®, RETIN-A MICRO®, SALIX®, SCLERALFIL®, SECONAL SODIUM®, SHOWER TO SHOWER®, SILIQ®, SILSOFT®, SOFLENS®, SOLODYN®, SOLTA MEDICAL®, STELLARIS®, STELLARIS ELITE®, SYNERGETICS®, SYPRINE®, TARGRETIN®, THERMAGE®, THERMAGE FLX®, THROMBO ASS®, TRULANCE®, TRULIGN®, UCERIS®, VALEANT®, VASERLIPO®, VICTUS®, VIRAZOLE®, VITESSE®, VYZULTA®, XENAZINE®, ZEGERID®, ZIANA®, and ZYLET®.
In addition to the trademarks previously noted, we have filed trademark applications and/or obtained trademark registrations for many of our other trademarks in the U.S., Canada and in other jurisdictions and have implemented, on an ongoing basis, a trademark protection program for new trademarks.
WELLBUTRIN®, WELLBUTRIN XL® and ZOVIRAX® are trademarks of GlaxoSmithKline LLC and are used by us under license. ELIDEL® and XERESE® are registered trademarks of Meda Pharma SARL and are used by us under license. EMERADE® is a registered trademark of Medeca Pharma AB and is used by us under license. ISUPREL® and NITROPRESS® are registered trademarks of Hospira, Inc. and are used by us under license. XIFAXAN® is a registered trademark of Alfasigma S.p.A. and is used by us under license. PEPCID® is a brand of Johnson & Johnson and is used by us under license. MOVIPREP® is a registered trademark of Velinor AG and is used by us under license. PLENVU® is a registered trademark of Velinor AG and is used by us under license. LOCOID® is a registered trademark of Leo Pharma A/S and is used by us under license. TANGIBLE® and HYDRA-PEG® are registered trademarks of Tangible Science, LLC and are used by us under license. LUMINATE® is a registered trademark of Allegro Ophthalmics, LLC and we have entered into an agreement for an option to acquire all ophthalmology assets of Allegro Ophthalmics, LLC. XIPERE is a trademark of Clearside Biomedical, Inc. and is used by us under license. CONTRAVE® and MYSIMBA® are used by us under license.
Forward-Looking Statements
Caution regarding forward-looking information and statements and “Safe-Harbor” statements under the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws:
To the extent any statements made in this Form 10-K contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, “forward-looking statements”).
These forward-looking statements relate to, among other things: our business strategy, business plans and prospects and forecasts and changes thereto; product pipeline, prospective products and product approvals, product development and future performance and results of current and anticipated products; anticipated revenues for our products; anticipated growth in our Ortho Dermatologics business; expected research and development ("R&D") and marketing spend; our expected primary cash and working capital requirements for 2021 and beyond; our plans for continued improvement in operational efficiency and the anticipated impact of such plans; our liquidity and our ability to satisfy our debt maturities as they become due; our ability to reduce debt levels; our ability to meet the financial and other covenants contained in our Fourth Amended and Restated Credit
ii


and Guaranty Agreement (the "Restated Credit Agreement") and senior notes indentures; the impact of our distribution, fulfillment and other third-party arrangements; proposed pricing actions; exposure to foreign currency exchange rate changes and interest rate changes; the outcome of contingencies, such as litigation, subpoenas, investigations, reviews, audits and regulatory proceedings; the anticipated impact of the adoption of new accounting standards; general market conditions; our expectations regarding our financial performance, including revenues, expenses, gross margins and income taxes; our impairment assessments, including the assumptions used therein and the results thereof; the anticipated impact of the evolving COVID-19 pandemic and related responses from governments and private sector participants on the Company, its supply chain, third-party suppliers, project development timelines, costs, revenue, margins, liquidity and financial condition, the anticipated timing, speed and magnitude of recovery from these COVID-19 pandemic related impacts and the Company’s planned actions and responses to this pandemic; and the Company’s plan to separate its eye-health business, including the structure and timing of completing such separation transaction.
Forward-looking statements can generally be identified by the use of words such as “believe”, “anticipate”, “expect”, “intend”, “estimate”, “plan”, “continue”, “will”, “may”, “could”, “would”, “should”, “target”, “potential”, “opportunity”, “designed”, “create”, “predict”, “project”, “forecast”, “seek”, “strive”, “ongoing” or “increase” and variations or other similar expressions. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements may not be appropriate for other purposes. Although we have previously indicated certain of these statements set out herein, all of the statements in this Form 10-K that contain forward-looking statements are qualified by these cautionary statements. These statements are based upon the current expectations and beliefs of management. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making such forward-looking statements, including, but not limited to, factors and assumptions regarding the items previously outlined, those factors, risks and uncertainties outlined below and the assumption that none of these factors, risks and uncertainties will cause actual results or events to differ materially from those described in such forward-looking statements. Actual results may differ materially from those expressed or implied in such statements. Important factors, risks and uncertainties that could cause actual results to differ materially from these expectations include, among other things, the following:
the risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, the fear of that pandemic, the availability and effectiveness of vaccines for COVID-19, the rapidly evolving reaction of governments, private sector participants and the public to that pandemic, and the potential effects and economic impact of the pandemic and the reaction to it, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a significant adverse impact on the Company, including but not limited to its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition and costs (which may increase) and revenue and margins (both of which may decrease);
with respect to the proposed separation of the Company’s eye-health business, the risks and uncertainties include, but are not limited to, the expected benefits and costs of the separation transaction, the expected timing of completion of the separation transaction and its terms, the Company’s ability to complete the separation transaction considering the various conditions to the completion of the separation transaction (some of which are outside the Company’s control, including conditions related to regulatory matters and a possible shareholder vote, if applicable), that market or other conditions are no longer favorable to completing the transaction, that any shareholder, stock exchange, regulatory or other approval (if required) is not obtained on the terms or timelines anticipated or at all, business disruption during the pendency of or following the separation transaction, diversion of management time on separation transaction-related issues, retention of existing management team members, the reaction of customers and other parties to the separation transaction, the qualification of the separation transaction as a tax-free transaction for Canadian and/or U.S. federal income tax purposes (including whether or not an advance ruling from either or both of the Canada Revenue Agency and the Internal Revenue Service will be sought or obtained), potential dyssynergy costs resulting from the separation transaction, the impact of the separation transaction on relationships with customers, suppliers, employees and other business counterparties, general economic conditions, conditions in the markets the Company is engaged in, behavior of customers, suppliers and competitors, technological developments, as well as legal and regulatory rules affecting the Company’s business;
the expense, timing and outcome of legal and governmental proceedings, investigations and information requests relating to, among other matters, our past distribution, marketing, pricing, disclosure and accounting practices (including with respect to our former relationship with Philidor Rx Services, LLC ("Philidor")), including a number of pending non-class securities litigations (including certain pending opt-out actions in the U.S. related to the previously settled securities class action (which remains subject to an objector's appeal of the Court's final approval order) and certain opt-out actions in Canada relating to the recently settled class action in Canada) and purported class actions
iii


under the federal RICO statute and other claims, investigations or proceedings that may be initiated or that may be asserted;
potential additional litigation and regulatory investigations (and any costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom), negative publicity and reputational harm on our Company, products and business that may result from the past and ongoing public scrutiny of our past distribution, marketing, pricing, disclosure and accounting practices and from our former relationship with Philidor;
the past and ongoing scrutiny of our legacy business practices, including with respect to pricing, and any pricing controls or price adjustments that may be sought or imposed on our products as a result thereof;
pricing decisions that we have implemented, or may in the future elect to implement, such as the Patient Access and Pricing Committee’s commitment that the average annual price increase for our branded prescription pharmaceutical products will be set at no greater than single digits, or any future pricing actions we may take following review by our Patient Access and Pricing Committee (which is responsible for the pricing of our drugs);
legislative or policy efforts, including those that may be introduced and passed by the U.S. Congress, designed to reduce patient out-of-pocket costs for medicines, which could result in new mandatory rebates and discounts or other pricing restrictions, controls or regulations (including mandatory price reductions);
ongoing oversight and review of our products and facilities by regulatory and governmental agencies, including periodic audits by the U.S. Food and Drug Administration (the "FDA") and equivalent agencies outside of the U.S. and the results thereof;
actions by the FDA or other regulatory authorities with respect to our products or facilities;
our substantial debt (and potential additional future indebtedness) and current and future debt service obligations, our ability to reduce our outstanding debt levels and the resulting impact on our financial condition, cash flows and results of operations;
our ability to meet the financial and other covenants contained in our Restated Credit Agreement, senior notes indentures, 2023 Revolving Credit Facility (as defined below) and other current or future debt agreements and the limitations, restrictions and prohibitions such covenants impose or may impose on the way we conduct our business, including prohibitions on incurring additional debt if certain financial covenants are not met, limitations on the amount of additional obligations we are able to incur pursuant to other covenants, our ability to draw under our 2023 Revolving Credit Facility and restrictions on our ability to make certain investments and other restricted payments;
any default under the terms of our senior notes indentures or Restated Credit Agreement and our ability, if any, to cure or obtain waivers of such default;
any downgrade by rating agencies in our credit ratings, which may impact, among other things, our ability to raise debt and the cost of capital for additional debt issuances;
any reductions in, or changes in the assumptions used in, our forecasts for fiscal year 2021 or beyond, including as a result of the impacts of the COVID-19 pandemic on our business and operations, which could lead to, among other things: (i) a failure to meet the financial and/or other covenants contained in our Restated Credit Agreement and/or senior notes indentures and/or (ii) impairment in the goodwill associated with certain of our reporting units or impairment charges related to certain of our products or other intangible assets, which impairments could be material;
changes in the assumptions used in connection with our impairment analyses or assessments, which would lead to a change in such impairment analyses and assessments and which could result in an impairment in the goodwill associated with any of our reporting units or impairment charges related to certain of our products or other intangible assets;
the uncertainties associated with the acquisition and launch of new products, including, but not limited to, our ability to provide the time, resources, expertise and funds required for the commercial launch of new products, the acceptance and demand for new pharmaceutical products, and the impact of competitive products and pricing, which could lead to material impairment charges;
our ability or inability to extend the profitable life of our products, including through line extensions and other life-cycle programs;
our ability to retain, motivate and recruit executives and other key employees;
iv


our ability to implement effective succession planning for our executives and key employees;
factors impacting our ability to achieve anticipated growth in our Ortho Dermatologics business, including the success of recently launched products (such as Arazlo®), expected geographic expansion in our Solta business (including with respect to Next Generation Thermage FLX®), the ability to successfully implement and operate our cash-pay prescription program for certain of our Ortho Dermatologics branded products, and the ability of such program to achieve the anticipated goals respecting patient access and fulfillment, the approval of pending and pipeline products (and the timing of such approvals), changes in estimates on market potential for dermatology products and continued investment in and success of our sales force;
factors impacting our ability to achieve anticipated revenues for our products, including changes in anticipated marketing spend on such products and launch of competing products;
the challenges and difficulties associated with managing a large complex business, which has, in the past, grown rapidly;
our ability to compete against companies that are larger and have greater financial, technical and human resources than we do, as well as other competitive factors, such as technological advances achieved, patents obtained and new products introduced by our competitors;
our ability to effectively operate and grow our businesses in light of the challenges that the Company has faced and market conditions, including with respect to its substantial debt, pending investigations and legal proceedings, scrutiny of our past pricing and other practices, limitations on the way we conduct business imposed by the covenants contained in our Restated Credit Agreement, senior notes indentures and the agreements governing our other indebtedness, and the impacts of the COVID-19 pandemic;
the extent to which our products are reimbursed by government authorities, pharmacy benefit managers ("PBMs") and other third-party payors; the impact our distribution, pricing and other practices may have on the decisions of such government authorities, PBMs and other third-party payors to reimburse our products; and the impact of obtaining or maintaining such reimbursement on the price and sales of our products;
the inclusion of our products on formularies or our ability to achieve favorable formulary status, as well as the impact on the price and sales of our products in connection therewith;
the consolidation of wholesalers, retail drug chains and other customer groups and the impact of such industry consolidation on our business;
our eligibility for benefits under tax treaties and the continued availability of low effective tax rates for the business profits of certain of our subsidiaries;
the actions of our third-party partners or service providers of research, development, manufacturing, marketing, distribution or other services, including their compliance with applicable laws and contracts, which actions may be beyond our control or influence, and the impact of such actions on our Company, including the impact to the Company of our former relationship with Philidor and any alleged legal or contractual non-compliance by Philidor;
the risks associated with the international scope of our operations, including our presence in emerging markets and the challenges we face when entering and operating in new and different geographic markets (including the challenges created by new and different regulatory regimes in such countries and the need to comply with applicable anti-bribery and economic sanctions laws and regulations);
adverse global economic conditions and credit markets and foreign currency exchange uncertainty and volatility in certain of the countries in which we do business;
the impact of the United States-Mexico-Canada Agreement (“USMCA”) and any potential changes to other trade agreements;
the final outcome and impact of Brexit negotiations;
the trade conflict between the United States and China;
our ability to obtain, maintain and license sufficient intellectual property rights over our products and enforce and defend against challenges to such intellectual property (such as in connection with the filing by Norwich Pharmaceuticals Inc. (“Norwich”) of its Abbreviated New Drug Application (“ANDA”) for Xifaxan® (rifaximin) 550 mg tablets and the Company’s related lawsuit filed against Norwich in connection therewith);
v


the introduction of generic, biosimilar or other competitors of our branded products and other products, including the introduction of products that compete against our products that do not have patent or data exclusivity rights;
our ability to identify, finance, acquire, close and integrate acquisition targets successfully and on a timely basis and the difficulties, challenges, time and resources associated with the integration of acquired companies, businesses and products;
any divestitures of our assets or businesses and our ability to successfully complete any such divestitures on commercially reasonable terms and on a timely basis, or at all, and the impact of any such divestitures on our Company, including the reduction in the size or scope of our business or market share, loss of revenue, any loss on sale, including any resultant impairments of goodwill or other assets, or any adverse tax consequences suffered as a result of any such divestitures;
the expense, timing and outcome of pending or future legal and governmental proceedings, arbitrations, investigations, subpoenas, tax and other regulatory audits, examinations, reviews and regulatory proceedings against us or relating to us and settlements thereof;
our ability to negotiate the terms of or obtain court approval for the settlement of certain legal and regulatory proceedings;
our ability to obtain components, raw materials or finished products supplied by third parties (some of which may be single-sourced) and other manufacturing and related supply difficulties, interruptions and delays;
the disruption of delivery of our products and the routine flow of manufactured goods;
economic factors over which the Company has no control, including changes in inflation, interest rates, foreign currency rates, and the potential effect of such factors on revenues, expenses and resulting margins;
interest rate risks associated with our floating rate debt borrowings;
our ability to effectively distribute our products and the effectiveness and success of our distribution arrangements, including the impact of our arrangements with Walgreen Co. (“Walgreens”);
our ability to effectively promote our own products and those of our co-promotion partners;
the success of our fulfillment arrangements with Walgreens, including market acceptance of, or market reaction to, such arrangements (including by customers, doctors, patients, PBMs, third-party payors and governmental agencies), and the continued compliance of such arrangements with applicable laws;
our ability to secure and maintain third-party research, development, manufacturing, licensing, marketing or distribution arrangements;
the risk that our products could cause, or be alleged to cause, personal injury and adverse effects, leading to potential lawsuits, product liability claims and damages and/or recalls or withdrawals of products from the market;
the mandatory or voluntary recall or withdrawal of our products from the market and the costs associated therewith;
the availability of, and our ability to obtain and maintain, adequate insurance coverage and/or our ability to cover or insure against the total amount of the claims and liabilities we face, whether through third-party insurance or self-insurance;
the difficulty in predicting the expense, timing and outcome within our legal and regulatory environment, including with respect to approvals by the FDA, Health Canada and similar agencies in other countries, legal and regulatory proceedings and settlements thereof, the protection afforded by our patents and other intellectual and proprietary property, successful generic challenges to our products and infringement or alleged infringement of the intellectual property of others;
the results of continuing safety and efficacy studies by industry and government agencies;
the success of preclinical and clinical trials for our drug development pipeline or delays in clinical trials that adversely impact the timely commercialization of our pipeline products, as well as other factors impacting the commercial success of our products, which could lead to material impairment charges;
vi


the results of management reviews of our research and development portfolio (including following the receipt of clinical results or feedback from the FDA or other regulatory authorities), which could result in terminations of specific projects which, in turn, could lead to material impairment charges;
the seasonality of sales of certain of our products;
declines in the pricing and sales volume of certain of our products that are distributed or marketed by third parties, over which we have no or limited control;
compliance by the Company or our third-party partners and service providers (over whom we may have limited influence), or the failure of our Company or these third parties to comply, with health care “fraud and abuse” laws and other extensive regulation of our marketing, promotional and business practices (including with respect to pricing), worldwide anti-bribery laws (including the U.S. Foreign Corrupt Practices Act and the Canadian Corruption of Foreign Public Officials Act), worldwide economic sanctions and/or export laws, worldwide environmental laws and regulation and privacy and security regulations;
the impacts of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the “Health Care Reform Act”) and potential amendment thereof and other legislative and regulatory health care reforms in the countries in which we operate, including with respect to recent government inquiries on pricing;
the impact of any changes in or reforms to the legislation, laws, rules, regulation and guidance that apply to the Company and its businesses and products or the enactment of any new or proposed legislation, laws, rules, regulations or guidance that will impact or apply to the Company or its businesses or products;
the impact of changes in federal laws and policy that may be undertaken following the change in the U.S. administration;
illegal distribution or sale of counterfeit versions of our products;
interruptions, breakdowns or breaches in our information technology systems; and
risks in Item 1A. “Risk Factors” in this Form 10-K.
Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found elsewhere in this Form 10-K, under Item 1A. "Risk Factors" and in the Company's other filings with the U.S. Securities and Exchange Commission (the “SEC”) and the Canadian Securities Administrators (the “CSA”). When relying on our forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. These forward-looking statements speak only as of the date made. We undertake no obligation to update or revise any of these forward-looking statements to reflect events or circumstances after the date of this Form 10-K or to reflect actual outcomes, except as required by law. We caution that, as it is not possible to predict or identify all relevant factors that may impact forward-looking statements, the foregoing list of important factors that may affect future results is not exhaustive and should not be considered a complete statement of all potential risks and uncertainties.
vii


PART I
Item 1.    Business
Introduction
Bausch Health Companies Inc. is a global company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market, primarily in the therapeutic areas of eye-health, gastroenterology (“GI”) and dermatology, a broad range of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) over-the-counter (“OTC”) products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in approximately 100 countries.
Our portfolio of products falls into four operating and reportable segments: (i) Bausch + Lomb/International, (ii) Salix, (iii) Ortho Dermatologics and (iv) Diversified Products.
The Bausch + Lomb/International segment consists of: (i) sales in the U.S. of pharmaceutical products, OTC products and medical device products, primarily comprised of Bausch + Lomb products, with a focus on the Vision Care, Surgical, Consumer and Ophthalmology Rx products and (ii) with the exception of sales of Solta products, sales in Canada, Europe, Asia, Australia, Latin America, Africa and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products, OTC products, medical device products and Bausch + Lomb products.
The Salix segment consists of sales in the U.S. of GI products.
The Ortho Dermatologics segment consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta medical aesthetic devices.
The Diversified Products segment consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products.
For additional discussion of our reportable segments, see the discussion in Item 1. "Business — Segment Information" and Note 22, "SEGMENT INFORMATION" to our audited Consolidated Financial Statements for further details on these reportable segments.
As discussed further in Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Overview — Separation of Bausch + Lomb Eye-Health Business” of this Form 10-K, on August 6, 2020, the Company announced that it intends to separate its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the “Separation”). The Separation will establish two separate companies that include: (i) a fully integrated eye-health company which will consist of the Company’s Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmology Rx businesses and (ii) a diversified pharmaceutical company which will include the Company’s Salix, International Rx, Solta, generic products, neurology, dentistry and medical dermatology pharmaceutical businesses. The anticipated separation is subject to regulatory approvals and certain conditions, including final approval by the Company’s Board of Directors and any shareholder vote requirements that may be applicable. In connection with the Separation, the Company expects to realign and begin managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Separation during the first quarter of 2021. Accordingly, the Company expects to begin reporting under the following reporting segments on a retrospective basis beginning with its first quarter of 2021: Bausch + Lomb, International Rx, Salix, Ortho Dermatologics and Diversified Products.
We are in the process of addressing the organization, structure and pro forma capitalizations of the two entities post-separation. As a result, the information in this Form 10-K relating to the Separation is preliminary and may change as the transaction progresses and any such change may be material. Further, there can be no assurance that the Separation will occur. See Item 1A. “Risk Factors — Risk Relating to the Separation” of this Form 10-K for additional risks relating to the Separation.
COVID-19 Pandemic
In December 2019, a novel strain of the coronavirus disease, COVID-19, was identified in Wuhan, China. Since then, COVID-19 has spread to most of the world, including the United States, Canada and Europe, and was declared a global pandemic by the World Health Organization (the "WHO") on March 11, 2020. As a global health care company, now more than ever, we remain focused on our mission of helping to improve people’s lives with our health care products.
We are and will continue to closely monitor the impacts of the COVID-19 pandemic and related responses from governments and private sector participants on the Company, our customers, supply chain, third-party suppliers, project
1


development timelines, costs, revenue, margins, liquidity and financial condition and our planned actions and responses to this pandemic. To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing.
We believe we have responded quickly to the human and commercial challenges brought on by the COVID-19 pandemic and that our early actions have, so far, enabled us to keep our employees safe and our supply lines largely intact and we believe these actions have laid the foundation for us to work our way through the uncertainties to come. Importantly, we believe that the steps we took over the last several years to manage our capital structure place us in a strong position to maintain sufficient liquidity to continue operations through an extended pandemic and we believe that our businesses will not see their long-term value diminished by this unprecedented situation. See Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Overview — Impacts of COVID-19” of this Form 10-K for additional information on the impacts of the COVID-19 pandemic and Item 1A. “Risk Factors — Risk Relating to COVID-19” of this Form 10-K for additional risks relating to the COVID-19 pandemic.
Business Strategy
Our strategy is to focus our business on core therapeutic classes that offer attractive growth opportunities. Within our chosen therapeutic classes, we prioritize durable products which we believe have the potential for strong operating margins and evidence of growth opportunities. We believe this strategy has reduced complexity in our operations and maximizes the value of our: (i) eye-health, (ii) GI and (iii) dermatology businesses, which collectively now represent a substantial portion of our revenues. We have found and continue to believe there is significant opportunity in these businesses and we believe our existing portfolio, commercial footprint and pipeline of product development projects position us to successfully compete in these markets and provide us with the greatest opportunity to build value for our shareholders. We identify these businesses as “core”, meaning that we believe we are best positioned to grow and develop them.
We believe we have a well-established product portfolio that is mixed within our core businesses and provides a sustainable revenue stream to fund our operations. Our continued success is dependent upon our ability to continually refresh our pipeline and bring new product solutions to the market that meet changing demands and replace other products that have lost momentum. We have a robust pipeline that we believe not only provides for the next generation of our existing products, but is also poised to bring new and innovative solutions to market. Our R&D organization focuses on the development of products through clinical trials and, as of December 31, 2020, included approximately 1,300 dedicated R&D and quality assurance employees in 23 R&D facilities.
We have focused our R&D to advance development programs that we believe will drive growth in our core businesses, while creating efficiencies in our R&D efforts and expenses. Although we primarily rely on our R&D organization to build-out and refresh our product portfolio, to supplement those efforts, we continually seek out opportunities, such as co-promotions, licensing agreements and strategic acquisitions, to leverage our commercial footprint, particularly our sales force, by strategically aligning ourselves with other innovative product solutions that, when coupled with our existing product portfolio, address specific needs in the market. See Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Overview — Focus on Core Businesses” of this Form 10-K.
Segment Information
Our revenues for 2020, 2019 and 2018 were $8,027 million, $8,601 million and $8,380 million, respectively. We have approximately 1,300 products in our portfolio of products, which fall into four operating and reportable segments: (i) Bausch + Lomb/International, (ii) Salix, (iii) Ortho Dermatologics and (iv) Diversified Products. Segment revenues for the years 2020, 2019 and 2018 were as follows:
202020192018
(in millions)AmountPct.AmountPct.AmountPct.
Bausch + Lomb/International$4,408 55 %$4,739 55 %$4,664 56 %
Salix1,904 24 %2,022 23 %1,749 21 %
Ortho Dermatologics553 %565 %617 %
Diversified Products1,162 14 %1,275 15 %1,350 16 %
Total revenues$8,027 100 %$8,601 100 %$8,380 100 %
Comparative segment information for 2020, 2019 and 2018 is further presented in Note 22, "SEGMENT INFORMATION" to our audited Consolidated Financial Statements.
2


Bausch + Lomb/International
Our Bausch + Lomb/International segment includes our global Bausch + Lomb eye-health business and our International Rx business. Our global Bausch + Lomb eye-health business includes our Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmology Rx products, which in aggregate accounted for approximately 41%, 42% and 43% of our Company's revenues for 2020, 2019 and 2018, respectively. Our International Rx business, with the exception of our Solta products, includes sales in Canada, Europe, Asia, Australia, Latin America, Africa and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products and OTC products, which in aggregate accounted for approximately 14%, 13% and 13% of our Company's revenues for 2020, 2019 and 2018, respectively.
Our global Bausch + Lomb business is a fully integrated eye-health business, which we believe is critical to maintaining and developing our position in the global eye-health market. As a fully integrated eye-health business with a 165-year legacy, Bausch + Lomb has an established line of contact lenses, intraocular lenses and other medical devices, surgical systems and devices, vitamin and mineral supplements, lens care products, prescription eye-medications and other consumer products that positions us to compete in all areas of the eye-health market.
As part of our global Bausch + Lomb business strategy, we continually look for key trends in the eye-health market to meet changing consumer/patient needs and identify areas for investment and growth. For instance, one of these trends is the increasing rate of myopia, and importantly, myopia as a potential risk factor for glaucoma, macular degeneration and retinal detachment. We continue to see increased demand for new eye-health products that address conditions brought on by factors, such as increased screen time, lack of outdoor activities and academic pressures, as well as conditions brought on by an aging population (for example, as more and more baby-boomers in the U.S. are reaching the age of 65). To supplement our well-established Bausch + Lomb product lines, we continue to identify new products tailored to address these key trends, which we develop internally with our own R&D team to generate organic growth. We also license selective molecules or technology in leveraging our own R&D expertise through development, as well as seek out external product development opportunities. Recent product launches include Biotrue® ONEday daily disposable contact lenses, the next generation of Bausch + Lomb ULTRA® contact lenses, SiHy Daily contact lenses, Lumify® (an eye redness treatment), Vyzulta® (a pressure lowering eye drop for patients with angle glaucoma or ocular hypertension) and Ocuvite® Eye Performance (vitamins to protect the eye from stressors such as sunlight and blue light emitted from digital devices).
Currently our principal products in the eye-health business include:
Vision Care
SofLens® Daily Disposable Contact Lenses, which use ComfortMoist® Technology (a combination of thin lens design and moisture-rich packaging solution) and High Definition Optics which is an aspheric design that reduces spherical aberration over a range of powers, especially in low light.
PureVision® is a silicone hydrogel frequent replacement contact lens using AerGel® technology lens material to allow natural levels of oxygen to reach the eye as well as resist protein buildup. The lens also incorporates an aspheric optical design that reduces spherical aberration.
Biotrue® ONEday daily disposable contact lenses, which are made of a unique material that works like the eye to form a dehydration barrier. The lens maintains over 98% of its moisture for up to 16 hours, it matches the water content of the cornea at 78% and allows for the oxygen a healthy eye needs.
Biotrue® ONEday for Astigmatism is a daily disposable contact lens for astigmatic patients. The Biotrue® ONEday lenses incorporates Surface Active Technologyto provide a dehydration barrier.  The Biotrue® ONEday for Astigmatism also includes evolved peri-ballast geometry to deliver stability and comfort for the astigmatic patient.
Bausch + Lomb ULTRA® is a silicone hydrogel frequent replacement contact lens that uses the proprietary MoistureSeal® technology which allows the contact lens to retain 95% of moisture after 16 hours of wear, limiting lens dryness and resulting symptoms.
Bausch + Lomb ULTRA® for Astigmatism is a monthly planned replacement contact lens for astigmatic patients.  The Bausch + Lomb ULTRA® for Astigmatism lens was developed using the proprietary MoistureSeal® technology. In addition, the Bausch + Lomb ULTRA® for Astigmatism lens integrates an OpticAlign® design engineered for lens stability and to promote a successful wearing experience for the astigmatic patient.
Bausch + Lomb ULTRA® for Presbyopia is a monthly planned replacement contact lens for presbyopic patients. The Bausch + Lomb ULTRA® for Presbyopia lens was developed using the proprietary MoistureSeal® technology. In addition, the Bausch + Lomb ULTRA® for Presbyopia lens integrates a 3-zone progressive design for near, intermediate and distance vision. We launched expanded parameters of this product throughout 2017.
3


SiHy Daily is a silicone hydrogel daily disposable contact lens designed to provide clear vision throughout the day. In September 2018, we launched SiHy Daily in Japan under the branded name AQUALOX® ONE DAY.  In August 2020, we launched SiHy Daily in the U.S. under the branded name Bausch + Lomb INFUSE SiHy Daily Disposable contact lens. SiHy Daily has also received regulatory approval for Canada, Australia, New Zealand, Hong Kong, South Korea, Singapore and Malaysia where it will be branded as Bausch + Lomb Ultra® ONE DAY.
Surgical
The Stellaris Elite® Vision Enhancement System is our next phacoemulsification cataract platform, which offers new innovations, as well as the opportunity to add upgrades and enhancements every one to two years. Stellaris Elite® is the first phacoemulsification platform on the market to offer Adaptive Fluidics, which combines aspiration control with predictive infusion management to create a responsive and controlled surgical environment for efficient and safe cataract lens removal. Our Stellaris Elite® Vision Enhancement System was launched in April 2017.
The Vitesse® hypersonic vitrectomy system advances the process of vitreous removal using an innovative and effective approach. Available exclusively on the Stellaris Elite® system, Vitesse® brings an exceptional level of surgical control and precision to vitrectomies.
A portfolio of ophthalmic surgical products, including: (i) pre-loaded intraocular lenses such as Akreos®, enVista®, LuxSmart and LuxGood, (ii) handcrafted surgical instruments including Storz® and Synergetics® and (iii) a suite of surgical equipment including TENEO® excimer laser for refractive and VICTUS® femtosecond laser for cataract surgery and keratoplasty.
Consumer
PreserVision® AREDS 2 is an eye vitamin formula for those with moderate-to-advanced age-related macular degeneration.
Ocuvite® is a vitamin and mineral supplement for the eye that contains lutein (an antioxidant carotenoid), a nutrient that supports macular health by helping filter harmful blue light.
Biotrue® multi-purpose solution helps prevent certain tear proteins from denaturing and fights germs for healthy contact lens wear. Biotrue® multi-purpose solution uses a lubricant found in eyes and is pH balanced to match healthy tears.
Lumify® (brimonidine tartrate ophthalmic solution, 0.025%) is an OTC eye drop developed as an ocular redness reliever. Lumify® was launched in the U.S. in May 2018. We plan to launch Lumify® in South Korea in the second half of 2021 and in Canada in 2022.
Bausch + Lomb Renu® Advanced Formula multi-purpose solution is a novel soft and silicone hydrogel contact lenses solution that makes use of three disinfectants and two moisture agents.
Boston® solution is a specialty cleansing solution design for gas permeable contact lenses.
Bedoyecta Tri® (Injectable Hydroxocobalamine, vitamin B complex) is indicated for the prevention and treatment of certain vitamin deficiencies. It is useful in the treatment of Neuritis and polyneuritis of nutritional, diabetic, alcoholic and toxic origin due to the use of drugs. Bedoyecta® is also available in soft gel and capsule form. Bedoyecta® is commercialized in Mexico and South America.
Cold FX® is a product derived from the roots of North American ginseng. COLD-FX® Daily Support has a clinically proven formula that helps reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system.
Artelac® is an eye moisturizer eye drop which enables quick wetting of dry eyes. Artelac® contains hypromellose, a known moisturizer, and is used to treat dehydration of the surface of the eye, especially for dry eyes with an unpleasant foreign body sensation. Artelac® is particularly suitable for alleviating mild symptoms of dry eyes and can also be used to moisten hard contact lenses while being worn. Artelac® is commercialized widely in Europe, the Middle East and Africa, Asia Pacific, Canada and Latin America.
Ophthalmology Rx
Lotemax® Gel is a topical corticosteroid indicated for the treatment of inflammation and pain following ocular surgery. This formulation is a technology that allows the drug to adhere to the ocular surface and offers dose uniformity, which
4


eliminates the need to shake the product in order to ensure the drug is in suspension. The product contains a low concentration of preservative and two known moisturizers. Lotemax® Gel is commercialized globally.
Vyzulta® (latanoprostene bunod ophthalmic solution, 0.024%) is an intraocular pressure lowering single-agent eye drop dosed once daily for patients with open angle glaucoma or ocular hypertension. Vyzulta® was launched in the U.S. (December 2017), Canada (July 2019), Hong Kong (2020), Mexico (2020) and Argentina (2020). We are planning to launch Vyzulta® in Taiwan in 2021 and in South Korea in 2022.
Prolensa® (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-inflammatory drug indicated to treat inflammation and reduce eye pain in patients after cataract surgery. This product is commercialized widely in Europe under the brand name Yellox®.
International Rx
Bisocard® (bisoprolol fumarate) is an orally administered tablet dosed once daily for patients with hypertension, angina pectoris or heart failure and is a leading brand in Poland.
Thrombo ASS® (gastroprotective coated form of acetylsalicylic acid 50mg and 100mg) is an antithrombotic agent dosed once daily for secondary prophylaxis of thrombotic complications after such events as a stroke or heart attack. Thrombo ASS® is a leading brand in Russia.
Contrave® / Mysimba® is a fixed-dose combination prolonged-release tablet for the treatment of obesity. Used alongside diet and exercise it is designed to help manage weight in adults who are obese or overweight. The formulation is designed to initiate weight loss and sustain it over a longer period of time by switching off natural compensatory mechanisms involved in the typical weight loss plateau stage. Contrave® / Mysimba® is commercialized in Canada, Greece, and Central Eastern Europe.
Jublia® (efinaconazole 10% topical solution) is a topical azole approved for the treatment of onychomycosis of the toenails (toenail fungus). Jublia® is commercialized in Canada (the only market outside the U.S.).
Ivexterm® (Ivermectin 6 mg tablets) is an antiparasitic drug, which is commercialized in Mexico and Central America, and is currently under investigational studies for treating COVID-19 patients.
Espaven® (Dimethicone tablets, drops, suspension) is a complete line of gastrointestinal treatments for diverse digestive indications such as: antiflatulence, dyspepsia, absolute or relative enzyme deficiency, steatorrhea, irritable colon syndrome, pancreatic insufficiency and poor fat digestion. Espaven® is commercialized primarily in Mexico and South America.
Salix
The Salix segment consists of sales in the U.S. of GI products and includes our Xifaxan® product. We have been making investments in our Salix business since 2017, including: (i) hiring 200 trained and experienced sales force representatives to expand the commercial field force for Xifaxan®, (ii) increasing the focus on the development of next generation formulations of our Salix products to address new indications, (iii) completing the strategic acquisition of certain assets of Synergy Pharmaceuticals Inc. (“Synergy”), which included the Trulance® product, and (iv) increasing the number of sales force representatives for Trulance®. In addition, we have entered into licensing agreements for investigational products, which, once developed and if approved by the U.S. Food and Drug Administration (the "FDA"), will be new treatments for certain GI and liver diseases and we anticipate will contribute to the future growth. Each of these opportunities potentially provides us with the ability to expand our GI portfolio and allows us to leverage our existing GI sales force, supply channel and distribution channel.
Currently our principal products in the Salix segment (including products of our third-party co-promotion partners) include:
Xifaxan® which includes: (i) tablets indicated for the treatment of IBS-D in adults and for the reduction in risk of overt hepatic encephalopathy recurrence in adults and (ii) tablets indicated for the treatment of travelers’ diarrhea caused by noninvasive strains of Escherichia coli in patients 12 years of age and older. Our Xifaxan® product accounted for revenues of $1,482 million, $1,452 million and $1,195 million for 2020, 2019 and 2018, respectively.
Glumetza® (metformin hydrochloride) extended release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Relistor® (methylnaltrexone) is given to adults who use narcotic medicine to treat severe chronic pain that is not caused by cancer to prevent constipation without reducing the pain-relieving effects of the narcotic.
5


Trulance® (plecanatide) is a once-daily tablet for adults with chronic idiopathic constipation, or CIC, and irritable bowel syndrome with constipation, or IBS-C.
Plenvu® is a novel, lower-volume polyethylene glycol-based bowel preparation developed to help provide complete bowel cleansing, with an additional focus on the ascending colon. Plenvu® was launched in September 2018.
Ortho Dermatologics
The Ortho Dermatologics segment consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological products) and (ii) global sales of Solta dermatological devices.
The Ortho Dermatologics business is our medical dermatology business dedicated to the treatment of a range of therapeutic areas, including aesthetics, psoriasis, actinic keratosis, acne, atopic dermatitis, onychomycosis and other dermatoses. As part of our business strategy for the Ortho Dermatologics segment, we have made significant investments to build out our psoriasis, atopic dermatitis and acne product portfolios, which are the markets within dermatology where we see the greatest opportunities, with a focus on topical gel and lotion products over injectable biologics. We continue to support the use of injectable biologics; however, we believe some patients prefer topical products as an alternative to injectable biologics. Further, as topical products can, in many cases, defer the use of injectable biologics that often come with associated risk/benefit profiles, a topical product is usually readily adopted by payors, is less expensive and can be more cost-effective than injectable biologics. Therefore, we believe topical products represent alternative treatments for physicians, payors and patients, and as the preferred choice of treatment, have the potential to drive greater volumes, generate better margins and potentially be a key contributing factor of our Ortho Dermatologics business.
During 2017 through 2020, we have made significant investments to build out our aesthetics, psoriasis and acne product portfolios, which we believe, coupled with our experienced dermatology sales leadership team and the reorganization of our Ortho Dermatologics sales force, will position our Ortho Dermatologics business for future growth.
Currently our principal products in the medical dermatology business include:
Jublia® (efinaconazole 10% topical solution) is a topical azole approved for the treatment of onychomycosis of the toenails (toenail fungus).
Targretin® (bexarotene) capsules and gel are prescription medicines used to treat the skin problems arising from the disease cutaneous T-cell lymphoma, or CTCL, in patients who have not responded well to other treatments.
Bryhali® was launched in November 2018 and is a novel product that contains a unique, lower concentration of halobetasol propionate for the treatment of moderate-to-severe psoriasis.
Siliq® was launched in the U.S. in 2017 and is an IL-17 receptor blocker monoclonal antibody for patients with moderate-to-severe plaque psoriasis.
Altreno® (tretinoin 0.05%) was launched in the U.S. in October 2018 and is a lotion approved for the topical treatment of acne vulgaris in patients 9 years of age and older.
Duobrii® was launched in June 2019 and is the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene for the treatment of moderate-to-severe plaque psoriasis in adults.
Arazlo® (tazarotene) Lotion, 0.045% is an acne product containing lower concentration of tazarotene in a lotion form to help reduce irritation while maintaining efficacy and was launched in June 2020.
An Acne franchise, which includes Solodyn®, a prescription oral antibiotic approved to treat only the red, pus-filled pimples of moderate to severe acne in patients 12 years of age and older, as well as Retin-A®, Clindagel® and Onexton® Gel, a fixed combination 1.2% clindamycin phosphate and 3.75% benzoyl peroxide medication for the once-daily treatment of comedonal (non-inflammatory) and inflammatory acne in patients 12 years of age and older.
Our Solta business is dedicated to the development of innovative treatment technologies that provide proven and effective medical aesthetic and therapeutic benefits to consumers. Global Solta revenues were $253 million, $194 million and $135 million for 2020, 2019 and 2018, respectively. The increase in revenue is primarily attributable to Next Generation Thermage FLX®, a fourth-generation non-invasive treatment option using a radiofrequency platform designed to optimize key functional characteristics and improve patient outcomes. During 2018 and 2019, Next Generation Thermage FLX® was launched in Hong Kong, Japan, Korea, Taiwan, Philippines, Singapore, Indonesia, Malaysia, China, Thailand, Vietnam, and Australia as part of our Solta medical aesthetic devices portfolio. These launches have been successful as Next Generation Thermage FLX® revenues for 2020 and 2019 were $142 million and $77 million, respectively. We expect additional launches of Next Generation Thermage FLX® in Europe in the near term, paced by country-specific regulatory registrations.
6


Currently our principal products in the Solta business include:
Thermage® is a non-invasive radiofrequency treatment that can smooth, tighten and contour skin for an overall younger-looking appearance.
Fraxel® is a treatment that improves tone, texture and radiance for aging, sun damaged or scarred skin.
Clear + Brilliant® is a laser treatment that can help prevent the visible signs of aging and address the overall effects time and the environment can have on skin.
VASERlipo® for minimally-invasive aesthetic body contouring that yields dramatic results with less pain and downtime of traditional liposuction.
Diversified Products
The Diversified Products segment consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products. The Company utilizes the Diversified Products segment to extend the long-term cash flows from a number of assets that are expected to decline over time due to the loss of exclusivity, by launching and selling authorized generic versions of certain branded assets. Our principal products in this segment include:
Pharmaceutical
Wellbutrin XL® is an extended release formulation of bupropion indicated for the treatment of major depressive disorder in adults.
Cuprimine® is a treatment for Wilson's disease (a condition in which high levels of copper in the body cause damage to the liver, brain, and other organs), cystinuria (a condition which leads to cystine stones in the kidneys) and for patients with severe rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.
Migranal® (dihydroergotamine mesylate) Nasal Spray is used to treat an active migraine headache with or without aura.
Ativan® (lorazepam) is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. 
Xenazine® is indicated for the treatment of chorea associated with Huntington’s disease. In the U.S., Xenazine® is distributed for us by Lundbeck LLC under an exclusive marketing, distribution and supply agreement.
Syprine® is a treatment for Wilson's disease in patients who cannot take the medication known as penicillamine.
Aplenzin® (bupropion hydrobromide extended release tablets) is indicated for the treatment of major depressive disorder, and for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder. 
Librax® (chlordiazepoxide and clidinium) is indicated to control emotional and somatic factors in gastrointestinal disorders. Librax® may also be used as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis.
Generics
Diastat® authorized generic (“AG”) (diazepam rectal gel) is a gel formulation of diazepam intended for rectal administration for certain patients with epilepsy who are already taking antiepileptic medications, and who require occasional use of diazepam to control bouts of increased seizure activity.
Uceris® AG (budesonide) extended release tablets are a prescription corticosteroid medicine used to help get mild to moderate ulcerative colitis under control (induce remission).
Elidel® AG (pimecrolimus) is a second-line therapy for short term and intermittent long-term therapy of mild to moderate atopic dermatitis.
Apriso® AG is an aminosalicylate anti-inflammatory drug used to treat ulcerative colitis, proctitis and proctosigmoiditis. Apriso is also used to prevent the symptoms of ulcerative colitis from recurring. Apriso® AG was launched in December 2019.
7


Tobramycin and Dexamethasone Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
Latanoprost Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Dentistry
Arestin® (minocycline hydrochloride) is a subgingival sustained-release antibiotic. Arestin® is indicated as an adjunct to scaling and root planing ("SRP") procedures for reduction of pocket depth in patients with adult periodontitis. Arestin® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.
NeutraSal® is indicated for dryness of the mouth (hyposalivation, xerostomia) and dryness of the oral mucosa due to drugs that suppress salivary secretion.
Research and Development
Our R&D organization focuses on the development of products through clinical trials. Currently, we have approximately 200 R&D projects in our pipeline. As of December 31, 2020, approximately 1,300 dedicated R&D and quality assurance employees in 23 R&D facilities were involved in our R&D efforts.
Our R&D expenses for 2020, 2019 and 2018, were $452 million, $471 million and $413 million, respectively. R&D expenses as a percentage of revenue were approximately 6% in 2020, as compared to approximately 5% in 2019 and 2018. We have rebalanced our portfolio to better align with our long-term plans and focus on core businesses. Our investment in R&D reflects our commitment to drive organic growth through internal development of new products, a pillar of our strategy. We further supplement these efforts by continually seeking out other opportunities, such as co-promotions, licensing agreements and strategic acquisitions. See Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Overview — Focus on Core Businesses” of this Form 10-K.
Trademarks, Patents, Exclusivity and Proprietary Know-How
We rely on a combination of contractual provisions, confidentiality policies and procedures and patent, trademark, copyright and trade secrecy laws to protect the proprietary aspects of our technology and business. Our policy is to vigorously protect, enforce and defend our rights to our intellectual property and proprietary rights, as appropriate. See Item 1A. “Risk Factors” of this Form 10-K for additional information on the risks associated with our intellectual property and proprietary rights.
Trademarks
We believe that trademark protection is an important part of establishing product and brand recognition. We own or license a number of registered trademarks and trademark applications in the U.S., Canada and in various other countries throughout the world. U.S. federal registrations for trademarks remain in force for 10 years and may be renewed every 10 years after issuance, provided the mark is still being used in commerce. Trademark registrations in Canada issued on or before June 17, 2019 remain in force for 15 years and may be renewed for 10-year terms, provided that, as in the case of U.S. federal trademark registrations, the mark is still being used in commerce. Trademark registrations in Canada issued after June 17, 2019 remain in force for 10 years and may be renewed every 10 years after issuance, provided that, as in the case of U.S. federal trademark registrations, the mark is still being used in commerce. Other countries generally have similar but varying terms and renewal policies with respect to trademarks registered in those countries.
Data and Patent Exclusivity
For certain of our products, we rely on a combination of regulatory and patent rights to protect the value of our investment in the development of these products.
A patent is the grant of a property right which allows its holder to exclude others from, among other things, selling the subject invention in, or importing such invention into, the jurisdiction that granted the patent. In the U.S., Canada and the European Union (“EU”), generally patents expire 20 years from the date of application. We have obtained, acquired or in-licensed a number of patents and patent applications covering key aspects of certain of our principal products. In the aggregate, our patents are of material importance to our business taken as a whole.
In the U.S., the Hatch-Waxman Act provides non-patent regulatory exclusivity for five years from the date of the first FDA approval of a new drug compound in a New Drug Application (“NDA”). The FDA, with one exception, is prohibited
8


during those five years from accepting for filing a generic, or an Abbreviated New Drug Application (“ANDA”), that references the NDA. In reference to the foregoing exception, if a patent is indexed in the FDA Orange Book for the new drug compound, a generic may file an ANDA four years from the NDA approval date if it also files a Paragraph IV Certification with the FDA challenging the patent. Protection under the Hatch-Waxman Act will not prevent the filing or approval of another full NDA. However, the NDA applicant would be required to conduct its own pre-clinical and adequate and well-controlled clinical trials to independently demonstrate safety and effectiveness.
A similar data exclusivity scheme exists in the EU, whereby only the pioneer drug company can use data obtained at the pioneer’s expense for up to eight years from the date of the first approval of a drug by the European Medicines Agency (“EMA”) and no generic drug can be marketed for ten years from the approval of the innovator product. Under both the U.S. and the EU data exclusivity programs, products without patent protection can be marketed by others so long as they repeat the clinical trials necessary to show safety and efficacy.
In the U.S., the Biologics Price Competition and Innovation Act ("BPCIA") allows companies to seek FDA approval to manufacture and sell biosimilar or interchangeable versions of brand name biological products. Due to the size and complexity of biological products, as compared to small molecule drugs, a biosimilar must be “highly similar” to the reference product with “no clinically meaningful differences” in safety, purity and potency between the two. The BPCIA provides reference product sponsors with 12 years (with potential for six additional months of pediatric exclusivity) of market exclusivity, but unlike the Hatch-Waxman Act which covers small molecules, it does not require reference product sponsors to list patents in an Orange Book equivalent and does not include an automatic 30-month stay of FDA approval upon the timely filing of a lawsuit. The BPCIA, however, does provide pre-litigation procedures for the parties to follow, including identification of relevant patents and each party’s basis for infringement and invalidity.  A biosimilar patent application cannot be filed until four years after the reference product is first licensed and a biosimilar cannot be launched, at the earliest (assumes no patent litigation or an adverse decision on all patents), until the expiration of the twelve years of data exclusivity from the approval of the reference product. 
Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a disease or condition that affects populations of fewer than 200,000 individuals in the U.S. or a disease whose incidence rates number more than 200,000 where the sponsor establishes that it does not realistically anticipate that its product sales will be sufficient to recover its costs. The sponsor that obtains the first marketing approval for a designated orphan drug for a given rare disease is eligible to receive marketing exclusivity for use of that drug for the orphan indication for a period of seven years.
In Canada, the Patented Medicines (Notice of Compliance) Regulations (“PM(NOC) Regulations”) create a regime analogous to the U.S. Hatch-Waxman Act, and link the regulatory approval process for generic and biosimilar drugs to the adjudication of innovator patent rights. To be eligible for protection under the PM(NOC) Regulations, patents must first be listed on the Patent Register in connection with an innovator’s drug submission to Health Canada. A generic or biosimilar manufacturer must then provide notice to the innovator of its plans to market a drug that it compared to the innovator’s patented drug in the Health Canada approval process. Within 45 days of receiving such a notice of allegation, an innovator drug company may commence patent infringement proceedings against the generic or biosimilar manufacturer. The commencement of an action by the innovator under the PM(NOC) Regulations may stay Health Canada’s regulatory approval of the generic or biosimilar drug for a period of 24 months.
Canada also employs a data exclusivity regime for innovative drugs that provides an eight-year period of data protection from the date of market approval by Health Canada. An additional six months of data exclusivity is provided for drugs studied in clinical trials relating to use in pediatric populations. Drug submissions seeking approval based on a comparison to an innovative drug cannot be filed during the first six years of the data exclusivity period. Generic or biosimilar drug submissions remain on hold until expiry of the innovator’s data protection term, unless the innovative product is a patented drug subject to further protection under the PM(NOC) Regulations. Canada has no distinct drug submission process for biosimilar or orphan drug products.
Proprietary Know-How
We also rely upon unpatented proprietary know-how, trade secrets and technological innovation in the development and manufacture of many of our principal products. We protect our proprietary rights through a variety of methods, including confidentiality and non-disclosure agreements and proprietary information agreements with vendors, employees, consultants and others who may have access to proprietary information.
9


Government Regulations
Government authorities in the U.S., at the federal, state and local level, in Canada, in the EU and in all other countries extensively regulate, among other things, the research, development, testing, approval, manufacturing, labeling, post-approval monitoring and reporting, packaging, advertising and promotion, storage, distribution, marketing and export and import of pharmaceutical products and medical devices. As such, our products and product candidates are subject to extensive regulation both before and after approval. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with these regulations could result in, among other things, warning letters, civil penalties, delays in approving or refusal to approve a product candidate, product recall, product seizure, interruption of production, operating restrictions, suspension or withdrawal of product approval, injunctions or criminal prosecution.
Prior to human use, FDA approval (drugs (in the form of an NDA or ANDA for generic equivalents), biologics (in the form of a Biologics License Application (“BLA”)) and some medical devices) or marketing clearance (other devices) must be obtained in the U.S., approval by Health Canada must be obtained in Canada, EMA approval (drugs) or a CE Marking (devices) must be obtained for countries that are part of the EU and approval must be obtained from comparable agencies in other countries prior to manufacturing or marketing new pharmaceutical products or medical devices. Generally, preclinical studies and clinical trials of the products must first be conducted and the results submitted to the applicable regulatory agency (such as the FDA) for approval.
Regulation by other federal agencies, such as the Drug Enforcement Administration, and state and local authorities in the U.S., and by comparable agencies in certain foreign countries, is also required. In the U.S., the Federal Trade Commission (the “FTC”), the FDA and state and local authorities regulate the advertising of medical devices, prescription drugs, OTC drugs and cosmetics. The Federal Food, Drug and Cosmetic Act, as amended and the regulations promulgated thereunder, and other federal and state statutes and regulations, govern, among other things, the testing, manufacture, safety, effectiveness, labeling, storage, record keeping, approval, sale, distribution, advertising and promotion of our products. The FDA requires a Boxed Warning (sometimes referred to as a “Black Box” Warning) for products that have shown a significant risk of severe or life-threatening adverse events and similar warnings are also required to be displayed on the product in certain other jurisdictions.
Manufacturers of pharmaceutical products and medical devices are required to comply with manufacturing regulations, including current good manufacturing practices and quality system management requirements, enforced by the FDA and Health Canada, in the U.S. and Canada respectively, and similar regulations enforced by regulatory agencies in other countries and we face annual audits of our facilities and plants and those of our contract manufacturers by the FDA and such other regulatory agencies. In addition, we are subject to price control restrictions on our pharmaceutical products in many countries in which we operate.
We are also subject to extensive U.S. federal and state health care marketing and fraud and abuse regulations, such as the federal False Claims Act, federal and provincial marketing regulations in Canada and similar regulations in foreign countries in which we may conduct our business. The federal False Claims Act imposes civil and criminal liability on individuals or entities who submit (or cause the submission of) false or fraudulent claims for payment to the government. The U.S. federal Anti-Kickback Statute prohibits persons or entities from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal or state health care program such as the Medicare and Medicaid programs. Some state anti-kickback laws also prohibit such conduct where commercial insurance, rather than federal or state, programs are involved. Due to recent legislative changes, violations of the U.S. federal Anti-Kickback Statute also carry potential federal False Claims Act liability. In addition, in the U.S., Canada and various other countries, companies may not promote drugs or medical devices for “off-label” uses - that is, uses that are not described in the product’s labeling and that differ from those that were approved or cleared by the FDA, Health Canada or applicable regulatory agency in such other countries - and “off-label promotion” in the U.S. has also formed the predicate for False Claims Act liability resulting in significant financial settlements. These and other laws and regulations, rules and policies may significantly impact the manner in which we are permitted to market our products. If our operations are found to be in violation of any of these laws, regulations, rules or policies or any other law or governmental regulation, or if interpretations of the foregoing change, we may be subject to civil and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs and the curtailment or restructuring of our operations.
We are also subject to various state, federal and international laws and regulations governing the collection, transmission, dissemination, use, privacy, confidentiality, security, retention, availability, integrity and other processing of health-related and other sensitive and personal information, including, but not limited to, the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (collectively, “HIPAA”). HIPAA mandates, among other things, the adoption of uniform standards for the electronic exchange of information in common health care transactions (e.g., health care claims information and plan eligibility, referral certification and
10


authorization, claims status, plan enrollment, coordination of benefits and related information), as well as standards relating to the privacy and security of individually identifiable health information. These standards require the adoption of administrative, physical and technical safeguards to protect such information. Many states in which we operate have laws that protect the privacy and security of sensitive and personal information, including health-related information. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance efforts. For example, the California Consumer Privacy Act (the “CCPA”), which went into effect on January 1, 2020, imposes stringent data privacy and security requirements and obligations with respect to the personal information of California residents, including, among other things, new disclosures to California consumers and providing such consumers new data protection and privacy rights, including the ability to opt out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches that result in the loss of personal data that may increase the likelihood of, and risks associated with, data breach litigation. It remains unclear how various provisions of the CCPA will be interpreted and enforced, and multiple states have enacted or are expected to enact similar laws. The effects on our business of the CCPA and other similar state laws are potentially significant, and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply. State laws are changing rapidly and there is discussion in Congress of a new federal data protection and privacy law to which we may be subject.
Additionally, some statutory requirements, both in the U.S. and abroad, include obligations for companies to notify individuals of security breaches involving particular personal information, which could result from breaches experienced by us or our service providers. For example, laws in all 50 U.S. states require businesses to provide notice to customers whose personal data has been disclosed as a result of a data breach. The laws are not consistent, and compliance in the event of a widespread data breach is difficult and may be costly. Moreover, states have been frequently amending existing laws, requiring attention to changing regulatory requirements.
Internationally, laws and regulations in many jurisdictions apply broadly to the collection, transmission, dissemination, use, privacy, confidentiality, security, retention, availability, integrity and other processing of health-related and other sensitive and personal information. For example, in the European Economic Area (the “EEA”) and, for the duration of the transition period (as defined below), the United Kingdom, the collection and use of personal data, including clinical trial data, is governed by the provisions of the General Data Protection Regulation (the “GDPR”). The GDPR became effective on May 25, 2018, repealing its predecessor directive and increasing responsibility and liability of companies in relation to the processing of personal data of EU data subjects. The GDPR, together with national legislation, regulations and guidelines of the EU member states and the United Kingdom governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze, store, transfer and otherwise process personal data, including health data from clinical trials and adverse event reporting. In particular, the GDPR includes obligations and restrictions concerning the consent and rights of the individuals to whom the personal data relates, the transfer of personal data out of the EEA or the United Kingdom, security breach notifications and the security and confidentiality of personal data. The GDPR authorizes fines for certain violations of up to 4% of global annual revenue or €20 million, whichever is greater. European data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which contributes to the complexity of processing personal data in or from the EEA or United Kingdom. Guidance on implementation and compliance practices is often updated or otherwise revised. We are also subject to Canada's federal Personal Information Protection and Electronic Documents Act and substantially similar equivalents at the provincial level with respect to the collection, use and disclosure of personal information in Canada. Such federal and provincial legislation impose data privacy and security obligations on our processing of personal information of Canadian residents. The federal and Alberta legislation include mandatory data breach notification requirements. Canada’s Anti-Spam Legislation (“CASL”) also applies to the extent that we send commercial electronic messages from Canada or to electronic addresses in Canada. CASL contains prescriptive consent, form, content and unsubscribe mechanism requirements. Penalties for non-compliance with CASL are up to CAD 10 million per violation. These laws and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible they will be interpreted and applied in ways that will materially and adversely affect our business. The regulatory framework for data privacy, data security and data transfers worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Complying with all of these laws and regulations involves costs to our business, and failure to comply with these laws and regulations can result in the imposition of significant civil and criminal penalties, as well as litigation.
Successful commercialization of our products may depend, in part, on the availability of governmental and third-party payor reimbursement for the cost of our products. Third-party payors may include government health administration authorities, private health insurers and other organizations. In the U.S., the E.U. and other significant or potentially significant markets for our products and product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, which has resulted in lower average realized prices. In the U.S., these pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and health care reform, pharmaceutical reimbursement policies and pricing in general. In particular, sales of our products may be subject to discounts from list price and rebate obligations, as well as formulary
11


coverage decisions impacting or limiting the types of patients for whom coverage will be provided. Various U.S. health care and other laws regulate our interactions with government agencies, private insurance companies and other third-party payors regarding coverage and reimbursement for our products. Failure to comply with these laws could subject us to civil, criminal and administrative sanctions. In countries outside the U.S., the success of our products may depend, at least in part, on obtaining and maintaining government reimbursement because, in many countries, patients are unlikely to use prescription drugs that are not reimbursed by their governments. In addition, negotiating prices with certain governmental authorities for newly developed products can delay commercialization. In Canada and many international markets, governments control the prices of prescription pharmaceuticals, including through the implementation of reference pricing, price cuts, rebates, revenue-related taxes, tenders and profit control, and they expect prices of prescription pharmaceuticals to decline over the life of the product or as volumes increase.
In the U.S. and certain foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health care system in ways that could impact our ability to sell our products profitably. The Patient Protection and Affordable Care Act (the “PPACA”), as amended by the Health Care Reform Act, may affect the operational results of companies in the pharmaceutical and medical device industries, including the Company and other health care related industries, by imposing on them additional costs. Although efforts at replacing the Health Care Reform Act have stalled in Congress, there are a number of proposals that we expect to be introduced to Congress and put forth by the Biden administration that may result in further changes to the health care system that could materially impact the Company.
For example, on January 28, 2021, President Biden issued the “Executive Order on Strengthening Medicaid and the Affordable Care Act,” which directs federal agencies to review all existing regulations, orders, guidance documents, policies and any other similar agency actions that limit Americans’ access to high-quality health care, and to consider actions that will protect and strengthen Medicaid, the PPACA and access to affordable health care for every American. Under this order, federal agencies must make determinations as to whether additional actions are necessary to advance President Biden’s overall access policy and specifically examine (i) policies that may undermine protections for people with pre-existing conditions, including complications related to COVID-19, (ii) demonstrations and waivers that may reduce coverage under or otherwise undermine Medicaid or the PPACA, (iii) policies that may undermine the Health Insurance Marketplace or other markets for health insurance, (iv) policies that may present unnecessary barriers to enroll in Medicaid or the PPACA and (v) policies or practices that may reduce the affordability of coverage or financial assistance for coverage, including for dependents. We cannot predict what changes will result from the Executive Order or when they will take effect, nor is it possible at this time to estimate the impact of any such changes on the Company.
See Item 1A. “Risk Factors” of this Form 10-K for additional information on the risks associated with these regulations and related matters.
Environmental and Other Regulation
Our facilities and operations are subject to federal, state and local environmental and occupational health and safety laws and regulations in both the U.S. and countries outside the U.S. (including Canada), including those governing the discharge of substances into the air, water and land, the handling, treatment, storage and disposal of hazardous substances and wastes, wastewater and solid waste, the cleanup of contaminated properties and other environmental matters. Certain of our development and manufacturing activities involve the use of hazardous substances. We believe we are in compliance in all material respects with applicable environmental and occupational health and safety laws and regulations. We are not aware of any pending environmental or occupational health and safety litigation or significant liabilities that are likely to have a material adverse effect on our financial position. We cannot assure, however, that environmental liabilities relating to us or facilities owned, leased or operated by us will not develop in the future, and we cannot predict whether any such liabilities, if they were to develop, would require significant expenditures on our part. In addition, we are unable to predict what environmental or and occupational health and safety legislation or regulations may be adopted or enacted in the future. See Item 1A. “Risk Factors” of this Form 10-K for additional information.
Customers and Marketing
In 2020, the U.S. and Puerto Rico accounted for approximately 60% of our total revenue. No other country accounted for more than 5%. See Note 22, "SEGMENT INFORMATION" to our audited Consolidated Financial Statements for revenues by geographic area.
12


Customers that accounted for 10% or more of our total revenue for 2020, 2019 and 2018 are as follows:
202020192018
McKesson Corporation17%17%18%
AmerisourceBergen Corporation17%16%18%
Cardinal Health, Inc.13%14%13%
We currently promote our pharmaceutical products to physicians, hospitals, pharmacies and wholesalers through our own sales force and sell through wholesalers. In some markets, we additionally sell directly to physicians, hospitals and large drug store chains and we sell through distributors in countries where we do not have our own sales staff. As part of our marketing program for pharmaceuticals, we use direct to customer advertising, direct mailings, advertise in trade, social media and medical periodicals, exhibit products at medical conventions and sponsor medical education symposia.
Competition
Competitive Landscape for Products and Products in Development
The pharmaceutical and medical device industries are highly competitive. Our competitors include specialty and other large pharmaceutical companies, medical device companies, biotechnology companies, OTC companies and generic manufacturers, in the U.S., Canada, Europe, Asia, Latin America, Middle East, Africa and in other countries in which we market our products. The dermatology competitive landscape is highly fragmented, with a large number of mid-size and smaller companies competing in both the prescription sector and the OTC and cosmeceutical sectors. With respect to the GI market, generic entrants continue to capture significant share for treatment of many GI conditions. In the area of irritable bowel syndrome ("IBS") and OIC, competitors have recently launched new competing products, which should increase the size of these markets and intensify competition. The market for Bausch + Lomb products is very competitive, both across product categories and geographies. In addition to larger diversified pharmaceutical and medical device companies, we face competition in the eye-health market from mid-size and smaller, regional and entrepreneurial companies with fewer products in niche areas or regions.
Our competitors are pursuing the development and/or acquisition of pharmaceuticals, medical devices and OTC products that target the same diseases and conditions that we are targeting in dermatology, GI, eye-health and other therapeutic areas. Academic and other research and development institutions may also develop products or technologies that compete with our products, which technologies and products may be acquired or licensed by our competitors. These competitors may have greater financial, R&D or marketing resources than we do. If competitors introduce new products, delivery systems or processes with therapeutic or cost advantages, our products can be subject to progressive price reductions or decreased volume of sales, or both. Most new products that we introduce must compete with other products already on the market or products that are later developed by competitors.
We sell a broad range of products, and competitive factors vary by product line and geographic area in which the products are sold. The principal methods of competition for our products include quality, efficacy, market acceptance, price and marketing and promotional efforts.
Generic Competition and Loss of Exclusivity
We face increased competition from manufacturers of generic pharmaceutical products when patents covering certain of our currently marketed products expire or are successfully challenged or when the regulatory exclusivity for our products expires or is otherwise lost. Generic versions are generally significantly less expensive than branded versions, and, where available, may be required to be utilized before or in preference to the branded version under third-party reimbursement programs, or substituted by pharmacies. Accordingly, when a branded product loses its market exclusivity, it normally faces intense price competition from generic forms of the product. To successfully compete for business with managed care and pharmacy benefits management organizations, we must often demonstrate that our products offer not only medical benefits, but also cost advantages as compared with other forms of care.
For details regarding products that are facing generic competition, products that could potentially face generic competition, the corresponding potential revenue impact and infringement proceedings we initiated against potential generic competition, see Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Business Trends — Generic Competition and Loss of Exclusivity” of this Form 10-K. See Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements for further details regarding certain infringement proceedings. See Item 1A. “Risk Factors” of this Form 10-K for additional information on our competition risks.
13


Manufacturing
We currently operate approximately 38 manufacturing sites worldwide and continue to make capital investments in these facilities as discussed in Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Overview — Focus on Core Businesses” of this Form 10-K.
In the normal course of business, our products, devices and facilities are the subject of ongoing oversight and review by regulatory and governmental agencies, including general, for cause and pre-approval inspections by the relevant competent authorities where we have business operations. Through the date of this filing, all of our global operations and facilities have the relevant operational good manufacturing practices certificates and all Company products and operating sites are in good compliance standing with all relevant notified bodies and global health authorities. Further, all sites under FDA jurisdiction are rated as either No Action Indicated (where there was no Form 483 observation) or Voluntary Action Indicated (“VAI”) (where there was a Form 483 with one or more observations). In the case of VAI inspection outcomes, the FDA has accepted our responses to the issues cited, which will be verified when the agency makes its next inspection of those specific facilities. A Form 483 is issued at the end of each inspection when FDA investigators have observed any condition that in their judgment may constitute violations of current good manufacturing practices.
We also subcontract the manufacturing of certain of our products, including products manufactured under the rights acquired from other pharmaceutical companies. Products representing approximately 20% of our product sales for 2020 are produced in total, or in part, by third-party manufacturers under manufacturing arrangements.
In some cases, the principal raw materials, including active pharmaceutical ingredients, used by us (or our third-party manufacturers) for our various products are purchased in the open market or are otherwise available from several sources. However, some of the active pharmaceutical ingredients and other raw materials used in our products and some of the finished products themselves are currently only available from a single source; or others may in the future become available from only one source. For example, with respect to some of our largest or most significant products, the supply of the finished product for each of our Siliq®, Duobrii®, Bryhali®, Lumify®, Trulance®, Vyzulta®, SofLens®, Wellbutrin XL®, Ocuvite®, PreserVision®, Renu®, Xenazine®, Aplenzin®, Relistor® Oral and PureVision® products are only available from a single source and the supply of active pharmaceutical ingredient for each of our Siliq®, Duobrii®, Bryhali®, Trulance®, Vyzulta®, Xenazine®, Aplenzin®, and Relistor® Oral products are also only available from a single source. Any disruption in the supply of any such single-sourced active pharmaceutical ingredient, other raw material or finished product or an increase in the cost of such materials or products could adversely impact our ability to manufacture or sell such products, the ability of our third-party manufacturers to supply us with such products, or our profitability. We attempt to manage the risks associated with reliance on single sources of active pharmaceutical ingredient, other raw materials or finished products by carrying additional inventories or, where possible, developing second sources of supply. See Item 1A. “Risk Factors” for additional information on the risks associated with our manufacturing arrangements.
Our global supply team worked diligently to stay ahead of the challenges presented by the COVID-19 pandemic once it appeared in Asia. See Item 7. "Management's Discussion and Analysis — Impacts of COVID-19 Pandemic" for further information.
Human Capital Resources
In order to achieve our vision of being a trusted health care partner, we strive to ensure our employees around the world feel proud to be a part of Bausch Health Companies Inc.
As of December 31, 2020, we had approximately 21,600 employees, which included approximately 11,100 in production, 7,600 in sales and marketing, 1,600 in general and administrative positions and 1,300 in R&D. These employees are located around the world, with 7,100 in the United States and Canada, 6,500 in Europe, 2,800 in the Middle East and Africa, 2,400 in Asia-Pacific countries, 2,100 in Latin America, and 700 in Russia and Commonwealth of Independent State countries.
Collective bargaining exists for some employees in several countries in which we do business. We consider our relations with our employees to be good and have not experienced any work stoppages, slowdowns or other serious labor problems that have materially impeded our business operations.
During fiscal 2020, our voluntary turnover rate was lower than in prior years, partially attributable to the impact of the COVID-19 pandemic. We have not experienced any significant business disruption to date as a result of turnover, and we regularly conduct an employee engagement survey globally in order to keep a pulse on the organization. Based on the survey results, we believe that our employees are proud to work for Bausch Health Companies Inc. and 87% would recommend our Company as a good place to work.
14


Health, Safety and Wellness
Our employees' health, safety, and wellness are important to us. With the COVID-19 outbreak, a focus in 2020 was protecting the health and safety of our employees and their families. We broadened our existing remote work policies to enable our global employees to work from home wherever possible. In circumstances where remote work was not possible (such as at our manufacturing and distribution facilities) we implemented safety measures to ensure we prevented the spread of COVID-19 in the workplace, such as mandatory face coverings, social distancing, hand hygiene, plexiglass barriers, limited face-to-face meetings and other procedures as prescribed by global public health organizations, such as the WHO and U.S. Centers for Disease Control and Prevention.
On an ongoing basis, we measure how well we are fostering the health and safety of our employees through our Days Away Rate ("DAR"), which captures globally the number of days that our employees are away from work due to illness or injury. In 2020, we achieved an annual DAR of 11, which surpassed our annual goal of 13 and exceeds the industry standard of 24 days away.
We also recognize that physical, emotional and financial wellbeing are significant contributors to our employees success at work and home, especially in 2020. We aim to support our employees in all aspects of their everyday life by centering programs and activities around these three pillars of wellbeing. Across each of these pillars, we offer a range of resources to help our employees be healthy and feel successful in both their professional and personal lives, including through employee assistance programs. For 2020, we also provided resources for our employees specifically in response to COVID-19, including launching a website – Collaborating in the New Normal – to help our employees encourage each other, lead with empathy and adapt as we navigated these unprecedented times.
Diversity and Inclusion
We are dedicated to fostering an inclusive work environment where everyone feels welcomed, supported and valued for their talents and contributions. Our Bausch Health Diversity & Inclusion ("D&I") strategy centers on connecting our employees to our Company, each other, and our communities to cultivate a sense of trust, respect and belonging for all. We have a D&I Council that is led by our Company's Executive Committee members sponsored by our Chief Human Resources Officer, General Counsel, and Chief Medical Officer/President R&D that provides oversight for our D&I strategy and initiatives.
We strive to advance candid conversations among our employees about racism and expanding diversity and inclusion training and education for them. Specifically, we have provided all employees with educational tools and resources to understand how to talk about these topics at work and have introduced training aimed at helping employees become more aware of unconscious biases.
We are focused on continuing to expand our Employee Resource Groups ("ERGs"), providing opportunities for professional growth, development and informal networking. The Bausch Health Women’s Leadership Network advances the growth and leadership development of women at our Company. In 2020, they facilitated a roundtable discussion with three female members of our Executive Committee – our Chief Human Resources Officer, General Counsel, and President of our Diversified Business – to discuss their views on the most important qualities of leadership. They also hosted guest speakers focused on the importance of building resilience and practicing mindfulness, as well as effectively managing stress. Our Bausch Health Military Network Employee Resource Group was recently formed as well, and in their inaugural year they hosted a virtual Veterans Day tribute and organized a Toys for Tots drive to support local communities.
Talent Development
We are committed to the development of our employees and believe that our success coincides with our employees’ achievements of personal and professional goals.
Through our Employee Development Framework, we endeavor to support our employees’ interests to grow to their full potential, achieve career goals, and contribute to the success of our Company. We empower employees to explore roles that are of interest and gain insights into their strengths and development needs. We provide a variety of development programs to support our employees at every stage of their career and incorporate individual development plans that aim to help our employees reach their career goals.
We also have a robust, global succession planning process that allows us to define talent needs based on business strategy, identify talent and drive their development and growth, strengthen the pipeline for critical leadership positions, and optimize talent deployment across the business. As detailed in its charter, the Talent and Compensation Committee of the Board of Directors assists the Board with oversight of our Company’s talent management and succession planning process. The Board of Directors reviews succession planning progress and specifically the plans for Executive Committee roles. To support
15


this process, the Board interacts with leaders and managers throughout the organization during the year to get to know these employees and their work.
Total Rewards
Our Company’s total rewards philosophy is designed to attract, retain, motivate, and engage our employees. We provide comprehensive and market competitive compensation and benefit programs across our geographies, aligning these programs with the interests of our shareholders and balancing appropriate risk taking. Collectively, these programs comprise our Total Rewards package.
Our compensation program includes base pay, short-term incentives, and long-term incentives. We provide the opportunity for our employees to earn more when we deliver against objectives – both as a total company and individually. We also provide competitive benefit programs based on local practice in the countries where our employees work. Our programs include medical coverage, retirement benefits, paid time off, and life and other insurances. Based on local market practice in the geographies in which we operate, we also offer family planning benefits to our employees such as adoption and surrogacy assistance programs.
Corporate Social Responsibility
In 2017, we established The Bausch Foundation, which supports initiatives aimed at disease prevention, improving patient outcomes, and community support related to our core businesses. Additionally, it supports global relief efforts and those who need help in the communities in which we live and work.
The support of our employees is essential to the success of the foundation. For example, in order to offer support to others during the pandemic, we established a campaign for our employees to donate to Feeding America, with the foundation matching up to $100,000 of these contributions. Our employees may also submit a request to the foundation for a financial contribution to support the charitable efforts of an organization they support. During 2020, the foundation, which is managed by our employees, donated medicines and health care products to assist in the global fight against the COVID-19 virus.
We are committed to supporting patients who have lost employment health benefits due to the COVID-19 pandemic, and because it is important to continue prescribed treatments, we are proud to offer certain of our prescription medicines through our Bausch Health Assistance Program. In the face of the COVID-19 pandemic, some people have financial obstacles that keep them from obtaining and continuing their prescribed treatments. The purpose of the Bausch Health Patient Assistance Program is to provide eligible unemployed patients in the U.S., who have lost their health insurance due to the COVID-19 pandemic, with certain of our prescription products although their financial circumstances or insurance status may otherwise interfere with their ability to do so. If approved, patients receive their Bausch Health Companies Inc. prescription product(s) at no cost to them for up to one year, and may be able to reapply to the program annually if they continue to meet eligibility requirements and have a valid prescription.
See Item 7. “Management's Discussion and Analysis — Overview — Focus on Core Businesses — Improve Patient Access” for additional discussion regarding Company programs to address the affordability and availability of our products.
Product Liability Insurance
Since March 31, 2014, we have self-insured substantially all of our product liability risk for claims arising after that date. In the future, we will continue to re-evaluate our decision to self-insure and may purchase additional product liability insurance to cover product liability risk. See Item 1A. “Risk Factors” of this Form 10-K for additional information.
Seasonality of Business
Historically, revenues from our business tend to be weighted toward the second half of the year. Sales in the first quarter tend to be lower as patient co-pays and deductibles reset at the beginning of each year.  Sales in the fourth quarter tend to be higher based on consumer and customer purchasing patterns associated with health care reimbursement programs. However, there are no assurances that these historical trends will continue in the future.
Geographic Areas
A significant portion of our revenues is generated from operations or otherwise earned outside the U.S. and Canada. All of our foreign operations are subject to risks inherent in conducting business abroad, including price and currency exchange controls, fluctuations in the relative values of currencies, political and economic instability and restrictive governmental actions including possible nationalization or expropriation. Changes in the relative values of currencies may materially affect our results of operations. For a discussion of these risks, see Item 1A. “Risk Factors” of this Form 10-K.
16


See Note 22, "SEGMENT INFORMATION" to our audited Consolidated Financial Statements for revenues and long-lived assets by geographic area.
A portion of our revenue and income was earned in Canada and Ireland, which have low effective tax rates. See Item 1A. “Risk Factors” of this Form 10-K relating to tax rates for more information.
Available Information
Our Internet address is www.bauschhealth.com. We post links on our website to the following filings as soon as reasonably practicable after they are electronically filed or furnished to the SEC: annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendment to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended. All such filings are available through our website free of charge. The information on our Internet website is not incorporated by reference into this Form 10-K or our other securities filings and is not a part of such filings. The SEC also maintains an Internet website at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers, including us, that file electronically with the SEC.
We are also required to file reports and other information with the securities commissions in all provinces in Canada. You are invited to read and copy any reports, statements or other information, other than confidential filings, that we file with the provincial securities commissions. These filings are also electronically available from the Canadian System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com, the Canadian equivalent of the SEC’s electronic document gathering and retrieval system.
17


Item 1A.    Risk Factors
Our business, financial condition, cash flows and results of operations are subject to various risks and uncertainties. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Form 10-K, including those risks set forth under the heading entitled “Forward-Looking Statements” and in other documents that we file with the SEC and the CSA, before making any investment decision with respect to our common shares or debt securities. If any of the risks or uncertainties actually occur or develop, our business, financial condition, cash flows, results of operations and/or future growth prospects could change, and such change could be materially adverse. Under these circumstances, the market value of our common shares and/or debt securities could decline, and you could lose all or part of your investment in our common shares and/or debt securities.
Summary of Risk Factors
The following is a summary of the risk factors our business faces. The list below is not exhaustive, and investors should read this “Risk Factors” section in full. Some of the risks we face include:
the effect of the COVID-19 pandemic on our business, financial condition, cash flows, and results of operations;
the impact on our business from the separation of our eye-health business into an independent publicly traded entity;
the ongoing legal proceedings, investigations, and inquiries respecting certain of our historical distribution, marketing, pricing, disclosure and accounting practices;
the impact of changes to our pricing practices, whether imposed, legislated or voluntary;
the potential adverse impact of legal proceedings, litigation, and government investigations;
our dependence on third parties to meet their contractual, legal, regulatory, and other obligations;
the impact of product recalls and related product liability claims;
our ability to comply with extensive regulation concerning marketing, promotional and business practices;
our ability to comply with restrictive covenants in our debt agreements;
our ability to generate cash in order to service our debt;
the impact on our business of restrictions imposed by our significant indebtedness;
the effect of interest rate changes, including the potential discontinuation of LIBOR;
our ability to recruit and retain executives and key personnel;
the potential increase of our effective tax rates;
our ability to compete with generic competitors in products that represent a significant amount of our revenue;
our ability to obtain, maintain, enforce or defend the intellectual property rights required to conduct our business;
our ability to develop or acquire more effective or less costly pharmaceutical or OTC products or medical devices than our competitors;
the effect of our commitment to the cessation of or limitation on pricing increases for certain of our products;
the impact of divestitures of certain of our assets and business;
the potential adverse effect of acquisitions of assets, products and businesses;
our ability to maintain and provide appropriate training in our products to our health care providers;
our ability to achieve or maintain expected levels of market acceptance for our new products;
our dependence on reimbursements from governmental and other third-party payors;
the impact of a failure to be included in formularies developed by managed care organizations and third-party payors;
the failure of our fulfillment arrangements with Walgreens and our dermatology cash-pay prescription program;
18


risks associated with the international scope of our operations;
foreign currency exposure on the translation into U.S. dollars of the financial results of our international operations;
our ability to successfully commercialize our pipeline products;
our ability to comply with ongoing regulatory review of our marketed drugs;
the effect that the United Kingdom’s exit from the European Union may have on the development, regulatory approval and review of our products;
the impact on our business of interruptions in our manufacturing processes;
our dependence on a limited number of sources for certain of our finished products and raw materials;
the effect of changes in inventory levels or fluctuations in buying patterns by our large distributor and retail customers;
our ability to comply with applicable laws and regulations and prevail in any litigation related to noncompliance;
the impact that reforms of the health care system may have on our ability to sell our products profitably;
our ability to comply with environmental laws and regulations and environmental remediation obligations;
the potential adverse effect of shareholder activism;
the impact on our profitability from the potential impairment of goodwill and other intangible assets;
the breakdown, interruption, breach or other compromise of our information technology systems;
our ability to effectively monitor and respond to expectations regarding environmental, social and governance matters;
the restatement of our previously issued financial statements and potential exposure to additional risks therefrom;
the decline in pricing and/or volume of our products in our distribution agreements with other companies;
the illegal distribution and sale of counterfeit versions of our products;
the reduction of profits due to imports from countries where our products are available at lower prices;
the reduction of revenues in future fiscal periods due to our policies regarding returns, allowances, and chargebacks;
the decline in sales volumes or prices of our products as the result of the concentration of sales to wholesalers;
our potential obligations under our indemnity agreements and arrangements; and
the fluctuation of our operating results and financial condition from quarter to quarter.
Risk Relating to COVID-19
The ongoing COVID-19 pandemic, the rapidly evolving reaction of governments, private sector participants and the public to that pandemic and/or the associated economic impact of the pandemic and the reactions to it, could adversely and materially impact our business, financial condition, cash flows and results of operations.
In December 2019, a novel strain of the coronavirus disease, COVID-19, was identified in Wuhan, China. Since then, COVID-19 has spread to other parts of the world, including the United States, Canada and Europe, and was declared a global pandemic by the World Health Organization on March 11, 2020. The pandemic and the rapidly evolving reaction of governments, private sector participants and the public in an effort to contain the spread of COVID-19 and/or address its impacts have intensified and have had significant direct and indirect effects on businesses and commerce generally, including disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions, and significantly increased demand for certain goods and services, such as pandemic-related medical services and supplies, alongside decreased demand for others, such as retail, hospitality, travel and elective surgery.
As a result of the impact of COVID-19, we have experienced delays in and postponement of our clinical trial programs and reduced demand for certain of our products due to the deferral of elective medical procedures and of doctor and dentist
19


visits. We expect to continue to experience those effects as a result of the pandemic, the reactions of governments, private sector participants and the public to the pandemic and the associated disruption to business and commerce generally.
In addition, as a result of these factors, we may experience additional disruptions that could materially impact our business, financial condition, cash flows and results of operations. For example, we may experience:
material closures or disruptions to our manufacturing sites (for example, we experienced closures at our Milan, Bothell, Washington USA sites and our two sites in China in 2020);
lack of availability of active pharmaceutical ingredients ("API"), and intermediates, or other supply chain disruptions, including for some of our key products;
alternative working arrangements, including personnel working remotely and additional cleaning or sterilization protocols at our production facilities, which could negatively impact our business should such arrangements remain for an extended period of time;
interruption or delays in the operations of the FDA, the EMA and other regulatory authorities, which may impact review and approval timelines for our planned trials and launches;
delays or difficulties in enrolling patients in our clinical trials;
delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;
diversion of health care resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;
interruption or postponement of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints;
limitations on employee resources that would otherwise be focused on our business and operations, such as the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;
delays in or postponements of our clinical trial programs as a result of “stay at home” orders affecting our research facilities or the closure of such research facilities, which may impact the timing, approval and launch of the affected clinical trial programs;
deferral of elective medical procedures and of doctor and dentist visits, and reduced usage of contact lens, which may reduce demand for certain of the Company’s products, including our contact lens products and certain branded pharmaceutical products in our eye-care, dermatology, GI and dentistry businesses; and
adverse effects on the regional economies in which we operate which could reduce demand for certain of the Company’s products.
The extent and duration of the pandemic, the reactions of governments, private sector participants and the public to that pandemic and the associated disruption to business and commerce generally, and the extent to which these may impact our business, financial condition, cash flows and results of operations in particular, will depend on future developments which are highly uncertain and many of which are outside our control and cannot be predicted with confidence. Such developments include the ultimate geographic spread and duration of the pandemic, the availability and effectiveness of vaccines for COVID-19, new information which may emerge concerning the severity of COVID-19, the effectiveness and intensity of measures to contain COVID-19 and/or address its impacts, and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on our business, financial condition, cash flows and results of operations and may exacerbate other risk factors disclosed in this Item 1A. “Risk Factors.”
Developments such as those described above, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company's business, financial condition, cash flows and results of operations.
Risk Relating to the Separation
Our plan to separate our eye-health business into an independent publicly traded entity from the remainder of the Company is subject to various risks and uncertainties and may not be completed in accordance with the expected plans or anticipated
20


timeline, or at all, and will involve significant time, expense, and distraction, which could disrupt or have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
On August 6, 2020, we announced that we intend to separate our eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the “Separation”). The Separation will establish two separate companies that include: (i) a fully integrated eye-health company which will consist of our Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmology Rx businesses and (ii) a diversified pharmaceutical company which will include our Salix, International Rx, Solta, neurology and medical dermatology pharmaceutical businesses. The anticipated Separation is subject to regulatory approvals and certain conditions, including final approval by the Company’s Board of Directors, any shareholder vote requirements that may be applicable, compliance with (including completion of all necessary filings required by) U.S. and Canadian securities laws and stock exchange rules, receipt of any applicable opinions and/or rulings with respect to the Canadian and U.S. federal income tax treatment of the Separation and determination of the pro forma capitalizations of the two separate companies. The failure to satisfy all of the required conditions could delay the completion of the Separation for a significant period of time or prevent it from occurring at all.
Unanticipated developments, including disruptions to business and commerce induced by the COVID-19 pandemic, changes in market conditions, possible delays in obtaining any necessary shareholder, stock exchange, regulatory or other approval or the failure to obtain any such approvals, possible delays in obtaining any required tax opinions or rulings or the failure to obtain any such tax opinions or rulings, negotiating challenges, the uncertainty of the financial markets, changes in the law, and other challenges in executing the Separation, could delay or prevent the completion of the Separation, or cause the Separation to occur on terms or conditions that are different or less favorable than expected. While we anticipate that we will be able to complete the internal organizational design and structure of the Bausch + Lomb entity by the end of 2021, we will need to complete a number of additional steps that will depend on the ultimate structure of the transaction (in addition to obtaining the regulatory approvals and satisfying the conditions described above) before we can complete the Separation. Any changes to the Separation or delay in completing the Separation could cause us not to realize some or all of the expected benefits, or realize them on a different timeline than expected. Further, our Board of Directors could decide, either because of a failure to satisfy conditions or because of market or other factors, to abandon the Separation. No assurance can be given as to whether and when the Separation will occur or whether the Separation will achieve the benefits we expect. As a result, there can be no assurance as to the timing of the completion of the Separation or its terms, and, the information in this Form 10-K relating to the Separation is preliminary and may change as the transaction progresses and any such change may be material.
Executing the Separation will require significant resources, time and attention from our senior management and employees, which could cause distractions and divert attention and resources away from other projects and the day-to-day operation of our business. We may also experience increased difficulties in attracting, retaining, and motivating management and employees during the pendency of the Separation and following its completion. The Separation, whether or not completed, may also have an adverse impact on our relationships with our customers, suppliers and other business counterparties.
We have already incurred expenses in connection with the Separation, and expect that the process of completing the Separation will be time-consuming and involve significant additional costs and expenses, which may not yield a discernible benefit if the Separation is not completed. In addition, if the Separation is not completed, we will still be required to pay certain costs and expenses incurred in connection therewith, such as legal, accounting, and other professional and advisory fees. Furthermore, the Separation, if completed, may result in potential dyssynergy costs, which may be greater than we anticipate and/or may be significant.
Any of the above factors could cause the Separation (or the failure to consummate the Separation) to have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Legal and Reputational Risks
We are the subject of a number of ongoing legal proceedings, investigations and inquiries respecting certain of our historical distribution, marketing, pricing, disclosure and accounting practices, including our former relationship with Philidor, which have had and could continue to have a material adverse effect on our reputation, business, financial condition, cash flows and results of operations, could result in additional claims and material liabilities, and could cause the market value of our common shares and/or debt securities to decline.
While we have successfully settled or otherwise resolved a number of legacy legal proceedings, investigations and inquiries relating to, among other things, our disclosure and accounting practices and our former relationship with Philidor, including the securities class action litigation matters in both the U.S. and Canada, the investigation by the SEC and the investigation order from the Autorité des marches financiers (the “AMF”) (our principal securities regulator in Canada), we are
21


currently still the subject of a number of other ongoing legal proceedings and investigations and inquiries by governmental agencies, including, but not limited to, the following: (i) a number of pending securities litigations, including certain opt-out actions in the U.S. (related to the U.S. Securities class action which has been settled, but remains subject to an objector's appeal of the final court approval), and in Canada (related to the securities class action litigation in Canada which has been settled), have been instituted, the allegations of which relate to, among other things, allegedly false and misleading statements by the Company and/or failures to disclose information about our business and prospects, including relating to drug pricing, our policies and accounting practices, our use of specialty pharmacies, and our former relationship with Philidor and (ii) purported class actions under the federal RICO statute on behalf of third-party payors arising out of our pricing and use of specialty pharmacies, and our former relationship with Philidor. In addition, we could, in the future, face additional legal proceedings and investigations and inquiries by governmental agencies relating to these or similar matters. For more information regarding legal proceedings, see Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements.
We are unable to predict how long such proceedings, investigations and inquiries will continue, but we anticipate that we will continue to incur significant costs in connection with some or all of these matters and that some or all of these proceedings, investigations and inquiries will result in a substantial distraction of management’s time, regardless of the outcome. Some or all of these proceedings, investigations and inquiries will likely result in damages, settlement payments (such as the $1,210 million payment to be made by the Company in connection with the previously settled U.S. Securities class action (subject to an objector's appeal of the final court approval)), fines, penalties, consent orders or other administrative sanctions (including exclusion from federal programs) against the Company and/or certain of our directors and officers, any of which could be material, or in changes to our business practices, which, in turn, may result in or may contribute to an inability by us to meet the financial covenant contained in our Restated Credit Agreement. Furthermore, publicity surrounding these proceedings, investigations and inquiries or any enforcement action as a result thereof, even if ultimately resolved favorably for us could result in additional investigations and legal proceedings. As a result, these proceedings, investigations and inquiries could have a material adverse effect on our reputation, business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Our historical business practices, including with respect to past pricing practices, are under scrutiny. Any changes to our practices relating to pricing or the current prices of products, whether imposed, legislated or voluntary, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
We are under scrutiny with respect to our historical business practices (including with respect to past pricing practices), including various securities litigations, including certain opt-out actions in the U.S. (related to the previously settled securities class action (subject to an objector's appeal of the final court approval)) and in Canada (related to the recently settled securities class action), and purported class actions under the federal RICO statute on behalf of third-party payors. We are unable to predict how such proceedings, investigations and inquiries will impact our current business practices, including with respect to pricing, or the prices of our products, including whether we will be required to impose pricing freezes or controls, pricing reductions (including on a retroactive basis) or other price regulation for some or all of our products.
In addition, in recent years, in the U.S., state and federal governments have considered implementing legislation that would control or regulate the prices of drugs. Other countries have announced or implemented measures on pricing, including suspensions on price increases, prospective and possibly retroactive price reductions and other recoupments. These measures and proposed measures vary by country. These measures and these proposed measures and legislation, if implemented, could lead to impairment of certain of our intangible assets which could be significant, and/or could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
We are involved in various other legal and governmental proceedings that are uncertain, costly and time-consuming and could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
We are involved in a number of other legal and governmental proceedings and may be involved in additional litigation in the future. These proceedings are complex and extended and occupy the resources of our management and employees. These proceedings are also costly to prosecute and defend and may involve substantial awards or damages payable by us if not found in our favor. We may also be required to pay substantial amounts or grant certain rights on unfavorable terms in order to settle such proceedings. Defending against or settling such claims and any unfavorable legal decisions, settlements or orders could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. For more information regarding legal proceedings, see Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements.
22


For example, the pharmaceutical industry, including our Company, has been the focus of both private payor and governmental concern regarding pricing of pharmaceutical products. Related actions, including Congressional and other governmental investigations and litigation, are costly and time-consuming, and adverse resolution of such actions or changes in our business practices, such as our approach to the pricing of our pharmaceutical products, could adversely affect our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Further, the pharmaceutical and medical device industries historically have generated substantial litigation concerning the manufacture, use and sale of products and we expect this litigation activity to continue. As a result, we expect that patents related to our products will be routinely challenged, and the validity or enforceability of our patents may not be upheld. In order to protect or enforce patent rights, we may initiate litigation against third parties. Our patents may also be challenged in administrative proceedings in the United States Patent and Trademark Office and patent offices outside of the United States. If we are not successful in defending an attack on our patents and maintaining exclusive rights to market one or more of our products still under patent protection, we could lose a significant portion of sales in a very short period. We may also become subject to infringement claims by third parties and may have to defend against charges that we infringed or otherwise violated patents or the intellectual property or proprietary rights of third parties. If we infringe or otherwise violate the intellectual property rights of others, we could lose our right to develop, manufacture or sell products, including our generic products, or could be required to pay monetary damages or royalties to license proprietary rights from third parties, which could be substantial.
In addition, in the U.S., it has become increasingly common for patent infringement actions to prompt claims that antitrust laws have been violated during the prosecution of the patent or during litigation involving the defense of that patent. Such claims by direct and indirect purchasers and other payers are typically filed as class actions. The relief sought may include treble damages and restitution claims. Similarly, antitrust claims may be brought by government entities or private parties following settlement of patent litigation, alleging that such settlements are anti-competitive and in violation of antitrust laws. In the U.S. and Europe, regulatory authorities have continued to challenge as anti-competitive so-called “reverse payment” settlements between branded and generic drug manufacturers. We may also be subject to other antitrust litigation involving competition claims unrelated to patent infringement and prosecution. For more information regarding legal proceedings, see Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements. A successful antitrust claim by a private party or government entity against us could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
We depend on third parties to meet their contractual, legal, regulatory, and other obligations.
We rely on distributors, suppliers, contract research organizations, vendors, service providers, business partners and other third parties to research, develop, manufacture, distribute, market and sell many of our products, as well as perform other services relating to our business. We rely on these third parties to meet their contractual, legal, regulatory and other obligations. A failure to maintain these relationships or poor performance by these third parties could negatively impact our business. In addition, we cannot guarantee that the contractual terms and protections and compliance controls, policies and procedures we have put in place will be sufficient to ensure that such third parties will meet their legal, contractual and regulatory obligations or that these terms, controls, policies, procedures and other protections will protect us from acts committed by our agents, contractors, distributors, suppliers, service providers or business partners that violate contractual obligations or the laws or regulations of the jurisdictions in which we operate, including matters respecting anti-corruption, fraud, kickbacks and false claims, pricing, sales and marketing practices, privacy laws and other legal obligations. Any failure of such third parties to meet these legal, contractual and regulatory obligations or any improper actions by such third parties or even allegations of such non-compliance or actions could damage our reputation, adversely impact our ability to conduct business in certain markets and subject us to civil or criminal legal proceedings and regulatory investigations, monetary and non-monetary damages and penalties and could cause us to incur significant legal and investigatory fees and, as a result, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. For example, the allegations about the activities of Philidor and our former relationship with Philidor have resulted in a number of investigations, inquiries and legal proceedings against us, which may damage our reputation and result in damages, fines, penalties or administrative sanctions against the Company and/or certain of our officers. For more information regarding legal proceedings, see Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements.
If our products cause, or are alleged to cause, serious or widespread personal injury, we may have to withdraw those products from the market and/or incur significant costs, including payment of substantial sums in damages, and we may be
23


subject to exposure relating to product liability claims. In addition, our product liability self-insurance program may not be adequate to cover future losses.
We face an inherent business risk of exposure to significant product liability and other claims in the event that the use of our products caused, or is alleged to have caused, adverse effects. These product liability proceedings may be costly to prosecute and defend and may involve substantial awards or damages payable by us if not found in our favor.
Furthermore, our products may cause, or may appear to have caused, adverse side effects (including death) or potentially dangerous drug interactions that we may not learn about or understand fully until the drug has been administered to patients for some time. The withdrawal of a product following complaints and/or incurring significant costs, including the requirement to pay substantial damages in personal injury cases or product liability cases, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
In addition, since March 31, 2014, we have self-insured substantially all of our product liability risk for claims arising after that date. We periodically evaluate and adjust our claims reserves to reflect trends in our own experience, as well as industry trends. However, historical loss trends may not be adequate to cover future losses, as historical trends may not be indicative of future losses. If ultimate results exceed our estimates, this would result in losses in excess of our reserved amounts. If we were required to pay a significant amount on account of these liabilities for which we self-insure, this could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Our marketing, promotional and business practices, as well as the manner in which sales forces interact with purchasers, prescribers and patients, are subject to extensive regulation and any material failure to comply could result in significant sanctions against us.
The marketing, promotional and business practices of pharmaceutical and medical device companies, as well as the manner in which companies’ in-house or third-party sales forces interact with purchasers, prescribers, and patients, are subject to extensive regulation, enforcement of which may result in the imposition of civil and/or criminal penalties, injunctions, and/or limitations on marketing practice for some of our products and/or pricing restrictions or mandated price reductions for some of our products. Many companies, including us, have been the subject of claims related to these practices asserted by federal authorities. These claims have resulted in fines and other consequences, such as entering into corporate integrity agreements with the U.S. government. Companies may not promote drugs for “off-label” uses-that is, uses that are not described in the product’s labeling and that differ from those approved by the FDA, Health Canada, EMA or other applicable regulatory agencies. A company that is found to have improperly promoted off-label uses may be subject to significant liability, including civil and administrative remedies (such as entering into corporate integrity agreements with the U.S. government), as well as criminal sanctions. In addition, management’s attention could be diverted from our business operations and our reputation could be damaged. For more information regarding legal proceedings, see Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements.
Debt-related Risks
Our Restated Credit Agreement and the indentures governing our senior notes impose restrictive covenants on us. Our failure to comply with these covenants could trigger events, which could result in the acceleration of the related debt, a cross-default or cross-acceleration to other debt, foreclosure upon any collateral securing the debt and termination of any commitments to lend, each of which would have a material adverse effect on our business, financial condition, cash flows and results of operations and would cause the market value of our common shares and/or securities to decline and could lead to bankruptcy or liquidation.
Our Restated Credit Agreement and the various indentures governing our senior notes contain covenants that restrict the way we conduct business and require us to satisfy certain financial tests in order to incur debt or take other actions. For example, our Restated Credit Agreement contains a financial covenant that requires us to maintain a certain financial ratio at fiscal quarter end.
The Company’s Restated Credit Agreement contains a specified quarterly financial maintenance covenant (consisting of a first lien leverage ratio). As of December 31, 2020, we were in compliance with this financial maintenance covenant. However, we can make no assurance that we will be able to comply with the restrictive covenants contained in the Restated Credit Agreement and indentures in the future. Based on our current forecast for the next twelve months from the date of issuance of this Form 10-K, we expect to remain in compliance with this financial maintenance covenant and meet our debt obligations over that same period. In the event that we perform below our forecasted levels, we may also implement certain additional cost-efficiency initiatives, such as rationalization of selling, general and administrative expenses ("SG&A") and R&D spend, which would allow us to continue to comply with the financial maintenance covenant. The Company may consider taking other
24


actions, including divesting other businesses, refinancing debt, issuing equity or equity-linked securities as deemed appropriate, to provide additional coverage in complying with the financial maintenance covenant and meeting its debt service obligations, or may negotiate with the applicable lenders for an amendment or modification to such covenant, as deemed appropriate. However, we cannot guarantee that any of the above-noted actions would be achieved. If we perform below our forecasted levels and the actions referenced above are not effective, we would fail to comply with our financial maintenance covenant. In that instance, we would be in default, and our lenders would be permitted to accelerate our debt unless we could obtain an amendment. If our debt was accelerated, we would not have sufficient funds to repay our debt absent a refinancing, and we cannot provide assurance that we would be able to obtain a refinancing.
Our inability to comply with the covenants in our debt instruments could lead to a default or an event of default under the terms thereof, for which we may need to seek relief from our lenders and noteholders in order to waive the associated default or event of default and avoid a potential acceleration of the related indebtedness or cross-default or cross-acceleration to other debt. There can be no assurance that we would be able to obtain such relief on commercially reasonable terms or otherwise and we may be required to incur significant additional costs. In addition, the lenders under our Restated Credit Agreement and holders of our senior notes may impose additional operating and financial restrictions on us as a condition to granting any such waiver. If an event of default is not cured or is not otherwise waived, a majority of lenders in principal amount under our Restated Credit Agreement or the trustee or holders of at least 25% in principal amount of a series of our senior notes may accelerate the maturity of the related debt under these agreements, foreclose upon any collateral securing the debt and terminate any commitments to lend, any of which would have a material adverse effect on our business, financial condition, cash flows and results of operations and would cause the market value of our securities to decline. Furthermore, under these circumstances, we may not have sufficient funds or other resources to satisfy all of our obligations and we may be unable to obtain alternative financing on terms acceptable to us or at all. In such circumstances, we could be forced into bankruptcy or liquidation and, as a result, investors could lose all or a portion of their investment in our securities.
To service our debt, we will be required to generate a significant amount of cash. Our ability to generate cash depends on a number of factors, some of which are beyond our control, and any failure to meet our debt obligations would have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
We have a significant amount of indebtedness. For details regarding our debt and the maturity dates thereof, see Note 10, "FINANCING ARRANGEMENTS" to our audited Consolidated Financial Statements. Our ability to satisfy our debt obligations will depend principally upon our future operating performance. As a result, prevailing economic conditions and financial, business and other factors, many of which are beyond our control, may affect our ability to make payments on our debt. If we do not generate sufficient cash flow to satisfy our debt obligations, we may have to undertake alternative financing plans, such as refinancing or restructuring our debt, selling assets, reducing or delaying capital investments or seeking to raise additional capital. Alternatively, as we have done in the past, we may also elect to refinance certain of our debt, for example, to extend maturities. Our ability to restructure or refinance our debt will depend on the capital markets and our financial condition at such time. If we are unable to access the capital markets, whether because of the condition of those capital markets or our own financial condition or reputation within such capital markets, we may be unable to refinance our debt. In addition, any refinancing of our debt could be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations. Further, given our capital structure, any refinancing of our senior unsecured debt may be with secured debt, thereby increasing our first lien and/or secured leverage ratios. Our inability to generate sufficient cash flow to satisfy our debt obligations or to refinance our obligations on commercially reasonable terms, or at all, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Repayment of our indebtedness is dependent on the generation of cash flow by our subsidiaries and their ability to make such cash available to us, by dividend, debt repayment or otherwise. Our subsidiaries may not be able to, or may not be permitted to, make distributions to enable us to make payments in respect of our indebtedness. Each subsidiary is a distinct legal entity and, under certain circumstances, legal and contractual restrictions may limit our ability to obtain cash from our subsidiaries. Certain subsidiaries include non-U.S. subsidiaries that may be prohibited by law or other regulations from distributing funds to us and/or we may be subject to payment of taxes and withholdings on such distributions. In the event that we do not receive distributions from our subsidiaries or receive cash via services rendered, loans and intellectual property licensed, we may be unable to make required principal and interest payments on our indebtedness.
Our ability to continue to reduce our indebtedness will depend upon factors including our future operating performance, our ability to access the capital markets to refinance existing debt and prevailing economic conditions and financial, business and other factors, many of which are beyond our control. We can provide no assurance of the amount by which we will reduce our debt, if at all. In addition, servicing our debt will result in a reduction in the amount of our cash flow available for other
25


purposes, including operating costs and capital expenditures that could improve our competitive position and results of operations.
We have incurred significant indebtedness, which restricts the manner in which we conduct business.
We have incurred significant indebtedness, including in connection with our prior acquisitions. We may incur additional long-term debt and working capital lines of credit to meet future financing needs, subject to certain restrictions and prohibitions under the agreements governing our indebtedness, which would increase our total debt. This additional debt may be substantial and some of this indebtedness may be secured.
The agreements governing our indebtedness contain restrictive covenants which impose certain limitations on the way we conduct our business, including limitations on the amount of additional debt we are able to incur, prohibitions on incurring additional debt if certain financial covenants are not met and restrictions on our ability to make certain investments and other restricted payments. Any additional debt, to the extent we are able to incur it, may further restrict the manner in which we conduct business. Such restrictions, prohibitions and limitations could impact our ability to implement elements of our strategy, including in the following ways:
our flexibility to plan for, or react to, competitive challenges in our business and the pharmaceutical and medical device industries may be compromised;
we may be put at a competitive disadvantage relative to competitors that do not have as much debt as we have, and competitors that may be in a more favorable position to access additional capital resources;
our ability to make acquisitions and execute business development activities through acquisitions will be limited and may, in future years, continue to be limited; and
our ability to resolve regulatory and litigation matters may be limited.
In the past, our credit ratings have been downgraded. Any further downgrade in our corporate credit ratings or other credit ratings may increase our cost of borrowing and may negatively impact our ability to raise additional debt capital.
We are exposed to risks related to interest rates.
Our senior secured credit facilities bear interest based on U.S. dollar London Interbank Offering Rates or U.S. Prime Rate, or Federal Funds effective rate (for U.S. dollar loans) and Canadian Prime Rate or Canada Bankers’ Acceptance Rate (for Canadian dollar loans). Thus, a change in the short-term interest rate environment (especially a material change) could have an adverse effect on our business, financial condition, cash flows and results of operations (which adverse effect could be material) and could cause the market value of our common shares and/or debt securities to decline. As of December 31, 2020, we did not have any outstanding interest rate swap contracts.
In July 2017, the head of the United Kingdom Financial Conduct Authority announced the desire to phase out the use of LIBOR by the end of 2021. In November 2020, ICE Benchmark Administration Limited, the administrator of LIBOR, announced that it will consult on its intention to cease the publication of the one week and two month USD LIBOR settings immediately following the LIBOR publication on December 31, 2021 and the remaining USD LIBOR settings immediately following the LIBOR publication on June 30, 2023. If LIBOR ceases to exist, we will need to endeavor, with the administrative agent thereunder, to amend the credit facilities to substitute LIBOR with an alternative rate of interest that gives due consideration to the then-prevailing market convention for syndicated loans in the U.S., subject to notice to all lenders and the absence of objection by the “required lenders,” or pay interest based on the "base rate" until we can otherwise renegotiate our Senior Secured Credit Facilities to include a LIBOR replacement. Any change in accordance with the aforementioned procedures, or the conversion of loans to base rate or U.S. prime rate loans, could have an adverse impact on our cost of capital. Currently, there is no definitive information regarding the future utilization of LIBOR or of any particular replacement rate. As such, the potential effect of any such event on our business, financial condition, cash flows and results of operations cannot yet be determined. However, any such event could have a material adverse effect on our business, financial condition, cash flows and results from operations and could cause the market value of our common shares and/or debt securities to decline.
Employment-related Risks
The loss of the services of, or our inability to recruit, retain or motivate, our executives and other key employees could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
We must continue to retain and motivate our executives and other key employees, and to recruit other executives and employees, in order to strengthen our management team and workforce. Our ability to retain or recruit executive and other key employees may be hindered or delayed by, among other things, competition from other employers who may be able to offer more attractive compensation packages or the reputational challenges the Company faces as a result of historical issues and may
26


in the future continue to face. A failure by us to retain, motivate and recruit executives and other key employees or the unanticipated loss of the services of any of these executives or key employees for any reason, whether temporary or permanent, could create disruptions in our business, could cause concerns and instability for management and employees, current and potential customers, credit rating agencies and other third parties with whom we do business and our shareholders and debt holders and could cause concern regarding our ability to execute our business strategy or to manage operations in the manner previously conducted and, as a result, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. Furthermore, as a result of any failure to retain, or loss of, any executives or key employees, we may experience increased costs in order to identify and recruit a suitable replacement in a timely manner (and, even if we are able to hire a qualified successor, the search process and transition period may be difficult to manage and result in additional periods of uncertainty), which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. In addition, once identified and recruited, the transition of new executives and key employees may be difficult to manage and we cannot guarantee that new executives and employees will efficiently transition into their roles or ultimately be successful in their roles. Finally, as a result of changes in our executives and key employees, there may be changes in the way we conduct our business, as well as changes to our business strategy. We cannot predict what these changes may involve or the timing of any such changes and how they will impact our product sales, revenue, business, financial condition, cash flows or results of operations, but any such changes could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. Any of these factors could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Tax-related Risks
Our effective tax rates may increase.
We have operations in various countries that have differing tax laws and rates. Our tax reporting is supported by current domestic tax laws in the countries in which we operate and the application of tax treaties between the various countries in which we operate. Our income tax reporting is subject to audit by domestic and foreign authorities. Our effective tax rate may change from year to year based on changes in the mix of activities and income earned among the different jurisdictions in which we operate; changes in tax laws in these jurisdictions; changes in the tax treaties between various countries in which we operate; changes in our eligibility for benefits under those tax treaties; and changes in the estimated values of deferred tax assets and liabilities. Tax laws, regulations, and administrative practices in various jurisdictions may be subject to significant change, with or without notice, due to economic, political, and other conditions, and significant judgment is required in evaluating and estimating our provision and accruals for these taxes. Such changes could result in a substantial increase in the effective tax rate on all or a portion of our income.
Our provision for income taxes is based on certain estimates and assumptions made by management. Our consolidated income tax rate is affected by the amount of pre-tax income earned in our various operating jurisdictions, the availability of benefits under tax treaties, and the rates of taxes payable in respect of that income. We enter into many transactions and arrangements in the ordinary course of business in respect of which the tax treatment is not entirely certain. We therefore make estimates and judgments based on our knowledge and understanding of applicable tax laws and tax treaties, and the application of those tax laws and tax treaties to our business, in determining our consolidated tax provision. For example, certain countries could seek to tax a greater share of income than we will allocate to our business in such countries. The final outcome of any audits by taxation authorities may differ from the estimates and assumptions that we may use in determining our consolidated tax provisions and accruals. This could result in a material adverse effect on our consolidated income tax provision, financial condition and the net income for the period in which such determinations are made.
Our deferred tax liabilities, deferred tax assets and any related valuation allowances are affected by events and transactions arising in the ordinary course of business, acquisitions of assets and businesses, and non-recurring items. The assessment of the appropriate amount of a valuation allowance against the deferred tax assets is dependent upon several factors, including estimates of the realization of deferred income tax assets, which realization will be primarily based on future taxable income, including the reversal of existing taxable temporary differences. Significant judgment is applied to determine the appropriate amount of valuation allowance to record. Changes in the amount of any valuation allowance required could materially increase or decrease our provision for income taxes in a given period.
See Note 17, "INCOME TAXES" to our audited Consolidated Financial Statements.
Risks Relating to Intellectual Property and Exclusivity
27


Products representing a significant amount of our revenue are not protected by patent or marketing or data exclusivity rights or are nearing the end of their exclusivity period. In addition, we have faced generic competition in the past and expect to face additional generic competition in the future. Competitors (including generic and biosimilar competitors) of our products could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
A significant number of the products we sell either: (i) have no meaningful exclusivity protection via patent or marketing or data exclusivity rights or (ii) are protected by patents or regulatory exclusivity periods that will be expiring in the near future. These products represent a significant amount of our revenues (See Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Business Trends — Generic Competition and Loss of Exclusivity” in this Form 10-K for a list of some of these products). Without exclusivity protection, competitors and other third parties (including generics and biosimilars) face fewer barriers in introducing competing products. Upon the expiration or loss of patent exclusivity or regulatory exclusivity for our products or otherwise upon the introduction of generic, biosimilar or other competitors (which may be sold at significantly lower prices than our products), we could lose a significant portion of sales and market share of the applicable products in a very short period and, as a result, our revenues could be lower. In addition, the introduction of generic and biosimilar competitors may have a significant downward pressure on the pricing of our branded products which compete with such generics and biosimilars. Where we have the rights, we may elect to launch an authorized generic of such product (either ourselves or through a third party) prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with the launch of an authorized generic, the decline in product sales of such product would still be expected to be significant, and the effect on our future revenues could be material. The introduction of competing products (including generic products and biosimilars) could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
We may fail to obtain, maintain, license, enforce or defend the intellectual property and proprietary rights required to conduct our business, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
We strive to acquire, maintain, enforce and defend patent, trademark and other intellectual property and proprietary protections over our products and the processes used to manufacture these products. However, we may not be successful in obtaining such protections, or the patent, trademark and other intellectual property and proprietary rights we do obtain may not be sufficient in breadth and scope to fully protect our products or prevent competing products, or such rights may be susceptible to third-party challenges, which could result in the loss of such intellectual property rights or the narrowing of scope of protection afforded by such rights. Our intellectual property and proprietary rights may also be circumvented by third parties. The failure to obtain, maintain, enforce or defend such intellectual property and proprietary rights, for any reason, could allow third parties to manufacture and sell products that compete with our products or may impact our ability to develop, manufacture and market our own products, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
For certain of our products and manufacturing processes, we rely on trade secrets and other proprietary information, which we seek to protect, in part, by confidentiality and nondisclosure agreements with our employees, contractors, consultants, advisors and partners. We also seek to enter into agreements whereby such employees, contractors, consultants, advisors and partners assign to us the rights in any intellectual property they develop. We may not enter into such agreements with all applicable parties, such agreements may be breached or otherwise may not effectively prevent disclosure or misappropriation of such information, and disputes may still arise with respect to the ownership of intellectual property. In addition, third parties may independently develop the same or similar proprietary information. The disclosure of such proprietary information or the loss of such intellectual property and proprietary rights may impact our ability to develop, manufacture and market our own products or may assist competitors or other third parties in the development, manufacture and sale of competing products, which could have a material adverse effect on our revenues, financial condition, cash flows or results of operations and could cause the market value of our common shares and/or debt securities to decline.
For a number of our commercialized products and pipeline products, including Xifaxan®, Siliq®, Lumify®, Plenvu®, Vyzulta®, Relistor®, Jublia® and the pipeline products that are the subject of our recently announced licenses with Eyenovia, Inc., Novaliq GmbH, BHVI and Clearside Biomedical, Inc., we rely on licenses to patents and other technologies, know-how and intellectual property and proprietary rights held by third parties. Any loss, expiration, termination or suspension of our rights to such licensed intellectual property would result in our inability to continue to develop, manufacture and market the applicable products or product candidates and, as a result, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. In the future, we may also need to obtain additional licenses from third parties to develop, manufacture, market or continue to manufacture or market our products. If we are unable to timely obtain these licenses on commercially reasonable terms or at all, our ability to develop, manufacture and market our products may be inhibited or prevented, which could have a
28


material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Competitive Risks
We operate in extremely competitive industries. If competitors develop or acquire more effective or less costly pharmaceutical or OTC products or medical devices for our target indications, it could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
The pharmaceutical, OTC and medical device industries are extremely competitive. Our success and future growth depend, in part, on our ability to develop, license or acquire products that are more effective than those of our competitors or that incorporate the latest technologies and our ability to effectively manufacture and market those products. Many of our competitors, particularly larger pharmaceutical, OTC and medical device companies, have substantially greater financial, technical and human resources than we do. Many of our competitors spend significantly more on research and development related activities than we do. Others may succeed in developing or acquiring products and technologies that are more effective, more advanced or less costly than those currently marketed or proposed for development by us. In addition, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products and may also establish exclusive collaborative or licensing relationships with our competitors. These competitors and the introduction of competing products (that may be more effective or less costly than our products) could make our products less competitive or obsolete, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Risks Relating to Our Business Strategy
We have made commitments and public statements with respect to the cessation of or limitation on pricing increases for certain of our products. These pricing decisions could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
In May 2016, we formed a new Patient Access and Pricing Committee responsible for the pricing of our drugs. The new committee’s first action was a recommendation, which we implemented, for an enhanced rebate program to all hospitals in the U.S. to reduce the price of our Nitropress® and Isuprel® products. In addition, the Patient Access and Pricing Committee made a commitment that the average annual price increase for our branded prescription pharmaceutical products will be set at no greater than single digits. This commitment was reaffirmed for 2021. All future pricing actions will be subject to review by the Patient Access and Pricing Committee and we expect that the Patient Access and Pricing Committee will implement or recommend additional price changes and/or new programs to enhance patient access to our drugs.
At this time, we cannot predict what specific pricing changes the committee will make nor can we predict what other changes in our business practices we may implement with respect to pricing (such as imposing limits or prohibitions on the amount of pricing increases we may take on certain of our products or taking retroactive or future price reductions). We also cannot predict the impact such pricing decisions or changes will or would have on our business. However, any such changes could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
For example, any pricing changes and programs could affect the average realized prices for our products and may have a significant impact on our revenue trends. In addition, limiting or eliminating price increases on certain of our products will result in fewer or lower price appreciation credits from certain of our wholesalers. Price appreciation credits are generated when we increase a product’s wholesaler acquisition cost (“WAC”) under our contracts with certain wholesalers. Under such contracts, we are entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. In wholesaler contracts, such credits, which can be significant, are offset against the total distribution service fees we pay on all of our products to each wholesaler. As a result, to the extent we decide to cease or limit price increases, we will have fewer or lower price appreciation credits to use to offset against our distribution fees owing to these wholesalers. In addition, under certain of our agreements with our wholesaler customers, we have price protection or price depreciation provisions, pursuant to which we have agreed to adjust the value of any on-hand or in-transit inventory with such customers in the event we reduce the price of any of our products. As a result, to the extent we reduce the WAC price for any of our products, we may owe a payment to such customers (or such customers may earn a credit to be offset against any amounts owing to us) equal to the amount of such inventory multiplied by the difference between the price at which they acquired the product inventory and the new reduced price.
29


In prior years, we have undertaken a number of divestitures of certain of our assets and business. We may, in the future, seek to divest additional asset and/or businesses, some of which may be material and/or transformative, which could adversely affect our business, prospects and opportunities for growth.
In recent years, we have completed a number of divestitures of our assets, products or businesses that were not considered core to our ongoing operations or the needs of our primary-customer base, including the divestitures of our Obagi Medical Products business, our iNova Pharmaceuticals business, our Dendreon Pharmaceuticals subsidiary, our Sprout Pharmaceuticals subsidiary and the CeraVe®, AcneFree and AMBI® skincare brands. We may, in the future, seek to complete additional divestitures.
Each of these divestitures has been time-consuming and has diverted management’s attention. As a result of these divestitures (and others we may in the future complete), we may experience lower revenue and lower cash flows from operations. In addition, as was the case with our sale of our Sprout Pharmaceuticals subsidiary, we may recognize a loss on sale in connection with such divestitures. We may also suffer adverse tax consequences as a result of such divestitures, including capital gains tax or the accelerated use of NOLs or other attributes. Furthermore, divesting certain of our businesses or assets may require us to incur restructuring charges, and we may not be able to achieve the cost savings that we expect from any such restructuring efforts or divestitures. Any such divestiture could reduce the size or scope of our business, our market share in particular markets, our opportunities with respect to certain markets, products or therapeutic categories or our ability to compete in certain markets and therapeutic categories. Furthermore, we will be required to use the net proceeds (or substantial portions thereof) from certain asset sales to repay the term loans under the Restated Credit Agreement, subject to certain reinvestment rights.
In addition, should we seek to divest other of our assets and business, we may be unable to dispose of such businesses and assets on satisfactory or commercially reasonable terms within our anticipated timeline. In addition, our ability to identify, enter into and/or consummate divestitures may be limited by competition we face from other companies in pursuing similar transactions in the pharmaceutical industry. Any divestiture or other disposition we pursue, whether we are able to complete it or not, may be complex, time consuming and expensive, may divert the management’s attention, have a negative impact on our customer relationships, cause us to incur costs associated with maintaining the business of the targeted divestiture during the disposition process and also to incur costs of closing and disposing the affected business or transferring the operations of the business to other facilities. The divestiture process may also further expose us to operational inefficiencies. In addition, if such transactions are not completed for any reason, the market price of our common shares may reflect a market assumption that such transactions will occur, and a failure to complete such transactions could result in a negative perception by the market of us generally and a decline in the market price of our common shares.
As a result of these factors, any divestiture (whether or not completed) could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
As part of our business strategy, we seek to identify and acquire certain assets, products and businesses.
Historically, part of our business strategy included acquiring and integrating complementary businesses, products, technologies or other assets. As part of our current business strategy, we again are seeking to complete certain acquisitions of assets, products and businesses, including by way of in-license arrangements, although not at the volume and pace that we did historically. Acquisitions or similar arrangements may be complex, time consuming and expensive. We may not consummate some negotiations for acquisitions or other arrangements, which could result in significant diversion of management and other employee time, as well as substantial out-of-pocket costs. In addition, there are a number of risks and uncertainties relating to our closing transactions. If such transactions are not completed for any reason, we will be subject to several risks, including the following: (i) the market price of our common shares may reflect a market assumption that such transactions will occur, and a failure to complete such transactions could result in a negative perception by the market of us generally and a decline in the market price of our common shares; and (ii) many costs relating to such transactions may be payable by us whether or not such transactions are completed.
If an acquisition is consummated, the integration of the acquired business, product or other assets into our Company may also be complex and time-consuming and, if such businesses, products and assets are not successfully integrated, we may not achieve the anticipated benefits, cost-savings or growth opportunities. Potential difficulties that may be encountered in the integration process include the following: integrating personnel, operations and systems, while maintaining focus on selling and promoting existing and newly-acquired products; coordinating geographically dispersed organizations; distracting management and employees from operations; retaining existing customers and attracting new customers; maintaining the business relationships the acquired company has established, including with health care providers; and managing inefficiencies associated with integrating the operations of the Company and the acquired business, product or other assets.
30


Furthermore, we may incur restructuring and integration costs and a number of non-recurring transaction costs associated with these acquisitions, combining the operations of the Company and the acquired company and achieving desired synergies. These fees and costs may be substantial. Non-recurring transaction costs include, but are not limited to, fees paid to legal, financial and accounting advisors, filing fees and printing costs. Additional unanticipated costs may be incurred in the integration of the businesses of the Company and the acquired company. There can be no assurance that the elimination of certain duplicative costs, as well as the realization of other efficiencies related to the integration of the acquired business, will offset the incremental transaction-related costs over time. Therefore, any net benefit may not be achieved in the near term, the long term or at all.
Finally, these acquisitions and other arrangements, even if successfully integrated, may fail to further our business strategy as anticipated or to achieve anticipated benefits and success, expose us to increased competition or challenges with respect to our products or geographic markets, and expose us to additional liabilities associated with an acquired business, product, technology or other asset or arrangement. Any one of these challenges or risks could impair our ability to realize any benefit from our acquisition or arrangement after we have expended resources on them.
If we fail to maintain our relationships with, and provide appropriate training in our products to, health care providers, including physicians, hospitals, large drug store chains, wholesale distributors, pharmacies, government entities and group purchasing organizations, customers may not buy certain of our products and our sales and profitability may decline.
We market our pharmaceutical products to physicians, hospitals, pharmacies and wholesalers through our own sales force and sell through wholesalers. In some markets, we additionally sell directly to physicians, hospitals and large drug store chains and we sell through distributors in countries where we do not have our own sales staff. We have developed and strive to maintain strong relationships with members of each of these groups who assist in product research and development and advise us on how to satisfy the full range of consumer needs. We rely on these groups to recommend our products to their patients and to other members of their organizations. Consumers in the pharmaceutical industry, particularly the contact lens and lens care customers in the eye-health industry, have a tendency not to switch products regularly and are repeat consumers. As a result, the success of certain of our products, particularly our vision care products, is impacted by a physician's initial recommendation of such products and a consumer's initial choice to use such products. As a result, the failure of certain of our products, particularly in our vision care business, to retain the support of pharmaceutical professionals, hospitals or group purchasing organizations and to retain the support of the end-users and the distributors and retailers to whom we sell such products, could have a material adverse effect on our sales and profitability.
Commercialization Risks
Our approved products may not achieve or maintain expected levels of market acceptance.
Even if we are able to obtain and maintain regulatory approvals for our pharmaceutical and medical device products, generic or branded, the success of these products is dependent upon achieving and maintaining market acceptance. Launching and commercializing products is time consuming, expensive and unpredictable. The commercial launch of a product takes significant time, resources, personnel and expertise, which we may not have in sufficient levels to achieve success, and is subject to various market conditions, some of which may be beyond our control. There can be no assurance that we will be able to, either by ourselves or in collaboration with our partners or through our licensees or distributors, successfully launch and commercialize new products or gain market acceptance for such products. New product candidates that appear promising in development may fail to reach the market or may have only limited or no commercial success. While we have been successful in launching some of our products, we may not achieve the same level of success with respect to all of our new products. Our inability to successfully launch our new products may negatively impact the commercial success of such product, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. Our inability to successfully launch our new products could also lead to material impairment charges.
Levels of market acceptance for our new products could be impacted by several factors, some of which are not within our control, including but not limited to the following:
safety, efficacy, convenience and cost-effectiveness of our products compared to products of our competitors;
scope of approved uses and marketing approval;
availability of patent or regulatory exclusivity;
timing of market approvals and market entry;
ongoing regulatory obligations following approval, such as the requirement to conduct a Risk Evaluation and Mitigation Strategy ("REMS") programs;
any restrictions or “black box” warnings required on the labeling of such products;
availability of alternative products from our competitors;
31


acceptance of the price of our products;
effectiveness of our sales forces and promotional efforts;
the level of reimbursement of our products;
acceptance of our products on government and private formularies;
ability to market our products effectively at the retail level or in the appropriate setting of care; and
the reputation of our products.
Further, the market perception and reputation of our products and their safety and efficacy are important to our business and the continued acceptance of our products. Any negative publicity about our products, such as the discovery of safety issues with our products, adverse events involving our products, or even public rumors about such events, could have a material adverse effect on our business, financial condition, cash flows or results of operation or could cause the market value of our common shares and/or debt securities to decline. In addition, the discovery of significant problems with a product similar to one of our products that implicate (or are perceived to implicate) an entire class of products or the withdrawal or recall of such similar products could have a material adverse effect on sales of our products. Accordingly, new data about our products, or products similar to our products, could cause us reputational harm and could negatively impact demand for our products due to real or perceived side effects or uncertainty regarding safety or efficacy and, in some cases, could result in product withdrawal.
If our products fail to gain, or lose, market acceptance, our revenues would be adversely impacted and we may be required to take material impairment charges, all of which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
For certain of our products, we depend on reimbursement from governmental and other third-party payors and a reduction in reimbursement could reduce our product sales and revenue. In addition, failure to be included in formularies developed by managed care organizations and coverage by other organizations may negatively impact the utilization of our products, which could harm our market share and could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Sales of certain of our products are dependent, in part, on the availability and extent of reimbursement from government health administration authorities, private health insurers, pharmacy benefit managers and other organizations of the costs of our products and the continued reimbursement and coverage of our products in such programs. Changes in government regulations or private third-party payors’ reimbursement policies may reduce reimbursement for our products. In addition, such third-party payors may otherwise make the decision to reduce reimbursement of some or all our products or fail to cover some or all our products in such programs or assert that reimbursements were not in accordance with applicable requirements. For example, these decisions may be based on the price of our products or our current or former pricing practices and decisions. Any reduction or elimination of such reimbursement or coverage could result in a negative impact on the utilization of our products and, as a result, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Managed care organizations and other third-party payors try to negotiate the pricing of medical services and products to control their costs. Managed care organizations and pharmacy benefit managers typically develop formularies to reduce their cost for medications. Formularies can be based on the prices and therapeutic benefits of the available products. Due to their lower costs, generic products are often favored. The breadth of the products covered by formularies varies considerably from one managed care organization to another, and many formularies include alternative and competitive products for treatment of particular medical conditions. Failure to be included in such formularies or to achieve favorable formulary status may negatively impact the utilization and market share of our products. If our products are not included within an adequate number of formularies or adequate reimbursement levels are not provided, or if those policies increasingly favor generic products, this could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Our fulfillment arrangements with Walgreens and our dermatology cash-pay prescription program may not be successful.
At the beginning of 2016, we launched a brand fulfillment arrangement with Walgreen Co. ("Walgreens"), pursuant to which we have made certain of our dermatology and ophthalmology products available to eligible patients through a patient access and co-pay program available at Walgreens U.S. retail pharmacy locations, as well as participating independent retail pharmacies. We have, in the past, experienced certain operational and other issues respecting this arrangement, including lower than anticipated average realized prices associated with these products through this arrangement. In July 2019, we entered into an amendment to the existing fulfillment agreement to address some of these issues. We cannot guarantee this arrangement will continue to be successful in the future, nor can we guarantee that additional operational issues will not be encountered, nor can we guarantee that we will be able to successfully negotiate with Walgreens any improvements or amendments to this arrangement we identify as necessary or desired. In addition, we cannot predict how the market, including customers, doctors,
32


patients, pharmacy benefit managers and third-party payors, or governmental agencies, will continue to react to these arrangements and programs. If this arrangement or program fails, if they do not achieve sufficient success and market acceptance, if we face retaliation from third parties as a result of this arrangement and program (for example, in the form of limitations on or exclusions from the reimbursement of our products) or if any part of this arrangement is found to be non-compliant with applicable law or regulations, this could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
In addition, in February 2019, we launched Dermatology.com, a cash-pay product acquisition program offering certain branded Ortho Dermatologics products directly to patients. In March 2020, the name Dermatology.com was removed as the cash-pay product program name, with the name Dermatology.com limited to only online usage, including future digital teledermatology and e-commerce offerings. This program is designed to address the affordability and availability of certain branded dermatology products, when insurers and pharmacy benefit managers are no longer offering those branded prescription pharmaceutical products under their designated pharmacy benefit offerings. We cannot guarantee that this program will be successful or that we will continue to add new products to the program. In addition, we cannot predict how the market, including customers, doctors and patients will react to this program. If this program fails, if it does not achieve sufficient success and market acceptance or if any part of this program is found to be non-compliant with applicable law or regulations, this could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Risks Relating to the International Scope of our Business
Our business, financial condition, cash flows and results of operations are subject to risks arising from the international scope of our operations.
We conduct a significant portion of our business outside the U.S. and Canada and may, in the future, expand our operations into new countries, including emerging markets. We sell our pharmaceutical and medical device products in many countries around the world. All of our foreign operations are subject to risks inherent in conducting business abroad, including, among other things:
difficulties in coordinating and managing foreign operations, including ensuring that foreign operations comply with foreign laws as well as Canadian and U.S. laws applicable to Canadian companies with U.S. and foreign operations, such as export and sanctions laws and the U.S. Foreign Corrupt Practices Act (“FCPA”), the Canadian Corruption of Foreign Public Officials Act, and other applicable worldwide anti-bribery laws;
price and currency exchange controls;
restrictions on the repatriation of funds;
scarcity of hard currency, including the U.S. dollar, which may require a transfer or loan of funds to the operations in such countries, which they may not be able to repay on a timely basis;
political and economic instability;
compliance with multiple regulatory regimes;
compliance with economic sanctions laws and other laws that apply to our activities in the countries where we operate;
less established legal and regulatory regimes in certain jurisdictions, including as relates to enforcement of anti-bribery and anti-corruption laws and the reliability of the judicial systems;
differing degrees of protection for intellectual property;
unexpected changes in foreign regulatory requirements, including quality standards and other certification requirements;
new export license requirements;
adverse changes in tariff and trade protection measures;
differing labor regulations;
potentially negative consequences from changes in or interpretations of tax laws;
restrictive governmental actions;
possible nationalization or expropriation;
credit market uncertainty;
differing local practices, customs and cultures, some of which may not align or comply with our Company practices and policies or U.S. laws and regulations;
difficulties with licensees, contract counterparties, or other commercial partners; and
differing local product preferences and product requirements.
As a result of changes to U.S. policy, there may be changes to existing trade agreements and greater restrictions on trade generally. On November 30, 2018, the United States, Canada and Mexico signed the United States-Mexico-Canada Agreement
33


(“USMCA”) as an overhaul and update to the North American Free Trade Agreement. It is difficult to anticipate the full impact of this agreement on our business, financial condition, cash flows and results of operations.
Notwithstanding the USMCA, support for protectionism and rising anti-globalization sentiment in the United States and other countries may slow global growth. In particular, a protracted and wide-ranging trade conflict between the United States and China could adversely affect global economic growth. Concerns also remain around the social, political and economic impacts of the changing political landscape in Europe, including the final outcome of Brexit (as defined below) negotiations. In addition, there are growing concerns over an economic slowdown in emerging markets in light of capital outflows in favor of developed markets and expected interest rate increases. Broader geopolitical tensions remained high amongst the U.S., Russia, China, and across the Middle East.
Given the international scope of our operations, any of the above factors, including tariffs, trade wars and other governmental actions, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Similarly, adverse economic conditions impacting our customers in these countries or uncertainty about global economic conditions could cause purchases of our products to decline, which would adversely affect our revenues and operating results. Moreover, our projected revenues and operating results are based on assumptions concerning certain levels of customer spending. Any failure to attain our projected revenues and operating results as a result of adverse economic or market conditions could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Due to the large portion of our business conducted in currency other than U.S. dollars, we have significant foreign currency risk.
We face foreign currency exposure on the translation into U.S. dollars of the financial results of our operations in Europe, Canada, Latin America, Asia, Africa and the Middle East and other regions. Where possible, we manage foreign currency risk by managing same currency revenue in relation to same currency expenses. We may also use derivative financial instruments from time to time to mitigate our foreign currency risk and not for trading or speculative purposes. We face foreign currency exposure in those countries where we have revenue denominated in the local foreign currency and expenses denominated in other currencies. Both favorable and unfavorable foreign currency impacts to our foreign currency-denominated operating expenses are mitigated to a certain extent by the natural, opposite impact on our foreign currency-denominated revenue. In addition, the repurchase of our U.S. dollar denominated debt may result in foreign exchange gains or losses for Canadian income tax purposes. One half of any foreign exchange gains or losses will be included in our Canadian taxable income. Any foreign exchange gain will result in a corresponding reduction in our available Canadian tax attributes. Further strengthening of the U.S. dollar and/or the devaluation of other countries' currencies could have a negative impact on our reported international revenue.
Development and Regulatory Risks
The successful development of our pipeline products is highly uncertain and requires significant expenditures and time. In addition, obtaining necessary government approvals is time-consuming and not assured. The failure to commercialize certain of our pipeline products could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
We currently have a number of pipeline products in development. We and our development partners, as applicable, conduct extensive preclinical studies and clinical trials to demonstrate the safety and efficacy in humans of our pipeline products in order to obtain regulatory approval for the sale of our pipeline products. Preclinical studies and clinical trials are expensive, complex, can take many years and have uncertain outcomes. None of, or only a small number of, our research and development programs may actually result in the commercialization of a product. We will not be able to commercialize our pipeline products if preclinical studies do not produce successful results or if clinical trials do not demonstrate safety and efficacy in humans. Furthermore, success in preclinical studies or early-stage clinical trials does not ensure that later stage clinical trials will be successful nor does it ensure that regulatory approval for the product candidate will be obtained. In addition, the process for the completion of pre-clinical and clinical trials is lengthy and may be subject to a number of delays for various reasons, which would delay the commercialization of any successful product. If our development projects are not successful or are significantly delayed, we may not recover our substantial investments in the pipeline product and our failure to bring these pipeline products to market on a timely basis, or at all, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
In addition, FDA and Health Canada approval must be obtained in the U.S. and Canada, respectively, EMA approval (drugs) and CE Marking (devices) must be obtained in countries in the EU and similar approvals must be obtained from
34


comparable agencies in other countries, prior to marketing or manufacturing new pharmaceutical and medical device products for use by humans. Obtaining such regulatory approvals for new products and devices and manufacturing processes can take a number of years and involves the expenditure of substantial resources. Furthermore, the Trump administration took several executive actions, including the issuance of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA’s ability to engage in routine regulatory and oversight activities such as issuance of guidance and review and approval of marketing applications. It is unclear how these executive actions will be implemented or whether they will be rescinded or replaced under the Biden administration, and therefore their effects on the FDA approval process cannot be determined at this time.
Even if such products appear promising in development stages, regulatory approval may not be achieved and no assurance can be given that we will obtain approval in those countries where we wish to commercialize such products. Nor can any assurance be given that if such approval is secured, the approved labeling will not have significant labeling limitations, including limitations on the indications for which we can market a product, or require onerous risk management programs. Furthermore, from time to time, changes to the applicable legislation or regulations may be introduced that change these review and approval processes for our products, which changes may make it more difficult and costly to obtain or maintain regulatory approvals.
Our marketed drugs will be subject to ongoing regulatory review.
Following initial regulatory approval of any products, we or our partners may develop or acquire, we will be subject to continuing regulatory review by various government authorities in those countries where our products are marketed or intended to be marketed, including the review of adverse drug events and clinical results that are reported after product candidates become commercially available. In addition, we are subject to ongoing audits and investigations of our facilities and products by the FDA, as well as other regulatory agencies in and outside the U.S.
If we fail to comply with the regulatory requirements in those countries where our products are sold, we could lose our marketing approvals or be subject to fines or other sanctions. Also, as a condition to granting marketing approval of a product, the applicable regulatory agencies may require a company to conduct additional clinical trials or remediate Current Good Manufacturing Practice ("CGMP") issues, the results of which could result in the subsequent loss of marketing approval, changes in product labeling or new or increased concerns about side effects or efficacy of a product.
In May 2017, the European Commission published the Medical Device Regulation (MDR) 2017/745, which replaced the Medical Device Directive (MDD). Pursuant to the terms of the new regulations, in order to continue to market medical device products in the EU, such products must achieve compliance with these new regulations and be re-registered in the EU within a specified transition period, which, for a portion of products, will end as early as May 26, 2021. These new regulations impact all of our existing and pipeline medical device products being sold in the EU for which we are legal manufacturer and/or distributor, including contact lens, lens care, eye-health, aesthetic and surgical areas, as well as certain of our products outside the EU, which rely on the EU registration to support registration in those other countries. These products, in the aggregate, account for a meaningful portion of our net revenue in this region. While we are working to ensure compliance with these new regulations for all impacted products, we may not be able to achieve compliance for all products within the applicable transition period. If we fail to achieve compliance, we will not be able to market and sell the non-compliant products in the EU, nor will we be able to rely on the non-compliant registration for such products in regions outside of the EU, which could have a material adverse effect on our business, financial condition, cash flows and results of operations in the EU and, possibly, on a consolidated basis, and could cause the market value of our common shares and/or debt securities to decline.
In addition, incidents of adverse drug reactions, unintended side effects or misuse relating to our products could result in additional regulatory controls or restrictions, or even lead to the regulatory authority requiring us to withdraw the product from the market. Further, if faced with these incidents of adverse drug reactions, unintended side effects or misuse relating to our products, we may elect to voluntarily implement a recall or market withdrawal of our product. A recall or market withdrawal, whether voluntary or required by a regulatory authority, may involve significant costs to us, potential disruptions in the supply of our products to our customers and reputational harm to our products and business, all of which could harm our ability to market our products and could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
The United Kingdom’s exit from the European Union may impact the development and the regulatory approval and review of our products.
On June 23, 2016, the United Kingdom held a referendum on its membership in the European Union, in which United Kingdom voters approved an exit from the European Union (“Brexit”). On March 29, 2017, the United Kingdom formally notified the European Council pursuant to Article 50 of the Treaty of Lisbon of its intention to leave the European Union. On January 31, 2020 (“Exit Day”), the United Kingdom ceased to be a member state of the European Union. EU law applicable to
35


the United Kingdom continued to apply to and in the United Kingdom for the duration of a transition period which expired on December 31, 2020 (the “Transition Period”). During the Transition Period, the European Union and the United Kingdom negotiated the terms of their future relationship and on December 31, 2020 entered into a Trade and Cooperation Agreement, an Agreement on Nuclear Cooperation and an Agreement on Security Procedures for Exchanging and Protecting Classified Information. Subject to certain exceptions, domestic law derived from EU law, EU law directly applicable in the UK and EU rights, powers, liabilities and obligations recognized and available in the UK in each case immediately before the expiration of the Transition Period was retained by the UK, but in the future UK law may diverge from EU law. Following the Brexit vote, the European Union moved the European Medicines Agency’s headquarters from the United Kingdom to the Netherlands, which could result in disruptions and delays in new drug approvals in the European Union. In addition, we could face new regulatory costs and challenges that could have a material adverse effect on our business, financial condition, cash flows and results of operations.
Manufacturing and Supply Risks
If we or our third-party manufacturers are unable to manufacture our products or the manufacturing process is interrupted due to failure to comply with regulations or for other reasons, the interruption of the manufacture of our products could adversely affect our business. Other manufacturing and supply difficulties or delays may also have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Our manufacturing facilities and those of our contract manufacturers must be inspected and found to be in full compliance with CGMP, quality system management requirements or similar standards before approval for marketing. Compliance with CGMP regulations requires the dedication of substantial resources and requires significant expenditures. In addition, while we attempt to build in certain contractual obligations on our third-party manufacturers, we may not be able to ensure that such third-parties comply with these obligations. Our failure or that of our contract manufacturers to comply with CGMP regulations, quality system management requirements or similar regulations outside of the U.S. could result in enforcement action by the FDA or its foreign counterparts, including, but not limited to, warning letters, fines, injunctions, civil or criminal penalties, recall or seizure of products, total or partial suspension of production or importation, suspension or withdrawal of regulatory approval for approved or in-market products, refusal of the government to renew marketing applications or approve pending applications or supplements, refusal of certificates for export to foreign jurisdictions, suspension of ongoing clinical trials, imposition of new manufacturing requirements, closure of facilities and criminal prosecution. These enforcement actions could lead to a delay or suspension in production, which could have a material adverse effect on our competitive position, business, financial condition, results of operations and cash flows.
In addition, our manufacturing and other processes use complicated and sophisticated equipment, which sometimes requires a significant amount of time to obtain and install. Manufacturing complexity, testing requirements and safety and security processes combine to increase the overall difficulty of manufacturing these products and resolving manufacturing problems that we may encounter. Although we endeavor to properly maintain our equipment (and require our contract manufacturers to properly maintain their equipment), including through on-site quality control and experienced manufacturing supervision, and have key spare parts on hand, our business could suffer if certain manufacturing or other equipment, or all or a portion of our or their facilities, were to become inoperable for a period of time. We could experience substantial production delays or inventory shortages in the event of any such occurrence until we or they repair such equipment or facility or we or they build or locate replacement equipment or a replacement facility, as applicable, and seek to obtain necessary regulatory approvals for such replacement. Any interruption in our manufacture of products could adversely affect the sales of our current products or introduction of new products and could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
The supply of our products to our customers (or, in some cases, supply from our contract manufacturers to us) is subject to and dependent upon the use of transportation services. Disruption of transportation services (including as a result of weather conditions) could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. In addition, any prolonged disruption in the operations of our existing distribution facilities, whether due to technical, labor or other difficulties, weather conditions, equipment malfunction, contamination, failure to follow specific protocols and procedures, destruction of or damage to any facility or other reasons, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
For some of our finished products and raw materials, we obtain supply from one or a limited number of sources. If we are unable to obtain components or raw materials, or products supplied by third parties, our ability to manufacture and deliver our products to the market would be impeded, which could have a material adverse effect on our business, financial
36


condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Some components and raw materials used in our manufactured products, and some finished products sold by us, are currently available only from one or a limited number of domestic or foreign suppliers. For example, with respect to some of our largest or most significant products, the supply of the finished product for each of our Siliq®, Duobrii®, Bryhali®, Lumify®, Trulance®, Vyzulta®, SofLens®, Wellbutrin XL®, Ocuvite®, PreserVision®, Renu®, Aplenzin®, Xenazine®, Relistor® Oral and PureVision® products are only available from a single source and the supply of active pharmaceutical ingredient for each of our Siliq®, Duobrii®, Bryhali®, Trulance®, Vyzulta®, Xenazine®, Aplenzin® and Relistor® Oral products are also only available from a single source. In the event an existing supplier fails to supply product on a timely basis and/or in the requested amount, supplies product that fails to meet regulatory requirements, becomes unavailable through business interruption or financial insolvency or loses its regulatory status as an approved source or we are unable to renew current supply agreements when such agreements expire and we do not have a second supplier, we may be unable to obtain the required components, raw materials or products on a timely basis or at commercially reasonable prices. We attempt to mitigate these risks by maintaining safety stock of these products, but such safety stock may not be sufficient. In addition, in some cases, only a single source of active pharmaceutical ingredient is identified in filings with regulatory agencies, including the FDA, and cannot be changed without prior regulatory approval, which would involve time and expense to us. A prolonged interruption in the supply of a single-sourced raw material, including the active pharmaceutical ingredient, or single-sourced finished product could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. In addition, these third-party manufacturers may have the ability to increase the supply price payable by us for the manufacture and supply of our products, in some cases without our consent.
As a result, our dependence upon others to manufacture our products may adversely affect our profit margins and our ability to obtain approval for and produce our products on a timely and competitive basis, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Changes in inventory levels or fluctuations in buying patterns by our large distributor and retail customers may adversely affect our sales and earnings and add to sales variability from quarter to quarter.
We balance the need to maintain inventory levels that are sufficient to ensure competitive lead times against the risk of inventory obsolescence because of changing customer requirements, fluctuating commodity prices, changes to our products, product transfers or the life-cycle of our products. In order to successfully manage our inventories, we must estimate demand from our customers and produce products that substantially correspond to that demand. If we fail to adequately forecast demand for any new or existing product, or fail to determine the appropriate product mix for production purposes, we may face production capacity issues in manufacturing sufficient quantities of a given product. In addition, failures in our information technology systems or human error could also lead to inadequate forecasting of our overall demand or product mix.
We have a significant number of unique products, and we anticipate that number will continue to grow over time. As a result, the demand forecasting precision required for us to avoid production capacity issues will also increase, which could increase the risk of product unavailability and lost sales. Additionally, an increasing number of unique products could increase global inventory requirements, negatively impacting our working capital performance and leading to write-offs due to obsolescence and expired products.
Due to the lead times necessary to obtain and install new equipment and ramp up production of product lines, if we fail to adequately forecast the need for additional manufacturing capacity, whether for new or existing products, we may be unable to scale production in a timely manner to meet demand for our products. In addition, the technically complex manufacturing processes required to manufacture many of our products increase the risk of production failures, and can increase the cost of producing our goods. As a result, because the production process for many of our products is so complex and sensitive, the cost of production and the chance of production failures and lengthy supply interruptions is increased, which can have a substantial impact on our inventory levels.
Finally, a significant portion of our products are sold to major health care distributors and major retail chains in Canada, the United States and abroad. Consequently, our sales and quarterly growth comparisons, as well as our estimates for required inventory levels, may be affected by fluctuations in the buying patterns of major distributors, retail chains and other trade buyers. These fluctuations may result from seasonality, pricing, large retailers' and distributors' buying decisions or other factors. If we overestimate demand and produce too much of a particular product, we face a risk of inventory obsolescence, leaving us with inventory that we cannot sell profitably or at all. In addition, we may have to write down such inventory if we are unable to sell it for its recorded value. Conversely, if we underestimate demand and produce insufficient quantities of a product, we could be forced to produce that product at a higher price and forego profitability in order to meet customer demand. For example, if a competitor initiates a recall and there is an unexpected increase in the demand for our products, we may not be
37


able to meet such increased demand. Insufficient inventory levels may lead to shortages that result in loss of sales opportunities altogether as potential end-customers turn to competitors' products that are readily available. If any of these situations occur frequently or in large volumes or if we are unable to effectively manage our inventory and that of our distribution partners, this could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Risks Relating to Specific Legislation and Regulations
We are subject to various laws and regulations, including “fraud and abuse” laws, anti-bribery laws, environmental laws and privacy and security regulations, and a failure to comply with such laws and regulations or prevail in any litigation related to noncompliance could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Pharmaceutical and medical device companies have faced lawsuits and investigations pertaining to violations of health care “fraud and abuse” laws, such as the federal False Claims Act, the federal Anti-Kickback Statute (“AKS”) and other state and federal laws and regulations. The AKS prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any health care item or service reimbursable under federally financed health care programs. This statute has been interpreted to apply to arrangements between pharmaceutical or medical device manufacturers, on the one hand, and prescribers, purchasers, formulary managers and other health care related professionals, on the other hand. More generally, the federal False Claims Act, among other things, prohibits any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government. Pharmaceutical and medical device companies have been prosecuted or faced civil liability under these laws for a variety of alleged promotional and marketing activities, including engaging in off-label promotion that caused claims to be submitted for non-covered off-label uses. If we are in violation of any of these requirements or any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, this could have a significant impact on our business, including the imposition of significant criminal and civil fines and penalties, exclusion from federal health care programs or other sanctions, including consent orders or corporate integrity agreements.
In addition, the U.S. Department of Health and Human Services Office of Inspector General recommends, and increasingly states require pharmaceutical companies to have comprehensive compliance programs. Moreover, the Physician Payment Sunshine Act enacted in 2010 imposes reporting and disclosure requirements on device and drug manufacturers for any “transfer of value” made or distributed to prescribers and other health care providers. Failure to submit this required information may result in significant civil monetary penalties. While we have developed corporate compliance programs based on what we believe to be current best practices, we cannot provide assurance that we or our employees or agents are or will be in compliance with all applicable federal, state or foreign regulations and laws. If we are in violation of any of these requirements or any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant criminal and civil fines and penalties, exclusion from federal health care programs or other sanctions, including consent orders or corporate integrity agreements.
The U.S. FCPA and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to officials for the purpose of obtaining or retaining business. Our policies mandate compliance with these anti-bribery laws. We operate in many parts of the world that have experienced governmental corruption and in certain circumstances, strict compliance with anti-bribery laws may conflict with local customs and practices or may require us to interact with doctors and hospitals, some of which may be state controlled, in a manner that is different than in the U.S. and Canada. We cannot provide assurance that our internal control policies and procedures will protect us from reckless or criminal acts committed by our employees, consultants, distributors, third party contractors or agents. Violations of these laws, or allegations of such violations, could disrupt our business and result in criminal or civil penalties or remedial measures, any of which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
We are also subject to various state, federal and international laws and regulations governing the collection, transmission, dissemination, use, privacy, confidentiality, security, retention, availability, integrity and other processing of health-related and other sensitive and personal information, including HIPAA. Many states in which we operate have laws that protect the privacy and security of sensitive and personal information, including health-related information. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance efforts. For example, the CCPA imposes stringent data privacy and security requirements and obligations with respect to the personal information of California residents and provides for civil penalties for violations, as well as a private right of action for certain data breaches that result in the loss of personal data that may increase the likelihood of, and risks associated with, data breach litigation. The effects on our business of the CCPA and other similar state laws are potentially significant, and may require us to
38


modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply. State laws are changing rapidly and there is discussion in Congress of a new federal data protection and privacy law to which we may be subject.
Internationally, laws and regulations in many jurisdictions apply broadly to the collection, transmission, dissemination, use, privacy, confidentiality, security, retention, availability, integrity and other processing of health-related and other sensitive and personal information. For example, the GDPR, together with national legislation, regulations and guidelines of the EU member states and the United Kingdom governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze, store, transfer and otherwise process personal data, including health data from clinical trials and adverse event reporting. The GDPR authorizes fines for certain violations of up to 4% of global annual revenue or €20 million, whichever is greater. European data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which contributes to the complexity of processing personal data in or from the EEA or United Kingdom. Guidance on implementation and compliance practices is often updated or otherwise revised. We are also subject to Canada's federal Personal Information Protection and Electronic Documents Act and substantially similar equivalents at the provincial level with respect to the collection, use and disclosure of personal information in Canada. Such federal and provincial legislation impose data privacy and security obligations on our processing of personal information of Canadian residents. The federal and Alberta legislation include mandatory data breach notification requirements. Canada’s Anti-Spam Legislation (“CASL”) also applies to the extent that we send commercial electronic messages from Canada or to electronic addresses in Canada. CASL contains prescriptive consent, form, content and unsubscribe mechanism requirements. Penalties for non-compliance with CASL are up to CAD $10 million per violation. These laws and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible they will be interpreted and applied in ways that will materially and adversely affect our business. The regulatory framework for data privacy, data security and data transfers worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Complying with all of these laws and regulations involves costs to our business, and failure to comply with these laws and regulations can result in the imposition of significant civil and criminal penalties, as well as litigation, all of which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. For more information regarding applicable data privacy and security laws and regulations, see Item 1. “Business — Government Regulations” of this Form 10-K.
We are also subject to U.S. federal laws regarding reporting and payment obligations with respect to our participation in federal health care programs, including Medicare and Medicaid. Because our processes for calculating applicable government prices and the judgments involved in making these calculations involve subjective decisions and complex methodologies, these calculations are subject to risk of errors and differing interpretations. In addition, they are subject to review and challenge by the applicable governmental agencies, and it is possible that such reviews could result in changes that could have material adverse legal, regulatory, or economic consequences.
Legislative or regulatory reform of the health care system may affect our ability to sell our products profitably and could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
In the U.S. and certain foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health care system in ways that could impact our ability to sell our products profitably. The Patient Protection and Affordable Care Act, as amended by the Health Care Reform Act may affect the operational results of companies in the pharmaceutical and medical device industries, including the Company and other health care related industries, by imposing on them additional costs. Effective January 1, 2010, the Health Care Reform Act increased the minimum Medicaid drug rebates for pharmaceutical companies, expanded the 340B drug discount program, and made changes to affect the Medicare Part D coverage gap, or “donut hole.” The law also revised the definition of “average manufacturer price” for reporting purposes, which may affect the amount of our Medicaid drug rebates to states. Beginning in 2011, the law imposed a significant annual fee on companies that manufacture or import branded prescription drug products. More recently, the Bipartisan Budget Act of 2018 amended the Patient Protection and Affordable Care Act, effective January 1, 2019, to close the donut hole in most Medicare drug plans. In addition, in April 2018, the Centers for Medicare & Medicaid Services published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the Patient Protection and Affordable Care Act for plans sold through such marketplaces.
Although efforts at replacing the Health Care Reform Act have stalled in Congress, there are a number of proposals that we expect to be introduced to Congress and put forth by the Biden administration, including proposals relating to drug pricing and drug delivery reforms, that may result in further changes to the health care system that could materially impact the Company. We cannot predict what those changes will be or when they will take effect, and we could face additional risks arising from such changes. Because of this continued uncertainty, the number of proposals and the indeterminable position that
39


the Biden administration may take with regard to the Health Care Reform Act, we cannot quantify or predict with any certainty the likely impact of these proposals on our business model, prospects, financial condition or results of operations, in particular on the pricing, coverage or reimbursement of any of our product candidates that may receive marketing approval. Additionally, policy efforts designed specifically to reduce patient out-of-pocket costs for medicines could result in new mandatory rebates and discounts or other pricing restrictions. Legislative efforts relating to drug pricing, the cost of prescription drugs under Medicare, the relationship between pricing and manufacturer patient programs, and government program reimbursement methodologies for drugs have been proposed and considered at the U.S. federal and state level. While some of these proposed measures will require authorization through additional legislation to become effective, Congress and the administration have each indicated an intent to continue to seek new legislative or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We also anticipate that Congress, state legislatures, and third-party payors may continue to review and assess alternative health care delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations effecting additional fundamental changes in the health care delivery system. We cannot provide assurance as to the ultimate content, timing, or effect of changes, nor is it possible at this time to estimate the impact of any such potential legislation.
In 2019, the U.S. Health and Human Services Administration announced a preliminary plan to allow for the importation of certain lower-cost drugs from Canada. The preliminary plan excludes insulin, biological drugs, controlled substances and intravenous drugs. The preliminary plan relies on individual states to develop proposals for safe importation of those drugs from Canada and submit those proposals to the federal government for approval. At this time, studies to evaluate the related costs and benefits, evaluate the reasonableness of the logistics, and measure the public reaction of such a plan have not been performed. We cannot provide assurance as to the ultimate content, timing, effect or impact of such a plan.
In 2019, the Government of Canada (Health Canada) published in the Canadian Gazette the new pricing regulation for patented drugs. These regulations will become effective on July 1, 2021. The new regulations will change the mechanics of establishing the pricing for products submitted for approval after August 21, 2019; they will also require full transparency of discounts agreed with provincial bodies; and finally, will change the number and composition of reference countries used to determine if a drug’s price is excessive. While we do not believe this will have a significant impact on our future cash flows, as additional facts materialize, we cannot provide assurance as to the ultimate content, timing, effect or impact of such regulations.
The Health Care Reform Act and further changes to health care laws or regulatory framework that reduce our revenues or increase our costs could also have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
We are subject to a broad range of environmental laws and regulations and may be subject to environmental remediation obligations under such safety and related laws and regulations. The impact of these obligations and the Company’s ability to respond effectively to them may have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
We are subject to a broad range of federal, state, provincial and local environmental laws and regulations concerning the environment, safety matters, regulation of chemicals and product safety in the countries where we manufacture and sell our products or otherwise operate our business. These requirements include, among other matters, regulation of the handling, manufacture, transportation, storage, use and disposal of materials, including the discharge of pollutants, hazardous substances and waste into the environment. In the normal course of our business, such substances and waste may be released into the environment, which could cause environmental or property damage or personal injuries, and which could subject us to remediation obligations regarding contaminated soil and groundwater, potential liability for damage claims or to social or reputational harm and other similar adverse impacts. Under certain laws, we may be required to remediate contamination at certain of our properties regardless of whether the contamination was caused by us or by previous occupants of the property or by others and at third-party sites where we send waste.
In recent years, the operations of all companies have become subject to increasingly stringent legislation and regulation related to environmental protection. Such legislation and regulations are complex and constantly changing. Future events, such as changes in existing laws or regulations or the enforcement thereof or the discovery of contamination at our facilities may, among other things, require us to install additional controls for certain of our emission sources, undertake changes in our manufacturing processes, remediate soil or groundwater contamination at facilities where such cleanup is not currently required or to take action to address social expectations or concerns arising from or relating to such changes and our response to such changes. The cost of such additional compliance or remediation obligations or responding to such social expectations or concerns may be significant and could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
40


Other Risks
Our business and operations could be negatively affected by shareholder activism, which could cause us to incur significant expenses, hinder execution of our business strategy and impact our share price.
In recent years, shareholder activism involving corporate governance, fiduciary duties of directors and officers, strategic direction and operations has become increasingly prevalent. One of our investors, which owns approximately 7.8% of our outstanding common shares, filed a Schedule 13D with the SEC in February 2021, in which it was indicated that the investor intended to engage in discussions with our management and board regarding ways to enhance shareholder value, including our ongoing strategic review and that it may also seek board representation. Another of our investors, which owns approximately 6% of our outstanding common shares, filed a Schedule 13D with the SEC in July 2020, in which it indicated that it intended to consider, explore and/or develop plans and/or make proposals respecting, among other things, our businesses, assets, operations, and strategy, and to explore ways to strengthen the company and enhance shareholder value. In February 2021, this investor also sent the Company a public letter, in which it stated that the proposed Separation should be completed by the end of 2021 and recommended, among other things, the divestiture of certain of our businesses and assets.
In the event such investors continue to pursue such proposals or we become the subject of additional shareholder activism, this may create a significant distraction for our management and employees. This could negatively impact our ability to execute our business plans (including the Separation) and may require our management to expend significant time, resources and costs, including legal fees and other expenses incurred in connection with any proxy contest that may result from any such shareholder activism. Furthermore, if individuals are elected to our Board with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our shareholders and could lead us to adopt other plans that we cannot predict and which could focus on short-term benefits with longer-term costs. Such shareholder activism may also create uncertainties with respect to our financial position and operations, may adversely affect our ability to attract and retain key employees and may result in loss of potential business opportunities with our current and potential customers and business partners, any of which could have a material adverse effect on our business, financial condition, cash flows and results of operations. In addition, such shareholder activism may cause significant fluctuations in our share price based on temporary or speculative market perceptions, uncertainties or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business, and could cause the market value of our common shares to decline. While we will remain responsive to shareholder demands, there is no assurance that we will achieve their objectives, or that doing so will decrease the likelihood of activist shareholder engagement in the future.
We have significant goodwill and other intangible assets and potential impairment of goodwill and other intangibles may have a significant adverse impact on our profitability.
Goodwill and intangible assets represent a significant portion of our total assets. Finite-lived intangible assets are subject to an impairment analysis whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that the asset may be impaired. If impairment exists, we would be required to take an impairment charge with respect to the impaired asset.
For example, in 2020, 2019 and 2018, we recognized impairments, including a loss on assets held for sale, to finite-lived and indefinite-lived intangible assets of $114 million, $75 million and $568 million, respectively. These asset impairments were primarily attributable to: (i) assets being classified as held for sale and (ii) revisions in sales forecasts associated with discontinuances, generic competition and other market forces. In addition to impairments to finite-lived and indefinite-lived intangible assets, in 2018, we recognized goodwill impairments of $2,322 million. These impairments to goodwill were primarily the result of: (i) the adoption of new accounting guidance in 2018 and (ii) revisions to forecasts to certain reporting units, as a result of changing business dynamics and market conditions. There were no goodwill impairments in 2020 and 2019.
The Company conducted its annual goodwill impairment test as of October 1, 2020. No impairment to the goodwill of any reporting unit was identified. If market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future.
See Note 5, "FAIR VALUE MEASUREMENTS" and Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our audited Consolidated Financial Statements for further information on these impairment charges.
Events giving rise to impairment are difficult to predict, including the uncertainties associated with the launch of new products, and are an inherent risk in the pharmaceutical and medical device industries. As a result of the significance of goodwill and intangible assets, our financial condition and results of operations in a future period could be negatively impacted should such an impairment of goodwill or intangible assets occur, which could cause the market value of our common shares and/or debt securities to decline. We may be required to take additional impairment charges in the future and such impairment charges may be material.
41


We have become increasingly dependent on information technology systems and infrastructure and any breakdown, interruption, breach or other compromise of our or our third-party vendors' information technology systems could subject us to liability or interrupt the operation of our business, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
We are increasingly dependent upon our information technology systems and infrastructure, as well as those of third parties with whom we interact, and internal and public internet sites, data hosting and processing facilities, cloud-based services and hardware, social media sites and mobile technology, in connection with the conduct of our business.
We must constantly update our information technology systems and infrastructure and undertake investments in new information technology systems and infrastructure. However, we cannot provide assurance that the information technology systems and infrastructure on which we depend, including those of third parties, will continue to meet our current and future business needs or adequately safeguard our operations. Furthermore, modification, upgrade or replacement of such systems and infrastructure may be costly or out of our control.
Any failure to so modify, upgrade or replace such systems and infrastructure, any disruptions that occur during the process of such modification, upgrade or replacement and/or any breakdown, interruption or corruption of the information technology systems and infrastructure on which we rely could create system disruptions, shutdowns, delays in generating or the corruption of data and information or other disruptions that could result in negative financial, operational, business or reputational consequences for us.
The size and complexity of the information technology systems and infrastructure on which we rely makes such systems and infrastructure potentially vulnerable to internal or external inadvertent or intentional security breaches, including as a result of private or state-sponsored cybercrimes, terrorism, war, malware, ransomware, human error, system malfunction, telecommunication and electrical failures, natural disaster, fire, misplaced or lost data, socially engineered breaches or other similar events.
In addition, during the normal course of our business operations, including through the use of information technology systems and infrastructure, we are involved in the collection, transmission, use, retention and other processing of sensitive, confidential, non-public or personal data and information in Canada, the United States and abroad.
Cyber-attacks are increasing in frequency, sophistication and intensity and are made by groups and individuals with a wide range of motives and expertise. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, worms, social engineering, improper modification of information, fraudulent “phishing” e-mails and other means to affect service reliability or threaten data confidentiality, integrity or availability. Techniques used in these attacks are often highly sophisticated, change frequently and may be difficult to detect for long periods of time.
We have established physical, electronic and organizational measures intended to safeguard and secure our systems to prevent a compromise and policies and procedures designed to provide for the timely investigation of cybersecurity incidents and the timely disclosure of cybersecurity incidents consistent with our legal and contractual obligations. We also rely on commercially available systems, software, tools and monitoring to provide security for the processing, transmission and storage of digital information.
While we attempt to take appropriate security and cybersecurity measures to protect our information technology systems and infrastructure (including any confidential or other sensitive information) and to prevent and detect breakdowns, unauthorized breaches and cyber-attacks, we cannot guarantee that such measures will be successful and that breakdowns and breaches of, or attacks on, our systems and data, or those of third parties upon which we rely, will be prevented. Any such incidents, or the public perception that we or any third party upon which we rely have suffered such an incident, may cause business interruption and damage our reputation with customers, employees and third parties with whom we do business, and we may suffer litigation, financial damage, regulatory investigations, enforcement, orders and other actions, which could result in injunctions, fines and penalties, as well as costs relating to investigation of an incident, corrective actions, required notification, credit monitoring services and other expenses, and could have a material adverse effect on our business, financial condition, cash flows and results of operations.
In addition, we provide confidential and other sensitive information to third parties when necessary to pursue our business objectives. While we obtain assurances that these third parties will protect this information and, where appropriate, monitor the protections employed by these third parties, there is a risk that the confidentiality of information held by third parties, including trade secrets and sensitive personal information, may be compromised, including as a result of cybersecurity breaches, breakdowns or other incidents. If personal information of our customers or employees is misappropriated, our reputation with our customers and employees may be injured, resulting in loss of business and/or morale. Any such incidents could require us to incur costs to remediate possible injury to our customers and employees, to further improve our protective
42


measures or to pay fines or take other action with respect to litigation, judicial or regulatory actions arising out of such incidents, which may be significant.
While we maintain insurance against some of these risks, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from a breakdown, breach, cyber-attack or other compromise of or interruption to our information technology systems and infrastructure or confidential and other sensitive information. We also cannot ensure that any limitation of liability or indemnity provisions in our contracts, including with vendors and service providers, for a security lapse or breach or other security incident would be enforceable or adequate or would otherwise protect us from any liabilities or damages with respect to any particular claim. Any of the foregoing could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
The Company’s ability to effectively monitor and respond to the rapid and ongoing developments and expectations relating to environmental, social and governance (“ESG”) matters, including related social expectations and concerns, may impose unexpected costs on the Company or result in reputational or other harm to the Company that could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
If the Company is not able to adequately recognize and respond to the rapid and ongoing developments and governmental and social expectations relating to ESG matters such as climate change and access to health care and affordable drugs, this failure could result in missed corporate opportunities for the Company, additional regulatory, social or other scrutiny of the Company and its businesses, the imposition of unexpected costs on the Company or in damage to the reputation of the Company or its various brands with governments, customers, employees, third parties and the communities in which we operate, in each case that could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
The restatement of our previously issued financial statements was time-consuming and expensive and could expose us to additional risks that could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
We restated our previously issued audited Consolidated Financial Statements for the year ended December 31, 2014 and the unaudited financial information for the quarters ended December 31, 2014 and March 31, 2015. This restatement and the review of the misstatements that necessitated the restatement was time consuming and expensive and could expose us to potential claims and additional risks that could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. In particular, we could be subject to further shareholder litigation and additional governmental investigations and proceedings in connection with the restatements or related other matters. If we do not prevail in any such proceedings, we could be required to pay substantial damages or settlement costs. In addition, although the remediation of the material weaknesses in our internal control over financial reporting that contributed to the material misstatements in the Consolidated Financial Statements previously described has been completed, if our remedial measures were insufficient to properly and fully address the material weaknesses, or if additional material weaknesses in our internal controls are discovered or occur in the future, it may materially adversely affect our ability to report our financial condition and results of operations in a timely and accurate manner and there will continue to be an increased risk of future misstatements.
We have entered into distribution agreements with other companies to distribute certain of our products at supply prices based on net sales. Declines in the pricing and/or volume, over which we have no or limited control, of such products, and therefore the amounts paid to us, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Certain of our products are the subject of third-party distribution or sublicense agreements, pursuant to which we may manufacture and sell products to other companies, which distribute such products in return for a royalty or a supply price, in both cases which are often based on net sales. Our ability to control pricing and volume of these products may be limited and, in some cases, these companies make all distribution and pricing decisions independently of us. If the pricing or volume of such products declines, our revenues would be adversely impacted which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
The illegal distribution and sale of counterfeit versions of our products may reduce demand for our products or have a negative impact on the reputation of our products, which could have a material adverse effect on our business, financial
43


condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Third parties may illegally distribute and sell counterfeit versions of our products, which do not meet or adhere to the rigorous quality, safety, manufacturing, storage and handling standards and regulations that apply to our products. The prevalence of counterfeit products is a growing industry-wide issue due to the widespread use of the Internet, which has greatly facilitated the ease by which counterfeit products can be advertised, purchased and delivered. The discovery of safety or efficacy issues, adverse events or even death or personal injury associated with or caused by counterfeit products may be attributed to our products and may cause reputational harm to our products or the Company. We may not be able to detect or, if detected, prevent or prohibit the sale of such counterfeit products. As a result, the illegal sale or distribution of counterfeit products may negatively impact the demand for and sales of our products, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Our revenues and profits could be reduced by imports from countries where our products are available at lower prices.
Prices for our products are based on local market economics and competition and differ from country to country. Our sales in countries with relatively higher prices may be reduced if products can be imported into those or other countries from lower price markets. If this happens with our products, our revenues and profits may be adversely affected, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
Our policies regarding returns, allowances and chargebacks, and marketing programs adopted by wholesalers, may reduce our revenues in future fiscal periods.
We provide certain rebates, allowances, chargebacks and other credits to our customers with respect to certain of our products. For example, we make payments or give credits to certain wholesalers for the difference between the invoice price paid to us by our wholesaler customer for a particular product and the negotiated price that such wholesaler sells such products to its hospitals, group purchasing organizations, pharmacies or other retail customers. We also give certain of our customers credits on our products that such customers hold in inventory after we have decreased the WAC prices of such products, such credit being for the difference between the old and new price. In addition, we also implement and maintain returns policies, pursuant to which our customers may return product to us in certain circumstances in return for a credit. Although we establish reserves based on our prior experience, wholesaler data, then-current on-hand inventory, our best estimates of the impact that these policies may have in subsequent periods and certain other considerations, we cannot ensure that our reserves are adequate or that actual product returns, rebates, allowances and chargebacks will not exceed our estimates, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
We may experience declines in sales volumes or prices of certain of our products as the result of the concentration of sales to wholesalers and the continuing trend towards consolidation of such wholesalers and other customer groups and this could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
For certain of our products, a significant portion of our sales are to a relatively small number of customers. If our relationship with one or more of such customers is disrupted or changes adversely or if one or more of such customers experience financial difficulty or other material adverse changes in their businesses, it could materially and adversely affect our sales and financial results, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
In addition, wholesalers and retail drug chains have undergone, and are continuing to undergo, significant consolidation. This consolidation may result in these groups gaining additional purchasing leverage and consequently increasing the product pricing pressures facing our business. The result of these developments could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.
We have various indemnity agreements and indemnity arrangements in place, which may result in an obligation to indemnify or reimburse the relevant counterparty, which amounts may be material.
All directors and/or officers of the Company, and each of its various subsidiary entities, are indemnified by the Company in respect of their service as directors and/or officers, subject to certain restrictions. We have purchased directors’ and officers’ liability insurance to mitigate the cost of any potential future lawsuits or actions. The maximum amount of any potential future payment cannot be reasonably estimated but could have a material adverse effect on the Company.
44


In the normal course of business, we have entered or may enter into agreements that include indemnities in favor of third parties, such as purchase and sale agreements, license agreements, engagement letters with advisors and consultants and various product and service agreements. These indemnification arrangements may require us to compensate counterparties for losses incurred by the counterparties as a result of breaches in representations, covenants and warranties provided by us or as a result of litigation or other third-party claims or statutory sanctions that may be suffered by the counterparties as a consequence of the relevant transaction. In some instances, the terms of these indemnities are not explicitly defined. We, whenever possible, try to limit this potential liability within the particular agreement or contract, but due to the unpredictability of future events the maximum amount of any potential reimbursement cannot be reasonably estimated, but could have a material adverse effect on the Company.
General Risk Factors
Our operating results and financial condition may fluctuate.
Our operating results and financial condition may fluctuate from quarter to quarter for a number of reasons. In addition, our stock price can be volatile. The following events or occurrences, among others, could cause fluctuations in our financial performance and/or stock price from period to period:
development and launch of new competitive products;
the timing and receipt of FDA and other regulatory approvals or lack of approvals;
costs related to business development transactions;
changes in the amount we spend to promote our products;
delays between our expenditures to acquire new products, technologies or businesses and the generation of revenues from those acquired products, technologies or businesses;
changes in treatment practices of physicians that currently prescribe certain of our products;
increases in the cost of raw materials used to manufacture our products;
FDA or other regulatory actions relating to our manufacturers or suppliers;
manufacturing and supply interruptions;
our responses to price competition;
new legislation that would control or regulate the prices of drugs;
a protracted and wide-ranging trade conflict between the United States and China;
expenditures as a result of legal actions (and settlements thereof), including the defense of our patents and other intellectual property;
market acceptance of our products;
the timing of wholesaler and distributor purchases and success of our wholesaler and distributor arrangements;
general economic and industry conditions, including potential fluctuations in interest rates;
changes in seasonality of demand for certain of our products;
foreign currency exchange rate fluctuations;
changes to, or the confidence in, our business strategy;
changes to, or the confidence in, our management; and
expectations for future growth.
As a result, quarter-to-quarter comparisons of results from operations, or any other similar period-to-period comparisons, may not be reliable indicators of our future performance. In any quarterly period, our results may be below the expectations of market analysts and investors, which could cause the market value of our common shares and/or debt securities to decline.
Item 1B.    Unresolved Staff Comments
None.
Item 2.    Properties
We own and lease a number of important properties. Our headquarters and one of our manufacturing facilities are located in Laval, Quebec. We own several manufacturing facilities throughout the U.S. We also own or have an interest in manufacturing plants or other properties outside the U.S., including in Canada, Mexico, and certain countries in Europe, North Africa, Asia and South America.
We consider our facilities to be in satisfactory condition and suitable for their intended use, although some limited investments to improve our manufacturing and other related facilities are contemplated, based on the needs and requirements of our business. Our administrative, marketing, research/laboratory, distribution and warehousing facilities are located in various parts of the world. We co-locate our R&D activities with our manufacturing at the plant level in a number of facilities. Our
45


scientists, engineers, quality assurance/quality control professionals and manufacturing technicians work side-by-side in designing and manufacturing products that fit the needs and requirements of our customers, regulators and business units.
We believe that we have sufficient facilities to conduct our operations during 2021. Our facilities in aggregate are over 10 million square feet and include, among others, the following list of principal properties by segment:
LocationPurposeOwned
or
Leased
Approximate
Square
Footage
Corporate & Administration
Laval, Quebec, Canada
Corporate headquarters, R&D, manufacturing and warehouse facility
Owned338,000 
Bridgewater, New Jersey(1)
AdministrationLeased310,000 
Bausch + Lomb/International   
Rochester, New YorkOffices, R&D and manufacturing facilityOwned953,000 
San Juan del Rio, MexicoOffices and manufacturing facilityOwned853,000 
El Obour City, Egypt(2)
Offices, R&D, manufacturing and warehouse facilityOwned630,000 
Jelenia Gora, PolandOffices, R&D, manufacturing and warehouse facilityOwned521,000 
Waterford, IrelandR&D and manufacturing facilityOwned500,000 
Woodruff, South CarolinaDistribution facilityLeased432,000 
Jinan, ChinaOffices and manufacturing facilityOwned418,000 
Rzeszow, PolandOffices, R&D, manufacturing and warehouse facilityOwned380,000 
Berlin, GermanyManufacturing, distribution and office facilityOwned339,000 
Greenville, South CarolinaManufacturing and distribution facilityOwned314,000 
Chattanooga, TennesseeDistribution facilityLeased240,000 
Aubenas, FranceOffices, manufacturing and warehouse facilityOwned148,000 
Macherio, ItalyOffices, R&D, manufacturing and warehouse facilityOwned119,000 
Beijing, ChinaWarehouse facility and distributionOwned97,000 
Salix   
Steinbach, Manitoba, CanadaOffices, manufacturing and warehouse facilityOwned241,000 
____________________________________
(1) — A lease for a second building in Bridgewater, New Jersey was signed in 2015 and was not included in the square footage shown in the table above as the Company never occupied the second building. In 2016, the Company concluded that it would not occupy the second building and recognized the appropriate charge for all future rents due, net of the anticipated sub-let income associated with the second building.
(2) — This property is part of a business within our Bausch + Lomb/International segment business which, as of December 31, 2020, is classified as held for sale. See Note 3, "ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE" to our audited Consolidated Financial Statements for additional information.
Item 3.    Legal Proceedings
See Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements for details on legal proceedings.
Item 4.    Mine Safety Disclosures
Not applicable.
46


PART II
Item 5.    Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Information
Our common shares are traded on the New York Stock Exchange (“NYSE”) and on the Toronto Stock Exchange (“TSX”) under the symbol “BHC”.
Market Price Volatility of Common Shares
Market prices for the securities of pharmaceutical, medical devices and biotechnology companies, including our securities, have historically been highly volatile, and the market has experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Factors such as fluctuations in our operating results, the aftermath of public announcements by us or by others about us, changes in our executive management, changes in our business strategy, concern as to the safety of drugs and medical devices, the commencement or outcome of legal or governmental proceedings, changes in our ability to access credit markets, changes in the cost of capital, investigations or inquiries, and general market conditions can have an adverse effect on the market price of our common shares and other securities. For example, during 2015 and 2016, we experienced significant fluctuations and decreases in the market price of our common shares as a result of, among other things, legal and governmental proceedings and investigations with respect to certain of our distribution, marketing, pricing, disclosure and accounting practices, rising interest rates and certain public allegations made by short sellers and other third parties relating to certain of these matters. See Item 1A. “Risk Factors” of this Form 10-K for additional information.
Holders
The approximate number of holders of record of our common shares as of February 18, 2021 was 1,834.
47


Performance Graph
The following performance graphs compare the cumulative total return on a $100 investment on December 31, 2015 and December 31, 2016, assuming reinvestment of all dividends, in: (i) our common shares, (ii) the S&P 500 Index, (iii) the S&P/TSX Composite Index and (iv) a composite peer group of 11 major U.S. based pharmaceutical companies for the four and five years ended December 31, 2020. The composite peer group of 11 major U.S. based pharmaceutical companies consists of Alexion Pharmaceuticals Inc, Amgen Inc, Biogen Inc, Bristol-Myers Squibb Co, Eli Lilly And Co, Endo International Plc, Jazz Pharmaceuticals Plc, Mallinckrodt Plc, Perrigo Company Plc, United Therapeutics Corp and Zoetis Inc.
Five Year Performance - Cumulative total return on a $100 investment on December 31, 2015
bhc-20201231_g1.jpg
As of December 31,
 201520162017201820192020
Bausch Health Companies Inc.$100$14$20$18$29$20
S&P 500$100$112$136$130$171$203
S&P/TSX Composite$100$121$132$120$148$156
Peer Group$100$85$98$105$128$140

48


Prior to 2016, the Company completed a series of mergers and acquisitions, which, at the time, were in-line with the Company's strategy for growth. However, in response to changing business dynamics within our Company, we recognized the need to change our focus in order to build a world-class health organization. To do so, in 2016, we retained a new executive team, which, in 2017, implemented a multi-year plan to stabilize, turnaround and transform our Company. The performance graph below of cumulative total return as of December 31, 2016 is provided to coincide with the implementation of the Company's turnaround strategies in 2017 to focus on our core businesses, eye-health, GI and dermatology.
Four Year Performance - Cumulative total return on a $100 investment on December 31, 2016
bhc-20201231_g2.jpg
As of December 31,
 20162017201820192020
Bausch Health Companies Inc.$100$143$127$206$143
S&P 500$100$122$116$153$181
S&P/TSX Composite$100$109$99$122$129
Peer Group$100$115$123$149$164

Dividends
No dividends were declared or paid in 2020, 2019 or 2018. While our Board of Directors will review our dividend policy periodically, we currently do not intend to pay any cash dividends in the foreseeable future. In addition, our Restated Credit Agreement and indentures include restrictions on the payment of dividends.  See Note 10, "FINANCING ARRANGEMENTS" to our audited Consolidated Financial Statements for further details regarding these restrictions.
49


Restrictions on Share Ownership by Non-Canadians
There are no limitations under the laws of Canada or in our organizational documents on the right of foreigners to hold or vote securities of our Company, except that the Investment Canada Act (Canada) (the “Investment Canada Act”) may require review and approval by the Minister of Innovation, Science and Economic Development (Canada) (the “Minister”) of an acquisition of “control” of our Company by a “non-Canadian”.
Investment Canada Act
An acquisition of control of a Canadian business by a non-Canadian is either reviewable (a “Reviewable Transaction”), in which case it is subject to both a reporting obligation and an approval process, or notifiable, in which case it is subject to only a reporting obligation. In the case of a Reviewable Transaction, the non-Canadian acquirer must submit an application for review with the prescribed information. The Minister is then required to determine whether the Reviewable Transaction is likely to be of net benefit to Canada, taking into account the assessment factors specified in the Investment Canada Act and any written undertakings that may have been given by the non-Canadian acquirer.
The Investment Canada Act provides that any investment by a non-Canadian in a Canadian business, even where control has not been acquired, can be reviewed on grounds of whether it may be injurious to national security. Where an investment is determined to be injurious to national security, Cabinet can prohibit closing or, if closed, can order the investor to divest control. Short of a prohibition or divestment order, Cabinet can impose terms or conditions on the investment or can require the investor to provide binding undertakings to remove the national security concern.
Competition Act
Part IX of the Competition Act (Canada) (the “Competition Act”) requires that a pre-merger notification filing be submitted to the Commissioner of Competition (the “Commissioner”) in respect of certain classes of merger transactions that exceed certain prescribed thresholds. If a proposed transaction exceeds such thresholds, subject to certain exceptions, the notification filing must be submitted to the Commissioner and the statutory waiting period must expire or be terminated early or waived by the Commissioner before the transaction can be completed.
All mergers, regardless of whether they are subject to Part IX of the Competition Act, are subject to the substantive mergers provisions under Section 92 of the Competition Act. In particular, the Commissioner may challenge a transaction before the Competition Tribunal where the transaction prevents or lessens, or is likely to prevent or lessen, competition substantially in a market. The Commissioner may not make an application to the Competition Tribunal under Section 92 of the Competition Act more than one year after the merger has been substantially completed.
Exchange Controls
Canada has no system of exchange controls. There are no Canadian exchange restrictions on the repatriation of capital or earnings of a Canadian public company to non-resident investors. There are no Canadian exchange restrictions affecting the remittance of dividends, profits, interest, royalties and other payments to non-resident holders of our securities.
Taxation
Canadian Federal Income Taxation
The following discussion is a summary of the principal Canadian federal income tax considerations generally applicable to a holder of our common shares who, at all relevant times, for purposes of the Income Tax Act (Canada) and the Income Tax Regulations (collectively, the “Canadian Tax Act”) deals at arm’s-length with, and is not affiliated with, our Company, beneficially owns its common shares as capital property, does not use or hold and is not deemed to use or hold such common shares in carrying on a business in Canada, does not with respect to common shares enter into a “derivative forward agreement” as defined in the Canadian Tax Act, and who, at all relevant times, for purposes of the application of the Canadian Tax Act and the Canada-U.S. Income Tax Convention (1980, as amended) (the “U.S. Treaty”), is resident in the U.S., is not, and is not deemed to be, resident in Canada and is eligible for benefits under the U.S. Treaty (a “U.S. Holder”). Special rules, which are not discussed in the summary, may apply to a non-resident holder that is an insurer that carries on an insurance business in Canada and elsewhere or that is an “authorized foreign bank” as defined in the Canadian Tax Act.
The U.S. Treaty includes limitation on benefits rules that restrict the ability of certain persons who are resident in the U.S. to claim any or all benefits under the U.S. Treaty. Furthermore, limited liability companies (“LLCs”) that are not taxed as corporations pursuant to the provisions of the U.S. Internal Revenue Code of 1986, as amended do not generally qualify as resident in the U.S. for purposes of the U.S. Treaty. Under the U.S. Treaty, a resident of the U.S. who is a member of such an LLC and is otherwise eligible for benefits under the U.S. Treaty may generally be entitled to claim benefits under the
50


U.S. Treaty in respect of income, profits or gains derived through the LLC. Residents of the U.S. should consult their own tax advisors with respect to their eligibility for benefits under the U.S. Treaty, having regard to these rules.
This summary is based upon the current provisions of the U.S. Treaty and the Canadian Tax Act and our understanding of the current administrative policies and assessing practices of the Canada Revenue Agency published in writing prior to the date hereof. This summary takes into account all specific proposals to amend the U.S. Treaty and the Canadian Tax Act publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date hereof. This summary does not otherwise take into account or anticipate changes in law or administrative policies and assessing practices, whether by judicial, regulatory, administrative or legislative decision or action, nor does it take into account provincial, territorial or foreign tax legislation or considerations, which may differ from those discussed herein.
This summary is of a general nature only and is not intended to be, nor should it be construed to be, legal or tax advice generally or to any particular holder. Holders should consult their own tax advisors with respect to their own particular circumstances.
Gains on Disposition of Common Shares
In general, a U.S. Holder will not be subject to tax under the Canadian Tax Act on capital gains arising on the disposition of such holder’s common shares unless the common shares are “taxable Canadian property” to the U.S. Holder and are not “treaty-protected property”.
As long as the common shares are then listed on a “designated stock exchange”, which currently includes the NYSE and TSX, the common shares generally will not constitute taxable Canadian property of a U.S. Holder, unless: (a) at any time during the 60-month period preceding the disposition, the U.S. Holder, persons not dealing at arm’s length with such U.S. Holder or the U.S. Holder together with all such persons, owned 25% or more of the issued shares of any class or series of the capital stock of the Company and (b) more than 50% of the fair market value of the common shares was derived, directly or indirectly, from any combination of: (i) real or immoveable property situated in Canada, (ii) “Canadian resource property” (as such term is defined in the Canadian Tax Act), (iii) “timber resource property” (as such term is defined in the Canadian Tax Act) or (iv) options in respect of, or interests in, or for civil law rights in, any such properties whether or not the property exists or the common shares are otherwise deemed to be taxable Canadian property.
Common shares will be treaty-protected property where the U.S. Holder is exempt from income tax under the Canadian Tax Act on the disposition of common shares because of the U.S. Treaty. Common shares owned by a U.S. Holder will generally be treaty-protected property where the value of the common shares is not derived principally from real property situated in Canada, as defined in the U.S. Treaty.
Dividends on Common Shares
Dividends paid or credited on the common shares or deemed to be paid or credited on the common shares to a U.S. Holder that is the beneficial owner of such dividends will generally be subject to non-resident withholding tax under the Canadian Tax Act and the U.S. Treaty at the rate of: (a) 5% of the amounts paid or credited if the U.S. Holder is a company that owns (or is deemed to own) at least 10% of our voting stock or (b) 15% of the amounts paid or credited in all other cases. The rate of withholding under the Canadian Tax Act in respect of dividends paid to non-residents of Canada is 25% where no tax treaty applies.
Securities Authorized for Issuance under Equity Compensation Plans
Information required under this Item will be included in our definitive proxy statement for the 2021 Annual Meeting of Shareholders expected to be filed with the SEC no later than 120 days after the end of the fiscal year covered by this Form 10-K (the “2021 Proxy Statement”), and such required information is incorporated herein by reference.
Purchases of Equity Securities by the Company and Affiliated Purchases
There were no purchases of equity securities by the Company during the fourth quarter of the year ended December 31, 2020.
Item 6.    Selected Financial Data
Not applicable.
51


Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations
INTRODUCTION
This “Management’s Discussion and Analysis of Financial Condition and Results of Operations” has been updated through February 24, 2021 and should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto included elsewhere in this Annual Report on Form 10-K. The matters discussed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, “Forward-Looking Statements”). See “Forward-Looking Statements” at the end of this discussion. Additional company information, including this Form 10-K, is available on SEDAR at www.sedar.com and on the U.S. Securities and Exchange Commission (the “SEC”) website at www.sec.gov. All currency amounts are expressed in U.S. dollars, unless otherwise noted.
OVERVIEW
Bausch Health Companies Inc. (“we”, “us”, “our” or the “Company”) is a global company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market, primarily in the therapeutic areas of eye-health, gastroenterology (“GI”) and dermatology, a broad range of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) over-the-counter (“OTC”) products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in approximately 100 countries.
We generated revenues for 2020, 2019 and 2018, of $8,027 million, $8,601 million and $8,380 million, respectively. Our portfolio of products falls into four operating and reportable segments: (i) Bausch + Lomb/International, (ii) Salix, (iii) Ortho Dermatologics and (iv) Diversified Products.
The Bausch + Lomb/International segment consists of: (i) sales in the U.S. of pharmaceutical products, OTC products and medical device products, primarily comprised of Bausch + Lomb products, with a focus on the Vision Care, Surgical, Consumer and Ophthalmology Rx products and (ii) with the exception of sales of Solta products, sales in Canada, Europe, Asia, Australia, Latin America, Africa and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products, OTC products, medical device products and Bausch + Lomb products.
The Salix segment consists of sales in the U.S. of GI products.
The Ortho Dermatologics segment consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta medical aesthetic devices.
The Diversified Products segment consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products.
For additional discussion of our reportable segments, see the discussion in Item 1. "Business — Segment Information" and Note 22, "SEGMENT INFORMATION" to our audited Consolidated Financial Statements for further details on these reportable segments.
As discussed further below, on August 6, 2020, the Company announced that it intends to separate its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the “Separation”). In connection with the Separation, the Company expects to realign and begin managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Separation during the first quarter of 2021.
Our Focus on Value
In 2016, we retained a new executive team which implemented a multi-year plan designed to transform and bring out value in our Company. The multi-year plan increased our focus on, among other factors, our: product portfolio, infrastructure, geographic footprint, capital structure and risk management. Since that time, we have been executing and continue to execute on our commitments to transform the Company and generate value. Under the multi-year plan, we have taken the following actions, among others:
divested non-core assets in order to narrow the Company's activities to our core businesses where we believe we have an existing and sustainable competitive edge and the ability to generate operational efficiencies. To date we received approximately $3,500 million in net proceeds from these divestitures;
52


made strategic investments in our core businesses in order to support recent revenue growth and prepare for additional growth opportunities we plan to capitalize on for our core businesses;
made measurable progress in improving our capital structure as we have repaid over $8,600 million in debt obligations (net of additional borrowings, amounts refinanced and excluding the $1,210 million financing of the U.S. Securities Litigation settlement discussed below) during the period January 1, 2016 through the date of this filing using the proceeds from the divestiture of non-core assets, cash generated from our operations and improved working capital management; and
resolved many of the Company's legacy litigation matters originating back to 2015 and prior, including the most significant legacy legal matter, the U.S. Securities Litigation settlement discussed below, significantly reducing related possible disruptions and other uncertainties to our operations.
We believe that these and other positive actions we have taken to transform our Company, have properly focused our operations and improved our capital structure, and we also believe that, as a result of such actions, we are now presented with an opportunity to unlock additional value across our portfolio of assets by creating two highly attractive but dissimilar businesses.
Separation of the Bausch + Lomb Eye-Health Business
On August 6, 2020, we announced that we intend to separate our eye-health business into an independent publicly traded entity (“Bausch + Lomb”) from the remainder of Bausch Health Companies Inc. The Separation will establish two separate companies that include:
a fully integrated, pure play eye-health company built on the iconic Bausch + Lomb brand and long history of innovation; and
a diversified pharmaceutical company with leading positions in gastroenterology, aesthetics/dermatology, neurology and international pharmaceuticals.
The Bausch + Lomb entity will consist of the Company's Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmology Rx businesses. The remaining pharmaceutical entity will comprise a diversified portfolio of our leading durable brands across the Salix, International Rx, Solta, neurology and medical dermatology businesses. We believe the Separation will unlock value across the two post-separation entities and create two highly attractive but dissimilar businesses.
As separate entities, management believes that each company will be better positioned to individually focus on its core businesses to drive additional growth, more effectively allocate capital and best manage its respective capital needs. Further, the Separation allows us and the market to compare the operating results of each entity with other “pure play” peer companies. Although management believes the Separation will bring out additional value, there can be no assurance that it will be successful in doing so. In connection with the Separation, we expect to realign and begin managing our operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Separation during the first quarter of 2021. Accordingly, we expect to begin reporting our segment results to reflect the proposed realignment of our operating segments on a retrospective basis beginning with our first quarter of 2021.
We are in the process of addressing the organization, structure and pro forma capitalizations of the two entities post-separation. Based on our assessment, we believe that, by the end of 2021, we will be able to address the organizational matters and regulatory requirements needed to operate the businesses separately and put the Bausch + Lomb entity in position to become an independent publicly traded company. Management is also considering the form of the Separation and exploring a number of alternative capitalization structures in order to properly capitalize the entities post-separation. Although a public offering of a portion of the Bausch + Lomb business is among the alternate capital structures being considered, this Form 10-K does not constitute an offer of any securities of Bausch + Lomb for sale. There are considerations, approvals and conditions that will determine the ultimate timing and structure of this transaction, including regulatory approvals, final approval by our board of directors, any shareholder vote requirements that may be applicable, compliance with U.S. and Canadian securities laws and stock exchange rules, receipt of any applicable opinions and/or rulings with respect to the Canadian and U.S. federal income tax treatment of such transaction and determination of the pro forma capitalizations of the two entities. The failure to satisfy all of the required conditions could delay the completion of this transaction for a significant period of time or prevent it from occurring at all.
See Item 1A. “Risk Factors — Risk Relating to the Separation” of this Form 10-K for additional risks relating to the Separation.
53


Impacts of COVID-19 Pandemic
In December 2019, a novel strain of the coronavirus disease, COVID-19, was identified in Wuhan, China. Since then, COVID-19 has spread to other parts of the world, including the United States, Canada and Europe, and was declared a global pandemic by the World Health Organization (the "WHO") on March 11, 2020. As a global health care company, now more than ever, we remain focused on our mission of helping to improve people’s lives with our health care products.
The unprecedented nature of the COVID-19 pandemic has adversely impacted the global economy. The COVID-19 pandemic and the rapidly evolving reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have intensified and have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions. The COVID-19 pandemic has also significantly increased demand for certain goods and services, such as pandemic-related medical services and supplies, alongside decreased demand for others, such as retail, hospitality, elective medical procedures and travel.
As the global economic landscape changes, there is a wide range of possible outcomes regarding the nature and timing of events related to the COVID-19 pandemic, each of which are highly dependent on variables that are difficult to predict. Developments, including the ultimate geographic spread and duration of the pandemic, the extent and duration of a resurgence, if any, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus, the availability and effectiveness of vaccines for the COVID-19 virus and the economic impact of the pandemic and the reactions to it, could have a significant adverse effect on our business, development programs, financial condition, cash flows and results of operations. The extent of these developments and the related impacts are highly uncertain and many are outside the Company's control.
To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand. As a result of our assessment, we immediately initiated profit protection measures to manage and reduce operating expenses and preserve cash during the COVID-19 pandemic. We have also taken actions to manage the level of our investment in support of certain existing products, anticipated launches and the expansion of our sales footprint in Europe. Postponing these investments may impact the extent and timing in achieving our longer-term forecasts for certain business units, however, we believe these actions will not have a material impact on the underlying value of the related businesses or their associated assets.
We are and will continue to closely monitor the impacts of the COVID-19 pandemic and related responses from governments and private sector participants on the Company, our customers, supply chain, third-party suppliers, project development timelines, costs, revenue, margins, liquidity and financial condition and our planned actions and responses to this pandemic.
We believe we have responded quickly to the human and commercial challenges brought on by the COVID-19 pandemic and that our early actions have, so far, enabled us to keep our employees safe and our supply lines largely intact and we believe these actions have laid the foundation for us to work our way through the uncertainties to come. Importantly, we believe that the steps we took over the last several years to manage our capital structure place us in a strong position to maintain sufficient liquidity to continue operations through an extended pandemic and we believe that our businesses will not see their long-term value diminished by this unprecedented situation.
Our Employees
Our employees' health, safety, and wellness are important to us. With the COVID-19 outbreak, a focus in 2020 was protecting the health and safety of our employees and their families. We broadened our existing remote work policies to enable our global employees to work from home wherever possible. In circumstances where remote work was not possible (such as at our manufacturing and distribution facilities) we implemented safety measures to ensure we prevented the spread of COVID-19 in the workplace, such as mandatory face coverings, social distancing, hand hygiene, plexiglass barriers, limited face-to-face meetings and other procedures as prescribed by global public health organizations, such as the WHO and U.S. Centers for Disease Control and Prevention. We also provided resources for our employees specifically in response to COVID-19, including launching a website – Collaborating in the New Normal – to help our employees encourage each other, lead with empathy and adapt as we navigate these unprecedented times.
54


Our Supply Chain and Manufacturing Facilities
Our objective is to maintain the uninterrupted availability of our products to meet the needs of patients, consumers and our customers. Business continuity plans and site-level biosecurity procedures are in place to ensure the well-being of our employees while we work to maintain the integrity of our supply chain. We have been successful in keeping our manufacturing facilities operational, although, due to shelter-in-place orders, our facilities in Milan and China were forced to temporarily close in March and April of 2020. These facilities were closed for only a short period of time and were immediately and continually operational once the shelter-in-place orders in the respective geographies were lifted.
As of the date of this filing, we have not experienced any disruption in our supply chain that would have a material impact on our results or operations. Our global supply chain team worked diligently to stay ahead of the challenges presented by the COVID-19 pandemic once it appeared in Asia. Although we have put in place procedures to mitigate the risks associated with closures and disruptions at our manufacturing facilities, the COVID-19 pandemic has had an impact on our inventory levels and the manner in which we manage our inventories. From time to time during 2020, our inventory levels were higher than usual as a result of: (i) lower demand across multiple business units due to COVID-19 pandemic related matters, (ii) securing additional quantities of active pharmaceutical ingredients ("API") for our Xifaxan® products from our suppliers in Italy in contemplation of potential supply disruptions in that region, (iii) securing additional quantities of API for our Trulance® products which have longer procurement times and higher costs and (iv) the acquisition of additional quantities of certain products that were at the lower end of their optimal levels at December 31, 2019. During our third and fourth quarters, we continued to manage our inventory levels and effectively reduced our inventory levels to be in line with our pre-pandemic inventory levels as of December 31, 2020.
We have dual sources of API and intermediates for many of our products, the availability of which has not had, and at this time we do not expect will have, a material impact on our supply chain. With respect to our largest product, Xifaxan®, as of January 31, 2021, we have over four months’ supply of Xifaxan® finished goods on hand and enough API to manufacture another seven months’ supply of Xifaxan® finished goods. We also have open orders for API for Xifaxan® that we currently expect will arrive on schedule. However, if we were to experience a lack of availability of API for Xifaxan®, such disruption to our supply chain could have a significant adverse effect on our business, financial condition and results of operations.
We continue to monitor the impacts of the COVID-19 pandemic and take the actions appropriate to regulate our inventories at levels in line with the current supply and demand for our products. These actions have been effective at meeting our objectives, and presuming there continues to be increased availability of effective vaccines and any resurgence of the COVID-19 virus and variant strains thereof do not have a material adverse impact on efforts to contain the COVID-19 virus, we believe we can maintain our inventories at their pre-pandemic levels during 2021. We will continue to monitor our inventories and continue to take the appropriate actions and make the necessary adjustments to maintain the uninterrupted availability of our products to meet the needs of patients, consumers and our customers.
Our Product Pipeline
Our leadership team actively manages the Company's product pipeline to identify what we believe are innovative and realizable projects aligned with our core businesses that are expected to provide incremental and sustainable revenues and growth. During the COVID-19 pandemic, our R&D team remains focused on meeting these objectives in a timely manner; however, there are significant events and circumstances regarding the COVID-19 pandemic that may materially affect our R&D team’s ability to do so, many of which are beyond the Company's control.
Due to the challenges of the COVID-19 pandemic, most notably those attributable to "stay at home" and travel restrictions, certain of our R&D activities were forced to pause. Clinical trials that started prior to governmental shutdowns remained enrolled and existing patients have progressed, while new patient enrollments were paused as most trial sites were not able to accept new patients. However, during our third quarter of 2020, we saw the pace of new patient enrollments increase, getting close to their pre-COVID-19 pandemic levels in the U.S., and as a result have not had to make material changes to our development timelines.
We continue to monitor the timing and completion of our ongoing and anticipated clinical trial programs. As of the date of this filing, the delays in our clinical trials have not had a material impact on our operating results; however, a resurgence of the virus significant enough to necessitate reenacting certain social restrictions could result in unanticipated delays in our ability to conduct new patient enrollments. Other possible COVID-19 pandemic and resurgence related challenges include, but are not limited to, facility closures, delays by third-party service providers, deferrals of doctor visits, postponement of elective medical procedures and surgeries and changes in prioritization by the FDA and other regulatory authorities. Delays, if any, caused by the COVID-19 pandemic and a possible resurgence of the virus such as these and others will likely adversely affect the timely approval, launch and commercialization and the commercial success of our products, particularly those in early stage clinical trials, which could have a material adverse effect on our future operating results.
55


Our Liquidity
Our primary sources of liquidity are our cash and cash equivalents, cash collected from customers, funds as available from our revolving credit facility of $1,225 million due in June 2023 (the “2023 Revolving Credit Facility”), issuances of long-term debt and issuances of equity and equity-linked securities. We believe these sources will be sufficient to meet our current liquidity needs for at least twelve months from the date of issuance of this Form 10-K. Further, for the years ended December 31, 2020, 2019 and 2018, we generated positive cash from operations of $1,111 million, $1,501 million and $1,501 million, respectively. Should our operating results during the COVID-19 pandemic materially suffer in comparison to our 2020, 2019 and 2018 operating results, we believe we would continue to generate sufficient cash flows from operations to meet our obligations in the ordinary course of business.
We have no debt maturities or mandatory amortization payments until 2024. Additionally, we have no outstanding borrowings, $104 million of issued and outstanding letters of credit and remaining availability of $1,121 million under our 2023 Revolving Credit Facility. In the event of a future, unexpected, need for near-term liquidity, our 2023 Revolving Credit Facility would be a source of funding for us. After reviewing the terms of our Restated Credit Agreement and considering a broad range of possible outcomes of the COVID-19 pandemic, we expect that we will have access to capital under our 2023 Revolving Credit Facility across a broad range of scenarios in the event it is required.
See this Item “— Liquidity and Capital Resources — Long-term Debt” and Note 10, "FINANCING ARRANGEMENTS" to our audited Consolidated Financial Statements for additional discussion of these matters.
Our Operating Results
While we are taking actions to mitigate the impact of the COVID-19 pandemic on daily operations, the global response to the pandemic has and is expected to impact our operating results until the impacts of the pandemic subside, the timing of which is uncertain and may be dependent upon, among other matters, the availability and effectiveness of vaccines for the COVID-19 virus. The changing dynamics of the pandemic, related responses from governments and private sector participants and the precautionary measures taken by our customers and the health care patients and consumers we serve, are expected to impact the timing and amount of our revenues.
During the pandemic, the public has been advised to engage in certain "social restrictions" such as: (i) remaining at home or shelter-in-place, (ii) limiting social interaction, (iii) closing non-essential businesses and (iv) postponing certain surgical and elective medical procedures in order to prioritize/conserve available health care resources. During the three months ended March 31, 2020, these factors negatively impacted, most notably, the revenues of the Company's Global Vision Care and Global Surgical businesses in Asia where the COVID-19 pandemic originated. Beginning in March 2020, and throughout most of the second quarter of 2020, the Company experienced steeper declines in these revenues and the revenues of other businesses as social restrictions expanded worldwide, particularly in the U.S. and Europe. Social restrictions negatively impacted the Company's revenues for contact lenses, intraocular lenses, medical devices, surgical systems and certain pre- and post-operative eye-medications of its Global Ophtho Rx business, medical aesthetics and therapeutic products of its Global Solta business, and certain branded pharmaceutical products of its Salix, Ortho Dermatologics and Dentistry businesses, as the offices of many health care providers were closed and certain surgeries and elective medical procedures were deferred.
Our 2020 revenues were most negatively impacted during our second quarter by the social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize prior to our third quarter of 2020. Our revenues for the three months ended December 31, 2020 and 2019 were $2,213 million and $2,224 million, respectively, a decrease of $11 million. This decrease of less than 1% represents a continuing improving trend over the decreases in our year-over-year revenues for the three month periods ended June 30, 2020 and September 30, 2020 of 23% and 3%, respectively, and suggests that a recovery is underway. Presuming there continues to be increased availability of effective vaccines and any resurgence of the COVID-19 virus and variant strains thereof do not have a material adverse impact on efforts to contain the COVID-19 virus, the Company anticipates an ongoing, gradual global recovery from the significant macroeconomic and health care impacts of the pandemic that occurred during the first-half of 2020 and anticipates that its affected businesses could return to pre-pandemic levels during 2021. However, the rates of recovery for each business will vary by geography and will be dependent upon, among other things, the availability and effectiveness of vaccines for the COVID-19 virus, government responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus and other actions taken in response to the COVID-19 pandemic.
In the U.S., the recovery is progressing more quickly in our surgical, vision care and ophthalmology businesses, while our consumer business has been less impacted by the COVID-19 pandemic than any of our other businesses. Although certain
56


social restrictions were lifted in Europe and Asia during the summer, recovery in these regions has been more gradual, as consumers have been slower to return to their pre-pandemic habits. Further, various geographies are reinstituting lockdowns or partial lockdowns in response to resurgence of the original COVID-19 virus and as variant strains, possibly more contagious than the original virus, have been identified. For instance, parts of Europe, such as England, Germany, France and Ireland, and parts of Canada have already announced returns to lockdowns of various lengths and have enacted or are considering enacting other social restrictions. In the U.S., variant strains of the virus have been identified and there has been a rise in the number of daily average COVID-19 cases heading into 2021 which suggests a possible resurgence in the U.S. and could lead to new lockdowns or other social restrictions.
As we monitor the direction and pace of the recovery in each business and geography, we are also continually monitoring the effectiveness of the profit protection measures we initiated to manage and reduce our operating expenses and preserve cash during the COVID-19 pandemic. These profit protection measures have been successful in expanding the profit margins in many of our businesses as referenced in the discussion of our operating results to follow. As the pace of recovery in each geography accelerates, we expect to allocate more resources to selling and other promotional activities to drive our return to sustainable revenue and profit growth. Therefore, if the recovery continues, we expect our operating expenses to increase in support of our existing products, product launches and products in development and expect to see our operating expenses in 2021 exceed our operating expenses in 2020 as a result.
We believe our diverse portfolio of durable products and strong brands has served us well through the COVID-19 pandemic and we continue to be well positioned to grow market share and return to growth as the world recovers. However, this remains a very fluid situation and we continue to monitor the availability and effectiveness of vaccines and any resurgence of the COVID-19 virus and variant strains thereof on our operations, business and primary goals. Given these circumstances, we continue to focus on: (i) revising our go-to-market and sales force strategies to address the changing business dynamics created by the COVID-19 pandemic, (ii) building out our e-commerce presence to enable us to reach customers in new ways, (iii) investing in our key promoted brands and product launches to increase market share, (iv) optimizing our cost structure and (v) looking for key trends in the market to meet changing consumer/patient needs and identify areas for investment and growth. We believe focusing on these priorities will best enable us to effectively manage the changing business dynamics created by the COVID-19 pandemic, best prepare us for a possible resurgence of the virus and any variant strains thereof and return us to growth once the impacts of the COVID-19 pandemic substantially subside.
The changes in our segment revenues and segment profits, including the impacts of COVID-19 pandemic related matters for the year ended December 31, 2020, are discussed in further detail in the respective subsequent sections “ — Reportable Segment Revenues and Profits”.
The Company continually updates its near term forecasts for the changing facts and circumstances regarding the COVID-19 pandemic and believes that its long-term forecasted cash flows are not materially impacted by COVID-19 pandemic events and related factors. As more fully discussed in Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our audited Consolidated Financial Statements, as of December 31, 2020 the Company has not identified any impairments in connection with the impacts of the COVID-19 pandemic. However, if market conditions further deteriorate, if facts and circumstances regarding the COVID-19 pandemic escalate beyond management’s expectations, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges can be material.
For a further discussion of these and other COVID-19 related risks, see Item 1A. "Risk Factors— Risk Relating to COVID-19" of this Form 10-K.
Focus on Core Businesses
Our strategy is to focus our business on core therapeutic classes that offer attractive growth opportunities. Within our chosen therapeutic classes, we prioritize durable products which we believe have the potential for strong operating margins and evidence of growth opportunities. We believe this strategy has reduced complexity in our operations and maximizes the value of our: (i) eye-health, (ii) GI and (iii) dermatology businesses, which collectively now represent a substantial portion of our revenues. We have found and continue to believe there is significant opportunity in these businesses and we believe our existing portfolio, commercial footprint and pipeline of product development projects position us to successfully compete in these markets and provide us with the greatest opportunity to build value for our shareholders. We identify these businesses as “core”, meaning that we believe we are best positioned to grow and develop them. In order to continue to focus on our core businesses we have: (i) directed capital allocation to drive growth within our core businesses, (ii) made measurable progress in effectively managing our capital structure, (iii) increased our efforts to improve patient access and (iv) continued to invest in sustainable growth drivers to position us for long-term growth.
57


Direct Capital Allocation to Drive Growth Within Our Core Businesses
Our capital allocation is driven by our long-term growth strategies. We have been aggressively allocating resources to promote our core businesses globally through: (i) strategic acquisitions, (ii) research and development (“R&D”) investment, (iii) strategic licensing agreements and (iv) strategic investments in our infrastructure. The outcome of this process allows us to better drive value in our product portfolio and generate operational efficiencies.
Strategic Acquisitions
We remain very selective when considering any acquisition and pursue only those opportunities that we believe align well with our current organization and strategic plan. We sometimes refer to these opportunities as "bolt on" acquisitions. In being selective, we seek to enter into only those acquisitions that provide us with significant synergies with our existing business, thereby minimizing risks to our core businesses and providing long-term growth opportunities. Recently, we have entered into transactions that although not immediately impactful to our operating results, are expected to be accretive to our bottom line in future years and contribute to our long-term growth strategies.
In September 2020, we entered into an agreement which provides the Company an option to acquire all ophthalmology assets of Allegro Ophthalmics, LLC ("Allegro") (the "Option"), a privately held biopharmaceutical company focused on the development of therapies that regulate integrin functions for the treatment of ocular diseases. Among the assets to be acquired, if the Option is exercised, is the worldwide rights to risuteganib (Luminate®), Allegro's lead investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry Age-related Macular Degeneration ("AMD"). A U.S. Phase 2a study with risuteganib in intermediate dry AMD met its primary endpoint of vision recovery and Phase 3 testing is in the planning stages. We believe the addition of the ophthalmic assets of Allegro would significantly enhance our comprehensive portfolio of products for AMD and if approved, risuteganib may be the first treatment indicated to help reverse vision loss due to dry AMD and address a significant unmet medical need affecting millions of people globally.
In March 2019, we completed the acquisition of certain assets of Synergy Pharmaceuticals Inc. (“Synergy”) whereby we acquired the worldwide rights to the Trulance® (plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation, or CIC, and irritable bowel syndrome with constipation, or IBS-C. We believe that the Trulance® product complements our existing Salix products and allows us to effectively leverage our existing GI sales force.
In February 2019, we acquired the U.S. rights to EM-100 (an investigational preservative-free formulation eye drop) from Eton Pharmaceuticals, Inc. On September 25, 2020, the Company announced that the FDA had approved Alaway® Preservative Free (ketotifen fumarate) ophthalmic solution, 0.035%, antihistamine eye drops (EM-100) as the first over-the-counter (OTC) preservative-free formulation eye drop approved to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander. Alaway® Preservative Free was launched in February 2021 and is expected to complement our broad range of Bausch + Lomb integrated eye-health products.
We are considering further acquisition opportunities within our core therapeutic areas, some of which could be material in size.
R&D Investment
Our R&D expenses for 2020, 2019 and 2018, were $452 million, $471 million and $413 million, respectively, and was approximately 6% as a percentage of revenue for 2020 and approximately 5% for 2019 and 2018. Our investment in R&D reflects our commitment to drive organic growth through internal development of new products, a pillar of our strategy. We continuously search for new product opportunities through internal development and strategic licensing agreements, that if successful, will allow us to leverage our commercial footprint, particularly our sales force, and supplement our existing product portfolio and address specific unmet needs in the market.
Our internal R&D organization focuses on the development of products through clinical trials. As of December 31, 2020, approximately 1,300 dedicated R&D and quality assurance employees in 23 R&D facilities were involved in our R&D efforts internally. We have approximately 200 projects in our global pipeline.
Certain core internal R&D projects that have received a significant portion of our R&D investment in current and prior periods are listed below. However, due to the challenges of the COVID-19 pandemic, most notably those attributable to "stay at home" and travel restrictions, certain of our R&D activities were forced to pause. Clinical trials that started prior to governmental shutdowns remained enrolled and existing patients have progressed, while new patient enrollments were paused as most trial sites were not able to accept new patients. However, during our third quarter of 2020, we saw the pace of new
58


patient enrollments increase, getting close to their pre-COVID-19 pandemic levels in the U.S., and as a result have not had to make material changes to our development timelines.
We continue to monitor the timing and completion of our ongoing and anticipated clinical trial programs. As of the date of this filing, the delays in our clinical trials have not had a material impact on our operating results; however, a resurgence of the virus significant enough to necessitate reenacting certain social restrictions could result in unanticipated delays in our ability to conduct new patient enrollments. Other possible COVID-19 pandemic and resurgence related challenges include, but are not limited to, facility closures, delays by third-party service providers, deferrals of doctor visits, postponement of elective medical procedures and surgeries and changes in prioritization by the FDA and other regulatory authorities. Delays, if any, caused by the COVID-19 pandemic and a possible resurgence of the virus such as these and others will likely adversely affect the timely approval, launch and commercialization and the commercial success of our products, particularly those in early stage clinical trials. As a result, our estimates regarding the timing and success of our R&D efforts (some of which are set out below), including as it relates to study initiation, enrollment and completion, availability of study results, regulatory submissions, regulatory approvals and commercial launches, may change.
Bausch + Lomb
Bausch + Lomb ULTRA® for Astigmatism - A monthly planned replacement contact lens for astigmatic patients.  The Bausch + Lomb ULTRA® for Astigmatism lens was developed using the proprietary MoistureSeal® technology. In addition, the Bausch + Lomb ULTRA® for Astigmatism lens integrates an OpticAlign® design engineered for lens stability and to promote a successful wearing experience for the astigmatic patient. In 2017, we launched this product and the extended power range for this product. In 2018, we launched the Bausch + Lomb ULTRA® for Astigmatism -2.75 cylinder expanded SKU range.
SiHy Daily - A silicone hydrogel daily disposable contact lens designed to provide clear vision throughout the day. In September 2018, we launched SiHy Daily in Japan under the branded name AQUALOX ONE DAY.  In August 2020, we launched SiHy Daily in the U.S. under the branded name Bausch + Lomb INFUSE SiHy Daily Disposable contact lens. In the fourth quarter of 2020, SiHy Daily was launched in Australia, Hong Kong and Canada under the branded name Ultra® ONE DAY. SiHy Daily has also received regulatory approval for New Zealand, South Korea, Singapore and Malaysia, where it will be branded as Ultra® ONE DAY.
Lumify® (brimonidine tartrate ophthalmic solution, 0.025%) - An OTC eye drop developed as an ocular redness reliever. We launched this product in May 2018. Currently, we have several line extensions under development and expect Phase 3 clinical studies to commence in 2021.
Biotrue® ONEday for Astigmatism - A daily disposable contact lens for astigmatic patients. The Biotrue® ONEday contact lens incorporates Surface Active Technologyto provide a dehydration barrier.  The Biotrue® ONEday for Astigmatism also includes evolved peri-ballast geometry to deliver stability and comfort for the astigmatic patient. We launched this product in December 2016 and launched an extended power range and further extended power ranges in 2017, 2018, 2019 and July 2020.
New Ophthalmic Viscosurgical Device ("OVD") product - With a formulation to protect corneal endothelium during phacoemulsification process during a cataract surgery and to help chamber maintenance and lubrication during interocular lens delivery. In January 2020, we commenced an FDA clinical study for cohesive OVD. The clinical study has now achieved its enrollment target, despite COVID-19 slowdowns, and we expect results in the fourth quarter of 2021. In April 2020, we filed a Premarket Approval application for the dispersive OVD with the FDA.
Lotemax® SM (loteprednol etabonate ophthalmic gel) 0.38% - A new formulation for the treatment of post-operative inflammation and pain following ocular surgery. Lotemax® SM is the lowest concentrated loteprednol ophthalmic corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery in the U.S. We launched this product in April 2019.
enVista® Trifocal intraocular lens - An innovative lens design. We initiated an investigative device exemption study for this product in May 2018 and initiated the last phase of this three phase study in the fourth quarter of 2020.
SimplifEYE preloaded intraocular lens injector platform for enVista interocular lens - We have received approvals from the European Union and Canada and received FDA clearance for the injector and launched this platform in October 2020.
Extended depth of focus intraocular lens - Currently under development, however, the timing and completion of which has been delayed due to COVID-19 pandemic related matters. Once developed and if approved, we anticipate that this product could be launched in the second half of 2021.
59


Bausch + Lomb ULTRA® monthly silicone hydrogel lens - Specifically designed to address the lifestyle and vision needs of patients with MoistureSeal® technology which maintains 95% of contact lens moisture for a full 16 hours. In the second quarter of 2020, Bausch + Lomb ULTRA® received a seven day extended wear indication approval from the European Union and received regulatory approval from the National Medical Products Administration in China.
Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lens - The first and only multifocal toric lens available as a standard offering in the eye care professional's fit set. The new monthly silicone hydrogel lens, which was specifically designed to address the lifestyle and vision needs of patients with both astigmatism and presbyopia, combines the Company's unique 3-Zone Progressive multifocal design with the stability of its OpticAlign® toric with MoistureSeal® technology to provide eye care professionals and their patients an advanced contact lens technology that offers the convenience of same-day fitting during the initial lens exam. Bausch + Lomb ULTRA® Multifocal for Astigmatism was launched in June 2019 and received European Union regulatory approval in the second quarter of 2020.
Renu® Advanced Multi-Purpose Solution (“MPS”) - Contains a triple disinfectant system that kills 99.9% of germs, and has a dual surfactant system that provides up to 20 hours of moisture. Renu® Advanced MPS is FDA cleared with indications for use to condition, clean, remove protein, disinfectant, rinse and store soft contact lenses including those composed of silicone hydrogels. Renu® Advanced MPS has gained regulatory approvals in Korea, India, Mexico, Indonesia, Malaysia, Singapore and, during the second quarter of 2020, the European Union.
Custom soft contact lens (Ultra Buttons) - A latheable silicone hydrogel button for custom soft specialty lenses including; Sphere, Toric, Multifocal, Toric Multifocal and irregular corneas. This project has been placed on hold as we reprioritize other projects in our pipeline.
Zen Multifocal Scleral Lens for presbyopia - In January 2019, we launched this product exclusively available with Zenlens and Zen RC scleral lenses and will allow eye care professionals to fit presbyopic patients with irregular and regular corneas and those with ocular surface disease, such as dry eye. The Zen Multifocal Scleral Lens incorporates decentered optics, enabling the near power to be positioned over the visual axis.
Tangible® Hydra-PEG® - A high-water polymer coating that is bonded to the surface of a contact lens and designed to address contact lens discomfort and dry eye. We launched this product in March 2019. Tangible® Hydra-PEG® coating technology in combination with our Boston® materials and Zenlens family of scleral lenses will help eye care professionals provide a better lens wearing experience for their patients with challenging vision needs.
Gastrointestinal
Rifaximin - Top line results from a Phase 2 study for the treatment of overt hepatic encephalopathy with a new formulation (SSD IR) of rifaximin showed a treatment benefit. Patients receiving 40 mg twice daily showed a statistically significant separation from placebo. The top line results from this Phase 2 study will help inform further research on potential new indications for rifaximin; this will include the commencement of a Phase 3 study (RED-C) in 2021 to seek an indication for the prevention of the first episode of Hepatic Encephalopathy. A separate new formulation is planned to be studied for the treatment of sickle cell anemia which rifaximin recently received orphan drug designation for and for which clinical trials are expected to commence in 2021.
Rifaximin - Commencement of a Phase 2 study to evaluate rifaximin for the treatment of small intestinal bacterial overgrowth or SIBO remains pending results from a new formulation study expected to be available in first half 2021. Development of a fit for purpose Patient Reported Outcomes tool for small intestinal bacterial overgrowth (SIBO is continuing in 2021.
Rifaximin - We have entered into an agreement with Cedars Sinai Medical Center to evaluate a new formulation of rifaximin for the treatment of IBS-D. Two preclinical studies have been completed. A Proof of Concept study that was paused due to COVID-19 pandemic related factors has recommenced.
Rifaximin - Our partner Alfasigma S.p.A. ("Alfasigma") is planning a Phase 2/3 study for the treatment of postoperative Crohn's disease using a novel rifaximin extended release formulation.
Envive - We developed a probiotic supplement to address gastrointestinal disturbances. We launched this product in October 2020. 
Amiselimod (S1P modulator) - We are preparing to initiate a Phase 2 study to evaluate Amiselimod (S1P modulator) for the treatment of mild to moderate Ulcerative Colitis. We anticipate the clinical trial to commence in the first half of 2021.
60


Dermatology
Duobrii® - The first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene for the treatment of plaque psoriasis in adults.  Halobetasol propionate and tazarotene are each approved to treat plaque psoriasis when used separately, but the duration of halobetasol propionate is limited by FDA labeling constraints and the use of tazarotene can be limited due to tolerability concerns.  However, the combination of these ingredients in Duobrii®, with a dual mechanism of action, allows for expanded duration of use, with reduced adverse events. We launched this product in June 2019.
Arazlo® (tazarotene) Lotion, 0.045% (formerly IDP-123) - An acne product containing lower concentration of tazarotene in a lotion form to help reduce irritation while maintaining efficacy. We launched this product in June 2020.
Internal Development Project ("IDP") 120 - An acne product with a fixed combination of mutually incompatible ingredients: benzoyl peroxide and tretinoin. Phase 3 clinical studies have been completed and met the primary endpoints. We are currently evaluating next steps for this project.
IDP-126 - An acne product with a fixed combination of benzoyl peroxide, clindamycin phosphate and adapalene. Phase 3 clinical studies initiated in December 2019 were paused due to COVID-19 pandemic related factors, but resumed in June 2020. The first Phase 3 trial has been completed, and the second Phase 3 trial results are expected in 2021. We are currently evaluating next steps for this project.
Clear + Brilliant® Touch - Next generation Clear + Brilliant® laser that is designed to deliver a customized and more comprehensive treatment protocol by providing patients of all ages and skin types the benefits of two wavelengths. We expect to launch this product during the first half of 2021.
IDP-124 - A topical lotion product designed to treat moderate to severe atopic dermatitis, with pimecrolimus. Phase 3 clinical studies have been completed with one of the two studies meeting the primary endpoint. As a result, we have determined to no longer pursue this project.
Strategic Licensing Agreements
To supplement our internal R&D initiatives and to build-out and refresh our product portfolio, we also search for opportunities to augment our pipeline through arrangements that allow us to gain access to unique products and investigational treatments, by strategically aligning ourselves with other innovative product solutions.
In the normal course of business, the Company will enter into select licensing and collaborative agreements for the commercialization and/or development of unique products primarily in the U.S. and Canada. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by the FDA, (iii) covered by third-party payors or (iv) profitable for distribution is highly uncertain. Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones.
In October 2020, we announced that we entered into two exclusive license agreements which present us with unique developmental opportunities to address the unmet need of treatment for myopia in children. The first of these two licensing agreements is with Eyenovia, Inc. for the development and commercialization in the United States and Canada of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. We expect to complete enrollment for a Phase 3 study during the second half of 2022. If approved by the FDA, we believe this investigational product could potentially change the treatment paradigm for the reduction of myopia progression in children. The second is an exclusive global licensing agreement with BHVI for a myopia control contact lens design developed by BHVI. The Company plans to pair BHVI's novel contact lens design with our leading contact lens technologies to develop potential contact lens treatments designed to slow the progression of myopia in children.
In December 2019, we announced that we had acquired an exclusive license from Novaliq GmbH for the commercialization and development in the U.S. and Canada of the investigational treatment NOV03 (perfluorohexyloctane), a first-in-class investigational drug with a novel mechanism of action to treat Dry Eye Disease ("DED") associated with Meibomian gland dysfunction ("MGD"). In an Open Label Safety study, NOV03 has achieved its enrollment target. We expect the readout of topline results from the first of two Phase 3 studies during the second half of 2021 and anticipate filing an NDA in 2022. If approved by the FDA, we believe the addition of this investigational treatment for DED will help build upon our strong portfolio of integrated eye-health products.
In October 2019, we acquired an exclusive license from Clearside Biomedical, Inc. ("Clearside") for the commercialization and development of Xipere (triamcinolone acetonide suprachoroidal injectable suspension) in the U.S. and
61


Canada. Xipere is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for suprachoroidal administration via Clearside's proprietary SCS Microinjector that is being investigated as a targeted treatment of macular edema associated with uveitis. We are working closely with Clearside on the resubmission of the NDA for Xipere to the FDA.
In April 2019, we entered into two licensing agreements which present us with unique developmental opportunities to address unmet needs of individuals suffering with certain GI and liver diseases. The first of these two licensing agreements is with the University of California for certain intellectual property relating to an investigational compound targeting the pituitary adenylate cyclase receptor 1 in non-alcoholic fatty liver disease (“NAFLD”), nonalcoholic steatohepatitis (“NASH”) and other GI and liver diseases. The second is an exclusive licensing agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as inflammatory bowel disease and ulcerative colitis. We have completed a thorough QTC study, which evaluated the cardiac safety profile of the compound. Topline results were positive and we expect to initiate a Phase 2 study in the first half of 2021.
On February 27, 2018, we announced that we entered into an exclusive license agreement with Kaken Pharmaceutical Co., Ltd. ("Kaken") to develop and commercialize a new chemical entity, IDP-131 (KP-470), for the topical treatment of psoriasis. An early proof of concept study has been completed and the results did not meet expectations. As a result, the Company and Kaken have terminated the license agreement.
Strategic Investments in our Infrastructure
In support of our core businesses, we have and continue to make strategic investments in our infrastructure, the most significant of which are at our Waterford facility in Ireland, our Rochester facility in New York and our Lynchburg facility in Virginia.
To meet the forecasted demand for our Biotrue® ONEday lenses, in July 2017, we placed into service a $175 million multi-year strategic expansion project of the Waterford facility. The emphasis of the expansion project was to: (i) develop new technology to manufacture, automatically inspect and package contact lenses, (ii) bring that technology to full validation and (iii) increase the size of the Waterford facility.
To address the expected global demand for our Bausch + Lomb ULTRA® contact lens, in December 2017, we completed a multi-year, $200 million strategic upgrade to our Rochester facility. The upgrade increased production capacity in support of our Bausch + Lomb Ultra® and SiHy Daily AQUALOX product lines and better supports the production of other well-established contact lenses, such as our PureVision®, PureVision®2 (SVS, Toric, and Multifocal), SofLens® 38 and SilSoft®.
To address the expected global demand for our SiHy Daily disposable contact lenses, in November 2018, we initiated $300 million of additional expansion projects to add multiple production lines to our Rochester and Waterford facilities. SiHy Daily disposable contact lenses were launched in the U.S. in September 2020.
To further help us meet the anticipated demand of our contact lenses, in 2020, we initiated an expansion of the Company's Lynchburg distribution center. The new facility is expected to create new jobs over the next five years and expand the overall site to 190,000 square feet, which will provide distribution capabilities for medical devices, primarily contact lens products, and be the main point of distribution for these products in the U.S.
We believe the investments in our Waterford, Rochester and Lynchburg facilities and related expansion of labor forces further demonstrates the growth potential we see in our Bausch + Lomb products and our eye-health business.
Effectively Managing Our Capital Structure
We continue to effectively manage our capital structure by: (i) reducing our debt through repayments, (ii) extending the maturities of debt through refinancing and (iii) improving our credit ratings.
Debt Repayments - Excluding the impact of the $1,210 million financing of the U.S. Securities Litigation settlement discussed below, we have been able to repay (net of additional borrowings) over $8,600 million of long-term debt during the period January 1, 2016 through the date of this filing using the net cash proceeds from divestitures of non-core assets, cash generated from operations and cash generated from tighter working capital management. This includes approximately $900 million of repayments with cash on hand and cash generated from operations during 2020.
2018 Refinancing Transactions - In March, June and November 2018, we accessed the credit markets and completed a series of transactions, whereby we extended approximately $8,300 million in aggregate maturities of certain debt obligations due to mature in March 2020 through July 2022, out to June 2025 through January 2027.  As part of these transactions we obtained less stringent loan financial maintenance covenants under our Senior Secured Credit Facilities and extended commitments under our revolving credit facility by more than three years by replacing our then-existing revolving credit
62


facility, set to expire in April 2020 with a revolving credit facility of $1,225 million due in June 2023 (the “2023 Revolving Credit Facility”).
2019 Refinancing Transactions - In March, May and December 2019, we accessed the credit markets and completed a series of transactions, whereby, we extended approximately $4,200 million in aggregate maturities of certain debt obligations due to mature in December 2021 through May 2023, out to January 2027 through January 2030.
Financing of Litigation Settlement - In December 2019, we announced that we had agreed to resolve the putative securities class action litigation in the U.S. (the "U.S. Securities Litigation") for $1,210 million. Final court approval of this settlement was granted in January 2021. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Subject to an objector's appeal of the Court's final approval order, this settlement resolves and discharges all claims against the Company in the class action, and as a result resolves the most significant of the Company's remaining legacy legal matters and eliminates a material uncertainty regarding our Company.
To finance the settlement of the U.S. Securities Litigation and extend certain debt maturities, on December 30, 2019, we accessed the credit markets and issued: (i) $1,250 million aggregate principal amount of 5.00% Senior Unsecured Notes due January 2028 (the "5.00% January 2028 Unsecured Notes") and (ii) $1,250 million aggregate principal amount of 5.25% Senior Unsecured Notes due January 2030 (the "January 2030 Unsecured Notes") in a private placement. The proceeds and cash on hand were used to: (i) redeem $1,240 million of May 2023 Unsecured Notes on January 16, 2020, (ii) finance amounts owed under the Company's $1,210 million settlement agreement relating to the U.S. Securities Litigation (which is subject to an objector's appeal of the final court approval), the full $1,210 million of which was paid into an escrow fund in accordance with the related settlement agreement and is included in our Restricted cash balance as of December 31, 2020, and (iii) pay all fees and expenses associated with these transactions (collectively, the "December 2019 Financing and Refinancing Transactions"). Through this financing, we have in effect extended the payments of the pending litigation settlement of $1,210 million out to 2028 and 2030, without negatively impacting our working capital available for operations.
2020 Refinancing Transactions - In May and December 2020, we accessed the credit markets and completed a series of transactions, whereby we extended $3,250 million in aggregate maturities of certain debt obligations due to mature in 2022 and 2023 out to 2029 through 2031 and $250 million in aggregate amortization payments due in 2022 out to 2029. In addition to extending $3,500 million in payments due in 2022 and 2023 to 2029 through 2031, the refinancing transactions replaced secured debt of $1,500 million with unsecured debt. This provides us with more secured debt capacity under our Restated Credit Agreement and existing indentures if the market for unsecured debt in the future is less favorable. Further, by replacing $1,500 million of secured debt with unsecured debt we now have additional room under the debt maintenance covenant of our 2023 Revolving Credit Facility that requires us to maintain a first lien net leverage ratio of not greater than 4.00 to 1.00. The refinancing transactions also repaid in full €1,500 million of debt denominated in euros, thereby reducing our exposure to fluctuations in the value of the euro.
See Note 10, "FINANCING ARRANGEMENTS" to our audited Consolidated Financial Statements for the details of our debt portfolio as of December 31, 2020 and 2019.
The debt repayments and refinancing transactions outlined above have allowed us to: (i) improve our credit ratings, (ii) finance amounts owed under the Company's previously announced $1,210 million settlement agreement relating to the U.S. Securities Litigation (which is subject to an objector's appeal of the final court approval) without negatively impacting our working capital available for operations, (iii) extend maturities of certain debt obligations due out to the year 2025 and beyond, (iv) satisfy all debt mandatory amortization payments and maturities until 2024 and (v) reduce our exposure to fluctuations in the value of the euro.
Our prepayment of debt and refinancing transactions over the last four years translate into lower repayments of principal over the next four years, which, in turn, we believe will permit more cash flows to be directed toward developing our core assets, identifying new product opportunities and repaying additional debt amounts. The mandatory scheduled principal repayments of our debt obligations as of December 31, 2020, were as follows:
(in millions)
20212022202320242025202620272028202920302031Total
$— $— $— $2,291 $10,632 $1,500 $2,250 $2,012 $3,250 $1,250 $1,000 $24,185 
63


In addition, as a result of the changes in our debt portfolio, approximately 80% of our debt is fixed rate debt as of December 31, 2020, as compared to approximately 60% as of January 1, 2016. The weighted average stated interest rate of the Company's outstanding debt as of December 31, 2020 and 2019 was 6.02% and 6.21%, respectively.
We continue to monitor our capital structure and to evaluate other opportunities to simplify our business and improve our capital structure, giving us the ability to better focus on our core businesses. While we anticipate focusing any future divestiture activities on non-core assets, consistent with our duties to our shareholders and other stakeholders, we will consider dispositions in core areas that we believe represent attractive opportunities for the Company. Also, the Company regularly evaluates market conditions, its liquidity profile and various financing alternatives for opportunities to enhance its capital structure. If the Company determines that conditions are favorable, the Company may refinance or repurchase existing debt or issue additional debt, equity or equity-linked securities.
See Note 10, "FINANCING ARRANGEMENTS" to our audited Consolidated Financial Statements for further details and this Item “— Liquidity and Capital Resources — Liquidity and Debt — Long-term Debt” for additional discussion of these matters. Cash requirements for future debt repayments including interest can be found in this Item “— Off-Balance Sheet Arrangements and Contractual Obligations.”
Improve Patient Access
Improving patient access to our products, as well as making them more affordable, is a key element of our business strategy.
Patient Access and Pricing Committee - In 2016, we formed the Patient Access and Pricing Committee which is responsible for setting, changing and monitoring the pricing of our products and evaluating contract arrangements that determine the placement of our products on drug formularies. The Patient Access and Pricing Committee considers new to market product pricing, price changes and their impact across channels on patient accessibility and affordability. The Patient Access and Pricing Committee remains committed to limiting the average annual price increase for our branded prescription pharmaceutical products to no greater than single digits and has reaffirmed this commitment for 2021. These pricing changes and programs could affect the average realized pricing for our products and may have a significant impact on our company revenue and profit.
Bausch Health Assistance Program - We are committed to supporting patients who have lost employment health benefits due to the COVID-19 pandemic, and because it is important to continue prescribed treatments, we are proud to offer certain of our prescription medicines through our Bausch Health Assistance Program. In the face of the COVID-19 pandemic, some people have financial obstacles that keep them from obtaining and continuing their prescribed treatments. The purpose of the Bausch Health Patient Assistance Program is to provide eligible unemployed patients in the U.S., who have lost their health insurance due to the COVID-19 pandemic, with certain of our prescription products although their financial circumstances or insurance status may otherwise interfere with their ability to do so. If approved, patients receive their Bausch Health Companies Inc. prescription product(s) at no cost to them for up to one year, and may be able to reapply to the program annually if they continue to meet eligibility requirements and have a valid prescription.
Cash-pay Prescription Program - In February 2019, we launched Dermatology.com, a cash-pay product acquisition program offering certain branded Ortho Dermatologics products directly to patients. In March 2020, the name Dermatology.com was removed as the cash-pay product program name, with the name Dermatology.com limited to only online usage, including future digital teledermatology and e-commerce offerings. The cash-pay program is designed to address the affordability and availability of certain branded dermatology products, when insurers and pharmacy benefit managers are no longer offering those branded prescription pharmaceutical products under their designated pharmacy benefit offerings.
Walgreens Fulfillment Arrangements - In the beginning of 2016, we launched a brand fulfillment arrangement with Walgreen Co. ("Walgreens"). Under the terms of the brand fulfillment arrangement, as amended in July 2019, we made certain dermatology and ophthalmology products available to eligible patients through patient access and co-pay assistance programs at Walgreens U.S. retail pharmacy locations, as well as participating independent retail pharmacies. Our products available under this fulfillment agreement include certain Ortho Dermatologics products, including our Duobrii®, Bryhali®, Arazlo®, Jublia®, Luzu®, Retin-A Micro® Gel and Onexton® and select branded prescription pharmaceutical products included in our cash-pay prescription program, and certain ophthalmology products, including our Vyzulta®, Besivance®, Lotemax®, Alrex®, Prolensa®, Bepreve® and Zylet® products.
Invest in Sustainable Growth Drivers to Position us for Long-Term Growth
We are constantly challenged by the changing dynamics of our industry to innovate and bring new products to market. We have divested certain businesses where we saw limited growth opportunities, so that we can be more aggressive in
64


redirecting our R&D spend and other corporate investments to innovate within our core businesses where we believe we can be most profitable and where we aim to be an industry leader.
We believe that we have a well-established product portfolio that is diversified within our core businesses and provides a sustainable revenue stream to fund our operations. However, our future success is also dependent upon our ability to continually refresh our pipeline, to provide a rotation of product launches that meet new and changing demands and replace other products that have lost momentum. We believe we have a robust pipeline that not only provides for the next generation of our existing products, but is also poised to bring new products to market.
Invest in our Eye-Health Business - As part of our global Bausch + Lomb business strategy, we continually look for key trends in the eye-health market to meet changing consumer/patient needs and identify areas for investment to extend our market share through new launches and effective pricing.
For instance, there is an increasing rate of myopia, and importantly, myopia as a potential risk factor for glaucoma, macular degeneration and retinal detachment. We continue to see increased demand for new eye-health products that address conditions brought on by factors such as increased screen time, lack of outdoor activities and academic pressures, as well as conditions brought on by an aging population (for example, as more and more baby-boomers in the U.S. are reaching the age of 65). To extend our market share in eye-health, we continually seek to identify new products tailored to address these key trends for development internally with our own R&D team to generate organic growth. Recent product launches include Biotrue® ONEday daily disposable contact lenses, the next generation of Bausch + Lomb ULTRA® contact lenses, SiHy Daily contact lenses, Lumify® (an eye redness treatment), Vyzulta® (a pressure lowering eye drop for patients with angle glaucoma or ocular hypertension) and Ocuvite® Eye Performance (vitamins to protect the eye from stressors such as sunlight and blue light emitted from digital devices).
We also license selective molecules or technology in leveraging our own R&D expertise through development, as well as seek out external product development opportunities. As previously discussed, we acquired global exclusive licenses for a myopia control contact lens design developed by BHVI, which we plan to pair with our leading contact lens technologies to develop potential contact lens treatments designed to slow the progression of myopia in children, and for the commercialization and development in the U.S. and Canada of: a microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression in children ages 3-12; Xipere which, if approved by the FDA, will be the first treatment for patients suffering from macular edema associated with uveitis; and NOV03, an investigational drug with a novel mechanism of action to treat DED associated with MGD. We also acquired the U.S. rights to EM-100, which was recently approved by the FDA as Alaway® Preservative-Free and is the first OTC preservative-free formulation eye drop for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair, and dander in adults and children 3 years of age and older. Recently, we entered into an agreement which provides the Company an option to acquire all ophthalmology assets of Allegro, including risuteganib (Luminate®), an investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry AMD. A U.S. Phase 2a study with risuteganib in intermediate dry AMD met its primary endpoint of vision recovery and Phase 3 testing is in the planning stages. We believe investments in these investigational treatments, if approved by the FDA, will complement, and help build upon, our strong portfolio of integrated eye-health products.
As previously discussed, we have also made strategic investments in our infrastructure, the most significant of which are at our Waterford facility in Ireland to meet the forecasted demand for our Biotrue® ONEday lenses, our Rochester facility in New York to address the expected global demand for our Bausch + Lomb ULTRA® contact lens and our Lynchburg facility in Virginia to be our main point of distribution for medical devices in the U.S. During late 2018, we began investing in additional expansion projects at the Waterford and Rochester facilities in order to address the expected global demand for our SiHy Daily disposable contact lenses, which we launched in the U.S. in August 2020, under the branded name Bausch + Lomb INFUSE SiHy Daily Disposable contact lens.
We believe our recent product launches, licensing arrangements and the investments in our Waterford, Rochester and Lynchburg facilities demonstrate the growth potential we see in our Bausch + Lomb products and our eye-health business and that these investments will position us to further extend our market share in the eye-health market.
Leveraging our Salix Infrastructure - We strongly believe in our GI product portfolio and we have implemented initiatives, including increasing our marketing presence and identifying additional opportunities outside our existing GI portfolio, to further capitalize on the value of the infrastructure we built around these products to extend our market share.
In the first quarter of 2017, we hired approximately 250 trained and experienced sales force representatives and managers to create, bolster and sustain deep relationships with primary care physicians (“PCP”). With approximately 70% of IBS-D patients initially presenting symptoms to a PCP, we continue to believe that the dedicated PCP sales force is better positioned to reach more patients in need of IBS-D treatment.
65


This initiative provided us with positive results, as we experienced consistent growth in demand for our GI products throughout 2017 through 2020, which was evident by our growth in Salix revenues of 22% when comparing 2020 to 2017. These results encouraged us to seek out ways to bring out further value through leveraging our existing sales force and, in the later portion of 2018 and in 2019, we identified and executed on certain opportunities which we describe below.
Strategic Acquisition - As previously discussed, in March 2019, we completed the acquisition of certain assets of Synergy, whereby we acquired the worldwide rights to the Trulance® product, a once-daily tablet for adults with chronic idiopathic constipation, or CIC and irritable bowel syndrome with constipation, or IBS-C. We believe that the Trulance® product complements our existing Salix products and allows us to effectively leverage our existing GI sales force.
Licensing Arrangements - As previously discussed, in April 2019, we entered into two licensing agreements. The first is for certain intellectual property relating to an investigational compound targeting the pituitary adenylate cyclase receptor 1 in NAFLD, NASH and other GI and liver diseases. The second is to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as inflammatory bowel disease and ulcerative colitis. These licenses present unique developmental opportunities to address unmet needs of individuals suffering with certain GI and liver diseases and if developed and approved by the FDA, will allow us to further utilize our existing sales force and infrastructure to extend our market share in the future and create value.
Investment in Next Generation Formulations - Revenues from our Xifaxan® product increased approximately 2%, 22% and 22% in 2020, 2019 and 2018, respectively. In order to extend growth in Xifaxan®, we continue to directly invest in next generation formulations of Xifaxan® and rifaximin, the principal semi-synthetic antibiotic used in our Xifaxan® product. In addition to one R&D program in progress, we have three other R&D programs planned for next generation formulations of Xifaxan® (rifaximin) which address new indications.
We believe that the acquisition and licensing opportunities discussed above will be accretive to our business by providing us access to products and investigational compounds that are a natural pairing to our Xifaxan® business, allowing us to effectively leverage our existing infrastructure and sales force. We believe these opportunities, coupled with our investment in next generation formulations, will allow our GI franchise to continue to further extend market share.
Position the Ortho Dermatologics Business for Growth - In 2018, we realigned our Solta aesthetics business and combined it with our medical dermatology business, creating a complete dermatology portfolio. We continue to make investments in our Solta portfolio and anticipate building out our Solta sales force, particularly in Europe to address the growing demand. Our Ortho Dermatologics business continues to work towards improving the treatment options for medical dermatology patients. In light of persistent insurance coverage pressures within the United States for patients needing topical acne and psoriasis products, we are exploring both strategic e-commerce and partnership expansion opportunities which can enable increased accessibility for patients. We are continuing to invest in our on market products and are evaluating various opportunities for our key pipeline products.
In support of the complete dermatology portfolio, we have taken and are taking a number of actions that we believe will help our efforts to stabilize our dermatology business. These actions include: (i) rebranding our dermatology business including our aesthetics business, (ii) appointing a new leader, (iii) making key investments in our core medical device and dermatological products portfolios, (iv) right sizing and reorganizing our dermatology sales force across roughly 195 sales territories, as we work to rebuild relationships with prescribers of our products and (v) improving patient access to our Ortho Dermatologics products through our cash-pay prescription program previously discussed.
Investment in Our Core Dermatology Portfolio - We have made significant investments to build out our aesthetics, psoriasis and acne product portfolios, which are the markets within dermatology where we see the greatest opportunities to extend our market share.
Aesthetics - In 2017, we launched our Next Generation Thermage FLX® product in the U.S., a fourth-generation non-invasive treatment option using a radiofrequency platform designed to optimize key functional characteristics and improve patient outcomes. During 2018 and 2019, Next Generation Thermage FLX® was launched in Hong Kong, Japan, Korea, Taiwan, Philippines, Singapore, Indonesia, Malaysia, China, Thailand, Vietnam, and Australia as part of our Solta medical aesthetic devices portfolio. These launches have been successful as Next Generation Thermage FLX® revenues for 2020 and 2019 were $142 million and $77 million, respectively. We expect additional launches of Next Generation Thermage FLX® in Europe in the near term, paced by country-specific regulatory registrations.
Psoriasis - As the number of reported cases of psoriasis in the U.S. has increased, we believe there is a need to make further investments in this market in order to maximize our opportunity and supplement our current psoriasis product portfolio. We launched Duobrii® in June 2019 and launched Bryhali® in November 2018. We expect that
66


Duobrii® and Bryhali® will align well with our existing topical portfolio of psoriasis treatments and, supplemented by our injectable biologic products, such as Siliq® (launched in July 2017), will provide a diverse choice of psoriasis treatments to doctors and patients.
Acne - In support of our established acne product portfolio, we have developed and launched several products, which includes Arazlo® (tazarotene) Lotion (launched in June 2020), Altreno® (launched in the U.S. in October 2018), the first lotion (rather than a gel or cream) product containing tretinoin for the treatment of acne, and Retin-A Micro® 0.06% (launched in January 2018). We also have two other unique acne projects in our pipeline that, if approved by the FDA, we believe will further innovate and advance the treatment of acne.
Bolstered by new product launches in our aesthetics, psoriasis and acne product lines and the potential of other products under development, our experienced dermatology sales leadership team, our sales force and our cash-pay prescription program, we believe we have set the groundwork to position the Ortho Dermatologics business for future growth.
Business Trends
In addition to the actions previously outlined, the events described below have affected and may affect our business trends:
Health Care Reform
The U.S. federal and state governments continue to propose and pass legislation designed to regulate the health care industry. In March 2010, the Patient Protection and Affordable Care Act (the “ACA”) was enacted in the U.S. The ACA contains several provisions that impact our business, including: (i) an increase in the minimum Medicaid rebate to states participating in the Medicaid program, (ii) the extension of the Medicaid rebates to Managed Care Organizations that dispense drugs to Medicaid beneficiaries, (iii) the expansion of the 340(B) Public Health Services drug pricing program, which provides outpatient drugs at reduced rates, to include additional hospitals, clinics and health care centers and (iv) a fee payable to the federal government based on our prior-calendar-year share relative to other companies of branded prescription drug sales to specified government programs.
In addition, in 2013 federal subsidies began to be phased in for brand-name prescription drugs filled in the Medicare Part D coverage gap. The ACA also included provisions designed to increase the number of Americans covered by health insurance. In 2014, the ACA's private health insurance exchanges began to operate. The ACA also allows states to expand Medicaid coverage with most of the expansion’s cost paid for by the federal government.
For 2020, 2019 and 2018, we incurred costs of $21 million, $20 million and $36 million, respectively, related to the annual fee assessed on prescription drug manufacturers and importers that sell branded prescription drugs to specified U.S. government programs (e.g., Medicare and Medicaid). For 2020, 2019 and 2018, we also incurred costs of $131 million, $137 million and $90 million, respectively, on Medicare Part D utilization incurred by beneficiaries whose prescription drug costs cause them to be subject to the Medicare Part D coverage gap (i.e., the “donut hole”).
The financial impact of the ACA will be affected by certain additional developments over the next few years, including pending implementation guidance and certain health care reform proposals. Additionally, policy efforts designed specifically to reduce patient out-of-pocket costs for medicines could result in new mandatory rebates and discounts or other pricing restrictions. Also, it is possible, as discussed further below, that legislation will be passed by Congress repealing the ACA in whole or in part. Adoption of legislation at the federal or state level could materially affect demand for, or pricing of, our products.
In 2018, we faced uncertainties due to federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA. However, we believe there is low likelihood of repeal of the ACA, given the recent failure of the Senate’s multiple attempts to repeal various combinations of ACA provisions and the recent change in administration. There is no assurance that any replacement or administrative modifications of the ACA will not adversely affect our business and financial results, particularly if the replacing legislation reduces incentives for employer-sponsored insurance coverage, and we cannot predict how future federal or state legislative or administrative changes relating to the reform will affect our business.
In 2019, the U.S. Health and Human Services Administration announced a preliminary plan to allow for the importation of certain lower-cost drugs from Canada. The preliminary plan excludes insulin, biological drugs, controlled substances and intravenous drugs. The preliminary plan relies on individual states to develop proposals for safe importation of those drugs from Canada and submit those proposals to the federal government for approval. Although the preliminary plan has some support from the prior administration, at this time, studies to evaluate the related costs and benefits, evaluate the reasonableness of the logistics, and measure the public reaction of such a plan have not been performed. While we do not believe this will have
67


a significant impact on our future cash flows, we cannot provide assurance as to the ultimate context, timing, effect or impact of such a plan.
In 2019, the Government of Canada (Health Canada) published in the Canadian Gazette the new pricing regulation for patented drugs. These regulations will become effective on July 1, 2021. The new regulations will change the mechanics of establishing the pricing for products submitted for approval after August 21, 2019; they will also require full transparency of discounts agreed with provincial bodies; and finally, will change the number and composition of reference countries used to determine if a drug’s price is excessive. While we do not believe this will have a significant impact on our future cash flows, as additional facts materialize, we cannot provide assurance as to the ultimate content, timing, effect or impact of such regulations.
In July 2020, U.S. President Donald Trump signed four Executive Orders related to drug pricing, including orders addressing: (i) Part D rebate reform, (ii) the provision of deeply discounted insulin and/or an EpiPen to patients of Federally Qualified Health Centers, (iii) drug importation from Canada and (iv) most favored nation pricing for Medicare. In November 2020, U.S. President Donald Trump announced the Most Favored Nation Model for Medicare Part B Payment which was to be implemented by the Centers for Medicare & Medicaid Services Innovation Center on January 1, 2021; however, it has not been implemented, as it is currently being challenged in court. It is also uncertain whether the Biden administration intends to reverse these measures or adopt similar policy initiatives. However, President Biden and several members of the current U.S. Congress have indicated that lowering drug prices is a legislative and political priority, and some have introduced proposals that seek to address drug pricing. We are currently reviewing those Executive Orders and the Most Favored Nation Model, the impact of which is uncertain at this time.
Other legislative efforts relating to drug pricing have been enacted and others have been proposed at the U.S. federal and state levels. For instance, certain states have enacted legislation related to prescription drug pricing transparency. Several states have passed importation legislation and Florida is working with the U.S. government to implement an importation program from Canada. We also anticipate that Congress, state legislatures and third-party payors may continue to review and assess alternative health care delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations affecting additional fundamental changes in the health care delivery system. We continually review newly enacted and proposed U.S. federal and state legislation, as well as proposed rulemaking and guidance published by the Department of Health and Human Services and the FDA; however, at this time, it is unclear the effect these matters may have on our businesses.
Generic Competition and Loss of Exclusivity
Certain of our products face the expiration of their patent or regulatory exclusivity in 2021 or in later years, following which we anticipate generic competition of these products. In addition, in certain cases, as a result of negotiated settlements of some of our patent infringement proceedings against generic competitors, we have granted licenses to such generic companies, which will permit them to enter the market with their generic products prior to the expiration of our applicable patent or regulatory exclusivity. Finally, for certain of our products that lost patent or regulatory exclusivity in prior years, we anticipate that generic competitors may launch in 2021 or in later years. Following a loss of exclusivity ("LOE") of and/or generic competition for a product, we would anticipate that product sales for such product would decrease significantly shortly following the LOE or entry of a generic competitor. Where we have the rights, we may elect to launch an authorized generic of such product (either ourselves or through a third-party) prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product would still be expected to be significant, and the effect on our future revenues could be material.
A number of our products already face generic competition. Prior to and during 2020, in the U.S., these products include, among others, Ammonul®, Apriso®, Benzaclin®, Bupap®, Cuprimine®, Demser®, Edecrin®, Elidel®, Glumetza®, Istalol®, Isuprel®, Locoid® Lotion, Lotemax® Suspension, Mephyton®, Migranal®, MoviPrep®, Nitropress®, Solodyn®, Syprine®, Timoptic® in Ocudose®, Uceris® Tablet, Virazole®, Wellbutrin XL®, Xenazine®, Zegerid® and Zovirax® cream. In Canada, these products include, among others, Glumetza®, Wellbutrin® XL and Zovirax® ointment.
2020 LOE Branded Products - Branded products that began facing generic competition in the U.S. during 2020 include, Migranal® and MoviPrep®. In aggregate, these products accounted for less than 1% of our total revenues in 2020. While certain of these products have already begun experiencing an adverse impact on volume and/or pricing as a result of the entry into the market of generic competition, we are unable to predict the complete magnitude or timing of this impact.
2021 through 2025 LOE Branded Products - Based on current patent expiration dates, settlement agreements and/or competitive information, we have identified branded products that we believe could begin facing potential LOE and/or generic competition in the U.S. during the years 2021 through 2025. These products and year of expected LOE include, but are not limited to, Clindagel® (2021), Lotemax® Gel (2021), Noritate® (2021), Targretin® Gel (2022), Xerese® (2022) and certain other products that are subject to settlement agreements which could impact their exclusivity during the years 2021 through 2025. In
68


aggregate, these products accounted for 2% of our total revenues in 2020. These dates may change based on, among other things, successful challenge to our patents, settlement of existing or future patent litigation and at-risk generic launches. We believe the entry into the market of generic competition generally would have an adverse impact on the volume and/or pricing of the affected products, however we are unable to predict the magnitude or timing of this impact.
2021 OTC Product Patent Expiry - PreserVision® AREDS and PreserVision® AREDS 2 are OTC eye vitamin formulas for those with moderate-to-advanced age-related macular degeneration. PreserVision® products accounted for 3% of our total revenues in 2020. The PreserVision® U.S. formulation patent expires in 2021, but a patent covering methods of using the formulation remains in force until 2026. While the Company cannot predict the magnitude or timing of the impact from its patent expiry, this is an OTC product and thus, the impact is not expected to be as significant as the LOE of a branded pharmaceutical product.
In addition, for a number of our products (including Relistor®, Plenvu®, Xifaxan® 550mg, Bryhali®, Duobrii® and Jublia® in the U.S. and Jublia® in Canada), we have commenced (or anticipate commencing) and have (or may have) ongoing infringement proceedings against potential generic competitors in the U.S. and Canada. If we are not successful in these proceedings, we may face increased generic competition for these products.
Bryhali® Lotion, 0.01% (Glenmark) - In December 2019, the Company announced that it had reached an agreement to resolve the outstanding intellectual property litigation with Glenmark Pharmaceuticals, Ltd. ("Glenmark"). Under the terms of the agreement, the Company will grant Glenmark a non-exclusive license to its intellectual property relating to Bryhali® in the U.S. and, beginning in 2026 (or earlier under certain circumstances), Glenmark will have the option to market a royalty-free generic version of Bryhali® Lotion, should it receive approval from the FDA. The parties have agreed to dismiss all litigation related to Bryhali® Lotion, and all intellectual property protecting Bryhali® Lotion remains intact.
Bryhali® Lotion, 0.01% (Perrigo) - On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (“Perrigo”), in which Perrigo asserted that certain U.S. patents, each of which is listed in the FDA’s Orange Book for Bryhali® (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Perrigo’s generic halobetasol propionate lotion, for which an Abbreviated New Drug Application ("ANDA") has been filed by Perrigo.  On May 1, 2020, the Company filed suit against Perrigo pursuant to the Hatch-Waxman Act, alleging infringement by Perrigo of one or more claims of the Bryhali® Patents, thereby triggering a 30-month stay of the approval of the Perrigo ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Perrigo described below, regarding Perrigo’s ANDA for generic Duobrii® (halobetasol propionate and tazarotine) lotion. The Company remains confident in the strength of the Bryhali® patents and intends to vigorously pursue this matter and defend its intellectual property.
Duobrii® Lotion (Perrigo) - On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo, in which Perrigo asserted that certain U.S. patents, each of which is listed in the FDA's Orange Book for Duobrii® (halobetasol propionate and tazarotine) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Perrigo’s generic lotion, for which an ANDA has been filed by Perrigo. On August 28, 2020, the Company filed suit against Perrigo pursuant to the Hatch-Waxman Act, alleging infringement by Perrigo of one or more claims of the Duobrii® Patents, thereby triggering a 30-month stay of the approval of the Perrigo ANDA. On September 3, 2020, this action was consolidated with the action between the Company and Perrigo described above, regarding Perrigo’s ANDA for generic Bryhali® (halobetasol propionate) lotion. We remain confident in the strength of the Duobrii® patents and will vigorously defend our intellectual property.
Xifaxan® 550mg Patent Litigation (Actavis) - On March 23, 2016, the Company initiated litigation against Actavis Laboratories FL, Inc.’s ("Actavis"), which alleged infringement by Actavis of one or more claims of each of the Xifaxan® patents. On September 12, 2018, we announced that we had reached an agreement with Actavis that resolved the existing litigation and eliminated the pending challenges to our intellectual property protecting Xifaxan® (rifaximin) 550 mg tablets. As part of the agreement, the parties agreed to dismiss all litigation related to Xifaxan® (rifaximin), Actavis acknowledged the validity of the licensed patents for Xifaxan® (rifaximin) 550 mg tablets and all intellectual property protecting Xifaxan® (rifaximin) 550 mg tablets will remain intact and enforceable until expiry in 2029. The agreement also grants Actavis a non-exclusive license to the intellectual property relating to Xifaxan® (rifaximin) 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). The Company will not make any financial payments or other transfers of value as part of the agreement. In addition, under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Actavis will have the option to: (1) market a royalty-free generic version of Xifaxan® tablets, 550 mg, should it receive approval from the FDA on its ANDA, or (2) market an authorized generic version of Xifaxan® tablets, 550 mg, in which case, we will receive a share of the economics from Actavis on its sales of such an authorized generic. Actavis will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed before January 1, 2028.
69


Xifaxan® 550mg Patent Litigation (Sandoz) - In October 2019, the Company announced that it and its licensor, Alfasigma had commenced litigation against Sandoz Inc. ("Sandoz"), a Novartis division, alleging patent infringement of 14 patents by Sandoz's filing of its ANDA for Xifaxan® (rifaximin) 550 mg tablets. On May 6, 2020, the Company announced that an agreement had been reached with Sandoz that resolved this litigation. Under the terms of the agreement, the parties agreed to dismiss all litigation related to Xifaxan® (rifaximin), Sandoz acknowledged the validity of the licensed patents for Xifaxan® (rifaximin) 550 mg tablets and all intellectual property protecting Xifaxan® (rifaximin) 550 mg tablets will remain intact and enforceable until expiry in October 2029. The agreement also grants Sandoz a non-exclusive license to the intellectual property relating to Xifaxan® (rifaximin) 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sandoz will have the right to market a royalty-free generic version of Xifaxan® (rifaximin) 550 mg tablets, should it receive approval from the FDA on its ANDA. Sandoz will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the U.S. before January 1, 2028. The Company did not make any financial payments or other transfers of value as part of this agreement with Sandoz.
Xifaxan® 550mg Patent Litigation (Norwich) - On March 26, 2020, the Company and its licensor Alfasigma filed suit against Norwich Pharmaceuticals Inc. (“Norwich”), alleging infringement by Norwich of one or more claims of the 23 Xifaxan® patents by Norwich’s filing of its ANDA for Xifaxan® (rifaximin) 550 mg tablets. On November 13, 2020, an additional three patents alleged to be infringed by Norwich were added to the suit. Xifaxan® 500mg is protected by 26 patents covering the composition of matter and the use of Xifaxan® listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. The Company remains confident in the strength of the Xifaxan® patents and will continue to vigorously pursue this matter and defend its intellectual property.
Xifaxan® 200mg and 550mg Patent Litigation (Sun) - In April 2019, the Company and its licensor, Alfasigma, commenced litigation against Sun Pharmaceutical Industries Ltd. (“Sun”), alleging patent infringement by Sun’s filing of its ANDA for Xifaxan® (rifaximin) 200 mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from Sun, in which Sun asserted that the U.S. patents listed in the FDA's Orange Book for the Company’s Xifaxan® tablets, 200 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun’s generic rifaximin tablets, 200 mg. Subsequently, on August 10, 2020, the Company received an additional Notice of Paragraph IV Certification from Sun, in which Sun asserted that the U.S. patents listed in the FDA's Orange Book for the Company’s Xifaxan® tablets, 550 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun’s generic rifaximin tablets, 550 mg, for which an ANDA had been filed by Sun. On September 22, 2020, the Company announced that an agreement had been reached with Sun that resolved the outstanding intellectual property disputes with Sun regarding Xifaxan® (rifaximin) 200 mg and 550 mg tablets. Under the terms of the agreement, the parties agreed to dismiss all litigation related to Xifaxan® (rifaximin) and all intellectual property protecting Xifaxan® (rifaximin) 200 mg and 550 mg tablets will remain intact and enforceable until expiry in July and October 2029, respectively. The agreement also grants Sun a non-exclusive license to the intellectual property relating to Xifaxan® (rifaximin) 200 mg and 550 mg tablets in the U.S. beginning January 1, 2028 (or earlier under certain circumstances). Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sun will have the right to market royalty-free generic versions of Xifaxan® (rifaximin) 200 mg and 550 mg tablets, should it receive approval from the FDA on its ANDAs. Sun will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the U.S. before January 1, 2028.
Relistor® Tablets Patent Litigation (Actavis) - On December 6, 2016, the Company initiated litigation against Actavis, which alleged infringement by Actavis of one or more claims of U.S. Patent No. 8,524,276 (the “‘276 Patent”), which protects the formulation of RELISTOR® tablets. Actavis had challenged the validity of such patent and alleged non-infringement by its generic version of such product. In July 2019, we announced that the U.S. District Court of New Jersey had upheld the validity of and determined that Actavis infringed the ‘276 Patent, expiring in March 2031. Actavis has appealed this decision to the U.S. Court of Appeals for the Federal Circuit.
Generic Competition to Uceris® - In July 2018, a generic competitor launched a product which will directly compete with our Uceris® Tablet product. As disclosed in our prior filings, the Company initiated various infringement proceedings against this generic competitor. The Court construed the claims of the asserted patents on August 2, 2019 and, on October 24, 2019, the Company agreed to a judgment that the asserted patents did not cover the generic tablets under the Court’s claim construction, while reserving its right to appeal the claim construction. On November 22, 2019, the Company filed a Notice of Appeal with respect to the claim construction in the Court of Appeals for the Federal Circuit. On December 18, 2020, the Court of Appeals for the Federal Circuit affirmed the District Court’s claim construction. The ultimate impact of this generic competitor on our future revenues cannot be predicted; however, Uceris® Tablet revenues for 2020, 2019 and 2018 were approximately $15 million, $20 million and $84 million, respectively.
70


Generic Competition to Jublia® - On June 6, 2018, the U.S. Patent and Trial Appeal Board (“PTAB”) completed its inter partes review for an Orange Book-listed patent covering Jublia® (U.S. Patent No 7,214,506 (the “’506 Patent”)) and issued a written determination invalidating such patent.  On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings.  As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion. The ‘506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia® revenues for 2020, 2019 and 2018 were approximately $111 million, $110 million and $89 million, respectively.  Jublia® is covered by fourteen additional Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, we received notices of the filing of a number of ANDAs with paragraph IV certification, and have timely filed patent infringement suits against these ANDA filers, and, in addition, we have also commenced certain patent infringement proceedings in Canada against three separate defendants.
See Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements for further details regarding certain infringement proceedings.
The risks of generic competition are a fact of the health care industry and are not specific to our operations or product portfolio. These risks are not avoidable, but we believe they are manageable. To manage these risks, our leadership team continually evaluates the impact that generic competition may have on future profitability and operations. In addition to aggressively defending the Company's patents and other intellectual property, our leadership team makes operational and investment decisions regarding these products and businesses at risk, not the least of which are decisions regarding our pipeline. Our leadership team actively manages the Company's pipeline in order to identify innovative and realizable projects aligned with our core businesses that are expected to provide incremental and sustainable revenues and growth into the future. We believe that our current pipeline is strong enough to meet these objectives and provide future sources of revenues, in our core businesses, sufficient enough to sustain our growth and corporate health as other products in our established portfolio face generic competition and lose momentum.
We believe that we have a well-established product portfolio that is diversified within our core businesses. We also believe that we have a robust pipeline that not only provides for the next generation of our existing products, but also brings new solutions into the market.
See Item 1A. “Risk Factors” of this Form 10-K for additional information on our competition risks.
71


FINANCIAL PERFORMANCE HIGHLIGHTS
The following table provides financial performance highlights for each of the last three years:
 Years Ended December 31,Change
(in millions, except per share data)2020201920182019 to 20202018 to 2019
Revenues$8,027 $8,601 $8,380 $(574)$221 
Operating income (loss)$676 $(203)$(2,384)$879 $2,181 
Loss before benefit from income taxes$(934)$(1,837)$(4,154)$903 $2,317 
Net loss$(559)$(1,783)$(4,144)$1,224 $2,361 
Net loss attributable to Bausch Health Companies Inc.$(560)$(1,788)$(4,148)$1,228 $2,360 
Loss per share attributable to Bausch Health Companies Inc.
Basic $(1.58)$(5.08)$(11.81)$3.50 $6.73 
Diluted $(1.58)$(5.08)$(11.81)$3.50 $6.73 
Financial Performance
Summary of 2020 Compared with 2019
Revenues for 2020 and 2019 were $8,027 million and $8,601 million, respectively, a decrease of $574 million, or 7%. The decrease was primarily driven by: (i) lower volumes driven by: (a) social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, and (b) the impact of the LOE of certain products, (ii) the unfavorable effect of foreign currencies, primarily in Latin America, and (iii) the impact of divestitures and discontinuations. These decreases in our revenues were partially offset by the incremental sales of our Trulance® product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy. Net realized pricing was flat with increases in Bausch + Lomb/International and Diversified Products being offset by decreases in Salix and Ortho Dermatologics. The changes in our segment revenues and segment profits are discussed in further detail in the subsequent section titled “Reportable Segment Revenues and Profits”.
Operating income for 2020 was $676 million compared to Operating loss for 2019 of $203 million, an increase in our operating results of $879 million which reflects, among other factors:
a decrease in contribution (product sales revenue less cost of goods sold, exclusive of amortization and impairments of intangible assets) of $470 million. The decrease was primarily driven by: (i) the decrease in revenues, as previously discussed and (ii) higher manufacturing variances primarily due to the impacts of the COVID-19 pandemic. The decrease was partially offset by lower third-party royalty costs;
a decrease in Selling, general, and administrative (“SG&A”) expenses of $187 million, primarily attributable to profit protection measures taken to manage and reduce operating expenses during the COVID-19 pandemic;
a decrease in R&D of $19 million primarily attributable to social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed;
a decrease in Amortization of intangible assets of $252 million primarily attributable to fully amortized intangible assets no longer being amortized in 2020;
an increase in Asset impairments, including loss on assets held for sale of $39 million. Asset impairments, including loss on assets held for sale in 2020 were primarily related to: (i) reclassifying a business within our Bausch + Lomb/International segment as held for sale and (ii) certain product lines as a result of changes to forecasted sales. Impairments during 2019 were primarily related to: (i) certain product lines as a result of changes to forecasted sales due to generic competition and other factors and (ii) impairments related to assets being classified as held for sale; and
a decrease in Other expense (income), net of $960 million, primarily attributable the decrease in net charges to Litigation and other matters. The decrease in Litigation and other matters was primarily related to the settlement of a legacy U.S. securities class action matter (which is subject to an objector's appeal of the final court approval) in 2019, to which the Company and the other settling defendants admitted no liability as to the claims against it and denied all allegations of wrongdoing.
Operating income for 2020 was $676 million compared to Operating loss for 2019 of $203 million and includes non-cash charges for Depreciation and amortization of intangible assets of $1,825 million and $2,075 million, Asset impairments,
72


including loss on assets held for sale of $114 million and $75 million and Share-based compensation of $105 million and $102 million for 2020 and 2019, respectively.
Our Loss before benefit from income taxes for 2020 and 2019 was $934 million and $1,837 million, respectively, an increase in our results before benefit from income taxes of $903 million. The decrease in our Loss before benefit from income taxes is primarily attributable to: (i) the increase in our operating results of $879 million, as previously discussed, and (ii) a decrease in Interest expense of $78 million as a result of: (a) a lower weighted average stated rate of interest, (b) lower interest as a result of debt repayments during the year and (c) a benefit related to the Company's cross-currency swaps. These decreases in Interest expense were partially offset by the interest associated with $1,210 million of additional financing in December 2019 relating to the U.S. Securities Litigation. The decrease in our Loss before benefit from income taxes was partially offset by: (i) an unfavorable net change in Foreign exchange and other of $38 million and (ii) an increase in the Loss on extinguishment of debt of $17 million.
Net loss attributable to Bausch Health Companies Inc. for 2020 and 2019 was $560 million and $1,788 million, respectively, an increase in our results of $1,228 million. The increase in our results was primarily due to: (i) the decrease in Loss before benefit from income taxes of $903 million, as previously discussed, and (ii) the favorable net change in the Benefit from income taxes of $321 million.
Summary of 2019 Compared with 2018
Revenues for 2019 and 2018 were $8,601 million and $8,380 million, respectively, an increase of $221 million, or 3%. The increase was primarily driven by: (i) higher net realized pricing, (ii) higher volumes and (iii) sales of our Trulance® product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy. These increases in Revenues were partially offset by: (i) the unfavorable effect of foreign currencies, primarily in Europe, Asia and Latin America, and (ii) the impact of divestitures and discontinuations.
Operating loss for 2019 and 2018 was $203 million and $2,384 million, respectively, an increase in our operating results of $2,181 million which reflects, among other factors:
an increase in contribution (product sales revenue less cost of goods sold, exclusive of amortization and impairments of intangible assets) of $230 million. The increase was primarily driven by: (i) higher gross selling prices, (ii) higher volumes, (iii) the incremental contribution of the sales of our Trulance® product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy and (iv) better inventory management, partially offset by: (i) the unfavorable effect of foreign currencies, (ii) the impact of divestitures and discontinuations, (iii) higher sales deductions and (iv) the amortization of the inventory fair value step-up recorded in acquisition accounting related to the inventories we acquired as part of the acquisition of certain assets of Synergy;
an increase in SG&A expenses of $81 million, primarily attributable to: (i) higher selling, advertising and promotion expenses, (ii) the impact of the acquisition of certain assets of Synergy, (iii) costs in 2019 attributable to our IT infrastructure improvement projects and (iv) the charge associated with the termination of a co-promotional agreement with US WorldMeds, LLC. The increase was partially offset by: (i) the favorable effect of foreign currencies, (ii) lower costs related to professional services and (iii) the impact of divestitures and discontinuations;
an increase in R&D of $58 million primarily attributable to a number of projects within our Bausch + Lomb and GI businesses;
a decrease in Amortization of intangible assets of $747 million, primarily due to: (i) the impact of the change in the estimated useful life of the Xifaxan® related intangible assets made in September 2018 to reflect management's changes in assumptions, (ii) fully amortized intangible assets no longer being amortized in 2019 and (iii) lower amortization as a result of impairments to intangible assets in prior periods;
a decrease in Goodwill impairments of $2,322 million, as a result of impairments in 2018 to the goodwill of our: (i) Salix reporting unit upon adopting the new guidance for goodwill impairment accounting at January 1, 2018, (ii) Ortho Dermatologics reporting unit due to unforeseen changes in business dynamics during the three months ended March 31, 2018 and (iii) Dentistry reporting unit as a result of revised forecasts due to changing market conditions during the three months ended December 31, 2018;
a decrease in Asset impairments, including loss on assets held for sale of $493 million, primarily related to specific impairments in 2018 as a result of: (i) decreases in forecasted sales for the Uceris® Tablet product due to generic competition and (ii) decreases in forecasted sales for the Arestin® product due to changing market conditions; and
an increase in Other expense (income), net of $1,434 million, primarily attributable to: (i) an increase in net charges to Litigation and other matters primarily related to the settlement of a legacy U.S. securities class action matter (which is
73


subject to an objector's appeal of the final court approval) in 2019, to which the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing and (ii) Acquired in-process research and development costs incurred during 2019 associated with the upfront payments to enter into certain exclusive licensing agreements. These increases in other expenses were partially offset by the expected receipt for the achievement of a milestone related to a certain product.
Operating loss for 2019 and 2018 was $203 million and $2,384 million, respectively, and includes non-cash charges for Depreciation and amortization of intangible assets of $2,075 million and $2,819 million, Goodwill impairments of $0 and $2,322 million, asset impairments of $75 million and $568 million and Share-based compensation of $102 million and $87 million, respectively.
Our Loss before benefit from income taxes for 2019 and 2018 was $1,837 million and $4,154 million, respectively, an increase in our results before benefit from income taxes of $2,317 million. The decrease in our Loss before benefit from income taxes is primarily attributable to: (i) the increase in our operating results of $2,181 million previously discussed, (ii) the decrease in the Loss on extinguishment of debt of $77 million and (iii) a decrease in Interest expense of $73 million as a result of lower principal amounts of outstanding debt for most of 2019, partially offset by the effect of higher interest rates during 2019. The decrease in our Loss before benefit from income taxes was partially offset by an unfavorable net change in Foreign exchange and other of $15 million.
Net loss attributable to Bausch Health Companies Inc. for 2019 and 2018 was $1,788 million and $4,148 million, respectively, an increase in our results of $2,360 million. The increase in our results was primarily due to the decrease in Loss before benefit from income taxes of $2,317 million, as previously discussed, and the increase in the Benefit from income taxes of $44 million.
74


RESULTS OF OPERATIONS
Our results for the years 2020, 2019 and 2018 were as follows:
 Years Ended December 31,Change
(in millions)2020201920182019 to 20202018 to 2019
Revenues
Product sales$7,924 $8,489 $8,271 $(565)$218 
Other revenues103 112 109 (9)
8,027 8,601 8,380 (574)221 
Expenses   
Cost of goods sold (excluding amortization and impairments of intangible assets)2,202 2,297 2,309 (95)(12)
Cost of other revenues47 53 42 (6)11 
Selling, general and administrative2,367 2,554 2,473 (187)81 
Research and development452 471 413 (19)58 
Amortization of intangible assets1,645 1,897 2,644 (252)(747)
Goodwill impairments— — 2,322 — (2,322)
Asset impairments, including loss on assets held for sale114 75 568 39 (493)
Restructuring, integration and separation costs22 31 22 (9)
Acquisition-related contingent consideration48 12 (9)36 21 
Other expense (income), net454 1,414 (20)(960)1,434 
7,351 8,804 10,764 (1,453)(1,960)
Operating income (loss)676 (203)(2,384)879 2,181 
Interest income13 12 11 
Interest expense(1,534)(1,612)(1,685)78 73 
Loss on extinguishment of debt(59)(42)(119)(17)77 
Foreign exchange and other(30)23 (38)(15)
Loss before benefit from income taxes(934)(1,837)(4,154)903 2,317 
Benefit from income taxes375 54 10 321 44 
Net loss(559)(1,783)(4,144)1,224 2,361 
Net income attributable to noncontrolling interest(1)(5)(4)(1)
Net loss attributable to Bausch Health Companies Inc.$(560)$(1,788)$(4,148)$1,228 $2,360 
A detailed discussion of the year-over-year changes of the Company’s 2019 results compared with that of 2018 can be found under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2019 filed on February 19, 2020.
75


2020 Compared with 2019
Revenues
Our revenues are primarily generated from product sales, principally in the therapeutic areas of eye-health, GI and dermatology, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, "SEGMENT INFORMATION" to our audited Consolidated Financial Statements for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.
Our revenues were $8,027 million and $8,601 million for 2020 and 2019, respectively, a decrease of $574 million, or 7%. The decrease was primarily driven by: (i) lower volumes of $528 million primarily in our Bausch + Lomb/International and Diversified Products segments primarily due to social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, (ii) the unfavorable effect of foreign currencies of $39 million primarily in Latin America and (iii) the impact of divestitures and discontinuations of $20 million. The decreases in our revenues were partially offset by the incremental product sales of our Trulance® product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy of $13 million. Net realized pricing was flat with increases in Bausch + Lomb/International and Diversified Products being offset by decreases in Salix and Ortho Dermatologics.
Our 2020 revenues were most negatively impacted during our second quarter by the social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize prior to our third quarter of 2020. Our revenues for the three months ended December 31, 2020 and 2019 were $2,213 million and $2,224 million, respectively, a decrease of $11 million. This decrease of less than 1% represents a continuing improving trend over the decreases in our year-over-year revenues for the three month periods ended June 30, 2020 and September 30, 2020 of 23% and 3%, respectively, and suggests that a recovery is underway. Presuming there continues to be increased availability of effective vaccines and any resurgence of the COVID-19 virus and variant strains thereof do not have a material adverse impact on efforts to contain the COVID-19 virus, the Company anticipates an ongoing, gradual global recovery from the significant macroeconomic and health care impacts of the pandemic that occurred during the first-half of 2020 and anticipates that its affected businesses could return to pre-pandemic levels during 2021. However, the rates of recovery for each business will vary by geography and will be dependent upon, among other things, the availability and effectiveness of vaccines for the COVID-19 virus, government responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus and other actions taken in response to the COVID-19 pandemic.
The changes in our year over year segment revenues and segment profits, including the impacts of COVID-19 pandemic related matters for 2020, are discussed in further detail in the respective subsequent sections “ — Reportable Segment Revenues and Profits”.
Cash Discounts and Allowances, Chargebacks and Distribution Fees
As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at net product sales. Provisions for these deductions are recognized concurrently with the recognition of gross product sales. These provisions include cash discounts and allowances, chargebacks, and distribution fees, which are paid or credited to direct customers, as well as rebates and returns, which can be paid or credited to direct and indirect customers. As more fully discussed in Note 2, "SIGNIFICANT ACCOUNTING POLICIES" to our audited Consolidated Financial Statements, the Company continually monitors the provisions for these deductions and evaluates the estimates used as additional information becomes available. Price appreciation credits are generated when we increase a product’s wholesaler acquisition cost (“WAC”) under our contracts with certain wholesalers. Under such contracts, we are entitled to credits from such wholesalers for the impact of that WAC increase on inventory on hand at the wholesalers. In wholesaler contracts, such credits are offset against the total distribution service fees we pay on all of our products to each such wholesaler. In addition, some payor contracts require discounting if a price increase or series of price increases in a contract period exceeds a negotiated threshold. Provision balances relating to amounts payable to direct customers are netted against trade receivables and balances relating to indirect customers are included in accrued liabilities. 
76


We actively manage these offerings, focusing on the incremental costs of our patient assistance programs, the level of discounting to non-retail accounts and identifying opportunities to minimize product returns. We also concentrate on managing our relationships with our payors and wholesalers, reviewing the ranges of our offerings and being disciplined as to the amount and type of incentives we negotiate.
Provisions recorded to reduce gross product sales to net product sales and revenues for 2020 and 2019 were as follows:
Years Ended December 31,
20202019
(in millions)AmountPct.AmountPct.
Gross product sales$12,960 100.0 %$13,776 100.0 %
Provisions to reduce gross product sales to net product sales
Discounts and allowances621 4.8 %776 5.6 %
Returns120 0.9 %113 0.8 %
Rebates2,174 16.8 %2,265 16.4 %
Chargebacks1,925 14.9 %1,938 14.1 %
Distribution service fees196 1.5 %195 1.5 %
5,036 38.9 %5,287 38.4 %
Net product sales$7,924 61.1 %$8,489 61.6 %
Cash discounts and allowances, returns, rebates, chargebacks and distribution fees as a percentage of gross product sales were 38.9% and 38.4% in 2020 and 2019, respectively. Changes in cash discounts and allowances, returns, rebates, chargebacks and distribution fees as a percentage of gross product sales were primarily driven by:
discounts and allowances as a percentage of gross product sales was lower primarily due to lower discount rates for certain generic products, such as Glumetza® AG, Migranal® AG and Syprine® AG, partially offset by the impact of higher gross product sales of Xifaxan® and Lotemax® AG;
returns as a percentage of gross product sales was relatively unchanged. Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Included in the product sales return provisions for 2020 and 2019 are reductions in variable consideration for sales returns related to past sales of approximately $38 million and $80 million, respectively. See Note 2, "SIGNIFICANT ACCOUNTING POLICIES" to our audited Consolidated Financial Statements regarding further details related to product sales provisions;
rebates as a percentage of gross product sales was higher primarily due the impact of: (i) increases in gross product sales for products that carry higher contractual rebates and co-pay assistance programs, including the impact of incremental rebates from contractual price increase limitations for promoted products, such as Xifaxan® and Jublia® and (ii) sales of our Trulance® product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy, partially offset by decreases in gross product sales for products which carry higher rebate rates, such as Apriso® as a result of its generic release, Lotemax® Suspension and Lotemax® Gel;
chargebacks as a percentage of gross product sales was higher primarily due to the impact of: (i) higher chargeback rates and gross product sales for Glumetza® SLX, Xifaxan® and Nifedical® and (ii) the release of the generic Apriso® AG (December 2019). The higher chargebacks as a percentage of gross product sales were partially offset by the impact of lower gross product sales of: (i) certain generic products, such as Glumetza® AG, Targretin® AG, and Ofloxacin and (ii) the branded product Nifedical®; and
distribution service fees as a percentage of gross product sales was unchanged as the impact of: (i) higher gross product sales and higher distribution service fee rates associated with our Xifaxan® and Glumetza® SLX products and (ii) sales of our Trulance® product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy were offset by the impact of lower gross product sales of certain branded products, such as Apriso® as a result of its generic release. Price appreciation credits are offset against the distribution service fees we pay wholesalers and were $15 million and $11 million for 2020 and 2019, respectively.
77


Operating Expenses
Cost of Goods Sold (exclusive of amortization and impairments of intangible assets)
Cost of goods sold primarily includes: manufacturing and packaging; the cost of products we purchase from third parties; royalty payments we make to third parties; depreciation of manufacturing facilities and equipment; and lower of cost or market adjustments to inventories. Cost of goods sold excludes the amortization and impairments of intangible assets.
Cost of goods sold was $2,202 million and $2,297 million for 2020 and 2019, respectively, a decrease of $95 million, or 4%. The decrease was primarily driven by: (i) lower third-party royalty costs, (ii) lower volumes, as previously discussed, and (iii) the favorable impact of foreign currencies. The decrease was partially offset by: (i) higher manufacturing variances primarily due to the impacts of the COVID-19 pandemic and (ii) changes in product mix.
Cost of goods sold as a percentage of Product sales revenue was 27.8% and 27.1% for 2020 and 2019, respectively, an increase of 0.7 percentage points. Costs of goods sold as a percentage of Product sales revenue was unfavorably impacted as a result of: (i) changes in product mix and (ii) higher manufacturing variances primarily due to the impacts of the COVID-19 pandemic. These factors were partially offset by lower third-party royalty costs.
Selling, General and Administrative Expenses
SG&A expenses primarily include: employee compensation associated with sales and marketing, finance, legal, information technology, human resources and other administrative functions; certain outside legal fees and consultancy costs; product promotion expenses; overhead and occupancy costs; depreciation of corporate facilities and equipment; and other general and administrative costs. Also included in SG&A expenses for 2020 are separation-related costs. The Company has incurred, and will incur, separation-related costs which are incremental costs indirectly related to the Separation. Separation-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification.
SG&A expenses were $2,367 million and $2,554 million for 2020 and 2019, respectively, a decrease of $187 million, or 7%. The decrease was primarily attributable to: (i) the impacts of social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, and (ii) profit protection measures taken to manage and reduce operating expenses during the COVID-19 pandemic and resulted in decreases in: (a) advertising and promotion expenses and (b) selling expenses. The profit protection measures have been successful in expanding the profit margins in many of our businesses. As the pace of recovery in each geography accelerates, we expect to allocate more resources to selling and other promotional activities to drive our return to sustainable revenue and profit growth. Therefore, if the recovery continues, we expect our operating expenses to increase in support of our existing products, product launches and products in development and expect to see our operating expenses in 2021 exceed our operating expenses in 2020 as a result. Included within SG&A expenses for 2020 were $21 million of separation-related costs. Included within SG&A expenses for 2019 was a charge associated with the termination of a certain co-promotional agreement.
Research and Development Expenses
Included in Research and development are costs related to our product development and quality assurance programs. Expenses related to product development include: employee compensation costs; overhead and occupancy costs; depreciation of research and development facilities and equipment; clinical trial costs; clinical manufacturing and scale-up costs; and other third-party development costs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards and include: employee compensation costs; overhead and occupancy costs; amortization of software; and other third-party costs.
R&D expenses were $452 million and $471 million for 2020 and 2019, respectively, a decrease of $19 million, or 4%. R&D expenses as a percentage of Product sales were approximately 6% and 5% for 2020 and 2019, respectively.
As previously discussed, primarily during our second quarter of 2020, certain of our R&D activities were limited and others, including new patient enrollments in clinical trials, were temporarily paused as most trial sites were not able to accept new patients due to government mandated shutdowns. However, during our third quarter of 2020, many of these trial sites began to reopen and we saw the pace of new patient enrollments increasing, getting close to their pre-COVID-19 levels in the U.S. As of the date of this filing, we have not had to make material changes to our development timelines and the pause in our clinical trials have not had a material impact on our operating results; however, a resurgence of the virus could result in unanticipated delays in our ability to conduct new patient enrollments and create other delays which could have a significant adverse effect on our future operating results.
78


Amortization of Intangible Assets
Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives, generally 2 to 20 years. Management continually assesses the useful lives related to the Company's long-lived assets to reflect the most current assumptions.
Amortization of intangible assets was $1,645 million and $1,897 million for 2020 and 2019, respectively, a decrease of $252 million, or 13%. The decrease was primarily attributable to fully amortized intangible assets no longer being amortized in 2020.
See Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our audited Consolidated Financial Statements for further details related to our intangible assets.
Asset impairments, including loss on assets held for sale
Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present.
Asset impairments, including loss on assets held for sale were $114 million and $75 million for 2020 and 2019, respectively, an increase of $39 million. Asset impairments, including loss on assets held for sale for 2020 included impairments of: (i) $96 million to reduce the carrying value of a business within the Bausch + Lomb/International segment to its estimated fair value less costs to sell due to classifying the business as held for sale, (ii) $16 million, in aggregate, due to decreases in forecasted sales of certain product lines, (iii) $1 million, in aggregate, related to the discontinuance of certain product lines not aligned with the focus of the Company's core businesses and (iv) $1 million related to Acquired in-process research and development not in service. Asset impairments, including loss on assets held for sale for 2019 included impairments of: (i) $58 million reflecting decreases in forecasted sales of certain product lines due to generic competition and other factors, (ii) $8 million related to assets being classified as held for sale, (iii) $5 million related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses and (iv) $4 million related to Acquired in-process research and development not in service.
See Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our audited Consolidated Financial Statements for further details related to our intangible assets.
Restructuring, Integration and Separation Costs
Restructuring, integration and separation costs were $22 million and $31 million for 2020 and 2019, respectively, a decrease of $9 million.
Restructuring and integration costs
The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i) reducing headcount, (ii) eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives.
Restructuring and integration costs were $11 million and $31 million for 2020 and 2019, respectively, a decrease of $20 million. During 2020, these costs included: (i) $10 million of facility closure costs and (ii) $1 million of severance and other costs. During 2019, these costs included: (i) $11 million of severance costs and other costs associated with the acquisition of certain assets of Synergy, (ii) $11 million of facility closure costs and (iii) $9 million of other severance costs. The Company continues to evaluate opportunities to streamline its operations and identify additional cost savings globally. Although a specific plan does not exist at this time, the Company may identify and take additional exit and cost-rationalization restructuring actions in the future, the costs of which could be material.
Separation costs
The Company has incurred, and will incur, costs associated with activities to effectuate the Separation. These activities include: (i) separating the eye-health business from the remainder of the Company and (ii) registering the eye-health business as an independent publicly traded entity. Separation costs are incremental costs directly related to the Separation and include, but are not limited to: (i) legal, audit and advisory fees, (ii) employee hiring, relocation and travel costs and (iii) costs associated with establishing a new board of directors and audit committee. Separation costs were $11 million for 2020. The Company is in
79


the planning phase of the Separation and the extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.
See Note 4, "RESTRUCTURING, INTEGRATION AND SEPARATION COSTS" to our audited Consolidated Financial Statements for further details regarding these actions.
Acquisition-Related Contingent Consideration
Acquisition-related contingent consideration primarily consists of potential milestone payments and royalty obligations associated with businesses and assets we acquired in the past. These obligations are recorded in the Consolidated Balance Sheets at their estimated fair values at the acquisition date, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in fair value measurement accounting.
Acquisition-related contingent consideration was a loss of $48 million in 2020 and included: (i) net fair value adjustments of $25 million, which included net fair value adjustments to expected future royalty payments and (ii) accretion for the time value of money of $23 million. Acquisition-related contingent consideration was a loss of $12 million in 2019 and included accretion for the time value of money of $22 million, partially offset by net fair value adjustments of $10 million, which included net fair value adjustments to expected future royalty payments.
See Note 5, "FAIR VALUE MEASUREMENTS" to our audited Consolidated Financial Statements for further details.
Other expense (income), net
Other expense (income), net for 2020 and 2019 consists of the following:
(in millions)20202019
Litigation and other matters$422 $1,401 
Acquired in-process research and development costs32 41 
Net (gain) loss on sales of assets(1)(31)
Acquisition-related costs— 
Other, net(5)
Other expense (income), net$454 $1,414 
In 2020, Litigation and other matters includes net charges related to the U.S. Securities Litigation, the SEC Investigation and the Canadian Securities Litigation and related opt-outs. In 2020, Litigation and other matters also includes an insurance recovery related to a certain litigation matter. In 2019, Litigation and other matters includes the settlement of a legacy U.S. securities class action matter (which is subject to an objector's appeal of the final court approval). In December 2019, we announced that we had agreed to resolve the U.S. Securities Litigation for $1,210 million. Final court approval of this settlement was granted in January 2021. Subject to an objector's appeal of the Court's final approval order, the settlement resolves and discharges all claims against the Company in this class action and resolves the most significant of the Company's remaining legacy legal matters and eliminates a material uncertainty. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and denied all allegations of wrongdoing.
In addition to the anticipated resolution of the U.S. Securities Litigation, through the date of this filing, we achieved dismissals and other positive outcomes in a number of litigations, disputes and investigations, as we continue to actively address others. These matters and other significant matters are discussed in further detail in Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements.
In 2020 and 2019, Acquired in-process research and development costs of $32 million and $41 million, primarily consist of costs associated with the upfront payments to enter into certain exclusive licensing agreements. In 2019, Net gain on sales of assets includes $20 million related to the achievement of a milestone related to a certain product.
Non-Operating Income and Expense
Interest Expense
Interest expense primarily consists of interest payments due, amortization of debt premiums, discounts and deferred issuance costs on indebtedness under our credit facilities and notes and the amortization of amounts excluded from the assessment of hedge effectiveness over the term of the Company's cross-currency swaps.
80


Interest expense was $1,534 million and $1,612 million and included non-cash amortization and write-offs of debt discounts and deferred financing costs of $61 million and $63 million for 2020 and 2019, respectively. Interest expense decreased $78 million, or 5%, primarily due to: (i) a lower weighted average stated rate of interest, (ii) lower interest as a result of debt repayments during the year and (iii) a benefit related to the Company's cross-currency swaps. These decreases were partially offset by the interest associated with $1,210 million of additional financing in December 2019 relating to the U.S. Securities Litigation. The weighted average stated rate of interest as of December 31, 2020 and 2019 was 6.02% and 6.21%, respectively.
See Note 10, "FINANCING ARRANGEMENTS" to our audited Consolidated Financial Statements for further details.
Loss on Extinguishment of Debt
Loss on extinguishment of debt represents the differences between the amounts paid to settle extinguished debts and the carrying value of the related extinguished debt. Loss on extinguishment of debt was $59 million and $42 million for 2020 and 2019, respectively, associated with a series of transactions which allowed us to refinance and extend the maturities of portions of our debt arrangements.
See Note 10, "FINANCING ARRANGEMENTS" to our audited Consolidated Financial Statements for further details.
Foreign Exchange and Other
Foreign exchange and other primarily includes: (i) translation gains/losses on intercompany loans and third-party liabilities and (ii) the gain/loss due to foreign currency exchange contracts. Foreign exchange and other was a loss of $30 million for 2020 as compared to a gain of $8 million for 2019, an unfavorable net change of $38 million.
Income Taxes
Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future. Benefit from income taxes was $375 million and $54 million in 2020 and 2019, respectively, an increase of $321 million.
Our consolidated foreign rate differential reflects the net total tax cost or benefit on income earned or losses incurred in jurisdictions outside of Canada as compared to the net total tax cost or benefit of such income (on a jurisdictional basis) at the Canadian statutory rate of 26.9%. Tax costs below the Canadian statutory rate generate a beneficial foreign rate differential as do tax benefits generated in jurisdictions where the statutory tax rate exceeds the Canadian statutory tax rate. The net total foreign rate differentials generated in each jurisdiction in which we operate is not expected to bear a direct relationship to the net total amount of foreign income (or loss) earned outside of Canada.
In 2020 and 2019, our effective tax rate differs from the statutory Canadian income tax rate primarily due to: (i) the recording of valuation allowance on entities for which no tax benefit of losses is expected, (ii) the tax benefit generated from our annualized mix of earnings by jurisdiction and (iii) the discrete treatment of certain tax matters, primarily related to: (a) the release of a valuation allowance, (b) internal restructurings, (c) changes in uncertain tax positions and (d) changes in the manner in which an outside basis difference will be recovered in future periods.
We record a valuation allowance against our deferred tax assets to reduce their net carrying value to an amount that we believe is more likely than not to be realized. In determining our deferred tax asset valuation allowance, we estimate our ability to utilize future sources of income to realize the benefits of our temporary income tax differences including: (i) net operating loss carryforwards in each jurisdiction, primarily in Canada, the U.S. and Ireland, (ii) research and development tax credit carryforwards, (iii) scientific research and experimental development pool carryforwards and (iv) investment tax credit carryforwards. When we establish/increase or reduce/decrease the valuation allowance, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. Our valuation allowance against deferred tax assets as of December 31, 2020 and 2019 was $2,252 million and $2,831 million, respectively, a decrease of $579 million which was primarily driven by a release of valuation allowance for a change in judgment during 2020 related to previously established deferred tax assets.
See Note 17, "INCOME TAXES" to our audited Consolidated Financial Statements for further details.
81


Reportable Segment Revenues and Profits
Our portfolio of products falls into four operating and reportable segments: (i) Bausch + Lomb/International, (ii) Salix, (iii) Ortho Dermatologics and (iv) Diversified Products.
The following is a brief description of our segments:
The Bausch + Lomb/International segment consists of: (i) sales in the U.S. of pharmaceutical products, OTC products and medical device products, primarily comprised of Bausch + Lomb products, with a focus on the Vision Care, Surgical, Consumer and Ophthalmology Rx products and (ii) with the exception of sales of Solta products, sales in Canada, Europe, Asia, Australia, Latin America, Africa and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products, OTC products, medical device products and Bausch + Lomb products.
The Salix segment consists of sales in the U.S. of GI products.
The Ortho Dermatologics segment consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta medical aesthetic devices.
The Diversified Products segment consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products.
Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, including loss on assets held for sale, Restructuring, integration and separation costs, Acquisition-related contingent consideration costs and Other expense (income), net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. See Note 22, "SEGMENT INFORMATION" to our audited Consolidated Financial Statements for a reconciliation of segment profit to Loss before benefit from income taxes.
The following table presents segment revenues, segment revenues as a percentage of total revenues and the year over year changes in segment revenues for 2020 and 2019. The following table also presents segment profits, segment profits as a percentage of segment revenues and the year over year changes in segment profits for 2020 and 2019.
 Years Ended December 31,Change
 202020192019 to 2020
(in millions)AmountPct.AmountPct.AmountPct.
Segment Revenue
Bausch + Lomb/International$4,408 55 %$4,739 55 %$(331)(7)%
Salix1,904 24 %2,022 23 %(118)(6)%
Ortho Dermatologics553 %565 %(12)(2)%
Diversified Products1,162 14 %1,275 15 %(113)(9)%
Total revenues$8,027 100 %$8,601 100 %$(574)(7)%
Segment Profits / Segment Profit Margins
Bausch + Lomb/International$1,159 26 %$1,332 28 %$(173)(13)%
Salix1,338 70 %1,349 67 %(11)(1)%
Ortho Dermatologics233 42 %222 39 %11 %
Diversified Products848 73 %932 73 %(84)(9)%
Total segment profit $3,578 45 %$3,835 45 %$(257)(7)%
Organic Revenues and Organic Growth Rates (non-GAAP)
Organic growth, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of recent acquisitions, divestitures and discontinuations. Organic revenue growth (non-GAAP) is growth in GAAP Revenue (its most directly comparable GAAP financial measure), adjusted for certain items, of businesses that have been owned for one or more years. Organic revenue (non-GAAP) is impacted by changes in product volumes and price. The price component is made up of two key drivers: (i) changes in product gross selling price and (ii) changes in sales deductions. The Company uses organic revenue (non-GAAP) and organic revenue growth (non-GAAP) to assess performance of its reportable segments, and the Company in total, without the impact of foreign currency exchange
82


fluctuations and recent acquisitions, divestitures and product discontinuations. The Company believes that such measures are useful to investors as they provide a supplemental period-to-period comparison.
Organic revenue growth (non-GAAP) reflects adjustments for: (i) the impact of period-over-period changes in foreign currency exchange rates on revenues and (ii) the revenues associated with acquisitions, divestitures and discontinuations of businesses divested and/or discontinued. These adjustments are determined as follows:
Foreign currency exchange rates: Although changes in foreign currency exchange rates are part of our business, they are not within management’s control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the underlying business performance. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.
Acquisitions, divestitures and discontinuations: In order to present period-over-period organic revenues (non-GAAP) on a comparable basis, revenues associated with acquisitions, divestitures and discontinuations are adjusted to include only revenues from those businesses and assets owned during both periods. Accordingly, organic revenue growth (non-GAAP) excludes from the current period, all revenues attributable to each acquisition for twelve months subsequent to the day of acquisition, as there are no revenues from those businesses and assets included in the comparable prior period. Organic revenue growth (non-GAAP) excludes from the prior period (but not the current period), all revenues attributable to each divestiture and discontinuance during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period.
The following table presents a reconciliation of GAAP revenues to organic revenues (non-GAAP) and presents organic revenue (Non-GAAP) and the year over year changes in organic revenue (Non-GAAP) for 2020 and 2019 by segment.
 Year Ended December 31, 2020Year ended December 31, 2019Change in
Organic Revenue
Revenue
as
Reported
Changes in Exchange RatesAcquisitionOrganic Revenue (Non-GAAP)Revenue
as
Reported
Divestitures and DiscontinuationsOrganic Revenue (Non-GAAP)
(in millions)AmountPct.
Bausch + Lomb/International$4,408 $42 $— $4,450 $4,739 $(19)$4,720 $(270)(6)%
Salix1,904 — (13)1,891 2,022 — 2,022 (131)(6)%
Ortho Dermatologics553 (3)— 550 565 — 565 (15)(3)%
Diversified Products1,162 — — 1,162 1,275 (1)1,274 (112)(9)%
Total$8,027 $39 $(13)$8,053 $8,601 $(20)$8,581 $(528)(6)%
Bausch + Lomb/International Segment:
Bausch + Lomb/International Segment Revenue
The Bausch + Lomb/International segment has a diversified product line with no single product group representing 10% or more of its segment revenues. The Bausch + Lomb/International segment revenue was $4,408 million and $4,739 million for 2020 and 2019, respectively, a decrease of $331 million, or 7%. The decrease was primarily attributable to: (i) a decrease in volume of $334 million, as discussed below, (ii) the unfavorable effect of foreign currencies of $42 million, primarily in Latin America and (iii) the impact of divestitures and discontinuations of $19 million. These decreases were partially offset by an increase in net realized pricing of $64 million, primarily driven by our International Rx and Global Consumer businesses.
The volumes of our Bausch + Lomb/International segment were negatively impacted, primarily in Europe, Asia and the U.S., by social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed. The postponement of certain surgical and elective medical procedures related to the COVID-19 pandemic, and associated declines in pre- and post-operative prescriptions, negatively impacted the volumes of our Global Ophthalmology and Global Surgical businesses. The reduction in the consumption of contact lenses worldwide due to limited social interactions and in some regions government recommended use of frames, negatively impacted the volumes of our Global Vision Care business. During our first quarter of 2020, certain customers engaged in "pantry-loading", which, along with stay-at-home orders, negatively impacted the volumes of our Global Consumer business for our second quarter of 2020. However, as governments began lifting social restrictions, the negative trend in the revenues of these businesses began to level off and stabilize prior to our third quarter of 2020 and continued in the fourth quarter of 2020. Therefore, our revenues for the year 2020 were most impacted by the COVID-19 pandemic in our second quarter of 2020. Although we experienced additional COVID-19 pandemic related declines in year-over-year revenues in certain geographies during our third and fourth quarters of 2020, total Bausch + Lomb/International segment revenues for the three months ended December 31, 2020 and 2019 were $1,242 million and $1,238 million, respectively, an increase of $4 million. This increase of less than 1% represents a continuing improving trend over the decreases in our year-over-year revenues for the three month periods ended June 30, 2020 and September 30, 2020 of 27% and 1%, respectively, and suggests that a recovery is underway. Presuming the increased availability of effective vaccines,
83


and any resurgence of the COVID-19 virus and variant strains thereof or reenactment of social restrictions are not significant, we anticipate that our affected businesses could possibly return to pre-pandemic levels in 2021.
Bausch + Lomb/International Segment Profit
The Bausch + Lomb/International segment profit was $1,159 million and $1,332 million for 2020 and 2019, respectively, a decrease of $173 million, or 13%. The decrease was primarily driven by the decrease in contribution as a result of social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, partially offset by lower SG&A expenses.
Salix Segment:
Salix Segment Revenue
The Salix segment includes the Xifaxan® product line, which accounted for approximately 78% and 72% of the Salix segment revenues and approximately 18% and 17% of the Company's revenues for 2020 and 2019, respectively. No other single product group represents 10% or more of the Salix segment revenues. The Salix segment revenue was $1,904 million and $2,022 million for 2020 and 2019, respectively, a decrease of $118 million, or 6%. The decrease includes: (i) a decrease in net realized pricing of $96 million, primarily attributable to higher sales deductions for Glumetza® SLX, partially offset by higher gross selling prices for Xifaxan®, and (ii) a decrease in volume of $35 million primarily attributable to the decrease in demand for Apriso® due to LOE. The decrease in revenue was partially offset by sales of our Trulance® product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy, of $13 million.
Certain branded pharmaceutical products within our Salix segment were negatively impacted by social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed. Although we experienced COVID-19 pandemic related declines in year-over-year revenues in 2020, Salix segment revenues for the three months ended December 31, 2020 and 2019 were $527 million and $517 million, respectively, an increase of $10 million. This increase of 2% represents a continuing improving trend over the decreases in our year-over-year revenues for the three month periods ended June 30, 2020 and September 30, 2020 of 21% and 10%, respectively, and suggests that a recovery is underway. Presuming the increased availability of effective vaccines, and any resurgence of the COVID-19 virus and variant strains thereof or reenactment of social restrictions are not significant, we anticipate that our affected Salix businesses could possibly return to pre-pandemic levels in 2021.
Salix Segment Profit
The Salix segment profit was $1,338 million and $1,349 million for 2020 and 2019, respectively, a decrease of $11 million, or 1%. The decrease was primarily driven by the decrease in contribution as a result of the decrease in revenue, as previously discussed, partially offset by lower third-party royalty costs. The decrease in segment profit was partially offset by: (i) decreases in SG&A expenses due to: (a) COVID-19 pandemic related matters, as previously discussed, and (b) a charge associated with the termination of a certain co-promotional agreement during 2019 and (ii) the contribution from the sales of our Trulance® product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy.
Ortho Dermatologics Segment:
Ortho Dermatologics Segment Revenue
The Ortho Dermatologics segment includes the Thermage® and Jublia® product lines, which accounted for approximately 38% and 12% of the Ortho Dermatologics segment revenues for 2020, respectively. No other single product group represents 10% or more of the Ortho Dermatologics segment revenues. The Ortho Dermatologics segment revenue was $553 million and $565 million for 2020 and 2019, respectively, a decrease of $12 million, or 2%. The decrease was primarily attributable to a decrease in net realized pricing of $26 million partially offset by: (i) an increase in volume of $11 million and (ii) the favorable effect of foreign currencies of $3 million. The decrease in average realized pricing was the result of higher sales deductions in our medical dermatology products. The increase in volume was primarily due to increased demand of Thermage FLX®, primarily in China, and was partially offset by the impact of generic competition as certain products, such as Elidel®, Zovirax® and Solodyn®, lost exclusivity.
Certain medical aesthetics, therapeutic products and branded pharmaceutical products within our Ortho Dermatologics segment were negatively impacted by social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. Although we experienced COVID-19 pandemic related declines in year-over-year revenues in 2020, Ortho Dermatologics segment revenues for the three months ended December 31, 2020 and 2019 were $160 million and $158 million, respectively, an increase of $2 million. This increase of 1% represents a continuing improving trend over the decreases in our year-over-year revenues for the three month periods ended June 30, 2020 and September 30, 2020 of 5% and 2%, respectively, and suggests that a recovery is underway. Presuming the increased availability of effective vaccines, and any resurgence of the
84


COVID-19 virus and variant strains thereof or reenactment of social restrictions are not significant, we anticipate that our affected businesses could possibly return to pre-pandemic levels in 2021.
Ortho Dermatologics Segment Profit
The Ortho Dermatologics segment profit was $233 million and $222 million for 2020 and 2019, respectively, an increase of $11 million, or 5%. The increase was primarily driven by decreases in: (i) selling expenses and (ii) R&D expenses and was partially offset by the decrease in contribution as a result of the decrease in revenue, as previously discussed.
Diversified Products Segment:
Diversified Products Segment Revenue
The following table displays the Diversified Products segment revenues by product and product revenues as a percentage of segment revenue for 2020 and 2019.
 Years Ended December 31,Change
 202020192019 to 2020
(in millions)AmountPct.AmountPct.AmountPct.
Wellbutrin® Franchise
$271 23%$244 19%$27 11%
Aplenzin®
98 8%83 6%15 18%
Arestin®
63 5%87 7%(24)(28)%
Ativan® Franchise
50 4%43 3%16%
Neo/Poly/HC Otic35 3%22 2%13 59%
Tobramycin/Dexamethasone33 3%31 2%6%
Pepcid®
31 3%—%29 1,450%
Diastat® Franchise
30 3%35 3%(5)(14)%
Librax® Franchise
30 3%25 2%20%
Xenazine® Franchise
29 3%38 3%(9)(24)%
Other492 42%665 53%(173)(26)%
Total Diversified Products revenues $1,162 100%$1,275 100%$(113)(9)%
The Diversified Products segment revenue was $1,162 million and $1,275 million for 2020 and 2019, respectively, a decrease of $113 million, or 9%. The decrease was primarily driven by: (i) a decrease in volume of $170 million and (ii) the impact of divestitures and discontinuations of $1 million. The decrease was partially offset by an increase in net realized pricing of $58 million due to lower sales deductions, primarily within the Wellbutrin® Franchise, and higher gross selling prices. The decrease in volume was primarily attributable to: (i) the impact of generic competition as certain products in our Neurology and Other business, such as Cuprimine®, Migranal®, Syprine®, Isuprel® and Xenazine®, lost exclusivity and (ii) the postponement of certain surgeries and elective medical procedures in response to the COVID-19 pandemic primarily impacting our Dentistry business. The decrease in volume was partially offset by an increase in volumes for Pepcid® due to a competitor recall in 2020.
Diversified Products Segment Profit
The Diversified Products segment profit was $848 million and $932 million for 2020 and 2019, respectively, a decrease of $84 million, or 9%. The decrease was primarily driven by the decrease in revenue, as previously discussed.
85


LIQUIDITY AND CAPITAL RESOURCES
Cash Flows
Summarized cash flow information for the years 2020, 2019 and 2018 is as follows:
 Years Ended December 31,Change
(in millions)2020201920182019 to 20202018 to 2019
Net loss$(559)$(1,783)$(4,144)$1,224 $2,361 
Adjustments to reconcile Net loss to net cash provided by operating activities2,036 3,602 5,627 (1,566)(2,025)
Cash provided by operating activities before changes in operating assets and liabilities1,477 1,819 1,483 (342)336 
Changes in operating assets and liabilities(366)(318)18 (48)(336)
Net cash provided by operating activities1,111 1,501 1,501 (390)— 
Net cash used in investing activities(261)(419)(196)158 (223)
Net cash (used in) provided by financing activities(2,294)1,443 (1,353)(3,737)2,796 
Effect of exchange rate changes on cash and cash equivalents16 (4)(26)20 22 
Net (decrease) increase in Cash and cash equivalents and Restricted cash(1,428)2,521 (74)(3,949)2,595 
Cash and cash equivalents and Restricted cash, beginning of year3,244 723 797 2,521 (74)
Cash and cash equivalents and Restricted cash, end of year$1,816 $3,244 $723 $(1,428)$2,521 
A detailed discussion of the year-over-year changes of the Company’s 2019 summarized cash flow information compared with that of 2018 can be found under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2019 filed on February 19, 2020.
Operating Activities
Net cash provided by operating activities was $1,111 million and $1,501 million in 2020 and 2019, respectively, a decrease of $390 million. The decrease was attributable to net decreases in: (i) Cash provided by operating activities before changes in operating assets and liabilities and (ii) Changes in operating assets and liabilities.
Cash provided by operating activities before changes in operating assets and liabilities for the years 2020 and 2019 was $1,477 million and $1,819 million, respectively, a decrease of $342 million. The decrease was primarily attributable to: (i) the negative impacts to our operating results associated with the social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, (ii) higher payments of legal settlements in 2020 as compared to 2019 of $153 million and (iii) the upfront payment of $10 million in 2020 with respect to the option to acquire all ophthalmology assets of Allegro, as previously discussed.
Changes in operating assets and liabilities resulted in a net decrease in cash of $366 million and $318 million in 2020 and 2019, respectively, a decrease of $48 million. During 2020, Changes in operating assets and liabilities was negatively impacted by: (i) the timing of other payments in the ordinary course of business of $495 million and (ii) an increase in inventories of $77 million and was partially offset by: (i) the collection of trade receivables of $170 million and (ii) an increase in accrued interest due to timing of payments of $36 million. During 2019, Changes in operating assets and liabilities was negatively impacted by: (i) the build-up of inventories of $209 million and (ii) the timing of other payments in the ordinary course of business of $180 million and was partially offset by: (i) the collection of trade receivables of $39 million and (ii) an increase in accrued interest due to timing of payments of $32 million.
Investing Activities
Net cash used in investing activities was $261 million in 2020 and was primarily driven by Purchases of property, plant and equipment of $302 million partially offset by: (i) Interest settlements from cross-currency swaps of $23 million and (ii) Proceeds from sale of assets and businesses, net of costs to sell of $21 million, primarily related to the receipt of a milestone payment associated with a prior year divestiture.
Net cash used in investing activities was $419 million in 2019 and was driven by: (i) Purchases of property, plant and equipment of $270 million and (ii) Acquisition of businesses, net of cash acquired of $180 million, related to the acquisition of certain assets of Synergy. Net cash used in investing activities was partially offset by Proceeds from sale of assets and businesses, net of costs to sell of $45 million, primarily related to the receipt of a milestone payment associated with a prior year divestiture.
86


Financing Activities
Our financing activities reflect our leadership's commitment to improve the Company’s capital structure. Through debt repayments and refinancings during 2020 and 2019, we have effectively managed our capital structure which has allowed us to, among other things: (i) improve our credit ratings, (ii) access the credit markets to finance amounts owed under the Company's previously announced $1,210 million settlement agreement relating to the U.S. Securities Litigation without negatively impacting our working capital available for operations and (iii) eliminate our mandatory scheduled principal repayments of our debt obligations through 2024.
Net cash used in financing activities during 2020 was $2,294 million and was primarily driven by repayments of long-term debt, net of issuances and related discounts, of $2,187 million. These repayments primarily include: (i) $1,240 million of May 2023 Unsecured Notes, which was previously financed as part of the December 2019 Financing and Refinancing Transactions and (ii) debt repayments during 2020 with cash on hand of $902 million.
Net cash provided by financing activities during 2019 was $1,443 million and primarily reflects the aggregate net proceeds from the issuance of the 5.00% January 2028 Unsecured Notes and January 2030 Unsecured Notes of $2,472 million, partially offset by: (i) debt repayments during 2019 with cash on hand of $906 million and (ii) payments for all other financing activities. The aggregate net proceeds from the issuance of the January 2028 Unsecured Notes and January 2030 Unsecured Notes are to be used and were used to: (i) pay the Company's previously announced $1,210 million settlement agreement relating to the U.S. Securities Litigation (which is subject to an objector's appeal of the final court approval), the full amount of which we paid into an escrow fund under the terms of a settlement agreement and is included within Restricted cash as of December 31, 2020, and (ii) redeem $1,240 million of May 2023 Unsecured Notes on January 16, 2020.
See Note 10, "FINANCING ARRANGEMENTS" to our audited Consolidated Financial Statements for further details regarding the financing activities previously described.
Liquidity and Debt
Future Sources of Liquidity
Our primary sources of liquidity are our cash and cash equivalents, cash collected from customers, funds as available from our revolving credit facility, issuances of long-term debt and issuances of equity and equity-linked securities. We believe these sources will be sufficient to meet our current liquidity needs for the next twelve months.
The Company regularly evaluates market conditions, its liquidity profile, and various financing alternatives for opportunities to enhance its capital structure. If opportunities are favorable, the Company may refinance or repurchase existing debt or issue equity or equity-linked securities. As a result of prepayments and the series of refinancing transactions, we have no debt maturities or mandatory amortization payments due until 2024. We believe our existing cash and cash generated from operations will be sufficient to service our debt obligations in the years 2021 through 2023.
Long-term Debt
Long-term debt, net of unamortized discounts and finance costs was $23,925 million and $25,895 million as of December 31, 2020 and 2019, respectively. Aggregate contractual principal amounts due under our debt obligations were $24,185 million and $26,188 million as of December 31, 2020 and 2019, respectively, a decrease of $2,003 million. The decrease was primarily driven by net debt repayments previously discussed under " - Cash Flows - Financing Activities".
2020 Refinancing Transactions - In May and December 2020, we accessed the credit markets and completed a series of transactions, whereby we extended $3,250 million in aggregate maturities of certain debt obligations due to mature in 2022 and 2023 out to 2029 through 2031 and $250 million in aggregate amortization payments due in 2022 out to 2029. In addition to extending $3,500 million in payments due in 2022 and 2023 to 2029 through 2031, the refinancing transactions replaced secured debt of $1,500 million with unsecured debt. This provides us with more secured debt capacity under our Restated Credit Agreement and existing indentures if the market for unsecured debt in the future is less favorable. Further, by replacing $1,500 million of secured debt with unsecured debt we now have additional room under the debt maintenance covenant of our 2023 Revolving Credit Facility that requires us to maintain a first lien net leverage ratio of not greater than 4.00 to 1.00. The refinancing transactions also repaid in full €1,500 million of debt denominated in euros, thereby reducing our exposure to fluctuations in the value of the euro.
Our prepayments of debt and refinancing transactions over the last four years translate into lower mandatory repayments of principal over the next four years, which, in turn, we believe will permit more cash flows to be directed toward developing our core assets, identifying new product opportunities and repaying additional debt amounts.
87


The mandatory scheduled principal repayments of our debt obligations as of December 31, 2020, were as follows:
(in millions)
20212022202320242025202620272028202920302031Total
$— $— $— $2,291 $10,632 $1,500 $2,250 $2,012 $3,250 $1,250 $1,000 $24,185 
See Note 10, "FINANCING ARRANGEMENTS" to our audited Consolidated Financial Statements for further details.
The weighted average stated rate of interest as of December 31, 2020 and 2019 was 6.02% and 6.21%, respectively.
Current Description of Senior Secured Credit Facilities
On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the “Senior Secured Credit Facilities” under the Company’s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018, and as further amended (the “Restated Credit Agreement”) with a syndicate of financial institutions and investors as lenders. The Restated Credit Agreement provides for a revolving credit facility of $1,225 million, which matures on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. ("BHA") in an aggregate principal amount in excess of $1,000 million (the "2023 Revolving Credit Facility") and term loan facilities of original principal amounts of $4,565 million and $1,500 million, maturing in June 2025 (the “June 2025 Term Loan B Facility”) and November 2025 (the "November 2025 Term Loan B Facility"), respectively. Both the Company and BHA are borrowers under the 2023 Revolving Credit Facility, borrowings under which may be made in U.S. dollars, Canadian dollars or euros.
Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% or (c) the eurocurrency rate (as defined in the Restated Credit Agreement) for a period of one month plus 1.00% (or if such eurocurrency rate shall not be ascertainable, 1.00%) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.
Borrowings under the 2023 Revolving Credit Facility in euros bear interest at a eurocurrency rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), plus an applicable margin.
Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the “Canadian Prime Rate” or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus 1.00% (provided however, that the prime rate shall at no time be less than 0.00%) or (ii) the bankers’ acceptance rate for Canadian dollar deposits in the Toronto interbank market (the “BA rate”) for the interest period relevant to such borrowing (provided however, that the BA rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.
Subject to certain exceptions and customary baskets set forth in the Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the Restated Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights). These mandatory prepayments may be used to satisfy future amortization.
The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are 2.00% and 1.75%, respectively, with respect to base rate and prime rate borrowings and 3.00% and 2.75%, respectively, with respect to eurocurrency rate and BA rate borrowings. As of December 31, 2020, the stated rates of interest on the Company’s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were 3.15% and 2.90% per annum, respectively.
The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is 5.00% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of December 31, 2020, the aggregate remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities were $405 million through November 1, 2025.
88


The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are 1.50% - 2.00% with respect to base rate or prime rate borrowings and 2.50% - 3.00% with respect to eurocurrency rate or BA rate borrowings.  As of December 31, 2020, the stated rate of interest on the 2023 Revolving Credit Facility was 3.15% per annum. As of December 31, 2020, the Company had no outstanding borrowings, $104 million of issued and outstanding letters of credit, and remaining availability of $1,121 million under its 2023 Revolving Credit Facility. In addition, the Company is required to pay commitment fees of 0.25% - 0.50% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.
The Restated Credit Agreement permits the incurrence of incremental credit facility borrowings, up to the greater of $1,000 million and 28.5% of Consolidated Adjusted EBITDA (as defined in the Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.
Senior Secured Notes
The Senior Secured Notes are guaranteed by each of the Company’s subsidiaries that is a guarantor under the Restated Credit Agreement and existing Senior Unsecured Notes (together, the “Note Guarantors”). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company’s obligations under the Restated Credit Agreement under the terms of the indentures governing the Senior Secured Notes.
The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company’s and Note Guarantors’ respective existing and future unsubordinated indebtedness and senior to the Company’s and Note Guarantors’ respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively pari passu with the Company’s and the Note Guarantors’ respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company’s and the Note Guarantors’ respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company’s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company’s debt that is secured by assets that are not collateral.
Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder’s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.
The aggregate principal amount of our Senior Secured Notes as of December 31, 2020 and 2019 was $4,250 million and $5,500 million, respectively, a decrease of $1,250 million representing the repayment of the 6.50% Senior Secured Notes due March 2022 as part of the 2020 Refinancing Transactions.
Senior Unsecured Notes
The Senior Unsecured Notes issued by the Company are the Company’s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by the Company’s subsidiary, BHA, are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes.
If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.
The aggregate principal amount of our Senior Unsecured Notes as of December 31, 2020 and 2019 was $15,500 million and $15,532 million, respectively, a decrease of $32 million.
89


Covenant Compliance
Any inability to comply with the covenants under the terms of our Restated Credit Agreement, Senior Secured Notes indentures or Senior Unsecured Notes indentures could lead to a default or an event of default for which we may need to seek relief from our lenders and noteholders in order to waive the associated default or event of default and avoid a potential acceleration of the related indebtedness or cross-default or cross-acceleration to other debt. There can be no assurance that we would be able to obtain such relief on commercially reasonable terms or otherwise and we may be required to incur significant additional costs. In addition, the lenders under our Restated Credit Agreement, holders of our Senior Secured Notes and holders of our Senior Unsecured Notes may impose additional operating and financial restrictions on us as a condition to granting any such waiver.
During 2019 and 2020, the Company completed several actions which included using cash flows from operations to repay debt and refinancing debt with near term maturities. These actions have reduced the Company’s debt balance and positively affected the Company’s ability to comply with its financial maintenance covenant. As of December 31, 2020, the Company was in compliance with the financial maintenance covenant related to its outstanding debt. The Company, based on its current forecast for the next twelve months from the date of issuance of this Form 10-K, expects to remain in compliance with the financial maintenance covenant and meet its debt service obligations over that same period.
The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and take other actions to reduce its debt levels to align with the Company’s long-term strategy. The Company may consider taking other actions, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate, to provide additional coverage in complying with the financial maintenance covenant and meeting its debt service obligations.
The Senior Notes and Secured Notes are guaranteed by a substantial portion of the Company’s subsidiaries. On a non-consolidated basis, the non-guarantor subsidiaries had total assets of $2,442 million and $2,682 million and total liabilities of $1,804 million and $1,075 million as of December 31, 2020 and 2019, respectively, and revenues of $1,320 million and $1,463 million for 2020 and 2019, respectively, and operating loss of $38 million for 2020 and operating income of $121 million for 2019.
Credit Ratings
As of February 24, 2021, the credit ratings and outlook from Moody's, Standard & Poor's and Fitch for certain outstanding obligations of the Company were as follows:
Rating AgencyCorporate RatingSenior Secured Rating Senior Unsecured RatingOutlook
Moody’s B2Ba2B3Stable
Standard & Poor’sB+BBBStable
FitchBBBBStable
Any downgrade in our corporate credit ratings or other credit ratings may increase our cost of borrowing and may negatively impact our ability to raise additional debt capital.
OFF-BALANCE SHEET ARRANGEMENTS AND CONTRACTUAL OBLIGATIONS
We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material future effect on our results of operations, financial condition, capital expenditures, liquidity, or capital resources.
Our other future cash requirements relate to working capital, capital expenditures, business development transactions (contingent consideration), restructuring, integration and separation costs, benefit obligations and litigation settlements. In addition, we may use cash to enter into licensing arrangements and/or to make strategic acquisitions. We are considering further acquisition opportunities within our core therapeutic areas, some of which could be sizable.
In addition to our working capital requirements, we expect our primary cash requirements for 2021 to include:
Debt repayments—As a result of prepayments and a series of refinancing transactions we have reduced and extended the maturities of a substantial portion of our long-term debt and have no debt maturities or mandatory amortization payments due until 2024. We expect to make interest payments of approximately $1,425 million during 2021. We may also elect to make additional principal payments under certain circumstances. Further, in the ordinary course of business, we may borrow and repay amounts under our 2023 Revolving Credit Facility to meet business needs;
90


IT Infrastructure Investment—We expect to make payments of approximately $60 million for licensing, maintenance and capitalizable costs associated with our IT infrastructure improvement projects during 2021;
Capital expenditures—We expect to make payments of approximately $275 million for property, plant and equipment during 2021;
Contingent consideration payments—We expect to make contingent consideration and other development/approval/sales-based milestone payments of $164 million during 2021;
Restructuring and integration payments—We expect to make payments of $7 million during 2021 for employee separation costs and lease termination obligations associated with restructuring and integration actions we have taken through December 31, 2020;
Benefit obligations—We expect to make aggregate payments under our pension and postretirement obligations of $14 million during 2021. See Note 11, "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS" to our audited Consolidated Financial Statements for further details of our benefit obligations; and
U.S. Securities Litigation Settlement—As more fully discussed in Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements, we announced that we had agreed to resolve the U.S. Securities Litigation for $1,210 million. Final court approval of this settlement was granted in January 2021. Subject to an objector's appeal of the Court's final approval order, the settlement resolves and discharges all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. This settlement resolves the most significant of the Company's remaining legacy legal matters and eliminates a material uncertainty regarding our Company. As of December 31, 2020, Restricted cash includes $1,210 million of payments into an escrow fund under the terms of a settlement agreement regarding the U.S. Securities Litigation.
Costs of Separation
As previously discussed, with the goal of unlocking additional Company value, on August 6, 2020, the Company announced that it intends to separate its eye-health business into an independent publicly traded entity. The Company has incurred, and will incur, costs associated with activities to effectuate the Separation. These activities include: (i) separating the eye-health business from the remainder of the Company and (ii) registering the eye-health business as an independent publicly traded entity. Separation costs are incremental costs directly related to the Separation and include, but are not limited to: (i) legal, audit and advisory fees, (ii) employee hiring, relocation and travel costs and (iii) costs associated with establishing a new board of directors and audit committee. The Company has also incurred, and will incur, separation-related costs which are incremental costs indirectly related to the Separation. Separation-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. As of the date of this filing, we are in the planning phase of the Separation and future payments for separation costs and separation-related costs cannot be reasonably estimated at this time and could be material.
Future Cost Savings Programs
We continue to evaluate opportunities to improve our operating results and may initiate additional cost savings programs to streamline our operations and eliminate redundant processes and expenses. These cost savings programs may include, but are not limited to: (i) reducing headcount, (ii) eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The expenses associated with the implementation of these cost savings programs could be material and may impact our cash flows.
Option to Acquire All Ophthalmology Assets of Allegro
As previously discussed, on September 21, 2020, we announced that we entered into an agreement which provides us an option to acquire all ophthalmology assets of Allegro. Aggregate payments under the Option are up to $50 million and include an upfront payment of $10 million and a second payment of $40 million should Allegro raise additional funding. During 2020, we made and expensed the upfront payment of $10 million as Acquired in-process research and development. If the Option is exercised, additional payments to acquire all of the ophthalmology assets of Allegro will be due over time.
Future Litigation Payments
In addition to the U.S. Securities Litigation discussed above, in the ordinary course of business, the Company is involved in litigation, claims, government inquiries, investigations, charges and proceedings. See Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements for further details of these matters. Our ability to successfully defend the Company against pending and future litigation may impact future cash flows.
91


Future Licensing Payments
In the ordinary course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products primarily in the U.S. and Canada. In connection with these agreements, the Company may pay an upfront fee to secure the agreement. See Note 3, "ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE" to our audited Consolidated Financial Statements. Payments associated with the upfront fee for these agreements cannot be reasonably estimated at this time and could be material.
Unrecognized Tax Benefits
As of December 31, 2020, the Company had unrecognized tax benefits totaling $414 million, of which, $145 million is expected to be realized within the next twelve months, however a reliable estimate of the period in which the remaining uncertain tax positions will be payable, if ever, cannot be made.
OUTSTANDING SHARE DATA
Our common shares are listed on the TSX and the NYSE under the ticker symbol “BHC”.
At February 18, 2021, we had 355,619,826 issued and outstanding common shares. In addition, as of February 18, 2021, we had 8,601,400 stock options and 5,530,821 time-based RSUs that each represent the right of a holder to receive one of the Company’s common shares, and 2,529,506 performance-based RSUs that represent the right of a holder to receive a number of the Company's common shares up to a specified maximum. A maximum of 4,164,425 common shares could be issued upon vesting of the performance-based RSUs outstanding.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Our business and financial results are affected by fluctuations in world financial markets, including the impacts of foreign currency exchange rate and interest rate movements. We evaluate our exposure to such risks on an ongoing basis, and seek ways to manage these risks to an acceptable level, based on management’s judgment of the appropriate trade-off between risk, opportunity and cost. We may use derivative financial instruments from time to time as a risk management tool and not for trading or speculative purposes.
Inflation; Seasonality
We are subject to price control restrictions on our pharmaceutical products in a number of countries in which we now operate. As a result, our ability to raise prices in a timely fashion in anticipation of inflation may be limited in some markets.
Historically, revenues from our business tend to be weighted toward the second half of the year. Sales in the first quarter tend to be lower as patient co-pays and deductibles reset at the beginning of each year.  Sales in the fourth quarter tend to be higher based on consumer and customer purchasing patterns associated with health care reimbursement programs. However, there are no assurances that these historical trends will continue in the future.
Foreign Currency Risk
In the year ended December 31, 2020, a majority of our revenue and expense activities and capital expenditures were denominated in U.S. dollars.  We have exposure to multiple foreign currencies, including, among others, the Euro, Chinese yuan, Polish zloty, Canadian dollar and Mexican peso. Our operations are subject to risks inherent in conducting business abroad, including price and currency exchange controls and fluctuations in the relative values of currencies. In addition, to the extent that we require, as a source of debt repayment, earnings and cash flows from some of our operations located in foreign countries, we are subject to risk of changes in the value of the U.S. dollar, relative to all other currencies in which we operate, which may materially affect our results of operations. Where possible, we manage foreign currency risk by managing same currency revenues in relation to same currency expenses. Further strengthening of the U.S. dollar and/or further devaluation of foreign currencies will have a negative impact on our reported revenue and reported results. As of December 31, 2020, a 1% change in foreign currency exchange rates would have impacted our shareholders’ equity by approximately $51 million, which could be partially mitigated by our cross-currency swaps discussed below.
As of December 31, 2020, the unrealized foreign exchange gain on the translation of the remaining principal amount of U.S. denominated senior secured and unsecured notes was $361 million, for Canadian income tax purposes. Additionally, as of December 31, 2020, the unrealized foreign exchange loss on certain intercompany balances was equal to $235 million. One-half of any realized foreign exchange gain or loss will be included in our Canadian taxable income. Any resulting gain will result in a corresponding reduction in our available Canadian Losses, Scientific Research and Experimental Development Pool, and/or Investment Tax Credit carryforward balances. However, the repayment of the senior notes and the intercompany loans
92


denominated in U.S. dollars does not result in a foreign exchange gain or loss being recognized in our Consolidated Financial Statements, as these statements are prepared in U.S. dollars.
We may use derivative financial instruments from time to time to mitigate our foreign currency risk and not for trading or speculative purposes. During 2019, we entered into cross-currency swaps, with aggregate notional amounts of $1,250 million, to mitigate fluctuation in the value of a portion of our euro-denominated net investment in our consolidated financial statements from adverse movements in exchange rates. The euro-denominated net investment being hedged is the Company’s investment in certain euro-denominated subsidiaries. Prior to 2019, the Company had no derivative instruments for any period presented.
Interest Rate Risk
We currently do not hold financial instruments for speculative purposes. Our financial assets are not subject to significant interest rate risk due to their short duration. The primary objective of our policy for the investment of temporary cash surpluses is the protection of principal, and accordingly, we generally invest in high quality, money market investments and time deposits with varying maturities, but typically less than three months. As it is our intent and policy to hold these investments until maturity, we do not have a material exposure to interest rate risk.
As of December 31, 2020, we had $19,762 million and $4,423 million principal amount of issued fixed rate debt and variable rate debt, respectively, that requires U.S. dollar repayment. The estimated fair value of our issued fixed rate debt as of December 31, 2020 was $20,984 million. If interest rates were to increase by 100 basis-points, the fair value of our issued fixed rate debt would decrease by approximately $430 million. If interest rates were to decrease by 100 basis-points, the fair value of our issued fixed rate debt would increase by approximately $375 million. We are subject to interest rate risk on our variable rate debt as changes in interest rates could adversely affect earnings and cash flows. A 100 basis-points increase in interest rates, based on 3-month LIBOR, would have an annualized pre-tax effect of approximately $44 million in our Consolidated Statements of Operations and Consolidated Statements of Cash Flows, based on current outstanding borrowings and effective interest rates on our variable rate debt. While our variable-rate debt may impact earnings and cash flows as interest rates change, it is not subject to changes in fair value.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Critical accounting policies and estimates are those policies and estimates that are most important and material to the preparation of our Consolidated Financial Statements, and which require management’s most subjective and complex judgments due to the need to select policies from among alternatives available, and to make estimates about matters that are inherently uncertain. We base our estimates on historical experience and other factors that we believe to be reasonable under the circumstances. On an ongoing basis, we review our estimates to ensure that these estimates appropriately reflect changes in our business and new information as it becomes available. If historical experience and other factors we use to make these estimates do not reasonably reflect future activity, our results of operations and financial condition could be materially impacted.
Revenue Recognition
In May 2014, the Financial Accounting Standards Board ("FASB") issued guidance on recognizing revenue from contracts with customers. The core principle of the revenue model is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In applying the revenue model to contracts within its scope, an entity will: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. In addition to these provisions, the new standard provides implementation guidance on several other topics, including the accounting for certain revenue-related costs, as well as enhanced disclosure requirements. The new guidance requires entities to disclose both quantitative and qualitative information that enables users of financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.
The Company adopted this guidance effective January 1, 2018 using the modified retrospective approach. Based upon review of customer contracts, the Company concluded the implementation of the new guidance did not have a material quantitative impact on its 2018 Consolidated Financial Statements as the timing of revenue recognition for product sales did not significantly change. The new guidance did however result in additional disclosures as to the nature, amounts, and concentrations of revenue.
The development and application of the critical accounting policies associated with the current revenue recognition guidance, including the policies associated with each of our product sales provisions and the table showing the activity and ending balances for our product sales provisions, are discussed in more detail in Note 2, "SIGNIFICANT ACCOUNTING POLICIES".
93


Other Revenues 
We generate alliance revenue and service revenue from the licensing of products and from contract services mainly in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties.
Acquisition-Related Contingent Consideration
Some of the business combinations that we have consummated include contingent consideration to be potentially paid based upon the occurrence of future events, such as sales performance and the achievement of certain future development, regulatory and sales milestones. Acquisition-related contingent consideration associated with a business combination is initially recognized at fair value and remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The estimates of fair value involve the use of acceptable valuation methods, such as probability-weighted discounted cash flow analysis and Monte Carlo Simulation (when appropriate), and contain uncertainties as they require assumptions about the likelihood of achieving specified milestone criteria, projections of future financial performance and assumed discount rates. Changes in the fair value of the acquisition-related contingent consideration result from several factors including changes in the timing and amount of revenue estimates, changes in probability assumptions with respect to the likelihood of achieving specified milestone criteria and changes in discount rates. A change in any of these assumptions could produce a different fair value, which could have a material impact on our results of operations. At December 31, 2020, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 25%.
Intangible Assets
We evaluate potential impairments of amortizable intangible assets acquired through asset acquisitions or business combinations if events or changes in circumstances indicate that the carrying amounts of these assets may not be recoverable. Our evaluation is based on an assessment of potential indicators of impairment, such as:
an adverse change in legal factors or in the business climate that could affect the value of an asset. For example, a successful challenge of our patent rights resulting in earlier than expected generic competition;
an adverse change in the extent or manner in which an asset is used or is expected to be used. For example, a decision not to pursue a product line-extension strategy to enhance an existing product due to changes in market conditions and/or technological advances; or
current or forecasted reductions in revenue, operating income, or cash flows associated with the use of an asset. For example, the introduction of a competing product that results in a significant loss of market share.
Impairment exists when the carrying value of the asset exceeds the related estimated undiscounted future cash flows expected to be derived from the asset. If impairment exists, the carrying value of the asset is adjusted to its fair value. A discounted cash flow analysis is typically used to determine an asset's fair value, using estimates and assumptions that market participants would apply. Some of the estimates and assumptions inherent in a discounted cash flow model include the amount and timing of the projected future cash flows, and the discount rate used to reflect the risks inherent in the future cash flows. A change in any of these estimates and assumptions could produce a different fair value, which could have a material impact on our results of operations. In addition, an intangible asset’s expected useful life can increase estimation risk, as longer-lived assets necessarily require longer-term cash flow forecasts, which for some of our intangible assets can be up to 20 years. In connection with an impairment evaluation, we also reassess the remaining useful life of the intangible asset and modify it, as appropriate.
Management continually assesses the useful lives of the Company's long-lived assets.
Indefinite-lived intangible assets, including Acquired in-process research and development and the B&L corporate trademark, are tested for impairment annually, or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of their fair value to carrying value, without consideration of any recoverability test. In particular, we will continue to monitor closely the progression of our R&D programs as their likelihood of success is contingent upon the achievement of future milestones. See Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Overview — Focus on Core Business” for additional information regarding our R&D programs.
Goodwill
Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by
94


first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1).
The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit's terminal value.
To forecast a reporting unit's cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management's and a market participant's view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected LOE to the Company's product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company’s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future.
Adoption of New Accounting Guidance for Goodwill Impairment Testing
Effective January 1, 2018, the Company elected to early adopt a new accounting standard which simplifies the subsequent measurement of goodwill by eliminating “Step 2” from the goodwill impairment test. Goodwill impairment is now measured as the amount by which a reporting unit's carrying value exceeds its fair value. Upon adopting the new standard, the Company tested goodwill for impairment and determined that the carrying value of the Salix reporting unit exceeded its fair value resulting in the Company recognizing a goodwill impairment of $1,970 million associated with the Salix reporting unit.
2018 Annual Goodwill Impairment Test
The Company conducted its 2018 annual goodwill impairment test as of October 1, 2018 and determined that the carrying value of the Dentistry reporting unit exceeded its fair value and, as a result, the Company recognized a goodwill impairment of $109 million, representing the full amount of goodwill for the Dentistry reporting unit. Changing market conditions such as: (i) an increasing competitive environment and (ii) increasing pricing pressures negatively impacted the reporting unit's operating results. As of October 1, 2018, the fair value of each reporting unit with associated goodwill exceeded its carrying value by more than 15%.
2019 Annual Goodwill Impairment Test
The Company conducted its annual goodwill impairment test as of October 1, 2019 by first assessing qualitative factors. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. In each quantitative fair value test performed, the fair value was greater than the carrying value of the reporting unit. As a result, there was no impairment to the goodwill of any reporting unit.
2020 Interim Goodwill Impairment Assessments
An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company’s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, during 2020 the Company continually monitored among other matters the possible affects and outcomes of the COVID-19 pandemic on, among other things, its supply chain, customers and distributors, employee base, product sustainability, research and development activities, product pipeline and consumer demand and related rebates and discounts and has made adjustments, although not considered to be material, to its long-term forecasts as of October 1, 2019 (the date goodwill was last tested for impairment) for these and other matters. After completing this assessment, although not completely insulated from the negative effects of the COVID-19 pandemic, the Company believed that its long-term forecasted cash flows, as adjusted for the possible outcome of the COVID-19 pandemic
95


and other matters, did not indicate that the fair value of any reporting unit may be below its carrying value.
On a quarterly basis, using its latest forecasts of cash flows, the Company gave consideration to the nature and timing of the expected revenue losses resulting from COVID-19 pandemic related matters. No events occurred or circumstances changed during the period October 1, 2019 through September 30, 2020 that would indicate that the fair value of any reporting unit, with the exception of the Ortho Dermatologics reporting unit as discussed below, might be below its carrying value. The changes in the amounts and timing of revenues as presented in the Company's forecasts during 2020 included a range of potential outcomes and, with the exception of the Ortho Dermatologics reporting unit as discussed below, were not substantial enough to materially adversely affect the recoverability of any of the associated reporting units’ assets and were not material enough to indicate that the fair values of those reporting units might be below their respective carrying values. However, based on the results of the October 1, 2019 annual goodwill impairment test, the Company continued to assess the performance of the Ortho Dermatologics reporting unit and the Neuro and Other reporting unit on a quarterly basis 2020.
2020 Interim Goodwill Impairment Assessments - Neuro and Other
As part of its quarterly qualitative interim assessments of the Neuro and Other reporting unit, management considered the totality of all relevant events or circumstances that could have affected the carrying amount or fair value of the reporting unit, including comparing the reporting unit’s operating results to the forecast used to test the goodwill of the Neuro and Other reporting unit as of October 1, 2019. Based on the qualitative assessments, management believed that the carrying value of Neuro and Other reporting unit did not exceed its fair value and, therefore, concluded a quantitative fair value test was not required for any quarterly period.
2020 Interim Goodwill Impairment Assessments and Testing - Ortho Dermatologics
During the three months ended March 31, 2020, the operating results for the Ortho Dermatologics reporting unit were less than those forecasted at October 1, 2019 for that period. As part of its qualitative assessment as of March 31, 2020, the Company revised its forecasts for the year 2020, for among other matters, the lower than originally forecasted operating results for the three months ended March 31, 2020 and the range of potential impacts of the COVID-19 pandemic, including longer than expected launch cycles for certain new products. Management believed that the revisions to its forecasts for the year 2020 were indicators that there was less headroom as of March 31, 2020 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2019). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed at March 31, 2020. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit continued to be greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit at March 31, 2020.
During the three months ended June 30, 2020, the Company identified certain Ortho Dermatologics’ products that were experiencing longer launch cycles than originally anticipated due to the COVID-19 pandemic and, as a direct result, took actions to mitigate the impact of these matters, including right-sizing its Ortho Dermatologics’ sales force. As part of its qualitative assessment as of June 30, 2020, the Company revised its long-term forecasts for, among other matters, the decrease in forecasted revenues of the identified products, the reduction in sales force and related costs and a range of potential impacts of COVID-19 pandemic related matters. Management believed that these events were indicators that there was less headroom as of June 30, 2020 as compared to the headroom calculated on the date Ortho Dermatologics goodwill was last tested for impairment (March 31, 2020). Therefore, a quantitative fair value test for impairment to the goodwill of the Ortho Dermatologics reporting unit was performed at June 30, 2020. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit continued to be greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit at June 30, 2020.
Management believed that based on its qualitative assessments as of September 30, 2020, it was more likely than not that the carrying amount of the Ortho Dermatologics reporting unit was less than its fair value and, therefore, concluded a quantitative fair value test was not required at September 30, 2020.
2020 Annual Goodwill Impairment Test
The Company conducted its annual goodwill impairment test as of October 1, 2020 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2020, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded a quantitative fair value test for those reporting units was not required. The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2020, utilizing a long-term growth rate of 2.0% and a range of discount rates between 9.5% and 9.75%, in estimation of the fair value of this reporting unit. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit. If market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment
96


charges in the future. Specifically, the Company continues to assess the performance of the Ortho Dermatologics reporting unit as compared to its respective projections and will perform qualitative interim assessments of the carrying value and fair value on a quarterly basis to determine if impairment testing of goodwill will be warranted.
See Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our audited Consolidated Financial Statements for further details on the goodwill impairments recognized in 2018.
The Company expects to realign and begin managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Separation during the first quarter of 2021, and as a result the Company may need to perform an impairment test upon realignment of its operating segments.
Contingencies
In the normal course of business, we are subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Other than loss contingencies that are assumed in business combinations for which we can reliably estimate the fair value, we are required to accrue for such loss contingencies if it is probable that the outcome will be unfavorable and if the amount of the loss can be reasonably estimated. We evaluate our exposure to loss based on the progress of each contingency, experience in similar contingencies and consultation with our legal counsel. We re-evaluate all contingencies as additional information becomes available. Given the uncertainties inherent in complex litigation and other contingencies, these evaluations can involve significant judgment about future events. The ultimate outcome of any litigation or other contingency may be material to our results of operations, financial condition and cash flows. See Note 20, "LEGAL PROCEEDINGS" to our audited Consolidated Financial Statements for further details regarding our current legal proceedings. If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred.
Income Taxes
We have operations in various countries that have differing tax laws and rates. Our tax structure is supported by current domestic tax laws in the countries in which we operate and the application of tax treaties between the various countries in which we operate. Our income tax reporting is subject to audit by domestic and foreign tax authorities. Our effective tax rate may change from year to year based on changes in the mix of activities and income earned under our intercompany arrangements among the different jurisdictions in which we operate, changes in tax laws in these jurisdictions, changes in tax treaties between various countries in which we operate, changes in our eligibility for benefits under those tax treaties and changes in the estimated values of deferred tax assets and liabilities. Such changes could result in an increase in the effective tax rate on all or a portion of our income and/or any of our subsidiaries.
Our provision for income taxes is based on a number of estimates and assumptions made by management. Our consolidated income tax rate is affected by the amount of income earned in our various operating jurisdictions, the availability of benefits under tax treaties and the rates of taxes payable in respect of that income. We enter into many transactions and arrangements in the ordinary course of business in which the tax treatment is not entirely certain. We must therefore make estimates and judgments based on our knowledge and understanding of applicable tax laws and tax treaties, and the application of those tax laws and tax treaties to our business, in determining our consolidated tax provision. For example, certain countries could seek to tax a greater share of income than has been provided for by us. The final outcome of any audits by taxation authorities may differ from the estimates and assumptions we have used in determining our consolidated income tax provisions and accruals. This could result in a material effect on our consolidated income tax provision, results of operations, and financial condition for the period in which such determinations are made.
Our income tax returns are subject to audit in various jurisdictions. Existing and future audits by, or other disputes with, tax authorities may not be resolved favorably for us and could have a material adverse effect on our reported effective tax rate and after-tax cash flows. We record liabilities for uncertain tax positions, which involve significant management judgment. New laws and new interpretations of laws and rulings by tax authorities may affect the liability for uncertain tax positions. Due to the subjectivity and complex nature of the underlying issues, actual payments or assessments may differ from our estimates. To the extent that our estimates differ from amounts eventually assessed and paid our income and cash flows may be materially and adversely affected.
We assess whether it is more likely than not that we will realize the tax benefits associated with our deferred tax assets and establish a valuation allowance for assets that are not expected to result in a realized tax benefit. A significant amount of judgment is used in this process, including preparation of forecasts of future taxable income and evaluation of tax planning initiatives. If we revise these forecasts or determine that certain planning events will not occur, an adjustment to the valuation allowance will be made to tax expense in the period such determination is made.
97


NEW ACCOUNTING STANDARDS
Information regarding the recently issued new accounting guidance (adopted and not adopted as of December 31, 2020) is contained in Note 2, "SIGNIFICANT ACCOUNTING POLICIES" to our audited Consolidated Financial Statements.
FORWARD-LOOKING STATEMENTS
Caution regarding forward-looking information and statements and “Safe-Harbor” statements under the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws:
To the extent any statements made in this Form 10-K contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, “forward-looking statements”).
These forward-looking statements relate to, among other things: our business strategy, business plans and prospects and forecasts and changes thereto; product pipeline, prospective products and product approvals, product development and future performance and results of current and anticipated products; anticipated revenues for our products; anticipated growth in our Ortho Dermatologics business; expected R&D and marketing spend; our expected primary cash and working capital requirements for 2021 and beyond; our plans for continued improvement in operational efficiency and the anticipated impact of such plans; our liquidity and our ability to satisfy our debt maturities as they become due; our ability to reduce debt levels; our ability to meet the financial and other covenants contained in our Fourth Amended and Restated Credit and Guaranty Agreement (the "Restated Credit Agreement") and senior notes indentures; the impact of our distribution, fulfillment and other third-party arrangements; proposed pricing actions; exposure to foreign currency exchange rate changes and interest rate changes; the outcome of contingencies, such as litigation, subpoenas, investigations, reviews, audits and regulatory proceedings; the anticipated impact of the adoption of new accounting standards; general market conditions; our expectations regarding our financial performance, including revenues, expenses, gross margins and income taxes; our impairment assessments, including the assumptions used therein and the results thereof; the anticipated impact of the evolving COVID-19 pandemic and related responses from governments and private sector participants on the Company, its supply chain, third-party suppliers, project development timelines, costs, revenue, margins, liquidity and financial condition, the anticipated timing, speed and magnitude of recovery from these COVID-19 pandemic related impacts and the Company’s planned actions and responses to this pandemic; and the Company’s plan to separate its eye-health business, including the structure and timing of completing such separation transaction.
Forward-looking statements can generally be identified by the use of words such as “believe”, “anticipate”, “expect”, “intend”, “estimate”, “plan”, “continue”, “will”, “may”, “could”, “would”, “should”, “target”, “potential”, “opportunity”, “designed”, “create”, “predict”, “project”, “forecast”, “seek”, “strive”, “ongoing” or “increase” and variations or other similar expressions. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements may not be appropriate for other purposes. Although we have previously indicated certain of these statements set out herein, all of the statements in this Form 10-K that contain forward-looking statements are qualified by these cautionary statements. These statements are based upon the current expectations and beliefs of management. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making such forward-looking statements, including, but not limited to, factors and assumptions regarding the items previously outlined, those factors, risks and uncertainties outlined below and the assumption that none of these factors, risks and uncertainties will cause actual results or events to differ materially from those described in such forward-looking statements. Actual results may differ materially from those expressed or implied in such statements. Important factors, risks and uncertainties that could cause actual results to differ materially from these expectations include, among other things, the following:
the risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, the fear of that pandemic, the availability and effectiveness of vaccines for COVID-19, the rapidly evolving reaction of governments, private sector participants and the public to that pandemic, and the potential effects and economic impact of the pandemic and the reaction to it, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a significant adverse impact on the Company, including but not limited to its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition and costs (which may increase) and revenue and margins (both of which may decrease);
with respect to the proposed separation of the Company’s eye-health business, the risks and uncertainties include, but are not limited to, the expected benefits and costs of the separation transaction, the expected timing of completion of the separation transaction and its terms, the Company’s ability to complete the separation transaction considering the
98


various conditions to the completion of the separation transaction (some of which are outside the Company’s control, including conditions related to regulatory matters and a possible shareholder vote, if applicable), that market or other conditions are no longer favorable to completing the transaction, that any shareholder, stock exchange, regulatory or other approval (if required) is not obtained on the terms or timelines anticipated or at all, business disruption during the pendency of or following the separation transaction, diversion of management time on separation transaction-related issues, retention of existing management team members, the reaction of customers and other parties to the separation transaction, the qualification of the separation transaction as a tax-free transaction for Canadian and/or U.S. federal income tax purposes (including whether or not an advance ruling from either or both of the Canada Revenue Agency and the Internal Revenue Service will be sought or obtained), potential dyssynergy costs resulting from the separation transaction, the impact of the separation transaction on relationships with customers, suppliers, employees and other business counterparties, general economic conditions, conditions in the markets the Company is engaged in, behavior of customers, suppliers and competitors, technological developments, as well as legal and regulatory rules affecting the Company’s business;
the expense, timing and outcome of legal and governmental proceedings, investigations and information requests relating to, among other matters, our past distribution, marketing, pricing, disclosure and accounting practices (including with respect to our former relationship with Philidor Rx Services, LLC ("Philidor")), including a number of pending non-class securities litigations (including certain pending opt-out actions in the U.S. related to the previously settled securities class action (which is subject to an objector's appeal of the final court approval) and certain opt-out actions in Canada relating to the recently settled class action in Canada) and purported class actions under the federal RICO statute and other claims, investigations or proceedings that may be initiated or that may be asserted;
potential additional litigation and regulatory investigations (and any costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom), negative publicity and reputational harm on our Company, products and business that may result from the past and ongoing public scrutiny of our past distribution, marketing, pricing, disclosure and accounting practices and from our former relationship with Philidor;
the past and ongoing scrutiny of our legacy business practices, including with respect to pricing, and any pricing controls or price adjustments that may be sought or imposed on our products as a result thereof;
pricing decisions that we have implemented, or may in the future elect to implement, such as the Patient Access and Pricing Committee’s commitment that the average annual price increase for our branded prescription pharmaceutical products will be set at no greater than single digits, or any future pricing actions we may take following review by our Patient Access and Pricing Committee (which is responsible for the pricing of our drugs);
legislative or policy efforts, including those that may be introduced and passed by the U.S. Congress, designed to reduce patient out-of-pocket costs for medicines, which could result in new mandatory rebates and discounts or other pricing restrictions, controls or regulations (including mandatory price reductions);
ongoing oversight and review of our products and facilities by regulatory and governmental agencies, including periodic audits by the FDA and equivalent agencies outside of the U.S. and the results thereof;
actions by the FDA or other regulatory authorities with respect to our products or facilities;
our substantial debt (and potential additional future indebtedness) and current and future debt service obligations, our ability to reduce our outstanding debt levels and the resulting impact on our financial condition, cash flows and results of operations;
our ability to meet the financial and other covenants contained in our Restated Credit Agreement, senior notes indentures, 2023 Revolving Credit Facility and other current or future debt agreements and the limitations, restrictions and prohibitions such covenants impose or may impose on the way we conduct our business, including prohibitions on incurring additional debt if certain financial covenants are not met, limitations on the amount of additional obligations we are able to incur pursuant to other covenants, our ability to draw under our 2023 Revolving Credit Facility and restrictions on our ability to make certain investments and other restricted payments;
any default under the terms of our senior notes indentures or Restated Credit Agreement and our ability, if any, to cure or obtain waivers of such default;
any downgrade by rating agencies in our credit ratings, which may impact, among other things, our ability to raise debt and the cost of capital for additional debt issuances;
any reductions in, or changes in the assumptions used in, our forecasts for fiscal year 2021 or beyond, including as a result of the impacts of the COVID-19 pandemic on our business and operations, which could lead to, among other
99


things: (i) a failure to meet the financial and/or other covenants contained in our Restated Credit Agreement and/or senior notes indentures and/or (ii) impairment in the goodwill associated with certain of our reporting units or impairment charges related to certain of our products or other intangible assets, which impairments could be material;
changes in the assumptions used in connection with our impairment analyses or assessments, which would lead to a change in such impairment analyses and assessments and which could result in an impairment in the goodwill associated with any of our reporting units or impairment charges related to certain of our products or other intangible assets;
the uncertainties associated with the acquisition and launch of new products, including, but not limited to, our ability to provide the time, resources, expertise and funds required for the commercial launch of new products, the acceptance and demand for new pharmaceutical products, and the impact of competitive products and pricing, which could lead to material impairment charges;
our ability or inability to extend the profitable life of our products, including through line extensions and other life-cycle programs;
our ability to retain, motivate and recruit executives and other key employees;
our ability to implement effective succession planning for our executives and key employees;
factors impacting our ability to achieve anticipated growth in our Ortho Dermatologics business, including the success of recently launched products (such as Arazlo®), expected geographic expansion in our Solta business (including with respect to Next Generation Thermage FLX®), the ability to successfully implement and operate our cash-pay prescription program for certain of our Ortho Dermatologics branded products, and the ability of such program to achieve the anticipated goals respecting patient access and fulfillment, the approval of pending and pipeline products (and the timing of such approvals), changes in estimates on market potential for dermatology products and continued investment in and success of our sales force;
factors impacting our ability to achieve anticipated revenues for our products, including changes in anticipated marketing spend on such products and launch of competing products;
the challenges and difficulties associated with managing a large complex business, which has, in the past, grown rapidly;
our ability to compete against companies that are larger and have greater financial, technical and human resources than we do, as well as other competitive factors, such as technological advances achieved, patents obtained and new products introduced by our competitors;
our ability to effectively operate and grow our businesses in light of the challenges that the Company has faced and market conditions, including with respect to its substantial debt, pending investigations and legal proceedings, scrutiny of our past pricing and other practices, limitations on the way we conduct business imposed by the covenants contained in our Restated Credit Agreement, senior notes indentures and the agreements governing our other indebtedness, and the impacts of the COVID-19 pandemic;
the extent to which our products are reimbursed by government authorities, pharmacy benefit managers ("PBMs") and other third-party payors; the impact our distribution, pricing and other practices may have on the decisions of such government authorities, PBMs and other third-party payors to reimburse our products; and the impact of obtaining or maintaining such reimbursement on the price and sales of our products;
the inclusion of our products on formularies or our ability to achieve favorable formulary status, as well as the impact on the price and sales of our products in connection therewith;
the consolidation of wholesalers, retail drug chains and other customer groups and the impact of such industry consolidation on our business;
our eligibility for benefits under tax treaties and the continued availability of low effective tax rates for the business profits of certain of our subsidiaries;
the actions of our third-party partners or service providers of research, development, manufacturing, marketing, distribution or other services, including their compliance with applicable laws and contracts, which actions may be beyond our control or influence, and the impact of such actions on our Company, including the impact to the Company of our former relationship with Philidor and any alleged legal or contractual non-compliance by Philidor;
100


the risks associated with the international scope of our operations, including our presence in emerging markets and the challenges we face when entering and operating in new and different geographic markets (including the challenges created by new and different regulatory regimes in such countries and the need to comply with applicable anti-bribery and economic sanctions laws and regulations);
adverse global economic conditions and credit markets and foreign currency exchange uncertainty and volatility in certain of the countries in which we do business;
the impact of the United States-Mexico-Canada Agreement (“USMCA”) and any potential changes to other trade agreements;
the final outcome and impact of Brexit negotiations;
the trade conflict between the United States and China;
our ability to obtain, maintain and license sufficient intellectual property rights over our products and enforce and defend against challenges to such intellectual property (such as in connection with the filing by Norwich Pharmaceuticals Inc. (“Norwich”) of its Abbreviated New Drug Application (“ANDA”) for Xifaxan® (rifaximin) 550 mg tablets and the Company’s related lawsuit filed against Norwich in connection therewith);
the introduction of generic, biosimilar or other competitors of our branded products and other products, including the introduction of products that compete against our products that do not have patent or data exclusivity rights;
our ability to identify, finance, acquire, close and integrate acquisition targets successfully and on a timely basis and the difficulties, challenges, time and resources associated with the integration of acquired companies, businesses and products;
any divestitures of our assets or businesses and our ability to successfully complete any such divestitures on commercially reasonable terms and on a timely basis, or at all, and the impact of any such divestitures on our Company, including the reduction in the size or scope of our business or market share, loss of revenue, any loss on sale, including any resultant impairments of goodwill or other assets, or any adverse tax consequences suffered as a result of any such divestitures;
the expense, timing and outcome of pending or future legal and governmental proceedings, arbitrations, investigations, subpoenas, tax and other regulatory audits, examinations, reviews and regulatory proceedings against us or relating to us and settlements thereof;
our ability to negotiate the terms of or obtain court approval for the settlement of certain legal and regulatory proceedings;
our ability to obtain components, raw materials or finished products supplied by third parties (some of which may be single-sourced) and other manufacturing and related supply difficulties, interruptions and delays;
the disruption of delivery of our products and the routine flow of manufactured goods;
economic factors over which the Company has no control, including changes in inflation, interest rates, foreign currency rates, and the potential effect of such factors on revenues, expenses and resulting margins;
interest rate risks associated with our floating rate debt borrowings;
our ability to effectively distribute our products and the effectiveness and success of our distribution arrangements, including the impact of our arrangements with Walgreens;
our ability to effectively promote our own products and those of our co-promotion partners;
the success of our fulfillment arrangements with Walgreens, including market acceptance of, or market reaction to, such arrangements (including by customers, doctors, patients, PBMs, third-party payors and governmental agencies), and the continued compliance of such arrangements with applicable laws;
our ability to secure and maintain third-party research, development, manufacturing, licensing, marketing or distribution arrangements;
the risk that our products could cause, or be alleged to cause, personal injury and adverse effects, leading to potential lawsuits, product liability claims and damages and/or recalls or withdrawals of products from the market;
101


the mandatory or voluntary recall or withdrawal of our products from the market and the costs associated therewith;
the availability of, and our ability to obtain and maintain, adequate insurance coverage and/or our ability to cover or insure against the total amount of the claims and liabilities we face, whether through third-party insurance or self-insurance;
the difficulty in predicting the expense, timing and outcome within our legal and regulatory environment, including with respect to approvals by the FDA, Health Canada and similar agencies in other countries, legal and regulatory proceedings and settlements thereof, the protection afforded by our patents and other intellectual and proprietary property, successful generic challenges to our products and infringement or alleged infringement of the intellectual property of others;
the results of continuing safety and efficacy studies by industry and government agencies;
the success of preclinical and clinical trials for our drug development pipeline or delays in clinical trials that adversely impact the timely commercialization of our pipeline products, as well as other factors impacting the commercial success of our products, which could lead to material impairment charges;
the results of management reviews of our research and development portfolio (including following the receipt of clinical results or feedback from the FDA or other regulatory authorities), which could result in terminations of specific projects which, in turn, could lead to material impairment charges;
the seasonality of sales of certain of our products;
declines in the pricing and sales volume of certain of our products that are distributed or marketed by third parties, over which we have no or limited control;
compliance by the Company or our third-party partners and service providers (over whom we may have limited influence), or the failure of our Company or these third parties to comply, with health care “fraud and abuse” laws and other extensive regulation of our marketing, promotional and business practices (including with respect to pricing), worldwide anti-bribery laws (including the U.S. Foreign Corrupt Practices Act and the Canadian Corruption of Foreign Public Officials Act), worldwide economic sanctions and/or export laws, worldwide environmental laws and regulation and privacy and security regulations;
the impacts of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the “Health Care Reform Act”) and potential amendment thereof and other legislative and regulatory health care reforms in the countries in which we operate, including with respect to recent government inquiries on pricing;
the impact of any changes in or reforms to the legislation, laws, rules, regulation and guidance that apply to the Company and its businesses and products or the enactment of any new or proposed legislation, laws, rules, regulations or guidance that will impact or apply to the Company or its businesses or products;
the impact of changes in federal laws and policy that may be undertaken following the change in the U.S. administration;
illegal distribution or sale of counterfeit versions of our products;
interruptions, breakdowns or breaches in our information technology systems; and
risks in Item 1A. “Risk Factors” in this Form 10-K.
Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found elsewhere in this Form 10-K, under Item 1A. "Risk Factors" and in the Company's other filings with the SEC and the Canadian Securities Administrators (the “CSA”). When relying on our forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. These forward-looking statements speak only as of the date made. We undertake no obligation to update or revise any of these forward-looking statements to reflect events or circumstances after the date of this Form 10-K or to reflect actual outcomes, except as required by law. We caution that, as it is not possible to predict or identify all relevant factors that may impact forward-looking statements, the foregoing list of important factors that may affect future results is not exhaustive and should not be considered a complete statement of all potential risks and uncertainties.
102


Item 7A.    Quantitative and Qualitative Disclosures About Market Risk
Information relating to quantitative and qualitative disclosures about market risk is detailed in Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Quantitative and Qualitative Disclosures About Market Risk” and is incorporated herein by reference.
Item 8.    Financial Statements and Supplementary Data
The information required by this Item is contained in the financial statements set forth in Item 15. “Exhibits and Financial Statement Schedules” as part of this Form 10-K and is incorporated herein by reference.
Item 9.    Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Not applicable.
Item 9A.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of December 31, 2020. Based on that evaluation, the Company’s Chief Executive Officer and the Company’s Chief Financial Officer have concluded that as of December 31, 2020, the Company’s disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.
Management’s Annual Report on Internal Control Over Financial Reporting
The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. The Company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Under the supervision and with the participation of management, including the Company’s Chief Executive Officer and the Company’s Chief Financial Officer, the Company conducted an evaluation of the effectiveness of its internal control over financial reporting as of December 31, 2020 based on the framework described in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation, management has concluded that the Company maintained effective internal control over financial reporting as of December 31, 2020.
The effectiveness of the Company’s internal control over financial reporting as of December 31, 2020 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears herein.
Changes in Internal Control over Financial Reporting
There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the last fiscal quarter of 2020 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
Item 9B.    Other Information
None.
103


PART III
Item 10.    Directors, Executive Officers and Corporate Governance
Information required under this Item is incorporated herein by reference from information included in the 2021 Proxy Statement.
The Board of Directors has adopted a Code of Ethics that applies to our Chief Executive Officer, Chief Financial Officer, the principal accounting officer, controller, and all vice presidents and above in the finance department of the Company worldwide. A copy of the Code of Ethics can be found as an annex to our Standards of Business Conduct, which is located on our website at: www.bauschhealth.com. We intend to satisfy the SEC disclosure requirements regarding amendments to, or waivers from, any provisions of our Code of Ethics on our website.
Item 11.    Executive Compensation
Information required under this Item relating to executive compensation is incorporated herein by reference from information included in the 2021 Proxy Statement.
Item 12.    Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Information required under this Item relating to securities authorized for issuance under equity compensation plans and to security ownership of certain beneficial owners and management is incorporated herein by reference from information included in the 2021 Proxy Statement.
Item 13.    Certain Relationships and Related Transactions, and Director Independence
Information required under this Item relating to certain relationships and transactions with related parties and about director independence is incorporated herein by reference from information included in the 2021 Proxy Statement.
Item 14.    Principal Accounting Fees and Services
Information required under this Item relating to the fees for professional services rendered by our independent auditors in 2020 and 2019 is incorporated herein by reference from information included in the 2021 Proxy Statement.
104


PART IV
Item 15.    Exhibits and Financial Statement Schedules
(a)Documents filed as a part of the report:
(1)The consolidated financial statements required to be filed in the Annual Report on Form 10-K are listed on page F-1 hereof.
(2)Exhibits
All schedules are omitted because they are not applicable or the required information is included in the financial statements or notes.

Item 16.    Form 10-K Summary
None.

105


INDEX TO EXHIBITS
Exhibit
Number
Exhibit Description
3.1
3.2
3.3
3.4
3.5
4.1
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
106


4.10
4.11
4.12
4.13
4.14
10.1*
10.2
10.3
10.4
10.5
10.6
10.7
10.8
10.9
10.10
10.11
107


10.12
10.13
10.14*
10.15
10.16
10.17
10.18
10.19
10.20
10.21
10.22
10.23
10.24
10.25
10.26
10.27
10.28
108


10.29
10.30
21.1*
23.1*
31.1*
31.2*
32.1*
32.2*
101.INS*Inline XBRL Instance Document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document
104*Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
____________________________________
* Filed herewith.
†    Management contract or compensatory plan or arrangement.
††    One or more exhibits or schedules to this exhibit have been omitted pursuant to Item 601(a)(5) or Item 601(b)(2) of Regulation S-K. We undertake to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon request.
109


SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 BAUSCH HEALTH COMPANIES INC.
(Registrant)
Date:February 24, 2021By:/s/ JOSEPH C. PAPA 
 
Joseph C. Papa
Chief Executive Officer
(Principal Executive Officer and Chairman of the Board)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
 Signature Title Date
      
 
/s/ JOSEPH C. PAPA
Joseph C. Papa

 Chief Executive Officer and Chairman of the Board February 24, 2021
 
/s/ PAUL S. HERENDEEN
Paul S. Herendeen
 Executive Vice President and Chief Financial Officer (Principal Financial Officer)  February 24, 2021
 
/s/ SAM ELDESSOUKY
Sam Eldessouky
 Senior Vice President, Controller and Chief Accounting Officer (Principal Accounting Officer) February 24, 2021
/s/ RICHARD U. DESCHUTTER
Richard U. DeSchutter
Director February 24, 2021
/s/ D. ROBERT HALE
D. Robert Hale
DirectorFebruary 24, 2021
/s/ ARGERIS N. KARABELAS
Argeris N. Karabelas
DirectorFebruary 24, 2021
/s/ SARAH B. KAVANAGH
Sarah B. Kavanagh
DirectorFebruary 24, 2021
/s/ JOHN A. PAULSON
John A. Paulson
DirectorFebruary 24, 2021
 
/s/ ROBERT N. POWER
Robert N. Power
 Director February 24, 2021
/s/ RUSSEL C. ROBERTSON
Russel C. Robertson
Director February 24, 2021
/s/ THOMAS W. ROSS, SR.
Thomas W. Ross, Sr.
Director February 24, 2021
/s/ ANDREW C. VON ESCHENBACH
Andrew C. von Eschenbach
Director February 24, 2021
/s/ AMY B. WECHSLER
Amy B. Wechsler
Director February 24, 2021
110


BAUSCH HEALTH COMPANIES INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Page
Report of Management on Financial Statements
Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets as of December 31, 2020 and 2019
Consolidated Statements of Operations for the years ended December 31, 2020, 2019 and 2018
Consolidated Statements of Comprehensive Loss for the years ended December 31, 2020, 2019 and 2018
Consolidated Statements of Shareholders’ Equity for the years ended December 31, 2020, 2019 and 2018
Consolidated Statements of Cash Flows for the years ended December 31, 2020, 2019 and 2018
Notes to Consolidated Financial Statements
F-1


REPORT OF MANAGEMENT ON FINANCIAL STATEMENTS

The Company’s management is responsible for preparing the accompanying consolidated financial statements in conformity with United States generally accepted accounting principles (“U.S. GAAP”). In preparing these consolidated financial statements, management selects appropriate accounting policies and uses its judgment and best estimates to report events and transactions as they occur. Management has determined such amounts on a reasonable basis in order to ensure that the consolidated financial statements are presented fairly, in all material respects. Financial information included throughout this Annual Report is prepared on a basis consistent with that of the accompanying consolidated financial statements.
PricewaterhouseCoopers LLP has been engaged by the Company to audit the consolidated financial statements.
The Board of Directors is responsible for ensuring that management fulfills its responsibility for financial reporting and is ultimately responsible for reviewing and approving the consolidated financial statements. The Board of Directors carries out this responsibility principally through its Audit and Risk Committee. The members of the Audit and Risk Committee are outside Directors. The Audit and Risk Committee considers, for review by the Board of Directors and approval by the shareholders, the engagement or reappointment of the external auditors. PricewaterhouseCoopers LLP has full and free access to the Audit and Risk Committee.


/s/ JOSEPH C. PAPA/s/ PAUL S. HERENDEEN
Joseph C. Papa
Chief Executive Officer
 Paul S. Herendeen
Executive Vice President and
Chief Financial Officer
February 24, 2021
F-2


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of Bausch Health Companies Inc.
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheets of Bausch Health Companies Inc. and its subsidiaries (the “Company”) as of December 31, 2020 and 2019, and the related consolidated statements of operations, of comprehensive loss, of shareholders' equity and of cash flows for each of the three years in the period ended December 31, 2020, including the related notes (collectively referred to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.
Changes in Accounting Principles
As discussed in Note 2 to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2019 and the manner in which it accounts for income taxes and goodwill in 2018.
Basis for Opinions
The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Annual Report on Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the
F-3


company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
Medicaid Rebates and Sales Returns Allowances
As described in Note 2 to the consolidated financial statements, gross product sales are subject to a variety of deductions in arriving at reported net product sales. The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. The provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue as a reduction in revenue. The variable consideration provisions, either recognized within accrued and other current liabilities or as a reduction of trade receivables, included $575 million related to return allowances and $779 million related to rebates, including Medicaid rebates as of December 31, 2020. For certain rebate programs, such as Medicaid, provisions recognized by management are based on the terms of state government-managed programs, estimates of outstanding and future claims for end-customer sales and the sales mix. For sales returns, management estimates provisions utilizing existing return policies with customers, historical sales and return rates, inventory levels in the distribution channel, prescription demand and product shelf lives.
The principal considerations for our determination that performing procedures relating to Medicaid rebates and sales return allowances is a critical audit matter are (i) the significant judgment by management when developing the estimate of Medicaid rebates and allowances for sales returns and (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures to evaluate management’s estimates, including significant assumptions related to terms of state government-managed Medicaid programs, existing return policies with customers, and projected outstanding and future claims for end-customer sales.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to provisions for Medicaid rebates and allowances for sales returns, including controls over the assumptions used to estimate these rebates and allowances. These procedures also included, among others (i) developing an independent estimate of Medicaid rebates by utilizing third-party information on inventory levels in the distribution channel, the terms of the specific Medicaid rebate programs, and the historical trends of actual Medicaid rebate claims paid adjusted for price and projected market conditions (ii) comparing the independent estimate for these Medicaid rebates to management’s estimates, (iii) evaluating the reasonableness of management’s assumptions related to the allowances for sales returns, including existing return policies, comparing to historical trends and considering whether these assumptions were consistent with evidence obtained in other areas of the audit, (iv) evaluating the appropriateness of the sales return model and testing the completeness and accuracy of underlying data used in the model, and (v) testing Medicaid rebate and sales return claims processed by the Company, including evaluating those claims for consistency with the contractual terms of the Company’s arrangements and policies.
Finite-Lived Intangible Assets Impairment Assessment
As described in Note 8 to the consolidated financial statements, the Company’s consolidated finite-lived net intangible assets balance was $6,740 million as of December 31, 2020, which consists of product and corporate brands, product rights/patents, partner relationships and technology and other assets. Finite-lived intangible assets are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. As disclosed by management, recoverability is measured through the use of an undiscounted future cash flow model when an indication of impairment is determined to exist. If an asset is determined to not be recoverable, a discounted cash flow model is used to estimate fair value. Management’s impairment tests included significant estimates and assumptions related to the amount and timing of projected future cash flows and in the situation when the asset is determined to not be recoverable, the discount rate.
F-4


The principal considerations for our determination that performing procedures relating to the finite-lived intangible assets impairment assessment is a critical audit matter are (i) the significant judgment by management in the identification of events that suggest an asset group might not be recoverable and in developing the assumptions used in the impairment testing assessment and (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence related to management’s undiscounted future cash flow projections.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management’s finite-lived intangible assets impairment assessment, including controls over the development of assumptions used to estimate recoverability and controls over the identification of events that suggest an asset group might not be recoverable. These procedures also included, among others (i) testing management’s process for identifying potential impairment events and determining the recoverability of the intangible assets, (ii) evaluating the appropriateness of the undiscounted cash flow model used in the impairment testing assessment, (iii) testing the completeness and accuracy of underlying data used in the model, and (iv) evaluating the reasonableness of the significant assumptions used by management related to the undiscounted future cash flow projections. Evaluating the reasonableness of management's assumptions for undiscounted future cash flow projections involved evaluating whether the assumptions used by management were reasonable considering the current and past performance of the asset group and whether these assumptions were consistent with evidence obtained in other areas of the audit.
Goodwill Impairment Assessment – Ortho Dermatologics Reporting Unit
As described in Note 8 to the consolidated financial statements, the Company’s consolidated goodwill balance was $13,044 million as of December 31, 2020, and the goodwill associated with the Ortho Dermatologics segment was $1,267 million. The Ortho Dermatologics segment consists of the Ortho Dermatologics and Global Solta reporting units. Management conducted its annual goodwill impairment test as of October 1, 2020 by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. As disclosed by management, goodwill impairment is measured by the amount the carrying value exceeds the fair value. Fair value of each reporting unit is estimated by management based on the income approach. Management’s discounted cash flow model includes judgments and assumptions relating to revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates.
The principal considerations for our determination that performing procedures relating to the goodwill impairment assessment of the Ortho Dermatologics reporting unit is a critical audit matter are (i) the significant judgment by management when developing the fair value estimate of the reporting unit (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence related to management’s significant assumptions related to revenue growth rates, terminal growth rate, gross profit, and the discount rate, and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management’s goodwill impairment assessment, including controls over the valuation of the Company’s Ortho Dermatologics reporting unit. These procedures also included, among others (i) testing management’s process for developing the fair value estimate of the Ortho Dermatologics reporting unit, (ii) evaluating the appropriateness of the discounted cash flow model, (iii) testing the completeness and accuracy of underlying data used in the model, and (iv) evaluating the reasonableness of the significant assumptions used by management related to the revenue growth rates, terminal growth rate, gross profit and the discount rate. Evaluating management’s assumptions related to revenue growth rates and gross profit involved evaluating whether the assumptions used by management were reasonable considering (i) the current and past performance of the reporting unit, (ii) the consistency with external market and industry data, and (iii) whether these assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in the evaluation of the Company’s discounted cash flow model and terminal growth rate and discount rate assumptions.
/s/ PricewaterhouseCoopers LLP
Florham Park, New Jersey
February 24, 2021
We have served as the Company’s auditor since 2012.
F-5



BAUSCH HEALTH COMPANIES INC.
CONSOLIDATED BALANCE SHEETS
(in millions, except share amounts)
 December 31,
 20202019
Assets  
Current assets:  
Cash and cash equivalents$605 $3,243 
Restricted cash1,211 1 
Trade receivables, net1,577 1,839 
Inventories, net1,094 1,107 
Prepaid expenses and other current assets855 779 
Total current assets5,342 6,969 
Property, plant and equipment, net1,567 1,466 
Intangible assets, net8,445 10,201 
Goodwill13,044 13,126 
Deferred tax assets, net2,137 1,690 
Other non-current assets664 411 
Total assets$31,199 $33,863 
Liabilities 
Current liabilities: 
Accounts payable$337 $503 
Accrued and other current liabilities4,576 4,511 
Current portion of long-term debt and other 1,234 
Total current liabilities4,913 6,248 
Acquisition-related contingent consideration216 262 
Non-current portion of long-term debt23,925 24,661 
Deferred tax liabilities, net 528 705 
Other non-current liabilities1,012 851 
Total liabilities30,594 32,727 
Commitments and contingencies (Notes 20 and 21)
Equity  
Common shares, no par value, unlimited shares authorized, 355,422,347 and 352,562,636 issued and outstanding at December 31, 2020 and 2019, respectively
10,227 10,172 
Additional paid-in capital454 429 
Accumulated deficit(8,013)(7,452)
Accumulated other comprehensive loss(2,133)(2,086)
Total Bausch Health Companies Inc. shareholders’ equity535 1,063 
Noncontrolling interest70 73 
Total equity605 1,136 
Total liabilities and equity$31,199 $33,863 
On behalf of the Board:
/s/ JOSEPH C. PAPA/s/ RUSSEL C. ROBERTSON
Joseph C. Papa Russel C. Robertson
Chief Executive Officer Chairperson, Audit and Risk Committee
The accompanying notes are an integral part of these consolidated financial statements.
F-6


BAUSCH HEALTH COMPANIES INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in millions, except per share amounts)
 Years Ended December 31,
 202020192018
Revenues   
Product sales$7,924 $8,489 $8,271 
Other revenues103 112 109 
8,027 8,601 8,380 
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets)2,202 2,297 2,309 
Cost of other revenues47 53 42 
Selling, general and administrative2,367 2,554 2,473 
Research and development452 471 413 
Amortization of intangible assets1,645 1,897 2,644 
Goodwill impairments  2,322 
Asset impairments, including loss on assets held for sale114 75 568 
Restructuring, integration and separation costs22 31 22 
Acquisition-related contingent consideration48 12 (9)
Other expense (income), net454 1,414 (20)
7,351 8,804 10,764 
Operating income (loss)676 (203)(2,384)
Interest income13 12 11 
Interest expense(1,534)(1,612)(1,685)
Loss on extinguishment of debt(59)(42)(119)
Foreign exchange and other(30)8 23 
Loss before benefit from income taxes(934)(1,837)(4,154)
Benefit from income taxes375 54 10 
Net loss(559)(1,783)(4,144)
Net income attributable to noncontrolling interest(1)(5)(4)
Net loss attributable to Bausch Health Companies Inc.$(560)$(1,788)$(4,148)
Basic and diluted loss per share attributable to Bausch Health Companies Inc.
$(1.58)$(5.08)$(11.81)
Basic and diluted weighted-average common shares355.0 352.1 351.3 
The accompanying notes are an integral part of these consolidated financial statements.
F-7


BAUSCH HEALTH COMPANIES INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(in millions)
Years Ended December 31,
202020192018
Net loss$(559)$(1,783)$(4,144)
Other comprehensive (loss) income
Pension and postretirement benefit plan adjustments:
Net actuarial loss arising during the year(15)(8)(7)
Amortization of prior service credit(4)(4)(4)
Amortization or settlement recognition of net loss1 2 1 
Income tax benefit (expense)2 (2)3 
Foreign currency impact (2) 
Net pension and postretirement benefit plan adjustments(16)(14)(7)
Foreign currency translation adjustment(29)64 (237)
Other comprehensive (loss) income(45)50 (244)
Comprehensive loss(604)(1,733)(4,388)
Comprehensive income attributable to noncontrolling interest(3)(4)(1)
Comprehensive loss attributable to Bausch Health Companies Inc.$(607)$(1,737)$(4,389)
The accompanying notes are an integral part of these consolidated financial statements.
F-8


BAUSCH HEALTH COMPANIES INC.
CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(in millions)
 Bausch Health Companies Inc. Shareholders' Equity  
 Common Shares  Accumulated
Other
Comprehensive
Loss
Bausch Health
Companies Inc.
Shareholders'
Equity
 
 SharesAmountAdditional
Paid-In
Capital
Accumulated
Deficit
Noncontrolling
Interest
Total
Equity
Balance, January 1, 2018348.7 $10,090 $380 $(2,725)$(1,896)$5,849 $95 $5,944 
Effect of application of new accounting standard: Income taxes
— — — 1,209 — 1,209 — 1,209 
Common shares issued under share-based compensation plans
1.2 31 (29)— — 2 — 2 
Share-based compensation— — 87 — — 87 — 87 
Share-based awards tax withholding
— — (10)— — (10)— (10)
Acquisition of noncontrolling interest— — (15)— — (15)(3)(18)
Noncontrolling interest distributions— — — — — — (11)(11)
Net (loss) income— — — (4,148)— (4,148)4 (4,144)
Other comprehensive loss— — — — (241)(241)(3)(244)
Balance, December 31, 2018349.9 10,121 413 (5,664)(2,137)2,733 82 2,815 
Common shares issued under share-based compensation plans
2.7 51 (46)— — 5 — 5 
Share-based compensation— — 102 — — 102 — 102 
Share-based awards tax withholding
— — (40)— — (40)— (40)
Noncontrolling interest distributions— — — — — — (13)(13)
Net (loss) income— — — (1,788)— (1,788)5 (1,783)
Other comprehensive income (loss)— — — — 51 51 (1)50 
Balance, December 31, 2019352.6 10,172 429 (7,452)(2,086)1,063 73 1,136 
Effect of application of new accounting standard: financial instruments - credit losses
— — — (1)— (1)— (1)
Common shares issued under share-based compensation plans
2.8 55 (50)— — 5 — 5 
Share-based compensation— — 105 — — 105 — 105 
Share-based awards tax withholding
— — (30)— — (30)— (30)
Noncontrolling interest distributions— — — — — — (6)(6)
Net (loss) income— — — (560)— (560)1 (559)
Other comprehensive (loss) income— — — — (47)(47)2 (45)
Balance, December 31, 2020355.4 $10,227 $454 $(8,013)$(2,133)$535 $70 $605 

The accompanying notes are an integral part of these consolidated financial statements.
F-9


BAUSCH HEALTH COMPANIES INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions)
 Years Ended December 31,
 202020192018
Cash Flows From Operating Activities   
Net loss$(559)$(1,783)$(4,144)
Adjustments to reconcile net loss to net cash provided by operating activities:   
Depreciation and amortization of intangible assets1,825 2,075 2,819 
Amortization and write-off of debt discounts and debt issuance costs61 63 79 
Asset impairments, including loss on assets held for sale114 75 568 
Goodwill impairment  2,322 
Acquisition-related contingent consideration48 12 (9)
Allowances for losses on trade receivables and inventories60 75 69 
Deferred income taxes(475)(230)(144)
(Gain) loss on disposal of assets(1)(31)6 
Additions (reductions) to accrued legal settlements442 1,401 (27)
Payments of accrued legal settlements(168)(15)(224)
Share-based compensation105 102 87 
Foreign exchange loss (gain)8 7 (19)
Gain excluded from hedge effectiveness(23)(9) 
Loss on extinguishment of debt59 42 119 
Payments of contingent consideration adjustments, including accretion(1)(1)(2)
Other(18)36 (17)
Changes in operating assets and liabilities:   
Trade receivables170 39 216 
Inventories(77)(209)(5)
Prepaid expenses and other current assets12 1 (72)
Accounts payable, accrued and other liabilities(471)(149)(121)
Net cash provided by operating activities1,111 1,501 1,501 
Cash Flows From Investing Activities   
Acquisition of businesses, net of cash acquired (180)5 
Acquisition of intangible assets and other assets(7)(8)(78)
Purchases of property, plant and equipment(302)(270)(157)
Purchases of marketable securities(4)(16)(7)
Proceeds from sale of marketable securities8 10 7 
Proceeds from sale of assets and businesses, net of costs to sell21 45 34 
Interest settlements from cross-currency swaps23   
Net cash used in investing activities(261)(419)(196)
Cash Flows From Financing Activities   
Issuance of long-term debt, net of discounts3,455 5,960 8,944 
Repayments of long-term debt(5,642)(4,406)(10,101)
Borrowings of short-term debt1 12  
Repayments of short-term debt(1)(12)(3)
Payment of employee withholding taxes related to share-based awards(30)(40)(10)
Payments of acquisition-related contingent consideration(35)(35)(37)
Payments of deferred consideration  (18)
Payments of financing costs(39)(28)(102)
Other(3)(8)(26)
Net cash (used in) provided by financing activities(2,294)1,443 (1,353)
Effect of exchange rate changes on cash and cash equivalents16 (4)(26)
Net (decrease) increase in Cash and cash equivalents and Restricted cash(1,428)2,521 (74)
Cash and cash equivalents and Restricted cash, beginning of year3,244 723 797 
Cash and cash equivalents and Restricted cash, end of year$1,816 $3,244 $723 
Cash and cash equivalents, end of year$605 $3,243 $721 
Restricted cash, end of year1,211 1 2 
Cash and cash equivalents and Restricted cash, end of year$1,816 $3,244 $723 

The accompanying notes are an integral part of these consolidated financial statements.
F-10


BAUSCH HEALTH COMPANIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1.DESCRIPTION OF BUSINESS
Bausch Health Companies Inc. (the “Company”), formerly known as Valeant Pharmaceuticals International, Inc., is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately 100 countries. Effective August 9, 2013, the Company continued from the federal jurisdiction of Canada to the Province of British Columbia, meaning that the Company became a company registered under the laws of the Province of British Columbia as if it had been incorporated under the laws of the Province of British Columbia. As a result of this continuance, the legal domicile of the Company became the Province of British Columbia, the Canada Business Corporations Act ceased to apply to the Company and the Company became subject to the British Columbia Business Corporations Act.
2.SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation and Use of Estimates
The Consolidated Financial Statements have been prepared by the Company in United States (“U.S.”) dollars and in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.
Separation of the Bausch + Lomb Eye-Health Business
On August 6, 2020, the Company announced that it intends to separate its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the “Separation”). The Separation will establish two separate companies that include: (i) a fully integrated eye-health company which will consist of the Company’s Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmology Rx businesses and (ii) a diversified pharmaceutical company which will include the Company’s Salix, International Rx, Solta, neurology and medical dermatology pharmaceutical businesses. The anticipated separation is subject to regulatory approvals and certain conditions, including final approval by the Company’s Board of Directors and any shareholder vote requirements that may be applicable.
The Company has begun addressing the internal organizational design and structure of the new entity which it anticipates having substantially completed by late 2021. Management is also exploring various capitalization structures and the form of the Separation transaction in order to properly capitalize both entities post-separation. As of the date of the issuance of these financial statements, the Company is in the planning phase of the Separation. As such, there are considerations, approvals and conditions that will determine the ultimate timing and structure of the Separation and there can be no assurance that such a transaction will occur. These Consolidated Financial Statements do not include any adjustments to give effect to the Separation.
Impacts of COVID-19 Pandemic
The unprecedented nature of the COVID-19 pandemic has adversely impacted the global economy. The COVID-19 pandemic and the rapidly evolving reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have intensified and have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions. The COVID-19 pandemic has also significantly increased demand for certain goods and services, such as pandemic-related medical services and supplies, alongside decreased demand for others, such as retail, hospitality, elective medical procedures and travel.
The extent to which these events may continue to impact the Company's business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company's control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, the ultimate geographic spread and duration of the pandemic, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, if any, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the
F-11


reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company's business, financial condition, cash flows and results of operations.
To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable.
Use of Estimates
In preparing the Company's Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company’s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks.
On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s Consolidated Financial Statements could be materially impacted.
Reclassifications
Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Acquisitions
Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition. Acquired in-process research and development (“IPR&D”) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&D with no alternative future use is charged to expense at the acquisition date and any future contingent consideration is not recorded until it becomes probable.
Fair Value of Financial Instruments
The estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events.
F-12


Fair Value of Derivative Instruments
The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.
The Company’s cross-currency swaps qualify for and have been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value is determined via a mark-to-market analysis, using observable (Level 2) inputs. These inputs may include: (i) the foreign currency exchange spot rate between the euro and U.S. dollar, (ii) the interest rate yield curves in the euro and U.S. dollar and (iii) the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Loss as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulated other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps was ineffective. The Company uses the spot method of assessing hedge effectiveness. The Company has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as a reduction of Interest expense in the Consolidated Statements of Operations.
The Company uses foreign currency exchange contracts to economically hedge the foreign exchange exposure on certain of the Company’s intercompany and third party balances. The Company's foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other.
Cash and Cash Equivalents
Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of three months or less when purchased.
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, cross-currency swaps and foreign currency exchange contracts.
The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than three months. Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.
The Company’s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company’s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Brazil, Egypt, Greece, among other members of the European Union, Turkey, Ukraine and Venezuela have been weak in recent years. These conditions have increased, and may continue to increase, the average length of time that it takes to collect on the Company’s trade receivables outstanding in these countries.
As of December 31, 2020, the Company’s three largest U.S. wholesaler customers accounted for approximately 38% of net trade receivables. In addition, as of December 31, 2020 and 2019, the Company’s net trade receivable balance from Argentina, Brazil, Egypt, Greece, Serbia, Turkey, Ukraine, Venezuela and Vietnam amounted to $166 million and $156 million, respectively, the majority of which is current or less than 90 days past due. The portion of the net trade receivable from these countries that is past due more than 90 days amounted to $2 million, as of December 31, 2020, a portion of which is comprised of public hospitals. Based on an analysis of credit risk, including an analysis of bad debt experience
F-13


and assessment of historical payment patterns for such customers, the Company has established a reserve covering more than half of the balance past due more than 90 days for such countries. Over the three-year period ended December 31, 2020, the Company has not experienced any material losses from uncollectible accounts in excess of the established reserves.
The Company does not enter into financial instruments for trading or speculative purposes. Further, the Company has a policy of only entering into contracts with parties that have at least an investment grade credit rating. The Company enters into cross-currency swaps and foreign currency exchange contracts with high credit quality financial institutions. The counter-parties to the Company's cross-currency swaps and foreign currency exchange contracts are major financial institutions, and there is no significant concentration of exposure with any one counter-party. To date, no counterparty has failed to meet its obligations to the Company and management believes the risk of loss associated with these contracts is remote. See Note 5, "FAIR VALUE MEASUREMENTS" for additional details regarding the Company's cross-currency swaps and foreign currency exchange contracts.
Allowance for Credit Losses
An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.  Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. Allowance for credit losses were $39 million, $48 million and $47 million as of December 31, 2020, 2019 and 2018, respectively. The activity in the allowance for credit losses for trade receivables for the years 2020, 2019 and 2018 is as follows.
(in millions)202020192018
Balance, beginning of period$48 $47 $97 
Retrospective effect of application of new accounting standard1   
Provision2 10 4 
Write-offs(12)(10)(50)
Recoveries3 1 2 
Foreign exchange and other
(3) (6)
Balance, end of period$39 $48 $47 
Inventories
Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads.
The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.
Property, Plant and Equipment
Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful lives:
Land improvements
15 - 30 years
Buildings and improvements
Up to 40 years
Machinery and equipment
3 - 20 years
Other equipment
3 - 10 years
Equipment on operating lease
Up to 5 years
Leasehold improvements
Lesser of term of lease or 10 years
F-14


Intangible Assets
Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. Amortization is calculated primarily using the straight-line method based on the following estimated useful lives:
Product brands
1 - 20 years
Corporate brands
7 - 20 years
Product rights/patents
4 - 15 years
Partner relationships
7 - 9 years
Out-licensed technology and other
8 - 9 years
Divestitures of Products
The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense (income), net. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.
IPR&D
The fair value of IPR&D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and amortized. Acquired IPR&D assets are tested for impairment at least annually or when triggering events are identified.
The fair value of an acquired IPR&D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset’s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset’s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow streams.
Impairment of Long-Lived Assets
Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows.
Indefinite-lived intangible assets, which includes acquired IPR&D and the corporate trademark acquired in the acquisition of Bausch & Lomb Holdings Incorporated (the ‘‘B&L Trademark’’), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.
Goodwill
Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. A reporting unit is the same as, or one level below, an operating segment. An entity is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit’s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.
An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company’s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors
F-15


changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company’s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values.
Effective January 1, 2018, the Company elected to early adopt guidance issued by the Financial Accounting Standards Board ("FASB") which simplified the subsequent measurement of goodwill by eliminating “Step 2” from the goodwill impairment test. Instead, as of January 1, 2018 and all subsequent periods, goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value.
Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs
Debt discounts, premiums and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility.
Foreign Currency Translation
The assets and liabilities of the Company’s foreign operations having a functional currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets.
Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation’s functional currency are recognized as a component of Foreign exchange and other in the Consolidated Statements of Operations.
Revenue Recognition
The Company’s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, gastroenterology ("GI") and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, "SEGMENT INFORMATION" for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.
The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
Product Sales
A contract with the Company’s customers exists for each product sale. Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed below. The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products.
Product Sales Provisions
As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.  The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers.
F-16


Provisions for variable consideration are established to reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.
Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities. 
The following table presents the activity and ending balances of the Company’s variable consideration provisions the years 2020 and 2019.
(in millions)Discounts
and
Allowances
ReturnsRebatesChargebacksDistribution
Fees
Total
Reserve balance, January 1, 2019$175 $813 $1,024 $209 $163 $2,384 
Acquisition of Synergy 3 12  1 16 
Current period provision776 113 2,265 1,938 195 5,287 
Payments and credits(769)(238)(2,374)(1,979)(277)(5,637)
Reserve balance, December 31, 2019182 691 927 168 82 2,050 
Current period provision621 120 2,174 1,925 196 5,036 
Payments and credits(613)(236)(2,322)(1,909)(193)(5,273)
Reserve balance, December 31, 2020$190 $575 $779 $184 $85 $1,813 
Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $32 million and $29 million as of December 31, 2020 and 2019, respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets.
The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company’s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics. The following describes the major sources of variable consideration in the Company’s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration.
Cash Discounts and Allowances
Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within one month of incurring the liability.
Returns
Consistent with industry practice, customers are generally allowed to return a product within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The
F-17


returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.
In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information. These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. A change of 1% in the estimated return rates would have impacted the Company’s pre-tax earnings by approximately $76 million for the year 2020.
The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not warrant revision to the provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S. National Drug Codes (“NDC”) of products. Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S. customers generally permit only one NDC per product for identification and tracking within their inventory systems.
Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for 2020 and 2019 were $120 million and $113 million, respectively, and includes reductions in variable consideration for sales return provisions related to past sales of approximately $38 million and $80 million, respectively.
Rebates and Chargebacks
Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates.  The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270 days after the quarter in which the product is dispensed to the Medicaid participant. As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. A change of 1% in the estimated rates used in the Medicaid rebate reserve would have impacted the Company’s pre-tax earnings by approximately $76 million for 2020. Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods.
Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market share.
Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers.
F-18


In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or chargebacks.
The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts implemented in each of the last three years, changes in the Company’s product portfolio due to recent acquisitions and increased Medicaid utilization due to expansion of government funding for these programs. Management’s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel.
Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2020 and 2019 were not material to the Company’s revenues or earnings.
Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company’s products. Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management’s estimate of the discount, rebate and loyalty incentives attributable to a sale. That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any.
Distribution Fees
The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart. The Company has Distribution Services Agreements ("DSAs") with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty. Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes. Additionally, price appreciation credits are generated when the Company increases a product’s wholesaler acquisition cost (“WAC”) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $15 million and $11 million for the years 2020 and 2019, respectively.
Contract Assets and Contract Liabilities
There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented.
Sales Commissions
Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.
Financing Component
The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less. The Company's global payment terms are generally between thirty to ninety days.
Leases
The Company leases certain facilities, vehicles and equipment principally under multi-year agreements generally having a lease term of one to twenty years, some of which include termination options and options to extend the lease term from one to five years or on a month-to-month basis. The Company includes options that are reasonably certain to be exercised as part of the lease term. The Company may negotiate termination clauses in anticipation of changes in market conditions but
F-19


generally, these termination options are not exercised. Certain lease agreements also include variable payments that are dependent on usage or may vary month-to-month such as insurance, taxes and maintenance costs. None of the Company's lease agreements contain material residual value guarantees or material restrictive covenants.
Effective January 1, 2019, the Company adopted a new standard revising the accounting for leases, using the modified retrospective approach. Upon adoption, the Company elected the available practical expedients, including: (i) the package of practical expedients as defined in the accounting guidance, which among other things, allowed the carry forward of historical lease classifications, (ii) the election to use hindsight in determining the lease terms for all leases, (iii) the transition method, which does not require the restatement of prior periods, (iv) the election to aggregate lease components with non-lease components and account for these payments as a single lease component and (v) the short-term lease exemption, which does not require recognition on the balance sheet for leases with an initial term of 12 months or less. The Company has updated its systems, processes and controls to track, record and account for its lease portfolio, including implementation of a third-party software tool to assist in complying with the new standard. Upon adoption of the new standard, the Company recognized a right-of-use asset and a corresponding lease liability of $302 million. The adoption of the standard did not have a material impact on the Consolidated Statements of Operations, Comprehensive Loss, Equity and Cash Flows for any of the periods presented. See Note 12, "LEASES" for additional details and application of this standard.
The Company is required to record a right-of-use asset and corresponding lease liability, equal to the present value of the lease payments at the commencement date of each lease. For all asset classes, in determining future lease payments, the Company has elected to aggregate lease components, such as payments for rent, taxes and insurance costs with non-lease components such as maintenance costs, and account for these payments as a single lease component. In limited circumstances, when the information necessary to determine the rate implicit in a lease is available, the present value of the lease payments is determined using the rate implicit in that lease. If the information necessary to determine the rate implicit in a lease is not available, the Company uses its incremental borrowing rate at the commencement of the lease, which represents the rate of interest that the Company would incur to borrow on a collateralized basis over a similar term.
All leases must be classified as either an operating lease or finance lease. The classification is determined based on whether substantive control has been transferred to the lessee. The classification governs the pattern of lease expense recognition. For leases classified as operating leases, total lease expense over the term of the lease is equal to the undiscounted payments due in accordance with the lease arrangement. Fixed lease expense is recognized periodically on a straight-line basis over the term of each lease and includes: (i) imputed interest during the period on the lease liability determined using the effective interest rate method plus (ii) amortization of the right-of-use asset for that period. Amortization of the right-of-use asset during the period is calculated as the difference between the straight-line expense and the imputed interest on the lease liability for that period. Variable lease expense is recognized when the achievement of the specific target is considered probable.
Research and Development Expenses
Costs related to internal research and development programs, including costs associated with the development of acquired IPR&D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses. Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.
Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.
Legal Costs
Legal fees and other costs related to litigation and other legal proceedings or services are expensed as incurred and are included in Selling, general and administrative expenses. Certain legal costs associated with acquisitions are included in Acquisition-related costs and certain legal costs associated with divestitures, legal settlements and other business development activities are included in Litigation and other matters or Net (gain) loss on sales of assets within Other expense (income), net, as appropriate. Legal costs expensed are reported net of expected insurance recoveries. A claim for insurance recovery is recognized when realization becomes probable.
F-20


Advertising Costs
Advertising costs comprise product samples, print media, promotional materials and television advertising and are expensed on the first use of the advertisement. Included in Selling, general and administrative expenses are advertising costs of $451 million, $544 million and $481 million, for 2020, 2019 and 2018, respectively.
Share-Based Compensation
The Company recognizes all share-based payments to employees, including grants of employee stock options and restricted share units (“RSUs”), at estimated fair value. The Company amortizes the fair value of stock option or RSU grants on a straight-line basis over the requisite service period of the individual stock option or RSU grant, which generally equals the vesting period. Stock option and RSU forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation is recorded in Research and development expenses and Selling, general and administrative expenses, as appropriate.
Acquisition-Related Contingent Consideration
Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in fair value measurement accounting.
Interest Expense
Interest expense includes standby fees, the amortization of debt discounts and deferred financing costs, accretion of debt premiums and the amortization of amounts excluded from the assessment of effectiveness related to the Company's cross-currency swaps. Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized. Capitalized interest related to construction in progress as of December 31, 2020 and 2019 was $45 million and $34 million, respectively, and is included in Property, plant and equipment, net.
Income Taxes
Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and laws. Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future.
In October 2016, the FASB issued guidance requiring an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, rather than when the asset has been sold to an outside party. This guidance was effective for the Company January 1, 2018 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit and deferred income taxes as of the effective date. The Company recorded a net cumulative-effect adjustment of $1,209 million to increase deferred income tax assets and decrease the opening balance of Accumulated deficit for the income tax consequences deferred from past intra-entity transfers involving assets other than inventory.
The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than 50% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within one year. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance sheets.
Loss Per Share Attributable to Bausch Health Companies Inc.
Basic loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. Diluted loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period
F-21


after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock method.
Comprehensive Loss
Comprehensive loss comprises Net loss and Other comprehensive (loss) income. Other comprehensive (loss) income includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders’ equity.
Contingencies
In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a liability. These accruals are adjusted periodically as assessments change or additional information becomes available.
If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred.
Employee Benefit Plans
The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed 10 percent of the greater of the plan’s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements.
Adoption of New Accounting Standards
In June 2016, the FASB issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses. The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to Accumulated deficit of less than $1 million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows.
In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement.  The guidance was effective for the Company beginning January 1, 2020. The application of this guidance did not have a material effect on the Company's disclosures.
In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.  Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging. The optional amendments are effective for all entities as of March 12, 2020, through December 31, 2022. During 2020, the Company has not entered into any contract modifications in which the optional expedients were applied.  However, if prior to December 31, 2022 the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.
In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans.  The guidance was effective for annual periods ending after December 15, 2020. The application of this guidance did not have a material effect on the Company's disclosures.
F-22


Recently Issued Accounting Standards, Not Adopted as of December 31, 2020
In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.  The guidance is effective for annual periods beginning after December 15, 2020.  The application of this guidance is not expected to have a material effect on the Company's financial position, results of operations and cash flows.
3.ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE
Acquisition Agreement for Synergy Pharmaceuticals Inc.
On March 6, 2019, the Company acquired certain assets of Synergy Pharmaceuticals Inc. ("Synergy") for a cash purchase price of approximately $180 million and the assumption of certain liabilities, pursuant to the terms approved by the U.S. Bankruptcy Court for the Southern District of New York on March 1, 2019. Among the assets acquired are the worldwide rights to the Trulance® (plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. This acquired business is included in the Company's Salix segment and is expected to result in additional revenues and costs savings associated with business synergies.
Assets Acquired and Liabilities Assumed
The acquisition of certain assets of Synergy has been accounted for as a business combination under the acquisition method of accounting since: (i) substantially all of the fair value of the assets acquired is not concentrated in a single identifiable asset or group of similar identifiable assets and (ii) substantive inputs and processes were acquired to contribute to the creation of outputs. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:
(in millions)
Accounts receivable$7 
Inventories24 
Prepaid expenses and other current assets5 
Product brand intangible assets (estimated useful life 7 years)
159 
Accounts payable(1)
Accrued expenses(17)
Total identifiable net assets177 
Goodwill3 
Total fair value of consideration transferred$180 
Goodwill associated with the acquisition of certain assets of Synergy is not deductible for income tax purposes.
Revenue and Operating Results
Revenues associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 were $55 million. Operating results associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 and pro-forma revenues and operating results for the year 2019 were not material. Included in Other expense (income), net for 2019 are acquisition-related costs of $8 million directly related to the acquisition of certain assets of Synergy, which include expenditures for advisory, legal, valuation, accounting and other similar services.
Noncontrolling Interest in Medpharma
On October 16, 2018, using cash on hand, the Company acquired the 40% noncontrolling interest of Medpharma Pharmaceutical & Chemical Industries LLC (“Medpharma”) for $18 million. The difference between the carrying value and the price paid for the noncontrolling interest in Medpharma of $15 million, is a reduction of additional paid-in capital.
There were no other material business combinations in 2020, 2019 or 2018. The measurement period for all acquisitions has closed.
F-23


Option to Purchase All Ophthalmology Assets of Allegro Ophthalmics, LLC ("Allegro")
On September 21, 2020, the Company announced that it had entered into an agreement to acquire an option to purchase all of the ophthalmology assets of Allegro (the "Option"), a privately held biopharmaceutical company focused on the development of therapies that regulate integrin functions for the treatment of ocular diseases. Among the assets to be acquired if the Option is exercised, is the worldwide rights to risuteganib (Luminate®), Allegro's lead investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry Age-related Macular Degeneration ("AMD"). A U.S. Phase 2a study with risuteganib in intermediate dry AMD met its primary endpoint of vision recovery and Phase 3 testing is in the planning stages. The aggregate payments to acquire the Option are $50 million and include an upfront payment of $10 million and a second payment of $40 million should Allegro raise additional funding. During the three months ended September 30, 2020, the Company made and expensed the upfront payment of $10 million as acquired IPR&D included in Other expense (income), net. If the Option is exercised, additional payments to acquire all ophthalmology assets of Allegro will be due.
Licensing Agreements
In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. The commitment periods under these agreements vary and include customary termination provisions. Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.
Assets Held for Sale
During the three months ended December 31, 2020, the Company identified for disposal a certain business within the Bausch + Lomb/International segment. This business was classified as held for sale as of December 31, 2020.
The carrying amounts of the assets and liabilities held for sale included in the Consolidated Balance Sheet as of December 31, 2020 are as follows:
(in millions)
Prepaid expenses and other current assets:
Trade receivables, net$91 
Inventories, net63 
Prepaid expenses and other current assets8 
$162 
Other non-current assets:
Property, plant and equipment, net$68 
Goodwill and Intangible assets, net245 
Deferred tax assets, net2 
$315 
Accrued and other current liabilities:
Accounts payable$7 
Accrued and other current liabilities28 
$35 
Other non-current liabilities:
Deferred tax liabilities, net$36 
Other non-current liabilities21 
$57 
Included within Deferred tax liabilities, net, are book to income tax differences related to the Company's intangible assets.
F-24


As a result of meeting the criteria for held for sale classification, the carrying value of this business, was adjusted to its estimated fair value, less costs to sell, and the Company recognized a loss of $96 million within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. This loss was primarily due to the anticipated release of non-cash cumulative foreign currency translation losses of $344 million, which were included as part of the carrying value of this business when measuring for impairment. These losses will be reclassified from Accumulated other comprehensive loss to Net loss upon the disposal of this business.
4.RESTRUCTURING, INTEGRATION AND SEPARATION COSTS
Restructuring and integration costs
The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i) reducing headcount, (ii) eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of December 31, 2020 was $20 million.
During 2020, the Company incurred $11 million of restructuring and integration-related costs. These costs included: (i) $10 million of facility closure costs and (ii) $1 million of severance and other costs. The Company made payments of $18 million during 2020.
During 2019, the Company incurred $31 million of restructuring and integration costs. These costs included: (i) $11 million of severance costs and other costs associated with the acquisition of certain assets of Synergy, (ii) $11 million of facility closure costs and (iii) $9 million of other severance costs. The Company made payments of $31 million during 2019.
During 2018, the Company incurred $22 million of restructuring and integration costs. These costs included: (i) $11 million of severance costs, (ii) $10 million of facility closure costs and (iii) $1 million of other costs. The Company made payments of $33 million during 2018.
Separation costs and separation-related costs
The Company has incurred, and will incur, costs associated with activities to effectuate the Separation. These activities include: (i) separating the eye-health business from the remainder of the Company and (ii) registering the eye-health business as an independent publicly traded entity. Separation costs are incremental costs directly related to the Separation and include, but are not limited to: (i) legal, audit and advisory fees, (ii) employee hiring, relocation and travel costs and (iii) costs associated with establishing a new board of directors and audit committee. Included in Restructuring, integration and separation costs for 2020 is $11 million of separation costs.
The Company has also incurred, and will incur, separation-related costs which are incremental costs indirectly related to the Separation. Separation-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative expenses for 2020 is $21 million of separation-related costs.
The Company is in the planning phase of the Separation and the extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.
5.FAIR VALUE MEASUREMENTS
Fair value measurements are estimated based on valuation techniques and inputs categorized as follows:
Level 1 — Quoted prices in active markets for identical assets or liabilities;
Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
Level 3 — Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.
If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
F-25


Assets and Liabilities Measured at Fair Value on a Recurring Basis
The following fair value hierarchy table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a recurring basis as of:
 December 31, 2020December 31, 2019
 (in millions)Carrying
Value
Level 1Level 2Level 3Carrying
Value
Level 1Level 2Level 3
Assets:        
Cash equivalents$41 $8 $33 $ $2,696 $2,646 $50 $ 
Restricted Cash$1,211 $1,211 $ $ $1 $1 $ $ 
Foreign currency exchange contracts$3 $ $3 $ $ $ $ $ 
Liabilities:    
Acquisition-related contingent consideration
$328 $ $ $328 $316 $ $ $316 
Cross-currency swaps
$70 $ $70 $ $13 $ $13 $ 
Foreign currency exchange contracts$11 $ $11 $ $ $ $ $ 
Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.
As of December 31, 2020, Restricted cash includes $1,210 million of payments into an escrow fund under the terms of a settlement agreement regarding certain U.S. securities litigation, subject to an objector's appeal of the final court approval, and is reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to its short-term nature. These payments will remain in escrow until final approval of the settlement as discussed in Note 20, "LEGAL PROCEEDINGS".
There were no transfers into or out of Level 3 during 2020 and 2019.
Cross-currency Swaps
During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,250 million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from adverse movements in exchange rates. The euro-denominated net investment being hedged is the Company’s investment in certain euro-denominated subsidiaries. Prior to 2019, the Company had no cross-currency swaps.
The fair value of the Company’s cross-currency swaps liability as of December 31, 2020 and 2019 was $70 million and $13 million, respectively. Included in Other non-current liabilities is $79 million and $22 million of cross-currency swaps and included in Prepaid expenses and other current assets is $9 million and $9 million of earned interest within the Consolidated Balance Sheets as of December 31, 2020 and 2019, respectively.
The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for 2020 and 2019:
(in millions)20202019
Loss recognized in Other comprehensive loss$(57)$(22)
Gain excluded from assessment of hedge effectiveness$23 $9 
Location of gain of excluded componentInterest Expense
Settlement of the Company's cross-currency swaps occurs in February and August each year. During 2020, the Company received $23 million in settlements which are reported as Investing activities in the Consolidated Statements of Cash Flows.
Foreign Currency Exchange Contracts
During 2020, the Company entered into foreign currency exchange contracts, with an aggregate notional amount of $485 million. Prior to 2020, the Company had no foreign currency exchange contracts for any period presented.
The fair value of the Company's foreign currency exchange contracts liability as of December 31, 2020 was $8 million. Included in Accrued and other current liabilities are $11 million and included in Prepaid expenses and other current assets are $3 million of foreign currency exchange contracts within the Consolidated Balance Sheets. During 2020, the net change
F-26


in fair value was a loss of $8 million. Settlements of the Company's foreign currency exchange contracts are reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Consolidated Statements of Cash Flows. During 2020, the Company reported a realized loss of $2 million related to settlements of the Company's foreign currency exchange contracts.
Acquisition-related Contingent Consideration Obligations
The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level 3) inputs. These inputs may include: (i) the estimated amount and timing of projected cash flows, (ii) the probability of the achievement of the factor(s) on which the contingency is based and (iii) the risk-adjusted discount rate used to present value the probability-weighted cash flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At December 31, 2020, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 25%, and a weighted average risk-adjusted discount rate of 8%. The weighted average risk-adjusted discount rate was calculated by weighting each contract's relative fair value at December 31, 2020.
The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3) for the years 2020 and 2019:
(in millions)20202019
Beginning balance, January 1, $316 $339 
Adjustments to Acquisition-related contingent consideration:
Accretion for the time value of money$23 $22 
Fair value adjustments25 (10)
Acquisition-related contingent consideration adjustments48 12 
Payments / Settlements(36)(36)
Foreign currency translation adjustment included in other comprehensive loss 1 
Ending balance, December 31,328 316 
Current portion112 54 
Non-current portion$216 $262 
Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis
The following table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a non-recurring basis:
 December 31, 2020December 31, 2019
(in millions)Carrying
Value
Level 1Level 2Level 3Carrying
Value
Level 1Level 2Level 3
Other non-current assets:
Non-current assets held for sale$245 $ $ $245 $39 $ $ $39 
Non-current assets held for sale of $245 million as of December 31, 2020 were remeasured to estimated fair value, less costs to sell, which utilized Level 3 unobservable inputs. See Note 3, "ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE" for additional details regarding these assets held for sale.
In 2019, the Company identified certain products in the Bausch + Lomb/International segment and one product in the Diversified Products segment for disposal. The products and the related assets and liabilities of this disposal group qualified as a business and an impairment of $8 million associated with this business was recognized during the three months ended September 30, 2019. As a result of changing business dynamics, during the three months ended March 31, 2020, the Company decided not to sell these assets and reclassified $39 million of held for sale assets as assets held and used at their respective fair values at the date of the decision not to sell. This reclassification did not impact the Consolidated Statement of Operations for 2020.
Fair Value of Long-term Debt
The fair value of long-term debt as of December 31, 2020 and 2019 was $25,378 million and $27,520 million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2).
F-27


6.INVENTORIES
Inventories, net, as of December 31, 2020 and 2019 consist of:
(in millions)20202019
Raw materials$286 $319 
Work in process143 149 
Finished goods665 639 
$1,094 $1,107 
7.PROPERTY, PLANT AND EQUIPMENT
The major components of property, plant and equipment as of December 31, 2020 and 2019 consist of:
(in millions)20202019
Land$79 $79 
Buildings and improvements686 696 
Machinery and equipment1,722 1,606 
Other equipment and leasehold improvements360 369 
Equipment on operating lease65 56 
Construction in progress436 301 
3,348 3,107 
Accumulated depreciation(1,781)(1,641)
$1,567 $1,466 
Depreciation expense was $180 million, $178 million and $175 million for 2020, 2019 and 2018, respectively.
8.INTANGIBLE ASSETS AND GOODWILL
Intangible Assets
The major components of intangible assets as of December 31, 2020 and 2019 consist of:
 Weighted-
Average
Remaining
Useful
Lives
(Years)
20202019
(in millions)Gross
Carrying
Amount
Accumulated
Amortization and Impairments
Net
Carrying
Amount
Gross
Carrying
Amount
Accumulated
Amortization and Impairments
Net
Carrying
Amount
Finite-lived intangible assets:
       
Product brands6$20,890 $(14,914)$5,976 $21,011 $(13,544)$7,467 
Corporate brands7907 (404)503 930 (338)592 
Product rights/patents33,305 (3,055)250 3,297 (2,887)410 
Partner relationships1169 (168)1 166 (165)1 
Technology and other3210 (200)10 209 (189)20 
Total finite-lived intangible assets25,481 (18,741)6,740 25,613 (17,123)8,490 
Acquired IPR&D not in serviceNA7 — 7 13 — 13 
B&L TrademarkNA1,698 — 1,698 1,698 — 1,698 
 $27,186 $(18,741)$8,445 $27,324 $(17,123)$10,201 
Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments, including loss on assets held for sale in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present.
Asset impairments, including loss on assets held for sale in 2020 included impairments of: (i) $96 million to reduce the carrying value of a business within the Bausch + Lomb/International segment to its estimated fair value less costs to sell due to classifying the business as held for sale as discussed in Note 3, "ACQUISITIONS, LICENSING AGREEMENTS
F-28


AND ASSETS HELD FOR SALE", (ii) $16 million in aggregate, due to decreases in forecasted sales of certain product lines, (iii) $1 million in aggregate, related to the discontinuance of certain product lines not aligned with the focus of the Company's core businesses and (iv) $1 million related to Acquired IPR&D not in service.
Asset impairments, including loss on assets held for sale in 2019 included impairments of: (i) $58 million reflecting decreases in forecasted sales of certain product lines due to generic competition and other factors, (ii) $8 million related to assets being classified as held for sale, (iii) $5 million related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses and (iv) $4 million related to Acquired IPR&D not in service.
Asset impairments, including loss on assets held for sale in 2018 included impairments of: (i) $263 million reflecting decreases in forecasted sales for the Uceris® Tablet product in the Company's Salix reporting unit due to generic competition, (ii) $85 million reflecting decreases in forecasted sales of certain other product lines due to generic competition, (iii) $132 million reflecting decreases in forecasted sales for the Arestin® product in the Company's Dentistry reporting unit and other product lines due to changing market conditions, (iv) $55 million, in aggregate, related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses, (v) $28 million to Acquired IPR&D not in service related to a certain product and (vi) $5 million related to assets being classified as held for sale.
The impairments to assets reclassified as held for sale were measured as the difference of the carrying value of these assets as compared to the estimated fair values of these assets less costs to sell determined using a discounted cash flow analysis which utilized Level 3 unobservable inputs. The other impairments and adjustments to finite-lived intangible assets were measured as the difference of the historical carrying value of these finite-lived assets as compared to the estimated fair value as determined using a discounted cash flow analysis using Level 3 unobservable inputs.
Periodically, the Company’s products face the expiration of their patent or regulatory exclusivity. The Company anticipates that product sales for such product would decrease shortly following a loss of exclusivity ("LOE"), due to the possible entry of a generic competitor. Where the Company has the rights, it may elect to launch an authorized generic of such product (either as the Company’s own branded generic or through a third-party). This may occur prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product could still be significant, and the effect on future revenues could be material.
Management continually assesses the useful lives related to the Company's long-lived assets to reflect the most current assumptions.
Effective September 12, 2018, the Company changed the estimated useful life of its Xifaxan®-related intangible assets due to the positive impact of an agreement between the Company and Actavis Laboratories FL, Inc. ("Actavis") resolving the intellectual property litigation regarding Xifaxan® tablets, 550 mg. Under the agreement, the parties agreed to dismiss all litigation related to Xifaxan® tablets, 550 mg and all intellectual property protecting Xifaxan® will remain intact and enforceable. As a result, the useful life of the Xifaxan®-related intangible assets was extended from 2024 to January 1, 2028. As this change in the estimated useful life is a change in an accounting estimate, amortization expense is impacted prospectively. The change in the estimated useful life of the Xifaxan®-related intangible assets resulted in a decrease to the Net loss attributable to Bausch Health Companies Inc. of $476 million, $473 million and $143 million, and a decrease to the Basic and Diluted Loss per share attributable to Bausch Health Companies Inc. of $1.34, $1.34 and $0.41 for the years 2020, 2019 and 2018, respectively. As of December 31, 2020, the net carrying value of the Xifaxan®-related intangible assets was $3,771 million.
Estimated amortization expense of finite-lived intangible assets for the five years ending December 31 and thereafter are as follows:
(in millions)20212022202320242025ThereafterTotal
Amortization$1,389 $1,204 $1,030 $905 $822 $1,390 $6,740 
F-29


Goodwill
The changes in the carrying amounts of goodwill during the years ended December 31, 2020, 2019 and 2018 were as follows:
(in millions)Bausch +
Lomb/
International
Branded RxU.S. Diversified ProductsSalixOrtho DermatologicsDiversified ProductsTotal
Balance, January 1, 2018$6,016 $6,631 $2,946 $— $— $— $15,593 
Impairment of the Salix and Ortho Dermatologics reporting units
— (2,213)— — — — (2,213)
Realignment of Global Solta reporting unit goodwill
(82)115 (33)— — — — 
Goodwill reclassified to assets held for sale and subsequently disposed
(2)— — — — — (2)
Realignment of segment goodwill
— (4,533)(2,913)3,156 1,267 3,023 — 
Impairment of the Dentistry reporting unit
— — — — — (109)(109)
Foreign exchange and other(127)— — — — — (127)
Balance, December 31, 20185,805   3,156 1,267 2,914 13,142 
Acquisition of certain assets of Synergy
— — — 3 — — 3 
Goodwill reclassified to assets held for sale (Note 5)(18)— — — — — (18)
Foreign exchange and other(1)— — — — — (1)
Balance, December 31, 20195,786   3,159 1,267 2,914 13,126 
Assets held for sale reclassified to goodwill (Note 5)18 — — — — — 18 
Goodwill reclassified to assets held for sale (Note 3)(217)— — — — — (217)
Foreign exchange and other117 — — — — — 117 
Balance, December 31, 2020$5,704 $ $ $3,159 $1,267 $2,914 $13,044 
Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1).
The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit's terminal value.
To forecast a reporting unit's cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management's and a market participant's view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected LOE to the Company's product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company’s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future.
F-30


2018
Adoption of New Accounting Guidance for Goodwill Impairment Testing
Effective January 1, 2018, the Company elected to early adopt a new accounting standard which simplifies the subsequent measurement of goodwill by eliminating “Step 2” from the goodwill impairment test. Goodwill impairment is now measured as the amount by which a reporting unit's carrying value exceeds its fair value. Upon adopting the new standard, the Company tested goodwill for impairment and determined that the carrying value of the Salix reporting unit exceeded its fair value resulting in the Company recognizing a goodwill impairment of $1,970 million associated with the Salix reporting unit.
The Company conducted its 2017 annual goodwill impairment test as of October 1, 2017 and determined that the fair value of the Ortho Dermatologics reporting unit exceeded its carrying value. However, at January 1, 2018, unforeseen changes in the business dynamics of the Ortho Dermatologics reporting unit, such as: (i) changes in the dermatology sector, (ii) increased pricing pressures from third-party payors, (iii) additional risks to the exclusivity of certain products and (iv) an expected longer launch cycle for a new product, were factors that negatively impacted the reporting unit's operating results beyond management's expectations as of October 1, 2017. In response to these adverse business indicators, as of January 1, 2018, the Company reduced its near and long term financial projections for the Ortho Dermatologics reporting unit. As a result of the reductions in the near and long term financial projections, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at January 1, 2018 and the Company recognized a goodwill impairment of $243 million.
2018 Realignment of Solta Business
Effective March 1, 2018, revenues and profits from the U.S. Solta business included in the former U.S. Diversified Products segment in prior periods and revenues and profits from the international Solta business included in the Bausch + Lomb/International segment in prior periods, are reported in a new Global Solta reporting unit, which, at that time, was a part of the former Branded Rx segment. As a result of this change, $115 million of goodwill was reallocated to the new Global Solta reporting unit and the Company assessed the impact on the fair values of each of the reporting units affected. After considering, among other matters: (i) the limited period of time between last impairment test (January 1, 2018) and the realignment (March 1, 2018), (ii) the results of the last impairment test and (iii) the amount of goodwill reallocated to the new Global Solta reporting unit, the Company did not identify any indicators of impairment at the time of the realignment.
2018 Realignment of Segment Structure
In the second quarter of 2018, the Company began operating in the following reportable segments: (i) Bausch + Lomb/International segment, (ii) Salix segment, (iii) Ortho Dermatologics segment and (iv) Diversified Products segment. The Bausch + Lomb/International segment consists of the: (i) U.S. Bausch + Lomb and (ii) International reporting units. The Salix segment consists of the Salix reporting unit. The Ortho Dermatologics segment consists of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. There was no triggering event which would require the Company to test goodwill for impairment as a result of the second quarter realignment of the segment structure as it did not result in a change in the reporting units.
2018 Annual Goodwill Impairment Test
The Company conducted its 2018 annual goodwill impairment test as of October 1, 2018 and determined that the carrying value of the Dentistry reporting unit exceeded its fair value and, as a result, the Company recognized a goodwill impairment of $109 million, representing the full amount of goodwill for the Dentistry reporting unit. Changing market conditions such as: (i) an increasing competitive environment and (ii) increasing pricing pressures negatively impacted the reporting unit's operating results.
The Company's remaining reporting units passed the goodwill impairment test as the estimated fair value of each reporting unit exceeded its carrying value at the date of testing and, therefore, there was no impairment to goodwill for any reporting unit other than the Dentistry reporting unit. In order to evaluate the sensitivity of its fair value calculations on the goodwill impairment test, the Company compared the carrying value of each reporting unit to its fair value as of October 1, 2018, the date of testing. As of October 1, 2018, the fair value of each reporting unit with associated goodwill exceeded its carrying value by more than 15%.
F-31


2019
2019 Annual Goodwill Impairment Test
The Company conducted its annual goodwill impairment test as of October 1, 2019 by first assessing qualitative factors. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. In each quantitative fair value test performed, the fair value was greater than the carrying value of the reporting unit. As a result, there was no impairment to the goodwill of any reporting unit.
2020
2020 Interim Goodwill Impairment Assessment
In response to the COVID-19 pandemic, the Company has taken actions to protect its employees, customers and other stakeholders and mitigate the negative impact of the COVID-19 pandemic on its operations and operating results. These and additional actions can increase the costs of doing business during the pandemic and, in the periods that follow, may include the costs of idling and reopening certain facilities in affected areas. Further, social restrictions and other precautionary measures taken by customers, health care patients and consumers in response to the pandemic are expected to impact the timing and amount of revenues during the COVID-19 pandemic. Although the Company's revenues for 2020 were less than those forecasted on the date goodwill was last tested for impairment (October 1, 2019), there were no indications that these trends are materially related to developments other than the COVID-19 pandemic.
The negative impacts of the COVID-19 pandemic on the global economy have led to significant volatility in the global equity markets. The Company has been able to continue its operations with limited disruptions and has assessed the potential impact that the COVID-19 pandemic is likely to have on its forecasted cash flows. In performing its assessment, the Company considered the possible affects and outcomes of the COVID-19 pandemic on, among other things, its supply chain, customers and distributors, employee base, product sustainability, research and development activities, product pipeline and consumer demand and related rebates and discounts and has made adjustments, although not considered to be material, to its long-term forecasts as of October 1, 2019 (the date goodwill was last tested for impairment) for these and other matters. After completing this assessment, although not completely insulated from the negative effects of the COVID-19 pandemic, the Company believes that its long-term forecasted cash flows, as adjusted for the possible outcome of the COVID-19 pandemic and other matters, do not indicate that the fair value of any reporting unit may be below its carrying value.
During the pandemic, the public has been advised to engage in certain "social restrictions" such as: (i) remaining at home or shelter-in-place, (ii) limiting social interaction, (iii) closing non-essential businesses and (iv) postponing certain surgical and elective medical procedures in order to prioritize/conserve available health care resources. During the three months ended March 31, 2020, these factors negatively impacted, most notably, the revenues of the Company's Global Vision Care and Global Surgical businesses in Asia where the COVID-19 pandemic originated. Beginning in March 2020, and throughout most of the second quarter of 2020, the Company experienced steeper declines in these revenues and the revenues of other businesses as social restrictions expanded worldwide, particularly in the U.S. and Europe. Social restrictions negatively impacted the Company's revenues for contact lenses, intraocular lenses, medical devices, surgical systems and certain pre- and post-operative eye-medications of its Global Ophtho Rx business, medical aesthetics and therapeutic products of its Global Solta business, and certain branded pharmaceutical products of its Salix, Ortho Dermatologics and Dentistry businesses, as the offices of many health care providers were closed and certain surgeries and elective medical procedures were deferred.
The Company's 2020 revenues were most negatively impacted during its second quarter by the social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize prior to the third quarter. Revenues for the three months ended December 31, 2020 and 2019 were $2,213 million and $2,224 million, respectively, a decrease of $11 million. This decrease of less than 1% represents a continuing improving trend over the decreases in year-over-year revenues for the three month periods ended June 30, 2020 and September 30, 2020 of 23% and 3%, respectively. Presuming there continues to be increased availability of effective vaccines and any further resurgence of the COVID-19 virus and variant strains thereof do not have a material adverse impact on efforts to contain the COVID-19 virus, the Company anticipates an ongoing, gradual global recovery from the macroeconomic and health care impacts of the pandemic that occurred during the first-half of 2020 and anticipates that its affected businesses could return to pre-pandemic levels during 2021. However, the rates of recovery for each business will vary by geography and will be dependent upon, among other things, the availability and effectiveness of vaccines for the COVID-19 virus, government
F-32


responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus and other actions taken in response to the COVID-19 pandemic.
On a quarterly basis, using its latest forecasts of cash flows, the Company gave consideration to the nature and timing of the expected revenue losses discussed above. No events occurred or circumstances changed during the period October 1, 2019 through September 30, 2020 that would indicate that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, might be below its carrying value. The changes in the amounts and timing of revenues as presented in the Company's latest forecasts included a range of potential outcomes and, with the exception of the Ortho Dermatologics reporting unit as discussed below, were not substantial enough to materially adversely affect the recoverability of any of the associated reporting units’ assets and were not material enough to indicate that the fair values of those reporting units might be below their respective carrying values. However, based on the results of the October 1, 2019 annual goodwill impairment test, the Company continued to assess the performance of the Ortho Dermatologics reporting unit and the Neuro and Other reporting unit on a quarterly basis throughout 2020.
2020 Interim Goodwill Impairment Assessments - Neuro and Other
As part of its quarterly qualitative interim assessments of the Neuro and Other reporting unit, management considered the totality of all relevant events or circumstances that could have affected the carrying amount or fair value of the reporting unit, including comparing the reporting unit’s operating results to the forecast used to test the goodwill of the Neuro and Other reporting unit as of October 1, 2019. Based on the qualitative assessments, management believed that the carrying value of Neuro and Other reporting unit did not exceed its fair value and, therefore, concluded a quantitative fair value test was not required for any quarterly period.
2020 Interim Goodwill Impairment Assessments and Testing - Ortho Dermatologics
During the three months ended March 31, 2020, the operating results for the Ortho Dermatologics reporting unit were less than those forecasted at October 1, 2019 for that period. As part of its qualitative assessment as of March 31, 2020, the Company revised its forecasts for the year 2020, for among other matters, the lower than originally forecasted operating results for the three months ended March 31, 2020 and the range of potential impacts of the COVID-19 pandemic, including longer than expected launch cycles for certain new products. Management believed that the revisions to its forecasts for the year 2020 were indicators that there was less headroom as of March 31, 2020 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2019). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed at March 31, 2020. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit continued to be greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit at March 31, 2020.
During the three months ended June 30, 2020, the Company identified certain Ortho Dermatologics’ products that were experiencing longer launch cycles than originally anticipated due to the COVID-19 pandemic and, as a direct result, took actions to mitigate the impact of these matters, including right-sizing its Ortho Dermatologics’ sales force. As part of its qualitative assessment as of June 30, 2020, the Company revised its long-term forecasts for, among other matters, the decrease in forecasted revenues of the identified products, the reduction in sales force and related costs and a range of potential impacts of COVID-19 pandemic related matters. Management believed that these events were indicators that there was less headroom as of June 30, 2020 as compared to the headroom calculated on the date Ortho Dermatologics goodwill was last tested for impairment (March 31, 2020). Therefore, a quantitative fair value test for impairment to the goodwill of the Ortho Dermatologics reporting unit was performed at June 30, 2020. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit continued to be greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit at June 30, 2020.
Management believed that based on its qualitative assessments as of September 30, 2020, it was more likely than not that the carrying amount of the Ortho Dermatologics reporting unit was less than its fair value and, therefore, concluded a quantitative fair value test was not required at September 30, 2020.
2020 Annual Goodwill Impairment Test
The Company conducted its annual goodwill impairment test as of October 1, 2020 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2020, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded a quantitative fair value test for those reporting units was not required.
F-33


As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2020, the Company considered, among other matters, a range of potential impacts of COVID-19 pandemic related matters and the limited headroom calculated on the date Ortho Dermatologics goodwill was last tested for impairment (June 30, 2020). The Company believed that these factors may suggest that it is more likely than not that the fair value of the Ortho Dermatologics reporting unit is less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit.
The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2020, utilizing a long-term growth rate of 2.0% and a range of discount rates between 9.5% and 9.75%, in estimation of the fair value of this reporting unit. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit. If market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future. Specifically, the Company continues to assess the performance of the Ortho Dermatologics reporting unit as compared to its respective projections and will perform qualitative interim assessments of the carrying value and fair value on a quarterly basis to determine if impairment testing of goodwill will be warranted.
In addition, the Company expects to realign and begin managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Separation during the first quarter of 2021, and as a result the Company may need to perform an impairment test upon realignment of its operating segments.
Accumulated goodwill impairment charges through December 31, 2020 were $3,711 million.
9.ACCRUED AND OTHER CURRENT LIABILITIES
Accrued and other current liabilities as of December 31, 2020 and 2019 consist of:
(in millions)20202019
Legal matters and related fees$1,672 $1,397 
Product rebates747 898 
Product returns575 691 
Interest341 305 
Employee compensation and benefit costs316 304 
Income taxes payable158 196 
Other767 720 
$4,576 $4,511 
F-34


10.FINANCING ARRANGEMENTS
Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2020 and 2019 consists of the following:
20202019
(in millions)MaturityPrincipal AmountNet of Premiums, Discounts and Issuance CostsPrincipal AmountNet of Premiums, Discounts and Issuance Costs
Senior Secured Credit Facilities:
2023 Revolving Credit FacilityJune 2023$ $ $ $ 
June 2025 Term Loan B FacilityJune 20253,298 3,220 3,869 3,768 
November 2025 Term Loan B FacilityNovember 20251,125 1,112 1,275 1,257 
Senior Secured Notes:
6.50% Secured Notes
March 2022  1,250 1,242 
7.00% Secured Notes
March 20242,000 1,987 2,000 1,983 
5.50% Secured Notes
November 20251,750 1,736 1,750 1,733 
5.75% Secured Notes
August 2027500 494 500 493 
Senior Unsecured Notes: 
5.50%
March 2023  402 400 
5.875%
May 2023  1,448 1,441 
4.50% euro-denominated debt
May 2023  1,682 1,674 
6.125%
April 20253,250 3,234 3,250 3,230 
9.00%
December 20251,500 1,478 1,500 1,473 
9.25%
April 20261,500 1,487 1,500 1,484 
8.50%
January 20271,750 1,755 1,750 1,756 
7.00%
January 2028750 742 750 741 
5.00%
January 20281,250 1,236 1,250 1,234 
6.25%
February 20291,500 1,480   
5.00%
February 20291,000 988   
7.25%
May 2029750 741 750 740 
5.25%
January 20301,250 1,235 1,250 1,234 
5.25%
February 20311,000 988   
OtherVarious12 12 12 12 
Total long-term debt and other $24,185 23,925 $26,188 25,895 
Less: Current portion of long-term debt and other 1,234 
Non-current portion of long-term debt  $23,925 $24,661 
Covenant Compliance
The Senior Secured Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes and Senior Unsecured Notes contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company’s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of December 31, 2020, the amount available for restricted payments under the "builder basket" in the Company’s most restrictive indentures (as defined by those indentures) was approximately $13,000 million (although such availability is subject to the Company's compliance with a 2.00:1.00 fixed charge coverage ratio). The 2023 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that requires the Company to maintain a first lien net leverage ratio of not greater than 4.00:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.
F-35


As of December 31, 2020, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period.
The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company’s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.
Senior Secured Credit Facilities
On February 13, 2012, the Company and certain of its subsidiaries as guarantors entered into the “Senior Secured Credit Facilities” under the Company’s Third Amended and Restated Credit and Guaranty Agreement, as amended (the “Third Amended Credit Agreement”) with a syndicate of financial institutions and investors, as lenders. As of January 1, 2018, the Third Amended Credit Agreement provided for: (i) a $1,500 million Revolving Credit Facility maturing on April 20, 2020 (the "2020 Revolving Credit Facility") and (ii) a $3,521 million term loan under the Company's Series F Tranche B Term Loan Facility maturing in 2022 (the “Series F Tranche B Term Loan Facility”). There was $250 million outstanding under the 2020 Revolving Credit Facility as of January 1, 2018.
2018 Activity
During 2018, the Company repaid (net of additional borrowings) $571 million of outstanding debt under its Senior Secured Credit Facilities using cash on hand.
On June 1, 2018, the Company entered into a Restatement Agreement in respect of a Fourth Amended and Restated Credit and Guaranty Agreement (the “Restated Credit Agreement”) which restated in full the Third Amended Credit Agreement. The Restated Credit Agreement replaced the 2020 Revolving Credit Facility with a revolving credit facility of $1,225 million (the "2023 Revolving Credit Facility") and replaced the Series F Tranche B Term Loan Facility principal amount outstanding of $3,315 million with a new seven year Tranche B Term Loan Facility of $4,565 million (the “June 2025 Term Loan B Facility”) borrowed by the Company’s subsidiary, Bausch Health Americas, Inc. ("BHA").
The 2023 Revolving Credit Facility matures on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company or BHA in an aggregate principal amount in excess of $1,000 million. Both the Company and BHA are borrowers with respect to the 2023 Revolving Credit Facility. Borrowings under the 2023 Revolving Credit Facility may be made in U.S. dollars, Canadian dollars or euros.
On June 1, 2018, the Company issued an irrevocable notice of redemption for the remaining outstanding principal amounts of: (i) $691 million of the March 2020 Unsecured Notes (as defined below), (ii) $578 million of 6.75% Senior Unsecured Notes due August 2021 (the “August 2021 Unsecured Notes”), (iii) $550 million of 7.25% Senior Unsecured Notes due July 2022 (the “July 2022 Unsecured Notes”) and (iv) $146 million of 6.375% Senior Unsecured Notes due October 2020 (the March 2020 Unsecured Notes (as defined below), together with the August 2021 Unsecured Notes, the July 2022 Unsecured Notes and the 6.375% Senior Unsecured Notes due October 2020 the “June 2018 Unsecured Refinanced Debt”). On June 1, 2018, using the remaining net proceeds from the June 2025 Term Loan B Facility, the net proceeds from the issuance of $750 million in aggregate principal amount of 8.50% Senior Unsecured Notes due 2027 (the "January 2027 Unsecured Notes") by BHA and cash on hand, the Company prepaid the remaining Series F Tranche B Term Loan Facility and redeemed the June 2018 Unsecured Refinanced Debt at its aggregate redemption price and the indentures governing the June 2018 Unsecured Refinanced Debt were discharged (collectively, the “June 2018 Refinancing Transactions”).
The Restated Credit Agreement was accounted for as a modification of debt, to the extent the June 2018 Unsecured Refinanced Debt was replaced with newly issued debt to the same creditor, and as an extinguishment of debt if: (i) the June 2018 Unsecured Refinanced Debt was replaced with newly issued debt to a different creditor, (ii) a portion of the unamortized deferred financing fees was allocated to debt that was paid down or (iii) the borrowing capacity declined when issuing a new revolving credit facility. The following was accounted for as an extinguishment of debt: (i) the difference between the amounts paid to redeem the June 2018 Unsecured Refinanced Debt and the June 2018 Unsecured Refinanced Debt’s carrying value, (ii) the replacement of the Series F Tranche B Term Loan Facility with the June 2025 Term Loan B Facility to the extent any unamortized deferred financing fees were associated with the portion of the Series F Tranche B Term Loan Facility that was paid down and (iii) the replacement of the 2020 Revolving Credit Facility with the 2023 Revolving Credit Facility to the extent any unamortized deferred financing fees were associated with the decline in borrowing capacity. For amounts accounted for as an extinguishment of debt, the Company incurred a loss on extinguishment of debt of $48 million. Payments made to the lenders and a portion of payments made to third parties of $74 million associated with the June 2018 Refinancing Transactions were capitalized and are being amortized as interest
F-36


expense over the remaining terms of the debt, ranging from 2023 through 2027. Third-party expenses of $4 million associated with the modification of debt were expensed as incurred and included in Interest expense.
On November 27, 2018, the Company entered into the First Incremental Amendment to the Restated Credit Agreement, which provided an additional seven year Tranche B Term Loan Facility of $1,500 million (the "November 2025 Term Loan B Facility") and used the net proceeds, and cash on hand, to repay $1,483 million of 7.50% Senior Unsecured Notes due July 2021 (the “July 2021 Unsecured Notes”) in a tender offer (the "November 2018 Refinancing Transactions"). On December 27, 2018, the Company redeemed, using cash on hand, the remaining outstanding principal amount of $17 million of the July 2021 Unsecured Notes.
The repayment of the July 2021 Unsecured Notes was accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $43 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt’s carrying value. Payments made to the lenders and other third parties of $25 million associated with the issuance of the November 2025 Term Loan B Facility were capitalized and are being amortized as interest expense over the remaining term of the November 2025 Term Loan B Facility.
2019 Activity
During 2019, the Company repaid (net of additional borrowings) $806 million of outstanding debt under its Senior Secured Credit Facilities using cash on hand.
2020 Activity
During 2020, the Company repaid: (i) $471 million of outstanding debt under its Senior Secured Credit Facilities using cash on hand and (ii) $250 million of outstanding debt under its Senior Secured Credit Facilities as part of the May 2020 Refinancing Transactions (as defined below).
As of December 31, 2020, the Company had no outstanding borrowings, $104 million of issued and outstanding letters of credit, and remaining availability of $1,121 million under its 2023 Revolving Credit Facility.
Current Description of Senior Secured Credit Facilities
Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% or (c) the eurocurrency rate (as defined in the Restated Credit Agreement) for a period of one month plus 1.00% (or if such eurocurrency rate shall not be ascertainable, 1.00%) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.
Borrowings under the 2023 Revolving Credit Facility in euros bear interest at a eurocurrency rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), plus an applicable margin.
Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the “Canadian Prime Rate” or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus 1.00% (provided however, that the prime rate shall at no time be less than 0.00%) or (ii) the bankers’ acceptance rate for Canadian dollar deposits in the Toronto interbank market (the “BA rate”) for the interest period relevant to such borrowing (provided however, that the BA rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.
Subject to certain exceptions and customary baskets set forth in the Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the Restated Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights). These mandatory prepayments may be used to satisfy future amortization.
F-37


The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are 2.00% and 1.75%, respectively, with respect to base rate and prime rate borrowings and 3.00% and 2.75%, respectively, with respect to eurocurrency rate and BA rate borrowings. As of December 31, 2020, the stated rates of interest on the Company’s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were 3.15% and 2.90% per annum, respectively.
The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is 5.00% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of December 31, 2020, the aggregate remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities are $405 million through November 1, 2025.
The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are 1.50%-2.00% with respect to base rate or prime rate borrowings and 2.50%-3.00% with respect to eurocurrency rate or BA rate borrowings.  As of December 31, 2020, the stated rate of interest on the 2023 Revolving Credit Facility was 3.15% per annum. In addition, the Company is required to pay commitment fees of 0.25% - 0.50% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.
The Restated Credit Agreement permits the incurrence of incremental credit facility borrowings, up to the greater of $1,000 million and 28.5% of Consolidated Adjusted EBITDA (as defined in the Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.
Senior Secured Notes
The Senior Secured Notes are guaranteed by each of the Company’s subsidiaries that is a guarantor under the Restated Credit Agreement and existing Senior Unsecured Notes (together, the “Note Guarantors”). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company’s obligations under the Restated Credit Agreement under the terms of the indentures governing the Senior Secured Notes.
The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company’s and Note Guarantors’ respective existing and future unsubordinated indebtedness and senior to the Company’s and Note Guarantors’ respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively pari passu with the Company’s and the Note Guarantors’ respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company’s and the Note Guarantors’ respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company’s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company’s debt that is secured by assets that are not collateral.
Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder’s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.
6.50% Senior Secured Notes due 2022 and 7.00% Senior Secured Notes due 2024
In March 2017, the Company issued $1,250 million aggregate principal amount of 6.50% senior secured notes due March 15, 2022 (the “March 2022 Secured Notes”) and $2,000 million aggregate principal amount of 7.00% senior secured notes due March 15, 2024 (the “March 2024 Secured Notes”), in a private placement. Interest on these notes is payable semi-annually in arrears on each March 15 and September 15.
The March 2022 Secured Notes were repaid in full as part of the May 2020 Refinancing Transactions (as defined below).
The March 2024 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time, at the redemption prices set forth in the indenture.
F-38


5.50% Senior Secured Notes due 2025
On October 17, 2017, the Company issued $1,000 million, and, on November 21, 2017, the Company issued $750 million, aggregate principal amount of 5.50% Senior Secured Notes due November 2025 (the “November 2025 Secured Notes”), in a private placement. Interest on the November 2025 Secured Notes is payable semi-annually in arrears on each May 1 and November 1.
The November 2025 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time, at the redemption prices set forth in the indenture.
5.75% Senior Secured Notes due 2027 - March 2019 Refinancing Transactions
On March 8, 2019, BHA and the Company issued: (i) $1,000 million aggregate principal amount of January 2027 Unsecured Notes and (ii) $500 million aggregate principal amount of 5.75% Senior Secured Notes due August 2027 (the "August 2027 Secured Notes"), respectively, in a private placement. A portion of the proceeds and cash on hand were used to: (i) repurchase $584 million of 5.875% Senior Unsecured Notes due 2023 (the "May 2023 Unsecured Notes"), (ii) repurchase $518 million of 5.625% Senior Unsecured Notes due 2021 (the “December 2021 Unsecured Notes”), (iii) repurchase $216 million of 5.50% Senior Unsecured Notes due 2023 (the "March 2023 Unsecured Notes”) and (iv) pay all fees and expenses associated with these transactions (collectively, the “March 2019 Refinancing Transactions”). During April 2019, the Company redeemed $182 million of the December 2021 Unsecured Notes, representing the remaining outstanding principal balance of the December 2021 Unsecured Notes and completing the refinancing of $1,500 million of debt in connection with the March 2019 Refinancing Transactions. The March 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $8 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt’s carrying value. Interest on the August 2027 Secured Notes is payable semi-annually in arrears on each February 15 and August 15.
The August 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after August 15, 2022, at the redemption prices set forth in the indenture. The Company may redeem some or all of the August 2027 Secured Notes prior to August 15, 2022 at a price equal to 100% of the principal amount thereof plus a “make-whole” premium. Prior to August 15, 2022, the Company may redeem up to 40% of the aggregate principal amount of the August 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.
Senior Unsecured Notes
The Senior Unsecured Notes issued by the Company are the Company’s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes.
If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.
5.625% Senior Unsecured Notes due 2021
On December 2, 2013, the Company issued $900 million aggregate principal amount of December 2021 Unsecured Notes in a private placement. The December 2021 Unsecured Notes accrued interest at the rate of 5.625% per year and were subsequently repaid in full: (i) using cash on hand of $200 million in December 2018 and (ii) as part of the March 2019 Refinancing Transactions.
5.50% Senior Unsecured Notes due 2023
On January 30, 2015, the Company issued $1,000 million aggregate principal amount of March 2023 Unsecured Notes in a private placement. The March 2023 Unsecured Notes accrued interest at the rate of 5.50% per year, payable semi-annually in arrears. On March 8, 2019 and May 23, 2019, the Company repurchased $216 million and $382 million of March 2023 Unsecured Notes as part of the March 2019 Refinancing Transactions and the May 2019 Refinancing Transactions (as defined below), respectively. Throughout 2020, the Company repurchased, in aggregate, $169 million of March 2023 Unsecured Notes using cash on hand. The Company repurchased the remaining outstanding balance of $233 million in December 2020 as part of the December 2020 Refinancing Transactions (as defined below).
F-39


5.375% Senior Unsecured Notes due 2020, 5.875% Senior Unsecured Notes due 2023, 4.50% Senior Unsecured Notes due 2023 and 6.125% Senior Unsecured Notes due 2025
On March 27, 2015, VRX Escrow Corp. (the "VRX Issuer"), a newly formed wholly owned subsidiary of the Company, issued $2,000 million aggregate principal amount of 5.375% Senior Unsecured Notes due 2020 (the "March 2020 Unsecured Notes"), $3,250 million aggregate principal amount of 5.875% Senior Unsecured Notes due 2023 (the "May 2023 Unsecured Notes"), €1,500 million aggregate principal amount of 4.50% Senior Unsecured Notes due 2023 (the "Euro Notes”) and $3,250 million aggregate principal amount of 6.125% Senior Unsecured Notes due 2025 (the "April 2025 Unsecured Notes" and, together with the March 2020 Unsecured Notes, the May 2023 Unsecured Notes and the Euro Notes, the "VRX Notes") in a private placement.
The March 2020 Unsecured Notes accrued interest at the rate of 5.375% per year and were repaid in full as part of: (i) the December 2017 Refinancing Transactions (as defined below), (ii) the March 2018 Refinancing Transactions (as defined below) and (iii) the June 2018 Refinancing Transactions. The May 2023 Unsecured Notes and the Euro Notes accrued interest at the rate of 5.875% and 4.50% per year, respectively and were each repaid in full as of December 31, 2020, as discussed below. The April 2025 Unsecured Notes accrue interest at the rate of 6.125% per year, payable semi-annually in arrears.
As part of the June 2018 Refinancing Transactions, the Company repaid the remaining outstanding principal amounts of the March 2020 Unsecured Notes.
On March 8, 2019 and May 23, 2019, the Company repurchased $584 million and $1,118 million of May 2023 Unsecured Notes as part of the March 2019 Refinancing Transactions and the May 2019 Refinancing Transactions (as defined below), respectively, and on October 3, 2019, the Company repaid an additional $100 million of May 2023 Unsecured Notes using cash on hand. On January 16, 2020, the Company redeemed $1,240 million aggregate principal amount of the May 2023 Unsecured Notes as part of the December 2019 Financing and Refinancing Transactions (as defined below). Throughout 2020, the Company repaid, in aggregate, $208 million of the May 2023 Unsecured Notes, with the May 2023 Unsecured Notes having been fully repaid during November 2020.
The Company may redeem all or a portion of the April 2025 Unsecured Notes at the redemption prices set forth in the applicable indenture, plus accrued and unpaid interest to the date of redemption.
On December 3, 2020, the Company redeemed the remaining outstanding balance of the Euro Notes as part of the December 2020 Refinancing Transactions, as defined below.
9.00% Senior Unsecured Notes due 2025
On December 18, 2017, the Company issued $1,500 million aggregate principal amount of 9.00% Senior Unsecured Notes due 2025 (the “December 2025 Unsecured Notes”) in a private placement, the net proceeds of which were used to repurchase $1,500 million in aggregate principal amount of previously outstanding senior unsecured notes (the "December 2017 Refinancing Transactions"). The related fees and expenses were paid using cash on hand. The December 2025 Unsecured Notes accrue interest at the rate of 9.00% per year, payable semi-annually in arrears on each of June 15 and December 15.
The Company may redeem all or a portion of the December 2025 Unsecured Notes at any time prior to December 15, 2021, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a “make-whole” premium. In addition, at any time prior to December 15, 2020, the Company may redeem up to 40% of the aggregate principal amount of the outstanding December 2025 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the December 2025 Unsecured Notes indenture. On or after December 15, 2021, the Company may redeem all or a portion of the December 2025 Unsecured Notes at the applicable redemption prices set forth in the December 2025 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.
9.25% Senior Unsecured Notes due 2026 - March 2018 Refinancing Transactions
On March 26, 2018, BHA issued $1,500 million in aggregate principal amount of 9.25% Senior Unsecured Notes due 2026 (the “April 2026 Unsecured Notes”) in a private placement, the net proceeds of which, and cash on hand, were used to repurchase $1,500 million in aggregate principal amount of unsecured notes. All fees and expenses associated with these transactions were paid with cash on hand (collectively, the “March 2018 Refinancing Transactions”). The March 2018 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $26 million representing the difference between the amount paid to settle the extinguished debt
F-40


and the extinguished debt’s carrying value. The April 2026 Unsecured Notes accrue interest at the rate of 9.25% per year, payable semi-annually in arrears on each of April 1 and October 1.
BHA may redeem all or a portion of the April 2026 Unsecured Notes at any time prior to April 1, 2022, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a “make-whole” premium. In addition, at any time prior to April 1, 2021, BHA may redeem up to 40% of the aggregate principal amount of the outstanding April 2026 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the April 2026 Unsecured Notes indenture. On or after April 1, 2022, BHA may redeem all or a portion of the April 2026 Unsecured Notes at the applicable redemption prices set forth in the April 2026 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.
8.50% Senior Unsecured Notes due 2027 - June 2018 Refinancing Transactions and March 2019 Refinancing Transactions
As part of the June 2018 Refinancing Transactions, BHA issued $750 million in aggregate principal amount of January 2027 Unsecured Notes in a private placement, the net proceeds of which, when combined with the remaining net proceeds from the June 2025 Term Loan B Facility and cash on hand, were used to redeem the June 2018 Unsecured Refinanced Debt at its aggregate redemption price and the indentures governing the June 2018 Unsecured Refinanced Debt were discharged. The January 2027 Unsecured Notes accrue interest at the rate of 8.50% per year, payable semi-annually in arrears on each of January 31 and July 31.
As part of the March 2019 Refinancing Transactions described above, BHA issued $1,000 million aggregate principal amount of 8.50% Senior Unsecured Notes due January 2027. These are additional notes and form part of the same series as BHA’s existing January 2027 Unsecured Notes.
BHA may redeem all or a portion of the January 2027 Unsecured Notes at any time prior to July 31, 2022, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a “make-whole” premium. In addition, at any time prior to July 31, 2021, BHA may redeem up to 40% of the aggregate principal amount of the outstanding January 2027 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the January 2027 Unsecured Notes indenture. On or after July 31, 2022, BHA may redeem all or a portion of the January 2027 Unsecured Notes at the applicable redemption prices set forth in the January 2027 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.
7.00% Senior Unsecured Notes due 2028 and 7.25% Senior Unsecured Notes due 2029 - May 2019 Refinancing Transactions
On May 23, 2019, the Company issued: (i) $750 million aggregate principal amount of 7.00% Senior Unsecured Notes due January 2028 (the "7.00% January 2028 Unsecured Notes") and (ii) $750 million aggregate principal amount of 7.25% Senior Unsecured Notes due May 2029 (the "May 2029 Unsecured Notes"), respectively, in a private placement. The proceeds and cash on hand were used to: (i) repurchase $1,118 million of May 2023 Unsecured Notes, (ii) repurchase $382 million of March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the “May 2019 Refinancing Transactions”). The May 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $32 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt’s carrying value. Interest on the 7.00% January 2028 Unsecured Notes is payable semi-annually in arrears on each January 15 and July 15. Interest on the May 2029 Unsecured Notes is payable semi-annually in arrears on each May 30 and November 30.
The 7.00% January 2028 Unsecured Notes and the May 2029 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 15, 2023 and May 30, 2024, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the 7.00% January 2028 Unsecured Notes or the May 2029 Unsecured Notes prior to January 15, 2023 and May 30, 2024, respectively, at a price equal to 100% of the principal amount thereof plus a “make-whole” premium. Prior to July 15, 2022, and May 30, 2022, the Company may redeem up to 40% of the aggregate principal amount of the 7.00% January 2028 Unsecured Notes or the May 2029 Unsecured Notes, respectively, using the proceeds of certain equity offerings at the redemption price set forth in the respective indenture.
5.00% Senior Unsecured Notes due 2028 and 5.25% Senior Unsecured Notes due 2030 - December 2019 Financing and Refinancing Transactions
On December 30, 2019, the Company issued: (i) $1,250 million aggregate principal amount of 5.00% Senior Unsecured Notes due January 2028 (the "5.00% January 2028 Unsecured Notes") and (ii) $1,250 million aggregate principal amount of 5.25% Senior Unsecured Notes due January 2030 (the "January 2030 Unsecured Notes") in a private placement. The proceeds and cash on hand were used to: (i) redeem $1,240 million of May 2023 Unsecured Notes on January 16, 2020, (ii)
F-41


finance the $1,210 million settlement of certain U.S. Securities litigation as discussed in Note 20, "LEGAL PROCEEDINGS" and (iii) pay all fees and expenses associated with these transactions (collectively, the "December 2019 Financing and Refinancing Transactions"). The redemption of $1,240 million of May 2023 Unsecured notes was accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $24 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value.
Interest on the 5.00% January 2028 Unsecured Notes is payable semi-annually in arrears on each January 30 and July 30. Interest on the January 2030 Unsecured Notes is payable semi-annually in arrears on each January 30 and July 30. The 5.00% January 2028 Unsecured Notes and the January 2030 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 30, 2023 and January 30, 2025, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the 5.00% January 2028 Unsecured Notes or the January 2030 Unsecured Notes prior to January 30, 2023 and January 30, 2025, respectively, at a price equal to 100% of the principal amount thereof plus a “make-whole” premium. Prior to January 30, 2023, the Company may redeem up to 40% of the aggregate principal amount of the 5.00% January 2028 Unsecured Notes or the January 2030 Unsecured Notes using the proceeds of certain equity offerings at the redemption price set forth in the respective indenture.
6.25% Senior Unsecured Notes due 2029 - May 2020 Refinancing Transactions
On May 26, 2020, the Company issued $1,500 million aggregate principal amount of 6.25% Senior Unsecured Notes due February 2029 (the "6.25% February 2029 Unsecured Notes") in a private placement. The proceeds and cash on hand were used to: (i) repurchase $1,250 million aggregate principal amount of the outstanding March 2022 Secured Notes, (ii) prepay $303 million of mandatory amortization scheduled for payment in 2022 under the Company's June 2025 and November 2025 Term Loan B Facilities and (iii) pay all fees and expenses associated with these transactions (collectively, the "May 2020 Refinancing Transactions"). The May 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $27 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The 6.25% February 2029 Unsecured Notes accrue interest at the rate of 6.25% per year, payable semi-annually in arrears on each of February 15 and August 15.
The Company may redeem all or a portion of the 6.25% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a “make-whole” premium. In addition, at any time prior to August 15, 2023, the Company may redeem up to 40% of the aggregate principal amount of the outstanding 6.25% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the 6.25% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the 6.25% February 2029 Unsecured Notes at the applicable redemption prices set forth in the 6.25% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.
5.00% Senior Unsecured Notes due 2029 and 5.25% Senior Unsecured Notes due 2031 – December 2020 Refinancing Transactions
On December 3, 2020, the Company issued $1,000 million aggregate principal amount of 5.00% Senior Unsecured Notes due February 2029 (the "5.00% February 2029 Unsecured Notes") and $1,000 million aggregate principal amount of 5.25% Senior Unsecured Notes due February 2031 (the "February 2031 Unsecured Notes") in a private placement. The aggregate proceeds and cash on hand were used to repurchase the remaining outstanding principal amounts of: (i) €1,500 million of the Euro Notes, (ii) $233 million of the March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the "December 2020 Refinancing Transactions"). The December 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $7 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The 5.00% February 2029 Unsecured Notes accrue interest at the rate of 5.00% per year, payable semi-annually in arrears on each of February 15 and August 15. The February 2031 Unsecured Notes accrue interest at the rate of 5.25% per year, payable semi-annually in arrears on each of February 15 and August 15.
The Company may redeem all or a portion of the 5.00% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a “make-whole” premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to 40% of the aggregate principal amount of the outstanding 5.00% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the 5.00% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the 5.00% February 2029 Unsecured
F-42


Notes at the applicable redemption prices set forth in the 5.00% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.
The Company may redeem all or a portion of the February 2031 Unsecured Notes at any time prior to February 15, 2026, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a “make-whole” premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to 40% of the aggregate principal amount of the outstanding February 2031 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the February 2031 Unsecured Notes indenture. On or after February 15, 2026, the Company may redeem all or a portion of the February 2031 Unsecured Notes at the applicable redemption prices set forth in the February 2031 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.
Weighted Average Stated Rate of Interest
The weighted average stated rate of interest for the Company's outstanding debt obligations as of December 31, 2020 and 2019 was 6.02% and 6.21%, respectively.
Maturities and Mandatory Payments
Maturities and mandatory payments of debt obligations for the five succeeding years ending December 31 and thereafter are as follows:
(in millions)
2021$ 
2022 
2023 
20242,291 
202510,632 
Thereafter11,262 
Total gross maturities24,185 
Unamortized discounts(260)
Total long-term debt and other$23,925 
Under the Restated Credit Agreement, there is no Excess Cash Flow payment due for 2020.
11.PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS
The Company has defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers a closed grandfathered group of legacy Bausch & Lomb Holdings Incorporated (‘‘B&L’’) U.S. employees and employees in certain other countries. The U.S. defined benefit accruals were frozen as of December 31, 2004 and benefits that were earned up to December 31, 2004 were preserved. Participants continue to earn interest credits on their cash balance at an interest crediting rate that is equal to the greater of: (i) the average annual yield on 10-year treasury bonds in effect for the November preceding the plan year or (ii) 4.50%. The most significant non-U.S. plans are two defined benefit plans in Ireland. In 2011, both Ireland defined benefit plans were closed to future service benefit accruals; however, additional accruals related to annual salary increases continued. In December 2014, one of the Ireland defined benefit plans was amended effective August 2014 to eliminate future benefit accruals related to salary increases. All of the pension benefits accrued through the plan amendment date were preserved. As a result of the plan amendment, there are no active plan participants accruing benefits under the amended Ireland defined benefit plan. The U.S. postretirement benefit plan was amended effective January 1, 2005 to eliminate employer contributions after age 65 for participants who did not meet the minimum requirements of age and service on that date. The employer contributions for medical and prescription drug benefits for participants retiring after March 1, 1989 were frozen effective January 1, 2010. Effective January 1, 2014, the Company no longer offers medical and life insurance coverage to new retirees.
In addition to the B&L benefit plans, outside of the U.S., a limited group of the Company's employees are covered by defined benefit pension plans.
The Company uses December 31 as the year-end measurement date for all of its defined benefit pension plans and the postretirement benefit plan.
F-43


Accounting for Pension Benefit Plans and Postretirement Benefit Plan
The Company recognizes in its Consolidated Balance Sheets an asset or liability equal to the over- or under-funded benefit obligation of each defined benefit pension plan and postretirement benefit plan. Actuarial gains or losses and prior service costs or credits that arise during the period but are not recognized as components of net periodic benefit cost are recognized, net of tax, as a component of Other comprehensive income (loss).
The amounts included in Accumulated other comprehensive loss as of December 31, 2020 and 2019 were as follows:
Pension Benefit PlansU.S. Postretirement
Benefit Plan
U.S. PlanNon-U.S. Plans
(in millions)202020192020201920202019
Unrecognized actuarial losses$(21)$(20)$(76)$(65)$(3)$(2)
Unrecognized prior service credits$ $ $27 $26 $11 $14 
Net Periodic (Benefit) Cost
The following table provides the components of net periodic (benefit) cost for the Company’s defined benefit pension plans and postretirement benefit plan in 2020, 2019 and 2018:
 Pension Benefit PlansU.S. Postretirement
Benefit Plan
U.S. PlanNon-U.S. Plans
(in millions)202020192018202020192018202020192018
Service cost$1 $2 $2 $3 $3 $3 $ $ $ 
Interest cost6 8 7 4 5 5 1 1 1 
Expected return on plan assets(13)(13)(15)(5)(5)(5)   
Amortization of net loss   2 1 1    
Amortization of prior service credit   (1)(1)(1)(3)(2)(2)
Other    1     
Net periodic (benefit) cost$(6)$(3)$(6)$3 $4 $3 $(2)$(1)$(1)
F-44


Benefit Obligation, Change in Plan Assets and Funded Status
The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2020 and 2019:
 Pension Benefit PlansU.S. Postretirement
Benefit Plan
U.S. PlanNon-U.S. Plans
(in millions)202020192020201920202019
Change in Projected Benefit Obligation
Projected benefit obligation, beginning of year$227 $214 $259 $235 $41 $41 
Service cost1 2 3 3   
Interest cost6 8 4 5 1 1 
Employee contributions     1 
Settlements  (3)(2)  
Benefits paid(15)(15)(4)(8)(4)(4)
Actuarial losses17 18 13 30 1 2 
Currency translation adjustments  22 (4)  
Projected benefit obligation, end of year236 227 294 259 39 41 
Change in Plan Assets
Fair value of plan assets, beginning of year216 187 161 147   
Actual return on plan assets29 42 11 17   
Employee contributions     1 
Company contributions1 2 8 10 4 3 
Settlements  (2)(2)  
Benefits paid(15)(15)(4)(8)(4)(4)
Currency translation adjustments  15 (3)  
Fair value of plan assets, end of year231 216 189 161   
Funded status, end of year$(5)$(11)$(105)$(98)$(39)$(41)
Recognized as:
Accrued and other current liabilities$ $ $(2)$(2)$(4)$(5)
Other non-current liabilities$(5)$(11)$(103)$(96)$(35)$(36)
A number of the Company’s pension benefit plans were underfunded as of December 31, 2020 and 2019, having accumulated benefit obligations exceeding the fair value of plan assets. Information for the underfunded pension benefit plans is as follows:
U.S. PlanNon-U.S. Plans
(in millions)2020201920202019
Projected benefit obligation$236 $227 $294 $259 
Accumulated benefit obligation236 227 286 251 
Fair value of plan assets231 216 189 161 
The Company’s policy for funding its pension benefit plans is to make contributions that meet or exceed the minimum statutory funding requirements. These contributions are determined based upon recommendations made by the actuary under accepted actuarial principles. In 2021, the Company expects to contribute $0, $10 million and $4 million to the U.S. pension benefit plan, the non-U.S. pension benefit plans and the U.S. postretirement benefit plan, respectively. The Company plans to use postretirement benefit plan assets and cash on hand, as necessary, to fund the U.S. postretirement benefit plan benefit payments in 2021.
F-45


Estimated Future Benefit Payments
Future benefit payments over the next 10 years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows:
(in millions)Pension Benefit PlansU.S. Postretirement
Benefit
Plan
U.S. PlanNon-U.S. Plans
2021$14 $6 $4 
202219 6 4 
202317 7 4 
202417 7 3 
202517 7 3 
2026-203075 42 12 
Assumptions
The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2020, 2019 and 2018 were as follows:
Pension Benefit PlansU.S. Postretirement Benefit Plan
202020192018202020192018
For Determining Net Periodic (Benefit) Cost
U.S. Plans:
Discount rate3.16 %4.25 %3.56 %3.04 %4.16 %3.47 %
Expected rate of return on plan assets6.25 %7.25 %7.50 %   
Rate of compensation increase      
Interest crediting rate5.00 %5.00 %5.00 %
Non-U.S. Plans:
Discount rate1.68 %2.39 %2.29 %
Expected rate of return on plan assets2.98 %3.46 %3.66 %
Rate of compensation increase3.05 %2.89 %2.87 %
Interest crediting rate   
 Pension Benefit PlansU.S. Postretirement Benefit Plan
2020201920202019
For Determining Benefit Obligation
U.S. Plans:
Discount rate2.25 %3.16 %2.09 %3.04 %
Rate of compensation increase    
Interest crediting rate4.75 %5.00 %
Non-U.S. Plans:
Discount rate1.37 %1.68 %
Rate of compensation increase2.60 %3.05 %
Interest crediting rate  
The expected long-term rate of return on plan assets was developed based on a capital markets model that uses expected asset class returns, variance and correlation assumptions. The expected asset class returns were developed starting with current Treasury (for the U.S. pension plan) or Eurozone (for the Ireland pension plans) government yields and then adding corporate bond spreads and equity risk premiums to develop the return expectations for each asset class. The expected asset class returns are forward-looking. The variance and correlation assumptions are also forward-looking. They take into account historical relationships, but are adjusted to reflect expected capital market trends. The expected return on plan assets for the Company’s U.S. pension plan for 2020 was 6.25%. The expected return on plan assets for the Company’s Ireland pension plans was 3.00% for 2020.
F-46


The discount rate used to determine benefit obligations represents the current rate at which the benefit plan liabilities could be effectively settled considering the timing of expected payments for plan participants.
The 2021 expected rate of return for the U.S. pension benefit plan will be 5.00%. The 2021 expected rate of return for the Ireland pension benefit plans will be 2.75%.
Pension Benefit Plans Assets
Pension benefit plan assets are invested in several asset categories. The following presents the actual asset allocation as of December 31, 2020 and 2019:
20202019
U.S. Plan
Cash and cash equivalents1 %1 %
Equity securities39 %55 %
Fixed income securities60 %44 %
Non-U.S. Plans
Cash and cash equivalents3 %6 %
Equity securities28 %25 %
Fixed income securities58 %64 %
Other11 %6 %
The investment strategy underlying pension plan asset allocation is to manage the assets of the plan to provide for the non-current liabilities while maintaining sufficient liquidity to pay current benefits. Pension plan assets are diversified to protect against large investment losses and to reduce the probability of excessive performance volatility. Diversification of assets is achieved by allocating funds to various asset classes and investment styles within asset classes, and retaining investment management firm(s) with complementary investment philosophies, styles and approaches.
The Company’s pension plan assets are managed by outside investment managers using a total return investment approach, whereby a mix of equity and debt securities investments are used to maximize the long-term rate of return on plan assets. A significant portion of the assets of the U.S. and Ireland pension plans have been invested in equity securities, as equity portfolios have historically provided higher returns than debt and other asset classes over extended time horizons. Correspondingly, equity investments also entail greater risks than other investments. Equity risks are balanced by investing a significant portion of plan assets in broadly diversified fixed income securities.
Fair Value of Plan Assets
The Company measured the fair value of plan assets based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. See Note 5, "FAIR VALUE MEASUREMENTS" for details on the Company's fair value measurements based on a three-tier hierarchy.
The table below presents total plan assets by investment category as of December 31, 2020 and 2019 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2020 and 2019.
Pension Benefit Plans - U.S. Plans
December 31, 2020December 31, 2019
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Cash and cash equivalents$2 $ $ $2 $1 $ $ $1 
Commingled funds:    
Equity securities:
U.S. broad market 48  48  64  64 
Emerging markets 9  9  15  15 
Worldwide developed markets 20  20  26  26 
Other assets 14  14  15  15 
Fixed income securities:
Investment grade 138  138  95  95 
$2 $229 $ $231 $1 $215 $ $216 
F-47


Pension Benefit Plans - Non-U.S. Plans
December 31, 2020December 31, 2019
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Cash equivalents$ $5 $ $5 $ $9 $ $9 
Commingled funds:    
Equity securities:
Emerging markets 1  1  2  2 
Worldwide developed markets 51  51  38  38 
Fixed income securities:
Investment grade 6  6  9  9 
Global high yield 1  1  3  3 
Government bond funds1 102  103 1 90  91 
Other assets 20 2 22  8 1 9 
$1 $186 $2 $189 $1 $159 $1 $161 
Cash equivalents consisted primarily of term deposits and money market instruments. The fair value of the term deposits approximates their carrying amounts due to their short term maturities. The money market instruments also have short maturities and are valued using a market approach based on the quoted market prices of identical instruments.
Commingled funds are not publicly traded. The underlying assets in these funds are publicly traded on the exchanges and have readily available price quotes. The Ireland pension plans held approximately 96% and 95% of the non-U.S. commingled funds in 2020 and 2019, respectively. The commingled funds held by the U.S. and Ireland pension plans are primarily invested in index funds.
The underlying assets in the fixed income funds are generally valued using the net asset value per fund share, which is derived using a market approach with inputs that include broker quotes, benchmark yields, base spreads and reported trades.
Defined Contribution Plans
The Company sponsors defined contribution plans in the U.S., Ireland and certain other countries. Under these plans, employees are allowed to contribute a portion of their salaries to the plans, and the Company matches a portion of the employee contributions. The Company contributed $43 million, $41 million and $36 million to these plans during the years ended December 31, 2020, 2019 and 2018, respectively.
12.LEASES
Right-of-use assets and lease liabilities associated with the Company's operating leases are included in the Consolidated Balance Sheet as of December 31, 2020 and 2019 as follows:
(in millions)20202019
Right-of-use assets included in:
Other non-current assets$259 $271 
Lease liabilities included in:
Accrued and other current liabilities$52 $53 
Other non-current liabilities227 240 
Total lease liabilities$279 $293 
As of December 31, 2020 and 2019, the Company's finance leases were not material and for the years 2020 and 2019 sub-lease income and short-term lease expense were not material. Lease expense for the years 2020 and 2019 include:
(in millions)20202019
Operating lease costs$65 $62 
Variable operating lease costs$12 $16 
F-48


Upon adoption of the new standard for accounting for leases on January 1, 2019, the Company elected the modified retrospective approach without revising prior periods. Rent expense related to operating lease agreements was $92 million for 2018.
Other information related to operating leases for 2020 and 2019 is as follows:
(dollars in millions)20202019
Cash paid from operating cash flows for amounts included in the measurement of lease liabilities$74 $73 
Right-of-use assets obtained in exchange for new operating lease liabilities$39 $47 
Weighted-average remaining lease term7.6 years8.2 years
Weighted-average discount rate6.2 %6.2 %
Right-of-use assets obtained in exchange for new operating lease liabilities during the year ended December 31, 2019 of $47 million in the table above does not include $282 million of right-of-use assets recognized upon adoption of the new standard for accounting for leases on January 1, 2019. See Note 2, "SIGNIFICANT ACCOUNTING POLICIES" for further detail regarding the impact of adoption.
As of December 31, 2020, future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as follows:
(in millions)
2021$68 
202253 
202345 
202435 
202534 
Thereafter121 
Total356 
Less: Imputed interest77 
Present value of remaining lease payments279 
Less: Current portion52 
Non-current portion$227 
13.SHARE-BASED COMPENSATION
In May 2014, shareholders approved the Company’s 2014 Omnibus Incentive Plan (the “2014 Plan”) which replaced the Company’s 2011 Omnibus Incentive Plan (the “2011 Plan”) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company’s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares of common stock for issuance under the 2014 Plan.
Effective April 30, 2018, the Company amended and restated the 2014 Plan (the “Amended and Restated 2014 Plan”). The Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Amended and Restated 2014 Plan has been increased by an additional 11,900,000 common shares, as approved by the requisite number of shareholders at the Company’s annual general meeting held on April 30, 2018, (ii) introduction of a $750,000 aggregate fair market value limit on awards (in either equity, cash or other compensation) that can be granted in any calendar year to a participant who is a non-employee director, (iii) housekeeping changes to address recent changes to Section 162(m) of the Internal Revenue Code, (iv) awards are expressly subject to the Company’s clawback policy and (v) awards not assumed or substituted in connection with a Change of Control (as defined in the Amended and Restated 2014 Plan) will only vest on a pro rata basis.
Effective April 28, 2020, the Company further amended and restated the Amended and Restated 2014 Plan (the “Further Amended and Restated 2014 Plan”). The Further Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Further Amended and Restated 2014 Plan has been
F-49


increased by an additional 13,500,000 common shares, as approved by the requisite number of shareholders at the Company’s annual general meeting held on April 28, 2020, (ii) the exercise price of stock options and share appreciation rights (“SARs”) will be based on the closing price of the underlying common shares on the date such stock options or SARs are granted (rather than on the last preceding trading date), (iii) additional provisions clarifying that: (a) stock options and SARs will not be eligible for the payment of dividend or dividend equivalents and (b) the Talent and Compensation Committee of the Board of Directors of the Company cannot, without shareholder approval, seek to effect any repricing of any previously granted “underwater” stock option or SAR and (iv) other housekeeping and/or clerical changes.
Approximately 16,902,000 common shares were available for future grants as of December 31, 2020. The Company uses reserved and unissued common shares to satisfy its obligation under its share-based compensation plans.
The Company has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company’s focus on improving its tangible capital usage and allocation, while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based RSUs and performance-based RSUs. Performance-based RSUs are comprised of: (i) awards that vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (“TSR”) and (ii) awards that vest upon attainment of certain performance targets that are based on the Company’s return on tangible capital (“ROTC”).
The components and classification of share-based compensation expense related to stock options and RSUs for the years 2020, 2019 and 2018 were as follows:
(in millions)202020192018
Stock options$15 $21 $23 
RSUs90 81 64 
Share-based compensation expense$105 $102 $87 
Research and development expenses$11 $9 $9 
Selling, general and administrative expenses94 93 78 
Share-based compensation expense$105 $102 $87 
Stock Options
Stock options granted under the 2011 Plan and the Amended and Restated 2014 Plan generally expire on the fifth or tenth anniversary of the grant date. The exercise price of any stock option granted under the 2011 Plan and the Amended and Restated 2014 Plan will not be less than the closing price per common share on the date of grant. Stock options generally vest 33% and 25% each year over a three-year and four-year period, respectively, on the anniversary of the date of grant.
The fair values of all stock options granted for the years 2020, 2019 and 2018 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:
202020192018
Expected stock option life (years)3.03.03.0
Expected volatility38.7 %46.5 %54.0 %
Risk-free interest rate1.2 %2.5 %2.7 %
Expected dividend yield % % %
The expected stock option life was determined based on historical exercise and forfeiture patterns. The expected volatility was determined based on implied volatility in the market traded options of the Company’s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S. government bonds with maturity dates equal to the expected life of the stock option. The expected dividend yield was determined based on the stock option’s exercise price and expected annual dividend rate at the time of grant.
The Black-Scholes option-pricing model used by the Company to calculate stock option values was developed to estimate the fair value of freely tradeable, fully transferable stock options without vesting restrictions, which significantly differ from the Company’s stock option awards. This model also requires highly subjective assumptions, including future stock price volatility and expected time until exercise, which greatly affect the calculated values.
F-50


The following table summarizes stock option activity during 2020:
(in millions, except per share amounts)OptionsWeighted-
Average
Exercise
Price Per Share
Weighted-
Average
Remaining
Contractual
Term
(Years)
Aggregate
Intrinsic
Value
Outstanding, January 1, 20207.1 $26.99   
Granted2.3 $24.74   
Exercised(0.4)$14.65   
Expired or forfeited(0.3)$72.40   
Outstanding, December 31, 20208.7 $25.59 7.2$14 
Vested and expected to vest, December 31, 20208.2 $25.73 7.1$14 
Vested and exercisable, December 31, 20204.8 $27.74 6.0$11 
The weighted-average fair values of all stock options granted in 2020, 2019 and 2018 were $6.60, $8.45 and $7.83, respectively. The total intrinsic values of stock options exercised in 2020, 2019 and 2018 were $2 million, $3 million and $1 million, respectively. Proceeds received on the exercise of stock options in 2020, 2019 and 2018 were $5 million, $5 million and $2 million, respectively.
As of December 31, 2020, the total remaining unrecognized compensation expense related to non-vested stock options amounted to $10 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.5 years. The total fair value of stock options vested in 2020, 2019 and 2018 were $15 million, $18 million and $17 million, respectively.
RSUs
RSUs generally vest on the first or third anniversary date from the date of grant or 33% a year over a three-year period. Annual RSUs granted to non-management directors vest immediately prior to the next Annual Meeting of Shareholders. Pursuant to the applicable unit agreement, certain RSUs may be subject to the attainment of any applicable performance goals specified by the Board of Directors. If the vesting of the RSUs is conditional upon the attainment of performance goals, any RSUs that do not vest as a result of a determination that the prescribed performance goals failed to be attained will be forfeited immediately upon such determination. RSUs are credited with dividend equivalents, in the form of additional RSUs, when dividends are paid on the Company’s common shares. Such additional RSUs will have the same vesting dates and will vest under the same terms as the RSUs in respect of which such additional RSUs are credited.
To the extent provided for in a RSU agreement, the Company may, in lieu of all or a portion of the common shares which would otherwise be provided to a holder, elect to pay a cash amount equivalent to the market price of the Company’s common shares on the vesting date for each vested RSU. The amount of cash payment will be determined based on the average market price of the Company’s common shares on the vesting date. The Company’s current intent is to settle vested RSUs through the issuance of common shares.
Time-Based RSUs
Each vested time-based RSU represents the right of a holder to receive one of the Company’s common shares. The fair value of each RSU granted is estimated based on the trading price of the Company’s common shares on the date of grant.
The following table summarizes non-vested time-based RSU activity during 2020:
(in millions, except per share amounts)Time-Based
RSUs
Weighted-
Average
Grant-Date
Fair Value Per Share
Non-vested, January 1, 20206.1 $20.54 
Granted3.3 $21.92 
Vested(3.4)$19.37 
Forfeited(0.3)$21.78 
Non-vested, December 31, 20205.7 $21.98 
F-51


As of December 31, 2020, the total remaining unrecognized compensation expense related to non-vested time-based RSUs amounted to $55 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.5 years. The total fair value of time-based RSUs vested in 2020, 2019 and 2018 were $66 million, $34 million and $30 million, respectively.
Performance-Based RSUs
Each vested performance-based RSU represents the right of a holder to receive a number of the Company’s common shares up to a specified maximum. Performance-based RSUs vest upon achievement of certain share price appreciation conditions or attainment of certain performance targets. If the Company’s performance is below a specified performance level, no common shares will be paid.
The fair value of each TSR performance-based RSU granted during 2020, 2019 and 2018 was estimated using a Monte Carlo Simulation model, which utilizes multiple input variables to estimate the probability that the performance condition will be achieved. The fair value of the ROTC performance-based RSUs is estimated based on the trading price of the Company’s common shares on the date of grant. Expense recognized for the ROTC performance-based RSUs in each reporting period reflects the Company’s latest estimate of the number of ROTC performance-based RSUs that are expected to vest. If the ROTC performance-based RSUs do not ultimately vest due to the ROTC targets not being met, no compensation expense is recognized and any previously recognized compensation expense is reversed.
The fair values of TSR performance-based RSUs granted during 2020, 2019 and 2018 were estimated with the following assumptions:
202020192018
Contractual term (years)3.03.03.0
Expected Company share volatility38.6%46.5%54.2%
Risk-free interest rate1.2%2.5%2.7%
The expected company share volatility was determined based on implied volatility in the market traded options of the Company’s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S. government bonds with maturity dates equal to the contractual term of the performance-based RSUs.
The following table summarizes non-vested performance-based RSU activity during 2020:
(in millions, except per share amounts)Performance-based
RSUs
Weighted-
Average
Grant-Date
Fair Value Per Share
Non-vested, January 1, 20202.0 $25.80 
Granted0.9 $26.61 
Vested(0.6)$19.02 
Non-vested, December 31, 20202.3 $28.10 
During 2020, the Company granted approximately 897,000 performance-based RSUs, consisting of approximately 425,000 units of TSR performance-based RSUs with an average grant date fair value of $26.13 per RSU and approximately 472,000 units of ROTC performance-based RSUs with a weighted-average grant date fair value of $27.05 per RSU.
As of December 31, 2020, the total remaining unrecognized compensation expense related to non-vested performance-based RSUs amounted to $22 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.4 years. A maximum of approximately 3,729,000 common shares could be issued upon vesting of the performance-based RSUs outstanding as of December 31, 2020.
In connection with the 2018 grant of long-term incentive awards with an aggregate value of $10 million, approximately 933,000 performance-based RSUs received by the Company’s Chief Executive Officer ("CEO") upon his hire in 2016 were canceled, and the shares underlying those performance-based RSUs were permanently retired and are not available for future grants under the 2014 Plan. The CEO's long-term incentive award was accounted for as an award modification whereby the Company continues to recognize the unamortized compensation associated with the original award plus the incremental fair value of the new award measured at the date of grant, over the vesting period of the new award.
F-52


14.ACCUMULATED OTHER COMPREHENSIVE LOSS
Accumulated other comprehensive loss as of December 31, 2020 and 2019 consists of:
(in millions)20202019
Foreign currency translation adjustment$(2,077)$(2,046)
Pension adjustment, net of tax(56)(40)
Accumulated other comprehensive loss$(2,133)$(2,086)
Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company’s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company’s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.
15.RESEARCH AND DEVELOPMENT
Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs for the years 2020, 2019 and 2018 consists of:
(in millions)202020192018
Product related research and development$420 $434 $376 
Quality assurance32 37 37 
Research and development$452 $471 $413 
16.OTHER EXPENSE (INCOME), NET
Other expense (income), net for the years 2020, 2019 and 2018 consists of:
(in millions)202020192018
Litigation and other matters$422 $1,401 $(27)
Acquired in-process research and development costs32 41 1 
Net (gain) loss on sales of assets(1)(31)6 
Acquisition-related costs 8 1 
Other, net1 (5)(1)
Other expense (income), net$454 $1,414 $(20)
In 2020, Litigation and other matters of $422 million includes net charges related to the U.S. Securities Litigation, the SEC Investigation and the Canadian Securities Litigation and related opt-outs. In 2020, Litigation and other matters also includes an insurance recovery related to a certain litigation matter. In 2019, Litigation and other matters of $1,401 million includes the settlement of a legacy U.S. securities class action matter (which is subject to an objector’s appeal of the final court approval). In 2018, Litigation and other matters of $27 million includes a favorable adjustment of $40 million related to the Salix legacy litigation matter. These matters and other significant matters are discussed in further detail in Note 20, "LEGAL PROCEEDINGS".
In 2020 and 2019, Acquired in-process research and development costs of $32 million and $41 million, primarily consist of costs associated with the upfront payments to enter into certain exclusive licensing agreements. In 2019, Net (gain) loss on sales of assets includes $20 million related to the achievement of a milestone related to a certain product.
17.INCOME TAXES
The components of Loss before benefit from income taxes for 2020, 2019 and 2018 consist of:
(in millions)202020192018
Domestic$(410)$(2,396)$(1,475)
Foreign(524)559 (2,679)
$(934)$(1,837)$(4,154)
F-53


The components of Benefit from income taxes for 2020, 2019 and 2018 consist of:
(in millions)202020192018
Current:   
Domestic$(8)$(12)$ 
Foreign(216)(116)(327)
(224)(128)(327)
Deferred: 
Domestic9 (5)17 
Foreign590 187 320 
599 182 337 
$375 $54 $10 
The Benefit from income taxes differs from the expected amount calculated by applying the Company’s Canadian statutory rate of 26.9% to Loss before benefit from income taxes for 2020, 2019 and 2018 as follows:
(in millions)202020192018
Loss before benefit from income taxes$(934)$(1,837)$(4,154)
Benefit from income taxes
Expected benefit from income taxes at Canadian statutory rate$251 $494 $1,117 
Non-deductible amount of share-based compensation(9)(7)(10)
Adjustments to tax attributes26 (99)(4)
Change in valuation allowance related to foreign tax credits and NOLs
62 21 (3)
Change in valuation allowance on Canadian deferred tax assets and tax rate changes
687 (142)(875)
Change in uncertain tax positions(163)(350)(47)
Foreign tax rate differences(128)186 (3)
Non-deductible portion of Goodwill impairments  (488)
Tax benefit on intra-entity transfers(338) 356 
Other(13)(49)(33)
$375 $54 $10 

F-54


Deferred tax assets and liabilities as of December 31, 2020 and 2019 consist of:
(in millions)20202019
Deferred tax assets:  
Tax loss carryforwards$2,924 $2,911 
Provisions1,004 641 
Research and development tax credits172 155 
Scientific Research and Experimental Development pool55 52 
Tax credit carryforwards20 25 
Deferred revenue9 5 
Unrealized FX on U.S. dollar debt and other financing cost 94 
Prepaid expenses27 41 
Share-based compensation16 19 
Other24 23 
Total deferred tax assets4,251 3,966 
Less valuation allowance(2,252)(2,831)
Net deferred tax assets1,999 1,135 
Deferred tax liabilities: 
Intangible assets228 53 
Plant, equipment and technology89 56 
Outside basis differences71 41 
Unrealized FX on U.S. dollar debt and other financing cost2  
Total deferred tax liabilities390 150 
Net deferred tax asset$1,609 $985 
The following table presents a reconciliation of the deferred tax asset valuation allowance for 2020, 2019 and 2018:
(in millions)202020192018
Balance, beginning of year$2,831 $2,913 $2,001 
Charged to Benefit from income taxes(773)13 870 
Charged to other accounts194 (95)42 
Balance, end of year$2,252 $2,831 $2,913 
The Company’s U.S. interest expense is subject to limitation rules which limit U.S. interest expense to 30% of adjusted taxable income, defined similar to EBITDA through 2021 and EBIT thereafter. Disallowed interest can be carried forward indefinitely and any unused interest deduction assessed for recoverability. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law. The CARES Act also amended the annual limitation on the deduction of interest in the following respects: (i) increasing the limitation to 50% of adjusted taxable income (“ATI”), (ii) providing a rule for a partnership’s 2019 section 163(j)-disallowed interest expense and (iii) allowing an election to apply 2019 ATI to the 2020 section 163(j) computation. For corporations, the increase to 50% of ATI applies to all taxable years beginning in 2019 or 2020 and permits taxpayers whose 2020 income will decrease from its 2019 level, an election to apply their 2019 ATI, rather than their 2020 ATI, to their 2020 computation. The Company considered such provisions and expects to fully utilize any interest carry forwards in future periods.
On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was signed into law and included a number of changes in the U.S. tax law, most notably a reduction of the U.S. corporate income tax rate from 35% to 21% for tax years beginning after December 31, 2017. The Tax Act also implemented a modified territorial tax system that included a one-time transition tax on the accumulated previously untaxed earnings of foreign subsidiaries (the “Transition Toll Tax”) equal to 15.5% (reinvested in liquid assets) or 8% (reinvested in non-liquid assets). At the taxpayer's election, the Transition Toll Tax can be paid over an eight-year period without interest, starting in 2018. The Company elected not to use this option and instead used a portion of its U.S. net operating losses ("NOLs") to offset this income inclusion.
F-55


The provisional amounts included in Benefit from income taxes for the year 2017, including the Transition Toll Tax, were finalized during 2018. Differences between the provisional net income tax benefits provided for the year 2017 attributable to the Tax Act and the benefit for income taxes as finalized are included in the Benefit from income taxes for 2018 and were not material to the Company’s financial results for the year 2018.
The Company has provided for income taxes in accordance with guidance issued by accounting regulatory bodies, the U.S. Internal Revenue Service and state and local governments through the date of the issuance of these Consolidated Financial Statements. Additional guidance and interpretations can be expected and such guidance, if any, could impact future results. While management continues to monitor these matters, the ultimate impact, if any, as a result of the application of any guidance issued in the future cannot be determined at this time.
The realization of deferred tax assets is dependent on the Company generating sufficient domestic and foreign taxable income in the years that the temporary differences become deductible. A valuation allowance has been provided for the portion of the deferred tax assets that the Company determined is more likely than not to remain unrealized based on estimated future taxable income and tax planning strategies. As a result of taxable losses in Canada as offset by a reduction of deferred tax assets due to internal restructurings, the valuation allowance decreased by $579 million during 2020 and decreased by $82 million during 2019. Given the Company’s history of pre-tax losses and expected future losses in Canada, the Company maintained that there was insufficient objective evidence to release the valuation allowance against Canadian tax loss carryforwards, International Tax Credits (“ITC”) and pooled Scientific Research and Experimental Development Tax Incentive (“SR&ED”) expenditures. The Canadian valuation allowance represents a material portion of the Company's total valuation allowance.
As of December 31, 2020 and 2019, the Company had accumulated taxable losses available to offset future years’ federal and provincial taxable income in Canada of approximately $6,530 million and $7,441 million, respectively.  As of December 31, 2020 and 2019, unclaimed ITCs available to offset future federal taxes in Canada were approximately $37 million and $34 million, respectively, which expire in the years 2021 through 2040.  In addition, as of December 31, 2020 and 2019, pooled SR&ED expenditures available to offset against future taxable income in Canada were approximately $206 million and $192 million, respectively, which may be carried forward indefinitely. As of December 31, 2020 and 2019, a full valuation allowance against the net Canadian deferred tax assets has been provided of $1,966 million and $2,461 million, respectively.
As of December 31, 2020 and 2019, the Company had accumulated taxable losses available to offset future years' federal taxable income in the U.S. of approximately $814 million and $636 million, respectively, including acquired losses which expire in the years 2021 through 2037. While the remaining taxable losses are subject to multiple annual loss limitations as a result of previous ownership changes, the Company believes that the recoverability of the deferred tax assets associated with these taxable losses are more likely than not to be realized. As of December 31, 2020 and 2019 U.S. research and development credits available to offset future years' federal income taxes in the U.S. were approximately $110 million and $106 million, respectively, which includes acquired research and development credits and which expire in the years 2021 through 2040.
As of December 31, 2020 and 2019, the Company had accumulated taxable losses available to offset future years’ taxable income in Ireland of approximately $8,387 million and $6,765 million, respectively.  As of December 31, 2020 and 2019, the Company recognized a capital loss and established a valuation allowance on the portion of the loss for which a benefit is not expected to be realized.
The Company provides for Canadian tax on the unremitted earnings of its direct foreign affiliates except for its direct U.S. subsidiaries. The Company continues to assert that the unremitted earnings of its U.S. subsidiaries will be permanently reinvested and not repatriated. As of December 31, 2020, the Company estimates there will be no tax liability attributable to the permanently reinvested U.S. earnings.
As of December 31, 2020 and 2019, unrecognized tax benefits (including interest and penalties) were $1,025 million and $1,002 million, of which $414 million and $355 million would affect the effective income tax rate, respectively. In 2020 and 2019, the remaining unrecognized tax benefits would not impact the effective tax rate as the tax positions are offset against existing tax attributes or are timing in nature. In 2020 and 2019, the Company recognized net increases to unrecognized tax benefits for current year tax positions of $66 million and $362 million, respectively. The Company recognized a net reduction of $42 million during 2020 and a net reduction of $13 million during 2019 in the unrecognized tax benefits related to tax positions taken in the prior years.
The Company provides for interest and penalties related to unrecognized tax benefits in the provision for income taxes. As of December 31, 2020 and 2019, accrued interest and penalties related to unrecognized tax benefits were approximately
F-56


$49 million and $45 million, respectively. In 2020 and 2019, the Company recognized a net increase of approximately $4 million and $3 million of interest and penalties, respectively.
The Company and one or more of its subsidiaries file federal income tax returns in Canada, the U.S., and other foreign jurisdictions, as well as various provinces and states in Canada and the U.S. The Company and its subsidiaries have open tax years, primarily from 2005 to 2019, with significant taxing jurisdictions, respectively, including Canada and the U.S. These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations and tax treaties, as they relate to the amount, timing, or inclusion of revenues and expenses, or the sustainability of income tax positions of the Company and its subsidiaries. Certain of these tax years are expected to remain open indefinitely.
Jurisdiction:Open Years
United States - Federal
2015 - 2019
Canada
2005 - 2019
Germany
2014 - 2019
France
2013 - 2019
China
2016 - 2019
Ireland
2016 - 2019
Netherlands
2016 - 2019
Australia
2011 - 2019
The Internal Revenue Service completed its examinations of the Company’s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company's taxable income as a result of these examinations. The 2014 tax year remains open to the extent of a 2017 capital loss carried back to that year. Additionally, the Internal Revenue Service has selected for examination the Company's annual tax filings for 2015 and 2016 and the Company's short period tax return for the period ended September 8, 2017, which was filed as a result of the Company's internal restructuring efforts during 2017. At this time, the Company does not expect that proposed adjustments, if any, for these periods would be material to the Company's Consolidated Financial Statements.
The Company is currently under examination by the Canada Revenue Agency for four separate cycles: (a) years 2005 through 2006, (b) years 2007 through 2009, (c) years 2012 through 2013 and (d) years 2014 through 2015. The Company received from the Canada Revenue Agency a proposed audit adjustment for the years 2005 through 2009. The Company disagrees with the adjustments and has filed the respective Notices of Objection. The total proposed adjustment will result in a loss of tax attributes which are subject to a full valuation allowance and will not result in material change to the provision for income taxes. The Canada Revenue Agency audits of the 2010 and 2011 tax years were closed in 2016, and resulted in no material adjustments. The Company received an assessment for certain transfer pricing matters in 2012 and 2013 for CAD 85 million and CAD 90 million, respectively.  The Company disagrees with the adjustments and has filed a Notice of Objection for 2012 and will file an objection for 2013.  Of the total proposed adjustments, all but CAD 3 million will result in a loss of tax attributes which are subject to a full valuation allowance and will not result in a material change to the provision for income taxes.
The Company’s subsidiaries in Germany are under audit for tax years 2014 through 2016. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.
The Company’s subsidiaries in Australia are under audit by the Australian Tax Office for various years beginning in 2010. On August 8, 2017, the Australian Taxation Office issued a notice of assessment for the tax years 2011 through 2017 in the aggregate amount of $117 million, which includes penalties and interest. The Company disagrees with the assessment and continues to believe that its tax positions are appropriate and supported by the facts, circumstances and applicable laws. The Company intends to defend its tax position in this matter vigorously and has filed a holding objection against the assessment by the Australian Taxation Office and has secured a bank guarantee to cover any potential cash outlays regarding this assessment.
The Company's U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2018.
Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits.
F-57


At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.
The following table presents a reconciliation of the unrecognized tax benefits for 2020, 2019 and 2018:
(in millions)202020192018
Balance, beginning of year$1,002 $654 $598 
Additions based on tax positions related to the current year66 361 18 
Additions for tax positions of prior years171 63 55 
Reductions for tax positions of prior years(209)(58)(11)
Lapse of statute of limitations(5)(18)(6)
Balance, end of year$1,025 $1,002 $654 
The Company believes it is reasonably possible that the total amount of unrecognized tax benefits at December 31, 2020 could decrease by approximately $145 million in the next twelve months as a result of the resolution of certain tax and transfer pricing audits and other events.
18.LOSS PER SHARE
Loss per share attributable to Bausch Health Companies Inc. for 2020, 2019 and 2018 were calculated as follows:
(in millions, except per share amounts)202020192018
Net loss attributable to Bausch Health Companies Inc.$(560)$(1,788)$(4,148)
Basic and diluted weighted-average common shares355.0 352.1 351.3 
Basic and diluted loss per share attributable to Bausch Health Companies Inc.$(1.58)$(5.08)$(11.81)
In 2020, 2019 and 2018, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 3,154,000, 5,106,000 and 3,763,000 common shares for 2020, 2019 and 2018, respectively.
Additionally, in 2020, 2019 and 2018, stock options, time-based RSUs and performance-based RSUs to purchase approximately 9,551,000, 2,598,000 and 4,185,000 common shares of the Company, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method.
19.SUPPLEMENTAL CASH FLOW DISCLOSURES
Supplemental cash flow disclosures for 2020, 2019 and 2018 are as follows:
(in millions)202020192018
Other payments
Interest paid$1,474 $1,537 $1,665 
Income taxes paid$162 $172 $138 
20.LEGAL PROCEEDINGS
From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described below. Going forward, in the Company's subsequent Quarterly Reports on Form 10-Q, the Company will only include a description of these matters to the extent there has been a material update with respect thereto during the applicable quarter or to the extent otherwise required by law.
F-58


On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of December 31, 2020, the Company's Consolidated Balance Sheets includes accrued current loss contingencies of $1,672 million related to matters which the Company believes a potential resolution or settlement is both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company’s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.
Governmental and Regulatory Inquiries
Investigation by the U.S. Attorney's Office for the District of Massachusetts - re OraPharma
In August 2019, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin®, including related support services, and other matters. The Company is cooperating with this investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.
Securities and RICO Class Actions and Related Matters
U.S. Securities Litigation - Opt-Out Litigation
On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658). On January 31, 2021 the District Court issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill filed a notice of appeal of the Court’s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options. The deadline for other parties to file notices of appeal from the final approval order is March 2, 2021.
In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company’s business and prospects, including relating to drug pricing, the Company’s use of specialty pharmacies, and the Company’s relationship with Philidor. On May 31, 2016, the court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $1,210 million. This settlement received final approval from the court on January 31, 2021 and will resolve and discharge all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and denied all allegations of wrongdoing. In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payment was paid into an escrow fund in accordance with the settlement agreement. The opt-out litigations discussed below remain ongoing.
On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246) (“Timber Hill”), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company’s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.
In addition to the consolidated putative class action, thirty-seven groups of individual investors in the Company’s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions pending in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions are captioned: T. Rowe Price Growth Stock Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-5034); Equity Trustees Limited as Responsible Entity for T. Rowe Price Global Equity Fund v. Valeant Pharmaceuticals International Inc. (Case No. 16-cv-6127); Principal Funds, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-6128); BloombergSen Partners Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-
F-59


cv-7212); Discovery Global Citizens Master Fund, Ltd. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7321); MSD Torchlight Partners, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7324); BlueMountain Foinaven Master Fund, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7328) (“BlueMountain”); Incline Global Master LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7494); VALIC Company I v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7496); Janus Aspen Series v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7497) (“Janus Aspen”); Okumus Opportunistic Value Fund, LTD v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6513) (“Okumus”); Lord Abbett Investment Trust- Lord Abbett Short Duration Income Fund, v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6365) (“Lord Abbett”); Pentwater Equity Opportunities Master Fund LTD v. Valeant Pharmaceuticals International, Inc., et al. (Case No. 17-cv-7552) (“Pentwater”); Public Employees’ Retirement System of Mississippi v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-7625) (“Mississippi”); The Boeing Company Employee Retirement Plans Master Trust v. Valeant Pharmaceuticals International Inc., et al., (Case No. 17-cv-7636) (“Boeing”); State Board of Administration of Florida v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-12808); The Regents of the University of California v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-13488); GMO Trust v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0089); Första AP Fonden v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-12088); New York City Employees’ Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0032) (“NYCERS”); Hound Partners Offshore Fund, LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08705) (“Hound Partners”); Blackrock Global Allocation Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0343) (“Blackrock”); Colonial First State Investments Limited As Responsible Entity for Commonwealth Global Shares Fund 1 v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0383); Bharat Ahuja v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0846); Brahman Capital Corp. v. Valeant Pharmaceuticals International, Inc (Case No. 18-cv-0893); The Prudential Insurance Company of America v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-01223) (“Prudential”); Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) (“Senzar”); 2012 Dynasty UC LLC v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08595) ("2012 Dynasty"); Catalyst Dynamic Alpha Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-12673) (“Catalyst”); Northwestern Mutual Life Insurance Co., v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-15286) (“Northwestern Mutual”); Bahaa Aly, et al. v. Valeant Pharmaceuticals International, Inc., (Case No. 18-cv-17393) (“Aly”); Office of the Treasurer as Trustee for the Connecticut Retirement Plans and Trust Funds v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18473) (“Connecticut”); Delaware Public Employees’ Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18475) (“Delaware”); Maverick Neutral Levered Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-02190) (“Maverick”), Templeton v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-05478) (“Templeton”), USAA Mutual Funds Trust, et al. v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 20-cv-07462) (“USAA”), and GIC Private Ltd. v. Valeant Pharmaceuticals International, Inc., (Case No. 20-cv-07460) (“GIC”). Twelve of the thirty-seven opt out actions have been dismissed; and the total number of remaining opt out actions pending in the District of New Jersey is twenty-five actions. Four additional matters have been settled and dismissals are expected in March 2021.
These individual shareholder actions assert claims under Sections 10(b), and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss have been filed and in most cases decided in many of these individual actions. To date, the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case. On September 10, 2019, the Court granted defendants’ motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (“Aly”) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. Oral argument on Plaintiffs’ appeal was held on October 20, 2020. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut, and Delaware actions. On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds and Equity Trustees actions.
The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.
F-60


Canadian Securities Litigation
In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. These actions are captioned: (a) Alladina v. Valeant, et al. (Case No. S-1594B6) (Supreme Court of British Columbia) (filed November 17, 2015); (b) Kowalyshyn v. Valeant, et al. (CV-15-540593-00CP) (Ontario Superior Court) (filed November 16, 2015); (c) Kowalyshyn et al. v. Valeant, et al. (CV-15-541082-00CP) (Ontario Superior Court) (filed November 23, 2015); (d) O’Brien v. Valeant et al. (CV-15-543678-00CP) (Ontario Superior Court) (filed December 30, 2015); (e) Catucci v. Valeant, et al. (Court File No. 540-17-011743159) (Quebec Superior Court) (filed October 26, 2015); and (f) Rousseau-Godbout v. Valeant, et al. (Court File No. 500-06-000770-152) (Quebec Superior Court) (filed October 27, 2015).
The Company is also aware of two additional putative class actions that were filed with the applicable court but which have not been served on the Company. These actions are captioned: (i) Okeley v. Valeant, et al. (Case No. S-159991) (Supreme Court of British Columbia) (filed December 2, 2015); and (ii) Sukenaga v Valeant et al. (CV-15-540567-00CP) (Ontario Superior Court) (filed November 16, 2015), and the factual allegations made in these actions are substantially similar to those outlined above.
The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.
Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, has been discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.
After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company’s auditors and the action was dismissed as against them.
On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD 94,000,000 plus payment of an additional amount to cover notice and settlement administration costs and disbursements. As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.
In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.
The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights (“CalSTRS”) served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers’ Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.
On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision.
On October 8 and 9, 2020, respectively, CalSTRS delivered amended proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of “price appreciation credits” in respect of Glumetza®
F-61


during the period covered by the claims. CalSTRS has filed an application for permission to amend and the Company has filed an application to strike the amendments.
The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.
Insurance Coverage Lawsuit
On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16.  The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; 3:18-CV-00493).  In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (under the 2013-2014 coverage period), and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and certain of the investigations described herein and in the Company's prior annual and quarterly reports (under the 2015-2016 coverage period). 
RICO Class Actions
Between May 27, 2016 and September 16, 2016, three actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (“RICO”) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company branded drugs between January 2, 2013 and November 9, 2015.  On November 30, 2016, the Court entered an order consolidating the three actions under the caption In re Valeant Pharmaceuticals International, Inc. Third-Party Payor Litigation, No. 3:16-cv-03087. A consolidated class action complaint was filed on December 14, 2016. The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured’s consent to renew the prescription.  The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.
A Special Master appointed by the Court has recommended that the Company’s motion to dismiss be denied, but a final decision is still pending with the Court. The Company believes these claims are without merit and intends to defend itself vigorously.
Hound Partners Lawsuit
In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County. This action is captioned Hound Partners Offshore Fund, LP et al., v. Valeant Pharmaceuticals International, Inc., et al. (No. MER-L-002185-18). This suit asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. This matter is currently stayed pending the completion of discovery in one of the above-noted federal opt-out cases. The Company disputes the claims and intends to vigorously defend this matter.
Derivative Lawsuits
On September 10, 2019 and September 13, 2019, two alleged stockholders filed derivative lawsuits purportedly on behalf of the Company against former Company board members and executives. The cases are Wessels v. Pearson (Case No. 3:19-cv-17833) and Shabbouei v. Pearson (Case No. 3:19-cv-17987). On March 7, 2020, a consolidated amended derivative complaint was filed, captioned In re Bausch Health Companies Inc. F/K/A/ Valeant Pharmaceuticals International, Inc. Stockholder Derivative Litigation (Case No. 19-cv-17833).
Plaintiffs assert claims for breach of fiduciary duty, waste of corporate assets, and unjust enrichment related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company’s business and prospects, including relating to drug pricing, the Company’s use of specialty pharmacies, and the Company’s relationship with Philidor. The consolidated complaint also asserts a claim for contribution and indemnification by the Defendants for any liability the Company ultimately faces as a result of the conduct alleged in the complaint. The claims
F-62


alleged in these cases are based on the same purported conduct that is at issue in In re Valeant Pharmaceuticals International, Inc. Securities Litigation, all of which occurred prior to 2017. The Shabbouei complaint also asserts a claim for contribution and indemnification by the Defendants for any liability the Company ultimately faces as a result of the conduct alleged in the complaint. On January 3, 2020, the parties submitted a letter to the Court requesting consolidation of the two derivative lawsuits. On April 21, 2020, the Defendants filed a motion to dismiss the consolidated amended complaint. Briefing on this motion concluded on August 3, 2020. On November 24, 2020, the Special Master appointed by the Court issued a report recommending that the motion to dismiss be granted in full. While a final decision is still pending with the Court, Plaintiffs are not contesting the dismissal in full. The Company continues to believe these claims are without merit and intends to defend itself vigorously.
Antitrust
Generic Pricing Antitrust Litigation
The Company's subsidiaries, Oceanside Pharmaceuticals, Inc. (“Oceanside”), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (“Bausch Health US”), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (“Bausch Health Americas”) (for the purposes of this paragraph, collectively, the “Company”), are defendants in multidistrict antitrust litigation (“MDL”) entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16-MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company’s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been or are expected to be consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. In July 2019, 87 health plans commenced an action in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed and the case has been put in deferred status. In May 2020, seven health plans commenced an additional action in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed. The Company disputes the claims against it and continues to defend itself vigorously.
Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively “the Company”) have been named as defendants in a proposed class proceeding entitled Kathryn Eaton vs. Teva Canada Limited, et al. in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the Competition Act by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the In re: Generic Pharmaceuticals Pricing Antitrust Litigation pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and will defend itself vigorously.
Glumetza Antitrust Litigation
Between August 2019 and July 2020, eight (8) putative antitrust class actions and four (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (for purposes of this subsection, collectively, the “Company”), among other defendants, were filed or transferred to the Northern District of California. Three (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020. The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020. In December 2020, the court denied the Company’s motion to dismiss as to the insurer plaintiff’s direct claims but dismissed the insurer plaintiff’s indirect claims. On February 2, 2021, the insurer plaintiff’s motion for leave to amend its complaint was denied. On February 8, 2021, the insurer plaintiff filed an action in state court asserting state law claims.
The federal actions, five (5) of which remain pending, have been consolidated and coordinated in In re Glumetza Antitrust Litigation, Case No. 3:19-cv-05822-WHA. The lawsuits allege that a 2012 settlement of a patent litigation regarding Glumetza® delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza® or grant any other company a license to do so. The complaints allege that the settlement agreement resulted in higher prices for
F-63


Glumetza® and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs seek damages under federal antitrust laws for claims based on direct purchases. All Plaintiffs have filed a motion for partial summary judgment concerning market power, whereas all Defendants have filed a motion for summary judgment on all claims against them. The Company disputes the claims against it and intends to vigorously defend these matters.
Intellectual Property
Patent Litigation/Paragraph IV Matters
From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Relistor®, Xifaxan® 550mg, Plenvu®, Bryhali®, Duobrii® and Jublia® in the United States and Jublia® in Canada, or other similar suits. These matters are proceeding in the ordinary course.
In September 2019, the Company received a Notice of Paragraph IV Certification from Sandoz, Inc. (“Sandoz”), in which Sandoz asserted that the following U.S. patents, each of which is listed in the FDA’s Orange Book for Salix Pharmaceuticals, Inc.’s (“Salix Inc.”) Xifaxan® tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Sandoz’s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (“ANDA”) has been filed by Sandoz: U.S. Patent No. 8,309,569 (the “‘569 patent”), U.S. Patent No. 7,045,620 (the “‘620 patent”), U.S. Patent No. 7,612,199 (the “‘199 patent”), U.S. Patent No. 7,902,206 (the “‘206 patent”), U.S. Patent No. 7,906,542 (the “‘542 patent”), U.S. Patent No. 7,915,275 (the “‘275 patent”), U.S. Patent No. 8,158,644 (the “‘644 patent”), U.S. Patent No. 8,158,781 (the “‘781 patent”), U.S. Patent No. 8,193,196 (the “‘196 patent”), U.S. Patent No. 8,518,949 (the “‘949 patent”), U.S. Patent No. 8,741,904 (the “‘904 patent”), U.S. Patent No. 8,835,452 (the “‘452 patent”), U.S. Patent No. 8,853,231 (the “‘231 patent”), and U.S. Patent No. 9,271,968 (the “’968 Patent”) (collectively, the “Xifaxan® Patents”). Salix Inc. holds the New Drug Application ("NDA") for Xifaxan® and its affiliate, Salix Pharmaceuticals, Ltd. (“Salix Ltd.”), is the owner of the ‘569 patent and Alfasigma S.p.A. (“Alfasigma”) is the owner of the ‘620 patent, the ‘199 patent, the ‘206 patent, the ‘542 patent, the ‘275 patent, the ‘644 patent, the ‘781 patent, the ‘196 patent, the ‘949 patent, the ‘904 patent, the ‘452 patent, the ‘231 patent, and the ‘968 patent, each of which has been exclusively licensed to Salix Inc. and its affiliate, Bausch Health Ireland Limited (“BIRL”) to market Xifaxan® tablets, 550 mg.   On September 30, 2019, Salix Inc. and its affiliates, Salix Ltd. and BIRL, and Alfasigma (the “Plaintiffs”) filed suit against Sandoz in the U.S. District Court for the District of New Jersey (Case No. 19-18566) pursuant to the Hatch-Waxman Act, alleging infringement by Sandoz of one or more claims of each of the Xifaxan® Patents, thereby triggering a 30-month stay of the approval of Sandoz’s ANDA for rifaximin tablets, 550 mg. Xifaxan® 550 mg is protected by 26 patents covering the composition of matter and the use of Xifaxan® listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book.   On May 6, 2020, the Company announced that an agreement had been reached with Sandoz that resolved this litigation. Under the terms of the agreement, the parties agreed to dismiss all litigation related to Xifaxan® (rifaximin), Sandoz acknowledged the validity of the licensed patents for Xifaxan® (rifaximin) 550 mg tablets and all intellectual property protecting Xifaxan® (rifaximin) 550 mg tablets will remain intact and enforceable until expiry in October 2029. The agreement also grants Sandoz a non-exclusive license to the intellectual property relating to Xifaxan® (rifaximin) 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sandoz will have the right to market a royalty-free generic version of Xifaxan® (rifaximin) 550 mg tablets, should it receive approval from the FDA on its ANDA. Sandoz will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the United States before January 1, 2028. The Company will not make any financial payments or other transfers of value as part of this agreement with Sandoz.
On February 17, 2020, the Company and Alfasigma S.p.A. ("Alfasigma") received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (“Norwich”), in which Norwich asserted that the following U.S. patents, each of which is listed in the FDA’s Orange Book for the Company's Xifaxan® tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich’s generic rifaximin tablets, 550 mg, for which an ANDA has been filed by Norwich: each of the Xifaxan® Patents (as described above), as well as U.S. Patent No. 8,642,573 (the “573 patent”), U.S. Patent No. 8,829,017 (the “017 patent”), U.S. Patent No. 8,946,252 (the “252 patent”), U.S. Patent No. 8,969,398 (the “‘398 patent”), U.S. Patent No. 9,421,195 (the “‘195 patent”), U.S. Patent No. 9,629,828 (the “‘9828 patent”), U.S. Patent No. 10,314,828 (the “’4828 patent”), U.S. Patent No. 10,335,397 (the “‘397 patent”), U.S. Patent No. 10,456,384 (the “‘384 patent”), U.S. Patent No. 10,703,763 (the “‘763 patent”), U.S. Patent No. 10,709,694 (the “‘694 patent”), and U.S. Patent No. 10,765,667 (the “‘667 patent”). Salix Inc. holds the NDA for Xifaxan® and is the
F-64


owner of the ‘569 patent, the ‘573 patent, the ‘017 patent, the ‘252 patent, the ‘398 patent, the ‘195 patent, the ‘9828 patent, the ‘4828 patent, the ‘397 patent, the ‘384 patent, the ‘694 patent, and the ‘667 patent. Alfasigma is the owner of the ‘620 patent, the ‘199 patent, the ‘206 patent, the ‘542 patent, the ‘275 patent, the ‘644 patent, the ‘781 patent, the ‘196 patent, the ‘949 patent, the ‘904 patent, the ‘452 patent, the ‘231 patent, the ‘968 patent, and the ‘763 patent, each of which has been exclusively licensed to Salix Inc. and/or its affiliate, Bausch Health Ireland Limited (“BIRL”) to market Xifaxan® tablets, 550 mg.  On March 26, 2020, certain of the Company’s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan® Patents, thereby triggering a 30-month stay of the approval of Norwich’s ANDA for rifaximin tablets, 550 mg. Xifaxan® 550 mg is protected by 26 patents covering the composition of matter and the use of Xifaxan® listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. The Company remains confident in the strength of the Xifaxan® patents and will continue to vigorously pursue this matter and defend its intellectual property.
In April 2019, the Company and Alfasigma commenced litigation against Sun Pharmaceutical Industries Ltd. (“Sun”), alleging patent infringement by Sun’s filing of its ANDA for Xifaxan® (rifaximin) 200 mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from Sun, in which Sun had asserted that the U.S. patents listed in the FDA's Orange Book for the Company’s Xifaxan® tablets, 200 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun’s generic rifaximin tablets, 200 mg. Subsequently, on August 10, 2020, the Company received an additional Notice of Paragraph IV Certification from Sun, in which Sun asserted that the U.S. patents listed in the FDA's Orange Book for the Company’s Xifaxan® tablets, 550 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun’s generic rifaximin tablets, 550 mg, for which an ANDA had been filed by Sun. On September 22, 2020, the Company announced that an agreement had been reached with Sun that resolved the outstanding intellectual property disputes with Sun regarding Xifaxan® (rifaximin) 200 mg and 550 mg tablets. Under the terms of the agreement, the parties agreed to dismiss all litigation related to Xifaxan® (rifaximin) and all intellectual property protecting Xifaxan® (rifaximin) 200 mg and 550 mg tablets will remain intact and enforceable until expiry in July and October 2029, respectively. The agreement also grants Sun a non-exclusive license to the intellectual property relating to Xifaxan® (rifaximin) 200 mg and 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sun will have the right to market royalty-free generic versions of Xifaxan® (rifaximin) 200 mg and 550 mg tablets, should it receive approval from the FDA on its ANDAs. Sun will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the United States before January 1, 2028.
On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (“Perrigo”), in which Perrigo asserted that certain U.S. patents, each of which is listed in the U.S. Food and Drug Administration's (the "FDA") Orange Book for Duobrii® (halobetasol propionate and tazarotine) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Perrigo’s generic lotion, for which an Abbreviated New Drug Application (“ANDA”) has been filed by Perrigo. On August 28, 2020, the Company filed suit against Perrigo pursuant to the Hatch-Waxman Act, alleging infringement by Perrigo of one or more claims of the Duobrii® Patents, thereby triggering a 30-month stay of the approval of the Perrigo ANDA. On September 3, 2020, this action was consolidated with the action between the Company and Perrigo described below, regarding Perrigo’s ANDA for generic Bryhali® (halobetasol propionate) lotion. The Company remains confident in the strength of the Duobrii® related patents and will vigorously defend its intellectual property.
On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo, in which Perrigo asserted that certain U.S. patents, each of which is listed in the FDA’s Orange Book for Bryhali® (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Perrigo’s generic halobetasol propionate lotion, for which an ANDA has been filed by Perrigo. On May 1, 2020, the Company filed suit against Perrigo pursuant to the Hatch-Waxman Act, alleging infringement by Perrigo of one or more claims of the Bryhali® Patents, thereby triggering a 30-month stay of the approval of the Perrigo ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Perrigo described above, regarding Perrigo’s ANDA for generic Duobrii® (halobetasol propionate and tazarotine) lotion. The Company remains confident in the strength of the Bryhali® Patents and intends to vigorously pursue this matter and defend its intellectual property.
In addition, patents covering the Company's branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review ("IPR") at the U.S. Patent & Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution.  IPR challenges have been brought against patents covering the Company's branded pharmaceutical products.  For example, following Acrux DDS’s IPR petition, the U.S. Patent and Trial Appeal Board ("PTAB"), in May 2017, instituted inter
F-65


partes review for an Orange Book-listed patent covering Jublia®, U.S. Patent No. 7,214,506 (the “‘506 patent”). On June 6, 2018, the PTAB issued a written determination invalidating such patent; and on March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion. The ‘506 Patent therefore remains valid and enforceable until its expected expiration in 2026. Jublia® continues to be covered by fourteen other Orange Book-listed patents owned by the Company and its licensor, which expire in the years 2028 through 2035.
Product Liability
Shower to Shower® Products Liability Litigation
Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower® body powder product acquired in September 2012 from Johnson & Johnson; due to dismissals, only twenty-eight (28) of such product liability suits currently remain pending, and these twenty-eight (28) matters are subject to the Johnson & Johnson indemnification referenced below.
Potential liability (including its attorneys’ fees and costs) arising out of the covered Shower to Shower® lawsuits filed against the Company is subject to certain indemnification obligations of Johnson & Johnson owed to the Company, and legal fees and costs will be paid by Johnson & Johnson. The Company and Johnson & Johnson reached an agreement on April 17, 2019, regarding the scope of the indemnification relating to the majority of the Shower to Shower® matters (the “Covered Matters”) and the Company has dismissed the demand for arbitration that the Company filed against Johnson & Johnson to assert its rights to indemnification. Johnson & Johnson will fully indemnify the Company in the Covered Matters, which include: (i) personal injury and products liability actions arising from alleged exposure to Shower to Shower® prior to March 2020 and (ii) consumer fraud, consumer protection, false advertising or other regulatory actions arising out of the manufacture, use, or sale of Shower to Shower® up to and including September 9, 2012. The Company does not believe that the Covered Matters will have a material impact on the Company’s financial results going forward.
The various lawsuits include a number of cases, either originally filed in or transferred to the In re Johnson & Johnson Talcum Powder Litigation, Multidistrict Litigation 2738, pending in the United States District Court for the District of New Jersey (“MDL”). The Company and Bausch Health US were first named in a lawsuit filed directly into the MDL alleging that the use of the Shower to Shower® product caused the plaintiff to develop ovarian cancer. The plaintiff agreed to a dismissal of all claims against the Company and Bausch Health US in that matter without prejudice. The Company has subsequently been named in one additional lawsuit, originally filed in the District of Puerto Rico and subsequently transferred into the MDL, but has not been served in that case. The Company has also been named in eighteen additional lawsuits filed directly into the MDL that have also not yet been served.
These lawsuits also include a number of matters filed in the Superior Court of Delaware and the Superior Court of New Jersey alleging that the use of Shower to Shower® caused the plaintiffs to develop ovarian cancer. Nearly all of these actions have been voluntarily dismissed. Presently, two cases remain pending in New Jersey and one in Delaware. One of the New Jersey cases has not yet been served. The allegations in these cases generally include failure to warn, design defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, and punitive damages.
In addition, these lawsuits also include a number of cases filed in certain state courts in the United States (including the Superior Courts of California, Delaware and New Jersey); the District Court of Louisiana; the Supreme Court of New York (Niagara County); the District Court of Oklahoma City, Oklahoma; the South Carolina Court of Common Pleas (Richland County); the Ohio Court of Common Pleas (Cuyahoga County); and the District Court of Nueces County, Texas (transferred to the asbestos multidistrict litigation docket in the District Court of Harris County, Texas for pre-trial purposes) alleging use of Shower to Shower® and other products resulted in the plaintiffs developing mesothelioma. The Company has been successful in obtaining voluntary dismissals in most of these cases or the plaintiffs have not opposed summary judgment. Presently, four cases remain pending in the Superior Court of New Jersey, and one case in the Court of Common Pleas of Cuyahoga County, Ohio, in which a Notice of Voluntary Dismissal Without Prejudice has been agreed to between the parties. The allegations in these cases generally include design defect, manufacturing defect, failure to warn, negligence, and punitive damages, and in some cases breach of express and implied warranties, misrepresentation, and loss of consortium. The damages sought by the various plaintiffs include compensatory damages, including medical expenses, lost wages or earning capacity, and loss of consortium. In addition, plaintiffs seek compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys’ fees.
F-66


Additionally, two proposed class actions have been filed in Canada against the Company and various Johnson & Johnson entities (one in the Supreme Court of British Columbia and one in the Superior Court of Quebec). The Company also acquired the rights to the Shower to Shower® product in Canada from Johnson & Johnson in September 2012. In the British Columbia matter, the plaintiff sought to certify a proposed class action on behalf of persons in British Columbia and Canada who have purchased or used Johnson & Johnson’s Baby Powder or Shower to Shower®, including their estates, executors and personal representatives, and is alleging that the use of this product increases certain health risks. On November 7, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower®, and at this time no appeal of that judgment has been filed. In the Quebec matter, the plaintiff sought to certify a proposed class action on behalf of persons in Quebec who have used Johnson & Johnson’s Baby Powder or Shower to Shower®, as well as their family members, assigns and heirs, and is alleging negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner. A certification (also known as authorization) hearing was held in the Quebec matter and the Court certified (or as stated under Quebec law, authorized) the bringing of a class action by a representative plaintiff on behalf of people in Quebec who have used Johnson & Johnson's Baby Powder and/or Shower to Shower® in their perineal area and have been diagnosed with ovarian cancer and/or family members, assigns and heirs. The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages.
In accordance with the indemnification agreement, Johnson & Johnson will continue to vigorously defend the Company in each of the remaining actions that are not voluntarily dismissed or subject to a grant of summary judgment.
General Civil Actions
California Proposition 65 Related Matters
On April 15, 2019, a plaintiff filed a pre-suit notice letter with the California Attorney General notifying the Attorney General’s office of its intent to file suit after 60 days against the Company and certain of its subsidiaries, alleging they committed violations of the California Safe Drinking Water and Toxic Enforcement Act of 1986 (“Proposition 65”) by manufacturing and distributing Shower to Shower® that they allege contained silica, arsenic, lead and chromium (hexavalent compounds), which they allege are known to cause cancer and/or reproductive toxicity. That notice letter was served on the Company on April 18, 2019.
On January 29, 2020, Plaintiff Jan Graham filed a lawsuit (Graham v. Bausch Health Companies, Inc., et al., Case No. 20STCV03578) in Los Angeles County Superior Court against the Company, Bausch Health US and several other manufacturers, distributors and retailers of talcum powder products, alleging violations of Proposition 65 by manufacturing and distributing talcum powder products containing chemicals listed under the statute, without a compliant warning on the label. On January 29, 2021, certain defendants including the Company and Bausch Health US filed a Motion for Summary Judgment or in the Alternative Motion for Summary Adjudication, which remains pending.
On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson & Johnson (Gutierrez, et al. v. Johnson & Johnson, et al., Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. The Company filed a motion to dismiss plaintiffs’ claims, which was granted in April 2020 without prejudice. In May 2020, plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted. In August 2020, plaintiffs filed the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss on all claims and dismissed the case with prejudice. On February 19, 2021, plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals.
The Company and Bausch Health US dispute the claims against them and intend to defend each of these lawsuits vigorously.
New Mexico Attorney General Consumer Protection Action
The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson & Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson & Johnson and Johnson & Johnson Consumer Companies, Inc., the Company and Bausch Health US related to Shower to Shower® and its alleged causal link to mesothelioma and other cancers. In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The
F-67


State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its Answer to the Complaint on November 16, 2020. On December 30, 2020 Johnson & Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which remains pending.
The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.
Doctors Allergy Formula Lawsuit
In April 2018, Doctors Allergy Formula, LLC (“Doctors Allergy”), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, Index No. 651597/2018. Doctors Allergy asserts breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.  Doctors Allergy claims its damages are not less than $23 million.  On June 14, 2018, Bausch Health Americas filed a motion to dismiss the complaint in part and a motion to strike. On July 16, 2019 the court granted the Company's motion in part and dismissed Doctor's Allergy's fraud and punitive damages claims. On August 28, 2019, the Company filed an Amended Answer and asserted Counterclaims against Doctors Allergy alleging breach of the covenant of good faith and fair dealing and tortious interference with contract. Bausch Health Americas disputes the claims against it and intends to vigorously defend against those claims and enforce its rights as asserted in its Counterclaims.
Litigation with Former Salix CEO
On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, Case No. 2019-0059, asserting claims for breach of contract and declaratory relief. The lawsuit arises out of the contractual termination of approximately $30 million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd. Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification.  On June 19, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. The Company disputes the claims and intends to vigorously defend the matter.
Completed or Inactive Matters
The following matters have concluded, have settled, are the subject of an agreement to settle or have otherwise been closed since January 1, 2020, have been inactive from the Company’s perspective for several quarters or the Company anticipates that no further material activity will take place with respect thereto. Due to the closure, settlement, inactivity or change in status of the matters referenced below, these matters will no longer appear in the Company's next public reports and disclosures, unless required. With respect to inactive matters, to the extent material activity takes place in subsequent quarters with respect thereto, the Company will provide updates as required or as deemed appropriate.
SEC Investigation
Beginning in November 2015, the Company received from the staff of the Los Angeles Regional Office of the SEC ("the Staff") subpoenas for documents, as well as various document, testimony and interview requests, related to its investigation of the Company, including requests concerning the Company's former relationship with Philidor Rx Services, LLC ("Philidor"), its accounting practices and policies, its public disclosures and other matters. On March 27, 2020, the Staff issued a Wells Notice informing the Company that they had reached a preliminary determination to recommend that the SEC bring charges against the Company for violating the federal securities laws as a result of SEC filings and other statements made by Valeant and its former executives in 2014-2015 concerning Philidor, as well as other accounting and disclosure matters, including the Company’s disclosure of certain price appreciation credits in 2015 - 2016. The Company has entered into a settlement with the SEC that has resolved all allegations by the SEC against the Company. Under the terms of the settlement, the Company neither admitted nor denied the SEC’s allegations and agreed to pay a $45 million civil monetary penalty.
AMF Investigation
On April 12, 2016, the Company received a letter from the Autorité des marchés financiers (the “AMF”) requesting documents concerning the work of the Company’s ad hoc committee of independent directors, the Company’s former relationship with Philidor, the Company's accounting practices and policies and other matters. In July 2018, the Company
F-68


was advised by the AMF that it had issued a formal investigation order against it. On September 30, 2020, the AMF confirmed that it had closed its investigation.
California Proposition 65 Related Matters
On February 11, 2019, plaintiffs filed a pre-suit notice letter with the California Attorney General notifying the Attorney General’s office of their intent to file suit after 60 days against the Company and certain of its subsidiaries, alleging they committed violations of Proposition 65 by manufacturing and distributing Shower to Shower® that they allege contained talc contaminated with asbestos, a listed carcinogen. That notice letter was served on the Company on February 22, 2019. By statute, a private lawsuit may not be filed until at least 60 days have passed following service of this pre-suit notice letter. In April 2019, rather than filing a lawsuit against Bausch Health US, the plaintiffs moved for leave to amend their complaint in a pending Proposition 65 lawsuit (Luna, et al. v. Johnson & Johnson, et al., case 2:18-cv-04830-GW-KS) against Johnson & Johnson in federal court in California to add Bausch Health US as a defendant. Plaintiffs subsequently filed a motion to dismiss the lawsuit without prejudice. The court dismissed the case without prejudice on December 18, 2019.
Contact Lens Antitrust Class Actions
Beginning in March 2015, a number of civil antitrust class action suits were filed by purchasers of contact lenses against B&L Inc., three other contact lens manufacturers, and a contact lens distributor, alleging that the defendants engaged in an anticompetitive scheme to eliminate price competition on certain contact lens lines through the use of unilateral pricing policies, and alleging violations of Section 1 of the Sherman Act, 15 U.S.C. § 1, and of various state antitrust and consumer protection laws. These cases have been consolidated in the Middle District of Florida by the Judicial Panel for Multidistrict Litigation, under the caption In re Disposable Contact Lens Antitrust Litigation, Case No. 3:15-md-02626-HES-JRK. On August 19, 2019, B&L Inc. entered into a settlement, subject to court approval, by which it agreed to pay $10 million to fully and finally resolve plaintiffs’ class claims against B&L Inc. in the case. On October 8, 2019, the settlement agreement was preliminarily approved by the court. A final fairness hearing regarding the settlement was held on February 25, 2020. On March 4, 2020, the Court granted final approval of the settlement agreement in all respects and dismissed the case with prejudice as to B&L Inc., except as to any claim by persons who validly and timely requested exclusion from the settlement classes.
Mississippi Attorney General Consumer Protection Action
The Company and Bausch Health US were named in an action brought by James Hood, Attorney General of Mississippi, in the Chancery Court of the First Judicial District of Hinds County, Mississippi (Hood ex rel. State of Mississippi, Civil Action No. G2014-1207013, filed on August 22, 2014), alleging consumer protection claims against Johnson & Johnson and Johnson & Johnson Consumer Companies, Inc., the Company and Bausch Health US related to the Shower to Shower® body powder product and its alleged causal link to ovarian cancer. As indicated above, the Company acquired the Shower to Shower® body powder product in September 2012 from Johnson & Johnson. The State sought compensatory damages, punitive damages, injunctive relief requiring warnings for talc-containing products, removal from the market of products that fail to warn, and to prevent the continued violation of the Mississippi Consumer Protection Act. The State also sought disgorgement of profits from the sale of the product and civil penalties. The State did not make specific allegations as to the Company or Bausch Health US. The Company and Bausch Health US agreed to resolve this litigation pursuant to a settlement agreement with the State of Mississippi for a non-material amount. On January 8, 2020, an order of dismissal with prejudice was entered by the Court.
Investigation by the State of Texas
On May 27, 2014, the State of Texas served Bausch & Lomb Incorporated (“B&L Inc.”) with a Civil Investigative Demand (“CID”) concerning various price reporting matters relating to the State's Medicaid program and the amounts the State paid in reimbursement for B&L products for the period from 1995 to the date of the CID.  B&L Inc. and the State agreed to settle the matter for $10 million. The Company made the payment on April 1, 2020. On July 1, 2020, the State moved to dismiss the case by filing a notice that it was taking a nonsuit, with prejudice to refiling, effective immediately.
21.COMMITMENTS AND CONTINGENCIES
The Company has commitments related to capital expenditures of approximately $54 million as of December 31, 2020.
Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones. As of December 31, 2020, the Company believes it is reasonably possible that it may potentially make milestone and license fee payments, including sales-based milestone payments, of
F-69


approximately $360 million over time, in the aggregate, to third parties for products currently under development or being marketed, primarily consisting of the following:
Under the terms of a June 2013 distribution and supply agreement with Mylan Pharmaceuticals Inc. (as assignee of Spear Pharmaceuticals, Inc and Spear Dermatology Products Inc.), the Company may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $70 million, in the aggregate.
Under the terms of an April 2019 agreement with Mitsubishi Tanabe Pharma Corporation, the Company has acquired an exclusive license to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate (S1P) receptor that plays a role in autoimmune diseases, such as Inflammatory Bowel Disease and ulcerative colitis. The Company may be required to make development and sales-based milestone payments over time of up to $60 million, in the aggregate, as well as royalties on future sales.
Under the terms of a December 2019 agreement with Novaliq GmbH, the Company has acquired an exclusive license for the commercialization and development in the U.S. and Canada of NOV03 (perfluorohexyloctane), an investigational drug to treat Dry Eye Disease associated with Meibomian gland dysfunction and may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $45 million, in the aggregate, as well as royalties on future sales.
Under the terms of a November 2019 agreement with Cedars-Sinai Medical Center, to evaluate a new formulation of rifaximin for the treatment of irritable bowel syndrome, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $36 million, in the aggregate.
Under the terms of an October 2020 agreement with Eyenovia, Inc., the Company has acquired an exclusive license in the United States and Canada for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. Under the terms of the agreement, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $35 million, in the aggregate.
Under the terms of a May 2020 agreement with STADA Arzneimittel AG and its development partner, Xbrane Biopharma AB, to commercialize in the United States and Canada a biosimilar candidate to Lucentis (ranibizumab), the Company may be required to make development and sales-based milestone payments.
In addition, under the terms of a September 2020 agreement with Allegro, the Company may be required to make a payment of $40 million should Allegro raise additional funding. This amount is excluded from the milestone and license fee payments disclosed above. See Note 3, "ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE" for additional details regarding this agreement.
On February 27, 2018, the Company announced that it entered into an exclusive license agreement with Kaken Pharmaceutical Co., Ltd. ("Kaken") to develop and commercialize a new chemical entity, IDP-131 (KP-470), for the topical treatment of psoriasis. An early proof of concept study has been completed and the results did not meet expectations. As a result, the Company and Kaken have terminated the license agreement.
Due to the nature of these arrangements, the future potential payments related to the attainment of the specified milestones over a period of several years are inherently uncertain. As of December 31, 2020, no accruals related to the aforementioned agreements exist because the milestone targets are not yet probable of being achieved.
Indemnification Provisions
In the normal course of business, the Company enters into agreements that include indemnification provisions for product liability and other matters. These provisions are generally subject to maximum amounts, specified claim periods and other conditions and limits. In addition, the Company is obligated to indemnify its officers and directors in respect of any legal claims or actions initiated against them in their capacity as officers and directors of the Company in accordance with applicable law. Pursuant to such indemnities, the Company is indemnifying certain former officers and directors in respect of certain litigation and regulatory matters. As of December 31, 2020 and 2019, no material amounts were accrued for the Company’s obligations under these indemnification provisions.
F-70


22.SEGMENT INFORMATION
Reportable Segments
The Company’s CEO, who is the Company’s Chief Operating Decision Maker, manages the business through operating and reportable segments consistent with how the Company’s CEO: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. The Company operates in the following reportable segments: (i) Bausch + Lomb/International segment, (ii) Salix segment, (iii) Ortho Dermatologics segment and (iv) Diversified Products segment.
The following is a brief description of the Company’s segments:
The Bausch + Lomb/International segment consists of: (i) sales in the U.S. of pharmaceutical products, OTC products and medical device products, primarily comprised of Bausch + Lomb products, with a focus on the Vision Care, Surgical, Consumer and Ophthalmology Rx products and (ii) with the exception of sales of Solta products, sales in Canada, Europe, Asia, Australia, Latin America, Africa and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products, OTC products, medical device products and Bausch + Lomb products.
The Salix segment consists of sales in the U.S. of GI products.
The Ortho Dermatologics segment consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta medical aesthetic devices.
The Diversified Products segment consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products.
Effective in the first quarter of 2019, one product historically included in the reported results of the Ortho Dermatologics business unit in the Ortho Dermatologics segment is now included in the reported results of the Generics business unit in the Diversified Products segment and another product historically included in the reported results of the Ortho Dermatologics business unit in the Ortho Dermatologics segment is now included in the reported results of the Dentistry business unit in the Diversified Products segment as management believes the products better align with the new respective business units. These changes in product alignment are not material. Prior period presentations of business unit and segment revenues and profits have been conformed to current segment and business unit reporting structures.
Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, including loss on assets held for sale, Restructuring, integration and separation costs, Acquisition-related contingent consideration costs and Other expense (income), net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.
Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company’s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single segment.
In connection with the planned separation of its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company has begun addressing the internal organizational design and structure of the new entity, which it anticipates having substantially complete by late 2021. As of the date of the issuance of these financial statements, these matters are in the planning phase. In connection with the Separation, the Company expects to realign and begin managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Separation during the first quarter of 2021. Accordingly, the Company expects to begin reporting under the following reporting segments on a retrospective basis beginning with its first quarter of 2021: Bausch + Lomb, International Rx, Salix, Ortho Dermatologics and Diversified Products.
F-71


Segment Revenues and Profit
Segment revenues and profits for the years 2020, 2019 and 2018 were as follows:
(in millions)202020192018
Revenues:   
Bausch + Lomb/International$4,408 $4,739 $4,664 
Salix1,904 2,022 1,749 
Ortho Dermatologics553 565 617 
Diversified Products1,162 1,275 1,350 
Total revenues$8,027 $8,601 $8,380 
Segment profit:   
Bausch + Lomb/International$1,159 $1,332 $1,330 
Salix1,338 1,349 1,149 
Ortho Dermatologics233 222 257 
Diversified Products848 932 1,012 
Total segment profit3,578 3,835 3,748 
Corporate(619)(609)(605)
Amortization of intangible assets(1,645)(1,897)(2,644)
Goodwill impairments  (2,322)
Asset impairments, including loss on assets held for sale(114)(75)(568)
Restructuring, integration and separation costs(22)(31)(22)
Acquisition-related contingent consideration(48)(12)9 
Other (expense) income, net(454)(1,414)20 
Operating income (loss)676 (203)(2,384)
Interest income13 12 11 
Interest expense(1,534)(1,612)(1,685)
Loss on extinguishment of debt(59)(42)(119)
Foreign exchange and other(30)8 23 
Loss before benefit from income taxes$(934)$(1,837)$(4,154)
Capital Expenditures
Capital expenditures by segment for the years 2020, 2019 and 2018 were as follows:
(in millions)202020192018
Capital expenditures:   
Bausch + Lomb/International$282 $225 $139 
Salix3 2 2 
Ortho Dermatologics2 1 1 
Diversified Products2 2 2 
289 230 144 
Corporate13 40 13 
Total capital expenditures$302 $270 $157 
F-72


Revenues by Product and by Product Category
Revenues for the Company's top ten products for the years 2020, 2019 and 2018 represented 41%, 39% and 36% of total product sales, respectively. Revenues by segment and product category were as follows:
(in millions)Bausch + Lomb/ InternationalSalixOrtho DermatologicsDiversified ProductsTotal
202020192018202020192018202020192018202020192018202020192018
Pharmaceuticals$759 $885 $892 $1,899 $2,022 $1,752 $279 $355 $457 $741 $810 $927 $3,678 $4,072 $4,028 
Devices1,313 1,524 1,505    253 193 135    1,566 1,717 1,640 
OTC1,432 1,452 1,412          1,432 1,452 1,412 
Branded and Other Generics 838 801 784       410 447 407 1,248 1,248 1,191 
Other revenues66 77 71 5  (3)21 17 25 11 18 16 103 112 109 
$4,408 $4,739 $4,664 $1,904 $2,022 $1,749 $553 $565 $617 $1,162 $1,275 $1,350 $8,027 $8,601 $8,380 
Geographic Information
Revenues are attributed to a geographic region based on the location of the customer for the years 2020, 2019 and 2018 were as follows:
(in millions)202020192018
U.S. and Puerto Rico$4,791 $5,164 $5,011 
China341 368 361 
Canada331 339 319 
Egypt243 218 178 
Poland238 231 218 
Japan226 241 226 
Mexico225 228 211 
France179 201 205 
Germany144 150 170 
Russia137 180 154 
United Kingdom86 115 117 
Spain78 86 83 
Other1,008 1,080 1,127 
$8,027 $8,601 $8,380 
Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December 31, 2020 and 2019 were as follows:
(in millions)20202019
U.S. and Puerto Rico$725 $656 
Ireland328 255 
Canada110 103 
Poland83 90 
Germany80 68 
Mexico49 50 
France34 30 
China31 27 
Serbia30 27 
Italy 23 22 
Other 74 138 
$1,567 $1,466 
F-73


Major Customers
Customers that accounted for 10% or more of total revenues were as follows:
202020192018
McKesson Corporation17%17%18%
AmerisourceBergen Corporation17%16%18%
Cardinal Health, Inc.13%14%13%
F-74


SUPPLEMENTARY DATA (UNAUDITED)
Selected unaudited quarterly consolidated financial data are shown below:
2020
(in millions, except per share amounts)First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
Revenue$2,012 $1,664 $2,138 $2,213 
Expenses1,764 1,691 1,678 2,218 
Operating income (loss)$248 $(27)$460 $(5)
Net (loss) income attributable to Bausch Health Companies Inc.$(152)$(326)$71 $(153)
Basic and Diluted (loss) earnings per share attributable to Bausch Health Companies Inc.$(0.43)$(0.92)$0.20 $(0.43)
Net cash provided by operating activities$261 $200 $256 $394 
2019
(in millions, except per share amounts)First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
Revenue$2,016 $2,152 $2,209 $2,224 
Expenses1,729 1,895 1,880 3,300 
Operating income (loss)$287 $257 $329 $(1,076)
Net loss attributable to Bausch Health Companies Inc.
$(52)$(171)$(49)$(1,516)
Basic and Diluted loss per share attributable to Bausch Health Companies Inc.$(0.15)$(0.49)$(0.14)$(4.30)
Net cash provided by operating activities$413 $339 $515 $234 
F-75
EX-10.1 2 exhibit1012020ye.htm EX-10.1 Document

EXHIBIT 10.1

Bausch Health Companies Inc.
2014 OMNIBUS INCENTIVE PLAN
(As Amended and Restated, Effective as of April 28, 2020)
1.Purpose and Background
The purposes of the Amended and Restated 2014 Omnibus Incentive Plan (the “Plan”) are to (i) align the long-term financial interests of employees, directors, consultants, agents and other service providers of the Company and its Subsidiaries with those of the Company’s shareholders; (ii) attract and retain those individuals by providing compensation opportunities that are competitive with other companies; and (iii) provide incentives to those individuals who contribute significantly to the long-term performance and growth of the Company and its Subsidiaries.
Bausch Health Companies Inc., a British Columbia corporation, adopted the 2014 Omnibus Incentive Plan (the “2014 Plan”) effective as of April 7, 2014, which was approved by the shareholders at the 2014 annual meeting. The 2014 Plan reserved approximately 18 million Common Shares for the issuance of Awards. On April 30, 2018, the shareholders approved an amendment to the 2014 Plan to increase the number of Common Shares authorized under the 2014 Plan by an additional 11,900,000 Common Shares. As of December 31, 2019, 9,864,096 Common Shares were available for further issuance. On February 11, 2020, the Talent and Compensation Committee of the Board of Directors approved an amendment and restatement of the 2014 Plan to increase the number of authorized Common Shares by an additional 13,500,000 Common Shares. The Plan, as amended and restated, has been adopted and approved by the Board (defined below) and shall be effective as of April 28, 2020 (the “Effective Date”), subject to the approval of shareholders.
2.Term
Subject to the right of the Board to amend or terminate the Plan at any time pursuant to Section 18 hereof, the Plan shall remain in effect until the earlier of (i) the date all Common Shares subject to the Plan have been purchased or acquired according to the Plan’s provisions or (ii) the tenth anniversary of the Effective Date. No Awards shall be granted under the Plan after such termination date, but Awards granted prior to such termination date shall remain outstanding in accordance with their terms.
3.Definitions
Award” shall mean an Option, SAR, Share Award or Cash Award granted under the Plan.
Award Agreement” shall mean any written agreement, contract, or other instrument or document evidencing an Award.
Board” shall mean the Board of Directors of the Company.
Blackout Period” means a period self-imposed by the Company (within the meaning of Section 613(m) of the TSX Company Manual) when the Participant is prohibited from trading in the Company’s securities.
Business Day” means any day, other than a Saturday, Sunday or statutory or civic holiday, on which banks in Toronto, Ontario are open for business.
Cash Award” means cash awarded under Section 7(d) of the Plan, including cash awarded as a bonus or upon the attainment of Performance Criteria or otherwise as permitted under the Plan.
Cause” shall have the meaning set forth in the Participant’s employment agreement with the Company, as in effect on the date an Award is granted; provided that if no such agreement or definition exists, “Cause” shall mean, unless otherwise specified in the Award Agreement: (i) conviction of any felony or indictable offense (other than one related to a vehicular offense) or other criminal act involving fraud; (ii) willful misconduct that results in a material economic detriment to the Company; (iii) material violation of Company policies and directives, which is not cured after written notice and an opportunity for cure; (iv) continued refusal by the Participant to perform the Participant’s duties after written notice identifying the deficiencies and an opportunity for cure; (v) a material violation by the Participant of any material covenants to the Company and (vi) such other actions constituting cause under applicable common law. No action or inaction shall be deemed willful if not demonstrably willful and if taken or not taken by the Participant in good faith and with the understanding that such action or inaction was not adverse to the best interests of the Company. Reference in this definition to the Company shall also include direct and indirect Subsidiaries of the Company, and materiality shall be measured based on the action or inaction and the impact upon the Company taken as a whole.
Change of Control” shall have the meaning set forth in Section 10.
Code” shall mean the U.S. Internal Revenue Code of 1986, as amended, including any rules and regulations promulgated thereunder and any successor thereto.



Committee” shall mean the Board or a committee designated by the Board to administer the Plan.
Common Shares” shall mean the common shares of the Company, no par value per share.
Company” shall mean Bausch Health Companies Inc., a British Columbia corporation.
Deferred Shares” shall mean an Award payable in Common Shares at the end of a specified deferral period that is subject to the terms, conditions and limitations described or referred to in Section 7(c)(iv).
Disability” shall mean, unless otherwise provided in an Award Agreement, that the Participant is (i) unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months or (ii) by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months, receiving income replacement benefits for a period of not less than three (3) months under an accident and health plan covering employees of the Company; provided, that, if applicable to the Award, “Disability” shall be determined in a manner consistent with Section 409A of the Code.
Eligible Recipient” shall mean (i) any employee (including any officer) of the Company or any Subsidiary, (ii) any director of the Company or any Subsidiary or (iii) any individual performing services for the Company or a Subsidiary in the capacity of a consultant, agent or otherwise.
Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, including the rules and regulations promulgated thereunder and any successor thereto.
Good Reason” shall have the meaning set forth in the Participant’s employment agreement with the Company, as in effect on the date an Award is granted; provided that if no such agreement or definition exists, “Good Reason” shall mean, unless otherwise specified in the Award Agreement, the occurrence of any of the events or conditions described in clauses (i) and (ii) immediately below which are not cured by the Company (if susceptible to cure by the Company) within thirty (30) days after the Company has received written notice from the Participant which notice must be provided by the Participant within ninety (90) days of the initial existence of the event or condition constituting Good Reason specifying the particular events or conditions which constitute Good Reason and the specific cure requested by the Participant: (i) any material reduction in the Participant’s duties or responsibilities as in effect immediately prior thereto; provided that diminution of responsibility shall not include any such diminution resulting from a promotion, death or Disability, the termination of the Participant’s employment for Cause, or the Participant’s termination of employment other than for Good Reason; and (ii) any reduction in the Participant’s base salary or target bonus opportunity which is not comparable to reductions in the base salary or target bonus opportunity of other similarly-situated employees at the Company.
Insider” shall mean a reporting insider, as defined in National Instrument 55-104 — Insider Reporting Requirements and Exemptions of the Canadian Securities Administrators.
ISO” shall mean an Option intended to be and designated as an incentive stock option within the meaning of Section 422 of the Code.
Market Price” shall mean, with respect to Common Shares, (i) the closing price per Common Share on the national securities exchange on which the Common Shares are principally traded (as of the Effective Date, the New York Stock Exchange), or (ii) if the Common Shares are not then listed on a national securities exchange but are then traded in an over-the-counter market, the average of the closing bid and asked prices for the Common Shares in such over-the-counter market, or (iii) if the Common Shares are not then listed on a national securities exchange or traded in an over-the-counter market, such value as the Committee, using any reasonable method of valuation, shall determine. With respect to property other than Common Shares, the Market Price shall mean the fair market value of such other property determined by such methods or procedures as shall be established from time to time by the Committee.
Nonqualified Stock Option” shall mean an Option that is granted to a Participant that is not designated as an ISO.
Option” shall mean the right to purchase a specified number of Common Shares at a stated exercise price for a specified period of time subject to the terms, conditions and limitations described or referred to in Section 7(a). The term “Option” as used in the Plan includes the terms “Nonqualified Stock Option” and “ISO.”
Original Term” shall have the meaning set forth in Section 7(a).
Participant” shall mean an Eligible Recipient who has been granted an Award under the Plan.



Performance Criteria” shall mean performance criteria based on the attainment by the Company or any Subsidiary (or any division or business unit of such entity) of performance measures pre-established by the Committee in its sole discretion, including one or more of the following:
(i)    revenues, income before taxes and extraordinary items, net income, operating income, earnings before income tax, earnings before interest, taxes, depreciation and amortization, cash flow or a combination of any or all of the foregoing;
(ii)    after-tax or pre-tax profits including, without limitation, that attributable to continuing and/or other operations;
(iii)    the level of the Company’s bank debt or other long-term or short-term public or private debt or other similar financial obligations of the Company either in absolute terms or as it relates to a profitability ratio including operating income or EBITA;
(iv)    return on capital employed, return on assets, or return on invested capital;
(v)    after-tax or pre-tax return on stockholders’ equity;
(vi)    economic value added targets based on a cash flow return on investment formula;
(vii)    the Market Price of the Common Shares;
 
(viii)    the market capitalization or enterprise value of the Company, either in amount or relative to industry peers;
(ix)    the value of an investment in the Common Shares assuming the reinvestment of dividends;
(x)    the achievement of operating margin targets or other measures of improving profitability;
(xi)    the filing of one or more new drug application(s) (“NDA”) or one or more new drug submission(s) (“NDS”) or the approval of one or more NDA(s) or one or more NDS(s) by the U.S. Food and Drug Administration or the Canadian Therapeutic Products Directorate, as applicable;
(xii)    the achievement of, or progress toward, a launch of one or more new drug(s);
(xiii)    the achievement of research and development milestones;
(xiv)    the achievement of other strategic milestones including, without limitation, the achievement of specific synergy capture and cost savings realization relating to integrations and the successful creation or execution of a restructuring plan for a specific business or function;
(xv)    the successful completion of clinical trial phases;
(xvi)    licensing or acquiring new products or product platforms;
(xvii)    acquisition or divestiture of products or business;
(xviii)    the entering into new, or exiting from existing, geographic markets or industry segments; or
(xix)    the attainment of a certain level of, reduction of, or other specified objectives with regard to limiting the level in or increase in, all or a portion of controllable expenses or costs or other expenses or costs.
For purposes of item (i) above, “extraordinary items” shall mean all items of gain, loss or expense for the fiscal year determined to be extraordinary or unusual in nature or infrequent in occurrence or related to a corporate transaction (including, without limitation, a disposition or acquisition) or restructuring or related to a change in accounting principles, all as determined in accordance with standards established by Opinion No. 30 of the Accounting Principles Board. Each financial metric described in item (i) above may be on a business unit, geographic segment, total company or per-share basis, and on a GAAP or non-GAAP adjusted basis. The Performance Criteria may be based upon the attainment of specified levels of performance under one or more of the measures described above relative to the performance of other entities. The Committee may designate additional business criteria on which the Performance Criteria may be based or adjust, modify or amend the aforementioned business criteria, including to take into account actions approved by the Board or a committee thereof that affect the achievement of the original performance criteria. Performance Criteria may include a threshold level of performance below which no Award will be earned, a level of performance at which the target amount of an Award will be earned and a level of performance at which the maximum amount of the Award will be earned. The Committee, in its sole discretion, shall make equitable adjustments to the Performance Criteria in recognition of unusual or non-recurring events affecting the Company or any Subsidiary or the financial statements of the Company or any Subsidiary, in response to changes in applicable laws or regulations, including changes in generally accepted accounting principles, or to account for items of gain, loss or expense determined to be extraordinary or unusual in nature or infrequent in occurrence or related to the disposal of a segment of a business or related to a change in accounting principles, as applicable.
Person” shall have the meaning set forth in Section 14(d)(2) of the Exchange Act.
Restricted Shares” shall mean an Award of Common Shares that is subject to the terms, conditions, restrictions and limitations described or referred to in Section 7(c)(iii).



SAR” shall mean a share appreciation right that is subject to the terms, conditions, restrictions and limitations described or referred to in Section 7(b).
Section 16(a) Officer” shall mean an Eligible Recipient who is subject to the reporting requirements of Section 16(a) of the Exchange Act.
Separation from Service” shall have the meaning set forth in Section 1.409A-1(h) of the Treasury Regulations.
Specified Employee” shall have the meaning set forth in Section 409A of the Code and the Treasury Regulations promulgated thereunder.
Share Award” shall have the meaning set forth in Section 7(c)(i).
Share Payment” shall mean a share payment that is subject to the terms, conditions, and limitations described or referred to in Section 7(c)(ii).
Share Unit” shall mean a share unit that is subject to the terms, conditions and limitations described or referred to in Section 7(c)(v).
Subsidiary” means any corporation (other than the Company) in an unbroken chain of corporations beginning with the Company, if each of the corporations (other than the last corporation) in the unbroken chain owns shares possessing fifty percent (50%) or more of the total combined voting power of all classes of shares in one of the other corporations in the chain (or such lesser percent as is permitted by Section 1.409A-1(b)(5)(iii)(E) of the Treasury Regulations).
Transferred Shares” shall have the meaning set forth in Section 6(a).
Treasury Regulations” shall mean the regulations promulgated under the Code by the United States Internal Revenue Service, as amended.
4.Administration
(a)    Committee Authority. Subject to applicable law, the Committee shall have full and exclusive power to administer and interpret the Plan, to grant Awards and to adopt such administrative rules, regulations, procedures and guidelines governing the Plan and the Awards as it deems appropriate, in its sole discretion, from time to time. The Committee’s authority shall include, but not be limited to, the authority to (i) determine the type of Awards to be granted under the Plan; (ii) select Award recipients and determine the extent of their participation; (iii) determine Performance Criteria; and (iv) establish all other terms, conditions, and limitations applicable to Awards, Award programs and, if applicable, the Common Shares issued pursuant thereto. The Committee may accelerate or defer the vesting or payment of Awards, cancel or modify outstanding Awards, waive any conditions or restrictions imposed with respect to Awards or the Common Shares issued pursuant to Awards and make any and all other determinations that it deems appropriate with respect to the administration of the Plan, subject to the limitations contained in Sections 6(d) and 18 of the Plan and applicable law and listing rules with respect to all Participants.
(b)    Administration of the Plan. The administration of the Plan shall be managed by the Committee. All determinations of the Committee shall be made by a majority of its members either present in person or participating by conference telephone at a meeting or by written consent. The Committee shall have the power to prescribe and modify the forms of Award Agreement, correct any defect, supply any omission or clarify any inconsistency in the Plan and/or in any Award Agreement and take such actions and make such administrative determinations that the Committee deems appropriate in its sole discretion. Any decision of the Committee in the administration of the Plan, as described herein, shall be final, binding and conclusive on all parties concerned, including the Company, its shareholders and Subsidiaries and all Participants.
(c)    Delegation of Authority. To the extent permitted by applicable law, the Committee may at any time delegate to one or more officers or directors of the Company some or all of its authority over the administration of the Plan, with respect to individuals who are not Section 16(a) Officers.
(d)    Indemnification. No member of the Committee or any other Person to whom any duty or power relating to the administration or interpretation of the Plan has been delegated shall be personally liable for any action or determination made with respect to the Plan, except for his or her own willful misconduct or as expressly provided by statute. The members of the Committee and its delegates, including any employee with responsibilities relating to the administration of the Plan, shall be entitled to indemnification and reimbursement from the Company, to the extent permitted by applicable law and the by-laws and policies of the Company. To the fullest extent permitted by the law, in the performance of its functions under the Plan, the Committee (and each member of the Committee and its delegates) shall be entitled to rely upon information and advice furnished by the Company’s officers, accountants,



counsel and any other party they deem appropriate, and neither the Committee nor any such Person shall be liable for any action taken or not taken in reliance upon any such advice.
5.Participation
(a)    Eligible Recipients. Subject to applicable law and Section 7 hereof, the Committee shall determine, in its sole discretion, which Eligible Recipients shall be granted Awards under the Plan. Unless otherwise determined by the Committee, members of the Board shall generally not be eligible to receive SARs or Options.
(b)    Participation outside of the United States. In order to facilitate the granting of Awards to Employees who are foreign nationals or who are employed outside of the U.S., the Committee may provide for such special terms and conditions, including, without limitation, substitutes for Awards, as the Committee may consider necessary or appropriate to accommodate differences in local law, tax policy or custom. The Committee may approve any supplements to, or amendments, restatements or alternative versions of, this Plan as it may consider necessary or appropriate for the purposes of this Section 5(b) without thereby affecting the terms of this Plan as in effect for any other purpose, and the appropriate officer of the Company may certify any such documents as having been approved and adopted pursuant to properly delegated authority; provided, that no such supplements, amendments, restatements or alternative versions shall include any provisions that are inconsistent with the intent and purpose of this Plan, as then in effect; and further provided that any such action taken with respect to an Employee who is subject to Section 409A of the Code shall be taken in compliance with Section 409A of the Code.
6.Available Shares of Common Shares
(a)    Shares Subject to the Plan. Subject to the following provisions of this Section 6, the maximum number of Common Shares that may be issued to Participants pursuant to Awards (all of which may be granted as ISOs) shall be equal to the sum of (i) 30,268,825 Common Shares, (ii) 13,500,000 Common Shares and (iii) the number of Common Shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered following the Effective Date under the Company’s 2011 Omnibus Incentive Plan and the 2007 Equity Compensation Plan (the “Transferred Shares”). For the avoidance of doubt, the Transferred Shares shall no longer be available under the Company’s 2011 Omnibus Incentive Plan and the 2007 Equity Compensation Plan. Common Shares issued pursuant to Awards granted under the Plan may be shares that have been authorized but unissued, or have been purchased in open market transactions or otherwise.
(b)    Forfeited and Expired Awards. If any shares subject to an Award are forfeited, canceled, exchanged or surrendered, or if an Award terminates or expires without a distribution of Common Shares to the Participant, the shares with respect to such Award shall, to the extent of any such forfeiture, cancellation, exchange, surrender, termination or expiration, again be available for Awards under the Plan. Notwithstanding the foregoing, the shares surrendered or withheld as payment of either the exercise price of an Option (including shares otherwise underlying an Award of a SAR that are retained by the Company to account for the exercise price of such SAR) and/or withholding taxes in respect of an Award shall no longer be available for Awards under the Plan.
(c)    Other Items Not Included in Allocation. The maximum number of Common Shares that may be issued under the Plan as set forth in Section 6(a) shall not be affected by (i) the payment in cash of dividends or dividend equivalents in connection with outstanding Awards; (ii) the granting or payment of share-denominated Awards that by their terms may be settled only in cash, (iii) the granting of Cash Awards; or (iv) Awards that are granted in connection with a transaction between the Company or a Subsidiary and another entity or business in substitution or exchange for, or conversion adjustment, assumption or replacement of, awards previously granted by such other entity to any individuals who have become Eligible Recipients as a result of such transaction.
(d)    Other Limitations on Shares that May be Granted under the Plan. Subject to Section 6(e), (i) the number of Common Shares issuable to Insiders, at any time, under all security-based compensation arrangements of the Company, cannot exceed 10% of issued and outstanding Common Shares of the Company; (ii) the number of Common Shares issued to Insiders, within any one year period, under all security-based compensation arrangements of the Company, cannot exceed 10% of issued and outstanding securities; (iii) the number of Common Shares issuable to non-employee members of the Board, at any time, under all security-based compensation arrangements of the Company, cannot exceed 1% of issued and outstanding Common Shares of the Company; and (iv) the aggregate number of Common Shares that were granted prior to November 2, 2017 to any “covered employee” under Section 162(m) of the Code during a calendar year in the form of Options, Share Appreciation Rights, and/or Share Awards and intended to qualify as “performance-based compensation” under Section 162(m) of the Code was not permitted to exceed the number of Common Shares initially authorized for grant.
(e)    Adjustments. In the event of any change in the Company’s capital structure, including, but not limited to, a change in the number of Common Shares outstanding, on account of (i) any stock dividend, stock split, reverse stock split or any similar equity restructuring or (ii) any combination or exchange of equity securities, merger, consolidation,



recapitalization, reorganization, or divesture or any other similar event affecting the Company’s capital structure, to reflect such change in the Company’s capital structure, the Committee shall make appropriate equitable adjustments to the maximum number of Common Shares that may be issued under the Plan as set forth in Section 6(a) and to the maximum number of shares that may be granted to any single individual pursuant to Section 6(d). In the event of any extraordinary dividend, divestiture or other distribution (other than ordinary cash dividends) of assets to shareholders, or any transaction or event described above, to the extent necessary to prevent the enlargement or diminution of the rights of Participants, the Committee shall make appropriate equitable adjustments to the number or kind of shares subject to an outstanding Award, the exercise price applicable to an outstanding Award, and/or any measure of performance that relates to an outstanding Award, including any applicable Performance Criteria. Any adjustment to ISOs under this Section 6(e) shall be made only to the extent not constituting a “modification” within the meaning of Section 424(h)(3) of the Code. With respect to Awards subject to Section 409A of the Code, any adjustments under this Section 6(e) shall conform to the requirements of Section 409A of the Code. Notwithstanding anything set forth herein to the contrary, the Committee may, in its discretion, decline to adjust any Award made to a Participant, if it determines that such adjustment would violate applicable law or result in adverse tax consequences to the Participant or to the Company. If, as a result of any adjustment under this section 6(e), a Participant would become entitled to a fractional Common Share, the Participant has the right to acquire only the adjusted number of full Common Shares and no payment or other adjustment will be made with respect to the fractional Common Shares so disregarded. Adjustments under this Section 6(e) are subject to any applicable regulatory approvals.
7.Awards Under The Plan
Awards under the Plan may be granted as Options, SARs, Share Awards or Cash Awards as described below. Awards may be granted singly, in combination or in tandem as determined by the Committee, in its sole discretion.
(a)    Options. Options granted under the Plan shall be designated as Nonqualified Stock Options or ISOs. Options shall expire after such period, not to exceed a maximum of ten years, as may be determined by the Committee (the “Original Term”). If an Option is exercisable in installments, such installments or portions thereof that become exercisable shall remain exercisable until the Option expires or is otherwise canceled pursuant to its terms. Notwithstanding anything to the contrary in this Section 7(a), if the Original Term of an Option held by a Participant expires during a Blackout Period, the term of such Option shall be extended until the tenth Business Day following the end of the Blackout Period, at which time any unexercised portion of the Option shall expire. Except as otherwise provided in this Section 7(a), Options shall be subject to the terms, conditions, restrictions, and limitations determined by the Committee, in its sole discretion, from time to time.
(i)    Exercise Price. The Committee shall determine the exercise price per share for each Option, which shall not be less than 100% of the Market Price (as of the date of grant) of the Common Shares subject to the Option.
(ii)    Exercise of Options. Upon satisfaction of the applicable conditions relating to vesting and exercisability, as determined by the Committee, and upon provision for the payment in full of the exercise price and applicable taxes due, the Participant shall be entitled to exercise the Option and receive the number of Common Shares issuable in connection with the Option exercise. The Common Shares issued in connection with the Option exercise may be subject to such conditions and restrictions as the Committee may determine, from time to time. The exercise price of an Option and applicable withholding taxes relating to an Option exercise may be paid by methods permitted by the Committee from time to time including, but not limited to, (1) a cash payment; (2) tendering (either actually or by attestation) Common Shares owned by the Participant (for any minimum period of time that the Committee, in its discretion, may specify), valued at the Market Price at the time of exercise; (3) arranging to have the appropriate number of Common Shares issuable upon the exercise of an Option withheld or sold; or (4) any combination of the above. Additionally, the Committee may provide that an Option may be “net exercised,” meaning that upon the exercise of an Option or any portion thereof, the Company shall deliver the number of whole Common Shares equal to (A) the difference between (x) the aggregate Market Price of the Common Shares subject to the Option (or the portion of such Option then being exercised) and (y) the aggregate exercise price for all such Common Shares under the Option (or the portion thereof then being exercised) plus (to the extent it would not give rise to adverse accounting consequences pursuant to applicable accounting principles or to adverse tax consequences to the Participants under Canadian federal, provincial or territorial tax laws) the amount of withholding tax due upon exercise divided by (B) the Market Price of a Common Share on the date of exercise. Any fractional share that would result from such equation shall be canceled.
(iii)    ISOs. The terms and conditions of ISOs granted hereunder shall be subject to the provisions of Section 422 of the Code and the terms, conditions, limitations and administrative procedures established by the Committee from time to time in accordance with the Plan. At the discretion of the Committee, ISOs may be granted only to an employee of the Company, its “parent corporation” (as such term is defined in Section 424(e) of the Code) or a Subsidiary.



(1)    ISO Grants to 10% Shareholders. Notwithstanding anything to the contrary in this Section 7(a), if an ISO is granted to a Participant who owns shares representing more than ten percent of the voting power of all classes of shares of the Company, its “parent corporation” (as such term is defined in Section 424 (e) of the Code) or a Subsidiary, the term of the Option shall not exceed five years from the time of grant of such Option and the exercise price shall be at least 110 percent of the Market Price (as of the date of grant) of the Common Shares subject to the Option.
(2)    $100,000 Per Year Limitation for ISOs. To the extent the aggregate Market Price (determined as of the date of grant) of the Common Shares for which ISOs are exercisable for the first time by any Participant during any calendar year (under all plans of the Company) exceeds $100,000, such excess ISOs shall be treated as Nonqualified Stock Options.
(3)    Disqualifying Dispositions. Each Participant awarded an ISO under the Plan shall notify the Company in writing immediately after the date he or she makes a “disqualifying disposition” of any Common Shares acquired pursuant to the exercise of such ISO. A “disqualifying disposition” is any disposition (including any sale) of such Common Shares before the later of (i) two years after the date of grant of the ISO and (ii) one year after the date the Participant acquired the Common Shares by exercising the ISO. The Company may, if determined by the Committee and in accordance with procedures established by it, retain possession of any Common Shares acquired pursuant to the exercise of an ISO as agent for the applicable Participant until the end of the period described in the preceding sentence, subject to complying with any instructions from such Participant as to the sale of such shares.
(iv)    No Option will be eligible for the payment of dividends or dividend equivalents.
(b)    Share Appreciation Rights. A SAR represents the right to receive a payment in cash, Common Shares, or a combination thereof, in an amount equal to the product of (1) the excess of the Market Price per Common Share on the date the SAR is exercised over the exercise price per Common Share of such SAR (which exercise price shall be no less than 100% of the Market Price of the Common Shares subject to the SAR as of the date the SAR was granted) and (2) the number of Common Shares subject to the portion of the SAR being exercised. If a SAR is paid in Common Shares, the number of Common Shares to be delivered will equal the amount determined to be payable in accordance with the prior sentence divided by the Market Price of a Common Share at the time of payment. The Committee shall establish the Original Term of a SAR, which shall not exceed a maximum of ten years. Notwithstanding anything to the contrary in this Section 7(b), if the Original Term of a SAR held by the Participant expires during a Blackout Period, the term of such SAR shall be extended until the tenth Business Day following the end of the Blackout Period, at which time any unexercised portion of the SAR shall expire. Except as otherwise provided in this Section 7(b), SARs shall be subject to the terms, conditions, restrictions and limitations determined by the Committee, in its sole discretion, from time to time. A SAR may only be granted to an Eligible Recipient to whom an Option could be granted under the Plan. No SAR will be eligible for the payment of dividends or dividend equivalents.
(c)    Share Awards.
(i)    Form of Awards. The Committee may grant Awards that are payable in Common Shares or denominated in units equivalent in value to Common Shares or are otherwise based on or related to Common Shares (“Share Awards”), including, but not limited to, Share Payments, Restricted Shares, Deferred Shares, and Share Units. Share Awards shall be subject to such terms, conditions (including, without limitation, service-based and performance-based vesting conditions), restrictions and limitations as the Committee may determine to be applicable to such Share Awards, in its sole discretion, from time to time.
(ii)    Share Payment. If not prohibited by applicable law, the Committee may issue unrestricted Common Shares in such amounts and subject to such terms and conditions as the Committee shall from time to time in its sole discretion determine. A Share Payment may be granted as, or in payment of, a bonus, or to provide incentives or recognize special achievements or contributions.
(iii)    Restricted Shares. Restricted Shares shall be subject to the terms, conditions, restrictions, and limitations determined by the Committee, in its sole discretion, from time to time. The number of Restricted Shares allocable to an Award under the Plan shall be determined by the Committee in its sole discretion.
(iv)    Deferred Shares. Subject to Code Section 409A to the extent applicable, Deferred Shares shall be subject to the terms, conditions, restrictions and limitations determined by the Committee, in its sole discretion, from time to time. A Participant who receives an Award of Deferred Shares shall be entitled to receive the number of Common Shares allocable to his or her Award, as determined by the Committee in its sole discretion, from time to time, at the end of a specified deferral period determined by the Committee. Awards of Deferred Shares represent only an unfunded, unsecured promise to deliver shares in the future and shall not give Participants any greater rights than those of an unsecured general creditor of the Company.



(v)    Share Units. A Share Unit is an Award denominated in Common Shares that may be settled either in Common Shares or in cash, in the discretion of the Committee, and, subject to Code Section 409A to the extent applicable, shall be subject to such other terms, conditions, restrictions and limitations determined by the Committee from time to time in its sole discretion.
(vi)    Blackout Period. In the event that any Share Unit is scheduled by its terms to be delivered (the “Original Distribution Date”) during a Blackout Period, then, if the Participant is restricted from selling Shares during the Blackout Period, such shares subject to the Share Unit shall not be delivered on such Original Distribution Date and shall instead be delivered as soon as practicable following the expiration of the Blackout Period; provided, however, that in no event shall the delivery of the shares be delayed pursuant to this provision beyond the latest date on which such delivery could be made without violating Code Section 409A.
(d)    Cash Awards. The Committee may grant Awards that are payable to Participants solely in cash, as deemed by the Committee to be consistent with the purposes of the Plan, and, except as otherwise provided in this Section 7(d), such Cash Awards shall be subject to the terms, conditions, restrictions, and limitations determined by the Committee, in its sole discretion, from time to time. Awards granted pursuant to this Section 7(d) may be granted with value and payment contingent upon the achievement of Performance Criteria. The maximum amount that any Participant (other than a non-employee director of the Company) may receive with respect to a Cash Award granted pursuant to this Section 7(d) in respect of any annual performance period is $10,000,000 and for any other performance period, such amount multiplied by a fraction, the numerator of which is the number of months in the performance period and the denominator of which is twelve. Payments earned hereunder may be decreased or increased in the sole discretion of the Committee based on such factors as it deems appropriate.
(e)    Unless the applicable Award Agreement provides otherwise or the Committee determines otherwise, vesting with respect to an Award will cease upon termination of a Participant’s employment or service with the Company, and unvested Awards shall be forfeited upon such termination. In the case of termination for Cause, vested Awards shall also be forfeited.
(f)    Non-Employee Director Limitations. Subject to adjustment in accordance with Section 6(e), in any calendar year, no Participant who is a non-employee director of the Company shall be granted Options, Share Appreciation Rights, Share Awards, Cash Awards or any other compensation with an aggregate fair market value as of the grant date (as determined in accordance with applicable accounting standards) or payment date, as applicable, in excess of $750,000.
8.Dividends and Dividend Equivalents
The Committee may, in its sole discretion, provide that Share Awards shall earn dividends or dividend equivalents, as applicable. Such dividends or dividend equivalents may be credited to an account maintained on the books of the Company. Any payment or crediting of dividends or dividend equivalents will be subject to such terms, conditions, restrictions and limitations as the Committee may establish, from time to time, in its sole discretion, including, without limitation, reinvestment in additional Common Shares or common share equivalents; provided, however, if the payment or crediting of dividends or dividend equivalents is in respect of a Share Award that is subject to Code Section 409A, then the payment or crediting of such dividends or dividend equivalents shall conform to the requirements of Code Section 409A and such requirements shall be specified in writing. Notwithstanding the foregoing, dividends or dividend equivalents (i) shall have the same vesting dates and shall be paid in accordance with the same terms as the Award to which they relate and (ii) with respect to any Award subject to the achievement of Performance Criteria, shall not be paid unless and until the relevant Performance Criteria have been satisfied, and then only to the extent determined by the Committee, as specified in the Award Agreement.
9.Nontransferability
Awards granted under the Plan, and during any period of restriction on transferability, Common Shares issued in connection with the exercise of an Option or a SAR, may not be sold, pledged, hypothecated, assigned, margined or otherwise transferred in any manner other than by will or the laws of descent and distribution, unless and until the shares underlying such Award have been issued, and all restrictions applicable to such shares have lapsed or have been waived by the Committee. No Award or interest or right therein shall be subject to the debts, contracts or engagements of a Participant or his or her successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law, by judgment, lien, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy and divorce), and any attempted disposition thereof shall be null and void, of no effect, and not binding on the Company in any way. Notwithstanding the foregoing, the Committee may, in its sole discretion, permit (on such terms, conditions and limitations as it may establish) Nonqualified Stock Options and/or shares issued in connection with an Option or a SAR exercise that are subject to restrictions on transferability, to be transferred to a member of a Participant’s immediate family or to a trust or similar vehicle for the benefit of a Participant’s immediate family members. During the lifetime of a Participant, all rights with respect to Awards shall be exercisable only by such Participant or, if applicable pursuant to the preceding sentence, a permitted transferee.



10.Change of Control
(a)    Unless otherwise determined in an Award Agreement, in the event of a Change of Control:
(i)    With respect to each outstanding Award that is assumed or substituted in connection with a Change of Control, in the event of a termination of a Participant’s employment or service without Cause or by the Participant for Good Reason during the 12-month period following such Change of Control, (i) such Award shall become fully vested and exercisable, (ii) the restrictions, payment conditions, and forfeiture conditions applicable to any such Award granted shall lapse, and (iii) any performance conditions imposed with respect to Awards shall be deemed to be achieved at target performance levels.
(ii)    With respect to each outstanding Award that is not assumed or substituted in connection with a Change of Control immediately upon the occurrence of the Change of Control, (x) such Award (including both time-based and performance-based Awards) shall become fully vested and exercisable based on a fraction, the numerator of which is the number of days between the grant date and the date of the Change of Control and the denominator of which is the number of days during the period beginning on the grant date of the Award and ending on the date of vesting of the Award, (y) the restrictions, payment conditions, and forfeiture conditions applicable to any such Award granted shall lapse, and (z) any performance conditions imposed with respect to performance-based Awards shall be deemed to be achieved at target performance levels (for the avoidance of doubt, prorated in accordance with clause (x)).
(iii)    For purposes of this Section 10, an Award shall be considered assumed or substituted for if, following the Change of Control, the Award remains subject to the same terms and conditions that were applicable to the Award immediately prior to the Change of Control except that, if the Award related to Common Shares, the Award instead confers the right to receive common shares of the acquiring entity.
(iv)    Notwithstanding any other provision of the Plan, in the event of a Change of Control, the Committee (a) may, in its discretion provide that each Option and each SAR which may, by its terms, only be settled in shares shall, immediately prior to the occurrence of a Change of Control, be deemed to have been exercised on a “net exercise” basis; and (b) may, in its discretion, except as would otherwise result in adverse tax consequences under Code Section 409A, provide that each Award, other than Options and SARs which may, by their terms, only be settled in shares, shall, immediately upon the occurrence of a Change of Control, be cancelled in exchange for a payment in cash or securities in an amount equal to (i) the excess of the consideration paid per Common Share in the Change of Control over the purchase price (if any) per Common Share subject to the Award multiplied by (ii) the number of Common Shares then outstanding under the Award.
(b)    For purposes of this Agreement and, except to the extent as would result in a violation of Code Section 409A, a “Change of Control” shall be deemed to occur if and when the first of the following occurs:
(i)    the acquisition (other than from the Company), by any person (as such term is defined in Section 13(d) or 14(d) of the Exchange Act) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of fifty percent (50%) or more of the combined voting power of the Company’s then outstanding voting securities;
(ii)    the individuals who, as of the date hereof, are members of the Board (the “Incumbent Board”), cease for any reason to constitute at least a majority of the Board, unless the election, or nomination for election by the Company’s shareholders, of any new director was approved by a vote of at least a majority of the Incumbent Board, and such new director shall be considered as a member of the Incumbent Board;
(iii)    the closing of an amalgamation or similar business combination (each, an “Amalgamation”) involving the Company if (i) the shareholders of the Company, immediately before such Amalgamation, do not, as a result of such Amalgamation, own, directly or indirectly, more than fifty percent (50%) of the combined voting power of the then outstanding voting securities of the entity resulting from such Amalgamation in substantially the same proportion as their ownership of the combined voting power of the voting securities of the Company outstanding immediately before such Amalgamation or (ii) immediately following the Amalgamation, the individuals who comprised the Board immediately prior thereto do not constitute at least a majority of the board of directors of the entity resulting from such Amalgamation (or, if the entity resulting from such Amalgamation is then a subsidiary, the ultimate parent thereof);
(iv)    a complete liquidation or dissolution of the Company or the closing of an agreement for the sale or other disposition of all or substantially all of the assets of the Company.
(c)    Notwithstanding the foregoing, a Change of Control shall not be deemed to occur solely because fifty percent (50%) or more of the combined voting power of the Company’s then outstanding securities is acquired by (i) a trustee or other fiduciary holding securities under one or more employee benefit plans maintained by the Company or any of its subsidiaries or (ii) any corporation which, immediately prior to such acquisition, is owned directly or indirectly by the shareholders of the Company in the same proportion as their ownership of shares in the Company immediately prior to



such acquisition. In addition, notwithstanding the foregoing, solely to the extent required by Section 409A, a Change of Control shall be deemed to have occurred only if a change in the ownership or effective control of the Company or a change in ownership of a substantial portion of the assets of the Company shall also be deemed to have occurred under Section 409A.
11.Clawback
Awards granted under the Plan are subject to any policy the Company adopts regarding the recovery of incentive compensation and any additional clawback provisions as required by law and applicable listing rules.
12.Award Agreements
Each Award under the Plan shall be evidenced by an Award Agreement (as such may be amended from time to time) that sets forth the terms, conditions, restrictions and limitations applicable to the Award, including, but not limited to, the provisions governing vesting, exercisability, payment, forfeiture, and termination of employment, all or some of which may be incorporated by reference into one or more other documents delivered or otherwise made available to a Participant in connection with an Award.
13.Tax Withholding
Participants shall be solely responsible for any applicable taxes (including, without limitation, income, payroll and excise taxes) and penalties, and any interest that accrues thereon, which they incur in connection with the receipt, vesting or exercise of an Award. The Company and its Subsidiaries shall have the right to require payment of, or may deduct from any payment made under the Plan or otherwise to a Participant, or may permit shares to be tendered or sold, including Common Shares delivered or vested in connection with an Award, in an amount sufficient to cover withholding of any federal, state, provincial, territorial, local, foreign or other governmental taxes or charges required by law or such greater amount of withholding as the Committee shall determine from time to time and to take such other action as may be necessary to satisfy any such withholding obligations. It shall be a condition to the obligation of the Company to issue Common Shares upon the exercise of an Option, or SAR, or upon settlement of a Share Award, that the Participant pay to the Company, on demand, such amount as may be requested by the Company for the purpose of satisfying any tax withholding liability. If the amount is not paid, the Company may refuse to issue shares.
14.Other Benefit and Compensation Programs
Awards received by Participants under the Plan shall not be deemed a part of a Participant’s regular, recurring compensation for purposes of calculating payments or benefits from any Company benefit plan or severance program unless specifically provided for under the plan or program. Unless specifically set forth in an Award Agreement, Awards under the Plan are not intended as payment for compensation that otherwise would have been delivered in cash, and even if so intended, such Awards shall be subject to such vesting requirements and other terms, conditions and restrictions as may be provided in the Award Agreement.
15.Unfunded Plan
The Plan is intended to constitute an “unfunded” plan for incentive and deferred compensation. The Plan shall not establish any fiduciary relationship between the Company and any Participant or other Person. To the extent any Participant holds any rights by virtue of an Award granted under the Plan, such rights shall constitute general unsecured liabilities of the Company and shall not confer upon any Participant or any other Person any right, title, or interest in any assets of the Company.
16.Rights as a Shareholder
Unless the Committee determines otherwise, a Participant shall not have any rights as a shareholder with respect to Common Shares covered by an Award until the date the Participant becomes the holder of record with respect to such shares. No adjustment will be made for dividends or other rights for which the record date is prior to such date, except as provided in Section 8.
17.Future Rights
No Eligible Recipient shall have any claim or right to be granted an Award under the Plan. There shall be no obligation of uniformity of treatment of Eligible Recipients under the Plan. Further, the Company and its Subsidiaries may adopt other compensation programs, plans or arrangements as deemed appropriate or necessary. The adoption of the Plan, or grant of an Award, shall not confer upon any Eligible Recipient any right to continued employment or service in any particular position or at any particular rate of compensation, nor shall it interfere in any way with the right of the Company or a Subsidiary to terminate the employment or service of Eligible Recipients at any time, free from any claim or liability under the Plan.
18.Amendment and Termination
(a)    The Plan and any Award may be amended, suspended or terminated at any time by the Board, provided that no amendment shall be made without shareholder approval if such shareholder approval is required in order to comply with applicable law or the rules of the New York Stock Exchange, the rules of the Toronto Stock Exchange, or any other securities exchange on which the Common Shares are traded or quoted. Except as otherwise provided in



Section 10(a), no termination, suspension or amendment of the Plan or any Award shall adversely affect the right of any Participant with respect to any Award theretofore granted, as determined by the Committee, without such Participant’s written consent.
(b)    Notwithstanding Section 18(a), the Company shall obtain shareholder approval for: (i) except as provided in Section 6(e), a reduction in the exercise price or purchase price of an Award (or the cancellation and re-grant of an Award resulting in a lower exercise price or purchase price); (ii) the extension of the Original Term of an Option; (iii) any amendment to remove or to exceed the participation limits described in Section 6(d), including but not limited to those applicable to Insiders; (iv) an increase to the maximum number of Common Shares issuable under the Plan pursuant to Section 6(a) (other than adjustments in accordance with Section 6(e)); (v) amendments to this Section 18 other than amendments of a clerical nature; and (vi) any amendment that permits Awards to be transferable or assignable other than for normal estate settlement purposes or for other purposes not involving the receipt of monetary consideration.
19.Option and SAR Repricing
Except as provided in Section 6(e) and without limiting Section 18(b)(i), the Committee may not, without shareholder approval, seek to effect any re-pricing of any previously granted “underwater” Option or SAR by: (i) amending or modifying the terms of the Option or SAR to lower the exercise price; (ii) cancelling the underwater Option or SAR and granting either (A) replacement Options or SARs having a lower exercise price or (B) Restricted Shares, Share Units, or Other Share Awards in exchange; or (iii) cancelling or repurchasing the underwater Options or SARs for cash or other securities. An Option or SAR will be deemed to be “underwater” at any time when the Market Value of the Common Shares covered by such Award is less than the exercise price of the Award.
20.Successors and Assigns
The Plan and any applicable Award Agreement shall be binding on all successors and assigns of a Participant, including, without limitation, the estate of such Participant and the executor, administrator or trustee of such estate, or any receiver or trustee in bankruptcy or representative of the Participant’s creditors.
21.Governing Law
The Plan and all agreements entered into under the Plan shall be governed, construed and administered in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein.
22.Interpretation
The Plan is designed and intended, to the extent applicable, to provide for grants and other transactions which are exempt under Rule 16b-3, and all provisions hereof shall be construed in a manner to so comply. Awards under the Plan are also intended to comply with Code Section 409A to the extent subject thereto, and the Plan and all Awards shall be interpreted in accordance with Code Section 409A and Treasury Regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the effective date of the Plan. Notwithstanding any provision in the Plan to the contrary, no payment or distribution under this Plan that constitutes an item of deferred compensation under Code Section 409A and becomes payable by reason of a Participant’s termination of employment or service with the Company shall be made to such Participant until such Participant’s termination of employment or service constitutes a Separation from Service. For purposes of this Plan, each amount to be paid or benefit to be provided shall be construed as a separate identified payment for purposes of Code Section 409A. If a participant is a Specified Employee, then to the extent necessary to avoid the imposition of taxes under Code Section 409A, such Participant shall not be entitled to any payments upon a termination of his or her employment or service until the earlier of: (i) the expiration of the six (6)-month period measured from the date of such Participant’s Separation from Service or (ii) the date of such Participant’s death. Upon the expiration of the applicable waiting period set forth in the preceding sentence, all payments and benefits deferred pursuant to this Section 22 (whether they would have otherwise been payable in a single lump sum or in installments in the absence of such deferral) shall be paid to such Participant in a lump sum as soon as practicable, but in no event later than sixty (60) calendar days, following such expired period, and any remaining payments due under this Plan will be paid in accordance with the normal payment dates specified for them herein. Notwithstanding any provision of the Plan to the contrary, in no event shall the Company or any affiliate be liable to a Participant on account of an Award’s failure to (i) qualify for favorable U.S. or foreign tax treatment or (ii) avoid adverse tax treatment under U.S. or foreign law, including, without limitation, Code Section 409A.

EX-10.14 3 exhibit10142020ye.htm EX-10.14 Document
Exhibit 10.14

image_01a.jpg




November 2, 2020

[Name]

Dear [Name]:

I am pleased to share with you two important compensation and benefits updates.

First, as you know, we recently announced our intent to spin off Bausch + Lomb (“B+L”) to be an independent, publicly traded entity, separate from the remainder of Bausch Health (“BHC” or the “Company”). The effort to accomplish the spinoff is significant, particularly as it is coupled with our
need to continue to rebound from the impact COVID-19 has had on our business. As such, the Talent and Compensation Committee (the “Committee”) of the Board of Directors of Bausch Health Companies, Inc. has approved your participation in our Spinoff Bonus Program as follows:

Spinoff Bonus Award (the “Award”) – You will be eligible to receive a cash bonus of [$] (subject to applicable withholdings and deductions) payable in two installments, as set forth below:
The first 50% will be payable as soon as administratively practicable following the completion of all three of the following key milestones in the separation process: 1) regulatory and SEC filings completed; 2) operational separation plans successfully executed; and 3) B+L and BHC are operationally separated (targeted for on or about January 1, 2022).

The second 50% will be payable as soon as administratively practicable following the completion of the closing of the spinoff, resulting in full separation of B+L and BHC.

In order to receive this Award, you must be employed by either BHC, B+L or one of their affiliates, on the applicable payment date; provided, however, that, if the Company terminates your employment other than for performance or “cause”, as defined in your employment contract, or if no such agreement or definition exists, as defined in the Bausch Health Companies, Inc. 2014 Omnibus Incentive Plan (as Amended and Restated, Effective as of April 28, 2020), prior to the payment of the Award, any remaining balance will be paid to you as soon as administratively practicable following your termination date, subject to you delivering a general release of claims in a form reasonably acceptable to the Company within forty-five days following your termination of employment (and not revoking such release). Additionally, if the Company’s business strategy is altered, resulting in the award milestones being unachievable, the bonus milestones and payout terms may be changed, with the approval of the Committee.

Second, recognizing that the separation process can create some uncertainty, the Committee has also approved an enhancement to the severance amount currently provided to you through your employment contract as follows:
Enhanced Severance Benefit (effective January 1, 2021) – In the event of a qualifying termination of employment under the terms of your employment contract with the Company,



Page 2

your severance shall be equal to one and a half (1.5) times the sum of your annual base pay and your target annual bonus. The enhanced severance benefits will remain in effect through December 31, 2023. Except as modified in this letter, your employment agreement will remain in effect in accordance with its terms, including your right to receive other payments and benefits upon your termination of employment (without duplication hereunder).

As this opportunity is only being extended to a limited number of key employees, we ask that you keep this information confidential. Questions may be directed to Kelly Webber, Kim Azerski, or me.

Our ~22,000 employees around the world are counting on us to lead them through the successful separation into two companies. I am excited by this important opportunity to evolve our business and better meet customer and patient needs, and I look forward to your continued contributions to this effort.

Very truly yours,

Joseph C. Papa
Chairman and CEO

Section 409A Information
The intent of the parties is that payments and benefits under this letter and any other plans or arrangements in which you participate (together, the “Arrangements”) comply with Section 409A of the Internal Revenue Code and the treasury regulations and other interpretive guidance issued thereunder (“Section 409A”), to the extent subject thereto, and accordingly, to the maximum extent permitted, the Arrangements shall be interpreted and administered to be in compliance therewith. Notwithstanding anything contained therein to the contrary, you shall not be considered to have terminated employment with the Company for purposes of any payments under the Arrangements which are subject to Section 409A until you have incurred a “separation from service” from the Company within the meaning of Section 409A. Each amount to be paid or benefit to be provided under this letter shall be construed as a separate identified payment for purposes of Section 409A. Without limiting the foregoing under any Arrangements, to the extent required in order to avoid an accelerated or additional tax under Section 409A, (a) if you are a “specified employee” as such term is defined under Section 409A, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to the Arrangements during the six-month period immediately following your separation from service shall instead be paid on the first business day after the date that is six months following your separation from service (or, if earlier, your date of death) and (b) references to a termination on account of disability shall be deemed to refer to a “disability” as defined under Section 409A. To the extent required to avoid an accelerated or additional tax under Section 409A, amounts reimbursable to you shall be paid to you on or before the last day of the year following the year in which the expense was incurred and the amount of expenses eligible for reimbursement (and in kind benefits provided to you) during one year may not affect amounts reimbursable or provided in any subsequent year. With respect to the Award, to the extent the forty-five day period following your termination begins in one taxable year and ends in a second taxable year, the Award shall be made in the second taxable year to the extent required to avoid any additional tax, interest or penalties under Section 409A. The Company makes no representation that any or all of the payments described in the Arrangements will be exempt from or comply with Section 409A and makes no undertaking to preclude Section 409A from applying to any such payment.

By signing below, you indicate acceptance of the terms set forth in this letter.


Name: ________________________________ Date: ________________________
[Name]

EX-21.1 4 exhibit2112020ye.htm EX-21.1 Document

Exhibit 21.1

Subsidiary Information
As of February 24, 2021
CompanyJurisdiction of
Incorporation
Doing Business As
Bausch & Lomb Argentina S.R.L.ArgentinaBausch & Lomb Argentina S.R.L.
Waicon Vision S.A.ArgentinaWaicon Vision S.A.
Bausch & Lomb (Australia) Pty LimitedAustraliaBausch & Lomb (Australia) Pty Limited
Bausch Health Australia Pty LimitedAustraliaBausch Health Australia Pty Limited
Wirra Holdings Pty LimitedAustraliaWirra Holdings Pty Limited
Bausch & Lomb Gesellschaft m.b.H.AustriaBausch & Lomb GmbH
Bausch Health Closed Joint-Stock CompanyBelarusBausch Health CJSC
Bausch & Lomb Pharma S.A.BelgiumBausch & Lomb Pharma S.A.
PharmaSwiss BH Društvo za trgovinu na veliko d.o.o. SarajevoBosniaPharmaSwiss BH d.o.o. Sarajevo
BL Importações Ltda.BrazilBL Importações Ltda.
BL Indústria Ótica Ltda.BrazilBL Indústria Ótica Ltda.
0909657 B.C. Ltd.British Columbia
(Canada)
0909657 B.C. Ltd.
1261229 B.C. Ltd.British Columbia
(Canada)
1261229 B.C. Ltd.
PharmaSwiss EOODBulgariaPharmaSwiss EOOD
12279282 Canada Ltd.Canada12279282 Canada Ltd.
12279967 Canada Ltd.Canada12279967 Canada Ltd.
12283778 Canada Ltd.Canada12283778 Canada Ltd.
Bausch Health, Canada Inc./ Santé Bausch, Canada Inc.CanadaBausch Health, Canada Inc. / Santé Bausch, Canada Inc.
Valeant Canada GP Limited/ Commandité Valeant Canada LimitéeCanadaValeant Canada GP Limited/ Commandité Valeant Canada Limitée
Valeant Canada Limited / Valeant Canada LimitéeCanadaValeant Canada Limited / Valeant Canada Limitée
Valeant Canada S.E.C./Valeant Canada LPCanadaValeant Canada S.E.C./Valeant Canada LP
V-BAC Holding Corp.CanadaV-BAC Holding Corp.
9079-8851 Quebec Inc.Quebec (Canada)9079-8851 Quebec Inc.
Mercury (Cayman) HoldingsCayman IslandsMercury (Cayman) Holdings
Bausch & Lomb (Shanghai) Trading Co., Ltd.ChinaBausch & Lomb (Shanghai) Trading Co., Ltd.
Beijing Bausch & Lomb Eyecare Co., Ltd.ChinaBeijing Bausch & Lomb Eyecare Co., Ltd.
Shandong Bausch & Lomb Freda New Packing Materials Co., Ltd.ChinaShandong Bausch & Lomb Freda New Packing Materials Co., Ltd.
Shandong Bausch & Lomb Freda Pharmaceutical Co., Ltd.ChinaShandong Bausch & Lomb Freda Pharmaceutical Co., Ltd.
Solta (Shanghai) Health Management Co., Ltd.ChinaSolta (Shanghai) Health Management Co., Ltd.
Cambridge Pharmaceutical S.A.S.ColombiaCambridge Pharmaceutical S.A.S.
Farmatech S.A.ColombiaFarmatech S.A.
Humax Pharmaceutical S.A.ColombiaHumax Pharmaceutical S.A.
PharmaSwiss društvo s ograničenom odgovornošću za trgovinu i uslugeCroatiaPharmaSwiss društvo s ograničenom odgovornošću za trgovinu i usluge
PharmaSwiss Ceská republika s.r.o.Czech RepublicPharmaSwiss Ceská republika s.r.o.
Amoun Distribution LLCEgyptAmoun Distribution LLC
Amoun Pharmaceutical Company S.A.E.EgyptAmoun Pharmaceutical Company S.A.E.



ICN Egypt LLCEgyptICN Egypt LLC
PharmaSwiss Eesti OÜEstoniaPharmaSwiss Eesti OÜ
Bausch & Lomb France S.A.S.FranceBausch & Lomb France S.A.S.
Laboratoire Chauvin S.A.S.FranceLaboratoire Chauvin S.A.S.
Bausch & Lomb GmbHGermanyBausch & Lomb GmbH
B L E P Holding GmbHGermanyB L E P Holding GmbH
Dr. Gerhard Mann chem.-pharm. Fabrik Gesellschaft mit beschränkter HaftungGermanyDr. Gerhard Mann chem.-pharm. Fabrik GmbH
Dr. Robert Winzer Pharma GmbHGermanyDr. Robert Winzer Pharma GmbH
Grundstücksverwaltungsgesellschaft Dr.Gerhard Mann chem.- pharm. Fabrik GmbHGermanyGrundstücksverwaltungsgesellschaft Dr.Gerhard Mann chem.- pharm. Fabrik GmbH
Pharmaplast Vertriebsgesellschaft mbHGermanyPharmaplast Vertriebsgesellschaft mbH
Technolas Perfect Vision GmbHGermanyTechnolas Perfect Vision GmbH
Bausch Health Hellas Single-Member Pharmaceuticals Société AnonymeGreeceBausch Health Hellas
Bausch & Lomb (Hong Kong) LimitedHong KongBausch & Lomb (Hong Kong) Limited
Sino Concept Technology LimitedHong KongSino Concept Technology Limited
Bausch Health Magyarország Korlátolt Felelõsségû Társaság
Hungary
Bausch Health Magyarország Korlátolt Felelõsségû Társaság
Bausch & Lomb India Private LimitedIndiaBausch & Lomb India Private Limited
PT Bausch Lomb IndonesiaIndonesiaPT Bausch Lomb Indonesia
Bausch + Lomb Ireland LimitedIrelandBausch + Lomb Ireland Limited
Bausch Health HoldCo LimitedIrelandBausch Health HoldCo Limited
Bausch Health Ireland LimitedIrelandBausch Health Ireland Limited
Oceana Therapeutics LimitedIrelandOceana Therapeutics Limited
Valeant Holdings IrelandIrelandValeant Holdings Ireland
Bausch & Lomb-IOM S.p.A.ItalyBausch & Lomb-IOM S.p.A.
B.L.J. Company LimitedJapanB.L.J. Company Limited
Bausch & Lomb (Jersey) LimitedJerseyBausch & Lomb (Jersey) Limited
Bausch Health LLPKazakhstanBausch Health LLP
Bausch & Lomb Korea Co., Ltd.KoreaBausch & Lomb Korea Co., Ltd.
Bausch Health Korea Co., LimitedKoreaBausch Health Korea Co., Limited
Bescon Co., Ltd.KoreaBescon Co., Ltd.
UAB PharmaSwissLithuaniaUAB PharmaSwiss
Bausch & Lomb Luxembourg S.à r.l.LuxembourgBausch & Lomb Luxembourg S.à r.l.
Valeant Finance Luxembourg S.à r.l.LuxembourgValeant Finance Luxembourg S.à r.l.
Valeant Pharmaceuticals Luxembourg S.à r.l.LuxembourgValeant Pharmaceuticals Luxembourg S.à r.l.
Bausch & Lomb (Malaysia) Sdn. Bhd.MalaysiaBausch & Lomb (Malaysia) Sdn. Bhd.
Bausch & Lomb México, S.A. de C.V.MexicoBausch & Lomb México, S.A. de C.V.
Laboratorios Fedal, S.A.MexicoLaboratorios Fedal, S.A.
Laboratorios Grossman, S.A.MexicoLaboratorios Grossman, S.A.
Nysco de México, S.A. de C.V.MexicoNysco de México, S.A. de C.V.
Tecnofarma, S.A. de C.V.MexicoTecnofarma, S.A. de C.V.
Valeant Servicios y Administración, S. de R.L. de C.V.MexicoValeant Servicios y Administración, S. de R.L. de C.V.
Bausch Health NetherlandsNetherlandsBausch Health Netherlands
Bausch+Lomb OPS B.V.NetherlandsBausch+Lomb OPS B.V.
Natur Produkt Europe B.V.NetherlandsNatur Produkt Europe B.V.
Bausch+Lomb Netherlands B.V.NetherlandsBausch+Lomb Netherlands B.V.



Bausch & Lomb (New Zealand) LimitedNew ZealandBausch & Lomb (New Zealand) Limited
Valeant Farmacéutica Panamá, S.A.PanamaValeant Farmacéutica Panamá, S.A.
Bausch Health Perú S.R.L.PeruBausch Health Perú S.R.L.
Bausch & Lomb Philippines Inc.PhilippinesBausch & Lomb Philippines Inc.
Bausch Health Poland spółka z ograniczoną PolandBausch Health Poland sp.z o.o.
Emo-Farm spółka z ograniczoną odpowiedzialnościąPolandEmo-Farm sp. z o.o.
ICN Polfa Rzeszow Spółka AkcyjnaPolandICN Polfa Rzeszow SA
Przedsiebiorstwo Farmaceutyczne Jelfa Spółka AkcyjnaPolandPrzedsiebiorstwo Farmaceutyczne Jelfa SA
Valeant Med spółka z ograniczoną odpowiedzialnościąPolandValeant Med sp. z o.o.
Valeant spółka z ograniczoną odpowiedzialnością Europe spółka jawnaPolandValeant sp. z o.o. Europe sp. j.
Amoun Pharmaceutical Romania SRLRomaniaAmoun Pharmaceutical Romania SRL
Bausch Health Romania SRL (f/k/a S.C. Valeant Pharma SRL)RomaniaBausch Health Romania SRL (f/k/a Valeant Pharma SRL)
Bausch Health Limited Liability Company RussiaBausch Health LLC
CJSC Natur Produkt InternationalRussiaCJSC Natur Produkt International
PharmaSwiss doo preduzeće za proizvodnju, unutrašnju, spoljnu trgovinu i zastupanje BeogradSerbiaPharmaSwiss doo, Beograd
Bausch & Lomb (Singapore) Private LimitedSingaporeBausch & Lomb (Singapore) Private Limited
Technolas Singapore Pte. Ltd.SingaporeTechnolas Singapore Pte. Ltd.
Bausch Health Slovakia s.r.o.SlovakiaBausch Health Slovakia s.r.o.
PharmaSwiss, trgovsko in proizvodno podjetje, d.o.o.SloveniaPharmaSwiss d.o.o.
Bausch & Lomb (South Africa) (Pty) LtdSouth AfricaBausch & Lomb (South Africa) (Pty) Ltd
Soflens (Pty) LtdSouth AfricaSoflens (Pty) Ltd
Bausch & Lomb S.A.SpainBausch & Lomb S.A.
Bausch & Lomb Nordic AktiebolagSwedenBausch & Lomb Nordic AB
Bausch & Lomb Swiss AGSwitzerlandBausch & Lomb Swiss AG
PharmaSwiss SASwitzerlandPharmaSwiss SA
Bausch & Lomb Taiwan LimitedTaiwanBausch & Lomb Taiwan Limited
Bausch & Lomb (Thailand) LimitedThailandBausch & Lomb (Thailand) Limited
Bausch & Lomb Sağlik ve Optik Ürünleri Ticaret Anonim ŞirketiTurkeyBausch & Lomb Sağlik ve Optik Ürünleri Tic.Ş.Þ
Bausch Health Limited Liability CompanyUkraineBausch Health Limited Liability Company
Medpharma Pharmaceutical & Chemical Industries LLCUAEMedpharma Pharma & Chem Ind LLC
Bausch Health Trading DWC-LLCUAEBausch Health Trading DWC-LLC
Bausch & Lomb U.K. LimitedUnited KingdomBausch & Lomb U.K. Limited
Sterimedix LimitedUnited KingdomSterimedix Limited
Salix Pharmaceuticals, Inc.California (US)Salix Pharmaceuticals, Inc.
Visioncare Devices, Inc.California (US)Visioncare Devices, Inc.
Audrey Enterprise, LLCDelaware (US)Audrey Enterprise, LLC
Bausch & Lomb Americas Inc.Delaware (US)Bausch & Lomb Americas Inc.
Bausch & Lomb South Asia, Inc.Delaware (US)Bausch & Lomb South Asia, Inc.
Bausch Foundation, LLCDelaware (US)Bausch Foundation, LLC
Bausch Health Americas, Inc.Delaware (US)Bausch Health Americas, Inc.
Bausch Health US, LLCDelaware (US)Bausch Health US, LLC
Eye Essentials LLCDelaware (US)Eye Essentials LLC



Medicis Pharmaceutical CorporationDelaware (US)Medicis Pharmaceutical Corporation
Oceanside Pharmaceuticals, Inc.
Delaware (US)
Oceanside Pharmaceuticals, Inc.
OraPharma, Inc.Delaware (US)OraPharma, Inc.
PreCision Dermatology, Inc.Delaware (US)PreCision Dermatology, Inc.
Salix Pharmaceuticals, Ltd.Delaware (US)Salix Pharmaceuticals, Ltd.
Santarus, Inc.Delaware (US)Santarus, Inc.
Solta Medical, Inc.Delaware (US)Solta Medical, Inc.
Synergetics IP, Inc.Delaware (US)Synergetics IP, Inc.
Unilens Corp. USADelaware (US)Unilens Corp. USA
Unilens Vision Sciences Inc.Delaware (US)Unilens Vision Sciences Inc.
VRX Holdco LLCDelaware (US)VRX Holdco LLC
Synergetics, Inc.Missouri (US)Synergetics, Inc.
Alden Optical Laboratories, Inc.New York (US)Alden Optical Laboratories, Inc.
Bausch & Lomb IncorporatedNew York (US)Bausch & Lomb Incorporated

In accordance with the instructions of Item 601 of Regulation S-K, certain subsidiaries are omitted from the foregoing table.

EX-23.1 5 exhibit2312020ye.htm EX-23.1 Document

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-223388) and S-8 (Nos. 333-238084, 333-226786, 333-196120, 333-176205, 333-168254, 333-168629, and 333-138697 as amended, where applicable) of Bausch Health Companies Inc. of our report dated February 24, 2021 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.



/s/ PricewaterhouseCoopers LLP
Florham Park, New Jersey
February 24, 2021

EX-31.1 6 exhibit3112020ye.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO RULE 13a-14(a)
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Joseph C. Papa, certify that:
1.    I have reviewed this annual report on Form 10-K of Bausch Health Companies Inc. (the “Company”);
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
4.    The Company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:
a.    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.    Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.    Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting; and
5.    The Company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions):
a.    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information; and
b.    Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.
Date: February 24, 2021
/s/ JOSEPH C. PAPA
Joseph C. Papa
Chairman of the Board and Chief Executive Officer
(Principal Executive Officer)

EX-31.2 7 exhibit3122020ye.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
PURSUANT TO RULE 13a-14(a)
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Paul S. Herendeen, certify that:
1.    I have reviewed this annual report on Form 10-K of Bausch Health Companies Inc. (the “Company”);
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
4.    The Company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:
a.    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.    Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.    Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting; and
5.    The Company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions):
a.    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information; and
b.    Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.
Date: February 24, 2021
/s/ PAUL S. HERENDEEN
Paul S. Herendeen
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)

EX-32.1 8 exhibit3212020ye.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. § 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Joseph C. Papa, Chairman of the Board and Chief Executive Officer of Bausch Health Companies Inc. (the “Company”), certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
1.    The Annual Report of the Company on Form 10-K for the fiscal year ended December 31, 2020 (the “Annual Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
2.    The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: February 24, 2021
/s/ JOSEPH C. PAPA
Joseph C. Papa
Chairman of the Board and Chief Executive Officer
(Principal Executive Officer)
This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the U.S. Securities and Exchange Commission or its staff upon request.

EX-32.2 9 exhibit3222020ye.htm EX-32.2 Document

Exhibit 32.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. § 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Paul S. Herendeen, Executive Vice President and Chief Financial Officer of Bausch Health Companies Inc. (the “Company”), certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
1.    The Annual Report of the Company on Form 10-K for the fiscal year ended December 31, 2020 (the “Annual Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
2.    The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: February 24, 2021
/s/ PAUL S. HERENDEEN
Paul S. Herendeen
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the U.S. Securities and Exchange Commission or its staff upon request.

EX-101.SCH 10 bhc-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000010001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 100020003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 100040005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 100050006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 100060007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 210011001 - Disclosure - DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 240024001 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 210031002 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 220042001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 230053001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 240064002 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details) link:presentationLink link:calculationLink link:definitionLink 240074003 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details) link:presentationLink link:calculationLink link:definitionLink 240084004 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 240094005 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 240104006 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details) link:presentationLink link:calculationLink link:definitionLink 240114007 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240124008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 240134009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details) link:presentationLink link:calculationLink link:definitionLink 240144010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 240154011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 240164012 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 240174013 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details) link:presentationLink link:calculationLink link:definitionLink 210181003 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE link:presentationLink link:calculationLink link:definitionLink 230193002 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE (Tables) link:presentationLink link:calculationLink link:definitionLink 240204014 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240214015 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 240224016 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Assets and Liabilities Held For Sale (Details) link:presentationLink link:calculationLink link:definitionLink 210231004 - Disclosure - RESTRUCTURING, INTEGRATION AND SEPARATION COSTS link:presentationLink link:calculationLink link:definitionLink 240244017 - Disclosure - RESTRUCTURING, INTEGRATION AND SEPARATION COSTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 210251005 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 230263003 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 240274018 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 240284019 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240294020 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240304021 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 240314022 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240324023 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details) link:presentationLink link:calculationLink link:definitionLink 240334024 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 240344025 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis, Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240354026 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 210361006 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 230373004 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 240384027 - Disclosure - INVENTORIES - Summary of Inventories, Net (Details) link:presentationLink link:calculationLink link:definitionLink 210391007 - Disclosure - PROPERTY, PLANT AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 230403005 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 240414028 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 240424029 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 210431008 - Disclosure - INTANGIBLE ASSETS AND GOODWILL link:presentationLink link:calculationLink link:definitionLink 230443006 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables) link:presentationLink link:calculationLink link:definitionLink 240454030 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 240454030 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 240464031 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240474032 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 240484033 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 210491009 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 230503007 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 240514034 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 210521010 - Disclosure - FINANCING ARRANGEMENTS link:presentationLink link:calculationLink link:definitionLink 230533008 - Disclosure - FINANCING ARRANGEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 240544035 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 240554036 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details) link:presentationLink link:calculationLink link:definitionLink 240564037 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details) link:presentationLink link:calculationLink link:definitionLink 240574038 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2018 Activities (Details) link:presentationLink link:calculationLink link:definitionLink 240584039 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2019 Activities (Details) link:presentationLink link:calculationLink link:definitionLink 240594040 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2020 Activities (Details) link:presentationLink link:calculationLink link:definitionLink 240604041 - Disclosure - FINANCING ARRANGEMENTS - Current Description of Senior Secured Credit Facilities (Details) link:presentationLink link:calculationLink link:definitionLink 240614042 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details) link:presentationLink link:calculationLink link:definitionLink 240624043 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details) link:presentationLink link:calculationLink link:definitionLink 240634044 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details) link:presentationLink link:calculationLink link:definitionLink 240644045 - Disclosure - FINANCING ARRANGEMENTS - Maturities, Schedule of Maturities and Mandatory Payments of Debt Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 210651011 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS link:presentationLink link:calculationLink link:definitionLink 230663009 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables) link:presentationLink link:calculationLink link:definitionLink 240674046 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240684047 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 240694048 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of net periodic benefit cost (Details) link:presentationLink link:calculationLink link:definitionLink 240704049 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details) link:presentationLink link:calculationLink link:definitionLink 240704049 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details) link:presentationLink link:calculationLink link:definitionLink 240714050 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details) link:presentationLink link:calculationLink link:definitionLink 240724051 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future benefit payments for the pension benefit plans (Details) link:presentationLink link:calculationLink link:definitionLink 240734052 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-average assumptions used to determine net periodic benefit costs and benefit obligations (Details) link:presentationLink link:calculationLink link:definitionLink 240744053 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details) link:presentationLink link:calculationLink link:definitionLink 240754054 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair value of pension and postretirement benefit plan assets assumed in connection with the Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 210761012 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 230773010 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 240784055 - Disclosure - LEASES - Right-of-use Assets and Right-of-use Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 240794056 - Disclosure - LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240804057 - Disclosure - LEASES - Lease Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 240814058 - Disclosure - LEASES - Lease Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 240824059 - Disclosure - LEASES - Lease Future Payments (Details) link:presentationLink link:calculationLink link:definitionLink 240824059 - Disclosure - LEASES - Lease Future Payments (Details) link:presentationLink link:calculationLink link:definitionLink 210831013 - Disclosure - SHARE-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 230843011 - Disclosure - SHARE-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 240854060 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 240864061 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 240874062 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 240884063 - Disclosure - SHARE-BASED COMPENSATION - RSUs (Details) link:presentationLink link:calculationLink link:definitionLink 210891014 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 230903012 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) link:presentationLink link:calculationLink link:definitionLink 240914064 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 210921015 - Disclosure - RESEARCH AND DEVELOPMENT link:presentationLink link:calculationLink link:definitionLink 230933013 - Disclosure - RESEARCH AND DEVELOPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 240944065 - Disclosure - RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details) link:presentationLink link:calculationLink link:definitionLink 210951016 - Disclosure - OTHER EXPENSE (INCOME), NET link:presentationLink link:calculationLink link:definitionLink 230963014 - Disclosure - OTHER EXPENSE (INCOME), NET (Tables) link:presentationLink link:calculationLink link:definitionLink 240974066 - Disclosure - OTHER EXPENSE (INCOME), NET - Schedule of Other Expense (Income), Net (Details) link:presentationLink link:calculationLink link:definitionLink 240984067 - Disclosure - OTHER EXPENSE (INCOME), NET - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 210991017 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 231003015 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 241014068 - Disclosure - INCOME TAXES - Components of Benefit from Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 241024069 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 241034070 - Disclosure - INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 241044071 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details) link:presentationLink link:calculationLink link:definitionLink 241054072 - Disclosure - INCOME TAXES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 241064073 - Disclosure - INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details) link:presentationLink link:calculationLink link:definitionLink 241074074 - Disclosure - INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 211081018 - Disclosure - LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 231093016 - Disclosure - LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 241104075 - Disclosure - LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 241114076 - Disclosure - LOSS PER SHARE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 211121019 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES link:presentationLink link:calculationLink link:definitionLink 231133017 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables) link:presentationLink link:calculationLink link:definitionLink 241144077 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 211151020 - Disclosure - LEGAL PROCEEDINGS link:presentationLink link:calculationLink link:definitionLink 241164078 - Disclosure - LEGAL PROCEEDINGS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 211171021 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 241184079 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 211191022 - Disclosure - SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 231203018 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 241214080 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit, Assets and Capital Expenditures, Depreciation & Amortization of Intangible Assets & Asset Impairments (Details) link:presentationLink link:calculationLink link:definitionLink 241224081 - Disclosure - SEGMENT INFORMATION - Revenues by Product Category (Details) link:presentationLink link:calculationLink link:definitionLink 241234082 - Disclosure - SEGMENT INFORMATION - Geographic Information, Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 241244083 - Disclosure - SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details) link:presentationLink link:calculationLink link:definitionLink 241254084 - Disclosure - SEGMENT INFORMATION - Major Customers (Details) link:presentationLink link:calculationLink link:definitionLink 211261023 - Disclosure - SUPPLEMENTARY DATA (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 231273019 - Disclosure - SUPPLEMENTARY DATA (UNAUDITED) (Tables) link:presentationLink link:calculationLink link:definitionLink 241284085 - Disclosure - SUPPLEMENTARY DATA (UNAUDITED) - Schedule of Unaudited Quarterly Consolidated Financial Data (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 bhc-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 bhc-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 bhc-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Other non-current assets: Fair Value, Net Asset (Liability) [Abstract] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Other equipment Other Machinery and Equipment [Member] Intangible assets Deferred Tax Liabilities, Intangible Assets Restatement [Axis] Revision of Prior Period [Axis] Defined benefit plan, percentage of actual plan asset allocations Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Outstanding at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Potential asset acquisition, upfront payment included in aggregate purchase price Potential Asset Acquisition, Upfront Payment Included In Aggregate Purchase Price Potential Asset Acquisition, Upfront Payment Included In Aggregate Purchase Price Change in Projected Benefit Obligation Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Estimated company contributions in next fiscal year Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year Reporting Units Excluding Dentistry Reporting Units Excluding Dentistry [Member] Reporting Units Excluding Dentistry [Member] Payments / Settlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Interest expense Interest and Debt Expense Germany Germany GERMANY Change in Plan Assets Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Fair value of pension and postretirement benefit plan assets assumed in connection with the Acquisition Schedule of Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with Acquisition [Table Text Block] Schedule of Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with Acquisition [Table Text Block] China China CHINA Number of additional shares available for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Proceeds from sale of marketable securities Proceeds from Sale and Maturity of Marketable Securities Unrecognized actuarial losses Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax Estimated aggregate amortization expense Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Milestone payments in terms of collaboration and license agreements, aggregate Collaborative Agreement Milestone Payments, Aggregate Represents the amounts required to be paid by the reporting entity, which are contingent upon the achievement of specific development, regulatory or commercial milestones, in connection with the Collaboration Agreement. Statistical Measurement [Domain] Statistical Measurement [Domain] Payments or receipts in settlement of cross-currency swaps Payments for (Proceeds from) Hedge, Investing Activities Share-based compensation Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Noncontrolling interest distributions Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Other assets Other Assets, Fixed Income Securities [Member] Other Assets, Fixed Income Securities [Member] Percentage of fair value in excess of carrying value Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount Synergy Synergy Pharmaceuticals Inc. [Member] Synergy Pharmaceuticals Inc. [Member] Security Exchange Name Security Exchange Name Egypt EGYPT 5.875% Senior Notes Due May 2023 Senior Notes, 5.875%, Due May 2023 [Member] 5.875% Senior Notes due May 2023 [Member] Fair value of plan assets, beginning of year Fair value of plan assets, end of year Fair value of plan assets Defined Benefit Plan, Plan Assets, Amount Issuance of long-term debt, net of discounts Proceeds from issuance of long-term debt Proceeds from Issuance of Long-term Debt Schedule of assets by geographic region Long-lived Assets by Geographic Areas [Table Text Block] Total current liabilities Liabilities, Current Income Tax [Line Items] Income Tax [Line Items] -- None. No documentation exists for this element. -- Settlements Defined Benefit Plan, Plan Assets, Payment for Settlement Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Beginning of the period (in dollars per share) End of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Variable Rate [Domain] Variable Rate [Domain] 2024 Defined Benefit Plan, Expected Future Benefit Payment, Year Five Doctors Allergy Formula, LLC Litigation Doctors Allergy Formula, LLC Litigation [Member] Doctors Allergy Formula, LLC Litigation [Member] Assets Assets [Abstract] Term Loan B Facility Due November 2025 Term Loan B Facility Due November 2025 [Member] Term Loan B Facility Due November 2025 [Member] Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] Segment reporting information Revenue, Major Customer [Line Items] Common shares issued under share-based compensation plans Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Cash paid from operating cash flows for amounts included in the measurement of lease liabilities Operating Lease, Payments Sandoz Litigation Sandoz Litigation [Member] Sandoz Litigation [Member] ACCUMULATED OTHER COMPREHENSIVE LOSS Comprehensive Income (Loss) Note [Text Block] 2023 Long-Term Debt, Maturity, Year Three Amortization of intangible assets Amortization of intangible assets Amortization of Intangible Assets Excluding Amortization Allocated to Revenues Cost of Good Sold Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period. Entity Address, Country Entity Address, Country Potential asset acquisition, additional funding payment included in aggregate purchase price Potential Asset Acquisition, Additional Funding Payment Included In Aggregate Purchase Price Potential Asset Acquisition, Additional Funding Payment Included In Aggregate Purchase Price 2021 Lessee, Operating Lease, Liability, to be Paid, Year One Beginning of the period (in shares) End of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 2024 Lessee, Operating Lease, Liability, to be Paid, Year Four Schedule of components and classification of financial assets and liabilities measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Remaining unrecognized compensation expense related to non-vested awards Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount LEGAL PROCEEDINGS Legal Matters and Contingencies [Text Block] Quality assurance Research And Development Expense, Quality Assurance Research And Development Expense, Quality Assurance New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Canada Canada CANADA Tax credit carryforward Tax Credit Carryforward, Amount 7.25% Senior Notes Due May 2029 Senior Notes, 7.25%, Due May 2029 [Member] Senior Notes 7.25 Percent Due May 2029 [Member] 2023 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other non-current liabilities Other Liabilities, Noncurrent Deferred tax assets, net Deferred Income Tax Assets, Net Expired or forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Other, net Other Income (Expense), Net Other Income (Expense), Net SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] Amount available for restricted payments Debt Instrument, Amount Available For Restricted Payments Debt Instrument, Amount Available For Restricted Payments Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Investment grade Investment Grade [Member] Investment Grade [Member] Inventories, net Inventories, net Inventory, Net Measurement Frequency [Domain] Measurement Frequency [Domain] Concentration risk, percentage Concentration Risk, Percentage Fair value of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] 6.375% Senior Notes due in October 2020 Senior Notes 6.375 Percent Due October 2020 [Member] Represents senior notes with an interest rate of 6.375 percent, due in October, 2020. Revenue, year-over-year decrease Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax Statement [Line Items] Statement [Line Items] Tax Period [Axis] Tax Period [Axis] Number of defined benefit plans amended Defined Benefit Plan, Number of Defined Benefit Plans Amended Defined Benefit Plan, Number of Defined Benefit Plans Amended Debt instrument, term Debt Instrument, Term Deferred income taxes Deferred Income Tax Noncash Expense (Benefit) The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations. Measurement Input Type [Domain] Measurement Input Type [Domain] Statement [Table] Statement [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Write-offs Accounts Receivable, Allowance for Credit Loss, Writeoff Interest cost Defined Benefit Plan, Interest Cost Type of Restructuring [Domain] Type of Restructuring [Domain] Statistical Measurement [Axis] Statistical Measurement [Axis] Selling, general and administrative expenses Selling General and Administrative Expense [Member] The allocation (or location) of expense to (in) selling, general and administrative expense. Ireland IRELAND Nonemployee Director Nonemployee Director [Member] Nonemployee Director [Member] Outside basis differences Deferred Tax Liabilities, Undistributed Foreign Earnings Fair Value, Nonrecurring Non-recurring basis Fair Value, Nonrecurring [Member] Amount outstanding Line of Credit Facility, Fair Value of Amount Outstanding Other Other Long Term Debt [Member] Represents long-term debt obligations not elsewhere enumerated. Entity Smaller Reporting Company Entity Small Business Perrigo Israel Pharmaceuticals Litigation Perrigo Israel Pharmaceuticals Litigation [Member] Perrigo Israel Pharmaceuticals Litigation FINANCING ARRANGEMENTS Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Investigation by the State of Texas Investigation by the State of Texas, State's Medicaid Program [Member] Investigation by the State of Texas, State's Medicaid Program [Member] Amendment Flag Amendment Flag Future benefit payments period Defined Benefit Plan, Estimated Future Benefit Payments, Period Defined Benefit Plan, Estimated Future Benefit Payments, Period Method and assumptions on valuation of stock options Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Number of defined benefit plans Defined Benefit Plan, Number of Defined Benefit Plans Defined Benefit Plan, Number of Defined Benefit Plans Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Accrued interest and penalties related to unrecognized tax benefits Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Realignment of Global Solta reporting unit goodwill Goodwill, Transfers Total number of shares approved for grant by the Company under the share-based compensation plans (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Corporate Corporate, Non-Segment [Member] Number of shares available for future grants (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Other Other Accrued Liabilities, Current Spain SPAIN Tax Year 2013 Tax Year 2013 [Member] RESTRUCTURING, INTEGRATION AND SEPARATION COSTS Restructuring and Related Activities Disclosure [Text Block] Global high yield Global High Yield [Member] Global High Yield [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Accounting Standards Update 2016-16 Accounting Standards Update 2016-16-1 [Member] Accounting Standards Update 2016-16-1 United Kingdom UNITED KINGDOM Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Borrowings of short-term debt Proceeds from Short-term Debt IPR&D In Process Research and Development, Policy [Policy Text Block] Fair Value of Derivative Instruments Derivatives, Policy [Policy Text Block] Settlement period for cash discounts and allowances Cash Discounts And Allowances, Settlement Period Cash Discounts And Allowances, Settlement Period Argentina, Brazil, Egypt, Greece, Serbia, Turkey, Ukraine, Venezuela and Vietnam Argentina, Brazil, Egypt, Greece, Serbia, Turkey, Ukraine, Venezuela and Vietnam [Member] Argentina, Brazil, Egypt, Greece, Serbia, Turkey, Ukraine, Venezuela and Vietnam France France FRANCE Lease renewal term Lessee, Operating Lease, Renewal Term Adjustments to tax attributes Effective Income Tax Rate Reconciliation, Adjustments To Tax Attributes, Amount Effective Income Tax Rate Reconciliation, Adjustments To Tax Attributes, Amount Contingencies Commitments and Contingencies, Policy [Policy Text Block] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Schedule of revenues by product and by product category Revenue from External Customers by Products and Services [Table Text Block] Balance, beginning of year Balance, end of year Cooperative advertising credits included in rebates SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Income Statement Location [Domain] Income Statement Location [Domain] 2022 Lessee, Operating Lease, Liability, to be Paid, Year Two 5.00% Senior Unsecured Notes Due January 2028 5.00% Senior Notes Due January 2028 [Member] 5.00% Senior Notes Due January 2028 [Member] Percentage of cash proceeds from incurrence of debt Line of Credit Facility, Percentage of Net Proceeds from Incurrence of Debt Payable as Mandatory Pre-payments Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments. Selling, general and administrative Selling, General and Administrative Expense Other Other Debt Obligations [Member] Deferred revenue Deferred Tax Assets, Deferred Income Foreign currency exchange contracts Foreign Exchange Contract [Member] Summary of lease expenses Lease, Cost [Table Text Block] 2023 Lessee, Operating Lease, Liability, to be Paid, Year Three Other non-current assets Other Assets, Noncurrent Plan Name [Axis] Plan Name [Axis] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Concentration Risk [Table] Concentration Risk [Table] Total assets Assets reclassified, held and used Assets Impairment of indefinite-lived intangible assets Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Interest expense Interest Expense, Debt Beginning of the period (in shares) End of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Reporting Unit [Domain] Reporting Unit [Domain] Percentage of stock options that will vest on each of the first, second, third and fourth anniversaries from the date of grant Share Based Compensation, Arrangement by Share Based Payment Award, Options Vested Percentage Represents percentage of stock options that will vest in the future period. Amortization of prior service credit Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Reporting unit, impairment test, long-term growth rates Reporting Unit, Impairment Test, Long-Term Growth Rate Reporting Unit, Impairment Test, Long-Term Growth Rate Antidilutive Securities [Axis] Antidilutive Securities [Axis] 7.25% Senior Unsecured Notes due 2029 7.25% Senior Unsecured Notes Due 2029 [Member] 7.25% Senior Unsecured Notes Due 2029 [Member] Total Other non-current liabilities Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent Intangible Assets Intangible Assets, Finite-Lived, Policy [Policy Text Block] Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses Line of Credit Facility, Percentage of Net Cash Proceeds of Insurance and Condemnation Proceeds from Property or Asset Losses Payable as Mandatory Prepayments Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment. Concentrations of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Non-deductible amount of share-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount Total liabilities Liabilities Capital expenditures: Capital Expenditure and Depreciation and Amortization [Abstract] Represents the capital expenditures, depreciation and amortization by segment. Income Taxes Income Tax Contingency [Line Items] Interest crediting rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate Unrecognized tax benefits including interest and penalties Unrecognized Tax Benefits, Including Interest and Penalties The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date. Accrued and other current liabilities Pension and Other Postretirement Defined Benefit Plans, Accrued and Other Current Liabilities Pension and Other Postretirement Defined Benefit Plans, Accrued and Other Current Liabilities Schedule Of Other Income And Expenses [Line Items] Schedule Of Other Income And Expenses [Line Items] [Line Items] for Schedule Of Other Income And Expenses [Table] TSR Performance-Based Restricted Stock Units TSR Performance-Based Restricted Stock Units [Member] TSR Performance-Based Restricted Stock Units [Member] Prepaid expenses and other current assets Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current Schedule of amounts recognized in accumulated other comprehensive loss Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] Damages sought Loss Contingency, Damages Sought, Value Expected volatility Expected Company share volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Retirement Plan Type [Axis] Retirement Plan Type [Axis] Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Scenario, Adjustment Scenario, Adjustment [Member] Vested and expected to vest at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Employee contributions Defined Benefit Plan, Plan Assets, Contributions by Plan Participant 6.75% Senior Notes due in August 2021 Senior Notes 6.75 Percent Due August 2021 [Member] Represents senior unsecured notes with an interest rate of 6.75 percent, due August, 2021. Italy ITALY Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Net increase (decrease) recognized in interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Level 1 Fair Value, Inputs, Level 1 [Member] Vested and exercisable at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Acquisition-related contingent consideration Acquisition-related contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset Inventories Increase (Decrease) in Inventories Weighted average interest rate Debt, Weighted Average Interest Rate RESEARCH AND DEVELOPMENT Research, Development, and Computer Software Disclosure [Text Block] Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold RSUs Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Decrease in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Additional Paid-In Capital Additional Paid-in Capital [Member] Schedule of other (expense) income Schedule of Other Nonoperating Income (Expense) [Table Text Block] Pro-forma operating results Business Acquisition, Pro Forma Operating Income (Loss) Business Acquisition, Pro Forma Operating Income (Loss) Japan JAPAN Highly liquid investments, maturity period (or less) Highly Liquid Investments, Maturity Period Highly Liquid Investments, Maturity Period Machinery and equipment Machinery and Equipment [Member] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Acquisition of noncontrolling interest Reduction of additional paid-in capital Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Deferred tax assets: Deferred Tax Assets, Net [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Senior Secured Credit Facilities Revolving credit facility Revolving Credit Facility [Member] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Secured leverage ratio Secured leverage ratio (not greater than) Debt Instrument, Covenant Terms, Secured Leverage Ratio Debt Instrument, Covenant Terms, Secured Leverage Ratio Vested and exercisable at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Poland POLAND Beginning of the period (in dollars per share) End of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Acquisition of businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Percentage interest acquired Business Acquisition, Percentage of Voting Interests Acquired Proceeds from exercise of stock options Proceeds from Stock Options Exercised Property, plant and equipment, gross Property, Plant and Equipment, Gross Domestic Deferred Federal Income Tax Expense (Benefit) 2022 Defined Benefit Plan, Expected Future Benefit Payment, Year Two Schedule of segment revenues and profit Schedule of Segment Reporting Information, by Segment [Table Text Block] Funded status, end of year Defined Benefit Plan, Funded (Unfunded) Status of Plan Pension and postretirement benefit plan adjustments: Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax [Abstract] Glumetza Antitrust Litigation, Non-Class Complaints Glumetza Antitrust Litigation, Non-Class Complaints [Member] Glumetza Antitrust Litigation, Non-Class Complaints [Member] Other commitments Schedule of Commitments [Line Items] -- None. No documentation exists for this element. -- SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Branded and Other Generics Branded and Other Generic Products [Member] Branded and Other Generic Products [Member] Schedule of effect of hedging instruments on financial statements Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Income Statement [Abstract] Income Statement [Abstract] Accumulated Other Comprehensive Loss AOCI Attributable to Parent AOCI Attributable to Parent [Member] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets 5.25% Senior Notes Due January 2030 Senior Notes, 5.25%, Due January 2030 [Member] 5.25% Senior Notes Due January 2030 [Member] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Significant Acquisitions and Disposals [Table] Disposal Groups, Including Discontinued Operations [Table] Use of Estimates Use of Estimates, Policy [Policy Text Block] Income Tax Authority [Domain] Income Tax Authority [Domain] Performance-Based Restricted Stock Units Performance Based Restricted Stock Units [Member] Represents stock awards in the form of performance-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan. Weighted-average assumptions used to determine net periodic benefit costs and benefit obligations Defined Benefit Plan, Assumptions [Table Text Block] Interest settlements from cross-currency swaps Interest Settlement On Cross-Currency Swaps Interest Settlement On Cross-Currency Swaps Pharmaceuticals Pharmaceutical Products [Member] Pharmaceutical Products [Member] 2023 Revolving Credit Facility Due June 2023 Revolving Credit Facility Due June 2023 [Member] Revolving Credit Facility Due June 2023 [Member] Asset Acquisition [Domain] Asset Acquisition [Domain] Asset Acquisition Summary of non-vested performance-based RSU activity Schedule of Nonvested Performance-based Units Activity [Table Text Block] Scenario [Domain] Scenario [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Consolidation Items [Domain] Consolidation Items [Domain] Restatement Adjustment Revision of Prior Period, Adjustment [Member] Netherlands NETHERLANDS 5.75% Senior Notes Due August 2027 Senior Secured 5.75% Notes Due August 2027 [Member] Senior Secured 5.75% Notes Due August 2027 [Member] Schedule of Commitments [Table] Schedule of Commitments [Table] Represents information pertaining to commitments of the entity during the reporting period. INTANGIBLE ASSETS AND GOODWILL Goodwill and Intangible Assets Disclosure [Text Block] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Loss related to settlements during period Derivative Instruments Not Designated as Hedging Instruments, Loss Australian Taxation Office Australia Australian Taxation Office [Member] Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Mexico MEXICO Shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Property, plant and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent Other revenues Other Revenues [Member] Other Revenues [Member] Certain Products For Disposal, September 2019 Certain Products For Disposal, September Two Thousand Nineteen [Member] Certain Products For Disposal, September Two Thousand Nineteen [Member] ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block] Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block] Loss before benefit from income taxes Loss before benefit from income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Hedging Designation [Axis] Hedging Designation [Axis] Accumulated goodwill impairment charges to date Goodwill, Impaired, Accumulated Impairment Loss Ortho Dermatologics Reporting Unit Ortho Dermatologics Reporting Units Ortho Dermatologics Reporting Unit [Member] Ortho Dermatologics Reporting Unit [Member] Assets held for sale reclassified to goodwill (Note 5) Goodwill, Transfers Related To Sale of Business Unit Goodwill, Transfers Related To Sale of Business Unit 2026-2030 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Schedule of the components of inventories Schedule of Inventory, Current [Table Text Block] Trade receivables, net Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Schedule of carrying amounts of assets and liabilities held for sale Disclosure of Long Lived Assets Held-for-sale [Table Text Block] Operating Lease, Liability, Statement of Financial Position [Extensible List] Operating Lease, Liability, Statement of Financial Position [Extensible List] Annual amortization rate, percentage Debt Instrument, Annual Amortization Rate, Percentage Debt Instrument, Annual Amortization Rate, Percentage Payment of employee withholding taxes related to share-based awards Payment, Tax Withholding, Share-based Payment Arrangement Designated as Hedging Instrument Designated as Hedging Instrument [Member] Acquisition of certain assets of Synergy Goodwill, Acquired During Period SUPPLEMENTARY DATA (UNAUDITED) Quarterly Financial Information [Text Block] 9.00% Senior Unsecured Notes due December 2025 9.00% Senior Notes due December 2025 [Member] 9.00% Senior Notes due December 2025 [Member] Johnson & Johnson Talcum Powder Litigation, New Jersey Division Of Taxation Johnson & Johnson Talcum Powder Litigation, New Jersey Division Of Taxation [Member] Johnson & Johnson Talcum Powder Litigation, New Jersey Division Of Taxation [Member] 5.00% Senior Notes Due January 2028 Senior Notes, 5.00%, Due January 2028 [Member] 5.00% Senior Notes Due January 2028 [Member] Acquired IPR&D not in service Acquired IPR&D Acquired in Process Research and Development [Member] Represents intangible assets that the entity has acquired as a result of business acquisition, which is represented through the premium in the purchase price over book value attributed to research and development on new product that is not yet being sold. Price Appreciation Credit Price Appreciation Credit [Member] Price Appreciation Credit [Member] Estimated useful lives Property, Plant and Equipment, Useful Life Series F Tranche B Term Loan Facility Series F Tranche B Term Loan Facility [Member] Series F Tranche B Term Loan Facility [Member] Goodwill Goodwill [Line Items] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Salix Ltd. SEC Investigation Litigation Salix Ltd. SEC Investigation Litigation [Member] Salix Ltd. SEC Investigation Litigation [Member] Net deferred tax asset Deferred Tax Assets, Net Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Settled Litigation Settled Litigation [Member] 7.00% Senior Unsecured Notes due 2028 7.00% Senior Unsecured Notes Due 2028 [Member] 7.00% Senior Unsecured Notes Due 2028 [Member] Schedule Of Other Income And Expenses [Table] Schedule Of Other Income And Expenses [Table] Schedule Of Other Income And Expenses [Table] Number of products represented of total revenue Concentration Risk, Number Of Products Concentration Risk, Number Of Products Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs Deferred Charges, Policy [Policy Text Block] Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Repurchased face amount Debt Instrument, Repurchased Face Amount Summary of research and development Summary Of Research And Development Expense [Table Text Block] Summary Of Research And Development Expense [Table Text Block] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Gain excluded from assessment of hedge effectiveness Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax Land Land [Member] Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Accrued and other current liabilities Less: Current portion Operating Lease, Liability, Current Lease liabilities included in: Liabilities, Lessee [Abstract] Liabilities, Lessee [Abstract] U.S. broad market U.S. Broad Market [Member] U.S. Broad Market [Member] Number of groups of investors Loss Contingency, Plaintiffs, Number of Groups of Investors Loss Contingency, Plaintiffs, Number of Groups of Investors Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Schedule of weighted-average assumption as of the date of grant using the Black Scholes option-pricing model Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] 9.25% Senior Notes Due April 2026 Senior Notes, 9.25%, Due April 2026 [Member] 9.25% Senior Notes Due April 2026 [Member] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Acquisition-related contingent consideration Business Acquisition, Contingent Consideration Fair Value Disclosure Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares. FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Stock options, Time-based RSUs, Performance-based RSUs Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member] Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member] Trade receivables Accounts Receivable [Member] Name of Major Customer [Domain] Customer [Domain] Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Land improvements Land Improvements [Member] Weighted- Average Exercise Price Per Share Share Based Compensation, Arrangement by Share Based Payment Award Options Weighted Average Exercise Price [Roll Forward] -- None. No documentation exists for this element. -- Additional paid-in capital Additional Paid in Capital, Common Stock Entity Registrant Name Entity Registrant Name Business Combinations Business Acquisition [Line Items] Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Employee compensation and benefit costs Accrued Employee Benefits, Current Assets: Assets, Fair Value Disclosure [Abstract] Concentrations of Credit Risk Concentration Risk [Line Items] Asset impairments, including loss on assets held for sale Asset impairments, including loss on assets held for sale Asset impairments, including loss on assets held for sale Asset Impairment Charges Vested and exercisable at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Salix Salix Salix Segment [Member] Salix Segment [Member] Debt issuance cost Debt Issuance Costs, Net Open Years Open Tax Year Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Held For Sale Disposal Group, Held-for-sale, Not Discontinued Operations [Member] Depreciation and amortization of intangible assets Depreciation, Depletion and Amortization, Nonproduction Remaining restructuring liabilities Restructuring Reserve Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] (Gain) loss on disposal of assets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Term Loan B Facility Due June 2025 Term Loan B Facility Due June 2025 Term Loan B Facility Due June 2025 [Member] Term Loan B Facility Due June 2025 [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Debt Instrument, Redemption, Period Two Debt Instrument, Redemption, Period Two [Member] Restructuring Type [Axis] Restructuring Type [Axis] ACCRUED AND OTHER CURRENT LIABILITIES Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Time-Based RSUs Time Based RSU [Member] Represents stock awards in the form of time-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan. Goodwill Goodwill reallocated into (out of) Balance at the beginning of the period Balance at the end of the period Goodwill Additions (reductions) to accrued legal settlements Gain (Loss) Related To Litigation Settlement, Gross Gain (Loss) Related To Litigation Settlement, Gross Right-of-use assets included in: Assets, Lessee [Abstract] Assets, Lessee [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Components and classification of share-based compensation expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Discounts and Allowances Reserve For Discounts And Allowances [Member] Reserve For Discounts And Allowances [Member] Aggregate principal amount Aggregate principal amount Debt Instrument, Face Amount Branded Rx Branded RX [Member] Branded RX [Member] Buildings and improvements Buildings and improvements Building and Building Improvements [Member] Research and development tax credits Deferred Tax Assets, Tax Credit Carryforwards Research and Development The tax effect as of the balance sheet date of the amount of future tax deductions arising from unused research and development tax credit carryforwards; a tax credit carryforward is the amount by which tax credits available for utilization exceed statutory limitations for inclusion in historical filings, and which can only be utilized if sufficient tax-basis income is generated in future periods and providing tax laws continue to allow such utilization. Fair value, contingent consideration obligations, discount rate Business Combination, Contingent Consideration, Liability, Measurement Input Schedule of changes in the carrying amount of goodwill Schedule of Goodwill [Table Text Block] Number of distinct insurance policy periods Loss Contingency, Number Of Insurance Policy Periods Loss Contingency, Number Of Insurance Policy Periods Equity [Abstract] Equity [Abstract] A Certain International Business A Certain International Business [Member] A Certain International Business [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Provisions Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Accounting Standards Update [Extensible List] Accounting Standards Update [Extensible List] Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Customer concentration Customer Concentration Risk [Member] Repayments of short-term debt Repayments of Short-term Debt Senior Secured Credit Facilities Senior Secured Term Credit Facilities [Member] Represents the Senior Secured Credit Facilities which includes the Revolving Credit Facility, New Term Loan A Facility, and the Delayed Draw Facility. Schedule of estimated aggregate amortization expense for each of the five succeeding years Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Derivative Contract [Domain] Derivative Contract [Domain] Letter of Credit Letter of Credit [Member] Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Debt Disclosure [Abstract] Debt Disclosure [Abstract] Loss recognized in Other comprehensive loss Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Revenue Commissioners, Ireland Revenue Commissioners, Ireland [Member] Recoveries Accounts Receivable, Allowance for Credit Loss, Recovery Cash and cash equivalents Defined Benefit Plan, Cash and Cash Equivalents [Member] Restructuring and Integration-Related Costs Other Restructuring Integration Related Other Costs [Member] Represents the information pertaining to other restructuring, integration-related and other costs. Label: Other restructuring, integration-related and other costs. Amortization and write-off of debt discounts and debt issuance costs Amortization of Debt Issuance Costs and Discounts Senior Unsecured Notes Unsecured Debt Unsecured Debt [Member] Total Accrued and other current liabilities Disposal Group, Including Discontinued Operation, Other Liabilities, Current Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Repayments of long-term debt Repayments of long-term debt Repayments of Long-term Debt Revenues and long-lived assets by geographic region Revenues from External Customers and Long-Lived Assets [Line Items] Threshold percentage for amortization of net actuarial gains and losses Defined Benefit Plan, Actuarial Gain (Loss), Amortization Threshold Percentage Defined Benefit Plan, Actuarial Gain (Loss), Amortization Threshold Percentage Leasehold improvements Leaseholds and Leasehold Improvements [Member] Novaliq GmbH Novaliq GmbH [Member] Novaliq GmbH [Member] Balance, beginning of year Balance, end of year Unrecognized Tax Benefits Counterparty Name [Axis] Counterparty Name [Axis] Common shares, no par value, unlimited shares authorized, 355,422,347 and 352,562,636 issued and outstanding at December 31, 2020 and 2019, respectively Common Stock, Value, Issued 2025 Defined Benefit Plan, Expected Future Benefit Payment, Year Four Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Document Fiscal Year Focus Document Fiscal Year Focus 2022 Finite-Lived Intangible Asset, Expected Amortization, Year Two Restricted cash Restricted cash, end of year Restricted Cash, Current Current portion of long-term debt and other Less: Current portion of long-term debt and other Long-term Debt, Current Maturities Projected benefit obligation, beginning of year Projected benefit obligation, end of year Defined Benefit Plan, Benefit Obligation Entity Current Reporting Status Entity Current Reporting Status Number of other material business combinations Number Of Other Businesses Acquired Number Of Other Businesses Acquired Acquisition-related contingent consideration adjustments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 7.50% Senior Notes due July 2021 Senior Notes, 7.5%, July 2021 [Member] Senior Notes, 7.5%, July 2021 [Member] SEC Investigation Litigation SEC Investigation Litigation [Member] SEC Investigation Litigation Cross-currency swaps Currency Swap [Member] Loss Per Share Attributable to Bausch Health Companies Inc. Earnings Per Share, Policy [Policy Text Block] Alternate term, principal amount maturity threshold Debt Instrument, Alternate Term, Principal Amount Maturity Threshold Debt Instrument, Alternate Term, Principal Amount Maturity Threshold Product rebates Accrued Product Rebate Current Represents the current portion of accrued product rebates. Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Perrigo Litigation Perrigo Litigation [Member] Perrigo Litigation Percentage of vesting rights Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Common stock, shares issued (in shares) Beginning Balance (in shares) Ending Balance (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and cash equivalents, end of year Cash and Cash Equivalents, at Carrying Value Eurodollar Eurodollar [Member] Canadian Federal and Provincial Foreign Country State and Local [Member] The designated tax department of state or local government of a foreign country entitled to levy and collect income taxes from the entity. Lease liability Present value of remaining lease payments Operating Lease, Liability Payments of contingent consideration adjustments, including accretion Payment Of Accreted Interest On Contingent Consideration Payment Of Accreted Interest On Contingent Consideration Senior Unsecured Notes due 2023 Senior Unsecured Notes Due 2023 [Member] Senior Unsecured Notes Due 2023 [Member] Non-current portion of long-term debt Non-current portion of long-term debt Long-term Debt, Excluding Current Maturities Segment Reporting [Abstract] Segment Reporting [Abstract] Long-term debt, net of unamortized debt discount Debt Instrument [Line Items] Debt Instrument [Line Items] Total Bausch Health Companies Inc. shareholders’ equity Stockholders' Equity Attributable to Parent DESCRIPTION OF BUSINESS Nature of Operations [Text Block] Foreign tax rate differences Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Raw materials Inventory, Raw Materials, Gross Entity Address, City or Town Entity Address, City or Town Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Acquisition of intangible assets and other assets Payments to Acquire Intangible Assets RSUs Restricted Stock Units (RSUs) [Member] Bausch Health Companies Inc. Shareholders' Equity Parent [Member] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Five Type of Adoption [Domain] Accounting Standards Update [Domain] Noncash cumulative foreign currency translation loss Noncash Cumulative Foreign Currency Translation Loss Noncash Cumulative Foreign Currency Translation Loss Tax Year 2012 Tax Year 2012 [Member] Accretion for the time value of money Accretion For Time Value Of Money [Member] Accretion For Time Value Of Money [Member] Product sales Product [Member] Short-term lease expense Short-term Lease, Cost 6.125% Senior Notes Due April 2025 Senior Notes, 6.125%, Due April 2025 [Member] 6.125% Senior Notes due April 2025 [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Less valuation allowance Valuation allowance against deferred tax assets Deferred Tax Assets, Valuation Allowance Liabilities Liabilities [Abstract] Number of cases settled Loss Contingency, Claims Settled, Number Currency translation adjustments Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Three Construction in progress Construction in Progress [Member] Assets reclassified, held for sale Disposal Group, Including Discontinued Operation, Assets Amortization or settlement recognition of net loss Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization or Settlement Recognition Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization or Settlement Recognition Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Accrued and other current liabilities Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Current Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Current Other comprehensive (loss) income Other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax Work in process Inventory, Work in Process, Gross Leases [Abstract] Leases [Abstract] Bausch + Lomb/ International Bausch Lomb/International [Member] Bausch Lomb/International [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Product brands Product brands Product Brands [Member] Represents the rights to non-patented product brands. Total current assets Assets, Current U.S. Diversified Products U.S. Diversified Products Segment [Member] U.S. Diversified Products Segment [Member] Comprehensive income attributable to noncontrolling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Restructuring, integration and separation costs Restructuring, integration and separation costs Restructuring Charges Schedule of tax effect of major items recorded as deferred tax assets and liabilities and valuation allowance Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Number of entities, exercised opt-out right, pursuing action Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Foreign exchange loss (gain) Foreign Currency Transaction Gain (Loss), Unrealized Pooled Scientific Research and Experimental Development Pooled Scientific Research and Experimental Development Expenditures [Member] Represents the details pertaining to pooled scientific research and experimental development. Incremental credit facility borrowings Line Of Credit Facility, Threshold For Incremental Borrowings Line Of Credit Facility, Threshold For Incremental Borrowings Canada Bankers Acceptance Rate Canada Bankers Acceptance Rate [Member] Canada Bankers Acceptance Rate [Member] Out-licensed technology and other Technology and other Out Licensed Technology [Member] Represents the rights to receive cash flows under an out-license arrangement (for example, license fees, milestone payments and royalties). Pension adjustment, net of tax Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Disposal Group Name [Domain] Disposal Group Name [Domain] Equity Stockholders' Equity Attributable to Parent [Abstract] Deferred tax liabilities, net Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Fiscal Period Focus Document Fiscal Period Focus Branded Rx Segment Branded Rx Segment [Member] Branded Rx Segment [Member] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Litigation and other matters Favorable (unfavorable) adjustment, litigation and other matters Gain (Loss) Related to Litigation Settlement Company contributions Defined Benefit Plan, Plan Assets, Contributions by Employer Deferred Tax Asset [Domain] Deferred Tax Asset [Domain] Redemption price percentage (as a percent) Debt Instrument, Redemption Price, Percentage Aggregate value of long term incentive awards Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued Entity Filer Category Entity Filer Category Common Shares Common Stock [Member] Foreign currency translation adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Product and Service [Domain] Product and Service [Domain] Total leverage ratio (not greater than) Debt Instrument, Covenant, Total Leverage Ratio, Maximum Debt Instrument, Covenant Compliance, Total Leverage Ratio Base Rate or Prime Rate Base Rate Or Prime Rate [Member] Base Rate Or Prime Rate [Member] Portion of net trade receivables that is past due Trade Receivable, Net, Portion Past Due Trade Receivable, Net, Portion Past Due Notice of tax assessment, aggregate amount of possible loss Income Tax Examination, Estimate of Possible Loss Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Contributions recognized Defined Contribution Plan, Cost Senior Secured Notes Secured Debt Secured Debt [Member] Payment terms Revenue, Performance Obligation, Payment Terms Revenue, Performance Obligation, Payment Terms Recognized as: Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract] Restatement [Domain] Revision of Prior Period [Domain] Stated interest rate on debt (as a percent) Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Unrealized FX on U.S. dollar debt and other financing cost Deferred Tax Liabilities, Unrealized Currency Transaction Gains Prepaid expenses Deferred Tax Assets, Prepaid Expenses Deferred Tax Assets, Prepaid Expenses Stock Compensation Plan Share-based Payment Arrangement [Member] Accrued and other current liabilities: Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract] Cardinal Health, Inc. Cardinal Health Inc [Member] Represents the major customer of the entity, Cardinal Health, Inc. Discontinued Product Lines Discontinued Product Lines [Member] Discontinued Product Lines Other revenues Product and Service, Other [Member] Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Other non-current liabilities Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Noncurrent Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Noncurrent Net (decrease) increase in Cash and cash equivalents and Restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Number of subsidiaries file federal income tax returns in Canada, U.S., and other foreign jurisdictions (or more) Income Tax, Number Of Subsidiaries File Federal Income Tax Returns Income Tax, Number Of Subsidiaries File Federal Income Tax Returns Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Stock options Share-based Payment Arrangement, Option [Member] Ortho Dermatologics Ortho Dermatologics Ortho Dermatologics Segment [Member] Ortho Dermatologics Segment [Member] British Columbia BRITISH COLUMBIA Expenses Costs and Expenses [Abstract] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Glumetza Antitrust Litigation Glumetza Antitrust Litigation [Member] Glumetza Antitrust Class Actions Litigation [Member] 2025 Long-Term Debt, Maturity, Year Five Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Percentage of expected return on plan assets Expected rate of return on plan assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Tax Period [Domain] Tax Period [Domain] Total equity Beginning Balance Ending Balance Cumulative-effect adjustment Increase to accumulated deficit (less than) Accumulated other comprehensive loss Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Number of manufacturers Loss Contingency, Number Of Manufacturers Loss Contingency, Number Of Manufacturers 2021 Finite-Lived Intangible Asset, Expected Amortization, Year One Divestitures of Products Divestitures Of Non-core Products [Policy Text Block] Divestitures of Non-core Products [Policy Text Block] Summary of non-vested time-based RSU activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Accrued and other current liabilities Accrued and other current liabilities Accrued Liabilities, Current Reporting Units Excluding Ortho Dermatologics and Dentistry Reporting Units Excluding Ortho Dermatologics And Dentistry [Member] Reporting Units Excluding Ortho Dermatologics And Dentistry [Member] Schedule of revenues and long-lived assets by geographic region Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Reconciliation of the beginning and ending amounts of unrecognized tax benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of long-term debt Schedule of Debt [Table Text Block] 5.50% Senior Notes Due November 2025 Senior Secured 5.50% Notes Due November 2025 [Member] Senior Secured 5.50% Notes Due November 2025 [Member] Depreciation expense Depreciation Entity Address, Address Line One Entity Address, Address Line One Proceeds from sale of assets and businesses, net of costs to sell Proceeds from Divestiture of Businesses, Net of Cash Divested Other non-current liabilities: Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract] Deferred tax assets, net Disposal Group, Including Discontinued Operation, Deferred Tax Assets Entity Emerging Growth Company Entity Emerging Growth Company Net Carrying Amount Indefinite-lived Intangible Assets (Excluding Goodwill) Bausch + Lomb/International Baush and Lomb/International Segment [Member] Baush and Lomb/International Segment [Member] Total Deferred Income Tax Expense (Benefit) Pro-forma revenue Business Acquisition, Pro Forma Revenue Impairment of long-lived assets Impairment of Long-Lived Assets to be Disposed of Accumulated Amortization and Impairments Finite-Lived Intangible Assets, Accumulated Amortization Maximum Maximum [Member] Federal Funds Effective Swap Rate Fed Funds Effective Rate Overnight Index Swap Rate [Member] Noncontrolling Interest Noncontrolling Interest [Member] Share-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Mitsubishi Tanabe Pharma Corporation Mitsubishi Tanabe Pharma Corporation [Member] Mitsubishi Tanabe Pharma Corporation [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Past due period for receivables to be negligible (less than) Past Due Period for Accounts Receivable to be Negligible Represents the past due period for which accounts receivables are negligible. Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Allowance for doubtful accounts Balance, beginning of period Balance, end of period Accounts Receivable, Allowance for Credit Loss Postretirement Benefit Plan U.S. Postretirement Benefit Plan Other Postretirement Benefits Plan [Member] Trading Symbol Trading Symbol Realignment of segment goodwill Goodwill, Other Increase (Decrease) Plant, equipment and technology Deferred Tax Liabilities, Basis Difference of Convertible Notes Represents the deferred tax liability recognized for the original basis difference between the principal amount of the Convertible Notes and value allocated to the liability component, which resulted in a corresponding reduction to the valuation allowance recorded against deferred tax assets. Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] 5.875% Senior Unsecured Notes due May 2023 5.875% Senior Notes due May 2023 [Member] 5.875% Senior Notes due May 2023 [Member] Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments Line of Credit Facility, Percentage of Net Cash Proceeds from Asset Sales Outside Ordinary Course of Business Payable as Mandatory Prepayments Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments. Period net trade receivable balance outstanding (more than) Period Receivable Outstanding The period of time the accounts receivable has been outstanding. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Entity Shell Company Entity Shell Company Segment reporting information Segment Reporting Information [Line Items] Recurring basis Fair Value, Recurring [Member] Revenues Revenues Net [Member] Aggregate net revenues during the period in the normal course of business. Separation Costs Separation Costs [Member] Separation Costs Term Loan B Facility Due June 2025 and November 2025 Term Loan B Facility Due June 2025 And November 2025 [Member] Term Loan B Facility Due June 2025 And November 2025 Segment Reporting Segment Reporting, Policy [Policy Text Block] Entity Public Float Entity Public Float Acquisitions and Acquisition-Related Contingent Consideration Business Combinations Policy [Policy Text Block] Document Type Document Type ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Unclaimed investment tax credits and research and development credits Unclaimed Tax Credits and Research and Development Credits The amount of unclaimed tax credits and research and development credits. Charged to Benefit from income taxes SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Benefit From Income Taxes SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Benefit From Income Taxes Other expense, net Other expense (income), net Other Nonoperating Income (Expense) 4.50% Senior Notes euro-denominated debt Due May 2023 Senior Notes, 4.50%, Due May 2023 [Member] Senior Notes, 4.50%, 2023 [Member] Reporting Unit [Axis] Reporting Unit [Axis] Accounts payable, accrued and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Payables and Accruals [Abstract] Payables and Accruals [Abstract] Segments [Axis] Segments [Axis] PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS Retirement Benefits [Text Block] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Schedule of the components of accumulated other comprehensive loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value 5.625 % Senior Unsecured Notes due December 2021 Senior Notes 5.625 Percent Due December 2021 [Member] Senior Notes 5.625 Percent Due December 2021 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Other Defined Benefit Plan, Other Cost (Credit) Capital expenditures Contractual Obligation Net actuarial loss arising during the year Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax Other assets Non-U.S. Other Assets [Member] Non-U.S. Other Assets [Member] Canadian Securities Litigation Canadian Securities Litigation [Member] Canadian Securities Litigation Benefits paid Defined Benefit Plan, Plan Assets, Benefits Paid Foreign currency exchange contracts Derivative Asset Aggregate Intrinsic Value Share Based Compensation, Arrangement by Share Based Payment Award, Options Intrinsic Value [Abstract] -- None. No documentation exists for this element. -- Cost-rationalization and integration initiatives Restructuring Cost and Reserve [Line Items] Employee Benefit Plans Pension and Other Postretirement Plans, Policy [Policy Text Block] Deferred tax liabilities, net Deferred Income Tax Liabilities, Net Acquisition-related contingent consideration Business Combination, Contingent Consideration, Noncurrent Liability Business Combination, Contingent Consideration, Noncurrent Liability Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Carrying value of intangible assets, net Intangible Assets, Net (Excluding Goodwill) Revenue, year-over-year decrease, percentage Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax, Percentage Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax, Percentage Tax loss carryforwards Deferred Tax Assets, Tax Loss Carryforwards Represents the deferred tax assets on tax loss carryforwards available to the entity. Operating income (loss) Operating income (loss) Operating Income (Loss) Unrecognized tax benefits, net increase for tax positions of current year Unrecognized Tax Benefits, Net Increase Resulting From Current Period Tax Positions Unrecognized Tax Benefits, Net Increase Resulting from Current Period Tax Positions Payments of financing costs Payments of Debt Issuance Costs Percentage of net trade receivables accounted for by largest wholesale customers Concentration Risk, Percentage of Net Trade Receivables Concentration Risk, Percentage of Net Trade Receivables 1% change in estimated return rates, Impact on pre-tax earnings Sensitivity Analysis, Impact Of 1 Percent Change In Estimated Return Rate, Income (Loss) Before Tax Sensitivity Analysis, Impact Of 1 Percent Change In Estimated Return Rate, Income (Loss) Before Tax Severance costs Severance Costs Eyenovia, Inc. Eyenovia, Inc. [Member] Eyenovia, Inc. Variable Rate [Axis] Variable Rate [Axis] Uceris Uceris [Member] Uceris [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Commitments and contingencies (Notes 20 and 21) Commitments and Contingencies Share-based awards tax withholding Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Vesting Period Two Share-based Payment Arrangement, Tranche Two [Member] Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five AmerisourceBergen Corporation Amerisource Bergen Corporation [Member] Represents the major customer of the entity, AmerisourceBergen Corporation. Fair value of stock options vested Share Based Compensation Arrangement by Share Based Payment Award, Options Vested in Period, Total Fair Value Represents the total fair value of stock options vested during the period. Entity Address, State or Province Entity Address, State or Province Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Accounts payable Accounts Payable, Current Foreign exchange and other Goodwill, Foreign Currency Translation Gain (Loss) Operating results of acquiree since acquisition Business Combination, Pro Forma Information, Operating Income (Loss) Since Acquisition, Actual Business Combination, Pro Forma Information, Operating Income (Loss) Since Acquisition, Actual Sub-lease income Sublease Income Accumulated deficit Retained Earnings (Accumulated Deficit) Repayments of lines of credit Repayments of Lines of Credit Right-of-use asset Other non-current assets Operating Lease, Right-of-Use Asset Unamortized discounts Debt Instrument, Unamortized Discount Loss on extinguishment of debt Loss on extinguishment of debt Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Change in Accounting Estimate, Type [Domain] Change in Accounting Estimate, Type [Domain] Product Concentration Risk Product Concentration Risk [Member] Payments of accrued legal settlements Payments for legal settlements Payments for Legal Settlements Income taxes paid Income Taxes Paid 7.00 % Senior Notes Due March 2024 Senior Secured Notes 7.00 Percent Due March 2024 [Member] Senior Secured Notes 7.00 Percent Due March 2024 [Member] Major Customers [Axis] Customer [Axis] Credit concentration Credit Concentration Risk [Member] Net change in fair value, loss Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Income Taxes Income Tax, Policy [Policy Text Block] Hedging Designation [Domain] Hedging Designation [Domain] Government bond funds US Treasury and Government [Member] Domestic Plan Domestic Plan [Member] Share-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Expired or forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Thereafter Long-Term Debt, Maturity, after Year Five Revenue Price appreciation credits Revenue from Contract with Customer, Excluding Assessed Tax Advertising expenses Advertising Expense Settlements Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement Schedule of estimated useful lives of property, plant and equipment Schedule of Estimated Useful Lives of Property, Plant and Equipment [Table Text Block] Tabular disclosure of estimated useful lives of major classes of property, plant and equipment. Business Acquisition [Axis] Business Acquisition [Axis] Geographical [Domain] Geographical [Domain] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Salix Reporting Unit Salix Reporting Unit [Member] Salix Reporting Unit [Member] Foreign Deferred Foreign Income Tax Expense (Benefit) Scenario, Forecast Forecast [Member] 5.375% Senior Notes due March 2020 5.375% Senior Notes due March 2020 [Member] 5.375% Senior Notes due March 2020 [Member] Components of loss before benefit of income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] Prepaid expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Interest Interest Payable, Current Entity Voluntary Filers Entity Voluntary Filers Acquisition-related costs Business Combination, Acquisition Related Costs Non-current portion Business Combination, Contingent Consideration, Liability, Noncurrent Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Credit Facility [Axis] Credit Facility [Axis] Fair value of long-term debt Debt Instrument, Fair Value Disclosure Chargebacks Reserve For Chargebacks [Member] Reserve For Chargebacks [Member] For Determining Benefit Obligation Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] Ireland Foreign Tax Authority [Member] Tax benefit on intra-entity transfers Income Tax Reconciliation Deferred Intercompany Profit Represents the portion of the difference between total income tax expense (benefit) as reported in the income statement and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to deferred intercompany profit. Asset Acquisition [Axis] Asset Acquisition [Axis] Asset Acquisition Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Business Combinations [Abstract] Business Combinations [Abstract] Interest Expense Interest Expense, Policy [Policy Text Block] Basic and diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share) Decrease to earnings per share, basic and diluted (in dollars per share) Basic and Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share) Basic and Diluted (loss) earnings per share attributable to Bausch Health Companies Inc. (in dollars per share) Earnings Per Share, Basic and Diluted Scientific Research and Experimental Development pool Deferred Tax Assets, Scientific Research and Experimental Development Pool Represents the deferred tax assets on scientific research and experimental development pool, of the entity. Other expense (income), net Other (expense) income, net Other Operating Income (Expense), Net Increase (Decrease) in Shareholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Product related research and development Research And Development Expense, Product Related Research And Development Expense, Product Related Debt Instrument, Redemption, Period One Debt Instrument, Redemption, Period One [Member] Senior Credit Facilities Senior Secured Credit Facilities [Member] Senior Secured Credit Facilities [Member] Accounts payable Disposal Group, Including Discontinued Operation, Accounts Payable, Current Change in the carrying amount of goodwill Goodwill [Roll Forward] Contact Lens Antitrust Class Actions Contact Lens Antitrust Class Actions [Member] Contact Lens Antitrust Class Actions [Member] Schedule of calculation of loss per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Restructuring costs Restructuring and Related Cost, Incurred Cost Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Estimated fair values of assets acquired and liabilities assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Prepaid expenses and other current assets: Disposal Group, Including Discontinued Operation, Assets, Current [Abstract] Income tax benefit (expense) Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Other non-current assets: Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Goodwill and Intangible assets, net Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent Net cash provided by operating activities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate by Type [Axis] Entity Central Index Key Entity Central Index Key Number of groups of investors filing action, remain pending Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending Emerging markets Emerging Markets [Member] Represents the Emerging Markets segment of the entity. The segment consists of branded generic pharmaceutical products, as well as OTC products and agency/in-licensing arrangements with other research-based pharmaceutical companies (where the entity distributes and markets branded, patented products under long-term, renewable contracts). Products are sold primarily in Europe (Poland, Serbia, Hungary, Croatia and Russia), Latin America (Mexico, Brazil and exports out of Mexico to other Latin American markets), South East Asia and South Africa. Johnson & Johnson Talcum Powder Litigation Johnson & Johnson Talcum Powder Litigation [Member] Johnson & Johnson Talcum Powder Litigation [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of components of finite-lived intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Number of health plans commenced action Loss Contingency, Number Of Health Plans, Filed Lawsuits Loss Contingency, Number Of Health Plans, Filed Lawsuits SUPPLEMENTAL CASH FLOW DISCLOSURES Cash Flow, Supplemental Disclosures [Text Block] Other non-current liabilities Liability, Defined Benefit Plan Incremental borrowings interest rate Line Of Credit Facility Threshold For Incremental Borrowings Interest Rate Line Of Credit Facility Threshold For Incremental Borrowings Interest Rate Geographical [Axis] Geographical [Axis] Change in valuation allowance on Canadian deferred tax assets and tax rate changes Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Current period provision Sales return provisions Charged to other accounts SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds Segments [Domain] Segments [Domain] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] 2024 Long-Term Debt, Maturity, Year Four Number of largest wholesale customers Number of Largest Wholesale Customers Represents the number of largest wholesale customers. Capitalized interest Interest Costs Capitalized Income Statement Location [Axis] Income Statement Location [Axis] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Non-deductible portion of Goodwill impairments Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount Domestic Current Federal Tax Expense (Benefit) Aggregate notional amounts Derivative, Notional Amount Accrued expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses Legal Costs Legal Costs, Policy [Policy Text Block] 6.25% Senior Notes Due February 2029 Senior Notes, 6.25%, Due February 2029 [Member] Senior Notes, 6.25%, Due February 2029 SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Trade receivables, net Receivables, Net, Current Scenario [Axis] Scenario [Axis] Schedule of underfunded plans Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block] Gain excluded from hedge effectiveness Derivative, Gain, Excluded Component Derivative, Gain, Excluded Component Product returns Accrued Product Return Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Title of 12(b) Security Title of 12(b) Security Disposal Group Classification [Axis] Disposal Group Classification [Axis] Schedule of accrued and other current liabilities Schedule of Accrued Liabilities [Table Text Block] Number of additional suits filed, but not served Loss Contingency New Claims Filed But Not Yet Served Number Loss Contingency New Claims Filed But Not Yet Served Number Net Carrying Amount Finite-Lived Intangible Assets, Net Long-lived assets Long-Lived Assets Weighted-average grant date fair value of stock options (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Facility closure costs Business Exit Costs Income taxes payable Accrued Income Taxes, Current Chief Executive Officer Chief Executive Officer [Member] Vesting [Domain] Vesting [Domain] Distribution Fees Reserve For Distribution Fees [Member] Reserve For Distribution Fees [Member] Schedule of capital expenditures, depreciation and amortization by segment Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Components of benefit from income taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Canada Revenue Agency Canada Revenue Agency [Member] Product and Service [Axis] Product and Service [Axis] OTC Over the Counter Products [Member] Over the Counter Products [Member] Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Supplemental Cash Flow Elements [Abstract] Supplemental Cash Flow Elements [Abstract] Non-current assets held for sale Assets Held-for-sale, Long Lived, Fair Value Disclosure 2022 Long-Term Debt, Maturity, Year Two Net loss attributable to Bausch Health Companies Inc. Net loss attributable to Bausch Health Companies Inc. Net (loss) income attributable to Bausch Health Companies Inc. Net Income (Loss) Available to Common Stockholders, Basic Bausch Lomb/International And U.S. Diversified Products Segments Bausch Lomb/International And U.S. Diversified Products Segments [Member] Bausch Lomb/International And U.S. Diversified Products Segments [Member] Rental expense Operating Lease, Expense Legal matters and related fees Legal settlements and related fees Legal settlements and related fees 1% change in volume of product sold through to Medicaid plan participants, Impact on pre-tax earnings Sensitivity Analysis, Impact Of 1 Percent Change In Volume Of Product Sold Through To Medicaid Plan Participants, Income (Loss) Before Tax Sensitivity Analysis, Impact Of 1 Percent Change In Volume Of Product Sold Through To Medicaid Plan Participants, Income (Loss) Before Tax Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Intangible Assets, Amortization Period Intangible Assets, Amortization Period [Member] Xifaxan Xifaxan [Member] Xifaxan [Member] Debt Instrument [Axis] Debt Instrument [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Schedule of quarterly financial information Quarterly Financial Information [Table Text Block] Operating Segments Operating Segments [Member] Reporting unit, impairment test, estimated cash flows, discount rate Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Derivative liabilities Fair value cross-currency swaps liability, net Derivative Liability Adjustments to reconcile net loss to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Cedars-Sinai Medical Center Cedars-Sinai Medical Center [Member] Cedars-Sinai Medical Center Litigation Case [Axis] Litigation Case [Axis] Acquisition of Synergy SEC Schedule, 12-09, Valuation Allowances and Reserves, Business Acquired Revenue from Contract with Customer [Abstract] Percentage of annual excess cash flow Line of Credit Facility, Percentage of Consolidated Excess Cash Flow Payable as Mandatory Prepayments Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans. Potential asset acquisition, aggregate purchase price Potential Asset Acquisition, Aggregate Purchase Price Potential Asset Acquisition, Aggregate Purchase Price Variable operating lease costs Variable Lease, Cost Unrecognized tax benefits, net decrease for tax positions of prior years Unrecognized Tax Benefits, Net Decrease Resulting From Prior Period Tax Positions Unrecognized Tax Benefits, Net Decrease Resulting From Prior Period Tax Positions Foreign exchange and other Accounts Receivable, Allowance For Foreign Exchange And Other Accounts Receivable, Allowance For Foreign Exchange And Other Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Projected benefit obligation Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation Ohio OHIO United States - Federal Domestic Tax Authority [Member] Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Returns Reserve For Customer Returns [Member] Reserve For Customer Returns [Member] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Employer contribution maximum age Defined Benefit Plan, Employer Contribution, Maximum Age Defined Benefit Plan, Employer Contribution, Maximum Age Net (gain) loss on sales of assets Milestone achievement, included in net gain (loss) on other sales of assets Gain (Loss) on Disposition of Assets Milestone Payment Related To Certain Product Milestone Payment Related To Certain Product [Member] Milestone Payment Related To Certain Product [Member] Other non-current liabilities Non-current portion Operating Lease, Liability, Noncurrent 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Four ROTC Performance-Based Restricted Stock Units ROTC Performance-Based Restricted Stock Units [Member] ROTC Performance-Based Restricted Stock Units [Member] Payments of debt restructuring costs Payments of Debt Restructuring Costs Net pension and postretirement benefit plan adjustments Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Unrecognized prior service credits Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax Number of alleged stockholders filed lawsuits Loss Contingency, Number Of Alleged Stockholders, Filed Lawsuits Loss Contingency, Number Of Alleged Stockholders, Filed Lawsuits New Jersey NEW JERSEY Current assets: Assets, Current [Abstract] Interest income Investment Income, Interest Quebec QUEBEC Cash Flows From Investing Activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Mississippi Attorney General Consumer Protection Action Litigation Mississippi Attorney General Consumer Protection Action Litigation [Member] Mississippi Attorney General Consumer Protection Action Litigation [Member] Acquisition-related contingent consideration Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination. Comprehensive loss attributable to Bausch Health Companies Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Number of products for disposal Disposal Group, Number Of Products For Disposal Disposal Group, Number Of Products For Disposal Generic Pricing Antitrust Litigation Generic Pricing Antitrust Litigation [Member] Generic Pricing Antitrust Litigation Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Reconciliation of benefit from income taxes from the expected amount calculated by applying the Canadian statutory rate to loss before benefit of income taxes Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] 2021 Long-Term Debt, Maturity, Year One Partner relationships Partner relationships Partner Relationships [Member] Represents the information pertaining to existing arrangements with various other entities, for which the entity provides regulatory, compliance, sales, marketing and distribution functions. Rate of compensation increase Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Payments and credits SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Number of countries in which entity operates Number of Countries in which Entity Operates City Area Code City Area Code Income Tax Authority [Axis] Income Tax Authority [Axis] Document Period End Date Document Period End Date 8.50% Senior Unsecured Notes Due January 2027 8.50% Senior Notes Due January 2027 [Member] 8.50% Senior Notes Due January 2027 [Member] Three largest U.S. wholesaler customers Three Largest US Wholesaler Customers [Member] Represents information pertaining to the three largest U.S. wholesaler customers. Plaintiffs, Direct Purchasers Plaintiffs, Direct Purchasers [Member] Plaintiffs, Direct Purchasers [Member] Schedule of assumptions used to calculate the fair values of performance-based RSUs Schedule of Share Based Payment Award, Equity Instruments Other than Options Valuation Assumptions [Table Text Block] Tabular disclosure of the significant assumptions used during the year to estimate the fair value of equity based payment instruments, excluding stock (or unit) options, including but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. Underfunded plans having accumulated benefit obligations exceeding the fair value of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract] Net Investment Hedging Net Investment Hedging [Member] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Net loss Net loss Net (loss) income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 8.50% Senior Notes Due January 2027 Senior Notes, 8.50%, Due January 2027 [Member] 8.50% Senior Notes Due January 2027 [Member] Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Lease term Lessee, Operating Lease, Term of Contract Schedule of assets and liabilities measured at fair value on a non-recurring basis Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Quarterly Financial Information Disclosure [Abstract] Quarterly Financial Information Disclosure [Abstract] 4.50% Senior Unsecured Notes euro-denominated debt Due May 2023 Senior Notes, 4.50%, 2023 [Member] Senior Notes, 4.50%, 2023 [Member] Summary of the components and classification of share-based compensation expense Share-based Payment Arrangement, Cost by Plan [Table Text Block] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Share-based compensation Share-based Payment Arrangement, Noncash Expense Total capital expenditures Payments to Acquire Productive Assets Number of cases voluntarily dismissed Loss Contingency, Claims Dismissed, Number Other Proceeds from (Payments for) Other Financing Activities Cover [Abstract] Cover [Abstract] Measurement Input Type [Axis] Measurement Input Type [Axis] Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Components of loss before benefit from income taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Fixed income securities Fixed income securities: Fixed Income Securities [Member] Minimum period to classify uncertain tax position liabilities as long term liabilities Minimum Period to Classify Uncertain Tax Position, Liabilities as Long Term Liabilities Represents the minimum period to classify uncertain tax position liabilities as long term liabilities. Johnson & Johnson Talcum Powder Litigation, Delaware Division Of Revenue Johnson & Johnson Talcum Powder Litigation, Delaware Division Of Revenue [Member] Johnson & Johnson Talcum Powder Litigation, Delaware Division Of Revenue [Member] Total long-term debt and other Long-term debt Long-term Debt LEASES Lessee, Operating Leases [Text Block] Employee contributions Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant 9.25% Senior Unsecured Notes Due April 2026 9.25% Senior Notes Due April 2026 [Member] 9.25% Senior Notes Due April 2026 [Member] Service cost Defined Benefit Plan, Service Cost OTHER EXPENSE (INCOME), NET Other Income and Other Expense Disclosure [Text Block] Measurement Input, Weighted-Average Discount Rate Measurement Input, Weighted-Average Discount Rate [Member] Measurement Input, Weighted-Average Discount Rate [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues Cost of Goods and Services Sold Derivative Lawsuits Derivative Lawsuits [Member] Derivative Lawsuits [Member] Total Expenses Expenses Costs and Expenses Equipment on operating lease Equipment on operating lease Equipment Leased to Other Party [Member] Equity Components [Axis] Equity Components [Axis] Number of cases Loss Contingency, Pending Claims, Number Senior Secured and Unsecured Notes Senior Secured Notes And Senior Unsecured Notes [Member] Senior Secured Notes And Senior Unsecured Notes [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Total deferred tax assets Deferred Tax Assets, Gross Minimum Minimum [Member] 5.50% Senior Notes Due March 2023 Senior Notes, 5.50%, Due March 2023 [Member] 5.50% Senior Notes due March 2023 [Member] Accumulated benefit obligation Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation Schedule of Supplemental Cash Flow Disclosures Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Equity securities Equity securities: Defined Benefit Plan, Equity Securities [Member] Product rights/patents Product rights/patents Contractual Rights [Member] Net income attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Amortization of net loss Defined Benefit Plan, Amortization of Gain (Loss) Entity Interactive Data Current Entity Interactive Data Current Net periodic (benefit) cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) United States UNITED STATES Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Actual asset allocations Schedule of Allocation of Plan Assets [Table Text Block] Revenues Revenues [Abstract] Fixed charge coverage ratio Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio Summary of stock option activity Share-based Payment Arrangement, Option, Activity [Table Text Block] 5.25% Senior Unsecured Notes Due January 2030 5.25% Senior Notes Due January 2030 [Member] 5.25% Senior Notes Due January 2030 [Member] Insurance Coverage Lawsuit Insurance Coverage Lawsuit [Member] Insurance Coverage Lawsuit [Member] Share-Based Compensation Share-based Payment Arrangement [Policy Text Block] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Foreign Current Foreign Tax Expense (Benefit) Redemption price percentage due to change in control (as a percent) Debt Instrument, Redemption Price, Percentage, Change in Control Debt Instrument, Redemption Price, Percentage, Change in Control Total Prepaid expenses and other current assets Disposal Group, Including Discontinued Operation, Other Assets, Current Settlement, escrow fund included in restricted cash Litigation, amount agreed to pay Litigation Settlement, Amount Awarded to Other Party Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Maximum term of original maturity to classify instruments as cash and cash equivalents (less than) Maximum Term of Original Maturity to Classify Instruments as Cash and Cash Equivalents Represents the maximum original term of maturity for an instrument to be classified as cash or cash equivalent. Total deferred tax liabilities Deferred Tax Liabilities, Gross 2021 Defined Benefit Plan, Expected Future Benefit Payment, Year One Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Advertising Costs Advertising Cost [Policy Text Block] 5.25% Senior Notes, Due February 2031 Senior Notes, 5.25%, Due February 2031 [Member] Senior Notes, 5.25%, Due February 2031 Gross Carrying Amount Intangible Assets, Gross (Excluding Goodwill) Retirement Plan Type [Domain] Retirement Plan Type [Domain] Serbia SERBIA Possible decrease in unrecognized tax benefits realized in next twelve months Decrease in Unrecognized Tax Benefits is Reasonably Possible Foreign currency impact Other Comprehensive (Income) Loss, Defined Benefit Plan, Foreign Currency Adjustment, Net Of Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, Foreign Currency Adjustment, Net Of Tax Russia RUSSIAN FEDERATION Interest coverage ratio (not less than) Debt Instrument, Covenant, Interest Coverage Ratio, Minimum Debt Instrument, Covenant, Interest Coverage Ratio, Minimum Consolidation Items [Axis] Consolidation Items [Axis] Research and development expenses Research and Development Expense [Member] Percentage allocation of fund Defined Benefit Plan, Percentage Allocation of Fund Defined Benefit Plan, Percentage Allocation of Fund Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] 5.50% Senior Unsecured Notes due March 2023 5.50% Senior Notes due March 2023 [Member] 5.50% Senior Notes due March 2023 [Member] Goodwill impairments Impairments Goodwill, Impairment Loss Net trade receivable Accounts Receivable, after Allowance for Credit Loss, Current Finished goods Inventory, Finished Goods, Gross Total Lessee, Operating Lease, Liability, to be Paid Stay of the approval period Loss Contingency, Stay Of Approval, Period Loss Contingency, Stay Of Approval, Period Other Deferred Tax Assets, Other Shower to Shower Product Liability Litigation Shower to Shower Product Liability Litigation [Member] Shower to Shower Product Liability Litigation [Member] Research and Development [Abstract] Research and Development [Abstract] Foreign Plan Foreign Plan [Member] Interest crediting rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Quarterly amortization payments Debt Instrument, Periodic Payment, Quarterly Amortization Debt Instrument, Periodic Payment, Quarterly Amortization Unrealized FX on U.S. dollar debt and other financing cost Deferred Tax Assets, Unrealized Foreign Exchange On Debt And Other Financing Costs Deferred Tax Assets, Unrealized Foreign Exchange On Debt And Other Financing Costs Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] B&L Trademark Trademarks [Member] Basic and diluted weighted-average common shares (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Restructuring payments Payments for Restructuring Schedule of external customers that accounted for 10% or more of total revenues Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Document Transition Report Document Transition Report Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Title of Individual [Axis] Title of Individual [Axis] Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Current portion Business Combination, Contingent Consideration, Liability, Current Fair value adjustments Fair Value Adjustments [Member] Fair Value Adjustments Fair value cross-currency swaps asset Derivative Asset, Fair Value, Gross Asset Amortization of prior service credit Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax Estimate of possible loss, amount not subject to full valuation allowance Income Tax Examination, Estimate Of Possible Loss, Amount Not Subject To Full Valuation Allowance Income Tax Examination, Estimate Of Possible Loss, Amount Not Subject To Full Valuation Allowance Level 2 Level 2 Fair Value, Inputs, Level 2 [Member] Liabilities: Liabilities, Fair Value Disclosure [Abstract] Vesting [Axis] Vesting [Axis] Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] 5.00% Senior Note Due February 2029 Senior Notes, 5.00%, Due February 2029 [Member] Senior Notes, 5.00%, Due February 2029 Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Vested and expected to vest at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Credit Facility [Domain] Credit Facility [Domain] Litigation Case [Domain] Litigation Case [Domain] Portion of unrecognized tax benefits, if recognized, would affect the Company's effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Expected benefit from income taxes at Canadian statutory rate Foreign Income Tax Expense (Benefit), Continuing Operations Arestin Arestin [Member] Arestin [Member] 7.00 % Senior Notes Due January 2028 Senior Notes, 7.00%, Due January 2028 [Member] Senior Notes 7.00 Percent Due January 2028 [Member] Expected stock option life (years) Contractual term (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Entity File Number Entity File Number RICO Class Actions Litigation RICO Class Actions Litigation [Member] RICO Class Actions Litigation Weighted-average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Rate of compensation increase Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase 6.50% Senior Notes Due March 2022 Senior Secured Notes 6.50 Percent Due March 2022 [Member] Senior Secured Notes 6.50 Percent Due March 2022 [Member] Cash Flows From Operating Activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] 7.25% Senior Notes due in July 2022 Senior Notes 7.25 Percent Due July 2022 [Member] Represents senior unsecured notes with an interest rate of 7.25 percent, due July, 2022. Maximum common shares issuable upon vesting (in shares) Share Based Compensation, Arrangement by Share Based Payment Award, Number of Shares that could be Issued Represents the maximum number of common shares that could be issued upon vesting of outstanding awards. Vested and exercisable at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Devices Device Products [Member] Device Products [Member] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Disposal Group Name [Axis] Disposal Group Name [Axis] Impairment of finite-lived intangible assets Impairment of Intangible Assets, Finite-lived Document Annual Report Document Annual Report Summary of activity in allowance for credit losses Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Inventories, net Disposal Group, Including Discontinued Operation, Inventory, Current U.S. and Puerto Rico United States and Puerto Rico [Member] United States and Puerto Rico [Member] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Diversified Products Diversified Products Diversified Products Segment [Member] Diversified Products Segment [Member] Total Other non-current assets Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent Common shares issued under share-based compensation plans (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Summary of open tax years by jurisdiction Summary of Income Tax Contingencies [Table Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Total identifiable net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Noncontrolling interest Stockholders' Equity Attributable to Noncontrolling Interest Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Valuation Allowance by Deferred Tax Asset [Axis] Valuation Allowance by Deferred Tax Asset [Axis] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Assets Held For Sale Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Litigation Status [Axis] Litigation Status [Axis] Fair value cross-currency swaps liability Derivative Asset, Fair Value, Gross Liability Interest Expense Interest Expense [Member] Trade receivables Increase (Decrease) in Accounts Receivable Accumulated losses available for federal and provincial purposes Accumulated Losses Available for Federal Purposes Represents the details pertaining to accumulated losses available for federal and provincial purposes. Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Concentration Risk Type [Domain] Concentration Risk Type [Domain] McKesson Corporation Mc Kesson Corporation [Member] Represents the major customer of the entity, McKesson Corporation. Summary of variable consideration provisions Summary Of Valuation And Qualifying Accounts [Table Text Block] Summary Of Valuation And Qualifying Accounts [Table Text Block] Medpharma Medpharma Pharmaceutical & Chemical Industries LLC [Member] Medpharma Pharmaceutical & Chemical Industries LLC [Member] Total liabilities and equity Liabilities and Equity Legal proceedings and other matters Loss Contingencies [Line Items] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax INCOME TAXES Income Tax Disclosure [Text Block] Goodwill impairments Goodwill impairment Goodwill impairments Goodwill, Impairment Loss, Not Included In Asset Impairment Charges Goodwill, Impairment Loss, Not Included In Asset Impairment Charges Lapse of statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Operating lease costs Operating Lease, Cost Total fair value of consideration transferred Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Hedging Relationship [Axis] Hedging Relationship [Axis] Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Other costs Other Restructuring Costs Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Total Current Income Tax Expense (Benefit) Other Other Noncash Income (Expense) Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc. Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc. [Member] Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc. [Member] Repayment, outstanding debt Payment For Debt Amortization Prepayment Cost Payment For Debt Amortization Prepayment Cost Additions for tax positions of prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Additions based on tax positions related to the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Estimated useful lives Weighted- Average Remaining Useful Lives (Years) Finite-Lived Intangible Asset, Useful Life Equity Component [Domain] Equity Component [Domain] Acquired in-process research and development costs Upfront payments, included in acquired in-process research and development costs Research and Development in Process Future benefit payments for the pension benefit plans Schedule of Expected Benefit Payments [Table Text Block] Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Entity Tax Identification Number Entity Tax Identification Number Aggregate fair market value on awards granted during any calendar year Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Currency translation adjustments Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Rebates, Advertising Credits Portion Reserve For Rebates, Advertising Credits Portion [Member] Reserve For Rebates, Advertising Credits Portion [Member] SHARE-BASED COMPENSATION Share-based Payment Arrangement [Text Block] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] INVENTORIES Inventory Disclosure [Text Block] Corporate brands Trade Names [Member] Violation of Canadian Provincial Securities Legislation Violation of Canadian Provincial Securities Legislation [Member] Violation of Canadian Provincial Securities Legislation [Member] Current Fiscal Year End Date Current Fiscal Year End Date Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Other equipment and leasehold improvements Other Equipment and Leasehold Improvement [Member] Represents other equipment and leasehold improvements. Finance leases Finance Lease, Liability Reduction in variable consideration provision, adjustment SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment Allowances for losses on trade receivables and inventories Allowances for Losses on Accounts Receivable and Inventories Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions. Product brand intangible assets (estimated useful life 7 years) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Tax credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Right-of-use assets obtained in exchange for new operating lease liabilities, excluding amount recognized upon adoption of new accounting standard Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Excluding Amount Recognized Upon Adoption Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Excluding Amount Recognized Upon Adoption Change in uncertain tax positions Income Tax Reconciliation, Uncertain Tax Positions The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to uncertain tax positions. Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Other payments Supplemental Cash Flow Information [Abstract] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Property, plant and equipment [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] 9.00% Senior Notes Due December 2025 Senior Notes, 9.00%, Due December 2025 [Member] 9.00% Senior Notes due December 2025 [Member] Number of cases not yet served Loss Contingency, Pending Claims, Not Yet Served, Number Loss Contingency, Pending Claims, Not Yet Served, Number Benefits paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Foreign currency translation adjustment included in other comprehensive loss Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) Schedule of property, plant and equipment Property, Plant and Equipment [Table Text Block] 6.125% Senior Unsecured Notes due April 2025 6.125% Senior Notes due April 2025 [Member] 6.125% Senior Notes due April 2025 [Member] Worldwide developed markets Non-U.S. Developed Markets [Member] Non-U.S. Developed Markets [Member] Remaining availability Line of Credit Facility, Remaining Borrowing Capacity Gross Carrying Amount Finite-Lived Intangible Assets, Gross Retrospective effect of application of new accounting standard Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update Tax benefit recognition, measurement percentage (greater than) Tax Benefit Recognition, Measurement Percentage Tax Benefit Recognition, Measurement Percentage Provision Accounts Receivable, Credit Loss Expense (Reversal) Number of shares canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Vested and expected to vest at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Hedging Relationship [Domain] Hedging Relationship [Domain] Summary of operating lease future payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Benefit from income taxes Effective Income Tax Rate Reconciliation, Amount [Abstract] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Variable interest rate Debt Instrument, Basis Spread on Variable Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Benefit accrual, interest percentage earned on cash balance Defined Benefit Plan, Benefit Accrual, Interest Percentage Earned On Cash Balance Defined Benefit Plan, Benefit Accrual, Interest Percentage Earned On Cash Balance Cash and cash equivalents Cash and Cash Equivalents [Member] Loss Contingencies [Table] Loss Contingencies [Table] Plan Name [Domain] Plan Name [Domain] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Right-of-use assets obtained in exchange for new operating lease liabilities, upon adoption of new accounting standard Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Actuarial losses Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Foreign exchange and other Foreign Currency Transaction Gain (Loss), before Tax Inventories Inventory, Policy [Policy Text Block] Benefit from income taxes (Provision for) benefit from income taxes Income Tax Expense (Benefit) Omnibus Incentive Plan 2014 Omnibus Incentive Plan 2014 [Member] Omnibus Incentive Plan 2014 [Member] Other Other Countries [Member] Other Countries [Member] Cash and cash equivalents and Restricted cash, beginning of year Cash and cash equivalents and Restricted cash, end of year Cash and cash equivalents and Restricted cash, end of year Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Schedule of aggregate maturities of long-term debt Schedule of Maturities of Long-term Debt [Table Text Block] Purchases of marketable securities Payments to Acquire Marketable Securities Title of Individual [Domain] Title of Individual [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Allegro Allegro Ophthalmics, LLC [Member] Allegro Ophthalmics, LLC Local Phone Number Local Phone Number Unfavorable Regulatory Action Unfavorable Regulatory Action [Member] Payments of deferred consideration Payment Of Deferred Consideration Payment Of Deferred Consideration Cash payments to acquire certain assets and assumed liabilities Payments to Acquire Businesses, Gross Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Vesting Period One Share-based Payment Arrangement, Tranche One [Member] Intrinsic value of stock options exercised in the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Revenue of acquiree since acquisition date Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Schedule of estimated useful lives of intangible assets Schedule of Estimated Useful Lives of Finite Lived Intangible Assets [Table Text Block] Tabular disclosure of estimated useful lives of major classes of finite-lived intangible assets. Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of components of indefinite-lived intangible assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Principal Amount Total gross maturities Long-term Debt, Gross Dentistry Reporting Unit Dentistry Reporting Unit [Member] Dentistry Reporting Unit [Member] Reductions for tax positions of prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Litigation with Former Salix CEO Litigation with Former Salix CEO [Member] Litigation with Former Salix CEO [Member] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Rebates Reserve For Rebates [Member] Reserve For Rebates [Member] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Award Type [Axis] Award Type [Axis] For Determining Net Periodic (Benefit) Cost Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] Weighted- Average Grant-Date Fair Value Per Share Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Discount rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Total fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Allowance for Credit Losses Financing Receivable, Allowance for Credit Losses, Policy for Uncollectible Amounts [Policy Text Block] Restricted Cash Restricted Cash And Cash Equivalents, Fair Value Disclosure Restricted Cash And Cash Equivalents, Fair Value Disclosure Unrecognized tax benefits, net increase for tax positions of prior years Unrecognized Tax Benefits, Net Increase Resulting From Prior Period Tax Positions Unrecognized Tax Benefits, Net Increase Resulting From Prior Period Tax Positions Accumulated Deficit Retained Earnings [Member] Summary of other operating lease information Additional Operating Lease Information, Lessee [Table Text Block] Additional Operating Lease Information, Lessee [Table Text Block] Goodwill reclassified to assets held for sale Goodwill, Written off Related to Sale of Business Unit Summary of right-of-use assets and right-of-use liabilities Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Payments of acquisition-related contingent consideration Payment for Contingent Consideration Liability, Financing Activities Recent suits filed Loss Contingency, New Claims Filed, Number Income Tax [Table] Income Tax [Table] Schedule of information relating to income taxes. Components of net periodic benefit cost Schedule of Net Benefit Costs [Table Text Block] SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Additional disclosures Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Pending Litigation Pending Litigation [Member] Outstanding at the end of the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Components of the change in projected benefit obligations, change in plan assets and funded status Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block] Award Type [Domain] Award Type [Domain] Valeant US Securities Litigation Valeant US Securities Litigation Valeant US Securities Litigation [Member] Valeant US Securities Litigation [Member] Change in valuation allowance related to foreign tax credits and NOLs Income Tax Reconciliation Change in Operating Losses Valuation Allowance The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to change in valuation allowance related to operating losses. Weighted- Average Remaining Contractual Term (Years) Share Based Compensation, Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract] -- None. No documentation exists for this element. -- Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] PROPERTY, PLANT AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Commitment fee, unutilized commitments, percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Litigation Status [Domain] Litigation Status [Domain] LOSS PER SHARE Earnings Per Share [Text Block] Pension Benefit Plans Pension Plan [Member] Discount rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Current liabilities: Liabilities, Current [Abstract] Federal funds effective rate Expected Canadian statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Cash Flows From Financing Activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Research and development Research and development Research and Development Expense (Excluding Acquired in Process Cost) Vested and expected to vest at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Income Tax Contingency [Table] Income Tax Contingency [Table] Adoption of New Accounting Standards and Recently Issued Accounting Standards, Not Adopted as of December 31, 2020 New Accounting Pronouncements, Policy [Policy Text Block] Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] EX-101.PRE 14 bhc-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 15 bhc-20201231_g1.jpg PERFORMANCEGRAPH5YR begin 644 bhc-20201231_g1.jpg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˲ 9FM6^L3K%_9%]8V+ GS#>V3W(8=L!9H\=^N? MPK%^%ZS)X5E6YDCEN!JNIB62)"B,WV^?)526*@GH"3CU/6NMKE_AS_R+]W_V M&-4_]+[B@#J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HJAK>O:;X9TN?4M7O[;3-/@7=+=7DJQ1H/4LQ M%?)_Q6_X*(>'M&NFTCX=Z3-XPU9V\J.[E1X[3>> $4#S)3GC "@]F-<>(QE# M"J]:5OS^XX,7C\-@8\U>:7EU?HMSZZN;J&SMY)[B5(((U+O+(P554=22> *^ M:OB[^WU\/?AYYUGH+MXUU=,C9ISA;16_VIR"#_P /^%>+V_P(_: _:GN(KWX MB:W)X3\-NPD6PN5,>!V*6:$J)C8G/0A=WN:\SZQC<9IAX>SC_ #2W^2_S/'^M9CC],+3]E#^:>_RC M_GH?,BW'[27[7?,.[P7X-N.C*7L;9T/OS-."/3*9'\->R?"7_@GSX!\#^1>> M)GE\::HF&*W2^59J?:$'YO\ @;,#Z"OJ:BMJ65T8R]I7;J2[R_1;&]')? MC,PP^!C>O*S>RZOT1];>*O%^B>!]'EU7Q!JMIH^G1?>N+R41KGT&>I/8#D]J M^1OB?_P4-M[B_.@_"GP]<>)M5F8Q17]U _ELW;RH%_>2?\"V].AKF?"O[&_Q M,^/6M0^)_C1XGN[&!OF33ED5[H*>=JJ!Y5N#Z $^J@U]>?##X(^"O@[I_P!F M\*Z#;:?(R[9;PCS+F;_?E;+$9YQG [ 5YO/CL;\"]E#N]9/Y=#Q_:9EF/\-> MPI]WK-_+9?F?(&A_LE_%_P#:)U2#7?C!XHN='T_=YD>G,RR3JI[)"O[J#([G MYO5:^L?A-^SSX#^"ULH\,Z'%%?;=DFJ77[Z[D]&_#_@F?QCJ&N6-MX6AL_M[ZN9U-M]G*[A(KC(8$$8QG.1C.10!T%%123Q:G-');)Y<;,KLPE560 HV2P'3/2O/_AS^ MVK\$OBUX_?P5X3^(.G:OXE&\1VBQ31K.4Y80RNBQS' )Q&S9 )' )H ]MHKQ M#Q)^VS\#_"/Q0_X5[J_Q$TRR\6"9;=[5XYC#%*?^6. MQ69/DR^/+#_GY)?^DKK\_P #YZT/X"_&?]KK5+?7_B;J]QX9\+[O,M[*2,QM MM/\ SQML_+D<>9)\Q&#\PK[$^$WP'\%?!331:^%]&BMKAEVS:C-B2[G_ -^0 MC.,\[1A1V KT&BNW#9?1P[]H_>F]Y/5_\ ]'!Y70PDO:N\ZCWE+5_P# ^044 M45Z9[ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110!^5_P"T_P#!_P =_ +]H35/%7_"#V/Q7^&_ MCOQ%+J4VEVLIAU664Z9>1RV18 OY8BFN77:K\1K@HQ.?5?%'P+^%_P"TQ^R; MX8\<^'KO7M/^&GAGPAJ4VC^"9+^G3M:7,"M?\ M'_P&O/V6M7\$/&WA+Q9;V^F:+HX\+V\5UX3EE@A\@V=T,RLS%HS(S'G# M#E6'V9\,_P!E'1/"/[*EM\#/$E__ ,)7H@L;BPN;U;;[(TRRRO('5-[[&0N" MIW'!0'VKS?X5?L"ZAX2\8>![WQM\6=6^(OACP 6;PCXW/J:_1;]FG5+W6_P!G7X7ZAJ3.^H77AC39KAI,[FD:UC+$YYSG MUKYVU_\ X)P/>W/B3PWHGQ9UKPY\'/$VK?VQJ_@.VTZ%S+*65G2*]+;XHRRK M\FTC"@'/!K['TC2;30=)LM,T^W2UL+*!+:WMX_NQQHH55'L /PH KZUX@M= M!6)KF*^E$I(7[%83W1&/41(VWKWQFL7X7W"7GA66XC$BI+JNINHEC:-P#?SD M;E8!E/J" 1W%=;7+_#G_ )%^[_[#&J?^E]Q0!U%%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %175U!8VLMS .YKS MCXT_M#^#/@3I?G^(M0W:A(A:VTFUP]U<>X7/RKG^)B!QUSQ7QU)=?&/]O35C M' I\(?#:.7#'+?9N#W/#7,@]!A00/N9R?*Q680H2]E37/4?V5^O8\7&9I3P\ M_84E[2J]HK]7T1Z-\;OV\!)J1\(?!^R?Q)X@N'^SKJJ0&6(/TQ;QXS*W7YB- MO&<.*S/A'^PKJ_C+6O\ A,OC9JUSJFI7+"9M'%R7=O03S \ =/+C. ,?,.E? M17P0_9M\&? ?3=FA67VG5I$VW.L7@#W,OJ (M*L<_:-3LX/^NMPB_S- M8]U\3_"=GGS/$%@V/^>4PD_]!S7!5Q^$H?Q:T8^LDOS9U4\+B*O\.FWZ)LZB MBJ6CZQ9Z_IL-_I\ZW-G-G9*H(#8)!Z^X(_"KM=E.I"K!5*;O%ZIK5-/JCGE& M4).,E9H****LD**** "BBB@ HHHH **** "BBB@ KE_AS_R+]W_V&-4_]+[B MNHKE_AS_ ,B_=_\ 88U3_P!+[B@#J**** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBO,?C9^T1X-^ ^D_:/$%]YNI2INM=(M2'NI_0A<_*N?XFP.#U/%9U*D* M,7.H[)&-:M3H0=2K*T5U9Z1>7EOIUI-=7<\=K:PH9)9IG")&H&2S,> .YKX MU^-G[==QJ>K?\(;\&;&3Q!KER_D#5XX#*N[N+>+'[PC^^PVC&0&'->??\7C_ M &]-6[^$/AM'-_M?9N#^#7,@Q[("/X,\_8?P3_9W\&_ ?2?L_A^P\W4I4VW6 MKW0#W4_J"V/E7/\ "N!P.IYKPO;XG,=,-[E/^9[O_"OU/F_K.+S;W<)^[I?S MO=_X5^I\]_!?]A&YU;5O^$Q^,VH3:]K=R_GMI#7!E&[L;B7/SG_84[>!RPXK M[+L;&VTNS@M+.WBM+2!!'%! @2.-0,!54< #T%3T5ZF%P='"1Y:2WW?5^K/: MP> H8&'+1CJ]WU?JPHHHKM/0"BBB@ HHHH **** "BHKBZALXC)/+'#&.KR, M%'YFN9U+XJ^$M))$^O6C$=1;L9C_ .. UQ8C&X7!J^)JQ@O[S2_,Z*.&KXAV MHP%K7(MX[^];L8X0J_^/,#^E<])4G_=3E_Z2F>W2X=S2JKJBTO.R_-H]THKP?\ MX6!\5-:IV7WMHW_U?G#^/B*4/6>OW)'N]0W%Y;V:YGGC@'K(X7^= M>'?\*7\=:MSJGBWANJ_:II<>V" .YZ5-;_LQQ,=]YXAEE<\GR[8#]2QS3_MS M/*W^[Y6[=Y5(Q_#5A_9F64_XN.7_ &["3_$]6NO''AVRSY^NZ;$1_"UW'G\L MYK)NOB_X.M,[]>MVQ_SR5Y/_ $$&N5M?V:_#D>#-?ZE,?021J/\ T#/ZUK6O MP!\&V^-]E<7/_76Y<9_[Y(H^L\65?@P]&'^*4G_Z2'LLDOR/-KC]IS3%SY.BWOVHL?;@1\ M5[/;Z'IMKCR=/M8>,?NX%7C\!5T * ,"C^R>(ZGQYHH_P"&C'\VP^OY/'X< M$WZU)?HCPK_A=WC:\XL_"!8G@?Z-/)S^&*/^%@?%:_'[GPT+;(X_T&1GDM+_P"A M./>O=J*/]1\GG_'C.I_BJ3_1H/\ 67,(_P -QCZ1C_D>,VO[,NDIC[3K-Y+Z M^4B)_/=6O:_L[>$[?'F?;KK_ *ZW &?^^5%>GT5W4N$,AH_#A(_.[_-LY:G$ M&:5/BKOY:?E8S]!T&R\,Z3;Z9IT1ALX 0B%BQ&6+'DG/4D_C6A117UE.G"C" M-.G%*,59):));)>2/"G.523G-W;U;[A1116A 4444 %%%% !1110 4444 %% M%% !7+_#G_D7[O\ [#&J?^E]Q745R_PY_P"1?N_^PQJG_I?<4 =11110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !574]4L]%T^XO]0NH;&RMT,DUS<2"..-1U9F/ 'N: M\=^/'[6G@GX%0RVMUB020IL9+(-$? MW%.T8P2PXKZ)^#?[/_@WX%Z/]D\-Z:!>2*%N=4NL/=W'^\^!@?[*@+[9YKT> ML:>7SKR5;'2YGTC]E?Y_,YZ.5U,1-8C,I<\EM%?#'Y=7Z_B0V=G;Z=:0VMI! M':VL*".*&% B1J!@*JC@ #L*FHHKW3Z78**** "BBB@ HKCO$_Q:\,>%=\=S MJ"W-TO6VL_WKY]#C@'ZD5YQ=?&SQ5XRN&M/".AM$,X\\IYSK[DGY%_'/UKY+ M,.*1@JCZDUP^N?&[PCH99?[1.H2K_RSL4\S_P >X7]:X*'X)^+?&$R7 M'BO7VC7J(=YG9?8#(1?PS7Q;4IA_RTO7+_\ CHPOZ5Y?]H\1 MYE_N6%C0A_-5=Y?^ 1U3]3N^J9/@_P#>:[JR[06G_@3W^1QEW^T1J>L3FW\- M^&WN)>QEW3,?^ (!C\Z@:W^+_B[[TC:/;MZ,EOC\LR5[G9V-MIT(AM+>*UA' M2.% BC\!4]/_ %:Q^,US+,:DO*G:G'TTO="_MG"X?3!X2"\Y7F_QV/";?]G/ M4]4D6;7/$GFR?Q"-&F)_X&Y'\JZ?2_V>/"EC@W(O-1;OYT^T?^.!?YUZ?179 MAN#/(T"QR. MC2Q"4C\6S70V]K#9Q^7!#'"G]V-0H_(5+17U-#!X;"JV'IQAZ)+\CQ*N(K5W M>K-R]6W^84445UG.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 ?D7^T7\0O$OQ$_;#U[PIXH^+VK_"[5M#\1"#PG9M M=G3M*L[;^SKIHK^2;&UF>7R$);YBEQ(J[@=J?5'Q]\>?M)^'_@GH?A_PY8Z' M<^)F\+W6H^)_B)9W#_8+,0)RUJ#$F9IE&Y<+\I)PH4;QXQ^V9KGBWQ'\8-*\ M)?%?X$MXXT-->D'A?6?!^FN\FJ6,EE=A;.29I"T%-1@-A"?M$L;2I.T-JNS.]D5TCPN1E<#C% M%S]A'XA7FI?L3^"O%WC3Q%7>HZUK5X\TGEQW$^Z2660DD*B]2> OM M7SO\+?VF/'_QA_;^\(:K/>:MH7PFUG1-2N/#NAO/+#%?V4,)@'^0\D9'8@UYWJ'[+OQYT?\ ;.^%Z3?$^^UNQL?#\UNGC&S\ VUM8:;: MKY@.G&.,^2ID0%0Q8,OF#:.!0!S\5:!K>BZQ.^ MC^$K*Y"Z$EC!*B"&:TQME&='\2+$NKZ38ZJL))C6 M]MDF"$]<;@<9P.GI6+\+[6&Q\*RVUM#';V\.JZG'%#$H5$47\X"J!P , "@ M#K:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHJE)K6GPR-')?VLQ@CZC=6G9ZC::@K&UNH;D+@DPR!\9Z=#24HO1,E3C)V3+-%%%46%% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45D M>*?%VB>!]'FU7Q!JMIH^G1?>N;R41IGT&>I/8#D]J^//BG^W[>>(-4'ACX-: M%_L,^+OBEK@ M\6_&SQ%>2W,Q#G2X[@2W++U"/+RL2_[$>>#P5K[.\&^!] ^'FAPZ-X;TFUT? M38ONP6J;03_>8]68]V8DGN:\SEQN8?%^ZI_^3/\ R/'Y:^K M8XUBC5$4(BC"JHP /04ZBO7P^%HX6')1C9?GZGNX3!T,##V="-E^+]7U"BBB MNH[0HHJCJ^MV&@V;76HWD-E;K_RTF<*#[#U/L*SJ5(4HN=1I);MZ(J,93DHQ M5VR]4-U=P6-N\]S-';P(,M)*P55'J2>E>.^)/VADFN/L/A739-2NG.U)ID;! M/^S&/F;\QL5ENU_P"7NY_>2Y]0>B_\! KK*P_L'-,W][.\5:#_ .7=+W8^ MDI;R\U]S-?[4P. TRVA>7\\]7\ELOZT/,/"_[/\ X=T,)+J'F:S=#DF;Y8@? M9 ?_ $(FO2;2S@L+=(+:".W@3A8X4"J/H!4U%?7Y?E. RJ'L\%14%Y+5^KW? MS9X&+Q^*QTN;$U'+UV^2V7R"BBBO6. **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HK-UCQ-I'AV/S-5U6QTQ,9W7EPD0Q]6(]*\YU[]JWX1>&] MWVOQ]H\NWK]AE-Y_Z)#YK&I7I4OXDDO5V/3PN5X_':82A.I_ABY?DF>L45\O MZ_\ \%$_A1I.\60UO6V'W39V(12<>LKH0/P_"O/-6_X*9"\G^S>&OAY<4XM7A@I17][EA_Z4T?<=%? M!_\ PTY^TQX[X\.?#3^S+=_]7<#1[@]>1^\F;RSQ[=_I1_P@/[87Q"_Y"7B( M^&H9.G^G6]IM4_\ 7JI<8]^:Q_M:,_X-*/PKN?#O_!-GX=:; MM?5=9U[6)1U431P1'\%0M_X]1]:S"I_#PZC_ (I?HA_V'P?@_P#>\VE5?:E2 M:_\ )I.S/ISP?XQT;Q_X;L]?\/W\>IZ1>!C!=1A@K[79&X8 \,K#D=JV:Y_P M#X#T7X9>$=/\->'K5K+1[$.((6E:0KO=I&)9B2:W-RW]WFMI>UKVTOL%%%%6O)Q6;9?@E M?$UXQ]9*_P!VYK[&M:\:D92?W)-GOE4M6UK3] LGO-3O[;3K1/O7%W,L4 M:_5F( KX/\:?M!?M!^-F>'3$T?P59N=N+-DDFVG^](V_D>J!>G%><6?P)O/& MFH_VC\2?'>K:I<@]+16NW()Y EG==GT"$5\E7XXRF#Y:-12\VTE^K.9X7.ZS MY<)EU1OO)8A\3+KERO_ "PT6)KG=])!B/\ \?KQ M3Q!_P4N6^N/L?@[X?W>H3R'$;ZA)]=O\ ?GZQH!&?Q4U[%X=^.6C^&;<6F@?#^QTF+&%@TZ1(5X_V4A%>5+C3 M 5':>-C#_#"/"?%V*5YJ-)>7*W_P"3,\4_X6_^UO\ $O+Z#X0;PW X M^3;ID=L,>H:]8Y^H_#%._P"&=_VIO'F3KWQ$.C1-]^%M9EC!YZ;+9"I_$]J] M\_X:.U3_ *%;_P C/_\ $4-\?O$K$E?">%[964\?E4?ZR9%4_B8JI/\ [=G; M[N4O_B'V93_WFI*7K4BE]R9X/_P[C\5ZWQKGQ4,BD;6_T26YX'('SS+WK4L? M^"8.AQQXO/'FH3O@?-!IZ1#/?@NW\_SKV3_AH/Q!!\UQX5PG0Z.)#[=)UKZ&M/VF-#DQ]ITK4(? M^N6Q_P";"M_3_CQX.OL!]0DLV/\ #<6[C]5!'ZUZE',N%,5I"O#YR_@G\N9_DSY2_P"& _B;X=_>>&_BR8I^N?,NK3GZH[>@I#\&_P!KGP:/ M^)9XY_MW9T']K"XW?^!2#]:^U--\<>'M8P+/6K&=ST19UW?]\DYK;KZ*CE^! MK1Y\+4=N\9W_ ,SQ*G#='#OE7/3?E)K\SX./QL_:T^'W_(;\#?\ "0(GWW_L MC[1P.IW6; #UST_"K.F_\%)-6T*Z%GXR^&TMG./O-;7+PN/7]U*F?_'J^Z:J M:GI%CK5JUMJ-E;W]LW6&ZB61#^# BM_J.*I_P<2_^WDI&7]F8RE_ Q.=@T/QEHN MH2MTMTO$6;_OVQ##\JYOQ1^R7\(O%V\WO@73+>1_^6FFJUD0?7]R5&?K^->- M^*_^":?@74P[Z!XBUG0Y6Z+<>7=Q+]%PC?F]+FS2EO&,UY73_'07-G-#>,*B M\FXO\=#[ HKX(_X8R^.GPQPW@+XEB>UB^[:QW\]D6]!Y1W1D?5J!\6OVMOA6 MVW7?";^*+>/JS::EV-OKOLR#^+?C1_:@_MB=+_ 'K#3CYI MW%E<(?WCV-V0P_P"V,B C\7KUGPO^W]\( M/$6U;K5=0\/R-T35+%^OINB\Q1^)K>GFN"JZ*HEZZ?F=-'.\OK:1K)/ST_.Q M]&T5Q_ACXP^!O&BI_8?B_1=3=AD16]]&9!]4SN'XBNPKTXSC-7B[H]B%2%1< MT&FO(****LT"BBB@ HHHH ***YSQ?\1O"W@"V\_Q)XATW1(\947UTD;/_NJ3 MEOH :F4HP5Y.R(E.--//^"B7PS\,K+%H4>I>++M34S M;#1?)3;G+M%7_P" >'6SS"0ER46ZDNT%?\=OQ/M/Q_\ %3PC\+=.^V^*M?LM M%A(RBW$F99?]R,9=_P#@(-?)?Q!_X*%WWB+4#H'PD\)W>K:E.3'#?7D#2.Q] M8[9,D^H+'ZK4O@/_ ()US:MJAUKXJ>,+G7K^0AY;6PE=C(?^FES*-[>F H/^ MU7UCX!^%WA/X7Z;]A\*Z!9:+ 0 [6\?[R7'=Y#EG/NQ-8_\ "AC.U*/WR_R7 MYG/_ ,*N.[4(?^!3_P E^:/C/PK^QC\2_CIJT/B3XT>*KRSC;YDT]9%EN@IY MVJ!^Z@!ZX4'W4&OKWX7_ 5\&_!O3#9^%-$@TXNH6:Z/SW$_^_(WS'GG&<#L M!7<45V8;+Z&%?-%7EW>K^\]'!Y7AL&^>"O/K)ZR?S_R"BBBO2/6"BBL#Q1X[ MT/P?"6U34(X),96!3NE;Z*.?QZ5SXC$4<+3=;$348K=MV7WLVI4:E>:ITHN4 MGT6K-^LO7_$VE>%[3[3JM]#91=O,;YF]E4,;MM.\&Z1+&3 MQY[())0/7'W4'US]:G\/_ +4-;N_[2\9:K+/._+6\GT7/L:^$GQ3 M5S"3HY!AW6>W/+W::^;UEZ*WE<^GCD=/")5,UJJFOY5K-_+9>K%U[X^:AKEW M_9O@W299YWX%Q+&7?ZK&.!]6)]Q4>C_ _7?%EXNI>--6EWMS]FCRY_"O8M!\,Z7X7LQ;:78PV47?RU^9O=FZL?J:TZ=/A>KF$E6S^NZSWY%[M- M?):R]7\TQ3SN&%BZ>54E37\SUF_GT]%\C%\-^#=&\(V_E:5I\-KD8:0#,C_[ MS'D_G6U117W=&A2PU-4J$%&*V25DODCYBI5G6DYU)-M]7JPHHHKN7(KR;Q/^VE\' MO"^Y9/&$.HS#I%I<$ESGZ.J[/_'JYZF(HT?XDTO5GL8+)\RS)VP6&G4_PQD_ MR1[?17QIXE_X*:>$K-F70?".L:J1P&OIHK13]-OF''X5RW_#9WQT^(&%\%_" M\)!)P+A-.NKS;[^9E4'XBO,EGY82UQ%&-&'>I.,5]U M[_@?>E-DD6&-G=E1%&YF8X ZDFO@[_A&_VQ/B1DW>J/X9M9!E?])M;+;[?N M091^/-/C_P""?'Q \92"7QQ\4QB! MMQ_*O,_$'[=WP5>L>GV$S?DSJJG\#7#>'_P#@FKX L=KZOX@U M[5G7&5B>*WC;UR-C-^35Z7X>_8K^#?AW:T?@Z&^E&,R:AO/2OLSP M_P##3PCX3V?V)X6T;22F,-96$41X[Y50<^]=+1]4Q]3^)B+>D5^8O]8N%,)_ MN>3<[[U*LG_Y*E8^#O[?_;(\?#_1=.;P];2?>_<6=KM!Y'^N)D'X<^M'_#)O M[1?CCYO$WQ1^R0-]ZW.KW4N._P#JT41_KVK[QHH_LF$OXM6?^F*QU],T5M3RG T]J2^>OYGFXKQ!XHQ MFE3'37^&T/\ TA(\N\/_ ++_ ,)_#.TV7@'169>5:\MA=,".^9=QS[UZ'I6A MZ=H-OY&FZ?:Z=#P/+M85B7CIPH%7J*]&G1ITOX<4O16/C<5F6-QSOBZ\JG^* M3E^;84445L><%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R_PY M_P"1?N_^PQJG_I?<5U%/ M/#NAY%[K5E"Z]8_.#/\ ]\C)_2N>MB*.&CSUYJ*[MI+\36G1J5I&/-?H-V^X)_P" MH!C\Z^2Q'&61X>7(L0IR[03E?[DU^)[]'AW,ZJYG2Y5WDU'\]3W>D9@BEF(5 M1R2>@KP;S?C!XJSM1M*@;VCM\?G\]*OP!\2:\P?7_$XZ9SEP_@XN=2A#?6O'EAUDNK;< M?FW9%_XA?M82^'))(+[QLU_>J<-:Z#*DA';_ %D.(\^V_-MXE0'_9AP(P,],@D>M>^PPQVT*10QK%%&H5(T "J!T Z"M*? M/%/FS&M. M?DYN3^;T7X&M+B#/YOFYJ>'7:G3BW]\N9?@SYN\"_LU>)+M8KGQ?J6G:_'/I=C^S[X0LU42V]U>D=3/<$$_]\;:])HKZ?#<(9%A M5:&%B_\ $N;_ -*N=[SS-)*TL1)_.WY6_ Y"W^$?@^UQLT&U./\ GIN?_P!" M)K2M_ ?ANUQY6@:8A'&[[)'G\\9K=HKW*>59?1_AX>"](Q7Z'#/'8NI\=63] M9/\ S*EOI-C:_P"ILK>'I_JXE7ITZ"K=%%>C&$8*T58Y)2E)WD[A1115DA39 M(UE4JZAU/56&13J*-P,FZ\):'?9^TZ-I\_\ UTM4;^8KG]0^#/@[4 Q2M7P\)>L4_P T=M+'8JC_ JLH^C:/(M3_9KT M"XR;*_OK)_1BLJ_E@']:PS\#_&/AW+:!XG^5>B"62W)_ ;A^9KWFBOFZW!>2 M5)<].BZ3^*/V-_@]XLWM/X+M+"9NDFER26FWZ+&P3\UKO\ M1?BCX5U[:+76K82-TCN&\EL^@#XS^%=2K!U#*0RD9!'0U]33J8',H<]*4*B[ MJTO\SY7&9%%'U#$],3+[D']F8SIC)?M._X3W]L?Q1_QX^'!I._D?Z%:0[<\C_CX8XQ[_CS7W?11_9U: M7QXF?RL@_LFO+^)BY_)I'P;_ ,,W?M/?$C!\4?$3^QK9N)+'3[=;;)]#(YD+#\%-?:E%..3X6_-43 MF_[S;*CD."OS54YO^])O_@'EG@3]E_X7?#GRWT?P=I[72QCQD>=(%+?0=3^%>8>)/VC=*M&,&AV4VJSD[5ED!CCSVP,;C] M,"O!S+/_P#9Z;:[[+[WH>P5QGBSXN>& MO".^.>]%W>+Q]EL\2.#Z$]%_$UYG_9OQ.^*(_P!+D.AZ7)U1LVZ%?]T?.W_ MN*['PI\ ?#N@[)M0#:U=+S_I VQ ^R#K_P ")KYK^VLYS;W5= M/N@M7Y/;N>S_ &;E^ UQ]?GE_)3U^^6R\SCKCXD>.?B=,]KX7TY]-L<[6N(S M\P_WI3@*?9<'ZUM>%_V=[99A>>)K^35+ICN>"%V"$]]SGYF_2O88+>*UA2*& M-(8D&%CC4*JCT %25MA^$J-:HL3G%66)J+^;2"](+3[[KR,ZN?5*<'1R^"HP M\OB?K+PW$9/L. M:^>/'W_!0SX9^%3)!HBZAXMNUX!LX?)M\^ADDP?Q56%S;.I6R[#3J>:7N_.3]U?-GU#25\%-^U]\>/C QC^'/P^_L^TD.%O([1[ MLIZ9GD"PC\5I?^&3_P!H'XR?/\1/'_\ 95E+_K+&2\:XVYZX@AQ#^35YO]J^ MU_W6E*?G:R^]GVW^H+P&N>YA1PW>/-[2I_X!#?[SZM\:?M'?#/X?,Z:YXTTN MWG3[UM;R_:9E^L<09A^(KP_Q=_P4E\ :1OCT'1=8\02KTD=4M(6^C,2_YI5O MP3_P3E^'&@!)/$%[JOBFCDF^RP'Z+'\X_[[->Y>$_@3\// NQM#\&:-8S M)]VX%HCS#_MHP+?K1_PJ5NL::_\ G_D'-P+EFBC7QDEZ4H/_P!O1\BM^V-\ M=OBE\O@#X;_9+23[EU'8S7A7T_?-MB'XK31\#_VJ_BN-WB7QD_ARVDY>"34Q M "OIY5H"I^C8K[WHH_LN53_>*\I?.R^Y!_KW1P6F3Y70H=I.+J37_;TO\CX@ MT#_@F=;7$_VGQ5X^O+^:3F5=/M C9_ZZR,^?Q6O6?"_[!GP?\-^6T^B7>NS) MTDU2^D;)]2L91#^*XKZ&HKHIY5@J7PTE\]?SN>/C>/N)L>K5<;-+M"T/_2%$ MY7PO\*_!G@H)_8/A71](93D26=C'&^?4L%R3[DUU5%%>E&,8*T59'P];$5L3 M/VE>;E+NVV_O844459@%%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110!\0?'3_ (**:YX%^*6H^&_ ?PPN?&>B>&=3.G^(]7FO M%M@TJVD]S+;VBG[TB1P.Y8YSY3)M^='KU'XA_M[?"GX>? [0OB3=:L;B/Q%I MWV[1-!3'V^^;&#%L!.S:_P CN3M4@\G@'Y#^/W@S0-0_:4N/&O[/_P 63X<^ M($?BB6V\1:#JUJZ:?9ZE'I]X_P!J=)XP,,D-PGF;)%S,[*PZ'Z'\):UI_P"T MI^QJGQJ\6^%K"/Q\/!>LVD5[Y1(@ 6:.1X Q(02&(-D>^!_P!O M?7YO%_P]L/B5\&M2^&WA[X@NL/AG7VUJ#44N9'"F)9HD16@WB1,;LG+=,!F% MG]@GQKHOPX_X)Z^"O%'B._CTS0])TZ]N[RZESB.-;N*<+=.0?X75"6&5!01 MIN/F/0!Z!X@_X*-SZ?<>(O$VC?"36O$/P9\.:K_9&J^/K;484,GW"7=A>P)T_0_\ @DI\7]%U&^@M-7T_5+[3;NTG<+)'M '6T444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 45G:MXATO08]^HZA;6*XR//E5"?H">?PKA-:_:"\*Z7N M6V>YU20?\^\6U<^Y?'Z9KQ\;G&79;_O=>,'V;5_NW_ ]##9?B\9_ I.7HM/O MV/3**\(E^/GB3Q#(8O#GADN>FXJ]PWUPH 'XYIAT'XN>,/\ CZOFTB!NWG+ M /3$>6_.OEWQEA<1IEM"KB'WC!J/SR3KNN)50?J:X[5OCAX/TK*C4S>R#^"TB9_P#Q[ 7]:XS3?V:Q M<2>=K6OS7$C?>6VCY_[[5?\ DQQ^H_M+Q22>5I&@SW#L M<(UQ(%/_ 'PH.?SJE_PF'Q8\6?\ (/TDZ9$W1EMA$,?[TQ_45[=INBZ?H\>R MPL;:R3&-MO$J?R%7:/\ 5_-\7_O^9SMVIQ4/_)M7]XO[5R_#_P"ZX.-^\VY? MAL>"?\*8\<>)^=?\2>7$W6-IY)R/^ \+^1K>TG]FW0+7#7]]>7[CJJE8D/X M$_K7KM%=%'@O):$KO7M2F;RX;K4(VP[= MO+MXR7?/NRGVKWN;+LICR4XQAY123^Y'QN89W2I.^,K-R[-N3^[5GVK)(D,; M22,J1J"S,QP !U)->"_%3]MGX8?#'S;=-6_X2?54R/L6A[9@#Z-+D1KSU&XD M>E?/D?P!_:(_:69;CXA^(W\+:#(0PL+D[?E[8M(L#(_Z:D-7O7PL_89^&/PW M\FZN].?Q9JL>&^U:SB2,-_LP@;,?[P8CUJ/K.-Q7^[T^2/>6_P!QXOUS,<;I MA:/LX_S3W^45^NAX+-^T-^T#^TQ-)9_#CPY)X8T&1BAU"W&"%[AKN0!01Z1@ M-]:ZOX??\$Z8;V^.L_%'Q7=>(=3E;S)K6PE?:[=_,N)/WC_@%/'6OM&&&.VA M2*&-8HHU"I&@ 50.@ '04^KCE<)OGQ4W4EY[?)%PR6G4DJF-FZLO/X?E%:', M>!/ACX4^&.F_8?"V@6.BV^,,;:("23W>0Y9S[L2:Z>BBO9C&,%RQ5D?00A&G M%1@K)=@HHHJBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M K*UCPKH_B!2-2TRUO3TW31 L/HW4?A6K1656C3KP<*L5)/HU=?B:0J3I2YH M-I^1Y?K7[/'A?4MS6?VK2Y.WDR[T_$/D_D17+-\$?&'A5B_AOQ+N0'/EB1[< MM_P')4_B:]YHKX_$\'9-7E[2G1]E/O3;@U]VGX'OT>(/:24OSU_ M$\%7QU\4O"!VZMHQU.%>#(UOOX_WXCC\ZT-+_:8L6;9JFBW-JPX9K>19.?HV MW'YU[56?JGA[2];7&H:=:WO;_2(5<_F17)_8.L&D^\&X_ALKJ#8ZE: M7@/3R)U?^1KD-2^!?@[4,E=->S<_Q6T[K^A)'Z5RVH?LR:9(Q^Q:U=VX[">) M9?Y;:/K7%>%_BX:E6_P3<'_Y/H'L+= M*_Y!/BS9CI^]F@_]!W4O_"&_%O3_ /4Z[]IQS_Q][O\ T-:K_63,:7^\9757 M^%QG^5A?V/@Y_P '&P?JG'\SW:BO"3'\;(?D5_,5>C9LSG\^:3_B]W^?L-+_ M %N[Y=B?_!7_ -L']@?]1E'_ ,#_ . >[T5X3_9?QFOO];=_9]W!_>6RX_[X M'\J/^%;_ !0U@!;SQ-]FC[K]MD'Z(N#^-/\ UHQ-3^#EE=_XHJ/YL/[$HP_B M8VE\FW^A[C<74-G&9)Y8X8QU:1@H_,URFK_%SPCHNX3:W;S./X+7,Q^F4!'Y MFO/+?]FN:ZD$NJ>)'F?N(X"Q_P"^F;^E=3I/[/OA+3MIGANM2<C>5HVD7-]*3A6N M&$:Y]@-Q/Z5E_P!M_%?QV"+2S;1+1_XU06_'KNPWRG_ (&V3^'2N@HKV\NX;RK*WSX:@N?^9^]+[W=_=8\W&9QCLKD"2-3:VN?>1QN/X(0<=:X\1C,/A M5>M-+\_NW/H\IX=S?/9LG:*^;/JVN<\9?$;PO\/++[7XEU_3 M]$A(ROVRX6-G_P!Q2=S'V4$U\1_\+2_:?_:+ROA;1I/"&@S\+=6T7V-2AZ-] MHF.]OK%CZ5T?@W_@G')JU]_:OQ*\;7>KWTI#30::S,6;ONN)@6;_ +X!]Z\S M^T:V(TPE%M=Y:+_@GV_^IN693[W$690IR7_+NE^\J>CM[L7ZW1T/Q$_X*/\ M@K06>V\(Z1?>*[K)5;B7-I;'T(+ R'Z;!]:\^_X6+^U1^T!QX?T:3P;HLW2X MA@%BFWLPFF)D;ZQ_E7UQ\._V?/AY\*Q$_AOPM8VEW&!B^F3S[G/KYKY89] 0 M/:O1*?U+%XC7$U[+M#3\=P_UFX=R?W%O^"< MM_X@OAJOQ*\>76IWLG,T6G%I9&^MS-DG_OC\:^B?A_\ LK_"[X:^5)I7A*SG MO8^1?:D#=S;O[P,F0I_W0*]8HKKH9;A,.[P@K]WJ_P 3YW-.-L_SB/L\1BI* M'\L?!= _X0B3P?'I5O:^&'L&TS^S+1?(B2V*&,Q($QL&TD?+C':MZ MB@#RB\_99^&%]\$X/A%-X;8_#R @IHRZE=KTE,P!F$HE8>8=V"Y'3L*X#PK_ M ,$W_P!G7P3XGTCQ#HOP\^Q:QI-W%?65S_;>HR>5-$X>-]K7!5L,H.&!!QR# M7TM10!XCXD_8G^!_B[XG#X@ZO\.]+O?%9F%R]VSRB*64?\M)+<.(9&SR6="2 M>3DU[=110 5R_P .?^1?N_\ L,:I_P"E]Q745R_PY_Y%^[_[#&J?^E]Q0!U% M%%% !1110 4444 %%%% !1110 445E:UXJT?PY'NU/4K:RXR%ED 8_1>I_ 5 ME5K4Z$'4JR48KJW9?>S2G3G5ER4TV^RU-6BO)=>_:.T#3]R:9:W.JR#HV/)C M/XM\W_CM<[_PG7Q-\=\:+I1TRT?I,D04$?\ 723@_P# <5\9B.,LJIS]CA7* MO/\ EIQ\WR_AO\ @>[W%U#9PM+/+'!$OWI)&"J/ MJ37$Z[\;/".A[E_M+[?*O_+.Q7S<_P# N%_6N#MO@#K_ (AF6X\3^)&=^I1& M>=OIN8@+^ -=OH7P+\):+M9[%]2F7_EI>OO'_?(POYBN;Z_Q+F'^ZX2-"/>K M*[_\!CL_)FOU7)L)_'KRJOM!67WO?Y'&7G[0FK:U<-;>&?#CSR=FE#3-]=B= M/S-0?V'\6O&G_'W>MHULW\)E$ QZ8C!;_OJO<[.QMM/@6&UMXK:%>D<*!%'X M"IZ?^K.,QFN:9A4G_=A:G'TLM6']M8?#Z8'"1CYR]]_CL>+:3^S7:&3SM:UJ MXO)&.66W4)D^[-N)_(5W>B_"?PIH.TV^C6\L@_Y:70,S?7YLX_"NNHKV,%PQ MD^7ZT,-&_=KF?WRNSS\3G688O2K6=NRT7W*PR.-(8U2-%1%X"J, ?A3Z**^G MVT1X@45Y]XQ_:!^&_@%9/[<\::/:2Q_>MTN1-./^V4>Y_P!*\$\;?\%)_ FB M[XO#>AZKXDG7I)-MLX&],,VY_P T%<-;'X7#_P 2HE^?W+4\S$9G@\+_ !JJ M7E>[^Y:GUY67XB\4Z-X0TYK_ %S5K+1[)>MQ?W"0I],L0,U\,GXW_M.?'SY/ M!GA=O"NCS<+=PVPA!7U^T7'!/O& ?:M+P_\ \$]/$WC745U;XI_$&YO[IA\\ M5E(]U.1Z>?-]W'H$85P_VE4K:82BY>;]U?CN>;_:U;$:8'#REYOW8_CN>B?$ M;_@H=\-_"/F0:!'>^,+U>AM$-O;9]#+(,_BJ,/>O(?\ A;_[2_[2W[OP=HLG MA#P]-P+VU3[,A4]_M4OS,1_TQP?:OJ?X<_LI_"_X8^5)I7A:UNKZ/D7^J#[5 M/G^\"^0A_P!P+7K5+ZIC,3_O-;E7:&GX[B^HYAB_][K\L?Y8:?\ DSU/BOP# M_P $Y+>ZOO[6^)?BRZU_4)#OFM=/=@KM_MSR9=Q] I]Z^J? 7PI\(?"^R^R^ M%?#MCHJ%=KR6\7[V0?[H4445WGIA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 456U#4K32;.6[OKJ&RM8ANDGN)!&B#U+$X%>#?$+]NCX4> U MDBM]8D\47RYQ;Z''YR9[?O21'CZ,3[5SUL11PZO5FH^I[.6Y-F.<5/9Y?0E4 M?]U-I>KV7S/H*J>K:Q8:#82WVIWUMIUE$,R7-W*L4:#U+,0!7PI>?MD?&?XV MW4EA\*? SZ=;D[/MR0F\D3T+2N%AC_X$#]:ETG]AGXF?%B_BU7XL>/9$.=WV M1)FO9T!ZJ"2(XO\ @&X>U>3_ &HZVF#I.?GM'[V?H"X$IY:N?B3'T\-_<3]I M5_\ 8[>MV>P?$C]OCX7^!_-@TN[N/%VH)D"/2D_9\*1[IOKQ23]I?\ M:#_:$D:W^&_A)M TF0E1>V\(? [AKJ8",'']T*WI7TA\.?V-_A5\-O*EM_#D M>MW\>/\ 3M<(NGR.X0CRU/NJ U[7'&L,:HBJB*-JJHP !T %+ZKCL3_O%7D7 M:'^;'_;O"N2:91E[Q%1?\O,0[KY4X^ZUVO9GPUX9_P"">_B7QMJ2ZS\5O'MS M>WAN)N%^@1A[U]*_#?\ 9C^&OPK\J70_"]HU_'@C4;X?:;C< M/X@[YV'_ ' HKU*BNS#Y;A<.^:$+ON]7^)\[FW&N>YS'V6(Q#C3VY(>Y"W:T M;77K<****],^'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ KE_AS_P B_=_]AC5/_2^XKJ*Y?X<_\B_=_P#88U3_ -+[B@#J M**** "BBB@ HIDTR6\;22NL<:C+,YP /7_@*_S/5?$'Q*\, M^&=RWVKVZS+UAA;S9,^A5']%FO)F.$>Y.,GV1?\ QZO1='\.Z7X?A\O3=/M[%,8/D1A2 M?J>I_&I]CQ3F7\2I#"P?2*]I/[W[OS0_:9)@_@A*O+S]V/W;_>>*?9?BQX^_ MULCZ%9OV)^R@#TP,R'\:U-%_9LLED\[6]7N+Z5CN9+<; 3[L%]W]L>+M#TLJ,E;O488VZ9P 6R3["KAP?EJDJV93EB)]ZDFU\EHK>3N8 M5N)<12ARX?EH0_NI+\7J6-!^'GASPSM.GZ1;12KTF=?,D_[Z;)_6NBKP_7OV MUO@UX?W+)XRAO91TCL+6>?/T94*_F:\XU[_@I3\.M/W)I>B>(-6D'1FAB@C/ M/J9"W_CM?2T\1EF A[.BX0BND;?DCXK%9YA92Y\1B5)_XN9_J?6]%?!\W_!1 M#QMXOE:#P1\+OM4N2J[WGOR3[I$B=NV?QIG_ GG[8?Q$_Y!OAYO#4,F"?\ M0;>TV@_]?1+C\.:G^V,/+^#&4_2+_6QY?]O86?\ C.I_AB_UL?>=<]XF^(G MA7P8K'7_ !)I.B[1DB_O8X3^ 9@37Q9_PR=^T7\0.?%GQ-^Q6L@P]L^K7,O? M_GE&HC_7TKH/#/\ P3)\.PLLGB3QKJFIN?F==.MH[7)_WG,A/UP,^U'US&U/ MX6'MYR:7X"_M#,*W\#"->K^*/VYO@[X9W(OB5]8G7_EEI=G++^3E0 MA_[ZKR/Q-_P4VT96\GPQX(U'497.U&U*Y2WY/3Y(Q)GZ9%>P>%_V'_@[X8V/ M_P (M_:TZ_\ +;5+J6;/U3<$_P#':];\-^ ?#/@V,)H/AW2M%4#'_$OLHX/_ M $%12]EF=7XJD8>BO^8>QSBM\=6%/_"KO\3XE;X[?M4?%KY?"W@M_#EI+Q'< M1Z:(05_ZZW9*GZKB@?L;_';XJ?/X_P#B,+2UD^]:2WTUX5]?W*[8A^#5]\44 M?V3&I_O%64_G9?<@_L.-77%UIU/)NR^Y?YGR+X/_ .";'@#1VCE\0:WK'B*5 M?O1QLEI WU50S_D]>_>"/@/\/?ASY;>'?"&E:?/']VZ\@2W _P"VK[G_ /'J M[RBN^C@<-A_X5-+\_OW/3P^6X/"ZT:23[VN_O>H4445W'I!1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1163X@\6Z'X3M_/US6=/T M:#&?-U"ZC@7'U<@4G)15V:4Z#^+/VWO@_P"% Z_\)1_; M%PO_ "QTFVDGS]'P(_\ QZO%O$G_ 4EFU:[^P> _ -UJ-U)Q$^I2%G/_;"$ M$G\'KRZN:8.CI*HF_+7\C[G+^!.),R7-2P%?^";\NK7G]H_$/QW=ZI>2',L>F LS'WN)LEO\ O@5S?VAB*W^[ M4&_.7NK_ ()[G^I^499KGF;4XM?8HIU9>C:LHOUNCT7QU_P4%^%GA3S(M*GU M#Q5=KP%TZW,<6[WDEV\>ZAJ\BF_:\^.7QOE>V^%_@1M+LW)07TW:<_:]5!O),_WAYF54_[H%>N0PI;Q)'$ MBQQH-JH@P !T %'U7'XC^/6Y%V@OU>HO[1ZC\5OB#)&N[>+19GOI4]5 )6./\ X!N'M7O'P]_8E^$_ MP_\ *E.@?\)%?1\_:M=?[1D_]9_F4/8>W]E2Z0I)4XI=O=LVO5LAM+.#3[6*VM8([:WB7;'#"@1$'H . *FH MHKUCX!MR=V%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@#@O'OQZ^'7PN\0:-H7BWQIHOA_6-8E$5E97UVDU>PUW1[H%H-0TRY2XMY0"5)21"5;!! M'!Z@UD>$_BQX'\?:I?Z;X8\9>'_$>HZ?Q>6>DZI!=36W)7]XD;DIR".0.17Y M\Z=XPU/P3_P17BO])N)+2]FTY['SXF*LL<^J-%)@CU1V'XT?%KX>^%/V:]>_ M8Y\5_#_P]9^'-9O-1M-*U&ZT]!#)J,$\,*RBX91^]8^8_P S9/S'VP ?H-?_ M !9\#Z5XR@\(WOC+P_9^*[C;Y.A7&J0)?2;@2NV OO.0"1@ZL/$\R9OX9H[B+8(YOOH@Y^4'!R<]L?I MS^SWXJOO''P&^'/B+4Y&FU'5?#NGWMS(QR7EDMT9V)]223^- 'H%I&[LM9U)6NKE/+C^:\F<'9_K <-RK*I&*X,9CJ& I^UQ#LO)- MO[DFSWLHR',L^J2I9;1=1Q5W:VB^9]DU3U+6+#1H/.O[RWLHO[]Q($'ZFOB7 MQ!^VY_;RA+'765IN([+1[*3SG]@2NX'\17/36WQG\>,+C0/AIJTIF&Y;[Q#. MEN6&,Y*R.O\ Z%7P%3C#$XJ3IY5@9S?>7NK[M6_P.O,,GHY%+DSFLX3_ )(P ME.?I9+3YZ'UUK_[07A?2=R6;3ZM,.,6Z;4S[LV/T!KB[[XS>-?$T+OHFDQZ7 M9?\ /VX#!?K+)B,?B*^>H?V2_P!H7Q;(CW_B+2?#48;=LBOFC=?8&!&)Z]V[ M?2MNS_X)KZOKDZW/BGXF274W\0ALGG8_22248X _A_E7"\/Q3FC_ -IJ.E%_ M9IVB_P#P.5Y(\"7$&%P[MEN5RJO^:M)1_P#)5I^IVFL:AH=Q-YOCKXN>'[1E M.3:#5$NID]O+5L+^&:HQ_'C]F[P7@G6KOQ1=)R<64[KGV!1$/ZUI:%_P39^& MVG[6U'5_$&JR#JIN(H8ST[+'N]?XJ]#T/]BGX,Z#M,?@N&[D'62^NIY\]>JL MY7OV%=V#X3IT)^U="$I_S5'*I+\=+_(XL1Q%Q5C(\D'3HP[*Z_\ 2?U9Y-J' M_!23X>Z);_9_#_A'6KB-/NHZ06D7X;7?CIVKF7_X*+>,?%$C1^$OA:;ALX7= M/->D_A'&GY9K[ T/X/\ @3PSM.D^#- TYUY$EOIL*/GCG<%R3P._:NMCC6*- M410B*,*JC ]!7V$<'CFE%UU%=HQ1\^\)FM9WJXNWI%?F]3X0_X79^UKXV_Y M!?@/^P@W0_V.;?'XW;GT/7U^E'_"K/VO_&W&J>+CH/F<'_B9PVVW/_7HIQU[ M>GTK[QHJO[+;^=D+^Q7/^-B:DO^WK+[D?!W_#OWXC^+N?&'Q6\\OR_S M7-_SW_UKIGG-=3H/_!,OP9:[3K/BS7-1(Y(LTAME//\ M+(E\%-+Y(].G@< M)1_ATHKY(9##';QK'$BQQJ,*J# 'T%/HHKK.X**** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **2 MN$= W'4_%.BZ:%Y/VO488L<9_B85,I1BKR=C:E1JUYBL5N/'^C2$''^B3&Y'7'6,-7)W_[>?P7LU)B\2W-\<9Q;Z7BO#'BI:U,,HKSJ4 MU_[>?=M%?"A_;,^/FI,ZZ7\'79R-R#^QK^;"\P<_\ /)#S[CGI0O[+O[3NK;&O?BY]E0_*R+XAOP=O^ZD>T_G1_:59 M_#AI_.R#_4O+Z?\ &SK#K_"Y2_)'W945Q=0VDY(/;YF MG.1CV%'US&R^'"OYR2#_ %:X7I?Q\]C_ -NT:DOU1]@:A\4O!FD@F^\7:#9! M02?M&IPQXQUZM7+ZI^T]\)M'5S/\0=!D"]?LMXMQVSQY>[/X5X5I_P#P3,\$ M1L/MWBOQ!<#//V<01<8ZNGTO_@G;\)=/93.-=U(*!D75^%W?7RT3]*/; M9G+:E%>LK_D']G\#T?XF/K5/\-)1_P#2F;.L?MZ?!K2MPA\0W6J,O!6STZ?K MST+JH/3J#CFN&UC_ (*7> ;;A[ M3!X'LYV7^*\GGN,GCDB1R.WICKZUW&C_ <\!>']O]F>"O#]B5_B@TN!6_%@ MN2?K2]GFD_BJ0CZ)O\P^N<"8;^%A,16_QSA'_P!(/D2?_@I!X@\12M;>$_A@ M]S<=%\R[DNB2>G[N.)3US_%S47_"[/VLO'W_ "!? O\ PCZ/]Q_[)^S\'H=U MVY!^O2ONR&".VB6.&-8HUZ(B@ ?@*DH^H8JI_%Q,ODE$?^MN1X7_ '#)*2_Z M^2G5_!V/@W_AG[]J;XD<^)/'QT*"0?O;=M6:,8]/+M5V'Z9Q6KH/_!-"VNKK M[7XM\?WNHRR8,J6%J$'B^E*G&/YIO\3P'PG^PO\'_ J4=_#LNN7"])M6NWE_-%*H?Q6O:/#OA'0_ M"%I]ET+1M/T:VZ>3I]JD"_DH%:U%>G2PU&A_"@EZ(^'S#.\SS5WQV)G4_P 4 MFU\DW9?(****Z3Q0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH ^"/CQ^SS^T%H_QOTG4? 7C:#Q3X2USQ M(VH6EIXN6\OO^$9N'L;N.0@KN5;79+(%!*J',";<;BWT-\/?V;1\*_V2G^#N MBZC'?72Z%>Z>NH72F*.6ZN5E9Y"HW%$\R5C@;B%P.<5[C10!\P?#O]CZ=/V& M+?X">-]1M#=OI\]I<:AH[/-#%*UR\\,J>8J%MC&,X(7)4CWKB_A_^R/\8?$? MCKX6W'QE\7^%=5\*?"_$FA6WAN&X^UZE.J!(IKUI@ K*$0XCR#@CN6/VG10! M\":G^P;\7M)\+^+OA!X1\=^%[#X&>*-7;49Y+ZVN'US3X9'5Y+6!0/)9"449 M8@GD_+D@_<_A7PW8^#?#.D:!IB-%IVEVD-C;(QR5BC0(@)[G"BM2B@ K\G_V M[?V$;BZU?1I-:O_ /A(-'N6>:.V*7TR+*%SD0L%"N 04/(. M&^3]8*Y#P386VJ>$=3LKVWBN[.YU/5X9K>= \$M9BQ!JFBQW:W*V%SC)4K(I=D/5&W#(]PP&W-^P;\4OAY,TWP\^) MP15.\1^?<::Y]L1EU;\2 :\(^,7P]\5_\$Q?VAK+XD^ HIM0^%FO3&"?36>,'=M?=^G_PM^)WA[XQ^ M'\8>%[U;_1=4A$L,G1D/1H MW'\+JP*L.Q!K/.>%\OIN.-P'L*N)]K'K&I& M,T_G)_$]3_6S(LQTS?)Z=W]JBW2?KRZIOU9Y? MX-_;,^$/C38D/BZWTJY;K#K"-:;?J[C9^3&O8M-U2RUFS2[T^\@OK5_NSVTJ MR(WT920:^?/&7[ OPD\5>8]GIE]X;N'Y\S2;QMN?]R7>H'LH%>.ZG_P3W\;^ M!KQ]0^&WQ(:WN.JK,TMA+QV\R(MN/U"BCZQF-#^+24UWB[?@P_LG@S-/]QS" MIAI/[-:',O\ P*&B7FS[OHKX&_X3[]K3X+9&L:')XOTV+G?):)?KM'4E[,_!5_I,Z'9)+ILRS8/O%)L*_3<351SC#)\M9.F_[R M:,:WASG,H.MELJ>*@NM*I&7X.S^23/M>BO'O!G[77PD\<>6EGXSL;&X;C[/J MVZR8'TS*%4G_ '2:]^U"UTNU>YO;F&TMHQEYI MY B+]2>!7DOC#]KSX1^"=ZW?C2QOIUX\C2MUXQ/IF(,H/U(K&I6I45>I)+U= MCT\%E>.S*7)@J$ZC_NQ'X)#!X5\':EJTK':DFHS);*3 MV(5/,)^G!KF?^%Z_M3?%[Y?"O@YO#EG+PEQ%IHA!4]_.NR5/U7%>5+.,+?EI M7F^T4V??4?#C/>15<]<5XJ^-7@+P/N&N^,-%TV5>L$ MM[&9OPC!+'\!7Q[_ ,,<_'CXG+N\=_$@6UK+]^TFU">[*YZ_NEVQ#\&KM?"O M_!-+P3IOEOK_ (EUG6Y%^\MJL=I$WU&';'T;\:CZYCJO\'#V7>3M^&YO_J[P MK@/^1AF_M'_+1IN7W3?N_@=5XJ_X*$?"7P_O73[G5?$7:A_P4EU77+DV?A#X;R7=P1\AN+MYW/_ &RCC!_\>KZ+\*_LD_"/P>4: MS\#Z;=2K_P M-3#7I)]<3%@#] *]3TW2;'1K5;;3[.WL;=>D-M$L:#\% %/V M&95?XE90_P *O^8O[6X*P&F%RVIB'WJU.7\*>C]#X87XR?M;?$+YM$\&'P]' M)RC#2EMQ@\ YO&(/KG^E+_PHG]J[QW_R&O'QT*-_]9&=8:'CH1MM4*GCMG%? M>-%']E<_\:M.7SLON0O]?GA],NRS#4?/V?-+_P "D_T/A ?\$Z/%_B0[O$_Q M3\YVY;_1IKSGJ>9)4[D\_C71Z3_P3)\(P[?[3\8:U>>OV2*&#//^T'[5]F45 M4<[8U"C\A4M%%;'G-MN["BBB@04444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %*+%=0T35(##/$>&7NKH?X75@&5NQ -?EW\&?'_B?_@F3^TC? M?#7QW<37OPMUZ830ZEL/EJC';'?1KS@C 29!S\N1NVIN_6RO$/VN?V7]$_:H M^%=UX>OO+L]>M-USHNK,OS6EQCH2.3&^ KKZ8/55Q]%E.84Z'-A,7K0J;^3Z M27FC*I%OWH[H]IM+N#4+6&ZM9H[FVF19(IH6#)(A&0RD<$$$$$5-7YL?\$Z_ MVF]<^&GC.\_9N^*[2:=K&F7#6FA37S;(L?O*P^:$]"#M!(,8K])ZX&+AN0=.NR\>?=)0_'LI%>1W7[!?Q-^'%Q)=_#;XD[#G?Y1FFTZ1O8^675O M^!8!K[SHKR:F4X.H^90Y7W6GY'Z!@?$+B/!P]E+$^UAUC42J)^O-=_B? Q^+ M'[5WP9X\0^&I/%6GQ=9I;!;M0GJ9;4@CZO\ CZ5T/A7_ (*8Z3Y@M_%O@G4- M,F0[))--N%GY[YCD"%?IN-?;%<]XH^'OA?QQ'Y?B'P[I>MKC ^WV<E_K5P_F/_(VR>"D_M49.G_Y+K%_-GF?A#]L[X0>, M=B1>+[?2KANL.L1O:;?J[@1_DU>P:3K6G:]9K=:9?VNHVK?=GM)EE0_1E)%> M >,/V!?A%XHWO::7?>')VY,FE7C 9_W)=ZCZ "O(-6_X)R>(/#5VU]X!^([V M=T/N+=QR6KK]9H6)_P#'*/;YE1_B4E-?W7;\&']E\%9E_N>85,-)]*U/F7_@ M4-EYL^ZZ*^"O^$/_ &P?ACDV&LR^*+6,88_;(+[OF'>A^H&*?]KTX?QZJT_ 7_ !#O&8G7*L90Q/90 MJ)2^:E:WWGWI17QYX8_X*7>"=0V+KOAC6M'D;JUJT5W&OU)*-CZ+7IF@_MO? M!K7MJ_\ "6C3Y3_RSO[*>+'_ +9M_\ 'NU=5/,\'5^&JOF[?F>!C.!^)<"V MJV J:?RQYU]\;H]WHKB]'^-?P^\0 ?V;XX\.WC'_ )9Q:I"7'7JN[(Z'J.U= M?;W4-Y$)8)4FB/1XV# _B*]"-2$]8NY\C7PN(PKY:]-P?FFOS):***LY0HHH MH **** "BJM]JEGI<7FWMW!9QX)WSR*@XZ\DUQ.N?M ?#3PV674/'GA^&1>& MB748I)!VY126_2LYU84_CDEZG;A\#BL6[8>E*;_NQ;_)'H%%?/'B+]O7X.:& MK>1KMWK4B]8].T^7/_?4@13^=>6^(/\ @IKI'F>3X;\"ZCJ+LVV-M0NT@/M\ MB+)D^V?QKSJF:X*E\55?+7\KGV.#X"XGQW\+ S7^)*'_ *6XGVS17P9_PT]^ MTK\1<+X5^'/]EVSG"7*:3,PY]99F\OCZ"D;X*_M7_%, >)/&)\.VS_?B;4UM MP5]"EFI!^AKG_M95/X%&SV?^(?U,+KFN88>AW3J)^(/\ @I--JUU]A\#_ _NM0N9/]4^H3%G/_;&($G\'K)_ MX2K]KOXQ9%CIWF2LFT_0$5ZUX/\ ^"??PG\->6^H6FI> M)9UY+:E>%$S[)$$X]CFOI:BMZ>4X.F[\EWW>OYGF8WQ"XEQL?9_6G3ATC32@ MEZBBO5C&,%RQ5D? M UJ]7$S=2O-RD^K;;^]A1115& 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !117YR?\%6OBEXA\/:UX=\'WWBG6/!?P[UCP]JEQ+=:/&P.JZDD;"&RF MD4%EB),89?ND2G=Q\R 'Z-T5^<7CKQK\:?@K^PWXGU/P]\2[+Q_I:ZQ;Q:+X MUTB[_M34-/T9SB7[3((PIEC(5=X+D"1N5VKC3_9C\>:OX9_:[B\%>"?C%XA^ M.?PMN?"?]K:WJFMZD-6&EWOS[ MR!^[)VJ/*S_RU(8%DR #]"J*_+"'QI\5? MBA^SGX__ &I[3XO>*M UO1=8G?1_"5E<#=CF@#JJY?X<_P#(OW?_ M &&-4_\ 2^XKJ*Y?X<_\B_=_]AC5/_2^XH ZBBBB@#X;_P""DO[',WQ<\-K\ M3_ ]O)%\0O#D0DFCL\K+J-K'\PVXY\Z+[R$Q?=2[0>_ <#[K]@&45]8U^6/[;7P-\0?L<_&S2_VB M/A/#]CT6:]W:K80J?(M;B0X=74?\N\X)!'17/!&4Q]CE]2&;8;^R\0[36M.3 M[_ROR?3_ (9'/)PF?YO@$EA,74@ETC.27W) MV/D/6/\ @FG\/KK+:=XB\16#'^&:2"9!TZ#RU/KW[UR,_P#P33U'29C/H'Q- MDMI.H$FG-$P(Z?.DWK[<>]?=5%<$LGP,M?9V]&U^I];0\2.*J"Y5C')=I1A+ M_P!*BV?"7_#%?QUT5<:'\7S'M&%']K7]MU/(^0-C^M(W[.W[54#>6GQ.$JI\ MH<:__*9_.D_X4M^UMJ7[N?QW]D5?F#_ -L%,GTS&F?Z5]WT M4?V13_Y^3_\ A_\1$QJVP6&3[^Q7^9\(?\ #,_[4FJ#$_Q7^R;.G_%17J;L M_P#7./V[^M/_ .&'/C)K+%-:^+S20NVY_P#3KRX))ZG#%*>'_P!C/X.>'65X/!5K=R#JVH3S7(/_ M &1ROZ5ZEX?\%^'_"A3P]&C_#@EZ)(^ M.QF<9EF/^^8F=3_%.4OS;"BBBN@\@**** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "OBO\ X*/>+/B#X?\ VJV*_#K M3_'OPFU30+R'4+JVL&N=2T74!%(8+L@N4$*DHV\)E-KDL/E!^U*J:MI%CK^E MW>FZI96^I:=>1-!N^%_ VO>(])U6#X:7MT;6^U#3K>W<7?R!R4\V1XV$1.[$7R@[4!]B^!/ M@/4_''[87AWQM\//@MXA^ _PWTW09]/\26NM:6NBC6)71Q'&MJAQ)M9T;S,< M^622" #^AD<:0QI'&BQQH JJHP !T 'I3Z /ROM_!/Q8^%W[.OQ!_99M?A%X MH\0:OK6L31Z+XLL;8'0VL9I4?SI[HMMB<*C?*0.H!P1S^DWPI\$CX:?"_P ( M^$1*LXT+2+33/-7.',,*QEAGG!VYYKJJ* ,S6O#]KKZQ+U) MSZF)UW=.^<5B_"^W2S\*RV\9D9(M5U-%,LC2.0+^<#YKK:Y?X< M_P#(OW?_ &&-4_\ 2^XH ZBBBB@ K)\6>%-)\=>&=3\/:]8Q:GHVI6[VMW:3 M#*R1L,$>WL1R#@CFM:BG&3BU*+LT!^1G@O6?$/\ P2U_:LN/#FNS76H?"/Q0 MX9;HJ6#V^["7 _Y;0%MLB@?,I.!\T9'ZU:;J5KK&GVM_8W,5Y9742SP7$#A MXY8V 975AP00001U!KR/]J[]FO1/VHOA+?\ A;4O+M=5BS MI1ONNO<'U"D?'7_!./\ :2UOX8>-+_\ 9M^*7F:=JVG7,EOH;WCA!*@D,@K[/%16>81XVFOW]->^OYH])KTZ_\,<\?W?.AQN4CDJ".2$%?=E%>A@,;5R_$1Q%+=?BNJ?J3**DK, M^7OV!_VNK;]J#X6K#JL\4?CW0D2#5[<84W"]$ND7^Z^/F ^ZX(X!7/U#7Y3? MM9_";Q!^P3^T1I'QW^&%IY?@[4[LIJ&F196"&20YFM7 'RPS %D/1''&-J9_ M2?X0?%CP_P#&[X:Q%;O)Y5G86=NC-)=7#9!91M.$4@MM(W*2N0#Z?HKY1\,_ M\%"/"K? GQ;X[\7:!J/AK7_".H+HVL^%8W2YN/M[D"*.!P0)%D).&./N/V7) MZ_X*_M%?$'QUX^E\+>/O@7XB^&IFL?[0L-7-XFJ:?*F2/+FN(D5()L)M&^$FM>(?@SX48ZG1A!]*?7 MY\_\$T?VJM1N_M/P$^(S36/C/PX9+;2OMW$LL,.0]H^?^6D.T[?5!C^#)_0: MO.S# U,NQ$J%3IL^C71KU*C)25T%%%%>:6%%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 5\!_P#!3#PC\,_'5R(;CQU?^"OC M'HWA?4=1TJ&UAF5-6TX1R-/:O)M6-@PCE7:)-P#/E&!Q7WY7C_[3'[+_ (+_ M &HO =QH7BC3+5]2AAF&DZR\3--IL[K@2IL=&900K&,L%;:,]!0!^87[47Q) M^*?CC]GOQ/X(\?:G9Z]>?#3QEHQF\6:'!Y4;6]S:7'EF18U55DB8HIP 0S@< MGYC]$^!_ ^C?L\_MV^ /"?PAU6\G\+>.?"5U?>(+(ZO+?0S2B.5XM0T_0_^"2GQ?T74;Z"TU?3]4OM-N[2=PLD=R]Q% MLB(/.YNWK@^AK]&/V:=+O=#_ &=?A?I^I*Z:A:^&--AN%DSN61;6,,#GG.?6 MN:\2?L3_ /\7?$X?$'5_AWI=[XK,PN7NV>412RC_EI);AQ#(V>2SH23R_7'XUB_"]IG\*RM?_!2S]EK4XKBU_:!^&WG:=XO\.M'UE MN?A=XBG:*XTQ#B)%8[I;%CT4C!DA8]-N.=C9^RP"='\6>&KY-1T35K=;FVN%[J>"K#^%E(* MLIY!4@\BNBKX^490DXR5FCH"BBBI **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "N7^'/_(OW?_88U3_TON*Z MBN7^'/\ R+]W_P!AC5/_ $ON* .HHHHH **** "BBB@ HHHH *X_XN?"GP]\ M;/AWK/@SQ/:?:M(U2$QOMP'B<AD^!OQ&>:Q\;^'@]MI;W^4FN88W0_0&BBBOC3 MH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKEO MB3\4O"7P?\+7/B/QIX@L?#FC6X.ZZOI0N]@"=D:_>D<@'"("Q[ T =3167X8 M\4Z/XVT&RUOP_JEGK6CWJ>9;7]A,LT,J],JZD@\@CZ@U#:^-?#U]XIO?#-MK MVF7'B2QA6YNM'BO(VO+>)L;9)(0V]5.X88@ Y% &U17*7_Q9\#Z5XR@\(WOC M+P_9^*[C;Y.A7&J0)?2;@2NV OO.0"1@)C_ ):1!1N]4 /\!W?H;39$ M61&1U#HPP589!'H:]++\?5R[$*O3^:Z-=4R)14U9GSQ^Q)^UEIW[5/PKBOIF MBM?&6DJEMKFGIP!(1\L\8_YYR8)']TAEYP"?HFOR>_::^$7B?_@GG\?M/^-7 MPMMV;P'JER8[W2UR(+=I#F2SD Z0R8W1M_ P ZJI;]*/@K\8_#GQZ^&^D>-/ M"UU]HTS4(\M$^!+;2CAX9 .CJ>#V/!&003Z6;8"E34<=@]:%3;^Z^L7Z=/(B MG)_#+='FWFGB0DZ1<3(P74?+P=V MP%6SM(7R025^5E_1:OD3]O+X'_%/QIX?U'Q7\,?&%\AA\/7VEZOX'N7N9['5 M[:2*0;H;>+K: M_%:VWPUUE(H)H-;N%V1VUM#&OR1.5W'#/A8B!AAM.;^Q3X'\3_"_]N;XOV_C M76/^$@\97'A&WU?6+M3^[^U3R0RO%'_TS3<$7V48 & /3OAY_P $[?#OCV#7 M_%'[0%CIOC+QEXEN;6]FM=%EO-/LM/6&W$,<4>R5))"%)W-)R>.,@DQ_"+_@ MFOX/^$_[5FH_$#3]$TRV\#V5G _AO38M5OI;RQU!0HEFD#G#*1YF TCCYA\H M[ 'R[X0^&OA?XD?\$W_BU\7?$.BVNH_$JZUJ]U8>)YDS?PS1W$6P1S??1!S\ MH.#DY[8_3G]GOQ5?>./@-\.?$6IR--J.J^'=/O;F1CDO+);HSL3ZDDG\:^1- M3_8-^+VD^%_%WP@\(^._"]A\#/%&KMJ,\E];7#ZYI\,CJ\EK H'DLA**,L03 MR?ER0?N?PKX;L?!OAG2- TQ&BT[2[2&QMD8Y*Q1H$0$]SA10 NM>)M'\-K$V MKZM8Z4LQ(C:]N4A#D=<;B,XR.GK6+\+[J&^\*RW-M-'<6\VJZG)%-$P9'4W\ MY#*1P00<@BNMKE_AS_R+]W_V&-4_]+[B@#J**** "BBB@ HHHH **** "BBB M@ HHHH P_''@G1/B1X1U;PQXCL(M4T35(&MKJUF'#H?0]0P."&'((!&"!7Y4 M^%=:\5?\$K?VF9M UM[K6/A!XGD\Q+@*6$D ; G4#@7$.X+(@^\I''S(1^N5 M>6_M(?L\^&OVF/AC?^$/$4?E,W[ZPU%$#2V%R 0DJ>O4@KGYE)''4?093F,, M*Y8?$KFH5-)+MVDO-?UT,JD>;5;H]$T/7-/\2Z/8ZMI5Y#J.F7T*7%M=V[AX MYHV *NK#J""#5ZORM_9 _:%\3?L3_%V\^ 'QED-GX;:YQI>J3.?(LGD8E)4< M];68G.?X&))"_O,?JBK!@"#D'D$5S9GET\NK0 M:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%4]3$Y_P"^3AAW#?.__!/C]L;5/#^M?\* ^,+3Z3XJTF7^S]&N]2.UW*\" MRE8_QCCRVSAUPH.0N[]&*^.?V_/V&[?]HG03XQ\'Q1V'Q.TF(&)T/EC5(DY$ M+MVD'_+-S[*3@@K]3EN-HUJ/]FX]_NW\,OY)?Y/J8SBT^>.Y]C45\*_\$^_V MY+CXG*/A1\399-/^)6D!K:WN+\&.34UBR&CD#8(N4P=P/+ %NH:ONJO&QV!K M9?7="LM5]S7=>1I&2DKH****\\H**** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "N7^'/\ R+]W_P!AC5/_ $ON*ZBN7^'/_(OW?_88 MU3_TON* .HHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /A?]OK]A M.Y^*5Q_PM3X7A],^)FF;;B>WLW,3ZGY>"CQL"-MRF!M;^+ &<@&M']@O]O2+ MXY6Z?#[X@NND_%#3U:(-,GDKJP3(8A3C9.N#OCXS@LHQN5/M>OA/]O3]@N7X ME7#_ !4^%:-I/Q*T]EN[BUL7\EM3*899(V&-ERN 0PQOP ><&OK<%C:&/H++ MLP=DO@GUB^S_ +OY?EA*+B^>!]V45\0_L*_\% +3XS0VWP^^(\R:+\3K,FV2 M2X40IJQ7@X!QLN!@[H^,D$KW5?MZO!QN!KY?6="NK-?QBT]2IX_A;'OBO1_U?G2_WO$4Z M?DY7?W+_ #(]K?X4V?IIX@\5Z)X3M1=:YK&GZ-;'I-J%TD"<=>7(%>+>,/V] MO@!X($@OOB?HUXZC[FCE]1+'T!MU+?%L[VO@;X+-=W'1?-OYKUB3TS'%"I'/;=S7W+X M/_9/^#7@-4.B?#+PQ;2Q@!;B738YYQC_ *:R!G_6O4[6U@L;=(+:&.WA3A8X ME"JO?@"E]=R:C_"PCGYRFU^"T#EJ/>1^8?\ PU=^W'\1.= ^$7]@0R\12?\ M".3P\'H=]W(5/W@^UO_A'86^9%^U:7:X'4#%N"W?^ M+GCFOU HH_MV%/\ @X2DO6-W][8>S?63/S!'[$O[:/B3C5?CQ]A@.8WC7Q7J M664CGY(X@K#MR:/^'7OQTU)EGU/X\LURV!(WVN^F('3AF8$\>N*_3ZBE_K+C ME\"A'T@@]C'J?E^?^".?BC4/W&H_&S?:/_K!_9$LN<QI]C\O_P#ASGXIL?W%A\;-MHG$ M8_LF6+C_ '1D_X=5_&32_ETKXZ;$AYM_WEY!@CD<*YV\^F<5^H-%'^ MM&:/XII_]NQ_R#V,.Q^7_P#PPG^V-X9^;1?CU]HBCY6#_A*M43<3P?D:(I[Y M)[>M+_PI?_@H#X9RECX[&K!<1AO[7MILC^]_I" _CUK]/Z*/]8\3+^)2IR]8 M(/8KHV?F"WBS_@HOX3_>W^C+K4>2=HM='GR.F,6Y#=\^OZT?\-X?M>>!\_\ M"5? G[5:Q\O<+XJ[1] >WO7Z?44O[;H5/XV"IOT3C^3#V;Z29^8 M]C_P64U+1)UM/%GP:FL[@??:#5VB;(P#B*2WSUS_ !>WO7H'AS_@LA\)=094 MUCPMXLT=VZO'!;W$2]>I$RMZ=%/6OO"]L+;4K=H+NVANH&ZQS('4_@:\^\2? MLU_";Q/1I4[?\L=4TZY@QQW?RRG_ (]VKUWPQ^T-\+?&FQ=" M^(WA759&.!#:ZQ;O)G.,%-^X'ZBO'O$__!,[]G?Q,7<>!FTB=O\ EKI>IW46 M.<\(9"@Z_P!VO(O%'_!&OX7ZAO;0?&'BG1I&'"W36]W&IQV C1L9]6H]ED-; MX:M2G_B2?Y!>JNB9]^QR)-ⅅ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end GRAPHIC 16 bhc-20201231_g2.jpg PERFORMANCEGRAPH4YR begin 644 bhc-20201231_g2.jpg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end GRAPHIC 17 image_01a.jpg BHC LETTERHEAD begin 644 image_01a.jpg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end XML 18 bhc-20201231_htm.xml IDEA: XBRL DOCUMENT 0000885590 2020-01-01 2020-12-31 0000885590 2020-06-30 0000885590 2021-02-18 0000885590 2019-01-01 2019-12-31 0000885590 2018-01-01 2018-12-31 0000885590 us-gaap:RevolvingCreditFacilityMember bhc:RevolvingCreditFacilityDueJune2023Member 2020-12-31 0000885590 us-gaap:LetterOfCreditMember bhc:RevolvingCreditFacilityDueJune2023Member 2020-12-31 0000885590 2020-12-31 0000885590 2019-12-31 0000885590 us-gaap:ProductMember 2020-01-01 2020-12-31 0000885590 us-gaap:ProductMember 2019-01-01 2019-12-31 0000885590 us-gaap:ProductMember 2018-01-01 2018-12-31 0000885590 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-12-31 0000885590 us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-12-31 0000885590 us-gaap:ProductAndServiceOtherMember 2018-01-01 2018-12-31 0000885590 us-gaap:CommonStockMember 2017-12-31 0000885590 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000885590 us-gaap:RetainedEarningsMember 2017-12-31 0000885590 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000885590 us-gaap:ParentMember 2017-12-31 0000885590 us-gaap:NoncontrollingInterestMember 2017-12-31 0000885590 2017-12-31 0000885590 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2017-12-31 0000885590 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:ParentMember 2017-12-31 0000885590 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2017-12-31 0000885590 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0000885590 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0000885590 us-gaap:ParentMember 2018-01-01 2018-12-31 0000885590 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-12-31 0000885590 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000885590 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000885590 us-gaap:CommonStockMember 2018-12-31 0000885590 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000885590 us-gaap:RetainedEarningsMember 2018-12-31 0000885590 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000885590 us-gaap:ParentMember 2018-12-31 0000885590 us-gaap:NoncontrollingInterestMember 2018-12-31 0000885590 2018-12-31 0000885590 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000885590 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0000885590 us-gaap:ParentMember 2019-01-01 2019-12-31 0000885590 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-12-31 0000885590 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000885590 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000885590 us-gaap:CommonStockMember 2019-12-31 0000885590 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000885590 us-gaap:RetainedEarningsMember 2019-12-31 0000885590 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000885590 us-gaap:ParentMember 2019-12-31 0000885590 us-gaap:NoncontrollingInterestMember 2019-12-31 0000885590 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0000885590 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:ParentMember 2019-12-31 0000885590 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0000885590 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000885590 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000885590 us-gaap:ParentMember 2020-01-01 2020-12-31 0000885590 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0000885590 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000885590 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000885590 us-gaap:CommonStockMember 2020-12-31 0000885590 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000885590 us-gaap:RetainedEarningsMember 2020-12-31 0000885590 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000885590 us-gaap:ParentMember 2020-12-31 0000885590 us-gaap:NoncontrollingInterestMember 2020-12-31 0000885590 2017-01-01 2017-12-31 0000885590 bhc:ThreeLargestUSWholesalerCustomersMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2020-01-01 2020-12-31 0000885590 bhc:ArgentinaBrazilEgyptGreeceSerbiaTurkeyUkraineVenezuelaAndVietnamMember 2020-12-31 0000885590 bhc:ArgentinaBrazilEgyptGreeceSerbiaTurkeyUkraineVenezuelaAndVietnamMember 2019-12-31 0000885590 bhc:ArgentinaBrazilEgyptGreeceSerbiaTurkeyUkraineVenezuelaAndVietnamMember 2020-01-01 2020-12-31 0000885590 srt:MinimumMember us-gaap:LandImprovementsMember 2020-01-01 2020-12-31 0000885590 srt:MaximumMember us-gaap:LandImprovementsMember 2020-01-01 2020-12-31 0000885590 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2020-01-01 2020-12-31 0000885590 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2020-01-01 2020-12-31 0000885590 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2020-01-01 2020-12-31 0000885590 srt:MinimumMember us-gaap:OtherMachineryAndEquipmentMember 2020-01-01 2020-12-31 0000885590 srt:MaximumMember us-gaap:OtherMachineryAndEquipmentMember 2020-01-01 2020-12-31 0000885590 srt:MaximumMember us-gaap:EquipmentLeasedToOtherPartyMember 2020-01-01 2020-12-31 0000885590 srt:MaximumMember us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2020-01-01 2020-12-31 0000885590 srt:MinimumMember bhc:ProductBrandsMember 2020-01-01 2020-12-31 0000885590 srt:MaximumMember bhc:ProductBrandsMember 2020-01-01 2020-12-31 0000885590 srt:MinimumMember us-gaap:TradeNamesMember 2020-01-01 2020-12-31 0000885590 srt:MaximumMember us-gaap:TradeNamesMember 2020-01-01 2020-12-31 0000885590 srt:MinimumMember us-gaap:ContractualRightsMember 2020-01-01 2020-12-31 0000885590 srt:MaximumMember us-gaap:ContractualRightsMember 2020-01-01 2020-12-31 0000885590 srt:MinimumMember bhc:PartnerRelationshipsMember 2020-01-01 2020-12-31 0000885590 srt:MaximumMember bhc:PartnerRelationshipsMember 2020-01-01 2020-12-31 0000885590 srt:MinimumMember bhc:OutLicensedTechnologyMember 2020-01-01 2020-12-31 0000885590 srt:MaximumMember bhc:OutLicensedTechnologyMember 2020-01-01 2020-12-31 0000885590 bhc:ReserveForDiscountsAndAllowancesMember 2018-12-31 0000885590 bhc:ReserveForCustomerReturnsMember 2018-12-31 0000885590 bhc:ReserveForRebatesMember 2018-12-31 0000885590 bhc:ReserveForChargebacksMember 2018-12-31 0000885590 bhc:ReserveForDistributionFeesMember 2018-12-31 0000885590 bhc:ReserveForDiscountsAndAllowancesMember 2019-01-01 2019-12-31 0000885590 bhc:ReserveForCustomerReturnsMember 2019-01-01 2019-12-31 0000885590 bhc:ReserveForRebatesMember 2019-01-01 2019-12-31 0000885590 bhc:ReserveForChargebacksMember 2019-01-01 2019-12-31 0000885590 bhc:ReserveForDistributionFeesMember 2019-01-01 2019-12-31 0000885590 bhc:ReserveForDiscountsAndAllowancesMember 2019-12-31 0000885590 bhc:ReserveForCustomerReturnsMember 2019-12-31 0000885590 bhc:ReserveForRebatesMember 2019-12-31 0000885590 bhc:ReserveForChargebacksMember 2019-12-31 0000885590 bhc:ReserveForDistributionFeesMember 2019-12-31 0000885590 bhc:ReserveForDiscountsAndAllowancesMember 2020-01-01 2020-12-31 0000885590 bhc:ReserveForCustomerReturnsMember 2020-01-01 2020-12-31 0000885590 bhc:ReserveForRebatesMember 2020-01-01 2020-12-31 0000885590 bhc:ReserveForChargebacksMember 2020-01-01 2020-12-31 0000885590 bhc:ReserveForDistributionFeesMember 2020-01-01 2020-12-31 0000885590 bhc:ReserveForDiscountsAndAllowancesMember 2020-12-31 0000885590 bhc:ReserveForCustomerReturnsMember 2020-12-31 0000885590 bhc:ReserveForRebatesMember 2020-12-31 0000885590 bhc:ReserveForChargebacksMember 2020-12-31 0000885590 bhc:ReserveForDistributionFeesMember 2020-12-31 0000885590 bhc:ReserveForRebatesAdvertisingCreditsPortionMember 2020-12-31 0000885590 bhc:ReserveForRebatesAdvertisingCreditsPortionMember 2019-12-31 0000885590 bhc:PriceAppreciationCreditMember 2020-01-01 2020-12-31 0000885590 bhc:PriceAppreciationCreditMember 2019-01-01 2019-12-31 0000885590 srt:MinimumMember 2020-01-01 2020-12-31 0000885590 srt:MaximumMember 2020-01-01 2020-12-31 0000885590 srt:MinimumMember 2020-12-31 0000885590 srt:MaximumMember 2020-12-31 0000885590 2019-01-01 0000885590 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2018-01-01 0000885590 bhc:AccountingStandardsUpdate2016161Member 2018-01-01 0000885590 bhc:SynergyPharmaceuticalsInc.Member 2019-03-06 2019-03-06 0000885590 bhc:SynergyPharmaceuticalsInc.Member 2019-03-06 0000885590 bhc:SynergyPharmaceuticalsInc.Member 2019-03-06 2019-12-31 0000885590 bhc:SynergyPharmaceuticalsInc.Member 2019-01-01 2019-12-31 0000885590 bhc:MedpharmaPharmaceuticalChemicalIndustriesLLCMember 2018-10-16 0000885590 bhc:MedpharmaPharmaceuticalChemicalIndustriesLLCMember 2018-10-16 2018-10-16 0000885590 bhc:MedpharmaPharmaceuticalChemicalIndustriesLLCMember us-gaap:AdditionalPaidInCapitalMember 2018-10-16 2018-10-16 0000885590 bhc:AllegroOphthalmicsLLCMember 2020-09-21 2020-09-21 0000885590 bhc:AllegroOphthalmicsLLCMember 2020-10-01 2020-12-31 0000885590 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember bhc:ACertainInternationalBusinessMember 2020-12-31 0000885590 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember bhc:ACertainInternationalBusinessMember 2020-01-01 2020-12-31 0000885590 bhc:OtherRestructuringIntegrationRelatedOtherCostsMember 2020-12-31 0000885590 bhc:OtherRestructuringIntegrationRelatedOtherCostsMember 2020-01-01 2020-12-31 0000885590 bhc:OtherRestructuringIntegrationRelatedOtherCostsMember 2019-01-01 2019-12-31 0000885590 bhc:OtherRestructuringIntegrationRelatedOtherCostsMember 2018-01-01 2018-12-31 0000885590 bhc:SeparationCostsMember 2020-01-01 2020-12-31 0000885590 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000885590 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000885590 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000885590 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000885590 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000885590 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000885590 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000885590 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000885590 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2020-12-31 0000885590 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2020-12-31 0000885590 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2020-12-31 0000885590 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2020-12-31 0000885590 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2019-12-31 0000885590 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2019-12-31 0000885590 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2019-12-31 0000885590 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:NondesignatedMember 2019-12-31 0000885590 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000885590 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000885590 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000885590 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000885590 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885590 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885590 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885590 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885590 bhc:ValeantUSSecuritiesLitigationMember stpr:NJ us-gaap:SettledLitigationMember 2020-01-01 2020-12-31 0000885590 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000885590 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885590 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-12-31 0000885590 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-12-31 0000885590 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-01-01 2020-12-31 0000885590 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0000885590 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-12-31 0000885590 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-01-01 2020-12-31 0000885590 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputDiscountRateMember 2020-12-31 0000885590 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputDiscountRateMember 2020-12-31 0000885590 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember bhc:MeasurementInputWeightedAverageDiscountRateMember 2020-12-31 0000885590 bhc:AccretionForTimeValueOfMoneyMember 2020-01-01 2020-12-31 0000885590 bhc:AccretionForTimeValueOfMoneyMember 2019-01-01 2019-12-31 0000885590 bhc:FairValueAdjustmentsMember 2020-01-01 2020-12-31 0000885590 bhc:FairValueAdjustmentsMember 2019-01-01 2019-12-31 0000885590 us-gaap:FairValueMeasurementsNonrecurringMember 2020-12-31 0000885590 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember 2020-12-31 0000885590 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember 2020-12-31 0000885590 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2020-12-31 0000885590 us-gaap:FairValueMeasurementsNonrecurringMember 2019-12-31 0000885590 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember 2019-12-31 0000885590 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember 2019-12-31 0000885590 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2019-12-31 0000885590 bhc:DiversifiedProductsSegmentMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember bhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember 2019-12-31 0000885590 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember bhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember 2019-07-01 2019-09-30 0000885590 srt:RestatementAdjustmentMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember bhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember 2020-03-31 0000885590 us-gaap:LandMember 2020-12-31 0000885590 us-gaap:LandMember 2019-12-31 0000885590 us-gaap:BuildingAndBuildingImprovementsMember 2020-12-31 0000885590 us-gaap:BuildingAndBuildingImprovementsMember 2019-12-31 0000885590 us-gaap:MachineryAndEquipmentMember 2020-12-31 0000885590 us-gaap:MachineryAndEquipmentMember 2019-12-31 0000885590 bhc:OtherEquipmentAndLeaseholdImprovementMember 2020-12-31 0000885590 bhc:OtherEquipmentAndLeaseholdImprovementMember 2019-12-31 0000885590 us-gaap:EquipmentLeasedToOtherPartyMember 2020-12-31 0000885590 us-gaap:EquipmentLeasedToOtherPartyMember 2019-12-31 0000885590 us-gaap:ConstructionInProgressMember 2020-12-31 0000885590 us-gaap:ConstructionInProgressMember 2019-12-31 0000885590 bhc:ProductBrandsMember 2020-01-01 2020-12-31 0000885590 bhc:ProductBrandsMember 2020-12-31 0000885590 bhc:ProductBrandsMember 2019-12-31 0000885590 us-gaap:TradeNamesMember 2020-01-01 2020-12-31 0000885590 us-gaap:TradeNamesMember 2020-12-31 0000885590 us-gaap:TradeNamesMember 2019-12-31 0000885590 us-gaap:ContractualRightsMember 2020-01-01 2020-12-31 0000885590 us-gaap:ContractualRightsMember 2020-12-31 0000885590 us-gaap:ContractualRightsMember 2019-12-31 0000885590 bhc:PartnerRelationshipsMember 2020-01-01 2020-12-31 0000885590 bhc:PartnerRelationshipsMember 2020-12-31 0000885590 bhc:PartnerRelationshipsMember 2019-12-31 0000885590 bhc:OutLicensedTechnologyMember 2020-01-01 2020-12-31 0000885590 bhc:OutLicensedTechnologyMember 2020-12-31 0000885590 bhc:OutLicensedTechnologyMember 2019-12-31 0000885590 bhc:AcquiredInProcessResearchAndDevelopmentMember 2020-12-31 0000885590 bhc:AcquiredInProcessResearchAndDevelopmentMember 2019-12-31 0000885590 us-gaap:TrademarksMember 2020-12-31 0000885590 us-gaap:TrademarksMember 2019-12-31 0000885590 bhc:DiscontinuedProductLinesMember 2020-01-01 2020-12-31 0000885590 bhc:AcquiredInProcessResearchAndDevelopmentMember 2020-01-01 2020-12-31 0000885590 bhc:ProductBrandsMember 2019-01-01 2019-12-31 0000885590 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember bhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember 2019-01-01 2019-12-31 0000885590 us-gaap:ContractualRightsMember 2019-01-01 2019-12-31 0000885590 bhc:AcquiredInProcessResearchAndDevelopmentMember 2019-01-01 2019-12-31 0000885590 bhc:UcerisMember 2018-01-01 2018-12-31 0000885590 bhc:ProductBrandsMember 2018-01-01 2018-12-31 0000885590 bhc:ArestinMember 2018-01-01 2018-12-31 0000885590 us-gaap:ContractualRightsMember 2018-01-01 2018-12-31 0000885590 bhc:AcquiredInProcessResearchAndDevelopmentMember 2018-01-01 2018-12-31 0000885590 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2018-01-01 2018-12-31 0000885590 bhc:XifaxanMember us-gaap:IntangibleAssetsAmortizationPeriodMember 2020-01-01 2020-12-31 0000885590 bhc:XifaxanMember us-gaap:IntangibleAssetsAmortizationPeriodMember 2019-01-01 2019-12-31 0000885590 bhc:XifaxanMember us-gaap:IntangibleAssetsAmortizationPeriodMember 2018-01-01 2018-12-31 0000885590 bhc:XifaxanMember 2020-12-31 0000885590 bhc:BauschLombInternationalMember 2017-12-31 0000885590 bhc:BrandedRXMember 2017-12-31 0000885590 bhc:U.S.DiversifiedProductsSegmentMember 2017-12-31 0000885590 bhc:OrthoDermatologicsReportingUnitMember bhc:BrandedRXMember 2018-01-01 2018-12-31 0000885590 bhc:OrthoDermatologicsReportingUnitMember 2018-01-01 2018-12-31 0000885590 bhc:BauschLombInternationalMember 2018-01-01 2018-12-31 0000885590 bhc:BrandedRXMember 2018-01-01 2018-12-31 0000885590 bhc:U.S.DiversifiedProductsSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:SalixSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:OrthoDermatologicsSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:DiversifiedProductsSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:DentistryReportingUnitMember bhc:DiversifiedProductsSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:DentistryReportingUnitMember 2018-01-01 2018-12-31 0000885590 bhc:BauschLombInternationalMember 2018-12-31 0000885590 bhc:BrandedRXMember 2018-12-31 0000885590 bhc:U.S.DiversifiedProductsSegmentMember 2018-12-31 0000885590 bhc:SalixSegmentMember 2018-12-31 0000885590 bhc:OrthoDermatologicsSegmentMember 2018-12-31 0000885590 bhc:DiversifiedProductsSegmentMember 2018-12-31 0000885590 bhc:SalixSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:BauschLombInternationalMember 2019-01-01 2019-12-31 0000885590 bhc:BauschLombInternationalMember 2019-12-31 0000885590 bhc:BrandedRXMember 2019-12-31 0000885590 bhc:U.S.DiversifiedProductsSegmentMember 2019-12-31 0000885590 bhc:SalixSegmentMember 2019-12-31 0000885590 bhc:OrthoDermatologicsSegmentMember 2019-12-31 0000885590 bhc:DiversifiedProductsSegmentMember 2019-12-31 0000885590 bhc:BauschLombInternationalMember 2020-01-01 2020-12-31 0000885590 bhc:BauschLombInternationalMember 2020-12-31 0000885590 bhc:BrandedRXMember 2020-12-31 0000885590 bhc:U.S.DiversifiedProductsSegmentMember 2020-12-31 0000885590 bhc:SalixSegmentMember 2020-12-31 0000885590 bhc:OrthoDermatologicsSegmentMember 2020-12-31 0000885590 bhc:DiversifiedProductsSegmentMember 2020-12-31 0000885590 bhc:SalixReportingUnitMember bhc:BrandedRxSegmentMember 2018-01-01 2018-01-01 0000885590 bhc:OrthoDermatologicsReportingUnitMember bhc:BrandedRxSegmentMember 2018-01-01 2018-01-01 0000885590 us-gaap:ScenarioAdjustmentMember bhc:BrandedRxSegmentMember 2018-03-01 0000885590 us-gaap:ScenarioAdjustmentMember bhc:BauschLombInternationalAndU.S.DiversifiedProductsSegmentsMember 2018-03-31 0000885590 bhc:DentistryReportingUnitMember 2018-10-01 2018-10-01 0000885590 bhc:ReportingUnitsExcludingDentistryMember 2018-10-01 2018-10-01 0000885590 bhc:ReportingUnitsExcludingOrthoDermatologicsAndDentistryMember 2018-10-01 0000885590 2019-10-01 2019-10-01 0000885590 2020-10-01 2020-12-31 0000885590 2019-10-01 2019-12-31 0000885590 2020-04-01 2020-06-30 0000885590 2020-07-01 2020-09-30 0000885590 bhc:OrthoDermatologicsReportingUnitMember 2020-01-01 2020-03-31 0000885590 bhc:OrthoDermatologicsReportingUnitMember 2020-04-01 2020-06-30 0000885590 bhc:OrthoDermatologicsReportingUnitMember 2020-10-01 0000885590 srt:MinimumMember bhc:OrthoDermatologicsReportingUnitMember 2020-10-01 0000885590 srt:MaximumMember bhc:OrthoDermatologicsReportingUnitMember 2020-10-01 0000885590 bhc:OrthoDermatologicsReportingUnitMember 2020-10-01 2020-10-01 0000885590 us-gaap:RevolvingCreditFacilityMember bhc:RevolvingCreditFacilityDueJune2023Member 2019-12-31 0000885590 bhc:TermLoanBFacilityDueJune2025Member 2020-12-31 0000885590 bhc:TermLoanBFacilityDueJune2025Member 2019-12-31 0000885590 bhc:TermLoanBFacilityDueNovember2025Member 2020-12-31 0000885590 bhc:TermLoanBFacilityDueNovember2025Member 2019-12-31 0000885590 bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member us-gaap:SecuredDebtMember 2020-12-31 0000885590 bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member us-gaap:SecuredDebtMember 2019-12-31 0000885590 bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member us-gaap:SecuredDebtMember 2020-12-31 0000885590 bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member us-gaap:SecuredDebtMember 2019-12-31 0000885590 bhc:SeniorSecured5.50NotesDueNovember2025Member us-gaap:SecuredDebtMember 2020-12-31 0000885590 bhc:SeniorSecured5.50NotesDueNovember2025Member us-gaap:SecuredDebtMember 2019-12-31 0000885590 bhc:SeniorSecured5.75NotesDueAugust2027Member us-gaap:SecuredDebtMember 2020-12-31 0000885590 bhc:SeniorSecured5.75NotesDueAugust2027Member us-gaap:SecuredDebtMember 2019-12-31 0000885590 bhc:SeniorNotes550DueMarch2023Member us-gaap:UnsecuredDebtMember 2020-12-31 0000885590 bhc:SeniorNotes550DueMarch2023Member us-gaap:UnsecuredDebtMember 2019-12-31 0000885590 bhc:SeniorNotes5875DueMay2023Member us-gaap:UnsecuredDebtMember 2020-12-31 0000885590 bhc:SeniorNotes5875DueMay2023Member us-gaap:UnsecuredDebtMember 2019-12-31 0000885590 bhc:SeniorNotes450DueMay2023Member us-gaap:UnsecuredDebtMember 2020-12-31 0000885590 bhc:SeniorNotes450DueMay2023Member us-gaap:UnsecuredDebtMember 2019-12-31 0000885590 bhc:SeniorNotes6125DueApril2025Member us-gaap:UnsecuredDebtMember 2020-12-31 0000885590 bhc:SeniorNotes6125DueApril2025Member us-gaap:UnsecuredDebtMember 2019-12-31 0000885590 bhc:SeniorNotes900DueDecember2025Member us-gaap:UnsecuredDebtMember 2020-12-31 0000885590 bhc:SeniorNotes900DueDecember2025Member us-gaap:UnsecuredDebtMember 2019-12-31 0000885590 bhc:SeniorNotes925DueApril2026Member us-gaap:UnsecuredDebtMember 2020-12-31 0000885590 bhc:SeniorNotes925DueApril2026Member us-gaap:UnsecuredDebtMember 2019-12-31 0000885590 bhc:SeniorNotes850DueJanuary2027Member us-gaap:UnsecuredDebtMember 2020-12-31 0000885590 bhc:SeniorNotes850DueJanuary2027Member us-gaap:UnsecuredDebtMember 2019-12-31 0000885590 bhc:SeniorNotes700DueJanuary2028Member us-gaap:UnsecuredDebtMember 2020-12-31 0000885590 bhc:SeniorNotes700DueJanuary2028Member us-gaap:UnsecuredDebtMember 2019-12-31 0000885590 bhc:SeniorNotes500DueJanuary2028Member us-gaap:UnsecuredDebtMember 2020-12-31 0000885590 bhc:SeniorNotes500DueJanuary2028Member us-gaap:UnsecuredDebtMember 2019-12-31 0000885590 bhc:SeniorNotes625DueFebruary2029Member us-gaap:UnsecuredDebtMember 2020-12-31 0000885590 bhc:SeniorNotes625DueFebruary2029Member us-gaap:UnsecuredDebtMember 2019-12-31 0000885590 bhc:SeniorNotes500DueFebruary2029Member us-gaap:UnsecuredDebtMember 2020-12-31 0000885590 bhc:SeniorNotes500DueFebruary2029Member us-gaap:UnsecuredDebtMember 2019-12-31 0000885590 bhc:SeniorNotes725DueMay2029Member us-gaap:UnsecuredDebtMember 2020-12-31 0000885590 bhc:SeniorNotes725DueMay2029Member us-gaap:UnsecuredDebtMember 2019-12-31 0000885590 bhc:SeniorNotes525DueJanuary2030Member us-gaap:UnsecuredDebtMember 2020-12-31 0000885590 bhc:SeniorNotes525DueJanuary2030Member us-gaap:UnsecuredDebtMember 2019-12-31 0000885590 bhc:SeniorNotes525DueFebruary2031Member us-gaap:UnsecuredDebtMember 2020-12-31 0000885590 bhc:SeniorNotes525DueFebruary2031Member us-gaap:UnsecuredDebtMember 2019-12-31 0000885590 bhc:OtherLongTermDebtMember us-gaap:UnsecuredDebtMember 2020-12-31 0000885590 bhc:OtherLongTermDebtMember us-gaap:UnsecuredDebtMember 2019-12-31 0000885590 us-gaap:RevolvingCreditFacilityMember 2020-12-31 0000885590 us-gaap:RevolvingCreditFacilityMember 2018-01-01 0000885590 bhc:SeriesFTrancheBTermLoanFacilityMember 2018-01-01 0000885590 us-gaap:RevolvingCreditFacilityMember 2018-01-01 2018-12-31 0000885590 us-gaap:RevolvingCreditFacilityMember bhc:RevolvingCreditFacilityDueJune2023Member 2018-06-01 0000885590 bhc:SeriesFTrancheBTermLoanFacilityMember 2018-06-01 2018-06-01 0000885590 bhc:TermLoanBFacilityDueJune2025Member 2018-06-01 2018-06-01 0000885590 bhc:TermLoanBFacilityDueJune2025Member 2018-06-01 0000885590 us-gaap:RevolvingCreditFacilityMember bhc:RevolvingCreditFacilityDueJune2023Member 2018-06-01 2018-06-01 0000885590 bhc:A5.375SeniorNotesdueMarch2020Member us-gaap:UnsecuredDebtMember 2018-06-01 2018-06-01 0000885590 bhc:SeniorNotes6.75PercentDueAugust2021Member us-gaap:UnsecuredDebtMember 2018-06-01 2018-06-01 0000885590 bhc:SeniorNotes6.75PercentDueAugust2021Member us-gaap:UnsecuredDebtMember 2018-06-01 0000885590 bhc:SeniorNotes7.25PercentDueJuly2022Member us-gaap:UnsecuredDebtMember 2018-06-01 2018-06-01 0000885590 bhc:SeniorNotes7.25PercentDueJuly2022Member us-gaap:UnsecuredDebtMember 2018-06-01 0000885590 bhc:SeniorNotes6.375PercentDueOctober2020Member us-gaap:UnsecuredDebtMember 2018-06-01 2018-06-01 0000885590 bhc:SeniorNotes6.375PercentDueOctober2020Member us-gaap:UnsecuredDebtMember 2018-06-01 0000885590 bhc:A8.50SeniorNotesDueJanuary2027Member us-gaap:UnsecuredDebtMember 2018-06-01 2018-06-01 0000885590 bhc:A8.50SeniorNotesDueJanuary2027Member us-gaap:UnsecuredDebtMember 2018-06-01 0000885590 2018-06-01 0000885590 2018-06-01 2018-06-01 0000885590 bhc:TermLoanBFacilityDueJune2025Member 2018-11-27 2018-11-27 0000885590 bhc:TermLoanBFacilityDueJune2025Member 2018-11-27 0000885590 bhc:SeniorNotes7.5July2021Member us-gaap:UnsecuredDebtMember 2018-11-27 2018-11-27 0000885590 bhc:SeniorNotes7.5July2021Member us-gaap:UnsecuredDebtMember 2018-11-27 0000885590 bhc:SeniorNotes7.5July2021Member us-gaap:UnsecuredDebtMember 2018-12-27 0000885590 2018-11-27 0000885590 us-gaap:RevolvingCreditFacilityMember 2019-01-01 2019-12-31 0000885590 us-gaap:RevolvingCreditFacilityMember 2020-01-01 2020-12-31 0000885590 us-gaap:RevolvingCreditFacilityMember bhc:TermLoanBFacilityDueJune2025AndNovember2025Member 2020-05-26 2020-05-26 0000885590 bhc:SeniorSecuredCreditFacilitiesMember us-gaap:EurodollarMember 2020-01-01 2020-12-31 0000885590 srt:MinimumMember bhc:SeniorSecuredCreditFacilitiesMember us-gaap:EurodollarMember 2020-01-01 2020-12-31 0000885590 bhc:SeniorSecuredCreditFacilitiesMember 2020-01-01 2020-12-31 0000885590 srt:MinimumMember bhc:RevolvingCreditFacilityDueJune2023Member us-gaap:EurodollarMember 2020-01-01 2020-12-31 0000885590 bhc:RevolvingCreditFacilityDueJune2023Member bhc:CanadaBankersAcceptanceRateMember 2020-01-01 2020-12-31 0000885590 srt:MinimumMember bhc:RevolvingCreditFacilityDueJune2023Member bhc:CanadaBankersAcceptanceRateMember 2020-01-01 2020-12-31 0000885590 bhc:SeniorSecuredTermCreditFacilitiesMember 2020-01-01 2020-12-31 0000885590 bhc:TermLoanBFacilityDueJune2025Member bhc:BaseRateOrPrimeRateMember 2020-01-01 2020-12-31 0000885590 bhc:TermLoanBFacilityDueNovember2025Member bhc:BaseRateOrPrimeRateMember 2020-01-01 2020-12-31 0000885590 bhc:TermLoanBFacilityDueJune2025Member us-gaap:EurodollarMember 2020-01-01 2020-12-31 0000885590 bhc:TermLoanBFacilityDueNovember2025Member us-gaap:EurodollarMember 2020-01-01 2020-12-31 0000885590 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember bhc:RevolvingCreditFacilityDueJune2023Member bhc:BaseRateOrPrimeRateMember 2020-01-01 2020-12-31 0000885590 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember bhc:RevolvingCreditFacilityDueJune2023Member bhc:BaseRateOrPrimeRateMember 2020-01-01 2020-12-31 0000885590 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember bhc:RevolvingCreditFacilityDueJune2023Member us-gaap:EurodollarMember 2020-01-01 2020-12-31 0000885590 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember bhc:RevolvingCreditFacilityDueJune2023Member us-gaap:EurodollarMember 2020-01-01 2020-12-31 0000885590 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember bhc:RevolvingCreditFacilityDueJune2023Member 2020-01-01 2020-12-31 0000885590 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember bhc:RevolvingCreditFacilityDueJune2023Member 2020-01-01 2020-12-31 0000885590 us-gaap:RevolvingCreditFacilityMember us-gaap:SecuredDebtMember 2020-12-31 0000885590 us-gaap:RevolvingCreditFacilityMember us-gaap:UnsecuredDebtMember 2020-12-31 0000885590 bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member us-gaap:SecuredDebtMember 2017-03-31 0000885590 bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member us-gaap:SecuredDebtMember 2017-03-31 0000885590 bhc:SeniorSecured5.50NotesDueNovember2025Member us-gaap:SecuredDebtMember 2017-10-17 0000885590 bhc:SeniorSecured5.50NotesDueNovember2025Member us-gaap:SecuredDebtMember 2017-11-21 0000885590 bhc:SeniorSecured5.75NotesDueAugust2027Member us-gaap:SecuredDebtMember 2019-03-08 0000885590 bhc:A8.50SeniorNotesDueJanuary2027Member us-gaap:UnsecuredDebtMember 2020-03-31 0000885590 bhc:A5.875SeniorNotesdueMay2023Member us-gaap:UnsecuredDebtMember 2019-03-08 2019-03-08 0000885590 bhc:A5.875SeniorNotesdueMay2023Member us-gaap:UnsecuredDebtMember 2019-03-08 0000885590 bhc:SeniorNotes5.625PercentDueDecember2021Member us-gaap:UnsecuredDebtMember 2019-03-08 2019-03-08 0000885590 bhc:SeniorNotes5.625PercentDueDecember2021Member us-gaap:UnsecuredDebtMember 2019-03-08 0000885590 bhc:A5.50SeniorNotesdueMarch2023Member us-gaap:UnsecuredDebtMember 2019-03-08 2019-03-08 0000885590 bhc:A5.50SeniorNotesdueMarch2023Member us-gaap:UnsecuredDebtMember 2019-03-08 0000885590 bhc:SeniorNotes5.625PercentDueDecember2021Member us-gaap:UnsecuredDebtMember 2019-04-01 2019-04-30 0000885590 bhc:SeniorSecuredNotesAndSeniorUnsecuredNotesMember 2019-04-30 0000885590 2019-03-08 2019-03-08 0000885590 bhc:SeniorSecured5.75NotesDueAugust2027Member us-gaap:SecuredDebtMember 2019-03-08 2019-03-08 0000885590 us-gaap:UnsecuredDebtMember 2020-01-01 2020-12-31 0000885590 bhc:SeniorNotes5.625PercentDueDecember2021Member us-gaap:UnsecuredDebtMember 2013-12-02 0000885590 bhc:SeniorNotes5.625PercentDueDecember2021Member us-gaap:UnsecuredDebtMember 2018-12-01 2018-12-31 0000885590 bhc:A5.50SeniorNotesdueMarch2023Member us-gaap:UnsecuredDebtMember 2015-01-30 0000885590 bhc:A5.50SeniorNotesdueMarch2023Member us-gaap:UnsecuredDebtMember 2019-05-23 2019-05-23 0000885590 bhc:A5.50SeniorNotesdueMarch2023Member us-gaap:UnsecuredDebtMember 2020-01-01 2020-12-31 0000885590 bhc:A5.50SeniorNotesdueMarch2023Member us-gaap:UnsecuredDebtMember 2020-12-01 2020-12-31 0000885590 bhc:A5.375SeniorNotesdueMarch2020Member us-gaap:UnsecuredDebtMember 2015-03-27 0000885590 bhc:A5.875SeniorNotesdueMay2023Member us-gaap:UnsecuredDebtMember 2015-03-27 0000885590 bhc:SeniorNotes4.502023Member us-gaap:UnsecuredDebtMember 2015-03-27 0000885590 bhc:A6.125SeniorNotesdueApril2025Member us-gaap:UnsecuredDebtMember 2015-03-27 0000885590 bhc:A5.875SeniorNotesdueMay2023Member us-gaap:UnsecuredDebtMember 2019-05-23 2019-05-23 0000885590 bhc:SeniorUnsecuredNotesDue2023Member us-gaap:UnsecuredDebtMember 2019-10-03 2019-10-03 0000885590 bhc:SeniorUnsecuredNotesDue2023Member us-gaap:UnsecuredDebtMember 2020-01-16 0000885590 bhc:SeniorUnsecuredNotesDue2023Member us-gaap:UnsecuredDebtMember 2020-01-01 2020-12-31 0000885590 bhc:A9.00SeniorNotesdueDecember2025Member us-gaap:UnsecuredDebtMember 2017-12-18 0000885590 bhc:A5.375SeniorNotesdueMarch2020Member us-gaap:UnsecuredDebtMember 2017-12-18 0000885590 bhc:A9.00SeniorNotesdueDecember2025Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:UnsecuredDebtMember 2017-12-18 2017-12-18 0000885590 bhc:A9.00SeniorNotesdueDecember2025Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:UnsecuredDebtMember 2017-12-18 2017-12-18 0000885590 bhc:A9.25SeniorNotesDueApril2026Member us-gaap:UnsecuredDebtMember 2018-03-26 0000885590 bhc:A9.25SeniorNotesDueApril2026Member us-gaap:UnsecuredDebtMember 2018-03-26 2018-03-26 0000885590 bhc:A7.00SeniorUnsecuredNotesDue2028Member us-gaap:UnsecuredDebtMember 2019-05-23 0000885590 bhc:A7.25SeniorUnsecuredNotesDue2029Member us-gaap:UnsecuredDebtMember 2019-05-23 0000885590 us-gaap:UnsecuredDebtMember 2019-05-23 2019-05-23 0000885590 bhc:A7.25SeniorUnsecuredNotesDue2029Member us-gaap:UnsecuredDebtMember 2019-05-23 2019-05-23 0000885590 bhc:A7.00SeniorUnsecuredNotesDue2028Member us-gaap:UnsecuredDebtMember 2019-05-23 2019-05-23 0000885590 bhc:A5.00SeniorNotesDueJanuary2028Member us-gaap:UnsecuredDebtMember 2019-12-30 0000885590 bhc:A5.25SeniorNotesDueJanuary2030Member us-gaap:UnsecuredDebtMember 2019-12-30 0000885590 bhc:A5.875SeniorNotesdueMay2023Member us-gaap:UnsecuredDebtMember 2020-01-16 2020-01-16 0000885590 bhc:ValeantUSSecuritiesLitigationMember stpr:NJ us-gaap:SettledLitigationMember 2019-12-16 2019-12-16 0000885590 bhc:A5.00SeniorNotesDueJanuary2028Member us-gaap:UnsecuredDebtMember 2019-12-30 2019-12-30 0000885590 bhc:A5.25SeniorNotesDueJanuary2030Member us-gaap:UnsecuredDebtMember 2019-12-30 2019-12-30 0000885590 bhc:SeniorNotes625DueFebruary2029Member us-gaap:UnsecuredDebtMember 2020-05-26 0000885590 bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member us-gaap:SecuredDebtMember 2020-05-26 0000885590 bhc:TermLoanBFacilityDueJune2025AndNovember2025Member 2020-05-26 2020-05-26 0000885590 2020-05-26 2020-05-26 0000885590 bhc:SeniorNotes625DueFebruary2029Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:UnsecuredDebtMember 2020-05-26 2020-05-26 0000885590 bhc:SeniorNotes625DueFebruary2029Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:UnsecuredDebtMember 2020-05-26 2020-05-26 0000885590 bhc:SeniorNotes500DueFebruary2029Member us-gaap:UnsecuredDebtMember 2020-12-03 0000885590 bhc:SeniorNotes525DueFebruary2031Member us-gaap:UnsecuredDebtMember 2020-12-03 0000885590 bhc:SeniorNotes4.502023Member us-gaap:UnsecuredDebtMember 2020-12-03 0000885590 bhc:SeniorNotes550DueMarch2023Member us-gaap:UnsecuredDebtMember 2020-12-03 0000885590 bhc:SeniorNotes550DueMarch2023Member us-gaap:UnsecuredDebtMember 2020-12-03 2020-12-03 0000885590 bhc:SeniorNotes500DueFebruary2029Member us-gaap:UnsecuredDebtMember 2020-12-03 2020-12-03 0000885590 bhc:SeniorNotes525DueFebruary2031Member us-gaap:UnsecuredDebtMember 2020-12-03 2020-12-03 0000885590 bhc:SeniorSecuredTermCreditFacilitiesMember us-gaap:FederalFundsEffectiveSwapRateMember 2020-01-01 2020-12-31 0000885590 us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 country:IE us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 country:IE us-gaap:PensionPlansDefinedBenefitMember 2014-12-01 2014-12-31 0000885590 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-12-31 0000885590 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-12-31 0000885590 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-12-31 0000885590 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-12-31 0000885590 country:US us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-12-31 0000885590 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-12-31 0000885590 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-12-31 0000885590 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-12-31 0000885590 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-12-31 0000885590 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-01-01 2018-12-31 0000885590 country:US us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000885590 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0000885590 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-12-31 0000885590 country:US 2020-12-31 0000885590 us-gaap:ForeignPlanMember 2020-12-31 0000885590 country:US 2019-12-31 0000885590 us-gaap:ForeignPlanMember 2019-12-31 0000885590 country:IE us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-12-31 0000885590 srt:ScenarioForecastMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000885590 srt:ScenarioForecastMember country:IE us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000885590 us-gaap:CashAndCashEquivalentsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:CashAndCashEquivalentsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:DefinedBenefitPlanEquitySecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:DefinedBenefitPlanEquitySecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:FixedIncomeSecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:FixedIncomeSecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:CashAndCashEquivalentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:CashAndCashEquivalentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:FixedIncomeSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:FixedIncomeSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:OtherDebtSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:OtherDebtSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:U.S.BroadMarketMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:U.S.BroadMarketMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:U.S.BroadMarketMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:U.S.BroadMarketMember us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:U.S.BroadMarketMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:U.S.BroadMarketMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:U.S.BroadMarketMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:U.S.BroadMarketMember us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:EmergingMarketsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:EmergingMarketsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:EmergingMarketsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:EmergingMarketsMember us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:EmergingMarketsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:EmergingMarketsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:EmergingMarketsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:EmergingMarketsMember us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:NonU.S.DevelopedMarketsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:NonU.S.DevelopedMarketsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:NonU.S.DevelopedMarketsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:NonU.S.DevelopedMarketsMember us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:NonU.S.DevelopedMarketsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:NonU.S.DevelopedMarketsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:NonU.S.DevelopedMarketsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:NonU.S.DevelopedMarketsMember us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:NonU.S.OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:NonU.S.OtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:NonU.S.OtherAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:NonU.S.OtherAssetsMember us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:NonU.S.OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:NonU.S.OtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:NonU.S.OtherAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:NonU.S.OtherAssetsMember us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:InvestmentGradeMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:InvestmentGradeMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:InvestmentGradeMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:InvestmentGradeMember us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:InvestmentGradeMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:InvestmentGradeMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:InvestmentGradeMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:InvestmentGradeMember us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:FairValueMeasurementsRecurringMember country:US us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:EmergingMarketsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:EmergingMarketsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:EmergingMarketsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:EmergingMarketsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:EmergingMarketsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:EmergingMarketsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:EmergingMarketsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:EmergingMarketsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:NonU.S.DevelopedMarketsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:NonU.S.DevelopedMarketsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:NonU.S.DevelopedMarketsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:NonU.S.DevelopedMarketsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:NonU.S.DevelopedMarketsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:NonU.S.DevelopedMarketsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:NonU.S.DevelopedMarketsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:NonU.S.DevelopedMarketsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:InvestmentGradeMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:InvestmentGradeMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:InvestmentGradeMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:InvestmentGradeMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:InvestmentGradeMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:InvestmentGradeMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:InvestmentGradeMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:InvestmentGradeMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:GlobalHighYieldMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:GlobalHighYieldMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:GlobalHighYieldMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:GlobalHighYieldMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:GlobalHighYieldMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:GlobalHighYieldMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:GlobalHighYieldMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:GlobalHighYieldMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:OtherAssetsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:OtherAssetsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:OtherAssetsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:OtherAssetsFixedIncomeSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 bhc:OtherAssetsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:OtherAssetsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:OtherAssetsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 bhc:OtherAssetsFixedIncomeSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000885590 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0000885590 country:IE us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-12-31 0000885590 bhc:OmnibusIncentivePlan2014Member 2014-05-31 0000885590 bhc:OmnibusIncentivePlan2014Member 2018-04-30 2018-04-30 0000885590 bhc:NonemployeeDirectorMember bhc:OmnibusIncentivePlan2014Member 2018-04-30 2018-04-30 0000885590 bhc:OmnibusIncentivePlan2014Member 2020-04-28 2020-04-28 0000885590 bhc:OmnibusIncentivePlan2014Member 2020-12-31 0000885590 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000885590 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000885590 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0000885590 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0000885590 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0000885590 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0000885590 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0000885590 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0000885590 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0000885590 bhc:SellingGeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0000885590 bhc:SellingGeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0000885590 bhc:SellingGeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0000885590 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-01-01 2020-12-31 0000885590 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-01-01 2020-12-31 0000885590 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-01-01 2020-12-31 0000885590 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-01-01 2020-12-31 0000885590 us-gaap:EmployeeStockOptionMember 2019-12-31 0000885590 us-gaap:EmployeeStockOptionMember 2020-12-31 0000885590 bhc:TimeBasedRSUMember 2019-12-31 0000885590 bhc:TimeBasedRSUMember 2020-01-01 2020-12-31 0000885590 bhc:TimeBasedRSUMember 2020-12-31 0000885590 bhc:TimeBasedRSUMember 2019-01-01 2019-12-31 0000885590 bhc:TimeBasedRSUMember 2018-01-01 2018-12-31 0000885590 bhc:PerformanceBasedRestrictedStockUnitsMember 2020-01-01 2020-12-31 0000885590 bhc:PerformanceBasedRestrictedStockUnitsMember 2019-01-01 2019-12-31 0000885590 bhc:PerformanceBasedRestrictedStockUnitsMember 2018-01-01 2018-12-31 0000885590 bhc:PerformanceBasedRestrictedStockUnitsMember 2019-12-31 0000885590 bhc:PerformanceBasedRestrictedStockUnitsMember 2020-12-31 0000885590 bhc:TSRPerformanceBasedRestrictedStockUnitsMember 2020-01-01 2020-12-31 0000885590 bhc:ROTCPerformanceBasedRestrictedStockUnitsMember 2020-01-01 2020-12-31 0000885590 srt:ChiefExecutiveOfficerMember bhc:PerformanceBasedRestrictedStockUnitsMember 2018-01-01 2018-12-31 0000885590 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000885590 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000885590 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0000885590 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000885590 bhc:SalixLtd.SECInvestigationLitigationMember 2018-01-01 2018-12-31 0000885590 bhc:MilestonePaymentRelatedToCertainProductMember 2019-01-01 2019-12-31 0000885590 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-12-31 0000885590 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-12-31 0000885590 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-12-31 0000885590 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2020-01-01 2020-12-31 0000885590 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-01-01 2019-12-31 0000885590 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-01-01 2018-12-31 0000885590 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2020-12-31 0000885590 bhc:ForeignCountryStateAndLocalMember 2020-01-01 2020-12-31 0000885590 bhc:ForeignCountryStateAndLocalMember 2019-01-01 2019-12-31 0000885590 bhc:ForeignCountryStateAndLocalMember 2020-12-31 0000885590 bhc:ForeignCountryStateAndLocalMember 2019-12-31 0000885590 bhc:ForeignCountryStateAndLocalMember bhc:PooledScientificResearchAndExperimentalDevelopmentExpendituresMember 2020-12-31 0000885590 bhc:ForeignCountryStateAndLocalMember bhc:PooledScientificResearchAndExperimentalDevelopmentExpendituresMember 2019-12-31 0000885590 us-gaap:DomesticCountryMember 2020-12-31 0000885590 us-gaap:DomesticCountryMember 2019-12-31 0000885590 us-gaap:DomesticCountryMember us-gaap:RevenueCommissionersIrelandMember 2020-12-31 0000885590 us-gaap:ForeignCountryMember us-gaap:RevenueCommissionersIrelandMember 2019-12-31 0000885590 srt:MinimumMember us-gaap:DomesticCountryMember 2020-01-01 2020-12-31 0000885590 srt:MaximumMember us-gaap:DomesticCountryMember 2020-01-01 2020-12-31 0000885590 srt:MinimumMember country:CA 2020-01-01 2020-12-31 0000885590 srt:MaximumMember country:CA 2020-01-01 2020-12-31 0000885590 srt:MinimumMember country:DE 2020-01-01 2020-12-31 0000885590 srt:MaximumMember country:DE 2020-01-01 2020-12-31 0000885590 srt:MinimumMember country:FR 2020-01-01 2020-12-31 0000885590 srt:MaximumMember country:FR 2020-01-01 2020-12-31 0000885590 srt:MinimumMember country:CN 2020-01-01 2020-12-31 0000885590 srt:MaximumMember country:CN 2020-01-01 2020-12-31 0000885590 srt:MinimumMember country:IE 2020-01-01 2020-12-31 0000885590 srt:MaximumMember country:IE 2020-01-01 2020-12-31 0000885590 srt:MaximumMember country:NL 2020-01-01 2020-12-31 0000885590 srt:MinimumMember country:NL 2020-01-01 2020-12-31 0000885590 srt:MinimumMember us-gaap:AustralianTaxationOfficeMember 2020-01-01 2020-12-31 0000885590 srt:MaximumMember us-gaap:AustralianTaxationOfficeMember 2020-01-01 2020-12-31 0000885590 us-gaap:ForeignCountryMember us-gaap:CanadaRevenueAgencyMember us-gaap:TaxYear2012Member 2020-01-01 2020-12-31 0000885590 us-gaap:TaxYear2013Member 2020-01-01 2020-12-31 0000885590 us-gaap:ForeignCountryMember us-gaap:CanadaRevenueAgencyMember 2020-01-01 2020-12-31 0000885590 us-gaap:ForeignCountryMember us-gaap:AustralianTaxationOfficeMember 2017-08-08 2017-08-08 0000885590 us-gaap:StockCompensationPlanMember 2020-01-01 2020-12-31 0000885590 us-gaap:StockCompensationPlanMember 2019-01-01 2019-12-31 0000885590 us-gaap:StockCompensationPlanMember 2018-01-01 2018-12-31 0000885590 bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember 2020-01-01 2020-12-31 0000885590 bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember 2019-01-01 2019-12-31 0000885590 bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember 2018-01-01 2018-12-31 0000885590 bhc:ValeantUSSecuritiesLitigationMember stpr:NJ us-gaap:UnfavorableRegulatoryActionMember 2015-10-01 2015-10-31 0000885590 bhc:ValeantUSSecuritiesLitigationMember stpr:NJ 2020-01-01 2020-12-31 0000885590 bhc:CanadianSecuritiesLitigationMember country:CA 2016-01-01 2016-12-31 0000885590 bhc:CanadianSecuritiesLitigationMember country:CA bhc:ViolationofCanadianProvincialSecuritiesLegislationMember 2020-01-01 2020-12-31 0000885590 bhc:CanadianSecuritiesLitigationMember country:CA us-gaap:SettledLitigationMember bhc:ViolationofCanadianProvincialSecuritiesLegislationMember 2020-08-04 2020-08-04 0000885590 bhc:CanadianSecuritiesLitigationMember country:CA bhc:ViolationofCanadianProvincialSecuritiesLegislationMember 2019-02-15 0000885590 bhc:InsuranceCoverageLawsuitMember 2017-12-07 2017-12-07 0000885590 bhc:RICOClassActionsLitigationMember stpr:NJ us-gaap:UnfavorableRegulatoryActionMember 2016-05-27 2016-09-16 0000885590 bhc:DerivativeLawsuitsMember 2019-09-13 0000885590 bhc:DerivativeLawsuitsMember 2019-09-10 0000885590 bhc:DerivativeLawsuitsMember 2020-01-03 0000885590 bhc:GenericPricingAntitrustLitigationMember 2019-07-01 2019-07-31 0000885590 bhc:GenericPricingAntitrustLitigationMember 2020-05-01 2020-05-31 0000885590 bhc:GlumetzaAntitrustLitigationMember 2019-08-01 2020-07-30 0000885590 bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember 2019-08-01 2020-07-30 0000885590 bhc:PlaintiffsDirectPurchasersMember 2019-11-25 2019-11-25 0000885590 bhc:PlaintiffsDirectPurchasersMember bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember 2019-11-25 2019-11-25 0000885590 bhc:GlumetzaAntitrustLitigationMember us-gaap:PendingLitigationMember 2020-12-31 0000885590 bhc:SandozLitigationMember 2019-09-01 2019-09-30 0000885590 bhc:SandozLitigationMember 2020-02-17 2020-02-17 0000885590 bhc:PerrigoIsraelPharmaceuticalsLitigationMember 2020-08-28 2020-08-28 0000885590 bhc:PerrigoLitigationMember 2020-05-01 2020-05-01 0000885590 bhc:ShowertoShowerProductLiabilityLitigationMember us-gaap:PendingLitigationMember 2020-12-31 0000885590 bhc:JohnsonJohnsonTalcumPowderLitigationMember 2017-03-24 0000885590 bhc:JohnsonJohnsonTalcumPowderLitigationMember 2017-03-24 2017-03-24 0000885590 bhc:JohnsonJohnsonTalcumPowderLitigationNewJerseyDivisionOfTaxationMember 2020-12-31 0000885590 bhc:JohnsonJohnsonTalcumPowderLitigationDelawareDivisionOfRevenueMember 2020-12-31 0000885590 bhc:JohnsonJohnsonTalcumPowderLitigationNewJerseyDivisionOfTaxationMember 2020-01-01 2020-12-31 0000885590 bhc:JohnsonJohnsonTalcumPowderLitigationMember stpr:NJ 2020-12-31 0000885590 bhc:JohnsonJohnsonTalcumPowderLitigationMember stpr:OH 2020-12-31 0000885590 bhc:ShowertoShowerProductLiabilityLitigationMember country:CA 2020-12-31 0000885590 bhc:ShowertoShowerProductLiabilityLitigationMember stpr:CA-BC 2020-12-31 0000885590 bhc:ShowertoShowerProductLiabilityLitigationMember stpr:CA-QC 2020-12-31 0000885590 bhc:DoctorsAllergyFormulaLLCLitigationMember 2018-04-01 2018-04-30 0000885590 bhc:LitigationwithFormerSalixCEOMember 2019-01-28 2019-01-28 0000885590 bhc:SECInvestigationLitigationMember us-gaap:SettledLitigationMember 2020-01-01 2020-12-31 0000885590 bhc:ContactLensAntitrustClassActionsMember us-gaap:SettledLitigationMember 2016-03-31 0000885590 bhc:ContactLensAntitrustClassActionsMember us-gaap:SettledLitigationMember 2019-08-19 2019-08-19 0000885590 bhc:MississippiAttorneyGeneralConsumerProtectionActionLitigationMember us-gaap:SettledLitigationMember 2020-01-01 2020-12-31 0000885590 bhc:InvestigationbytheStateofTexasStatesMedicaidProgramMember us-gaap:SettledLitigationMember 2020-04-01 2020-04-01 0000885590 bhc:SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member 2020-12-31 0000885590 bhc:MitsubishiTanabePharmaCorporationMember 2020-12-31 0000885590 bhc:NovaliqGmbHMember 2020-12-31 0000885590 bhc:CedarsSinaiMedicalCenterMember 2020-12-31 0000885590 bhc:EyenoviaIncMember 2020-12-31 0000885590 bhc:AllegroOphthalmicsLLCMember 2020-09-01 2020-09-30 0000885590 us-gaap:OperatingSegmentsMember bhc:BaushandLombInternationalSegmentMember 2020-01-01 2020-12-31 0000885590 us-gaap:OperatingSegmentsMember bhc:BaushandLombInternationalSegmentMember 2019-01-01 2019-12-31 0000885590 us-gaap:OperatingSegmentsMember bhc:BaushandLombInternationalSegmentMember 2018-01-01 2018-12-31 0000885590 us-gaap:OperatingSegmentsMember bhc:SalixSegmentMember 2020-01-01 2020-12-31 0000885590 us-gaap:OperatingSegmentsMember bhc:SalixSegmentMember 2019-01-01 2019-12-31 0000885590 us-gaap:OperatingSegmentsMember bhc:SalixSegmentMember 2018-01-01 2018-12-31 0000885590 us-gaap:OperatingSegmentsMember bhc:OrthoDermatologicsSegmentMember 2020-01-01 2020-12-31 0000885590 us-gaap:OperatingSegmentsMember bhc:OrthoDermatologicsSegmentMember 2019-01-01 2019-12-31 0000885590 us-gaap:OperatingSegmentsMember bhc:OrthoDermatologicsSegmentMember 2018-01-01 2018-12-31 0000885590 us-gaap:OperatingSegmentsMember bhc:DiversifiedProductsSegmentMember 2020-01-01 2020-12-31 0000885590 us-gaap:OperatingSegmentsMember bhc:DiversifiedProductsSegmentMember 2019-01-01 2019-12-31 0000885590 us-gaap:OperatingSegmentsMember bhc:DiversifiedProductsSegmentMember 2018-01-01 2018-12-31 0000885590 us-gaap:OperatingSegmentsMember 2020-01-01 2020-12-31 0000885590 us-gaap:OperatingSegmentsMember 2019-01-01 2019-12-31 0000885590 us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0000885590 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-12-31 0000885590 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-12-31 0000885590 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:RevenuesNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-12-31 0000885590 bhc:RevenuesNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-12-31 0000885590 bhc:RevenuesNetMember us-gaap:ProductConcentrationRiskMember 2018-01-01 2018-12-31 0000885590 bhc:PharmaceuticalProductsMember bhc:BaushandLombInternationalSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:PharmaceuticalProductsMember bhc:BaushandLombInternationalSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:PharmaceuticalProductsMember bhc:BaushandLombInternationalSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:PharmaceuticalProductsMember bhc:SalixSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:PharmaceuticalProductsMember bhc:SalixSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:PharmaceuticalProductsMember bhc:SalixSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:PharmaceuticalProductsMember bhc:OrthoDermatologicsSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:PharmaceuticalProductsMember bhc:OrthoDermatologicsSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:PharmaceuticalProductsMember bhc:OrthoDermatologicsSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:PharmaceuticalProductsMember bhc:DiversifiedProductsSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:PharmaceuticalProductsMember bhc:DiversifiedProductsSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:PharmaceuticalProductsMember bhc:DiversifiedProductsSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:PharmaceuticalProductsMember 2020-01-01 2020-12-31 0000885590 bhc:PharmaceuticalProductsMember 2019-01-01 2019-12-31 0000885590 bhc:PharmaceuticalProductsMember 2018-01-01 2018-12-31 0000885590 bhc:DeviceProductsMember bhc:BaushandLombInternationalSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:DeviceProductsMember bhc:BaushandLombInternationalSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:DeviceProductsMember bhc:BaushandLombInternationalSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:DeviceProductsMember bhc:SalixSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:DeviceProductsMember bhc:SalixSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:DeviceProductsMember bhc:SalixSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:DeviceProductsMember bhc:OrthoDermatologicsSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:DeviceProductsMember bhc:OrthoDermatologicsSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:DeviceProductsMember bhc:OrthoDermatologicsSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:DeviceProductsMember bhc:DiversifiedProductsSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:DeviceProductsMember bhc:DiversifiedProductsSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:DeviceProductsMember bhc:DiversifiedProductsSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:DeviceProductsMember 2020-01-01 2020-12-31 0000885590 bhc:DeviceProductsMember 2019-01-01 2019-12-31 0000885590 bhc:DeviceProductsMember 2018-01-01 2018-12-31 0000885590 bhc:OvertheCounterProductsMember bhc:BaushandLombInternationalSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:OvertheCounterProductsMember bhc:BaushandLombInternationalSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:OvertheCounterProductsMember bhc:BaushandLombInternationalSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:OvertheCounterProductsMember bhc:SalixSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:OvertheCounterProductsMember bhc:SalixSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:OvertheCounterProductsMember bhc:SalixSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:OvertheCounterProductsMember bhc:OrthoDermatologicsSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:OvertheCounterProductsMember bhc:OrthoDermatologicsSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:OvertheCounterProductsMember bhc:OrthoDermatologicsSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:OvertheCounterProductsMember bhc:DiversifiedProductsSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:OvertheCounterProductsMember bhc:DiversifiedProductsSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:OvertheCounterProductsMember bhc:DiversifiedProductsSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:OvertheCounterProductsMember 2020-01-01 2020-12-31 0000885590 bhc:OvertheCounterProductsMember 2019-01-01 2019-12-31 0000885590 bhc:OvertheCounterProductsMember 2018-01-01 2018-12-31 0000885590 bhc:BrandedandOtherGenericProductsMember bhc:BaushandLombInternationalSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:BrandedandOtherGenericProductsMember bhc:BaushandLombInternationalSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:BrandedandOtherGenericProductsMember bhc:BaushandLombInternationalSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:BrandedandOtherGenericProductsMember bhc:SalixSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:BrandedandOtherGenericProductsMember bhc:SalixSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:BrandedandOtherGenericProductsMember bhc:SalixSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:BrandedandOtherGenericProductsMember bhc:OrthoDermatologicsSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:BrandedandOtherGenericProductsMember bhc:OrthoDermatologicsSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:BrandedandOtherGenericProductsMember bhc:OrthoDermatologicsSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:BrandedandOtherGenericProductsMember bhc:DiversifiedProductsSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:BrandedandOtherGenericProductsMember bhc:DiversifiedProductsSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:BrandedandOtherGenericProductsMember bhc:DiversifiedProductsSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:BrandedandOtherGenericProductsMember 2020-01-01 2020-12-31 0000885590 bhc:BrandedandOtherGenericProductsMember 2019-01-01 2019-12-31 0000885590 bhc:BrandedandOtherGenericProductsMember 2018-01-01 2018-12-31 0000885590 bhc:OtherRevenuesMember bhc:BaushandLombInternationalSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:OtherRevenuesMember bhc:BaushandLombInternationalSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:OtherRevenuesMember bhc:BaushandLombInternationalSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:OtherRevenuesMember bhc:SalixSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:OtherRevenuesMember bhc:SalixSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:OtherRevenuesMember bhc:SalixSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:OtherRevenuesMember bhc:OrthoDermatologicsSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:OtherRevenuesMember bhc:OrthoDermatologicsSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:OtherRevenuesMember bhc:OrthoDermatologicsSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:OtherRevenuesMember bhc:DiversifiedProductsSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:OtherRevenuesMember bhc:DiversifiedProductsSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:OtherRevenuesMember bhc:DiversifiedProductsSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:OtherRevenuesMember 2020-01-01 2020-12-31 0000885590 bhc:OtherRevenuesMember 2019-01-01 2019-12-31 0000885590 bhc:OtherRevenuesMember 2018-01-01 2018-12-31 0000885590 bhc:BaushandLombInternationalSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:BaushandLombInternationalSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:BaushandLombInternationalSegmentMember 2018-01-01 2018-12-31 0000885590 bhc:SalixSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:OrthoDermatologicsSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:OrthoDermatologicsSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:DiversifiedProductsSegmentMember 2020-01-01 2020-12-31 0000885590 bhc:DiversifiedProductsSegmentMember 2019-01-01 2019-12-31 0000885590 bhc:UnitedStatesandPuertoRicoMember 2020-01-01 2020-12-31 0000885590 bhc:UnitedStatesandPuertoRicoMember 2019-01-01 2019-12-31 0000885590 bhc:UnitedStatesandPuertoRicoMember 2018-01-01 2018-12-31 0000885590 country:CN 2020-01-01 2020-12-31 0000885590 country:CN 2019-01-01 2019-12-31 0000885590 country:CN 2018-01-01 2018-12-31 0000885590 country:CA 2020-01-01 2020-12-31 0000885590 country:CA 2019-01-01 2019-12-31 0000885590 country:CA 2018-01-01 2018-12-31 0000885590 country:EG 2020-01-01 2020-12-31 0000885590 country:EG 2019-01-01 2019-12-31 0000885590 country:EG 2018-01-01 2018-12-31 0000885590 country:PL 2020-01-01 2020-12-31 0000885590 country:PL 2019-01-01 2019-12-31 0000885590 country:PL 2018-01-01 2018-12-31 0000885590 country:JP 2020-01-01 2020-12-31 0000885590 country:JP 2019-01-01 2019-12-31 0000885590 country:JP 2018-01-01 2018-12-31 0000885590 country:MX 2020-01-01 2020-12-31 0000885590 country:MX 2019-01-01 2019-12-31 0000885590 country:MX 2018-01-01 2018-12-31 0000885590 country:FR 2020-01-01 2020-12-31 0000885590 country:FR 2019-01-01 2019-12-31 0000885590 country:FR 2018-01-01 2018-12-31 0000885590 country:DE 2020-01-01 2020-12-31 0000885590 country:DE 2019-01-01 2019-12-31 0000885590 country:DE 2018-01-01 2018-12-31 0000885590 country:RU 2020-01-01 2020-12-31 0000885590 country:RU 2019-01-01 2019-12-31 0000885590 country:RU 2018-01-01 2018-12-31 0000885590 country:GB 2020-01-01 2020-12-31 0000885590 country:GB 2019-01-01 2019-12-31 0000885590 country:GB 2018-01-01 2018-12-31 0000885590 country:ES 2020-01-01 2020-12-31 0000885590 country:ES 2019-01-01 2019-12-31 0000885590 country:ES 2018-01-01 2018-12-31 0000885590 bhc:OtherCountriesMember 2020-01-01 2020-12-31 0000885590 bhc:OtherCountriesMember 2019-01-01 2019-12-31 0000885590 bhc:OtherCountriesMember 2018-01-01 2018-12-31 0000885590 bhc:UnitedStatesandPuertoRicoMember 2020-12-31 0000885590 bhc:UnitedStatesandPuertoRicoMember 2019-12-31 0000885590 country:IE 2020-12-31 0000885590 country:IE 2019-12-31 0000885590 country:CA 2020-12-31 0000885590 country:CA 2019-12-31 0000885590 country:PL 2020-12-31 0000885590 country:PL 2019-12-31 0000885590 country:DE 2020-12-31 0000885590 country:DE 2019-12-31 0000885590 country:MX 2020-12-31 0000885590 country:MX 2019-12-31 0000885590 country:FR 2020-12-31 0000885590 country:FR 2019-12-31 0000885590 country:CN 2020-12-31 0000885590 country:CN 2019-12-31 0000885590 country:RS 2020-12-31 0000885590 country:RS 2019-12-31 0000885590 country:IT 2020-12-31 0000885590 country:IT 2019-12-31 0000885590 bhc:OtherCountriesMember 2020-12-31 0000885590 bhc:OtherCountriesMember 2019-12-31 0000885590 bhc:McKessonCorporationMember bhc:RevenuesNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000885590 bhc:McKessonCorporationMember bhc:RevenuesNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000885590 bhc:McKessonCorporationMember bhc:RevenuesNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0000885590 bhc:AmerisourceBergenCorporationMember bhc:RevenuesNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000885590 bhc:AmerisourceBergenCorporationMember bhc:RevenuesNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000885590 bhc:AmerisourceBergenCorporationMember bhc:RevenuesNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0000885590 bhc:CardinalHealthIncMember bhc:RevenuesNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000885590 bhc:CardinalHealthIncMember bhc:RevenuesNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000885590 bhc:CardinalHealthIncMember bhc:RevenuesNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0000885590 2020-01-01 2020-03-31 0000885590 2019-01-01 2019-03-31 0000885590 2019-04-01 2019-06-30 0000885590 2019-07-01 2019-09-30 iso4217:USD shares iso4217:USD shares bhc:country bhc:wholesaler pure bhc:businessCombination bhc:rate bhc:number bhc:product iso4217:EUR bhc:defined_benefit_plan bhc:subsidiary iso4217:CAD bhc:case bhc:group bhc:action bhc:entity bhc:insurance_policy_period bhc:shareholder bhc:healthPlan bhc:manufacturer 0000885590 2020 FY false us-gaap:AccountingStandardsUpdate201613Member us-gaap:AccountingStandardsUpdate201616Member P30D P1Y P1Y us-gaap:OtherLiabilities P7Y P7Y 0.005 us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent us-gaap:OtherLiabilitiesNoncurrent 10-K true 2020-12-31 --12-31 false 001-14956 Bausch Health Companies Inc. A1 CA 98-0448205 2150 St. Elzéar Blvd. West Laval QC CA H7L 4A8 514 744-6792 Common Shares, No Par Value BHC NYSE Yes No Yes Yes Large Accelerated Filer false false true false 5664997951 355619826 Part III incorporates certain information by reference from the registrant’s proxy statement for the 2021 Annual Meeting of Shareholders. Such proxy statement will be filed no later than 120 days after the close of the registrant’s fiscal year ended December 31, 2020. 1111000000 1501000000 1501000000 0 104000000 1121000000 605000000 3243000000 1211000000 1000000 1577000000 1839000000 1094000000 1107000000 855000000 779000000 5342000000 6969000000 1567000000 1466000000 8445000000 10201000000 13044000000 13126000000 2137000000 1690000000 664000000 411000000 31199000000 33863000000 337000000 503000000 4576000000 4511000000 0 1234000000 4913000000 6248000000 216000000 262000000 23925000000 24661000000 528000000 705000000 1012000000 851000000 30594000000 32727000000 355422347 355422347 352562636 352562636 10227000000 10172000000 454000000 429000000 -8013000000 -7452000000 -2133000000 -2086000000 535000000 1063000000 70000000 73000000 605000000 1136000000 31199000000 33863000000 7924000000 8489000000 8271000000 103000000 112000000 109000000 8027000000 8601000000 8380000000 2202000000 2297000000 2309000000 47000000 53000000 42000000 2367000000 2554000000 2473000000 452000000 471000000 413000000 1645000000 1897000000 2644000000 0 0 2322000000 114000000 75000000 568000000 22000000 31000000 22000000 -48000000 -12000000 9000000 -454000000 -1414000000 20000000 7351000000 8804000000 10764000000 676000000 -203000000 -2384000000 13000000 12000000 11000000 1534000000 1612000000 1685000000 -59000000 -42000000 -119000000 -30000000 8000000 23000000 -934000000 -1837000000 -4154000000 -375000000 -54000000 -10000000 -559000000 -1783000000 -4144000000 1000000 5000000 4000000 -560000000 -1788000000 -4148000000 -1.58 -5.08 -11.81 355000000.0 352100000 351300000 -559000000 -1783000000 -4144000000 -15000000 -8000000 -7000000 -4000000 -4000000 -4000000 -1000000 -2000000 -1000000 2000000 -2000000 3000000 0 -2000000 0 16000000 14000000 7000000 -29000000 64000000 -237000000 -45000000 50000000 -244000000 -604000000 -1733000000 -4388000000 3000000 4000000 1000000 -607000000 -1737000000 -4389000000 348700000 10090000000 380000000 -2725000000 -1896000000 5849000000 95000000 5944000000 1209000000 1209000000 1209000000 1200000 31000000 -29000000 2000000 2000000 87000000 87000000 87000000 10000000 10000000 10000000 15000000 15000000 3000000 18000000 11000000 11000000 -4148000000 -4148000000 4000000 -4144000000 -241000000 -241000000 -3000000 -244000000 349900000 10121000000 413000000 -5664000000 -2137000000 2733000000 82000000 2815000000 2700000 51000000 -46000000 5000000 5000000 102000000 102000000 102000000 40000000 40000000 40000000 13000000 13000000 -1788000000 -1788000000 5000000 -1783000000 51000000 51000000 -1000000 50000000 352600000 10172000000 429000000 -7452000000 -2086000000 1063000000 73000000 1136000000 -1000000 -1000000 -1000000 2800000 55000000 -50000000 5000000 5000000 105000000 105000000 105000000 30000000 30000000 30000000 6000000 6000000 -560000000 -560000000 1000000 -559000000 -47000000 -47000000 2000000 -45000000 355400000 10227000000 454000000 -8013000000 -2133000000 535000000 70000000 605000000 -559000000 -1783000000 -4144000000 1825000000 2075000000 2819000000 61000000 63000000 79000000 114000000 75000000 568000000 0 0 2322000000 48000000 12000000 -9000000 60000000 75000000 69000000 -475000000 -230000000 -144000000 1000000 31000000 -6000000 -442000000 -1401000000 27000000 168000000 15000000 224000000 105000000 102000000 87000000 -8000000 -7000000 19000000 23000000 9000000 0 -59000000 -42000000 -119000000 1000000 1000000 2000000 18000000 -36000000 17000000 -170000000 -39000000 -216000000 77000000 209000000 5000000 -12000000 -1000000 72000000 -471000000 -149000000 -121000000 1111000000 1501000000 1501000000 0 180000000 -5000000 7000000 8000000 78000000 302000000 270000000 157000000 4000000 16000000 7000000 8000000 10000000 7000000 21000000 45000000 34000000 23000000 0 0 -261000000 -419000000 -196000000 3455000000 5960000000 8944000000 5642000000 4406000000 10101000000 1000000 12000000 0 1000000 12000000 3000000 30000000 40000000 10000000 35000000 35000000 37000000 0 0 18000000 39000000 28000000 102000000 -3000000 -8000000 -26000000 -2294000000 1443000000 -1353000000 16000000 -4000000 -26000000 -1428000000 2521000000 -74000000 3244000000 723000000 797000000 1816000000 3244000000 723000000 605000000 3243000000 721000000 1211000000 1000000 2000000 1816000000 3244000000 723000000 DESCRIPTION OF BUSINESSBausch Health Companies Inc. (the “Company”), formerly known as Valeant Pharmaceuticals International, Inc., is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately 100 countries. Effective August 9, 2013, the Company continued from the federal jurisdiction of Canada to the Province of British Columbia, meaning that the Company became a company registered under the laws of the Province of British Columbia as if it had been incorporated under the laws of the Province of British Columbia. As a result of this continuance, the legal domicile of the Company became the Province of British Columbia, the Canada Business Corporations Act ceased to apply to the Company and the Company became subject to the British Columbia Business Corporations Act. 100 SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements have been prepared by the Company in United States (“U.S.”) dollars and in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation of the Bausch + Lomb Eye-Health Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, the Company announced that it intends to separate its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the “Separation”). The Separation will establish two separate companies that include: (i) a fully integrated eye-health company which will consist of the Company’s Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmology Rx businesses and (ii) a diversified pharmaceutical company which will include the Company’s Salix, International Rx, Solta, neurology and medical dermatology pharmaceutical businesses. The anticipated separation is subject to regulatory approvals and certain conditions, including final approval by the Company’s Board of Directors and any shareholder vote requirements that may be applicable. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has begun addressing the internal organizational design and structure of the new entity which it anticipates having substantially completed by late 2021. Management is also exploring various capitalization structures and the form of the Separation transaction in order to properly capitalize both entities post-separation. As of the date of the issuance of these financial statements, the Company is in the planning phase of the Separation. As such, there are considerations, approvals and conditions that will determine the ultimate timing and structure of the Separation and there can be no assurance that such a transaction will occur. These Consolidated Financial Statements do not include any adjustments to give effect to the Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impacts of COVID-19 Pandemic </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has adversely impacted the global economy. The COVID-19 pandemic and the rapidly evolving reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have intensified and have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions. The COVID-19 pandemic has also significantly increased demand for certain goods and services, such as pandemic-related medical services and supplies, alongside decreased demand for others, such as retail, hospitality, elective medical procedures and travel. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which these events may continue to impact the Company's business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company's control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, the ultimate geographic spread and duration of the pandemic, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, if any, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company's business, financial condition, cash flows and results of operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the Company's Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company’s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s Consolidated Financial Statements could be materially impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition. Acquired in-process research and development (“IPR&amp;D”) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;D with no alternative future use is charged to expense at the acquisition date and any future contingent consideration is not recorded until it becomes probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Derivative Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s cross-currency swaps qualify for and have been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value is determined via a mark-to-market analysis, using observable (Level 2) inputs. These inputs may include: (i) the foreign currency exchange spot rate between the euro and U.S. dollar, (ii) the interest rate yield curves in the euro and U.S. dollar and (iii) the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Loss as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulated other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps was ineffective. The Company uses the spot method of assessing hedge effectiveness. The Company has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as a reduction of Interest expense in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses foreign currency exchange contracts to economically hedge the foreign exchange exposure on certain of the Company’s intercompany and third party balances. The Company's foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of three months or less when purchased.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, cross-currency swaps and foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than three months.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company’s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Brazil, Egypt, Greece, among other members of the European Union, Turkey, Ukraine and Venezuela have been weak in recent years. These conditions have increased, and may continue to increase, the average length of time that it takes to collect on the Company’s trade receivables outstanding in these countries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company’s three largest U.S. wholesaler customers accounted for approximately 38% of net trade receivables. In addition, as of December 31, 2020 and 2019, the Company’s net trade receivable balance from Argentina, Brazil, Egypt, Greece, Serbia, Turkey, Ukraine, Venezuela and Vietnam amounted to $166 million and $156 million, respectively, the majority of which is current or less than 90 days past due. The portion of the net trade receivable from these countries that is past due more than 90 days amounted to $2 million, as of December 31, 2020, a portion of which is comprised of public hospitals. Based on an analysis of credit risk, including an analysis of bad debt experience </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and assessment of historical payment patterns for such customers, the Company has established a reserve covering more than half of the balance past due more than 90 days for such countries. Over the three-year period ended December 31, 2020, the Company has not experienced any material losses from uncollectible accounts in excess of the established reserves.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not enter into financial instruments for trading or speculative purposes. Further, the Company has a policy of only entering into contracts with parties that have at least an investment grade credit rating. The Company enters into cross-currency swaps and foreign currency exchange contracts with high credit quality financial institutions. The counter-parties to the Company's cross-currency swaps and foreign currency exchange contracts are major financial institutions, and there is no significant concentration of exposure with any one counter-party. To date, no counterparty has failed to meet its obligations to the Company and management believes the risk of loss associated with these contracts is remote. See Note 5, "FAIR VALUE MEASUREMENTS" for additional details regarding the Company's cross-currency swaps and foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.  Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. Allowance for credit losses were $39 million, $48 million and $47 million as of December 31, 2020, 2019 and 2018, respectively. The activity in the allowance for credit losses for trade receivables for the years 2020, 2019 and 2018 is as follows.</span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.199%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.965%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retrospective effect of application of new accounting standard</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful lives: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:31.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.859%"><tr><td style="width:1.0%"/><td style="width:56.220%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.802%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of term of lease or 10 years</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. Amortization is calculated primarily using the straight-line method based on the following estimated useful lives:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.859%"><tr><td style="width:1.0%"/><td style="width:56.220%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.802%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 9 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Out-licensed technology and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 - 9 years</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestitures of Products</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense (income), net. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IPR&amp;D </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of IPR&amp;D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and amortized. Acquired IPR&amp;D assets are tested for impairment at least annually or when triggering events are identified.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of an acquired IPR&amp;D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset’s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset’s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow streams.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, which includes acquired IPR&amp;D and the corporate trademark acquired in the acquisition of Bausch &amp; Lomb Holdings Incorporated (the ‘‘B&amp;L Trademark’’), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. A reporting unit is the same as, or one level below, an operating segment. A</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n entity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit’s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company’s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company’s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, the Company elected to early adopt guidance issued by the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board ("FASB") which simplified the subsequent measurement of goodwill by eliminating “Step 2” from the goodwill impairment test. Instead, as of January 1, 2018 and all subsequent periods, goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt discounts, premiums and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of the Company’s foreign operations having a functional currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation’s functional currency are recognized as a component of Foreign exchange and other in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, gastroenterology ("GI") and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, "SEGMENT INFORMATION" for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract with the Company’s customers exists for each product sale. Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed below. The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.  The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for variable consideration are established to reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity and ending balances of the Company’s variable consideration provisions the years 2020 and 2019.</span></div><div style="margin-bottom:5pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:28.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, January 1, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,024 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,384 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of Synergy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(769)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,979)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">691 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,050 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,036 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $32 million and $29 million as of December 31, 2020 and 2019, respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company’s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics. The following describes the major sources of variable consideration in the Company’s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Discounts and Allowances</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within one month of incurring the liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, customers are generally allowed to return a product within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information. These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. A change of 1% in the estimated return rates would have impacted the Company’s pre-tax earnings by approximately $76 million for the year 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not warrant revision to the provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S. National Drug Codes (“NDC”) of products. Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S. customers generally permit only one NDC per product for identification and tracking within their inventory systems.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for 2020 and 2019 were $120 million and $113 million, respectively, and includes reductions in variable consideration for sales return provisions related to past sales of approximately $38 million and $80 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates.  The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270 days after the quarter in which the product is dispensed to the Medicaid participant. As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. A change of 1% in the estimated rates used in the Medicaid rebate reserve would have impacted the Company’s pre-tax earnings by approximately $76 million for 2020. Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or chargebacks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts implemented in each of the last three years, changes in the Company’s product portfolio due to recent acquisitions and increased Medicaid utilization due to expansion of government funding for these programs. Management’s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2020 and 2019 were not material to the Company’s revenues or earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company’s products. Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management’s estimate of the discount, rebate and loyalty incentives attributable to a sale. That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart. The Company has Distribution Services Agreements ("DSAs") with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty. Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes. Additionally, price appreciation credits are generated when the Company increases a product’s wholesaler acquisition cost (“WAC”) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $15 million and $11 million for the years 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Commissions </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Component</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less. The Company's global payment terms are generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTVkODQ2NmZmOTQ4OGE5OGMyNjBjMjVjMzM2MzdkL3NlYzplMjE1ZDg0NjZmZjk0ODhhOThjMjYwYzI1YzMzNjM3ZF8yNzQvZnJhZzo1MzI0YzI0MGM3Mzk0NmJiOWExYTU0M2QwN2Y4MTE0ZS90ZXh0cmVnaW9uOjUzMjRjMjQwYzczOTQ2YmI5YTFhNTQzZDA3ZjgxMTRlXzM1ODM4_18231505-4f07-40b8-b890-a1c3a64729d1">thirty</span> to ninety days.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain facilities, vehicles and equipment principally under multi-year agreements generally having a lease term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTVkODQ2NmZmOTQ4OGE5OGMyNjBjMjVjMzM2MzdkL3NlYzplMjE1ZDg0NjZmZjk0ODhhOThjMjYwYzI1YzMzNjM3ZF8yNzQvZnJhZzo1MzI0YzI0MGM3Mzk0NmJiOWExYTU0M2QwN2Y4MTE0ZS90ZXh0cmVnaW9uOjUzMjRjMjQwYzczOTQ2YmI5YTFhNTQzZDA3ZjgxMTRlXzI3NDg3NzkxMjMxNDg_6571e92d-07c6-409e-942d-72894c267c55">one</span> to twenty years, some of which include termination options and options to extend the lease term from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTVkODQ2NmZmOTQ4OGE5OGMyNjBjMjVjMzM2MzdkL3NlYzplMjE1ZDg0NjZmZjk0ODhhOThjMjYwYzI1YzMzNjM3ZF8yNzQvZnJhZzo1MzI0YzI0MGM3Mzk0NmJiOWExYTU0M2QwN2Y4MTE0ZS90ZXh0cmVnaW9uOjUzMjRjMjQwYzczOTQ2YmI5YTFhNTQzZDA3ZjgxMTRlXzI3NDg3NzkxMjMxNTg_33b4676e-209d-4a1f-b3fd-6a57a5b7263c">one</span> to five years or on a month-to-month basis. The Company includes options that are reasonably certain to be exercised as part of the lease term. The Company may negotiate termination clauses in anticipation of changes in market conditions but </span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generally, these termination options are not exercised. Certain lease agreements also include variable payments that are dependent on usage or may vary month-to-month such as insurance, taxes and maintenance costs. None of the Company's lease agreements contain material residual value guarantees or material restrictive covenants.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2019, the Company adopted a new standard revising the accounting for leases, using the modified retrospective approach. Upon adoption, the Company elected the available practical expedients, including: (i) the package of practical expedients as defined in the accounting guidance, which among other things, allowed the carry forward of historical lease classifications, (ii) the election to use hindsight in determining the lease terms for all leases, (iii) the transition method, which does not require the restatement of prior periods, (iv) the election to aggregate lease components with non-lease components and account for these payments as a single lease component and (v) the short-term lease exemption, which does not require recognition on the balance sheet for leases with an initial term of 12 months or less. The Company has updated its systems, processes and controls to track, record and account for its lease portfolio, including implementation of a third-party software tool to assist in complying with the new standard. Upon adoption of the new standard, the Company recognized a right-of-use asset and a corresponding lease liability of $<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTVkODQ2NmZmOTQ4OGE5OGMyNjBjMjVjMzM2MzdkL3NlYzplMjE1ZDg0NjZmZjk0ODhhOThjMjYwYzI1YzMzNjM3ZF8yNzQvZnJhZzo1MzI0YzI0MGM3Mzk0NmJiOWExYTU0M2QwN2Y4MTE0ZS90ZXh0cmVnaW9uOjUzMjRjMjQwYzczOTQ2YmI5YTFhNTQzZDA3ZjgxMTRlXzE2NDkyNjc1MjU0NTQ_a5b561f6-10a8-489f-9e22-46ba9a72a3ea">302 million</span>. The adoption of the standard did not have a material impact on the Consolidated Statements of Operations, Comprehensive Loss, Equity and Cash Flows for any of the periods presented. See Note 12, "LEASES" for additional details and application of this standard.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to record a right-of-use asset and corresponding lease liability, equal to the present value of the lease payments at the commencement date of each lease. For all asset classes, in determining future lease payments, the Company has elected to aggregate lease components, such as payments for rent, taxes and insurance costs with non-lease components such as maintenance costs, and account for these payments as a single lease component. In limited circumstances, when the information necessary to determine the rate implicit in a lease is available, the present value of the lease payments is determined using the rate implicit in that lease. If the information necessary to determine the rate implicit in a lease is not available, the Company uses its incremental borrowing rate at the commencement of the lease, which represents the rate of interest that the Company would incur to borrow on a collateralized basis over a similar term.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All leases must be classified as either an operating lease or finance lease. The classification is determined based on whether substantive control has been transferred to the lessee. The classification governs the pattern of lease expense recognition. For leases classified as operating leases, total lease expense over the term of the lease is equal to the undiscounted payments due in accordance with the lease arrangement. Fixed lease expense is recognized periodically on a straight-line basis over the term of each lease and includes: (i) imputed interest during the period on the lease liability determined using the effective interest rate method plus (ii) amortization of the right-of-use asset for that period. Amortization of the right-of-use asset during the period is calculated as the difference between the straight-line expense and the imputed interest on the lease liability for that period. Variable lease expense is recognized when the achievement of the specific target is considered probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to internal research and development programs, including costs associated with the development of acquired IPR&amp;D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Costs </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal fees and other costs related to litigation and other legal proceedings or services are expensed as incurred and are included in Selling, general and administrative expenses. Certain legal costs associated with acquisitions are included in Acquisition-related costs and certain legal costs associated with divestitures, legal settlements and other business development activities are included in Litigation and other matters or Net (gain) loss on sales of assets within Other expense (income), net, as appropriate. Legal costs expensed are reported net of expected insurance recoveries. A claim for insurance recovery is recognized when realization becomes probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs comprise product samples, print media, promotional materials and television advertising and are expensed on the first use of the advertisement. Included in Selling, general and administrative expenses are advertising costs of $451 million, $544 million and $481 million, for 2020, 2019 and 2018, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes all share-based payments to employees, including grants of employee stock options and restricted share units (“RSUs”), at estimated fair value. The Company amortizes the fair value of stock option or RSU grants on a straight-line basis over the requisite service period of the individual stock option or RSU grant, which generally equals the vesting period. Stock option and RSU forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation is recorded in Research and development expenses and Selling, general and administrative expenses, as appropriate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-Related Contingent Consideration </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in fair value measurement accounting.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense includes standby fees, the amortization of debt discounts and deferred financing costs, accretion of debt premiums and the amortization of amounts excluded from the assessment of effectiveness related to the Company's cross-currency swaps. Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized. Capitalized interest related to construction in progress as of December 31, 2020 and 2019 was $45 million and $34 million, respectively, and is included in Property, plant and equipment, net. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and laws. Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2016, the FASB issued guidance requiring an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, rather than when the asset has been sold to an outside party. This guidance was effective for the Company January 1, 2018 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit and deferred income taxes as of the effective date. The Company recorded a net cumulative-effect adjustment of $1,209 million to increase deferred income tax assets and decrease the opening balance of Accumulated deficit for the income tax consequences deferred from past intra-entity transfers involving assets other than inventory. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than 50% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within one year. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share Attributable to Bausch Health Companies Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. Diluted loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock method.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss comprises Net loss and Other comprehensive (loss) income. Other comprehensive (loss) income includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders’ equity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a liability. These accruals are adjusted periodically as assessments change or additional information becomes available.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Benefit Plans </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed 10 percent of the greater of the plan’s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="margin-bottom:10pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses. The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to Accumulated deficit of less than $1 million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement.  The guidance was effective for the Company beginning January 1, 2020. The application of this guidance did not have a material effect on the Company's disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.  Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging. The optional amendments are effective for all entities as of March 12, 2020, through December 31, 2022. During 2020, the Company has not entered into any contract modifications in which the optional expedients were applied.  However, if prior to December 31, 2022 the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.</span></div><div style="margin-bottom:10pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans.  The guidance was effective for annual periods ending after December 15, 2020. The application of this guidance did not have a material effect on the Company's disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards, Not Adopted as of December 31, 2020</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.  The guidance is effective for annual periods beginning after December 15, 2020.  The application of this guidance is not expected to have a material effect on the Company's financial position, results of operations and cash flows.</span></div> Basis of Presentation and Use of Estimates The Consolidated Financial Statements have been prepared by the Company in United States (“U.S.”) dollars and in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated. <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the Company's Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company’s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s Consolidated Financial Statements could be materially impacted.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition. Acquired in-process research and development (“IPR&amp;D”) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;D with no alternative future use is charged to expense at the acquisition date and any future contingent consideration is not recorded until it becomes probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-Related Contingent Consideration </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in fair value measurement accounting.</span></div> Fair Value of Financial InstrumentsThe estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events. <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Derivative Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s cross-currency swaps qualify for and have been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value is determined via a mark-to-market analysis, using observable (Level 2) inputs. These inputs may include: (i) the foreign currency exchange spot rate between the euro and U.S. dollar, (ii) the interest rate yield curves in the euro and U.S. dollar and (iii) the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Loss as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulated other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps was ineffective. The Company uses the spot method of assessing hedge effectiveness. The Company has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as a reduction of Interest expense in the Consolidated Statements of Operations.</span></div>The Company uses foreign currency exchange contracts to economically hedge the foreign exchange exposure on certain of the Company’s intercompany and third party balances. The Company's foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of three months or less when purchased.</span></div> P3M <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, cross-currency swaps and foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than three months.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.</span></div>The Company’s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company’s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Brazil, Egypt, Greece, among other members of the European Union, Turkey, Ukraine and Venezuela have been weak in recent years. P3M 3 0.38 166000000 156000000 P90D P90D 2000000 P90D Allowance for Credit LossesAn allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.  Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. 39000000 48000000 47000000 The activity in the allowance for credit losses for trade receivables for the years 2020, 2019 and 2018 is as follows.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.199%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.965%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retrospective effect of application of new accounting standard</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 48000000 47000000 97000000 1000000 0 0 2000000 10000000 4000000 12000000 10000000 50000000 3000000 1000000 2000000 3000000 0 6000000 39000000 48000000 47000000 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful lives: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:31.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.859%"><tr><td style="width:1.0%"/><td style="width:56.220%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.802%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of term of lease or 10 years</span></div></td></tr></table></div> Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful lives: <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.859%"><tr><td style="width:1.0%"/><td style="width:56.220%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.802%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of term of lease or 10 years</span></div></td></tr></table> P15Y P30Y P40Y P3Y P20Y P3Y P10Y P5Y P10Y <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. Amortization is calculated primarily using the straight-line method based on the following estimated useful lives:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.859%"><tr><td style="width:1.0%"/><td style="width:56.220%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.802%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 9 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Out-licensed technology and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 - 9 years</span></div></td></tr></table></div> Amortization is calculated primarily using the straight-line method based on the following estimated useful lives:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.859%"><tr><td style="width:1.0%"/><td style="width:56.220%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.802%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 9 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Out-licensed technology and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 - 9 years</span></div></td></tr></table> P1Y P20Y P7Y P20Y P4Y P15Y P7Y P9Y P8Y P9Y <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestitures of Products</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense (income), net. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IPR&amp;D </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of IPR&amp;D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and amortized. Acquired IPR&amp;D assets are tested for impairment at least annually or when triggering events are identified.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of an acquired IPR&amp;D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset’s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset’s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow streams.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, which includes acquired IPR&amp;D and the corporate trademark acquired in the acquisition of Bausch &amp; Lomb Holdings Incorporated (the ‘‘B&amp;L Trademark’’), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. A reporting unit is the same as, or one level below, an operating segment. A</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n entity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit’s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company’s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors </span></div>changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company’s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values.<span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, the Company elected to early adopt guidance issued by the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board ("FASB") which simplified the subsequent measurement of goodwill by eliminating “Step 2” from the goodwill impairment test. Instead, as of January 1, 2018 and all subsequent periods, goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value.</span> <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt discounts, premiums and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of the Company’s foreign operations having a functional currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation’s functional currency are recognized as a component of Foreign exchange and other in the Consolidated Statements of Operations.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, gastroenterology ("GI") and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, "SEGMENT INFORMATION" for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract with the Company’s customers exists for each product sale. Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed below. The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.  The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for variable consideration are established to reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity and ending balances of the Company’s variable consideration provisions the years 2020 and 2019.</span></div><div style="margin-bottom:5pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:28.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, January 1, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,024 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,384 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of Synergy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(769)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,979)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">691 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,050 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,036 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $32 million and $29 million as of December 31, 2020 and 2019, respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company’s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics. The following describes the major sources of variable consideration in the Company’s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Discounts and Allowances</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within one month of incurring the liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, customers are generally allowed to return a product within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information. These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. A change of 1% in the estimated return rates would have impacted the Company’s pre-tax earnings by approximately $76 million for the year 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not warrant revision to the provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S. National Drug Codes (“NDC”) of products. Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S. customers generally permit only one NDC per product for identification and tracking within their inventory systems.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for 2020 and 2019 were $120 million and $113 million, respectively, and includes reductions in variable consideration for sales return provisions related to past sales of approximately $38 million and $80 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates.  The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270 days after the quarter in which the product is dispensed to the Medicaid participant. As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. A change of 1% in the estimated rates used in the Medicaid rebate reserve would have impacted the Company’s pre-tax earnings by approximately $76 million for 2020. Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or chargebacks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts implemented in each of the last three years, changes in the Company’s product portfolio due to recent acquisitions and increased Medicaid utilization due to expansion of government funding for these programs. Management’s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2020 and 2019 were not material to the Company’s revenues or earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company’s products. Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management’s estimate of the discount, rebate and loyalty incentives attributable to a sale. That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart. The Company has Distribution Services Agreements ("DSAs") with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty. Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes. Additionally, price appreciation credits are generated when the Company increases a product’s wholesaler acquisition cost (“WAC”) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $15 million and $11 million for the years 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Commissions </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Component</span></div>The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less. <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity and ending balances of the Company’s variable consideration provisions the years 2020 and 2019.</span></div><div style="margin-bottom:5pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:28.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, January 1, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,024 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,384 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of Synergy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(769)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,979)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">691 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,050 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,036 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 175000000 813000000 1024000000 209000000 163000000 2384000000 0 3000000 12000000 0 1000000 16000000 776000000 113000000 2265000000 1938000000 195000000 5287000000 769000000 238000000 2374000000 1979000000 277000000 5637000000 182000000 691000000 927000000 168000000 82000000 2050000000 621000000 120000000 2174000000 1925000000 196000000 5036000000 613000000 236000000 2322000000 1909000000 193000000 5273000000 190000000 575000000 779000000 184000000 85000000 1813000000 32000000 29000000 P1M 76000000 120000000 113000000 -38000000 -80000000 76000000 15000000 11000000 P90D P20Y P5Y 302000000 302000000 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to internal research and development programs, including costs associated with the development of acquired IPR&amp;D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.</span></div> Legal Costs Legal fees and other costs related to litigation and other legal proceedings or services are expensed as incurred and are included in Selling, general and administrative expenses. Certain legal costs associated with acquisitions are included in Acquisition-related costs and certain legal costs associated with divestitures, legal settlements and other business development activities are included in Litigation and other matters or Net (gain) loss on sales of assets within Other expense (income), net, as appropriate. Legal costs expensed are reported net of expected insurance recoveries. A claim for insurance recovery is recognized when realization becomes probable Advertising CostsAdvertising costs comprise product samples, print media, promotional materials and television advertising and are expensed on the first use of the advertisement. 451000000 544000000 481000000 Share-Based Compensation The Company recognizes all share-based payments to employees, including grants of employee stock options and restricted share units (“RSUs”), at estimated fair value. The Company amortizes the fair value of stock option or RSU grants on a straight-line basis over the requisite service period of the individual stock option or RSU grant, which generally equals the vesting period. Stock option and RSU forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation is recorded in Research and development expenses and Selling, general and administrative expenses, as appropriate. Interest Expense Interest expense includes standby fees, the amortization of debt discounts and deferred financing costs, accretion of debt premiums and the amortization of amounts excluded from the assessment of effectiveness related to the Company's cross-currency swaps. Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized. 45000000 34000000 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and laws. Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2016, the FASB issued guidance requiring an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, rather than when the asset has been sold to an outside party. This guidance was effective for the Company January 1, 2018 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit and deferred income taxes as of the effective date. The Company recorded a net cumulative-effect adjustment of $1,209 million to increase deferred income tax assets and decrease the opening balance of Accumulated deficit for the income tax consequences deferred from past intra-entity transfers involving assets other than inventory. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than 50% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within one year. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance sheets.</span></div> 1209000000 1209000000 0.50 P1Y <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share Attributable to Bausch Health Companies Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. Diluted loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period </span></div>after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock method. <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss comprises Net loss and Other comprehensive (loss) income. Other comprehensive (loss) income includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders’ equity.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a liability. These accruals are adjusted periodically as assessments change or additional information becomes available.</span></div>If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred. Employee Benefit Plans The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed 10 percent of the greater of the plan’s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements. 0.10 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="margin-bottom:10pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses. The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to Accumulated deficit of less than $1 million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement.  The guidance was effective for the Company beginning January 1, 2020. The application of this guidance did not have a material effect on the Company's disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.  Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging. The optional amendments are effective for all entities as of March 12, 2020, through December 31, 2022. During 2020, the Company has not entered into any contract modifications in which the optional expedients were applied.  However, if prior to December 31, 2022 the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.</span></div><div style="margin-bottom:10pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans.  The guidance was effective for annual periods ending after December 15, 2020. The application of this guidance did not have a material effect on the Company's disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards, Not Adopted as of December 31, 2020</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.  The guidance is effective for annual periods beginning after December 15, 2020.  The application of this guidance is not expected to have a material effect on the Company's financial position, results of operations and cash flows.</span></div> -1000000 ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition Agreement for Synergy Pharmaceuticals Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 6, 2019, the Company acquired certain assets of Synergy Pharmaceuticals Inc. ("Synergy") for a cash purchase price of approximately $180 million and the assumption of certain liabilities, pursuant to the terms approved by the U.S. Bankruptcy Court for the Southern District of New York on March 1, 2019. Among the assets acquired are the worldwide rights to the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. This acquired business is included in the Company's Salix segment and is expected to result in additional revenues and costs savings associated with business synergies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of certain assets of Synergy has been accounted for as a business combination under the acquisition method of accounting since: (i) substantially all of the fair value of the assets acquired is not concentrated in a single identifiable asset or group of similar identifiable assets and (ii) substantive inputs and processes were acquired to contribute to the creation of outputs. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:</span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:89.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.005%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brand intangible assets (estimated useful life 7 years)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill associated with the acquisition of certain assets of Synergy is not deductible for income tax purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue and Operating Results </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 were $55 million. Operating results associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 and pro-forma revenues and operating results for the year 2019 were not material. Included in Other expense (income), net for 2019 are acquisition-related costs of $8 million directly related to the acquisition of certain assets of Synergy, which include expenditures for advisory, legal, valuation, accounting and other similar services.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interest in Medpharm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2018, using cash on hand, the Company acquired the 40% noncontrolling interest of Medpharma Pharmaceutical &amp; Chemical Industries LLC (“Medpharma”) for $18 million. The difference between the carrying value and the price paid for the noncontrolling interest in Medpharma of $15 million, is a reduction of additional paid-in capital.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other material business combinations in 2020, 2019 or 2018. The measurement period for all acquisitions has closed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Option to Purchase All Ophthalmology Assets of Allegro Ophthalmics, LLC ("Allegro")</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 21, 2020, the Company announced that it had entered into an agreement to acquire an option to purchase all of the ophthalmology assets of Allegro (the "Option"), a privately held biopharmaceutical company focused on the development of therapies that regulate integrin functions for the treatment of ocular diseases. Among the assets to be acquired if the Option is exercised, is the worldwide rights to risuteganib (Luminate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Allegro's lead investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry Age-related Macular Degeneration ("AMD"). A U.S. Phase 2a study with risuteganib in intermediate dry AMD met its primary endpoint of vision recovery and Phase 3 testing is in the planning stages. The aggregate payments to acquire the Option are $50 million and include an upfront payment of $10 million and a second payment of $40 million should Allegro raise additional funding. During the three months ended September 30, 2020, the Company made and expensed the upfront payment of $10 million as acquired IPR&amp;D included in Other expense (income), net. If the Option is exercised, additional payments to acquire all ophthalmology assets of Allegro will be due.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. The commitment periods under these agreements vary and include customary termination provisions. Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held for Sale</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended December 31, 2020, the Company identified for disposal a certain business within the Bausch + Lomb/International segment. This business was classified as held for sale as of December 31, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying amounts of the assets and liabilities held for sale included in the Consolidated Balance Sheet as of December 31, 2020 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.637%"><tr><td style="width:1.0%"/><td style="width:90.276%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.919%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included within Deferred tax liabilities, net, are book to income tax differences related to the Company's intangible assets.</span></div>As a result of meeting the criteria for held for sale classification, the carrying value of this business, was adjusted to its estimated fair value, less costs to sell, and the Company recognized a loss of $96 million within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. This loss was primarily due to the anticipated release of non-cash cumulative foreign currency translation losses of $344 million, which were included as part of the carrying value of this business when measuring for impairment. These losses will be reclassified from Accumulated other comprehensive loss to Net loss upon the disposal of this business. 180000000 The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:89.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.005%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brand intangible assets (estimated useful life 7 years)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 7000000 24000000 5000000 P7Y 159000000 1000000 17000000 177000000 3000000 180000000 55000000 0 0 0 -8000000 0.40 18000000 15000000 0 0 0 50000000 10000000 40000000 -10000000 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying amounts of the assets and liabilities held for sale included in the Consolidated Balance Sheet as of December 31, 2020 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.637%"><tr><td style="width:1.0%"/><td style="width:90.276%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.919%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 91000000 63000000 8000000 162000000 68000000 245000000 2000000 315000000 7000000 28000000 35000000 36000000 21000000 57000000 96000000 344000000 RESTRUCTURING, INTEGRATION AND SEPARATION COSTS<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and integration costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i) reducing headcount, (ii) eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of December 31, 2020 was $20 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company incurred $11 million of restructuring and integration-related costs. These costs included: (i) $10 million of facility closure costs and (ii) $1 million of severance and other costs. The Company made payments of $18 million during 2020. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company incurred $31 million of restructuring and integration costs. These costs included: (i) $11 million of severance costs and other costs associated with the acquisition of certain assets of Synergy, (ii) $11 million of facility closure costs and (iii) $9 million of other severance costs. The Company made payments of $31 million during 2019. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2018, the Company incurred $22 million of restructuring and integration costs. These costs included: (i) $11 million of severance costs, (ii) $10 million of facility closure costs and (iii) $1 million of other costs. The Company made payments of $33 million during 2018.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation costs and separation-related costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and will incur, costs associated with activities to effectuate the Separation. These activities include: (i) separating the eye-health business from the remainder of the Company and (ii) registering the eye-health business as an independent publicly traded entity. Separation costs are incremental costs directly related to the Separation and include, but are not limited to: (i) legal, audit and advisory fees, (ii) employee hiring, relocation and travel costs and (iii) costs associated with establishing a new board of directors and audit committee. Included in Restructuring, integration and separation costs for 2020 is $11 million of separation costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also incurred, and will incur, separation-related costs which are incremental costs indirectly related to the Separation. Separation-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative expenses for 2020 is $21 million of separation-related costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in the planning phase of the Separation and the extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.</span></div> 20000000 11000000 10000000 1000000 18000000 31000000 11000000 11000000 9000000 31000000 22000000 11000000 10000000 1000000 33000000 11000000 21000000 FAIR VALUE MEASUREMENTS<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are estimated based on valuation techniques and inputs categorized as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 — Quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 — Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a recurring basis as of: </span></div><div style="margin-bottom:5pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.929%"><tr><td style="width:1.0%"/><td style="width:26.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"> (in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,696 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, Restricted cash includes $1,210 million of payments into an escrow fund under the terms of a settlement agreement regarding certain U.S. securities litigation, subject to an objector's appeal of the final court approval, and is reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to its short-term nature. These payments will remain in escrow until final approval of the settlement as discussed in Note 20, "LEGAL PROCEEDINGS".</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of Level 3 during 2020 and 2019.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross-currency Swaps</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,250 million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from adverse movements in exchange rates. The euro-denominated net investment being hedged is the Company’s investment in certain euro-denominated subsidiaries. Prior to 2019, the Company had no cross-currency swaps.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company’s cross-currency swaps liability as of December 31, 2020 and 2019 was $70 million and $13 million, respectively. Included in Other non-current liabilities is $79 million and $22 million of cross-currency swaps and included in Prepaid expenses and other current assets is $9 million and $9 million of earned interest within the Consolidated Balance Sheets as of December 31, 2020 and 2019, respectively. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for 2020 and 2019: </span></div><div style="margin-bottom:13pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.929%"><tr><td style="width:1.0%"/><td style="width:79.292%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.896%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss recognized in Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlement of the Company's cross-currency swaps occurs in February and August each year. During 2020, the Company received $23 million in settlements which are reported as Investing activities in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Contracts</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company entered into foreign currency exchange contracts, with an aggregate notional amount of $485 million. Prior to 2020, the Company had no foreign currency exchange contracts for any period presented.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's foreign currency exchange contracts liability as of December 31, 2020 was $8 million. Included in Accrued and other current liabilities are $11 million and included in Prepaid expenses and other current assets are $3 million of foreign currency exchange contracts within the Consolidated Balance Sheets. During 2020, the net change </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in fair value was a loss of $8 million. Settlements of the Company's foreign currency exchange contracts are reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Consolidated Statements of Cash Flows. During 2020, the Company reported a realized loss of $2 million related to settlements of the Company's foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related Contingent Consideration Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level 3) inputs. These inputs may include: (i) the estimated amount and timing of projected cash flows, (ii) the probability of the achievement of the factor(s) on which the contingency is based and (iii) the risk-adjusted discount rate used to present value the probability-weighted cash flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At December 31, 2020, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 25%, and a weighted average risk-adjusted discount rate of 8%. The weighted average risk-adjusted discount rate was calculated by weighting each contract's relative fair value at December 31, 2020.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3) for the years 2020 and 2019:</span></div><div style="margin-bottom:5pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.906%"><tr><td style="width:1.0%"/><td style="width:63.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance, January 1, </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments / Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment included in other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance, December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a non-recurring basis:</span></div><div style="margin-bottom:13pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.783%"><tr><td style="width:1.0%"/><td style="width:24.277%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current assets held for sale of $245 million as of December 31, 2020 were remeasured to estimated fair value, less costs to sell, which utilized Level 3 unobservable inputs. See Note 3, "ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE" for additional details regarding these assets held for sale.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company identified certain products in the Bausch + Lomb/International segment and one product in the Diversified Products segment for disposal. The products and the related assets and liabilities of this disposal group qualified as a business and an impairment of $8 million associated with this business was recognized during the three months ended September 30, 2019. As a result of changing business dynamics, during the three months ended March 31, 2020, the Company decided not to sell these assets and reclassified $39 million of held for sale assets as assets held and used at their respective fair values at the date of the decision not to sell. This reclassification did not impact the Consolidated Statement of Operations for 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of long-term debt as of December 31, 2020 and 2019 was $25,378 million and $27,520 million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2).</span></div> <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a recurring basis as of: </span></div><div style="margin-bottom:5pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.929%"><tr><td style="width:1.0%"/><td style="width:26.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"> (in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,696 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 41000000 8000000 33000000 0 2696000000 2646000000 50000000 0 1211000000 1211000000 0 0 1000000 1000000 0 0 3000000 0 3000000 0 0 0 0 0 328000000 0 0 328000000 316000000 0 0 316000000 70000000 0 70000000 0 13000000 0 13000000 0 11000000 0 11000000 0 0 0 0 0 P3M 1210000000 1250000000 70000000 13000000 79000000 22000000 9000000 9000000 <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for 2020 and 2019: </span></div><div style="margin-bottom:13pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.929%"><tr><td style="width:1.0%"/><td style="width:79.292%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.896%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss recognized in Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div> -57000000 -22000000 23000000 9000000 23000000 485000000 8000000 11000000 3000000 -8000000 2000000 0.06 0.25 0.08 <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3) for the years 2020 and 2019:</span></div><div style="margin-bottom:5pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.906%"><tr><td style="width:1.0%"/><td style="width:63.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance, January 1, </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments / Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment included in other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance, December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 316000000 339000000 23000000 22000000 25000000 -10000000 48000000 12000000 36000000 36000000 0 1000000 328000000 316000000 112000000 54000000 216000000 262000000 <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a non-recurring basis:</span></div><div style="margin-bottom:13pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.783%"><tr><td style="width:1.0%"/><td style="width:24.277%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 245000000 0 0 245000000 39000000 0 0 39000000 245000000 1 8000000 39000000 -39000000 25378000000 27520000000 INVENTORIES<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net, as of December 31, 2020 and 2019 consist of: </span></div><div style="margin-bottom:13pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net, as of December 31, 2020 and 2019 consist of: </span></div><div style="margin-bottom:13pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 286000000 319000000 143000000 149000000 665000000 639000000 1094000000 1107000000 PROPERTY, PLANT AND EQUIPMENT<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of property, plant and equipment as of December 31, 2020 and 2019 consist of: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,348 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,107 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,781)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,641)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,466 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $180 million, $178 million and $175 million for 2020, 2019 and 2018, respectively.</span></div> <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of property, plant and equipment as of December 31, 2020 and 2019 consist of: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,348 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,107 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,781)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,641)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,466 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 79000000 79000000 686000000 696000000 1722000000 1606000000 360000000 369000000 65000000 56000000 436000000 301000000 3348000000 3107000000 1781000000 1641000000 1567000000 1466000000 180000000 178000000 175000000 INTANGIBLE ASSETS AND GOODWILL<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets as of December 31, 2020 and 2019 consist of:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.906%"><tr><td style="width:1.0%"/><td style="width:27.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.984%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Useful<br/>Lives<br/>(Years)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,890 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,914)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,055)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,887)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,481 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,741)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,613 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,123)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,490 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D not in service</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B&amp;L Trademark</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,186 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,741)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,445 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,324 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,123)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,201 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments, including loss on assets held for sale in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2020 included impairments of: (i) $96 million to reduce the carrying value of a business within the Bausch + Lomb/International segment to its estimated fair value less costs to sell due to classifying the business as held for sale as discussed in Note 3, "ACQUISITIONS, LICENSING AGREEMENTS </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AND ASSETS HELD FOR SALE", (ii) $16 million in aggregate, due to decreases in forecasted sales of certain product lines, (iii) $1 million in aggregate, related to the discontinuance of certain product lines not aligned with the focus of the Company's core businesses and (iv) $1 million related to Acquired IPR&amp;D not in service.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2019 included impairments of: (i) $58 million reflecting decreases in forecasted sales of certain product lines due to generic competition and other factors, (ii) $8 million related to assets being classified as held for sale, (iii) $5 million related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses and (iv) $4 million related to Acquired IPR&amp;D not in service. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2018 included impairments of: (i) $263 million reflecting decreases in forecasted sales for the Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tablet product in the Company's Salix reporting unit due to generic competition, (ii) $85 million reflecting decreases in forecasted sales of certain other product lines due to generic competition, (iii) $132 million reflecting decreases in forecasted sales for the Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product in the Company's Dentistry reporting unit and other product lines due to changing market conditions, (iv) $55 million, in aggregate, related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses, (v) $28 million to Acquired IPR&amp;D not in service related to a certain product and (vi) $5 million related to assets being classified as held for sale.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impairments to assets reclassified as held for sale were measured as the difference of the carrying value of these assets as compared to the estimated fair values of these assets less costs to sell determined using a discounted cash flow analysis which utilized Level 3 unobservable inputs. The other impairments and adjustments to finite-lived intangible assets were measured as the difference of the historical carrying value of these finite-lived assets as compared to the estimated fair value as determined using a discounted cash flow analysis using Level 3 unobservable inputs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, the Company’s products face the expiration of their patent or regulatory exclusivity. The Company anticipates that product sales for such product would decrease shortly following a loss of exclusivity ("LOE"), due to the possible entry of a generic competitor. Where the Company has the rights, it may elect to launch an authorized generic of such product (either as the Company’s own branded generic or through a third-party). This may occur prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product could still be significant, and the effect on future revenues could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management continually assesses the useful lives related to the Company's long-lived assets to reflect the most current assumptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 12, 2018, the Company changed the estimated useful life of its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-related intangible assets due to the positive impact of an agreement between the Company and Actavis Laboratories FL, Inc. ("Actavis") resolving the intellectual property litigation regarding Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg. Under the agreement, the parties agreed to dismiss all litigation related to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg and all intellectual property protecting Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will remain intact and enforceable. As a result, the useful life of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-related intangible assets was extended from 2024 to January 1, 2028. As this change in the estimated useful life is a change in an accounting estimate, amortization expense is impacted prospectively. The change in the estimated useful life of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-related intangible assets resulted in a decrease to the Net loss attributable to Bausch Health Companies Inc. of $476 million, $473 million and $143 million, and a decrease to the Basic and Diluted Loss per share attributable to Bausch Health Companies Inc. of $1.34, $1.34 and $0.41 for the years 2020, 2019 and 2018, respectively. As of December 31, 2020, the net carrying value of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-related intangible assets was $3,771 million.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the five years ending December 31 and thereafter are as follows: </span></div><div style="margin-bottom:5pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.906%"><tr><td style="width:1.0%"/><td style="width:16.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,204 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the years ended December 31, 2020, 2019 and 2018 were as follows: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:35.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + <br/>Lomb/<br/>International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Branded Rx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, January 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,016 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,631 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,946 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,593 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of the Salix and Ortho Dermatologics reporting units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,213)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,213)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realignment of Global Solta reporting unit goodwill</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale and subsequently disposed</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,913)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,023 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of the Dentistry reporting unit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,805 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,156 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of certain assets of Synergy </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,786 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,126 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets held for sale reclassified to goodwill (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale (Note 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,704 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,044 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1). </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit's terminal value. </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To forecast a reporting unit's cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management's and a market participant's view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected LOE to the Company's product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company’s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2018</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adoption of New Accounting Guidance for Goodwill Impairment Testing</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, the Company elected to early adopt a new accounting standard which simplifies the subsequent measurement of goodwill by eliminating “Step 2” from the goodwill impairment test. Goodwill impairment is now measured as the amount by which a reporting unit's carrying value exceeds its fair value. Upon adopting the new standard, the Company tested goodwill for impairment and determined that the carrying value of the Salix reporting unit exceeded its fair value resulting in the Company recognizing a goodwill impairment of $1,970 million associated with the Salix reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its 2017 annual goodwill impairment test as of October 1, 2017 and determined that the fair value of the Ortho Dermatologics reporting unit exceeded its carrying value. However, at January 1, 2018, unforeseen changes in the business dynamics of the Ortho Dermatologics reporting unit, such as: (i) changes in the dermatology sector, (ii) increased pricing pressures from third-party payors, (iii) additional risks to the exclusivity of certain products and (iv) an expected longer launch cycle for a new product, were factors that negatively impacted the reporting unit's operating results beyond management's expectations as of October 1, 2017. In response to these adverse business indicators, as of January 1, 2018, the Company reduced its near and long term financial projections for the Ortho Dermatologics reporting unit. As a result of the reductions in the near and long term financial projections, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at January 1, 2018 and the Company recognized a goodwill impairment of $243 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Realignment of Solta Business</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective March 1, 2018, revenues and profits from the U.S. Solta business included in the former U.S. Diversified Products segment in prior periods and revenues and profits from the international Solta business included in the Bausch + Lomb/International segment in prior periods, are reported in a new Global Solta reporting unit, which, at that time, was a part of the former Branded Rx segment. As a result of this change, $115 million of goodwill was reallocated to the new Global Solta reporting unit and the Company assessed the impact on the fair values of each of the reporting units affected. After considering, among other matters: (i) the limited period of time between last impairment test (January 1, 2018) and the realignment (March 1, 2018), (ii) the results of the last impairment test and (iii) the amount of goodwill reallocated to the new Global Solta reporting unit, the Company did not identify any indicators of impairment at the time of the realignment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Realignment of Segment Structure</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2018, the Company began operating in the following reportable segments: (i) Bausch + Lomb/International segment, (ii) Salix segment, (iii) Ortho Dermatologics segment and (iv) Diversified Products segment. The Bausch + Lomb/International segment consists of the: (i) U.S. Bausch + Lomb and (ii) International reporting units. The Salix segment consists of the Salix reporting unit. The Ortho Dermatologics segment consists of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. There was no triggering event which would require the Company to test goodwill for impairment as a result of the second quarter realignment of the segment structure as it did not result in a change in the reporting units.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its 2018 annual goodwill impairment test as of October 1, 2018 and determined that the carrying value of the Dentistry reporting unit exceeded its fair value and, as a result, the Company recognized a goodwill impairment of $109 million, representing the full amount of goodwill for the Dentistry reporting unit. Changing market conditions such as: (i) an increasing competitive environment and (ii) increasing pricing pressures negatively impacted the reporting unit's operating results. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's remaining reporting units passed the goodwill impairment test as the estimated fair value of each reporting unit exceeded its carrying value at the date of testing and, therefore, there was no impairment to goodwill for any reporting unit other than the Dentistry reporting unit. In order to evaluate the sensitivity of its fair value calculations on the goodwill impairment test, the Company compared the carrying value of each reporting unit to its fair value as of October 1, 2018, the date of testing. As of October 1, 2018, the fair value of each reporting unit with associated goodwill exceeded its carrying value by more than 15%. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2019</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2019 by first assessing qualitative factors. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. In each quantitative fair value test performed, the fair value was greater than the carrying value of the reporting unit. As a result, there was no impairment to the goodwill of any reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2020</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Interim Goodwill Impairment Assessment</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, the Company has taken actions to protect its employees, customers and other stakeholders and mitigate the negative impact of the COVID-19 pandemic on its operations and operating results. These and additional actions can increase the costs of doing business during the pandemic and, in the periods that follow, may include the costs of idling and reopening certain facilities in affected areas. Further, social restrictions and other precautionary measures taken by customers, health care patients and consumers in response to the pandemic are expected to impact the timing and amount of revenues during the COVID-19 pandemic. Although the Company's revenues for 2020 were less than those forecasted on the date goodwill was last tested for impairment (October 1, 2019), there were no indications that these trends are materially related to developments other than the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative impacts of the COVID-19 pandemic on the global economy have led to significant volatility in the global equity markets. The Company has been able to continue its operations with limited disruptions and has assessed the potential impact that the COVID-19 pandemic is likely to have on its forecasted cash flows. In performing its assessment, the Company considered the possible affects and outcomes of the COVID-19 pandemic on, among other things, its supply chain, customers and distributors, employee base, product sustainability, research and development activities, product pipeline and consumer demand and related rebates and discounts and has made adjustments, although not considered to be material, to its long-term forecasts as of October 1, 2019 (the date goodwill was last tested for impairment) for these and other matters. After completing this assessment, although not completely insulated from the negative effects of the COVID-19 pandemic, the Company believes that its long-term forecasted cash flows, as adjusted for the possible outcome of the COVID-19 pandemic and other matters, do not indicate that the fair value of any reporting unit may be below its carrying value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the pandemic, the public has been advised to engage in certain "social restrictions" such as: (i) remaining at home or shelter-in-place, (ii) limiting social interaction, (iii) closing non-essential businesses and (iv) postponing certain surgical and elective medical procedures in order to prioritize/conserve available health care resources. During the three months ended March 31, 2020, these factors negatively impacted, most notably, the revenues of the Company's Global Vision Care and Global Surgical businesses in Asia where the COVID-19 pandemic originated. Beginning in March 2020, and throughout most of the second quarter of 2020, the Company experienced steeper declines in these revenues and the revenues of other businesses as social restrictions expanded worldwide, particularly in the U.S. and Europe. Social restrictions negatively impacted the Company's revenues for contact lenses, intraocular lenses, medical devices, surgical systems and certain pre- and post-operative eye-medications of its Global Ophtho Rx business, medical aesthetics and therapeutic products of its Global Solta business, and certain branded pharmaceutical products of its Salix, Ortho Dermatologics and Dentistry businesses, as the offices of many health care providers were closed and certain surgeries and elective medical procedures were deferred.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2020 revenues were most negatively impacted during its second quarter by the social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize prior to the third quarter. Revenues for the three months ended December 31, 2020 and 2019 were $2,213 million and $2,224 million, respectively, a decrease of $11 million. This decrease of less than 1% represents a continuing improving trend over the decreases in year-over-year revenues for the three month periods ended June 30, 2020 and September 30, 2020 of 23% and 3%, respectively. Presuming there continues to be increased availability of effective vaccines and any further resurgence of the COVID-19 virus and variant strains thereof do not have a material adverse impact on efforts to contain the COVID-19 virus, the Company anticipates an ongoing, gradual global recovery from the macroeconomic and health care impacts of the pandemic that occurred during the first-half of 2020 and anticipates that its affected businesses could return to pre-pandemic levels during 2021. However, the rates of recovery for each business will vary by geography and will be dependent upon, among other things, the availability and effectiveness of vaccines for the COVID-19 virus, government </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus and other actions taken in response to the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, using its latest forecasts of cash flows, the Company gave consideration to the nature and timing of the expected revenue losses discussed above. No events occurred or circumstances changed during the period October 1, 2019 through September 30, 2020 that would indicate that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, might be below its carrying value. The changes in the amounts and timing of revenues as presented in the Company's latest forecasts included a range of potential outcomes and, with the exception of the Ortho Dermatologics reporting unit as discussed below, were not substantial enough to materially adversely affect the recoverability of any of the associated reporting units’ assets and were not material enough to indicate that the fair values of those reporting units might be below their respective carrying values. However, based on the results of the October 1, 2019 annual goodwill impairment test, the Company continued to assess the performance of the Ortho Dermatologics reporting unit and the Neuro and Other reporting unit on a quarterly basis throughout 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Interim Goodwill Impairment Assessments - Neuro and Other</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its quarterly qualitative interim assessments of the Neuro and Other reporting unit, management considered the totality of all relevant events or circumstances that could have affected the carrying amount or fair value of the reporting unit, including comparing the reporting unit’s operating results to the forecast used to test the goodwill of the Neuro and Other reporting unit as of October 1, 2019. Based on the qualitative assessments, management believed that the carrying value of Neuro and Other reporting unit did not exceed its fair value and, therefore, concluded a quantitative fair value test was not required for any quarterly period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Interim Goodwill Impairment Assessments and Testing - Ortho Dermatologics</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020, the operating results for the Ortho Dermatologics reporting unit were less than those forecasted at October 1, 2019 for that period. As part of its qualitative assessment as of March 31, 2020, the Company revised its forecasts for the year 2020, for among other matters, the lower than originally forecasted operating results for the three months ended March 31, 2020 and the range of potential impacts of the COVID-19 pandemic, including longer than expected launch cycles for certain new products. Management believed that the revisions to its forecasts for the year 2020 were indicators that there was less headroom as of March 31, 2020 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2019). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed at March 31, 2020. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit continued to be greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit at March 31, 2020.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2020, the Company identified certain Ortho Dermatologics’ products that were experiencing longer launch cycles than originally anticipated due to the COVID-19 pandemic and, as a direct result, took actions to mitigate the impact of these matters, including right-sizing its Ortho Dermatologics’ sales force. As part of its qualitative assessment as of June 30, 2020, the Company revised its long-term forecasts for, among other matters, the decrease in forecasted revenues of the identified products, the reduction in sales force and related costs and a range of potential impacts of COVID-19 pandemic related matters. Management believed that these events were indicators that there was less headroom as of June 30, 2020 as compared to the headroom calculated on the date Ortho Dermatologics goodwill was last tested for impairment (March 31, 2020). Therefore, a quantitative fair value test for impairment to the goodwill of the Ortho Dermatologics reporting unit was performed at June 30, 2020. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit continued to be greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit at June 30, 2020.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believed that based on its qualitative assessments as of September 30, 2020, it was more likely than not that the carrying amount of the Ortho Dermatologics reporting unit was less than its fair value and, therefore, concluded a quantitative fair value test was not required at September 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2020 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2020, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded a quantitative fair value test for those reporting units was not required. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2020, the Company considered, among other matters, a range of potential impacts of COVID-19 pandemic related matters and the limited headroom calculated on the date Ortho Dermatologics goodwill was last tested for impairment (June 30, 2020). The Company believed that these factors may suggest that it is more likely than not that the fair value of the Ortho Dermatologics reporting unit is less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2020, utilizing a long-term growth rate of 2.0% and a range of discount rates between 9.5% and 9.75%, in estimation of the fair value of this reporting unit. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit. If market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future. Specifically, the Company continues to assess the performance of the Ortho Dermatologics reporting unit as compared to its respective projections and will perform qualitative interim assessments of the carrying value and fair value on a quarterly basis to determine if impairment testing of goodwill will be warranted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company expects to realign and begin managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Separation during the first quarter of 2021, and as a result the Company may need to perform an impairment test upon realignment of its operating segments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated goodwill impairment charges through December 31, 2020 were $3,711 million.</span></div> <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets as of December 31, 2020 and 2019 consist of:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.906%"><tr><td style="width:1.0%"/><td style="width:27.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.984%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Useful<br/>Lives<br/>(Years)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,890 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,914)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,055)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,887)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,481 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,741)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,613 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,123)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,490 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D not in service</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B&amp;L Trademark</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,186 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,741)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,445 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,324 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,123)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,201 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets as of December 31, 2020 and 2019 consist of:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.906%"><tr><td style="width:1.0%"/><td style="width:27.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.984%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Useful<br/>Lives<br/>(Years)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,890 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,914)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,011 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,055)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,887)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,481 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,741)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,613 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,123)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,490 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D not in service</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B&amp;L Trademark</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,186 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,741)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,445 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,324 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,123)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,201 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> P6Y 20890000000 14914000000 5976000000 21011000000 13544000000 7467000000 P7Y 907000000 404000000 503000000 930000000 338000000 592000000 P3Y 3305000000 3055000000 250000000 3297000000 2887000000 410000000 P1Y 169000000 168000000 1000000 166000000 165000000 1000000 P3Y 210000000 200000000 10000000 209000000 189000000 20000000 25481000000 18741000000 6740000000 25613000000 17123000000 8490000000 7000000 7000000 13000000 13000000 1698000000 1698000000 1698000000 1698000000 27186000000 18741000000 8445000000 27324000000 17123000000 10201000000 96000000 16000000 1000000 1000000 58000000 8000000 5000000 4000000 263000000 85000000 132000000 55000000 28000000 5000000 476000000 473000000 143000000 -1.34 -1.34 -0.41 3771000000 <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the five years ending December 31 and thereafter are as follows: </span></div><div style="margin-bottom:5pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.906%"><tr><td style="width:1.0%"/><td style="width:16.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,204 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div> 1389000000 1204000000 1030000000 905000000 822000000 1390000000 6740000000 <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the years ended December 31, 2020, 2019 and 2018 were as follows: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:35.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + <br/>Lomb/<br/>International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Branded Rx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, January 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,016 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,631 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,946 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,593 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of the Salix and Ortho Dermatologics reporting units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,213)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,213)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realignment of Global Solta reporting unit goodwill</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale and subsequently disposed</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,913)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,023 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of the Dentistry reporting unit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,805 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,156 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of certain assets of Synergy </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,786 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,126 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets held for sale reclassified to goodwill (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale (Note 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,704 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,044 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6016000000 6631000000 2946000000 15593000000 2213000000 2213000000 -82000000 115000000 -33000000 2000000 2000000 -4533000000 -2913000000 3156000000 1267000000 3023000000 109000000 109000000 -127000000 -127000000 5805000000 0 0 3156000000 1267000000 2914000000 13142000000 3000000 3000000 18000000 18000000 -1000000 -1000000 5786000000 0 0 3159000000 1267000000 2914000000 13126000000 18000000 18000000 217000000 217000000 117000000 117000000 5704000000 0 0 3159000000 1267000000 2914000000 13044000000 1970000000 243000000 115000000 -115000000 109000000 0 0.15 0 2213000000 2224000000 -11000000 -0.01 -0.23 -0.03 0 0 0.020 0.095 0.0975 0.10 0 3711000000 ACCRUED AND OTHER CURRENT LIABILITIES<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities as of December 31, 2020 and 2019 consist of: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,576 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,511 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities as of December 31, 2020 and 2019 consist of: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,576 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,511 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1672000000 1397000000 747000000 898000000 575000000 691000000 341000000 305000000 316000000 304000000 158000000 196000000 767000000 720000000 4576000000 4511000000 FINANCING ARRANGEMENTS<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2020 and 2019 consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:11pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:34.158%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,768 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.50% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.00% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,987 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.75% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.875%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.50% euro-denominated debt</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,682 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.50%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,185 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,925 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,188 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,895 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,925 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,661 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes and Senior Unsecured Notes contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company’s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of December 31, 2020, the amount available for restricted payments under the "builder basket" in the Company’s most restrictive indentures (as defined by those indentures) was approximately $13,000 million (although such availability is subject to the Company's compliance with a 2.00:1.00 fixed charge coverage ratio). The 2023 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that requires the Company to maintain a first lien net leverage ratio of not greater than 4.00:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company’s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 13, 2012, the Company and certain of its subsidiaries as guarantors entered into the “Senior Secured Credit Facilities” under the Company’s Third Amended and Restated Credit and Guaranty Agreement, as amended (the “Third Amended Credit Agreement”) with a syndicate of financial institutions and investors, as lenders. As of January 1, 2018, the Third Amended Credit Agreement provided for: (i) a $1,500 million Revolving Credit Facility maturing on April 20, 2020 (the "2020 Revolving Credit Facility") and (ii) a $3,521 million term loan under the Company's Series F Tranche B Term Loan Facility maturing in 2022 (the “Series F Tranche B Term Loan Facility”). There was $250 million outstanding under the 2020 Revolving Credit Facility as of January 1, 2018.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Activity</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2018, the Company repaid (net of additional borrowings) $571 million of outstanding debt under its Senior Secured Credit Facilities using cash on hand. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company entered into a Restatement Agreement in respect of a Fourth Amended and Restated Credit and Guaranty Agreement (the “Restated Credit Agreement”) which restated in full the Third Amended Credit Agreement. The Restated Credit Agreement replaced the 2020 Revolving Credit Facility with a revolving credit facility of $1,225 million (the "2023 Revolving Credit Facility") and replaced the Series F Tranche B Term Loan Facility principal amount outstanding of $3,315 million with a new <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTVkODQ2NmZmOTQ4OGE5OGMyNjBjMjVjMzM2MzdkL3NlYzplMjE1ZDg0NjZmZjk0ODhhOThjMjYwYzI1YzMzNjM3ZF8zMTMvZnJhZzo4ZDk4NWE5MDdhOWE0YzFlOWM1NDJjMWMwYjNmMTIxMy90ZXh0cmVnaW9uOjhkOTg1YTkwN2E5YTRjMWU5YzU0MmMxYzBiM2YxMjEzXzU4NTc_65ea6a61-c0f1-484b-aa94-c91ba6bbb376">seven</span> year Tranche B Term Loan Facility of $4,565 million (the “June 2025 Term Loan B Facility”) borrowed by the Company’s subsidiary, Bausch Health Americas, Inc. ("BHA").</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Revolving Credit Facility matures on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company or BHA in an aggregate principal amount in excess of $1,000 million. Both the Company and BHA are borrowers with respect to the 2023 Revolving Credit Facility. Borrowings under the 2023 Revolving Credit Facility may be made in U.S. dollars, Canadian dollars or euros. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company issued an irrevocable notice of redemption for the remaining outstanding principal amounts of: (i) $691 million of the March 2020 Unsecured Notes (as defined below), (ii) $578 million of 6.75% Senior Unsecured Notes due August 2021 (the “August 2021 Unsecured Notes”), (iii) $550 million of 7.25% Senior Unsecured Notes due July 2022 (the “July 2022 Unsecured Notes”) and (iv) $146 million of 6.375% Senior Unsecured Notes due October 2020 (the March 2020 Unsecured Notes (as defined below), together with the August 2021 Unsecured Notes, the July 2022 Unsecured Notes and the 6.375% Senior Unsecured Notes due October 2020 the “June 2018 Unsecured Refinanced Debt”). On June 1, 2018, using the remaining net proceeds from the June 2025 Term Loan B Facility, the net proceeds from the issuance of $750 million in aggregate principal amount of 8.50% Senior Unsecured Notes due 2027 (the "January 2027 Unsecured Notes") by BHA and cash on hand, the Company prepaid the remaining Series F Tranche B Term Loan Facility and redeemed the June 2018 Unsecured Refinanced Debt at its aggregate redemption price and the indentures governing the June 2018 Unsecured Refinanced Debt were discharged (collectively, the “June 2018 Refinancing Transactions”).</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Credit Agreement was accounted for as a modification of debt, to the extent the June 2018 Unsecured Refinanced Debt was replaced with newly issued debt to the same creditor, and as an extinguishment of debt if: (i) the June 2018 Unsecured Refinanced Debt was replaced with newly issued debt to a different creditor, (ii) a portion of the unamortized deferred financing fees was allocated to debt that was paid down or (iii) the borrowing capacity declined when issuing a new revolving credit facility. The following was accounted for as an extinguishment of debt: (i) the difference between the amounts paid to redeem the June 2018 Unsecured Refinanced Debt and the June 2018 Unsecured Refinanced Debt’s carrying value, (ii) the replacement of the Series F Tranche B Term Loan Facility with the June 2025 Term Loan B Facility to the extent any unamortized deferred financing fees were associated with the portion of the Series F Tranche B Term Loan Facility that was paid down and (iii) the replacement of the 2020 Revolving Credit Facility with the 2023 Revolving Credit Facility to the extent any unamortized deferred financing fees were associated with the decline in borrowing capacity. For amounts accounted for as an extinguishment of debt, the Company incurred a loss on extinguishment of debt of $48 million. Payments made to the lenders and a portion of payments made to third parties of $74 million associated with the June 2018 Refinancing Transactions were capitalized and are being amortized as interest </span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense over the remaining terms of the debt, ranging from 2023 through 2027. Third-party expenses of $4 million associated with the modification of debt were expensed as incurred and included in Interest expense.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2018, the Company entered into the First Incremental Amendment to the Restated Credit Agreement, which provided an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTVkODQ2NmZmOTQ4OGE5OGMyNjBjMjVjMzM2MzdkL3NlYzplMjE1ZDg0NjZmZjk0ODhhOThjMjYwYzI1YzMzNjM3ZF8zMTMvZnJhZzo4ZDk4NWE5MDdhOWE0YzFlOWM1NDJjMWMwYjNmMTIxMy90ZXh0cmVnaW9uOjhkOTg1YTkwN2E5YTRjMWU5YzU0MmMxYzBiM2YxMjEzXzk0Nzk_ee401720-a7da-4d81-8e91-90a05728d7ab">seven</span> year Tranche B Term Loan Facility of $1,500 million (the "November 2025 Term Loan B Facility") and used the net proceeds, and cash on hand, to repay $1,483 million of 7.50% Senior Unsecured Notes due July 2021 (the “July 2021 Unsecured Notes”) in a tender offer (the "November 2018 Refinancing Transactions"). On December 27, 2018, the Company redeemed, using cash on hand, the remaining outstanding principal amount of $17 million of the July 2021 Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The repayment of the July 2021 Unsecured Notes was accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $43 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt’s carrying value. Payments made to the lenders and other third parties of $25 million associated with the issuance of the November 2025 Term Loan B Facility were capitalized and are being amortized as interest expense over the remaining term of the November 2025 Term Loan B Facility. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Activity</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company repaid (net of additional borrowings) $806 million of outstanding debt under its Senior Secured Credit Facilities using cash on hand.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Activity</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company repaid: (i) $471 million of outstanding debt under its Senior Secured Credit Facilities using cash on hand and (ii) $250 million of outstanding debt under its Senior Secured Credit Facilities as part of the May 2020 Refinancing Transactions (as defined below). </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company had no outstanding borrowings, $104 million of issued and outstanding letters of credit, and remaining availability of $1,121 million under its 2023 Revolving Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Current Description of Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% or (c) the eurocurrency rate (as defined in the Restated Credit Agreement) for a period of one month plus 1.00% (or if such eurocurrency rate shall not be ascertainable, 1.00%) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in euros bear interest at a eurocurrency rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the “Canadian Prime Rate” or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus 1.00% (provided however, that the prime rate shall at no time be less than 0.00%) or (ii) the bankers’ acceptance rate for Canadian dollar deposits in the Toronto interbank market (the “BA rate”) for the interest period relevant to such borrowing (provided however, that the BA rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the Restated Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are 2.00% and 1.75%, respectively, with respect to base rate and prime rate borrowings and 3.00% and 2.75%, respectively, with respect to eurocurrency rate and BA rate borrowings. As of December 31, 2020, the stated rates of interest on the Company’s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were 3.15% and 2.90% per annum, respectively.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is 5.00% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of December 31, 2020, the aggregate remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities are $405 million through November 1, 2025. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are 1.50%-2.00% with respect to base rate or prime rate borrowings and 2.50%-3.00% with respect to eurocurrency rate or BA rate borrowings.  As of December 31, 2020, the stated rate of interest on the 2023 Revolving Credit Facility was 3.15% per annum. In addition, the Company is required to pay commitment fees of 0.25% - 0.50% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Credit Agreement permits the incurrence of incremental credit facility borrowings, up to the greater of $1,000 million and 28.5% of Consolidated Adjusted EBITDA (as defined in the Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company’s subsidiaries that is a guarantor under the Restated Credit Agreement and existing Senior Unsecured Notes (together, the “Note Guarantors”). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company’s obligations under the Restated Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company’s and Note Guarantors’ respective existing and future unsubordinated indebtedness and senior to the Company’s and Note Guarantors’ respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company’s and the Note Guarantors’ respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company’s and the Note Guarantors’ respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company’s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company’s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder’s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">6.50% Senior Secured Notes due 2022 and 7.00% Senior Secured Notes due 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company issued $1,250 million aggregate principal amount of 6.50% senior secured notes due March 15, 2022 (the “March 2022 Secured Notes”) and $2,000 million aggregate principal amount of 7.00% senior secured notes due March 15, 2024 (the “March 2024 Secured Notes”), in a private placement. Interest on these notes is payable semi-annually in arrears on each March 15 and September 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2022 Secured Notes were repaid in full as part of the May 2020 Refinancing Transactions (as defined below).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2024 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time, at the redemption prices set forth in the indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.50% Senior Secured Notes due 2025</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 17, 2017, the Company issued $1,000 million, and, on November 21, 2017, the Company issued $750 million, aggregate principal amount of 5.50% Senior Secured Notes due November 2025 (the “November 2025 Secured Notes”), in a private placement. Interest on the November 2025 Secured Notes is payable semi-annually in arrears on each May 1 and November 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The November 2025 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time, at the redemption prices set forth in the indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.75% Senior Secured Notes due 2027 - March 2019 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2019, BHA and the Company issued: (i) $1,000 million aggregate principal amount of January 2027 Unsecured Notes and (ii) $500 million aggregate principal amount of 5.75% Senior Secured Notes due August 2027 (the "August 2027 Secured Notes"), respectively, in a private placement. A portion of the proceeds and cash on hand were used to: (i) repurchase $584 million of 5.875% Senior Unsecured Notes due 2023 (the "May 2023 Unsecured Notes"), (ii) repurchase $518 million of 5.625% Senior Unsecured Notes due 2021 (the “December 2021 Unsecured Notes”), (iii) repurchase $216 million of 5.50% Senior Unsecured Notes due 2023 (the "March 2023 Unsecured Notes”) and (iv) pay all fees and expenses associated with these transactions (collectively, the “March 2019 Refinancing Transactions”). During April 2019, the Company redeemed $182 million of the December 2021 Unsecured Notes, representing the remaining outstanding principal balance of the December 2021 Unsecured Notes and completing the refinancing of $1,500 million of debt in connection with the March 2019 Refinancing Transactions. The March 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $8 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt’s carrying value. Interest on the August 2027 Secured Notes is payable semi-annually in arrears on each February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after August 15, 2022, at the redemption prices set forth in the indenture. The Company may redeem some or all of the August 2027 Secured Notes prior to August 15, 2022 at a price equal to 100% of the principal amount thereof plus a “make-whole” premium. Prior to August 15, 2022, the Company may redeem up to 40% of the aggregate principal amount of the August 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company’s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.625% Senior Unsecured Notes due 2021</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 2, 2013, the Company issued $900 million aggregate principal amount of December 2021 Unsecured Notes in a private placement. The December 2021 Unsecured Notes accrued interest at the rate of 5.625% per year and were subsequently repaid in full: (i) using cash on hand of $200 million in December 2018 and (ii) as part of the March 2019 Refinancing Transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.50% Senior Unsecured Notes due 2023</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2015, the Company issued $1,000 million aggregate principal amount of March 2023 Unsecured Notes in a private placement. The March 2023 Unsecured Notes accrued interest at the rate of 5.50% per year, payable semi-annually in arrears. On March 8, 2019 and May 23, 2019, the Company repurchased $216 million and $382 million of March 2023 Unsecured Notes as part of the March 2019 Refinancing Transactions and the May 2019 Refinancing Transactions (as defined below), respectively. Throughout 2020, the Company repurchased, in aggregate, $169 million of March 2023 Unsecured Notes using cash on hand. The Company repurchased the remaining outstanding balance of $233 million in December 2020 as part of the December 2020 Refinancing Transactions (as defined below).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.375% Senior Unsecured Notes due 2020, 5.875% Senior Unsecured Notes due 2023, 4.50% Senior Unsecured Notes due 2023 and 6.125% Senior Unsecured Notes due 2025</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2015, VRX Escrow Corp. (the "VRX Issuer"), a newly formed wholly owned subsidiary of the Company, issued $2,000 million aggregate principal amount of 5.375% Senior Unsecured Notes due 2020 (the "March 2020 Unsecured Notes"), $3,250 million aggregate principal amount of 5.875% Senior Unsecured Notes due 2023 (the "May 2023 Unsecured Notes"), €1,500 million aggregate principal amount of 4.50% Senior Unsecured Notes due 2023 (the "Euro Notes”) and $3,250 million aggregate principal amount of 6.125% Senior Unsecured Notes due 2025 (the "April 2025 Unsecured Notes" and, together with the March 2020 Unsecured Notes, the May 2023 Unsecured Notes and the Euro Notes, the "VRX Notes") in a private placement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2020 Unsecured Notes accrued interest at the rate of 5.375% per year and were repaid in full as part of: (i) the December 2017 Refinancing Transactions (as defined below), (ii) the March 2018 Refinancing Transactions (as defined below) and (iii) the June 2018 Refinancing Transactions. The May 2023 Unsecured Notes and the Euro Notes accrued interest at the rate of 5.875% and 4.50% per year, respectively and were each repaid in full as of December 31, 2020, as discussed below. The April 2025 Unsecured Notes accrue interest at the rate of 6.125% per year, payable semi-annually in arrears. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the June 2018 Refinancing Transactions, the Company repaid the remaining outstanding principal amounts of the March 2020 Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2019 and May 23, 2019, the Company repurchased $584 million and $1,118 million of May 2023 Unsecured Notes as part of the March 2019 Refinancing Transactions and the May 2019 Refinancing Transactions (as defined below), respectively, and on October 3, 2019, the Company repaid an additional $100 million of May 2023 Unsecured Notes using cash on hand. On January 16, 2020, the Company redeemed $1,240 million aggregate principal amount of the May 2023 Unsecured Notes as part of the December 2019 Financing and Refinancing Transactions (as defined below). Throughout 2020, the Company repaid, in aggregate, $208 million of the May 2023 Unsecured Notes, with the May 2023 Unsecured Notes having been fully repaid during November 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the April 2025 Unsecured Notes at the redemption prices set forth in the applicable indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2020, the Company redeemed the remaining outstanding balance of the Euro Notes as part of the December 2020 Refinancing Transactions, as defined below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">9.00% Senior Unsecured Notes due 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2017, the Company issued $1,500 million aggregate principal amount of 9.00% Senior Unsecured Notes due 2025 (the “December 2025 Unsecured Notes”) in a private placement, the net proceeds of which were used to repurchase $1,500 million in aggregate principal amount of previously outstanding senior unsecured notes (the "December 2017 Refinancing Transactions"). The related fees and expenses were paid using cash on hand. The December 2025 Unsecured Notes accrue interest at the rate of 9.00% per year, payable semi-annually in arrears on each of June 15 and December 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the December 2025 Unsecured Notes at any time prior to December 15, 2021, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a “make-whole” premium. In addition, at any time prior to December 15, 2020, the Company may redeem up to 40% of the aggregate principal amount of the outstanding December 2025 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the December 2025 Unsecured Notes indenture. On or after December 15, 2021, the Company may redeem all or a portion of the December 2025 Unsecured Notes at the applicable redemption prices set forth in the December 2025 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">9.25% Senior Unsecured Notes due 2026 - March 2018 Refinancing Transactions</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 26, 2018, BHA issued $1,500 million in aggregate principal amount of 9.25% Senior Unsecured Notes due 2026 (the “April 2026 Unsecured Notes”) in a private placement, the net proceeds of which, and cash on hand, were used to repurchase $1,500 million in aggregate principal amount of unsecured notes. All fees and expenses associated with these transactions were paid with cash on hand (collectively, the “March 2018 Refinancing Transactions”). The March 2018 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $26 million representing the difference between the amount paid to settle the extinguished debt </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the extinguished debt’s carrying value. The April 2026 Unsecured Notes accrue interest at the rate of 9.25% per year, payable semi-annually in arrears on each of April 1 and October 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BHA may redeem all or a portion of the April 2026 Unsecured Notes at any time prior to April 1, 2022, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a “make-whole” premium. In addition, at any time prior to April 1, 2021, BHA may redeem up to 40% of the aggregate principal amount of the outstanding April 2026 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the April 2026 Unsecured Notes indenture. On or after April 1, 2022, BHA may redeem all or a portion of the April 2026 Unsecured Notes at the applicable redemption prices set forth in the April 2026 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">8.50% Senior Unsecured Notes due 2027 - June 2018 Refinancing Transactions and March 2019 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the June 2018 Refinancing Transactions, BHA issued $750 million in aggregate principal amount of January 2027 Unsecured Notes in a private placement, the net proceeds of which, when combined with the remaining net proceeds from the June 2025 Term Loan B Facility and cash on hand, were used to redeem the June 2018 Unsecured Refinanced Debt at its aggregate redemption price and the indentures governing the June 2018 Unsecured Refinanced Debt were discharged. The January 2027 Unsecured Notes accrue interest at the rate of 8.50% per year, payable semi-annually in arrears on each of January 31 and July 31. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the March 2019 Refinancing Transactions described above, BHA issued $1,000 million aggregate principal amount of 8.50% Senior Unsecured Notes due January 2027. These are additional notes and form part of the same series as BHA’s existing January 2027 Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BHA may redeem all or a portion of the January 2027 Unsecured Notes at any time prior to July 31, 2022, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a “make-whole” premium. In addition, at any time prior to July 31, 2021, BHA may redeem up to 40% of the aggregate principal amount of the outstanding January 2027 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the January 2027 Unsecured Notes indenture. On or after July 31, 2022, BHA may redeem all or a portion of the January 2027 Unsecured Notes at the applicable redemption prices set forth in the January 2027 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">7.00% Senior Unsecured Notes due 2028 and 7.25% Senior Unsecured Notes due 2029 - May 2019 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 23, 2019, the Company issued: (i) $750 million aggregate principal amount of 7.00% Senior Unsecured Notes due January 2028 (the "7.00% January 2028 Unsecured Notes") and (ii) $750 million aggregate principal amount of 7.25% Senior Unsecured Notes due May 2029 (the "May 2029 Unsecured Notes"), respectively, in a private placement. The proceeds and cash on hand were used to: (i) repurchase $1,118 million of May 2023 Unsecured Notes, (ii) repurchase $382 million of March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the “May 2019 Refinancing Transactions”). The May 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $32 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt’s carrying value. Interest on the 7.00% January 2028 Unsecured Notes is payable semi-annually in arrears on each January 15 and July 15. Interest on the May 2029 Unsecured Notes is payable semi-annually in arrears on each May 30 and November 30. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 7.00% January 2028 Unsecured Notes and the May 2029 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 15, 2023 and May 30, 2024, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the 7.00% January 2028 Unsecured Notes or the May 2029 Unsecured Notes prior to January 15, 2023 and May 30, 2024, respectively, at a price equal to 100% of the principal amount thereof plus a “make-whole” premium. Prior to July 15, 2022, and May 30, 2022, the Company may redeem up to 40% of the aggregate principal amount of the 7.00% January 2028 Unsecured Notes or the May 2029 Unsecured Notes, respectively, using the proceeds of certain equity offerings at the redemption price set forth in the respective indenture. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.00% Senior Unsecured Notes due 2028 and 5.25% Senior Unsecured Notes due 2030 - December 2019 Financing and Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company issued: (i) $1,250 million aggregate principal amount of 5.00% Senior Unsecured Notes due January 2028 (the "5.00% January 2028 Unsecured Notes") and (ii) $1,250 million aggregate principal amount of 5.25% Senior Unsecured Notes due January 2030 (the "January 2030 Unsecured Notes") in a private placement. The proceeds and cash on hand were used to: (i) redeem $1,240 million of May 2023 Unsecured Notes on January 16, 2020, (ii) </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">finance the $1,210 million settlement of certain U.S. Securities litigation as discussed in Note 20, "LEGAL PROCEEDINGS" and (iii) pay all fees and expenses associated with these transactions (collectively, the "December 2019 Financing and Refinancing Transactions"). The redemption of $1,240 million of May 2023 Unsecured notes was accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $24 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on the 5.00% January 2028 Unsecured Notes is payable semi-annually in arrears on each January 30 and July 30. Interest on the January 2030 Unsecured Notes is payable semi-annually in arrears on each January 30 and July 30. The 5.00% January 2028 Unsecured Notes and the January 2030 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 30, 2023 and January 30, 2025, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the 5.00% January 2028 Unsecured Notes or the January 2030 Unsecured Notes prior to January 30, 2023 and January 30, 2025, respectively, at a price equal to 100% of the principal amount thereof plus a “make-whole” premium. Prior to January 30, 2023, the Company may redeem up to 40% of the aggregate principal amount of the 5.00% January 2028 Unsecured Notes or the January 2030 Unsecured Notes using the proceeds of certain equity offerings at the redemption price set forth in the respective indenture. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">6.25% Senior Unsecured Notes due 2029 - May 2020 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2020, the Company issued $1,500 million aggregate principal amount of 6.25% Senior Unsecured Notes due February 2029 (the "6.25% February 2029 Unsecured Notes") in a private placement. The proceeds and cash on hand were used to: (i) repurchase $1,250 million aggregate principal amount of the outstanding March 2022 Secured Notes, (ii) prepay $303 million of mandatory amortization scheduled for payment in 2022 under the Company's June 2025 and November 2025 Term Loan B Facilities and (iii) pay all fees and expenses associated with these transactions (collectively, the "May 2020 Refinancing Transactions"). The May 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $27 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The 6.25% February 2029 Unsecured Notes accrue interest at the rate of 6.25% per year, payable semi-annually in arrears on each of February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the 6.25% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a “make-whole” premium. In addition, at any time prior to August 15, 2023, the Company may redeem up to 40% of the aggregate principal amount of the outstanding 6.25% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the 6.25% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the 6.25% February 2029 Unsecured Notes at the applicable redemption prices set forth in the 6.25% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.00% Senior Unsecured Notes due 2029 and 5.25% Senior Unsecured Notes due 2031 – December 2020 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2020, the Company issued $1,000 million aggregate principal amount of 5.00% Senior Unsecured Notes due February 2029 (the "5.00% February 2029 Unsecured Notes") and $1,000 million aggregate principal amount of 5.25% Senior Unsecured Notes due February 2031 (the "February 2031 Unsecured Notes") in a private placement. The aggregate proceeds and cash on hand were used to repurchase the remaining outstanding principal amounts of: (i) €1,500 million of the Euro Notes, (ii) $233 million of the March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the "December 2020 Refinancing Transactions"). The December 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $7 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The 5.00% February 2029 Unsecured Notes accrue interest at the rate of 5.00% per year, payable semi-annually in arrears on each of February 15 and August 15. The February 2031 Unsecured Notes accrue interest at the rate of 5.25% per year, payable semi-annually in arrears on each of February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the 5.00% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a “make-whole” premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to 40% of the aggregate principal amount of the outstanding 5.00% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the 5.00% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the 5.00% February 2029 Unsecured </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes at the applicable redemption prices set forth in the 5.00% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the February 2031 Unsecured Notes at any time prior to February 15, 2026, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a “make-whole” premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to 40% of the aggregate principal amount of the outstanding February 2031 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the February 2031 Unsecured Notes indenture. On or after February 15, 2026, the Company may redeem all or a portion of the February 2031 Unsecured Notes at the applicable redemption prices set forth in the February 2031 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Stated Rate of Interest</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest for the Company's outstanding debt obligations as of December 31, 2020 and 2019 was 6.02% and 6.21%, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities and Mandatory Payments</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities and mandatory payments of debt obligations for the five succeeding years ending December 31 and thereafter are as follows:</span></div><div style="margin-bottom:13pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:88.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,632 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross maturities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,185 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,925 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Restated Credit Agreement, there is no Excess Cash Flow payment due for 2020.</span></div> <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2020 and 2019 consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:11pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:34.158%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,768 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.50% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.00% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,987 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.75% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.875%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.50% euro-denominated debt</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,682 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.50%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,185 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,925 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,188 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,895 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,925 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,661 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 0 0 3298000000 3220000000 3869000000 3768000000 1125000000 1112000000 1275000000 1257000000 0.0650 0 0 1250000000 1242000000 0.0700 2000000000 1987000000 2000000000 1983000000 0.0550 1750000000 1736000000 1750000000 1733000000 0.0575 500000000 494000000 500000000 493000000 0.0550 0 0 402000000 400000000 0.05875 0 0 1448000000 1441000000 0.0450 0 0 1682000000 1674000000 0.06125 3250000000 3234000000 3250000000 3230000000 0.0900 1500000000 1478000000 1500000000 1473000000 0.0925 1500000000 1487000000 1500000000 1484000000 0.0850 1750000000 1755000000 1750000000 1756000000 0.0700 750000000 742000000 750000000 741000000 0.0500 1250000000 1236000000 1250000000 1234000000 0.0625 1500000000 1480000000 0 0 0.0500 1000000000 988000000 0 0 0.0725 750000000 741000000 750000000 740000000 0.0525 1250000000 1235000000 1250000000 1234000000 0.0525 1000000000 988000000 0 0 12000000 12000000 12000000 12000000 24185000000 23925000000 26188000000 25895000000 0 1234000000 23925000000 24661000000 13000000000 2.00 4.00 1500000000 3521000000 250000000 571000000 1225000000 3315000000 4565000000 P91D 1000000000 691000000 578000000 0.0675 550000000 0.0725 146000000 0.06375 0.06375 750000000 0.0850 -48000000 74000000 4000000 1500000000 1483000000 0.0750 17000000 -43000000 25000000 806000000 471000000 250000000 0 104000000 1121000000 0.0100 0.0100 0.0000 0.0000 0.0100 0.0000 0.0000 1 1 0.50 1 0.0200 0.0175 0.0300 0.0275 0.0315 0.0290 0.0500 0.0500 405000000 0.0150 0.0200 0.0250 0.0300 0.0315 0.0025 0.0050 1000000000 0.285 3.50 6.50 2.00 1.01 0.0650 0.0700 1250000000 0.0650 2000000000 0.0700 0.0550 1000000000 750000000 0.0550 0.0575 1000000000 500000000 0.0575 584000000 0.05875 518000000 0.05625 216000000 0.0550 182000000 1500000000 -8000000 1 0.40 1.01 0.05625 900000000 0.05625 200000000 0.0550 1000000000 0.0550 216000000 382000000 169000000 233000000 0.05375 0.05875 0.0450 0.06125 2000000000 0.05375 3250000000 0.05875 1500000000 0.0450 3250000000 0.06125 0.05375 0.05875 0.0450 0.06125 584000000 1118000000 100000000 1240000000 208000000 0.0900 1500000000 0.0900 1500000000 0.0900 1 0.40 0.0925 1500000000 0.0925 1500000000 -26000000 0.0925 1 0.40 0.0850 750000000 0.0850 1000000000 0.0850 1 0.40 0.0700 0.0725 750000000 0.0700 0.0700 750000000 0.0725 1118000000 382000000 -32000000 0.0700 0.0700 0.0700 1 1 0.40 0.40 0.0700 0.0500 0.0525 1250000000 0.0500 0.0500 1250000000 0.0525 1240000000 1210000000 1240000000 -24000000 0.0500 0.0500 0.0500 1 1 0.40 0.40 0.0500 0.0625 1500000000 0.0625 0.0625 1250000000 303000000 -27000000 0.0625 0.0625 0.0625 1 0.40 0.0625 0.0625 0.0625 0.0625 0.0500 0.0525 1000000000 0.0500 0.0500 1000000000 0.0525 1500000000 233000000 -7000000 0.0500 0.0500 0.0525 0.0500 1 0.40 0.0500 0.0500 0.0500 0.0500 1 0.40 0.0602 0.0621 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities and Mandatory Payments</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities and mandatory payments of debt obligations for the five succeeding years ending December 31 and thereafter are as follows:</span></div><div style="margin-bottom:13pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:88.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,632 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross maturities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,185 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,925 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 0 2291000000 10632000000 11262000000 24185000000 260000000 23925000000 PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers a closed grandfathered group of legacy Bausch &amp; Lomb Holdings Incorporated (‘‘B&amp;L’’) U.S. employees and employees in certain other countries. The U.S. defined benefit accruals were frozen as of December 31, 2004 and benefits that were earned up to December 31, 2004 were preserved. Participants continue to earn interest credits on their cash balance at an interest crediting rate that is equal to the greater of: (i) the average annual yield on 10-year treasury bonds in effect for the November preceding the plan year or (ii) 4.50%. The most significant non-U.S. plans are two defined benefit plans in Ireland. In 2011, both Ireland defined benefit plans were closed to future service benefit accruals; however, additional accruals related to annual salary increases continued. In December 2014, one of the Ireland defined benefit plans was amended effective August 2014 to eliminate future benefit accruals related to salary increases. All of the pension benefits accrued through the plan amendment date were preserved. As a result of the plan amendment, there are no active plan participants accruing benefits under the amended Ireland defined benefit plan. The U.S. postretirement benefit plan was amended effective January 1, 2005 to eliminate employer contributions after age 65 for participants who did not meet the minimum requirements of age and service on that date. The employer contributions for medical and prescription drug benefits for participants retiring after March 1, 1989 were frozen effective January 1, 2010. Effective January 1, 2014, the Company no longer offers medical and life insurance coverage to new retirees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the B&amp;L benefit plans, outside of the U.S., a limited group of the Company's employees are covered by defined benefit pension plans. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses December 31 as the year-end measurement date for all of its defined benefit pension plans and the postretirement benefit plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Pension Benefit Plans and Postretirement Benefit Plan </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes in its Consolidated Balance Sheets an asset or liability equal to the over- or under-funded benefit obligation of each defined benefit pension plan and postretirement benefit plan. Actuarial gains or losses and prior service costs or credits that arise during the period but are not recognized as components of net periodic benefit cost are recognized, net of tax, as a component of Other comprehensive income (loss). </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts included in Accumulated other comprehensive loss as of December 31, 2020 and 2019 were as follows: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:38.413%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.963%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized actuarial losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized prior service credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Periodic (Benefit) Cost</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of net periodic (benefit) cost for the Company’s defined benefit pension plans and postretirement benefit plan in 2020, 2019 and 2018:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.637%"><tr><td style="width:1.0%"/><td style="width:25.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.504%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Benefit Obligation, Change in Plan Assets and Funded Status </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2020 and 2019: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.491%"><tr><td style="width:1.0%"/><td style="width:40.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.025%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Projected Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded status, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of the Company’s pension benefit plans were underfunded as of December 31, 2020 and 2019, having accumulated benefit obligations exceeding the fair value of plan assets. Information for the underfunded pension benefit plans is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:56.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.971%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s policy for funding its pension benefit plans is to make contributions that meet or exceed the minimum statutory funding requirements. These contributions are determined based upon recommendations made by the actuary under accepted actuarial principles. In 2021, the Company expects to contribute $0, $10 million and $4 million to the U.S. pension benefit plan, the non-U.S. pension benefit plans and the U.S. postretirement benefit plan, respectively. The Company plans to use postretirement benefit plan assets and cash on hand, as necessary, to fund the U.S. postretirement benefit plan benefit payments in 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Benefit Payments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future benefit payments over the next 10 years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:54.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.430%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Postretirement<br/> Benefit<br/> Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026-2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assumptions</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2020, 2019 and 2018 were as follows: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:43.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.427%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Net Periodic (Benefit) Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.04 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:55.197%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.073%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.09 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.04 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return on plan assets was developed based on a capital markets model that uses expected asset class returns, variance and correlation assumptions. The expected asset class returns were developed starting with current Treasury (for the U.S. pension plan) or Eurozone (for the Ireland pension plans) government yields and then adding corporate bond spreads and equity risk premiums to develop the return expectations for each asset class. The expected asset class returns are forward-looking. The variance and correlation assumptions are also forward-looking. They take into account historical relationships, but are adjusted to reflect expected capital market trends. The expected return on plan assets for the Company’s U.S. pension plan for 2020 was 6.25%. The expected return on plan assets for the Company’s Ireland pension plans was 3.00% for 2020.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate used to determine benefit obligations represents the current rate at which the benefit plan liabilities could be effectively settled considering the timing of expected payments for plan participants.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 expected rate of return for the U.S. pension benefit plan will be 5.00%. The 2021 expected rate of return for the Ireland pension benefit plans will be 2.75%. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pension Benefit Plans Assets </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension benefit plan assets are invested in several asset categories. The following presents the actual asset allocation as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:77.048%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investment strategy underlying pension plan asset allocation is to manage the assets of the plan to provide for the non-current liabilities while maintaining sufficient liquidity to pay current benefits. Pension plan assets are diversified to protect against large investment losses and to reduce the probability of excessive performance volatility. Diversification of assets is achieved by allocating funds to various asset classes and investment styles within asset classes, and retaining investment management firm(s) with complementary investment philosophies, styles and approaches.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s pension plan assets are managed by outside investment managers using a total return investment approach, whereby a mix of equity and debt securities investments are used to maximize the long-term rate of return on plan assets. A significant portion of the assets of the U.S. and Ireland pension plans have been invested in equity securities, as equity portfolios have historically provided higher returns than debt and other asset classes over extended time horizons. Correspondingly, equity investments also entail greater risks than other investments. Equity risks are balanced by investing a significant portion of plan assets in broadly diversified fixed income securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Plan Assets </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measured the fair value of plan assets based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. See Note 5, "FAIR VALUE MEASUREMENTS" for details on the Company's fair value measurements based on a three-tier hierarchy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents total plan assets by investment category as of December 31, 2020 and 2019 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2020 and 2019.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.929%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.062%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. broad market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:31.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.360%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global high yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government bond funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consisted primarily of term deposits and money market instruments. The fair value of the term deposits approximates their carrying amounts due to their short term maturities. The money market instruments also have short maturities and are valued using a market approach based on the quoted market prices of identical instruments. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commingled funds are not publicly traded. The underlying assets in these funds are publicly traded on the exchanges and have readily available price quotes. The Ireland pension plans held approximately 96% and 95% of the non-U.S. commingled funds in 2020 and 2019, respectively. The commingled funds held by the U.S. and Ireland pension plans are primarily invested in index funds.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underlying assets in the fixed income funds are generally valued using the net asset value per fund share, which is derived using a market approach with inputs that include broker quotes, benchmark yields, base spreads and reported trades. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Contribution Plans </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined contribution plans in the U.S., Ireland and certain other countries. Under these plans, employees are allowed to contribute a portion of their salaries to the plans, and the Company matches a portion of the employee contributions. The Company contributed $43 million, $41 million and $36 million to these plans during the years ended December 31, 2020, 2019 and 2018, respectively.</span></div> 0.0450 2 1 P65Y <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts included in Accumulated other comprehensive loss as of December 31, 2020 and 2019 were as follows: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:38.413%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.963%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized actuarial losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized prior service credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -21000000 -20000000 -76000000 -65000000 -3000000 -2000000 0 0 -27000000 -26000000 -11000000 -14000000 <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of net periodic (benefit) cost for the Company’s defined benefit pension plans and postretirement benefit plan in 2020, 2019 and 2018:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.637%"><tr><td style="width:1.0%"/><td style="width:25.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.504%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1000000 2000000 2000000 3000000 3000000 3000000 0 0 0 6000000 8000000 7000000 4000000 5000000 5000000 1000000 1000000 1000000 13000000 13000000 15000000 5000000 5000000 5000000 0 0 0 0 0 0 -2000000 -1000000 -1000000 0 0 0 0 0 0 -1000000 -1000000 -1000000 -3000000 -2000000 -2000000 0 0 0 0 1000000 0 0 0 0 -6000000 -3000000 -6000000 3000000 4000000 3000000 -2000000 -1000000 -1000000 <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2020 and 2019: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.491%"><tr><td style="width:1.0%"/><td style="width:40.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.025%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Projected Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded status, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 227000000 214000000 259000000 235000000 41000000 41000000 1000000 2000000 3000000 3000000 0 0 6000000 8000000 4000000 5000000 1000000 1000000 0 0 0 0 0 1000000 0 0 3000000 2000000 0 0 15000000 15000000 4000000 8000000 4000000 4000000 -17000000 -18000000 -13000000 -30000000 -1000000 -2000000 0 0 22000000 -4000000 0 0 236000000 236000000 227000000 294000000 294000000 259000000 39000000 41000000 216000000 187000000 161000000 147000000 0 0 29000000 42000000 11000000 17000000 0 0 0 0 0 0 0 1000000 1000000 2000000 8000000 10000000 4000000 3000000 0 0 2000000 2000000 0 0 15000000 15000000 4000000 8000000 4000000 4000000 0 0 15000000 -3000000 0 0 231000000 231000000 216000000 189000000 189000000 161000000 0 0 -5000000 -11000000 -105000000 -98000000 -39000000 -41000000 0 0 2000000 2000000 4000000 5000000 5000000 11000000 103000000 96000000 35000000 36000000 Information for the underfunded pension benefit plans is as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:56.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.971%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 236000000 236000000 227000000 294000000 294000000 259000000 236000000 227000000 286000000 251000000 231000000 231000000 216000000 189000000 189000000 161000000 0 10000000 4000000 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future benefit payments over the next 10 years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:54.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.430%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Postretirement<br/> Benefit<br/> Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026-2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P10Y 14000000 6000000 4000000 19000000 6000000 4000000 17000000 7000000 4000000 17000000 7000000 3000000 17000000 7000000 3000000 75000000 42000000 12000000 <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2020, 2019 and 2018 were as follows: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:43.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.427%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Net Periodic (Benefit) Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.04 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:55.197%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.073%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.09 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.04 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div> 0.0316 0.0425 0.0356 0.0304 0.0416 0.0347 0.0625 0.0725 0.0750 0 0 0 0 0 0 0 0 0 0.0500 0.0500 0.0500 0.0168 0.0239 0.0229 0.0298 0.0346 0.0366 0.0305 0.0289 0.0287 0 0 0 0.0225 0.0316 0.0209 0.0304 0 0 0 0 0.0475 0.0500 0.0137 0.0168 0.0260 0.0305 0 0 0.0625 0.0300 0.0500 0.0275 The following presents the actual asset allocation as of December 31, 2020 and 2019:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:77.048%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table> 0.01 0.01 0.39 0.55 0.60 0.44 0.03 0.06 0.28 0.25 0.58 0.64 0.11 0.06 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents total plan assets by investment category as of December 31, 2020 and 2019 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2020 and 2019.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.929%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.062%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. broad market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:31.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.360%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global high yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government bond funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 2000000 0 0 2000000 1000000 0 0 1000000 0 48000000 0 48000000 0 64000000 0 64000000 0 9000000 0 9000000 0 15000000 0 15000000 0 20000000 0 20000000 0 26000000 0 26000000 0 14000000 0 14000000 0 15000000 0 15000000 0 138000000 0 138000000 0 95000000 0 95000000 2000000 229000000 0 231000000 1000000 215000000 0 216000000 0 5000000 0 5000000 0 9000000 0 9000000 0 1000000 0 1000000 0 2000000 0 2000000 0 51000000 0 51000000 0 38000000 0 38000000 0 6000000 0 6000000 0 9000000 0 9000000 0 1000000 0 1000000 0 3000000 0 3000000 1000000 102000000 0 103000000 1000000 90000000 0 91000000 0 20000000 2000000 22000000 0 8000000 1000000 9000000 1000000 186000000 2000000 189000000 1000000 159000000 1000000 161000000 0.96 0.95 43000000 41000000 36000000 LEASES<div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities associated with the Company's operating leases are included in the Consolidated Balance Sheet as of December 31, 2020 and 2019 as follows:</span></div><div style="margin-bottom:11pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.637%"><tr><td style="width:1.0%"/><td style="width:82.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTVkODQ2NmZmOTQ4OGE5OGMyNjBjMjVjMzM2MzdkL3NlYzplMjE1ZDg0NjZmZjk0ODhhOThjMjYwYzI1YzMzNjM3ZF8zMjUvZnJhZzphMzcyMjE5ZGMxOGI0NmNmYjhkMWJiYjc4N2MwNWUwMS90YWJsZTozYmY2MmI0NWZmNDg0NWRjOTNhYmZmOTU3M2IxYTRiMS90YWJsZXJhbmdlOjNiZjYyYjQ1ZmY0ODQ1ZGM5M2FiZmY5NTczYjFhNGIxXzQtMC0xLTEtMA_0b5773c1-67b4-4b87-8c25-0da483b19129"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTVkODQ2NmZmOTQ4OGE5OGMyNjBjMjVjMzM2MzdkL3NlYzplMjE1ZDg0NjZmZjk0ODhhOThjMjYwYzI1YzMzNjM3ZF8zMjUvZnJhZzphMzcyMjE5ZGMxOGI0NmNmYjhkMWJiYjc4N2MwNWUwMS90YWJsZTozYmY2MmI0NWZmNDg0NWRjOTNhYmZmOTU3M2IxYTRiMS90YWJsZXJhbmdlOjNiZjYyYjQ1ZmY0ODQ1ZGM5M2FiZmY5NTczYjFhNGIxXzQtMC0xLTEtMA_cdb8c4f8-a250-4972-ae29-de8b09756fe7">Accrued and other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTVkODQ2NmZmOTQ4OGE5OGMyNjBjMjVjMzM2MzdkL3NlYzplMjE1ZDg0NjZmZjk0ODhhOThjMjYwYzI1YzMzNjM3ZF8zMjUvZnJhZzphMzcyMjE5ZGMxOGI0NmNmYjhkMWJiYjc4N2MwNWUwMS90YWJsZTozYmY2MmI0NWZmNDg0NWRjOTNhYmZmOTU3M2IxYTRiMS90YWJsZXJhbmdlOjNiZjYyYjQ1ZmY0ODQ1ZGM5M2FiZmY5NTczYjFhNGIxXzUtMC0xLTEtMA_9dc8e25a-e30e-4990-976f-99be556ed531"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTVkODQ2NmZmOTQ4OGE5OGMyNjBjMjVjMzM2MzdkL3NlYzplMjE1ZDg0NjZmZjk0ODhhOThjMjYwYzI1YzMzNjM3ZF8zMjUvZnJhZzphMzcyMjE5ZGMxOGI0NmNmYjhkMWJiYjc4N2MwNWUwMS90YWJsZTozYmY2MmI0NWZmNDg0NWRjOTNhYmZmOTU3M2IxYTRiMS90YWJsZXJhbmdlOjNiZjYyYjQ1ZmY0ODQ1ZGM5M2FiZmY5NTczYjFhNGIxXzUtMC0xLTEtMA_a63e87db-c321-43be-9021-aef373d28b3e">Other non-current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, the Company's finance leases were not material and for the years 2020 and 2019 sub-lease income and short-term lease expense were not material. Lease expense for the years 2020 and 2019 include:</span></div><div style="margin-bottom:11.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:82.815%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable operating lease costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon adoption of the new standard for accounting for leases on January 1, 2019, the Company elected the modified retrospective approach without revising prior periods. Rent expense related to operating lease agreements was $92 million for 2018.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to operating leases for 2020 and 2019 is as follows:</span></div><div style="margin-bottom:11.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.929%"><tr><td style="width:1.0%"/><td style="width:78.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.951%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid from operating cash flows for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for new operating lease liabilities during the year ended December 31, 2019 of $47 million in the table above does not include $282 million of right-of-use assets recognized upon adoption of the new standard for accounting for leases on January 1, 2019. See Note 2, "SIGNIFICANT ACCOUNTING POLICIES" for further detail regarding the impact of adoption.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:91.594%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of remaining lease payments</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities associated with the Company's operating leases are included in the Consolidated Balance Sheet as of December 31, 2020 and 2019 as follows:</span></div><div style="margin-bottom:11pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.637%"><tr><td style="width:1.0%"/><td style="width:82.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTVkODQ2NmZmOTQ4OGE5OGMyNjBjMjVjMzM2MzdkL3NlYzplMjE1ZDg0NjZmZjk0ODhhOThjMjYwYzI1YzMzNjM3ZF8zMjUvZnJhZzphMzcyMjE5ZGMxOGI0NmNmYjhkMWJiYjc4N2MwNWUwMS90YWJsZTozYmY2MmI0NWZmNDg0NWRjOTNhYmZmOTU3M2IxYTRiMS90YWJsZXJhbmdlOjNiZjYyYjQ1ZmY0ODQ1ZGM5M2FiZmY5NTczYjFhNGIxXzQtMC0xLTEtMA_0b5773c1-67b4-4b87-8c25-0da483b19129"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTVkODQ2NmZmOTQ4OGE5OGMyNjBjMjVjMzM2MzdkL3NlYzplMjE1ZDg0NjZmZjk0ODhhOThjMjYwYzI1YzMzNjM3ZF8zMjUvZnJhZzphMzcyMjE5ZGMxOGI0NmNmYjhkMWJiYjc4N2MwNWUwMS90YWJsZTozYmY2MmI0NWZmNDg0NWRjOTNhYmZmOTU3M2IxYTRiMS90YWJsZXJhbmdlOjNiZjYyYjQ1ZmY0ODQ1ZGM5M2FiZmY5NTczYjFhNGIxXzQtMC0xLTEtMA_cdb8c4f8-a250-4972-ae29-de8b09756fe7">Accrued and other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTVkODQ2NmZmOTQ4OGE5OGMyNjBjMjVjMzM2MzdkL3NlYzplMjE1ZDg0NjZmZjk0ODhhOThjMjYwYzI1YzMzNjM3ZF8zMjUvZnJhZzphMzcyMjE5ZGMxOGI0NmNmYjhkMWJiYjc4N2MwNWUwMS90YWJsZTozYmY2MmI0NWZmNDg0NWRjOTNhYmZmOTU3M2IxYTRiMS90YWJsZXJhbmdlOjNiZjYyYjQ1ZmY0ODQ1ZGM5M2FiZmY5NTczYjFhNGIxXzUtMC0xLTEtMA_9dc8e25a-e30e-4990-976f-99be556ed531"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTVkODQ2NmZmOTQ4OGE5OGMyNjBjMjVjMzM2MzdkL3NlYzplMjE1ZDg0NjZmZjk0ODhhOThjMjYwYzI1YzMzNjM3ZF8zMjUvZnJhZzphMzcyMjE5ZGMxOGI0NmNmYjhkMWJiYjc4N2MwNWUwMS90YWJsZTozYmY2MmI0NWZmNDg0NWRjOTNhYmZmOTU3M2IxYTRiMS90YWJsZXJhbmdlOjNiZjYyYjQ1ZmY0ODQ1ZGM5M2FiZmY5NTczYjFhNGIxXzUtMC0xLTEtMA_a63e87db-c321-43be-9021-aef373d28b3e">Other non-current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 259000000 271000000 52000000 53000000 227000000 240000000 279000000 293000000 0 0 0 0 0 0 Lease expense for the years 2020 and 2019 include:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:82.815%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.426%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable operating lease costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 65000000 62000000 12000000 16000000 92000000 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to operating leases for 2020 and 2019 is as follows:</span></div><div style="margin-bottom:11.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.929%"><tr><td style="width:1.0%"/><td style="width:78.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.951%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid from operating cash flows for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 74000000 73000000 39000000 47000000 P7Y7M6D P8Y2M12D 0.062 0.062 47000000 282000000 <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:91.594%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of remaining lease payments</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 68000000 53000000 45000000 35000000 34000000 121000000 356000000 77000000 279000000 52000000 227000000 SHARE-BASED COMPENSATION<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, shareholders approved the Company’s 2014 Omnibus Incentive Plan (the “2014 Plan”) which replaced the Company’s 2011 Omnibus Incentive Plan (the “2011 Plan”) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company’s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares of common stock for issuance under the 2014 Plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 30, 2018, the Company amended and restated the 2014 Plan (the “Amended and Restated 2014 Plan”). The Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Amended and Restated 2014 Plan has been increased by an additional 11,900,000 common shares, as approved by the requisite number of shareholders at the Company’s annual general meeting held on April 30, 2018, (ii) introduction of a $750,000 aggregate fair market value limit on awards (in either equity, cash or other compensation) that can be granted in any calendar year to a participant who is a non-employee director, (iii) housekeeping changes to address recent changes to Section 162(m) of the Internal Revenue Code, (iv) awards are expressly subject to the Company’s clawback policy and (v) awards not assumed or substituted in connection with a Change of Control (as defined in the Amended and Restated 2014 Plan) will only vest on a pro rata basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 28, 2020, the Company further amended and restated the Amended and Restated 2014 Plan (the “Further Amended and Restated 2014 Plan”). The Further Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Further Amended and Restated 2014 Plan has been </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased by an additional 13,500,000 common shares, as approved by the requisite number of shareholders at the Company’s annual general meeting held on April 28, 2020, (ii) the exercise price of stock options and share appreciation rights (“SARs”) will be based on the closing price of the underlying common shares on the date such stock options or SARs are granted (rather than on the last preceding trading date), (iii) additional provisions clarifying that: (a) stock options and SARs will not be eligible for the payment of dividend or dividend equivalents and (b) the Talent and Compensation Committee of the Board of Directors of the Company cannot, without shareholder approval, seek to effect any repricing of any previously granted “underwater” stock option or SAR and (iv) other housekeeping and/or clerical changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 16,902,000 common shares were available for future grants as of December 31, 2020. The Company uses reserved and unissued common shares to satisfy its obligation under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company’s focus on improving its tangible capital usage and allocation, while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based RSUs and performance-based RSUs. Performance-based RSUs are comprised of: (i) awards that vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (“TSR”) and (ii) awards that vest upon attainment of certain performance targets that are based on the Company’s return on tangible capital (“ROTC”). </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components and classification of share-based compensation expense related to stock options and RSUs for the years 2020, 2019 and 2018 were as follows: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:67.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted under the 2011 Plan and the Amended and Restated 2014 Plan generally expire on the fifth or tenth anniversary of the grant date. The exercise price of any stock option granted under the 2011 Plan and the Amended and Restated 2014 Plan will not be less than the closing price per common share on the date of grant. Stock options generally vest 33% and 25% each year over a three-year and four-year period, respectively, on the anniversary of the date of grant.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of all stock options granted for the years 2020, 2019 and 2018 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock option life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected stock option life was determined based on historical exercise and forfeiture patterns. The expected volatility was determined based on implied volatility in the market traded options of the Company’s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S. government bonds with maturity dates equal to the expected life of the stock option. The expected dividend yield was determined based on the stock option’s exercise price and expected annual dividend rate at the time of grant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model used by the Company to calculate stock option values was developed to estimate the fair value of freely tradeable, fully transferable stock options without vesting restrictions, which significantly differ from the Company’s stock option awards. This model also requires highly subjective assumptions, including future stock price volatility and expected time until exercise, which greatly affect the calculated values.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during 2020: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"><tr><td style="width:1.0%"/><td style="width:56.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.99 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair values of all stock options granted in 2020, 2019 and 2018 were $6.60, $8.45 and $7.83, respectively. The total intrinsic values of stock options exercised in 2020, 2019 and 2018 were $2 million, $3 million and $1 million, respectively. Proceeds received on the exercise of stock options in 2020, 2019 and 2018 were $5 million, $5 million and $2 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the total remaining unrecognized compensation expense related to non-vested stock options amounted to $10 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years. The total fair value of stock options vested in 2020, 2019 and 2018 were $15 million, $18 million and $17 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs generally vest on the first or third anniversary date from the date of grant or 33% a year over a three-year period. Annual RSUs granted to non-management directors vest immediately prior to the next Annual Meeting of Shareholders. Pursuant to the applicable unit agreement, certain RSUs may be subject to the attainment of any applicable performance goals specified by the Board of Directors. If the vesting of the RSUs is conditional upon the attainment of performance goals, any RSUs that do not vest as a result of a determination that the prescribed performance goals failed to be attained will be forfeited immediately upon such determination. RSUs are credited with dividend equivalents, in the form of additional RSUs, when dividends are paid on the Company’s common shares. Such additional RSUs will have the same vesting dates and will vest under the same terms as the RSUs in respect of which such additional RSUs are credited.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent provided for in a RSU agreement, the Company may, in lieu of all or a portion of the common shares which would otherwise be provided to a holder, elect to pay a cash amount equivalent to the market price of the Company’s common shares on the vesting date for each vested RSU. The amount of cash payment will be determined based on the average market price of the Company’s common shares on the vesting date. The Company’s current intent is to settle vested RSUs through the issuance of common shares. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Time-Based RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each vested time-based RSU represents the right of a holder to receive one of the Company’s common shares. The fair value of each RSU granted is estimated based on the trading price of the Company’s common shares on the date of grant.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested time-based RSU activity during 2020: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:72.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Time-Based<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.54 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the total remaining unrecognized compensation expense related to non-vested time-based RSUs amounted to $55 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.5 years. The total fair value of time-based RSUs vested in 2020, 2019 and 2018 were $66 million, $34 million and $30 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each vested performance-based RSU represents the right of a holder to receive a number of the Company’s common shares up to a specified maximum. Performance-based RSUs vest upon achievement of certain share price appreciation conditions or attainment of certain performance targets. If the Company’s performance is below a specified performance level, no common shares will be paid. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each TSR performance-based RSU granted during 2020, 2019 and 2018 was estimated using a Monte Carlo Simulation model, which utilizes multiple input variables to estimate the probability that the performance condition will be achieved. The fair value of the ROTC performance-based RSUs is estimated based on the trading price of the Company’s common shares on the date of grant. Expense recognized for the ROTC performance-based RSUs in each reporting period reflects the Company’s latest estimate of the number of ROTC performance-based RSUs that are expected to vest. If the ROTC performance-based RSUs do not ultimately vest due to the ROTC targets not being met, no compensation expense is recognized and any previously recognized compensation expense is reversed. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of TSR performance-based RSUs granted during 2020, 2019 and 2018 were estimated with the following assumptions:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.760%"><tr><td style="width:1.0%"/><td style="width:58.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.727%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected Company share volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.2%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected company share volatility was determined based on implied volatility in the market traded options of the Company’s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S. government bonds with maturity dates equal to the contractual term of the performance-based RSUs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested performance-based RSU activity during 2020: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:72.799%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.587%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance-based <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company granted approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">897,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance-based RSUs, consisting of approximately 425,000 units of TSR performance-based RSUs with an average grant date fair value of $26.13 per RSU and approximately 472,000 units of ROTC performance-based RSUs with a weighted-average grant date fair value of $27.05</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per RSU. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the total remaining unrecognized compensation expense related to non-vested performance-based RSUs amounted to $22 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.4 years. A maximum of approximately 3,729,000 common shares could be issued upon vesting of the performance-based RSUs outstanding as of December 31, 2020.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2018 grant of long-term incentive awards with an aggregate value of $10 million, approximately 933,000 performance-based RSUs received by the Company’s Chief Executive Officer ("CEO") upon his hire in 2016 were canceled, and the shares underlying those performance-based RSUs were permanently retired and are not available for future grants under the 2014 Plan. The CEO's long-term incentive award was accounted for as an award modification whereby the Company continues to recognize the unamortized compensation associated with the original award plus the incremental fair value of the new award measured at the date of grant, over the vesting period of the new award.</span></div> 18000000 20000000 11900000 750000 13500000 16902000 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components and classification of share-based compensation expense related to stock options and RSUs for the years 2020, 2019 and 2018 were as follows: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:67.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 15000000 21000000 23000000 90000000 81000000 64000000 105000000 102000000 87000000 11000000 9000000 9000000 94000000 93000000 78000000 105000000 102000000 87000000 0.33 0.25 P3Y P4Y <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of all stock options granted for the years 2020, 2019 and 2018 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock option life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> P3Y P3Y P3Y 0.387 0.465 0.540 0.012 0.025 0.027 0 0 0 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during 2020: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"><tr><td style="width:1.0%"/><td style="width:56.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.99 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7100000 26.99 2300000 24.74 400000 14.65 300000 72.40 8700000 25.59 P7Y2M12D 14000000 8200000 25.73 P7Y1M6D 14000000 4800000 27.74 P6Y 11000000 6.60 8.45 7.83 2000000 3000000 1000000 5000000 5000000 2000000 10000000 P1Y6M 15000000 18000000 17000000 0.33 P3Y <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested time-based RSU activity during 2020: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:72.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Time-Based<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.54 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6100000 20.54 3300000 21.92 3400000 19.37 300000 21.78 5700000 21.98 55000000 P1Y6M 66000000 34000000 30000000 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of TSR performance-based RSUs granted during 2020, 2019 and 2018 were estimated with the following assumptions:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.760%"><tr><td style="width:1.0%"/><td style="width:58.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.727%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected Company share volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.2%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7%</span></td></tr></table></div> P3Y P3Y P3Y 0.386 0.465 0.542 0.012 0.025 0.027 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested performance-based RSU activity during 2020: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:72.799%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.587%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance-based <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2000000.0 25.80 900000 26.61 600000 19.02 2300000 28.10 897000 425000 26.13 472000 27.05 22000000 P1Y4M24D 3729000 10000000 933000 ACCUMULATED OTHER COMPREHENSIVE LOSS<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss as of December 31, 2020 and 2019 consists of: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,046)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension adjustment, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,133)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,086)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company’s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company’s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.</span></div> <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss as of December 31, 2020 and 2019 consists of: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,046)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension adjustment, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,133)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,086)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -2077000000 -2046000000 -56000000 -40000000 -2133000000 -2086000000 RESEARCH AND DEVELOPMENT<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs for the years 2020, 2019 and 2018 consists of:</span></div><div style="margin-bottom:13pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> Research and development costs for the years 2020, 2019 and 2018 consists of:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 420000000 434000000 376000000 32000000 37000000 37000000 452000000 471000000 413000000 OTHER EXPENSE (INCOME), NET<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income), net for the years 2020, 2019 and 2018 consists of:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gain) loss on sales of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, Litigation and other matters of $422 million includes net charges related to the U.S. Securities Litigation, the SEC Investigation and the Canadian Securities Litigation and related opt-outs. In 2020, Litigation and other matters also includes an insurance recovery related to a certain litigation matter. In 2019, Litigation and other matters of $1,401 million includes the settlement of a legacy U.S. securities class action matter (which is subject to an objector’s appeal of the final court approval). In 2018, Litigation and other matters of $27 million includes a favorable adjustment of $40 million related to the Salix legacy litigation matter. These matters and other significant matters are discussed in further detail in Note 20, "LEGAL PROCEEDINGS".</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 and 2019, Acquired in-process research and development costs of $32 million and $41 million, primarily consist of costs associated with the upfront payments to enter into certain exclusive licensing agreements. In 2019, Net (gain) loss on sales of assets includes $20 million related to the achievement of a milestone related to a certain product.</span></div> <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income), net for the years 2020, 2019 and 2018 consists of:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gain) loss on sales of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -422000000 -1401000000 27000000 32000000 41000000 1000000 1000000 31000000 -6000000 0 8000000 1000000 1000000 -5000000 -1000000 -454000000 -1414000000 20000000 -422000000 -1401000000 27000000 40000000 32000000 41000000 20000000 INCOME TAXES<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Loss before benefit from income taxes for 2020, 2019 and 2018 consist of: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,396)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,475)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(524)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,679)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,154)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Benefit from income taxes for 2020, 2019 and 2018 consist of: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(327)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(327)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Benefit from income taxes differs from the expected amount calculated by applying the Company’s Canadian statutory rate of 26.9% to Loss before benefit from income taxes for 2020, 2019 and 2018 as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before benefit from income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,154)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected benefit from income taxes at Canadian statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible amount of share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to tax attributes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance related to foreign tax credits and NOLs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance on Canadian deferred tax assets and tax rate changes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(875)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible portion of Goodwill impairments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(488)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit on intra-entity transfers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities as of December 31, 2020 and 2019 consist of: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,911 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific Research and Experimental Development pool</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized FX on U.S. dollar debt and other financing cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,251 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,966 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plant, equipment and technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized FX on U.S. dollar debt and other financing cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the deferred tax asset valuation allowance for 2020, 2019 and 2018: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,001 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to Benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to other accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s U.S. interest expense is subject to limitation rules which limit U.S. interest expense to 30% of adjusted taxable income, defined similar to EBITDA through 2021 and EBIT thereafter. Disallowed interest can be carried forward indefinitely and any unused interest deduction assessed for recoverability. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law. The CARES Act also amended the annual limitation on the deduction of interest in the following respects: (i) increasing the limitation to 50% of adjusted taxable income (“ATI”), (ii) providing a rule for a partnership’s 2019 section 163(j)-disallowed interest expense and (iii) allowing an election to apply 2019 ATI to the 2020 section 163(j) computation. For corporations, the increase to 50% of ATI applies to all taxable years beginning in 2019 or 2020 and permits taxpayers whose 2020 income will decrease from its 2019 level, an election to apply their 2019 ATI, rather than their 2020 ATI, to their 2020 computation. The Company considered such provisions and expects to fully utilize any interest carry forwards in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was signed into law and included a number of changes in the U.S. tax law, most notably a reduction of the U.S. corporate income tax rate from 35% to 21% for tax years beginning after December 31, 2017. The Tax Act also implemented a modified territorial tax system that included a one-time transition tax on the accumulated previously untaxed earnings of foreign subsidiaries (the “Transition Toll Tax”) equal to 15.5% (reinvested in liquid assets) or 8% (reinvested in non-liquid assets). At the taxpayer's election, the Transition Toll Tax can be paid over an eight-year period without interest, starting in 2018. The Company elected not to use this option and instead used a portion of its U.S. net operating losses ("NOLs") to offset this income inclusion.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provisional amounts included in Benefit from income taxes for the year 2017, including the Transition Toll Tax, were finalized during 2018. Differences between the provisional net income tax benefits provided for the year 2017 attributable to the Tax Act and the benefit for income taxes as finalized are included in the Benefit from income taxes for 2018 and were not material to the Company’s financial results for the year 2018.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has provided for income taxes in accordance with guidance issued by accounting regulatory bodies, the U.S. Internal Revenue Service and state and local governments through the date of the issuance of these Consolidated Financial Statements. Additional guidance and interpretations can be expected and such guidance, if any, could impact future results. While management continues to monitor these matters, the ultimate impact, if any, as a result of the application of any guidance issued in the future cannot be determined at this time. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The realization of deferred tax assets is dependent on the Company generating sufficient domestic and foreign taxable income in the years that the temporary differences become deductible. A valuation allowance has been provided for the portion of the deferred tax assets that the Company determined is more likely than not to remain unrealized based on estimated future taxable income and tax planning strategies. As a result of taxable losses in Canada as offset by a reduction of deferred tax assets due to internal restructurings, the valuation allowance decreased by $579 million during 2020 and decreased by $82 million during 2019. Given the Company’s history of pre-tax losses and expected future losses in Canada, the Company maintained that there was insufficient objective evidence to release the valuation allowance against Canadian tax loss carryforwards, International Tax Credits (“ITC”) and pooled Scientific Research and Experimental Development Tax Incentive (“SR&amp;ED”) expenditures. The Canadian valuation allowance represents a material portion of the Company's total valuation allowance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, the Company had accumulated taxable losses available to offset future years’ federal and provincial taxable income in Canada of approximately $6,530 million and $7,441 million, respectively.  As of December 31, 2020 and 2019, unclaimed ITCs available to offset future federal taxes in Canada were approximately $37 million and $34 million, respectively, which expire in the years 2021 through 2040.  In addition, as of December 31, 2020 and 2019, pooled SR&amp;ED expenditures available to offset against future taxable income in Canada were approximately $206 million and $192 million, respectively, which may be carried forward indefinitely. As of December 31, 2020 and 2019, a full valuation allowance against the net Canadian deferred tax assets has been provided of $1,966 million and $2,461 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, the Company had accumulated taxable losses available to offset future years' federal taxable income in the U.S. of approximately $814 million and $636 million, respectively, including acquired losses which expire in the years 2021 through 2037. While the remaining taxable losses are subject to multiple annual loss limitations as a result of previous ownership changes, the Company believes that the recoverability of the deferred tax assets associated with these taxable losses are more likely than not to be realized. As of December 31, 2020 and 2019 U.S. research and development credits available to offset future years' federal income taxes in the U.S. were approximately $110 million and $106 million, respectively, which includes acquired research and development credits and which expire in the years 2021 through 2040. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, the Company had accumulated taxable losses available to offset future years’ taxable income in Ireland of approximately $8,387 million and $6,765 million, respectively.  As of December 31, 2020 and 2019, the Company recognized a capital loss and established a valuation allowance on the portion of the loss for which a benefit is not expected to be realized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for Canadian tax on the unremitted earnings of its direct foreign affiliates except for its direct U.S. subsidiaries. The Company continues to assert that the unremitted earnings of its U.S. subsidiaries will be permanently reinvested and not repatriated. As of December 31, 2020, the Company estimates there will be no tax liability attributable to the permanently reinvested U.S. earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, unrecognized tax benefits (including interest and penalties) were $1,025 million and $1,002 million, of which $414 million and $355 million would affect the effective income tax rate, respectively. In 2020 and 2019, the remaining unrecognized tax benefits would not impact the effective tax rate as the tax positions are offset against existing tax attributes or are timing in nature. In 2020 and 2019, the Company recognized net increases to unrecognized tax benefits for current year tax positions of $66 million and $362 million, respectively. The Company recognized a net reduction of $42 million during 2020 and a net reduction of $13 million during 2019 in the unrecognized tax benefits related to tax positions taken in the prior years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for interest and penalties related to unrecognized tax benefits in the provision for income taxes. As of December 31, 2020 and 2019, accrued interest and penalties related to unrecognized tax benefits were approximately </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$49 million and $45 million, respectively. In 2020 and 2019, the Company recognized a net increase of approximately $4 million and $3 million of interest and penalties, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and one or more of its subsidiaries file federal income tax returns in Canada, the U.S., and other foreign jurisdictions, as well as various provinces and states in Canada and the U.S. The Company and its subsidiaries have open tax years, primarily from 2005 to 2019, with significant taxing jurisdictions, respectively, including Canada and the U.S. These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations and tax treaties, as they relate to the amount, timing, or inclusion of revenues and expenses, or the sustainability of income tax positions of the Company and its subsidiaries. Certain of these tax years are expected to remain open indefinitely.</span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.760%"><tr><td style="width:1.0%"/><td style="width:82.106%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jurisdiction:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Open Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015 - 2019</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2005 - 2019</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 - 2019</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013 - 2019</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 - 2019</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 - 2019</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 - 2019</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2011 - 2019</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Internal Revenue Service completed its examinations of the Company’s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company's taxable income as a result of these examinations. The 2014 tax year remains open to the extent of a 2017 capital loss carried back to that year. Additionally, the Internal Revenue Service has selected for examination the Company's annual tax filings for 2015 and 2016 and the Company's short period tax return for the period ended September 8, 2017, which was filed as a result of the Company's internal restructuring efforts during 2017. At this time, the Company does not expect that proposed adjustments, if any, for these periods would be material to the Company's Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently under examination by the Canada Revenue Agency for four separate cycles: (a) years 2005 through 2006, (b) years 2007 through 2009, (c) years 2012 through 2013 and (d) years 2014 through 2015. The Company received from the Canada Revenue Agency a proposed audit adjustment for the years 2005 through 2009. The Company disagrees with the adjustments and has filed the respective Notices of Objection. The total proposed adjustment will result in a loss of tax attributes which are subject to a full valuation allowance and will not result in material change to the provision for income taxes. The Canada Revenue Agency audits of the 2010 and 2011 tax years were closed in 2016, and resulted in no material adjustments. The Company received an assessment for certain transfer pricing matters in 2012 and 2013 for CAD 85 million and CAD 90 million, respectively.  The Company disagrees with the adjustments and has filed a Notice of Objection for 2012 and will file an objection for 2013.  Of the total proposed adjustments, all but CAD 3 million will result in a loss of tax attributes which are subject to a full valuation allowance and will not result in a material change to the provision for income taxes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s subsidiaries in Germany are under audit for tax years 2014 through 2016. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s subsidiaries in Australia are under audit by the Australian Tax Office for various years beginning in 2010. On August 8, 2017, the Australian Taxation Office issued a notice of assessment for the tax years 2011 through 2017 in the aggregate amount of $117 million, which includes penalties and interest. The Company disagrees with the assessment and continues to believe that its tax positions are appropriate and supported by the facts, circumstances and applicable laws. The Company intends to defend its tax position in this matter vigorously and has filed a holding objection against the assessment by the Australian Taxation Office and has secured a bank guarantee to cover any potential cash outlays regarding this assessment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2018.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the unrecognized tax benefits for 2020, 2019 and 2018: </span></div><div style="margin-bottom:5pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes it is reasonably possible that the total amount of unrecognized tax benefits at December 31, 2020 could decrease by approximately $145 million in the next twelve months as a result of the resolution of certain tax and transfer pricing audits and other events.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Loss before benefit from income taxes for 2020, 2019 and 2018 consist of: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,396)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,475)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(524)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,679)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,154)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -410000000 -2396000000 -1475000000 -524000000 559000000 -2679000000 -934000000 -1837000000 -4154000000 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Benefit from income taxes for 2020, 2019 and 2018 consist of: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(327)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(327)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 8000000 12000000 0 216000000 116000000 327000000 224000000 128000000 327000000 -9000000 5000000 -17000000 -590000000 -187000000 -320000000 -599000000 -182000000 -337000000 -375000000 -54000000 -10000000 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Benefit from income taxes differs from the expected amount calculated by applying the Company’s Canadian statutory rate of 26.9% to Loss before benefit from income taxes for 2020, 2019 and 2018 as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before benefit from income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,154)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected benefit from income taxes at Canadian statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible amount of share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to tax attributes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance related to foreign tax credits and NOLs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance on Canadian deferred tax assets and tax rate changes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(875)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible portion of Goodwill impairments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(488)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit on intra-entity transfers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.269 0.269 0.269 -934000000 -1837000000 -4154000000 -251000000 -494000000 -1117000000 9000000 7000000 10000000 -26000000 99000000 4000000 -62000000 -21000000 3000000 -687000000 142000000 875000000 163000000 350000000 47000000 128000000 -186000000 3000000 0 0 488000000 338000000 0 -356000000 13000000 49000000 33000000 -375000000 -54000000 -10000000 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities as of December 31, 2020 and 2019 consist of: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,911 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific Research and Experimental Development pool</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized FX on U.S. dollar debt and other financing cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,251 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,966 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plant, equipment and technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized FX on U.S. dollar debt and other financing cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the deferred tax asset valuation allowance for 2020, 2019 and 2018: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,001 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to Benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to other accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2924000000 2911000000 1004000000 641000000 172000000 155000000 55000000 52000000 20000000 25000000 9000000 5000000 0 94000000 27000000 41000000 16000000 19000000 24000000 23000000 4251000000 3966000000 2252000000 2831000000 1999000000 1135000000 228000000 53000000 89000000 56000000 71000000 41000000 2000000 0 390000000 150000000 1609000000 985000000 2831000000 2913000000 2001000000 -773000000 13000000 870000000 194000000 -95000000 42000000 2252000000 2831000000 2913000000 -579000000 -82000000 6530000000 7441000000 37000000 34000000 206000000 192000000 1966000000 2461000000 814000000 636000000 110000000 106000000 8387000000 6765000000 1025000000 1002000000 414000000 355000000 66000000 362000000 42000000 13000000 49000000 45000000 4000000 3000000 1 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.760%"><tr><td style="width:1.0%"/><td style="width:82.106%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jurisdiction:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Open Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015 - 2019</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2005 - 2019</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 - 2019</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013 - 2019</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 - 2019</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 - 2019</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 - 2019</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2011 - 2019</span></div></td></tr></table> 2015 2019 2005 2019 2014 2019 2013 2019 2016 2019 2016 2019 2016 2019 2011 2019 85000000 90000000 3000000 117000000 <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the unrecognized tax benefits for 2020, 2019 and 2018: </span></div><div style="margin-bottom:5pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1002000000 654000000 598000000 66000000 361000000 18000000 171000000 63000000 55000000 209000000 58000000 11000000 5000000 18000000 6000000 1025000000 1002000000 654000000 145000000 LOSS PER SHARE<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per share attributable to Bausch Health Companies Inc. for 2020, 2019 and 2018 were calculated as follows: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(560)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,788)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,148)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355.0 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352.1 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351.3 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.58)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.08)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.81)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, 2019 and 2018, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 3,154,000, 5,106,000 and 3,763,000 common shares for 2020, 2019 and 2018, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in 2020, 2019 and 2018, stock options, time-based RSUs and performance-based RSUs to purchase approximately 9,551,000, 2,598,000 and 4,185,000 common shares of the Company, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per share attributable to Bausch Health Companies Inc. for 2020, 2019 and 2018 were calculated as follows: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(560)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,788)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,148)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355.0 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352.1 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351.3 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.58)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.08)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.81)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -560000000 -1788000000 -4148000000 355000000.0 352100000 351300000 -1.58 -5.08 -11.81 3154000 5106000 3763000 9551000 2598000 4185000 SUPPLEMENTAL CASH FLOW DISCLOSURES <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow disclosures for 2020, 2019 and 2018 are as follows: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow disclosures for 2020, 2019 and 2018 are as follows: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1474000000 1537000000 1665000000 162000000 172000000 138000000 LEGAL PROCEEDINGSFrom time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described below. Going forward, in the Company's subsequent Quarterly Reports on Form 10-Q, the Company will only include a description of these matters to the extent there has been a material update with respect thereto during the applicable quarter or to the extent otherwise required by law.<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of December 31, 2020, the Company's Consolidated Balance Sheets includes accrued current loss contingencies of $1,672 million related to matters which the Company believes a potential resolution or settlement is both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company’s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental and Regulatory Inquiries</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney's Office for the District of Massachusetts - re OraPharma</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including related support services, and other matters. The Company is cooperating with this investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - Opt-Out Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658). On January 31, 2021 the District Court issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill filed a notice of appeal of the Court’s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options. The deadline for other parties to file notices of appeal from the final approval order is March 2, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company’s business and prospects, including relating to drug pricing, the Company’s use of specialty pharmacies, and the Company’s relationship with Philidor. On May 31, 2016, the court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $1,210 million. This settlement received final approval from the court on January 31, 2021 and will resolve and discharge all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and denied all allegations of wrongdoing. In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payment was paid into an escrow fund in accordance with the settlement agreement. The opt-out litigations discussed below remain ongoing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246) (“Timber Hill”), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company’s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated putative class action, thirty-seven groups of individual investors in the Company’s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions pending in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions are captioned: T. Rowe Price Growth Stock Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-5034); Equity Trustees Limited as Responsible Entity for T. Rowe Price Global Equity Fund v. Valeant Pharmaceuticals International Inc. (Case No. 16-cv-6127); Principal Funds, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-6128); BloombergSen Partners Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cv-7212); Discovery Global Citizens Master Fund, Ltd. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7321); MSD Torchlight Partners, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7324); BlueMountain Foinaven Master Fund, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7328) (“BlueMountain”); Incline Global Master LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7494); VALIC Company I v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7496); Janus Aspen Series v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7497) (“Janus Aspen”); Okumus Opportunistic Value Fund, LTD v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6513) (“Okumus”); Lord Abbett Investment Trust- Lord Abbett Short Duration Income Fund, v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6365) (“Lord Abbett”); Pentwater Equity Opportunities Master Fund LTD v. Valeant Pharmaceuticals International, Inc., et al. (Case No. 17-cv-7552) (“Pentwater”); Public Employees’ Retirement System of Mississippi v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-7625) (“Mississippi”);</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Boeing Company Employee Retirement Plans Master Trust v. Valeant Pharmaceuticals International Inc., et al., (Case No. 17-cv-7636) (“Boeing”); State Board of Administration of Florida v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-12808); The Regents of the University of California v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-13488); GMO Trust v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0089); Första AP Fonden v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-12088); New York City Employees’ Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0032) (“NYCERS”); Hound Partners Offshore Fund, LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08705) (“Hound Partners”); Blackrock Global Allocation Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0343) (“Blackrock”); Colonial First State Investments Limited As Responsible Entity for Commonwealth Global Shares Fund 1 v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0383); Bharat Ahuja v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0846); Brahman Capital Corp. v. Valeant Pharmaceuticals International, Inc (Case No. 18-cv-0893); The Prudential Insurance Company of America v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-01223) (“Prudential”); Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) (“Senzar”); 2012 Dynasty UC LLC v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08595) ("2012 Dynasty"); Catalyst Dynamic Alpha Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-12673) (“Catalyst”); Northwestern Mutual Life Insurance Co., v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-15286) (“Northwestern Mutual”); Bahaa Aly, et al. v. Valeant Pharmaceuticals International, Inc., (Case No. 18-cv-17393) (“Aly”); Office of the Treasurer as Trustee for the Connecticut Retirement Plans and Trust Funds v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18473) (“Connecticut”); Delaware Public Employees’ Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18475) (“Delaware”); Maverick Neutral Levered Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-02190) (“Maverick”), Templeton v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-05478) (“Templeton”), USAA Mutual Funds Trust, et al. v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 20-cv-07462) (“USAA”), and GIC Private Ltd. v. Valeant Pharmaceuticals International, Inc., (Case No. 20-cv-07460) (“GIC”). Twelve of the thirty-seven opt out actions have been dismissed; and the total number of remaining opt out actions pending in the District of New Jersey is twenty-five actions. Four additional matters have been settled and dismissals are expected in March 2021.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These individual shareholder actions assert claims under Sections 10(b), and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss have been filed and in most cases decided in many of these individual actions. To date, the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case. On September 10, 2019, the Court granted defendants’ motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (“Aly”) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. Oral argument on Plaintiffs’ appeal was held on October 20, 2020. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut, and Delaware actions. On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 18, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds and Equity Trustees actions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Securities Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. These actions are captioned: (a) Alladina v. Valeant, et al. (Case No. S-1594B6) (Supreme Court of British Columbia) (filed November 17, 2015); (b) Kowalyshyn v. Valeant, et al. (CV-15-540593-00CP) (Ontario Superior Court) (filed November 16, 2015); (c) Kowalyshyn et al. v. Valeant, et al. (CV-15-541082-00CP) (Ontario Superior Court) (filed November 23, 2015); (d) O’Brien v. Valeant et al. (CV-15-543678-00CP) (Ontario Superior Court) (filed December 30, 2015); (e) Catucci v. Valeant, et al. (Court File No. 540-17-011743159) (Quebec Superior Court) (filed October 26, 2015); and (f) Rousseau-Godbout v. Valeant, et al. (Court File No. 500-06-000770-152) (Quebec Superior Court) (filed October 27, 2015).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also aware of two additional putative class actions that were filed with the applicable court but which have not been served on the Company. These actions are captioned: (i) Okeley v. Valeant, et al. (Case No. S-159991) (Supreme Court of British Columbia) (filed December 2, 2015); and (ii) Sukenaga v Valeant et al. (CV-15-540567-00CP) (Ontario Superior Court) (filed November 16, 2015), and the factual allegations made in these actions are substantially similar to those outlined above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, has been discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company’s auditors and the action was dismissed as against them.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD 94,000,000 plus payment of an additional amount to cover notice and settlement administration costs and disbursements. As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights (“CalSTRS”) served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers’ Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8 and 9, 2020, respectively, CalSTRS delivered amended proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of “price appreciation credits” in respect of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the period covered by the claims. CalSTRS has filed an application for permission to amend and the Company has filed an application to strike the amendments.</span></div><div style="margin-top:7.5pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Coverage Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16.  The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; 3:18-CV-00493).  In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (under the 2013-2014 coverage period), and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and certain of the investigations described herein and in the Company's prior annual and quarterly reports (under the 2015-2016 coverage period). </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RICO Class Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between May 27, 2016 and September 16, 2016, three actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (“RICO”) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company branded drugs between January 2, 2013 and November 9, 2015.  On November 30, 2016, the Court entered an order consolidating the three actions under the caption In re Valeant Pharmaceuticals International, Inc. Third-Party Payor Litigation, No. 3:16-cv-03087. A consolidated class action complaint was filed on December 14, 2016. The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured’s consent to renew the prescription.  The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Special Master appointed by the Court has recommended that the Company’s motion to dismiss be denied, but a final decision is still pending with the Court. The Company believes these claims are without merit and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hound Partners Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County. This action is captioned Hound Partners Offshore Fund, LP et al., v. Valeant Pharmaceuticals International, Inc., et al. (No. MER-L-002185-18). This suit asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. This matter is currently stayed pending the completion of discovery in one of the above-noted federal opt-out cases. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Lawsuits</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2019 and September 13, 2019, two alleged stockholders filed derivative lawsuits purportedly on behalf of the Company against former Company board members and executives. The cases are Wessels v. Pearson (Case No. 3:19-cv-17833) and Shabbouei v. Pearson (Case No. 3:19-cv-17987). On March 7, 2020, a consolidated amended derivative complaint was filed, captioned In re Bausch Health Companies Inc. F/K/A/ Valeant Pharmaceuticals International, Inc. Stockholder Derivative Litigation (Case No. 19-cv-17833). </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs assert claims for breach of fiduciary duty, waste of corporate assets, and unjust enrichment related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company’s business and prospects, including relating to drug pricing, the Company’s use of specialty pharmacies, and the Company’s relationship with Philidor. The consolidated complaint also asserts a claim for contribution and indemnification by the Defendants for any liability the Company ultimately faces as a result of the conduct alleged in the complaint. The claims </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alleged in these cases are based on the same purported conduct that is at issue in In re Valeant Pharmaceuticals International, Inc. Securities Litigation, all of which occurred prior to 2017. The Shabbouei complaint also asserts a claim for contribution and indemnification by the Defendants for any liability the Company ultimately faces as a result of the conduct alleged in the complaint. On January 3, 2020, the parties submitted a letter to the Court requesting consolidation of the two derivative lawsuits. On April 21, 2020, the Defendants filed a motion to dismiss the consolidated amended complaint. Briefing on this motion concluded on August 3, 2020. On November 24, 2020, the Special Master appointed by the Court issued a report recommending that the motion to dismiss be granted in full. While a final decision is still pending with the Court, Plaintiffs are not contesting the dismissal in full. The Company continues to believe these claims are without merit and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pricing Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's subsidiaries, Oceanside Pharmaceuticals, Inc. (“Oceanside”), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (“Bausch Health US”), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (“Bausch Health Americas”) (for the purposes of this paragraph, collectively, the “Company”), are defendants in multidistrict antitrust litigation (“MDL”) entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Generic Pharmaceuticals Pricing Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16-MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company’s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been or are expected to be consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. In July 2019, 87 health plans commenced an action in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed and the case has been put in deferred status. In May 2020, seven health plans commenced an additional action in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed. The Company disputes the claims against it and continues to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively “the Company”) have been named as defendants in a proposed class proceeding entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kathryn Eaton vs. Teva Canada Limited, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Generic Pharmaceuticals Pricing Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and will defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between August 2019 and July 2020, eight (8) putative antitrust class actions and four (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (for purposes of this subsection, collectively, the “Company”), among other defendants, were filed or transferred to the Northern District of California. Three (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020. The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020. In December 2020, the court denied the Company’s motion to dismiss as to the insurer plaintiff’s direct claims but dismissed the insurer plaintiff’s indirect claims. On February 2, 2021, the insurer plaintiff’s motion for leave to amend its complaint was denied. On February 8, 2021, the insurer plaintiff filed an action in state court asserting state law claims.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal actions, five (5) of which remain pending, have been consolidated and coordinated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA. The lawsuits allege that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so. The complaints allege that the settlement agreement resulted in higher prices for </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs seek damages under federal antitrust laws for claims based on direct purchases. All Plaintiffs have filed a motion for partial summary judgment concerning market power, whereas all Defendants have filed a motion for summary judgment on all claims against them. The Company disputes the claims against it and intends to vigorously defend these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation/Paragraph IV Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550mg, Plenvu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada, or other similar suits. These matters are proceeding in the ordinary course. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company received a Notice of Paragraph IV Certification from Sandoz, Inc. (“Sandoz”), in which Sandoz asserted that the following U.S. patents, each of which is listed in the FDA’s Orange Book for Salix Pharmaceuticals, Inc.’s (“Salix Inc.”) Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Sandoz’s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (“ANDA”) has been filed by Sandoz: U.S. Patent No. 8,309,569 (the “‘569 patent”), U.S. Patent No. 7,045,620 (the “‘620 patent”), U.S. Patent No. 7,612,199 (the “‘199 patent”), U.S. Patent No. 7,902,206 (the “‘206 patent”), U.S. Patent No. 7,906,542 (the “‘542 patent”), U.S. Patent No. 7,915,275 (the “‘275 patent”), U.S. Patent No. 8,158,644 (the “‘644 patent”), U.S. Patent No. 8,158,781 (the “‘781 patent”), U.S. Patent No. 8,193,196 (the “‘196 patent”), U.S. Patent No. 8,518,949 (the “‘949 patent”), U.S. Patent No. 8,741,904 (the “‘904 patent”), U.S. Patent No. 8,835,452 (the “‘452 patent”), U.S. Patent No. 8,853,231 (the “‘231 patent”), and U.S. Patent No. 9,271,968 (the “’968 Patent”) (collectively, the “Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents”). Salix Inc. holds the New Drug Application ("NDA") for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its affiliate, Salix Pharmaceuticals, Ltd. (“Salix Ltd.”), is the owner of the ‘569 patent and Alfasigma S.p.A. (“Alfasigma”) is the owner of the ‘620 patent, the ‘199 patent, the ‘206 patent, the ‘542 patent, the ‘275 patent, the ‘644 patent, the ‘781 patent, the ‘196 patent, the ‘949 patent, the ‘904 patent, the ‘452 patent, the ‘231 patent, and the ‘968 patent, each of which has been exclusively licensed to Salix Inc. and its affiliate, Bausch Health Ireland Limited (“BIRL”) to market Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg.   On September 30, 2019, Salix Inc. and its affiliates, Salix Ltd. and BIRL, and Alfasigma (the “Plaintiffs”) filed suit against Sandoz in the U.S. District Court for the District of New Jersey (Case No. 19-18566) pursuant to the Hatch-Waxman Act, alleging infringement by Sandoz of one or more claims of each of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of Sandoz’s ANDA for rifaximin tablets, 550 mg. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550 mg is protected by 26 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book.   On May 6, 2020, the Company announced that an agreement had been reached with Sandoz that resolved this litigation. Under the terms of the agreement, the parties agreed to dismiss all litigation related to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin), Sandoz acknowledged the validity of the licensed patents for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets and all intellectual property protecting Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets will remain intact and enforceable until expiry in October 2029. The agreement also grants Sandoz a non-exclusive license to the intellectual property relating to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sandoz will have the right to market a royalty-free generic version of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets, should it receive approval from the FDA on its ANDA. Sandoz will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the United States before January 1, 2028. The Company will not make any financial payments or other transfers of value as part of this agreement with Sandoz.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2020, the Company and Alfasigma S.p.A. ("Alfasigma") received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (“Norwich”), in which Norwich asserted that the following U.S. patents, each of which is listed in the FDA’s Orange Book for the Company's Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich’s generic rifaximin tablets, 550 mg, for which an ANDA has been filed by Norwich: each of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents (as described above), as well as U.S. Patent No. 8,642,573 (the “573 patent”), U.S. Patent No. 8,829,017 (the “017 patent”), U.S. Patent No. 8,946,252 (the “252 patent”), U.S. Patent No. 8,969,398 (the “‘398 patent”), U.S. Patent No. 9,421,195 (the “‘195 patent”), U.S. Patent No. 9,629,828 (the “‘9828 patent”), U.S. Patent No. 10,314,828 (the “’4828 patent”), U.S. Patent No. 10,335,397 (the “‘397 patent”), U.S. Patent No. 10,456,384 (the “‘384 patent”), U.S. Patent No. 10,703,763 (the “‘763 patent”), U.S. Patent No. 10,709,694 (the “‘694 patent”), and U.S. Patent No. 10,765,667 (the “‘667 patent”). Salix Inc. holds the NDA for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and is the </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">owner of the ‘569 patent, the ‘573 patent, the ‘017 patent, the ‘252 patent, the ‘398 patent, the ‘195 patent, the ‘9828 patent, the ‘4828 patent, the ‘397 patent, the ‘384 patent, the ‘694 patent, and the ‘667 patent. Alfasigma is the owner of the ‘620 patent, the ‘199 patent, the ‘206 patent, the ‘542 patent, the ‘275 patent, the ‘644 patent, the ‘781 patent, the ‘196 patent, the ‘949 patent, the ‘904 patent, the ‘452 patent, the ‘231 patent, the ‘968 patent, and the ‘763 patent, each of which has been exclusively licensed to Salix Inc. and/or its affiliate, Bausch Health Ireland Limited (“BIRL”) to market Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg.  On March 26, 2020, certain of the Company’s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of Norwich’s ANDA for rifaximin tablets, 550 mg. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550 mg is protected by 26 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. The Company remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, the Company and Alfasigma commenced litigation against Sun Pharmaceutical Industries Ltd. (“Sun”), alleging patent infringement by Sun’s filing of its ANDA for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from Sun, in which Sun had asserted that the U.S. patents listed in the FDA's Orange Book for the Company’s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 200 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun’s generic rifaximin tablets, 200 mg. Subsequently, on August 10, 2020, the Company received an additional Notice of Paragraph IV Certification from Sun, in which Sun asserted that the U.S. patents listed in the FDA's Orange Book for the Company’s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun’s generic rifaximin tablets, 550 mg, for which an ANDA had been filed by Sun. On September 22, 2020, the Company announced that an agreement had been reached with Sun that resolved the outstanding intellectual property disputes with Sun regarding Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets. Under the terms of the agreement, the parties agreed to dismiss all litigation related to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) and all intellectual property protecting Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets will remain intact and enforceable until expiry in July and October 2029, respectively. The agreement also grants Sun a non-exclusive license to the intellectual property relating to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sun will have the right to market royalty-free generic versions of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets, should it receive approval from the FDA on its ANDAs. Sun will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the United States before January 1, 2028. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (“Perrigo”), in which Perrigo asserted that certain U.S. patents, each of which is listed in the U.S. Food and Drug Administration's (the "FDA") Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Perrigo’s generic lotion, for which an Abbreviated New Drug Application (“ANDA”) has been filed by Perrigo. On August 28, 2020, the Company filed suit against Perrigo pursuant to the Hatch-Waxman Act, alleging infringement by Perrigo of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Perrigo ANDA. On September 3, 2020, this action was consolidated with the action between the Company and Perrigo described below, regarding Perrigo’s ANDA for generic Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion. The Company remains confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related patents and will vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo, in which Perrigo asserted that certain U.S. patents, each of which is listed in the FDA’s Orange Book for Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Perrigo’s generic halobetasol propionate lotion, for which an ANDA has been filed by Perrigo. On May 1, 2020, the Company filed suit against Perrigo pursuant to the Hatch-Waxman Act, alleging infringement by Perrigo of one or more claims of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Perrigo ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Perrigo described above, regarding Perrigo’s ANDA for generic Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion. The Company remains confident in the strength of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patents covering the Company's branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review ("IPR") at the U.S. Patent &amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution.  IPR challenges have been brought against patents covering the Company's branded pharmaceutical products.  For example, following Acrux DDS’s IPR petition, the U.S. Patent and Trial Appeal Board ("PTAB"), in May 2017, instituted inter </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patent No. 7,214,506 (the “‘506 patent”). On June 6, 2018, the PTAB issued a written determination invalidating such patent; and on March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ‘506 Patent therefore remains valid and enforceable until its expected expiration in 2026.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continues to be covered by fourteen other Orange Book-listed patents owned by the Company and its licensor, which expire in the years 2028 through 2035.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Products Liability Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> body powder product acquired in September 2012 from Johnson &amp; Johnson; due to dismissals, only twenty-eight (28) of such product liability suits currently remain pending, and these twenty-eight (28) matters are subject to the Johnson &amp; Johnson indemnification referenced below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential liability (including its attorneys’ fees and costs) arising out of the covered Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuits filed against the Company is subject to certain indemnification obligations of Johnson &amp; Johnson owed to the Company, and legal fees and costs will be paid by Johnson &amp; Johnson. The Company and Johnson &amp; Johnson reached an agreement on April 17, 2019, regarding the scope of the indemnification relating to the majority of the Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> matters (the “Covered Matters”) and the Company has dismissed the demand for arbitration that the Company filed against Johnson &amp; Johnson to assert its rights to indemnification. Johnson &amp; Johnson will fully indemnify the Company in the Covered Matters, which include: (i) personal injury and products liability actions arising from alleged exposure to Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prior to March 2020 and (ii) consumer fraud, consumer protection, false advertising or other regulatory actions arising out of the manufacture, use, or sale of Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> up to and including September 9, 2012. The Company does not believe that the Covered Matters will have a material impact on the Company’s financial results going forward.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The various lawsuits include a number of cases, either originally filed in or transferred to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Johnson &amp; Johnson Talcum Powder Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Multidistrict Litigation 2738, pending in the United States District Court for the District of New Jersey (“MDL”). The Company and Bausch Health US were first named in a lawsuit filed directly into the MDL alleging that the use of the Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product caused the plaintiff to develop ovarian cancer. The plaintiff agreed to a dismissal of all claims against the Company and Bausch Health US in that matter without prejudice. The Company has subsequently been named in one additional lawsuit, originally filed in the District of Puerto Rico and subsequently transferred into the MDL, but has not been served in that case. The Company has also been named in eighteen additional lawsuits filed directly into the MDL that have also not yet been served. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits also include a number of matters filed in the Superior Court of Delaware and the Superior Court of New Jersey alleging that the use of Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the plaintiffs to develop ovarian cancer. Nearly all of these actions have been voluntarily dismissed. Presently, two cases remain pending in New Jersey and one in Delaware. One of the New Jersey cases has not yet been served. The allegations in these cases generally include failure to warn, design defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, and punitive damages.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these lawsuits also include a number of cases filed in certain state courts in the United States (including the Superior Courts of California, Delaware and New Jersey); the District Court of Louisiana; the Supreme Court of New York (Niagara County); the District Court of Oklahoma City, Oklahoma; the South Carolina Court of Common Pleas (Richland County); the Ohio Court of Common Pleas (Cuyahoga County); and the District Court of Nueces County, Texas (transferred to the asbestos multidistrict litigation docket in the District Court of Harris County, Texas for pre-trial purposes) alleging use of Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other products resulted in the plaintiffs developing mesothelioma. The Company has been successful in obtaining voluntary dismissals in most of these cases or the plaintiffs have not opposed summary judgment. Presently, four cases remain pending in the Superior Court of New Jersey, and one case in the Court of Common Pleas of Cuyahoga County, Ohio, in which a Notice of Voluntary Dismissal Without Prejudice has been agreed to between the parties. The allegations in these cases generally include design defect, manufacturing defect, failure to warn, negligence, and punitive damages, and in some cases breach of express and implied warranties, misrepresentation, and loss of consortium. The damages sought by the various plaintiffs include compensatory damages, including medical expenses, lost wages or earning capacity, and loss of consortium. In addition, plaintiffs seek compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys’ fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, two proposed class actions have been filed in Canada against the Company and various Johnson &amp; Johnson entities (one in the Supreme Court of British Columbia and one in the Superior Court of Quebec). The Company also acquired the rights to the Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product in Canada from Johnson &amp; Johnson in September 2012. In the British Columbia matter, the plaintiff sought to certify a proposed class action on behalf of persons in British Columbia and Canada who have purchased or used Johnson &amp; Johnson’s Baby Powder or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including their estates, executors and personal representatives, and is alleging that the use of this product increases certain health risks. On November 7, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and at this time no appeal of that judgment has been filed. In the Quebec matter, the plaintiff sought to certify a proposed class action on behalf of persons in Quebec who have used Johnson &amp; Johnson’s Baby Powder or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as their family members, assigns and heirs, and is alleging negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner. A certification (also known as authorization) hearing was held in the Quebec matter and the Court certified (or as stated under Quebec law, authorized) the bringing of a class action by a representative plaintiff on behalf of people in Quebec who have used Johnson &amp; Johnson's Baby Powder and/or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in their perineal area and have been diagnosed with ovarian cancer and/or family members, assigns and heirs. The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the indemnification agreement, Johnson &amp; Johnson will continue to vigorously defend the Company in each of the remaining actions that are not voluntarily dismissed or subject to a grant of summary judgment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Proposition 65 Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2019, a plaintiff filed a pre-suit notice letter with the California Attorney General notifying the Attorney General’s office of its intent to file suit after 60 days against the Company and certain of its subsidiaries, alleging they committed violations of the California Safe Drinking Water and Toxic Enforcement Act of 1986 (“Proposition 65”) by manufacturing and distributing Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that they allege contained silica, arsenic, lead and chromium (hexavalent compounds), which they allege are known to cause cancer and/or reproductive toxicity. That notice letter was served on the Company on April 18, 2019. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2020, Plaintiff Jan Graham filed a lawsuit (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Graham v. Bausch Health Companies, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 20STCV03578) in Los Angeles County Superior Court against the Company, Bausch Health US and several other manufacturers, distributors and retailers of talcum powder products, alleging violations of Proposition 65 by manufacturing and distributing talcum powder products containing chemicals listed under the statute, without a compliant warning on the label. On January 29, 2021, certain defendants including the Company and Bausch Health US filed a Motion for Summary Judgment or in the Alternative Motion for Summary Adjudication, which remains pending. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp; Johnson (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Gutierrez, et al. v. Johnson &amp; Johnson, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. The Company filed a motion to dismiss plaintiffs’ claims, which was granted in April 2020 without prejudice. In May 2020, plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted. In August 2020, plaintiffs filed the Fifth Amended Complaint.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 22, 2021, the Court granted the motion to dismiss on all claims and dismissed the case with prejudice. On February 19, 2021, plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend each of these lawsuits vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Consumer Protection Action</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico ex rel. Balderas v. Johnson &amp; Johnson, et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc., the Company and Bausch Health US related to Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its alleged causal link to mesothelioma and other cancers. In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its Answer to the Complaint on November 16, 2020. On December 30, 2020 Johnson &amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which remains pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Doctors Allergy Formula Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Doctors Allergy Formula, LLC (“Doctors Allergy”), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, Index No. 651597/2018. Doctors Allergy asserts breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.  Doctors Allergy claims its damages are not less than $23 million.  On June 14, 2018, Bausch Health Americas filed a motion to dismiss the complaint in part and a motion to strike. On July 16, 2019 the court granted the Company's motion in part and dismissed Doctor's Allergy's fraud and punitive damages claims. On August 28, 2019, the Company filed an Amended Answer and asserted Counterclaims against Doctors Allergy alleging breach of the covenant of good faith and fair dealing and tortious interference with contract. Bausch Health Americas disputes the claims against it and intends to vigorously defend against those claims and enforce its rights as asserted in its Counterclaims.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Former Salix CEO</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, Case No. 2019-0059, asserting claims for breach of contract and declaratory relief. The lawsuit arises out of the contractual termination of approximately $30 million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd. Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification.  On June 19, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. The Company disputes the claims and intends to vigorously defend the matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Completed or Inactive Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following matters have concluded, have settled, are the subject of an agreement to settle or have otherwise been closed since January 1, 2020, have been inactive from the Company’s perspective for several quarters or the Company anticipates that no further material activity will take place with respect thereto. Due to the closure, settlement, inactivity or change in status of the matters referenced below, these matters will no longer appear in the Company's next public reports and disclosures, unless required. With respect to inactive matters, to the extent material activity takes place in subsequent quarters with respect thereto, the Company will provide updates as required or as deemed appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SEC Investigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in November 2015, the Company received from the staff of the Los Angeles Regional Office of the SEC ("the Staff") subpoenas for documents, as well as various document, testimony and interview requests, related to its investigation of the Company, including requests concerning the Company's former relationship with Philidor Rx Services, LLC ("Philidor"), its accounting practices and policies, its public disclosures and other matters. On March 27, 2020, the Staff issued a Wells Notice informing the Company that they had reached a preliminary determination to recommend that the SEC bring charges against the Company for violating the federal securities laws as a result of SEC filings and other statements made by Valeant and its former executives in 2014-2015 concerning Philidor, as well as other accounting and disclosure matters, including the Company’s disclosure of certain price appreciation credits in 2015 - 2016. The Company has entered into a settlement with the SEC that has resolved all allegations by the SEC against the Company. Under the terms of the settlement, the Company neither admitted nor denied the SEC’s allegations and agreed to pay a $45 million civil monetary penalty.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AMF Investigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 12, 2016, the Company received a letter from the Autorité des marchés financiers (the “AMF”) requesting documents concerning the work of the Company’s ad hoc committee of independent directors, the Company’s former relationship with Philidor, the Company's accounting practices and policies and other matters. In July 2018, the Company </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was advised by the AMF that it had issued a formal investigation order against it. On September 30, 2020, the AMF confirmed that it had closed its investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Proposition 65 Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2019, plaintiffs filed a pre-suit notice letter with the California Attorney General notifying the Attorney General’s office of their intent to file suit after 60 days against the Company and certain of its subsidiaries, alleging they committed violations of Proposition 65 by manufacturing and distributing Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that they allege contained talc contaminated with asbestos, a listed carcinogen. That notice letter was served on the Company on February 22, 2019. By statute, a private lawsuit may not be filed until at least 60 days have passed following service of this pre-suit notice letter. In April 2019, rather than filing a lawsuit against Bausch Health US, the plaintiffs moved for leave to amend their complaint in a pending Proposition 65 lawsuit (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Luna, et al. v. Johnson &amp; Johnson, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, case 2:18-cv-04830-GW-KS) against Johnson &amp; Johnson in federal court in California to add Bausch Health US as a defendant. Plaintiffs subsequently filed a motion to dismiss the lawsuit without prejudice. The court dismissed the case without prejudice on December 18, 2019.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contact Lens Antitrust Class Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in March 2015, a number of civil antitrust class action suits were filed by purchasers of contact lenses against B&amp;L Inc., three other contact lens manufacturers, and a contact lens distributor, alleging that the defendants engaged in an anticompetitive scheme to eliminate price competition on certain contact lens lines through the use of unilateral pricing policies, and alleging violations of Section 1 of the Sherman Act, 15 U.S.C. § 1, and of various state antitrust and consumer protection laws. These cases have been consolidated in the Middle District of Florida by the Judicial Panel for Multidistrict Litigation, under the caption In re Disposable Contact Lens Antitrust Litigation, Case No. 3:15-md-02626-HES-JRK. On August 19, 2019, B&amp;L Inc. entered into a settlement, subject to court approval, by which it agreed to pay $10 million to fully and finally resolve plaintiffs’ class claims against B&amp;L Inc. in the case. On October 8, 2019, the settlement agreement was preliminarily approved by the court. A final fairness hearing regarding the settlement was held on February 25, 2020. On March 4, 2020, the Court granted final approval of the settlement agreement in all respects and dismissed the case with prejudice as to B&amp;L Inc., except as to any claim by persons who validly and timely requested exclusion from the settlement classes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mississippi Attorney General Consumer Protection Action</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US were named in an action brought by James Hood, Attorney General of Mississippi, in the Chancery Court of the First Judicial District of Hinds County, Mississippi (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hood ex rel. State of Mississippi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Civil Action No. G2014-1207013, filed on August 22, 2014), alleging consumer protection claims against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc., the Company and Bausch Health US related to the Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> body powder product and its alleged causal link to ovarian cancer. As indicated above, the Company acquired the Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> body powder product in September 2012 from Johnson &amp; Johnson. The State sought compensatory damages, punitive damages, injunctive relief requiring warnings for talc-containing products, removal from the market of products that fail to warn, and to prevent the continued violation of the Mississippi Consumer Protection Act. The State also sought disgorgement of profits from the sale of the product and civil penalties. The State did not make specific allegations as to the Company or Bausch Health US. The Company and Bausch Health US agreed to resolve this litigation pursuant to a settlement agreement with the State of Mississippi for a non-material amount. On January 8, 2020, an order of dismissal with prejudice was entered by the Court.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the State of Texas</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2014, the State of Texas served Bausch &amp; Lomb Incorporated (“B&amp;L Inc.”) with a Civil Investigative Demand (“CID”) concerning various price reporting matters relating to the State's Medicaid program and the amounts the State paid in reimbursement for B&amp;L products for the period from 1995 to the date of the CID.  B&amp;L Inc. and the State agreed to settle the matter for $10 million. The Company made the payment on April 1, 2020. On July 1, 2020, the State moved to dismiss the case by filing a notice that it was taking a nonsuit, with prejudice to refiling, effective immediately.</span></div> 1672000000 4 4 1210000000 37 12 37 25 4 6 2 94000000 1 2 3 3 2 2 2 87 7 8 4 3 3 5 P30M P30M P30M P30M 28 28 1 18 2 1 1 4 1 2 1 1 23000000 30000000 45000000 3 10000000 0 10000000 COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has commitments related to capital expenditures of approximately $54 million as of December 31, 2020. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones. As of December 31, 2020, the Company believes it is reasonably possible that it may potentially make milestone and license fee payments, including sales-based milestone payments, of </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $360 million over time, in the aggregate, to third parties for products currently under development or being marketed, primarily consisting of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a June 2013 distribution and supply agreement with Mylan Pharmaceuticals Inc. (as assignee of Spear Pharmaceuticals, Inc and Spear Dermatology Products Inc.), the Company may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $70 million, in the aggregate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of an April 2019 agreement with Mitsubishi Tanabe Pharma Corporation, the Company has acquired an exclusive license to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate (S1P) receptor that plays a role in autoimmune diseases, such as Inflammatory Bowel Disease and ulcerative colitis. The Company may be required to make development and sales-based milestone payments over time of up to $60 million, in the aggregate, as well as royalties on future sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a December 2019 agreement with Novaliq GmbH, the Company has acquired an exclusive license for the commercialization and development in the U.S. and Canada of NOV03 (perfluorohexyloctane), an investigational drug to treat Dry Eye Disease associated with Meibomian gland dysfunction and may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $45 million, in the aggregate, as well as royalties on future sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a November 2019 agreement with Cedars-Sinai Medical Center, to evaluate a new formulation of rifaximin for the treatment of irritable bowel syndrome, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $36 million, in the aggregate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of an October 2020 agreement with Eyenovia, Inc., the Company has acquired an exclusive license in the United States and Canada for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. Under the terms of the agreement, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $35 million, in the aggregate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a May 2020 agreement with STADA Arzneimittel AG and its development partner, Xbrane Biopharma AB, to commercialize in the United States and Canada a biosimilar candidate to Lucentis (ranibizumab), the Company may be required to make development and sales-based milestone payments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the terms of a September 2020 agreement with Allegro, the Company may be required to make a payment of $40 million should Allegro raise additional funding. This amount is excluded from the milestone and license fee payments disclosed above. See Note 3, "ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE" for additional details regarding this agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2018, the Company announced that it entered into an exclusive license agreement with Kaken Pharmaceutical Co., Ltd. ("Kaken") to develop and commercialize a new chemical entity, IDP-131 (KP-470), for the topical treatment of psoriasis. An early proof of concept study has been completed and the results did not meet expectations. As a result, the Company and Kaken have terminated the license agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of these arrangements, the future potential payments related to the attainment of the specified milestones over a period of several years are inherently uncertain. As of December 31, 2020, no accruals related to the aforementioned agreements exist because the milestone targets are not yet probable of being achieved.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into agreements that include indemnification provisions for product liability and other matters. These provisions are generally subject to maximum amounts, specified claim periods and other conditions and limits. In addition, the Company is obligated to indemnify its officers and directors in respect of any legal claims or actions initiated against them in their capacity as officers and directors of the Company in accordance with applicable law. Pursuant to such indemnities, the Company is indemnifying certain former officers and directors in respect of certain litigation and regulatory matters.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, no material amounts were accrued for the Company’s obligations under these indemnification provisions.</span></div> 54000000 360000000 70000000 60000000 45000000 36000000 35000000 40000000 SEGMENT INFORMATION<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s CEO, who is the Company’s Chief Operating Decision Maker, manages the business through operating and reportable segments consistent with how the Company’s CEO: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. The Company operates in the following reportable segments: (i) Bausch + Lomb/International segment, (ii) Salix segment, (iii) Ortho Dermatologics segment and (iv) Diversified Products segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company’s segments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb/International segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of: (i) sales in the U.S. of pharmaceutical products, OTC products and medical device products, primarily comprised of Bausch + Lomb products, with a focus on the Vision Care, Surgical, Consumer and Ophthalmology Rx products and (ii) with the exception of sales of Solta products, sales in Canada, Europe, Asia, Australia, Latin America, Africa and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products, OTC products, medical device products and Bausch + Lomb products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Ortho Dermatologics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta medical aesthetic devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective in the first quarter of 2019, one product historically included in the reported results of the Ortho Dermatologics business unit in the Ortho Dermatologics segment is now included in the reported results of the Generics business unit in the Diversified Products segment and another product historically included in the reported results of the Ortho Dermatologics business unit in the Ortho Dermatologics segment is now included in the reported results of the Dentistry business unit in the Diversified Products segment as management believes the products better align with the new respective business units. These changes in product alignment are not material. Prior period presentations of business unit and segment revenues and profits have been conformed to current segment and business unit reporting structures. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, including loss on assets held for sale, Restructuring, integration and separation costs, Acquisition-related contingent consideration costs and Other expense (income), net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company’s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned separation of its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company has begun addressing the internal organizational design and structure of the new entity, which it anticipates having substantially complete by late 2021. As of the date of the issuance of these financial statements, these matters are in the planning phase. In connection with the Separation, the Company expects to realign and begin managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Separation during the first quarter of 2021. Accordingly, the Company expects to begin reporting under the following reporting segments on a retrospective basis beginning with its first quarter of 2021: Bausch + Lomb, International Rx, Salix, Ortho Dermatologics and Diversified Products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Revenues and Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits for the years 2020, 2019 and 2018 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb/International</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,739 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,664 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,380 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profit:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb/International</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,835 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,748 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,897)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(568)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration and separation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,414)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,384)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,612)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,685)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before benefit from income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,154)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures by segment for the years 2020, 2019 and 2018 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb/International</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues by Product and by Product Category </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the Company's top ten products for the years 2020, 2019 and 2018 represented 41%, 39% and 36% of total product sales, respectively. Revenues by segment and product category were as follows: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.906%"><tr><td style="width:1.0%"/><td style="width:10.942%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.540%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.540%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.540%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">759 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">885 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,899 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,022 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,752 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">355 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">810 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">927 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,072 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,028 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,313 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,524 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,505 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,566 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,717 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,640 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">801 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">784 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">447 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,248 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,248 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,191 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,408 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,739 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,664 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,904 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,022 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,749 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">553 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">565 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">617 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,162 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,275 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,350 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,027 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,601 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,380 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer for the years 2020, 2019 and 2018 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,164 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,011 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,380 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December 31, 2020 and 2019 were as follows: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:79.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serbia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,466 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as follows: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td></tr></table></div> <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company’s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned separation of its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company has begun addressing the internal organizational design and structure of the new entity, which it anticipates having substantially complete by late 2021. As of the date of the issuance of these financial statements, these matters are in the planning phase. In connection with the Separation, the Company expects to realign and begin managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Separation during the first quarter of 2021. Accordingly, the Company expects to begin reporting under the following reporting segments on a retrospective basis beginning with its first quarter of 2021: Bausch + Lomb, International Rx, Salix, Ortho Dermatologics and Diversified Products.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits for the years 2020, 2019 and 2018 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb/International</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,739 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,664 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,380 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profit:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb/International</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,835 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,748 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,897)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(568)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration and separation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,414)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,384)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,612)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,685)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before benefit from income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,154)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4408000000 4739000000 4664000000 1904000000 2022000000 1749000000 553000000 565000000 617000000 1162000000 1275000000 1350000000 8027000000 8601000000 8380000000 1159000000 1332000000 1330000000 1338000000 1349000000 1149000000 233000000 222000000 257000000 848000000 932000000 1012000000 3578000000 3835000000 3748000000 -619000000 -609000000 -605000000 1645000000 1897000000 2644000000 0 0 2322000000 114000000 75000000 568000000 22000000 31000000 22000000 -48000000 -12000000 9000000 -454000000 -1414000000 20000000 676000000 -203000000 -2384000000 13000000 12000000 11000000 1534000000 1612000000 1685000000 -59000000 -42000000 -119000000 -30000000 8000000 23000000 -934000000 -1837000000 -4154000000 <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures by segment for the years 2020, 2019 and 2018 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb/International</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 282000000 225000000 139000000 3000000 2000000 2000000 2000000 1000000 1000000 2000000 2000000 2000000 289000000 230000000 144000000 13000000 40000000 13000000 302000000 270000000 157000000 10 10 10 0.41 0.39 0.36 Revenues by segment and product category were as follows: <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.906%"><tr><td style="width:1.0%"/><td style="width:10.942%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.540%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.540%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.540%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">759 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">885 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,899 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,022 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,752 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">355 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">810 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">927 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,072 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,028 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,313 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,524 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,505 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,566 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,717 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,640 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">801 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">784 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">447 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,248 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,248 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,191 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,408 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,739 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,664 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,904 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,022 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,749 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">553 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">565 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">617 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,162 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,275 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,350 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,027 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,601 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,380 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 759000000 885000000 892000000 1899000000 2022000000 1752000000 279000000 355000000 457000000 741000000 810000000 927000000 3678000000 4072000000 4028000000 1313000000 1524000000 1505000000 0 0 0 253000000 193000000 135000000 0 0 0 1566000000 1717000000 1640000000 1432000000 1452000000 1412000000 0 0 0 0 0 0 0 0 0 1432000000 1452000000 1412000000 838000000 801000000 784000000 0 0 0 0 0 0 410000000 447000000 407000000 1248000000 1248000000 1191000000 66000000 77000000 71000000 5000000 0 -3000000 21000000 17000000 25000000 11000000 18000000 16000000 103000000 112000000 109000000 4408000000 4739000000 4664000000 1904000000 2022000000 1749000000 553000000 565000000 617000000 1162000000 1275000000 1350000000 8027000000 8601000000 8380000000 <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer for the years 2020, 2019 and 2018 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,164 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,011 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,380 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 4791000000 5164000000 5011000000 341000000 368000000 361000000 331000000 339000000 319000000 243000000 218000000 178000000 238000000 231000000 218000000 226000000 241000000 226000000 225000000 228000000 211000000 179000000 201000000 205000000 144000000 150000000 170000000 137000000 180000000 154000000 86000000 115000000 117000000 78000000 86000000 83000000 1008000000 1080000000 1127000000 8027000000 8601000000 8380000000 <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December 31, 2020 and 2019 were as follows: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:79.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serbia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,466 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 725000000 656000000 328000000 255000000 110000000 103000000 83000000 90000000 80000000 68000000 49000000 50000000 34000000 30000000 31000000 27000000 30000000 27000000 23000000 22000000 74000000 138000000 1567000000 1466000000 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as follows: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td></tr></table></div> 0.17 0.17 0.18 0.17 0.16 0.18 0.13 0.14 0.13 <div style="margin-bottom:8pt;margin-top:8pt;padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUPPLEMENTARY DATA (UNAUDITED)</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected unaudited quarterly consolidated financial data are shown below: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:54.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,012 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,664 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,213 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,678 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and Diluted (loss) earnings per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:54.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,016 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,152 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,224 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,895 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,880 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,076)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,516)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and Diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected unaudited quarterly consolidated financial data are shown below: </span></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:54.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,012 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,664 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,213 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,678 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and Diluted (loss) earnings per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:13pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:54.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.076%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,016 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,152 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,224 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,895 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,880 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,076)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,516)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and Diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2012000000 1664000000 2138000000 2213000000 1764000000 1691000000 1678000000 2218000000 248000000 -27000000 460000000 -5000000 -152000000 -326000000 71000000 -153000000 -0.43 -0.92 0.20 -0.43 261000000 200000000 256000000 394000000 2016000000 2152000000 2209000000 2224000000 1729000000 1895000000 1880000000 3300000000 287000000 257000000 329000000 -1076000000 -52000000 -171000000 -49000000 -1516000000 -0.15 -0.49 -0.14 -4.30 413000000 339000000 515000000 234000000 XML 19 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2020
Feb. 18, 2021
Jun. 30, 2020
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2020    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-14956    
Entity Registrant Name Bausch Health Companies Inc.    
Entity Incorporation, State or Country Code A1    
Entity Address, Country CA    
Entity Tax Identification Number 98-0448205    
Entity Address, Address Line One 2150 St. Elzéar Blvd. West    
Entity Address, City or Town Laval    
Entity Address, State or Province QC    
Entity Address, Postal Zip Code H7L 4A8    
City Area Code 514    
Local Phone Number 744-6792    
Title of 12(b) Security Common Shares, No Par Value    
Trading Symbol BHC    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Smaller Reporting Company false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 5,664,997,951
Entity Common Stock, Shares Outstanding (in shares)   355,619,826  
Documents Incorporated by Reference Part III incorporates certain information by reference from the registrant’s proxy statement for the 2021 Annual Meeting of Shareholders. Such proxy statement will be filed no later than 120 days after the close of the registrant’s fiscal year ended December 31, 2020.    
Entity Central Index Key 0000885590    
Document Fiscal Year Focus 2020    
Document Fiscal Period Focus FY    
Amendment Flag false    
XML 20 R2.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 605 $ 3,243
Restricted cash 1,211 1
Trade receivables, net 1,577 1,839
Inventories, net 1,094 1,107
Prepaid expenses and other current assets 855 779
Total current assets 5,342 6,969
Property, plant and equipment, net 1,567 1,466
Intangible assets, net 8,445 10,201
Goodwill 13,044 13,126
Deferred tax assets, net 2,137 1,690
Other non-current assets 664 411
Total assets 31,199 33,863
Current liabilities:    
Accounts payable 337 503
Accrued and other current liabilities 4,576 4,511
Current portion of long-term debt and other 0 1,234
Total current liabilities 4,913 6,248
Acquisition-related contingent consideration 216 262
Non-current portion of long-term debt 23,925 24,661
Deferred tax liabilities, net 528 705
Other non-current liabilities 1,012 851
Total liabilities 30,594 32,727
Commitments and contingencies (Notes 20 and 21)
Equity    
Common shares, no par value, unlimited shares authorized, 355,422,347 and 352,562,636 issued and outstanding at December 31, 2020 and 2019, respectively 10,227 10,172
Additional paid-in capital 454 429
Accumulated deficit (8,013) (7,452)
Accumulated other comprehensive loss (2,133) (2,086)
Total Bausch Health Companies Inc. shareholders’ equity 535 1,063
Noncontrolling interest 70 73
Total equity 605 1,136
Total liabilities and equity $ 31,199 $ 33,863
XML 21 R3.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares
Dec. 31, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Common stock, shares issued (in shares) 355,422,347 352,562,636
Common stock, shares outstanding (in shares) 355,422,347 352,562,636
XML 22 R4.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Revenues      
Revenue $ 8,027 $ 8,601 $ 8,380
Expenses      
Selling, general and administrative 2,367 2,554 2,473
Research and development 452 471 413
Amortization of intangible assets 1,645 1,897 2,644
Goodwill impairments 0 0 2,322
Asset impairments, including loss on assets held for sale 114 75 568
Restructuring, integration and separation costs 22 31 22
Acquisition-related contingent consideration 48 12 (9)
Other expense (income), net 454 1,414 (20)
Total Expenses 7,351 8,804 10,764
Operating income (loss) 676 (203) (2,384)
Interest income 13 12 11
Interest expense (1,534) (1,612) (1,685)
Loss on extinguishment of debt (59) (42) (119)
Foreign exchange and other (30) 8 23
Loss before benefit from income taxes (934) (1,837) (4,154)
Benefit from income taxes 375 54 10
Net loss (559) (1,783) (4,144)
Net income attributable to noncontrolling interest (1) (5) (4)
Net loss attributable to Bausch Health Companies Inc. $ (560) $ (1,788) $ (4,148)
Basic and diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share) $ (1.58) $ (5.08) $ (11.81)
Basic and diluted weighted-average common shares (in shares) 355.0 352.1 351.3
Product sales      
Revenues      
Revenue $ 7,924 $ 8,489 $ 8,271
Expenses      
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues 2,202 2,297 2,309
Other revenues      
Revenues      
Revenue 103 112 109
Expenses      
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues $ 47 $ 53 $ 42
XML 23 R5.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Statement of Comprehensive Income [Abstract]      
Net loss $ (559) $ (1,783) $ (4,144)
Pension and postretirement benefit plan adjustments:      
Net actuarial loss arising during the year (15) (8) (7)
Amortization of prior service credit (4) (4) (4)
Amortization or settlement recognition of net loss 1 2 1
Income tax benefit (expense) 2 (2) 3
Foreign currency impact 0 (2) 0
Net pension and postretirement benefit plan adjustments (16) (14) (7)
Foreign currency translation adjustment (29) 64 (237)
Other comprehensive (loss) income (45) 50 (244)
Comprehensive loss (604) (1,733) (4,388)
Comprehensive income attributable to noncontrolling interest (3) (4) (1)
Comprehensive loss attributable to Bausch Health Companies Inc. $ (607) $ (1,737) $ (4,389)
XML 24 R6.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
$ in Millions
Total
Cumulative Effect, Period of Adoption, Adjustment
Bausch Health Companies Inc. Shareholders' Equity
Bausch Health Companies Inc. Shareholders' Equity
Cumulative Effect, Period of Adoption, Adjustment
Common Shares
Additional Paid-In Capital
Accumulated Deficit
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Loss
Noncontrolling Interest
Beginning Balance (in shares) at Dec. 31, 2017         348,700,000          
Beginning Balance at Dec. 31, 2017 $ 5,944 $ 1,209 $ 5,849 $ 1,209 $ 10,090 $ 380 $ (2,725) $ 1,209 $ (1,896) $ 95
Increase (Decrease) in Shareholders' Equity                    
Common shares issued under share-based compensation plans (in shares)         1,200,000          
Common shares issued under share-based compensation plans 2   2   $ 31 (29)        
Share-based compensation 87   87     87        
Share-based awards tax withholding (10)   (10)     (10)        
Acquisition of noncontrolling interest (18)   (15)     (15)       (3)
Noncontrolling interest distributions (11)                 (11)
Net (loss) income (4,144)   (4,148)       (4,148)     4
Other comprehensive (loss) income (244)   (241)           (241) (3)
Ending Balance (in shares) at Dec. 31, 2018         349,900,000          
Ending Balance at Dec. 31, 2018 $ 2,815   2,733   $ 10,121 413 (5,664)   (2,137) 82
Increase (Decrease) in Shareholders' Equity                    
Accounting Standards Update [Extensible List] us-gaap:AccountingStandardsUpdate201613Member                  
Common shares issued under share-based compensation plans (in shares)         2,700,000          
Common shares issued under share-based compensation plans $ 5   5   $ 51 (46)        
Share-based compensation 102   102     102        
Share-based awards tax withholding (40)   (40)     (40)        
Noncontrolling interest distributions (13)                 (13)
Net (loss) income (1,783)   (1,788)       (1,788)     5
Other comprehensive (loss) income $ 50   51           51 (1)
Ending Balance (in shares) at Dec. 31, 2019 352,562,636       352,600,000          
Ending Balance at Dec. 31, 2019 $ 1,136 $ (1) 1,063 $ (1) $ 10,172 429 (7,452) $ (1) (2,086) 73
Increase (Decrease) in Shareholders' Equity                    
Common shares issued under share-based compensation plans (in shares)         2,800,000          
Common shares issued under share-based compensation plans 5   5   $ 55 (50)        
Share-based compensation 105   105     105        
Share-based awards tax withholding (30)   (30)     (30)        
Noncontrolling interest distributions (6)                 (6)
Net (loss) income (559)   (560)       (560)     1
Other comprehensive (loss) income $ (45)   (47)           (47) 2
Ending Balance (in shares) at Dec. 31, 2020 355,422,347       355,400,000          
Ending Balance at Dec. 31, 2020 $ 605   $ 535   $ 10,227 $ 454 $ (8,013)   $ (2,133) $ 70
XML 25 R7.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Cash Flows From Operating Activities      
Net loss $ (559) $ (1,783) $ (4,144)
Adjustments to reconcile net loss to net cash provided by operating activities:      
Depreciation and amortization of intangible assets 1,825 2,075 2,819
Amortization and write-off of debt discounts and debt issuance costs 61 63 79
Asset impairments, including loss on assets held for sale 114 75 568
Goodwill impairment 0 0 2,322
Acquisition-related contingent consideration 48 12 (9)
Allowances for losses on trade receivables and inventories 60 75 69
Deferred income taxes (475) (230) (144)
(Gain) loss on disposal of assets (1) (31) 6
Additions (reductions) to accrued legal settlements 442 1,401 (27)
Payments of accrued legal settlements (168) (15) (224)
Share-based compensation 105 102 87
Foreign exchange loss (gain) 8 7 (19)
Gain excluded from hedge effectiveness (23) (9) 0
Loss on extinguishment of debt 59 42 119
Payments of contingent consideration adjustments, including accretion (1) (1) (2)
Other (18) 36 (17)
Changes in operating assets and liabilities:      
Trade receivables 170 39 216
Inventories (77) (209) (5)
Prepaid expenses and other current assets 12 1 (72)
Accounts payable, accrued and other liabilities (471) (149) (121)
Net cash provided by operating activities 1,111 1,501 1,501
Cash Flows From Investing Activities      
Acquisition of businesses, net of cash acquired 0 (180) 5
Acquisition of intangible assets and other assets (7) (8) (78)
Purchases of property, plant and equipment (302) (270) (157)
Purchases of marketable securities (4) (16) (7)
Proceeds from sale of marketable securities 8 10 7
Proceeds from sale of assets and businesses, net of costs to sell 21 45 34
Interest settlements from cross-currency swaps 23 0 0
Net cash used in investing activities (261) (419) (196)
Cash Flows From Financing Activities      
Issuance of long-term debt, net of discounts 3,455 5,960 8,944
Repayments of long-term debt (5,642) (4,406) (10,101)
Borrowings of short-term debt 1 12 0
Repayments of short-term debt (1) (12) (3)
Payment of employee withholding taxes related to share-based awards (30) (40) (10)
Payments of acquisition-related contingent consideration (35) (35) (37)
Payments of deferred consideration 0 0 (18)
Payments of financing costs (39) (28) (102)
Other (3) (8) (26)
Net cash (used in) provided by financing activities (2,294) 1,443 (1,353)
Effect of exchange rate changes on cash and cash equivalents 16 (4) (26)
Net (decrease) increase in Cash and cash equivalents and Restricted cash (1,428) 2,521 (74)
Cash and cash equivalents and Restricted cash, beginning of year 3,244 723 797
Cash and cash equivalents and Restricted cash, end of year 1,816 3,244 723
Cash and cash equivalents, end of year 605 3,243 721
Restricted cash, end of year 1,211 1 2
Cash and cash equivalents and Restricted cash, end of year $ 3,244 $ 723 $ 723
XML 26 R8.htm IDEA: XBRL DOCUMENT v3.20.4
DESCRIPTION OF BUSINESS
12 Months Ended
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
DESCRIPTION OF BUSINESS DESCRIPTION OF BUSINESSBausch Health Companies Inc. (the “Company”), formerly known as Valeant Pharmaceuticals International, Inc., is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately 100 countries. Effective August 9, 2013, the Company continued from the federal jurisdiction of Canada to the Province of British Columbia, meaning that the Company became a company registered under the laws of the Province of British Columbia as if it had been incorporated under the laws of the Province of British Columbia. As a result of this continuance, the legal domicile of the Company became the Province of British Columbia, the Canada Business Corporations Act ceased to apply to the Company and the Company became subject to the British Columbia Business Corporations Act.
XML 27 R9.htm IDEA: XBRL DOCUMENT v3.20.4
SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation and Use of Estimates
The Consolidated Financial Statements have been prepared by the Company in United States (“U.S.”) dollars and in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.
Separation of the Bausch + Lomb Eye-Health Business
On August 6, 2020, the Company announced that it intends to separate its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the “Separation”). The Separation will establish two separate companies that include: (i) a fully integrated eye-health company which will consist of the Company’s Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmology Rx businesses and (ii) a diversified pharmaceutical company which will include the Company’s Salix, International Rx, Solta, neurology and medical dermatology pharmaceutical businesses. The anticipated separation is subject to regulatory approvals and certain conditions, including final approval by the Company’s Board of Directors and any shareholder vote requirements that may be applicable.
The Company has begun addressing the internal organizational design and structure of the new entity which it anticipates having substantially completed by late 2021. Management is also exploring various capitalization structures and the form of the Separation transaction in order to properly capitalize both entities post-separation. As of the date of the issuance of these financial statements, the Company is in the planning phase of the Separation. As such, there are considerations, approvals and conditions that will determine the ultimate timing and structure of the Separation and there can be no assurance that such a transaction will occur. These Consolidated Financial Statements do not include any adjustments to give effect to the Separation.
Impacts of COVID-19 Pandemic
The unprecedented nature of the COVID-19 pandemic has adversely impacted the global economy. The COVID-19 pandemic and the rapidly evolving reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have intensified and have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions. The COVID-19 pandemic has also significantly increased demand for certain goods and services, such as pandemic-related medical services and supplies, alongside decreased demand for others, such as retail, hospitality, elective medical procedures and travel.
The extent to which these events may continue to impact the Company's business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company's control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, the ultimate geographic spread and duration of the pandemic, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, if any, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the
reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company's business, financial condition, cash flows and results of operations.
To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable.
Use of Estimates
In preparing the Company's Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company’s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks.
On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s Consolidated Financial Statements could be materially impacted.
Reclassifications
Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Acquisitions
Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition. Acquired in-process research and development (“IPR&D”) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&D with no alternative future use is charged to expense at the acquisition date and any future contingent consideration is not recorded until it becomes probable.
Fair Value of Financial Instruments
The estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events.
Fair Value of Derivative Instruments
The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.
The Company’s cross-currency swaps qualify for and have been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value is determined via a mark-to-market analysis, using observable (Level 2) inputs. These inputs may include: (i) the foreign currency exchange spot rate between the euro and U.S. dollar, (ii) the interest rate yield curves in the euro and U.S. dollar and (iii) the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Loss as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulated other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps was ineffective. The Company uses the spot method of assessing hedge effectiveness. The Company has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as a reduction of Interest expense in the Consolidated Statements of Operations.
The Company uses foreign currency exchange contracts to economically hedge the foreign exchange exposure on certain of the Company’s intercompany and third party balances. The Company's foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other.
Cash and Cash Equivalents
Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of three months or less when purchased.
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, cross-currency swaps and foreign currency exchange contracts.
The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than three months. Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.
The Company’s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company’s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Brazil, Egypt, Greece, among other members of the European Union, Turkey, Ukraine and Venezuela have been weak in recent years. These conditions have increased, and may continue to increase, the average length of time that it takes to collect on the Company’s trade receivables outstanding in these countries.
As of December 31, 2020, the Company’s three largest U.S. wholesaler customers accounted for approximately 38% of net trade receivables. In addition, as of December 31, 2020 and 2019, the Company’s net trade receivable balance from Argentina, Brazil, Egypt, Greece, Serbia, Turkey, Ukraine, Venezuela and Vietnam amounted to $166 million and $156 million, respectively, the majority of which is current or less than 90 days past due. The portion of the net trade receivable from these countries that is past due more than 90 days amounted to $2 million, as of December 31, 2020, a portion of which is comprised of public hospitals. Based on an analysis of credit risk, including an analysis of bad debt experience
and assessment of historical payment patterns for such customers, the Company has established a reserve covering more than half of the balance past due more than 90 days for such countries. Over the three-year period ended December 31, 2020, the Company has not experienced any material losses from uncollectible accounts in excess of the established reserves.
The Company does not enter into financial instruments for trading or speculative purposes. Further, the Company has a policy of only entering into contracts with parties that have at least an investment grade credit rating. The Company enters into cross-currency swaps and foreign currency exchange contracts with high credit quality financial institutions. The counter-parties to the Company's cross-currency swaps and foreign currency exchange contracts are major financial institutions, and there is no significant concentration of exposure with any one counter-party. To date, no counterparty has failed to meet its obligations to the Company and management believes the risk of loss associated with these contracts is remote. See Note 5, "FAIR VALUE MEASUREMENTS" for additional details regarding the Company's cross-currency swaps and foreign currency exchange contracts.
Allowance for Credit Losses
An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.  Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. Allowance for credit losses were $39 million, $48 million and $47 million as of December 31, 2020, 2019 and 2018, respectively. The activity in the allowance for credit losses for trade receivables for the years 2020, 2019 and 2018 is as follows.
(in millions)202020192018
Balance, beginning of period$48 $47 $97 
Retrospective effect of application of new accounting standard— — 
Provision10 
Write-offs(12)(10)(50)
Recoveries
Foreign exchange and other
(3)— (6)
Balance, end of period$39 $48 $47 
Inventories
Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads.
The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.
Property, Plant and Equipment
Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful lives:
Land improvements
15 - 30 years
Buildings and improvements
Up to 40 years
Machinery and equipment
3 - 20 years
Other equipment
3 - 10 years
Equipment on operating lease
Up to 5 years
Leasehold improvements
Lesser of term of lease or 10 years
Intangible Assets
Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. Amortization is calculated primarily using the straight-line method based on the following estimated useful lives:
Product brands
1 - 20 years
Corporate brands
7 - 20 years
Product rights/patents
4 - 15 years
Partner relationships
7 - 9 years
Out-licensed technology and other
8 - 9 years
Divestitures of Products
The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense (income), net. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.
IPR&D
The fair value of IPR&D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and amortized. Acquired IPR&D assets are tested for impairment at least annually or when triggering events are identified.
The fair value of an acquired IPR&D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset’s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset’s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow streams.
Impairment of Long-Lived Assets
Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows.
Indefinite-lived intangible assets, which includes acquired IPR&D and the corporate trademark acquired in the acquisition of Bausch & Lomb Holdings Incorporated (the ‘‘B&L Trademark’’), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.
Goodwill
Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. A reporting unit is the same as, or one level below, an operating segment. An entity is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit’s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.
An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company’s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors
changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company’s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values.
Effective January 1, 2018, the Company elected to early adopt guidance issued by the Financial Accounting Standards Board ("FASB") which simplified the subsequent measurement of goodwill by eliminating “Step 2” from the goodwill impairment test. Instead, as of January 1, 2018 and all subsequent periods, goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value.
Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs
Debt discounts, premiums and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility.
Foreign Currency Translation
The assets and liabilities of the Company’s foreign operations having a functional currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets.
Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation’s functional currency are recognized as a component of Foreign exchange and other in the Consolidated Statements of Operations.
Revenue Recognition
The Company’s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, gastroenterology ("GI") and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, "SEGMENT INFORMATION" for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.
The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
Product Sales
A contract with the Company’s customers exists for each product sale. Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed below. The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products.
Product Sales Provisions
As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.  The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers.
Provisions for variable consideration are established to reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.
Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities. 
The following table presents the activity and ending balances of the Company’s variable consideration provisions the years 2020 and 2019.
(in millions)Discounts
and
Allowances
ReturnsRebatesChargebacksDistribution
Fees
Total
Reserve balance, January 1, 2019$175 $813 $1,024 $209 $163 $2,384 
Acquisition of Synergy— 12 — 16 
Current period provision776 113 2,265 1,938 195 5,287 
Payments and credits(769)(238)(2,374)(1,979)(277)(5,637)
Reserve balance, December 31, 2019182 691 927 168 82 2,050 
Current period provision621 120 2,174 1,925 196 5,036 
Payments and credits(613)(236)(2,322)(1,909)(193)(5,273)
Reserve balance, December 31, 2020$190 $575 $779 $184 $85 $1,813 
Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $32 million and $29 million as of December 31, 2020 and 2019, respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets.
The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company’s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics. The following describes the major sources of variable consideration in the Company’s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration.
Cash Discounts and Allowances
Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within one month of incurring the liability.
Returns
Consistent with industry practice, customers are generally allowed to return a product within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The
returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.
In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information. These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. A change of 1% in the estimated return rates would have impacted the Company’s pre-tax earnings by approximately $76 million for the year 2020.
The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not warrant revision to the provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S. National Drug Codes (“NDC”) of products. Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S. customers generally permit only one NDC per product for identification and tracking within their inventory systems.
Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for 2020 and 2019 were $120 million and $113 million, respectively, and includes reductions in variable consideration for sales return provisions related to past sales of approximately $38 million and $80 million, respectively.
Rebates and Chargebacks
Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates.  The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270 days after the quarter in which the product is dispensed to the Medicaid participant. As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. A change of 1% in the estimated rates used in the Medicaid rebate reserve would have impacted the Company’s pre-tax earnings by approximately $76 million for 2020. Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods.
Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market share.
Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers.
In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or chargebacks.
The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts implemented in each of the last three years, changes in the Company’s product portfolio due to recent acquisitions and increased Medicaid utilization due to expansion of government funding for these programs. Management’s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel.
Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2020 and 2019 were not material to the Company’s revenues or earnings.
Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company’s products. Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management’s estimate of the discount, rebate and loyalty incentives attributable to a sale. That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any.
Distribution Fees
The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart. The Company has Distribution Services Agreements ("DSAs") with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty. Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes. Additionally, price appreciation credits are generated when the Company increases a product’s wholesaler acquisition cost (“WAC”) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $15 million and $11 million for the years 2020 and 2019, respectively.
Contract Assets and Contract Liabilities
There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented.
Sales Commissions
Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.
Financing Component
The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less. The Company's global payment terms are generally between thirty to ninety days.
Leases
The Company leases certain facilities, vehicles and equipment principally under multi-year agreements generally having a lease term of one to twenty years, some of which include termination options and options to extend the lease term from one to five years or on a month-to-month basis. The Company includes options that are reasonably certain to be exercised as part of the lease term. The Company may negotiate termination clauses in anticipation of changes in market conditions but
generally, these termination options are not exercised. Certain lease agreements also include variable payments that are dependent on usage or may vary month-to-month such as insurance, taxes and maintenance costs. None of the Company's lease agreements contain material residual value guarantees or material restrictive covenants.
Effective January 1, 2019, the Company adopted a new standard revising the accounting for leases, using the modified retrospective approach. Upon adoption, the Company elected the available practical expedients, including: (i) the package of practical expedients as defined in the accounting guidance, which among other things, allowed the carry forward of historical lease classifications, (ii) the election to use hindsight in determining the lease terms for all leases, (iii) the transition method, which does not require the restatement of prior periods, (iv) the election to aggregate lease components with non-lease components and account for these payments as a single lease component and (v) the short-term lease exemption, which does not require recognition on the balance sheet for leases with an initial term of 12 months or less. The Company has updated its systems, processes and controls to track, record and account for its lease portfolio, including implementation of a third-party software tool to assist in complying with the new standard. Upon adoption of the new standard, the Company recognized a right-of-use asset and a corresponding lease liability of $302 million. The adoption of the standard did not have a material impact on the Consolidated Statements of Operations, Comprehensive Loss, Equity and Cash Flows for any of the periods presented. See Note 12, "LEASES" for additional details and application of this standard.
The Company is required to record a right-of-use asset and corresponding lease liability, equal to the present value of the lease payments at the commencement date of each lease. For all asset classes, in determining future lease payments, the Company has elected to aggregate lease components, such as payments for rent, taxes and insurance costs with non-lease components such as maintenance costs, and account for these payments as a single lease component. In limited circumstances, when the information necessary to determine the rate implicit in a lease is available, the present value of the lease payments is determined using the rate implicit in that lease. If the information necessary to determine the rate implicit in a lease is not available, the Company uses its incremental borrowing rate at the commencement of the lease, which represents the rate of interest that the Company would incur to borrow on a collateralized basis over a similar term.
All leases must be classified as either an operating lease or finance lease. The classification is determined based on whether substantive control has been transferred to the lessee. The classification governs the pattern of lease expense recognition. For leases classified as operating leases, total lease expense over the term of the lease is equal to the undiscounted payments due in accordance with the lease arrangement. Fixed lease expense is recognized periodically on a straight-line basis over the term of each lease and includes: (i) imputed interest during the period on the lease liability determined using the effective interest rate method plus (ii) amortization of the right-of-use asset for that period. Amortization of the right-of-use asset during the period is calculated as the difference between the straight-line expense and the imputed interest on the lease liability for that period. Variable lease expense is recognized when the achievement of the specific target is considered probable.
Research and Development Expenses
Costs related to internal research and development programs, including costs associated with the development of acquired IPR&D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses. Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.
Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.
Legal Costs
Legal fees and other costs related to litigation and other legal proceedings or services are expensed as incurred and are included in Selling, general and administrative expenses. Certain legal costs associated with acquisitions are included in Acquisition-related costs and certain legal costs associated with divestitures, legal settlements and other business development activities are included in Litigation and other matters or Net (gain) loss on sales of assets within Other expense (income), net, as appropriate. Legal costs expensed are reported net of expected insurance recoveries. A claim for insurance recovery is recognized when realization becomes probable.
Advertising Costs
Advertising costs comprise product samples, print media, promotional materials and television advertising and are expensed on the first use of the advertisement. Included in Selling, general and administrative expenses are advertising costs of $451 million, $544 million and $481 million, for 2020, 2019 and 2018, respectively.
Share-Based Compensation
The Company recognizes all share-based payments to employees, including grants of employee stock options and restricted share units (“RSUs”), at estimated fair value. The Company amortizes the fair value of stock option or RSU grants on a straight-line basis over the requisite service period of the individual stock option or RSU grant, which generally equals the vesting period. Stock option and RSU forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation is recorded in Research and development expenses and Selling, general and administrative expenses, as appropriate.
Acquisition-Related Contingent Consideration
Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in fair value measurement accounting.
Interest Expense
Interest expense includes standby fees, the amortization of debt discounts and deferred financing costs, accretion of debt premiums and the amortization of amounts excluded from the assessment of effectiveness related to the Company's cross-currency swaps. Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized. Capitalized interest related to construction in progress as of December 31, 2020 and 2019 was $45 million and $34 million, respectively, and is included in Property, plant and equipment, net.
Income Taxes
Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and laws. Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future.
In October 2016, the FASB issued guidance requiring an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, rather than when the asset has been sold to an outside party. This guidance was effective for the Company January 1, 2018 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit and deferred income taxes as of the effective date. The Company recorded a net cumulative-effect adjustment of $1,209 million to increase deferred income tax assets and decrease the opening balance of Accumulated deficit for the income tax consequences deferred from past intra-entity transfers involving assets other than inventory.
The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than 50% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within one year. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance sheets.
Loss Per Share Attributable to Bausch Health Companies Inc.
Basic loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. Diluted loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period
after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock method.
Comprehensive Loss
Comprehensive loss comprises Net loss and Other comprehensive (loss) income. Other comprehensive (loss) income includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders’ equity.
Contingencies
In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a liability. These accruals are adjusted periodically as assessments change or additional information becomes available.
If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred.
Employee Benefit Plans
The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed 10 percent of the greater of the plan’s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements.
Adoption of New Accounting Standards
In June 2016, the FASB issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses. The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to Accumulated deficit of less than $1 million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows.
In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement.  The guidance was effective for the Company beginning January 1, 2020. The application of this guidance did not have a material effect on the Company's disclosures.
In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.  Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging. The optional amendments are effective for all entities as of March 12, 2020, through December 31, 2022. During 2020, the Company has not entered into any contract modifications in which the optional expedients were applied.  However, if prior to December 31, 2022 the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.
In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans.  The guidance was effective for annual periods ending after December 15, 2020. The application of this guidance did not have a material effect on the Company's disclosures.
Recently Issued Accounting Standards, Not Adopted as of December 31, 2020
In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.  The guidance is effective for annual periods beginning after December 15, 2020.  The application of this guidance is not expected to have a material effect on the Company's financial position, results of operations and cash flows.
XML 28 R10.htm IDEA: XBRL DOCUMENT v3.20.4
ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE
12 Months Ended
Dec. 31, 2020
Business Combinations [Abstract]  
ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE
Acquisition Agreement for Synergy Pharmaceuticals Inc.
On March 6, 2019, the Company acquired certain assets of Synergy Pharmaceuticals Inc. ("Synergy") for a cash purchase price of approximately $180 million and the assumption of certain liabilities, pursuant to the terms approved by the U.S. Bankruptcy Court for the Southern District of New York on March 1, 2019. Among the assets acquired are the worldwide rights to the Trulance® (plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. This acquired business is included in the Company's Salix segment and is expected to result in additional revenues and costs savings associated with business synergies.
Assets Acquired and Liabilities Assumed
The acquisition of certain assets of Synergy has been accounted for as a business combination under the acquisition method of accounting since: (i) substantially all of the fair value of the assets acquired is not concentrated in a single identifiable asset or group of similar identifiable assets and (ii) substantive inputs and processes were acquired to contribute to the creation of outputs. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:
(in millions)
Accounts receivable$
Inventories24 
Prepaid expenses and other current assets
Product brand intangible assets (estimated useful life 7 years)
159 
Accounts payable(1)
Accrued expenses(17)
Total identifiable net assets177 
Goodwill
Total fair value of consideration transferred$180 
Goodwill associated with the acquisition of certain assets of Synergy is not deductible for income tax purposes.
Revenue and Operating Results
Revenues associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 were $55 million. Operating results associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 and pro-forma revenues and operating results for the year 2019 were not material. Included in Other expense (income), net for 2019 are acquisition-related costs of $8 million directly related to the acquisition of certain assets of Synergy, which include expenditures for advisory, legal, valuation, accounting and other similar services.
Noncontrolling Interest in Medpharma
On October 16, 2018, using cash on hand, the Company acquired the 40% noncontrolling interest of Medpharma Pharmaceutical & Chemical Industries LLC (“Medpharma”) for $18 million. The difference between the carrying value and the price paid for the noncontrolling interest in Medpharma of $15 million, is a reduction of additional paid-in capital.
There were no other material business combinations in 2020, 2019 or 2018. The measurement period for all acquisitions has closed.
Option to Purchase All Ophthalmology Assets of Allegro Ophthalmics, LLC ("Allegro")
On September 21, 2020, the Company announced that it had entered into an agreement to acquire an option to purchase all of the ophthalmology assets of Allegro (the "Option"), a privately held biopharmaceutical company focused on the development of therapies that regulate integrin functions for the treatment of ocular diseases. Among the assets to be acquired if the Option is exercised, is the worldwide rights to risuteganib (Luminate®), Allegro's lead investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry Age-related Macular Degeneration ("AMD"). A U.S. Phase 2a study with risuteganib in intermediate dry AMD met its primary endpoint of vision recovery and Phase 3 testing is in the planning stages. The aggregate payments to acquire the Option are $50 million and include an upfront payment of $10 million and a second payment of $40 million should Allegro raise additional funding. During the three months ended September 30, 2020, the Company made and expensed the upfront payment of $10 million as acquired IPR&D included in Other expense (income), net. If the Option is exercised, additional payments to acquire all ophthalmology assets of Allegro will be due.
Licensing Agreements
In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. The commitment periods under these agreements vary and include customary termination provisions. Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.
Assets Held for Sale
During the three months ended December 31, 2020, the Company identified for disposal a certain business within the Bausch + Lomb/International segment. This business was classified as held for sale as of December 31, 2020.
The carrying amounts of the assets and liabilities held for sale included in the Consolidated Balance Sheet as of December 31, 2020 are as follows:
(in millions)
Prepaid expenses and other current assets:
Trade receivables, net$91 
Inventories, net63 
Prepaid expenses and other current assets
$162 
Other non-current assets:
Property, plant and equipment, net$68 
Goodwill and Intangible assets, net245 
Deferred tax assets, net
$315 
Accrued and other current liabilities:
Accounts payable$
Accrued and other current liabilities28 
$35 
Other non-current liabilities:
Deferred tax liabilities, net$36 
Other non-current liabilities21 
$57 
Included within Deferred tax liabilities, net, are book to income tax differences related to the Company's intangible assets.
As a result of meeting the criteria for held for sale classification, the carrying value of this business, was adjusted to its estimated fair value, less costs to sell, and the Company recognized a loss of $96 million within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. This loss was primarily due to the anticipated release of non-cash cumulative foreign currency translation losses of $344 million, which were included as part of the carrying value of this business when measuring for impairment. These losses will be reclassified from Accumulated other comprehensive loss to Net loss upon the disposal of this business.
XML 29 R11.htm IDEA: XBRL DOCUMENT v3.20.4
RESTRUCTURING, INTEGRATION AND SEPARATION COSTS
12 Months Ended
Dec. 31, 2020
Restructuring and Related Activities [Abstract]  
RESTRUCTURING, INTEGRATION AND SEPARATION COSTS RESTRUCTURING, INTEGRATION AND SEPARATION COSTS
Restructuring and integration costs
The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i) reducing headcount, (ii) eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of December 31, 2020 was $20 million.
During 2020, the Company incurred $11 million of restructuring and integration-related costs. These costs included: (i) $10 million of facility closure costs and (ii) $1 million of severance and other costs. The Company made payments of $18 million during 2020.
During 2019, the Company incurred $31 million of restructuring and integration costs. These costs included: (i) $11 million of severance costs and other costs associated with the acquisition of certain assets of Synergy, (ii) $11 million of facility closure costs and (iii) $9 million of other severance costs. The Company made payments of $31 million during 2019.
During 2018, the Company incurred $22 million of restructuring and integration costs. These costs included: (i) $11 million of severance costs, (ii) $10 million of facility closure costs and (iii) $1 million of other costs. The Company made payments of $33 million during 2018.
Separation costs and separation-related costs
The Company has incurred, and will incur, costs associated with activities to effectuate the Separation. These activities include: (i) separating the eye-health business from the remainder of the Company and (ii) registering the eye-health business as an independent publicly traded entity. Separation costs are incremental costs directly related to the Separation and include, but are not limited to: (i) legal, audit and advisory fees, (ii) employee hiring, relocation and travel costs and (iii) costs associated with establishing a new board of directors and audit committee. Included in Restructuring, integration and separation costs for 2020 is $11 million of separation costs.
The Company has also incurred, and will incur, separation-related costs which are incremental costs indirectly related to the Separation. Separation-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative expenses for 2020 is $21 million of separation-related costs.
The Company is in the planning phase of the Separation and the extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.
XML 30 R12.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE MEASUREMENTS
12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
Fair value measurements are estimated based on valuation techniques and inputs categorized as follows:
Level 1 — Quoted prices in active markets for identical assets or liabilities;
Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
Level 3 — Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.
If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
Assets and Liabilities Measured at Fair Value on a Recurring Basis
The following fair value hierarchy table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a recurring basis as of:
 December 31, 2020December 31, 2019
 (in millions)Carrying
Value
Level 1Level 2Level 3Carrying
Value
Level 1Level 2Level 3
Assets:        
Cash equivalents$41 $$33 $— $2,696 $2,646 $50 $— 
Restricted Cash$1,211 $1,211 $— $— $$$— $— 
Foreign currency exchange contracts$$— $$— $— $— $— $— 
Liabilities:    
Acquisition-related contingent consideration
$328 $— $— $328 $316 $— $— $316 
Cross-currency swaps
$70 $— $70 $— $13 $— $13 $— 
Foreign currency exchange contracts$11 $— $11 $— $— $— $— $— 
Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.
As of December 31, 2020, Restricted cash includes $1,210 million of payments into an escrow fund under the terms of a settlement agreement regarding certain U.S. securities litigation, subject to an objector's appeal of the final court approval, and is reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to its short-term nature. These payments will remain in escrow until final approval of the settlement as discussed in Note 20, "LEGAL PROCEEDINGS".
There were no transfers into or out of Level 3 during 2020 and 2019.
Cross-currency Swaps
During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,250 million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from adverse movements in exchange rates. The euro-denominated net investment being hedged is the Company’s investment in certain euro-denominated subsidiaries. Prior to 2019, the Company had no cross-currency swaps.
The fair value of the Company’s cross-currency swaps liability as of December 31, 2020 and 2019 was $70 million and $13 million, respectively. Included in Other non-current liabilities is $79 million and $22 million of cross-currency swaps and included in Prepaid expenses and other current assets is $9 million and $9 million of earned interest within the Consolidated Balance Sheets as of December 31, 2020 and 2019, respectively.
The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for 2020 and 2019:
(in millions)20202019
Loss recognized in Other comprehensive loss$(57)$(22)
Gain excluded from assessment of hedge effectiveness$23 $
Location of gain of excluded componentInterest Expense
Settlement of the Company's cross-currency swaps occurs in February and August each year. During 2020, the Company received $23 million in settlements which are reported as Investing activities in the Consolidated Statements of Cash Flows.
Foreign Currency Exchange Contracts
During 2020, the Company entered into foreign currency exchange contracts, with an aggregate notional amount of $485 million. Prior to 2020, the Company had no foreign currency exchange contracts for any period presented.
The fair value of the Company's foreign currency exchange contracts liability as of December 31, 2020 was $8 million. Included in Accrued and other current liabilities are $11 million and included in Prepaid expenses and other current assets are $3 million of foreign currency exchange contracts within the Consolidated Balance Sheets. During 2020, the net change
in fair value was a loss of $8 million. Settlements of the Company's foreign currency exchange contracts are reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Consolidated Statements of Cash Flows. During 2020, the Company reported a realized loss of $2 million related to settlements of the Company's foreign currency exchange contracts.
Acquisition-related Contingent Consideration Obligations
The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level 3) inputs. These inputs may include: (i) the estimated amount and timing of projected cash flows, (ii) the probability of the achievement of the factor(s) on which the contingency is based and (iii) the risk-adjusted discount rate used to present value the probability-weighted cash flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At December 31, 2020, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 25%, and a weighted average risk-adjusted discount rate of 8%. The weighted average risk-adjusted discount rate was calculated by weighting each contract's relative fair value at December 31, 2020.
The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3) for the years 2020 and 2019:
(in millions)20202019
Beginning balance, January 1, $316 $339 
Adjustments to Acquisition-related contingent consideration:
Accretion for the time value of money$23 $22 
Fair value adjustments25 (10)
Acquisition-related contingent consideration adjustments48 12 
Payments / Settlements(36)(36)
Foreign currency translation adjustment included in other comprehensive loss— 
Ending balance, December 31,328 316 
Current portion112 54 
Non-current portion$216 $262 
Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis
The following table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a non-recurring basis:
 December 31, 2020December 31, 2019
(in millions)Carrying
Value
Level 1Level 2Level 3Carrying
Value
Level 1Level 2Level 3
Other non-current assets:
Non-current assets held for sale$245 $— $— $245 $39 $— $— $39 
Non-current assets held for sale of $245 million as of December 31, 2020 were remeasured to estimated fair value, less costs to sell, which utilized Level 3 unobservable inputs. See Note 3, "ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE" for additional details regarding these assets held for sale.
In 2019, the Company identified certain products in the Bausch + Lomb/International segment and one product in the Diversified Products segment for disposal. The products and the related assets and liabilities of this disposal group qualified as a business and an impairment of $8 million associated with this business was recognized during the three months ended September 30, 2019. As a result of changing business dynamics, during the three months ended March 31, 2020, the Company decided not to sell these assets and reclassified $39 million of held for sale assets as assets held and used at their respective fair values at the date of the decision not to sell. This reclassification did not impact the Consolidated Statement of Operations for 2020.
Fair Value of Long-term Debt
The fair value of long-term debt as of December 31, 2020 and 2019 was $25,378 million and $27,520 million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2).
XML 31 R13.htm IDEA: XBRL DOCUMENT v3.20.4
INVENTORIES
12 Months Ended
Dec. 31, 2020
Inventory Disclosure [Abstract]  
INVENTORIES INVENTORIES
Inventories, net, as of December 31, 2020 and 2019 consist of:
(in millions)20202019
Raw materials$286 $319 
Work in process143 149 
Finished goods665 639 
$1,094 $1,107 
XML 32 R14.htm IDEA: XBRL DOCUMENT v3.20.4
PROPERTY, PLANT AND EQUIPMENT
12 Months Ended
Dec. 31, 2020
Property, Plant and Equipment [Abstract]  
PROPERTY, PLANT AND EQUIPMENT PROPERTY, PLANT AND EQUIPMENT
The major components of property, plant and equipment as of December 31, 2020 and 2019 consist of:
(in millions)20202019
Land$79 $79 
Buildings and improvements686 696 
Machinery and equipment1,722 1,606 
Other equipment and leasehold improvements360 369 
Equipment on operating lease65 56 
Construction in progress436 301 
3,348 3,107 
Accumulated depreciation(1,781)(1,641)
$1,567 $1,466 
Depreciation expense was $180 million, $178 million and $175 million for 2020, 2019 and 2018, respectively.
XML 33 R15.htm IDEA: XBRL DOCUMENT v3.20.4
INTANGIBLE ASSETS AND GOODWILL
12 Months Ended
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS AND GOODWILL INTANGIBLE ASSETS AND GOODWILL
Intangible Assets
The major components of intangible assets as of December 31, 2020 and 2019 consist of:
 Weighted-
Average
Remaining
Useful
Lives
(Years)
20202019
(in millions)Gross
Carrying
Amount
Accumulated
Amortization and Impairments
Net
Carrying
Amount
Gross
Carrying
Amount
Accumulated
Amortization and Impairments
Net
Carrying
Amount
Finite-lived intangible assets:
       
Product brands6$20,890 $(14,914)$5,976 $21,011 $(13,544)$7,467 
Corporate brands7907 (404)503 930 (338)592 
Product rights/patents33,305 (3,055)250 3,297 (2,887)410 
Partner relationships1169 (168)166 (165)
Technology and other3210 (200)10 209 (189)20 
Total finite-lived intangible assets25,481 (18,741)6,740 25,613 (17,123)8,490 
Acquired IPR&D not in serviceNA— 13 — 13 
B&L TrademarkNA1,698 — 1,698 1,698 — 1,698 
 $27,186 $(18,741)$8,445 $27,324 $(17,123)$10,201 
Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments, including loss on assets held for sale in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present.
Asset impairments, including loss on assets held for sale in 2020 included impairments of: (i) $96 million to reduce the carrying value of a business within the Bausch + Lomb/International segment to its estimated fair value less costs to sell due to classifying the business as held for sale as discussed in Note 3, "ACQUISITIONS, LICENSING AGREEMENTS
AND ASSETS HELD FOR SALE", (ii) $16 million in aggregate, due to decreases in forecasted sales of certain product lines, (iii) $1 million in aggregate, related to the discontinuance of certain product lines not aligned with the focus of the Company's core businesses and (iv) $1 million related to Acquired IPR&D not in service.
Asset impairments, including loss on assets held for sale in 2019 included impairments of: (i) $58 million reflecting decreases in forecasted sales of certain product lines due to generic competition and other factors, (ii) $8 million related to assets being classified as held for sale, (iii) $5 million related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses and (iv) $4 million related to Acquired IPR&D not in service.
Asset impairments, including loss on assets held for sale in 2018 included impairments of: (i) $263 million reflecting decreases in forecasted sales for the Uceris® Tablet product in the Company's Salix reporting unit due to generic competition, (ii) $85 million reflecting decreases in forecasted sales of certain other product lines due to generic competition, (iii) $132 million reflecting decreases in forecasted sales for the Arestin® product in the Company's Dentistry reporting unit and other product lines due to changing market conditions, (iv) $55 million, in aggregate, related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses, (v) $28 million to Acquired IPR&D not in service related to a certain product and (vi) $5 million related to assets being classified as held for sale.
The impairments to assets reclassified as held for sale were measured as the difference of the carrying value of these assets as compared to the estimated fair values of these assets less costs to sell determined using a discounted cash flow analysis which utilized Level 3 unobservable inputs. The other impairments and adjustments to finite-lived intangible assets were measured as the difference of the historical carrying value of these finite-lived assets as compared to the estimated fair value as determined using a discounted cash flow analysis using Level 3 unobservable inputs.
Periodically, the Company’s products face the expiration of their patent or regulatory exclusivity. The Company anticipates that product sales for such product would decrease shortly following a loss of exclusivity ("LOE"), due to the possible entry of a generic competitor. Where the Company has the rights, it may elect to launch an authorized generic of such product (either as the Company’s own branded generic or through a third-party). This may occur prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product could still be significant, and the effect on future revenues could be material.
Management continually assesses the useful lives related to the Company's long-lived assets to reflect the most current assumptions.
Effective September 12, 2018, the Company changed the estimated useful life of its Xifaxan®-related intangible assets due to the positive impact of an agreement between the Company and Actavis Laboratories FL, Inc. ("Actavis") resolving the intellectual property litigation regarding Xifaxan® tablets, 550 mg. Under the agreement, the parties agreed to dismiss all litigation related to Xifaxan® tablets, 550 mg and all intellectual property protecting Xifaxan® will remain intact and enforceable. As a result, the useful life of the Xifaxan®-related intangible assets was extended from 2024 to January 1, 2028. As this change in the estimated useful life is a change in an accounting estimate, amortization expense is impacted prospectively. The change in the estimated useful life of the Xifaxan®-related intangible assets resulted in a decrease to the Net loss attributable to Bausch Health Companies Inc. of $476 million, $473 million and $143 million, and a decrease to the Basic and Diluted Loss per share attributable to Bausch Health Companies Inc. of $1.34, $1.34 and $0.41 for the years 2020, 2019 and 2018, respectively. As of December 31, 2020, the net carrying value of the Xifaxan®-related intangible assets was $3,771 million.
Estimated amortization expense of finite-lived intangible assets for the five years ending December 31 and thereafter are as follows:
(in millions)20212022202320242025ThereafterTotal
Amortization$1,389 $1,204 $1,030 $905 $822 $1,390 $6,740 
Goodwill
The changes in the carrying amounts of goodwill during the years ended December 31, 2020, 2019 and 2018 were as follows:
(in millions)Bausch +
Lomb/
International
Branded RxU.S. Diversified ProductsSalixOrtho DermatologicsDiversified ProductsTotal
Balance, January 1, 2018$6,016 $6,631 $2,946 $— $— $— $15,593 
Impairment of the Salix and Ortho Dermatologics reporting units
— (2,213)— — — — (2,213)
Realignment of Global Solta reporting unit goodwill
(82)115 (33)— — — — 
Goodwill reclassified to assets held for sale and subsequently disposed
(2)— — — — — (2)
Realignment of segment goodwill
— (4,533)(2,913)3,156 1,267 3,023 — 
Impairment of the Dentistry reporting unit
— — — — — (109)(109)
Foreign exchange and other(127)— — — — — (127)
Balance, December 31, 20185,805 — — 3,156 1,267 2,914 13,142 
Acquisition of certain assets of Synergy
— — — — — 
Goodwill reclassified to assets held for sale (Note 5)(18)— — — — — (18)
Foreign exchange and other(1)— — — — — (1)
Balance, December 31, 20195,786 — — 3,159 1,267 2,914 13,126 
Assets held for sale reclassified to goodwill (Note 5)18 — — — — — 18 
Goodwill reclassified to assets held for sale (Note 3)(217)— — — — — (217)
Foreign exchange and other117 — — — — — 117 
Balance, December 31, 2020$5,704 $— $— $3,159 $1,267 $2,914 $13,044 
Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1).
The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit's terminal value.
To forecast a reporting unit's cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management's and a market participant's view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected LOE to the Company's product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company’s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future.
2018
Adoption of New Accounting Guidance for Goodwill Impairment Testing
Effective January 1, 2018, the Company elected to early adopt a new accounting standard which simplifies the subsequent measurement of goodwill by eliminating “Step 2” from the goodwill impairment test. Goodwill impairment is now measured as the amount by which a reporting unit's carrying value exceeds its fair value. Upon adopting the new standard, the Company tested goodwill for impairment and determined that the carrying value of the Salix reporting unit exceeded its fair value resulting in the Company recognizing a goodwill impairment of $1,970 million associated with the Salix reporting unit.
The Company conducted its 2017 annual goodwill impairment test as of October 1, 2017 and determined that the fair value of the Ortho Dermatologics reporting unit exceeded its carrying value. However, at January 1, 2018, unforeseen changes in the business dynamics of the Ortho Dermatologics reporting unit, such as: (i) changes in the dermatology sector, (ii) increased pricing pressures from third-party payors, (iii) additional risks to the exclusivity of certain products and (iv) an expected longer launch cycle for a new product, were factors that negatively impacted the reporting unit's operating results beyond management's expectations as of October 1, 2017. In response to these adverse business indicators, as of January 1, 2018, the Company reduced its near and long term financial projections for the Ortho Dermatologics reporting unit. As a result of the reductions in the near and long term financial projections, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at January 1, 2018 and the Company recognized a goodwill impairment of $243 million.
2018 Realignment of Solta Business
Effective March 1, 2018, revenues and profits from the U.S. Solta business included in the former U.S. Diversified Products segment in prior periods and revenues and profits from the international Solta business included in the Bausch + Lomb/International segment in prior periods, are reported in a new Global Solta reporting unit, which, at that time, was a part of the former Branded Rx segment. As a result of this change, $115 million of goodwill was reallocated to the new Global Solta reporting unit and the Company assessed the impact on the fair values of each of the reporting units affected. After considering, among other matters: (i) the limited period of time between last impairment test (January 1, 2018) and the realignment (March 1, 2018), (ii) the results of the last impairment test and (iii) the amount of goodwill reallocated to the new Global Solta reporting unit, the Company did not identify any indicators of impairment at the time of the realignment.
2018 Realignment of Segment Structure
In the second quarter of 2018, the Company began operating in the following reportable segments: (i) Bausch + Lomb/International segment, (ii) Salix segment, (iii) Ortho Dermatologics segment and (iv) Diversified Products segment. The Bausch + Lomb/International segment consists of the: (i) U.S. Bausch + Lomb and (ii) International reporting units. The Salix segment consists of the Salix reporting unit. The Ortho Dermatologics segment consists of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. There was no triggering event which would require the Company to test goodwill for impairment as a result of the second quarter realignment of the segment structure as it did not result in a change in the reporting units.
2018 Annual Goodwill Impairment Test
The Company conducted its 2018 annual goodwill impairment test as of October 1, 2018 and determined that the carrying value of the Dentistry reporting unit exceeded its fair value and, as a result, the Company recognized a goodwill impairment of $109 million, representing the full amount of goodwill for the Dentistry reporting unit. Changing market conditions such as: (i) an increasing competitive environment and (ii) increasing pricing pressures negatively impacted the reporting unit's operating results.
The Company's remaining reporting units passed the goodwill impairment test as the estimated fair value of each reporting unit exceeded its carrying value at the date of testing and, therefore, there was no impairment to goodwill for any reporting unit other than the Dentistry reporting unit. In order to evaluate the sensitivity of its fair value calculations on the goodwill impairment test, the Company compared the carrying value of each reporting unit to its fair value as of October 1, 2018, the date of testing. As of October 1, 2018, the fair value of each reporting unit with associated goodwill exceeded its carrying value by more than 15%.
2019
2019 Annual Goodwill Impairment Test
The Company conducted its annual goodwill impairment test as of October 1, 2019 by first assessing qualitative factors. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. In each quantitative fair value test performed, the fair value was greater than the carrying value of the reporting unit. As a result, there was no impairment to the goodwill of any reporting unit.
2020
2020 Interim Goodwill Impairment Assessment
In response to the COVID-19 pandemic, the Company has taken actions to protect its employees, customers and other stakeholders and mitigate the negative impact of the COVID-19 pandemic on its operations and operating results. These and additional actions can increase the costs of doing business during the pandemic and, in the periods that follow, may include the costs of idling and reopening certain facilities in affected areas. Further, social restrictions and other precautionary measures taken by customers, health care patients and consumers in response to the pandemic are expected to impact the timing and amount of revenues during the COVID-19 pandemic. Although the Company's revenues for 2020 were less than those forecasted on the date goodwill was last tested for impairment (October 1, 2019), there were no indications that these trends are materially related to developments other than the COVID-19 pandemic.
The negative impacts of the COVID-19 pandemic on the global economy have led to significant volatility in the global equity markets. The Company has been able to continue its operations with limited disruptions and has assessed the potential impact that the COVID-19 pandemic is likely to have on its forecasted cash flows. In performing its assessment, the Company considered the possible affects and outcomes of the COVID-19 pandemic on, among other things, its supply chain, customers and distributors, employee base, product sustainability, research and development activities, product pipeline and consumer demand and related rebates and discounts and has made adjustments, although not considered to be material, to its long-term forecasts as of October 1, 2019 (the date goodwill was last tested for impairment) for these and other matters. After completing this assessment, although not completely insulated from the negative effects of the COVID-19 pandemic, the Company believes that its long-term forecasted cash flows, as adjusted for the possible outcome of the COVID-19 pandemic and other matters, do not indicate that the fair value of any reporting unit may be below its carrying value.
During the pandemic, the public has been advised to engage in certain "social restrictions" such as: (i) remaining at home or shelter-in-place, (ii) limiting social interaction, (iii) closing non-essential businesses and (iv) postponing certain surgical and elective medical procedures in order to prioritize/conserve available health care resources. During the three months ended March 31, 2020, these factors negatively impacted, most notably, the revenues of the Company's Global Vision Care and Global Surgical businesses in Asia where the COVID-19 pandemic originated. Beginning in March 2020, and throughout most of the second quarter of 2020, the Company experienced steeper declines in these revenues and the revenues of other businesses as social restrictions expanded worldwide, particularly in the U.S. and Europe. Social restrictions negatively impacted the Company's revenues for contact lenses, intraocular lenses, medical devices, surgical systems and certain pre- and post-operative eye-medications of its Global Ophtho Rx business, medical aesthetics and therapeutic products of its Global Solta business, and certain branded pharmaceutical products of its Salix, Ortho Dermatologics and Dentistry businesses, as the offices of many health care providers were closed and certain surgeries and elective medical procedures were deferred.
The Company's 2020 revenues were most negatively impacted during its second quarter by the social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize prior to the third quarter. Revenues for the three months ended December 31, 2020 and 2019 were $2,213 million and $2,224 million, respectively, a decrease of $11 million. This decrease of less than 1% represents a continuing improving trend over the decreases in year-over-year revenues for the three month periods ended June 30, 2020 and September 30, 2020 of 23% and 3%, respectively. Presuming there continues to be increased availability of effective vaccines and any further resurgence of the COVID-19 virus and variant strains thereof do not have a material adverse impact on efforts to contain the COVID-19 virus, the Company anticipates an ongoing, gradual global recovery from the macroeconomic and health care impacts of the pandemic that occurred during the first-half of 2020 and anticipates that its affected businesses could return to pre-pandemic levels during 2021. However, the rates of recovery for each business will vary by geography and will be dependent upon, among other things, the availability and effectiveness of vaccines for the COVID-19 virus, government
responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus and other actions taken in response to the COVID-19 pandemic.
On a quarterly basis, using its latest forecasts of cash flows, the Company gave consideration to the nature and timing of the expected revenue losses discussed above. No events occurred or circumstances changed during the period October 1, 2019 through September 30, 2020 that would indicate that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, might be below its carrying value. The changes in the amounts and timing of revenues as presented in the Company's latest forecasts included a range of potential outcomes and, with the exception of the Ortho Dermatologics reporting unit as discussed below, were not substantial enough to materially adversely affect the recoverability of any of the associated reporting units’ assets and were not material enough to indicate that the fair values of those reporting units might be below their respective carrying values. However, based on the results of the October 1, 2019 annual goodwill impairment test, the Company continued to assess the performance of the Ortho Dermatologics reporting unit and the Neuro and Other reporting unit on a quarterly basis throughout 2020.
2020 Interim Goodwill Impairment Assessments - Neuro and Other
As part of its quarterly qualitative interim assessments of the Neuro and Other reporting unit, management considered the totality of all relevant events or circumstances that could have affected the carrying amount or fair value of the reporting unit, including comparing the reporting unit’s operating results to the forecast used to test the goodwill of the Neuro and Other reporting unit as of October 1, 2019. Based on the qualitative assessments, management believed that the carrying value of Neuro and Other reporting unit did not exceed its fair value and, therefore, concluded a quantitative fair value test was not required for any quarterly period.
2020 Interim Goodwill Impairment Assessments and Testing - Ortho Dermatologics
During the three months ended March 31, 2020, the operating results for the Ortho Dermatologics reporting unit were less than those forecasted at October 1, 2019 for that period. As part of its qualitative assessment as of March 31, 2020, the Company revised its forecasts for the year 2020, for among other matters, the lower than originally forecasted operating results for the three months ended March 31, 2020 and the range of potential impacts of the COVID-19 pandemic, including longer than expected launch cycles for certain new products. Management believed that the revisions to its forecasts for the year 2020 were indicators that there was less headroom as of March 31, 2020 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2019). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed at March 31, 2020. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit continued to be greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit at March 31, 2020.
During the three months ended June 30, 2020, the Company identified certain Ortho Dermatologics’ products that were experiencing longer launch cycles than originally anticipated due to the COVID-19 pandemic and, as a direct result, took actions to mitigate the impact of these matters, including right-sizing its Ortho Dermatologics’ sales force. As part of its qualitative assessment as of June 30, 2020, the Company revised its long-term forecasts for, among other matters, the decrease in forecasted revenues of the identified products, the reduction in sales force and related costs and a range of potential impacts of COVID-19 pandemic related matters. Management believed that these events were indicators that there was less headroom as of June 30, 2020 as compared to the headroom calculated on the date Ortho Dermatologics goodwill was last tested for impairment (March 31, 2020). Therefore, a quantitative fair value test for impairment to the goodwill of the Ortho Dermatologics reporting unit was performed at June 30, 2020. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit continued to be greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit at June 30, 2020.
Management believed that based on its qualitative assessments as of September 30, 2020, it was more likely than not that the carrying amount of the Ortho Dermatologics reporting unit was less than its fair value and, therefore, concluded a quantitative fair value test was not required at September 30, 2020.
2020 Annual Goodwill Impairment Test
The Company conducted its annual goodwill impairment test as of October 1, 2020 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2020, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded a quantitative fair value test for those reporting units was not required.
As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2020, the Company considered, among other matters, a range of potential impacts of COVID-19 pandemic related matters and the limited headroom calculated on the date Ortho Dermatologics goodwill was last tested for impairment (June 30, 2020). The Company believed that these factors may suggest that it is more likely than not that the fair value of the Ortho Dermatologics reporting unit is less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit.
The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2020, utilizing a long-term growth rate of 2.0% and a range of discount rates between 9.5% and 9.75%, in estimation of the fair value of this reporting unit. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit. If market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future. Specifically, the Company continues to assess the performance of the Ortho Dermatologics reporting unit as compared to its respective projections and will perform qualitative interim assessments of the carrying value and fair value on a quarterly basis to determine if impairment testing of goodwill will be warranted.
In addition, the Company expects to realign and begin managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Separation during the first quarter of 2021, and as a result the Company may need to perform an impairment test upon realignment of its operating segments.
Accumulated goodwill impairment charges through December 31, 2020 were $3,711 million.
XML 34 R16.htm IDEA: XBRL DOCUMENT v3.20.4
ACCRUED AND OTHER CURRENT LIABILITIES
12 Months Ended
Dec. 31, 2020
Payables and Accruals [Abstract]  
ACCRUED AND OTHER CURRENT LIABILITIES ACCRUED AND OTHER CURRENT LIABILITIES
Accrued and other current liabilities as of December 31, 2020 and 2019 consist of:
(in millions)20202019
Legal matters and related fees$1,672 $1,397 
Product rebates747 898 
Product returns575 691 
Interest341 305 
Employee compensation and benefit costs316 304 
Income taxes payable158 196 
Other767 720 
$4,576 $4,511 
XML 35 R17.htm IDEA: XBRL DOCUMENT v3.20.4
FINANCING ARRANGEMENTS
12 Months Ended
Dec. 31, 2020
Debt Disclosure [Abstract]  
FINANCING ARRANGEMENTS FINANCING ARRANGEMENTS
Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2020 and 2019 consists of the following:
20202019
(in millions)MaturityPrincipal AmountNet of Premiums, Discounts and Issuance CostsPrincipal AmountNet of Premiums, Discounts and Issuance Costs
Senior Secured Credit Facilities:
2023 Revolving Credit FacilityJune 2023$— $— $— $— 
June 2025 Term Loan B FacilityJune 20253,298 3,220 3,869 3,768 
November 2025 Term Loan B FacilityNovember 20251,125 1,112 1,275 1,257 
Senior Secured Notes:
6.50% Secured Notes
March 2022— — 1,250 1,242 
7.00% Secured Notes
March 20242,000 1,987 2,000 1,983 
5.50% Secured Notes
November 20251,750 1,736 1,750 1,733 
5.75% Secured Notes
August 2027500 494 500 493 
Senior Unsecured Notes: 
5.50%
March 2023— — 402 400 
5.875%
May 2023— — 1,448 1,441 
4.50% euro-denominated debt
May 2023— — 1,682 1,674 
6.125%
April 20253,250 3,234 3,250 3,230 
9.00%
December 20251,500 1,478 1,500 1,473 
9.25%
April 20261,500 1,487 1,500 1,484 
8.50%
January 20271,750 1,755 1,750 1,756 
7.00%
January 2028750 742 750 741 
5.00%
January 20281,250 1,236 1,250 1,234 
6.25%
February 20291,500 1,480 — — 
5.00%
February 20291,000 988 — — 
7.25%
May 2029750 741 750 740 
5.25%
January 20301,250 1,235 1,250 1,234 
5.25%
February 20311,000 988 — — 
OtherVarious12 12 12 12 
Total long-term debt and other $24,185 23,925 $26,188 25,895 
Less: Current portion of long-term debt and other— 1,234 
Non-current portion of long-term debt  $23,925 $24,661 
Covenant Compliance
The Senior Secured Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes and Senior Unsecured Notes contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company’s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of December 31, 2020, the amount available for restricted payments under the "builder basket" in the Company’s most restrictive indentures (as defined by those indentures) was approximately $13,000 million (although such availability is subject to the Company's compliance with a 2.00:1.00 fixed charge coverage ratio). The 2023 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that requires the Company to maintain a first lien net leverage ratio of not greater than 4.00:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.
As of December 31, 2020, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period.
The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company’s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.
Senior Secured Credit Facilities
On February 13, 2012, the Company and certain of its subsidiaries as guarantors entered into the “Senior Secured Credit Facilities” under the Company’s Third Amended and Restated Credit and Guaranty Agreement, as amended (the “Third Amended Credit Agreement”) with a syndicate of financial institutions and investors, as lenders. As of January 1, 2018, the Third Amended Credit Agreement provided for: (i) a $1,500 million Revolving Credit Facility maturing on April 20, 2020 (the "2020 Revolving Credit Facility") and (ii) a $3,521 million term loan under the Company's Series F Tranche B Term Loan Facility maturing in 2022 (the “Series F Tranche B Term Loan Facility”). There was $250 million outstanding under the 2020 Revolving Credit Facility as of January 1, 2018.
2018 Activity
During 2018, the Company repaid (net of additional borrowings) $571 million of outstanding debt under its Senior Secured Credit Facilities using cash on hand.
On June 1, 2018, the Company entered into a Restatement Agreement in respect of a Fourth Amended and Restated Credit and Guaranty Agreement (the “Restated Credit Agreement”) which restated in full the Third Amended Credit Agreement. The Restated Credit Agreement replaced the 2020 Revolving Credit Facility with a revolving credit facility of $1,225 million (the "2023 Revolving Credit Facility") and replaced the Series F Tranche B Term Loan Facility principal amount outstanding of $3,315 million with a new seven year Tranche B Term Loan Facility of $4,565 million (the “June 2025 Term Loan B Facility”) borrowed by the Company’s subsidiary, Bausch Health Americas, Inc. ("BHA").
The 2023 Revolving Credit Facility matures on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company or BHA in an aggregate principal amount in excess of $1,000 million. Both the Company and BHA are borrowers with respect to the 2023 Revolving Credit Facility. Borrowings under the 2023 Revolving Credit Facility may be made in U.S. dollars, Canadian dollars or euros.
On June 1, 2018, the Company issued an irrevocable notice of redemption for the remaining outstanding principal amounts of: (i) $691 million of the March 2020 Unsecured Notes (as defined below), (ii) $578 million of 6.75% Senior Unsecured Notes due August 2021 (the “August 2021 Unsecured Notes”), (iii) $550 million of 7.25% Senior Unsecured Notes due July 2022 (the “July 2022 Unsecured Notes”) and (iv) $146 million of 6.375% Senior Unsecured Notes due October 2020 (the March 2020 Unsecured Notes (as defined below), together with the August 2021 Unsecured Notes, the July 2022 Unsecured Notes and the 6.375% Senior Unsecured Notes due October 2020 the “June 2018 Unsecured Refinanced Debt”). On June 1, 2018, using the remaining net proceeds from the June 2025 Term Loan B Facility, the net proceeds from the issuance of $750 million in aggregate principal amount of 8.50% Senior Unsecured Notes due 2027 (the "January 2027 Unsecured Notes") by BHA and cash on hand, the Company prepaid the remaining Series F Tranche B Term Loan Facility and redeemed the June 2018 Unsecured Refinanced Debt at its aggregate redemption price and the indentures governing the June 2018 Unsecured Refinanced Debt were discharged (collectively, the “June 2018 Refinancing Transactions”).
The Restated Credit Agreement was accounted for as a modification of debt, to the extent the June 2018 Unsecured Refinanced Debt was replaced with newly issued debt to the same creditor, and as an extinguishment of debt if: (i) the June 2018 Unsecured Refinanced Debt was replaced with newly issued debt to a different creditor, (ii) a portion of the unamortized deferred financing fees was allocated to debt that was paid down or (iii) the borrowing capacity declined when issuing a new revolving credit facility. The following was accounted for as an extinguishment of debt: (i) the difference between the amounts paid to redeem the June 2018 Unsecured Refinanced Debt and the June 2018 Unsecured Refinanced Debt’s carrying value, (ii) the replacement of the Series F Tranche B Term Loan Facility with the June 2025 Term Loan B Facility to the extent any unamortized deferred financing fees were associated with the portion of the Series F Tranche B Term Loan Facility that was paid down and (iii) the replacement of the 2020 Revolving Credit Facility with the 2023 Revolving Credit Facility to the extent any unamortized deferred financing fees were associated with the decline in borrowing capacity. For amounts accounted for as an extinguishment of debt, the Company incurred a loss on extinguishment of debt of $48 million. Payments made to the lenders and a portion of payments made to third parties of $74 million associated with the June 2018 Refinancing Transactions were capitalized and are being amortized as interest
expense over the remaining terms of the debt, ranging from 2023 through 2027. Third-party expenses of $4 million associated with the modification of debt were expensed as incurred and included in Interest expense.
On November 27, 2018, the Company entered into the First Incremental Amendment to the Restated Credit Agreement, which provided an additional seven year Tranche B Term Loan Facility of $1,500 million (the "November 2025 Term Loan B Facility") and used the net proceeds, and cash on hand, to repay $1,483 million of 7.50% Senior Unsecured Notes due July 2021 (the “July 2021 Unsecured Notes”) in a tender offer (the "November 2018 Refinancing Transactions"). On December 27, 2018, the Company redeemed, using cash on hand, the remaining outstanding principal amount of $17 million of the July 2021 Unsecured Notes.
The repayment of the July 2021 Unsecured Notes was accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $43 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt’s carrying value. Payments made to the lenders and other third parties of $25 million associated with the issuance of the November 2025 Term Loan B Facility were capitalized and are being amortized as interest expense over the remaining term of the November 2025 Term Loan B Facility.
2019 Activity
During 2019, the Company repaid (net of additional borrowings) $806 million of outstanding debt under its Senior Secured Credit Facilities using cash on hand.
2020 Activity
During 2020, the Company repaid: (i) $471 million of outstanding debt under its Senior Secured Credit Facilities using cash on hand and (ii) $250 million of outstanding debt under its Senior Secured Credit Facilities as part of the May 2020 Refinancing Transactions (as defined below).
As of December 31, 2020, the Company had no outstanding borrowings, $104 million of issued and outstanding letters of credit, and remaining availability of $1,121 million under its 2023 Revolving Credit Facility.
Current Description of Senior Secured Credit Facilities
Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% or (c) the eurocurrency rate (as defined in the Restated Credit Agreement) for a period of one month plus 1.00% (or if such eurocurrency rate shall not be ascertainable, 1.00%) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.
Borrowings under the 2023 Revolving Credit Facility in euros bear interest at a eurocurrency rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), plus an applicable margin.
Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the “Canadian Prime Rate” or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus 1.00% (provided however, that the prime rate shall at no time be less than 0.00%) or (ii) the bankers’ acceptance rate for Canadian dollar deposits in the Toronto interbank market (the “BA rate”) for the interest period relevant to such borrowing (provided however, that the BA rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.
Subject to certain exceptions and customary baskets set forth in the Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the Restated Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights). These mandatory prepayments may be used to satisfy future amortization.
The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are 2.00% and 1.75%, respectively, with respect to base rate and prime rate borrowings and 3.00% and 2.75%, respectively, with respect to eurocurrency rate and BA rate borrowings. As of December 31, 2020, the stated rates of interest on the Company’s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were 3.15% and 2.90% per annum, respectively.
The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is 5.00% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of December 31, 2020, the aggregate remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities are $405 million through November 1, 2025.
The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are 1.50%-2.00% with respect to base rate or prime rate borrowings and 2.50%-3.00% with respect to eurocurrency rate or BA rate borrowings.  As of December 31, 2020, the stated rate of interest on the 2023 Revolving Credit Facility was 3.15% per annum. In addition, the Company is required to pay commitment fees of 0.25% - 0.50% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.
The Restated Credit Agreement permits the incurrence of incremental credit facility borrowings, up to the greater of $1,000 million and 28.5% of Consolidated Adjusted EBITDA (as defined in the Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.
Senior Secured Notes
The Senior Secured Notes are guaranteed by each of the Company’s subsidiaries that is a guarantor under the Restated Credit Agreement and existing Senior Unsecured Notes (together, the “Note Guarantors”). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company’s obligations under the Restated Credit Agreement under the terms of the indentures governing the Senior Secured Notes.
The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company’s and Note Guarantors’ respective existing and future unsubordinated indebtedness and senior to the Company’s and Note Guarantors’ respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively pari passu with the Company’s and the Note Guarantors’ respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company’s and the Note Guarantors’ respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company’s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company’s debt that is secured by assets that are not collateral.
Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder’s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.
6.50% Senior Secured Notes due 2022 and 7.00% Senior Secured Notes due 2024
In March 2017, the Company issued $1,250 million aggregate principal amount of 6.50% senior secured notes due March 15, 2022 (the “March 2022 Secured Notes”) and $2,000 million aggregate principal amount of 7.00% senior secured notes due March 15, 2024 (the “March 2024 Secured Notes”), in a private placement. Interest on these notes is payable semi-annually in arrears on each March 15 and September 15.
The March 2022 Secured Notes were repaid in full as part of the May 2020 Refinancing Transactions (as defined below).
The March 2024 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time, at the redemption prices set forth in the indenture.
5.50% Senior Secured Notes due 2025
On October 17, 2017, the Company issued $1,000 million, and, on November 21, 2017, the Company issued $750 million, aggregate principal amount of 5.50% Senior Secured Notes due November 2025 (the “November 2025 Secured Notes”), in a private placement. Interest on the November 2025 Secured Notes is payable semi-annually in arrears on each May 1 and November 1.
The November 2025 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time, at the redemption prices set forth in the indenture.
5.75% Senior Secured Notes due 2027 - March 2019 Refinancing Transactions
On March 8, 2019, BHA and the Company issued: (i) $1,000 million aggregate principal amount of January 2027 Unsecured Notes and (ii) $500 million aggregate principal amount of 5.75% Senior Secured Notes due August 2027 (the "August 2027 Secured Notes"), respectively, in a private placement. A portion of the proceeds and cash on hand were used to: (i) repurchase $584 million of 5.875% Senior Unsecured Notes due 2023 (the "May 2023 Unsecured Notes"), (ii) repurchase $518 million of 5.625% Senior Unsecured Notes due 2021 (the “December 2021 Unsecured Notes”), (iii) repurchase $216 million of 5.50% Senior Unsecured Notes due 2023 (the "March 2023 Unsecured Notes”) and (iv) pay all fees and expenses associated with these transactions (collectively, the “March 2019 Refinancing Transactions”). During April 2019, the Company redeemed $182 million of the December 2021 Unsecured Notes, representing the remaining outstanding principal balance of the December 2021 Unsecured Notes and completing the refinancing of $1,500 million of debt in connection with the March 2019 Refinancing Transactions. The March 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $8 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt’s carrying value. Interest on the August 2027 Secured Notes is payable semi-annually in arrears on each February 15 and August 15.
The August 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after August 15, 2022, at the redemption prices set forth in the indenture. The Company may redeem some or all of the August 2027 Secured Notes prior to August 15, 2022 at a price equal to 100% of the principal amount thereof plus a “make-whole” premium. Prior to August 15, 2022, the Company may redeem up to 40% of the aggregate principal amount of the August 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.
Senior Unsecured Notes
The Senior Unsecured Notes issued by the Company are the Company’s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes.
If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.
5.625% Senior Unsecured Notes due 2021
On December 2, 2013, the Company issued $900 million aggregate principal amount of December 2021 Unsecured Notes in a private placement. The December 2021 Unsecured Notes accrued interest at the rate of 5.625% per year and were subsequently repaid in full: (i) using cash on hand of $200 million in December 2018 and (ii) as part of the March 2019 Refinancing Transactions.
5.50% Senior Unsecured Notes due 2023
On January 30, 2015, the Company issued $1,000 million aggregate principal amount of March 2023 Unsecured Notes in a private placement. The March 2023 Unsecured Notes accrued interest at the rate of 5.50% per year, payable semi-annually in arrears. On March 8, 2019 and May 23, 2019, the Company repurchased $216 million and $382 million of March 2023 Unsecured Notes as part of the March 2019 Refinancing Transactions and the May 2019 Refinancing Transactions (as defined below), respectively. Throughout 2020, the Company repurchased, in aggregate, $169 million of March 2023 Unsecured Notes using cash on hand. The Company repurchased the remaining outstanding balance of $233 million in December 2020 as part of the December 2020 Refinancing Transactions (as defined below).
5.375% Senior Unsecured Notes due 2020, 5.875% Senior Unsecured Notes due 2023, 4.50% Senior Unsecured Notes due 2023 and 6.125% Senior Unsecured Notes due 2025
On March 27, 2015, VRX Escrow Corp. (the "VRX Issuer"), a newly formed wholly owned subsidiary of the Company, issued $2,000 million aggregate principal amount of 5.375% Senior Unsecured Notes due 2020 (the "March 2020 Unsecured Notes"), $3,250 million aggregate principal amount of 5.875% Senior Unsecured Notes due 2023 (the "May 2023 Unsecured Notes"), €1,500 million aggregate principal amount of 4.50% Senior Unsecured Notes due 2023 (the "Euro Notes”) and $3,250 million aggregate principal amount of 6.125% Senior Unsecured Notes due 2025 (the "April 2025 Unsecured Notes" and, together with the March 2020 Unsecured Notes, the May 2023 Unsecured Notes and the Euro Notes, the "VRX Notes") in a private placement.
The March 2020 Unsecured Notes accrued interest at the rate of 5.375% per year and were repaid in full as part of: (i) the December 2017 Refinancing Transactions (as defined below), (ii) the March 2018 Refinancing Transactions (as defined below) and (iii) the June 2018 Refinancing Transactions. The May 2023 Unsecured Notes and the Euro Notes accrued interest at the rate of 5.875% and 4.50% per year, respectively and were each repaid in full as of December 31, 2020, as discussed below. The April 2025 Unsecured Notes accrue interest at the rate of 6.125% per year, payable semi-annually in arrears.
As part of the June 2018 Refinancing Transactions, the Company repaid the remaining outstanding principal amounts of the March 2020 Unsecured Notes.
On March 8, 2019 and May 23, 2019, the Company repurchased $584 million and $1,118 million of May 2023 Unsecured Notes as part of the March 2019 Refinancing Transactions and the May 2019 Refinancing Transactions (as defined below), respectively, and on October 3, 2019, the Company repaid an additional $100 million of May 2023 Unsecured Notes using cash on hand. On January 16, 2020, the Company redeemed $1,240 million aggregate principal amount of the May 2023 Unsecured Notes as part of the December 2019 Financing and Refinancing Transactions (as defined below). Throughout 2020, the Company repaid, in aggregate, $208 million of the May 2023 Unsecured Notes, with the May 2023 Unsecured Notes having been fully repaid during November 2020.
The Company may redeem all or a portion of the April 2025 Unsecured Notes at the redemption prices set forth in the applicable indenture, plus accrued and unpaid interest to the date of redemption.
On December 3, 2020, the Company redeemed the remaining outstanding balance of the Euro Notes as part of the December 2020 Refinancing Transactions, as defined below.
9.00% Senior Unsecured Notes due 2025
On December 18, 2017, the Company issued $1,500 million aggregate principal amount of 9.00% Senior Unsecured Notes due 2025 (the “December 2025 Unsecured Notes”) in a private placement, the net proceeds of which were used to repurchase $1,500 million in aggregate principal amount of previously outstanding senior unsecured notes (the "December 2017 Refinancing Transactions"). The related fees and expenses were paid using cash on hand. The December 2025 Unsecured Notes accrue interest at the rate of 9.00% per year, payable semi-annually in arrears on each of June 15 and December 15.
The Company may redeem all or a portion of the December 2025 Unsecured Notes at any time prior to December 15, 2021, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a “make-whole” premium. In addition, at any time prior to December 15, 2020, the Company may redeem up to 40% of the aggregate principal amount of the outstanding December 2025 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the December 2025 Unsecured Notes indenture. On or after December 15, 2021, the Company may redeem all or a portion of the December 2025 Unsecured Notes at the applicable redemption prices set forth in the December 2025 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.
9.25% Senior Unsecured Notes due 2026 - March 2018 Refinancing Transactions
On March 26, 2018, BHA issued $1,500 million in aggregate principal amount of 9.25% Senior Unsecured Notes due 2026 (the “April 2026 Unsecured Notes”) in a private placement, the net proceeds of which, and cash on hand, were used to repurchase $1,500 million in aggregate principal amount of unsecured notes. All fees and expenses associated with these transactions were paid with cash on hand (collectively, the “March 2018 Refinancing Transactions”). The March 2018 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $26 million representing the difference between the amount paid to settle the extinguished debt
and the extinguished debt’s carrying value. The April 2026 Unsecured Notes accrue interest at the rate of 9.25% per year, payable semi-annually in arrears on each of April 1 and October 1.
BHA may redeem all or a portion of the April 2026 Unsecured Notes at any time prior to April 1, 2022, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a “make-whole” premium. In addition, at any time prior to April 1, 2021, BHA may redeem up to 40% of the aggregate principal amount of the outstanding April 2026 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the April 2026 Unsecured Notes indenture. On or after April 1, 2022, BHA may redeem all or a portion of the April 2026 Unsecured Notes at the applicable redemption prices set forth in the April 2026 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.
8.50% Senior Unsecured Notes due 2027 - June 2018 Refinancing Transactions and March 2019 Refinancing Transactions
As part of the June 2018 Refinancing Transactions, BHA issued $750 million in aggregate principal amount of January 2027 Unsecured Notes in a private placement, the net proceeds of which, when combined with the remaining net proceeds from the June 2025 Term Loan B Facility and cash on hand, were used to redeem the June 2018 Unsecured Refinanced Debt at its aggregate redemption price and the indentures governing the June 2018 Unsecured Refinanced Debt were discharged. The January 2027 Unsecured Notes accrue interest at the rate of 8.50% per year, payable semi-annually in arrears on each of January 31 and July 31.
As part of the March 2019 Refinancing Transactions described above, BHA issued $1,000 million aggregate principal amount of 8.50% Senior Unsecured Notes due January 2027. These are additional notes and form part of the same series as BHA’s existing January 2027 Unsecured Notes.
BHA may redeem all or a portion of the January 2027 Unsecured Notes at any time prior to July 31, 2022, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a “make-whole” premium. In addition, at any time prior to July 31, 2021, BHA may redeem up to 40% of the aggregate principal amount of the outstanding January 2027 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the January 2027 Unsecured Notes indenture. On or after July 31, 2022, BHA may redeem all or a portion of the January 2027 Unsecured Notes at the applicable redemption prices set forth in the January 2027 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.
7.00% Senior Unsecured Notes due 2028 and 7.25% Senior Unsecured Notes due 2029 - May 2019 Refinancing Transactions
On May 23, 2019, the Company issued: (i) $750 million aggregate principal amount of 7.00% Senior Unsecured Notes due January 2028 (the "7.00% January 2028 Unsecured Notes") and (ii) $750 million aggregate principal amount of 7.25% Senior Unsecured Notes due May 2029 (the "May 2029 Unsecured Notes"), respectively, in a private placement. The proceeds and cash on hand were used to: (i) repurchase $1,118 million of May 2023 Unsecured Notes, (ii) repurchase $382 million of March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the “May 2019 Refinancing Transactions”). The May 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $32 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt’s carrying value. Interest on the 7.00% January 2028 Unsecured Notes is payable semi-annually in arrears on each January 15 and July 15. Interest on the May 2029 Unsecured Notes is payable semi-annually in arrears on each May 30 and November 30.
The 7.00% January 2028 Unsecured Notes and the May 2029 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 15, 2023 and May 30, 2024, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the 7.00% January 2028 Unsecured Notes or the May 2029 Unsecured Notes prior to January 15, 2023 and May 30, 2024, respectively, at a price equal to 100% of the principal amount thereof plus a “make-whole” premium. Prior to July 15, 2022, and May 30, 2022, the Company may redeem up to 40% of the aggregate principal amount of the 7.00% January 2028 Unsecured Notes or the May 2029 Unsecured Notes, respectively, using the proceeds of certain equity offerings at the redemption price set forth in the respective indenture.
5.00% Senior Unsecured Notes due 2028 and 5.25% Senior Unsecured Notes due 2030 - December 2019 Financing and Refinancing Transactions
On December 30, 2019, the Company issued: (i) $1,250 million aggregate principal amount of 5.00% Senior Unsecured Notes due January 2028 (the "5.00% January 2028 Unsecured Notes") and (ii) $1,250 million aggregate principal amount of 5.25% Senior Unsecured Notes due January 2030 (the "January 2030 Unsecured Notes") in a private placement. The proceeds and cash on hand were used to: (i) redeem $1,240 million of May 2023 Unsecured Notes on January 16, 2020, (ii)
finance the $1,210 million settlement of certain U.S. Securities litigation as discussed in Note 20, "LEGAL PROCEEDINGS" and (iii) pay all fees and expenses associated with these transactions (collectively, the "December 2019 Financing and Refinancing Transactions"). The redemption of $1,240 million of May 2023 Unsecured notes was accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $24 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value.
Interest on the 5.00% January 2028 Unsecured Notes is payable semi-annually in arrears on each January 30 and July 30. Interest on the January 2030 Unsecured Notes is payable semi-annually in arrears on each January 30 and July 30. The 5.00% January 2028 Unsecured Notes and the January 2030 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 30, 2023 and January 30, 2025, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the 5.00% January 2028 Unsecured Notes or the January 2030 Unsecured Notes prior to January 30, 2023 and January 30, 2025, respectively, at a price equal to 100% of the principal amount thereof plus a “make-whole” premium. Prior to January 30, 2023, the Company may redeem up to 40% of the aggregate principal amount of the 5.00% January 2028 Unsecured Notes or the January 2030 Unsecured Notes using the proceeds of certain equity offerings at the redemption price set forth in the respective indenture.
6.25% Senior Unsecured Notes due 2029 - May 2020 Refinancing Transactions
On May 26, 2020, the Company issued $1,500 million aggregate principal amount of 6.25% Senior Unsecured Notes due February 2029 (the "6.25% February 2029 Unsecured Notes") in a private placement. The proceeds and cash on hand were used to: (i) repurchase $1,250 million aggregate principal amount of the outstanding March 2022 Secured Notes, (ii) prepay $303 million of mandatory amortization scheduled for payment in 2022 under the Company's June 2025 and November 2025 Term Loan B Facilities and (iii) pay all fees and expenses associated with these transactions (collectively, the "May 2020 Refinancing Transactions"). The May 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $27 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The 6.25% February 2029 Unsecured Notes accrue interest at the rate of 6.25% per year, payable semi-annually in arrears on each of February 15 and August 15.
The Company may redeem all or a portion of the 6.25% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a “make-whole” premium. In addition, at any time prior to August 15, 2023, the Company may redeem up to 40% of the aggregate principal amount of the outstanding 6.25% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the 6.25% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the 6.25% February 2029 Unsecured Notes at the applicable redemption prices set forth in the 6.25% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.
5.00% Senior Unsecured Notes due 2029 and 5.25% Senior Unsecured Notes due 2031 – December 2020 Refinancing Transactions
On December 3, 2020, the Company issued $1,000 million aggregate principal amount of 5.00% Senior Unsecured Notes due February 2029 (the "5.00% February 2029 Unsecured Notes") and $1,000 million aggregate principal amount of 5.25% Senior Unsecured Notes due February 2031 (the "February 2031 Unsecured Notes") in a private placement. The aggregate proceeds and cash on hand were used to repurchase the remaining outstanding principal amounts of: (i) €1,500 million of the Euro Notes, (ii) $233 million of the March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the "December 2020 Refinancing Transactions"). The December 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $7 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The 5.00% February 2029 Unsecured Notes accrue interest at the rate of 5.00% per year, payable semi-annually in arrears on each of February 15 and August 15. The February 2031 Unsecured Notes accrue interest at the rate of 5.25% per year, payable semi-annually in arrears on each of February 15 and August 15.
The Company may redeem all or a portion of the 5.00% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a “make-whole” premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to 40% of the aggregate principal amount of the outstanding 5.00% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the 5.00% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the 5.00% February 2029 Unsecured
Notes at the applicable redemption prices set forth in the 5.00% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.
The Company may redeem all or a portion of the February 2031 Unsecured Notes at any time prior to February 15, 2026, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a “make-whole” premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to 40% of the aggregate principal amount of the outstanding February 2031 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the February 2031 Unsecured Notes indenture. On or after February 15, 2026, the Company may redeem all or a portion of the February 2031 Unsecured Notes at the applicable redemption prices set forth in the February 2031 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.
Weighted Average Stated Rate of Interest
The weighted average stated rate of interest for the Company's outstanding debt obligations as of December 31, 2020 and 2019 was 6.02% and 6.21%, respectively.
Maturities and Mandatory Payments
Maturities and mandatory payments of debt obligations for the five succeeding years ending December 31 and thereafter are as follows:
(in millions)
2021$— 
2022— 
2023— 
20242,291 
202510,632 
Thereafter11,262 
Total gross maturities24,185 
Unamortized discounts(260)
Total long-term debt and other$23,925 
Under the Restated Credit Agreement, there is no Excess Cash Flow payment due for 2020.
XML 36 R18.htm IDEA: XBRL DOCUMENT v3.20.4
PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS
12 Months Ended
Dec. 31, 2020
Retirement Benefits [Abstract]  
PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS
The Company has defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers a closed grandfathered group of legacy Bausch & Lomb Holdings Incorporated (‘‘B&L’’) U.S. employees and employees in certain other countries. The U.S. defined benefit accruals were frozen as of December 31, 2004 and benefits that were earned up to December 31, 2004 were preserved. Participants continue to earn interest credits on their cash balance at an interest crediting rate that is equal to the greater of: (i) the average annual yield on 10-year treasury bonds in effect for the November preceding the plan year or (ii) 4.50%. The most significant non-U.S. plans are two defined benefit plans in Ireland. In 2011, both Ireland defined benefit plans were closed to future service benefit accruals; however, additional accruals related to annual salary increases continued. In December 2014, one of the Ireland defined benefit plans was amended effective August 2014 to eliminate future benefit accruals related to salary increases. All of the pension benefits accrued through the plan amendment date were preserved. As a result of the plan amendment, there are no active plan participants accruing benefits under the amended Ireland defined benefit plan. The U.S. postretirement benefit plan was amended effective January 1, 2005 to eliminate employer contributions after age 65 for participants who did not meet the minimum requirements of age and service on that date. The employer contributions for medical and prescription drug benefits for participants retiring after March 1, 1989 were frozen effective January 1, 2010. Effective January 1, 2014, the Company no longer offers medical and life insurance coverage to new retirees.
In addition to the B&L benefit plans, outside of the U.S., a limited group of the Company's employees are covered by defined benefit pension plans.
The Company uses December 31 as the year-end measurement date for all of its defined benefit pension plans and the postretirement benefit plan.
Accounting for Pension Benefit Plans and Postretirement Benefit Plan
The Company recognizes in its Consolidated Balance Sheets an asset or liability equal to the over- or under-funded benefit obligation of each defined benefit pension plan and postretirement benefit plan. Actuarial gains or losses and prior service costs or credits that arise during the period but are not recognized as components of net periodic benefit cost are recognized, net of tax, as a component of Other comprehensive income (loss).
The amounts included in Accumulated other comprehensive loss as of December 31, 2020 and 2019 were as follows:
Pension Benefit PlansU.S. Postretirement
Benefit Plan
U.S. PlanNon-U.S. Plans
(in millions)202020192020201920202019
Unrecognized actuarial losses$(21)$(20)$(76)$(65)$(3)$(2)
Unrecognized prior service credits$— $— $27 $26 $11 $14 
Net Periodic (Benefit) Cost
The following table provides the components of net periodic (benefit) cost for the Company’s defined benefit pension plans and postretirement benefit plan in 2020, 2019 and 2018:
 Pension Benefit PlansU.S. Postretirement
Benefit Plan
U.S. PlanNon-U.S. Plans
(in millions)202020192018202020192018202020192018
Service cost$$$$$$$— $— $— 
Interest cost
Expected return on plan assets(13)(13)(15)(5)(5)(5)— — — 
Amortization of net loss— — — — — — 
Amortization of prior service credit— — — (1)(1)(1)(3)(2)(2)
Other— — — — — — — — 
Net periodic (benefit) cost$(6)$(3)$(6)$$$$(2)$(1)$(1)
Benefit Obligation, Change in Plan Assets and Funded Status
The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2020 and 2019:
 Pension Benefit PlansU.S. Postretirement
Benefit Plan
U.S. PlanNon-U.S. Plans
(in millions)202020192020201920202019
Change in Projected Benefit Obligation
Projected benefit obligation, beginning of year$227 $214 $259 $235 $41 $41 
Service cost— — 
Interest cost
Employee contributions— — — — — 
Settlements— — (3)(2)— — 
Benefits paid(15)(15)(4)(8)(4)(4)
Actuarial losses17 18 13 30 
Currency translation adjustments— — 22 (4)— — 
Projected benefit obligation, end of year236 227 294 259 39 41 
Change in Plan Assets
Fair value of plan assets, beginning of year216 187 161 147 — — 
Actual return on plan assets29 42 11 17 — — 
Employee contributions— — — — — 
Company contributions10 
Settlements— — (2)(2)— — 
Benefits paid(15)(15)(4)(8)(4)(4)
Currency translation adjustments— — 15 (3)— — 
Fair value of plan assets, end of year231 216 189 161 — — 
Funded status, end of year$(5)$(11)$(105)$(98)$(39)$(41)
Recognized as:
Accrued and other current liabilities$— $— $(2)$(2)$(4)$(5)
Other non-current liabilities$(5)$(11)$(103)$(96)$(35)$(36)
A number of the Company’s pension benefit plans were underfunded as of December 31, 2020 and 2019, having accumulated benefit obligations exceeding the fair value of plan assets. Information for the underfunded pension benefit plans is as follows:
U.S. PlanNon-U.S. Plans
(in millions)2020201920202019
Projected benefit obligation$236 $227 $294 $259 
Accumulated benefit obligation236 227 286 251 
Fair value of plan assets231 216 189 161 
The Company’s policy for funding its pension benefit plans is to make contributions that meet or exceed the minimum statutory funding requirements. These contributions are determined based upon recommendations made by the actuary under accepted actuarial principles. In 2021, the Company expects to contribute $0, $10 million and $4 million to the U.S. pension benefit plan, the non-U.S. pension benefit plans and the U.S. postretirement benefit plan, respectively. The Company plans to use postretirement benefit plan assets and cash on hand, as necessary, to fund the U.S. postretirement benefit plan benefit payments in 2021.
Estimated Future Benefit Payments
Future benefit payments over the next 10 years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows:
(in millions)Pension Benefit PlansU.S. Postretirement
Benefit
Plan
U.S. PlanNon-U.S. Plans
2021$14 $$
202219 
202317 
202417 
202517 
2026-203075 42 12 
Assumptions
The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2020, 2019 and 2018 were as follows:
Pension Benefit PlansU.S. Postretirement Benefit Plan
202020192018202020192018
For Determining Net Periodic (Benefit) Cost
U.S. Plans:
Discount rate3.16 %4.25 %3.56 %3.04 %4.16 %3.47 %
Expected rate of return on plan assets6.25 %7.25 %7.50 %— — — 
Rate of compensation increase— — — — — — 
Interest crediting rate5.00 %5.00 %5.00 %
Non-U.S. Plans:
Discount rate1.68 %2.39 %2.29 %
Expected rate of return on plan assets2.98 %3.46 %3.66 %
Rate of compensation increase3.05 %2.89 %2.87 %
Interest crediting rate— — — 
 Pension Benefit PlansU.S. Postretirement Benefit Plan
2020201920202019
For Determining Benefit Obligation
U.S. Plans:
Discount rate2.25 %3.16 %2.09 %3.04 %
Rate of compensation increase— — — — 
Interest crediting rate4.75 %5.00 %
Non-U.S. Plans:
Discount rate1.37 %1.68 %
Rate of compensation increase2.60 %3.05 %
Interest crediting rate— — 
The expected long-term rate of return on plan assets was developed based on a capital markets model that uses expected asset class returns, variance and correlation assumptions. The expected asset class returns were developed starting with current Treasury (for the U.S. pension plan) or Eurozone (for the Ireland pension plans) government yields and then adding corporate bond spreads and equity risk premiums to develop the return expectations for each asset class. The expected asset class returns are forward-looking. The variance and correlation assumptions are also forward-looking. They take into account historical relationships, but are adjusted to reflect expected capital market trends. The expected return on plan assets for the Company’s U.S. pension plan for 2020 was 6.25%. The expected return on plan assets for the Company’s Ireland pension plans was 3.00% for 2020.
The discount rate used to determine benefit obligations represents the current rate at which the benefit plan liabilities could be effectively settled considering the timing of expected payments for plan participants.
The 2021 expected rate of return for the U.S. pension benefit plan will be 5.00%. The 2021 expected rate of return for the Ireland pension benefit plans will be 2.75%.
Pension Benefit Plans Assets
Pension benefit plan assets are invested in several asset categories. The following presents the actual asset allocation as of December 31, 2020 and 2019:
20202019
U.S. Plan
Cash and cash equivalents%%
Equity securities39 %55 %
Fixed income securities60 %44 %
Non-U.S. Plans
Cash and cash equivalents%%
Equity securities28 %25 %
Fixed income securities58 %64 %
Other11 %%
The investment strategy underlying pension plan asset allocation is to manage the assets of the plan to provide for the non-current liabilities while maintaining sufficient liquidity to pay current benefits. Pension plan assets are diversified to protect against large investment losses and to reduce the probability of excessive performance volatility. Diversification of assets is achieved by allocating funds to various asset classes and investment styles within asset classes, and retaining investment management firm(s) with complementary investment philosophies, styles and approaches.
The Company’s pension plan assets are managed by outside investment managers using a total return investment approach, whereby a mix of equity and debt securities investments are used to maximize the long-term rate of return on plan assets. A significant portion of the assets of the U.S. and Ireland pension plans have been invested in equity securities, as equity portfolios have historically provided higher returns than debt and other asset classes over extended time horizons. Correspondingly, equity investments also entail greater risks than other investments. Equity risks are balanced by investing a significant portion of plan assets in broadly diversified fixed income securities.
Fair Value of Plan Assets
The Company measured the fair value of plan assets based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. See Note 5, "FAIR VALUE MEASUREMENTS" for details on the Company's fair value measurements based on a three-tier hierarchy.
The table below presents total plan assets by investment category as of December 31, 2020 and 2019 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2020 and 2019.
Pension Benefit Plans - U.S. Plans
December 31, 2020December 31, 2019
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Cash and cash equivalents$$— $— $$$— $— $
Commingled funds:    
Equity securities:
U.S. broad market— 48 — 48 — 64 — 64 
Emerging markets— — — 15 — 15 
Worldwide developed markets— 20 — 20 — 26 — 26 
Other assets— 14 — 14 — 15 — 15 
Fixed income securities:
Investment grade— 138 — 138 — 95 — 95 
$$229 $— $231 $$215 $— $216 
Pension Benefit Plans - Non-U.S. Plans
December 31, 2020December 31, 2019
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Cash equivalents$— $$— $$— $$— $
Commingled funds:    
Equity securities:
Emerging markets— — — — 
Worldwide developed markets— 51 — 51 — 38 — 38 
Fixed income securities:
Investment grade— — — — 
Global high yield— — — — 
Government bond funds102 — 103 90 — 91 
Other assets— 20 22 — 
$$186 $$189 $$159 $$161 
Cash equivalents consisted primarily of term deposits and money market instruments. The fair value of the term deposits approximates their carrying amounts due to their short term maturities. The money market instruments also have short maturities and are valued using a market approach based on the quoted market prices of identical instruments.
Commingled funds are not publicly traded. The underlying assets in these funds are publicly traded on the exchanges and have readily available price quotes. The Ireland pension plans held approximately 96% and 95% of the non-U.S. commingled funds in 2020 and 2019, respectively. The commingled funds held by the U.S. and Ireland pension plans are primarily invested in index funds.
The underlying assets in the fixed income funds are generally valued using the net asset value per fund share, which is derived using a market approach with inputs that include broker quotes, benchmark yields, base spreads and reported trades.
Defined Contribution Plans
The Company sponsors defined contribution plans in the U.S., Ireland and certain other countries. Under these plans, employees are allowed to contribute a portion of their salaries to the plans, and the Company matches a portion of the employee contributions. The Company contributed $43 million, $41 million and $36 million to these plans during the years ended December 31, 2020, 2019 and 2018, respectively.
XML 37 R19.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES
12 Months Ended
Dec. 31, 2020
Leases [Abstract]  
LEASES LEASES
Right-of-use assets and lease liabilities associated with the Company's operating leases are included in the Consolidated Balance Sheet as of December 31, 2020 and 2019 as follows:
(in millions)20202019
Right-of-use assets included in:
Other non-current assets$259 $271 
Lease liabilities included in:
Accrued and other current liabilities$52 $53 
Other non-current liabilities227 240 
Total lease liabilities$279 $293 
As of December 31, 2020 and 2019, the Company's finance leases were not material and for the years 2020 and 2019 sub-lease income and short-term lease expense were not material. Lease expense for the years 2020 and 2019 include:
(in millions)20202019
Operating lease costs$65 $62 
Variable operating lease costs$12 $16 
Upon adoption of the new standard for accounting for leases on January 1, 2019, the Company elected the modified retrospective approach without revising prior periods. Rent expense related to operating lease agreements was $92 million for 2018.
Other information related to operating leases for 2020 and 2019 is as follows:
(dollars in millions)20202019
Cash paid from operating cash flows for amounts included in the measurement of lease liabilities$74 $73 
Right-of-use assets obtained in exchange for new operating lease liabilities$39 $47 
Weighted-average remaining lease term7.6 years8.2 years
Weighted-average discount rate6.2 %6.2 %
Right-of-use assets obtained in exchange for new operating lease liabilities during the year ended December 31, 2019 of $47 million in the table above does not include $282 million of right-of-use assets recognized upon adoption of the new standard for accounting for leases on January 1, 2019. See Note 2, "SIGNIFICANT ACCOUNTING POLICIES" for further detail regarding the impact of adoption.
As of December 31, 2020, future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as follows:
(in millions)
2021$68 
202253 
202345 
202435 
202534 
Thereafter121 
Total356 
Less: Imputed interest77 
Present value of remaining lease payments279 
Less: Current portion52 
Non-current portion$227 
XML 38 R20.htm IDEA: XBRL DOCUMENT v3.20.4
SHARE-BASED COMPENSATION
12 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]  
SHARE-BASED COMPENSATION SHARE-BASED COMPENSATION
In May 2014, shareholders approved the Company’s 2014 Omnibus Incentive Plan (the “2014 Plan”) which replaced the Company’s 2011 Omnibus Incentive Plan (the “2011 Plan”) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company’s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares of common stock for issuance under the 2014 Plan.
Effective April 30, 2018, the Company amended and restated the 2014 Plan (the “Amended and Restated 2014 Plan”). The Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Amended and Restated 2014 Plan has been increased by an additional 11,900,000 common shares, as approved by the requisite number of shareholders at the Company’s annual general meeting held on April 30, 2018, (ii) introduction of a $750,000 aggregate fair market value limit on awards (in either equity, cash or other compensation) that can be granted in any calendar year to a participant who is a non-employee director, (iii) housekeeping changes to address recent changes to Section 162(m) of the Internal Revenue Code, (iv) awards are expressly subject to the Company’s clawback policy and (v) awards not assumed or substituted in connection with a Change of Control (as defined in the Amended and Restated 2014 Plan) will only vest on a pro rata basis.
Effective April 28, 2020, the Company further amended and restated the Amended and Restated 2014 Plan (the “Further Amended and Restated 2014 Plan”). The Further Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Further Amended and Restated 2014 Plan has been
increased by an additional 13,500,000 common shares, as approved by the requisite number of shareholders at the Company’s annual general meeting held on April 28, 2020, (ii) the exercise price of stock options and share appreciation rights (“SARs”) will be based on the closing price of the underlying common shares on the date such stock options or SARs are granted (rather than on the last preceding trading date), (iii) additional provisions clarifying that: (a) stock options and SARs will not be eligible for the payment of dividend or dividend equivalents and (b) the Talent and Compensation Committee of the Board of Directors of the Company cannot, without shareholder approval, seek to effect any repricing of any previously granted “underwater” stock option or SAR and (iv) other housekeeping and/or clerical changes.
Approximately 16,902,000 common shares were available for future grants as of December 31, 2020. The Company uses reserved and unissued common shares to satisfy its obligation under its share-based compensation plans.
The Company has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company’s focus on improving its tangible capital usage and allocation, while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based RSUs and performance-based RSUs. Performance-based RSUs are comprised of: (i) awards that vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (“TSR”) and (ii) awards that vest upon attainment of certain performance targets that are based on the Company’s return on tangible capital (“ROTC”).
The components and classification of share-based compensation expense related to stock options and RSUs for the years 2020, 2019 and 2018 were as follows:
(in millions)202020192018
Stock options$15 $21 $23 
RSUs90 81 64 
Share-based compensation expense$105 $102 $87 
Research and development expenses$11 $$
Selling, general and administrative expenses94 93 78 
Share-based compensation expense$105 $102 $87 
Stock Options
Stock options granted under the 2011 Plan and the Amended and Restated 2014 Plan generally expire on the fifth or tenth anniversary of the grant date. The exercise price of any stock option granted under the 2011 Plan and the Amended and Restated 2014 Plan will not be less than the closing price per common share on the date of grant. Stock options generally vest 33% and 25% each year over a three-year and four-year period, respectively, on the anniversary of the date of grant.
The fair values of all stock options granted for the years 2020, 2019 and 2018 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:
202020192018
Expected stock option life (years)3.03.03.0
Expected volatility38.7 %46.5 %54.0 %
Risk-free interest rate1.2 %2.5 %2.7 %
Expected dividend yield— %— %— %
The expected stock option life was determined based on historical exercise and forfeiture patterns. The expected volatility was determined based on implied volatility in the market traded options of the Company’s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S. government bonds with maturity dates equal to the expected life of the stock option. The expected dividend yield was determined based on the stock option’s exercise price and expected annual dividend rate at the time of grant.
The Black-Scholes option-pricing model used by the Company to calculate stock option values was developed to estimate the fair value of freely tradeable, fully transferable stock options without vesting restrictions, which significantly differ from the Company’s stock option awards. This model also requires highly subjective assumptions, including future stock price volatility and expected time until exercise, which greatly affect the calculated values.
The following table summarizes stock option activity during 2020:
(in millions, except per share amounts)OptionsWeighted-
Average
Exercise
Price Per Share
Weighted-
Average
Remaining
Contractual
Term
(Years)
Aggregate
Intrinsic
Value
Outstanding, January 1, 20207.1 $26.99   
Granted2.3 $24.74   
Exercised(0.4)$14.65   
Expired or forfeited(0.3)$72.40   
Outstanding, December 31, 20208.7 $25.59 7.2$14 
Vested and expected to vest, December 31, 20208.2 $25.73 7.1$14 
Vested and exercisable, December 31, 20204.8 $27.74 6.0$11 
The weighted-average fair values of all stock options granted in 2020, 2019 and 2018 were $6.60, $8.45 and $7.83, respectively. The total intrinsic values of stock options exercised in 2020, 2019 and 2018 were $2 million, $3 million and $1 million, respectively. Proceeds received on the exercise of stock options in 2020, 2019 and 2018 were $5 million, $5 million and $2 million, respectively.
As of December 31, 2020, the total remaining unrecognized compensation expense related to non-vested stock options amounted to $10 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.5 years. The total fair value of stock options vested in 2020, 2019 and 2018 were $15 million, $18 million and $17 million, respectively.
RSUs
RSUs generally vest on the first or third anniversary date from the date of grant or 33% a year over a three-year period. Annual RSUs granted to non-management directors vest immediately prior to the next Annual Meeting of Shareholders. Pursuant to the applicable unit agreement, certain RSUs may be subject to the attainment of any applicable performance goals specified by the Board of Directors. If the vesting of the RSUs is conditional upon the attainment of performance goals, any RSUs that do not vest as a result of a determination that the prescribed performance goals failed to be attained will be forfeited immediately upon such determination. RSUs are credited with dividend equivalents, in the form of additional RSUs, when dividends are paid on the Company’s common shares. Such additional RSUs will have the same vesting dates and will vest under the same terms as the RSUs in respect of which such additional RSUs are credited.
To the extent provided for in a RSU agreement, the Company may, in lieu of all or a portion of the common shares which would otherwise be provided to a holder, elect to pay a cash amount equivalent to the market price of the Company’s common shares on the vesting date for each vested RSU. The amount of cash payment will be determined based on the average market price of the Company’s common shares on the vesting date. The Company’s current intent is to settle vested RSUs through the issuance of common shares.
Time-Based RSUs
Each vested time-based RSU represents the right of a holder to receive one of the Company’s common shares. The fair value of each RSU granted is estimated based on the trading price of the Company’s common shares on the date of grant.
The following table summarizes non-vested time-based RSU activity during 2020:
(in millions, except per share amounts)Time-Based
RSUs
Weighted-
Average
Grant-Date
Fair Value Per Share
Non-vested, January 1, 20206.1 $20.54 
Granted3.3 $21.92 
Vested(3.4)$19.37 
Forfeited(0.3)$21.78 
Non-vested, December 31, 20205.7 $21.98 
As of December 31, 2020, the total remaining unrecognized compensation expense related to non-vested time-based RSUs amounted to $55 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.5 years. The total fair value of time-based RSUs vested in 2020, 2019 and 2018 were $66 million, $34 million and $30 million, respectively.
Performance-Based RSUs
Each vested performance-based RSU represents the right of a holder to receive a number of the Company’s common shares up to a specified maximum. Performance-based RSUs vest upon achievement of certain share price appreciation conditions or attainment of certain performance targets. If the Company’s performance is below a specified performance level, no common shares will be paid.
The fair value of each TSR performance-based RSU granted during 2020, 2019 and 2018 was estimated using a Monte Carlo Simulation model, which utilizes multiple input variables to estimate the probability that the performance condition will be achieved. The fair value of the ROTC performance-based RSUs is estimated based on the trading price of the Company’s common shares on the date of grant. Expense recognized for the ROTC performance-based RSUs in each reporting period reflects the Company’s latest estimate of the number of ROTC performance-based RSUs that are expected to vest. If the ROTC performance-based RSUs do not ultimately vest due to the ROTC targets not being met, no compensation expense is recognized and any previously recognized compensation expense is reversed.
The fair values of TSR performance-based RSUs granted during 2020, 2019 and 2018 were estimated with the following assumptions:
202020192018
Contractual term (years)3.03.03.0
Expected Company share volatility38.6%46.5%54.2%
Risk-free interest rate1.2%2.5%2.7%
The expected company share volatility was determined based on implied volatility in the market traded options of the Company’s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S. government bonds with maturity dates equal to the contractual term of the performance-based RSUs.
The following table summarizes non-vested performance-based RSU activity during 2020:
(in millions, except per share amounts)Performance-based
RSUs
Weighted-
Average
Grant-Date
Fair Value Per Share
Non-vested, January 1, 20202.0 $25.80 
Granted0.9 $26.61 
Vested(0.6)$19.02 
Non-vested, December 31, 20202.3 $28.10 
During 2020, the Company granted approximately 897,000 performance-based RSUs, consisting of approximately 425,000 units of TSR performance-based RSUs with an average grant date fair value of $26.13 per RSU and approximately 472,000 units of ROTC performance-based RSUs with a weighted-average grant date fair value of $27.05 per RSU.
As of December 31, 2020, the total remaining unrecognized compensation expense related to non-vested performance-based RSUs amounted to $22 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.4 years. A maximum of approximately 3,729,000 common shares could be issued upon vesting of the performance-based RSUs outstanding as of December 31, 2020.
In connection with the 2018 grant of long-term incentive awards with an aggregate value of $10 million, approximately 933,000 performance-based RSUs received by the Company’s Chief Executive Officer ("CEO") upon his hire in 2016 were canceled, and the shares underlying those performance-based RSUs were permanently retired and are not available for future grants under the 2014 Plan. The CEO's long-term incentive award was accounted for as an award modification whereby the Company continues to recognize the unamortized compensation associated with the original award plus the incremental fair value of the new award measured at the date of grant, over the vesting period of the new award.
XML 39 R21.htm IDEA: XBRL DOCUMENT v3.20.4
ACCUMULATED OTHER COMPREHENSIVE LOSS
12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
ACCUMULATED OTHER COMPREHENSIVE LOSS ACCUMULATED OTHER COMPREHENSIVE LOSS
Accumulated other comprehensive loss as of December 31, 2020 and 2019 consists of:
(in millions)20202019
Foreign currency translation adjustment$(2,077)$(2,046)
Pension adjustment, net of tax(56)(40)
Accumulated other comprehensive loss$(2,133)$(2,086)
Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company’s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company’s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.
XML 40 R22.htm IDEA: XBRL DOCUMENT v3.20.4
RESEARCH AND DEVELOPMENT
12 Months Ended
Dec. 31, 2020
Research and Development [Abstract]  
RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT
Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs for the years 2020, 2019 and 2018 consists of:
(in millions)202020192018
Product related research and development$420 $434 $376 
Quality assurance32 37 37 
Research and development$452 $471 $413 
XML 41 R23.htm IDEA: XBRL DOCUMENT v3.20.4
OTHER EXPENSE (INCOME), NET
12 Months Ended
Dec. 31, 2020
Other Income and Expenses [Abstract]  
OTHER EXPENSE (INCOME), NET OTHER EXPENSE (INCOME), NET
Other expense (income), net for the years 2020, 2019 and 2018 consists of:
(in millions)202020192018
Litigation and other matters$422 $1,401 $(27)
Acquired in-process research and development costs32 41 
Net (gain) loss on sales of assets(1)(31)
Acquisition-related costs— 
Other, net(5)(1)
Other expense (income), net$454 $1,414 $(20)
In 2020, Litigation and other matters of $422 million includes net charges related to the U.S. Securities Litigation, the SEC Investigation and the Canadian Securities Litigation and related opt-outs. In 2020, Litigation and other matters also includes an insurance recovery related to a certain litigation matter. In 2019, Litigation and other matters of $1,401 million includes the settlement of a legacy U.S. securities class action matter (which is subject to an objector’s appeal of the final court approval). In 2018, Litigation and other matters of $27 million includes a favorable adjustment of $40 million related to the Salix legacy litigation matter. These matters and other significant matters are discussed in further detail in Note 20, "LEGAL PROCEEDINGS".
In 2020 and 2019, Acquired in-process research and development costs of $32 million and $41 million, primarily consist of costs associated with the upfront payments to enter into certain exclusive licensing agreements. In 2019, Net (gain) loss on sales of assets includes $20 million related to the achievement of a milestone related to a certain product.
XML 42 R24.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES
12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The components of Loss before benefit from income taxes for 2020, 2019 and 2018 consist of:
(in millions)202020192018
Domestic$(410)$(2,396)$(1,475)
Foreign(524)559 (2,679)
$(934)$(1,837)$(4,154)
The components of Benefit from income taxes for 2020, 2019 and 2018 consist of:
(in millions)202020192018
Current:   
Domestic$(8)$(12)$— 
Foreign(216)(116)(327)
(224)(128)(327)
Deferred: 
Domestic(5)17 
Foreign590 187 320 
599 182 337 
$375 $54 $10 
The Benefit from income taxes differs from the expected amount calculated by applying the Company’s Canadian statutory rate of 26.9% to Loss before benefit from income taxes for 2020, 2019 and 2018 as follows:
(in millions)202020192018
Loss before benefit from income taxes$(934)$(1,837)$(4,154)
Benefit from income taxes
Expected benefit from income taxes at Canadian statutory rate$251 $494 $1,117 
Non-deductible amount of share-based compensation(9)(7)(10)
Adjustments to tax attributes26 (99)(4)
Change in valuation allowance related to foreign tax credits and NOLs
62 21 (3)
Change in valuation allowance on Canadian deferred tax assets and tax rate changes
687 (142)(875)
Change in uncertain tax positions(163)(350)(47)
Foreign tax rate differences(128)186 (3)
Non-deductible portion of Goodwill impairments— — (488)
Tax benefit on intra-entity transfers(338)— 356 
Other(13)(49)(33)
$375 $54 $10 
Deferred tax assets and liabilities as of December 31, 2020 and 2019 consist of:
(in millions)20202019
Deferred tax assets:  
Tax loss carryforwards$2,924 $2,911 
Provisions1,004 641 
Research and development tax credits172 155 
Scientific Research and Experimental Development pool55 52 
Tax credit carryforwards20 25 
Deferred revenue
Unrealized FX on U.S. dollar debt and other financing cost— 94 
Prepaid expenses27 41 
Share-based compensation16 19 
Other24 23 
Total deferred tax assets4,251 3,966 
Less valuation allowance(2,252)(2,831)
Net deferred tax assets1,999 1,135 
Deferred tax liabilities: 
Intangible assets228 53 
Plant, equipment and technology89 56 
Outside basis differences71 41 
Unrealized FX on U.S. dollar debt and other financing cost— 
Total deferred tax liabilities390 150 
Net deferred tax asset$1,609 $985 
The following table presents a reconciliation of the deferred tax asset valuation allowance for 2020, 2019 and 2018:
(in millions)202020192018
Balance, beginning of year$2,831 $2,913 $2,001 
Charged to Benefit from income taxes(773)13 870 
Charged to other accounts194 (95)42 
Balance, end of year$2,252 $2,831 $2,913 
The Company’s U.S. interest expense is subject to limitation rules which limit U.S. interest expense to 30% of adjusted taxable income, defined similar to EBITDA through 2021 and EBIT thereafter. Disallowed interest can be carried forward indefinitely and any unused interest deduction assessed for recoverability. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law. The CARES Act also amended the annual limitation on the deduction of interest in the following respects: (i) increasing the limitation to 50% of adjusted taxable income (“ATI”), (ii) providing a rule for a partnership’s 2019 section 163(j)-disallowed interest expense and (iii) allowing an election to apply 2019 ATI to the 2020 section 163(j) computation. For corporations, the increase to 50% of ATI applies to all taxable years beginning in 2019 or 2020 and permits taxpayers whose 2020 income will decrease from its 2019 level, an election to apply their 2019 ATI, rather than their 2020 ATI, to their 2020 computation. The Company considered such provisions and expects to fully utilize any interest carry forwards in future periods.
On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was signed into law and included a number of changes in the U.S. tax law, most notably a reduction of the U.S. corporate income tax rate from 35% to 21% for tax years beginning after December 31, 2017. The Tax Act also implemented a modified territorial tax system that included a one-time transition tax on the accumulated previously untaxed earnings of foreign subsidiaries (the “Transition Toll Tax”) equal to 15.5% (reinvested in liquid assets) or 8% (reinvested in non-liquid assets). At the taxpayer's election, the Transition Toll Tax can be paid over an eight-year period without interest, starting in 2018. The Company elected not to use this option and instead used a portion of its U.S. net operating losses ("NOLs") to offset this income inclusion.
The provisional amounts included in Benefit from income taxes for the year 2017, including the Transition Toll Tax, were finalized during 2018. Differences between the provisional net income tax benefits provided for the year 2017 attributable to the Tax Act and the benefit for income taxes as finalized are included in the Benefit from income taxes for 2018 and were not material to the Company’s financial results for the year 2018.
The Company has provided for income taxes in accordance with guidance issued by accounting regulatory bodies, the U.S. Internal Revenue Service and state and local governments through the date of the issuance of these Consolidated Financial Statements. Additional guidance and interpretations can be expected and such guidance, if any, could impact future results. While management continues to monitor these matters, the ultimate impact, if any, as a result of the application of any guidance issued in the future cannot be determined at this time.
The realization of deferred tax assets is dependent on the Company generating sufficient domestic and foreign taxable income in the years that the temporary differences become deductible. A valuation allowance has been provided for the portion of the deferred tax assets that the Company determined is more likely than not to remain unrealized based on estimated future taxable income and tax planning strategies. As a result of taxable losses in Canada as offset by a reduction of deferred tax assets due to internal restructurings, the valuation allowance decreased by $579 million during 2020 and decreased by $82 million during 2019. Given the Company’s history of pre-tax losses and expected future losses in Canada, the Company maintained that there was insufficient objective evidence to release the valuation allowance against Canadian tax loss carryforwards, International Tax Credits (“ITC”) and pooled Scientific Research and Experimental Development Tax Incentive (“SR&ED”) expenditures. The Canadian valuation allowance represents a material portion of the Company's total valuation allowance.
As of December 31, 2020 and 2019, the Company had accumulated taxable losses available to offset future years’ federal and provincial taxable income in Canada of approximately $6,530 million and $7,441 million, respectively.  As of December 31, 2020 and 2019, unclaimed ITCs available to offset future federal taxes in Canada were approximately $37 million and $34 million, respectively, which expire in the years 2021 through 2040.  In addition, as of December 31, 2020 and 2019, pooled SR&ED expenditures available to offset against future taxable income in Canada were approximately $206 million and $192 million, respectively, which may be carried forward indefinitely. As of December 31, 2020 and 2019, a full valuation allowance against the net Canadian deferred tax assets has been provided of $1,966 million and $2,461 million, respectively.
As of December 31, 2020 and 2019, the Company had accumulated taxable losses available to offset future years' federal taxable income in the U.S. of approximately $814 million and $636 million, respectively, including acquired losses which expire in the years 2021 through 2037. While the remaining taxable losses are subject to multiple annual loss limitations as a result of previous ownership changes, the Company believes that the recoverability of the deferred tax assets associated with these taxable losses are more likely than not to be realized. As of December 31, 2020 and 2019 U.S. research and development credits available to offset future years' federal income taxes in the U.S. were approximately $110 million and $106 million, respectively, which includes acquired research and development credits and which expire in the years 2021 through 2040.
As of December 31, 2020 and 2019, the Company had accumulated taxable losses available to offset future years’ taxable income in Ireland of approximately $8,387 million and $6,765 million, respectively.  As of December 31, 2020 and 2019, the Company recognized a capital loss and established a valuation allowance on the portion of the loss for which a benefit is not expected to be realized.
The Company provides for Canadian tax on the unremitted earnings of its direct foreign affiliates except for its direct U.S. subsidiaries. The Company continues to assert that the unremitted earnings of its U.S. subsidiaries will be permanently reinvested and not repatriated. As of December 31, 2020, the Company estimates there will be no tax liability attributable to the permanently reinvested U.S. earnings.
As of December 31, 2020 and 2019, unrecognized tax benefits (including interest and penalties) were $1,025 million and $1,002 million, of which $414 million and $355 million would affect the effective income tax rate, respectively. In 2020 and 2019, the remaining unrecognized tax benefits would not impact the effective tax rate as the tax positions are offset against existing tax attributes or are timing in nature. In 2020 and 2019, the Company recognized net increases to unrecognized tax benefits for current year tax positions of $66 million and $362 million, respectively. The Company recognized a net reduction of $42 million during 2020 and a net reduction of $13 million during 2019 in the unrecognized tax benefits related to tax positions taken in the prior years.
The Company provides for interest and penalties related to unrecognized tax benefits in the provision for income taxes. As of December 31, 2020 and 2019, accrued interest and penalties related to unrecognized tax benefits were approximately
$49 million and $45 million, respectively. In 2020 and 2019, the Company recognized a net increase of approximately $4 million and $3 million of interest and penalties, respectively.
The Company and one or more of its subsidiaries file federal income tax returns in Canada, the U.S., and other foreign jurisdictions, as well as various provinces and states in Canada and the U.S. The Company and its subsidiaries have open tax years, primarily from 2005 to 2019, with significant taxing jurisdictions, respectively, including Canada and the U.S. These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations and tax treaties, as they relate to the amount, timing, or inclusion of revenues and expenses, or the sustainability of income tax positions of the Company and its subsidiaries. Certain of these tax years are expected to remain open indefinitely.
Jurisdiction:Open Years
United States - Federal
2015 - 2019
Canada
2005 - 2019
Germany
2014 - 2019
France
2013 - 2019
China
2016 - 2019
Ireland
2016 - 2019
Netherlands
2016 - 2019
Australia
2011 - 2019
The Internal Revenue Service completed its examinations of the Company’s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company's taxable income as a result of these examinations. The 2014 tax year remains open to the extent of a 2017 capital loss carried back to that year. Additionally, the Internal Revenue Service has selected for examination the Company's annual tax filings for 2015 and 2016 and the Company's short period tax return for the period ended September 8, 2017, which was filed as a result of the Company's internal restructuring efforts during 2017. At this time, the Company does not expect that proposed adjustments, if any, for these periods would be material to the Company's Consolidated Financial Statements.
The Company is currently under examination by the Canada Revenue Agency for four separate cycles: (a) years 2005 through 2006, (b) years 2007 through 2009, (c) years 2012 through 2013 and (d) years 2014 through 2015. The Company received from the Canada Revenue Agency a proposed audit adjustment for the years 2005 through 2009. The Company disagrees with the adjustments and has filed the respective Notices of Objection. The total proposed adjustment will result in a loss of tax attributes which are subject to a full valuation allowance and will not result in material change to the provision for income taxes. The Canada Revenue Agency audits of the 2010 and 2011 tax years were closed in 2016, and resulted in no material adjustments. The Company received an assessment for certain transfer pricing matters in 2012 and 2013 for CAD 85 million and CAD 90 million, respectively.  The Company disagrees with the adjustments and has filed a Notice of Objection for 2012 and will file an objection for 2013.  Of the total proposed adjustments, all but CAD 3 million will result in a loss of tax attributes which are subject to a full valuation allowance and will not result in a material change to the provision for income taxes.
The Company’s subsidiaries in Germany are under audit for tax years 2014 through 2016. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.
The Company’s subsidiaries in Australia are under audit by the Australian Tax Office for various years beginning in 2010. On August 8, 2017, the Australian Taxation Office issued a notice of assessment for the tax years 2011 through 2017 in the aggregate amount of $117 million, which includes penalties and interest. The Company disagrees with the assessment and continues to believe that its tax positions are appropriate and supported by the facts, circumstances and applicable laws. The Company intends to defend its tax position in this matter vigorously and has filed a holding objection against the assessment by the Australian Taxation Office and has secured a bank guarantee to cover any potential cash outlays regarding this assessment.
The Company's U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2018.
Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits.
At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.
The following table presents a reconciliation of the unrecognized tax benefits for 2020, 2019 and 2018:
(in millions)202020192018
Balance, beginning of year$1,002 $654 $598 
Additions based on tax positions related to the current year66 361 18 
Additions for tax positions of prior years171 63 55 
Reductions for tax positions of prior years(209)(58)(11)
Lapse of statute of limitations(5)(18)(6)
Balance, end of year$1,025 $1,002 $654 
The Company believes it is reasonably possible that the total amount of unrecognized tax benefits at December 31, 2020 could decrease by approximately $145 million in the next twelve months as a result of the resolution of certain tax and transfer pricing audits and other events.
XML 43 R25.htm IDEA: XBRL DOCUMENT v3.20.4
LOSS PER SHARE
12 Months Ended
Dec. 31, 2020
Earnings Per Share [Abstract]  
LOSS PER SHARE LOSS PER SHARE
Loss per share attributable to Bausch Health Companies Inc. for 2020, 2019 and 2018 were calculated as follows:
(in millions, except per share amounts)202020192018
Net loss attributable to Bausch Health Companies Inc.$(560)$(1,788)$(4,148)
Basic and diluted weighted-average common shares355.0 352.1 351.3 
Basic and diluted loss per share attributable to Bausch Health Companies Inc.$(1.58)$(5.08)$(11.81)
In 2020, 2019 and 2018, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 3,154,000, 5,106,000 and 3,763,000 common shares for 2020, 2019 and 2018, respectively.
Additionally, in 2020, 2019 and 2018, stock options, time-based RSUs and performance-based RSUs to purchase approximately 9,551,000, 2,598,000 and 4,185,000 common shares of the Company, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method.
XML 44 R26.htm IDEA: XBRL DOCUMENT v3.20.4
SUPPLEMENTAL CASH FLOW DISCLOSURES
12 Months Ended
Dec. 31, 2020
Supplemental Cash Flow Elements [Abstract]  
SUPPLEMENTAL CASH FLOW DISCLOSURES SUPPLEMENTAL CASH FLOW DISCLOSURES
Supplemental cash flow disclosures for 2020, 2019 and 2018 are as follows:
(in millions)202020192018
Other payments
Interest paid$1,474 $1,537 $1,665 
Income taxes paid$162 $172 $138 
XML 45 R27.htm IDEA: XBRL DOCUMENT v3.20.4
LEGAL PROCEEDINGS
12 Months Ended
Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
LEGAL PROCEEDINGS LEGAL PROCEEDINGSFrom time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described below. Going forward, in the Company's subsequent Quarterly Reports on Form 10-Q, the Company will only include a description of these matters to the extent there has been a material update with respect thereto during the applicable quarter or to the extent otherwise required by law.
On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of December 31, 2020, the Company's Consolidated Balance Sheets includes accrued current loss contingencies of $1,672 million related to matters which the Company believes a potential resolution or settlement is both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company’s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.
Governmental and Regulatory Inquiries
Investigation by the U.S. Attorney's Office for the District of Massachusetts - re OraPharma
In August 2019, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin®, including related support services, and other matters. The Company is cooperating with this investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.
Securities and RICO Class Actions and Related Matters
U.S. Securities Litigation - Opt-Out Litigation
On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658). On January 31, 2021 the District Court issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill filed a notice of appeal of the Court’s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options. The deadline for other parties to file notices of appeal from the final approval order is March 2, 2021.
In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company’s business and prospects, including relating to drug pricing, the Company’s use of specialty pharmacies, and the Company’s relationship with Philidor. On May 31, 2016, the court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $1,210 million. This settlement received final approval from the court on January 31, 2021 and will resolve and discharge all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and denied all allegations of wrongdoing. In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payment was paid into an escrow fund in accordance with the settlement agreement. The opt-out litigations discussed below remain ongoing.
On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246) (“Timber Hill”), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company’s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.
In addition to the consolidated putative class action, thirty-seven groups of individual investors in the Company’s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions pending in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions are captioned: T. Rowe Price Growth Stock Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-5034); Equity Trustees Limited as Responsible Entity for T. Rowe Price Global Equity Fund v. Valeant Pharmaceuticals International Inc. (Case No. 16-cv-6127); Principal Funds, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-6128); BloombergSen Partners Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-
cv-7212); Discovery Global Citizens Master Fund, Ltd. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7321); MSD Torchlight Partners, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7324); BlueMountain Foinaven Master Fund, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7328) (“BlueMountain”); Incline Global Master LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7494); VALIC Company I v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7496); Janus Aspen Series v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7497) (“Janus Aspen”); Okumus Opportunistic Value Fund, LTD v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6513) (“Okumus”); Lord Abbett Investment Trust- Lord Abbett Short Duration Income Fund, v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6365) (“Lord Abbett”); Pentwater Equity Opportunities Master Fund LTD v. Valeant Pharmaceuticals International, Inc., et al. (Case No. 17-cv-7552) (“Pentwater”); Public Employees’ Retirement System of Mississippi v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-7625) (“Mississippi”); The Boeing Company Employee Retirement Plans Master Trust v. Valeant Pharmaceuticals International Inc., et al., (Case No. 17-cv-7636) (“Boeing”); State Board of Administration of Florida v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-12808); The Regents of the University of California v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-13488); GMO Trust v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0089); Första AP Fonden v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-12088); New York City Employees’ Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0032) (“NYCERS”); Hound Partners Offshore Fund, LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08705) (“Hound Partners”); Blackrock Global Allocation Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0343) (“Blackrock”); Colonial First State Investments Limited As Responsible Entity for Commonwealth Global Shares Fund 1 v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0383); Bharat Ahuja v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0846); Brahman Capital Corp. v. Valeant Pharmaceuticals International, Inc (Case No. 18-cv-0893); The Prudential Insurance Company of America v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-01223) (“Prudential”); Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) (“Senzar”); 2012 Dynasty UC LLC v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08595) ("2012 Dynasty"); Catalyst Dynamic Alpha Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-12673) (“Catalyst”); Northwestern Mutual Life Insurance Co., v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-15286) (“Northwestern Mutual”); Bahaa Aly, et al. v. Valeant Pharmaceuticals International, Inc., (Case No. 18-cv-17393) (“Aly”); Office of the Treasurer as Trustee for the Connecticut Retirement Plans and Trust Funds v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18473) (“Connecticut”); Delaware Public Employees’ Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18475) (“Delaware”); Maverick Neutral Levered Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-02190) (“Maverick”), Templeton v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-05478) (“Templeton”), USAA Mutual Funds Trust, et al. v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 20-cv-07462) (“USAA”), and GIC Private Ltd. v. Valeant Pharmaceuticals International, Inc., (Case No. 20-cv-07460) (“GIC”). Twelve of the thirty-seven opt out actions have been dismissed; and the total number of remaining opt out actions pending in the District of New Jersey is twenty-five actions. Four additional matters have been settled and dismissals are expected in March 2021.
These individual shareholder actions assert claims under Sections 10(b), and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss have been filed and in most cases decided in many of these individual actions. To date, the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case. On September 10, 2019, the Court granted defendants’ motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (“Aly”) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. Oral argument on Plaintiffs’ appeal was held on October 20, 2020. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut, and Delaware actions. On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds and Equity Trustees actions.
The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.
Canadian Securities Litigation
In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. These actions are captioned: (a) Alladina v. Valeant, et al. (Case No. S-1594B6) (Supreme Court of British Columbia) (filed November 17, 2015); (b) Kowalyshyn v. Valeant, et al. (CV-15-540593-00CP) (Ontario Superior Court) (filed November 16, 2015); (c) Kowalyshyn et al. v. Valeant, et al. (CV-15-541082-00CP) (Ontario Superior Court) (filed November 23, 2015); (d) O’Brien v. Valeant et al. (CV-15-543678-00CP) (Ontario Superior Court) (filed December 30, 2015); (e) Catucci v. Valeant, et al. (Court File No. 540-17-011743159) (Quebec Superior Court) (filed October 26, 2015); and (f) Rousseau-Godbout v. Valeant, et al. (Court File No. 500-06-000770-152) (Quebec Superior Court) (filed October 27, 2015).
The Company is also aware of two additional putative class actions that were filed with the applicable court but which have not been served on the Company. These actions are captioned: (i) Okeley v. Valeant, et al. (Case No. S-159991) (Supreme Court of British Columbia) (filed December 2, 2015); and (ii) Sukenaga v Valeant et al. (CV-15-540567-00CP) (Ontario Superior Court) (filed November 16, 2015), and the factual allegations made in these actions are substantially similar to those outlined above.
The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.
Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, has been discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.
After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company’s auditors and the action was dismissed as against them.
On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD 94,000,000 plus payment of an additional amount to cover notice and settlement administration costs and disbursements. As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.
In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.
The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights (“CalSTRS”) served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers’ Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.
On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision.
On October 8 and 9, 2020, respectively, CalSTRS delivered amended proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of “price appreciation credits” in respect of Glumetza®
during the period covered by the claims. CalSTRS has filed an application for permission to amend and the Company has filed an application to strike the amendments.
The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.
Insurance Coverage Lawsuit
On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16.  The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; 3:18-CV-00493).  In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (under the 2013-2014 coverage period), and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and certain of the investigations described herein and in the Company's prior annual and quarterly reports (under the 2015-2016 coverage period). 
RICO Class Actions
Between May 27, 2016 and September 16, 2016, three actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (“RICO”) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company branded drugs between January 2, 2013 and November 9, 2015.  On November 30, 2016, the Court entered an order consolidating the three actions under the caption In re Valeant Pharmaceuticals International, Inc. Third-Party Payor Litigation, No. 3:16-cv-03087. A consolidated class action complaint was filed on December 14, 2016. The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured’s consent to renew the prescription.  The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.
A Special Master appointed by the Court has recommended that the Company’s motion to dismiss be denied, but a final decision is still pending with the Court. The Company believes these claims are without merit and intends to defend itself vigorously.
Hound Partners Lawsuit
In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County. This action is captioned Hound Partners Offshore Fund, LP et al., v. Valeant Pharmaceuticals International, Inc., et al. (No. MER-L-002185-18). This suit asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. This matter is currently stayed pending the completion of discovery in one of the above-noted federal opt-out cases. The Company disputes the claims and intends to vigorously defend this matter.
Derivative Lawsuits
On September 10, 2019 and September 13, 2019, two alleged stockholders filed derivative lawsuits purportedly on behalf of the Company against former Company board members and executives. The cases are Wessels v. Pearson (Case No. 3:19-cv-17833) and Shabbouei v. Pearson (Case No. 3:19-cv-17987). On March 7, 2020, a consolidated amended derivative complaint was filed, captioned In re Bausch Health Companies Inc. F/K/A/ Valeant Pharmaceuticals International, Inc. Stockholder Derivative Litigation (Case No. 19-cv-17833).
Plaintiffs assert claims for breach of fiduciary duty, waste of corporate assets, and unjust enrichment related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company’s business and prospects, including relating to drug pricing, the Company’s use of specialty pharmacies, and the Company’s relationship with Philidor. The consolidated complaint also asserts a claim for contribution and indemnification by the Defendants for any liability the Company ultimately faces as a result of the conduct alleged in the complaint. The claims
alleged in these cases are based on the same purported conduct that is at issue in In re Valeant Pharmaceuticals International, Inc. Securities Litigation, all of which occurred prior to 2017. The Shabbouei complaint also asserts a claim for contribution and indemnification by the Defendants for any liability the Company ultimately faces as a result of the conduct alleged in the complaint. On January 3, 2020, the parties submitted a letter to the Court requesting consolidation of the two derivative lawsuits. On April 21, 2020, the Defendants filed a motion to dismiss the consolidated amended complaint. Briefing on this motion concluded on August 3, 2020. On November 24, 2020, the Special Master appointed by the Court issued a report recommending that the motion to dismiss be granted in full. While a final decision is still pending with the Court, Plaintiffs are not contesting the dismissal in full. The Company continues to believe these claims are without merit and intends to defend itself vigorously.
Antitrust
Generic Pricing Antitrust Litigation
The Company's subsidiaries, Oceanside Pharmaceuticals, Inc. (“Oceanside”), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (“Bausch Health US”), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (“Bausch Health Americas”) (for the purposes of this paragraph, collectively, the “Company”), are defendants in multidistrict antitrust litigation (“MDL”) entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16-MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company’s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been or are expected to be consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. In July 2019, 87 health plans commenced an action in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed and the case has been put in deferred status. In May 2020, seven health plans commenced an additional action in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed. The Company disputes the claims against it and continues to defend itself vigorously.
Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively “the Company”) have been named as defendants in a proposed class proceeding entitled Kathryn Eaton vs. Teva Canada Limited, et al. in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the Competition Act by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the In re: Generic Pharmaceuticals Pricing Antitrust Litigation pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and will defend itself vigorously.
Glumetza Antitrust Litigation
Between August 2019 and July 2020, eight (8) putative antitrust class actions and four (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (for purposes of this subsection, collectively, the “Company”), among other defendants, were filed or transferred to the Northern District of California. Three (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020. The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020. In December 2020, the court denied the Company’s motion to dismiss as to the insurer plaintiff’s direct claims but dismissed the insurer plaintiff’s indirect claims. On February 2, 2021, the insurer plaintiff’s motion for leave to amend its complaint was denied. On February 8, 2021, the insurer plaintiff filed an action in state court asserting state law claims.
The federal actions, five (5) of which remain pending, have been consolidated and coordinated in In re Glumetza Antitrust Litigation, Case No. 3:19-cv-05822-WHA. The lawsuits allege that a 2012 settlement of a patent litigation regarding Glumetza® delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza® or grant any other company a license to do so. The complaints allege that the settlement agreement resulted in higher prices for
Glumetza® and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs seek damages under federal antitrust laws for claims based on direct purchases. All Plaintiffs have filed a motion for partial summary judgment concerning market power, whereas all Defendants have filed a motion for summary judgment on all claims against them. The Company disputes the claims against it and intends to vigorously defend these matters.
Intellectual Property
Patent Litigation/Paragraph IV Matters
From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Relistor®, Xifaxan® 550mg, Plenvu®, Bryhali®, Duobrii® and Jublia® in the United States and Jublia® in Canada, or other similar suits. These matters are proceeding in the ordinary course.
In September 2019, the Company received a Notice of Paragraph IV Certification from Sandoz, Inc. (“Sandoz”), in which Sandoz asserted that the following U.S. patents, each of which is listed in the FDA’s Orange Book for Salix Pharmaceuticals, Inc.’s (“Salix Inc.”) Xifaxan® tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Sandoz’s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (“ANDA”) has been filed by Sandoz: U.S. Patent No. 8,309,569 (the “‘569 patent”), U.S. Patent No. 7,045,620 (the “‘620 patent”), U.S. Patent No. 7,612,199 (the “‘199 patent”), U.S. Patent No. 7,902,206 (the “‘206 patent”), U.S. Patent No. 7,906,542 (the “‘542 patent”), U.S. Patent No. 7,915,275 (the “‘275 patent”), U.S. Patent No. 8,158,644 (the “‘644 patent”), U.S. Patent No. 8,158,781 (the “‘781 patent”), U.S. Patent No. 8,193,196 (the “‘196 patent”), U.S. Patent No. 8,518,949 (the “‘949 patent”), U.S. Patent No. 8,741,904 (the “‘904 patent”), U.S. Patent No. 8,835,452 (the “‘452 patent”), U.S. Patent No. 8,853,231 (the “‘231 patent”), and U.S. Patent No. 9,271,968 (the “’968 Patent”) (collectively, the “Xifaxan® Patents”). Salix Inc. holds the New Drug Application ("NDA") for Xifaxan® and its affiliate, Salix Pharmaceuticals, Ltd. (“Salix Ltd.”), is the owner of the ‘569 patent and Alfasigma S.p.A. (“Alfasigma”) is the owner of the ‘620 patent, the ‘199 patent, the ‘206 patent, the ‘542 patent, the ‘275 patent, the ‘644 patent, the ‘781 patent, the ‘196 patent, the ‘949 patent, the ‘904 patent, the ‘452 patent, the ‘231 patent, and the ‘968 patent, each of which has been exclusively licensed to Salix Inc. and its affiliate, Bausch Health Ireland Limited (“BIRL”) to market Xifaxan® tablets, 550 mg.   On September 30, 2019, Salix Inc. and its affiliates, Salix Ltd. and BIRL, and Alfasigma (the “Plaintiffs”) filed suit against Sandoz in the U.S. District Court for the District of New Jersey (Case No. 19-18566) pursuant to the Hatch-Waxman Act, alleging infringement by Sandoz of one or more claims of each of the Xifaxan® Patents, thereby triggering a 30-month stay of the approval of Sandoz’s ANDA for rifaximin tablets, 550 mg. Xifaxan® 550 mg is protected by 26 patents covering the composition of matter and the use of Xifaxan® listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book.   On May 6, 2020, the Company announced that an agreement had been reached with Sandoz that resolved this litigation. Under the terms of the agreement, the parties agreed to dismiss all litigation related to Xifaxan® (rifaximin), Sandoz acknowledged the validity of the licensed patents for Xifaxan® (rifaximin) 550 mg tablets and all intellectual property protecting Xifaxan® (rifaximin) 550 mg tablets will remain intact and enforceable until expiry in October 2029. The agreement also grants Sandoz a non-exclusive license to the intellectual property relating to Xifaxan® (rifaximin) 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sandoz will have the right to market a royalty-free generic version of Xifaxan® (rifaximin) 550 mg tablets, should it receive approval from the FDA on its ANDA. Sandoz will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the United States before January 1, 2028. The Company will not make any financial payments or other transfers of value as part of this agreement with Sandoz.
On February 17, 2020, the Company and Alfasigma S.p.A. ("Alfasigma") received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (“Norwich”), in which Norwich asserted that the following U.S. patents, each of which is listed in the FDA’s Orange Book for the Company's Xifaxan® tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich’s generic rifaximin tablets, 550 mg, for which an ANDA has been filed by Norwich: each of the Xifaxan® Patents (as described above), as well as U.S. Patent No. 8,642,573 (the “573 patent”), U.S. Patent No. 8,829,017 (the “017 patent”), U.S. Patent No. 8,946,252 (the “252 patent”), U.S. Patent No. 8,969,398 (the “‘398 patent”), U.S. Patent No. 9,421,195 (the “‘195 patent”), U.S. Patent No. 9,629,828 (the “‘9828 patent”), U.S. Patent No. 10,314,828 (the “’4828 patent”), U.S. Patent No. 10,335,397 (the “‘397 patent”), U.S. Patent No. 10,456,384 (the “‘384 patent”), U.S. Patent No. 10,703,763 (the “‘763 patent”), U.S. Patent No. 10,709,694 (the “‘694 patent”), and U.S. Patent No. 10,765,667 (the “‘667 patent”). Salix Inc. holds the NDA for Xifaxan® and is the
owner of the ‘569 patent, the ‘573 patent, the ‘017 patent, the ‘252 patent, the ‘398 patent, the ‘195 patent, the ‘9828 patent, the ‘4828 patent, the ‘397 patent, the ‘384 patent, the ‘694 patent, and the ‘667 patent. Alfasigma is the owner of the ‘620 patent, the ‘199 patent, the ‘206 patent, the ‘542 patent, the ‘275 patent, the ‘644 patent, the ‘781 patent, the ‘196 patent, the ‘949 patent, the ‘904 patent, the ‘452 patent, the ‘231 patent, the ‘968 patent, and the ‘763 patent, each of which has been exclusively licensed to Salix Inc. and/or its affiliate, Bausch Health Ireland Limited (“BIRL”) to market Xifaxan® tablets, 550 mg.  On March 26, 2020, certain of the Company’s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan® Patents, thereby triggering a 30-month stay of the approval of Norwich’s ANDA for rifaximin tablets, 550 mg. Xifaxan® 550 mg is protected by 26 patents covering the composition of matter and the use of Xifaxan® listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. The Company remains confident in the strength of the Xifaxan® patents and will continue to vigorously pursue this matter and defend its intellectual property.
In April 2019, the Company and Alfasigma commenced litigation against Sun Pharmaceutical Industries Ltd. (“Sun”), alleging patent infringement by Sun’s filing of its ANDA for Xifaxan® (rifaximin) 200 mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from Sun, in which Sun had asserted that the U.S. patents listed in the FDA's Orange Book for the Company’s Xifaxan® tablets, 200 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun’s generic rifaximin tablets, 200 mg. Subsequently, on August 10, 2020, the Company received an additional Notice of Paragraph IV Certification from Sun, in which Sun asserted that the U.S. patents listed in the FDA's Orange Book for the Company’s Xifaxan® tablets, 550 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun’s generic rifaximin tablets, 550 mg, for which an ANDA had been filed by Sun. On September 22, 2020, the Company announced that an agreement had been reached with Sun that resolved the outstanding intellectual property disputes with Sun regarding Xifaxan® (rifaximin) 200 mg and 550 mg tablets. Under the terms of the agreement, the parties agreed to dismiss all litigation related to Xifaxan® (rifaximin) and all intellectual property protecting Xifaxan® (rifaximin) 200 mg and 550 mg tablets will remain intact and enforceable until expiry in July and October 2029, respectively. The agreement also grants Sun a non-exclusive license to the intellectual property relating to Xifaxan® (rifaximin) 200 mg and 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sun will have the right to market royalty-free generic versions of Xifaxan® (rifaximin) 200 mg and 550 mg tablets, should it receive approval from the FDA on its ANDAs. Sun will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the United States before January 1, 2028.
On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (“Perrigo”), in which Perrigo asserted that certain U.S. patents, each of which is listed in the U.S. Food and Drug Administration's (the "FDA") Orange Book for Duobrii® (halobetasol propionate and tazarotine) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Perrigo’s generic lotion, for which an Abbreviated New Drug Application (“ANDA”) has been filed by Perrigo. On August 28, 2020, the Company filed suit against Perrigo pursuant to the Hatch-Waxman Act, alleging infringement by Perrigo of one or more claims of the Duobrii® Patents, thereby triggering a 30-month stay of the approval of the Perrigo ANDA. On September 3, 2020, this action was consolidated with the action between the Company and Perrigo described below, regarding Perrigo’s ANDA for generic Bryhali® (halobetasol propionate) lotion. The Company remains confident in the strength of the Duobrii® related patents and will vigorously defend its intellectual property.
On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo, in which Perrigo asserted that certain U.S. patents, each of which is listed in the FDA’s Orange Book for Bryhali® (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Perrigo’s generic halobetasol propionate lotion, for which an ANDA has been filed by Perrigo. On May 1, 2020, the Company filed suit against Perrigo pursuant to the Hatch-Waxman Act, alleging infringement by Perrigo of one or more claims of the Bryhali® Patents, thereby triggering a 30-month stay of the approval of the Perrigo ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Perrigo described above, regarding Perrigo’s ANDA for generic Duobrii® (halobetasol propionate and tazarotine) lotion. The Company remains confident in the strength of the Bryhali® Patents and intends to vigorously pursue this matter and defend its intellectual property.
In addition, patents covering the Company's branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review ("IPR") at the U.S. Patent & Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution.  IPR challenges have been brought against patents covering the Company's branded pharmaceutical products.  For example, following Acrux DDS’s IPR petition, the U.S. Patent and Trial Appeal Board ("PTAB"), in May 2017, instituted inter
partes review for an Orange Book-listed patent covering Jublia®, U.S. Patent No. 7,214,506 (the “‘506 patent”). On June 6, 2018, the PTAB issued a written determination invalidating such patent; and on March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion. The ‘506 Patent therefore remains valid and enforceable until its expected expiration in 2026. Jublia® continues to be covered by fourteen other Orange Book-listed patents owned by the Company and its licensor, which expire in the years 2028 through 2035.
Product Liability
Shower to Shower® Products Liability Litigation
Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower® body powder product acquired in September 2012 from Johnson & Johnson; due to dismissals, only twenty-eight (28) of such product liability suits currently remain pending, and these twenty-eight (28) matters are subject to the Johnson & Johnson indemnification referenced below.
Potential liability (including its attorneys’ fees and costs) arising out of the covered Shower to Shower® lawsuits filed against the Company is subject to certain indemnification obligations of Johnson & Johnson owed to the Company, and legal fees and costs will be paid by Johnson & Johnson. The Company and Johnson & Johnson reached an agreement on April 17, 2019, regarding the scope of the indemnification relating to the majority of the Shower to Shower® matters (the “Covered Matters”) and the Company has dismissed the demand for arbitration that the Company filed against Johnson & Johnson to assert its rights to indemnification. Johnson & Johnson will fully indemnify the Company in the Covered Matters, which include: (i) personal injury and products liability actions arising from alleged exposure to Shower to Shower® prior to March 2020 and (ii) consumer fraud, consumer protection, false advertising or other regulatory actions arising out of the manufacture, use, or sale of Shower to Shower® up to and including September 9, 2012. The Company does not believe that the Covered Matters will have a material impact on the Company’s financial results going forward.
The various lawsuits include a number of cases, either originally filed in or transferred to the In re Johnson & Johnson Talcum Powder Litigation, Multidistrict Litigation 2738, pending in the United States District Court for the District of New Jersey (“MDL”). The Company and Bausch Health US were first named in a lawsuit filed directly into the MDL alleging that the use of the Shower to Shower® product caused the plaintiff to develop ovarian cancer. The plaintiff agreed to a dismissal of all claims against the Company and Bausch Health US in that matter without prejudice. The Company has subsequently been named in one additional lawsuit, originally filed in the District of Puerto Rico and subsequently transferred into the MDL, but has not been served in that case. The Company has also been named in eighteen additional lawsuits filed directly into the MDL that have also not yet been served.
These lawsuits also include a number of matters filed in the Superior Court of Delaware and the Superior Court of New Jersey alleging that the use of Shower to Shower® caused the plaintiffs to develop ovarian cancer. Nearly all of these actions have been voluntarily dismissed. Presently, two cases remain pending in New Jersey and one in Delaware. One of the New Jersey cases has not yet been served. The allegations in these cases generally include failure to warn, design defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, and punitive damages.
In addition, these lawsuits also include a number of cases filed in certain state courts in the United States (including the Superior Courts of California, Delaware and New Jersey); the District Court of Louisiana; the Supreme Court of New York (Niagara County); the District Court of Oklahoma City, Oklahoma; the South Carolina Court of Common Pleas (Richland County); the Ohio Court of Common Pleas (Cuyahoga County); and the District Court of Nueces County, Texas (transferred to the asbestos multidistrict litigation docket in the District Court of Harris County, Texas for pre-trial purposes) alleging use of Shower to Shower® and other products resulted in the plaintiffs developing mesothelioma. The Company has been successful in obtaining voluntary dismissals in most of these cases or the plaintiffs have not opposed summary judgment. Presently, four cases remain pending in the Superior Court of New Jersey, and one case in the Court of Common Pleas of Cuyahoga County, Ohio, in which a Notice of Voluntary Dismissal Without Prejudice has been agreed to between the parties. The allegations in these cases generally include design defect, manufacturing defect, failure to warn, negligence, and punitive damages, and in some cases breach of express and implied warranties, misrepresentation, and loss of consortium. The damages sought by the various plaintiffs include compensatory damages, including medical expenses, lost wages or earning capacity, and loss of consortium. In addition, plaintiffs seek compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys’ fees.
Additionally, two proposed class actions have been filed in Canada against the Company and various Johnson & Johnson entities (one in the Supreme Court of British Columbia and one in the Superior Court of Quebec). The Company also acquired the rights to the Shower to Shower® product in Canada from Johnson & Johnson in September 2012. In the British Columbia matter, the plaintiff sought to certify a proposed class action on behalf of persons in British Columbia and Canada who have purchased or used Johnson & Johnson’s Baby Powder or Shower to Shower®, including their estates, executors and personal representatives, and is alleging that the use of this product increases certain health risks. On November 7, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower®, and at this time no appeal of that judgment has been filed. In the Quebec matter, the plaintiff sought to certify a proposed class action on behalf of persons in Quebec who have used Johnson & Johnson’s Baby Powder or Shower to Shower®, as well as their family members, assigns and heirs, and is alleging negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner. A certification (also known as authorization) hearing was held in the Quebec matter and the Court certified (or as stated under Quebec law, authorized) the bringing of a class action by a representative plaintiff on behalf of people in Quebec who have used Johnson & Johnson's Baby Powder and/or Shower to Shower® in their perineal area and have been diagnosed with ovarian cancer and/or family members, assigns and heirs. The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages.
In accordance with the indemnification agreement, Johnson & Johnson will continue to vigorously defend the Company in each of the remaining actions that are not voluntarily dismissed or subject to a grant of summary judgment.
General Civil Actions
California Proposition 65 Related Matters
On April 15, 2019, a plaintiff filed a pre-suit notice letter with the California Attorney General notifying the Attorney General’s office of its intent to file suit after 60 days against the Company and certain of its subsidiaries, alleging they committed violations of the California Safe Drinking Water and Toxic Enforcement Act of 1986 (“Proposition 65”) by manufacturing and distributing Shower to Shower® that they allege contained silica, arsenic, lead and chromium (hexavalent compounds), which they allege are known to cause cancer and/or reproductive toxicity. That notice letter was served on the Company on April 18, 2019.
On January 29, 2020, Plaintiff Jan Graham filed a lawsuit (Graham v. Bausch Health Companies, Inc., et al., Case No. 20STCV03578) in Los Angeles County Superior Court against the Company, Bausch Health US and several other manufacturers, distributors and retailers of talcum powder products, alleging violations of Proposition 65 by manufacturing and distributing talcum powder products containing chemicals listed under the statute, without a compliant warning on the label. On January 29, 2021, certain defendants including the Company and Bausch Health US filed a Motion for Summary Judgment or in the Alternative Motion for Summary Adjudication, which remains pending.
On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson & Johnson (Gutierrez, et al. v. Johnson & Johnson, et al., Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. The Company filed a motion to dismiss plaintiffs’ claims, which was granted in April 2020 without prejudice. In May 2020, plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted. In August 2020, plaintiffs filed the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss on all claims and dismissed the case with prejudice. On February 19, 2021, plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals.
The Company and Bausch Health US dispute the claims against them and intend to defend each of these lawsuits vigorously.
New Mexico Attorney General Consumer Protection Action
The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson & Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson & Johnson and Johnson & Johnson Consumer Companies, Inc., the Company and Bausch Health US related to Shower to Shower® and its alleged causal link to mesothelioma and other cancers. In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The
State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its Answer to the Complaint on November 16, 2020. On December 30, 2020 Johnson & Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which remains pending.
The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.
Doctors Allergy Formula Lawsuit
In April 2018, Doctors Allergy Formula, LLC (“Doctors Allergy”), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, Index No. 651597/2018. Doctors Allergy asserts breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.  Doctors Allergy claims its damages are not less than $23 million.  On June 14, 2018, Bausch Health Americas filed a motion to dismiss the complaint in part and a motion to strike. On July 16, 2019 the court granted the Company's motion in part and dismissed Doctor's Allergy's fraud and punitive damages claims. On August 28, 2019, the Company filed an Amended Answer and asserted Counterclaims against Doctors Allergy alleging breach of the covenant of good faith and fair dealing and tortious interference with contract. Bausch Health Americas disputes the claims against it and intends to vigorously defend against those claims and enforce its rights as asserted in its Counterclaims.
Litigation with Former Salix CEO
On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, Case No. 2019-0059, asserting claims for breach of contract and declaratory relief. The lawsuit arises out of the contractual termination of approximately $30 million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd. Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification.  On June 19, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. The Company disputes the claims and intends to vigorously defend the matter.
Completed or Inactive Matters
The following matters have concluded, have settled, are the subject of an agreement to settle or have otherwise been closed since January 1, 2020, have been inactive from the Company’s perspective for several quarters or the Company anticipates that no further material activity will take place with respect thereto. Due to the closure, settlement, inactivity or change in status of the matters referenced below, these matters will no longer appear in the Company's next public reports and disclosures, unless required. With respect to inactive matters, to the extent material activity takes place in subsequent quarters with respect thereto, the Company will provide updates as required or as deemed appropriate.
SEC Investigation
Beginning in November 2015, the Company received from the staff of the Los Angeles Regional Office of the SEC ("the Staff") subpoenas for documents, as well as various document, testimony and interview requests, related to its investigation of the Company, including requests concerning the Company's former relationship with Philidor Rx Services, LLC ("Philidor"), its accounting practices and policies, its public disclosures and other matters. On March 27, 2020, the Staff issued a Wells Notice informing the Company that they had reached a preliminary determination to recommend that the SEC bring charges against the Company for violating the federal securities laws as a result of SEC filings and other statements made by Valeant and its former executives in 2014-2015 concerning Philidor, as well as other accounting and disclosure matters, including the Company’s disclosure of certain price appreciation credits in 2015 - 2016. The Company has entered into a settlement with the SEC that has resolved all allegations by the SEC against the Company. Under the terms of the settlement, the Company neither admitted nor denied the SEC’s allegations and agreed to pay a $45 million civil monetary penalty.
AMF Investigation
On April 12, 2016, the Company received a letter from the Autorité des marchés financiers (the “AMF”) requesting documents concerning the work of the Company’s ad hoc committee of independent directors, the Company’s former relationship with Philidor, the Company's accounting practices and policies and other matters. In July 2018, the Company
was advised by the AMF that it had issued a formal investigation order against it. On September 30, 2020, the AMF confirmed that it had closed its investigation.
California Proposition 65 Related Matters
On February 11, 2019, plaintiffs filed a pre-suit notice letter with the California Attorney General notifying the Attorney General’s office of their intent to file suit after 60 days against the Company and certain of its subsidiaries, alleging they committed violations of Proposition 65 by manufacturing and distributing Shower to Shower® that they allege contained talc contaminated with asbestos, a listed carcinogen. That notice letter was served on the Company on February 22, 2019. By statute, a private lawsuit may not be filed until at least 60 days have passed following service of this pre-suit notice letter. In April 2019, rather than filing a lawsuit against Bausch Health US, the plaintiffs moved for leave to amend their complaint in a pending Proposition 65 lawsuit (Luna, et al. v. Johnson & Johnson, et al., case 2:18-cv-04830-GW-KS) against Johnson & Johnson in federal court in California to add Bausch Health US as a defendant. Plaintiffs subsequently filed a motion to dismiss the lawsuit without prejudice. The court dismissed the case without prejudice on December 18, 2019.
Contact Lens Antitrust Class Actions
Beginning in March 2015, a number of civil antitrust class action suits were filed by purchasers of contact lenses against B&L Inc., three other contact lens manufacturers, and a contact lens distributor, alleging that the defendants engaged in an anticompetitive scheme to eliminate price competition on certain contact lens lines through the use of unilateral pricing policies, and alleging violations of Section 1 of the Sherman Act, 15 U.S.C. § 1, and of various state antitrust and consumer protection laws. These cases have been consolidated in the Middle District of Florida by the Judicial Panel for Multidistrict Litigation, under the caption In re Disposable Contact Lens Antitrust Litigation, Case No. 3:15-md-02626-HES-JRK. On August 19, 2019, B&L Inc. entered into a settlement, subject to court approval, by which it agreed to pay $10 million to fully and finally resolve plaintiffs’ class claims against B&L Inc. in the case. On October 8, 2019, the settlement agreement was preliminarily approved by the court. A final fairness hearing regarding the settlement was held on February 25, 2020. On March 4, 2020, the Court granted final approval of the settlement agreement in all respects and dismissed the case with prejudice as to B&L Inc., except as to any claim by persons who validly and timely requested exclusion from the settlement classes.
Mississippi Attorney General Consumer Protection Action
The Company and Bausch Health US were named in an action brought by James Hood, Attorney General of Mississippi, in the Chancery Court of the First Judicial District of Hinds County, Mississippi (Hood ex rel. State of Mississippi, Civil Action No. G2014-1207013, filed on August 22, 2014), alleging consumer protection claims against Johnson & Johnson and Johnson & Johnson Consumer Companies, Inc., the Company and Bausch Health US related to the Shower to Shower® body powder product and its alleged causal link to ovarian cancer. As indicated above, the Company acquired the Shower to Shower® body powder product in September 2012 from Johnson & Johnson. The State sought compensatory damages, punitive damages, injunctive relief requiring warnings for talc-containing products, removal from the market of products that fail to warn, and to prevent the continued violation of the Mississippi Consumer Protection Act. The State also sought disgorgement of profits from the sale of the product and civil penalties. The State did not make specific allegations as to the Company or Bausch Health US. The Company and Bausch Health US agreed to resolve this litigation pursuant to a settlement agreement with the State of Mississippi for a non-material amount. On January 8, 2020, an order of dismissal with prejudice was entered by the Court.
Investigation by the State of Texas
On May 27, 2014, the State of Texas served Bausch & Lomb Incorporated (“B&L Inc.”) with a Civil Investigative Demand (“CID”) concerning various price reporting matters relating to the State's Medicaid program and the amounts the State paid in reimbursement for B&L products for the period from 1995 to the date of the CID.  B&L Inc. and the State agreed to settle the matter for $10 million. The Company made the payment on April 1, 2020. On July 1, 2020, the State moved to dismiss the case by filing a notice that it was taking a nonsuit, with prejudice to refiling, effective immediately.
XML 46 R28.htm IDEA: XBRL DOCUMENT v3.20.4
COMMITMENTS AND CONTINGENCIES
12 Months Ended
Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
The Company has commitments related to capital expenditures of approximately $54 million as of December 31, 2020.
Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones. As of December 31, 2020, the Company believes it is reasonably possible that it may potentially make milestone and license fee payments, including sales-based milestone payments, of
approximately $360 million over time, in the aggregate, to third parties for products currently under development or being marketed, primarily consisting of the following:
Under the terms of a June 2013 distribution and supply agreement with Mylan Pharmaceuticals Inc. (as assignee of Spear Pharmaceuticals, Inc and Spear Dermatology Products Inc.), the Company may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $70 million, in the aggregate.
Under the terms of an April 2019 agreement with Mitsubishi Tanabe Pharma Corporation, the Company has acquired an exclusive license to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate (S1P) receptor that plays a role in autoimmune diseases, such as Inflammatory Bowel Disease and ulcerative colitis. The Company may be required to make development and sales-based milestone payments over time of up to $60 million, in the aggregate, as well as royalties on future sales.
Under the terms of a December 2019 agreement with Novaliq GmbH, the Company has acquired an exclusive license for the commercialization and development in the U.S. and Canada of NOV03 (perfluorohexyloctane), an investigational drug to treat Dry Eye Disease associated with Meibomian gland dysfunction and may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $45 million, in the aggregate, as well as royalties on future sales.
Under the terms of a November 2019 agreement with Cedars-Sinai Medical Center, to evaluate a new formulation of rifaximin for the treatment of irritable bowel syndrome, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $36 million, in the aggregate.
Under the terms of an October 2020 agreement with Eyenovia, Inc., the Company has acquired an exclusive license in the United States and Canada for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. Under the terms of the agreement, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $35 million, in the aggregate.
Under the terms of a May 2020 agreement with STADA Arzneimittel AG and its development partner, Xbrane Biopharma AB, to commercialize in the United States and Canada a biosimilar candidate to Lucentis (ranibizumab), the Company may be required to make development and sales-based milestone payments.
In addition, under the terms of a September 2020 agreement with Allegro, the Company may be required to make a payment of $40 million should Allegro raise additional funding. This amount is excluded from the milestone and license fee payments disclosed above. See Note 3, "ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE" for additional details regarding this agreement.
On February 27, 2018, the Company announced that it entered into an exclusive license agreement with Kaken Pharmaceutical Co., Ltd. ("Kaken") to develop and commercialize a new chemical entity, IDP-131 (KP-470), for the topical treatment of psoriasis. An early proof of concept study has been completed and the results did not meet expectations. As a result, the Company and Kaken have terminated the license agreement.
Due to the nature of these arrangements, the future potential payments related to the attainment of the specified milestones over a period of several years are inherently uncertain. As of December 31, 2020, no accruals related to the aforementioned agreements exist because the milestone targets are not yet probable of being achieved.
Indemnification Provisions
In the normal course of business, the Company enters into agreements that include indemnification provisions for product liability and other matters. These provisions are generally subject to maximum amounts, specified claim periods and other conditions and limits. In addition, the Company is obligated to indemnify its officers and directors in respect of any legal claims or actions initiated against them in their capacity as officers and directors of the Company in accordance with applicable law. Pursuant to such indemnities, the Company is indemnifying certain former officers and directors in respect of certain litigation and regulatory matters. As of December 31, 2020 and 2019, no material amounts were accrued for the Company’s obligations under these indemnification provisions.
XML 47 R29.htm IDEA: XBRL DOCUMENT v3.20.4
SEGMENT INFORMATION
12 Months Ended
Dec. 31, 2020
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
Reportable Segments
The Company’s CEO, who is the Company’s Chief Operating Decision Maker, manages the business through operating and reportable segments consistent with how the Company’s CEO: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. The Company operates in the following reportable segments: (i) Bausch + Lomb/International segment, (ii) Salix segment, (iii) Ortho Dermatologics segment and (iv) Diversified Products segment.
The following is a brief description of the Company’s segments:
The Bausch + Lomb/International segment consists of: (i) sales in the U.S. of pharmaceutical products, OTC products and medical device products, primarily comprised of Bausch + Lomb products, with a focus on the Vision Care, Surgical, Consumer and Ophthalmology Rx products and (ii) with the exception of sales of Solta products, sales in Canada, Europe, Asia, Australia, Latin America, Africa and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products, OTC products, medical device products and Bausch + Lomb products.
The Salix segment consists of sales in the U.S. of GI products.
The Ortho Dermatologics segment consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta medical aesthetic devices.
The Diversified Products segment consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products.
Effective in the first quarter of 2019, one product historically included in the reported results of the Ortho Dermatologics business unit in the Ortho Dermatologics segment is now included in the reported results of the Generics business unit in the Diversified Products segment and another product historically included in the reported results of the Ortho Dermatologics business unit in the Ortho Dermatologics segment is now included in the reported results of the Dentistry business unit in the Diversified Products segment as management believes the products better align with the new respective business units. These changes in product alignment are not material. Prior period presentations of business unit and segment revenues and profits have been conformed to current segment and business unit reporting structures.
Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, including loss on assets held for sale, Restructuring, integration and separation costs, Acquisition-related contingent consideration costs and Other expense (income), net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.
Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company’s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single segment.
In connection with the planned separation of its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company has begun addressing the internal organizational design and structure of the new entity, which it anticipates having substantially complete by late 2021. As of the date of the issuance of these financial statements, these matters are in the planning phase. In connection with the Separation, the Company expects to realign and begin managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Separation during the first quarter of 2021. Accordingly, the Company expects to begin reporting under the following reporting segments on a retrospective basis beginning with its first quarter of 2021: Bausch + Lomb, International Rx, Salix, Ortho Dermatologics and Diversified Products.
Segment Revenues and Profit
Segment revenues and profits for the years 2020, 2019 and 2018 were as follows:
(in millions)202020192018
Revenues:   
Bausch + Lomb/International$4,408 $4,739 $4,664 
Salix1,904 2,022 1,749 
Ortho Dermatologics553 565 617 
Diversified Products1,162 1,275 1,350 
Total revenues$8,027 $8,601 $8,380 
Segment profit:   
Bausch + Lomb/International$1,159 $1,332 $1,330 
Salix1,338 1,349 1,149 
Ortho Dermatologics233 222 257 
Diversified Products848 932 1,012 
Total segment profit3,578 3,835 3,748 
Corporate(619)(609)(605)
Amortization of intangible assets(1,645)(1,897)(2,644)
Goodwill impairments— — (2,322)
Asset impairments, including loss on assets held for sale(114)(75)(568)
Restructuring, integration and separation costs(22)(31)(22)
Acquisition-related contingent consideration(48)(12)
Other (expense) income, net(454)(1,414)20 
Operating income (loss)676 (203)(2,384)
Interest income13 12 11 
Interest expense(1,534)(1,612)(1,685)
Loss on extinguishment of debt(59)(42)(119)
Foreign exchange and other(30)23 
Loss before benefit from income taxes$(934)$(1,837)$(4,154)
Capital Expenditures
Capital expenditures by segment for the years 2020, 2019 and 2018 were as follows:
(in millions)202020192018
Capital expenditures:   
Bausch + Lomb/International$282 $225 $139 
Salix
Ortho Dermatologics
Diversified Products
289 230 144 
Corporate13 40 13 
Total capital expenditures$302 $270 $157 
Revenues by Product and by Product Category
Revenues for the Company's top ten products for the years 2020, 2019 and 2018 represented 41%, 39% and 36% of total product sales, respectively. Revenues by segment and product category were as follows:
(in millions)Bausch + Lomb/ InternationalSalixOrtho DermatologicsDiversified ProductsTotal
202020192018202020192018202020192018202020192018202020192018
Pharmaceuticals$759 $885 $892 $1,899 $2,022 $1,752 $279 $355 $457 $741 $810 $927 $3,678 $4,072 $4,028 
Devices1,313 1,524 1,505 — — — 253 193 135 — — — 1,566 1,717 1,640 
OTC1,432 1,452 1,412 — — — — — — — — — 1,432 1,452 1,412 
Branded and Other Generics 838 801 784 — — — — — — 410 447 407 1,248 1,248 1,191 
Other revenues66 77 71 — (3)21 17 25 11 18 16 103 112 109 
$4,408 $4,739 $4,664 $1,904 $2,022 $1,749 $553 $565 $617 $1,162 $1,275 $1,350 $8,027 $8,601 $8,380 
Geographic Information
Revenues are attributed to a geographic region based on the location of the customer for the years 2020, 2019 and 2018 were as follows:
(in millions)202020192018
U.S. and Puerto Rico$4,791 $5,164 $5,011 
China341 368 361 
Canada331 339 319 
Egypt243 218 178 
Poland238 231 218 
Japan226 241 226 
Mexico225 228 211 
France179 201 205 
Germany144 150 170 
Russia137 180 154 
United Kingdom86 115 117 
Spain78 86 83 
Other1,008 1,080 1,127 
$8,027 $8,601 $8,380 
Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December 31, 2020 and 2019 were as follows:
(in millions)20202019
U.S. and Puerto Rico$725 $656 
Ireland328 255 
Canada110 103 
Poland83 90 
Germany80 68 
Mexico49 50 
France34 30 
China31 27 
Serbia30 27 
Italy 23 22 
Other 74 138 
$1,567 $1,466 
Major Customers
Customers that accounted for 10% or more of total revenues were as follows:
202020192018
McKesson Corporation17%17%18%
AmerisourceBergen Corporation17%16%18%
Cardinal Health, Inc.13%14%13%
XML 48 R30.htm IDEA: XBRL DOCUMENT v3.20.4
SUPPLEMENTARY DATA (UNAUDITED)
12 Months Ended
Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]  
SUPPLEMENTARY DATA (UNAUDITED)
SUPPLEMENTARY DATA (UNAUDITED)
Selected unaudited quarterly consolidated financial data are shown below:
2020
(in millions, except per share amounts)First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
Revenue$2,012 $1,664 $2,138 $2,213 
Expenses1,764 1,691 1,678 2,218 
Operating income (loss)$248 $(27)$460 $(5)
Net (loss) income attributable to Bausch Health Companies Inc.$(152)$(326)$71 $(153)
Basic and Diluted (loss) earnings per share attributable to Bausch Health Companies Inc.$(0.43)$(0.92)$0.20 $(0.43)
Net cash provided by operating activities$261 $200 $256 $394 
2019
(in millions, except per share amounts)First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
Revenue$2,016 $2,152 $2,209 $2,224 
Expenses1,729 1,895 1,880 3,300 
Operating income (loss)$287 $257 $329 $(1,076)
Net loss attributable to Bausch Health Companies Inc.
$(52)$(171)$(49)$(1,516)
Basic and Diluted loss per share attributable to Bausch Health Companies Inc.$(0.15)$(0.49)$(0.14)$(4.30)
Net cash provided by operating activities$413 $339 $515 $234 
XML 49 R31.htm IDEA: XBRL DOCUMENT v3.20.4
SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Basis of Presentation Basis of Presentation and Use of Estimates The Consolidated Financial Statements have been prepared by the Company in United States (“U.S.”) dollars and in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.
Use of Estimates
Use of Estimates
In preparing the Company's Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company’s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks.
On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s Consolidated Financial Statements could be materially impacted.
Reclassifications
Reclassifications
Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Acquisitions and Acquisition-Related Contingent Consideration
Acquisitions
Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition. Acquired in-process research and development (“IPR&D”) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&D with no alternative future use is charged to expense at the acquisition date and any future contingent consideration is not recorded until it becomes probable.
Acquisition-Related Contingent Consideration
Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in fair value measurement accounting.
Fair Value of Financial Instruments Fair Value of Financial InstrumentsThe estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events.
Fair Value of Derivative Instruments
Fair Value of Derivative Instruments
The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.
The Company’s cross-currency swaps qualify for and have been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value is determined via a mark-to-market analysis, using observable (Level 2) inputs. These inputs may include: (i) the foreign currency exchange spot rate between the euro and U.S. dollar, (ii) the interest rate yield curves in the euro and U.S. dollar and (iii) the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Loss as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulated other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps was ineffective. The Company uses the spot method of assessing hedge effectiveness. The Company has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as a reduction of Interest expense in the Consolidated Statements of Operations.
The Company uses foreign currency exchange contracts to economically hedge the foreign exchange exposure on certain of the Company’s intercompany and third party balances. The Company's foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other.
Cash and Cash Equivalents
Cash and Cash Equivalents
Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of three months or less when purchased.
Concentrations of Credit Risk
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, cross-currency swaps and foreign currency exchange contracts.
The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than three months. Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.
The Company’s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company’s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Brazil, Egypt, Greece, among other members of the European Union, Turkey, Ukraine and Venezuela have been weak in recent years.
Allowance for Credit Losses Allowance for Credit LossesAn allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.  Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses.
Inventories
Inventories
Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads.
The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.
Property, Plant and Equipment
Property, Plant and Equipment
Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful lives:
Land improvements
15 - 30 years
Buildings and improvements
Up to 40 years
Machinery and equipment
3 - 20 years
Other equipment
3 - 10 years
Equipment on operating lease
Up to 5 years
Leasehold improvements
Lesser of term of lease or 10 years
Intangible Assets
Intangible Assets
Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. Amortization is calculated primarily using the straight-line method based on the following estimated useful lives:
Product brands
1 - 20 years
Corporate brands
7 - 20 years
Product rights/patents
4 - 15 years
Partner relationships
7 - 9 years
Out-licensed technology and other
8 - 9 years
Divestitures of Products
Divestitures of Products
The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense (income), net. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.
IPR&D
IPR&D
The fair value of IPR&D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and amortized. Acquired IPR&D assets are tested for impairment at least annually or when triggering events are identified.
The fair value of an acquired IPR&D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset’s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset’s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow streams.
Impairment of Long-Lived Assets
Impairment of Long-Lived Assets
Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows.
Indefinite-lived intangible assets, which includes acquired IPR&D and the corporate trademark acquired in the acquisition of Bausch & Lomb Holdings Incorporated (the ‘‘B&L Trademark’’), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.
Goodwill
Goodwill
Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. A reporting unit is the same as, or one level below, an operating segment. An entity is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit’s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.
An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company’s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors
changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company’s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values.Effective January 1, 2018, the Company elected to early adopt guidance issued by the Financial Accounting Standards Board ("FASB") which simplified the subsequent measurement of goodwill by eliminating “Step 2” from the goodwill impairment test. Instead, as of January 1, 2018 and all subsequent periods, goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value.
Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs
Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs
Debt discounts, premiums and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility.
Foreign Currency Translation
Foreign Currency Translation
The assets and liabilities of the Company’s foreign operations having a functional currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets.
Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation’s functional currency are recognized as a component of Foreign exchange and other in the Consolidated Statements of Operations.
Revenue Recognition
Revenue Recognition
The Company’s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, gastroenterology ("GI") and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, "SEGMENT INFORMATION" for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.
The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
Product Sales
A contract with the Company’s customers exists for each product sale. Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed below. The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products.
Product Sales Provisions
As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.  The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers.
Provisions for variable consideration are established to reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.
Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities. 
The following table presents the activity and ending balances of the Company’s variable consideration provisions the years 2020 and 2019.
(in millions)Discounts
and
Allowances
ReturnsRebatesChargebacksDistribution
Fees
Total
Reserve balance, January 1, 2019$175 $813 $1,024 $209 $163 $2,384 
Acquisition of Synergy— 12 — 16 
Current period provision776 113 2,265 1,938 195 5,287 
Payments and credits(769)(238)(2,374)(1,979)(277)(5,637)
Reserve balance, December 31, 2019182 691 927 168 82 2,050 
Current period provision621 120 2,174 1,925 196 5,036 
Payments and credits(613)(236)(2,322)(1,909)(193)(5,273)
Reserve balance, December 31, 2020$190 $575 $779 $184 $85 $1,813 
Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $32 million and $29 million as of December 31, 2020 and 2019, respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets.
The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company’s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics. The following describes the major sources of variable consideration in the Company’s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration.
Cash Discounts and Allowances
Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within one month of incurring the liability.
Returns
Consistent with industry practice, customers are generally allowed to return a product within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The
returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.
In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information. These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. A change of 1% in the estimated return rates would have impacted the Company’s pre-tax earnings by approximately $76 million for the year 2020.
The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not warrant revision to the provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S. National Drug Codes (“NDC”) of products. Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S. customers generally permit only one NDC per product for identification and tracking within their inventory systems.
Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for 2020 and 2019 were $120 million and $113 million, respectively, and includes reductions in variable consideration for sales return provisions related to past sales of approximately $38 million and $80 million, respectively.
Rebates and Chargebacks
Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates.  The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270 days after the quarter in which the product is dispensed to the Medicaid participant. As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. A change of 1% in the estimated rates used in the Medicaid rebate reserve would have impacted the Company’s pre-tax earnings by approximately $76 million for 2020. Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods.
Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market share.
Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers.
In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or chargebacks.
The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts implemented in each of the last three years, changes in the Company’s product portfolio due to recent acquisitions and increased Medicaid utilization due to expansion of government funding for these programs. Management’s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel.
Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2020 and 2019 were not material to the Company’s revenues or earnings.
Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company’s products. Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management’s estimate of the discount, rebate and loyalty incentives attributable to a sale. That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any.
Distribution Fees
The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart. The Company has Distribution Services Agreements ("DSAs") with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty. Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes. Additionally, price appreciation credits are generated when the Company increases a product’s wholesaler acquisition cost (“WAC”) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $15 million and $11 million for the years 2020 and 2019, respectively.
Contract Assets and Contract Liabilities
There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented.
Sales Commissions
Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.
Financing Component
The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less.
Research and Development Expenses
Research and Development Expenses
Costs related to internal research and development programs, including costs associated with the development of acquired IPR&D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses. Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.
Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.
Legal Costs Legal Costs Legal fees and other costs related to litigation and other legal proceedings or services are expensed as incurred and are included in Selling, general and administrative expenses. Certain legal costs associated with acquisitions are included in Acquisition-related costs and certain legal costs associated with divestitures, legal settlements and other business development activities are included in Litigation and other matters or Net (gain) loss on sales of assets within Other expense (income), net, as appropriate. Legal costs expensed are reported net of expected insurance recoveries. A claim for insurance recovery is recognized when realization becomes probable
Advertising Costs Advertising CostsAdvertising costs comprise product samples, print media, promotional materials and television advertising and are expensed on the first use of the advertisement.
Share-Based Compensation Share-Based Compensation The Company recognizes all share-based payments to employees, including grants of employee stock options and restricted share units (“RSUs”), at estimated fair value. The Company amortizes the fair value of stock option or RSU grants on a straight-line basis over the requisite service period of the individual stock option or RSU grant, which generally equals the vesting period. Stock option and RSU forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation is recorded in Research and development expenses and Selling, general and administrative expenses, as appropriate.
Interest Expense Interest Expense Interest expense includes standby fees, the amortization of debt discounts and deferred financing costs, accretion of debt premiums and the amortization of amounts excluded from the assessment of effectiveness related to the Company's cross-currency swaps. Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized.
Income Taxes
Income Taxes
Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and laws. Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future.
In October 2016, the FASB issued guidance requiring an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, rather than when the asset has been sold to an outside party. This guidance was effective for the Company January 1, 2018 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit and deferred income taxes as of the effective date. The Company recorded a net cumulative-effect adjustment of $1,209 million to increase deferred income tax assets and decrease the opening balance of Accumulated deficit for the income tax consequences deferred from past intra-entity transfers involving assets other than inventory.
The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than 50% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within one year. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance sheets.
Loss Per Share Attributable to Bausch Health Companies Inc.
Loss Per Share Attributable to Bausch Health Companies Inc.
Basic loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. Diluted loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period
after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock method.
Comprehensive Loss
Comprehensive Loss
Comprehensive loss comprises Net loss and Other comprehensive (loss) income. Other comprehensive (loss) income includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders’ equity.
Contingencies
Contingencies
In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a liability. These accruals are adjusted periodically as assessments change or additional information becomes available.
If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred.
Employee Benefit Plans Employee Benefit Plans The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed 10 percent of the greater of the plan’s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements.
Adoption of New Accounting Standards and Recently Issued Accounting Standards, Not Adopted as of December 31, 2020
Adoption of New Accounting Standards
In June 2016, the FASB issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses. The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to Accumulated deficit of less than $1 million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows.
In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement.  The guidance was effective for the Company beginning January 1, 2020. The application of this guidance did not have a material effect on the Company's disclosures.
In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.  Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging. The optional amendments are effective for all entities as of March 12, 2020, through December 31, 2022. During 2020, the Company has not entered into any contract modifications in which the optional expedients were applied.  However, if prior to December 31, 2022 the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.
In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans.  The guidance was effective for annual periods ending after December 15, 2020. The application of this guidance did not have a material effect on the Company's disclosures.
Recently Issued Accounting Standards, Not Adopted as of December 31, 2020
In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.  The guidance is effective for annual periods beginning after December 15, 2020.  The application of this guidance is not expected to have a material effect on the Company's financial position, results of operations and cash flows.
Segment Reporting
Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company’s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single segment.
In connection with the planned separation of its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company has begun addressing the internal organizational design and structure of the new entity, which it anticipates having substantially complete by late 2021. As of the date of the issuance of these financial statements, these matters are in the planning phase. In connection with the Separation, the Company expects to realign and begin managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Separation during the first quarter of 2021. Accordingly, the Company expects to begin reporting under the following reporting segments on a retrospective basis beginning with its first quarter of 2021: Bausch + Lomb, International Rx, Salix, Ortho Dermatologics and Diversified Products.
XML 50 R32.htm IDEA: XBRL DOCUMENT v3.20.4
SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Summary of activity in allowance for credit losses The activity in the allowance for credit losses for trade receivables for the years 2020, 2019 and 2018 is as follows.
(in millions)202020192018
Balance, beginning of period$48 $47 $97 
Retrospective effect of application of new accounting standard— — 
Provision10 
Write-offs(12)(10)(50)
Recoveries
Foreign exchange and other
(3)— (6)
Balance, end of period$39 $48 $47 
Schedule of estimated useful lives of property, plant and equipment Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful lives:
Land improvements
15 - 30 years
Buildings and improvements
Up to 40 years
Machinery and equipment
3 - 20 years
Other equipment
3 - 10 years
Equipment on operating lease
Up to 5 years
Leasehold improvements
Lesser of term of lease or 10 years
Schedule of estimated useful lives of intangible assets Amortization is calculated primarily using the straight-line method based on the following estimated useful lives:
Product brands
1 - 20 years
Corporate brands
7 - 20 years
Product rights/patents
4 - 15 years
Partner relationships
7 - 9 years
Out-licensed technology and other
8 - 9 years
Summary of variable consideration provisions
The following table presents the activity and ending balances of the Company’s variable consideration provisions the years 2020 and 2019.
(in millions)Discounts
and
Allowances
ReturnsRebatesChargebacksDistribution
Fees
Total
Reserve balance, January 1, 2019$175 $813 $1,024 $209 $163 $2,384 
Acquisition of Synergy— 12 — 16 
Current period provision776 113 2,265 1,938 195 5,287 
Payments and credits(769)(238)(2,374)(1,979)(277)(5,637)
Reserve balance, December 31, 2019182 691 927 168 82 2,050 
Current period provision621 120 2,174 1,925 196 5,036 
Payments and credits(613)(236)(2,322)(1,909)(193)(5,273)
Reserve balance, December 31, 2020$190 $575 $779 $184 $85 $1,813 
XML 51 R33.htm IDEA: XBRL DOCUMENT v3.20.4
ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE (Tables)
12 Months Ended
Dec. 31, 2020
Business Combinations [Abstract]  
Estimated fair values of assets acquired and liabilities assumed The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:
(in millions)
Accounts receivable$
Inventories24 
Prepaid expenses and other current assets
Product brand intangible assets (estimated useful life 7 years)
159 
Accounts payable(1)
Accrued expenses(17)
Total identifiable net assets177 
Goodwill
Total fair value of consideration transferred$180 
Schedule of carrying amounts of assets and liabilities held for sale
The carrying amounts of the assets and liabilities held for sale included in the Consolidated Balance Sheet as of December 31, 2020 are as follows:
(in millions)
Prepaid expenses and other current assets:
Trade receivables, net$91 
Inventories, net63 
Prepaid expenses and other current assets
$162 
Other non-current assets:
Property, plant and equipment, net$68 
Goodwill and Intangible assets, net245 
Deferred tax assets, net
$315 
Accrued and other current liabilities:
Accounts payable$
Accrued and other current liabilities28 
$35 
Other non-current liabilities:
Deferred tax liabilities, net$36 
Other non-current liabilities21 
$57 
XML 52 R34.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE MEASUREMENTS (Tables)
12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Schedule of components and classification of financial assets and liabilities measured at fair value on a recurring basis
The following fair value hierarchy table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a recurring basis as of:
 December 31, 2020December 31, 2019
 (in millions)Carrying
Value
Level 1Level 2Level 3Carrying
Value
Level 1Level 2Level 3
Assets:        
Cash equivalents$41 $$33 $— $2,696 $2,646 $50 $— 
Restricted Cash$1,211 $1,211 $— $— $$$— $— 
Foreign currency exchange contracts$$— $$— $— $— $— $— 
Liabilities:    
Acquisition-related contingent consideration
$328 $— $— $328 $316 $— $— $316 
Cross-currency swaps
$70 $— $70 $— $13 $— $13 $— 
Foreign currency exchange contracts$11 $— $11 $— $— $— $— $— 
Schedule of effect of hedging instruments on financial statements
The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for 2020 and 2019:
(in millions)20202019
Loss recognized in Other comprehensive loss$(57)$(22)
Gain excluded from assessment of hedge effectiveness$23 $
Location of gain of excluded componentInterest Expense
Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs
The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3) for the years 2020 and 2019:
(in millions)20202019
Beginning balance, January 1, $316 $339 
Adjustments to Acquisition-related contingent consideration:
Accretion for the time value of money$23 $22 
Fair value adjustments25 (10)
Acquisition-related contingent consideration adjustments48 12 
Payments / Settlements(36)(36)
Foreign currency translation adjustment included in other comprehensive loss— 
Ending balance, December 31,328 316 
Current portion112 54 
Non-current portion$216 $262 
Schedule of assets and liabilities measured at fair value on a non-recurring basis
The following table presents the components and classification of the Company’s financial assets and liabilities measured at fair value on a non-recurring basis:
 December 31, 2020December 31, 2019
(in millions)Carrying
Value
Level 1Level 2Level 3Carrying
Value
Level 1Level 2Level 3
Other non-current assets:
Non-current assets held for sale$245 $— $— $245 $39 $— $— $39 
XML 53 R35.htm IDEA: XBRL DOCUMENT v3.20.4
INVENTORIES (Tables)
12 Months Ended
Dec. 31, 2020
Inventory Disclosure [Abstract]  
Schedule of the components of inventories
Inventories, net, as of December 31, 2020 and 2019 consist of:
(in millions)20202019
Raw materials$286 $319 
Work in process143 149 
Finished goods665 639 
$1,094 $1,107 
XML 54 R36.htm IDEA: XBRL DOCUMENT v3.20.4
PROPERTY, PLANT AND EQUIPMENT (Tables)
12 Months Ended
Dec. 31, 2020
Property, Plant and Equipment [Abstract]  
Schedule of property, plant and equipment
The major components of property, plant and equipment as of December 31, 2020 and 2019 consist of:
(in millions)20202019
Land$79 $79 
Buildings and improvements686 696 
Machinery and equipment1,722 1,606 
Other equipment and leasehold improvements360 369 
Equipment on operating lease65 56 
Construction in progress436 301 
3,348 3,107 
Accumulated depreciation(1,781)(1,641)
$1,567 $1,466 
XML 55 R37.htm IDEA: XBRL DOCUMENT v3.20.4
INTANGIBLE ASSETS AND GOODWILL (Tables)
12 Months Ended
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of components of finite-lived intangible assets
The major components of intangible assets as of December 31, 2020 and 2019 consist of:
 Weighted-
Average
Remaining
Useful
Lives
(Years)
20202019
(in millions)Gross
Carrying
Amount
Accumulated
Amortization and Impairments
Net
Carrying
Amount
Gross
Carrying
Amount
Accumulated
Amortization and Impairments
Net
Carrying
Amount
Finite-lived intangible assets:
       
Product brands6$20,890 $(14,914)$5,976 $21,011 $(13,544)$7,467 
Corporate brands7907 (404)503 930 (338)592 
Product rights/patents33,305 (3,055)250 3,297 (2,887)410 
Partner relationships1169 (168)166 (165)
Technology and other3210 (200)10 209 (189)20 
Total finite-lived intangible assets25,481 (18,741)6,740 25,613 (17,123)8,490 
Acquired IPR&D not in serviceNA— 13 — 13 
B&L TrademarkNA1,698 — 1,698 1,698 — 1,698 
 $27,186 $(18,741)$8,445 $27,324 $(17,123)$10,201 
Schedule of components of indefinite-lived intangible assets
The major components of intangible assets as of December 31, 2020 and 2019 consist of:
 Weighted-
Average
Remaining
Useful
Lives
(Years)
20202019
(in millions)Gross
Carrying
Amount
Accumulated
Amortization and Impairments
Net
Carrying
Amount
Gross
Carrying
Amount
Accumulated
Amortization and Impairments
Net
Carrying
Amount
Finite-lived intangible assets:
       
Product brands6$20,890 $(14,914)$5,976 $21,011 $(13,544)$7,467 
Corporate brands7907 (404)503 930 (338)592 
Product rights/patents33,305 (3,055)250 3,297 (2,887)410 
Partner relationships1169 (168)166 (165)
Technology and other3210 (200)10 209 (189)20 
Total finite-lived intangible assets25,481 (18,741)6,740 25,613 (17,123)8,490 
Acquired IPR&D not in serviceNA— 13 — 13 
B&L TrademarkNA1,698 — 1,698 1,698 — 1,698 
 $27,186 $(18,741)$8,445 $27,324 $(17,123)$10,201 
Schedule of estimated aggregate amortization expense for each of the five succeeding years
Estimated amortization expense of finite-lived intangible assets for the five years ending December 31 and thereafter are as follows:
(in millions)20212022202320242025ThereafterTotal
Amortization$1,389 $1,204 $1,030 $905 $822 $1,390 $6,740 
Schedule of changes in the carrying amount of goodwill
The changes in the carrying amounts of goodwill during the years ended December 31, 2020, 2019 and 2018 were as follows:
(in millions)Bausch +
Lomb/
International
Branded RxU.S. Diversified ProductsSalixOrtho DermatologicsDiversified ProductsTotal
Balance, January 1, 2018$6,016 $6,631 $2,946 $— $— $— $15,593 
Impairment of the Salix and Ortho Dermatologics reporting units
— (2,213)— — — — (2,213)
Realignment of Global Solta reporting unit goodwill
(82)115 (33)— — — — 
Goodwill reclassified to assets held for sale and subsequently disposed
(2)— — — — — (2)
Realignment of segment goodwill
— (4,533)(2,913)3,156 1,267 3,023 — 
Impairment of the Dentistry reporting unit
— — — — — (109)(109)
Foreign exchange and other(127)— — — — — (127)
Balance, December 31, 20185,805 — — 3,156 1,267 2,914 13,142 
Acquisition of certain assets of Synergy
— — — — — 
Goodwill reclassified to assets held for sale (Note 5)(18)— — — — — (18)
Foreign exchange and other(1)— — — — — (1)
Balance, December 31, 20195,786 — — 3,159 1,267 2,914 13,126 
Assets held for sale reclassified to goodwill (Note 5)18 — — — — — 18 
Goodwill reclassified to assets held for sale (Note 3)(217)— — — — — (217)
Foreign exchange and other117 — — — — — 117 
Balance, December 31, 2020$5,704 $— $— $3,159 $1,267 $2,914 $13,044 
XML 56 R38.htm IDEA: XBRL DOCUMENT v3.20.4
ACCRUED AND OTHER CURRENT LIABILITIES (Tables)
12 Months Ended
Dec. 31, 2020
Payables and Accruals [Abstract]  
Schedule of accrued and other current liabilities
Accrued and other current liabilities as of December 31, 2020 and 2019 consist of:
(in millions)20202019
Legal matters and related fees$1,672 $1,397 
Product rebates747 898 
Product returns575 691 
Interest341 305 
Employee compensation and benefit costs316 304 
Income taxes payable158 196 
Other767 720 
$4,576 $4,511 
XML 57 R39.htm IDEA: XBRL DOCUMENT v3.20.4
FINANCING ARRANGEMENTS (Tables)
12 Months Ended
Dec. 31, 2020
Debt Disclosure [Abstract]  
Schedule of long-term debt
Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2020 and 2019 consists of the following:
20202019
(in millions)MaturityPrincipal AmountNet of Premiums, Discounts and Issuance CostsPrincipal AmountNet of Premiums, Discounts and Issuance Costs
Senior Secured Credit Facilities:
2023 Revolving Credit FacilityJune 2023$— $— $— $— 
June 2025 Term Loan B FacilityJune 20253,298 3,220 3,869 3,768 
November 2025 Term Loan B FacilityNovember 20251,125 1,112 1,275 1,257 
Senior Secured Notes:
6.50% Secured Notes
March 2022— — 1,250 1,242 
7.00% Secured Notes
March 20242,000 1,987 2,000 1,983 
5.50% Secured Notes
November 20251,750 1,736 1,750 1,733 
5.75% Secured Notes
August 2027500 494 500 493 
Senior Unsecured Notes: 
5.50%
March 2023— — 402 400 
5.875%
May 2023— — 1,448 1,441 
4.50% euro-denominated debt
May 2023— — 1,682 1,674 
6.125%
April 20253,250 3,234 3,250 3,230 
9.00%
December 20251,500 1,478 1,500 1,473 
9.25%
April 20261,500 1,487 1,500 1,484 
8.50%
January 20271,750 1,755 1,750 1,756 
7.00%
January 2028750 742 750 741 
5.00%
January 20281,250 1,236 1,250 1,234 
6.25%
February 20291,500 1,480 — — 
5.00%
February 20291,000 988 — — 
7.25%
May 2029750 741 750 740 
5.25%
January 20301,250 1,235 1,250 1,234 
5.25%
February 20311,000 988 — — 
OtherVarious12 12 12 12 
Total long-term debt and other $24,185 23,925 $26,188 25,895 
Less: Current portion of long-term debt and other— 1,234 
Non-current portion of long-term debt  $23,925 $24,661 
Schedule of aggregate maturities of long-term debt
Maturities and Mandatory Payments
Maturities and mandatory payments of debt obligations for the five succeeding years ending December 31 and thereafter are as follows:
(in millions)
2021$— 
2022— 
2023— 
20242,291 
202510,632 
Thereafter11,262 
Total gross maturities24,185 
Unamortized discounts(260)
Total long-term debt and other$23,925 
XML 58 R40.htm IDEA: XBRL DOCUMENT v3.20.4
PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)
12 Months Ended
Dec. 31, 2020
Retirement Benefits [Abstract]  
Schedule of amounts recognized in accumulated other comprehensive loss
The amounts included in Accumulated other comprehensive loss as of December 31, 2020 and 2019 were as follows:
Pension Benefit PlansU.S. Postretirement
Benefit Plan
U.S. PlanNon-U.S. Plans
(in millions)202020192020201920202019
Unrecognized actuarial losses$(21)$(20)$(76)$(65)$(3)$(2)
Unrecognized prior service credits$— $— $27 $26 $11 $14 
Components of net periodic benefit cost
The following table provides the components of net periodic (benefit) cost for the Company’s defined benefit pension plans and postretirement benefit plan in 2020, 2019 and 2018:
 Pension Benefit PlansU.S. Postretirement
Benefit Plan
U.S. PlanNon-U.S. Plans
(in millions)202020192018202020192018202020192018
Service cost$$$$$$$— $— $— 
Interest cost
Expected return on plan assets(13)(13)(15)(5)(5)(5)— — — 
Amortization of net loss— — — — — — 
Amortization of prior service credit— — — (1)(1)(1)(3)(2)(2)
Other— — — — — — — — 
Net periodic (benefit) cost$(6)$(3)$(6)$$$$(2)$(1)$(1)
Components of the change in projected benefit obligations, change in plan assets and funded status
The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2020 and 2019:
 Pension Benefit PlansU.S. Postretirement
Benefit Plan
U.S. PlanNon-U.S. Plans
(in millions)202020192020201920202019
Change in Projected Benefit Obligation
Projected benefit obligation, beginning of year$227 $214 $259 $235 $41 $41 
Service cost— — 
Interest cost
Employee contributions— — — — — 
Settlements— — (3)(2)— — 
Benefits paid(15)(15)(4)(8)(4)(4)
Actuarial losses17 18 13 30 
Currency translation adjustments— — 22 (4)— — 
Projected benefit obligation, end of year236 227 294 259 39 41 
Change in Plan Assets
Fair value of plan assets, beginning of year216 187 161 147 — — 
Actual return on plan assets29 42 11 17 — — 
Employee contributions— — — — — 
Company contributions10 
Settlements— — (2)(2)— — 
Benefits paid(15)(15)(4)(8)(4)(4)
Currency translation adjustments— — 15 (3)— — 
Fair value of plan assets, end of year231 216 189 161 — — 
Funded status, end of year$(5)$(11)$(105)$(98)$(39)$(41)
Recognized as:
Accrued and other current liabilities$— $— $(2)$(2)$(4)$(5)
Other non-current liabilities$(5)$(11)$(103)$(96)$(35)$(36)
Schedule of underfunded plans Information for the underfunded pension benefit plans is as follows:
U.S. PlanNon-U.S. Plans
(in millions)2020201920202019
Projected benefit obligation$236 $227 $294 $259 
Accumulated benefit obligation236 227 286 251 
Fair value of plan assets231 216 189 161 
Future benefit payments for the pension benefit plans
Future benefit payments over the next 10 years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows:
(in millions)Pension Benefit PlansU.S. Postretirement
Benefit
Plan
U.S. PlanNon-U.S. Plans
2021$14 $$
202219 
202317 
202417 
202517 
2026-203075 42 12 
Weighted-average assumptions used to determine net periodic benefit costs and benefit obligations
The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2020, 2019 and 2018 were as follows:
Pension Benefit PlansU.S. Postretirement Benefit Plan
202020192018202020192018
For Determining Net Periodic (Benefit) Cost
U.S. Plans:
Discount rate3.16 %4.25 %3.56 %3.04 %4.16 %3.47 %
Expected rate of return on plan assets6.25 %7.25 %7.50 %— — — 
Rate of compensation increase— — — — — — 
Interest crediting rate5.00 %5.00 %5.00 %
Non-U.S. Plans:
Discount rate1.68 %2.39 %2.29 %
Expected rate of return on plan assets2.98 %3.46 %3.66 %
Rate of compensation increase3.05 %2.89 %2.87 %
Interest crediting rate— — — 
 Pension Benefit PlansU.S. Postretirement Benefit Plan
2020201920202019
For Determining Benefit Obligation
U.S. Plans:
Discount rate2.25 %3.16 %2.09 %3.04 %
Rate of compensation increase— — — — 
Interest crediting rate4.75 %5.00 %
Non-U.S. Plans:
Discount rate1.37 %1.68 %
Rate of compensation increase2.60 %3.05 %
Interest crediting rate— — 
Actual asset allocations The following presents the actual asset allocation as of December 31, 2020 and 2019:
20202019
U.S. Plan
Cash and cash equivalents%%
Equity securities39 %55 %
Fixed income securities60 %44 %
Non-U.S. Plans
Cash and cash equivalents%%
Equity securities28 %25 %
Fixed income securities58 %64 %
Other11 %%
Fair value of pension and postretirement benefit plan assets assumed in connection with the Acquisition
The table below presents total plan assets by investment category as of December 31, 2020 and 2019 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2020 and 2019.
Pension Benefit Plans - U.S. Plans
December 31, 2020December 31, 2019
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Cash and cash equivalents$$— $— $$$— $— $
Commingled funds:    
Equity securities:
U.S. broad market— 48 — 48 — 64 — 64 
Emerging markets— — — 15 — 15 
Worldwide developed markets— 20 — 20 — 26 — 26 
Other assets— 14 — 14 — 15 — 15 
Fixed income securities:
Investment grade— 138 — 138 — 95 — 95 
$$229 $— $231 $$215 $— $216 
Pension Benefit Plans - Non-U.S. Plans
December 31, 2020December 31, 2019
(in millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Cash equivalents$— $$— $$— $$— $
Commingled funds:    
Equity securities:
Emerging markets— — — — 
Worldwide developed markets— 51 — 51 — 38 — 38 
Fixed income securities:
Investment grade— — — — 
Global high yield— — — — 
Government bond funds102 — 103 90 — 91 
Other assets— 20 22 — 
$$186 $$189 $$159 $$161 
XML 59 R41.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES (Tables)
12 Months Ended
Dec. 31, 2020
Leases [Abstract]  
Summary of right-of-use assets and right-of-use liabilities
Right-of-use assets and lease liabilities associated with the Company's operating leases are included in the Consolidated Balance Sheet as of December 31, 2020 and 2019 as follows:
(in millions)20202019
Right-of-use assets included in:
Other non-current assets$259 $271 
Lease liabilities included in:
Accrued and other current liabilities$52 $53 
Other non-current liabilities227 240 
Total lease liabilities$279 $293 
Summary of lease expenses Lease expense for the years 2020 and 2019 include:
(in millions)20202019
Operating lease costs$65 $62 
Variable operating lease costs$12 $16 
Summary of other operating lease information
Other information related to operating leases for 2020 and 2019 is as follows:
(dollars in millions)20202019
Cash paid from operating cash flows for amounts included in the measurement of lease liabilities$74 $73 
Right-of-use assets obtained in exchange for new operating lease liabilities$39 $47 
Weighted-average remaining lease term7.6 years8.2 years
Weighted-average discount rate6.2 %6.2 %
Summary of operating lease future payments
As of December 31, 2020, future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as follows:
(in millions)
2021$68 
202253 
202345 
202435 
202534 
Thereafter121 
Total356 
Less: Imputed interest77 
Present value of remaining lease payments279 
Less: Current portion52 
Non-current portion$227 
XML 60 R42.htm IDEA: XBRL DOCUMENT v3.20.4
SHARE-BASED COMPENSATION (Tables)
12 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]  
Summary of the components and classification of share-based compensation expense
The components and classification of share-based compensation expense related to stock options and RSUs for the years 2020, 2019 and 2018 were as follows:
(in millions)202020192018
Stock options$15 $21 $23 
RSUs90 81 64 
Share-based compensation expense$105 $102 $87 
Research and development expenses$11 $$
Selling, general and administrative expenses94 93 78 
Share-based compensation expense$105 $102 $87 
Schedule of weighted-average assumption as of the date of grant using the Black Scholes option-pricing model
The fair values of all stock options granted for the years 2020, 2019 and 2018 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:
202020192018
Expected stock option life (years)3.03.03.0
Expected volatility38.7 %46.5 %54.0 %
Risk-free interest rate1.2 %2.5 %2.7 %
Expected dividend yield— %— %— %
Summary of stock option activity
The following table summarizes stock option activity during 2020:
(in millions, except per share amounts)OptionsWeighted-
Average
Exercise
Price Per Share
Weighted-
Average
Remaining
Contractual
Term
(Years)
Aggregate
Intrinsic
Value
Outstanding, January 1, 20207.1 $26.99   
Granted2.3 $24.74   
Exercised(0.4)$14.65   
Expired or forfeited(0.3)$72.40   
Outstanding, December 31, 20208.7 $25.59 7.2$14 
Vested and expected to vest, December 31, 20208.2 $25.73 7.1$14 
Vested and exercisable, December 31, 20204.8 $27.74 6.0$11 
Summary of non-vested time-based RSU activity
The following table summarizes non-vested time-based RSU activity during 2020:
(in millions, except per share amounts)Time-Based
RSUs
Weighted-
Average
Grant-Date
Fair Value Per Share
Non-vested, January 1, 20206.1 $20.54 
Granted3.3 $21.92 
Vested(3.4)$19.37 
Forfeited(0.3)$21.78 
Non-vested, December 31, 20205.7 $21.98 
Schedule of assumptions used to calculate the fair values of performance-based RSUs
The fair values of TSR performance-based RSUs granted during 2020, 2019 and 2018 were estimated with the following assumptions:
202020192018
Contractual term (years)3.03.03.0
Expected Company share volatility38.6%46.5%54.2%
Risk-free interest rate1.2%2.5%2.7%
Summary of non-vested performance-based RSU activity
The following table summarizes non-vested performance-based RSU activity during 2020:
(in millions, except per share amounts)Performance-based
RSUs
Weighted-
Average
Grant-Date
Fair Value Per Share
Non-vested, January 1, 20202.0 $25.80 
Granted0.9 $26.61 
Vested(0.6)$19.02 
Non-vested, December 31, 20202.3 $28.10 
XML 61 R43.htm IDEA: XBRL DOCUMENT v3.20.4
ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)
12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Schedule of the components of accumulated other comprehensive loss
Accumulated other comprehensive loss as of December 31, 2020 and 2019 consists of:
(in millions)20202019
Foreign currency translation adjustment$(2,077)$(2,046)
Pension adjustment, net of tax(56)(40)
Accumulated other comprehensive loss$(2,133)$(2,086)
XML 62 R44.htm IDEA: XBRL DOCUMENT v3.20.4
RESEARCH AND DEVELOPMENT (Tables)
12 Months Ended
Dec. 31, 2020
Research and Development [Abstract]  
Summary of research and development Research and development costs for the years 2020, 2019 and 2018 consists of:
(in millions)202020192018
Product related research and development$420 $434 $376 
Quality assurance32 37 37 
Research and development$452 $471 $413 
XML 63 R45.htm IDEA: XBRL DOCUMENT v3.20.4
OTHER EXPENSE (INCOME), NET (Tables)
12 Months Ended
Dec. 31, 2020
Other Income and Expenses [Abstract]  
Schedule of other (expense) income
Other expense (income), net for the years 2020, 2019 and 2018 consists of:
(in millions)202020192018
Litigation and other matters$422 $1,401 $(27)
Acquired in-process research and development costs32 41 
Net (gain) loss on sales of assets(1)(31)
Acquisition-related costs— 
Other, net(5)(1)
Other expense (income), net$454 $1,414 $(20)
XML 64 R46.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES (Tables)
12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Components of loss before benefit from income taxes
The components of Loss before benefit from income taxes for 2020, 2019 and 2018 consist of:
(in millions)202020192018
Domestic$(410)$(2,396)$(1,475)
Foreign(524)559 (2,679)
$(934)$(1,837)$(4,154)
Components of benefit from income taxes
The components of Benefit from income taxes for 2020, 2019 and 2018 consist of:
(in millions)202020192018
Current:   
Domestic$(8)$(12)$— 
Foreign(216)(116)(327)
(224)(128)(327)
Deferred: 
Domestic(5)17 
Foreign590 187 320 
599 182 337 
$375 $54 $10 
Reconciliation of benefit from income taxes from the expected amount calculated by applying the Canadian statutory rate to loss before benefit of income taxes
The Benefit from income taxes differs from the expected amount calculated by applying the Company’s Canadian statutory rate of 26.9% to Loss before benefit from income taxes for 2020, 2019 and 2018 as follows:
(in millions)202020192018
Loss before benefit from income taxes$(934)$(1,837)$(4,154)
Benefit from income taxes
Expected benefit from income taxes at Canadian statutory rate$251 $494 $1,117 
Non-deductible amount of share-based compensation(9)(7)(10)
Adjustments to tax attributes26 (99)(4)
Change in valuation allowance related to foreign tax credits and NOLs
62 21 (3)
Change in valuation allowance on Canadian deferred tax assets and tax rate changes
687 (142)(875)
Change in uncertain tax positions(163)(350)(47)
Foreign tax rate differences(128)186 (3)
Non-deductible portion of Goodwill impairments— — (488)
Tax benefit on intra-entity transfers(338)— 356 
Other(13)(49)(33)
$375 $54 $10 
Schedule of tax effect of major items recorded as deferred tax assets and liabilities and valuation allowance
Deferred tax assets and liabilities as of December 31, 2020 and 2019 consist of:
(in millions)20202019
Deferred tax assets:  
Tax loss carryforwards$2,924 $2,911 
Provisions1,004 641 
Research and development tax credits172 155 
Scientific Research and Experimental Development pool55 52 
Tax credit carryforwards20 25 
Deferred revenue
Unrealized FX on U.S. dollar debt and other financing cost— 94 
Prepaid expenses27 41 
Share-based compensation16 19 
Other24 23 
Total deferred tax assets4,251 3,966 
Less valuation allowance(2,252)(2,831)
Net deferred tax assets1,999 1,135 
Deferred tax liabilities: 
Intangible assets228 53 
Plant, equipment and technology89 56 
Outside basis differences71 41 
Unrealized FX on U.S. dollar debt and other financing cost— 
Total deferred tax liabilities390 150 
Net deferred tax asset$1,609 $985 
The following table presents a reconciliation of the deferred tax asset valuation allowance for 2020, 2019 and 2018:
(in millions)202020192018
Balance, beginning of year$2,831 $2,913 $2,001 
Charged to Benefit from income taxes(773)13 870 
Charged to other accounts194 (95)42 
Balance, end of year$2,252 $2,831 $2,913 
Summary of open tax years by jurisdiction
Jurisdiction:Open Years
United States - Federal
2015 - 2019
Canada
2005 - 2019
Germany
2014 - 2019
France
2013 - 2019
China
2016 - 2019
Ireland
2016 - 2019
Netherlands
2016 - 2019
Australia
2011 - 2019
Reconciliation of the beginning and ending amounts of unrecognized tax benefits
The following table presents a reconciliation of the unrecognized tax benefits for 2020, 2019 and 2018:
(in millions)202020192018
Balance, beginning of year$1,002 $654 $598 
Additions based on tax positions related to the current year66 361 18 
Additions for tax positions of prior years171 63 55 
Reductions for tax positions of prior years(209)(58)(11)
Lapse of statute of limitations(5)(18)(6)
Balance, end of year$1,025 $1,002 $654 
XML 65 R47.htm IDEA: XBRL DOCUMENT v3.20.4
LOSS PER SHARE (Tables)
12 Months Ended
Dec. 31, 2020
Earnings Per Share [Abstract]  
Schedule of calculation of loss per share
Loss per share attributable to Bausch Health Companies Inc. for 2020, 2019 and 2018 were calculated as follows:
(in millions, except per share amounts)202020192018
Net loss attributable to Bausch Health Companies Inc.$(560)$(1,788)$(4,148)
Basic and diluted weighted-average common shares355.0 352.1 351.3 
Basic and diluted loss per share attributable to Bausch Health Companies Inc.$(1.58)$(5.08)$(11.81)
XML 66 R48.htm IDEA: XBRL DOCUMENT v3.20.4
SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)
12 Months Ended
Dec. 31, 2020
Supplemental Cash Flow Elements [Abstract]  
Schedule of Supplemental Cash Flow Disclosures
Supplemental cash flow disclosures for 2020, 2019 and 2018 are as follows:
(in millions)202020192018
Other payments
Interest paid$1,474 $1,537 $1,665 
Income taxes paid$162 $172 $138 
XML 67 R49.htm IDEA: XBRL DOCUMENT v3.20.4
SEGMENT INFORMATION (Tables)
12 Months Ended
Dec. 31, 2020
Segment Reporting [Abstract]  
Schedule of segment revenues and profit
Segment revenues and profits for the years 2020, 2019 and 2018 were as follows:
(in millions)202020192018
Revenues:   
Bausch + Lomb/International$4,408 $4,739 $4,664 
Salix1,904 2,022 1,749 
Ortho Dermatologics553 565 617 
Diversified Products1,162 1,275 1,350 
Total revenues$8,027 $8,601 $8,380 
Segment profit:   
Bausch + Lomb/International$1,159 $1,332 $1,330 
Salix1,338 1,349 1,149 
Ortho Dermatologics233 222 257 
Diversified Products848 932 1,012 
Total segment profit3,578 3,835 3,748 
Corporate(619)(609)(605)
Amortization of intangible assets(1,645)(1,897)(2,644)
Goodwill impairments— — (2,322)
Asset impairments, including loss on assets held for sale(114)(75)(568)
Restructuring, integration and separation costs(22)(31)(22)
Acquisition-related contingent consideration(48)(12)
Other (expense) income, net(454)(1,414)20 
Operating income (loss)676 (203)(2,384)
Interest income13 12 11 
Interest expense(1,534)(1,612)(1,685)
Loss on extinguishment of debt(59)(42)(119)
Foreign exchange and other(30)23 
Loss before benefit from income taxes$(934)$(1,837)$(4,154)
Schedule of capital expenditures, depreciation and amortization by segment
Capital expenditures by segment for the years 2020, 2019 and 2018 were as follows:
(in millions)202020192018
Capital expenditures:   
Bausch + Lomb/International$282 $225 $139 
Salix
Ortho Dermatologics
Diversified Products
289 230 144 
Corporate13 40 13 
Total capital expenditures$302 $270 $157 
Schedule of revenues by product and by product category Revenues by segment and product category were as follows:
(in millions)Bausch + Lomb/ InternationalSalixOrtho DermatologicsDiversified ProductsTotal
202020192018202020192018202020192018202020192018202020192018
Pharmaceuticals$759 $885 $892 $1,899 $2,022 $1,752 $279 $355 $457 $741 $810 $927 $3,678 $4,072 $4,028 
Devices1,313 1,524 1,505 — — — 253 193 135 — — — 1,566 1,717 1,640 
OTC1,432 1,452 1,412 — — — — — — — — — 1,432 1,452 1,412 
Branded and Other Generics 838 801 784 — — — — — — 410 447 407 1,248 1,248 1,191 
Other revenues66 77 71 — (3)21 17 25 11 18 16 103 112 109 
$4,408 $4,739 $4,664 $1,904 $2,022 $1,749 $553 $565 $617 $1,162 $1,275 $1,350 $8,027 $8,601 $8,380 
Schedule of revenues and long-lived assets by geographic region
Revenues are attributed to a geographic region based on the location of the customer for the years 2020, 2019 and 2018 were as follows:
(in millions)202020192018
U.S. and Puerto Rico$4,791 $5,164 $5,011 
China341 368 361 
Canada331 339 319 
Egypt243 218 178 
Poland238 231 218 
Japan226 241 226 
Mexico225 228 211 
France179 201 205 
Germany144 150 170 
Russia137 180 154 
United Kingdom86 115 117 
Spain78 86 83 
Other1,008 1,080 1,127 
$8,027 $8,601 $8,380 
Schedule of assets by geographic region
Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December 31, 2020 and 2019 were as follows:
(in millions)20202019
U.S. and Puerto Rico$725 $656 
Ireland328 255 
Canada110 103 
Poland83 90 
Germany80 68 
Mexico49 50 
France34 30 
China31 27 
Serbia30 27 
Italy 23 22 
Other 74 138 
$1,567 $1,466 
Schedule of external customers that accounted for 10% or more of total revenues
Customers that accounted for 10% or more of total revenues were as follows:
202020192018
McKesson Corporation17%17%18%
AmerisourceBergen Corporation17%16%18%
Cardinal Health, Inc.13%14%13%
XML 68 R50.htm IDEA: XBRL DOCUMENT v3.20.4
SUPPLEMENTARY DATA (UNAUDITED) (Tables)
12 Months Ended
Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]  
Schedule of quarterly financial information
Selected unaudited quarterly consolidated financial data are shown below:
2020
(in millions, except per share amounts)First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
Revenue$2,012 $1,664 $2,138 $2,213 
Expenses1,764 1,691 1,678 2,218 
Operating income (loss)$248 $(27)$460 $(5)
Net (loss) income attributable to Bausch Health Companies Inc.$(152)$(326)$71 $(153)
Basic and Diluted (loss) earnings per share attributable to Bausch Health Companies Inc.$(0.43)$(0.92)$0.20 $(0.43)
Net cash provided by operating activities$261 $200 $256 $394 
2019
(in millions, except per share amounts)First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
Revenue$2,016 $2,152 $2,209 $2,224 
Expenses1,729 1,895 1,880 3,300 
Operating income (loss)$287 $257 $329 $(1,076)
Net loss attributable to Bausch Health Companies Inc.
$(52)$(171)$(49)$(1,516)
Basic and Diluted loss per share attributable to Bausch Health Companies Inc.$(0.15)$(0.49)$(0.14)$(4.30)
Net cash provided by operating activities$413 $339 $515 $234 
XML 69 R51.htm IDEA: XBRL DOCUMENT v3.20.4
DESCRIPTION OF BUSINESS - Narrative (Details)
Dec. 31, 2020
country
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of countries in which entity operates 100
XML 70 R52.htm IDEA: XBRL DOCUMENT v3.20.4
SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)
$ in Millions
12 Months Ended
Dec. 31, 2020
USD ($)
wholesaler
Dec. 31, 2019
USD ($)
Concentrations of Credit Risk    
Maximum term of original maturity to classify instruments as cash and cash equivalents (less than) 3 months  
Percentage of net trade receivables accounted for by largest wholesale customers 38.00%  
Argentina, Brazil, Egypt, Greece, Serbia, Turkey, Ukraine, Venezuela and Vietnam    
Concentrations of Credit Risk    
Net trade receivable $ 166 $ 156
Past due period for receivables to be negligible (less than) 90 days  
Period net trade receivable balance outstanding (more than) 90 days  
Portion of net trade receivables that is past due $ 2  
Trade receivables | Three largest U.S. wholesaler customers | Credit concentration    
Concentrations of Credit Risk    
Number of largest wholesale customers | wholesaler 3  
XML 71 R53.htm IDEA: XBRL DOCUMENT v3.20.4
SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Revenue from Contract with Customer [Abstract]      
Allowance for doubtful accounts $ 39 $ 47 $ 97
Accounts Receivable, Allowance for Credit Loss [Roll Forward]      
Balance, beginning of period 48 47 97
Retrospective effect of application of new accounting standard 1 0 0
Provision 2 10 4
Write-offs (12) (10) (50)
Recoveries 3 1 2
Foreign exchange and other (3) 0 (6)
Balance, end of period $ 39 $ 48 $ 47
XML 72 R54.htm IDEA: XBRL DOCUMENT v3.20.4
SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)
12 Months Ended
Dec. 31, 2020
Minimum | Land improvements  
Property, plant and equipment [Line Items]  
Estimated useful lives 15 years
Minimum | Machinery and equipment  
Property, plant and equipment [Line Items]  
Estimated useful lives 3 years
Minimum | Other equipment  
Property, plant and equipment [Line Items]  
Estimated useful lives 3 years
Maximum | Land improvements  
Property, plant and equipment [Line Items]  
Estimated useful lives 30 years
Maximum | Buildings and improvements  
Property, plant and equipment [Line Items]  
Estimated useful lives 40 years
Maximum | Machinery and equipment  
Property, plant and equipment [Line Items]  
Estimated useful lives 20 years
Maximum | Other equipment  
Property, plant and equipment [Line Items]  
Estimated useful lives 10 years
Maximum | Equipment on operating lease  
Property, plant and equipment [Line Items]  
Estimated useful lives 5 years
Maximum | Leasehold improvements  
Property, plant and equipment [Line Items]  
Estimated useful lives 10 years
XML 73 R55.htm IDEA: XBRL DOCUMENT v3.20.4
SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)
12 Months Ended
Dec. 31, 2020
Product brands  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful lives 6 years
Corporate brands  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful lives 7 years
Product rights/patents  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful lives 3 years
Partner relationships  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful lives 1 year
Out-licensed technology and other  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful lives 3 years
Minimum | Product brands  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful lives 1 year
Minimum | Corporate brands  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful lives 7 years
Minimum | Product rights/patents  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful lives 4 years
Minimum | Partner relationships  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful lives 7 years
Minimum | Out-licensed technology and other  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful lives 8 years
Maximum | Product brands  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful lives 20 years
Maximum | Corporate brands  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful lives 20 years
Maximum | Product rights/patents  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful lives 15 years
Maximum | Partner relationships  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful lives 9 years
Maximum | Out-licensed technology and other  
Finite-Lived Intangible Assets [Line Items]  
Estimated useful lives 9 years
XML 74 R56.htm IDEA: XBRL DOCUMENT v3.20.4
SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]    
Balance, beginning of year $ 2,050 $ 2,384
Acquisition of Synergy   16
Current period provision 5,036 5,287
Payments and credits (5,273) (5,637)
Balance, end of year 1,813 2,050
Discounts and Allowances    
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]    
Balance, beginning of year 182 175
Acquisition of Synergy   0
Current period provision 621 776
Payments and credits (613) (769)
Balance, end of year 190 182
Returns    
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]    
Balance, beginning of year 691 813
Acquisition of Synergy   3
Current period provision 120 113
Payments and credits (236) (238)
Balance, end of year 575 691
Rebates    
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]    
Balance, beginning of year 927 1,024
Acquisition of Synergy   12
Current period provision 2,174 2,265
Payments and credits (2,322) (2,374)
Balance, end of year 779 927
Chargebacks    
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]    
Balance, beginning of year 168 209
Acquisition of Synergy   0
Current period provision 1,925 1,938
Payments and credits (1,909) (1,979)
Balance, end of year 184 168
Distribution Fees    
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]    
Balance, beginning of year 82 163
Acquisition of Synergy   1
Current period provision 196 195
Payments and credits (193) (277)
Balance, end of year $ 85 $ 82
XML 75 R57.htm IDEA: XBRL DOCUMENT v3.20.4
SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]                      
Cooperative advertising credits included in rebates $ 1,813       $ 2,050       $ 1,813 $ 2,050 $ 2,384
Settlement period for cash discounts and allowances                 1 month    
1% change in estimated return rates, Impact on pre-tax earnings                 $ 76    
Sales return provisions                 5,036 5,287  
1% change in volume of product sold through to Medicaid plan participants, Impact on pre-tax earnings                 76    
Price appreciation credits 2,213 $ 2,138 $ 1,664 $ 2,012 2,224 $ 2,209 $ 2,152 $ 2,016 8,027 8,601 8,380
Price Appreciation Credit                      
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]                      
Price appreciation credits                 $ 15 11  
Minimum                      
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]                      
Payment terms                 30 days    
Maximum                      
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]                      
Payment terms                 90 days    
Rebates, Advertising Credits Portion                      
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]                      
Cooperative advertising credits included in rebates 32       29       $ 32 29  
Returns                      
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]                      
Cooperative advertising credits included in rebates $ 575       $ 691       575 691 $ 813
Sales return provisions                 120 113  
Reduction in variable consideration provision, adjustment                 $ 38 $ 80  
XML 76 R58.htm IDEA: XBRL DOCUMENT v3.20.4
SIGNIFICANT ACCOUNTING POLICIES - Leases (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Jan. 01, 2019
Lessee, Lease, Description [Line Items]      
Right-of-use asset $ 259 $ 271 $ 302
Lease liability $ 279 $ 293 $ 302
Operating Lease, Liability, Statement of Financial Position [Extensible List]     us-gaap:OtherLiabilities
Minimum      
Lessee, Lease, Description [Line Items]      
Lease term 1 year    
Lease renewal term 1 year    
Maximum      
Lessee, Lease, Description [Line Items]      
Lease term 20 years    
Lease renewal term 5 years    
XML 77 R59.htm IDEA: XBRL DOCUMENT v3.20.4
SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Accounting Policies [Abstract]      
Advertising expenses $ 451 $ 544 $ 481
XML 78 R60.htm IDEA: XBRL DOCUMENT v3.20.4
SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Accounting Policies [Abstract]    
Capitalized interest $ 45 $ 34
XML 79 R61.htm IDEA: XBRL DOCUMENT v3.20.4
SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Jan. 01, 2018
Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative-effect adjustment $ 605 $ 1,136 $ 2,815   $ 5,944
Deferred tax assets, net $ 2,137 1,690      
Tax benefit recognition, measurement percentage (greater than) 50.00%        
Minimum period to classify uncertain tax position liabilities as long term liabilities 1 year        
Accounting Standards Update 2016-16          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Deferred tax assets, net       $ 1,209  
Accumulated Deficit          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative-effect adjustment $ (8,013) (7,452) $ (5,664)   (2,725)
Cumulative Effect, Period of Adoption, Adjustment          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative-effect adjustment   (1)     1,209
Cumulative Effect, Period of Adoption, Adjustment | Accumulated Deficit          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative-effect adjustment   $ (1)   $ 1,209 $ 1,209
XML 80 R62.htm IDEA: XBRL DOCUMENT v3.20.4
SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)
12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Threshold percentage for amortization of net actuarial gains and losses 10.00%
XML 81 R63.htm IDEA: XBRL DOCUMENT v3.20.4
SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Jan. 01, 2018
Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Increase to accumulated deficit (less than) $ (605) $ (1,136) $ (2,815)   $ (5,944)
Accumulated Deficit          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Increase to accumulated deficit (less than) $ 8,013 7,452 $ 5,664   2,725
Cumulative Effect, Period of Adoption, Adjustment          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Increase to accumulated deficit (less than)   1     (1,209)
Cumulative Effect, Period of Adoption, Adjustment | Accumulated Deficit          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Increase to accumulated deficit (less than)   $ 1   $ (1,209) $ (1,209)
XML 82 R64.htm IDEA: XBRL DOCUMENT v3.20.4
ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Narrative (Details)
1 Months Ended 3 Months Ended 10 Months Ended 12 Months Ended
Sep. 21, 2020
USD ($)
Mar. 06, 2019
USD ($)
Oct. 16, 2018
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2020
USD ($)
businessCombination
Dec. 31, 2019
USD ($)
businessCombination
Dec. 31, 2018
USD ($)
businessCombination
Business Combinations                  
Other expense, net             $ 454,000,000 $ 1,414,000,000 $ (20,000,000)
Reduction of additional paid-in capital                 $ 18,000,000
Number of other material business combinations | businessCombination             0 0 0
Held For Sale                  
Business Combinations                  
Impairment of long-lived assets                 $ 5,000,000
Held For Sale | A Certain International Business                  
Business Combinations                  
Impairment of long-lived assets             $ 96,000,000    
Noncash cumulative foreign currency translation loss             $ 344,000,000    
Additional Paid-In Capital                  
Business Combinations                  
Reduction of additional paid-in capital                 $ 15,000,000
Allegro                  
Business Combinations                  
Other expense, net         $ 10,000,000        
Potential asset acquisition, aggregate purchase price $ 50,000,000                
Potential asset acquisition, upfront payment included in aggregate purchase price 10,000,000                
Potential asset acquisition, additional funding payment included in aggregate purchase price $ 40,000,000     $ 40,000,000          
Synergy                  
Business Combinations                  
Cash payments to acquire certain assets and assumed liabilities   $ 180,000,000              
Revenue of acquiree since acquisition date           $ 55,000,000      
Pro-forma revenue               $ 0  
Pro-forma operating results               0  
Operating results of acquiree since acquisition           $ 0      
Other expense, net               $ 8,000,000  
Medpharma                  
Business Combinations                  
Cash payments to acquire certain assets and assumed liabilities     $ 18,000,000            
Percentage interest acquired     40.00%            
Medpharma | Additional Paid-In Capital                  
Business Combinations                  
Reduction of additional paid-in capital     $ 15,000,000            
XML 83 R65.htm IDEA: XBRL DOCUMENT v3.20.4
ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Millions
Mar. 06, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Business Combinations          
Goodwill   $ 13,044 $ 13,126 $ 13,142 $ 15,593
Synergy          
Business Combinations          
Accounts receivable $ 7        
Inventories 24        
Prepaid expenses and other current assets 5        
Product brand intangible assets (estimated useful life 7 years) 159        
Accounts payable (1)        
Accrued expenses (17)        
Total identifiable net assets 177        
Goodwill 3        
Total fair value of consideration transferred $ 180        
Weighted- Average Remaining Useful Lives (Years) 7 years        
XML 84 R66.htm IDEA: XBRL DOCUMENT v3.20.4
ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Assets and Liabilities Held For Sale (Details) - A Certain International Business - Held For Sale
$ in Millions
Dec. 31, 2020
USD ($)
Prepaid expenses and other current assets:  
Trade receivables, net $ 91
Inventories, net 63
Prepaid expenses and other current assets 8
Total Prepaid expenses and other current assets 162
Other non-current assets:  
Property, plant and equipment, net 68
Goodwill and Intangible assets, net 245
Deferred tax assets, net 2
Total Other non-current assets 315
Accrued and other current liabilities:  
Accounts payable 7
Accrued and other current liabilities 28
Total Accrued and other current liabilities 35
Other non-current liabilities:  
Deferred tax liabilities, net 36
Other non-current liabilities 21
Total Other non-current liabilities $ 57
XML 85 R67.htm IDEA: XBRL DOCUMENT v3.20.4
RESTRUCTURING, INTEGRATION AND SEPARATION COSTS - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Cost-rationalization and integration initiatives      
Restructuring, integration and separation costs $ 22 $ 31 $ 22
Selling, general and administrative 2,367 2,554 2,473
Restructuring and Integration-Related Costs      
Cost-rationalization and integration initiatives      
Remaining restructuring liabilities 20    
Restructuring costs 11 31 22
Facility closure costs 10 11 10
Severance costs 1 11 11
Restructuring payments 18 31 33
Other costs   $ 9 $ 1
Separation Costs      
Cost-rationalization and integration initiatives      
Restructuring, integration and separation costs 11    
Selling, general and administrative $ 21    
XML 86 R68.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Foreign currency exchange contracts | Not Designated as Hedging Instrument    
Liabilities:    
Derivative liabilities $ 8  
Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument    
Liabilities:    
Derivative liabilities 70 $ 13
Recurring basis    
Assets:    
Cash equivalents 41 2,696
Restricted Cash 1,211 1
Liabilities:    
Acquisition-related contingent consideration 328 316
Recurring basis | Foreign currency exchange contracts | Not Designated as Hedging Instrument    
Assets:    
Foreign currency exchange contracts 3 0
Liabilities:    
Derivative liabilities 11 0
Recurring basis | Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument    
Liabilities:    
Derivative liabilities 70 13
Recurring basis | Level 1    
Assets:    
Cash equivalents 8 2,646
Restricted Cash 1,211 1
Liabilities:    
Acquisition-related contingent consideration 0 0
Recurring basis | Level 1 | Foreign currency exchange contracts | Not Designated as Hedging Instrument    
Assets:    
Foreign currency exchange contracts 0 0
Liabilities:    
Derivative liabilities 0 0
Recurring basis | Level 1 | Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument    
Liabilities:    
Derivative liabilities 0 0
Recurring basis | Level 2    
Assets:    
Cash equivalents 33 50
Restricted Cash 0 0
Liabilities:    
Acquisition-related contingent consideration 0 0
Recurring basis | Level 2 | Foreign currency exchange contracts | Not Designated as Hedging Instrument    
Assets:    
Foreign currency exchange contracts 3 0
Liabilities:    
Derivative liabilities 11 0
Recurring basis | Level 2 | Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument    
Liabilities:    
Derivative liabilities 70 13
Recurring basis | Level 3    
Assets:    
Cash equivalents 0 0
Restricted Cash 0 0
Liabilities:    
Acquisition-related contingent consideration 328 316
Recurring basis | Level 3 | Foreign currency exchange contracts | Not Designated as Hedging Instrument    
Assets:    
Foreign currency exchange contracts 0 0
Liabilities:    
Derivative liabilities 0 0
Recurring basis | Level 3 | Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument    
Liabilities:    
Derivative liabilities $ 0 $ 0
XML 87 R69.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 16, 2019
Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Highly liquid investments, maturity period (or less)   3 months
Valeant US Securities Litigation | New Jersey | Settled Litigation    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Settlement, escrow fund included in restricted cash $ 1,210 $ 1,210
XML 88 R70.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Payments or receipts in settlement of cross-currency swaps $ 23  
Cross-currency swaps | Net Investment Hedging | Designated as Hedging Instrument    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Aggregate notional amounts 1,250  
Fair value cross-currency swaps liability, net 70 $ 13
Fair value cross-currency swaps liability 79 22
Fair value cross-currency swaps asset $ 9 $ 9
XML 89 R71.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details) - Cross-currency swaps - Net Investment Hedging - Designated as Hedging Instrument - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]    
Loss recognized in Other comprehensive loss $ (57) $ (22)
Interest Expense    
Derivative Instruments, Gain (Loss) [Line Items]    
Gain excluded from assessment of hedge effectiveness $ 23 $ 9
XML 90 R72.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details) - Not Designated as Hedging Instrument - Foreign currency exchange contracts
12 Months Ended
Dec. 31, 2020
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Aggregate notional amounts $ 485,000,000
Fair value cross-currency swaps liability, net 8,000,000
Fair value cross-currency swaps liability 11,000,000
Fair value cross-currency swaps asset 3,000,000
Net change in fair value, loss 8,000,000
Loss related to settlements during period $ 2,000,000
XML 91 R73.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details)
$ in Millions
12 Months Ended
Dec. 31, 2020
USD ($)
number
rate
Dec. 31, 2019
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance $ 316 $ 339
Acquisition-related contingent consideration adjustments 48 12
Payments / Settlements (36) (36)
Foreign currency translation adjustment included in other comprehensive loss 0 1
Ending balance 328 316
Current portion 112 54
Non-current portion 216 262
Accretion for the time value of money    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Acquisition-related contingent consideration adjustments 23 22
Fair value adjustments    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Acquisition-related contingent consideration adjustments $ 25 $ (10)
Measurement Input, Weighted-Average Discount Rate | Level 3 | Recurring basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, contingent consideration obligations, discount rate | number 0.08  
Minimum | Measurement Input, Discount Rate | Level 3 | Recurring basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, contingent consideration obligations, discount rate | rate 0.06  
Maximum | Measurement Input, Discount Rate | Level 3 | Recurring basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, contingent consideration obligations, discount rate | rate 0.25  
XML 92 R74.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details) - Fair Value, Nonrecurring - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Other non-current assets:    
Non-current assets held for sale $ 245 $ 39
Level 1    
Other non-current assets:    
Non-current assets held for sale 0 0
Level 2    
Other non-current assets:    
Non-current assets held for sale 0 0
Level 3    
Other non-current assets:    
Non-current assets held for sale $ 245 $ 39
XML 93 R75.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis, Narrative (Details)
$ in Millions
3 Months Ended 12 Months Ended
Sep. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
product
Dec. 31, 2018
USD ($)
Dec. 31, 2020
USD ($)
Mar. 31, 2020
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Assets reclassified, held and used   $ 33,863   $ 31,199  
Non-recurring basis          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Non-current assets held for sale   39   245  
Level 3 | Non-recurring basis          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Non-current assets held for sale   39   $ 245  
Held For Sale          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Impairment of long-lived assets     $ 5    
Held For Sale | Certain Products For Disposal, September 2019          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Impairment of long-lived assets $ 8 $ 8      
Held For Sale | Certain Products For Disposal, September 2019 | Restatement Adjustment          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Assets reclassified, held for sale         $ 39
Assets reclassified, held and used         $ 39
Diversified Products | Held For Sale | Certain Products For Disposal, September 2019          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Number of products for disposal | product   1      
XML 94 R76.htm IDEA: XBRL DOCUMENT v3.20.4
FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Non-recurring basis | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of long-term debt $ 25,378 $ 27,520
XML 95 R77.htm IDEA: XBRL DOCUMENT v3.20.4
INVENTORIES - Summary of Inventories, Net (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Inventory Disclosure [Abstract]    
Raw materials $ 286 $ 319
Work in process 143 149
Finished goods 665 639
Inventories, net $ 1,094 $ 1,107
XML 96 R78.htm IDEA: XBRL DOCUMENT v3.20.4
PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Property, plant and equipment [Line Items]    
Property, plant and equipment, gross $ 3,348 $ 3,107
Accumulated depreciation (1,781) (1,641)
Property, plant and equipment, net 1,567 1,466
Land    
Property, plant and equipment [Line Items]    
Property, plant and equipment, gross 79 79
Buildings and improvements    
Property, plant and equipment [Line Items]    
Property, plant and equipment, gross 686 696
Machinery and equipment    
Property, plant and equipment [Line Items]    
Property, plant and equipment, gross 1,722 1,606
Other equipment and leasehold improvements    
Property, plant and equipment [Line Items]    
Property, plant and equipment, gross 360 369
Equipment on operating lease    
Property, plant and equipment [Line Items]    
Property, plant and equipment, gross 65 56
Construction in progress    
Property, plant and equipment [Line Items]    
Property, plant and equipment, gross $ 436 $ 301
XML 97 R79.htm IDEA: XBRL DOCUMENT v3.20.4
PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Property, Plant and Equipment [Abstract]      
Depreciation expense $ 180 $ 178 $ 175
XML 98 R80.htm IDEA: XBRL DOCUMENT v3.20.4
INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 25,481 $ 25,613
Accumulated Amortization and Impairments (18,741) (17,123)
Net Carrying Amount 6,740 8,490
Indefinite-lived Intangible Assets [Line Items]    
Gross Carrying Amount 27,186 27,324
Intangible Assets, Net (Excluding Goodwill) 8,445 10,201
Acquired IPR&D not in service    
Indefinite-lived Intangible Assets [Line Items]    
Net Carrying Amount 7 13
B&L Trademark    
Indefinite-lived Intangible Assets [Line Items]    
Net Carrying Amount $ 1,698 1,698
Product brands    
Finite-Lived Intangible Assets [Line Items]    
Weighted- Average Remaining Useful Lives (Years) 6 years  
Gross Carrying Amount $ 20,890 21,011
Accumulated Amortization and Impairments (14,914) (13,544)
Net Carrying Amount $ 5,976 7,467
Corporate brands    
Finite-Lived Intangible Assets [Line Items]    
Weighted- Average Remaining Useful Lives (Years) 7 years  
Gross Carrying Amount $ 907 930
Accumulated Amortization and Impairments (404) (338)
Net Carrying Amount $ 503 592
Product rights/patents    
Finite-Lived Intangible Assets [Line Items]    
Weighted- Average Remaining Useful Lives (Years) 3 years  
Gross Carrying Amount $ 3,305 3,297
Accumulated Amortization and Impairments (3,055) (2,887)
Net Carrying Amount $ 250 410
Partner relationships    
Finite-Lived Intangible Assets [Line Items]    
Weighted- Average Remaining Useful Lives (Years) 1 year  
Gross Carrying Amount $ 169 166
Accumulated Amortization and Impairments (168) (165)
Net Carrying Amount $ 1 1
Technology and other    
Finite-Lived Intangible Assets [Line Items]    
Weighted- Average Remaining Useful Lives (Years) 3 years  
Gross Carrying Amount $ 210 209
Accumulated Amortization and Impairments (200) (189)
Net Carrying Amount $ 10 $ 20
XML 99 R81.htm IDEA: XBRL DOCUMENT v3.20.4
INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) - USD ($)
3 Months Ended 12 Months Ended
Oct. 01, 2020
Oct. 01, 2019
Oct. 01, 2018
Jan. 01, 2018
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Mar. 31, 2018
Mar. 01, 2018
Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]                                    
Net loss attributable to Bausch Health Companies Inc.         $ (153,000,000) $ 71,000,000 $ (326,000,000) $ (152,000,000) $ (1,516,000,000) $ (49,000,000) $ (171,000,000) $ (52,000,000) $ (560,000,000) $ (1,788,000,000) $ (4,148,000,000)      
Decrease to earnings per share, basic and diluted (in dollars per share)         $ 0.43 $ (0.20) $ 0.92 $ 0.43 $ 4.30 $ 0.14 $ 0.49 $ 0.15 $ 1.58 $ 5.08 $ 11.81      
Carrying value of intangible assets, net         $ 8,445,000,000       $ 10,201,000,000       $ 8,445,000,000 $ 10,201,000,000        
Goodwill impairments   $ 0                                
Goodwill reallocated into (out of)         13,044,000,000       13,126,000,000       13,044,000,000 13,126,000,000 $ 13,142,000,000     $ 15,593,000,000
Revenue         2,213,000,000 $ 2,138,000,000 $ 1,664,000,000 $ 2,012,000,000 $ 2,224,000,000 $ 2,209,000,000 $ 2,152,000,000 $ 2,016,000,000 8,027,000,000 8,601,000,000 8,380,000,000      
Revenue, year-over-year decrease         $ 11,000,000                          
Revenue, year-over-year decrease, percentage         1.00% 3.00% 23.00%                      
Accumulated goodwill impairment charges to date         $ 3,711,000,000               3,711,000,000          
Ortho Dermatologics Reporting Unit                                    
Finite-Lived Intangible Assets [Line Items]                                    
Goodwill impairments $ 0           $ 0 $ 0             2,213,000,000      
Percentage of fair value in excess of carrying value 10.00%                                  
Reporting unit, impairment test, long-term growth rates 2.00%                                  
Dentistry Reporting Unit                                    
Finite-Lived Intangible Assets [Line Items]                                    
Goodwill impairments     $ 109,000,000                       109,000,000      
Reporting Units Excluding Dentistry                                    
Finite-Lived Intangible Assets [Line Items]                                    
Goodwill impairments     $ 0                              
Reporting Units Excluding Ortho Dermatologics and Dentistry                                    
Finite-Lived Intangible Assets [Line Items]                                    
Percentage of fair value in excess of carrying value     15.00%                              
Maximum | Ortho Dermatologics Reporting Unit                                    
Finite-Lived Intangible Assets [Line Items]                                    
Reporting unit, impairment test, estimated cash flows, discount rate 9.75%                                  
Minimum | Ortho Dermatologics Reporting Unit                                    
Finite-Lived Intangible Assets [Line Items]                                    
Reporting unit, impairment test, estimated cash flows, discount rate 9.50%                                  
Branded Rx Segment | Scenario, Adjustment                                    
Finite-Lived Intangible Assets [Line Items]                                    
Goodwill reallocated into (out of)                                 $ 115,000,000  
Branded Rx Segment | Salix Reporting Unit                                    
Finite-Lived Intangible Assets [Line Items]                                    
Goodwill impairments       $ 1,970,000,000                            
Branded Rx Segment | Ortho Dermatologics Reporting Unit                                    
Finite-Lived Intangible Assets [Line Items]                                    
Goodwill impairments       $ 243,000,000                            
Bausch Lomb/International And U.S. Diversified Products Segments | Scenario, Adjustment                                    
Finite-Lived Intangible Assets [Line Items]                                    
Goodwill reallocated into (out of)                               $ (115,000,000)    
Uceris                                    
Finite-Lived Intangible Assets [Line Items]                                    
Impairment of finite-lived intangible assets                             263,000,000      
Arestin                                    
Finite-Lived Intangible Assets [Line Items]                                    
Impairment of finite-lived intangible assets                             132,000,000      
Xifaxan                                    
Finite-Lived Intangible Assets [Line Items]                                    
Carrying value of intangible assets, net         $ 3,771,000,000               3,771,000,000          
Xifaxan | Intangible Assets, Amortization Period                                    
Finite-Lived Intangible Assets [Line Items]                                    
Net loss attributable to Bausch Health Companies Inc.                         $ 476,000,000 $ 473,000,000 $ 143,000,000      
Decrease to earnings per share, basic and diluted (in dollars per share)                         $ 1.34 $ 1.34 $ 0.41      
Acquired IPR&D                                    
Finite-Lived Intangible Assets [Line Items]                                    
Impairment of indefinite-lived intangible assets                         $ 1,000,000 $ 4,000,000 $ 28,000,000      
Held For Sale                                    
Finite-Lived Intangible Assets [Line Items]                                    
Impairment of long-lived assets                             5,000,000      
Held For Sale | Certain Products For Disposal, September 2019                                    
Finite-Lived Intangible Assets [Line Items]                                    
Impairment of long-lived assets                   $ 8,000,000       8,000,000        
Held For Sale | A Certain International Business                                    
Finite-Lived Intangible Assets [Line Items]                                    
Impairment of long-lived assets                         96,000,000          
Product brands                                    
Finite-Lived Intangible Assets [Line Items]                                    
Impairment of finite-lived intangible assets                         16,000,000 58,000,000 85,000,000      
Discontinued Product Lines                                    
Finite-Lived Intangible Assets [Line Items]                                    
Impairment of finite-lived intangible assets                         $ 1,000,000          
Product rights/patents                                    
Finite-Lived Intangible Assets [Line Items]                                    
Impairment of finite-lived intangible assets                           $ 5,000,000 $ 55,000,000      
XML 100 R82.htm IDEA: XBRL DOCUMENT v3.20.4
INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Estimated aggregate amortization expense    
2021 $ 1,389  
2022 1,204  
2023 1,030  
2024 905  
2025 822  
Thereafter 1,390  
Net Carrying Amount $ 6,740 $ 8,490
XML 101 R83.htm IDEA: XBRL DOCUMENT v3.20.4
INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details) - USD ($)
3 Months Ended 12 Months Ended
Oct. 01, 2020
Oct. 01, 2019
Oct. 01, 2018
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Change in the carrying amount of goodwill                
Balance at the beginning of the period         $ 13,126,000,000 $ 13,126,000,000 $ 13,142,000,000 $ 15,593,000,000
Impairments   $ 0            
Acquisition of certain assets of Synergy             3,000,000  
Assets held for sale reclassified to goodwill (Note 5)           18,000,000    
Goodwill reclassified to assets held for sale           (217,000,000) (18,000,000) (2,000,000)
Foreign exchange and other           117,000,000 (1,000,000) (127,000,000)
Balance at the end of the period           13,044,000,000 13,126,000,000 13,142,000,000
Ortho Dermatologics Reporting Units                
Change in the carrying amount of goodwill                
Impairments $ 0     $ 0 0     (2,213,000,000)
Dentistry Reporting Unit                
Change in the carrying amount of goodwill                
Impairments     $ (109,000,000)         (109,000,000)
Bausch + Lomb/ International                
Change in the carrying amount of goodwill                
Balance at the beginning of the period         5,786,000,000 5,786,000,000 5,805,000,000 6,016,000,000
Realignment of Global Solta reporting unit goodwill               (82,000,000)
Assets held for sale reclassified to goodwill (Note 5)           18,000,000    
Goodwill reclassified to assets held for sale           (217,000,000) (18,000,000) (2,000,000)
Foreign exchange and other           117,000,000 (1,000,000) (127,000,000)
Balance at the end of the period           5,704,000,000 5,786,000,000 5,805,000,000
Branded Rx                
Change in the carrying amount of goodwill                
Balance at the beginning of the period         0 0 0 6,631,000,000
Realignment of Global Solta reporting unit goodwill               115,000,000
Realignment of segment goodwill               (4,533,000,000)
Balance at the end of the period           0 0 0
Branded Rx | Ortho Dermatologics Reporting Units                
Change in the carrying amount of goodwill                
Impairments               (2,213,000,000)
U.S. Diversified Products                
Change in the carrying amount of goodwill                
Balance at the beginning of the period         0 0 0 2,946,000,000
Realignment of Global Solta reporting unit goodwill               (33,000,000)
Realignment of segment goodwill               (2,913,000,000)
Balance at the end of the period           0 0 0
Salix                
Change in the carrying amount of goodwill                
Balance at the beginning of the period         3,159,000,000 3,159,000,000 3,156,000,000  
Acquisition of certain assets of Synergy             3,000,000  
Realignment of segment goodwill               3,156,000,000
Balance at the end of the period           3,159,000,000 3,159,000,000 3,156,000,000
Ortho Dermatologics                
Change in the carrying amount of goodwill                
Balance at the beginning of the period         1,267,000,000 1,267,000,000 1,267,000,000  
Realignment of segment goodwill               1,267,000,000
Balance at the end of the period           1,267,000,000 1,267,000,000 1,267,000,000
Diversified Products                
Change in the carrying amount of goodwill                
Balance at the beginning of the period         $ 2,914,000,000 2,914,000,000 2,914,000,000  
Realignment of segment goodwill               3,023,000,000
Balance at the end of the period           $ 2,914,000,000 $ 2,914,000,000 2,914,000,000
Diversified Products | Dentistry Reporting Unit                
Change in the carrying amount of goodwill                
Impairments               $ (109,000,000)
XML 102 R84.htm IDEA: XBRL DOCUMENT v3.20.4
ACCRUED AND OTHER CURRENT LIABILITIES (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Payables and Accruals [Abstract]    
Legal matters and related fees $ 1,672 $ 1,397
Product rebates 747 898
Product returns 575 691
Interest 341 305
Employee compensation and benefit costs 316 304
Income taxes payable 158 196
Other 767 720
Accrued and other current liabilities $ 4,576 $ 4,511
XML 103 R85.htm IDEA: XBRL DOCUMENT v3.20.4
FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details) - USD ($)
Dec. 31, 2020
Dec. 03, 2020
May 26, 2020
Dec. 31, 2019
Mar. 08, 2019
Oct. 17, 2017
Mar. 31, 2017
Long-term debt, net of unamortized debt discount              
Principal Amount $ 24,185,000,000     $ 26,188,000,000      
Total long-term debt and other 23,925,000,000     25,895,000,000      
Less: Current portion of long-term debt and other 0     1,234,000,000      
Non-current portion of long-term debt $ 23,925,000,000     24,661,000,000      
Term Loan B Facility Due June 2025              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 3.15%            
Principal Amount $ 3,298,000,000     3,869,000,000      
Total long-term debt and other $ 3,220,000,000     3,768,000,000      
Term Loan B Facility Due November 2025              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 2.90%            
Principal Amount $ 1,125,000,000     1,275,000,000      
Total long-term debt and other $ 1,112,000,000     1,257,000,000      
Senior Secured Notes | 6.50% Senior Notes Due March 2022              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 6.50%           6.50%
Principal Amount $ 0     1,250,000,000      
Total long-term debt and other $ 0     1,242,000,000      
Senior Secured Notes | 7.00 % Senior Notes Due March 2024              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 7.00%           7.00%
Principal Amount $ 2,000,000,000     2,000,000,000      
Total long-term debt and other $ 1,987,000,000     1,983,000,000      
Senior Secured Notes | 5.50% Senior Notes Due November 2025              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 5.50%         5.50%  
Principal Amount $ 1,750,000,000     1,750,000,000      
Total long-term debt and other $ 1,736,000,000     1,733,000,000      
Senior Secured Notes | 5.75% Senior Notes Due August 2027              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 5.75%       5.75%    
Principal Amount $ 500,000,000     500,000,000      
Total long-term debt and other $ 494,000,000     493,000,000      
Senior Unsecured Notes | 5.50% Senior Notes Due March 2023              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 5.50%            
Principal Amount $ 0     402,000,000      
Total long-term debt and other $ 0     400,000,000      
Senior Unsecured Notes | 5.875% Senior Notes Due May 2023              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 5.875%            
Principal Amount $ 0     1,448,000,000      
Total long-term debt and other $ 0     1,441,000,000      
Senior Unsecured Notes | 4.50% Senior Notes euro-denominated debt Due May 2023              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 4.50%            
Principal Amount $ 0     1,682,000,000      
Total long-term debt and other $ 0     1,674,000,000      
Senior Unsecured Notes | 6.125% Senior Notes Due April 2025              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 6.125%            
Principal Amount $ 3,250,000,000     3,250,000,000      
Total long-term debt and other $ 3,234,000,000     3,230,000,000      
Senior Unsecured Notes | 9.00% Senior Notes Due December 2025              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 9.00%            
Principal Amount $ 1,500,000,000     1,500,000,000      
Total long-term debt and other $ 1,478,000,000     1,473,000,000      
Senior Unsecured Notes | 9.25% Senior Notes Due April 2026              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 9.25%            
Principal Amount $ 1,500,000,000     1,500,000,000      
Total long-term debt and other $ 1,487,000,000     1,484,000,000      
Senior Unsecured Notes | 8.50% Senior Notes Due January 2027              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 8.50%            
Principal Amount $ 1,750,000,000     1,750,000,000      
Total long-term debt and other $ 1,755,000,000     1,756,000,000      
Senior Unsecured Notes | 7.00 % Senior Notes Due January 2028              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 7.00%            
Principal Amount $ 750,000,000     750,000,000      
Total long-term debt and other $ 742,000,000     741,000,000      
Senior Unsecured Notes | 5.00% Senior Notes Due January 2028              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 5.00%            
Principal Amount $ 1,250,000,000     1,250,000,000      
Total long-term debt and other $ 1,236,000,000     1,234,000,000      
Senior Unsecured Notes | 6.25% Senior Notes Due February 2029              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 6.25%   6.25%        
Principal Amount $ 1,500,000,000     0      
Total long-term debt and other $ 1,480,000,000     0      
Senior Unsecured Notes | 5.00% Senior Note Due February 2029              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 5.00% 5.00%          
Principal Amount $ 1,000,000,000     0      
Total long-term debt and other $ 988,000,000     0      
Senior Unsecured Notes | 7.25% Senior Notes Due May 2029              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 7.25%            
Principal Amount $ 750,000,000     750,000,000      
Total long-term debt and other $ 741,000,000     740,000,000      
Senior Unsecured Notes | 5.25% Senior Notes Due January 2030              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 5.25%            
Principal Amount $ 1,250,000,000     1,250,000,000      
Total long-term debt and other $ 1,235,000,000     1,234,000,000      
Senior Unsecured Notes | 5.25% Senior Notes, Due February 2031              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 5.25% 5.25%          
Principal Amount $ 1,000,000,000     0      
Total long-term debt and other 988,000,000     0      
Senior Unsecured Notes | Other              
Long-term debt, net of unamortized debt discount              
Principal Amount 12,000,000     12,000,000      
Total long-term debt and other $ 12,000,000     12,000,000      
Senior Secured Credit Facilities | 2023 Revolving Credit Facility Due June 2023              
Long-term debt, net of unamortized debt discount              
Stated interest rate on debt (as a percent) 3.15%            
Principal Amount $ 0     0      
Total long-term debt and other $ 0     $ 0      
XML 104 R86.htm IDEA: XBRL DOCUMENT v3.20.4
FINANCING ARRANGEMENTS - Covenant Compliance (Details) - Revolving credit facility
$ in Millions
Dec. 31, 2020
USD ($)
Debt Instrument [Line Items]  
Amount available for restricted payments $ 13,000
Fixed charge coverage ratio 2.00
Secured leverage ratio 4.00
XML 105 R87.htm IDEA: XBRL DOCUMENT v3.20.4
FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details) - USD ($)
Dec. 31, 2020
Dec. 31, 2019
Jan. 01, 2018
Debt Instrument [Line Items]      
Long-term debt $ 23,925,000,000 $ 25,895,000,000  
Series F Tranche B Term Loan Facility      
Debt Instrument [Line Items]      
Long-term debt     $ 3,521,000,000
Revolving credit facility      
Debt Instrument [Line Items]      
Maximum borrowing capacity     1,500,000,000
Amount outstanding     $ 250,000,000
XML 106 R88.htm IDEA: XBRL DOCUMENT v3.20.4
FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2018 Activities (Details) - USD ($)
12 Months Ended
May 26, 2020
May 23, 2019
Mar. 08, 2019
Nov. 27, 2018
Jun. 01, 2018
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Mar. 31, 2020
Dec. 27, 2018
Jan. 01, 2018
Dec. 18, 2017
Mar. 27, 2015
Debt Instrument [Line Items]                          
Repayments of long-term debt           $ 5,642,000,000 $ 4,406,000,000 $ 10,101,000,000          
Proceeds from issuance of long-term debt           3,455,000,000 5,960,000,000 8,944,000,000          
Loss on extinguishment of debt $ 27,000,000   $ 8,000,000     $ 59,000,000 $ 42,000,000 119,000,000          
Debt issuance cost       $ 25,000,000 $ 74,000,000                
Payments of debt restructuring costs         4,000,000                
Senior Unsecured Notes                          
Debt Instrument [Line Items]                          
Loss on extinguishment of debt   $ 32,000,000                      
Series F Tranche B Term Loan Facility                          
Debt Instrument [Line Items]                          
Repayments of long-term debt         3,315,000,000                
Loss on extinguishment of debt         $ 48,000,000                
Term Loan B Facility Due June 2025                          
Debt Instrument [Line Items]                          
Debt instrument, term       7 years 7 years                
Aggregate principal amount       $ 1,500,000,000 $ 4,565,000,000                
Stated interest rate           3.15%              
5.375% Senior Notes due March 2020 | Senior Unsecured Notes                          
Debt Instrument [Line Items]                          
Repayments of long-term debt         691,000,000                
Aggregate principal amount                         $ 2,000,000,000
Stated interest rate                         5.375%
Repurchased face amount                       $ 1,500,000,000  
6.75% Senior Notes due in August 2021 | Senior Unsecured Notes                          
Debt Instrument [Line Items]                          
Repayments of long-term debt         $ 578,000,000                
Stated interest rate         6.75%                
7.25% Senior Notes due in July 2022 | Senior Unsecured Notes                          
Debt Instrument [Line Items]                          
Repayments of long-term debt         $ 550,000,000                
Stated interest rate         7.25%                
6.375% Senior Notes due in October 2020 | Senior Unsecured Notes                          
Debt Instrument [Line Items]                          
Repayments of long-term debt         $ 146,000,000                
Stated interest rate         6.375%                
8.50% Senior Unsecured Notes Due January 2027 | Senior Unsecured Notes                          
Debt Instrument [Line Items]                          
Aggregate principal amount         $ 750,000,000       $ 1,000,000,000        
Stated interest rate         8.50%                
Proceeds from issuance of long-term debt         $ 750,000,000                
7.50% Senior Notes due July 2021 | Senior Unsecured Notes                          
Debt Instrument [Line Items]                          
Repayments of long-term debt       $ 1,483,000,000                  
Stated interest rate       7.50%                  
Loss on extinguishment of debt       $ 43,000,000                  
Repurchased face amount                   $ 17,000,000      
Revolving credit facility                          
Debt Instrument [Line Items]                          
Repayments of long-term debt               $ 571,000,000          
Maximum borrowing capacity                     $ 1,500,000,000    
Revolving credit facility | 2023 Revolving Credit Facility Due June 2023                          
Debt Instrument [Line Items]                          
Maximum borrowing capacity         $ 1,225,000,000                
Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold         91 days                
Alternate term, principal amount maturity threshold         $ 1,000,000,000                
Stated interest rate           3.15%              
XML 107 R89.htm IDEA: XBRL DOCUMENT v3.20.4
FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2019 Activities (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Revolving credit facility    
Debt Instrument [Line Items]    
Repayments of lines of credit $ 471 $ 806
XML 108 R90.htm IDEA: XBRL DOCUMENT v3.20.4
FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2020 Activities (Details) - USD ($)
12 Months Ended
May 26, 2020
Dec. 31, 2020
Dec. 31, 2019
Debt Instrument [Line Items]      
Long-term debt   $ 23,925,000,000 $ 25,895,000,000
Term Loan B Facility Due June 2025 and November 2025      
Debt Instrument [Line Items]      
Repayment, outstanding debt $ 303,000,000    
Revolving credit facility      
Debt Instrument [Line Items]      
Repayments of lines of credit   471,000,000 806,000,000
Revolving credit facility | Term Loan B Facility Due June 2025 and November 2025      
Debt Instrument [Line Items]      
Repayment, outstanding debt $ 250,000,000    
Revolving credit facility | 2023 Revolving Credit Facility Due June 2023      
Debt Instrument [Line Items]      
Long-term debt   0 $ 0
Remaining availability   1,121,000,000  
Letter of Credit | 2023 Revolving Credit Facility Due June 2023      
Debt Instrument [Line Items]      
Long-term debt   $ 104,000,000  
XML 109 R91.htm IDEA: XBRL DOCUMENT v3.20.4
FINANCING ARRANGEMENTS - Current Description of Senior Secured Credit Facilities (Details)
12 Months Ended
Dec. 31, 2020
USD ($)
Dec. 31, 2019
Dec. 31, 2018
Debt Instrument [Line Items]      
Federal funds effective rate 26.90% 26.90% 26.90%
Revolving credit facility      
Debt Instrument [Line Items]      
Quarterly amortization payments $ 405,000,000    
Incremental credit facility borrowings $ 1,000,000,000    
Incremental borrowings interest rate 28.50%    
Secured leverage ratio (not greater than) 4.00    
Interest coverage ratio (not less than) 2.00    
Revolving credit facility | Secured Debt      
Debt Instrument [Line Items]      
Secured leverage ratio (not greater than) 3.50    
Revolving credit facility | Unsecured Debt      
Debt Instrument [Line Items]      
Total leverage ratio (not greater than) 6.50    
Senior Secured Credit Facilities      
Debt Instrument [Line Items]      
Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses 100.00%    
Percentage of cash proceeds from incurrence of debt 100.00%    
Percentage of annual excess cash flow 50.00%    
Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments 100.00%    
Senior Credit Facilities      
Debt Instrument [Line Items]      
Variable interest rate 0.00%    
2023 Revolving Credit Facility Due June 2023 | Revolving credit facility      
Debt Instrument [Line Items]      
Stated interest rate 3.15%    
2023 Revolving Credit Facility Due June 2023 | Minimum | Revolving credit facility      
Debt Instrument [Line Items]      
Commitment fee, unutilized commitments, percentage 0.25%    
2023 Revolving Credit Facility Due June 2023 | Maximum | Revolving credit facility      
Debt Instrument [Line Items]      
Commitment fee, unutilized commitments, percentage 0.50%    
Term Loan B Facility Due June 2025      
Debt Instrument [Line Items]      
Stated interest rate 3.15%    
Annual amortization rate, percentage 5.00%    
Term Loan B Facility Due November 2025      
Debt Instrument [Line Items]      
Stated interest rate 2.90%    
Annual amortization rate, percentage 5.00%    
Federal Funds Effective Swap Rate | Senior Secured Credit Facilities      
Debt Instrument [Line Items]      
Variable interest rate 0.50%    
Eurodollar | Senior Credit Facilities      
Debt Instrument [Line Items]      
Variable interest rate 1.00%    
Eurodollar | Senior Credit Facilities | Minimum      
Debt Instrument [Line Items]      
Variable interest rate 1.00%    
Eurodollar | 2023 Revolving Credit Facility Due June 2023 | Minimum      
Debt Instrument [Line Items]      
Variable interest rate 0.00%    
Eurodollar | 2023 Revolving Credit Facility Due June 2023 | Minimum | Revolving credit facility      
Debt Instrument [Line Items]      
Variable interest rate 2.50%    
Eurodollar | 2023 Revolving Credit Facility Due June 2023 | Maximum | Revolving credit facility      
Debt Instrument [Line Items]      
Variable interest rate 3.00%    
Eurodollar | Term Loan B Facility Due June 2025      
Debt Instrument [Line Items]      
Variable interest rate 3.00%    
Eurodollar | Term Loan B Facility Due November 2025      
Debt Instrument [Line Items]      
Variable interest rate 2.75%    
Canada Bankers Acceptance Rate | 2023 Revolving Credit Facility Due June 2023      
Debt Instrument [Line Items]      
Variable interest rate 1.00%    
Canada Bankers Acceptance Rate | 2023 Revolving Credit Facility Due June 2023 | Minimum      
Debt Instrument [Line Items]      
Variable interest rate 0.00%    
Base Rate or Prime Rate | 2023 Revolving Credit Facility Due June 2023 | Minimum | Revolving credit facility      
Debt Instrument [Line Items]      
Variable interest rate 1.50%    
Base Rate or Prime Rate | 2023 Revolving Credit Facility Due June 2023 | Maximum | Revolving credit facility      
Debt Instrument [Line Items]      
Variable interest rate 2.00%    
Base Rate or Prime Rate | Term Loan B Facility Due June 2025      
Debt Instrument [Line Items]      
Variable interest rate 2.00%    
Base Rate or Prime Rate | Term Loan B Facility Due November 2025      
Debt Instrument [Line Items]      
Variable interest rate 1.75%    
XML 110 R92.htm IDEA: XBRL DOCUMENT v3.20.4
FINANCING ARRANGEMENTS - Senior Secured Notes (Details) - USD ($)
1 Months Ended 12 Months Ended
May 26, 2020
Jan. 16, 2020
May 23, 2019
Mar. 08, 2019
Jun. 01, 2018
Apr. 30, 2019
Dec. 31, 2018
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Mar. 31, 2020
Nov. 21, 2017
Oct. 17, 2017
Mar. 31, 2017
Mar. 27, 2015
Dec. 02, 2013
Debt Instrument [Line Items]                                
Redemption price percentage due to change in control (as a percent)               101.00%                
Repayments of long-term debt               $ 5,642,000,000 $ 4,406,000,000 $ 10,101,000,000            
Loss on extinguishment of debt $ 27,000,000     $ 8,000,000       $ 59,000,000 $ 42,000,000 $ 119,000,000            
Senior Unsecured Notes                                
Debt Instrument [Line Items]                                
Redemption price percentage due to change in control (as a percent)               101.00%                
Loss on extinguishment of debt     $ 32,000,000                          
6.50% Senior Notes Due March 2022 | Senior Secured Notes                                
Debt Instrument [Line Items]                                
Stated interest rate               6.50%           6.50%    
Aggregate principal amount                           $ 1,250,000,000    
7.00 % Senior Notes Due March 2024 | Senior Secured Notes                                
Debt Instrument [Line Items]                                
Stated interest rate               7.00%           7.00%    
Aggregate principal amount                           $ 2,000,000,000    
5.50% Senior Notes Due November 2025 | Senior Secured Notes                                
Debt Instrument [Line Items]                                
Stated interest rate               5.50%         5.50%      
Aggregate principal amount                       $ 750,000,000 $ 1,000,000,000      
5.75% Senior Notes Due August 2027 | Senior Secured Notes                                
Debt Instrument [Line Items]                                
Stated interest rate       5.75%       5.75%                
Aggregate principal amount       $ 500,000,000                        
Redemption price percentage (as a percent)       100.00%                        
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings       40.00%                        
8.50% Senior Unsecured Notes Due January 2027 | Senior Unsecured Notes                                
Debt Instrument [Line Items]                                
Stated interest rate         8.50%                      
Aggregate principal amount         $ 750,000,000           $ 1,000,000,000          
Redemption price percentage (as a percent)         100.00%                      
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings         40.00%                      
5.875% Senior Unsecured Notes due May 2023 | Senior Unsecured Notes                                
Debt Instrument [Line Items]                                
Stated interest rate       5.875%                     5.875%  
Aggregate principal amount                             $ 3,250,000,000  
Repayments of long-term debt   $ 1,240,000,000 $ 1,118,000,000 $ 584,000,000                        
Loss on extinguishment of debt   $ 24,000,000                            
5.625 % Senior Unsecured Notes due December 2021 | Senior Unsecured Notes                                
Debt Instrument [Line Items]                                
Stated interest rate       5.625%                       5.625%
Aggregate principal amount                               $ 900,000,000
Repayments of long-term debt       $ 518,000,000   $ 182,000,000 $ 200,000,000                  
Senior Secured and Unsecured Notes                                
Debt Instrument [Line Items]                                
Aggregate principal amount           $ 1,500,000,000                    
XML 111 R93.htm IDEA: XBRL DOCUMENT v3.20.4
FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)
1 Months Ended 12 Months Ended
Dec. 03, 2020
USD ($)
May 26, 2020
USD ($)
Jan. 16, 2020
USD ($)
Dec. 30, 2019
USD ($)
Dec. 16, 2019
USD ($)
Oct. 03, 2019
USD ($)
May 23, 2019
USD ($)
Mar. 08, 2019
USD ($)
Jun. 01, 2018
USD ($)
Mar. 26, 2018
USD ($)
Dec. 18, 2017
USD ($)
Dec. 31, 2020
USD ($)
Apr. 30, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 03, 2020
EUR (€)
Mar. 31, 2020
USD ($)
Mar. 31, 2017
USD ($)
Mar. 27, 2015
USD ($)
Mar. 27, 2015
EUR (€)
Jan. 30, 2015
USD ($)
Dec. 02, 2013
USD ($)
Debt Instrument [Line Items]                                                
Redemption price percentage due to change in control (as a percent)                             101.00%                  
Repayments of long-term debt                             $ 5,642,000,000 $ 4,406,000,000 $ 10,101,000,000              
Loss on extinguishment of debt   $ 27,000,000           $ 8,000,000             59,000,000 $ 42,000,000 $ 119,000,000              
Settled Litigation | New Jersey | Valeant US Securities Litigation                                                
Debt Instrument [Line Items]                                                
Litigation, amount agreed to pay         $ 1,210,000,000                   $ 1,210,000,000                  
Term Loan B Facility Due June 2025 and November 2025                                                
Debt Instrument [Line Items]                                                
Repayment, outstanding debt   $ 303,000,000                                            
Senior Unsecured Notes                                                
Debt Instrument [Line Items]                                                
Redemption price percentage due to change in control (as a percent)                             101.00%                  
Loss on extinguishment of debt             $ 32,000,000                                  
Senior Unsecured Notes | 5.625 % Senior Unsecured Notes due December 2021                                                
Debt Instrument [Line Items]                                                
Stated interest rate               5.625%                               5.625%
Aggregate principal amount                                               $ 900,000,000
Repayments of long-term debt               $ 518,000,000         $ 182,000,000 $ 200,000,000                    
Senior Unsecured Notes | 5.50% Senior Unsecured Notes due March 2023                                                
Debt Instrument [Line Items]                                                
Stated interest rate               5.50%                             5.50%  
Aggregate principal amount                                             $ 1,000,000,000  
Repayments of long-term debt             382,000,000 $ 216,000,000       $ 233,000,000     $ 169,000,000                  
Senior Unsecured Notes | 5.375% Senior Notes due March 2020                                                
Debt Instrument [Line Items]                                                
Stated interest rate                                         5.375% 5.375%    
Aggregate principal amount                                         $ 2,000,000,000      
Repayments of long-term debt                 $ 691,000,000                              
Repurchased face amount                     $ 1,500,000,000                          
Senior Unsecured Notes | 5.875% Senior Unsecured Notes due May 2023                                                
Debt Instrument [Line Items]                                                
Stated interest rate               5.875%                         5.875% 5.875%    
Aggregate principal amount                                         $ 3,250,000,000      
Repayments of long-term debt     $ 1,240,000,000       $ 1,118,000,000 $ 584,000,000                                
Loss on extinguishment of debt     24,000,000                                          
Senior Unsecured Notes | 4.50% Senior Unsecured Notes euro-denominated debt Due May 2023                                                
Debt Instrument [Line Items]                                                
Stated interest rate                                         4.50% 4.50%    
Aggregate principal amount | €                                           € 1,500,000,000    
Repurchased face amount | €                                   € 1,500,000,000            
Senior Unsecured Notes | 6.125% Senior Unsecured Notes due April 2025                                                
Debt Instrument [Line Items]                                                
Stated interest rate                                         6.125% 6.125%    
Aggregate principal amount                                         $ 3,250,000,000      
Senior Unsecured Notes | Senior Unsecured Notes due 2023                                                
Debt Instrument [Line Items]                                                
Repayments of long-term debt           $ 100,000,000                 $ 208,000,000                  
Repurchased face amount     $ 1,240,000,000                                          
Senior Unsecured Notes | 9.00% Senior Unsecured Notes due December 2025                                                
Debt Instrument [Line Items]                                                
Stated interest rate                     9.00%                          
Aggregate principal amount                     $ 1,500,000,000                          
Senior Unsecured Notes | 9.00% Senior Unsecured Notes due December 2025 | Debt Instrument, Redemption, Period One                                                
Debt Instrument [Line Items]                                                
Redemption price percentage (as a percent)                     100.00%                          
Senior Unsecured Notes | 9.00% Senior Unsecured Notes due December 2025 | Debt Instrument, Redemption, Period Two                                                
Debt Instrument [Line Items]                                                
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings                     40.00%                          
Senior Unsecured Notes | 9.25% Senior Unsecured Notes Due April 2026                                                
Debt Instrument [Line Items]                                                
Stated interest rate                   9.25%                            
Aggregate principal amount                   $ 1,500,000,000                            
Repurchased face amount                   $ 1,500,000,000                            
Redemption price percentage (as a percent)                   100.00%                            
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings                   40.00%                            
Loss on extinguishment of debt                   $ 26,000,000                            
Senior Unsecured Notes | 8.50% Senior Unsecured Notes Due January 2027                                                
Debt Instrument [Line Items]                                                
Stated interest rate                 8.50%                              
Aggregate principal amount                 $ 750,000,000                   $ 1,000,000,000          
Redemption price percentage (as a percent)                 100.00%                              
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings                 40.00%                              
Senior Unsecured Notes | 7.00% Senior Unsecured Notes due 2028                                                
Debt Instrument [Line Items]                                                
Stated interest rate             7.00%                                  
Aggregate principal amount             $ 750,000,000                                  
Redemption price percentage (as a percent)             100.00%                                  
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings             40.00%                                  
Senior Unsecured Notes | 7.25% Senior Unsecured Notes due 2029                                                
Debt Instrument [Line Items]                                                
Stated interest rate             7.25%                                  
Aggregate principal amount             $ 750,000,000                                  
Redemption price percentage (as a percent)             100.00%                                  
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings             40.00%                                  
Senior Unsecured Notes | 5.00% Senior Unsecured Notes Due January 2028                                                
Debt Instrument [Line Items]                                                
Stated interest rate       5.00%                                        
Aggregate principal amount       $ 1,250,000,000                                        
Redemption price percentage (as a percent)       100.00%                                        
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings       40.00%                                        
Senior Unsecured Notes | 5.25% Senior Unsecured Notes Due January 2030                                                
Debt Instrument [Line Items]                                                
Stated interest rate       5.25%                                        
Aggregate principal amount       $ 1,250,000,000                                        
Redemption price percentage (as a percent)       100.00%                                        
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings       40.00%                                        
Senior Unsecured Notes | 6.25% Senior Notes Due February 2029                                                
Debt Instrument [Line Items]                                                
Stated interest rate   6.25%                   6.25%     6.25%                  
Aggregate principal amount   $ 1,500,000,000                                            
Senior Unsecured Notes | 6.25% Senior Notes Due February 2029 | Debt Instrument, Redemption, Period One                                                
Debt Instrument [Line Items]                                                
Redemption price percentage (as a percent)   100.00%                                            
Senior Unsecured Notes | 6.25% Senior Notes Due February 2029 | Debt Instrument, Redemption, Period Two                                                
Debt Instrument [Line Items]                                                
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings   40.00%                                            
Senior Unsecured Notes | 5.00% Senior Note Due February 2029                                                
Debt Instrument [Line Items]                                                
Stated interest rate 5.00%                     5.00%     5.00%     5.00%            
Aggregate principal amount $ 1,000,000,000                                              
Redemption price percentage (as a percent) 100.00%                                              
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings 40.00%                                              
Senior Unsecured Notes | 5.25% Senior Notes, Due February 2031                                                
Debt Instrument [Line Items]                                                
Stated interest rate 5.25%                     5.25%     5.25%     5.25%            
Aggregate principal amount $ 1,000,000,000                                              
Redemption price percentage (as a percent) 100.00%                                              
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings 40.00%                                              
Senior Unsecured Notes | 5.50% Senior Notes Due March 2023                                                
Debt Instrument [Line Items]                                                
Stated interest rate                       5.50%     5.50%                  
Repurchased face amount $ 233,000,000                                              
Loss on extinguishment of debt $ 7,000,000                                              
Senior Secured Notes | 6.50% Senior Notes Due March 2022                                                
Debt Instrument [Line Items]                                                
Stated interest rate                       6.50%     6.50%         6.50%        
Aggregate principal amount                                       $ 1,250,000,000        
Repurchased face amount   $ 1,250,000,000                                            
XML 112 R94.htm IDEA: XBRL DOCUMENT v3.20.4
FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)
Dec. 31, 2020
Dec. 31, 2019
Debt Disclosure [Abstract]    
Weighted average interest rate 6.02% 6.21%
XML 113 R95.htm IDEA: XBRL DOCUMENT v3.20.4
FINANCING ARRANGEMENTS - Maturities, Schedule of Maturities and Mandatory Payments of Debt Obligations (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Debt Disclosure [Abstract]    
2021 $ 0  
2022 0  
2023 0  
2024 2,291  
2025 10,632  
Thereafter 11,262  
Total gross maturities 24,185 $ 26,188
Unamortized discounts (260)  
Total long-term debt and other $ 23,925 $ 25,895
XML 114 R96.htm IDEA: XBRL DOCUMENT v3.20.4
PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)
$ in Millions
1 Months Ended 12 Months Ended
Dec. 31, 2014
defined_benefit_plan
Dec. 31, 2021
Dec. 31, 2020
USD ($)
defined_benefit_plan
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]          
Future benefit payments period     10 years    
Contributions recognized     $ 43 $ 41 $ 36
Pension Benefit Plans          
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]          
Benefit accrual, interest percentage earned on cash balance     4.50%    
Pension Benefit Plans | Foreign Plan          
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]          
Estimated company contributions in next fiscal year     $ 10    
Percentage of expected return on plan assets     2.98% 3.46% 3.66%
Pension Benefit Plans | Ireland          
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]          
Number of defined benefit plans | defined_benefit_plan     2    
Number of defined benefit plans amended | defined_benefit_plan 1        
Percentage of expected return on plan assets     3.00%    
Percentage allocation of fund     96.00% 95.00%  
Pension Benefit Plans | Ireland | Scenario, Forecast          
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]          
Percentage of expected return on plan assets   2.75%      
Pension Benefit Plans | United States          
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]          
Estimated company contributions in next fiscal year     $ 0    
Percentage of expected return on plan assets     6.25% 7.25% 7.50%
Pension Benefit Plans | United States | Scenario, Forecast          
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]          
Percentage of expected return on plan assets   5.00%      
Postretirement Benefit Plan          
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]          
Employer contribution maximum age     65 years    
Estimated company contributions in next fiscal year     $ 4    
Percentage of expected return on plan assets     0.00% 0.00% 0.00%
XML 115 R97.htm IDEA: XBRL DOCUMENT v3.20.4
PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
U.S. Postretirement Benefit Plan    
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]    
Unrecognized actuarial losses $ (3) $ (2)
Unrecognized prior service credits 11 14
United States | Pension Benefit Plans    
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]    
Unrecognized actuarial losses (21) (20)
Unrecognized prior service credits 0 0
Foreign Plan | Pension Benefit Plans    
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]    
Unrecognized actuarial losses (76) (65)
Unrecognized prior service credits $ 27 $ 26
XML 116 R98.htm IDEA: XBRL DOCUMENT v3.20.4
PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of net periodic benefit cost (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
U.S. Postretirement Benefit Plan      
Defined Benefit Plan Disclosure [Line Items]      
Service cost $ 0 $ 0 $ 0
Interest cost 1 1 1
Expected return on plan assets 0 0 0
Amortization of net loss 0 0 0
Amortization of prior service credit (3) (2) (2)
Other 0 0 0
Net periodic (benefit) cost (2) (1) (1)
United States | Pension Benefit Plans      
Defined Benefit Plan Disclosure [Line Items]      
Service cost 1 2 2
Interest cost 6 8 7
Expected return on plan assets (13) (13) (15)
Amortization of net loss 0 0 0
Amortization of prior service credit 0 0 0
Other 0 0 0
Net periodic (benefit) cost (6) (3) (6)
Foreign Plan | Pension Benefit Plans      
Defined Benefit Plan Disclosure [Line Items]      
Service cost 3 3 3
Interest cost 4 5 5
Expected return on plan assets (5) (5) (5)
Amortization of net loss 2 1 1
Amortization of prior service credit (1) (1) (1)
Other 0 1 0
Net periodic (benefit) cost $ 3 $ 4 $ 3
XML 117 R99.htm IDEA: XBRL DOCUMENT v3.20.4
PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
U.S. Postretirement Benefit Plan      
Change in Projected Benefit Obligation      
Projected benefit obligation, beginning of year $ 41 $ 41  
Service cost 0 0 $ 0
Interest cost 1 1 1
Employee contributions 0 1  
Settlements 0 0  
Benefits paid (4) (4)  
Actuarial losses 1 2  
Currency translation adjustments 0 0  
Projected benefit obligation, end of year 39 41 41
Change in Plan Assets      
Fair value of plan assets, beginning of year 0 0  
Actual return on plan assets 0 0  
Employee contributions 0 1  
Company contributions 4 3  
Settlements 0 0  
Benefits paid (4) (4)  
Currency translation adjustments 0 0  
Fair value of plan assets, end of year 0 0 0
Funded status, end of year (39) (41)  
Recognized as:      
Accrued and other current liabilities (4) (5)  
Other non-current liabilities (35) (36)  
United States | Pension Benefit Plans      
Change in Projected Benefit Obligation      
Projected benefit obligation, beginning of year 227 214  
Service cost 1 2 2
Interest cost 6 8 7
Employee contributions 0 0  
Settlements 0 0  
Benefits paid (15) (15)  
Actuarial losses 17 18  
Currency translation adjustments 0 0  
Projected benefit obligation, end of year 236 227 214
Change in Plan Assets      
Fair value of plan assets, beginning of year 216 187  
Actual return on plan assets 29 42  
Employee contributions 0 0  
Company contributions 1 2  
Settlements 0 0  
Benefits paid (15) (15)  
Currency translation adjustments 0 0  
Fair value of plan assets, end of year 231 216 187
Funded status, end of year (5) (11)  
Recognized as:      
Accrued and other current liabilities 0 0  
Other non-current liabilities (5) (11)  
Foreign Plan | Pension Benefit Plans      
Change in Projected Benefit Obligation      
Projected benefit obligation, beginning of year 259 235  
Service cost 3 3 3
Interest cost 4 5 5
Employee contributions 0 0  
Settlements (3) (2)  
Benefits paid (4) (8)  
Actuarial losses 13 30  
Currency translation adjustments 22 (4)  
Projected benefit obligation, end of year 294 259 235
Change in Plan Assets      
Fair value of plan assets, beginning of year 161 147  
Actual return on plan assets 11 17  
Employee contributions 0 0  
Company contributions 8 10  
Settlements (2) (2)  
Benefits paid (4) (8)  
Currency translation adjustments 15 (3)  
Fair value of plan assets, end of year 189 161 $ 147
Funded status, end of year (105) (98)  
Recognized as:      
Accrued and other current liabilities (2) (2)  
Other non-current liabilities $ (103) $ (96)  
XML 118 R100.htm IDEA: XBRL DOCUMENT v3.20.4
PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
United States    
Underfunded plans having accumulated benefit obligations exceeding the fair value of plan assets    
Projected benefit obligation $ 236 $ 227
Accumulated benefit obligation 236 227
Fair value of plan assets 231 216
Foreign Plan    
Underfunded plans having accumulated benefit obligations exceeding the fair value of plan assets    
Projected benefit obligation 294 259
Accumulated benefit obligation 286 251
Fair value of plan assets $ 189 $ 161
XML 119 R101.htm IDEA: XBRL DOCUMENT v3.20.4
PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future benefit payments for the pension benefit plans (Details)
$ in Millions
Dec. 31, 2020
USD ($)
Pension Benefit Plans | United States  
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]  
2021 $ 14
2022 19
2023 17
2024 17
2025 17
2026-2030 75
Pension Benefit Plans | Foreign Plan  
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]  
2021 6
2022 6
2023 7
2024 7
2025 7
2026-2030 42
U.S. Postretirement Benefit Plan  
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]  
2021 4
2022 4
2023 4
2024 3
2025 3
2026-2030 $ 12
XML 120 R102.htm IDEA: XBRL DOCUMENT v3.20.4
PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-average assumptions used to determine net periodic benefit costs and benefit obligations (Details)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Pension Benefit Plans | United States      
For Determining Net Periodic (Benefit) Cost      
Discount rate 3.16% 4.25% 3.56%
Expected rate of return on plan assets 6.25% 7.25% 7.50%
Rate of compensation increase 0.00% 0.00% 0.00%
Interest crediting rate 5.00% 5.00% 5.00%
For Determining Benefit Obligation      
Discount rate 2.25% 3.16%  
Rate of compensation increase 0.00% 0.00%  
Interest crediting rate 4.75% 5.00%  
Pension Benefit Plans | Foreign Plan      
For Determining Net Periodic (Benefit) Cost      
Discount rate 1.68% 2.39% 2.29%
Expected rate of return on plan assets 2.98% 3.46% 3.66%
Rate of compensation increase 3.05% 2.89% 2.87%
Interest crediting rate 0.00% 0.00% 0.00%
For Determining Benefit Obligation      
Discount rate 1.37% 1.68%  
Rate of compensation increase 2.60% 3.05%  
Interest crediting rate 0.00% 0.00%  
U.S. Postretirement Benefit Plan      
For Determining Net Periodic (Benefit) Cost      
Discount rate 3.04% 4.16% 3.47%
Expected rate of return on plan assets 0.00% 0.00% 0.00%
Rate of compensation increase 0.00% 0.00% 0.00%
For Determining Benefit Obligation      
Discount rate 2.09% 3.04%  
Rate of compensation increase 0.00% 0.00%  
XML 121 R103.htm IDEA: XBRL DOCUMENT v3.20.4
PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details) - Pension Benefit Plans
Dec. 31, 2020
Dec. 31, 2019
United States | Cash and cash equivalents    
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]    
Defined benefit plan, percentage of actual plan asset allocations 1.00% 1.00%
United States | Equity securities    
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]    
Defined benefit plan, percentage of actual plan asset allocations 39.00% 55.00%
United States | Fixed income securities    
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]    
Defined benefit plan, percentage of actual plan asset allocations 60.00% 44.00%
Foreign Plan | Cash and cash equivalents    
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]    
Defined benefit plan, percentage of actual plan asset allocations 3.00% 6.00%
Foreign Plan | Equity securities    
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]    
Defined benefit plan, percentage of actual plan asset allocations 28.00% 25.00%
Foreign Plan | Fixed income securities    
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]    
Defined benefit plan, percentage of actual plan asset allocations 58.00% 64.00%
Foreign Plan | Other    
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]    
Defined benefit plan, percentage of actual plan asset allocations 11.00% 6.00%
XML 122 R104.htm IDEA: XBRL DOCUMENT v3.20.4
PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair value of pension and postretirement benefit plan assets assumed in connection with the Acquisition (Details) - Pension Benefit Plans - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets $ 231 $ 216 $ 187
Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 189 161 $ 147
Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 231 216  
Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 189 161  
Level 1 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 2 1  
Level 1 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 1 1  
Level 2 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 229 215  
Level 2 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 186 159  
Level 3 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Level 3 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 2 1  
Cash and cash equivalents | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 2 1  
Cash and cash equivalents | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 5 9  
Cash and cash equivalents | Level 1 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 2 1  
Cash and cash equivalents | Level 1 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Cash and cash equivalents | Level 2 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Cash and cash equivalents | Level 2 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 5 9  
Cash and cash equivalents | Level 3 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Cash and cash equivalents | Level 3 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
U.S. broad market | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 48 64  
U.S. broad market | Level 1 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
U.S. broad market | Level 2 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 48 64  
U.S. broad market | Level 3 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Emerging markets | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 9 15  
Emerging markets | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 1 2  
Emerging markets | Level 1 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Emerging markets | Level 1 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Emerging markets | Level 2 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 9 15  
Emerging markets | Level 2 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 1 2  
Emerging markets | Level 3 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Emerging markets | Level 3 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Worldwide developed markets | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 20 26  
Worldwide developed markets | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 51 38  
Worldwide developed markets | Level 1 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Worldwide developed markets | Level 1 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Worldwide developed markets | Level 2 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 20 26  
Worldwide developed markets | Level 2 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 51 38  
Worldwide developed markets | Level 3 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Worldwide developed markets | Level 3 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Other assets | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 14 15  
Other assets | Level 1 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Other assets | Level 2 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 14 15  
Other assets | Level 3 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Investment grade | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 138 95  
Investment grade | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 6 9  
Investment grade | Level 1 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Investment grade | Level 1 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Investment grade | Level 2 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 138 95  
Investment grade | Level 2 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 6 9  
Investment grade | Level 3 | Recurring basis | United States      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Investment grade | Level 3 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Global high yield | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 1 3  
Global high yield | Level 1 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Global high yield | Level 2 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 1 3  
Global high yield | Level 3 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Government bond funds | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 103 91  
Government bond funds | Level 1 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 1 1  
Government bond funds | Level 2 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 102 90  
Government bond funds | Level 3 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Other assets | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 22 9  
Other assets | Level 1 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 0 0  
Other assets | Level 2 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets 20 8  
Other assets | Level 3 | Recurring basis | Foreign Plan      
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]      
Fair value of plan assets $ 2 $ 1  
XML 123 R105.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES - Right-of-use Assets and Right-of-use Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Jan. 01, 2019
Right-of-use assets included in:      
Other non-current assets $ 259 $ 271 $ 302
Lease liabilities included in:      
Accrued and other current liabilities $ 52 $ 53  
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesCurrent  
Other non-current liabilities $ 227 $ 240  
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] us-gaap:OtherLiabilitiesNoncurrent us-gaap:OtherLiabilitiesNoncurrent  
Present value of remaining lease payments $ 279 $ 293 $ 302
XML 124 R106.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Leases [Abstract]      
Finance leases $ 0 $ 0  
Sub-lease income 0 0  
Short-term lease expense 0 0  
Rental expense     $ 92
Right-of-use assets obtained in exchange for new operating lease liabilities, excluding amount recognized upon adoption of new accounting standard $ 39 47  
Right-of-use assets obtained in exchange for new operating lease liabilities, upon adoption of new accounting standard   $ 282  
XML 125 R107.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES - Lease Expenses (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Leases [Abstract]    
Operating lease costs $ 65 $ 62
Variable operating lease costs $ 12 $ 16
XML 126 R108.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES - Lease Additional Information (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Leases [Abstract]    
Cash paid from operating cash flows for amounts included in the measurement of lease liabilities $ 74 $ 73
Right-of-use assets obtained in exchange for new operating lease liabilities $ 39 $ 47
Weighted-average remaining lease term 7 years 7 months 6 days 8 years 2 months 12 days
Weighted-average discount rate 6.20% 6.20%
XML 127 R109.htm IDEA: XBRL DOCUMENT v3.20.4
LEASES - Lease Future Payments (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Jan. 01, 2019
Leases [Abstract]      
2021 $ 68    
2022 53    
2023 45    
2024 35    
2025 34    
Thereafter 121    
Total 356    
Less: Imputed interest 77    
Present value of remaining lease payments 279 $ 293 $ 302
Less: Current portion 52 53  
Non-current portion $ 227 $ 240  
XML 128 R110.htm IDEA: XBRL DOCUMENT v3.20.4
SHARE-BASED COMPENSATION - Narrative (Details) - Omnibus Incentive Plan 2014 - USD ($)
Apr. 28, 2020
Apr. 30, 2018
Dec. 31, 2020
May 31, 2014
Components and classification of share-based compensation expense        
Total number of shares approved for grant by the Company under the share-based compensation plans (in shares)       18,000,000
Shares reserved for future issuance (in shares)       20,000,000
Number of additional shares available for issuance (in shares) 13,500,000 11,900,000    
Number of shares available for future grants (in shares)     16,902,000  
Nonemployee Director        
Components and classification of share-based compensation expense        
Aggregate fair market value on awards granted during any calendar year   $ 750,000    
XML 129 R111.htm IDEA: XBRL DOCUMENT v3.20.4
SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Components and classification of share-based compensation expense      
Share-based compensation $ 105 $ 102 $ 87
Research and development expenses      
Components and classification of share-based compensation expense      
Share-based compensation 11 9 9
Selling, general and administrative expenses      
Components and classification of share-based compensation expense      
Share-based compensation 94 93 78
Stock options      
Components and classification of share-based compensation expense      
Share-based compensation 15 21 23
RSUs      
Components and classification of share-based compensation expense      
Share-based compensation $ 90 $ 81 $ 64
XML 130 R112.htm IDEA: XBRL DOCUMENT v3.20.4
SHARE-BASED COMPENSATION - Stock Options (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Stock options      
Method and assumptions on valuation of stock options      
Expected stock option life (years) 3 years 3 years 3 years
Expected volatility 38.70% 46.50% 54.00%
Risk-free interest rate 1.20% 2.50% 2.70%
Expected dividend yield 0.00% 0.00% 0.00%
Options      
Beginning of the period (in shares) 7.1    
Granted (in shares) 2.3    
Exercised (in shares) (0.4)    
Expired or forfeited (in shares) (0.3)    
End of the period (in shares) 8.7 7.1  
Vested and expected to vest at the end of the period (in shares) 8.2    
Vested and exercisable at the end of the period (in shares) 4.8    
Weighted- Average Exercise Price Per Share      
Beginning of the period (in dollars per share) $ 26.99    
Granted (in dollars per share) 24.74    
Exercised (in dollars per share) 14.65    
Expired or forfeited (in dollars per share) 72.40    
End of the period (in dollars per share) 25.59 $ 26.99  
Vested and expected to vest at the end of the period (in dollars per share) 25.73    
Vested and exercisable at the end of the period (in dollars per share) $ 27.74    
Weighted- Average Remaining Contractual Term (Years)      
Outstanding at the end of the period 7 years 2 months 12 days    
Vested and expected to vest at the end of the period 7 years 1 month 6 days    
Vested and exercisable at the end of the period 6 years    
Aggregate Intrinsic Value      
Outstanding at the end of the period $ 14    
Vested and expected to vest at the end of the period 14    
Vested and exercisable at the end of the period $ 11    
Additional disclosures      
Weighted-average grant date fair value of stock options (in dollars per share) $ 6.60 $ 8.45 $ 7.83
Intrinsic value of stock options exercised in the period $ 2 $ 3 $ 1
Proceeds from exercise of stock options 5 5 2
Remaining unrecognized compensation expense related to non-vested awards $ 10    
Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized 1 year 6 months    
Fair value of stock options vested $ 15 $ 18 $ 17
Vesting Period One      
Share-based compensation      
Vesting period 3 years    
Vesting Period One | Stock options      
Share-based compensation      
Percentage of stock options that will vest on each of the first, second, third and fourth anniversaries from the date of grant 33.00%    
Vesting Period Two      
Share-based compensation      
Vesting period 4 years    
Vesting Period Two | Stock options      
Share-based compensation      
Percentage of stock options that will vest on each of the first, second, third and fourth anniversaries from the date of grant 25.00%    
XML 131 R113.htm IDEA: XBRL DOCUMENT v3.20.4
SHARE-BASED COMPENSATION - RSUs (Details) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
RSUs      
Share-based compensation      
Percentage of vesting rights 33.00%    
Vesting period 3 years    
Time-Based RSUs      
Share-based compensation      
Remaining unrecognized compensation expense related to non-vested awards $ 55    
Total fair value $ 66 $ 34 $ 30
Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized 1 year 6 months    
RSUs      
Beginning of the period (in shares) 6,100,000    
Granted (in shares) 3,300,000    
Vested (in shares) (3,400,000)    
Forfeited (in shares) (300,000)    
End of the period (in shares) 5,700,000 6,100,000  
Weighted- Average Grant-Date Fair Value Per Share      
Beginning of the period (in dollars per share) $ 20.54    
Granted (in dollars per share) 21.92    
Vested (in dollars per share) 19.37    
Forfeited (in dollars per share) 21.78    
End of the period (in dollars per share) $ 21.98 $ 20.54  
Performance-Based Restricted Stock Units      
Share-based compensation      
Remaining unrecognized compensation expense related to non-vested awards $ 22    
Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized 1 year 4 months 24 days    
Maximum common shares issuable upon vesting (in shares) 3,729,000    
RSUs      
Beginning of the period (in shares) 2,000,000.0    
Granted (in shares) 897,000    
Vested (in shares) (600,000)    
End of the period (in shares) 2,300,000 2,000,000.0  
Weighted- Average Grant-Date Fair Value Per Share      
Beginning of the period (in dollars per share) $ 25.80    
Granted (in dollars per share) 26.61    
Vested (in dollars per share) 19.02    
End of the period (in dollars per share) $ 28.10 $ 25.80  
Method and assumptions on valuation of stock options      
Contractual term (years) 3 years 3 years 3 years
Expected Company share volatility 38.60% 46.50% 54.20%
Risk-free interest rate 1.20% 2.50% 2.70%
Performance-Based Restricted Stock Units | Chief Executive Officer      
Share-based compensation      
Aggregate value of long term incentive awards     $ 10
Number of shares canceled (in shares)     933,000
TSR Performance-Based Restricted Stock Units      
RSUs      
Granted (in shares) 425,000    
Weighted- Average Grant-Date Fair Value Per Share      
Granted (in dollars per share) $ 26.13    
ROTC Performance-Based Restricted Stock Units      
RSUs      
Granted (in shares) 472,000    
Weighted- Average Grant-Date Fair Value Per Share      
Granted (in dollars per share) $ 27.05    
XML 132 R114.htm IDEA: XBRL DOCUMENT v3.20.4
ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Accumulated other comprehensive loss $ 605 $ 1,136 $ 2,815 $ 5,944
Foreign currency translation adjustment        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Accumulated other comprehensive loss (2,077) (2,046)    
Pension adjustment, net of tax        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Accumulated other comprehensive loss (56) (40)    
AOCI Attributable to Parent        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Accumulated other comprehensive loss $ (2,133) $ (2,086) $ (2,137) $ (1,896)
XML 133 R115.htm IDEA: XBRL DOCUMENT v3.20.4
RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Research and Development [Abstract]      
Product related research and development $ 420 $ 434 $ 376
Quality assurance 32 37 37
Research and development $ 452 $ 471 $ 413
XML 134 R116.htm IDEA: XBRL DOCUMENT v3.20.4
OTHER EXPENSE (INCOME), NET - Schedule of Other Expense (Income), Net (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Other Income and Expenses [Abstract]      
Litigation and other matters $ 422 $ 1,401 $ (27)
Acquired in-process research and development costs 32 41 1
Net (gain) loss on sales of assets (1) (31) 6
Acquisition-related costs 0 8 1
Other, net 1 (5) (1)
Other expense (income), net $ 454 $ 1,414 $ (20)
XML 135 R117.htm IDEA: XBRL DOCUMENT v3.20.4
OTHER EXPENSE (INCOME), NET - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Schedule Of Other Income And Expenses [Line Items]      
Favorable (unfavorable) adjustment, litigation and other matters $ (422) $ (1,401) $ 27
Upfront payments, included in acquired in-process research and development costs 32 41 1
Milestone achievement, included in net gain (loss) on other sales of assets $ 1 31 (6)
Milestone Payment Related To Certain Product      
Schedule Of Other Income And Expenses [Line Items]      
Milestone achievement, included in net gain (loss) on other sales of assets   $ 20  
Salix Ltd. SEC Investigation Litigation      
Schedule Of Other Income And Expenses [Line Items]      
Favorable (unfavorable) adjustment, litigation and other matters     $ 40
XML 136 R118.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES - Components of Benefit from Income Taxes (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Components of loss before benefit of income taxes      
Domestic $ (410) $ (2,396) $ (1,475)
Foreign (524) 559 (2,679)
Loss before benefit from income taxes (934) (1,837) (4,154)
Current:      
Domestic (8) (12) 0
Foreign (216) (116) (327)
Total (224) (128) (327)
Deferred:      
Domestic 9 (5) 17
Foreign 590 187 320
Total 599 182 337
(Provision for) benefit from income taxes $ 375 $ 54 $ 10
XML 137 R119.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Tax Disclosure [Abstract]      
Expected Canadian statutory rate 26.90% 26.90% 26.90%
Loss before benefit from income taxes $ (934) $ (1,837) $ (4,154)
Benefit from income taxes      
Expected benefit from income taxes at Canadian statutory rate 251 494 1,117
Non-deductible amount of share-based compensation (9) (7) (10)
Adjustments to tax attributes 26 (99) (4)
Change in valuation allowance related to foreign tax credits and NOLs 62 21 (3)
Change in valuation allowance on Canadian deferred tax assets and tax rate changes 687 (142) (875)
Change in uncertain tax positions (163) (350) (47)
Foreign tax rate differences (128) 186 (3)
Non-deductible portion of Goodwill impairments 0 0 (488)
Tax benefit on intra-entity transfers (338) 0 356
Other (13) (49) (33)
(Provision for) benefit from income taxes $ 375 $ 54 $ 10
XML 138 R120.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Deferred tax assets:    
Tax loss carryforwards $ 2,924 $ 2,911
Provisions 1,004 641
Research and development tax credits 172 155
Scientific Research and Experimental Development pool 55 52
Tax credit carryforwards 20 25
Deferred revenue 9 5
Unrealized FX on U.S. dollar debt and other financing cost 0 94
Prepaid expenses 27 41
Share-based compensation 16 19
Other 24 23
Total deferred tax assets 4,251 3,966
Less valuation allowance (2,252) (2,831)
Net deferred tax assets 1,999 1,135
Deferred tax liabilities:    
Intangible assets 228 53
Plant, equipment and technology 89 56
Outside basis differences 71 41
Unrealized FX on U.S. dollar debt and other financing cost 2 0
Total deferred tax liabilities 390 150
Net deferred tax asset $ 1,609 $ 985
XML 139 R121.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance, beginning of year $ 2,050 $ 2,384  
Charged to other accounts 5,036 5,287  
Balance, end of year 1,813 2,050 $ 2,384
SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance, beginning of year 2,831 2,913 2,001
Charged to Benefit from income taxes (773) 13 870
Charged to other accounts 194 (95) 42
Balance, end of year $ 2,252 $ 2,831 $ 2,913
XML 140 R122.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES - Narrative (Details)
$ in Millions, $ in Millions
12 Months Ended
Aug. 08, 2017
USD ($)
Dec. 31, 2020
USD ($)
subsidiary
Dec. 31, 2020
CAD ($)
subsidiary
Dec. 31, 2019
USD ($)
Income Tax [Line Items]        
Valuation allowance against deferred tax assets   $ 2,252   $ 2,831
Unrecognized tax benefits including interest and penalties   1,025   1,002
Portion of unrecognized tax benefits, if recognized, would affect the Company's effective tax rate   414   355
Unrecognized tax benefits, net increase for tax positions of current year   66   362
Unrecognized tax benefits, net decrease for tax positions of prior years   42    
Unrecognized tax benefits, net increase for tax positions of prior years       13
Accrued interest and penalties related to unrecognized tax benefits   49   45
Net increase (decrease) recognized in interest and penalties   $ 4   3
Number of subsidiaries file federal income tax returns in Canada, U.S., and other foreign jurisdictions (or more) | subsidiary   1 1  
Possible decrease in unrecognized tax benefits realized in next twelve months       145
Tax Year 2013        
Income Tax [Line Items]        
Notice of tax assessment, aggregate amount of possible loss     $ 90  
Canadian Federal and Provincial        
Income Tax [Line Items]        
Decrease in valuation allowance   $ 579   82
Accumulated losses available for federal and provincial purposes   6,530   7,441
Unclaimed investment tax credits and research and development credits   37   34
Valuation allowance against deferred tax assets   1,966   2,461
Canadian Federal and Provincial | Pooled Scientific Research and Experimental Development        
Income Tax [Line Items]        
Tax credit carryforward   206   192
United States - Federal        
Income Tax [Line Items]        
Accumulated losses available for federal and provincial purposes   814   636
Unclaimed investment tax credits and research and development credits   110   106
United States - Federal | Revenue Commissioners, Ireland        
Income Tax [Line Items]        
Accumulated losses available for federal and provincial purposes   $ 8,387    
Ireland | Revenue Commissioners, Ireland        
Income Tax [Line Items]        
Accumulated losses available for federal and provincial purposes       $ 6,765
Ireland | Canada Revenue Agency        
Income Tax [Line Items]        
Estimate of possible loss, amount not subject to full valuation allowance     3  
Ireland | Australian Taxation Office        
Income Tax [Line Items]        
Notice of tax assessment, aggregate amount of possible loss $ 117      
Ireland | Tax Year 2012 | Canada Revenue Agency        
Income Tax [Line Items]        
Notice of tax assessment, aggregate amount of possible loss     $ 85  
XML 141 R123.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)
12 Months Ended
Dec. 31, 2020
United States - Federal | Minimum  
Income Taxes  
Open Years 2015
United States - Federal | Maximum  
Income Taxes  
Open Years 2019
Canada | Minimum  
Income Taxes  
Open Years 2005
Canada | Maximum  
Income Taxes  
Open Years 2019
Germany | Minimum  
Income Taxes  
Open Years 2014
Germany | Maximum  
Income Taxes  
Open Years 2019
France | Minimum  
Income Taxes  
Open Years 2013
France | Maximum  
Income Taxes  
Open Years 2019
China | Minimum  
Income Taxes  
Open Years 2016
China | Maximum  
Income Taxes  
Open Years 2019
Ireland | Minimum  
Income Taxes  
Open Years 2016
Ireland | Maximum  
Income Taxes  
Open Years 2019
Netherlands | Minimum  
Income Taxes  
Open Years 2019
Netherlands | Maximum  
Income Taxes  
Open Years 2016
Australia | Minimum  
Income Taxes  
Open Years 2011
Australia | Maximum  
Income Taxes  
Open Years 2019
XML 142 R124.htm IDEA: XBRL DOCUMENT v3.20.4
INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Balance, beginning of year $ 1,002 $ 654 $ 598
Additions based on tax positions related to the current year 66 361 18
Additions for tax positions of prior years 171 63 55
Reductions for tax positions of prior years (209) (58) (11)
Lapse of statute of limitations (5) (18) (6)
Balance, end of year $ 1,025 $ 1,002 $ 654
XML 143 R125.htm IDEA: XBRL DOCUMENT v3.20.4
LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Earnings Per Share [Abstract]                      
Net loss attributable to Bausch Health Companies Inc. $ (153) $ 71 $ (326) $ (152) $ (1,516) $ (49) $ (171) $ (52) $ (560) $ (1,788) $ (4,148)
Basic and diluted weighted-average common shares (in shares)                 355.0 352.1 351.3
Basic and Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share) $ (0.43) $ 0.20 $ (0.92) $ (0.43) $ (4.30) $ (0.14) $ (0.49) $ (0.15) $ (1.58) $ (5.08) $ (11.81)
XML 144 R126.htm IDEA: XBRL DOCUMENT v3.20.4
LOSS PER SHARE - Narrative (Details) - shares
shares in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Stock Compensation Plan      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares) 3,154 5,106 3,763
Stock options, Time-based RSUs, Performance-based RSUs      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares) 9,551 2,598 4,185
XML 145 R127.htm IDEA: XBRL DOCUMENT v3.20.4
SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Other payments      
Interest paid $ 1,474 $ 1,537 $ 1,665
Income taxes paid $ 162 $ 172 $ 138
XML 146 R128.htm IDEA: XBRL DOCUMENT v3.20.4
LEGAL PROCEEDINGS - Narrative (Details)
$ in Millions, $ in Millions
1 Months Ended 4 Months Ended 12 Months Ended
Aug. 28, 2020
Aug. 04, 2020
CAD ($)
May 01, 2020
Apr. 01, 2020
USD ($)
Feb. 17, 2020
Dec. 16, 2019
USD ($)
Nov. 25, 2019
case
Aug. 19, 2019
USD ($)
Jan. 28, 2019
USD ($)
Dec. 07, 2017
insurance_policy_period
Mar. 24, 2017
case
May 31, 2020
healthPlan
Sep. 30, 2019
Jul. 31, 2019
healthPlan
Apr. 30, 2018
USD ($)
Oct. 31, 2015
case
Sep. 16, 2016
action
Dec. 31, 2020
USD ($)
case
group
action
Jul. 30, 2020
case
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2016
case
Jan. 03, 2020
case
Sep. 13, 2019
shareholder
Sep. 10, 2019
shareholder
Feb. 15, 2019
entity
Mar. 31, 2016
manufacturer
Legal proceedings and other matters                                                      
Legal matters and related fees | $                                   $ 1,672   $ 1,397              
Payments for legal settlements | $                                   $ 168   $ 15 $ 224            
Plaintiffs, Direct Purchasers                                                      
Legal proceedings and other matters                                                      
Recent suits filed             3                                        
Valeant US Securities Litigation | New Jersey                                                      
Legal proceedings and other matters                                                      
Number of groups of investors | group                                   37                  
Number of cases voluntarily dismissed                                   12                  
Number of cases settled                                   4                  
Number of groups of investors filing action, remain pending | group                                   25                  
Valeant US Securities Litigation | New Jersey | Settled Litigation                                                      
Legal proceedings and other matters                                                      
Litigation, amount agreed to pay | $           $ 1,210                       $ 1,210                  
Valeant US Securities Litigation | New Jersey | Unfavorable Regulatory Action                                                      
Legal proceedings and other matters                                                      
Recent suits filed                               4                      
Canadian Securities Litigation | Canada                                                      
Legal proceedings and other matters                                                      
Recent suits filed                                           6          
Canadian Securities Litigation | Canada | Violation of Canadian Provincial Securities Legislation                                                      
Legal proceedings and other matters                                                      
Number of additional suits filed, but not served | action                                   2                  
Number of entities, exercised opt-out right, pursuing action | entity                                                   1  
Canadian Securities Litigation | Canada | Violation of Canadian Provincial Securities Legislation | Settled Litigation                                                      
Legal proceedings and other matters                                                      
Litigation, amount agreed to pay | $   $ 94                                                  
Insurance Coverage Lawsuit                                                      
Legal proceedings and other matters                                                      
Number of distinct insurance policy periods | insurance_policy_period                   2                                  
RICO Class Actions Litigation | New Jersey | Unfavorable Regulatory Action                                                      
Legal proceedings and other matters                                                      
Recent suits filed | action                                 3                    
Derivative Lawsuits                                                      
Legal proceedings and other matters                                                      
Number of alleged stockholders filed lawsuits | shareholder                                               2 2    
Number of cases                                             2        
Generic Pricing Antitrust Litigation                                                      
Legal proceedings and other matters                                                      
Number of health plans commenced action | healthPlan                       7   87                          
Glumetza Antitrust Litigation                                                      
Legal proceedings and other matters                                                      
Recent suits filed                                     8                
Glumetza Antitrust Litigation | Pending Litigation                                                      
Legal proceedings and other matters                                                      
Number of cases                                   5                  
Glumetza Antitrust Litigation, Non-Class Complaints                                                      
Legal proceedings and other matters                                                      
Recent suits filed                                     4                
Glumetza Antitrust Litigation, Non-Class Complaints | Plaintiffs, Direct Purchasers                                                      
Legal proceedings and other matters                                                      
Recent suits filed             3                                        
Sandoz Litigation                                                      
Legal proceedings and other matters                                                      
Stay of the approval period         30 months               30 months                            
Perrigo Israel Pharmaceuticals Litigation                                                      
Legal proceedings and other matters                                                      
Stay of the approval period 30 months                                                    
Perrigo Litigation                                                      
Legal proceedings and other matters                                                      
Stay of the approval period     30 months                                                
Shower to Shower Product Liability Litigation | Pending Litigation                                                      
Legal proceedings and other matters                                                      
Number of cases                                   28                  
Shower to Shower Product Liability Litigation | Canada                                                      
Legal proceedings and other matters                                                      
Number of cases                                   2                  
Shower to Shower Product Liability Litigation | British Columbia                                                      
Legal proceedings and other matters                                                      
Number of cases                                   1                  
Shower to Shower Product Liability Litigation | Quebec                                                      
Legal proceedings and other matters                                                      
Number of cases                                   1                  
Johnson & Johnson Talcum Powder Litigation                                                      
Legal proceedings and other matters                                                      
Recent suits filed                     18                                
Number of cases                     1                                
Johnson & Johnson Talcum Powder Litigation | New Jersey                                                      
Legal proceedings and other matters                                                      
Number of cases                                   4                  
Johnson & Johnson Talcum Powder Litigation | Ohio                                                      
Legal proceedings and other matters                                                      
Number of cases                                   1                  
Johnson & Johnson Talcum Powder Litigation, New Jersey Division Of Taxation                                                      
Legal proceedings and other matters                                                      
Number of cases                                   2                  
Number of cases not yet served                                   1                  
Johnson & Johnson Talcum Powder Litigation, Delaware Division Of Revenue                                                      
Legal proceedings and other matters                                                      
Number of cases                                   1                  
Doctors Allergy Formula, LLC Litigation                                                      
Legal proceedings and other matters                                                      
Damages sought | $                             $ 23                        
Litigation with Former Salix CEO                                                      
Legal proceedings and other matters                                                      
Damages sought | $                 $ 30                                    
SEC Investigation Litigation | Settled Litigation                                                      
Legal proceedings and other matters                                                      
Litigation, amount agreed to pay | $                                   $ 45                  
Contact Lens Antitrust Class Actions | Settled Litigation                                                      
Legal proceedings and other matters                                                      
Litigation, amount agreed to pay | $               $ 10                                      
Number of manufacturers | manufacturer                                                     3
Mississippi Attorney General Consumer Protection Action Litigation | Settled Litigation                                                      
Legal proceedings and other matters                                                      
Litigation, amount agreed to pay | $                                   $ 0                  
Investigation by the State of Texas | Settled Litigation                                                      
Legal proceedings and other matters                                                      
Payments for legal settlements | $       $ 10                                              
XML 147 R129.htm IDEA: XBRL DOCUMENT v3.20.4
COMMITMENTS AND CONTINGENCIES - Narrative (Details) - USD ($)
1 Months Ended
Sep. 21, 2020
Sep. 30, 2020
Dec. 31, 2020
Other commitments      
Capital expenditures     $ 54,000,000
Milestone payments in terms of collaboration and license agreements, aggregate     360,000,000
Allegro      
Other commitments      
Potential asset acquisition, additional funding payment included in aggregate purchase price $ 40,000,000 $ 40,000,000  
Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc.      
Other commitments      
Milestone payments in terms of collaboration and license agreements, aggregate     70,000,000
Mitsubishi Tanabe Pharma Corporation      
Other commitments      
Milestone payments in terms of collaboration and license agreements, aggregate     60,000,000
Novaliq GmbH      
Other commitments      
Milestone payments in terms of collaboration and license agreements, aggregate     45,000,000
Cedars-Sinai Medical Center      
Other commitments      
Milestone payments in terms of collaboration and license agreements, aggregate     36,000,000
Eyenovia, Inc.      
Other commitments      
Milestone payments in terms of collaboration and license agreements, aggregate     $ 35,000,000
XML 148 R130.htm IDEA: XBRL DOCUMENT v3.20.4
SEGMENT INFORMATION - Segment Revenues and Profit, Assets and Capital Expenditures, Depreciation & Amortization of Intangible Assets & Asset Impairments (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
May 26, 2020
Mar. 08, 2019
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Segment reporting information                          
Revenue     $ 2,213 $ 2,138 $ 1,664 $ 2,012 $ 2,224 $ 2,209 $ 2,152 $ 2,016 $ 8,027 $ 8,601 $ 8,380
Operating income (loss)     $ (5) $ 460 $ (27) $ 248 $ (1,076) $ 329 $ 257 $ 287 676 (203) (2,384)
Amortization of intangible assets                     (1,645) (1,897) (2,644)
Goodwill impairments                     0 0 (2,322)
Asset impairments, including loss on assets held for sale                     (114) (75) (568)
Restructuring, integration and separation costs                     (22) (31) (22)
Acquisition-related contingent consideration                     (48) (12) 9
Other (expense) income, net                     (454) (1,414) 20
Interest income                     13 12 11
Interest expense                     (1,534) (1,612) (1,685)
Loss on extinguishment of debt $ (27) $ (8)                 (59) (42) (119)
Foreign exchange and other                     (30) 8 23
Loss before benefit from income taxes                     (934) (1,837) (4,154)
Capital expenditures:                          
Total capital expenditures                     302 270 157
Bausch + Lomb/International                          
Segment reporting information                          
Revenue                     4,408 4,739 4,664
Salix                          
Segment reporting information                          
Revenue                     1,904 2,022 1,749
Ortho Dermatologics                          
Segment reporting information                          
Revenue                     553 565 617
Diversified Products                          
Segment reporting information                          
Revenue                     1,162 1,275 1,350
Operating Segments                          
Segment reporting information                          
Revenue                     8,027 8,601 8,380
Operating income (loss)                     3,578 3,835 3,748
Capital expenditures:                          
Total capital expenditures                     289 230 144
Operating Segments | Bausch + Lomb/International                          
Segment reporting information                          
Revenue                     4,408 4,739 4,664
Operating income (loss)                     1,159 1,332 1,330
Capital expenditures:                          
Total capital expenditures                     282 225 139
Operating Segments | Salix                          
Segment reporting information                          
Revenue                     1,904 2,022 1,749
Operating income (loss)                     1,338 1,349 1,149
Capital expenditures:                          
Total capital expenditures                     3 2 2
Operating Segments | Ortho Dermatologics                          
Segment reporting information                          
Revenue                     553 565 617
Operating income (loss)                     233 222 257
Capital expenditures:                          
Total capital expenditures                     2 1 1
Operating Segments | Diversified Products                          
Segment reporting information                          
Revenue                     1,162 1,275 1,350
Operating income (loss)                     848 932 1,012
Capital expenditures:                          
Total capital expenditures                     2 2 2
Corporate                          
Segment reporting information                          
Operating income (loss)                     (619) (609) (605)
Capital expenditures:                          
Total capital expenditures                     $ 13 $ 40 $ 13
XML 149 R131.htm IDEA: XBRL DOCUMENT v3.20.4
SEGMENT INFORMATION - Revenues by Product Category (Details)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2020
USD ($)
product
Dec. 31, 2019
USD ($)
product
Dec. 31, 2018
USD ($)
product
Revenue from External Customer [Line Items]                      
Number of products represented of total revenue | product                 10 10 10
Revenue $ 2,213 $ 2,138 $ 1,664 $ 2,012 $ 2,224 $ 2,209 $ 2,152 $ 2,016 $ 8,027 $ 8,601 $ 8,380
Pharmaceuticals                      
Revenue from External Customer [Line Items]                      
Revenue                 3,678 4,072 4,028
Devices                      
Revenue from External Customer [Line Items]                      
Revenue                 1,566 1,717 1,640
OTC                      
Revenue from External Customer [Line Items]                      
Revenue                 1,432 1,452 1,412
Branded and Other Generics                      
Revenue from External Customer [Line Items]                      
Revenue                 1,248 1,248 1,191
Other revenues                      
Revenue from External Customer [Line Items]                      
Revenue                 103 112 109
Bausch + Lomb/International                      
Revenue from External Customer [Line Items]                      
Revenue                 4,408 4,739 4,664
Bausch + Lomb/International | Pharmaceuticals                      
Revenue from External Customer [Line Items]                      
Revenue                 759 885 892
Bausch + Lomb/International | Devices                      
Revenue from External Customer [Line Items]                      
Revenue                 1,313 1,524 1,505
Bausch + Lomb/International | OTC                      
Revenue from External Customer [Line Items]                      
Revenue                 1,432 1,452 1,412
Bausch + Lomb/International | Branded and Other Generics                      
Revenue from External Customer [Line Items]                      
Revenue                 838 801 784
Bausch + Lomb/International | Other revenues                      
Revenue from External Customer [Line Items]                      
Revenue                 66 77 71
Salix                      
Revenue from External Customer [Line Items]                      
Revenue                 1,904 2,022 1,749
Salix | Pharmaceuticals                      
Revenue from External Customer [Line Items]                      
Revenue                 1,899 2,022 1,752
Salix | Devices                      
Revenue from External Customer [Line Items]                      
Revenue                 0 0 0
Salix | OTC                      
Revenue from External Customer [Line Items]                      
Revenue                 0 0 0
Salix | Branded and Other Generics                      
Revenue from External Customer [Line Items]                      
Revenue                 0 0 0
Salix | Other revenues                      
Revenue from External Customer [Line Items]                      
Revenue                 5 0 (3)
Ortho Dermatologics                      
Revenue from External Customer [Line Items]                      
Revenue                 553 565 617
Ortho Dermatologics | Pharmaceuticals                      
Revenue from External Customer [Line Items]                      
Revenue                 279 355 457
Ortho Dermatologics | Devices                      
Revenue from External Customer [Line Items]                      
Revenue                 253 193 135
Ortho Dermatologics | OTC                      
Revenue from External Customer [Line Items]                      
Revenue                 0 0 0
Ortho Dermatologics | Branded and Other Generics                      
Revenue from External Customer [Line Items]                      
Revenue                 0 0 0
Ortho Dermatologics | Other revenues                      
Revenue from External Customer [Line Items]                      
Revenue                 21 17 25
Diversified Products                      
Revenue from External Customer [Line Items]                      
Revenue                 1,162 1,275 1,350
Diversified Products | Pharmaceuticals                      
Revenue from External Customer [Line Items]                      
Revenue                 741 810 927
Diversified Products | Devices                      
Revenue from External Customer [Line Items]                      
Revenue                 0 0 0
Diversified Products | OTC                      
Revenue from External Customer [Line Items]                      
Revenue                 0 0 0
Diversified Products | Branded and Other Generics                      
Revenue from External Customer [Line Items]                      
Revenue                 410 447 407
Diversified Products | Other revenues                      
Revenue from External Customer [Line Items]                      
Revenue                 $ 11 $ 18 $ 16
Revenues | Product Concentration Risk                      
Revenue from External Customer [Line Items]                      
Concentration risk, percentage                 41.00% 39.00% 36.00%
XML 150 R132.htm IDEA: XBRL DOCUMENT v3.20.4
SEGMENT INFORMATION - Geographic Information, Revenue (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Revenues and long-lived assets by geographic region                      
Revenue $ 2,213 $ 2,138 $ 1,664 $ 2,012 $ 2,224 $ 2,209 $ 2,152 $ 2,016 $ 8,027 $ 8,601 $ 8,380
U.S. and Puerto Rico                      
Revenues and long-lived assets by geographic region                      
Revenue                 4,791 5,164 5,011
China                      
Revenues and long-lived assets by geographic region                      
Revenue                 341 368 361
Canada                      
Revenues and long-lived assets by geographic region                      
Revenue                 331 339 319
Egypt                      
Revenues and long-lived assets by geographic region                      
Revenue                 243 218 178
Poland                      
Revenues and long-lived assets by geographic region                      
Revenue                 238 231 218
Japan                      
Revenues and long-lived assets by geographic region                      
Revenue                 226 241 226
Mexico                      
Revenues and long-lived assets by geographic region                      
Revenue                 225 228 211
France                      
Revenues and long-lived assets by geographic region                      
Revenue                 179 201 205
Germany                      
Revenues and long-lived assets by geographic region                      
Revenue                 144 150 170
Russia                      
Revenues and long-lived assets by geographic region                      
Revenue                 137 180 154
United Kingdom                      
Revenues and long-lived assets by geographic region                      
Revenue                 86 115 117
Spain                      
Revenues and long-lived assets by geographic region                      
Revenue                 78 86 83
Other                      
Revenues and long-lived assets by geographic region                      
Revenue                 $ 1,008 $ 1,080 $ 1,127
XML 151 R133.htm IDEA: XBRL DOCUMENT v3.20.4
SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Revenues and long-lived assets by geographic region    
Long-lived assets $ 1,567 $ 1,466
U.S. and Puerto Rico    
Revenues and long-lived assets by geographic region    
Long-lived assets 725 656
Ireland    
Revenues and long-lived assets by geographic region    
Long-lived assets 328 255
Canada    
Revenues and long-lived assets by geographic region    
Long-lived assets 110 103
Poland    
Revenues and long-lived assets by geographic region    
Long-lived assets 83 90
Germany    
Revenues and long-lived assets by geographic region    
Long-lived assets 80 68
Mexico    
Revenues and long-lived assets by geographic region    
Long-lived assets 49 50
France    
Revenues and long-lived assets by geographic region    
Long-lived assets 34 30
China    
Revenues and long-lived assets by geographic region    
Long-lived assets 31 27
Serbia    
Revenues and long-lived assets by geographic region    
Long-lived assets 30 27
Italy    
Revenues and long-lived assets by geographic region    
Long-lived assets 23 22
Other    
Revenues and long-lived assets by geographic region    
Long-lived assets $ 74 $ 138
XML 152 R134.htm IDEA: XBRL DOCUMENT v3.20.4
SEGMENT INFORMATION - Major Customers (Details) - Customer concentration - Revenues
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
McKesson Corporation      
Segment reporting information      
Concentration risk, percentage 17.00% 17.00% 18.00%
AmerisourceBergen Corporation      
Segment reporting information      
Concentration risk, percentage 17.00% 16.00% 18.00%
Cardinal Health, Inc.      
Segment reporting information      
Concentration risk, percentage 13.00% 14.00% 13.00%
XML 153 R135.htm IDEA: XBRL DOCUMENT v3.20.4
SUPPLEMENTARY DATA (UNAUDITED) - Schedule of Unaudited Quarterly Consolidated Financial Data (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]                      
Revenue $ 2,213 $ 2,138 $ 1,664 $ 2,012 $ 2,224 $ 2,209 $ 2,152 $ 2,016 $ 8,027 $ 8,601 $ 8,380
Expenses 2,218 1,678 1,691 1,764 3,300 1,880 1,895 1,729 7,351 8,804 10,764
Operating income (loss) (5) 460 (27) 248 (1,076) 329 257 287 676 (203) (2,384)
Net (loss) income attributable to Bausch Health Companies Inc. $ (153) $ 71 $ (326) $ (152) $ (1,516) $ (49) $ (171) $ (52) $ (560) $ (1,788) $ (4,148)
Basic and Diluted (loss) earnings per share attributable to Bausch Health Companies Inc. (in dollars per share) $ (0.43) $ 0.20 $ (0.92) $ (0.43) $ (4.30) $ (0.14) $ (0.49) $ (0.15) $ (1.58) $ (5.08) $ (11.81)
Net cash provided by operating activities $ 394 $ 256 $ 200 $ 261 $ 234 $ 515 $ 339 $ 413 $ 1,111 $ 1,501 $ 1,501
XML 154 R9999.htm IDEA: XBRL DOCUMENT v3.20.4
Label Element Value
Accounting Standards Update [Extensible List] us-gaap_AccountingStandardsUpdateExtensibleList us-gaap:AccountingStandardsUpdate201616Member
EXCEL 155 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

<0?T$XO9!.!OX0W1Y%G_.UC*X+])/>@SX!]KHAK+T#&:2YYWF2 MT>>J$7+5L-,?'+R*WH)2!1JZQ=R))$8$%8DL5(*C3DD$A8')MZBA6:,WH$OS M*6RZ'@;!>S)@[7"-NKTQP 6C9S.U@J=PS/+[K!G&GL#89VF>(]O=W0"=78-I ME>$.$>P?KE\T1P23C'O='DR">3[T4S<&1>= C7_*#)V_$@/WO)4?JN3%RQKW M>UV8\>/-172;@PI),3=L%P9S'%U_CSD&A+I:?L2 +Y+[.[! !,J!<$7?9[:) M4];^I$9;O\(7R3'7Z-4PO' #<>[!":[TU],/E^>6RR^_PZ@C&!456 D6/<@B M4'\4QWWYP&.'*F]\AZFK+S48P=$5135KS,6J&;M89LMN+UX QIA8:]CM.S!X M1@?!!U ZT>ET"I:OCEN3^4M2YS"X>[/ R.N%"7W"7!@193!?"F)_-'0@>I,Z M.*\!JC5&GXU LS@C3>+1^3?@S!BG6X"-A\.> \S"X(%53U/8LK>4?@8IK54I M2.A*%>Q)W&P M"6%U<&VP#^KE?IV4PKQQ'63HM9SE$M6J814#I0_= M=2J*P+'!=VE>@$7Q0D2! M6NE,-#8^RSL*66FCY9=,81(*:0FNG*-CG!>9>OJ,.XBYVQ],<,KW'Z^>B=#M M N[_^!1RE5T59B>CT&D0\^#S9BX'M=0A8-*7^D1=?4!=NGD+. M+UY3WV.L3_\X?_OYQA''3SGRL=7_5_-Y"<+'RL27*!*>?3+N>/P33N? .$O% M[$N!QIW69*OU=S#T&IC_H^QI5S^G .,_3/,/[K0, MS\G[7$N1@KVJ%W/#64\2F=V7+V+21XS!J^ :G2[JWU_"1WJ3!JB7SPJQ6(H, M&'2E,.MZGA>K9^*\9>B3OA8*UT6=Z&* RZP$Y88!(2,P43"!KP#COG@QW5[/ MVV4WJR<19?:G (>3-FF&CD>@U%Y.]+W>Q!/(/)V;'OS17G2QR6#.3?3+.<9X M7KZ#PQ-DLSU_[#VD: $["7*$KBU!?YZFJX5XGH^R8\YN;S3V$&UFUU2^]D'-9;#]1R\Q:1B.88#MEED].2,6 F1ZNK%VR'/-EZW9Q_T3 M#PLPM&=SF=J!?R%2LD3.>;G9]!Z@\36$ <"!]!#<+!,07T* U6"] 2_*> M4D(O(^9>AUFV>]+Q[#P]EXN+WDJ*@>4OL /T3,/!V//K[+ANJE]N3D\-O_"& MWW)5YS>2[+;9J"$9#T:>:8#3>G%@P.E[U: M8JI(,TL08C,Q,!,JHA 950_J,*),7MG43Y57%!>DF"*,QKD"BFPVAFG$PG;$ MNU0956L@\\WA'$-M^F4L1L-LHXX>PHRF'LX!QSF.Q&2_$%#$%'*5_(JI5TY# MZ#PX)<$Y).8%$JE@"H.ATJ4V.43_4$ ^?C@BWU)8ZDW9F,9;(L_HYXO;8 #! MV#9I[,'8C:-N#X#;[VE0NT/SBAK4^MWW>8KQ/'C+2@>S M(?]+%JK)M=H<9)J7-G\,;]#2;N2JTF4-G>W547643+S\D[$0MI,]7N)?K]/: M8\]>T+:]MA"*:\<:.RNU=*+HEXP\0?(12XT,]&+HH=(: M=K>@R( .53&K%1:(H>$BBKN:2S$S;T:#-ST-9KD6,B4YXPJC3"K>)B=/PA)P MG^ \FQDH)R"]+!M, ():ECOJ5/2LSM[Q M!*[A 5]%D.2N)() A=?(OUA+*%-8E;K+"]!.Z09L!9&)1(EL1WWJ9:;K]4KU MM5V1!#5Z."TUQ23?+9.(*R<@A=5G17X/2&9]?(8PEPL,[H!1J$0,>UVA\J51 M_E[+*?:^/9B,1#OJ-$VQ),^/3[0$LV_ '3T9G*$_>E.OT$%RHJ$)"#S#./F4 MWVL!R^IC"-X.EE7\+5\C5RXV6?NDO\)DA\-!9WC2/^QTSJ]A0+,TF!S+'0J> MO66FD9MI%LRTY61L3]CM3'K/G;#7=Q,F!]&5EG98=A"X5,VY^J/QY(ES-00% MSR4/4+C5LYEJ7Q)MSCLL8<7M V2"VCCL=+OC01]V$L9F MDUIY7,#I](5?OS M ^!]+%D2]>'[/*&2S*?,W^D<=D:PWLYXW,'(QM,!,*2S595/;7^ M2;^#8:GLPN-:6[?E-5]Q_=\4%L8%R60:8CF_=GZ(Q\,:GRRUER M-7"#'7K83*C@\_PABJ-,O7+MT)ZD0^4;[77+7ISV(IWIE0TF+A$BTNXL <-E!A805)@HQ[\ M8"N?/.=(^_!P%^NL\?\M]'L.$T#@X8%KLXU!5XJEZUETS91^I4R[!O2;'_5. MO!58H6^[M%J9++:5X,(:822G=!V/GKB5_6/70(FUD=2U1QV"EVU#Q;B'II6) M;=XQVS:_UPF0AK'A274Z"Q@8X5YR'RMU#%@IH(IM']N &;COW*-: [46ZD\] M@:Y+M5TZ@4&NQ:B&SG=4N2F#)_\9'$"BV%.61H2NJT+=J8RKP;GAYCIHJ)NC M^R3 I!:%+G-SA-+U_0"_ 88M2Z]9L76GC//NEK>D@41QRNUU0C(Q=UKJO67>L5SOJ MS1O8,9Z0:Y(\/[V(3@8Q:#G\"Y#4I2TF1C\K\S64?HT:ON]AL[0_QG:D6V"8 MU9[E966LQ-*VOI7?6$?^/ZX2U^M'%Z6Q-HBXD7P\N8#DQY(L*/QN%:N(]9_KD@BLRIGF)0W( MV'M4W'W?TG"'%>JNM 7BE+G^C-GR4SPH(/H(ROR.B43[029/_9 QOVUY=KN8 MG>@.AX?=B3$D6^*,'EC/C#,:8@S#C#:6,?&WE]2Q6ZEMCS!N)"#1"7Q_PUM7 M-C[L=OKCP0FLK'\0[!/-XW,XA;VW@MO>II^#5XW9<;;:S$D%AF%Q.&-K;,40 MMWMFV3#GTP%,4)Z$CE$AQDP*4">_XLD?I=6(QK\OL.H1"4>Y(Q&\.%%W8GOY M&A$/6[<-!&:FM"AG>>_FI(;#<$:7!4YO;EV!B6',@%];F/2I3.F8^3NQ9_S\ M:$/#;K5G=K!*QPT6U4[6]8J?N+KD5H*IJ&MA=N95ST1=P@YP.%C/S.WOLZ-' M&7HX[O6 [+LO9^AMLV$74YN\ (?;# ^;!%QPTL&5[C=@/J1D@"8B]EQW49"O M,G:R_*@S&,#:1_^W+.]S6A F;:=WWQSWF$3[;1HUF:\&VMB"!8,&UBZ+CGF"LJFT'Y"2W.QK7="K!JPZP_D:GB[#\@ M'\_ "NAA5[.M.[ FD^O=6]8\7@$;V&KN :\**2ICJ&J9MZ(F +3D>+1?/:0/N?@@UGCL4Y M&/N>I TRZ*1.JE]P=KHV4VG!R:++%9I[*6/)YZT^@!"A)9SSRSX5M*OT&AG5Z^;R\" M9/O5//HJZO_0G1R>_WK8Z0Q.^@67TIU\ J!S2)&=^I+KD9FN M2-7QJ3;@MGH[.*5FP HY3UL!7@5&:1NVS.\H]D"*8'99)R:5:31O7+\N\J^; MZ%<3?-H12J)*KV;[I\OCI&QNA V5YD"DTBAN"A56-;6( :ZOX1;*O^@&3[V2 MMKS3>0WD4%7-)D4C-='V( MUP2\XTP'?0(%IZQT54$0CZ-6=6=IA.E!(V98[^_Y- M>[8(!;/4A^90C_TP$DT0N,/BTDW0A7B@S[!H-2CF,L$H='N!QL[B#.M-(":M M*_%H&[&A K>8#8:56$9G90:M6:O=Q]J$1+#]SC5@BH2#J\)/=>(GJ#Q&,UG$+HC M+C7O3,8@K,.NT\#.#[MRF4QS_R2,@5^T%(YC7V5#K&RWV>QAC)XQ.:/31?G0 M2LEGO2% 1 5+H5)] @4R#O6NPQ[K#:=@64&'E>EC3J;^F0AH!=I8?GALECZ; MRYP3!49!1TXP%.!>%:1A]KNL?!15H%?,2](GO(M%#(Q"YA-,H5J1GL@Z86$)\Z.S;4*Z 07N+UV&>EY*@L&!4@9]B- M=,@S^VVV> [DCKNJM]KN:JDW#@<$%-6XD0@_56]C]:81''KC1'@%7ULIN$3' MAMC4CL$I26)"<\418SJD+O&=6&,:-\1)G=&I-G-$;2*6@LB3XR#ZB##P!*9( M[8XE_=F0:V[X7!Q3N@5V=JZRRIGUKMZMD)SQ2KS37+9R!MOU5%.I=S^F-*S0 M1[48KPJM/D JG3/")H_5O#3U3J.^4>Z(;Z$FQOZ,ZNEU(XW6(F.CA^<\3>)' M6Y"VGOB 0H*1RO<1I,8SY^C!99@.H%/6W+.[/(#0#:%?M\-0GD:%Y8"RO2=$ M'W^4!:@-?"ZK-L&Y'F'TY]%N*U.J_:U-E2B]/[[]?/@!#.9>=X*!W -SM ^M M5I_NH7>7]-WS"VS#5#*BZL45MJK4J=?050%NVB"_:OJMC$R1ALL3VV%.Y\'8 MV"6E#@ZSG,2R-D("B_()I54AH3O2-C1?.:C!'I-4*(\21%-ZV5X\V33[^C;W MB)49.B1!M8>UN&T)-MPY M<%M=+824([^P-"S?1Q:<%B92,@,;W&B47V;8Y[C17..#9T,R( M=?8[)H-E!MI[H:V4_S]N[LG'S3UHDF+1E):60A^0Q>(2M(J:UEZ4.Y'+#"P% M'4+3ROW".X]''T/J\L4^>]8I'R1,6X(EBRU'V>!1O'@HO!$/S8)_O10MMX*' M2I^/;>."#5M;"6+GT"&OR 2^7$3C.QQK1,&*N3G!W+5:.$7 M3STBJE7V[CPK2EG3%,/F&%]/O'JCOE>Q[HI!@_*5I]G)YEA6'8UQ-K-W3%3; M"5-35]\$6S2O4["3?EM@INBY]G(<2/&"BQV1]O0F:2_.%8'S9+Z=82JU2O8\ MR>+^;@;WJ?G^0_1>.W37+$Z].YZJ\N#Z]V9P^FH&G Z_RR:S-]HO['.N<3#4 MN;_\3KU&T.&78KA73V !?31>0/IM6M.,ZKK M-3$!-Q*@I2EG5%1>)(#@5@ML,:+/=NC4%3YM6VZMDM+K*(+X!O9.H0Q*3#3/ M?MK#_SJ';5:]^&#AHD!#:@R@'QPE-%;](&7$WY0B>"NXY]H/05[++"LWZ;W MA/<^ !KUQLC\W='AQXM#_/D@2%24%,0W'K?VK8W]3B5?E#3WT 'OQ?HJBJT: M35S]J0VC#;:M)'R+:Q.Y-G:GS^US1;.\SHL]T"G(7PD.U"9_2J;,0B@ZHY_/ M3R_47315B3GM\PYCQM0D1Z?E4W2"/C[$49+<2^F9^,PJW,00<[%?ADWE72:7 M@<=SMI=Y3S/6,\4PL6:V** M@S T.= D@,Y590IRSTSS58FNX:?2GN3[AZ>XZDRFK H=)]GS;EARI&0 M<<#=WP_@P:L2_1="R;.ZNO@#&Y[5\(#^M^A =?.@[^LGS2B=1 $:TQ,0T.FS M-9U1<@UY2NK)\12R"HN00.W1H<3\[85F9:C3;7\3U:+89*!QZ#P&%(3R7C1J M'VU03-/$.ZU%M#69X3&!@-?54LMNTDS MA8O/N(:KK6>M/Q]8*G,ZQ&S+?V?;S7C*%#_AO28AYE7DZAB";27@QAC]&$W7 M!$2/I#RJ-"^WGU7LT9=%FC47_07R9ZV 74AYF*9KE6Y<$T/+WK02+N TH;5Z$-FQB;V+6=[0$CLYRI%94Y)F8!ZM=>F/U4 M?G*!\7SI)=Y=>&76/(7[\<2BZV?9@LZ^I5=F4 FCVLG>?A-BQ53U^C7Q_;\ MUOO=8WC4ZRI+EUJ0-I(#O/1PFLF#TWC%D=:N-#XF=>E8"FB>3Z*IQWBLIM./ MC@["9+H-?NI/&&CU$^_R-MC\XV]P:N^#@[$/*P?O(R4FV=(9@G \_.VGTX;# M[;O @L^F\YJ.N-1&T$<5O="#JW'8*F8%(WGC63&8A*7DG#1G 7'HU6M)0\\) MMB\5=3;CS@#7,6B&:2F;S?6GF2+W!;"9L8%TE061!?AF9=ZH1RBW//_69CF. M^#+:%Z!,*;9 WSG"130!,A6==NE_U&"TI3B0_L*A#G.3 *8.K@!+1]%9KN.- M6DCB@316 C64R(]D%)-F72$M8I^;'/ANJ4"/4&!:VP4YL])4_?H MD@M-;+VT#F>L\C5_JDKBJ7C:V8#QV;'U\8#BBY_M=]R>^0KN/LZL>;5+!(;S@$?]&'< ]NT MSR5LVK\@:<$0J&R.IGKP.2^J>V\U8JUK)_S4&VZ*_IH=?=''I".-9@I )@-X MR\\ BTZM: H$78?+[2DDYD,UB A=L7S05@CZR7TY+$#G>6".[+:#AOZ7(:FK-Q]B4;3E@QF\9><2_YPR92"0;N2]/[.?):IPF]'N*\S_H>:BZ_"?JYQ..PL[S 9(;/[ MVCUU5FQ@9.4N7-3YM%#*%T\_XVF.5F#M))>MQPS]N*\L:V],9YQN@P_^8J#- M;X#B:1H?DB9SQ;=@'OC$YB=[!M,#)$*;"SY%DO_9R%+P1><= $"LA/F&5N=^ M[=41C M.JP@<9TF]IOB/DO$G'HOZ#NCN'R'4 +;<$&!, )A9-O@(088:;"&T^D4ZQ?) MH,'*H0M,_?N]_/9TKT\7IU[L*(@K L0,Q@^\1UHZH\DSB?N=DW@X.J%*9N,D M$KBC5WB9]],[<;,QP#CN#(;Q",SOE@'P\N,#C+J]N'O2"@%>?GR DTXO[G5& M;0/@Y:<,,(J'@UXK#N#R$P;H#N/>>-@* 5Q^;(!)W!U.XM%@T(I$N/RT <:3 M;ML >/D) YSTX6\K$O'RXP,,NY/X9-"ZC7CY\0'&@R[L1"L.\/+C TSZPW@P M;-U&O/R$ 8;]N-=O12)>;@Z \K\YR G0 2QC--D>9/P*+U\'@T3[.R,U#3'& M[]FTZE'D)!]] JJTU87;,F(/A,/> 4F6QJBV)=?85 ]&JAI2%R]YJH(AR-<9 MGR9KEA(($IKP-)V+4MTM171SM#HZ]8\HU#AX8U F7V+_L1$9PV0F"X+)C M[_!IR[3!9<>*P67'8 U(6J=TS!!>[K2.[0@W!+#OIC1I(S,0$)FY%2IAJQ; MP4SKDE,0VOVCL)Y'4BV$$:9)+C''@R=LZO,3;#7 Y6>78XOCU4) M_\S@;Y&OX=]R(65U(2KQYC5HT3MY#DX$?9<]JW[]QI;WZI\A4.B8YEE2_IQX44X +B M W!_GN>5^04G6.?%%P+OS7\#4$L#!!0 ( *>)6%(C8W^'B@D )\9 9 M >&PO=V]R:W-H965T%TNY=)_>^?-OONS07!7<]4PJ--PMC"^[QU2[[KK2" M9V%3H?JCP>"P7W"I.\='X=F5/3XRE5=2BRO+7%44W*Y.A#*W[SK#SOK!9[G, M/3WH'Q^5?"GFPG\IKRR^]1LIF2R$=M)H9L7B76)'#\N1&G0BD2!#6^U3([S9&TL?UY+?U]L!VV)-R) M4Z/^*C.?O^N\Z;!,+'BE_&=S^U'4]AR0O-0H%_YGMW'MP:C#TLIY4]2;H4$A M=?S+[VH<6AO>#)[8,*HWC(+>\:"@Y1GW_/C(FEMF:36DT8=@:M@-Y:0FI\R] MQ5N)??[X]/+\?'9]/KVXGK/)Q1D[O;RXGEU\F%Z,ZXR=0EVIET*G4CAV)EVJC*NL8'^?),Y;L.8?.T[=;T[= M#Z?N_[=@_@_$L>M-E:$04B;"-5WKL"YQM62JL1QI@?&F%",=U MF6_I4O 52P14^%9)&W4H^%?!2KZ*RJ5K7WA6E3B/-O,TE^(FB*/#72E2N9 I M(N\&&:6DYUQU(719P3)C5UUF;#!9V%3"/"@O$$9:N!Z;/&[ ?343H>A$QZ1G MDA#CSFB> (O2."<3);"<>WI-%I7&0P> MV(TR# E9B.;SDI"-'D7)T MYL(H)'<\>,O^^($ER,CACJ4&L) ^+P6WVTN[M#;( MCZ_/!"5RH\QRQ:[60)"X5\]CZFYG]>Y%WG-IA'-=*P8:CP8E6JYG+UXW?G_H M[=Y.Y#6;P'^*L/_3 XRE=U4B72[9-8>"H@81AMC26.[#>7XKI_"TA@:RQ1W( M[%!<&[(#KYI. ?Q--,KO@IU?[PW'@S$\6$B49UF8#/!S1HEISWFT N ? A>[ M2@-NUC!QNQ3 AQ1Q90ZR&8>LR(9[96[P@!!Z.1]>O0+2J2B1">*^4O$5U&76 M '!*3I4WLBB(B2 AG"+ $E>E.66WF5XH7A0AC[ 3.D MWL7E;T284MB%JHPUN;A;*9-ZK@511V,K(LW+91 ,[F2V6H;\A[#S[ S>G*[$ MQI?.&2A"=3"&@)")*23D+%50:N46E4X;)?\WT\'^P>],"7C]:4J7 MFDL F%&^Q4.-_:'R"#"F(CTYT^C-:7R@ AV*UH)9N>"P VJOZ1$\M:[RTEJT M)H1)$H+0K71F#56YYV3IGPNWW]M-X\-_/VM?IMY$!XP&VPX H;6YD3S4N-[/ M1N4ZUK2D*)A[*./:0;=VRS:6#Z,X:KH=@(5,45]-C/^VY[FWIJ3$;(' M:> @H[IE/_:>FO/"WQ")ELQ,)YX<> M8W(2DL7]!N%'W.0LD2C^L =3E5(O[MA+G",3^;TJ>/+,WNYG M_34#9S*,30'2ZC'@YFA#U@GT(7P3I<32FN3'OLD^ST^G%'$,I2/%Y.MW,JI/Y?(J/'Z>?SMC[ MR\]L/ODT[83@;JF="4R2BIB_Y#;,23[HOX:PQRXU>R\26W'4]M%KFN.&;^YC MR;6&M:G(FG$M5"=\EQJX/IH6MWST*[#?GC\@']GVD\\P@W3"@LZKW0UOK(!T MG1;V$T,]QM39V14:X2%[^>O5WO[K 6C:U$)D,EIYKR:6SEC)'?6<$ZC.+64# M:_ &_S"34=/+G*^RF/X3 ^RL$G$(%0SKJ.V(J916643HLGU+4#H #J*Y8D5E I0HLE% M,P/7MQ<[+@DT2).FH)QZJ!-<%XP!A(1V)Q"P4Z6%PBD7*\B0_U#2J M3YN=9.E2:/(#0,?<^4\0+V8Y5*JJJ#,4C62-3U/%95'[T;5. >=COG!UQD(1 MVL[+;:.1/TRBZF8"1ZX-7(5Z91:PE$ ) P"2+UJO !&% H5';'16#(F6$":E M'%V4\#3J(%&NXDS!E^"1"]6YJ(N9I$)5\C3@].1A-9T;A>G2.C4VXR!G3$BH MZ8BSP _%;WOL"GZNN X0AB&V-HJZ_0?6-P83J]:7==2> 0Z/O[>-IY_(HC">AHG0C11:V(IU&NO8V*Q(L98J]^K+: >9?CZE\:) ?2F[KI= MA.T]=H/;;UV: X%E^&F [B"A2;P_;YXVOSY,XJ7[9GG\Z>(<<0R/@QH+;!WT M7A]T,.&$GP/B%R3T< 6?&.]-$3[F@D-U6G! U0]9K_Y"!S2_R1S_"U!+ P04 M " "GB5A2#&Y5>E8- !9) &0 'AL+W=ON3:J5*/)E59BD;7)KY:;TR2N:\:%F?J3C4_KVX,KDY[ M+KE>JK+652F,FKTY. M>O8N)G@E^T>J^'IP+TF1:5;_2Q67^YL G@52ALH8X M2!P^JW-5%,0(8OSF>![T6]+"X7G'_0/K#EVFLE;G5?%/G3>+-P?I@V&(&MSHA%7EU1!.EV24N\;@J<:ZYNW=Q<>KBY\^B)D$HKJJR6=3BHLQ5OLW@%!+U8H6= M6._"9SF^5]F)B )/A'[H/\,OZM6,F%^T3TTUAR?[V2+O"G^ M+GZLEM/3R[)1IF3Y9-%1.DWN9*$?MN[AYK5I8,/WBM)-551SG=4=B5/K\[%X MCS1F:CW3*AZ%8Z_8VY? MH5/G 2K!:*6Q0:XGT_N3FC/U4)"LTRUC.6$]\3UI_/^BA5=JIQ)/_KU:)9R&))1EB+VX=MZ=B S)KXJ8=,];!:O7%R5Q6-'$C2 W*. M4,NE)RY: P?SQ%FM<7764C8JZ/1'B@=Q!E$@&)[,Z,C[TFY7.L_A=A>R;FB; MJ9&4+ MPU$^N)3%\0[SSHMJ2@Z^;<\.%JEJ[ $('4"/I'XN1+\(AM5ECYTZ6CBO9 ZE M@A^QEY+HF4): DD%&D.$1JZ8A<@*SKDN^_3>\$AO3IIE _',>F"1B]E,)E!%U:1&_U1W M&6F7L?IZU):ZZ1@\YQ=(>B4*T-?N^=%BL6>C9TU)J,G2@OU_I_?[WM!_0/': MM0Q\-56%5I]=^]"[U%0UY!Q(!/-RDRU+-.I4C)T_;6UMZV^M1+:0Y=P&1@T5%H,-6&R[[G7(&E5(, MH/"*(PO3L0XM"1D6VZ)K1W@ MW,2W0K@C9PT!VMZ1!@Q-HCO<7?,]X,#6ZH.BZR9/Q.4N3(?]/K=\M"\1;%3V MAL+DE:IY7T0M3?N;5$0>>B(^M(;VA]\#>71>Y/^N)T,I52]MV%$0 1#K:+KN M/0^/)"XZ>Y(+(I@T"UI1OXV5HLK7ON MF7AF@F*;$-H,%8P<)"S=*XP^B:X*B9M;@48QCJA1:_5RH60!PMX0",\*W'&T M\C+Z[;306<'9A&*':D&S%C-3+5W1H#Z&;WB MN0RIFCVJQ2A/][GDDB$*!1M.UX(_S0*;4 ?/ M1KG$:)^AXD"+FB/ )1NV!!L3JJN]!KOK#;6-%SD2U4H8"+FBZ* A.#?1P09 M=I (*$710[0M3R9O]K!MB)_@VMQ7G>JZ/5:U,H6_:P7;/U(%/4W>N QE2;OH%>"EA^##\K3SCME.[5 M]LSBB>TI]O;!LP.+M[._(HOLZH8VQ?UVV$C^0DLHD%AE\OP"-T49 +'/,2NX*I.P%>/3NM'XK8B_V4CTDTX>-X M'+MA+? F?BQ"SP]#G"?Q9"<8HU$D1N.1& ?)[A8Q\((Q,0B3$3ZCD2\^50TV M[W$X%"GV2/@X]@,^1JG_J%/ZDB;89C3A8Q2%[NCWFD112I_0 71[- FC2(30 M-1SMT22-4S&)2!<_")T6VQV%B+Q1DN(SC4;X3+!@TQ,:@3>*[#9C$HF. M*6#YT<&G'FA#*+?H.J5<32';B(P=\P*R_@=T(Y34T6KR2,.HV3[I*/*/10HO MM#RG"E:@P:-4Y%A4\%F,*,"]<[G2Y)T7)'VN>?3H M;ZKA363VOJG]'^>@7?M]*8K#E&(W#$<4P4YN,\KC- ] M;8>JJWY_H[JW$BC0F\'XR\"C!MHI%@K&P0M/1),7_#0:O^ JSFITHS&_1/(& M4W6Q/MD2?CBS=HNR3O(O&'G;?H\*IS77+D/M-)%%_Y';_)G+FZV79&3#A(M" MFI)#I1-;&-()W;.%C:Z3D;4SW8U&1!F/J!PE,1>C@.P_X0(5>>/$EDL_">TQ M3*$IO_*C D,)Q!N%,7WZHR<9N3N&*)K!!/^C_33@,!Z3="BL5 5\?B.++,<5 M*![Q)[+5OO7?>GS*^9U[5;R9O/M78RGJ:8I:G:3Q-V\4 ] X3A"!I%@8I_UG M, G<1GUS B21"2!V !UA 0>(NP3P$BY&G8/ )0/."EY^Y.]?1.YM"U+8>N<3ETK:;-09]*\C[-T&4#?IOLER7;K_\!3;_ZSS-KYFY46V5@62W.JLL=!-2 M< 0@8C[Z /M\@7E(1(B,:(Q&9QRX[R]$%.$6L([ ]F*^7C4BC)&WR3@(F9NJ M8.DB*G !W_Z'1#Y$JA^#,.#CE7J@K2G[APBK$-M],#R-!0G+BO\C0$TC\IHS M>@"3!,C/MRTF2XEP@D?!&JB!XN=2$](_H"KG*)TI/"0@=TG$W8I>A$ HW$LC MYW#HZ7QR09^6>X$S\2Y3_UB5\Y<%TEG>]4QNYN)W%3,>FH CAAZ:!6V256A[ M5O:+/>I8:+C/LG;9V@XHI^R.$=..@T]=Y8FCU%N>H@V&S77-7POT3F._#'BO M,K6<0KWNJ_/.1R9?[R-[W"/A&CT>C<4E=7)4B\AF2)_.(0*$.06E,SV0GOB] M\8 CW,<9'!$(.SI31S'J;N=FL#CLI48TMY+FEDQN;VW8K'KU2@ M'Y[&+^BXZ\<)IX.?>RR)/_VHA=P2"MI??O1W^]_-G-F?BVS([8]NKJ29TVO! M0LVPU#])1@?"V!^RV LT+_SCD6G5 $X^72B)GIT(\'Q654UW01OTOR9Z^U]0 M2P,$% @ IXE84M5#"1NC P F0@ !D !X;"]W;W)K&ULK59M;^,V#/XKA'$?6B"(WYVD2 *D38LKL/:ROFP8AGU0;"86 MSI9\DMRT_WZ4[/IRP+5#L?LBB1+Y/!0IB9H?I/JJ2T0#SW4E],(KC6G.?%_G M)=9,CV6#@E9V4M7,D*CVOFX4LL(9U94?!4'FUXP+;SEW#Q^1;]R>Z>];)G&"UG]R0M3+KRI!P7N6%N9.WGXC/U^4HN7RTJ[%@Z=;IIX MD+?:R+HW)@]J+KJ>/?=Q.#*8!F\81+U!Y/SNB)R7:V;8;U>/Z^N'R_7IW#?$ M837]O,<[[_"B-_#""&ZD,*6&2U%@\2. 3\X-'D:O'IY'[R*N,1]#'(X@"J+@ M';QXV''L\.(W\'YOF3*HJA>XXH*)G+,*KD5WO.TY67.=5U*W"N'OU58;10?G MGW=XDX$W<;S)+XOTNWCVMI[IAN6X\.@Z:E1/Z/T'"=R[VX %M(*U!;>C;T,X M40Z(F@,3"G$03 M*R198(7T%&[IP>MU>@MFC.+;UK!MA6 DG+.6WD#XC*PB3R]DW3#!R85K00>2 M0,(TLI G<939?A)VD_$I66J> Z/-KGG5VG#V3,B4(!_U<9 ^R!J,D_BT&\P< M?S".@N\+=ELYTR4T2CYQNH&P?0$Y!,<]@MQ80(I,9EVFY]NV:49M/$M(#F>_ M/+-9E]$TZC(:S+H^2G[(;#2C=CI+;3L-(![%Y-L[F9U.G.>VC:.9"_\HF&1= M%*S6AZ/;IS2RF= UH3C$ M-@YIF-K(Q G\[.'RC\I%C6KOBJ*F^T\Y[2K',#O4W557;KZK=T7[AJD]%QHJ MW)%I,)ZD'JBN$':"D8TK/EMIJ)2Y84E_!U16@=9W4II7P1(,OY'EOU!+ P04 M " "GB5A28#MLA^PY !2RP &0 'AL+W=OLWKIF1( A)KNJ>AWFQ11+(2V1D9%R^B/SAMFZ^M-?.=/*^O;'@^,#_>)3L;KN\(LG/_VP M25?NTG6_;2X:^/3$MY(7:U>U15TEC5O^>'!Z_/V;DZ?X CWQU\+=MN;O!*=R M5==?\,-Y_N/!$8[(E2[KL(D4_KMQ9ZXLL248QS^DT0/?)[YH_];6W]/D83)7 M:>O.ZO)O1=Y=_WCP\B#)W3+MR^Y3??L7)Q-ZANUE==G2O\FM/'MTD&1]V]5K M>1E&L"XJ_C_]*H2XSPL+>6%!X^:.:)1OTR[]Z8>FODT:?!I:PS]HJO0V#*ZH M<%4NNP9^+>"][J?+\Y\_GK\_/SO]^#DY/3O[];>/G\\__IQ<_/KA_.S\W67R MZ*(NBZQP[>,?GG30'[[U)).VWW#;BSUM'R^27^JJNVZ3=U7N\KB!)S!0/]J% MCO;-8K+%MRZ;)R?'LV1QM#B::._$S_Z$VCO9T]YIEM5]U175*M%Y)O_W]*KM M&N"6_S?1P5/?P5/JX.F>#MZD;=$F]3*Y:%SKJBY%5ARCY#?*^J-(J*](RN83W'.RHKDVNTQN77#E7);"7 M-VD#SUUMDX[>76_2:IL45?);54 #?_J/X^='K^G=-GGTI_]XN5@>.)BPC M(/): N!LNNN:Z5O [VU_U19YD3;()?@K/G4#'].KTD&3G8/%Z1+HH.CP$1"9 MR>UUD5W'=&WI(TP6I2"L0>66P'CP]SPY+4MN)Y.'@0^K-B7YQ5U>I242UBZ@ M*PN0"SC7^03#/O,,^VR2TX;\-,:K#VLA.5_=*S4#657 ZX /^T1?(K5T-OWQQB?/=T(JT<+ILB%S("H5?Z7;_@]#F*FUR'1Q0LF_<+.F0 MJBMZV'TE#A/^*&#P68>KF'8\G5__>O[V\/A5 I/*W;K(@.UA(6F%@$N1=> 0 M;=*PBEG:7B=+.!"%8?>/K6]W=V:Z7,*11E\!6>N&MM':\S"\[CINJ036+$KB MQAD]GQ=M5M8M3!"?A-V#&P_G-OY2(C/$]='I+_TJM6$_\5X9'T_C;ES5R]S< M5U G6OB0]YX=^"62 *XIZAR(G! R7"E[ DO+WP(_S8 M-<553[)VZ>#;35H0YV6NZ4#A@=U=@[1*2]>TKW&IEGT)Y+MQO YKG-4_53BD MU:K /PVE89 PXVX[2S8ESI0(!/R]P:F])EIE2,QECRQIN(;9 @;@;M*R3XEV MNUT@'9!9BP;;F]'7;8O/HGB!9?82.G=7'7P)ZY0J+6!SX9.KFI^'1YM*6J E M?VV6K8=S(EE"/PD.1R1?A^M&+=0Y[8=X.)[@61H_!N2M0)<;M XK TM<4=P>6UQC4/]<0^((GF6RO[9CPDW6P @.LQX>J[)MTMZF&W@F;)BL!E8G M%M,-%KV^;V-F(@?QO$VN>EA61Q-=7^%9 ,W-9&_H+AN,*FQ].D-SD4]S./3A M;\_ANH]@R_7+%%= A6+;PT$,PFC5N!%1W>,>+RJV&FC_-/7:2C$\T(]?O*8A MK^' *XBR]"CM2-? @4%3!89(FP87.[7" %=.-L9PD[.,#?M\GOR*RA*P#K,S M<4HT7)!1J.Z3K Y=0,\@K+ 'E?5M)*LWN('A^.\<$ *,";0TL%^@*TY^=+I^ MJ7",R.B62"F. $YUY$=XXB8M2A0?\^1\FM5N/DT[:NH*,P"2$LF4P%"JBQJ=RM9L%*EC 8EV!_ M0"C4_/CXG%96GGMEY?FDJO')925L$#HI:)>.:2L/;"(Y$]9O=GX).A>=1$!6 M6'U@PZU+&W_BX?%0TYKBGT@WWOL=/[8Q"OP4"5YX$KR8'/\I"@(KH\P7AY]0 M3,+BG(7=?F9W^QBY'M#=J0HA96IDVL9KU'AR 77Z5D50&EY.U@YTZYPDG+< M9J(NBY(G*I9*0.UL1Q2BNN2(S5":-CD^8\^C&1]RJ";CF-Q7-#U$10SZ-:Q: M*X*6_X+50WU>SQT_ 1R#ZNVBH+X.)D0X)1PW) MYF.AWMW+CDF7L*\B%!X6J*@.059EV!/R7]H E4G% =VLK$G?\#;7^<6G M/Z7KS>NWWKXCO9O.J7\.:2LV'_1'FQN%+N[NAI]$)G%[[4BF1;3RXX)]2 VG)714B1[ @N$'PG+Z,7*>282B8=' M'AAI/9 L')XLY(S%A?..65GZQ;8B9B997@<=)B+8' V@L=>X0Y8;J@JQ93,R M9V)AZ&-\TM@C'WCTOK"DJN]VJ,0G:KRJ8KE'&_J"DSK=!NLDJ;> LE M6;LJBQ7+\9FN#\UI;*^]82L[N42W&EE!A4H@2T8]2?-(V(QX0.XC_%ADQ%K: MX+T[:<436\-YWB/WN)2$:6Q=B30T:HKIA.^QD[_J2@7I?%[AF4%D&CM>?W>CUE^01U87JO5H M(GH/ QZC\!LKYR#8\&1RQJNE^I2UP?Z#(# ME7R+3"5]Y[T3=0=^;*^!XU#G VL!MIZWZG<9_*',[5DI4$!-^%$[&60V>J"! MD=.FK)/+8MV7W-@C.&,JJ\(_AMFGY;8-3A@Q=74CLJSSIE^=B4WG8CDD@T"G M1]=.,=HKSVBO'L 3;X&8-RS^[^"TW]\J+9AQT.(1.#!O!LL)N] W5/B&X%LX MC_(6%\X>[>8)/-))L\X=2@E:65R&?_1@%RY9S4O0(N1NKEV^8KV*E[.]+C9L M"_&PNNV&!C3VW#QY#_,8'6@[WCTQ.O2OK9D7^ S?_2%9]RT>DZ;!F7!OOY%! MPBG-KK@KAR]C(_@4*AF6KO3]+'"U?H'Z"/_M/0=UXZ"SQ#L;? ]$--2#BNH& MMHZXSK ?><4[*">I@]+:4FB")"LTH=3_$BN0#SE;K)]0[2B6)^KJ'W@31KPM MNHJLPL&J!CLNGDQ:66[_PTG++R/,#SBI-V@ZHBSN7+=+5*;F+YO:@Y<86B'(TG%;N#+' MIF^"Q!EK@#Y#&])(!I0%);4IVB^)&&"X]$1H"A]E-%WC9]HR)7$99?2Q&K'' MC\>,K2YOW+PY =\R9=$X:/"LZ[O"2VOT<^/4R'D,3$82 M"&-B8,VI^>=_*@LXV//4^C5]^ R(_;%.B-_#KZ/DO263VL\CVO+L8J2&D=&, M2NW=W+R#_>MHY,5-X*GCQ.9&LXL]]L[[B\B%6 2?M,27#NHX=BNCU( 9_0,HZ/ A#@:%(C.%/=D?YX%W3'T<#_-[:5 MG.W34-6L\VHL4. JK;X$+95$=[&Z!D9C]C(BMV6K1G3.PHFKI7%@ C $ 33GLACPV&XGAZNA@?J3H]LW!CLPCZ!")HE'R_HSUC%MBSF7QE M7@T%&L%^^[O&"97A@2N$("5B!5E*3Q@J'+B@9P!BEY9EX<5KGOI ?=0T$ M7.&!3I/"!UL,43".C-1'F +Q7$JL =ISV2$29!@+HLAD7148"='H,;X&A%NB M_T=.DW;XXN0V7X1MOIAV?FM\F-0)V9)X:(_#)+Z]M=,JQ*)1QS K1\%M;VP* MZ4MZ*R:^"6,9W=G'E,V;"E(P6S08VHAOJ?M6PTLVJF@B4K:U$)V:"8 -%0Q^ MX!8.V&OQMII89(FZ"'!W"TK<$CV3CV?>1PFFF[LA8253D$"LAJPP#@FM$J^J M[0W"HD8IZ!J'^BXZ5 M?^I7W;(!HS(4P@Q107ONRC%U\.^W$_LWJ<,%2)$FO?6Q2Z " M DP3CHIG&L/%T$8+FB9Y_UOU5B.MB,%S=<(#(6 ?$+NCDM,0#1504#KU'A-S M+8NF[0Z+:B9_U7V$;Z,6>/L0QNS.4=$QJ9/SB"@SL;QH4%4HTRLQD=/*@S-8 M047E]AI1OP,IPP 4E3*15Y#/MM"Q(#=6/6X%B<%W##,!\5:KHL>'A(:ST<<0 MY P/#;9-L4F-QX_YCX)RC9YNTEUQ, 9C$U:'6<4E928C"!%J!/XB MC/L0Z2 VY8PA*J IP4,D:]40[%H)A 6HAF4=9!0P4F?A,&6'"(!+(!;^^!O&^3BI_KD+VF&IVVS M':S,"32WT(=^)0L__O%8?PQK75NDMV?RZ ?\[KHN!T/Z@+@ $GQJ M%O/+0"?M98KS V[U>!IV>AZBRJ>T-J/<_L VDO-=X-[]N%K1?][Q%Z!O[7RD M6=7(P680""$A*<0CD7OG LBA<;Z9)Z>VRYC#@PDWS>L/9=4+@8==@?T"HNS8 M\M59W0"5R/_'O[ZPO^J;#0ZA?8+B'+GE*3*?;0TLZF5X>HK- N+H>!HO]!8GCL92XP20S\?$*+=]6U/>%4D' MNN,C@M&[_@6*.>GS>L[XXS?8EGS\"$LRI]G@M_=9/E'-EKQ\R(P@/$4RB$?J M$>,D'Y,R"-Q6;6VHS@?=&;,#([2^B! >#"AF]H$A+B98;;DE">\T&2D)WJ N M39Z6 3MU/(UF\O"*T=6[Y[LC8;M&)]E]D#/BI*6U M9]\!,J$6%JNT9JP08& 93E_)0M"/:#\U M*NTY1)2EK5\CBC^$Z+6W/F'K "G92.U"0@ /B4X&"US-+:5-8",TK+$EWXB/ MG\'X5F*4*S^IVAQ%OTG6DJ8+VGKFT5/PU-_%8%8,78@)^.F(%PY_<5U 4*75 M2-0]'A[.Z##;9N7XO%+&Z6EPA"DGT!%%B6\I!+25Y3( (\DX-@3R3$A5!L\ M3<$N:6O4)E7WC[T%/E8+AZQ+U]/&;D"<'$^C0\X#\P-U/M35ZO #R84)A>=W MM1(?>3O9= MT $!77B8M+2#2X3FIQ$7>"0Q*U@YA1LZ#-ZWQHQ^M14+SX>@=\846I+S326F MV8W5)$9EL,LI]#X,.74>U>B?CEH=[ 'KFIX<](RW2T0.!=WX$3$1!1%!,:VX M072!B9,JKV\K?,OBX2*5P7)JZ3D#T,Y%&52 M#'%Z0*HW:=]"Z]00;(?U5?*76JRO\\JWER>/\%V24\]?RW]OZ*4/[$[#OD2, MR7_HX]Q_N)DS;8T>]R6"HN$71- O[[.A-.C.+5$W8[LL;"BSTD#W,!1VUY&3 M^,[%\#J;0#W\VJ>ZD=I]B2[11MKELDD)&J!4Q].HIY\%H3LJ*N_W:O+S .7+ MZND8S).@(5'"1VR5I:VH]V+JY]%D4>(&@Q2#8;'PG-3-4HY9P^%Y!0?"<=NI7W20Z%6B;FG[#8UB(,3C M9EH;1 ,Y+6[707-_WA%6'('C@&$@*&B@PX%(GFZ;HC;7$M@!P<4T/E@G$$\S MRBGR/I'6K7"8V%3%2<"4[+M!%;$3^4[N7-%R&);4$#[BMYULP.;7UA6/*#TNABR%XRK:][RX!)\W>8XQG?;W/89.W%WBR:YG MP[G39F.^Z.HN5648&#R$J8QHCN0Q$R2D[MJQ-6.F^W"X:'(S/JI8FU2#X1JB M\GN3"BR5]@@? '9W!BW;QXWU$ QG"^);99GUU$ RA6;6Z+K!MT6M8NB@^YJB MP@^;PX*#0*W)R,^T)RU.30*U@07Z;TXW)H:@"U:"-.PKKP_!K&%MG#6O*P[W MP7/#B" )O+ZRH01OC=PX8PH3@0@C6,H*AC48V3X5R!:V9_%<@)7#0",L*>+L M.I.E%W.61+3;Y)WBB9+_2F'18/=3J8OCE_'S!K($1CD*U[S>=,D*$5<<,6[[ M8"4&N(BI=G$)ZY*G#0C"-S7\ESPZ>']Z^>;@L8'9-"D83L@09?/1AO] M5QX94^5, NAJ,0V4>HN9UV^C+/0+H&X!^=2TMYIP+*L*@Z0? MQQ2:?U/7"37D,^EG* ZH%=%XI"%)KPM6V!XD\##W!MV$$I[,/6*.. F/.XGH M^U3+:0\HY;DK',;XUAO*>F 75G"0>W1?0*5J1(APB0/$GH?_*50)I:ZO!F"' M(7%PD 6J;V$XN.X^8_N3$# MI&\Q#<%3[.V9(M$^!^SMZ&;[]N8XS6(\SS^N21/TIR&VG)*3B?'!BJXR1KD$ M&%TM*%[Q"$30Z<9Y7#&;=+7]W=< \4@\LI]A#V/(DWKL+%,E7$L,.4 P/&)G MHEME-6R&"D5$1@"+B?Z@><^*/8L+.Z% MC+Z;U^>[T&T_;X+P\#I[PSHJ\\.)18R*P/&-K&%J5C[PQ,BZ#\SQW0GK./WP MPO;_HQ#(BX"O6TPCXC[)@G\*13%&M]J#6QE-%0EU:1IG J3!RTZ'C!; ((C) MS#PGY$%2I1O7@R*)#;':XK;N\-JE97<-:@F8P4V-YUW#L+4&2 MU9C5OJ[5V1)-3,^/G<9VEM OFUT./!UZ*@@Z6KE98SDHIXLG,NF[N8$)8_0UV)L6;I-:5-W=#S2M?!H=-7"N+ M!\YFMFF#O;%C:^&&P-@7FI"KNF$8N0>&CN.ZO=#R^S0X(_R[C-;B\CZPN80% MUD7K<6^8H<+K%*K35:H<[D9X!OZT>J1\FP&+@>5+;IZ233'&2Y*%ZZ4IKPS6 MD-L9#\P7(6_7!4P/^0"GP8*(B^#%)A]7O>-1+J&7PQ8M*R7-NLY=*95'F)H: MPJ>Z=1D<%BQ/) :ZC32L1^UC#4@J:47 1(^+%XI="R&;7G>1MJ:2Q@='%7_J MRRH0 F_&DD?+'HP_I&K]/;MF@0:M>NZ)F><1E7#@'#%QT+704LOYI7MZF7NH MRB6A#$]#=][INY.%Z,' [BM5*O#I9_8XH3 [;J!!BVF\.XC%R<]%9S]5.!@= MZ8!CA++M?M+2B+#*&;!T-8^ : MDT5B^+*)\9:34$Y+YF3?4BDC=+7&PB&@M4?$A*W^QKA0:F&)WNUQ:((6"@WN6X==ZD2(AGNLD<;;-&2D4#'&]G%62O % MA))ZL^E:?'=5W-,=-;>4G^ D2H!LT5_(.&B343NV8Z_(!O78?W6=>B_"GI.! MG_#AW((WRQ7"/-2TQ\X ^76R-Z68TMH=/.&#'LO(-AWPUI7NPMAV# MP@+_1Y P#$:P%P)#%2J+!Q7UQC:;5694_XP9UU^B"KG*H+!BS8F4O9L;4,H?(MQK%C.FMI>'!V_FB/4$NL9 ME?C48^.CU97^)*QS9N3G6\N0GS$Z!8^ALNE=,[.!._U5\EUR_.(9_/OR^ 3_ MGATMGL+_BR/ZY3E^MYB=O'QJZS7A;"^W M+4Y>XK^SDQ=/X7]X\P5]^^(%_/ML]OP$_M^9[UO@JS7&FT]TQL/J-%P\4[ M-SROS*%'!U?VN:IO'"=,U.(ZPL\8,P,%.'A1?26?L*YDH=Q) MT_YN\2I\;KF)82/A$\B(N95-ZXVR%G]4>& M+3,NP<.YW;UG:_U'.4U :>BD"F/HTPZBXYTA9SU/OEVP]8%9+2_+99[IF MSA1%S:@S6$1TF7JWQV[0F>MV6.#/>"U1@ZJ3QZ4Q >9I)3[ M* -"JZ1$]Y ",5MX#U1]D1V*%^QI*+L<4.ZQ\HO1NCG2DH>6N!;:[ M$@F\3O^.?K6Z;T0;VVM433IK!G%3 =#QP,DG/!O4Z0_RP["I/L+.%:U#-CXB MJ141Q^!/0Q'ZLX%-0FD_2T+FBAV_WOC,FX')PK8QJ_Y:[637>)ZT>M2&%J"N M9I(#O^&4*%&(I5L(IXE"W@2+#:7P4,>7UXB_YLDOH5!UG'R_>EMX\9L M[K$ASE4OC256^5)8.)V^(FL+3I/:>XO-,:E$#H)J[F^XR.\8&I4 "&V56W_Q M"ARRG2^\2%"T<%;.;-*4UBZN>E*KN,J1OR0"!UW>:/Z-WV,9>8_VUPUG%%H6 M\')MJ'R$2Q_<;*WKR+\A3F7T^E&U$\[PUG E#U1.DV"6GH4[6F@-U!$&!$"S MRI:)&/9+1%3G#;:&IX_()QE+FJ ZR5 ET=WQP$8FO>):);0:5">9B\1L"I$' M'*/F&D\X_G<]IC.CZ1W*6;.0#".2 L)2J 7U5 +!480$!\B2JMFQR(LH/:<# M$OUS4$)#_(#>&4 'H2DJ)9.34UC\!)YNQ&,[HQG/KP_)RE8]I:T3('#CL331 M8'B6]FV>TD $=N.D$ @I1R0,!72)*=PO 135AB@<@C$HF,W%D RKKPX1L/ MAM)%962&N*ONN)Q'ZX/LOVU'(HZB8V.8N39V'YHV.UFN04'W::/^&=03TPTI MAV(SM*!)."[!+6;9;'18PQ4WSE'L>)-VR!_LCFJ1"!#)TY$^GJTAC/IX2\S%#DXU5I06>Z\H MXM)2* S;G0LMQFQ>K; (I#S^3V\ #'A?I!]KIR3<]-Z(/0JW.\0K6+RBRFE^ MUFGQXKEW4FB\G'80NB?B6Y@LB]O,& URI^88]GA>J@UV[>.W6 B8?I(=Y^FX M3TJ-R2;)PS6;S-/S-FTT)<[;5868#\,N9NC9#^CUN *OO"O3[,!RK1NT%##= M 1\[Q*#CH?\>*.4?T9=I#N$JI-TI>M?_+:G8?-U*:V";X7 PI!>HR& ]^YU MAB@'C%?,='*<42U(#K&()?P0WQ85[BW!&G(*N@(AN2HJUDL";IPVR\QFL\\& ME]183JJ<-^8TU#9/W@M.@D;4]JL5X_CO25S.(3/4"?594>7FC#%$Y*\911H*_'NKT4K]_I%>".J MTNK%OK=-&)&M1[4);X#^2,A^=!IQI@ZIAK+=SK$V7QHJ':U/V%'= &% M2TP=7T"1D1-"U0^9@X^C1Z<(^1F&+VL6 RD> V%-^,V/J3@AWS8]0K4Q:T?O M^/CX]LS?[F'4DSE&%&QY;W@N4E\R<2UXMX[1N66O*+M;YXN^[H-T6"4&VJ9] M0X,-FFS0M3ESBL.5:'+@8#8NQ*\IYTR2^K-0: 4U55)ZQ4+HJ&A*8(9V"]MN MC>)%5>N2G$,H*X!:%)")'2K*8)S]ZKUHZQ1.%];C/1H3K:PEWN?(=XUY[;D@ M%!8N#^I%:3".R53>D4"VS!Z>+"@\U0;L:N934P>1K09H@!SYZL_8E8C"I5+L M$1TI8+,6FY)*&"#?$?_I1:AANW)!'\:BLR6@%U:T83)LYJ9\0#-V7E*PY5T- MOM+Y;JL$!B^P81H%-))?4T&-GD\O;5L#1T$4<$AN$6+S'49PHI@%!J'DBV%, MPH2%6^O***I]GB52TO:,:-0).194>1D/\.71^/CF/L"#C]D(X$44Y":5C(MF M!;>PE%!CC2(_S 3ZFHF87C7IVN]]VI<#7(K$K&-''\$7^3BDEZE&H.GT4+I+ M?B$<99'[KJ)XN)X[K,>:ROM+E]/.)&3HH.TPZEO$4EUM0UB],?54B?@ZRH*N M&_0M."D3-P_CLVT$>82>=&CKZ3/0S+>T>1BQWAL5)"EN7&!4=-P*0;5Z^L[PFC1IBW38BV'<@6K MK@)"SC<\2^4VBYP5V?CF6A^^P&:H9C9'B4 U%9)(8 @]:%JX,]:F-;.?!T(] M1O$N+F'IY=6$3HPT;/'XT((ZN+0E]&?(I]D!DFE=A)3S?51,R[9._+5CS('& M?4]J==K& "'99L77&2$=/-Q1,NC&8%T6\A'C9[@PKNZN.VVD$&^4W_9-[%]G M0+'=]'^8W;6>ZEXN-?"_X*I@!X0P!3+//'D;?)XYL!VQ C(9W0YGHQ?!@6'> MURL*?)D'-30$I$&0.1X1B6PY\OT%-;^(H#KC@#0O%K._1==2D,C?>TE%M5&& M62^$BCR2L'6S2BO):>7%%VR@7O_SQ\$WS,'(RE?M3"<#8;U1S)_5G9X*:0K*+T(GG1\JN*1K&55)]HE(I]<QF;^+&COW(EH.?ZM"[;E( M-7+X!8^"SWW'T[DGO\W FQ9I(#L*AW4QCX9M!OH*'>IB_DRO]$1T*&!QH MQ+5W+O(PO> R+E/V>_,9PUKVC@W%%2,PQ&2>M4:5\M>&[MRA^+B$V%4ZX %W MG^GRH6J*#(1)[EE1'_NQ" Y!?ZO>M(VH:'V&_297>K;.&^>>3FC_VG5%D4L< M@F>\G+:2R)]*M>_H=H) Q\@2#Z 6!FA(=$0$9$3:D;.W;N*K@6,\KCT!9N$X M"R)M'QWY BNJ_498?3N10:G#-*K\1QYEAW9M""!:?PV*>PPEBP9#MBI?.""6 MZAT7#BMW8^!^":9=K7%%]@[9,C.:(Z/6KI^^Y5QYF]P^K8)LPRFQ[%GG#/!= MW3^6B_SH!C[7<=K^T3Y8OR/OI7&JP17!P!H3"'E[ LIZV&!O6RR_$*,2(<8\&BK5T/\A% MGA?^U# ZFL(BR"O#)7 F]L+D,*+V-_*8+PWH#P/M<9C_4-/-&QF5UJ"K&@I1 M\"4 J8D1=*[)S:;(:0]@L" 0L_L]^K&@5\<:7R*P5O9*T-',GIF3F2:0\ M,^Q%LZ'*,G3O8UA[>_!Q\%I3*6:8Y^1U= WG4ANM=*]!8(O6 MRJ ;(W@'Q5WX$HMYC,E^C_DLUF^"RG;@2>,%H_02KVNJ0PK4NS5?QR?8SAH. M Y"1P9B 6$&D\JAL[]>TJM_2TMHN-N]^BH:WJ7F29X&B^#1P=O+T_9 T@/5 M7.)>1WSUON=?LO\-X@P:U1K0Y,4Z72.>BV!:;QPT,?CYC,+"T/Y?)'/ZO,KF M- '?W"4R,'+.//F-1"ER& YQJ'>W;->(;"6HAN9=SKP.'?Q76Y_^28(9%AT: MC26IIOM25E+8(SZ[U(0'>&^)K)X/;AUA[SZ:UKX8O2*O@[>)8LK#VELAS.%! M,'[7&8O#EHVC6PC4Y_^WT^#SCP\B!4>)V(F,*J8S+:Q_?#94&&T:K,Z&@A;T MGET6/5DLMA8V.(S-X$.M*RAD^,@]"0JAB$9Y2>,S= 2!2;=MFPM3J&+7Q*)J MM@V)@,' >>_L2S4; $FEKCPM7>G](,)H@ G7QW_&SHCA^-SK=3V0,F&?\T5$_QWWTP950^ M@*^>0M19PY'^4/R@\5GCN, LU57@[R\);Q'1,CQ3L&)0Q6Y02E!!8+LW M YAK VJM=4IU$'3&7E$U@TE+W/UX>1"="^+NI*M9&JINM\8+X#I@+K0T]>_0 M>\BKL24W%"-J K"D@[=17^@(O\$!H(498CV^QTG!/%RL$%V4=*T]Q/<5N1XP M'1[;R-"E[I'C4M[#>W.J?.2FD?%Z\CXUFAHFQR<1CJX?(5LE#P5;HJ'A (KU M5=^T?IW'KQ^@/)]>BUP_F$_':AY%)]R=%)^L9A2N8EI,7YWTP:V [ONK\]W[ M[83_)B7%)+(.I5#)ERSJDR M9CR <5D7NYYV4G?]CX<^ NF+$6;W:-Y>)C*3)QG)'E(\F$J^9N@>AAR.[<,8 MJ=<$$24"?P35\Q&JGH\3>Z]**\!]K:,_?<4*@\K"_01SX0.>;%@V>Q^1W,OG MBZ*&M#*I;%](>)%"N02@&3ZQ'=S6;B]>B3"=*M^F-DNXO6DQ??/2J8E8<%+.A!N)%M/7"%UBJ._P#=F?>!;# /97*?RVIO:59J)2 MK/2.I'/ZHQ[,*,J!="[2>58(_^2*4/)S N=:]B6I-\$!C?4@P7I _J7&N7ZU MMV,_7?[6JB$[2XQW*(\*>MLAZ^$F]9.BJM"V?]R[T+P?)J671-=D\8V?_H@D M90?O^?6FI,E!D<#;39%34&M?/[.=)!/RK_%828+YLHB@F=M6D%C8#.SCI3.7 M)NW-V:+^-/NJ(*AWL0P ]1E#B(>E=,C1@V*3;S2ULG-JIX7KHA9W7/FDQ4K%%!C=80]K8NSB=P'T$'SG M:BO%122:%RYX(_7)%MX5$HZ7CYU)A5O[9E2G=ZQ]30;C%"DWN),DW-/C"^56 M',38DW\]=NOW/! @% @>4TDH4*L?I@ DPZ A39"+(2+Q%NM#ZIFCHR7W*-6_1GTS4Y9[-'<,X2F!8\%;CPUME>MN.-TE4Z3MT.,KQ8]>A8&>IQO!$@!>@ MQC3:/P&HS<(6&IGQ\!/%XNG<3%0+Y+,S=VL3;D1O\5@<'3]GR83%X[7LO"]# MSYX N6A+ZNUQW%F*\TD&BO(([E22-FTOM-^FAOBOWFR3V*BA3%3$H/0 MD/^FQ-*P,K-.S@<3]O!0. RIDF]*N2(C#*49U+0@/*0QMI*:>BC-!)=#[:95 M*)9*OVYJ";_$AA1MPV)YKXM+HF9T=TKY!^0=C#'C11L*(M$+ ' M Z I\([F074ZO< /HW*=9P;M=6>RT5Q"<,>/,I)T45<"5HA Q0UC0D$C=:GW M5#\[^D\F27%=LPY]Y7 .7BS1O(,)/X]\_$/S?WQ1)/&QQ!N1:-O!/BCQECNZ MG;BO* M_<"4;189,[CMZTXWB0N *D.HE#<,H('M&H/'A65S.3LM&1KEP\9:M M#C>!X#W[/$.#'MLC818, ++8VATB$ MR1;B"[VN4$<"M0.9%GU U/*#VI.-?.O0Y'3YH9;-#V@G]'CC+L"QMA',WY0' M&M;31RA"25&B_P&33298^R3/$+CGM;#T2L,?(;W(31] MZ.L:*,PZ:*C6>XMF7NQ$!2'9H9G::+YS ,#:85/#Y&4/Q%4X)] !$E! M!>RGKQ Y"5>(G$S?^7&F82[$8XTRSP/>1[T;F;W"W'IT F,2Z$NM.W:U4VZ.Z*9I: MP>"1L22FGGC2YUR^$UUA>!3N3F+DAG!+ Q^1BVZKP])?.Z")<')Z*R"*A<18 M:AX)UVA%I;7&DES;X'8+E[4.P'!QO5QET31I_-4;A/&2QT+^JCZPV1 F0A+( MT0;O3*)2(G>#Z%4A>YJ9R:3Y5^Q?BZ2VEA(TB:K>.Q@:^+U&,)-@:56L^_7P M9B;?UIY!?)8<4V$$.K,4MQ=51$S;B'\U@:JY?SG&J4T?[C YF;Y]Y)WZM=^( MZ+I Y._H[O^6AF( X0;UNX;K5M8]99^JY!2EE,0K@8^M&][C0E6\Q@_JS[2= M%>P3B&- [,\7'0X'=;B6K_R[8L&JOX>Z^QS^5# M)I/X"PDF N!XGU&[4Z_(6SL^?D'@92E(?%LW7S@5+>2MLM)N[Q@GWD:'N#8V MIX,]]+]S@-*.Y'OFDN,CS6;03:)&DIIH0 H+:98;UY6(EDAB('-2F ^CAALQ MPZ6](?[/MPIR%J /="BBJ(X%6^[O==*2C*-AD)T$3;J*8;(AQ!IHV&*\"7%C M4?4_N8AS]R&.W%(HUSU6 5SJ9QA:= MYAK_60)'W(Y?R$A1':W<<--<=HYUZ/DCFW\+(&'C MM9L99Z2-9%("M?$@=S&4W7S( M>4E.[\;Q_CIX:\SGANJ/OS/W.X_:%' ]3B S&=?679H7.3FYI%2=1T-JJ8A( M>?MS*P,CMC;7W)'Y$%T0GYSV*YBJN2=UE!6)F%NU&3%J!FO(=8Q#(AHGJX?X ML+GM](]9ZW\!G<)4F!R_4#P5.YN@!H='N'2)UBT!%L\+;Z-QN,T#?W'(1#TJ M"_'SZ>E%=-_0++EV^8J==6Q%MM?%1N(ZXDRUE]SIW4L2@/AP_N;73Z2LF2^C M2L #EQQ%/;FLBH=X:7[=H 7"NZ[!5AZ;J"T28>O1RM[3LC)!!!H]V-\;%EU? M@*'5&=U^SI\HJ9-37+"D*%.)V<"3/@4&RP-Z+>8K!%EHC0H1\[S$QXN97V86 M!$/QO\"$>I*I@1UL @BRF2,WIES\J-71=TC0Q@4MQIB&$L-$A,V3OVCQK6(I MY9"A^9WQ12.BD;0RD#TK<>K% MG?WWR2?13'T9++8"]BK3/ME]1*.^^P23V\,5"B)W7S#.U"_G\;-_CW3[P]0B M7!;_)6<6[%T8)K)>B*WW@?B.=[ST@YNPU==EY*E &$R@-$),^/.=F^[P?DE2 M6"EDQM=Z%7K=EZE/+562I>@)57TUP]+CG>\NEQ;5MS&X-"<*D%L/S60LFE>H/BT(-,[Q+[[#?A%26KXKS"A><#S9*<<<^"0K MV\521NQ)]]]=\TWRZLI M,R<@GT^FL(]V %J@CZLAE2S[>QN='A(OJ - M1*6VT75IJ+ G7]@4@A8\2]^T9D% M%KH(I]PRA?E\8;<755@3PMNK_'R]KZA.75S*(Z\=\QK" F'_:COL'Y@G[_L& M^\>8]8SNTO-0FG8"YZ=9"#5Y$.7"][E:FQX\QU"BG+TI4P&R784-Q$I/E8P; M67&&/TCZD:T%0K?Y8BX@NY4)!]5R M2PM1.EA#...HF!!(LF,J5J;9WL;9C>>HTK_C B&[.#$.6U !6D;/L\,FK(1D MM;=N[X)=^H6*Z65N:J4(EI"")'/8$01]"(* SH,UQN MP+Y0?-S[?L>CSA^5_F(*SBU\*V5E+@:%M?79<&BR@I?,G*J:5WBR5+ID%I=Z M-32UYBQW3*42BY)71J@*-%]>#*;!V55"]([@#\$?S69+ \+/F,RXE"4(SOFYE#GJ5Q+@[[Z2_<[ZC+PMF M^$S)SR*WQ<4@'4#.EZR1]DX]_L:W_HQ)7J:D<2,\MK0Q$F>-L:K<,J,%I:C: M+_NVC<,.0^KO80BW#*&SNU7DK'S#++L\U^H1-%&C-)HX5QTW&BWE^_O[U^=SV;WC[ =#;[^.GVX?KV/P]$#6TANCL^'%K41 MSS#;2KYJ)8=[) /QIUSK+.,B[7+>;N+G!O.M'%!I] '$V!53I,4A %&="3: MG,(1JBJ%E%ANYM@QM/2.]HI)TN[!@J]$55'4,2XUUT+E\ I&*0T)#I,$[KC5 MRM31 MA!#X,(+/6EA^HI9+ T=!>(R#C\,8ASN>J35:A0&(4%((6/U8VQ7P;UG!JA5W M[BL,C(:CZ+A7<10?/_G(B63'NVBRX^(!9(U[9(T/(PLOY[R1G)1P8P5>3SR' MQO!E(T%BT(Q3K_'RUG;C08UV66";P&)T+,&X8"'N%HS(0EW#G9H M>=ZTV4>G/'?Q8D1;QA9O).MEU\_@ACP5)4I9<_+50#"&$XC\+9:O&B%S%&#@ M!\)/-5@%HX[R \L*= 2+^%GP$!HG".LMT4<'AN>'07?XMM\FT&(^F .KY.C2 M5MMX2WI#>X62WYETPS%2FA)JN2[IVS)CG#HM!R 5]Y"*_P=(B0J+;"4H3VW^ M7H+184734FDK_GX)1K5&M5K(S4\ ]5_Q,&_A! N-640P["9OIG2M,"F\.TUV M3SM.32:888UTE)(19;A+VYQIBQ#!NU,ZITPAZE;,I -(0^9G^)9!TRS/BDI) MM=KLW"3I$_6!7"9]+I-_VWC6&$]75AD:)G('/XQ;W5V(+R;PH/3]+>'X[P&_KN)*:]T(O2$4PSO >,Z%K7_081@PCHN@>VFK!?!,@) MLT9KNC6V/:3W&9(DA@"UA5X8CU'C)$HAF(QA[(5I@F# UZ0C,CB$.V>Q&BQ'\5[+(Z#R%D_-!X290-Q)OD16_S3!7JO;7X9V857MGND+9?'1[Z8%_F5Q M301XOE3*=@M2T/^W7?X#4$L#!!0 ( *>)6%(&'#)6&P0 (* 9 M>&PO=V]R:W-H965TMA7A15U4RY(9G"CQ-T_L>A!92+/ M\II9-NQKM0'MO G-#7RI/IK(<>DV96XU63G%V>%H\N?WV7RVF#WW:P%0FF+P%:% )51W1OHYQ=!3Q&N-S:(5G$#6C MYA&\5K4N+8_7.H W+@S-& ,3E2VY9$Y"!OX9+8W5I*1_CZ2XJ%)<^!07!U), MC>4D*TP@95S#,Q,%&E I,&/0&A+LSX)K,C.9@.!LR06WG%S(7F3O5ZUENQ;EORB9)3,>8NJ,GV1+'2P\ MA%5EF/,WW+S2:F6\EZM669JI,M9"$L'IP0A$9%\)MSBF,XE@5 MDJ(UQLB??25?H LS^8S2*NW81!?PJ#%G/ %\H9/-.(;$6%$"30VG-;GN6;3) M5R5%;&&IG1.7ELD5=[@[CY/7I2D,IH6@TE.DG%MDFBB%[:M76CG;>DXGH>>J M"ZR1. F[I[!0E@G@"7'@*??.$BLZ8;<+-THE&ZH86COGUQWQRT@+0>':ZQ5( MJM*DJ-VV?('PL@E'9-NN9-L^*MLYW0M)(ENY'%.JR/$:#-C06!1U -/!!$UH^)7CB-W3,!),QPMQ?CJ4, MZ9C!;$E*V1\UP+3+M>L@\UZ2G]9:#Q::)5B3KCGS>_\%KL*Z@LO93NM_R/C2 M;7XG@@=OE$K^\3XWR3RG!MR>04XU6P^%U&PY7;]VSZ-S^:H^YS![WPVE8W31 MIF7:J[>Z'G=6HWT=5L]< 9E??ZJWOY.KIC>L7I!A*8 M4FCSO$OMHLL71_EA5>YO^:6R]&;PPS4]TE [![*G2MG]ATM0/?N&_P%02P,$ M% @ IXE84J.I+15)!0 DA !D !X;"]W;W)K&ULQ5AM;QHY$/XK(ZXZ!2DM[/*6T 2)I.E=3TD;)6WOP^D^F-T!?/7: MU/:&<+_^9KS+0B@06IW4#ZS?QO/B>68\YFQN[!V5FJ&EE;&PF/ WMI.%F%D4:-F6J$3>;W48FI*X-SL+7$G9Q,/4\T!FHE+,B-3X6O*L M52)YXWI_R?UML)UL&0F'ET;]*5,_/:^=U"#%LPR$;XG)#'/0N! 4MWP@O!F?6S,$R-7'C3C U M[";EI&:GW'M+JY+V^<';X;L[^#R\_G0%-U?#^T]W5S=7[S_>P]%',5+HZF<- M3U*8MI&4'"\*CO$.CE$,-T;[J8,KG6+ZE$&#U*MTC)2)=CQK*1-=$I'0BU]_.8FCWFOW MOUI/+$A,'P@RF(W05K#9G(E.X4AJBBBE2#57ATMA[8+Y7.,#*HC*-B[;UO,$ MPZ!]GPC=%/!K+DG-TTUY;OD. H M$T^&!Y8O(#J.HVBM73%:]:+R]^T:93'*41KXP% G"\#'9"KTA-VF _!9U:<* MMG9(V=>[7KFN#\.$#L))]O]+BTJP-2R.#I+.AKM.IH2H !"2%Y_LX%ZLM*+N MKG5:N;3&N9>5?6XN9FQ2K_F$G9LXKL-O5/@P+%1.EQV,KJ1JS.$>M'0KM'0/1@L; M3F"@G+O496>(FI&2D](C55[>FHESQWU'X1-N .*4:S/BZR7 1.I9OAUR>_4^ MY+;:P*'XB?;!47D[U ,:&>T+%-8=BLL+I*#1A5!% 8O'\(?0.97/= E4^;#5 M.H5A^@]5BT4X>/-=>9>S=&(QV+_4TE/EO;QGQY 1#!=+U,8QO%W=PF)-;MR! MHZA9_[ZDO\Z@?0)4/MZ*13%L #T*O"J#_*C5K1>?;](RI6+MU"8_\D$921Q8 MN\)YF8$CKE>?G/23DH'OGW#'!)D>9L8&<1$IW&G#>S(UV5BBHPKNB;OQOOS> MJR*V=W#$_D"EI(,SGJT5]^KP ]'W<\K"+<;^G**PN$7T&CI$62:^_V:.K@J5 MA@AT5#DR<-J='65#L4)AOZ,8.MT*N,;:.S%#.PFO84?NR;4OGHS5;/7@'A;O MS!5Y\5J_$98RDP.%8]K:?-6C0L$6+^!BX,TLO#I'QM,;-G2G*"CJF8#6Q\;X MY8 %5']##/X#4$L#!!0 ( *>)6%((/M*B? ( ",% 9 >&PO=V]R M:W-H965T+(8.G_O\,*Q,7LRN$K62KTYY3Z?!9$CA (SZQ 8'>]XC4(X(*+QI\,, M^I0N<%_>H=_YVJF6-3-XK<0KSVTQ"RX#R''#:F&7JOF.73WG#B]3PO@O-*WO M, D@JXU591=,#$HNVY-]='W8"[B,#@0D74#B>;>)/,L;9ME\JE4#VGD3FA-\ MJ3Z:R''I_I25U73+*<[.[Q]?;A^??RSO;U=P\LS6 LWI-+2$[.[#K$-9M"C) M 90X@05[+CM4B.(MY@=@9I/( D2J(C>&E?9^KQTD-U MRG>45NE/N.$F$\K4&N'7U=I838/Q^TB&89]AZ#,,#V18T;[DM4!0&[ %0J;* M2DE*:IR%=_DYFJ_:>Q3:+>;$5"S#64";9U"_8]!71(@#D&@'P'PFZAR6:]1] M]X#)G(1X3)1HF8PEKPF<<$GS) 2MACEM_;S/DC4T7Q8U9\+ -T@N1_1-Z>:5 MUHOJ@$JK#(V!>)C2;PQW7'(:P!RV2N4&1J-S&*5C"HH'T7CHSSBZ@*]:'.X- M;HEZZ]?3$,]:VG:&>VO_ ERU@__/O7T^'IC> 2EQI,6]=,/\]1J.TDB(/]P2W?5-8=A--QPS9X MA_93L]2T"WN6DM_8V/G6)9,8.72GSAI:TFP2B $M>L M%?96;=_B+IZ!XRN4,'Z$;8?-D@"*UEA5[XQ)0K>\7M#N^)ZM!)J3<6C)E[,(BQWOO.--7N"-$[A6TE8&%K+$ M\D^"D$3V2I.]TGGR*N,5%F>0QJ>01$GT"E_:1YYZOO2ER#6];&V?*7+!I 4F M2UC\;'E#3\["M]G*6$UOYOLKKK+>5>9=92^XNJ-2*EN!H-;0]&Z;WBWNW?XK MSZ]2NYJ], TK ME43Q.9%1+1I+J LXYI*>HQ!46>:DPWG,>X<^@N%Y-\Q;+DHN-\:S\)H4/&+M M]>2C'/+S'*Y945%0^ODO.?'I,$EHS*,(AE@WET$"6YI!&,:2G:3:B,8Z&,"N* MMFX%LUA2U5.N"\Z\X3$)'<4G;LXSFH](\R ?^CG+<_C7^PD/"K9&O?%MR5"" M6VF[VNU/^\XWZPK^-[QKF]=,;[@T%-B:3*.SX2 W;6B;F-5X\M_I2PU$[^L MJ'NC=@"Z7RME]QOGH/\_F/X"4$L#!!0 ( *>)6%+V82L98@8 'D4 9 M >&PO=V]R:W-H965TR3"?,NL3R MW12820IEV:&4(73[L+,/BJTDVMI6*LD$]M?OD>PX*804^MP76Y>C<_G.19>C MI9!?U9PQ#?=E4:GCWESKQ>%@H+(Y*ZDZ$ M6X7$OL#3HN.2]9I;BH0++I<6](#D>QH;<$?W&V5!MM,)9,A/AJ.A?Y M<<\U"K&"9=IPH/B[8^]941A&J,:WEF>O$VD6;K97W#]8V]&6"57LO2B^\%S/ MCWM)#W(VI76A;\3R#];:$QI^F2B4_<*RI75[D-5*B[)=C!J4O&K^]+[%X24+ MO':!9_5N!%DM3ZFF)T=2+$$::N1F&M94NQJ5XY5QREA+G.6X3I]<7-T.K\XO M1I=G,!R/SV[',+PZA?-/GTZ_7%Q>0O^63@JF]H\&&H69)8.L93QJ&'O/,"8> M?!25GBLXJW*6?\]@@%IVJGHK54?>3HZG+#L GSC@N9Z[@Y_?F>Y;?OXS_,Z% MR)>\*(!6.5Q4FE8SCL;"4"FF%9QRE15"U9+!W\.)TA(#Z)\=8H-.;&#%!L^( M'6->Y37*$5/(1+D0%:M0'/:FO.*:O2TP3'/@:X6H56B;"W9*,OE\J!8T8\<] M3%C%Y!WKG=S.&<;/OT(^$OY$'O[,.*+.R@F3'?(6+L\E*3+ W%0:J0[ABPU_ MEK]M:.Q\GU<8LD6!V:?VX5P*I6"89759%Q1)X0IKSO;1#SN1.(1K*?(ZTS"1 MJ(R""/90HI.D+C;Z)'!2$NQC,W32V,X1QR7$SOE.&-BYV FB&-X+N1 2Y:Y8 MQ9"Z,?0#%XE"UX?4=Z'O^PGV4J^3*XVQ:K# A08^'WS'=T,D=-PPW &:2ETAD)*AH0:3.5\H($ BA(I$*,*T(],.3?N69?-*%&+V M8"$7>FZ\@,:@1EASD<3@;-8F*3$ =F'"'^N&8V( MCZ.Q0SQ_'Q(G0#"'V;>:2V1S<7WSAI:+=Z=0"8U,P003SQA<#1&Q-[\E'O'> M80M9K#K8'-DUEW K:8Y;B?QJR(D3I@5A,^=[ M@9UK-=Y#.!P,.]B1HF&7HN%/IBC'6O;Z--TI[5>:_DK37VFZF:91EZ;1B].4 M*H-.MQ M;8$G;LS"[_,;\YZ8CV<^OOD$YA/"[9I#$Z'#39W1;XZ?I/;ON8']N[Y)Y-0U MGDZ0H:6QR=U$ZPX7QYV+XY=7XCFBPY2):X-)1J5\,% @MG5ERAO,VA/=-O?M ME/-\#=XM5&U*A;R69LK0=;Y"MSXIS4Y3=]L"G<"2[?38B-9X%X/?861J'S*\ MN8?/!^,#/*'>,:GXE.-86_(4C&G![^&3U'.!DLV]Q=0FGJGMY(VK1[2@5<8< M^)-6-=[-P&I*$NM*ET3V'_FF-GM.&IC^J@QL;Y'0"5,?+LH%Y1+O<'J5;HUZ MQO1M*DJV,#&'(-:8%ZICB/79(U@]5OWG_BNZ&X9B9M5*\'DA)FCE6!2:/I*Q M]EX_\;!6$[,]O$!2=WF0+"LP6QM8M5AE[IP5N4U?14TZH[VJGBCVK4:5B@?( MN5H(A2OZWH]EK:U[8IEB,]OLK.AH RRY]H#<&RWU&V5M %[KX5[KP5\ MST#N!L'6/7:P\1Q48@C;1R^%]P#U<;-L]):_+F4>XCE3->*2C8 M%)>Z!S%>963ST-5TM%C8QZ6)T%J4MCEG>(Z4A@#GIP+Q;SM&0/?:>/(_4$L# M!!0 ( *>)6%)E2LA6XP( -P% 9 >&PO=V]R:W-H965TS* ];" MW9H&-=_LC*T%L6GWL6LLBBHXU2K.DF08UT+J:#8)9QL[FYB6E-2XL>#:NA;V M=8'*'*=1&IT/MG)_('\0SR:-V.,CTG.SL6S%%Y9*UJB=-!HL[J;1/+U;]#T^ M /Z4>'17>_"9%,;\\,:ZFD:)#P@5EN09!"\_<8E*>2(.XY\39W21]([7^S/[ M'R%WSJ40#I=&?9<5':;1*((*=Z)5M#7'SWC*9^#Y2J-<^,*QPPZ2",K6D:E/ MSAQ!+76WBI=3':X<1F\Y9">'+,3="84H[P6)V<2:(UB/9C:_":D&;PY.:O]3 M'LGRK60_FLV7R^WSZA[F7^_AV]/GU1:6S]OMZNL3/*SGB_7#^FF]>H2/3Z)0 MZ#Y-8F)-[QF7)_Y%QY^]P9]F\,5H.CA8Z0JK_Q/$'.PEXNP<\2)[E_$>RUOH MI3>0)5GR#E_O4H%>X.N]P;<1KR$Y$+J">5G:5B@'?\T+1Y;?S-_O2/0O$OT@ MT7]#XI%;J6H5@MGQ,V0%K(*:H0-:_LO6HB904A1229+H?E7G=R5\[]ZY1I0X MC;@Y'=J?&,WFOZ,%POFXN*Q8%PPYES9X94DZAM)P#SIBU!U\E)J?H5+<4>Y3 MAPN8!]P+Q0^3"&U72HM*$(OOD#4^0'HSS+.P]L8Y;*RIVI(85##(0=[/830> M79U3:[6#03Z X3B%M69>Y!AZ_11ZR0!6=:/,*R('5_. C?0FWR80XYY_,!^C>#?-BM:0J_>@#Q M5=>Q_\&[N?=%V+WD5!7NV#6YS0<1V&Z6= :9 M)O1O88BG0=@>>/RB]0"^WQE#9\,+7 ;Z[%]02P,$% @ IXE84K1LZJT3 M!0 )0T !D !X;"]W;W)K&ULI5=9;^,V$/XK M S=;)( 22]3I-#'@7-LL-FZ08_M0](&6:9M8B71)*MGTUW=(R;+L)-X !1)> MFOGF)&=\\BS5=[U@S,"/LA#ZM+C4,95%G_A^TB\I%[WAB3N[5<,369F""W:K0%=E2=7+&2OD\VDOZ*T.[OA\ M8>Q!?WBRI'-VS\SC\E;AKM^B3'G)A.92@&*ST]XH.#Z++;TC^,;9L^ZLP5HR MD?*[W5Q/3WN^58@5+#<6@>+TQ,Y945@@5..?!K/7BK2,W?4*_'4]'HW/K\>?871W-QI_OKRY'#_$!\XN_ "UN30X<7OHLW,7#! M=5Y(72D&?XTFVBA,C[]W@$.3 HW? [_'63*N"@9Q!(<7\T#!58II,S%NN MW(EE[^.Q7M**NXR/F2%D!+60FCK22+#W)2\#FUN:Z!BBDL M/T0I\.+C.0HH>55J#Z;HF9K<@G"M*RIR!KG4]LB!8$18.6&JC8HC)7XP0#*\ MK[J6918,9K+ >\_%_+@F=$3[7& N%X55X !NJ*D4-R^P-FWD%(9QK=MMJ]O% MAF[7*]W.G6[_D_V>"2X53CDFQ13.<> &KFC."VXXT\Z $.[8DRR>T* MBA?X M4@E6T^S!K[]D)""__62UXHCAP6;)5TD%G+T&C"'TR""S(WHP]+)D@&.:9#"6 M3W4@W@?9) F\H![QF@8>2>V:Q.FV\6-IK,')4>Q_VCS$:*E\8<%(:\9JME"^ M'2,"Z9'_/FL$Q/-]2SK(TLXZA/@-B=L6I$Y(&B:=M>5,XVW.437'%]3RI1"C MC&@0-7.XLOA1Z$V;:PU:5<-75D8^P7\?"3,K\8:^O$T7>%&4N3& R(&R2LG# M*1,2WW%J4*2[C#L DLQ&*4DCC 3&[1.,\$X7;4K$-AE(&'76/@R4:<.O0G H-6O MGFV$[>>UGJ'?T2W>T#/>UC,,=LC] U]&!=^HXK+28*_BZN]!&GR_-@N'>ZRD M8]D#$GE!%@,)O0$&%O<)[C,@L9<-8OC*-*;P>:44P_=O*97K?%Z5H@YBY^ZB M&6,I#O.?D@2PHW#&;>&,/UPXZ7RN&!8HAIV.JPWX_'ZLH.Z4\79! MO5F+L&ZYP8$:B4&\I2_8?1H-6Q1E2[%<4;Q56+%AKBL@=IW8\^8YPW*!9>.% M4:6!";?I5%*';6/"Z QM!(JM"=5- <6H;A9-3-B@4TDVWN.-UZ1Y;LD@:-X" MWTM"3+2UH !CGZQ2;ZZDUEVW-PGW*+")P(3XUSY;;1G=)XE_\(&DK=/EK2SI M=UK7DJFY:] U./RZBVU/V]\ H[KU79/7/R#PS9YS='S!9LCJ8SWH@:J;\GIC MY-(UPA-IL*UVRP7^CF'*$N#WF<02T&RL@/:7T? _4$L#!!0 ( *>)6%+K M6]6?N@D &PO=V]R:W-H965T>>2'MTYV0O^4;QA3YEB99?C;8*+4]&8WR:,-2F@_% MEF7P9B5D2A7XP2CE/)L<'ZJGRWD^:DH5,(SMI D+]*4 MRJ=+EHC=V< =E _N^'JC\,'H_'1+U^R>J2_;A82[435+S%.6Y5QD1++5V>#" M/;ET]0#=XQ^<[?(:37 I2R%^PYN;^&S@H$0L89'"*2@TC^R*)0G.!'+\;B<= M5#QQ8)TN9[_6BX?%+&G.KD3RE<=JJZ/FI%#LBL3?,AH1> MJAX-PO$,K7*O)+SE,$Z=+^:W]S>?;\G%[0>R^'S_<#=_N+F;?YK?/I#YI\7' MS_^Z7TEU[OC!]8-"1C]QWQ',_IF6]<:6.LYQMWS'?'%)<, M0*?()MZF^ER_Z]DF^I1$[&\!< M.9./;'#^L&&5$#R+DB(V(ER\0@1"*][\PQ>DUN1O:_NZ<70S#703^+H9FU?'S5FVD@N(:* ] M'C$2218C0-Z0O_]MYKG>3PW*F^(E@(OKXF5">N#C5_#Q>^%S!780&4.#@?(S M"-I;!C+%/")+J]4(5-F&C_Z)$0K&4#Q;$X4>#JL5CSP&70$$- (Z.!]9UL>: M-TPC]0B4E69/6B/3GW(,E< TK@3=6CALM641-MLF"JJ." 0P/)KVG;&M!=GL M+P:5.WOA]KZ$ BXS#CM=H\JV6ZBRO>T!*GI[S=DUC=::V!;E>*,E MT]<>]PTJ]PV^PWVU6VUHMF:(;O"V7XVA2]R+9<+76JWYNWK'FO71#U8%)E.2 M*ZJ*ULS0+Q-ZOO'W)99H1*<'E##Z+X5]M:PZ4C1RQO\\1UQ5DBZJ%96L/U;2"!PN>-@8/H?@?1X: M)C8LS--M(IX8CL^4Y,M"H^1%;]C[#53;*M&*?#ZJ],/#YU5%M*4\MN%&7R;P MG=D6OA>'N=:=$HB5+BS1T6N]*J1D6?1$H*S*\L3HF,:_0K7;+I'GZ8D/'_>; MA0&H2H-XXT";Q LGVASC$(U0LS[BZ,+@])IR21YI4N@BK8;@-DM[;@!K@_4% M8);)]'EP1%TD';'; RD\+ _"[;>SZ M&GB'CWNLT32P:VT1:EL\FZ8>>)I#W^ADB2'>1GK'W(8SDQQ"W4S@Y5VMGH1Z M%LID62"=566R7C1D4TZ7/.&*LZ[JT.866-3\0-IH"]\Z( =[ -Y6 ;R^MZH95@5:&;0^FXW?)\AML=HL\IHLUZC71<0 M9=A>7_3)N%JIW%:%MAFSETV[,;MXBT=FF&?LF\+ @S[W@DC:H_3;[@W!.[+; M\&B#!T-XP$-862:OC""V_GR'8*%;J%>@+ 6CP3V\K#HK 9.:4%8'51,[?T)- M J"SF\ W)- E)CR!T!_"G:;'F .FAIX8>HRT7Z.#]YX#&73JZZSA]2$FK! 3 M]B+FJSZT8O%["F:B:]ROYT6Z-;FBR(V&8@9E2 HCNS>> M1WB&0R3@FXR'$%/>DLD0H/,6[OQ -\Y$/W3-'10J;VL;2QP'T:F]2 G,3-.R M\1UHNLJ..SL5[AU 1R8F\@PV@31GKRY>GM>_>A.)2M&R^D,'A6@V38\[5(L[ M#&;0R1M"Y8>-%[Y> ]XPG!FU&>T%V/2O%!3N:SXSPVZ&"N]:3M?R_P24E=0A MMEKV.-VZ\THL:?1X0R?<0^K'#-ZEDLF-4KC5POSS>,'",[/YWV*,G MSKK._IC=Z8VT=B.@(44HQ)&H.T"^,%7SK*[:KV/"I.U<7CRL/:F?FU9)[(KF M&]TE0H+]7G"H9#0O%S6.'@3/U!,D6ZA739&J_&SD$K.T][=1\['WL$R,Y4UZYK)NNS:NW'$[>_XFJ6=]9A7SK++ ]$ M,'^9$W?8I&7V9ZH=5QMMRXL(5IMS?-@*DE[)NM-HZUF/$@I@4Q=N^01R/3*S M6P.+*+86\NGE4_^R=(L2F(BO>%2="S(*Y5K;G+ABT &.6NWUN>&0Y66T,>\A M-.<8K#''8T>>;0NU3_LIN#=6??OQ0P*+EB*0>FY9&K'6$8^LD>6 M (I18D-[) ;4@$\UEC3L",3O:R&S12,'3T US:JR9%^R-NV8/&A3]+_M]A1S M]MSZ>X0]GVY[IT\+(#6L$V;.Z"#*/O,UN]=:2D%CDE+Y&]L?ZTYF;21X78V< MITRN4;MF[/X$(&RA7+].?A4RB7<\9E#?@1[$EL7/9@&5MY%!G301P"*\FG_2 M2C8$Z @N)Y!#*CRO)8WWR<,=SUKIT*^3]N<"+VR::NR6/R:X?O,-I. N-!Y$ MT_\#(IM W$OM]]R%!W>O F(GE-P6RJM1KP&2[[:1-1,"^?UX"%JH.O!_3L02 M]+B!/0YYXBR)>]DX2MH*A#A2) R+-OR[,C1);_4^'I5!*I)K<,+""Q [P?B6$ M*F^00?7?E_/_ %!+ P04 " "GB5A2'?-![%0$ "Q"P &0 'AL+W=O M-SB2F]DAKO+;BR*(1]N49E-M.H%^T^/,A5[OE#9S99BQ4NT/^]OK>TZ]0H MJ2Q0.VDT6,RFT;QW=3UF^2#P0^+&-=; D2R-^<6;K^DTZK)#J##QC"#H]80W MJ!0#D1O_;3&CVB0K-M<[]#]"[!3+4CB\,>JG3'T^C2XB2#$3I?(/9O,G;N,9 M,EYBE M/V%2RHVX$2>F\*;;*Y$$A=?46S]L\-!0NCBG$6X4X^%T9"EY^$5[, M)M9LP+(TH?$BA!JTR3FIN2@+;^FO)#T_N[N=+VX7\/%1+!6Z3Y..)U#^U4FV M -<50'P$H!?#-Z-][N!6IYCN W3(F]JE>.?2=7P2\0LFY]#O?8:X&W=/X/7K M$/L!KW\L1*2J.?AGOG3>$@O^/8$YJ#$' 7-P!'-1<1A,!I;K?F:RL](A".?0 M.Q ZW?^NI%A*);U$UY;BD\:X+Z_<6B0XC:CQ'-HGC&8/1\PJCK9ICW^:1 J/ M*7'+Y^!SA!M3K(5^^=T!M;<57NI5I4GB%D'J1)5435ILQ;4S2J8!Y%HHH1.$ M11@:PG$2J&98+-'6=0N^Q-W>)0MD1E'SNROX2'B%5(KZT7VJY(),6S -'Z[@ M.WEA01M]EI36HO8[J0\0#R_Y.>[!W9O0]S#F26)+6K-G)N#ML)HJ'V 8\Z/? M8K,I%\=CB ==>#1>J):LLTO!LGQ8G[?9Q0DQH5"C8;\B.&'L)*GS2'U:L$>%Z W.I6V M49VVT7O35I7\T*;4U<%&0;1E\C1ZQ9 &!!U3*O2(-V\;BY-ZD$JWWQTIK3CA M1Q)[(UP.:R%3R*PI&@82_I$Q2# B"E/J_0X*U2S(C])BP52N>;3/V?& '_W6 MAC1+3X=\!8?/22[TJF**IK/W,*_[L'WNA,$8?H9#$M,S\43BI$[>$.:KFD=; MP/A\M&7>Q7F\7;W13*5+.$P@LP@C$ORM>IY@S;AFS?C=K#F(*RL]I9"J\,)I M;.V^D]CMW3=O'Z*?#\U!26=LF$D)CV#5UD85!U D.6-RW3.Z]]"M*TD04Q:K M,HHZ;!I& S&9TB@R*D0X"4Y.[QXW] 6O8AZ8].[#8,CO ?3#>PC] 3R^0O9( MIYJ8_>&(!K8CV*_%NO2!5B2!SL-X#/><&BKNDU EAE/V@"AU1GC*5C@WVRF] M-C;T(LWQOQK#>_?Y0QC=;2SI-*Y1!=I5N"PZ"#2K;E3UU_H^.J^N8:_BU67V MF[ KJ1TYFY%J]WQ,(]E6%\1JX\TZ7,J6QM,5+RQSNE.C90'ZGQGC=QLV4-_2 M9_\#4$L#!!0 ( *>)6%)?1&B&PO=V]R:W-H965T MJWQ"H6P M@LB,OVN9G4:E9=P=;Z6_<[Z3+_=,XY447WEJ5I>=40=27+!2F)GSZ[/I9'[]%JYN/MY>?YI/[C[= VIL<3=I!8YK40&+XCL!?!1YF:EX3I/,=T7T"7[&B.#K9'3H%7B M6TP\"'MO(/ #OT5>V#@=.GGA2TZOF,(S&\P4;MDC8"@@K1;8O#[7!4OPLD.)JU&ML3.^^S]LH;04S-"BD4!031Y %G:] MDC>;?]9 =["AH,((-*@1F*065"'T.)SPGJ MA!9TZEHK# M4<_WU/P,O3X]@IY]A)7&V(=1#P81S']D/7'[??<,Z#D:PHQVAZEDY8Q+<4TU MJW"(J#F<0JLK=K\Y%1.>+]_ $G-43#@VEE*:..,(XA"&HU>8U8+" M?H/"?CL*J9JGI4 ;U8TK59B>L359O;2;3S6YJ*JDW@(UI<#:\9+RPD"IR5$W M/Q6, D#R))6'.A!GA>*))02,HP+;AXA''E#^ 6B@=>G5S\BLE]@QO7#V4(A J?=H?0VH*R7/2^@ MU<"1!HZO$9GR-4^1-NN1HTCAUY]&02_XC2@.C%J@-VB@-SBV .[Y[AHR^74( M+JT27RYH3[$QMGO51PW^#P7UH&I(2V6I;:SVZ\X;RL8$"P,%JJH, LMD2:7R M%&YJ0'[=QG]G-%DN%2YM &Y*HPU!TA6(/UA>VCVH>Q@,/5>Q!EX]%I[881-Z@;V/(% DPQ>"C4T4P@1N44(E?4W3AV4$E8QA6'ORO0QG MO0W!(?;(&UGVH75T0"!V-;4%:,,&:,-C@993_JXK@Z@*;*LMM8=6U+6*?Q7J M?FS'ZR!X9X5-G; G['UJE#T'W* "G._UHP9P806XGA<'V^B=A#7:8B\0JKJO-]%:.O< MQ25/=O9>'XI]NQ$'&M3=?/:"^*93[83V!RWJ0'=I:R97=+ZVY].2SAQ4]+/V M%G)%APR6/]88VF\H@ZJ?N'82M'83UTQ<+VEK"G$3U?@5N7IP/UM3ME7+?TW9 M=G->E[FWSV0>E\"!*Y14O[! M1.WN7"LS5$MW>=9T9B5/JAMF,]O&=!Y4 MU86Y^C"R<)?4>VGHRNN&*V0I*DM ZPLIS?;#*FC^M1C_"U!+ P04 " "G MB5A2,"9@'I4" "*!0 &0 'AL+W=OV4]M_OV DI M*Q74"QG;;]Y\,&^&.ZF>=8IHX"WG0H^\U)CBRO=UG&+.]+DL4-#+1JJ<&3JJ MK:\+A2QQ3CGWPR#H^SG+A#<>NKN%&@]E:7@F<*% EWG.U/L4N=R-O(ZWOUAF MV]38"W\\+-@65V@>BX6BD]^P)%F.0F=2@,+-R)MTKJ8]BW> IPQW^L &6\E: MRF=[N$U&7F 30HZQL0R,/J\X0\XM$:7Q4G-Z34CK>&COV7^XVJF6-=,XD_Q7 MEIATY%UZD."&E=PLY>X&ZWHN+%\LN7:_L*NP_8$'<:F-S&MGRB#/1/5E;W4? M#APN@R,.8>T0NKRK0"[+:V;8>*CD#I1%$YLU7*G.FY++A/U35D;1:T9^9CR9 MS1[GCW>3A^@:[A]NHB7,[N>+9703_5S=/D5P=[]:0>N!K3GJ]M W%-(Z^G%- M/ZWHPR/TG1#F4IA40R023/XG\"G7)N%PG_ T/,EXC?$Y=#MG$ 9A<(*OVS2@ MZ_BZ1_BBES(S[_![LM9&T8S\.<'9:SA[CK-WA'-%TDE*CB W8%*$6.:%%"B, MMCE7M7F-I1?T7@4NO/.GTZYN0+K,!< M1"S->$V+<1F$C( MZ'PG'T)KE^<5M#)!(\W*Z #D1QHV 6-IU(HXG>@Q@E-H9W,DK\TM21; M ]^@%9X%@T&[MGK]-BQJ/7_ SD#0[K&=8F_0NB!,JQ>TX4OU.-Y.M[N/<-EO M?_;W^0?ZR%%MW1;01%@*4TFEN6T6S:32UP>\VE)SIK:9T,!Q0Z[!^>#" U4I MOSH863BUK:4A[3HSI66)R@+H?2.EV1]L@&;]CO\!4$L#!!0 ( *>)6%+A M!7(G?@( &H% 9 >&PO=V]R:W-H965TS.\M:\=I;VPO)WW?LA0V1 A(R MOIQS9HYWQH.MTL^F1+3P4@EIAD%I;=T/0Y.56#%SH6J4=%(H73%+2[T.3:V1 MY9Y4B3")HJNP8EP&HX'?F^O10#56<(ES#::I*J9?)RC4=AC$P7YCP=>E=1OA M:%"S-2[1_JKGFE9AIY+S"J7A2H+&8AB,X_ZDY_ >\,1Q:P[FX)RLE'IVBV_Y M,(A<0B@PLTZ!T=\&;U$()T1I_-MI!EU(1SR<[]6_>N_D9<4,WBKQF^>V' 8W M >18L$;8A=K>X<[/I=/+E#!^A&V+3:\"R!IC5;4C4P85E^T_>]G=PP'A)CI" M2':$Q.?=!O)93IEEHX%66] .36INXJUZ-B7'I?LH2ZOIE!//CA:SY6R\N+V# M\<,4IK.GV? PVTE.6LGDB&2!,S? GYTN2=%78_V3(OVR+E6>9-9OP(QI-),9 M0IK0@?L=-4#\R\2-U[$;XQ0^^C#A0?U7J->^RPVY:J1M6Z';[1Z2<=L_;_#V M%;IG>LVE 8$%4:.+Z\L =-O9[<*JVG?32EGJ33\MZ3%$[0!T7BAE]PL7H'M> M1_\!4$L#!!0 ( *>)6%+%(M UU ( -H% 9 >&PO=V]R:W-H965T ML "5JF5EHI*MV+-.V# M20X2U8E3VY3VW^]L0\:DPI?$=NZ>Y[F+G^MOA'Q2!:*&UXK7:N 56C>78:BR M BNFSD2#-7U9"EDQ35NY"E4CD>4VJ>)A$D7G8<7*VAOV[=E,#OMBK7E9XTR" M6E<5DV]CY&(S\&)O=_!0K@IM#L)AOV$KG*/^WLPD[<(6)2\KK%4I:I"X''BC M^'*U4RX(IO!+\9YGK8N#U/,AQR=92\O3P_O%F\@"37[/)=#X!_W9Z=7\W"4Y@.GD$_Y$M.*J@ M'VIB,O%AMD4=.]3D &J8_P\0DL169[+3.4Z.(EYC=@:=^ 22 M*(F.X'7:NCL6KW.H;EV@A-LZ$Q4"JW.8O-(]5ZC@]VBAM*3;\N<(3=K2I)8F M/4 S)Q/E:XX@EB LI8^.*(#2DK_7W..83OH6!GP'0[^L)@N32X$^PQLRJ6RO M3,?BS[9$6O0@$V0HI14INC3)=*DX)W^HP(:[:!OYK=3EBCGO4+:33S[02- ? M(4T2>L8G:133VT\N AAES^M28DZEG3929*@4&5>1EJRP&#F^T!AHR-2:A!@5 MG032&&*8DGA_14,D "XHC4@5H\MG&L>40@KUXP#\#CW.'9$JC;93B9QIXG1X MGS[TDCCY CW"M(UR?8G![P86X5CWJ*ANZHJ*4UM4%+QW"<(]OU4H5W:J*%*P MKK6S7GO:#JZ1\^N_<#?U[IA;0Q!.\Z'?P%02P,$% @ IXE84DWS)_*2!P A14 !D M !X;"]W;W)K&ULM5C;) M7MM5OLQL)C47E^W9;"J5!XB$),R2@!8 ?G"SX3=\)]6=P8O T[+:6LA;)2*V;$]*QW$9Y;O;C;R5U]SQ\U.C'YDA:6BC@3^J7PWCI"*GW#F#?R76N?/W MGZX^?WS+[B]^>7O'^O=\4@E[=#IT4$T"PV*IYK)5$^U1$T;LHU9N;ME;58IR M6\$0-G6&12O#+J.#&J]%<7[SOH*K0M6#W_(E=2UM4 MVC9&L']?3*PS"(W_'-@BZ;9(_!;)GBVN=+W02BAGF9XR[["!O!!Y*3*5C M4Z-K)EM+''\2=A?2AS>YGPM6;&WTX24;,?SMH21 PYQQ5=)@#%U(,.N@Z(3U MI4*,5172Q1YYZ5;8"UY#EW6R8#^P?A(&1_2,!G&>^5$X2$;I$4.F( \4ZZ=1 M9;)1[F3Q.EK+C>.1'R2!,DZ,#T*<=].DKH'\5W <5$R>>V 4OQ%D/ MI&>%>1"]'3ZX_/-POVJ,P38G6PX8MT!&]/C;7\91&/VXQCX*X9-^Z'_C"$CW M(_(&Q,>KF6LQ%5!;;FB%J^# <-3I2?. A>,1BV%.FN<81RR.1]@Q'J7X31/\ MA $[X+ZLX^+$/EO_29CZZD M#=4^J*U/*4:,>%%^1<6N/2D 8I@ YR1D\;!EBB#-(GC4%=SKF8"MK('7C6M M*DYX E-.0)=.BO9]A]=W ML=9!\W:SUO5++/ U$!V;J"< @B?U&QV['1B?>H9^B"&_.,9'CDIB2^ MB 9YE+3/,&0W1C](ZX,P' 1!PK(D9+K9R*1Q%+$Q3 M=E=("I0I"N'6.N(80U\ACE2-;?=^824=+UP!4;F#LQ/G=M0_,J51P*)%]H0'B*G+!6S=& M("=*7RN4)8X9,9S\;A];A1D#TFVX [XH9O>:#K8KS)(!\6,\R+.,?1!PP2YF M07<7I401$6@[1!KC,W*7LG"04PZTK-G-@:D2./&65D*^DJ3=HMK1B'!\@,.H*VC/I*SCWS4>81Q7%/!-M=$17['5IW>69/ MY?Y.N;[D%:T>@$9G4BDR"]L^(Q]\KL''RYR+_3,(0JH+9M86J_VENC\:@5*Q M:CP*-E>T8/.BH$*+,$%,]W,4FR1:FR+(*1M&(.!^9\P!'E[:TU*[];4QTI;2WR3L(M;#JO^QL?J$?2;M__*:ORA)=?X.G0E >L/> MB5(8A!=\D>+5^\57;HYQT$W])$R-?H]>DM7<.^/=CG'4V?1 M1D(WATB%#VC:;LU?-/1EC."CUW Y>P#GO,,Y?V6O3U&]CC>R#R[WP[H-"\@T MBK)AIGSVNG6=W]F<'S1@?W/^ZE3<:]2?D7U4V"CP,]^0I/D8[6:Y[+Q:JM?? M-F0;?2296[1?DJU"L'JB_-M20U=L:L/W"2$RWF1""2+.8RMYMVZN]:%4_ M"JBI2L?^J_2(?> +ZWN@MB/WPTK6TO%E'YF2($GC"W8/#0"-*/T&E5W!.=RX M&JL%:(-%>K:W%VPO*CV M"?,J,<72X'B4]IAI+_W: M%Z<7_J)MHIW3M1_.!4=&DP#^GVKM5B^T07?S>OX_4$L#!!0 ( *>)6%+[ M5!*/M@( 0& 9 >&PO=V]R:W-H965TV%20YBU;$SVRG=M]_9@8Q*!6G: MF^3LW/WN[XOO1CNEGTR!:.&E%-*,@\+:ZCJ*3%9@R4RH*I3T9:-TR2PM]38R ME4:6^Z!21&D<7T8EXS*8C/S>0D]&JK:"2UQH,'59,OU[AD+MQD$2'#:6?%M8 MMQ%-1A7;X@KMUVJA:16UE)R7* U7$C1NQL$TN9[UG;]W^,9Q9XYL<"=9*_7D M%O?Y.(B=(!2864=@]'K&&Q3"@4C&KSTS:%.ZP&/[0/_HSTYG63.#-TI\Y[DM MQL$P@!PWK!9VJ79WN#_/P/$R)8Q_PJ[Q[::O 1&I:J6E M!VFS]"SQ%K,0>DD7TCB-S_!Z[5%[GM<[P9LS+;G<&EB@AE7!-,*/Z=I833?C MYQE^O^7W/;]_@K^BALEK@: VD#&1U8+YBT=+H8R!BM(:E_:MXIY'/[R*!V:M MYNO:NG\%5L&,U=2M<(=,V )N5%DQR=' O:0*4N/Z"KHZ)A^ R=P90]@AD0XZ M,0=FR%50DYIKN."2+IL0)-]T 5\RK.QQ_E+5TIJ.YS98C_Q$0\0?]9\$OH.+ MP67<<>^D>S4<>JO?3?IDS9CAF=><@- M!F%,SS1,Z)F$O3<0XC^JZ42&@T8C96J,) F'2>>M*Q0==6:)>NOGCR'-5+^F M2=O==L1-F\[^Z][,QT>FMUP:$+BAT#B\&@2@FYG3+*RJ?)^OE:6IX&UL?53;3N,P$/V54;0/("&2IM>MVDJ] M(9#*4A%8'E;[X":3)L*QL[9#X>]W[+2A2+0OL3V><\[,9,:CG52O.D,T\%YP MH<=>9DPY]'T=9U@P?2U+%'232E4P0T>U]76ID"4.5' _#(*>7[!<>).1LZW5 M9"0KPW.!:P6Z*@JF/F;(Y6[LM;R#X3'?9L8:_,FH9%N,T#R7:T4GOV%)\@*% MSJ4 A>G8F[:&LX[U=PZ_<]SIHSW83#92OMK#73+V AL0@ MK#>QV8U+U:$IN%S8GQ(91;EZO5\O[Y:^GZ0KFT^@6;E8/+["XB^:K MA^CY<1G!Q1/;<-27(]^0H(7Y\9Y\5I.')\A;(=Q+83(-2Y%@\I7 ITB;<,-# MN+/P+.,"XVMHMZX@#,+@#%^[2;_M^-JGTJ_*DB,UF6$T:LTXAUG%CGE!A-5%)Q!)G"">%%KF,N=:50?U?NL_QV?H>Z9#&. M/1I0C>H-O:\9QE8HM4+)IQ#0:+MZVJJV?@(3B=T,@"D$9J\Y(?00+G)!+<@Y M39.^=(@:X)P?3(8*2O91%^Y.&"1N0Y8\@1_0NNKT.V[MMOMN[?6ZY!7+ L&P M=PKCX-D+[;?OONT!?%=X_ZCA"U1;-]8:8ED)4_=^8VU>CFD],)_N];-SS]0V M%QHXI@0-KOM=#U0]RO7!R-*-ST8:&D:WS>CU0V4=Z#Z5TAP.5J!Y3R?_ 5!+ M P04 " "GB5A2Z)!(+!8( " %0 &0 'AL+W=OX#\^CVW6Q8FV 9V4RZK];A]G^<^I,,[J7[7%XR6?"J&1P?VGN7ZOA0+DU= M->)2,;U<++AZ.!6UO#L:^(/5C:MJ-C=T8W)\V/*9N!;F6WNI<#7IN9350C2Z MD@U3XO9H<.(?G.9$;PG^58D[O7;.R)*IE+_3Q7EY-/!((5&+PA 'CN6[.!-U M38R@QA\=ST$ODC:NGZ^X?[2VPY8IU^),UO^N2C,_&F0#5HI;OJS-E;S[173V MQ,2OD+6V1W;7T7H#5BRUD8MN,S185(U;^7WGA]=L"+H-@=7;";):ON>&'Q\J M><<448,;G5A3[6XH5S44E&NC\+3"/G-\_>'3Q8O5QR,7/-/C2E*)\RF$"U7K]@I=]IL)/C M>U'LL] ?L\ +O!W\PM[>T/(+M]DK9H"485>BEOJGOGCW(M8,/:" .=I ME+.ORLPE>R\HEV0M9U6A61R'+$YBEO@I>X_T5+JZK43)+I4LEP5,\\=^0@R" M-,8QC#UV(PV$]W[88QEDI'9-/-^N8>:QE<.6FK-J+@Z M@7-1EQ:-FD.+H>]#V# E#>(D&P%7R#0X8ZFPE]@8,5-.?T*J%BWO+@NI27^2 M/PS]D3L[*?Y85KHB@I^4J.&5$H0-93$Y$:>Z*D7'81AE9#BV(5Y(#L6&XAZM M3(L1Z2\78LP:&#:,XLAZ*")ED09?6\L"QCDR-B0C1RQ)$ZCAA=:-809B"R*8 MM"+T0X;(^O[C@TXBL8]#)R8AE6C-X);/G?O$/0F$<7,+!P2S%%/H%E.P([N! MHH\^A"Y#Y,4@P^7T?S]&&5 M&ILJY4[9-,434H^O*-&+1.:^OJMMB$@)V"-B/@:DWB*NI=#WTB[J5 M/XTA>QI$%[)-P=H8)A>!OT#G_[F\G',(+<325 6O*8ZI;6M91J#*_*RGK-8 ;=_/\0^WTX!#DI!V& VHCZ$RWYSA++(]-(KM$?5VV_ZW MKL\YGRI.4ZR%B6LAGU!/%84SPT208=I(L^C-@B(X-(I29"$9%D19?_1SOQ/4 MYP=QO6[PVNM&K[UN^-HV;>TH#VE?'M*WEP=R?2V;V4\U\J=0768H;LVU0F=@I\H4QPJ@+&J&JZI#G#2,:?"[4OA"5U<&H>M2SZ88RN MW>L;HOEW=Y=O^]?[=N_E4BAH=E45T@4[IY#$"%UD5P_P.)M7#6%G8I@CG:HZ3Q:/O8[T#Y1G!F M/3BS5X/SC2#A:&5/,P9BV"Y/J8P&S<4E=S8RWI M613+Q=*-R>OCUG@#MI]9HI] NU*LG3]H:BJ/* =<(04OZ&(Q13Q6+^DK4.>O M!_46/*=V%$KBA)W3N(_G(8$,':I#L(]*2G6OPRJ@D7L]VA!XX+U#*(H<@-=A M,XPPWJSR A %P(2: HVXBXMS-.4'FJ11(1W44N VS&P1C!-7'",4YAVXRGM< MY:_&%5X":)2H^[JAX7IN*(YRV5"@J([XWCN&94'C/=69)V_#F_"W6X&S_UG6 M\_#^I4I=%+\*K0&4U>Q)H/'3=^Z?O<,++)JIEDM5B%.A\ [WG#)QE&='XKI5E= MD(#^H^OQ?P%02P,$% @ IXE84LZA#.:W P D @ !D !X;"]W;W)K M&ULK5;;;N,X#/T5PIB'! CB>RY%$B!M6DR!;:?; MRRP6BWU0;"86QI8\DMRT?[^4[+H=H U0S+Y(ID0>'I&BZ,5!JA^Z0#3P5)5" M+[W"F/K$]W568,7T6-8H:& M)DOM1CBTNFGB0=9H(ZO.F!A47+0S>^KB\,9@%GQ@$'4&D>/=.G(L-\RPU4+) M RBK36CVPQW561,Y+FQ2[HRB74YV9G7W<'/SQ_G5^?7]^O9OV*SOUS!XN%X_ M;"[OSS=#&-RS;8EZN/ -.;,F?M8!G[; T0? 80174IA"P[G(,?\5P">6/=7H MA>II=!1Q@]D8XG $41 %1_#B_NBQPXL_P/NS8T5O=N2+ '!K!FIS;KU?'F11:ECQG=OF5!H9;)"&%#&R#4!)!9F$$VMD$P"*Z1#N*9WKM/I+)@Q MBF\;8R\Z& FGK*&G#[XB*XGIF:QJ)CA1N!1T_0@D3",+.8BCB9VG8;L8#\E2 M\PP8'7;#R\:&L_.$3 GBJ-\&Z9->@W$2#]N/N?,?C*/@=<,>*V.Z@%K)1T[U M!MMGD'UPW-O'C06DR$PL97JU[9A.:(SG"J*G^*:=MP^A7^W:[;KO,JWK;JZ^8VG.AH<0=F0;C:>J!:OM?*QA9NYZS ME88ZF/LLZ))6%)O'I??&P( M !8$ 9 >&PO=V]R:W-H965TABQUF[H7 ,-$F#Y; DB-?M,.R@V'0L5)8\B:F;?OTDV3$R8-G%$BF^QT>1 M,QA2.N#E_LR^]+7;6O;,X%R)'[R@:AI\#J# DAT%[53[ M!?MZ;AU?KH3Q7VC[V"B _&A(U3W8*JBY[%;VVM_#!2 >7P'$/2#VNKM$7N6" M$4L3K5K0+MJRN8TOU:.M."Y=4S+2]I1;'*6+QVR^6VV_K39KV"QA]I2MUH]9 M!A]@S;1F[LK@W0*)<6'>)R'9E X8YCW]K*./K]%C/H+)^ ;B*(YR=92D3W^S MA%;PH#H>5,>>=G*%=J,/3/(WYAI[ W,EC1*\8%V?90%;C08E=0Y5PI)+)G/. M!&36B7:HR,#/A[TA;T5VCORVL@\7M0NPYZ52=#;<, V_@O0/4$L#!!0 ( *>) M6%(H2Q-:U0, &0+ 9 >&PO=V]R:W-H965TCKI1(+',AD*0B2$#2%&E#HY!TG\W,@;'BL:GM":':'[_'PV2@ M+3A]Z0N,+^?S]_G,R&/2KN7L]Z*O2"B[Q7H,IBX+IS0B%6E\%F\40%H:JXK:F!@47&[_ MV6M]$7L&G?B(05(;)#\9),<,.K5!IQ*Z95;)NF:6#?I:K4&[W83F/JJ[J:Q) M#9?.C3.K:963G1W,)K?3R:?)>#A]A.%X_.5I^CB9WL+]EW\FX\G-#/Z&L9(I M2JN9NW8#:@%CC1FW\,#-,YQN'ELBY(\*T)C+:$DF. M$(D3N%/2Y@9N9(;9CP AJ6JD)6_21HD7\1K3-G3B%B11$CW-KN'DP^DZ5P(- M$Z@/,!S_-EY\6>-Y:'8:#W0JV,X16._]>O#/&ORS"O_L"/X=>^5%68!%73AT MI?F22R8HBFRIN=V 59 *9@Q?;,B'QNJ2\M0:8 929G)@,MM^X+>2O]#EN<43 MND<#-F?R])"S_9PZ4%2^]LCK-O*Z7JA[U.[ZJ.0X<9(*'UUEAE1B4B2RH"&1DI9\ MTX*19M^Y:,'-XF"5WZ@=]G0N_0'%Z,@R4J$%6JNMN&S'UB4.7.DH%L*RBF:>2\K_*==1I"QC2\I MXFA7UJ/WTL(1/I0/U/8$([<"=75C*5ZX7,))H30>)_[.:;_!?*\AQ7[F2E<- M_F@V$TD+W,"J=LY!OO$OP9 <#H4XV1%+O,0>?V'R'SSFE)E-.7EJS]J[FJ)W M185VUGF3[B>4[[YV[2/^,_TCWC60V%^MIV4Q)S6$[*F;)-';7$?U(;T]EW1^ M!UA=*V;>!.Z!Y6 _^!U!+ P04 " "G MB5A2DX2<<[$# #."P &0 'AL+W=O="JSGH.@@%<\*8\T@(^S\ MCY^+1%P8^(,6@Z P"*H&_1:#7F'0>ZM!OS#HV\R5Y]7X?SQ.YJ'X;>GQ^^KQR]H_>WK*EQ] MVJ);-#<[0]0?1!B:4WU.,(L Z1.'0@$Q4>@KEQ(D>K\$A0F5'[3-TW:)WK_[ M@-X9HP="J=YB.7&5)FS"NE%!;G$F%[20\P/TP)E*)?K$8HBO';A::2DW>)&[ M"#H]+B&Z0SW_!@5>X#40"M]L[H\;S)=O-Q]UJ.F5F]>S_GHM_C9P!';0FR%X MAD*=*:&OD3Y *D6A/3H@T,_Y3MKU7QT!^V7 O@W8;PEXO?\Q/^Q4-ESNN0_O :LJQ#QJ^0*RGWI93[SMS-"\YH Q&0 M(]Y1N&D_W^CGAE.*=*DY81%WI7)0QA]TIG*!J0ET@W:P)XP1MD<\03D(PN.F M/)Z]#2Z3-*KDL0%2S6,=TI;'8:ECV*EC TIPF8.MWPB21(^,$ISGE$38%G<] M9?H%*(Z)D2H59K'.9)/288VC7Q%:1W@5G5V(*YFC4N:H4^9:\",QCUT3XU$M M6E!A7$?X5V%:NL+TRS:ANH5S?G3OW5 3$N?F\3Q1/+?MU(XK_<+:8:H;;A &H+\GG*N7B0E0MO"S_P%0 M2P,$% @ IXE84C[;(K%A P +Q !D !X;"]W;W)K&ULO9A=;]HP%(;_BI6K3>J:V'R5"I *_1A2/U!IMXMI%RXQQ*IC MI[936FD_?G8",96&@8ER W'B\QZ?)^Y;'SIS(9]50H@&;RGCJALD6F>G8:@F M"4FQ.A89X>;)5,@4:S.4LU!EDN"X"$I9B**H&::8\J#7*>Z-9*\CD3'1C]E(FE%8J<0T)5Q1P8$DTVYP M!D_[J&T#BAD_*)FKE6M@2WD2XMD.AG$WB.R*"",3;26P^7HE \*853+K>%F( M!E5.&[AZO52_+(HWQ3QA10:"_:2Q3KK!20!B,L4YT_=B_ITL"FI8O8E@JO@$ M\W)NJQZ 2:ZT2!?!9@4IY>4W?EN 6 F S34!:!& BG67B8I5GF.->QTIYD#: MV4;-7A2E%M%F<93;MS+6TCRE)D[WQL.KV^'E<'!V^P#.!H.[Q]N'X>T5&-U= M#P?#BS'X!D;2; &IWX_ B&&N >8QN'C):6;>C09?SHG&E*FOG5";Y5C1<+)( MW2]3HS6I(0(W@NM$@0L>D_BC0&CJJ(I!RV+ZR*MX3B;'H :/ (I0Y-&K57!J MA5Y]C=X-Y33-4_ '7-NJ:9I)\4ILWUF0Z& MFJ3JMR=9HTK6\)9RH30U>YC$(%=DFC/ S!^#^M=+\^O !G@G6/KJ;U9+:FY) M]P9/$O-0OG]DX,G1JG*T/I_Q297L9$^,_3JUC8C;U8K:6R*^TPF16Z&%D;.. MZ//APA6G@GO"NT%H,U^(W**0GS!^^P^+@,Z!8.T C)TEP?J^&/N%:M%FR,Z[ MH-]T'.1^3EE,^4R!76@[1X+- ]!VY@1;^Z+M%ZIO0=NY&/3;CZ.]NR]#YTRP M_?FHD?,J%.T)]08AM!DU];*5OL)Q1KLS.GIK0Z+AEMJTLN]-RH$56=(1/0IO^LKA, M3$=/I)U@GD^%T,N!35#]1M#["U!+ P04 " "GB5A2:9W>M!4$ !Q& M&0 'AL+W=O!;FRVZE;,NO5:(D$[E.9(Z4V$R].?YPS4;E@*K''XG8Z\8U*J>R MEO)KV5A&4R\H,Q*I"$TIP>W/-[$0:5HJV3S^.8IZ=Y_UT<)S0H]4*9ZNHOVA_Z#HF'PD(;F1T'VPRR M)#_\\I>C$8T!>/C. '(<0*J\#X&J+&^XX;.)DGNDRMY6K;RHIEJ-MLDE>?E6 MGHVR3Q,[SLR>EQ\?EW?+Q?SQ,YHO%D]?'C\O'S^BU=/]I/K7B6]L"J60'Q[#71_"D7?"88(>9&YBC6[S2$3_%_!M M[O4$R-L$KHE3\4:$EXCBWQ )2.#0H[4AM-)C[^BME(R*T*"UXGFD'8*L%F25 M('U'\"[)$R,N[NWBBWY@YE_WMC]:&I'IOQW1!G6T@3/]6VT2NU9MJ$*+39&B MU,;5/WI1;ITA>A58_K#,:.I464NVDLBFU6SJJ)4<]6#JNHXT[LM2M,VJU M]*K.Z.JD-:I*Y&A_9Y/+C4L8!X"#H =K<0,_N"-S6X1HJ[N80%+$[2]7)A?* M5IV4E[5#Q\G.J0QPP;0/>X$]F'5EKUL(5_:Z<@)"83=:G@ISD2:AK>PV+2/" M.)>IW+XB"P-B'TX D/.K*:;?0"0L9R(7=R'FP)F1%AOY%)Y")N#]^SK#8+=1> MZP@PC+C1\_TB/KGN$8 2&?3A-.")N+^*SG#:+<3:G0:&$3=Z&DZ?60$)((F, M^S :*$7^,NYQ9 "I&@?NSP*O*)=[?-:A$C0;C%0C;IA!!:?40XI\(GVL>^C MP"K:U@4DX%HU VB[]?QR?60 :%8'_M !H1B7>T#6X3PH-5J!AQC;OPT MK#ZS(#+ $NMC2\@:QU%=;0E;A*[:C0:<,3>%P.B?*8@,0,7ZV!TR(!?K:G?8 M(N0PW6^< F=";:NS;HU"6>3F<"!'4V3H?CB,?^!JF^0:I6)CAP:7 M(_OVU.%\^] P=*:^E,3*K+F/!(Z'*#O;Y1DKSUB@#U/]EF/T'4$L#!!0 M ( *>)6%("V>8*E04 .D; 9 >&PO=V]R:W-H965T,8 MF/[[=4(:A_AC4ZD7O0$2CH]?^_@\/HF'>\9?LA6E OQ9)VEVT5D)L3GO=K/% MBJY)=L8V-)7_/#.^)D)>\F4WVW!*HJ+1.NDBSPNZ:Q*GG=&PN/? 1T.V%4F< MT@<.LNUZ3?CK%4W8_J(#.V\WIO%R)?(;W=%P0Y9T1L7CYH'+JV[E)8K7-,UB ME@).GR\ZE_!\[..\06'Q%--]5OL-\J',&7O)+R;11=JL^\8?WWF_?;8O!R,'.2T3%+_HXCL;KH]#L@HL]DFX@IV_]% MRP'U#RWUBV$Z/9Y/O] MY'8ROKS_!2['XY^/][\F]]_!P\\?D_'D9@9.P93N:+JE\GO!EFF<3_X)>"(\ M)O.$@C&3$8TH)T50'CC;Q7F$,_#UF@H2)]DWZ>)Q=@V^?OD&OH X!7=QDN06 MPZZ0^G,5W46I]>J@%5FT0@3N6"I6&;A)(QH=.^C*@5>C1V^COT).C]=T<08P M/ '(0YY!T+AU\HS)O1#YW M3R39'F;Z,I$)2-(%S0!)(QF M);/GE'FY^+V5*Z^8&ZEO]II2OGPUA?3@)ZCU#@-SWT'5=^#L>[SE/ _0AO*8 M16#SE@2F"0JTWGL>#AH39#!"_= L,JQ$ADZ1#^0U7T6'Y;+@-(J%,05#K>_3 M'@IQ0Z')*L 6B?U*8K_=4J-2HF.1]?4(]F%3H6YTM!*/! XJ@0.GP.LX6[#M MVR2J%'2D&?04B+U/D_RPMCW #TS_TMEQ:% C,B:CL&>.#$1**/H@ )2.ZOU; MU@54X(;XPQ!0NJKW'R#8G"3=* PMG(**Y= -\[80*-T@I9C)*@P&%I&* MY-"-\K88@ :2#YI[C;.$.?:EN S#SY/W"L6P)8O; MY;U.VV"@+6G=J([M8Z$*R=#-Y'?D_4#KW]([4M!&WH?E?>GJ:"FBYGHU&=DF M"2F*(S?%V^8]TM%\BK3RQ&S5MXA4!$=N@K?->Z3SNU?;/TJ-NE%]11Y+5)A' M;LQ/Z9P(YWZ/%(N1_VGR'BGXHI;P;97W2*?K (7-4!@0["%+O8\4@Y&;P>T3 M'^GU-+1L 4AA&[GKZ7=EOEXN(QCZS7DR6*' 4A@A17+D)GGKW-?Q++,:-:LW MLUEH"Z?B.')SO'7VZQ0/PT%3I&Y47Y?'#^<*]OA_8+\B?"D)L'AQ$0 K*F/X M:0B %89Q2PRW(@#6.0N#?B,I$7'M9XH9Q>P!@O9BV5/Q8X1N[2^GW MY#_6"V4X0,TMRVAEVU:Q(CIV$[UM_F,=TZ>RGFZFEMDLM$53X1R[<=XV_[$! MYOTF2DU&@6TF%?*Q&_GR\5_P>+XM5MPM==8!6/$9]S\/!12.<4LLK)OMN)K>'@&^HK"V]*X+[[KKZ/1#P#:\]!LW2VFAD*0%\A73? MC?2V"/!U3LO<;C[VFZQ0:-E=?85SWXWSM@ HW=1?'_>;*#79-"N^;NW09"T7 M37&6E('B!=_A!*&Z6YU771:G-(W[5_!\?#AU4FX.AV!WLEZ(TPPD]%FZ],Y" M*8@?SI4.%X)MBJ.9.1."K8N?*THBRG,#^?\S8^+M(N^@.MT;_0=02P,$% M @ IXE84N<6X7*D!0 Z!@ !D !X;"]W;W)K&ULS5E1<]HX$/XK&J8WT\[08LE@($.8(9 F$$BYT/8>;NY!L07H:EN<+)/D MWY]D&QMLH?BF-YV\@&WVV_VTN]I=B\$3XS^B+2$"/ =^&%TVMD+L+EJMR-V2 M $>?V(Z$\II!:SC8X0U9$?%MM^3RKI5K\6A PHBR$'"R MOFR,X,4<.0J02'RGY"DZN@9J*8^,_5 W4^^R82E&Q">N4"JP_-J3,?%]I4GR M^"=3VLAM*N#Q]4'[YV3Q.! LRL&00T##]QL^9(XX 4H\>@#( *@/:9P!V!K#K MH9 MH%T7T,D G;H )P,X=0'=#-"M"^AE@%Y=0#\#],L YUS@K$/DK+HV8![L2K3/ M0@[AADF\6VEB)5DYP0(/!YP] :[DI3YUD:1V@I?)2$.U"U>"RU^IQ(GA:GIS M/_T\'8_NOX+1>/SEV_W7Z?T-6'Z93\?3ZQ7X"![(GH0QD=\NVX14[9TFN,>< M8[5_P/L)$9CZT0_??0#O W!@OJ^E(T&+2%Y*FLM-^-TE7)"9SC9 M8,%"L8W =>@13X.?F?$0&12TI(-R+Z&#EZZ04>.$N)^ #9L 6']PQ9;.=[W4[TV>="<3T&*]G&O=@G30#11ZO?!-^Q'^.T(88>^#W& M/EV_T' #1J[+XE!$8$(CUV=1S GX\(%C91IEQ./2LLT=/U8[F!53CAYQ()HJTEJI),845/'?@A[T!ZT]L=) M7A5"5L8!.84! M%T=;X,D8I=%24<2^'*YPZ&K=-3,;@2!0M=,072>GZY@U_0;<+0XW1(6/1(+* MF4G&DA,1I]V<9-?L M4^R3Z,!IQ]F>1F>:UBQ5Y!P9[UBV4TH.C1#J=?4<>SG'7GU'[ID?!P2PM6+K MQ=)W$?,](+:@X[5.A:XTF M"Z)2'=%Q0B5--QI-R.J?"MWJB'=*YJ9:3J6DFU4Y]2S4+66F1LBQ8*EL:83L MGJ6/.;2*&=.J$?71<=3'2=0-508>3;#P;;0UB I*Z/]+\UFF["0[.Z7H93+' MD8'P3%R*>0#:1IH+&M(@#DQ++EHY;+^1*!3M$II;V1*_),U2$![H'6_&VQ;P M\$MDXE+T0FANA@O\_)JKBY8%NV_$U46'@N86];JKS?C^ZZXN6@PT]YB'=%)L M@M'12#G.1LHEX\I)IG?"HJPAZVW$ 16U$,%?,5%G5HZKC5UNA!H95&IQLTRF M8]!S9]9SZH>B "-S 7Y(!CI3/J&B2J(W\MJ$BF*+?LF+$ZJ^I72ZG7*:3CHMLLI+T0B=95DT M"61N$@]$#?0JJ=2@CSG%CSX!KB1*O23<[(A\4T;^[S@2JNYJUU%]62J/Q7<: MF\B?YL?RH^1PLO3\"EY,H>;Y#%[,TT/W0GWZ M'\ "\PT-(^"3M31E?>I*HCP]5D]O!-LE1YN/3 @6))=;@J6OE(#\?5\W_G..;TU5UR\R 6 0NN8,MER%DHE MEZXK)PN(L:SP!)B>F7$18Z6[8N[*1 ">6E!,W<#SSMT8$^:TFW9L*-I-OE24 M,!@*))=QC,7;-5"^:CF^LQUX(/.%,@-NNYG@.8Q /25#H7MNQC(E,3!).$," M9BWGRK_L^J$!6(M?!%9RIXU,*&/.7TPGFK8P#5#:!J M,Y.&8O/0Q0JWFX*OD##6FLTT;#(M6H=/F*G[2 D]2S1.M4?173^ZC3I7_4=T MU>D,GOJ/4?\.#0>]J!/=C% 9]4"G5:+3+BA,J#S30T^C+CH].4,GB#!T3RC5 M%91-5VD]AM6=;'Q?I[Z#/;Z[,*F@T"^AP N\''CG:+C?R(%WB^$_,:L@+Q?N MZB1FF0RR3 :6+]S#UP,I 4IIODJH"W(B2&(7]Y^>MD61@E@^%W@*,T^A]53= MX\ENSC*?E9<2$-9>55[N4XZ:Y3"[_[4=U'2\=5OL?BG+ MQ@5,]8RI_LV;X2+S=''$6E(@XKQE M5(SUT1M@42"BD8EH'"%" (.5KO8^,<4 2)\L:4?QQ%[B8Z[TD\ V%_J9!\(8Z/D9YVK;,>^"[.'8_@=02P,$ M% @ IXE84MMG9-YG @ NP4 !D !X;"]W;W)K&ULC53;;MLP#/T5P>A#"VSU)4[7%8X!QVX[ VL:-.WV,.Q!L9E8J"QE MDG+9WT^2'3?MDB OEBCQ'/*0%J,U%Z^R E!H4U,F!TZEU.+&=65108WE)5\ MTS"+S2ID#-XX6> X34"^+L="6V[&4I 8F"6=(P&S@)/Y-%AI_Z_"# MP%KN[)%1,N7\U1AY.7 \DQ!0*)1AP'I900J4&B*=QI^6T^E"&N#N?LM^9[5K M+5,L(>7T)RE5-7"N'53"#"^I>N+K;]#JZ1N^@E-IOVC=^GH.*I92\;H%ZPQJ MPIH5;]HZ[ #\JP. H 4$'P'A 4"O!?1.!80MP);:;:38.F18X3@2?(V$\=9L M9F.+:=%:/F&F[1,E]"W1.!5/\OM1?I>GR>@9)6GZ^#)ZSD?W:/SX/4_SVPGZ MC))R!4(12=@:%O7R89.C^[0&>(,/1 *-7-E)&K=&HF@%NT M:0R;-((#:?@!>N!,51+=LA+*]P2NUM0)"[;"AL%1Q@R*2]3S/Z' "[P]":4G MP_VO>^#9Z?#K(VIZ79MZEJ]W@"\I"KYDRO1@S"DI"$CT*YE*)?3#^7TD0-@% M"&V \%" G2[#1@\5"7O;V+#T+8L9*:LX[/N1N]JM[/\^_3!\[Y/MX;E^XVDD MN#N_=0UB;L>#1+82S8_0G783*+$/[\/Y4$^F9I"\T31C[0&+.6$249AI2N_R MB\Y(-*.B,11?V,Q_\ 4$L#!!0 ( M *>)6%)_6_=D5@( "0% 9 >&PO=V]R:W-H965TICVXR6UCX=B9[;9LOWZV MDV8=HV@OB3_N.?<<7U\G6R&?5(6HX;EF7 V]2NOFPO=546%-U*EHD)N=I9 U MT68J5[YJ))+2@6KFAT%P[M>$+*3O!QZ@16$# MM&8CY;3!#QBR1D?&CX_3ZE!:X/]ZQ7SGOQLN"*,P$ M^TI+70V]CQZ4N"1KIN_%]C-V?LXL7R&8?7T_PJST;3!QAEV=WC]"&?7L/L[B;/\LLYO(><:Y2H-%P^FZNC M$(XGJ EEZL1L/LXG<'QT D= .=Q2QDQI5.)KH\SR^T6G8MRJ" ^H&(1P*[BN M%%SR$LN_"7QCJ?<5[GR-PS<9)UB<0C1X!V$0!J\(ROX;/OCTAIRH/^;(\44' M^$9%(=9<4[Z"F6"TH*C@VVBAM#3W^/L;">(^0>P2Q <29*2AFC#Z"TM3BK9B MK]6A93ES++;#-VE\EOB;_9/Y-R2*^Y!6G+]WX6J4*]>'"IS'MD;]:M_J(W?# M7ZR/S1/0=NP?FO;]N"5R1;D"ADM#&9Q^,()DVY/M1(O&7>N%T*9)W+ RSQA* M&V#VET+HW<0FZ!_&]#=02P,$% @ IXE84CHE;MP\! "1 !D !X M;"]W;W)K&ULS5=1;^(X$/XK([0GM5)IXD "K ") M MWCM.VBI;U[.-V#21SP;6)G;5-:Z7[\V4D: H0LE?K0%W"2^3[/C,??:/I; M+G[(-2$*GN.(R4%CK53RV;*DOR8QEM<\(4Q_";F(L=*/8F7)1! H9P"IQ9^4;&5I#2:4)><_S,,LL MXQ&)B*\,!=9_3V1,HL@P:3]^YJ2-8D\#+*]?V6_3X'4P2RS)F$=_T4"M!XUN M P(2XDVDOO/M[R0/R#5\/H]D^@O;W-9N@+^1BLUS 6X.<,\%>#G 2W.?)2O-] 0K/.P+O@5AK#6; M6:3'E:)U@BDSE;500G^E&J>&B]F7^]GM;#RZ?X#1>/SM\?YA=O\%YM^^SL:S MZ0*:,&,^CPD\X&W"3>>"<\ Y<,>96DN8LH $^P26#J>(R7F-Z<:I99P0_QI:Z H]"OCD?'BW CZMA_^!V378I^&WY^_>JR94>;3)"+P]U=-"#-%8OE/C3OMPIUVZD[[ MA#OC3;R)L!&C)@E#K4Z @W_U+3'N5)5>QN:F;$9DGX:>[?:MIW(U'-L@U/+V MC2;'1DX7'3#='ANYO7:[,-J+V"TB=FLCGI"0"$$"4/@9L)1$R2M@I#):]]A) MU.H>5PO9Y=[:17..G5.JG% 9:$D9 JW6Y\OF+4](TKB F6&Y%6"R1$ M^/I?]RNX6.DNJ(@ I:OGLBJ4^OU<^]JV?ZNIIT[A>*>6Z(XR&F]BXQOE.L<< M_$@GF88O8*I<:+%C:>83+M.0(*)X22.]UFJ()41L4OO(Z@"LG==S'ZO6S+- MJ?8NO&/WJF\ *C52]*O,9^*DO=#N4)^JNM"<':_S(7*]ZPBH]:X:G-.5\]WL MVJAUH$NY65F8FIVVZQP(<16;ZWGM RFN8G,ZCGOBE'?]!YW;@&":!G\%\TP[ M> BC@">9[HU.9&1_UUT/0.Z'J(&=WJ-Z 7YC#8QSNKWC0(='=FQ3PXJHF:RSBV>8V2V9YN4+F34AO)R(6FBFUCD!4! M)$6<)LEY+!E7T604]I9F,M(;$ESATH#=2,G,ZPR%WHZC?K3?>.!537XCGHP: M5N$*Z:E9&A?%'4O!)2K+M0*#Y3B:]B]G0Y\?$KYQW-J#-7@G:ZV??9 5XRCQ M!:' G#P#.,^HD/?!PO6>_"=Z=ES6S.-?B.R^H'D>?(RBP M9!M!#WK[!7=^SCQ?KH4-3]BVN1=I!/G&DI8[L*M 4_RHJ,.^4.1Y-5=KO(;K+Y=/$( MT_G\_FGQF"UN87G_-9MGUROX!->R$?H5$6:HL.0$2\&4A?=72(P+^V$4DZO# ML\7Y3G/6:J9'-/LIW&E%M85K56#Q/T'L#'0NTKV+67J2\0KS'@SZ'R%-TN0$ MWZ"[E4'@&QSAF^:YWBCBJH*E%CSG:.''=&W)N"[Z>4)@V D,@\#PB,!C;=#6 M6A30H,E1D1L <",&3&I#_ \++:M+4&XNG>:&&DKQ[RT%\T$02315&Q4*XB+:?NMUN&J=M$_Y+;T?YCIG*%RJP=-"D=W$6 M@6G'HPU(-Z$EUYI<@X=E[?XH:'R".R^UIGW@!;I_U.0O4$L#!!0 ( *>) M6%)FY4122@, !@, 9 >&PO=V]R:W-H965T.J[RRU7KUU794N28[5C5@1 M;M[,A M$28V?0TQ.WQ MD_JX2-XD\X 5B07[2C.][#L=!S(RQVNF[\3F#U(E%%J]5#!5?,*FPGH.I&NE M15Z1300YY>4W_EX58HN @B,$OR+XYQ):%:%U+B&H",&YA+ BA.<2HHH0%;4O MBU54>H0U'O2DV("T:*-F!X5=!=L4F'*[LV9:FK?4\/1@EKR?).,D'DX^PS". M/]U//B>3]S#]]"&)D]L97,,P$ZMB$X@Y3,Q.&::I6'--^0)F&O,,RTS!Q8AH M3)FZ-(3[V0@NWES"&Z 0 M=@>_Y M7@,]/IN.N@WTT?GT3@/]]C3]3\QOP#M.'Y^_>GN7[AJ#:Y?]VF6_T&L=T=OS M;2H%-^.4F!:A%0@)\1+S!;&&[< H3^F*$?CK@Q&$1)-<_7TBG%8=3JL()S@2 M3L)3TP45 2U,:TG7^9IA33+;$6A*-5PPHA1H$]-ET[XIQ<-"W';.Q\%UY(4] M]W%[=S2 $&I%NZA1 \KOH#VM<0,J[ 9!C=HI0E 7(3A9A.%6XJ,R\1.E#6O5 M\#4X'=7A1"_I='10^(Z'6GM.EZ!H"]0.0G_/Z$.E,(J"/9\/E?RV'S;;W*XK MT#Y9@;C,V1R?<#N?F_/T"J9$4I'9?OK46Z_,Z!_3[*U+)ZK>J=?LO(9-T*W# MZ;[@)HB[!ZZ@/=\.$=?(][K-QB'O^6CT_E_KX ?\WJ\:;1W3Z#58BIY/%.2_ MI*F5>GC)6%*G MH&',DP4 $9 9 >&PO=V]R:W-H965TJE1P+O$LOK=@/IA9SQ*/UO)\4@DBOLA6TD4)T% Y=,GQL7C M50=WGC^X]W=[I3_HCD<1W;$U4]^CE82[;H'B^0$+8U^$2++M56>"/][:?6V0 MKOC'9X]QY1II5S9"_- W"^^J8VE&C#-7:0@*?Q[8E'&ND8#'SQRT4SQ3&U:O MG]&O4^?!F0V-V53P?WU/[:\Z@P[RV)8F7-V+QQN6.]33>*[@9KK0YR MDUB)(#<&!H$?9G_IKSP0%0."&PQ(;D#:&MBY@=W6P,D-G+8&O=R@U]:@GQOT MVQI MODB++K6',O%#O3_62L*W/MBI\63Z]_?%>O%M\76Y/D-?%M/YNO]V@]^3)'YVA)I:2ZP-&'&5/4Y_%?HZX" M6AJ\Z^84/F442 .%-8LN$,%GB%C$^KZ>H0]_U*%,S2AW5%X@JZ]1\+ 9969& M^>JJ"X0SE$$SRKR%1[;UFD?79I09[ST MG%@'*U_XY!0^.4:?[IF79(U1;!'U/%]?4XXBZGOG?HA<&OF*\KIT.\?T!R9* MO8)2STAIF00;B#/P$6G H>=+:'Q2X R//10 5(6$.4SHQ7(2[ MY(C5R [[IM#B4CDQ,>\]$;HTWL.H$R0\&R1@Y(>9 M%I0@D9*%[A-2DH8Q3T, ? \#G%,D1Q1MYU#:7G(L51B;97A2JM1*J]0B1-,Z ME7H)7PHB=DZ;ZE+7L%G8?D-K<^078FO<3;@4(&Q6H GG;">%R<-2?/!IU0>7 M\H/-^M.J]U[C8\W!QC:)2]7!9ME9"05[5+>A=&/".?)GXL=I"L\0W>TDVT&? M0E$BW3T<#U$D?9?5SM[#)EULX$A*E2+6^SDFT58*4)F(/J5JXX'N]UTY%E+GT)7L>-%FY4NG*\.J67+7 M3R&3NR?3W%M*([%/NO](J8K$/"=.=5?(XQTC);+<2(;48U>P?R>*$ MU\X8BQRMQ:1+2@TGKVCXX8/-Z:G-S+' -]$JE9V8E;U5:UF08]DVGG;L4K5M MLVK?,2_:4\B,Z8A::JB-3WOX+87*-@O5Z25@9A^/B>8SI%TYJYNGQ!63+A"E M.P9= _\L.[./U:UAENU67J/J?P[<4;GSX)6%+3F4FF MW@, $0, 9 >&PO=V]R:W-H965T33,#:)&9M!]I_O^.0!E 3BH[."_%E MOIEOQN/QT-\*^5NM$#6\)G&J;AHKK=??+$L%*TR8NA9K3&DG$C)AFJ9R::FU M1!;FH"2V7-MN6PGC:6/0S]<>Y: O,AWS%!\EJ"Q)F'R[Q5AL;QI.XWWAB2]7 MVBQ8@_Z:+=%'_;)^E#2S2BTA3S!57*0@,;II#)UO4Z=E +G$3XY;=3 &X\I" MB-]F,@MO&K9AA#$&VJA@]-G@"./8:"(>?PJEC=*F 1Z.W[5/<^?)F053.!+Q M+Q[JU4VCVX 0(Y;%^DELOV/A4$XP$+'*?V%;R-H-"#*E15* B4'"T]V7O1:! M. X7@W +0#NN8!F 6B>"_ *@'URPNG! M)I/[R<.S#\.',0Q]?T+#[Y/Y&*8_GL ?SB=P!1.E.9TNAC!E7,)/%F<(0Z50 M*Q@&?S(N:8NE(JTM2].*/X>++)7P!GL(]CV/* M.M6W-'EH>%I!XC]TZ(<$LG7'4\.V0K1YJ:N!DX3=OS^M;F\!2JI!RW?2PUJ93RW&.I M:854J]5KEE)'+GJEB]Y)%_VW%.7R[42P6J6FUO]Z".U2;_LDPV$0B"RE6RHQ M0+YABQBK;EO[0W0ZU9'IE'8[)^W.T@VF6DBJ U7V=N#V@3W7JS;8+0UV3QI\ ME+AF/ 1\I;=84?4QU4CH%4JJKE(2&6!YO:JBT_U IU7-IE>RZ7W"1H19H&$A M#0V>:I8N.<6^X 76!;43&&4Q1#S"*$#;\BDNJSBV/O T6GUJEDZ]OY1L,]+ MCS5[J\N-0L6AY2NGQO#!:^1\9EAFN#^N2L-.A>&:O'3VU"HY"GU'D>_4T=@71^<_5\?; GIHL:90.?M*Y9PN53NW(_-Z;_+7 M6T004(VA0,B\VH"F7%41TET)*TEY'RMHUZZAM2][3NLDK5]Y1XCA%0PW1&2) M\(2F3^;I$EYV-V-.'2G=F']K;\8G)HI+555,K8-^RO37U%8L>:H@QHA4V=<= MTBQW+>MNHL4Z;[$60E/#E@]7U.:C- *T'PFAWR>F:RO_. S^ E!+ P04 M" "GB5A2D6 W[IT# !K# &0 'AL+W=O?T^H^EOL[I7^:-8 EK[&09N"MK4TN?=\LUA S)!A:E1K'P@T:C[<>,2V_83Y\]ZF%?;:S@$AXU,9LX9OKM"H3: M#3SJO3]XXJNU=0_\83]A*PC!OB2/&F=^YB7B,4C#E20:E@-O1"^O:,\9I"O^ MYK S1V/BJ,R5^NDFTVC@-1PB$+"PS@7#VQ:N00CG"7'\.CCULIC.\'C\[OU' M2A[)S)F!:R7^X9%=#[RN1R)8LHVP3VIW"P="+>=OH81)KV1W6-OPR&)CK(H/ MQH@@YG)_9Z^'1!P9!+3"(#@8!"GN?: 4Y9A9-NQKM2/:K49O;I!23:T1')=N M5T*K\2U'.SL<7?_U,@VGS].'67A&[J;7DUDXG=V0T\^%P'6F[UND[(#[BP.] MJSV]H(+>&!;GI$G/2- (&B_AF'S]\NVC%Q\3EF4MR+(6I&Z;%6X?-22,1P1> ML3L,[#.@[!HT[IG6("UA:6HN:X(ULV#---A%1;!GS2+ #E@ W[*Y '-&)-BR M7.S]M%(_KAVWPQ[M^]N2V!=9[(O:V%.Y13)*\YJH>P_MHZCM9GG45A:U51OU MY/26P6D5X'3+T;0S-.WZ_"N+%?J_,+4+F&@[*$?5R5!U:DOP(0TME?Q^>L5U M,]_=3_*/JJ_MVQE)!'.>D2K\VO $Y=A6UD&W6 <5F>]E.'JU.&Z4BG;8^RD M% PF5QP;X,"T$DBO "2X:)4CH8U<)QNU6,:P!,QS1"Q[_0S P=4'!!7QCW2: MGE"%5;M>BH(64#1I51YRY:/UTC=:+/0&TU L?Y%_ >J*D.:Z1^N%#T.IC<3O M2\+>G/"5DFP62'8J*.::1^M%[R2*I6"*4AA4M #-M9#6B^%^X_\[IJ(>-JN* M(%=$VOY#\3EU\W-YHYW3^^W(>W73=8I$VQ5$)6%([I_7V ML , +T- 9 >&PO=V]R:W-H965T(ZF&?&>+ M \HLI.TTM:+U-K,EN M+_6$/9LDOG GJZW@AH\+\@E-FZU@@/ K)XLQ9,8A)DOZC MWUDBSAS@H,7!S1S2CY)=-T#R=5;HOSD;'T7;-9/_N9IO5Q]OP++U>;N^WJ^63ZLP'RU ,'= MXSP;^@_!)@#78(4X1[I8X/,"2T2H^*)FGX(%^/SI"_@$2 +N":6JJ&)B2T51 M ]EA1N.VT($NN&>)W MPET0X*@>PE;9Z+R]U''6J\O%R>B>>UQ/.9D-HF'BR;+#JCE*3U-V#5F@D@BG(J+)IJJB M.TY9QED+@^]\QB_JZTW"+OZPCENEWV!2H]]I4Z;O%O3=#RRC WI5QZH6%6X= M?E254;>IK:4FFY9=!Q:="7J=,A[D'O/6"OB9]_GV/:[2JINT);=H7K"[>P5% M>WIORX-%VX#]/[7IP6);AQ_8U_];'\X0+EJ^10. P_^CB6912^V\RL4^.]?& MF._,_4 H?<=$IB? ?#:_@\S-R;LR?ZOO)N:\7(1)+S;WB.]((@#%6Q72N1DJ M0CR]*Z0#R0[F]/S,I#J+F\>]NE]AK@W4^RUC\FV@ ?(;V^Q?4$L#!!0 ( M *>)6%+V%\HCS04 "$C 9 >&PO=V]R:W-H965TS*2QA\5CH.>%DI-RT"P-6!C&P4PFV6 T++_[4HR&^<*D2::^ M%$0O9C-9_'ROTGQY.J"#WU_<)(]3X[X(1L.Y?%2WRMS-OQ3V**B]3)*9RG22 M9Z10#Z>#,_KN/.9N0&GQ-5%+O?:9N*GJ__%$E8FT C5H&L&H ZSN M5P/*S 6KR,II74@C1\,B7Y+"65MO[D.9FW*TG4V2N3+>FL+^FMAQ9O3A[.J& M?#W[='=)KB_/;N]N+J\O/_][2]Z0,ZV5T41F$_(ID?=)FIA$:7*MI%X4:D*D M(1]D4I"O,ETHXBI";M1X411)]DC>2YUH\OI"&9FD^B_K[N[V@KQ^]1=Y19*, M7"=I:HNHAX&QK>%E+O!=J_)9P^C=A(0L;AI_W'DY/-H<'-G-U M^EB=/E;ZB]K2EQ=VH63$S5MEXY]$_1A/9?:HR#C/3&$7J2:_R.?GJTR;8F&WA4&"X74PO R&MP2S5J9WB+NH=A>A<[M01?(DW2XC M*7AN*MG*CRC].&X\C8Z'P5/#J45]:H&>^K/EUU7VI+1QJ:FS]8N<%[G6;^IL MZZ61W*/:G='>TKNRD^\EMRCL,[N:LT?>?FGO+D QW5XQVAX ML)/OW4Y&)GQ2>SQ!\[?""98Z&@*S0C2Z02CN29]==,G:KT47:&!WUSDP9]>)KL&H)#H!%V3[6,07H4([. M]FQL"Z$3UY3?%"HM-Z&#GUT\;N_:CSJ9J$(Z@\94<&^2G!UO9Z+!B+85"@!' M<<)MK7(+DH/PG (&J=AUTP"_:+QKJVHL3^QG?KLXODG84AK (SW:RS(%H%&< M:/V!6SG:V'7>SO1MVJ8,@*0GSUR-!VR##.#+PGU4A@$N&8[+_I5A/@^]7MA@ MT]8,V9K*PV6>7YI/ZDFEA&() ((R7+=U[W(&2&,XTOJTQLK%>HJV>=M@PN*H M!;@,>,9P7=>C,U8>.CICDU5+< !(MA>%QX!A#-=XNW9&YDL_;[5C)IMA RG9 ML[0?+/9#]4<&R&2[BDH.7..XJ'QA?^2^AMPN$FJR&2U D]-]+%8.B.,XXOI3 MN'*$SA@SV0QP[>(6UYG8LCQ@H^2 8A[MI41 3X[3\QDE\O'HE0@SV0P0",IQ MB=E2HC__H''X#\-R $SEN"[LL>,!=!P'79]>R7VAQ[?U;X.-:,LEH(UWJ<'. M5EEY0*N,F6S>%0)01GL1@!&P+,(%X*Y],O(EWW8>4)/-L(&8T8M$8;7:#]4L M(P!HM*O,C-9N#>(R\X7-,O)EY?9F:C!IJQ2 ,\(OH_NN6 !=A(/N&;=&_6MC M3\PVV+1-&3@9X=JSL&5&0.3H>"^% HI&.$6?42B?E-ZU98--V[6E )P* M7'>BE>)(%@0 5N!BL7OG"Z">P*G7IVF*;H6(FFR&!H 370JQLV4*_SZB%QEF MLAD9X%+L10J*M>E8FX=\, E(CO?R2"<&D,8X2)]1)^X]>O3JA)FL @S6WE]P+X]9!D^5746*>HC1<2="XZGK] MX&K0=OZYPR/'G3F8@\MDJ=23,^[BKE=WA%!@9%T$1L,6!RB$"T0TGLN87G6D M Q[.7Z/?Y+E3+DMF<*#$3Q[;I.M]\R#&%5I#9EFOH]4.M/.F M:&Z2:Y.C*1LN717G5M,N)YSMW?3O9O#8'R]&,!GUYXO9:#*:_IC#%^@;@]8 MDS&,.5MRP2U' Q-D)M,8 [-PP[B&1R8R!%<1F&&4:"ZFDZOJ5T'"D_*JE?%]3#(]2'&%U"T*Y! M6 ^^OP,?? +>"!P\K+^%^R1BI618*1GF\1K'E*S$J'VH':GU3ROG-552OQ4/ M?HWI +BSF)K?)^@U*GJ-G%[S"+U;^I_%'@1_SGA,PF_16+J-EJI$ER'3W.YA M@YJK&,Z5!H'&7+PGZNE3&I J:1-S@G"S(MP\&8JD1"8M_2TP=](4$HYI6+.\ M _R!*76)>]0&]V10P[$"XP./$R1:%8G6_UC4=D6O?5*C(F=7QAJ@B1QZE4E7 MWDAD,;H)M5IC-8\L61$SR7OWK#BDE1_BVOZV%X0!W8GM8>$_<"KX^P>=R+T" M$Z;77!KZG58$JU]^);PN.FMA6+7)F]-266IU^32AQPBU M>G\!4$L#!!0 ( *>)6%()2>C4-0, "() 9 >&PO=V]R:W-H965T M>R82& 57:/NP+V)YS^<[%E_Y>Z>]FC6CA1R&D&01K M:S>?PM"D:RR8N50;E/1EI73!+$UU'IJ-1I9YI4*$211UPH)Q&0S[?NU>#_MJ M:P67>*_!;(N"Z><;%&H_".+@96'!\[5U"^&POV$Y+M$^;.XUS<+:2L8+E(8K M"1I7@V 4?QK'D5/P$H\<]^9@#"Z4)Z6^N\DL&P21(T*!J74F&/WM<(Q".$O$ M\4]E-*A].L7#\8OUSSYX"N:)&1PK\95G=CT(N@%DN&);81=J_P6K@-K.7JJ$ M\;^PKV2C -*ML:JHE(F@X++\9S^J1!PHQ)T3"DFED+Q5N#JAT*H46C[0DLR' M-6&6#?M:[4$[:;+F!CXW7INBX=*5<6DU?>6D9X>?1[,%/(YN'Z8PGXZ6#XOI M?'KWUQ(^PE@K8SZF6ZU1IL^PW+.-N8 [IC5SF8?W$[2,"_.!9!^6$WC_[@.\ M RYASH6@"IE^: G0N0G3"N:FA$E.P,0)S)6T:P-3F6'VJX&0(JO#2U["NTG. M6IQ@>@FM^ *2*(D:@,:_K1[WSN"TZFRWO+W6J6PSKN&1B2U>P,@8M :8S."6 MLRDKA=NF.$&_KXE!S"S6)AO9_"N:KPK MCW=U N^>/=,.)2BE:8NFR#L0OF.4N13]A@H;GDEG*)C/U^DP: MJ[=.]$S*.C52Y_]8T>L:[_ILQD9YKC&G#(!4[MAD EBAME3CIHJ5MCH'%8N3 M=M1+T"B;:+J'E%=OS*5N[A[U&KQB5;KU=B] M/X/=1-P[)NZ](3X629)FXCAZ/\IX5*7G#@UNH0)W[ MR]E ZMJMO)#JU?H!,/+77O@J7KX>YDS35J4LXXI4H\MK\JO+"[F<6+7Q=]J3 MLG1#^N&:'C&HG0!]7REE7R;.0?TL&OX+4$L#!!0 ( *>)6%+.HS(J^ ( M %@' 9 >&PO=V]R:W-H965T,_UZC4*M.D$M>!-,^"RS3A!VVW,V MPRG:Q_F#IEU8LB0\1VFXDJ Q[02]VE6_Y?2]PA/'E=E:@XOD6:D7MQDEG:#J M'$*!L74,C'Y+[*,0CHC<^+7A#$J3#KB]?F._\;%3+,_,8%^)[SRQ62?X'$"" M*5L(.U&K6]S$TW!\L1+&?V&UT:T&$"^,5?D&3![D7!9_MM[D80M0:QX 1!M MM NX. "H;P!U'VCAF0]KP"SKMK5:@7;:Q.86/C<>3=%PZ:HXM9I..>%L]Z8W MFL!3[^YQ".-A;_HX&8Z']]^F4(&^5L94XH76*.-7F*[8W)S!,$VI *!2N,5D MQN4,1M)8O:#"6@-4EQLNF8PY$^\.3@9H&1?F]".Q<<0DOJ9P.X.33*7P"+F',A: ;8MJAI02Y,,-XDXSK(AG1@634 M(A@K:3,#0YE@\IX@I,R6Z8W>TGL='64<8'P.]=H91-6HNL>A_C_#:Y='W*F7 MU:Y[OOI!/LV7S#7.=G7.X NU.YS<45U.X<<=@6!D,3<_CYB\*$U>>),7!TPZ M4FKW6,TD_TTE)$-?;88:8I73W,G<0"!W!*GM*UA!WO#D;B(MNY5&JQTNMW.X M1R>*2IUW7C=*KQM'O1Y)BYJN(@S7-"\-'DE$LZ1L_J_&I5RIP+AUI#*4<_\ M[#9T#1;2%@U52LOGH>>GXH[\FIZ-8LK_I2G>G#'3-!L,"$R)LGK>(G]T,<>+ MC55S/PJ?E:7!ZI<9/7VHG0*=ITK9MXTS4#ZFW3]02P,$% @ IXE84BEW MP)$3 P \0< !D !X;"]W;W)K&ULK951;]HP M$,>_RBG:0RO1!D*AM (D*%2M5% %:_A MV6ADB3?*1!@UF]TP8UP&P[Z?>]3#OLJMX!(?-9@\RYA^'Z-0NT'0"O83"YZN MK9L(A_T-2W&)]FGSJ&D45EX2GJ$T7$G0N!H$H];U^,JM]PN>.>[,P3NX3%Z4 M>G6#^V00-!T0"HRM\\#HL<4;%,(Y(HR?I<^@"ND,#]_WWF]][I3+"S-XH\0W MGMCU(.@%D."*Y<(NU.X.RWPZSE^LA/'_L"O7-@.(A^ M <^CAZ%D@I9Q84[)=*XL3-"0-;.8 #-PATG*90KWTEB=TZ;:@PCQ/@+N(\3[ M"/W04I(.-8S+A,9%0M$G";4BF)'UVL!4)IC\Z2 D=2J)HKU$XZC6XP3C;?LSY1G7\,Q$C@T8&8/6 ),)/'#VP@6W' W, MD)E(GP]L@I(!BO0U2$#2>YOT08U5\DQIJL/ASLZRA0>E.$,=>J;C:%B1K>F MJ,C5;-7/1D49_[V\:(8SIJE>TBG"%9DVSR\INBX:3#&P:N.+^HNRU"+\ZYIZ M,FJW@+ZOE++[@0M0=?GA+U!+ P04 " "GB5A2FRA((-<$ !5$P &0 M 'AL+W=O [21H@+@(G$U[*/9 2[3-+46Z)&4WP'[\DI0B.;:D]- 6[241Y>',FWGD M/(J#K52?]8I2 U]3+O1%9V7,^FT0Z'A%4Z)/Y)H*^\M"JI08.U3+0*\5)8F? ME/( AV$O2 D3G>' O[M3PX',#&>"WBG069H2]3BF7&XO.JCS]&+&EBOC7@3# MP9HLZ3TU#^L[94=!Z25A*16:20&*+BXZ(_1V@KMN@K?XP.A6[SR#2V4NY6+XTOAM%/&=!-WGY^\7_OD;3)SHNE$\H\L M,:N+3K\#"5V0C)N9W+ZC14(>8"RY]G]A6]B&'8@S;61:3+8(4B;R_^1K48B= M"1%JF("+"7AO FZ:$!43(I]HCLRG=4D,&0Z4W()RUM:;>_"U\;-M-DPX&N^- MLK\R.\\,KTO_W/1S#2&MJ-!"1P"TC<\:9853# ME!*=*9H ,7!-F((/A&<4'",PHW&F%!-+&!/--#QH]WS/EH(M6$R$@0!,8FZN &<9'4.$\* M-R2%,$RE,"L-5R*AR7,'@:U062;\5*8Q;O5X2>,3B- 1X!"'#_>7\/K5&Y&E M2;_:'SPE\+S*AD,_)NHR8V2T*.ZDFS-.V1=%3#B;.1(K:SB=MK M1S A/,ZX'\"GF>0<[![:$I7\TP+ZM 1]ZD&?-H >TR43P@&:$TY$7%?.<>ZB MZUVXUK091J@W"#:[):^QBYRI7;-YI-X.O-/^7@:')@C7)] K$^BU)G!''CT@ M","V9,-I([S>0>SC:+_"[3;/ )Z5 ,]: =J%9%NM +0P[VD#BU0?4K],J5^:TJVZ;RP MFOL'(2.\OQ9J;%!#K<]+8.>MP":^Q@;64KGRUB$[/RS&SA+,D1W:=$_K@:&P MDJ&P%=I[N\'BE^$57G9CXX,^4&?4:]A':$ *[ L'8\PQL MM*2E#W-Z*U$A#4KB#?E=;>@43C[CZMAS;'*&S@M5(9U"XS19&]E/@R M'L%'?\2GR?%H8^$O*5PR'$R\=N)\M#V=E>Z;:.W%_NK4!X,;05+>R7RD&:I>,:C\<-;,NYYPM_:-= MLQ?R87+L:\M#GN]I\$O;KJ<:5E.!V*9DRP=(LM:%K2/]N'.-*.##Z M%3G&E=Y@_(,Y;O@(&A>!]QAN.,7@2FEPN]),R=>?P7 E&OCTEV2XDA[<_AGS M QGNUC"\T]-SP,'.!45*U=+?VVCP$?*/\/)M>3^_'Z.TDO^&IW.07 M3E.B[&>D!DX7UF5X@ MO$D;_@]02P,$% @ IXE84GH]IY&K @ OP@ !D !X;"]W;W)K&ULK59=3R(Q%/TK-[-FHXDZ7X#B @D"1A-Q#2SN,D85VTOU7IYY?MJ MEF)&U+E8(C<[9:(Q/KMA=ZKPLCNDBU7? [K259X!CU9/DHS,62:CXT]!ZI7_ M:8';XU?V&V?>F)D2A3W!?M-$IVWOTH,$YR1G>B36MU@8JEN^F6#*_<*ZJ T\ MF.5*BZP &P49Y9LG>2F"V *$M3V J !$7P7$!2!V1C?*G*T^T:33DF(-TE8; M-CMPV3BT<4.Y?8UC+G>C>"I>S\9P'#0'4]&@^'@X=<8SJ"K%&H% MA"=P3\F4,JHI*A@B4;G$!.P[@ ?!ST8XRZ6D? '71%$%QWW4A#)U8DAN")7P M1%B.I[96EJ5G,!GWX?CH!(Z I1$ 4?P'M?AH?-7;AOHBSSC,H\(\<7[^'[J5.4P$TLUBER#<3E>%7!'9?< ML>.N[>%^>,<**;($S&$&11A^%-Z&L>X8[9%>=:):O>6OMA-Z7Q,WRY(=I;52 M::U2Z3VND$%8X;E>,M4/GF>CY&XE#(O/@_S^[>P M$?R(*EQ?EG27!T^T67(W#YYH\]-$JRIV9(;!VZT7?#73N,)WN'6-A@=/-7R[ M5,+HX+D6E-5'_X.B=V??W^HNMK4/B5Q0KH#AW(""\PN#EIMNN9EHL70-9RJT M:5]NF)HO#)2VP.S/A="O$]O#RF^6SC]02P,$% @ IXE84@7CHE4U! M!Q( !D !X;"]W;W)K&ULS5AM;^(X$/XK(VYU MVI7:)G& 0@^0>-56*E4%V^Z'TWTP9 #?.G'.=LJ>M#_^["1-H(4LM[. MBB72('4*N4-Y"]CD@T9Q$^2%!)&%+Y]P"YV'9K7NVE8\;6 M&VT[G%XGIFN<8B<6R3#XZ\/_NPR%>U2@C7!H4 M;P\EEB)(EOH V.ATL-9Q2N.348A['&52C3*E\CLH>U'WBW+U4UC_6+E2)N&) M\@0O3BG0LC2ME2E6N5^K\/N=&0!N-8;JCPIZ]8)>/:57/T(OIV1&X50IMF(8 M7, &>9".GZC#I9MA-E),NQ(\]WR_U?0[SO-NU@Y8>5Z[75CM$6X4A!N5A.WW M6\9D86-2$89F@=H\QRQ=%_2NOSMI.P!&&FA&+\V16:=!48Z'CWWZ5 MH+GYRN' MK$Q8;M,X)6/>SH+J5;+]:*F970_,WU#;1R0E(CG+!)6B[/F54[X-8T,QM/D1 M*^ B6E]RL_P'>;8.K60YXF[LCT6^%%^O6GWW(F\^ER%*L_N(X"%;4%7Z;L14 M+$S57(!9P4T(%BC3Q;HVSS%0IS%[S)V=JD"/N9JJU_R$-*TWVF98: M[56+]']*IK&?H=+4=-FI]H,_S4[:/E8%L11EKW6662X%W6O_X#:D0C(G.6CC ML&3N;Y)+[2;5VOU#.Z()>:O,1ZF4PDRJA7ED"EUF%,HJ^@;_EVJ04M_)6>H[ M*?6=5.O[?9).V"A&_!(46TA!'A03M.-GEF&.O;L2>Z]2Z>R<7T.4Z_2F0<%2 M))'.3F1%;W&;T4_/\*_ZA][-*+N3*&&R*Q)S'EFS2 ''E8%TKZY-;)6%(F ML8+@70( "\% 9 >&PO=V]R:W-H965T;D#$)4%^2 M._N^S]_=V1@T;[P*6% _JS :;R4J(-^N, MLK876$'(,-66@9C?'GO(F"4R,GZ7G%YUI 6>VR?VH. M/[I6^*J\C]!1"K4"PC,84[*BC&J*"B9(5"$Q W/=9Y44&V7$_=/6==I^CLT! M,-*8JU\WY#4J>8V;Z3MY^U/W6=7]S'3_4F^/;$W'9B?'/@F;4>LY]O?G+;P0 MU6K:;N_/I?IGU]F.D@F1&\H5,%P;7%!K&0)Y?)Y'1XN=N^$KH;63#24 M-L#LKX70)\<^FFI&)G\!4$L#!!0 ( *>)6%*/T6#D;@( $(& 9 M>&PO=V]R:W-H965TR"+;M8;4'DPQ@U;&SMB'MOU_;"1&%@'HA_IAWYID9V\0E%^]R#:#0 M1TZ9'#AKI8H[UY7I&G(L.[P IG>67.18Z:E8N;(0@#,KRJD;>%[DYI@P)XGM MVE0D,=\H2AA,!9*;/,?B\P$H+P>.[^P69F2U5F;!3>("KV .ZJ68"CUS&R\9 MR8%)PAD2L!PX]_[=,#+VUN"50"GWQLADLN#\W4S&V<#Q#!!02)7Q@/5G"T.@ MU#C2&/]JGTX3T@CWQSOO3S9WGL^N*/N@Y[ K][0A#4@N"[@K 6A#;1BLRF M-<(*)['@)1+&6GLS UL;J];9$&:Z.%="[Q*M4\EX\OHX^?UK-GZ8TF^CA=CD!A0N65MGN9C]#EQ16Z0(2A9T*I[HB,7:6!C%LW MK8,_5,&#$\%'D'90Z%^CP N\%OGPVW+_]JOJ4/]&( MR)1RN1& _MPOI!+ZM/T]$R%L(H0V0O=$A!DN=?,4"()I:[TJ><_*S07<)L%- M%+O;_:(M-7S;2R$#P%V4I6.8CVHOK=\("LS>8$6:\A MZYTE>R*,Z-.=H17G62M8[RAH%/4.P%ILPA-@40,6G07[OZC,6*,(DH++7,Z_2U7E0O5C51O+"7?L&5?D+L<*T? M>1#&0.\O.5>[B7E'FK^-Y#]02P,$% @ IXE84L*[<\"B P !P\ !D M !X;"]W;W)K&ULO5=1;YLZ%/XK%MK#)G4%FP22 M*8G4)KVZE9HM:]==75WMP25.\ :8V:99__V.@0(A!%6[2E\2;,XY_OP=^^.< MR4[('RID3*-?<92HJ15JG7ZP;16$+*;J7*0L@3<;(6.J82BWMDHEH^O<*8YL MXCB>'5.>6+-)/K>2LXG(=,03MI)(97%,Y=,EB\1N:F'K>>*6;T-M)NS9)*5; M=L?T?;J2,+*K*&L>LT1QD2#)-E/K G^8$]J&)S$?W#USJ< M6B,+K=F&9I&^%;N_6;FAH8D7B$CEOVA7VCH6"C*E15PZ X*8)\4__542T7# M@R,.I'0@+W5P2X><.;M EF]K036=3:38(6FL(9IYR+G)O6$W/#%IO-,2WG+P MT[/5[:?5U>V7?\_0ZN;BXQ=T\7&!KC[?7Z^65S!ZCY;TNY!H+N)4)"S1"HD- M6DDX15(_@4]$$WV&:+)&5S\SGD)^-7J[8)KR2+T#]_N[!7K[YAUZ@WB"ECR* M('5J8FM ;M:W@Q+E98&2'$&Y8,$Y0/<#7-8P1S^'UX3IKL #P^@X*'GM_!V& T\KQNN5\'U M>N'> +Z>T^178?S3']U1M=CH)$=W=,"?/VY1W&NR!W9<@1WW@KW,>+3FR5;E M,'F<2O'(#%#5PP1V:IUU3D\\;L@Z/@GU9=@FL=[(:Y'?930^ MTB"$*?FT#[:/CEI#L?L*[-<*B/LE\(_9/U0Z[!/2IK_#RG..\5_K(>X7Q$\Z M9++!B@$=,2B10A&]_$+4>H:]5TA)K7O8/TU*_ .R7<]I9Z3+Z(@>X5H]<;]\ MUB45U+L&/7Q&DVV1DSY.:L7#X].G@-022)R3I* ,NRAH0W*'T/H5)DT!O!^ M(X1^'IA>J.I]9[\!4$L#!!0 ( *>)6%*VVN63: ( +L% 9 >&PO M=V]R:W-H965TQZMBI;:#]]SL[(:,55'R)?>=[GGO+77\KU9/. 0QY*;C0 M R\WIKSU?9WF4%#=DB4(?%E*55"#HEKYNE1 ,P8LU5NK,*/^B5=P3V8QS)1*/D-2\8*$)I) M010L!]XPN(V[UMX9_&2PU7MW8C-92/EDA;MLX+5M0, A-9:!XK&!,7!NB3", MYYK3:UQ:X/Y]Q_[%Y8ZY+*B&L>2_6&;R@=?S2 9+NN9F+K=?H<[GRO*EDFOW M)=O*]N;:(^E:&UG48(R@8*(ZZ4M=ASU < P0UH#P/:![!-"I 9U3 =T:X$KM M5ZFX.L34T*BOY)8H:XUL]N**Z="8/A.V[?=&X2M#G(F2^?=D,G_X?4F2;\/9 M QG.8C+Y\7B73"-]3,[/+L@988),&>?80MWW M#09D:?VT=CZJG(='G % MWNS7^(#-3>^M37S(YJJQJ5+P]W[K M3*K0=-4KD6IOHE&FVS@89N\-[I1[B9 MJD7RGZ9::U.J5DQHPF&)E.W6#4:DJE51"4:6;G@6TN HNFN.VQ64-<#WI91F M)U@'S;Z._@%02P,$% @ IXE84KNX (['!0 CQP !D !X;"]W;W)K M&ULO9EM;^(X$,>_BH56IUUIV<0/)&2/(M'2[2%U MNU7IWNITNAU]^G-"&D.<&'1%?=.2,)[Y>^+Y>7 &&\9_BB6E M$CRE22;..DLI5Y\=1\R6- W%)[:BF?IFSG@:2G7)%XY8<1I&Q: T<9#K>DX: MQEEG."CNW?+A@*UE$F?TE@.Q3M.0/Y_3A&W..K#SK*J;Q$<4HS$;,,<#H_ZXS@YPO2RP<4%G_&="-V/H-\*@^,_Z05-DMR3TO&K=-JI8N8#=S^_>/]23%Y-YB$4]((E/^)( M+L\Z_0Z(Z#Q<)_*.;?Z@Y80*@3.6B.(OV)2V;@?,UD*RM!RL%*1QMOT?/I6) MV!D O98!J!R Z@-(RP!<#L#%1+?*BFF-0QD.!YQM ,^ME;?\0Y&;8K2:39SE MCW$JN?HV5N/D<')S/[JYFIQ?7X+1='IY/P6CFS&X^O9M_&-R?0VZ8*H63K1. M*&!S,,EDF"WB!W4U$H)* =Z/J0SC1'Q0EM^G8_#^W0?P#L09^!HGB7I,8N!( MI3*/Y=;1:A%$43@*\OD4H#++*+1O@-'3:^:(WJ9XSFR>AS3V2> X4> M7.0V"+HX>C@,+')PE7)<^,,M_K[$62QI]UHMWZ@AI7]?*WLPD305_UBBD2H: M*:*1EFA7G D!+D+.G^-L 48I6V>RZ:ELW?0*-WGQ/PY1C_3AP'G<3563E0=Q M9;6GL5=I[%DUCF:S=;I.0JD2H@1R&?\;;HL\4QE*5V',%3EDXV+:>O9V!'5A MWR=UW4UF/D0MPKU*N&<5?J,X>T1J/2.XYQ.WIM TZI/ ;=;G5_I\ZU*;J J: M;Y=;\KKEUJ\B]D^SW/K&=)$/^UXM*4U6&)'FK 25QL"JT4C"1Y _R/>73[-D M'>6RKQB+-HI@'YJ4!PT/BO1JPDTCJ. #FX5#5]/:/5 IO]8QSQ_D[=UO8;KZ M?0PR)G/@"LH?XQFU/$*XLR? -UHV$.F8Z!2E5'K93:Q?2WV#21N@H&8VQ%9Y MYT6VK\$]#R/52/&?MDEK-D/R5HG6K(5VV!Z;Z)Y!>N@%_7JN3:[N6>UKU%B% M=J[>L W'Y0W\V@ M"4 $7=@"0*0!B X!\/^W"J7K_2: !)#4M#?:X1YIV7:0YBJ"IRB]TLMNBGN! M7]\:2ZL]$A+/;]&H.8SL'+Y@?,6XRN_AXD.:GN@M6EZDN8KL3>\IBN] "/]@ M\2&-9&1'\M'%ATPH!VY]_T,FDP/4 M'C:;X:X2;BAO,$/]?IOTG:,.>]M\9/&57O:/%>HM16FTJY' %JYAO55@.\=O M0RXSR@&G29%4L8Q7UL6EJ8Y[;U%[FM#83NB3U)X]!"QJSZ968QG;L7Q\Z9E@ M5C\QZFO#!#/TO):UH<&,[6!^5>&91Q==Z-5_/S5;]5J$:^QC>S=_;-F9O7S] MW PW'&0TJR-ZDR!V@M_3V3)C"5L\%XEDH MN ,A#N]V1,.8V&%\_%%P XYA'=_OVI[I;O6T;%>^8 M'&V^?57W->2+.!,@H7,UU/WDJ\!\^_9K>R'9JGB!],"D9&GQ<4G#B/+<0'T_ M9TR^7.0!JG>0P_\ 4$L#!!0 ( *>)6%+6P8*QV0D )(Y 9 >&PO M=V]R:W-H965T5G%2?;QZ%'*]8_]?A8^\A7+>F+-$_7-@TA73*JWZ;*?K5/. M%@5H%?=MR_+[*Q8E1V>GQ6>S].Q4Y#*.$CY+29:O5BS]?L%C\?SQB!YM/KB+ MEH]2?] _.UVS)9]S^6T]2]6[_E;+(EKQ)(M$0E+^\/'HG/XX#P(-*"3^$?'G M;.-8:U+C^*U4>K2UJ8&[KS?: MKXK)J\GRUA$) M\TR*50E6(UA%R>O_[*5TQ Z N@T NP38;0%."7#: MP2X.X#O : 5P*\M@"_ M!/AM 4$)"-H"!B5@T!8P+ '#?8#?%#AK$SFKK0VZ#78MVHV03;AI+=Z-D$W M:2WBC9!-R&DMYHW3WP2=UJ+>"-F$G=;BWI2*=!-X6HM\(V03>EJ+?>/ -L&G M1?3[KZNW6/HC)MG9:2J>2:KEE3[]HN"/ J]6?)1HJIO+5'T;*9P\&T]^/I]\ M'E_FW^8A\ M^,L/IWVIQJ U]H/ Q#K]E*3KX+ZWG#@;N:^NY M@_";UG,'X;>MYP[")^^+^_1]KINUAT-)^U/[N4/PNQ9P9,G,VP\^J,+[BNFV M=&=OZ95QFY%\W2IZ,)5]E_T:L M.5MK3F'-;; V4:UJ++*,,"G3Z#Z73-N2@ERP7#6MY)JS6#Z22[%:LR3BF1I1 MV(-XY=6,5YC1S>O3V0GU'*OX=]I_VN60NFA (<%K0*=C^Y#HO0Z)?0%$* MJOT*R+I#2/(&T@I/ZQ80A8Z)3D'[@P$D.X-F1=U]V4H^N=M\R(H4X2Y,H669DS=7.Y9&E_%CW_%%(6+(@BRC.I4KQ#U%"%B*.6;HC M")7MJU?+PC$ZME[B05I&NX)C=N8^U(7T(S0!/M#2B<(=XV0SPT0RY5M_9=I05Y M8G'.B7@@D2$Y5I#<,4FXA#+ JR7NP'4]<)771:DJ;>""G+17.VVGMN(8?^L8 M'W7,9R$6SU$1 M2Q4A<#6^ZO1W/>%8K@L& Y*E,)-/WJ!W^@:]LZ >.8>Z(._. 5G/&^Y7LXJS M!UMG#U!GW_$GGN0<\NB@-AO;IG )'=0&J"1!LK^NBU+?!]TY!K1:%"ZB@*AM M@UJ_0J(67$2A:<&E\18<*YQ1=;\.+#L $PH0]6'2F &BFP@TI,APFR+#-BER M3+ZK"GHBGGAZHE^115E;H=P9UJ.,DA*US.[;>M=HCG75#A59L24XL@/J:<^R M_@KN-'&@<8QS8L:>/<=HE6^(K^#$6G-0K:A.#OH(B2&]>Q# MFZ(#94#]B59%HQ6R[)$\Q.(Y.R:+* M%KH12N+VZ.&!VV L\-$*&1FV<1F^5 MP_Z "#F&"!VKBU-B0X@.WNO^61$Z8';8\] UY!B&=7"&O4@5>^Y0CGSJGWJY3NGWM5 M1V18UL'I#_8WBZ.7-RP'PY".WX6_#4$Z+8_,\'K]R0%.DH8!>DK@&-9T M%]9KER/0]7JIOG*JX.-9;ZC.Q:GN/-6E/<'F:1C+[6)WZQJ681L/;Z;>=8=7W\(Z 7Q3/BEE M?5RV.@E#81Y.864 %"O7/*;H>:4KYG\+@B=JQQB)!>8Y0U)>%YM=;^>R%6_# M_JCG.R9>_>;3#<#[EBDH"MYCS0!1BI=KSY"JAY/JG_@HPJ0T7;UD=]Q]1[21 MF@%25L]MNF4WO.T=X.WPMSQ*=9;-[O[&5NN_C["$,A3N=4'AGJ%P[RT4'JF& M]\TT/O&@PTLP<^N"X)WF#!"TT>=G?%,7?+PN7/-X0:Y$JC=+''&A;ZJ#WT5U M\$UU\/'J4 U9<8+_&JSF0NO7B1[M"GW#\C[.\A5W*JZ_Y*ED:IUONW/]W2C* MUB)C\;'JU=?*$?=J\=?,QCN ME]WJ: RU^CBUEDN W.MS!,RA@2&OH(MCRG;5/\,+>NOF:P?.%55&Z(+NCBJ#'8>[L/[P'1K4CS#! M1R-GD""<]_V='P/I7RO>LG09)1F)^8."6CT=G/3U!X"O;Z18%[\/NA=2BE7Q M\I&S!4^U@/K^00BY>:-_;9_P!02P,$% @ IXE84G370XN. @ M&P< !D !X;"]W;W)K&ULC95M3]LP$,>_BA7Q M J2-/+<):B.5MF.5H" *X[5IKXF%$W>V2V&??K83LDYQ*6\:/]S_?G=7^SS8 M,?XB"@")WDI:B:%32+FY<%VQ+*#$XIQMH%([:\9++-64YZ[8<, K(RJI&WA> MSRTQJ9QL8-;N>#9@6TE)!7<L'-!ANEF1$BI!6(4XK(?.R+\8I]K>&/PBL!-[8Z0S>6;L14]FJZ'CZ8" MPE)J#UA]7F$,E&I'*HS?C4^G16KA_OC#^P^3N\KE&0L8,_I$5K(8.HF#5K#& M6RKOV>XG-/G$VM^246%^T:ZQ]1RTW K)RD:L(BA)57_Q6U.'/8$?'1 $C2#X MJB!L!*%)M([,I#7!$F<#SG:(:VOE30],;8Q:94,J_2\N)%>[1.ED-IL_C.97 ML\OK*1HM%M.'!1K-)^CJ]G;R-+N^1M_1J&1ZR">2R#B0X$,@$EN+P74I?@$%;:HT*"B M RB5L&^K5ZV*C4I?QM?,#Q.5VZN%%;6LZ!@KL+%J56^?%7B1G16WK/@8*[2Q MXB[+"ST[J]>R>L=8D8W5Z[!2+[:C^BVJ?PP5VU#]#BK1M;:ADA:5?(IZ*$!U MYK4$;@,FW3J&Z8$ZIBTQ_90X5^_&&'/^3JI<7_UM)6WHM',T>_WH'[J^L%VC M).K$Y^ZU+OULW&">DTH@"FLE\\[[2L_K5EQ/)-N8;O;,I.J-9EBHUPNX-E#[ M:\;DQT0WR/8]S/X"4$L#!!0 ( *>)6%+ZC840VP8 &PI 9 >&PO M=V]R:W-H965TN)A3J3Z*:3M="$8GN=$\;B// M"]IS&B6MB[/\NSMQ<<:7,HX2=B= NIS/J7B[8C%_.6_!UOL7]]%T)K,OVA=G M"SIE(R8?%G="?6JOO4RB.4O2B"= L*?SUB7\$I).9I C_HG82[IQ#;)4'CG_ MG7T()^MW[]_SY%4RCS1E M7WG\*YK(V7FKVP(3]D27L;SG+T-6)$0R?V,>I_G_X&6%[?@M,%ZFDL\+8Q7! M/$I6?^EK,1$;!K#* !4&J*D!+@QP4P._,/";&I#"@&P;!!4&06$0-#7H% := MI@;=PJ#;U*!7&/3R[;!:OWSQ^U32BS/!7X#(T,I;=I'OH-Q:K7F49)M])(7Z M-5)V\B*\^7EY,PBOKK^!R]'HV\\1N+SI@\'M;?]7>'T-3L!(':_),F: /X$! MYY.7*([!ISZ3-(K3SPKP,.J#3W]\/FM+%4[FM#TNAKY:#8TJAKX=RU/@P;\ M\I!G,?_:V!SV+.;]YN9=B_DWM_G?R^048*\R^.]N\Q]4*//JW =N\SX;.\V' MC) MS/;=M-AWCK'P>BR;2PI8GQUQ/C.R\;B"5!E!$BIHCW!QK$**GJ*V 1(OMZ+X-,- MEPP0&_$- B- V'5%V%E'V'%&N";@[:BH)71;8!TCL!,$.]9]:8$:2:QVIG5-A2ZYIS7I&9B3R!UL1L0+3MLY1: M;YU:;Q<:8EEB-00TZ)D)8L_WK2G:L!4$%%JQ!@&5TH2>+B\\9Z*W0LXXZ+.L M+N4QGT;C%-RS!11[ M 0FJ(:$%'#;;WEJM ! MP+<,QHK M<JA8J#F M!1'2Q(_@<4NBPG^CFLB&K2B*K&Z=*6^T2V[UV:TN0J9&5!5&%FA%961%NDLC MI'4'[=2C-2J."I=E#O#LQ9$5:^>+T(8U^:*@4]*-G)@I5 MOQ-\LAR[)U*3+SY^ X(U-V-W _*!^XYFOV'<;JR%#.LAH06">KZSW,5:+;!; M+0[$EMAD]!,W.6%-Z'@G0F_"EMAVZZM7L_\U?>.=NJ=&;(E-_C:V0BTD=$+* MV6CNQV[N'ZG9==4YON9=WSOZR?4UX?KN!F/_D^N;+0"&Q'I78; #=FC'.@^J MKQG?=S/^1^[+^Z8N 'QS_#FMI]-[5_X Q;RG,46-OGP0[883-L.5TM M'/[!ZW[?\OBD+AY-_?[ARW[?\EBB9C#54/66_##(BI%E7883-L.5TM+N3@XD(LXN(AI]@1+2[D M\.)"S ?TU9/9'!L24UQJ)W[C%0"WN-B.BVJE]WCN1+3PD.,+#]'"0]S"4],_ M%]8USYU68[?Y MY8S1"1,90/W^Q+E\_Y"]2K9^P?+B?U!+ P04 " "GB5A2YH)9XQ,# #A M" &0 'AL+W=OU% M*VW-$TE(!4@4F(K4!P1E>S'MA9,<8-6)F6U*^^UG)VE&@V%] W9\_[O?G7-V M>GO&G\4&0*+7G!:B;VVDW%[;MD@WD&-QQ;90J)45XSF6:LK7MMARP%DIRJGM M.4YHYY@4UJ!7/IOQ08_M)"4%S#@2NSS'_.T&*-OW+==Z?S GZXW4#^Q!;XO7 ML "YW,ZXFMF-EXSD4 C""L1AU;>&[O7(=;2@M/A!8"\.QDBGDC#VK"?3K&\Y MF@@HI%*[P.KO!49 J?:D./[43JTFIA8>CM^]?R^35\DD6,"(T9\DDYN^U;50 M!BN\HW+.]K=0)Q1H?RFCHOQ%^\HV\BR4[H1D>2U6!#DIJG_\6A?B0.!V3@B\ M6N!]5N#7 K],M"(KTQICB0<]SO:(:VOE30_*VI1JE0TI]#8N)%>K1.GD8#@: MS9>3,1H^C-'CT^UDCD;+^7SR\(3NIL.;Z=WT:3I9H(LQ2$RHN$3?T'(Q1A=? M+M$71 IT3RA5NR%ZME0PVJ6=UH%OJL#>BM5^GPGA-R'\,D3G M1(@[6&.J]DY*X%4<#A1+R- *P%C!RE]0^M/]^#)PP\CKV2^'=3(8^7'4&'U M[32HG;.H,\ZR72H58*( C6R5@_ @;-2)6FC'-MVX:R8+&K+@DV1RQ\WO77 4 M-8B"%MFQ31B[9K*P(0O/DDT+M:\@I DI/ KG=]P6DL'&")RJ-*'2%Z4YFF4Y<&YU!(1 E.""62F/NW]GMX;G2"J+W%1BNWW2GV MP?VC+_][S->D$(C"2LF76?5A/)MN65E#"I+KARN%'?(,"U@5I?,2;? M)_J6:[YJ!G\!4$L#!!0 ( *>)6%+U":K>RPD *9+ 9 >&PO=V]R M:W-H965TF.]/:"/1$)\E,FC1M M=]IL)]GNOB:VDC!K0R[@9+MS/_P%3'PP$A(VF+Y(_:!S^&,=G1^2.)R\Q,G? MZ:.4&?IGM8S2T\ECECV]G\W2^:-DT?I)1_LU]G*R"+'^;/,S2IT0&B])H MM9RYCL-FJR",)F)TMPTA^3U"Z7JV"Y.<'N8Q?3B=X\OK!3?CP MF!4?S,Y.GH('>2NS'T_?D_S=;.ME$:YDE(9QA!)Y?SHYQ^\_8TP+B[+)GZ%\ M26NO47$N=W'\=_'FR^)TXA22Y%+.L\)'D/_W+"_DIN5?]%*U M=29HODZS>%49YPI68;3Y/_BG^B5J!IBU&+B5@=LT("T&7F7@-0V\%@-2&9"N MDFAE0+M*8I4!ZVK *P/>U4!4!J+LW4UWE'UY&63!V4D2OZ"D:)U[*UZ4 5%: MYUT81D7PWF9)_FV8VV5G5U^NSZ\OOEQ_0NW011VF\#!=!)A?H:QP]O,MDLD*7\BY#;RYE%H3+]-?Y-I%J_DGL_GO\VR*,"_-N<;\C5^(;YK,\D+;1Y&ZCR2W]>2W^ M(#@6>7"\15&>??, 6D?!*DZR\-\\?HHOT"),Y_$ZR@R']+:'],I#DI9#?D_" M:!X^!4MTOE)=;J)OXX&6'HIL_GSF$BRH4_X[F3W7>UO3EF$A&FUWI)*M5&*4 M^D>B$;_RQNAC/=_7"-6VI\)MM=X33K7!J%/Y5INE[ M=+%.$AEEZ*GHRAP[>Q QUN#UMX?TC>=UFY5,":/\L#+-4)*_17G?E,=Y$Z0H0$\RF>?=IJ6*V;DW MQ?07@TCL ".=WCFF*=ZH$#<8MF1'K,CLWH@E#:L?FW'Y O*M9'>?:]=+5K)Z?)3=*AZR. MS6G]5D9AG*!;F;,ICXOK.),I^A]B4^K\@JHO-Q\6@R"_6)L_%B/ -74R9'L\ M6KK'D._Q41.^Q7OYPVFO@O>VV[W\!5*X_4GAJJ1H1IVK F([MEJBS@5 N$,# MPE4!H2A6N8!=TAQ3NXIKLPHS%UK&"9\Z#C(-%&+J4T"%.QHJ7$"%>U146+P7 MOYQVH.QOMWM^@!BW/V)<%3&O5R5*GG95Q&C:[HH%Q+A#(\;5(,8736Q4TC6( M\85GE Z(<0]"#-4CINMUE@N4<4>CC N4<8]*&8MWVD*93_O;[:YX &6\_I3Q M5,I@KB"D6O/0X$9MNRL6<.,-C1M/Q0WF'M-+UW"'>\;!XP%WO(.X0Z><:@;/ M^?IAG0=;/G1,2VE>;6%K-.YXP!WOJ-RQ>"]_.=TBZ?YVN^<'W/'Z<\=3N4,5 ME%3AIV)';;HK%:CC#4T=3Z4.\9L+:)5P%3K$-P\;8([7B3D_HK0;=;;7:YZI MBP$YWFC(\0 YWE&18_%N0PZ+F M>R5\-"M8A)AWA2#1DZ$3/5$3O:)8,ZL@Q+@;02##DP,S/%$SO%PG\;N%C.)5 M&)5!4YY>UV$ 69^,EO4)9'URU*QO\4XL69]"UJ?]LSZU9WVJF2/&/44*>9\>F/?9%+O:&<)3$BYMB +_&*Q4!T$EW+>:8V)0NJGHZ5^"JF?'C7U6[S[EH56!JF?]4_]3+-6 MU#;C91H&6*:\#!C AF8 TZP5$:[?=F<:&!!NG/0R@ $[$ ;^U,P"9NIF8 $; MC04,6,".R@*+]_*',^D$%+#^*&":_>S6,:"9#=C&0.U6I:%1P#2;#:1ELX'I MI@7"?),5H( =B *A7_CY+8C6Q3VFEB53!B1@HY& 0G844E@\2XLDP .).#] M2<#WV#7@^^\:<" !'YH$7+=K0/4WI'#=K@%M[C#L2@<2\ -)T+9?71L&PM33 M ,^&@PXP( ?%086[[:=9PXPX/UAP%48M(X"E06V00 HX$.C@*LHX,I=&)5P ME03K'KP#H)T3=!T! (^&@@X@( ?%006[]0R @2 0/0'@=" H&UF M+/:_6TD ",30(! :$+@MV\="=]N2^9YS 2 0!Z\/::<$5_(N>1T&OJFG 01B M-! ( ($X*@@LWIDZ*RCM+O>WVST_ (CH#Q"QQVQ"F"HC=C4".<30Y!#:242+ M8A4=;8H!&6(H9.PW5FK5#Z,A0P RQ%&18?&N049I=[&_W6YY!Z#&[X\:7X,: MIV6L^"IJ6B+/!\+X0Q/&5PGC*R5BE6 5,&V"@2O^P1,,+5>J?3;3,/$!*?YH M2/$!*?Y1D6+QSBUH\ $-?G\T^-WG%O[>YA>>8.AE X8]7)U?@NX^:X^%M\]+)P\9.KU73 M.>.5TSFU>CKGN 5U%O>:8;&Y?CK L'&.M5H\9X!B/$J!#TT;-NM/XJ'R8[C%[;=,E-=5KL"U%V(>,"/N-K.8V&[&SVN.$BB=8?0N2AS!* MT5+>YS;.M-CR2#;/A-J\R>*G\@E#=W&6Q:ORY:,,%C(I&N3?W\=Y5JW>% \M MVCZ:Z^S_4$L#!!0 ( *>)6%)P_Y4W6@( \% 9 >&PO=V]R:W-H M965TP\Z351M!9?X MH,'49+I;3Y6RQO(/I:C5=WMW%QAYV>!)V8V$AC=4U]92% M'U\H !862_/S#?AA#S_T\*,3\--2U83*&KH?MA$(-"_4M$3',XLY5.S%T1Z] MCQ9Y[)'=$#7I8!A%41(V1P2->D&C-P7=\F>BS0JF=P@9_4Q-,P::T2P5$%Q\) M0K?CUSI65;[E-\K2 'FSH!<+M0N@\ZU2]M5Q4]2_@>EO4$L#!!0 ( *>) M6%(D>.BAQ0( /L' 9 >&PO=V]R:W-H965T>>>["O.SLAG]0:0)/G-.&JZZRUWERZKHK7D%)5$QO@^&4I9$HU M3N7*51L)=&%!:>(&GM=P4\JXT^O8M7O9ZXA,)XS#O20J2U,J7ZX@$;NNXSO[ MA2E;K;59<'N=#5W!#/3CYE[BS"U9%BP%KIC@1,*RZ_3]RZ'O&8"-^,9@IP[& MQ)0R%^+)3,:+KN,919! K T%Q=<6!I DA@EU_"I(G3*G 1Z.]^PC6SP6,Z<* M!B+YSA9ZW75:#EG DF:)GHK=%R@*B@Q?+!)EGV27QS8Q.,Z4%FD!1@4IX_F; M/A=&' #\Q@E 4 ""]P+" A"^!40G /4"4+?.Y*58'X94TUY'BAV1)AK9S,": M:=%8/N/F?Y]IB5\9XG1O-)[T)X/QY(;TI]/^Y.;Z[GKR,",79 :<"8FO.).P M( -\,$U&-&8)TPP4.1N"IBQ1YQC\.!N2LT_G'5>C)$/LQD7ZJSQ]<"+]$.(: M"?W/)/ "[PA\\&ZXWSX"'U;#OU)>(UX.;[V&N^AC:690FAE8OO"DG+DF8ZZT MS/!H:/+C%@/(6$.J?E;0AR5]:.GK)^AO!5]=:) I;NRY/F9VCH\LWISX;2\( MVT'DV5_'W1XZ>R0V:K7?QKX26B^%UBN%SD":'3(B#Y)R[%3DBCP8V;>"\OT6 M>JDP)"KS1!_A=Z.D;_R?W\/&7QZ&4>!76=@L MYE4JZ:&ULM9KM M;YLX&,#_%2NZ29NT)1@P)%-;*7W)EJW-5>UV]^%T'USB)&B #!)OQ4*:]/F: M1?*;!8]#*N1EO!PDZYC1>284!@/3,)Q!2/VH=W:2_>TV/COAJ0C\B-W&*$G# MD,8OYRS@3Z<]W-O^XN17; @4)JD M'?_D2GO%/97@[N>M]DGFO'3F@2;L@@=_^G.Q.NT->VC.%C0-Q!U_^LIRAXC2 MY_$@R7ZBIWRLT4->F@@>YL+2@M"/-K_I)=MNG$EWXTBVX3C2L8;1;8IQUG.!YORS6K_D@IZ=A+S)Q2K\5*? M^I!-H$Q>EKP?J;E^+V+YK2_EQ-ED.AO/+J:S+VA\=S>>?;FZN9K]N$>?T#V+ M?![+7UX:LSFZD#]\@2;4\P-?^"Q!IH&':*RFZN;Z_243U ^2#U+XY_TE>O_; MAY.!D":J&PV\W)SSC3EF@SDW] 69SD>IW#1JI"\Z2%M*&H]JI"_;I.,^,H:- MXE>P^(P_]I'I9N+#&O$)+/XMC>3=<:/X%UC\DGE]9.'&R'WM+%[K^[2[>)WQ MWSI$'C#^>X>[ Y&_;HD\A2-_T^'N>%,V;HWXK(/ON?&D+#Z0<[F8T&8QH:R;LQO-SHY9EDU(K;/5H624^[KO M;'7H<"0C _A*"E\)Z.LU3V0:(\2>A1\M4S]9924C?6WP\)Q4 F^Z=49?5@<. MZ\9]J8XCH]J 50?6E]&45,*%\;[*4K2<(EH.&*UL9A4%X?&D+D)73C5"M14P MJ0YTP:2ZA9DN7, [\U.E47;D"@:>2&.9Y,SNI&YYRXR!7NYM3:+]*R,3MM&FX)8ZR:K GZ M$Y I+)-IG6]D8C6,,\UAG]+S(*;I,&9+-(5/-$=0@8,TQ[!PEPYI M&$;0AI3%#3XBE=_:CAK6XZ(71N-:6KU&LNR-!AB&"39>+F.VI(*AM22HYZ]I M@&C(TZB6_[FR4F^2UVIE":@9:Q,'KFR-1SR"B2&DR7.9!AE\N0*@6%[6[BM@ M-58?DW=07ZIY:L(\)7W+)>^V&\ML&4!S6=RR _966>N/_D4'+Q>F1JB)CU'V MYD[G;;XIV')UNV!S1F 3:VK(FC!D#RK:F5EMJ$VC4K1E4S1B31BQ'0MQUJ)F M4SY0HC1G39BS,E&IK#F:2+,65#9SC9&Y,:M]9\UT+MNA06S"':73KYT0?H3& MZ3*5H9*3 K]J4FA4F^Y1)H6FIPG3\^!)464B<<'UU=1(--\$B9,6-5G:H+VT M1J(%(]'MFPT%\"T-7E3ZS=>DW]),M(["1$LST7I;)N;J2NDGX'2S=HXN8"9V M37^+FBQI4' T&2T8:4[#BBCS_[LG^ .+7[TL6AJ&%CE*"6C*63#E#BZ!ZLX8 MV_OG0&5;-.XLN"_L7 *P&J=M+;(T'RV8C\,^,=XUY'?3^],HI7$& _=5E:#Q M:!UE1VUKW-DP[@YJ2B9V=3?M5E"P.5ZN&8I;^A=;,])NV7IWK)D6-5FBH3!J MIMHP4__'$>7$KO*U&M2R79JO=AL8=TI9TVR[E+VJD[%WSFWMHU2O!J7=VC4> MPK$KNZ9UM(<6&&L-51N&:L>BO&I1X[85I2:K#2/QX(.4JUQA:?<+1T=#U6YM M.CLV^-_MFOWZ_I%VV0K-4QON$^_8(P\>LT/7S=/31?LY'=$P)<8QZIUH[A$8 M6 ?6^S175^[

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

MBQ;,108NM'CU6BXU;%EN%Y66*QT7+6?DUFNYUMDN&-IT-VHMA_-$9]-]T;9% MM2ZWG^ MZ<2!6VBQZ[5\;Z %6IW?-""XW,<*BW[7\1/HZ4-&DQFKR1XRF5U+;7:A+:]6?QS8CL7*U_R__<$/ M$2FJ0RW+<&1#[ZI#V0S9G\VQ&Q.TUQ.TE1.\BE,VM0C1GUD8/2W"=%+L C;9 MFBD>VQ5CB"NS^KPZT).-NUV.<\0U\Z4K5E4H7]J[ZD",MU5NK):S7BU'N5I# MFF53EB!>A5GX%!2[^B]T0Y_1!4U2^L(^? NF-& +>#]D:27+)ME EDKR\8H] MZ:Z-UAJZ M8;B_-MQ7&OXU#\RK.(C0$?H4C,)IF+V@$X8Q++^B.3/9*(CRY/X'G3W0I/B- M8KVPP>L*HP^'8*%PP7HHM(OB199F;!HL6&LCM-0FKK%IF*HEQIPM, $B0%8K MJ6;)F0*;O2PCQW(,@7DO7 0\%28CS,$:=XS69[B*A>8V:&X:P[$00V H+9O_ M0O:>PV+M75U=G2\U2V;608A52\-!$?>"BIC#(E;CXC +,C:',&() $TSE+"/ MTHI1K:98G'?2]*^YX.94.%!B-5(>/C% 9QA/\SB(1N$\F)90+[7+KVRADDSK M]A#AT$F,+O.K\U+=1H*%I6G%C60H]J3YPA?)4 +,D&,W46.W(DIL0QDCK 09 M3?( ,55IOI#G]Y+H$X[?1)UUZP8(H*98%UF1U5QN8G7+,A5EE \=7%MLF9P,3S.07;$\&*7/S8\!2T-HUN3*K63RV@37A M9&"V2>.+4/*$4)+3T@M$2J9P.M1+SF]R+#?56*Y+2H":Y;+(MFY;P>\M!#?7 M@).(J2:19K%HRBH&6[WO.(2;:@AO&(LGI;K-XP)+>K)P)AN+YA$ M/R<)T^\C^BT._98:^G4)%5!CU:2DWYO+;4Z$\X:EYHWZ$&:N+&\FI :65^)& M Q:Q.(M8:A:I83.E2<-29S.3.*%80!%2M]^=/4S4Q';(EG8*G0I:PLV!UW.KU2P71KIYF@MN3H73@J6FA68,957!&V(HBZ.WI4;OV@VDV#D M(%HS54W,<254RZLO60Z_S;Z;=U0\F7'8ZSCAIG MKX.?X6PQ$]W&:"*;,,"M3T"S29"A&:L+'BAB:T7IC"W8B%FCHS*$ MH[K3"ZH['-6=3E#]$E!3K(O*(([J3H>H?NDT1W6'H[H#GK9KIAF7CN2<&[)# M>,L$.B5Y!8Q> LIA&'4XWCMJ2'Y;>'$)6 OC!>,#)C,L!VU6?@32"KXM2F;@+W$KE6@S]*AD*W2NZG 7<]J]E@@AS 2B'$<;E M[."JV>%M(%"&2H+9D]E J9 3.6O2"^0Q0 MXT*+SF'=5<-ZHV ^4: 9)OJQAT*RU6,:DG MO%+?R[F^Q^G" TH O4 ]!=38P.+[G!9\-= V"M137W9HKXY4GP.U#[US\XI( M/064PY'J_P[O74U_V0@X0J1RQ_1ZO#TX!Y1J1RO'<5]<);RU2 MU=;"D2JT6+4\:G+$2.7Q^8D^)"LJ5>6\S#EK$_*?>PA1; C]5D8GITS'D!ZG M&J6%X'5;P=L6@ENK0(15Z/!HZWBEKJQ CB'M,%QB0V@5,UJ^NM^A\]2WK-@06LF,?GK)#*&9S/@[,<@Q M9"Y((=@0NL^,EB2R49CEOVS&(6+';E\MNV+/;B<<<@3ID=1D)8>T%+QM*SAL M(;BU? +Y (W&C0=@VL%;N<@8;CMP4M1Y"Y,+2( M_=% @[1>)5G\"P MA>#6\@GL"_12-P47R9=6@. B\"'0COU:<'GM90\6^K4QT+#]UL %,!<&%Z&3 M&W?2RLV36*T&;BQT<.-^6KBQT,.-NVGBOH;TU'5QW[80W)J,P(1 ([?^^UQ' M6-+&7>UQWK)$X"6@C[OQ^T)'6-))O?T]2UOF" REUTD]K!1CZGU,E'X1V*N? M1FHL=%+C;EJIKR$]3OT^;B=XWT)P:Q4$9NFR"_L>2]JPH<-=+/1A8[@16S,< MC[&D";O6E('PG;#Y]WRS_?H41BF:TD+S_DWSR[_@+S@_\#4$L#!!0 ( *>)6%*\'<\F M"P( *0$ 9 >&PO=V]R:W-H965T:E$K2=>B=A<4:JS$BJF1[*!VIP44E4,C:FV5#<*6.Y ME:"A[X]IQ7CM);';6ZHDECL4O(:E(GI754R]7H.0[<0+O/W&BF]+M!LTB1NV MA37@SV:IC$4'EIQ74&LN:Z*@F'AI<#6-K+]S^,6AU0=K8BO92/EDC7D^\7R; M$ C(T#(P,SW#%(2P1":-OSVG-X2TP,/UGOW6U6YJV3 -4RD>>8[EQ/OFD1P* MMA.XDNT/Z.NYL'R9%-J-I.U\+\<>R78:9=6#3085K[N9O?0Z' ""\Q. L >$ M'P5$/< I1[O,7%DSABR)E6R)LMZ&S2Z<-@YMJN&UO<4U*G/*#0Z3V_DB74SG MBSN2KE;IXN[F_F;QL"9?R:,3 '*2/H,R]TG6R*RY,B.1!9G7" HTDD\S0,:% M_AQ3- E96IKUP:^[X.&)X#/(1B0*OI#0#_TC\.F'X<'WMW!J9!BT" 3;()EQG0FI=PK([W2C49E&^_,.>3201X[\_ 3YH"?K]>1[ 951])AV[_.- M1WYX=DRS_\'"X.Q8.?2@A^S[O6=JRVM-!!2&R!]=7GA$=6^B,U VKJTV$DV3 MNF5IOA%0UL&<%U+BWK"=.GQ,R3]02P,$% @ IXE84MBLV>CP @ < @ M !D !X;"]W;W)K&ULC9;1IYB;R%Y'Y)JSC$XD4GF:$OE^2[G8="W7VDY,V2K19L+N==9D16=4 M/Z\G$D9V[1*SE&:*B0Q)NNQ:??=FX!:"8L4/1C=JYQJ95.9"O)C!8]RU'!,1 MY72AC06!OUNM\7R4,RBLTW6B7D&[^%X*KX19MJK6.A1:ZT2"LQ1)"RK/PG;U4A=@1NZX 5P+\ M58%7";PBT3*R(JTAT:37D6*#I%D-;N:BJ$VAAFQ89K9QIB7<9:#3O?O'<7\\ M>!P_H/YTVA\_W(WNQD\S=(5&1.>2:4;5)9K!PQ/GG"*QW)E')(MAF,5$"_F. M)N0=MEM"XKJ0N/#S#OI! MRD.F%ERH7%+TJS]76L)3^ON(N5>;>X5YZX YI.@V5:A4^87*O+"O/:C$:P.H M58-:IT"X"52J@M,@OP;YIT!>$\C_*BBH0<$I4*L)%.R!,([<9E:[9K5/L?PF M5GN/Y3J!AYMA80T+C\*>$@I]>ZFI;$*&^T@7!P>048V,CB.%)ARMI% *>M"V M#S3AH_WJMMS0K_'E&QKM/;XX<,.P.4C7^=_2G*-A/FV MU-A@G+TPKW!PX(%S=UJJ^X4R<9&MKF!W4CA5H#689BETTKQ;E>&'2G@1_ERO MIF5^&/F? K9WC@-S%H^(7#%HPIPN0>=&ULS5EK;^(X%/TK%IJ19J19B!U( M'Z)(I8 6J:6HM+M:K58C$TR)FL2L[?2QVA^_U\%- I,XM)V5^ )Y^!P?7U_[ MV$[WB8L'N6),H>BK@KI6Q+(*(Q3+@,1)L>=8XQZ&C.GDEWP M\/=@H59GC>,&6K E34)UPY]^9:9!' 7AI[#?! M2B,]H(KVNH(_(:%+ YN^2+LK14. @UAGUDP)>!L 3O6FP\EL?#U!YY,!FE[/ M;F^&M^.;X=5P ],G5L8!\YO(Q=\0<7 ;4A5>+[[/60Q7ZOLZI'&9R+TI"2Z!#_:' M.W>S ?KRZ>N>PH;[M_7$,)>PC/9G.2YEV>H(-\M0-Z5U*VG3)J+^IHEH"DV4 MB,8+=*U63* IETHP%0@&$Y[:*79+YR%#M^P97H3F%42(NT3B:M8Z6Z@/$@ M@GFB)W ))N#S^SCXIW1P#39,G91)>]%CK^UV6X_%#"HI@K>+C'XLXGI9D:TV M>%D;/&L;IL;"MCK5$INCC/?H\'+J.!-W;&WT:VW4]T5"PV\PLRHFF%0ZJWS0 M XZ/($ET R V/I4K,%>0YK.ROK57UFYVG,\6T2>9Z).W]Q3Z%X']@[G'Z;VE M&NSD?N4<7M?A@IUB:QR&4@6PW@&!/H_6-'Z!_^(X!)>,=?7+0/HT3 =[6:>9 M6HIC"3OE8PF37!NIZ:,L??@2L>T>B$K)5)F%#VKH2?/D M^'.9^=3@W&;;*\.-:G'>+FX[,+G#8/==R3L6#*YLJPF<&P5N'V#>YF:![6XQ M2:(YJ("\,$N*W--,,/9<:@Q,15XA=4E%YN8V@.T^4*>.0LQ@V;>_RKZIL*@2 M5ZC,304?_;_CRT[O-AWK5(US@\'V2;\@E(:03S3=Y('F9;*;[4:9G>_$^U&: M&?HUP$Y=FW+_P>\S(#.&X6H&;::P+/N6FA+8IK)M$W)#(@=H2"0W)&(WI \F MY44-/6D>=6P=2')W(G7N5-Z!=W&@!<\4N*IM[4?RZ9XJ])=I/);%_MN*,*W*@69U_\DMR@R#LV*KO) M^^8Y*'<>:+BY1[AVC_A)4Z.I9>LPHWQJ M= NG5'5[B(]-C37T3M4*ZYVXT=MQF\"T"F?-$1/WZ5&ULS5;;;MI $/V5D=6' M5FKPA5M2 1(!5T5*B 6D557U86,&6&7MI;L+I%4_OK/&<8 :FE:MU!=[+W/. MGMD9CZ>UD>I>+Q -/"0BU6UG8OJ>($)TQ6YQ)1V9E(ES-!4S5V]5,BF M&2@1;N!Y#3=A/'4ZK6PM4IV67!G!4XP4Z%62,/7U$H75P8\?G"V 6W MTUJR.8[1W"XC13.W8)GR!%/-90H*9VVGZ[_I^54+R"S><]SHG3%85^ZDO+>3 MP;3M>%81"HR-I6#T6F,/A;!,I.-+3NH49UK@[OB1_6WF/#ESQS3VI/C IV;1 M=LX=F.*,K809R@[$*VUDDH-)0<+3[9L]Y!>Q _!K M1P!!#@B>"ZCF@.SFW*VRS*T^,ZS34G(#REH3FQUD=Y.AR1N>VC".C:)=3CC3 MB<+A>' SA.ZP#]'->#(*)X-1>!T.)Q!>1UBJ.QS#&703 MN4J-AA'&7+U[!"XN^YD)06'7+->25U>;&N0>76P^"(Q[T,:Y U7\-@1=X)?#> ML^'^Q3[J&R M_GR52\4E5394:QXCQ JGW)1*W7(V=G3X_H'4$I-:N=1&(;7Q"ZG4-][*OS>2:GT%Z1_7)H%\ _2RM_YP_C_7V+Y3_7:_T7!_MW4 MROGV\J;9. A8F5&C?B1F3X7?K_Z#],I)=^MGT#S46V+3.)#K[K09ML>[9FK. M*48"9P3R*DU"JVW;M)T8N)[:9*9K7S@]0 M2P,$% @ IXE84O\MO%_-! 0A< !D !X;"]W;W)K&ULO9A;;^(X&(;_BH7FHB-M&VP.A8HB%9+1(K44E797J]5>I,04 M:Q*;M4WIK/;'KW-HSOD"6FEN6A+>SWY?._83/#D*^5WM*-7H(_"YNNWLM-[? M6);:[&C@JBNQI]Q\LQ4R<+6YE&^6VDOJ>E%1X%NDVQU:@>V-M.AS>LZ63OOM$UU2_[E3175MJ*QP+* M%1,<2;J][=SA&YN,PX)(\1NC1Y7[C,(HKT)\#R\6WFVG&SJB/MWHL G7_'NG M<^K[84O&Q]])HYVTS[ P__FS]6]1>!/FU55T+OS?F:=WMYU1!WETZQY\_22. MO](DT"!L;R-\%?U%QT3;[:#-06D1),7&0#CO:RW-M\S4 MZ>G*6:X7CTMTM[31ZG']_.0\+YZ4K M^H(81P_,]\VDJXFE3830B+5)[,YBNZ3!+B;H07"]4\CA'O6*#5@F>SH Y', M9@1LT::;*]3#OR#2)=T:0_.3R_&XIMP^O7P$I.FET]F+VNLWM/=RM;Y"*S/X MDFHFJ5F@&LV2.5GY+@>ZZ*==]*,N>HV6M^:.5V@6V4QM?*$.DJ(_[\W7:*%I MH/X"NANDW0W 1&LJW]F&1D]4W?,25P^BZG"3>Y^:67S/3V"KPH84!=/#U/00 M-+W@FDJJ=*/KN'R8ZQ&77+[,;FZDU#\]! M]8[*VMV^VSH![1(;E!0MY[B(0E4R*ENO2JX;K&=TPS#>S@<%KL+J$IQL_G!LD(1N0I&@]0QZ!D7<^-TB57I>#8KT)K M$40?=]3UJ P%YONM$/KS(NP@/3:?_@=02P,$% @ IXE84FP[D@(;" MT#$ !D !X;"]W;W)K&ULM9MK3^,X%(;_BE7M MAQEIH(WM.&4$2$"*%FF BL[L:C^&UK2929-NXL*PVA^_21KJQI?CT.Y\@5Y> MVZ\O.8]/W)R^9/F/8L&Y0#^725J<]19"K#[W^\5TP9=1<9RM>%I^\Y3ERTB4 M;_-YOUCE/)K5A99)'P\&K+^,XK1W?EI_-L[/3[.U2.*4CW-4K)?+*'^]Y$GV MF\?/,3SA:@^Z)^?KJ(YGW#Q;37.RW?];2VS>,G3(LY2E/.GL]Z%]SD, M:%6@5OP1\Y=BYS6JNO*893^J-S>SL]Z@]80_-^%.T3L1#]O([;SKD5_5- MLZ2H_Z*71COHH>FZ$-FR*5PZ6,;IYG_TLQF(G0(>LQ3 30&L%J"6 J0I0+H6 MH$V!>JC[FZ[4XQ!&(CH_S;,7E%?JLK;J13V8=>FR^W%:S?M$Y.6W<5E.G(]' M=Y.;^SMT<1>B\?WDZ\/HZ\W#Z'9T]Q6-;L=?[O\:C=#EZ&YT??,5C;]?BWHFA>-B] M^!#H#=E.,:GKHY;ZOAU/CM$X*T3.19SS\J(5VXFK)@MH@FZ;H'43Q-*$7!'C M//M>7M+EA.MK VC(WS;D@WV1U3\VU6<[2^^1S^,TC=,YRI[0*X]RTV+:-.#7 M#511\?F<>J?]Y]WI!24MWVSKFX&^)SQ_CJ<<3AZM%PEV2NOQCH5>?RX M%K:P,G0.NJZPF#O9FCMQK ,ADOH2-#HZ<3J"%"U'WD 28 !Z:B[4 JVB>&8, MOP.MT2.J^((U;6<[;/) 9Q=3L8[R.$I0DI5 ,;/!FR.@I+UIEB#!!X($ M=P )K&D[DR#!,$CVB=98IX8ZB*"D;56"!<-@ 2*/(U1C-U[MFD3,XE62!,,D^9;&HKFYP OT+QHW=Z1V\UMH1X E$O#PUZ:X M6$9W#$?W_R')Q7IXQSA0I\0@\BRQED@*$)@"KE27Z %>W; ;)%@)4Z"D[5Q2 M@L"4<.:[1(_W3+6N2X:J=5T26*Q+:A"8&MUW5,1-"5#2-KAS#PI&@&/'0O1P MKKF")&U7,MX3>MB.I2G?BEJ>&MH(%*#;6@268.MI!+I3*5.&3"1 M$"(PA [-@(D)+MK(Z2)O: F&5!*(P@1Z;Q9,#2Q1]YL&#;4 ATK@4!@XW:,V M=2H&B6T )57H052A;JJ DK:KG<.0 ZE"NU#% M(6I[DU2A,%7V"=S4?3,+E+2M2L90F#'[9\)4QP@FVGHTB-0 %1I$]@ ED41A M)+TO'Z8Z.8ZTQ6+0>)9TF$JZ4)@NG=-A*K%"8:SLG0Y3]STM4-(^;I0L\6&6 MO#L9]@WWK]39,FELL^5+FO@P3:ZSG,?S9B?P_E38EU3P\:]-A7T9X/U#SBZZ MG??J$1[[*MY-(F()MKX$@0^#P)4*^WJ()ZHQIR0$)6WG.\?L,":Q\^]'!N6WS])$.[(VG26+)-7T+#=T'#G0K[AE1"&S9=0RS3R20A&$R(?794 MS)!Q*'>XK@P:VT$(DXQ@,",.2H:9X1S]1%T )I$:;D.3R!9NF>02Z\RE3LDP MDQABC@., Y-AIN/%8^J&U"2BEKTFDPQB,(/>FPPSG2:>YM2@L1F5R&$P;.1T!)V^#.3[@<][RZ)L-,A\90]6?(*VP&)5C806!A(#0:7]W!PB18V(%@ M81W 8M)8P,(D6!@,EKUBMP$TZ@;?H#FR[,D""9H !LW^^7!@.'(9JEM@DTB- M46$C\KO$J$!2*7!D+N_*AP,='D?>0)T"D^K$LF "B9@ 1DSGC#B0; E@MNR= M$0>&(W#U>H8U;<<2*0&,E'?GQ$U]?GO&U-V9276BGA#W=W[JON3YO'YDH"AC M\CH5FQ]X;S_=/I9P4?\87_G\TOL<;AXND-5LGG6XC?(2Z05*^%-9Y> X*!WE MF\<'-F]$MJI_4/^8"9$MZY<+'LUX7@G*[Y^R3+R]J1K8/L1Q_A]02P,$% M @ IXE84NL84Y_F @ :@D !H !X;"]W;W)KX[CVRDFF34:F'LA'PU8+BG)(.1(Y&F*^9]; MH.PPM%SK]<:";+92W[!'@QW>P!+DTR[D:F17+C%)(1.$98A#,K3&[LW$-0(3 M\9W 01Q=(YW*FK%G/;B/AY:CB8!")+4%5J<]3(!2[:0X?I>F5O5.+3R^?G6_ M,\FK9-98P(31'R26VZ'5LU ,"8[GU,@G'Y:[_?=R6Y6HJI-7U2U_8.^/)ZTFQNM6,>\P.Q5FIQ%SW%BP.M#"SV\$K8DY M!^I7H'XCZ-W'YJI@]&L8W1/&FAC7KV?L5HS=9D;&U<*7F<^ZH85ZE5WO?^WR M?H78_]0N[_];]'[[9&)J8CK]^HEQG;>%VOGD/B\-WW'T3AN]+JCCGH$]VE7< MS^OUTNMX57![_5/.FB#_E-,^V@CU7\@,\PU1[40A42KGNJODO-C8BX%D.[,W MKIE4.ZVYW*J?(> Z0#U/&).O [W=5K]7H[]02P,$% @ IXE84G(CF%: M P ] T !H !X;"]W;W)K1T",_C[**$TAES%,D8#WPSO'G$6D;@9WQ+8:]/+I& M9BD+SN_-8+(:>(')"!@LE0E!]=\#? '&3"2=Q^\LJ)<2?N+]MGGYJW,E-!/ M8ZU3PRBC:_">>3F_ JG,Y1>!5=7O\(0S0*I^'%9(ZBR_/I M#'U"%SNU$X 6D,(Z5FA+_^C7I"32>P2I#:!M]M+R"8RF$KT?@Z(QDQ_0.Q2G MZ"IF3$^2?5_I99AD_&66\NB0,BE)>0S+!FKBCX@$)+B=C='[=Q^>1_%U$?)* MD+P2Q(9ME54BRWJ491W9K/^BVS16L$(S117("DXSYS0MIUF:_EK?6;W@T'2% MKG7Q!(JX5 )4+,!4]<6T.5TP0'-XU \87]ZCGY7*MRB+H MDF+7&SFHVE9E&OUAB%M]_\%!:N>D=AV)N$@'5>>8U'.3.CFI4T=JNDB=4U+7 M3>KFI&X=J>4B=5]-.LM)9W6DMHMT]FI2+R?UZDB=3R1H!BY<[P37;;MQ."@, M*7A3'VH3UA:;VG'%3L='SH?_OT;$A1WA:C\J:\5,=EST3DG-"TO"S3E/C4;EJDA%CX#:XVG-O&K%'5$55;OK :W/O_.I(4SD2JG:FL(S/9LX*[ MZTT*24Z) M6%*@M5ZXP@0 "8: : >&PO=V]R:W-H965T8QVE/W@:XP%>$WBE-\8:R$VUY;%PS5.$#?I!J?R MS)*R! FYRU86WS",HAR4Q!:T[;Z5()(:XU%^;,[&([H5,4GQG &^31+$_IG@ MF.YN#,?8'W@DJ[7(#ECCT0:M\ *+Y\V*/V1[=Q%-X:=C0C'.!09!9)_/_$4QW'&),?Q=TEJ5#$S MX.'VGOUK+EZ*>4$<3VG\G41B?6,,#!#A)=K&XI'N_L"EH%[&%]*8Y[]@5UYK M&R#<O92(. $Z_ P!+ #P&>!T MP2X;P5X)<#+,U-(R?/@ M(X'&(T9W@&572[9L(T]FCI;R29K-^T(P>99(G!C/@]GB[F$&;F<^F#\LGAZ# MI[O'X#Z8/8'@?O[MX:\@ )-@%GR]>P+S;[>S!?@"ON?)Q-$7]!,S61P <5DV MFVP>.=AR' %!9>X%9G+ &*2R>C>8$1J1$+S@%"^) "'E@@.41M41^A*3%2I( M/OE8(!+SSR-+2)'94*VP%#0I!,$.00X$]S05:PZ"-,)1D\"2V:E2!/6:G91IG\=()OQ? M\)P2.:5@(9# 7!''J^)X>1RW(XYM&=D\Y:9EH0)>R#XLM2X&I7'&8R_[*<$1$MO"Z5H2:J-U'3V3>ZA\A9%$,>N M/=-^7[?1X&'7 M/@6MI44\&!ZSN772P:OL[5,?L#]JG1HV#ICML M;4M:'#S&-9775NU\E%=KB*$Y[$B)&N>:7NLMCZ_%]=4]J/9KY\*&K>%S3;MC MW:IQT!QT%(<6=Z7,1&W:SL5<6\/4W8?/P_FGXYHYJ)W;^4#KAK5UPW=:MP;O MF.[QI)\F'5KF#K+_W1< M4TMMW5!MW<_FP@1SZ9>ROQ.&$RQ+[=#&54%JVX:_PK9A;=OPG;:MP?CFNFI+9M>&';UO!U9^+,)^W3 M<H">8K?(/$1SD:2]>%%='JX\=M_DK_J/C$^?:+SY9U#3%%Y1[Q%9$ M/L7%>"DI;?F,:0!6?)0H=@3=Y*_I7Z@0-,DWUQA%F&47R/-+2L5^)PM0?1H: M_P=02P,$% @ IXE84H< GLY^ P >A$ !H !X;"]W;W)KO*> 4ID2=\#9F>67*1$J6[XM:5:P$DR4$I0K/E'8RKTV,J$L.+\SG4DR<#SC$3"(E3%!]-\/& -C MQI+VXWMAU"DY#7"__6#](@]>![,@$L:2,73 JP]2&FV^R?WQ4;L 7"K!N 7 /^E@* !'F@.\_R ML,Z)(L.^X%LDS&IMS33RO1ZBD;35]MDPNW'AW]G./[_&OW.(3U" WR'? M\[UGX.,7PW'O,=S5.U5NEU]NEY_;:]78^YA1!0F:*:) HE]H3.0*D2Q!L6G M]PW]01AD2EJX@I(KR+F"6M^7>B1YO(,YV;5:@4 1ETJ H@+T8Z6>+)N3!0,T MAWL]H06Z0U\OM3$T49#*;Q;G6J5S+>M&/#BW*%C7FO4=6H.(M2_Z^4=\:1Y1 MDR=F"I$\64B5+,^E@IT2GWC>?\^EP,&P1Q&WRXC;!TD?:K'53R0AW@BJ*-@D M[Y0.3_+1T[O3?2VZG#'IUFMMQ[7:#Z-TRYNY!HE_0>]VE6)GTO9*I M=WS28Z\J$]Z_%[^!L^/5J=\ ;+4:Y,=[Y1%;3>EW!?TFD.7[_(?G/:Z*"_:/ M, >J>H2#5\@!.V=0FP)V7*7M MG'ZW5OH&8-/ACZN*A^UUY(GVAY_^N"HTN'N$&5!5)]Q[A0RP<[;K,\ .[#2= M_WY5]WQ[*7F2 ;D6-L-58?'Q\>GM[]US[!>=OZ)W R>N?<-O -8>]N[>Q=A\ ME;@BXI;J_6.PU(:\DU-]*HO=17_747R=WY477.F;=]Y< 4E F 5Z?LFY>NB8 MZW?YN67X&U!+ P04 " "GB5A2_ .G=7\+ #)<@ &@ 'AL+W=OOV\O-U!_Q54[7OYFV[YN3R M[.+J_,L%>W=QRBZ_7%U_/;L^_WKV^>SBFIU]OOSTY=]G9^S]V<79Q_-K=OGI MW<45^SO[F.45>\R*!\'*6W:__19DZP6[+^NF$DU>B?:[T; ;L1:W>\SC7;9=U^_JWJU/V\T^_L)^Z#C_G1=$&U<>SIIV:[@)G\^TTO'^>!G]D M&D[%_ WC\#?F>[ZG:?[!N#FDFN:GYLV3?O-9B^<.5'\'JK_I+QCI[]LZ;]HI MOFJR1M1$?WS7']_TQT?'=]N^LAA,?@?XEQ:SBEWV8>^'76)CR<^A^/9(X9: M$P-1/^94C6FY;Q?3NXYP=QTA?1UEU9+4>C-KQ+1$N^XB]S"+=X.+[6'VW%74 MF^MT@)DF)AK@>AJKF 4CF"6[ZTC(Z_@JY@]5E:_ONMJ3U^Q_S#3UTMTGI.[! M")ZL'IX](+=]163VZ8)0^O7'B:H<[ F48;J!Y%SP'41*4CAPBTAQ@YS3!:&D MZX]3LCG0=/Y)/(J"08O0ZY,+).="Z"!HDL,AL@A:I&;.$#(U9 PP2>5 X/77OT#D_<,_*,M\R;X^ MN(>:CU;+]')Y+]2V??6RS!]2HRX(PA'D)(7[-(5/(F>8;KXD8S]P$#C)WO[$ MDGDOX$)-38N&P&F"PG0$.$GC/DWC"#A^6,I)5O9C!Y&3/.[3"^?]D$L44+PA M;E1(?XR2S'V:S"=1,TPW+JF9>^Z!QB6-A:1)*LN8."B=<$CNW*)UP51<)APBJ(2/UCDMVYS2[4PC:N+_CDL.Y@_)) M( D_L"B?!!IE9"A=JB$CZ1A(U@]HUG\MF(:)&4AJ#QP46 +)_(%%@250M9/A MDH8,Z8\12>4T_4]B:>.^,)!,'SBHO@2R$@06U9= E5841*F0_AAE.0CH"60U""S*,X&JO0QKIR9DI':&LB2$=$DP!/2P^\A0LG_HH'03 MRIH06I1N0E65&:8H&=(?HRP,(5T8#D+4,$5#60)"!R6=$/TGJ$5))U35&@50 M*J0_1ED70KHN?'MS]8;=5&6V8*NL^BZ:PW)1R)5R5$24A,SEI"19/R(9OP)+ ];Z$1HNXR# MLD\DN3^R*/M$JJ:C9"45TA^C+ 170#.5J*ZZU!ZQO$PR362C!XYJ/'$DNYC MBQI/K HXRE8GC<8S\E^+L23]F"9](^@,UZ*QI/'8044GEO0>6U1T8LUNF"%R M:H@_ ISD^)CF> UP-E8SL:3OV$$-)Y:T'EO4<.)I#8<,Z8\1;8:DN7U/#$W3 M4/)V[*!J$TM^CRVJ-K$JR2@04B'];:"2Y!.:Y,<@M+$>322+)PZ*-8FD^\2B M6).H2LRP$FI"QBIA(DD_H4G_-4@:9F0B63UQ4*1)). M.BC7I)+T4XMR3:K9FZ.@J(D9<5*DDOM3FOOWA=$T%26QIPX*-:ED_-2B4)-J M]N<,BZ,FAB9(H>3@_H->-CC9-7DI.HSP\2D8P;C1!XG MCZX"KP?5U*?A(3>4YZ"V Q[R0WDV#5'>](8=.F8P3N2'\NBR8("JC;M,\)!I MRG-0\P$/V:8\F[XI3V.<4L'5!(W9$CUDGO+HBE,SHWC7?Z /+OPH2!]WS]*.IF M,TEW5=:N@@Y#$)&[[Z):A#R\P&VJ15RSFX*Z"+&;&* '+SPH2=5P.@E=4.,NL"=U$+0G9> MX#:U(#Z]!8B.&8P3,?^$L7=/+(W3$G$Z=U'Y069>X#:5'SZ]%8B.&9Q@A4K MA*UW#$HKBU?DW(7 1;$'.7HAL"GV!)K]/FJMU$2-UDKD[H4)>^]K,#7-T0"? MCN:BR(,LO1#8%'D"5B&TJ?Z$!NH/&3,8)ZH-$];> MWXKR)BO8,K];LC]S42P.0Q Q?>BBY(,%P35&#Z&(#Y;DRX% M.@1M+&F14Q="%_4>9.F%T*;>$QKH/63,8)RH"DR8>T>QM+'^0>Y="%V4?Y"Y M%R*;\D]$'=BS!503,Y:I*PY)]GC M"HYJ5#IVG#)R^L*$U7<,2!NE$YEY(7)1#4*V7XALJD&1P6G+9$Q_G,C_"Q,& M8!)/&^43V7PA=E$10HY@B&TJ0K%&$?*40\\U4>D8X2)W,$S8@PUP/:R*(A

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

)6%)&6OIT1@D M +19 / " 3B# P!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 M " "GB5A2@_59A*X# "[3P &@ @ &KC , >&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "GB5A28!O&JLP" K M3 $P @ &1D , 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 1 D "0 ,PG ".DP, ! end XML 156 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 157 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 158 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 916 712 1 false 258 0 false 22 false false R1.htm 000010001 - Document - Document and Entity Information Sheet http://www.bauschhealth.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 100020003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 100030004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 100040005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 100050006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Sheet http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Statements 6 false false R7.htm 100060007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 210011001 - Disclosure - DESCRIPTION OF BUSINESS Sheet http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS DESCRIPTION OF BUSINESS Notes 8 false false R9.htm 210031002 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 210181003 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE Sheet http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALE ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE Notes 10 false false R11.htm 210231004 - Disclosure - RESTRUCTURING, INTEGRATION AND SEPARATION COSTS Sheet http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTS RESTRUCTURING, INTEGRATION AND SEPARATION COSTS Notes 11 false false R12.htm 210251005 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 12 false false R13.htm 210361006 - Disclosure - INVENTORIES Sheet http://www.bauschhealth.com/role/INVENTORIES INVENTORIES Notes 13 false false R14.htm 210391007 - Disclosure - PROPERTY, PLANT AND EQUIPMENT Sheet http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT PROPERTY, PLANT AND EQUIPMENT Notes 14 false false R15.htm 210431008 - Disclosure - INTANGIBLE ASSETS AND GOODWILL Sheet http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL INTANGIBLE ASSETS AND GOODWILL Notes 15 false false R16.htm 210491009 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES Sheet http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES ACCRUED AND OTHER CURRENT LIABILITIES Notes 16 false false R17.htm 210521010 - Disclosure - FINANCING ARRANGEMENTS Sheet http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS FINANCING ARRANGEMENTS Notes 17 false false R18.htm 210651011 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS Sheet http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS Notes 18 false false R19.htm 210761012 - Disclosure - LEASES Sheet http://www.bauschhealth.com/role/LEASES LEASES Notes 19 false false R20.htm 210831013 - Disclosure - SHARE-BASED COMPENSATION Sheet http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION SHARE-BASED COMPENSATION Notes 20 false false R21.htm 210891014 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS Sheet http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS ACCUMULATED OTHER COMPREHENSIVE LOSS Notes 21 false false R22.htm 210921015 - Disclosure - RESEARCH AND DEVELOPMENT Sheet http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT RESEARCH AND DEVELOPMENT Notes 22 false false R23.htm 210951016 - Disclosure - OTHER EXPENSE (INCOME), NET Sheet http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENET OTHER EXPENSE (INCOME), NET Notes 23 false false R24.htm 210991017 - Disclosure - INCOME TAXES Sheet http://www.bauschhealth.com/role/INCOMETAXES INCOME TAXES Notes 24 false false R25.htm 211081018 - Disclosure - LOSS PER SHARE Sheet http://www.bauschhealth.com/role/LOSSPERSHARE LOSS PER SHARE Notes 25 false false R26.htm 211121019 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES Sheet http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES SUPPLEMENTAL CASH FLOW DISCLOSURES Notes 26 false false R27.htm 211151020 - Disclosure - LEGAL PROCEEDINGS Sheet http://www.bauschhealth.com/role/LEGALPROCEEDINGS LEGAL PROCEEDINGS Notes 27 false false R28.htm 211171021 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 28 false false R29.htm 211191022 - Disclosure - SEGMENT INFORMATION Sheet http://www.bauschhealth.com/role/SEGMENTINFORMATION SEGMENT INFORMATION Notes 29 false false R30.htm 211261023 - Disclosure - SUPPLEMENTARY DATA (UNAUDITED) Sheet http://www.bauschhealth.com/role/SUPPLEMENTARYDATAUNAUDITED SUPPLEMENTARY DATA (UNAUDITED) Notes 30 false false R31.htm 220042001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 31 false false R32.htm 230053001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES 32 false false R33.htm 230193002 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE (Tables) Sheet http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALETables ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE (Tables) Tables http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALE 33 false false R34.htm 230263003 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS 34 false false R35.htm 230373004 - Disclosure - INVENTORIES (Tables) Sheet http://www.bauschhealth.com/role/INVENTORIESTables INVENTORIES (Tables) Tables http://www.bauschhealth.com/role/INVENTORIES 35 false false R36.htm 230403005 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) Sheet http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables PROPERTY, PLANT AND EQUIPMENT (Tables) Tables http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT 36 false false R37.htm 230443006 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables) Sheet http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables INTANGIBLE ASSETS AND GOODWILL (Tables) Tables http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL 37 false false R38.htm 230503007 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables) Sheet http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables ACCRUED AND OTHER CURRENT LIABILITIES (Tables) Tables http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES 38 false false R39.htm 230533008 - Disclosure - FINANCING ARRANGEMENTS (Tables) Sheet http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables FINANCING ARRANGEMENTS (Tables) Tables http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS 39 false false R40.htm 230663009 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables) Sheet http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables) Tables http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS 40 false false R41.htm 230773010 - Disclosure - LEASES (Tables) Sheet http://www.bauschhealth.com/role/LEASESTables LEASES (Tables) Tables http://www.bauschhealth.com/role/LEASES 41 false false R42.htm 230843011 - Disclosure - SHARE-BASED COMPENSATION (Tables) Sheet http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables SHARE-BASED COMPENSATION (Tables) Tables http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION 42 false false R43.htm 230903012 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) Sheet http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) Tables http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS 43 false false R44.htm 230933013 - Disclosure - RESEARCH AND DEVELOPMENT (Tables) Sheet http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables RESEARCH AND DEVELOPMENT (Tables) Tables http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT 44 false false R45.htm 230963014 - Disclosure - OTHER EXPENSE (INCOME), NET (Tables) Sheet http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables OTHER EXPENSE (INCOME), NET (Tables) Tables http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENET 45 false false R46.htm 231003015 - Disclosure - INCOME TAXES (Tables) Sheet http://www.bauschhealth.com/role/INCOMETAXESTables INCOME TAXES (Tables) Tables http://www.bauschhealth.com/role/INCOMETAXES 46 false false R47.htm 231093016 - Disclosure - LOSS PER SHARE (Tables) Sheet http://www.bauschhealth.com/role/LOSSPERSHARETables LOSS PER SHARE (Tables) Tables http://www.bauschhealth.com/role/LOSSPERSHARE 47 false false R48.htm 231133017 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables) Sheet http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables) Tables http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES 48 false false R49.htm 231203018 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables SEGMENT INFORMATION (Tables) Tables http://www.bauschhealth.com/role/SEGMENTINFORMATION 49 false false R50.htm 231273019 - Disclosure - SUPPLEMENTARY DATA (UNAUDITED) (Tables) Sheet http://www.bauschhealth.com/role/SUPPLEMENTARYDATAUNAUDITEDTables SUPPLEMENTARY DATA (UNAUDITED) (Tables) Tables http://www.bauschhealth.com/role/SUPPLEMENTARYDATAUNAUDITED 50 false false R51.htm 240024001 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details) Sheet http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails DESCRIPTION OF BUSINESS - Narrative (Details) Details 51 false false R52.htm 240064002 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details) Sheet http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details) Details 52 false false R53.htm 240074003 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details) Sheet http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details) Details 53 false false R54.htm 240084004 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details) Sheet http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details) Details 54 false false R55.htm 240094005 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details) Sheet http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details) Details 55 false false R56.htm 240104006 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details) Sheet http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details) Details 56 false false R57.htm 240114007 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details) Sheet http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details) Details 57 false false R58.htm 240124008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Leases (Details) Sheet http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails SIGNIFICANT ACCOUNTING POLICIES - Leases (Details) Details 58 false false R59.htm 240134009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details) Sheet http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details) Details 59 false false R60.htm 240144010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details) Sheet http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details) Details 60 false false R61.htm 240154011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details) Sheet http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details) Details 61 false false R62.htm 240164012 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details) Sheet http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details) Details 62 false false R63.htm 240174013 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details) Sheet http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details) Details 63 false false R64.htm 240204014 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Narrative (Details) Sheet http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Narrative (Details) Details http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALETables 64 false false R65.htm 240214015 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details) Sheet http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details) Details 65 false false R66.htm 240224016 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Assets and Liabilities Held For Sale (Details) Sheet http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Assets and Liabilities Held For Sale (Details) Details 66 false false R67.htm 240244017 - Disclosure - RESTRUCTURING, INTEGRATION AND SEPARATION COSTS - Narrative (Details) Sheet http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails RESTRUCTURING, INTEGRATION AND SEPARATION COSTS - Narrative (Details) Details 67 false false R68.htm 240274018 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Details 68 false false R69.htm 240284019 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details) Sheet http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details) Details 69 false false R70.htm 240294020 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details) Sheet http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details) Details 70 false false R71.htm 240304021 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details) Sheet http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details) Details 71 false false R72.htm 240314022 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details) Sheet http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details) Details 72 false false R73.htm 240324023 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details) Sheet http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details) Details 73 false false R74.htm 240334024 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details) Sheet http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details) Details 74 false false R75.htm 240344025 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis, Narrative (Details) Sheet http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis, Narrative (Details) Details 75 false false R76.htm 240354026 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details) Sheet http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details) Details 76 false false R77.htm 240384027 - Disclosure - INVENTORIES - Summary of Inventories, Net (Details) Sheet http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails INVENTORIES - Summary of Inventories, Net (Details) Details 77 false false R78.htm 240414028 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details) Sheet http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details) Details 78 false false R79.htm 240424029 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) Sheet http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) Details 79 false false R80.htm 240454030 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details) Sheet http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details) Details 80 false false R81.htm 240464031 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) Sheet http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) Details 81 false false R82.htm 240474032 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details) Sheet http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details) Details 82 false false R83.htm 240484033 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details) Sheet http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details) Details 83 false false R84.htm 240514034 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Details) Sheet http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails ACCRUED AND OTHER CURRENT LIABILITIES (Details) Details http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables 84 false false R85.htm 240544035 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details) Sheet http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details) Details 85 false false R86.htm 240554036 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details) Sheet http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails FINANCING ARRANGEMENTS - Covenant Compliance (Details) Details 86 false false R87.htm 240564037 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details) Sheet http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details) Details 87 false false R88.htm 240574038 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2018 Activities (Details) Sheet http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2018 Activities (Details) Details 88 false false R89.htm 240584039 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2019 Activities (Details) Sheet http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2019ActivitiesDetails FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2019 Activities (Details) Details 89 false false R90.htm 240594040 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2020 Activities (Details) Sheet http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2020ActivitiesDetails FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2020 Activities (Details) Details 90 false false R91.htm 240604041 - Disclosure - FINANCING ARRANGEMENTS - Current Description of Senior Secured Credit Facilities (Details) Sheet http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails FINANCING ARRANGEMENTS - Current Description of Senior Secured Credit Facilities (Details) Details 91 false false R92.htm 240614042 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details) Notes http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails FINANCING ARRANGEMENTS - Senior Secured Notes (Details) Details 92 false false R93.htm 240624043 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details) Notes http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details) Details 93 false false R94.htm 240634044 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details) Sheet http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details) Details 94 false false R95.htm 240644045 - Disclosure - FINANCING ARRANGEMENTS - Maturities, Schedule of Maturities and Mandatory Payments of Debt Obligations (Details) Sheet http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails FINANCING ARRANGEMENTS - Maturities, Schedule of Maturities and Mandatory Payments of Debt Obligations (Details) Details 95 false false R96.htm 240674046 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details) Sheet http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details) Details http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables 96 false false R97.htm 240684047 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details) Sheet http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details) Details 97 false false R98.htm 240694048 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of net periodic benefit cost (Details) Sheet http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of net periodic benefit cost (Details) Details 98 false false R99.htm 240704049 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details) Sheet http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details) Details 99 false false R100.htm 240714050 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details) Sheet http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details) Details 100 false false R101.htm 240724051 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future benefit payments for the pension benefit plans (Details) Sheet http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFuturebenefitpaymentsforthepensionbenefitplansDetails PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future benefit payments for the pension benefit plans (Details) Details 101 false false R102.htm 240734052 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-average assumptions used to determine net periodic benefit costs and benefit obligations (Details) Sheet http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-average assumptions used to determine net periodic benefit costs and benefit obligations (Details) Details 102 false false R103.htm 240744053 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details) Sheet http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details) Details 103 false false R104.htm 240754054 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair value of pension and postretirement benefit plan assets assumed in connection with the Acquisition (Details) Sheet http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair value of pension and postretirement benefit plan assets assumed in connection with the Acquisition (Details) Details 104 false false R105.htm 240784055 - Disclosure - LEASES - Right-of-use Assets and Right-of-use Liabilities (Details) Sheet http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails LEASES - Right-of-use Assets and Right-of-use Liabilities (Details) Details 105 false false R106.htm 240794056 - Disclosure - LEASES - Narrative (Details) Sheet http://www.bauschhealth.com/role/LEASESNarrativeDetails LEASES - Narrative (Details) Details 106 false false R107.htm 240804057 - Disclosure - LEASES - Lease Expenses (Details) Sheet http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails LEASES - Lease Expenses (Details) Details 107 false false R108.htm 240814058 - Disclosure - LEASES - Lease Additional Information (Details) Sheet http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails LEASES - Lease Additional Information (Details) Details 108 false false R109.htm 240824059 - Disclosure - LEASES - Lease Future Payments (Details) Sheet http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails LEASES - Lease Future Payments (Details) Details 109 false false R110.htm 240854060 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details) Sheet http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails SHARE-BASED COMPENSATION - Narrative (Details) Details 110 false false R111.htm 240864061 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details) Sheet http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details) Details 111 false false R112.htm 240874062 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details) Sheet http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails SHARE-BASED COMPENSATION - Stock Options (Details) Details 112 false false R113.htm 240884063 - Disclosure - SHARE-BASED COMPENSATION - RSUs (Details) Sheet http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails SHARE-BASED COMPENSATION - RSUs (Details) Details 113 false false R114.htm 240914064 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details) Sheet http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details) Details 114 false false R115.htm 240944065 - Disclosure - RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details) Sheet http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details) Details 115 false false R116.htm 240974066 - Disclosure - OTHER EXPENSE (INCOME), NET - Schedule of Other Expense (Income), Net (Details) Sheet http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETScheduleofOtherExpenseIncomeNetDetails OTHER EXPENSE (INCOME), NET - Schedule of Other Expense (Income), Net (Details) Details http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables 116 false false R117.htm 240984067 - Disclosure - OTHER EXPENSE (INCOME), NET - Narrative (Details) Sheet http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails OTHER EXPENSE (INCOME), NET - Narrative (Details) Details http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables 117 false false R118.htm 241014068 - Disclosure - INCOME TAXES - Components of Benefit from Income Taxes (Details) Sheet http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails INCOME TAXES - Components of Benefit from Income Taxes (Details) Details 118 false false R119.htm 241024069 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details) Sheet http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details) Details 119 false false R120.htm 241034070 - Disclosure - INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details) Sheet http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details) Details 120 false false R121.htm 241044071 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details) Sheet http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details) Details 121 false false R122.htm 241054072 - Disclosure - INCOME TAXES - Narrative (Details) Sheet http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails INCOME TAXES - Narrative (Details) Details 122 false false R123.htm 241064073 - Disclosure - INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details) Sheet http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details) Details 123 false false R124.htm 241074074 - Disclosure - INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details) Sheet http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details) Details 124 false false R125.htm 241104075 - Disclosure - LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details) Sheet http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details) Details 125 false false R126.htm 241114076 - Disclosure - LOSS PER SHARE - Narrative (Details) Sheet http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails LOSS PER SHARE - Narrative (Details) Details 126 false false R127.htm 241144077 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details) Sheet http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details) Details 127 false false R128.htm 241164078 - Disclosure - LEGAL PROCEEDINGS - Narrative (Details) Sheet http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails LEGAL PROCEEDINGS - Narrative (Details) Details 128 false false R129.htm 241184079 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) Sheet http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails COMMITMENTS AND CONTINGENCIES - Narrative (Details) Details 129 false false R130.htm 241214080 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit, Assets and Capital Expenditures, Depreciation & Amortization of Intangible Assets & Asset Impairments (Details) Sheet http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails SEGMENT INFORMATION - Segment Revenues and Profit, Assets and Capital Expenditures, Depreciation & Amortization of Intangible Assets & Asset Impairments (Details) Details 130 false false R131.htm 241224081 - Disclosure - SEGMENT INFORMATION - Revenues by Product Category (Details) Sheet http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails SEGMENT INFORMATION - Revenues by Product Category (Details) Details 131 false false R132.htm 241234082 - Disclosure - SEGMENT INFORMATION - Geographic Information, Revenue (Details) Sheet http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails SEGMENT INFORMATION - Geographic Information, Revenue (Details) Details 132 false false R133.htm 241244083 - Disclosure - SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details) Sheet http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details) Details 133 false false R134.htm 241254084 - Disclosure - SEGMENT INFORMATION - Major Customers (Details) Sheet http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails SEGMENT INFORMATION - Major Customers (Details) Details 134 false false R135.htm 241284085 - Disclosure - SUPPLEMENTARY DATA (UNAUDITED) - Schedule of Unaudited Quarterly Consolidated Financial Data (Details) Sheet http://www.bauschhealth.com/role/SUPPLEMENTARYDATAUNAUDITEDScheduleofUnauditedQuarterlyConsolidatedFinancialDataDetails SUPPLEMENTARY DATA (UNAUDITED) - Schedule of Unaudited Quarterly Consolidated Financial Data (Details) Details http://www.bauschhealth.com/role/SUPPLEMENTARYDATAUNAUDITEDTables 135 false false R9999.htm Uncategorized Items - bhc-20201231.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - bhc-20201231.htm Cover 136 false false All Reports Book All Reports bhc-20201231.htm bhc-20201231.xsd bhc-20201231_cal.xml bhc-20201231_def.xml bhc-20201231_lab.xml bhc-20201231_pre.xml exhibit1012020ye.htm exhibit10142020ye.htm exhibit2112020ye.htm exhibit2312020ye.htm exhibit3112020ye.htm exhibit3122020ye.htm exhibit3212020ye.htm exhibit3222020ye.htm bhc-20201231_g1.jpg bhc-20201231_g2.jpg http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/stpr/2018-01-31 true true JSON 161 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bhc-20201231.htm": { "axisCustom": 1, "axisStandard": 53, "contextCount": 916, "dts": { "calculationLink": { "local": [ "bhc-20201231_cal.xml" ] }, "definitionLink": { "local": [ "bhc-20201231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "bhc-20201231.htm" ] }, "labelLink": { "local": [ "bhc-20201231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "bhc-20201231_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "bhc-20201231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 1152, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 12, "http://www.bauschhealth.com/20201231": 1, "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 17 }, "keyCustom": 124, "keyStandard": 588, "memberCustom": 148, "memberStandard": 102, "nsprefix": "bhc", "nsuri": "http://www.bauschhealth.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000010001 - Document - Document and Entity Information", "role": "http://www.bauschhealth.com/role/DocumentandEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210181003 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE", "role": "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALE", "shortName": "ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i1913b0004a9544a9a5540b1b28d7686a_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240714050 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details)", "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails", "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i1913b0004a9544a9a5540b1b28d7686a_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "id8242642dba7454ca7b2a4ed27425b4c_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240724051 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future benefit payments for the pension benefit plans (Details)", "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFuturebenefitpaymentsforthepensionbenefitplansDetails", "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future benefit payments for the pension benefit plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "id8242642dba7454ca7b2a4ed27425b4c_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4fd96409433e4ff78226478b6b2c24fb_D20200101-20201231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240734052 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-average assumptions used to determine net periodic benefit costs and benefit obligations (Details)", "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails", "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-average assumptions used to determine net periodic benefit costs and benefit obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4fd96409433e4ff78226478b6b2c24fb_D20200101-20201231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i32d7228169b24394b00bd537b54f45f3_I20201231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240744053 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details)", "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails", "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i32d7228169b24394b00bd537b54f45f3_I20201231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets", "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "id8242642dba7454ca7b2a4ed27425b4c_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240754054 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair value of pension and postretirement benefit plan assets assumed in connection with the Acquisition (Details)", "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails", "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair value of pension and postretirement benefit plan assets assumed in connection with the Acquisition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bhc:ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "id0afb3f9e20a4698b5250bd927da1b9d_I20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bhc:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240784055 - Disclosure - LEASES - Right-of-use Assets and Right-of-use Liabilities (Details)", "role": "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails", "shortName": "LEASES - Right-of-use Assets and Right-of-use Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R106": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240794056 - Disclosure - LEASES - Narrative (Details)", "role": "http://www.bauschhealth.com/role/LEASESNarrativeDetails", "shortName": "LEASES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R107": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240804057 - Disclosure - LEASES - Lease Expenses (Details)", "role": "http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails", "shortName": "LEASES - Lease Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R108": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bhc:AdditionalOperatingLeaseInformationLesseeTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240814058 - Disclosure - LEASES - Lease Additional Information (Details)", "role": "http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails", "shortName": "LEASES - Lease Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bhc:AdditionalOperatingLeaseInformationLesseeTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R109": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240824059 - Disclosure - LEASES - Lease Future Payments (Details)", "role": "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails", "shortName": "LEASES - Lease Future Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210231004 - Disclosure - RESTRUCTURING, INTEGRATION AND SEPARATION COSTS", "role": "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTS", "shortName": "RESTRUCTURING, INTEGRATION AND SEPARATION COSTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R110": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "idee2a2b3bcf648f6b951f632e29973e2_I20140531", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240854060 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)", "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "idee2a2b3bcf648f6b951f632e29973e2_I20140531", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R111": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240864061 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)", "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails", "shortName": "SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i93e34156810b4298a2cc34ffe594c676_D20200101-20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R112": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "ia174e1111ffd449581791a5c6caa58bb_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240874062 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)", "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails", "shortName": "SHARE-BASED COMPENSATION - Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "ia174e1111ffd449581791a5c6caa58bb_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R113": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i0f6f7356ab5f442fbc2077677bd40df3_D20200101-20201231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240884063 - Disclosure - SHARE-BASED COMPENSATION - RSUs (Details)", "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails", "shortName": "SHARE-BASED COMPENSATION - RSUs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i0f6f7356ab5f442fbc2077677bd40df3_D20200101-20201231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R114": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240914064 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details)", "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails", "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i18340898edcf4f32b67a54a238206ae4_I20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R115": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "bhc:ResearchAndDevelopmentExpenseProductRelated", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240944065 - Disclosure - RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details)", "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails", "shortName": "RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "bhc:ResearchAndDevelopmentExpenseProductRelated", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R116": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GainLossRelatedToLitigationSettlement", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240974066 - Disclosure - OTHER EXPENSE (INCOME), NET - Schedule of Other Expense (Income), Net (Details)", "role": "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETScheduleofOtherExpenseIncomeNetDetails", "shortName": "OTHER EXPENSE (INCOME), NET - Schedule of Other Expense (Income), Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R117": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GainLossRelatedToLitigationSettlement", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240984067 - Disclosure - OTHER EXPENSE (INCOME), NET - Narrative (Details)", "role": "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails", "shortName": "OTHER EXPENSE (INCOME), NET - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "iae66cb3a6b5f4c0c990d06bd825b1e13_D20190101-20191231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:GainLossOnDispositionOfAssets1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R118": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241014068 - Disclosure - INCOME TAXES - Components of Benefit from Income Taxes (Details)", "role": "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails", "shortName": "INCOME TAXES - Components of Benefit from Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R119": { "firstAnchor": { "ancestors": [ "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "span", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241024069 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details)", "role": "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails", "shortName": "INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210251005 - Disclosure - FAIR VALUE MEASUREMENTS", "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R120": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "bhc:DeferredTaxAssetsTaxLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241034070 - Disclosure - INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details)", "role": "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails", "shortName": "INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "bhc:DeferredTaxAssetsTaxLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R121": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i37ade4cff0a644b5a47a9ec99443bd1c_I20191231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241044071 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details)", "role": "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails", "shortName": "INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "ib5e6bb403487488abd3dbd9982819149_I20171231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R122": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241054072 - Disclosure - INCOME TAXES - Narrative (Details)", "role": "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails", "shortName": "INCOME TAXES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "lang": "en-US", "name": "bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R123": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i9b722fd3f825405eb63dcf63fe62dbf3_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OpenTaxYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241064073 - Disclosure - INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)", "role": "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails", "shortName": "INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i9b722fd3f825405eb63dcf63fe62dbf3_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OpenTaxYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R124": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i37ade4cff0a644b5a47a9ec99443bd1c_I20191231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241074074 - Disclosure - INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details)", "role": "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails", "shortName": "INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i1b64bf071df84a8c872e7fbe1a84a958_I20171231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R125": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i1653b1e25bc74247a4b58c23c249df72_D20201001-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241104075 - Disclosure - LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)", "role": "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails", "shortName": "LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R126": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i37cee0de213f4f6aac9eecbe1efa0922_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241114076 - Disclosure - LOSS PER SHARE - Narrative (Details)", "role": "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails", "shortName": "LOSS PER SHARE - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i37cee0de213f4f6aac9eecbe1efa0922_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R127": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InterestPaidNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241144077 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details)", "role": "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails", "shortName": "SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InterestPaidNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R128": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "bhc:Legalsettlementsandrelatedfees", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241164078 - Disclosure - LEGAL PROCEEDINGS - Narrative (Details)", "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails", "shortName": "LEGAL PROCEEDINGS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i9cacecbb02804ea1bbb16c1b3a56bae8_D20191125-20191125", "decimals": "INF", "lang": "en-US", "name": "us-gaap:LossContingencyNewClaimsFiledNumber", "reportCount": 1, "unique": true, "unitRef": "case", "xsiNil": "false" } }, "R129": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractualObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241184079 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "role": "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractualObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210361006 - Disclosure - INVENTORIES", "role": "http://www.bauschhealth.com/role/INVENTORIES", "shortName": "INVENTORIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R130": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i1653b1e25bc74247a4b58c23c249df72_D20201001-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241214080 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit, Assets and Capital Expenditures, Depreciation & Amortization of Intangible Assets & Asset Impairments (Details)", "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails", "shortName": "SEGMENT INFORMATION - Segment Revenues and Profit, Assets and Capital Expenditures, Depreciation & Amortization of Intangible Assets & Asset Impairments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:InterestAndDebtExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R131": { "firstAnchor": { "ancestors": [ "bhc:ConcentrationRiskNumberOfProducts", "bhc:ConcentrationRiskNumberOfProducts", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "bhc:ConcentrationRiskNumberOfProducts", "reportCount": 1, "unique": true, "unitRef": "product", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241224081 - Disclosure - SEGMENT INFORMATION - Revenues by Product Category (Details)", "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails", "shortName": "SEGMENT INFORMATION - Revenues by Product Category (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "bhc:ConcentrationRiskNumberOfProducts", "bhc:ConcentrationRiskNumberOfProducts", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "bhc:ConcentrationRiskNumberOfProducts", "reportCount": 1, "unique": true, "unitRef": "product", "xsiNil": "false" } }, "R132": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i1653b1e25bc74247a4b58c23c249df72_D20201001-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241234082 - Disclosure - SEGMENT INFORMATION - Geographic Information, Revenue (Details)", "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails", "shortName": "SEGMENT INFORMATION - Geographic Information, Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i2e18b63a931c43058f4b9c242829aab5_D20200101-20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R133": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241244083 - Disclosure - SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details)", "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails", "shortName": "SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R134": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i9c2472fa90c94a478b0adb0d45dd2bd6_D20200101-20201231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241254084 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)", "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails", "shortName": "SEGMENT INFORMATION - Major Customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i9c2472fa90c94a478b0adb0d45dd2bd6_D20200101-20201231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R135": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i1653b1e25bc74247a4b58c23c249df72_D20201001-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "241284085 - Disclosure - SUPPLEMENTARY DATA (UNAUDITED) - Schedule of Unaudited Quarterly Consolidated Financial Data (Details)", "role": "http://www.bauschhealth.com/role/SUPPLEMENTARYDATAUNAUDITEDScheduleofUnauditedQuarterlyConsolidatedFinancialDataDetails", "shortName": "SUPPLEMENTARY DATA (UNAUDITED) - Schedule of Unaudited Quarterly Consolidated Financial Data (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i1653b1e25bc74247a4b58c23c249df72_D20201001-20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CostsAndExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210391007 - Disclosure - PROPERTY, PLANT AND EQUIPMENT", "role": "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT", "shortName": "PROPERTY, PLANT AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210431008 - Disclosure - INTANGIBLE ASSETS AND GOODWILL", "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL", "shortName": "INTANGIBLE ASSETS AND GOODWILL", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210491009 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES", "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES", "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210521010 - Disclosure - FINANCING ARRANGEMENTS", "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS", "shortName": "FINANCING ARRANGEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210651011 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS", "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS", "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210761012 - Disclosure - LEASES", "role": "http://www.bauschhealth.com/role/LEASES", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010002 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210831013 - Disclosure - SHARE-BASED COMPENSATION", "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION", "shortName": "SHARE-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210891014 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS", "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS", "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210921015 - Disclosure - RESEARCH AND DEVELOPMENT", "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT", "shortName": "RESEARCH AND DEVELOPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210951016 - Disclosure - OTHER EXPENSE (INCOME), NET", "role": "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENET", "shortName": "OTHER EXPENSE (INCOME), NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210991017 - Disclosure - INCOME TAXES", "role": "http://www.bauschhealth.com/role/INCOMETAXES", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211081018 - Disclosure - LOSS PER SHARE", "role": "http://www.bauschhealth.com/role/LOSSPERSHARE", "shortName": "LOSS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211121019 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES", "role": "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES", "shortName": "SUPPLEMENTAL CASH FLOW DISCLOSURES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211151020 - Disclosure - LEGAL PROCEEDINGS", "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGS", "shortName": "LEGAL PROCEEDINGS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211171021 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211191022 - Disclosure - SEGMENT INFORMATION", "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATION", "shortName": "SEGMENT INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesOutstanding", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "211261023 - Disclosure - SUPPLEMENTARY DATA (UNAUDITED)", "role": "http://www.bauschhealth.com/role/SUPPLEMENTARYDATAUNAUDITED", "shortName": "SUPPLEMENTARY DATA (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "220042001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230053001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230193002 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE (Tables)", "role": "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALETables", "shortName": "ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230263003 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230373004 - Disclosure - INVENTORIES (Tables)", "role": "http://www.bauschhealth.com/role/INVENTORIESTables", "shortName": "INVENTORIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230403005 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)", "role": "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230443006 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)", "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables", "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230503007 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)", "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables", "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230533008 - Disclosure - FINANCING ARRANGEMENTS (Tables)", "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables", "shortName": "FINANCING ARRANGEMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230663009 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)", "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables", "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bhc:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230773010 - Disclosure - LEASES (Tables)", "role": "http://www.bauschhealth.com/role/LEASESTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bhc:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230843011 - Disclosure - SHARE-BASED COMPENSATION (Tables)", "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables", "shortName": "SHARE-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230903012 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)", "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables", "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230933013 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)", "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables", "shortName": "RESEARCH AND DEVELOPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "230963014 - Disclosure - OTHER EXPENSE (INCOME), NET (Tables)", "role": "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables", "shortName": "OTHER EXPENSE (INCOME), NET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "231003015 - Disclosure - INCOME TAXES (Tables)", "role": "http://www.bauschhealth.com/role/INCOMETAXESTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "231093016 - Disclosure - LOSS PER SHARE (Tables)", "role": "http://www.bauschhealth.com/role/LOSSPERSHARETables", "shortName": "LOSS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "231133017 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)", "role": "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables", "shortName": "SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "231203018 - Disclosure - SEGMENT INFORMATION (Tables)", "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables", "shortName": "SEGMENT INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "231273019 - Disclosure - SUPPLEMENTARY DATA (UNAUDITED) (Tables)", "role": "http://www.bauschhealth.com/role/SUPPLEMENTARYDATAUNAUDITEDTables", "shortName": "SUPPLEMENTARY DATA (UNAUDITED) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-2", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfCountriesInWhichEntityOperates", "reportCount": 1, "unique": true, "unitRef": "country", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240024001 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)", "role": "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails", "shortName": "DESCRIPTION OF BUSINESS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-2", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfCountriesInWhichEntityOperates", "reportCount": 1, "unique": true, "unitRef": "country", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240064002 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)", "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240074003 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details)", "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "lang": "en-US", "name": "bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "idc4931bb35e142dc9c99738a3b03484d_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240084004 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)", "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "idc4931bb35e142dc9c99738a3b03484d_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "icdc23cf78a5a4782ae2364b8870caf2a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240094005 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)", "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "us-gaap:IntangibleAssetsFiniteLivedPolicy", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i878abda8300946b4b170b96c3b7b4629_D20200101-20201231", "decimals": null, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i37ade4cff0a644b5a47a9ec99443bd1c_I20191231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240104006 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details)", "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i01480d8569614dce90ab13a4f063de13_D20190101-20191231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240114007 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details)", "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "lang": "en-US", "name": "bhc:CashDiscountsAndAllowancesSettlementPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bhc:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240124008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)", "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i598be7cb2fe141aca1017705c0fc1262_I20201231", "decimals": null, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240134009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)", "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i9744221d00824d72b37d24240de76c04_I20171231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i9744221d00824d72b37d24240de76c04_I20171231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InterestCostsCapitalized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240144010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details)", "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InterestCostsCapitalized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240154011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details)", "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "INF", "lang": "en-US", "name": "bhc:TaxBenefitRecognitionMeasurementPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "bhc:DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240164012 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)", "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "bhc:DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240174013 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details)", "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherNonoperatingIncomeExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240204014 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Narrative (Details)", "role": "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails", "shortName": "ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "bhc:NumberOfOtherBusinessesAcquired", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "INF", "lang": "en-US", "name": "bhc:NumberOfOtherBusinessesAcquired", "reportCount": 1, "unique": true, "unitRef": "businesscombination", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240214015 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details)", "role": "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails", "shortName": "ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4513d86fc3534278b339e4d0fc68c571_I20190306", "decimals": "-6", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if7c808c3fc434c3998a7b00d30b395a6_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240224016 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Assets and Liabilities Held For Sale (Details)", "role": "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails", "shortName": "ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Assets and Liabilities Held For Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if7c808c3fc434c3998a7b00d30b395a6_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240244017 - Disclosure - RESTRUCTURING, INTEGRATION AND SEPARATION COSTS - Narrative (Details)", "role": "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails", "shortName": "RESTRUCTURING, INTEGRATION AND SEPARATION COSTS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i6847a03856fa40bbae85cfe2be5b0269_I20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "ie1bab33215114ae88721c86a09ded9ee_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240274018 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "ic8b70df8e3a6489db424e526acf15f2b_I20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bhc:HighlyLiquidInvestmentsMaturityPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240284019 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)", "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails", "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bhc:HighlyLiquidInvestmentsMaturityPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsForProceedsFromHedgeInvestingActivities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240294020 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details)", "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails", "shortName": "FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsForProceedsFromHedgeInvestingActivities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i86a450a752164f9c97074ba05fa85d4d_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240304021 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)", "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails", "shortName": "FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i86a450a752164f9c97074ba05fa85d4d_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "ie1bab33215114ae88721c86a09ded9ee_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240314022 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details)", "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails", "shortName": "FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "ie1bab33215114ae88721c86a09ded9ee_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i37ade4cff0a644b5a47a9ec99443bd1c_I20191231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240324023 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details)", "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details", "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if081eb0751724dca9cf81c5e3ee1cffd_I20181231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i88daded3f845487491049cf9d56dbb41_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240334024 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details)", "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails", "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i825705acbfff42de9e411ad1fa944464_I20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i37ade4cff0a644b5a47a9ec99443bd1c_I20191231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240344025 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis, Narrative (Details)", "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails", "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis, Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:Assets", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i58fb82fa6082489d8cf93e7b81ae526a_I20200331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4435a1127df64b94ad0b4479bdd652a9_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240354026 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details)", "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails", "shortName": "FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4435a1127df64b94ad0b4479bdd652a9_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240384027 - Disclosure - INVENTORIES - Summary of Inventories, Net (Details)", "role": "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails", "shortName": "INVENTORIES - Summary of Inventories, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240414028 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details)", "role": "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails", "shortName": "PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240424029 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)", "role": "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails", "shortName": "PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210011001 - Disclosure - DESCRIPTION OF BUSINESS", "role": "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS", "shortName": "DESCRIPTION OF BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240454030 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details)", "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails", "shortName": "INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i1653b1e25bc74247a4b58c23c249df72_D20201001-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240464031 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)", "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "shortName": "INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i1653b1e25bc74247a4b58c23c249df72_D20201001-20201231", "decimals": "-6", "lang": "en-US", "name": "bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240474032 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)", "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails", "shortName": "INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i37ade4cff0a644b5a47a9ec99443bd1c_I20191231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240484033 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details)", "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails", "shortName": "INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i01480d8569614dce90ab13a4f063de13_D20190101-20191231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "bhc:Legalsettlementsandrelatedfees", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240514034 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Details)", "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails", "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "lang": "en-US", "name": "bhc:AccruedProductRebateCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240544035 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)", "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails", "shortName": "FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i94056f769fa241f9a103edda2d9086c8_I20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "id7f7845522e9449a8159fd486725165a_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "bhc:DebtInstrumentAmountAvailableForRestrictedPayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240554036 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)", "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails", "shortName": "FINANCING ARRANGEMENTS - Covenant Compliance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "id7f7845522e9449a8159fd486725165a_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "bhc:DebtInstrumentAmountAvailableForRestrictedPayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240564037 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)", "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails", "shortName": "FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i58653b237e7f40daaa889524ad5f84c9_I20180101", "decimals": "-6", "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RepaymentsOfLongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240574038 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2018 Activities (Details)", "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "shortName": "FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2018 Activities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "idb43acf5470643b5a80d9923eefa8a72_I20181127", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if8d25bf6cc5140df906289dc6516ca31_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RepaymentsOfLinesOfCredit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240584039 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2019 Activities (Details)", "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2019ActivitiesDetails", "shortName": "FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2019 Activities (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "210031002 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240594040 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2020 Activities (Details)", "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2020ActivitiesDetails", "shortName": "FINANCING ARRANGEMENTS - Senior Secured Credit Facilities 2020 Activities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i2a48dd34b27142a8ab4dd242d323656a_D20200526-20200526", "decimals": "-6", "lang": "en-US", "name": "bhc:PaymentForDebtAmortizationPrepaymentCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "span", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240604041 - Disclosure - FINANCING ARRANGEMENTS - Current Description of Senior Secured Credit Facilities (Details)", "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "shortName": "FINANCING ARRANGEMENTS - Current Description of Senior Secured Credit Facilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if8d25bf6cc5140df906289dc6516ca31_D20200101-20201231", "decimals": "-6", "lang": "en-US", "name": "bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "bhc:DebtInstrumentRedemptionPricePercentageChangeinControl", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240614042 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)", "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "shortName": "FINANCING ARRANGEMENTS - Senior Secured Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i3ac9a00c79db49979ccb61474d0eabdd_I20170331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "bhc:DebtInstrumentRedemptionPricePercentageChangeinControl", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240624043 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)", "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "shortName": "FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "ibffcbdcbe20844bbaa92027ba50ca72e_I20190308", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:DebtWeightedAverageInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240634044 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)", "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails", "shortName": "FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:DebtWeightedAverageInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240644045 - Disclosure - FINANCING ARRANGEMENTS - Maturities, Schedule of Maturities and Mandatory Payments of Debt Obligations (Details)", "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails", "shortName": "FINANCING ARRANGEMENTS - Maturities, Schedule of Maturities and Mandatory Payments of Debt Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "if0aea468bdeb4fe9b112124748ad02b8_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bhc:DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240674046 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)", "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails", "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i4b131a9533a0415db88ad298669dbb9a_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "bhc:DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "iccca522732d44562a6b01b72aa9d90e0_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240684047 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details)", "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails", "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "iccca522732d44562a6b01b72aa9d90e0_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i556aede5eb494ed092f1b5b8f57165e7_D20200101-20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240694048 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of net periodic benefit cost (Details)", "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails", "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of net periodic benefit cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i556aede5eb494ed092f1b5b8f57165e7_D20200101-20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "ie0a4975800c1473ba79db8d9c141336a_I20191231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanBenefitObligation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "240704049 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details)", "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails", "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bhc-20201231.htm", "contextRef": "i556aede5eb494ed092f1b5b8f57165e7_D20200101-20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9999": { "firstAnchor": null, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - bhc-20201231.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - bhc-20201231.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 258, "tag": { "bhc_A5.00SeniorNotesDueJanuary2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5.00% Senior Notes Due January 2028 [Member]", "label": "5.00% Senior Notes Due January 2028 [Member]", "terseLabel": "5.00% Senior Unsecured Notes Due January 2028" } } }, "localname": "A5.00SeniorNotesDueJanuary2028Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "domainItemType" }, "bhc_A5.25SeniorNotesDueJanuary2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5.25% Senior Notes Due January 2030 [Member]", "label": "5.25% Senior Notes Due January 2030 [Member]", "terseLabel": "5.25% Senior Unsecured Notes Due January 2030" } } }, "localname": "A5.25SeniorNotesDueJanuary2030Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "domainItemType" }, "bhc_A5.375SeniorNotesdueMarch2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5.375% Senior Notes due March 2020 [Member]", "label": "5.375% Senior Notes due March 2020 [Member]", "terseLabel": "5.375% Senior Notes due March 2020" } } }, "localname": "A5.375SeniorNotesdueMarch2020Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "domainItemType" }, "bhc_A5.50SeniorNotesdueMarch2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5.50% Senior Notes due March 2023 [Member]", "label": "5.50% Senior Notes due March 2023 [Member]", "terseLabel": "5.50% Senior Unsecured Notes due March 2023" } } }, "localname": "A5.50SeniorNotesdueMarch2023Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "domainItemType" }, "bhc_A5.875SeniorNotesdueMay2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5.875% Senior Notes due May 2023 [Member]", "label": "5.875% Senior Notes due May 2023 [Member]", "terseLabel": "5.875% Senior Unsecured Notes due May 2023" } } }, "localname": "A5.875SeniorNotesdueMay2023Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "domainItemType" }, "bhc_A6.125SeniorNotesdueApril2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "6.125% Senior Notes due April 2025 [Member]", "label": "6.125% Senior Notes due April 2025 [Member]", "terseLabel": "6.125% Senior Unsecured Notes due April 2025" } } }, "localname": "A6.125SeniorNotesdueApril2025Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "domainItemType" }, "bhc_A7.00SeniorUnsecuredNotesDue2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "7.00% Senior Unsecured Notes Due 2028 [Member]", "label": "7.00% Senior Unsecured Notes Due 2028 [Member]", "terseLabel": "7.00% Senior Unsecured Notes due 2028" } } }, "localname": "A7.00SeniorUnsecuredNotesDue2028Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "domainItemType" }, "bhc_A7.25SeniorUnsecuredNotesDue2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "7.25% Senior Unsecured Notes Due 2029 [Member]", "label": "7.25% Senior Unsecured Notes Due 2029 [Member]", "terseLabel": "7.25% Senior Unsecured Notes due 2029" } } }, "localname": "A7.25SeniorUnsecuredNotesDue2029Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "domainItemType" }, "bhc_A8.50SeniorNotesDueJanuary2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "8.50% Senior Notes Due January 2027 [Member]", "label": "8.50% Senior Notes Due January 2027 [Member]", "terseLabel": "8.50% Senior Unsecured Notes Due January 2027" } } }, "localname": "A8.50SeniorNotesDueJanuary2027Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "domainItemType" }, "bhc_A9.00SeniorNotesdueDecember2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "9.00% Senior Notes due December 2025 [Member]", "label": "9.00% Senior Notes due December 2025 [Member]", "terseLabel": "9.00% Senior Unsecured Notes due December 2025" } } }, "localname": "A9.00SeniorNotesdueDecember2025Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "domainItemType" }, "bhc_A9.25SeniorNotesDueApril2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "9.25% Senior Notes Due April 2026 [Member]", "label": "9.25% Senior Notes Due April 2026 [Member]", "terseLabel": "9.25% Senior Unsecured Notes Due April 2026" } } }, "localname": "A9.25SeniorNotesDueApril2026Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "domainItemType" }, "bhc_ACertainInternationalBusinessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A Certain International Business [Member]", "label": "A Certain International Business [Member]", "terseLabel": "A Certain International Business" } } }, "localname": "ACertainInternationalBusinessMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails", "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_AccountingStandardsUpdate2016161Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-16-1", "label": "Accounting Standards Update 2016-16-1 [Member]", "terseLabel": "Accounting Standards Update 2016-16" } } }, "localname": "AccountingStandardsUpdate2016161Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bhc_AccountsReceivableAllowanceForForeignExchangeAndOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, Allowance For Foreign Exchange And Other", "label": "Accounts Receivable, Allowance For Foreign Exchange And Other", "negatedTerseLabel": "Foreign exchange and other" } } }, "localname": "AccountsReceivableAllowanceForForeignExchangeAndOther", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails" ], "xbrltype": "monetaryItemType" }, "bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update", "label": "Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update", "terseLabel": "Retrospective effect of application of new accounting standard" } } }, "localname": "AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails" ], "xbrltype": "monetaryItemType" }, "bhc_AccretionForTimeValueOfMoneyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accretion For Time Value Of Money [Member]", "label": "Accretion For Time Value Of Money [Member]", "terseLabel": "Accretion for the time value of money" } } }, "localname": "AccretionForTimeValueOfMoneyMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "domainItemType" }, "bhc_AccruedProductRebateCurrent": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the current portion of accrued product rebates.", "label": "Accrued Product Rebate Current", "terseLabel": "Product rebates" } } }, "localname": "AccruedProductRebateCurrent", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "bhc_AccruedProductReturnCurrent": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Product Return Current", "terseLabel": "Product returns" } } }, "localname": "AccruedProductReturnCurrent", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "bhc_AccumulatedLossesAvailableForFederalPurposes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the details pertaining to accumulated losses available for federal and provincial purposes.", "label": "Accumulated Losses Available for Federal Purposes", "terseLabel": "Accumulated losses available for federal and provincial purposes" } } }, "localname": "AccumulatedLossesAvailableForFederalPurposes", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhc_AcquiredInProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents intangible assets that the entity has acquired as a result of business acquisition, which is represented through the premium in the purchase price over book value attributed to research and development on new product that is not yet being sold.", "label": "Acquired in Process Research and Development [Member]", "terseLabel": "Acquired IPR&D not in service", "verboseLabel": "Acquired IPR&D" } } }, "localname": "AcquiredInProcessResearchAndDevelopmentMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]", "label": "Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]", "terseLabel": "ACQUISITIONS, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE" } } }, "localname": "AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALE" ], "xbrltype": "textBlockItemType" }, "bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional Operating Lease Information, Lessee [Table Text Block]", "label": "Additional Operating Lease Information, Lessee [Table Text Block]", "terseLabel": "Summary of other operating lease information" } } }, "localname": "AdditionalOperatingLeaseInformationLesseeTableTextBlock", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "bhc_AllegroOphthalmicsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allegro Ophthalmics, LLC", "label": "Allegro Ophthalmics, LLC [Member]", "terseLabel": "Allegro" } } }, "localname": "AllegroOphthalmicsLLCMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails", "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_AllowancesForLossesOnAccountsReceivableAndInventories": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.", "label": "Allowances for Losses on Accounts Receivable and Inventories", "terseLabel": "Allowances for losses on trade receivables and inventories" } } }, "localname": "AllowancesForLossesOnAccountsReceivableAndInventories", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bhc_AmerisourceBergenCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the major customer of the entity, AmerisourceBergen Corporation.", "label": "Amerisource Bergen Corporation [Member]", "terseLabel": "AmerisourceBergen Corporation" } } }, "localname": "AmerisourceBergenCorporationMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.", "label": "Amortization of Intangible Assets Excluding Amortization Allocated to Revenues Cost of Good Sold", "negatedTerseLabel": "Amortization of intangible assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "monetaryItemType" }, "bhc_ArestinMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arestin [Member]", "label": "Arestin [Member]", "terseLabel": "Arestin" } } }, "localname": "ArestinMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_ArgentinaBrazilEgyptGreeceSerbiaTurkeyUkraineVenezuelaAndVietnamMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Argentina, Brazil, Egypt, Greece, Serbia, Turkey, Ukraine, Venezuela and Vietnam", "label": "Argentina, Brazil, Egypt, Greece, Serbia, Turkey, Ukraine, Venezuela and Vietnam [Member]", "terseLabel": "Argentina, Brazil, Egypt, Greece, Serbia, Turkey, Ukraine, Venezuela and Vietnam" } } }, "localname": "ArgentinaBrazilEgyptGreeceSerbiaTurkeyUkraineVenezuelaAndVietnamMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "bhc_AssetAcquisitionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails", "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "bhc_AssetAcquisitionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails", "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets And Liabilities, Lessee [Table Text Block]", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Summary of right-of-use assets and right-of-use liabilities" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "bhc_AssetsLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets, Lessee [Abstract]", "label": "Assets, Lessee [Abstract]", "terseLabel": "Right-of-use assets included in:" } } }, "localname": "AssetsLesseeAbstract", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "bhc_BaseRateOrPrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Base Rate Or Prime Rate [Member]", "label": "Base Rate Or Prime Rate [Member]", "terseLabel": "Base Rate or Prime Rate" } } }, "localname": "BaseRateOrPrimeRateMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "bhc_BauschLombInternationalAndU.S.DiversifiedProductsSegmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bausch Lomb/International And U.S. Diversified Products Segments [Member]", "label": "Bausch Lomb/International And U.S. Diversified Products Segments [Member]", "terseLabel": "Bausch Lomb/International And U.S. Diversified Products Segments" } } }, "localname": "BauschLombInternationalAndU.S.DiversifiedProductsSegmentsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_BauschLombInternationalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bausch Lomb/International [Member]", "label": "Bausch Lomb/International [Member]", "terseLabel": "Bausch + Lomb/ International" } } }, "localname": "BauschLombInternationalMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" ], "xbrltype": "domainItemType" }, "bhc_BaushandLombInternationalSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Baush and Lomb/International Segment [Member]", "label": "Baush and Lomb/International Segment [Member]", "verboseLabel": "Bausch + Lomb/International" } } }, "localname": "BaushandLombInternationalSegmentMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "domainItemType" }, "bhc_BrandedRXMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Branded RX [Member]", "label": "Branded RX [Member]", "terseLabel": "Branded Rx" } } }, "localname": "BrandedRXMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" ], "xbrltype": "domainItemType" }, "bhc_BrandedRxSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Branded Rx Segment [Member]", "label": "Branded Rx Segment [Member]", "terseLabel": "Branded Rx Segment" } } }, "localname": "BrandedRxSegmentMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_BrandedandOtherGenericProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Branded and Other Generic Products [Member]", "label": "Branded and Other Generic Products [Member]", "terseLabel": "Branded and Other Generics" } } }, "localname": "BrandedandOtherGenericProductsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" ], "xbrltype": "domainItemType" }, "bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.", "label": "Business Acquisition, Contingent Consideration Fair Value Disclosure", "terseLabel": "Acquisition-related contingent consideration" } } }, "localname": "BusinessAcquisitionContingentConsiderationFairValueDisclosure", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "bhc_BusinessAcquisitionProFormaOperatingIncomeLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Acquisition, Pro Forma Operating Income (Loss)", "label": "Business Acquisition, Pro Forma Operating Income (Loss)", "terseLabel": "Pro-forma operating results" } } }, "localname": "BusinessAcquisitionProFormaOperatingIncomeLoss", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.", "label": "Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash", "terseLabel": "Acquisition-related contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bhc_BusinessCombinationContingentConsiderationNoncurrentLiability": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Noncurrent Liability", "label": "Business Combination, Contingent Consideration, Noncurrent Liability", "terseLabel": "Acquisition-related contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationNoncurrentLiability", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Pro Forma Information, Operating Income (Loss) Since Acquisition, Actual", "label": "Business Combination, Pro Forma Information, Operating Income (Loss) Since Acquisition, Actual", "terseLabel": "Operating results of acquiree since acquisition" } } }, "localname": "BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses", "negatedTerseLabel": "Accrued expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "bhc_CanadaBankersAcceptanceRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Canada Bankers Acceptance Rate [Member]", "label": "Canada Bankers Acceptance Rate [Member]", "terseLabel": "Canada Bankers Acceptance Rate" } } }, "localname": "CanadaBankersAcceptanceRateMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "bhc_CanadianSecuritiesLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Canadian Securities Litigation", "label": "Canadian Securities Litigation [Member]", "terseLabel": "Canadian Securities Litigation" } } }, "localname": "CanadianSecuritiesLitigationMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the capital expenditures, depreciation and amortization by segment.", "label": "Capital Expenditure and Depreciation and Amortization [Abstract]", "terseLabel": "Capital expenditures:" } } }, "localname": "CapitalExpenditureAndDepreciationAndAmortizationAbstract", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "stringItemType" }, "bhc_CardinalHealthIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the major customer of the entity, Cardinal Health, Inc.", "label": "Cardinal Health Inc [Member]", "terseLabel": "Cardinal Health,\u00a0Inc." } } }, "localname": "CardinalHealthIncMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "bhc_CashDiscountsAndAllowancesSettlementPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Discounts And Allowances, Settlement Period", "label": "Cash Discounts And Allowances, Settlement Period", "terseLabel": "Settlement period for cash discounts and allowances" } } }, "localname": "CashDiscountsAndAllowancesSettlementPeriod", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" ], "xbrltype": "durationItemType" }, "bhc_CedarsSinaiMedicalCenterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cedars-Sinai Medical Center", "label": "Cedars-Sinai Medical Center [Member]", "terseLabel": "Cedars-Sinai Medical Center" } } }, "localname": "CedarsSinaiMedicalCenterMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Certain Products For Disposal, September Two Thousand Nineteen [Member]", "label": "Certain Products For Disposal, September Two Thousand Nineteen [Member]", "terseLabel": "Certain Products For Disposal, September 2019" } } }, "localname": "CertainProductsForDisposalSeptemberTwoThousandNineteenMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_CollaborativeAgreementMilestonePaymentsAggregate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amounts required to be paid by the reporting entity, which are contingent upon the achievement of specific development, regulatory or commercial milestones, in connection with the Collaboration Agreement.", "label": "Collaborative Agreement Milestone Payments, Aggregate", "terseLabel": "Milestone payments in terms of collaboration and license agreements, aggregate" } } }, "localname": "CollaborativeAgreementMilestonePaymentsAggregate", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhc_ConcentrationRiskNumberOfProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration Risk, Number Of Products", "label": "Concentration Risk, Number Of Products", "terseLabel": "Number of products represented of total revenue" } } }, "localname": "ConcentrationRiskNumberOfProducts", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" ], "xbrltype": "integerItemType" }, "bhc_ConcentrationRiskPercentageofNetTradeReceivables": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration Risk, Percentage of Net Trade Receivables", "label": "Concentration Risk, Percentage of Net Trade Receivables", "terseLabel": "Percentage of net trade receivables accounted for by largest wholesale customers" } } }, "localname": "ConcentrationRiskPercentageofNetTradeReceivables", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "percentItemType" }, "bhc_ContactLensAntitrustClassActionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contact Lens Antitrust Class Actions [Member]", "label": "Contact Lens Antitrust Class Actions [Member]", "terseLabel": "Contact Lens Antitrust Class Actions" } } }, "localname": "ContactLensAntitrustClassActionsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold", "label": "Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold", "terseLabel": "Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold" } } }, "localname": "DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails" ], "xbrltype": "durationItemType" }, "bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Alternate Term, Principal Amount Maturity Threshold", "label": "Debt Instrument, Alternate Term, Principal Amount Maturity Threshold", "terseLabel": "Alternate term, principal amount maturity threshold" } } }, "localname": "DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhc_DebtInstrumentAmountAvailableForRestrictedPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Amount Available For Restricted Payments", "label": "Debt Instrument, Amount Available For Restricted Payments", "terseLabel": "Amount available for restricted payments" } } }, "localname": "DebtInstrumentAmountAvailableForRestrictedPayments", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" ], "xbrltype": "monetaryItemType" }, "bhc_DebtInstrumentAnnualAmortizationRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Annual Amortization Rate, Percentage", "label": "Debt Instrument, Annual Amortization Rate, Percentage", "terseLabel": "Annual amortization rate, percentage" } } }, "localname": "DebtInstrumentAnnualAmortizationRatePercentage", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "percentItemType" }, "bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum", "label": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum", "terseLabel": "Interest coverage ratio (not less than)" } } }, "localname": "DebtInstrumentCovenantInterestCoverageRatioMinimum", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "pureItemType" }, "bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio", "label": "Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio", "terseLabel": "Fixed charge coverage ratio" } } }, "localname": "DebtInstrumentCovenantTermsFixedChargeCoverageRatio", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" ], "xbrltype": "pureItemType" }, "bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Terms, Secured Leverage Ratio", "label": "Debt Instrument, Covenant Terms, Secured Leverage Ratio", "terseLabel": "Secured leverage ratio", "verboseLabel": "Secured leverage ratio (not greater than)" } } }, "localname": "DebtInstrumentCovenantTermsSecuredLeverageRatio", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "pureItemType" }, "bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Compliance, Total Leverage Ratio", "label": "Debt Instrument, Covenant, Total Leverage Ratio, Maximum", "terseLabel": "Total leverage ratio (not greater than)" } } }, "localname": "DebtInstrumentCovenantTotalLeverageRatioMaximum", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "pureItemType" }, "bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds", "label": "Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds", "terseLabel": "Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings" } } }, "localname": "DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "percentItemType" }, "bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Periodic Payment, Quarterly Amortization", "label": "Debt Instrument, Periodic Payment, Quarterly Amortization", "terseLabel": "Quarterly amortization payments" } } }, "localname": "DebtInstrumentPeriodicPaymentQuarterlyAmortization", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhc_DebtInstrumentRedemptionPricePercentageChangeinControl": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Redemption Price, Percentage, Change in Control", "label": "Debt Instrument, Redemption Price, Percentage, Change in Control", "terseLabel": "Redemption price percentage due to change in control (as a percent)" } } }, "localname": "DebtInstrumentRedemptionPricePercentageChangeinControl", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "percentItemType" }, "bhc_DeferredIncomeTaxNoncashExpenseBenefit": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.", "label": "Deferred Income Tax Noncash Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxNoncashExpenseBenefit", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bhc_DeferredTaxAssetsPrepaidExpenses": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Prepaid Expenses", "label": "Deferred Tax Assets, Prepaid Expenses", "terseLabel": "Prepaid expenses" } } }, "localname": "DeferredTaxAssetsPrepaidExpenses", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the deferred tax assets on scientific research and experimental development pool, of the entity.", "label": "Deferred Tax Assets, Scientific Research and Experimental Development Pool", "terseLabel": "Scientific Research and Experimental Development pool" } } }, "localname": "DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The tax effect as of the balance sheet date of the amount of future tax deductions arising from unused research and development tax credit carryforwards; a tax credit carryforward is the amount by which tax credits available for utilization exceed statutory limitations for inclusion in historical filings, and which can only be utilized if sufficient tax-basis income is generated in future periods and providing tax laws continue to allow such utilization.", "label": "Deferred Tax Assets, Tax Credit Carryforwards Research and Development", "terseLabel": "Research and development tax credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhc_DeferredTaxAssetsTaxLossCarryforwards": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the deferred tax assets on tax loss carryforwards available to the entity.", "label": "Deferred Tax Assets, Tax Loss Carryforwards", "terseLabel": "Tax loss carryforwards" } } }, "localname": "DeferredTaxAssetsTaxLossCarryforwards", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhc_DeferredTaxAssetsUnrealizedForeignExchangeOnDebtAndOtherFinancingCosts": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Unrealized Foreign Exchange On Debt And Other Financing Costs", "label": "Deferred Tax Assets, Unrealized Foreign Exchange On Debt And Other Financing Costs", "terseLabel": "Unrealized FX on U.S. dollar debt and other financing cost" } } }, "localname": "DeferredTaxAssetsUnrealizedForeignExchangeOnDebtAndOtherFinancingCosts", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the deferred tax liability recognized for the original basis difference between the principal amount of the Convertible Notes and value allocated to the liability component, which resulted in a corresponding reduction to the valuation allowance recorded against deferred tax assets.", "label": "Deferred Tax Liabilities, Basis Difference of Convertible Notes", "verboseLabel": "Plant, equipment and technology" } } }, "localname": "DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Actuarial Gain (Loss), Amortization Threshold Percentage", "label": "Defined Benefit Plan, Actuarial Gain (Loss), Amortization Threshold Percentage", "terseLabel": "Threshold percentage for amortization of net actuarial gains and losses" } } }, "localname": "DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Benefit Accrual, Interest Percentage Earned On Cash Balance", "label": "Defined Benefit Plan, Benefit Accrual, Interest Percentage Earned On Cash Balance", "terseLabel": "Benefit accrual, interest percentage earned on cash balance" } } }, "localname": "DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "percentItemType" }, "bhc_DefinedBenefitPlanEmployerContributionMaximumAge": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Employer Contribution, Maximum Age", "label": "Defined Benefit Plan, Employer Contribution, Maximum Age", "terseLabel": "Employer contribution maximum age" } } }, "localname": "DefinedBenefitPlanEmployerContributionMaximumAge", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "durationItemType" }, "bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Estimated Future Benefit Payments, Period", "label": "Defined Benefit Plan, Estimated Future Benefit Payments, Period", "terseLabel": "Future benefit payments period" } } }, "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "durationItemType" }, "bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Number of Defined Benefit Plans Amended", "label": "Defined Benefit Plan, Number of Defined Benefit Plans Amended", "terseLabel": "Number of defined benefit plans amended" } } }, "localname": "DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "integerItemType" }, "bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Number of Defined Benefit Plans", "label": "Defined Benefit Plan, Number of Defined Benefit Plans", "terseLabel": "Number of defined benefit plans" } } }, "localname": "DefinedBenefitPlanNumberofDefinedBenefitPlans", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "integerItemType" }, "bhc_DefinedBenefitPlanPercentageAllocationofFund": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Percentage Allocation of Fund", "label": "Defined Benefit Plan, Percentage Allocation of Fund", "terseLabel": "Percentage allocation of fund" } } }, "localname": "DefinedBenefitPlanPercentageAllocationofFund", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "percentItemType" }, "bhc_DentistryReportingUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dentistry Reporting Unit [Member]", "label": "Dentistry Reporting Unit [Member]", "terseLabel": "Dentistry Reporting Unit" } } }, "localname": "DentistryReportingUnitMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" ], "xbrltype": "domainItemType" }, "bhc_DerivativeGainExcludedComponent": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative, Gain, Excluded Component", "label": "Derivative, Gain, Excluded Component", "negatedTerseLabel": "Gain excluded from hedge effectiveness" } } }, "localname": "DerivativeGainExcludedComponent", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bhc_DerivativeLawsuitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Lawsuits [Member]", "label": "Derivative Lawsuits [Member]", "terseLabel": "Derivative Lawsuits" } } }, "localname": "DerivativeLawsuitsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_DeviceProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Device Products [Member]", "label": "Device Products [Member]", "terseLabel": "Devices" } } }, "localname": "DeviceProductsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" ], "xbrltype": "domainItemType" }, "bhc_DiscontinuedProductLinesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Discontinued Product Lines", "label": "Discontinued Product Lines [Member]", "terseLabel": "Discontinued Product Lines" } } }, "localname": "DiscontinuedProductLinesMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails": { "order": 2.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Current", "label": "Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Current", "terseLabel": "Accrued and other current liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails": { "order": 2.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Noncurrent", "label": "Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "bhc_DisposalGroupNumberOfProductsForDisposal": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disposal Group, Number Of Products For Disposal", "label": "Disposal Group, Number Of Products For Disposal", "terseLabel": "Number of products for disposal" } } }, "localname": "DisposalGroupNumberOfProductsForDisposal", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails" ], "xbrltype": "integerItemType" }, "bhc_DiversifiedProductsSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Diversified Products Segment [Member]", "label": "Diversified Products Segment [Member]", "terseLabel": "Diversified Products", "verboseLabel": "Diversified Products" } } }, "localname": "DiversifiedProductsSegmentMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "domainItemType" }, "bhc_DivestituresOfNoncoreProductsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divestitures of Non-core Products [Policy Text Block]", "label": "Divestitures Of Non-core Products [Policy Text Block]", "terseLabel": "Divestitures of Products" } } }, "localname": "DivestituresOfNoncoreProductsPolicyTextBlock", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "bhc_DoctorsAllergyFormulaLLCLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Doctors Allergy Formula, LLC Litigation [Member]", "label": "Doctors Allergy Formula, LLC Litigation [Member]", "terseLabel": "Doctors Allergy Formula, LLC Litigation" } } }, "localname": "DoctorsAllergyFormulaLLCLitigationMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Adjustments To Tax Attributes, Amount", "label": "Effective Income Tax Rate Reconciliation, Adjustments To Tax Attributes, Amount", "negatedTerseLabel": "Adjustments to tax attributes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "bhc_EmergingMarketsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Emerging Markets segment of the entity. The segment consists of branded generic pharmaceutical products, as well as OTC products and agency/in-licensing arrangements with other research-based pharmaceutical companies (where the entity distributes and markets branded, patented products under long-term, renewable contracts). Products are sold primarily in Europe (Poland, Serbia, Hungary, Croatia and Russia), Latin America (Mexico, Brazil and exports out of Mexico to other Latin American markets), South East Asia and South Africa.", "label": "Emerging Markets [Member]", "verboseLabel": "Emerging markets" } } }, "localname": "EmergingMarketsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "domainItemType" }, "bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]", "label": "Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]", "verboseLabel": "Stock options, Time-based RSUs, Performance-based RSUs" } } }, "localname": "EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_EyenoviaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eyenovia, Inc.", "label": "Eyenovia, Inc. [Member]", "terseLabel": "Eyenovia, Inc." } } }, "localname": "EyenoviaIncMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_FairValueAdjustmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair Value Adjustments", "label": "Fair Value Adjustments [Member]", "terseLabel": "Fair value adjustments" } } }, "localname": "FairValueAdjustmentsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "domainItemType" }, "bhc_ForeignCountryStateAndLocalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The designated tax department of state or local government of a foreign country entitled to levy and collect income taxes from the entity.", "label": "Foreign Country State and Local [Member]", "terseLabel": "Canadian Federal and Provincial" } } }, "localname": "ForeignCountryStateAndLocalMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_GainLossRelatedToLitigationSettlementGross": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) Related To Litigation Settlement, Gross", "label": "Gain (Loss) Related To Litigation Settlement, Gross", "negatedTerseLabel": "Additions (reductions) to accrued legal settlements" } } }, "localname": "GainLossRelatedToLitigationSettlementGross", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bhc_GenericPricingAntitrustLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Generic Pricing Antitrust Litigation", "label": "Generic Pricing Antitrust Litigation [Member]", "terseLabel": "Generic Pricing Antitrust Litigation" } } }, "localname": "GenericPricingAntitrustLitigationMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_GlobalHighYieldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Global High Yield [Member]", "label": "Global High Yield [Member]", "terseLabel": "Global high yield" } } }, "localname": "GlobalHighYieldMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "domainItemType" }, "bhc_GlumetzaAntitrustLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Glumetza Antitrust Class Actions Litigation [Member]", "label": "Glumetza Antitrust Litigation [Member]", "terseLabel": "Glumetza Antitrust Litigation" } } }, "localname": "GlumetzaAntitrustLitigationMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Glumetza Antitrust Litigation, Non-Class Complaints [Member]", "label": "Glumetza Antitrust Litigation, Non-Class Complaints [Member]", "terseLabel": "Glumetza Antitrust Litigation, Non-Class Complaints" } } }, "localname": "GlumetzaAntitrustLitigationNonClassComplaintsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Goodwill, Impairment Loss, Not Included In Asset Impairment Charges", "label": "Goodwill, Impairment Loss, Not Included In Asset Impairment Charges", "negatedLabel": "Goodwill impairments", "terseLabel": "Goodwill impairments", "verboseLabel": "Goodwill impairment" } } }, "localname": "GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "monetaryItemType" }, "bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Goodwill, Transfers Related To Sale of Business Unit", "label": "Goodwill, Transfers Related To Sale of Business Unit", "terseLabel": "Assets held for sale reclassified to goodwill (Note 5)" } } }, "localname": "GoodwillTransfersRelatedToSaleOfBusinessUnit", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "bhc_HighlyLiquidInvestmentsMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Highly Liquid Investments, Maturity Period", "label": "Highly Liquid Investments, Maturity Period", "terseLabel": "Highly liquid investments, maturity period (or less)" } } }, "localname": "HighlyLiquidInvestmentsMaturityPeriod", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" ], "xbrltype": "durationItemType" }, "bhc_IncomeTaxExaminationEstimateOfPossibleLossAmountNotSubjectToFullValuationAllowance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income Tax Examination, Estimate Of Possible Loss, Amount Not Subject To Full Valuation Allowance", "label": "Income Tax Examination, Estimate Of Possible Loss, Amount Not Subject To Full Valuation Allowance", "terseLabel": "Estimate of possible loss, amount not subject to full valuation allowance" } } }, "localname": "IncomeTaxExaminationEstimateOfPossibleLossAmountNotSubjectToFullValuationAllowance", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhc_IncomeTaxLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Income Tax [Line Items]", "terseLabel": "Income Tax [Line Items]" } } }, "localname": "IncomeTaxLineItems", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "stringItemType" }, "bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income Tax, Number Of Subsidiaries File Federal Income Tax Returns", "label": "Income Tax, Number Of Subsidiaries File Federal Income Tax Returns", "terseLabel": "Number of subsidiaries file federal income tax returns in Canada, U.S., and other foreign jurisdictions (or more)" } } }, "localname": "IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "integerItemType" }, "bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to change in valuation allowance related to operating losses.", "label": "Income Tax Reconciliation Change in Operating Losses Valuation Allowance", "negatedTerseLabel": "Change in valuation allowance related to foreign tax credits and NOLs" } } }, "localname": "IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "bhc_IncomeTaxReconciliationDeferredIntercompanyProfit": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of the difference between total income tax expense (benefit) as reported in the income statement and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to deferred intercompany profit.", "label": "Income Tax Reconciliation Deferred Intercompany Profit", "negatedTerseLabel": "Tax benefit on intra-entity transfers" } } }, "localname": "IncomeTaxReconciliationDeferredIntercompanyProfit", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "bhc_IncomeTaxReconciliationUncertainTaxPositions": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to uncertain tax positions.", "label": "Income Tax Reconciliation, Uncertain Tax Positions", "negatedTerseLabel": "Change in uncertain tax positions" } } }, "localname": "IncomeTaxReconciliationUncertainTaxPositions", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "bhc_IncomeTaxTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of information relating to income taxes.", "label": "Income Tax [Table]", "terseLabel": "Income Tax [Table]" } } }, "localname": "IncomeTaxTable", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "stringItemType" }, "bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax", "label": "Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax", "negatedTerseLabel": "Revenue, year-over-year decrease" } } }, "localname": "IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax, Percentage", "label": "Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax, Percentage", "negatedTerseLabel": "Revenue, year-over-year decrease, percentage" } } }, "localname": "IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "percentItemType" }, "bhc_InsuranceCoverageLawsuitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Insurance Coverage Lawsuit [Member]", "label": "Insurance Coverage Lawsuit [Member]", "terseLabel": "Insurance Coverage Lawsuit" } } }, "localname": "InsuranceCoverageLawsuitMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_InterestSettlementOnCrossCurrencySwaps": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest Settlement On Cross-Currency Swaps", "label": "Interest Settlement On Cross-Currency Swaps", "terseLabel": "Interest settlements from cross-currency swaps" } } }, "localname": "InterestSettlementOnCrossCurrencySwaps", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investigation by the State of Texas, State's Medicaid Program [Member]", "label": "Investigation by the State of Texas, State's Medicaid Program [Member]", "terseLabel": "Investigation by the State of Texas" } } }, "localname": "InvestigationbytheStateofTexasStatesMedicaidProgramMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_InvestmentGradeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investment Grade [Member]", "label": "Investment Grade [Member]", "terseLabel": "Investment grade" } } }, "localname": "InvestmentGradeMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "domainItemType" }, "bhc_JohnsonJohnsonTalcumPowderLitigationDelawareDivisionOfRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Johnson & Johnson Talcum Powder Litigation, Delaware Division Of Revenue [Member]", "label": "Johnson & Johnson Talcum Powder Litigation, Delaware Division Of Revenue [Member]", "terseLabel": "Johnson & Johnson Talcum Powder Litigation, Delaware Division Of Revenue" } } }, "localname": "JohnsonJohnsonTalcumPowderLitigationDelawareDivisionOfRevenueMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_JohnsonJohnsonTalcumPowderLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Johnson & Johnson Talcum Powder Litigation [Member]", "label": "Johnson & Johnson Talcum Powder Litigation [Member]", "terseLabel": "Johnson & Johnson Talcum Powder Litigation" } } }, "localname": "JohnsonJohnsonTalcumPowderLitigationMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_JohnsonJohnsonTalcumPowderLitigationNewJerseyDivisionOfTaxationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Johnson & Johnson Talcum Powder Litigation, New Jersey Division Of Taxation [Member]", "label": "Johnson & Johnson Talcum Powder Litigation, New Jersey Division Of Taxation [Member]", "terseLabel": "Johnson & Johnson Talcum Powder Litigation, New Jersey Division Of Taxation" } } }, "localname": "JohnsonJohnsonTalcumPowderLitigationNewJerseyDivisionOfTaxationMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_Legalsettlementsandrelatedfees": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Legal settlements and related fees", "label": "Legal settlements and related fees", "terseLabel": "Legal matters and related fees" } } }, "localname": "Legalsettlementsandrelatedfees", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails", "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhc_LiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liabilities, Lessee [Abstract]", "label": "Liabilities, Lessee [Abstract]", "terseLabel": "Lease liabilities included in:" } } }, "localname": "LiabilitiesLesseeAbstract", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.", "label": "Line of Credit Facility, Percentage of Consolidated Excess Cash Flow Payable as Mandatory Prepayments", "terseLabel": "Percentage of annual excess cash flow" } } }, "localname": "LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "percentItemType" }, "bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.", "label": "Line of Credit Facility, Percentage of Net Cash Proceeds from Asset Sales Outside Ordinary Course of Business Payable as Mandatory Prepayments", "terseLabel": "Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments" } } }, "localname": "LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "percentItemType" }, "bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.", "label": "Line of Credit Facility, Percentage of Net Cash Proceeds of Insurance and Condemnation Proceeds from Property or Asset Losses Payable as Mandatory Prepayments", "terseLabel": "Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses" } } }, "localname": "LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "percentItemType" }, "bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.", "label": "Line of Credit Facility, Percentage of Net Proceeds from Incurrence of Debt Payable as Mandatory Pre-payments", "terseLabel": "Percentage of cash proceeds from incurrence of debt" } } }, "localname": "LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "percentItemType" }, "bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Line Of Credit Facility, Threshold For Incremental Borrowings", "label": "Line Of Credit Facility, Threshold For Incremental Borrowings", "terseLabel": "Incremental credit facility borrowings" } } }, "localname": "LineOfCreditFacilityThresholdForIncrementalBorrowings", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line Of Credit Facility Threshold For Incremental Borrowings Interest Rate", "label": "Line Of Credit Facility Threshold For Incremental Borrowings Interest Rate", "terseLabel": "Incremental borrowings interest rate" } } }, "localname": "LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "percentItemType" }, "bhc_LitigationwithFormerSalixCEOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Litigation with Former Salix CEO [Member]", "label": "Litigation with Former Salix CEO [Member]", "terseLabel": "Litigation with Former Salix CEO" } } }, "localname": "LitigationwithFormerSalixCEOMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_LossContingencyNewClaimsFiledButNotYetServedNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency New Claims Filed But Not Yet Served Number", "label": "Loss Contingency New Claims Filed But Not Yet Served Number", "terseLabel": "Number of additional suits filed, but not served" } } }, "localname": "LossContingencyNewClaimsFiledButNotYetServedNumber", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "integerItemType" }, "bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of Alleged Stockholders, Filed Lawsuits", "label": "Loss Contingency, Number Of Alleged Stockholders, Filed Lawsuits", "terseLabel": "Number of alleged stockholders filed lawsuits" } } }, "localname": "LossContingencyNumberOfAllegedStockholdersFiledLawsuits", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "integerItemType" }, "bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action", "label": "Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action", "terseLabel": "Number of entities, exercised opt-out right, pursuing action" } } }, "localname": "LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "integerItemType" }, "bhc_LossContingencyNumberOfHealthPlansFiledLawsuits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of Health Plans, Filed Lawsuits", "label": "Loss Contingency, Number Of Health Plans, Filed Lawsuits", "terseLabel": "Number of health plans commenced action" } } }, "localname": "LossContingencyNumberOfHealthPlansFiledLawsuits", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "integerItemType" }, "bhc_LossContingencyNumberOfInsurancePolicyPeriods": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of Insurance Policy Periods", "label": "Loss Contingency, Number Of Insurance Policy Periods", "terseLabel": "Number of distinct insurance policy periods" } } }, "localname": "LossContingencyNumberOfInsurancePolicyPeriods", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "integerItemType" }, "bhc_LossContingencyNumberOfManufacturers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of Manufacturers", "label": "Loss Contingency, Number Of Manufacturers", "terseLabel": "Number of manufacturers" } } }, "localname": "LossContingencyNumberOfManufacturers", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "integerItemType" }, "bhc_LossContingencyPendingClaimsNotYetServedNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Pending Claims, Not Yet Served, Number", "label": "Loss Contingency, Pending Claims, Not Yet Served, Number", "terseLabel": "Number of cases not yet served" } } }, "localname": "LossContingencyPendingClaimsNotYetServedNumber", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "integerItemType" }, "bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Plaintiffs, Number of Groups of Investors", "label": "Loss Contingency, Plaintiffs, Number of Groups of Investors", "terseLabel": "Number of groups of investors" } } }, "localname": "LossContingencyPlaintiffsNumberofGroupsofInvestors", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "integerItemType" }, "bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending", "label": "Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending", "terseLabel": "Number of groups of investors filing action, remain pending" } } }, "localname": "LossContingencyPlaintiffsNumberofGroupsofInvestorsPending", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "integerItemType" }, "bhc_LossContingencyStayOfApprovalPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Stay Of Approval, Period", "label": "Loss Contingency, Stay Of Approval, Period", "terseLabel": "Stay of the approval period" } } }, "localname": "LossContingencyStayOfApprovalPeriod", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "durationItemType" }, "bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the maximum original term of maturity for an instrument to be classified as cash or cash equivalent.", "label": "Maximum Term of Original Maturity to Classify Instruments as Cash and Cash Equivalents", "terseLabel": "Maximum term of original maturity to classify instruments as cash and cash equivalents (less than)" } } }, "localname": "MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "durationItemType" }, "bhc_McKessonCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the major customer of the entity, McKesson Corporation.", "label": "Mc Kesson Corporation [Member]", "terseLabel": "McKesson Corporation" } } }, "localname": "McKessonCorporationMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "bhc_MeasurementInputWeightedAverageDiscountRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input, Weighted-Average Discount Rate [Member]", "label": "Measurement Input, Weighted-Average Discount Rate [Member]", "terseLabel": "Measurement Input, Weighted-Average Discount Rate" } } }, "localname": "MeasurementInputWeightedAverageDiscountRateMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "domainItemType" }, "bhc_MedpharmaPharmaceuticalChemicalIndustriesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medpharma Pharmaceutical & Chemical Industries LLC [Member]", "label": "Medpharma Pharmaceutical & Chemical Industries LLC [Member]", "terseLabel": "Medpharma" } } }, "localname": "MedpharmaPharmaceuticalChemicalIndustriesLLCMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_MilestonePaymentRelatedToCertainProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Payment Related To Certain Product [Member]", "label": "Milestone Payment Related To Certain Product [Member]", "terseLabel": "Milestone Payment Related To Certain Product" } } }, "localname": "MilestonePaymentRelatedToCertainProductMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the minimum period to classify uncertain tax position liabilities as long term liabilities.", "label": "Minimum Period to Classify Uncertain Tax Position, Liabilities as Long Term Liabilities", "terseLabel": "Minimum period to classify uncertain tax position liabilities as long term liabilities" } } }, "localname": "MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" ], "xbrltype": "durationItemType" }, "bhc_MississippiAttorneyGeneralConsumerProtectionActionLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mississippi Attorney General Consumer Protection Action Litigation [Member]", "label": "Mississippi Attorney General Consumer Protection Action Litigation [Member]", "terseLabel": "Mississippi Attorney General Consumer Protection Action Litigation" } } }, "localname": "MississippiAttorneyGeneralConsumerProtectionActionLitigationMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_MitsubishiTanabePharmaCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mitsubishi Tanabe Pharma Corporation [Member]", "label": "Mitsubishi Tanabe Pharma Corporation [Member]", "terseLabel": "Mitsubishi Tanabe Pharma Corporation" } } }, "localname": "MitsubishiTanabePharmaCorporationMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_NonU.S.DevelopedMarketsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-U.S. Developed Markets [Member]", "label": "Non-U.S. Developed Markets [Member]", "terseLabel": "Worldwide developed markets" } } }, "localname": "NonU.S.DevelopedMarketsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "domainItemType" }, "bhc_NonU.S.OtherAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-U.S. Other Assets [Member]", "label": "Non-U.S. Other Assets [Member]", "terseLabel": "Other assets" } } }, "localname": "NonU.S.OtherAssetsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "domainItemType" }, "bhc_NoncashCumulativeForeignCurrencyTranslationLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash Cumulative Foreign Currency Translation Loss", "label": "Noncash Cumulative Foreign Currency Translation Loss", "terseLabel": "Noncash cumulative foreign currency translation loss" } } }, "localname": "NoncashCumulativeForeignCurrencyTranslationLoss", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhc_NonemployeeDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nonemployee Director [Member]", "label": "Nonemployee Director [Member]", "terseLabel": "Nonemployee Director" } } }, "localname": "NonemployeeDirectorMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_NovaliqGmbHMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Novaliq GmbH [Member]", "label": "Novaliq GmbH [Member]", "terseLabel": "Novaliq GmbH" } } }, "localname": "NovaliqGmbHMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_NumberOfLargestWholesaleCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of largest wholesale customers.", "label": "Number of Largest Wholesale Customers", "terseLabel": "Number of largest wholesale customers" } } }, "localname": "NumberOfLargestWholesaleCustomers", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "integerItemType" }, "bhc_NumberOfOtherBusinessesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Other Businesses Acquired", "label": "Number Of Other Businesses Acquired", "terseLabel": "Number of other material business combinations" } } }, "localname": "NumberOfOtherBusinessesAcquired", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" ], "xbrltype": "integerItemType" }, "bhc_OmnibusIncentivePlan2014Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Omnibus Incentive Plan 2014 [Member]", "label": "Omnibus Incentive Plan 2014 [Member]", "terseLabel": "Omnibus Incentive Plan 2014" } } }, "localname": "OmnibusIncentivePlan2014Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_OrthoDermatologicsReportingUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ortho Dermatologics Reporting Unit [Member]", "label": "Ortho Dermatologics Reporting Unit [Member]", "terseLabel": "Ortho Dermatologics Reporting Unit", "verboseLabel": "Ortho Dermatologics Reporting Units" } } }, "localname": "OrthoDermatologicsReportingUnitMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" ], "xbrltype": "domainItemType" }, "bhc_OrthoDermatologicsSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ortho Dermatologics Segment [Member]", "label": "Ortho Dermatologics Segment [Member]", "terseLabel": "Ortho Dermatologics", "verboseLabel": "Ortho Dermatologics" } } }, "localname": "OrthoDermatologicsSegmentMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "domainItemType" }, "bhc_OtherAssetsFixedIncomeSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Assets, Fixed Income Securities [Member]", "label": "Other Assets, Fixed Income Securities [Member]", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsFixedIncomeSecuritiesMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "domainItemType" }, "bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 5.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Foreign Currency Adjustment, Net Of Tax", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Foreign Currency Adjustment, Net Of Tax", "terseLabel": "Foreign currency impact" } } }, "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization or Settlement Recognition", "label": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization or Settlement Recognition", "negatedTerseLabel": "Amortization or settlement recognition of net loss" } } }, "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "bhc_OtherCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Countries [Member]", "label": "Other Countries [Member]", "terseLabel": "Other" } } }, "localname": "OtherCountriesMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" ], "xbrltype": "domainItemType" }, "bhc_OtherEquipmentAndLeaseholdImprovementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents other equipment and leasehold improvements.", "label": "Other Equipment and Leasehold Improvement [Member]", "terseLabel": "Other equipment and leasehold improvements" } } }, "localname": "OtherEquipmentAndLeaseholdImprovementMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "bhc_OtherIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETScheduleofOtherExpenseIncomeNetDetails": { "order": 5.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Income (Expense), Net", "label": "Other Income (Expense), Net", "terseLabel": "Other, net" } } }, "localname": "OtherIncomeExpenseNet", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETScheduleofOtherExpenseIncomeNetDetails" ], "xbrltype": "monetaryItemType" }, "bhc_OtherLongTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents long-term debt obligations not elsewhere enumerated.", "label": "Other Long Term Debt [Member]", "terseLabel": "Other" } } }, "localname": "OtherLongTermDebtMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_OtherRestructuringIntegrationRelatedOtherCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to other restructuring, integration-related and other costs. Label: Other restructuring, integration-related and other costs.", "label": "Other Restructuring Integration Related Other Costs [Member]", "verboseLabel": "Restructuring and Integration-Related Costs" } } }, "localname": "OtherRestructuringIntegrationRelatedOtherCostsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_OtherRevenuesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Revenues [Member]", "label": "Other Revenues [Member]", "terseLabel": "Other revenues" } } }, "localname": "OtherRevenuesMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" ], "xbrltype": "domainItemType" }, "bhc_OutLicensedTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the rights to receive cash flows under an out-license arrangement (for example, license fees, milestone payments and royalties).", "label": "Out Licensed Technology [Member]", "terseLabel": "Technology and other", "verboseLabel": "Out-licensed technology and other" } } }, "localname": "OutLicensedTechnologyMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bhc_OvertheCounterProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Over the Counter Products [Member]", "label": "Over the Counter Products [Member]", "terseLabel": "OTC" } } }, "localname": "OvertheCounterProductsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" ], "xbrltype": "domainItemType" }, "bhc_PartnerRelationshipsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to existing arrangements with various other entities, for which the entity provides regulatory, compliance, sales, marketing and distribution functions.", "label": "Partner Relationships [Member]", "terseLabel": "Partner relationships", "verboseLabel": "Partner relationships" } } }, "localname": "PartnerRelationshipsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bhc_PastDuePeriodForAccountsReceivableToBeNegligible": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the past due period for which accounts receivables are negligible.", "label": "Past Due Period for Accounts Receivable to be Negligible", "terseLabel": "Past due period for receivables to be negligible (less than)" } } }, "localname": "PastDuePeriodForAccountsReceivableToBeNegligible", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "durationItemType" }, "bhc_PaymentForDebtAmortizationPrepaymentCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment For Debt Amortization Prepayment Cost", "label": "Payment For Debt Amortization Prepayment Cost", "terseLabel": "Repayment, outstanding debt" } } }, "localname": "PaymentForDebtAmortizationPrepaymentCost", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2020ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "monetaryItemType" }, "bhc_PaymentOfAccretedInterestOnContingentConsideration": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment Of Accreted Interest On Contingent Consideration", "label": "Payment Of Accreted Interest On Contingent Consideration", "negatedTerseLabel": "Payments of contingent consideration adjustments, including accretion" } } }, "localname": "PaymentOfAccretedInterestOnContingentConsideration", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bhc_PaymentOfDeferredConsideration": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment Of Deferred Consideration", "label": "Payment Of Deferred Consideration", "negatedTerseLabel": "Payments of deferred consideration" } } }, "localname": "PaymentOfDeferredConsideration", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Pension and Other Postretirement Defined Benefit Plans, Accrued and Other Current Liabilities", "label": "Pension and Other Postretirement Defined Benefit Plans, Accrued and Other Current Liabilities", "negatedTerseLabel": "Accrued and other current liabilities" } } }, "localname": "PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "bhc_PerformanceBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents stock awards in the form of performance-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.", "label": "Performance Based Restricted Stock Units [Member]", "terseLabel": "Performance-Based Restricted Stock Units" } } }, "localname": "PerformanceBasedRestrictedStockUnitsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "domainItemType" }, "bhc_PeriodReceivableOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of time the accounts receivable has been outstanding.", "label": "Period Receivable Outstanding", "terseLabel": "Period net trade receivable balance outstanding (more than)" } } }, "localname": "PeriodReceivableOutstanding", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "durationItemType" }, "bhc_PerrigoIsraelPharmaceuticalsLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Perrigo Israel Pharmaceuticals Litigation", "label": "Perrigo Israel Pharmaceuticals Litigation [Member]", "terseLabel": "Perrigo Israel Pharmaceuticals Litigation" } } }, "localname": "PerrigoIsraelPharmaceuticalsLitigationMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_PerrigoLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Perrigo Litigation", "label": "Perrigo Litigation [Member]", "terseLabel": "Perrigo Litigation" } } }, "localname": "PerrigoLitigationMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_PharmaceuticalProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmaceutical Products [Member]", "label": "Pharmaceutical Products [Member]", "terseLabel": "Pharmaceuticals" } } }, "localname": "PharmaceuticalProductsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" ], "xbrltype": "domainItemType" }, "bhc_PlaintiffsDirectPurchasersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plaintiffs, Direct Purchasers [Member]", "label": "Plaintiffs, Direct Purchasers [Member]", "terseLabel": "Plaintiffs, Direct Purchasers" } } }, "localname": "PlaintiffsDirectPurchasersMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the details pertaining to pooled scientific research and experimental development.", "label": "Pooled Scientific Research and Experimental Development Expenditures [Member]", "terseLabel": "Pooled Scientific Research and Experimental Development" } } }, "localname": "PooledScientificResearchAndExperimentalDevelopmentExpendituresMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential Asset Acquisition, Additional Funding Payment Included In Aggregate Purchase Price", "label": "Potential Asset Acquisition, Additional Funding Payment Included In Aggregate Purchase Price", "terseLabel": "Potential asset acquisition, additional funding payment included in aggregate purchase price" } } }, "localname": "PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails", "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhc_PotentialAssetAcquisitionAggregatePurchasePrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential Asset Acquisition, Aggregate Purchase Price", "label": "Potential Asset Acquisition, Aggregate Purchase Price", "terseLabel": "Potential asset acquisition, aggregate purchase price" } } }, "localname": "PotentialAssetAcquisitionAggregatePurchasePrice", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Potential Asset Acquisition, Upfront Payment Included In Aggregate Purchase Price", "label": "Potential Asset Acquisition, Upfront Payment Included In Aggregate Purchase Price", "terseLabel": "Potential asset acquisition, upfront payment included in aggregate purchase price" } } }, "localname": "PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhc_PriceAppreciationCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price Appreciation Credit [Member]", "label": "Price Appreciation Credit [Member]", "terseLabel": "Price Appreciation Credit" } } }, "localname": "PriceAppreciationCreditMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_ProductBrandsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the rights to non-patented product brands.", "label": "Product Brands [Member]", "terseLabel": "Product brands", "verboseLabel": "Product brands" } } }, "localname": "ProductBrandsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bhc_RICOClassActionsLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RICO Class Actions Litigation", "label": "RICO Class Actions Litigation [Member]", "terseLabel": "RICO Class Actions Litigation" } } }, "localname": "RICOClassActionsLitigationMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_ROTCPerformanceBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ROTC Performance-Based Restricted Stock Units [Member]", "label": "ROTC Performance-Based Restricted Stock Units [Member]", "terseLabel": "ROTC Performance-Based Restricted Stock Units" } } }, "localname": "ROTCPerformanceBasedRestrictedStockUnitsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "domainItemType" }, "bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate", "label": "Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate", "terseLabel": "Reporting unit, impairment test, estimated cash flows, discount rate" } } }, "localname": "ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "percentItemType" }, "bhc_ReportingUnitImpairmentTestLongTermGrowthRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reporting Unit, Impairment Test, Long-Term Growth Rate", "label": "Reporting Unit, Impairment Test, Long-Term Growth Rate", "terseLabel": "Reporting unit, impairment test, long-term growth rates" } } }, "localname": "ReportingUnitImpairmentTestLongTermGrowthRate", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "percentItemType" }, "bhc_ReportingUnitsExcludingDentistryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reporting Units Excluding Dentistry [Member]", "label": "Reporting Units Excluding Dentistry [Member]", "terseLabel": "Reporting Units Excluding Dentistry" } } }, "localname": "ReportingUnitsExcludingDentistryMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_ReportingUnitsExcludingOrthoDermatologicsAndDentistryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reporting Units Excluding Ortho Dermatologics And Dentistry [Member]", "label": "Reporting Units Excluding Ortho Dermatologics And Dentistry [Member]", "terseLabel": "Reporting Units Excluding Ortho Dermatologics and Dentistry" } } }, "localname": "ReportingUnitsExcludingOrthoDermatologicsAndDentistryMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_ResearchAndDevelopmentExpenseProductRelated": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails": { "order": 1.0, "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research And Development Expense, Product Related", "label": "Research And Development Expense, Product Related", "terseLabel": "Product related research and development" } } }, "localname": "ResearchAndDevelopmentExpenseProductRelated", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails" ], "xbrltype": "monetaryItemType" }, "bhc_ResearchAndDevelopmentExpenseQualityAssurance": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails": { "order": 2.0, "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research And Development Expense, Quality Assurance", "label": "Research And Development Expense, Quality Assurance", "terseLabel": "Quality assurance" } } }, "localname": "ResearchAndDevelopmentExpenseQualityAssurance", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails" ], "xbrltype": "monetaryItemType" }, "bhc_ReserveForChargebacksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reserve For Chargebacks [Member]", "label": "Reserve For Chargebacks [Member]", "terseLabel": "Chargebacks" } } }, "localname": "ReserveForChargebacksMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" ], "xbrltype": "domainItemType" }, "bhc_ReserveForCustomerReturnsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reserve For Customer Returns [Member]", "label": "Reserve For Customer Returns [Member]", "terseLabel": "Returns" } } }, "localname": "ReserveForCustomerReturnsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" ], "xbrltype": "domainItemType" }, "bhc_ReserveForDiscountsAndAllowancesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reserve For Discounts And Allowances [Member]", "label": "Reserve For Discounts And Allowances [Member]", "terseLabel": "Discounts and Allowances" } } }, "localname": "ReserveForDiscountsAndAllowancesMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" ], "xbrltype": "domainItemType" }, "bhc_ReserveForDistributionFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reserve For Distribution Fees [Member]", "label": "Reserve For Distribution Fees [Member]", "terseLabel": "Distribution Fees" } } }, "localname": "ReserveForDistributionFeesMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" ], "xbrltype": "domainItemType" }, "bhc_ReserveForRebatesAdvertisingCreditsPortionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reserve For Rebates, Advertising Credits Portion [Member]", "label": "Reserve For Rebates, Advertising Credits Portion [Member]", "terseLabel": "Rebates, Advertising Credits Portion" } } }, "localname": "ReserveForRebatesAdvertisingCreditsPortionMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_ReserveForRebatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reserve For Rebates [Member]", "label": "Reserve For Rebates [Member]", "terseLabel": "Rebates" } } }, "localname": "ReserveForRebatesMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" ], "xbrltype": "domainItemType" }, "bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restricted Cash And Cash Equivalents, Fair Value Disclosure", "label": "Restricted Cash And Cash Equivalents, Fair Value Disclosure", "terseLabel": "Restricted Cash" } } }, "localname": "RestrictedCashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "bhc_RevenuePerformanceObligationPaymentTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue, Performance Obligation, Payment Terms", "label": "Revenue, Performance Obligation, Payment Terms", "terseLabel": "Payment terms" } } }, "localname": "RevenuePerformanceObligationPaymentTerms", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" ], "xbrltype": "durationItemType" }, "bhc_RevenuesNetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate net revenues during the period in the normal course of business.", "label": "Revenues Net [Member]", "terseLabel": "Revenues" } } }, "localname": "RevenuesNetMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" ], "xbrltype": "domainItemType" }, "bhc_RevolvingCreditFacilityDueJune2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving Credit Facility Due June 2023 [Member]", "label": "Revolving Credit Facility Due June 2023 [Member]", "terseLabel": "2023 Revolving Credit Facility Due June 2023" } } }, "localname": "RevolvingCreditFacilityDueJune2023Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2020ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Excluding Amount Recognized Upon Adoption", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Excluding Amount Recognized Upon Adoption", "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities", "verboseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities, excluding amount recognized upon adoption of new accounting standard" } } }, "localname": "RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails", "http://www.bauschhealth.com/role/LEASESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhc_SECInvestigationLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SEC Investigation Litigation", "label": "SEC Investigation Litigation [Member]", "terseLabel": "SEC Investigation Litigation" } } }, "localname": "SECInvestigationLitigationMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Benefit From Income Taxes", "label": "SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Benefit From Income Taxes", "terseLabel": "Charged to Benefit from income taxes" } } }, "localname": "SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "bhc_SalixLtd.SECInvestigationLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Salix Ltd. SEC Investigation Litigation [Member]", "label": "Salix Ltd. SEC Investigation Litigation [Member]", "terseLabel": "Salix Ltd. SEC Investigation Litigation" } } }, "localname": "SalixLtd.SECInvestigationLitigationMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_SalixReportingUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Salix Reporting Unit [Member]", "label": "Salix Reporting Unit [Member]", "terseLabel": "Salix Reporting Unit" } } }, "localname": "SalixReportingUnitMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_SalixSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Salix Segment [Member]", "label": "Salix Segment [Member]", "terseLabel": "Salix", "verboseLabel": "Salix" } } }, "localname": "SalixSegmentMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "domainItemType" }, "bhc_SandozLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sandoz Litigation [Member]", "label": "Sandoz Litigation [Member]", "terseLabel": "Sandoz Litigation" } } }, "localname": "SandozLitigationMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_ScheduleOfCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Schedule of Commitments [Line Items]", "terseLabel": "Other commitments" } } }, "localname": "ScheduleOfCommitmentsLineItems", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "bhc_ScheduleOfCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to commitments of the entity during the reporting period.", "label": "Schedule of Commitments [Table]", "terseLabel": "Schedule of Commitments [Table]" } } }, "localname": "ScheduleOfCommitmentsTable", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of estimated useful lives of major classes of finite-lived intangible assets.", "label": "Schedule of Estimated Useful Lives of Finite Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of estimated useful lives of intangible assets" } } }, "localname": "ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of estimated useful lives of major classes of property, plant and equipment.", "label": "Schedule of Estimated Useful Lives of Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of estimated useful lives of property, plant and equipment" } } }, "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "bhc_ScheduleOfOtherIncomeAndExpensesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Schedule Of Other Income And Expenses [Table]", "label": "Schedule Of Other Income And Expenses [Line Items]", "terseLabel": "Schedule Of Other Income And Expenses [Line Items]" } } }, "localname": "ScheduleOfOtherIncomeAndExpensesLineItems", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails" ], "xbrltype": "stringItemType" }, "bhc_ScheduleOfOtherIncomeAndExpensesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Other Income And Expenses [Table]", "label": "Schedule Of Other Income And Expenses [Table]", "terseLabel": "Schedule Of Other Income And Expenses [Table]" } } }, "localname": "ScheduleOfOtherIncomeAndExpensesTable", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails" ], "xbrltype": "stringItemType" }, "bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of equity based payment instruments, excluding stock (or unit) options, including but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share Based Payment Award, Equity Instruments Other than Options Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of assumptions used to calculate the fair values of performance-based RSUs" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with Acquisition [Table Text Block]", "label": "Schedule of Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with Acquisition [Table Text Block]", "terseLabel": "Fair value of pension and postretirement benefit plan assets assumed in connection with the Acquisition" } } }, "localname": "ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "bhc_SellingGeneralAndAdministrativeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The allocation (or location) of expense to (in) selling, general and administrative expense.", "label": "Selling General and Administrative Expense [Member]", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpenseMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorNotes4.502023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.50%, 2023 [Member]", "label": "Senior Notes, 4.50%, 2023 [Member]", "terseLabel": "4.50% Senior Unsecured Notes euro-denominated debt Due May 2023" } } }, "localname": "SeniorNotes4.502023Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorNotes450DueMay2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 4.50%, 2023 [Member]", "label": "Senior Notes, 4.50%, Due May 2023 [Member]", "verboseLabel": "4.50% Senior Notes euro-denominated debt Due May 2023" } } }, "localname": "SeniorNotes450DueMay2023Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorNotes5.625PercentDueDecember2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 5.625 Percent Due December 2021 [Member]", "label": "Senior Notes 5.625 Percent Due December 2021 [Member]", "terseLabel": "5.625 % Senior Unsecured Notes due December 2021" } } }, "localname": "SeniorNotes5.625PercentDueDecember2021Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorNotes500DueFebruary2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 5.00%, Due February 2029", "label": "Senior Notes, 5.00%, Due February 2029 [Member]", "terseLabel": "5.00% Senior Note Due February 2029" } } }, "localname": "SeniorNotes500DueFebruary2029Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorNotes500DueJanuary2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5.00% Senior Notes Due January 2028 [Member]", "label": "Senior Notes, 5.00%, Due January 2028 [Member]", "terseLabel": "5.00% Senior Notes Due January 2028" } } }, "localname": "SeniorNotes500DueJanuary2028Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorNotes525DueFebruary2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 5.25%, Due February 2031", "label": "Senior Notes, 5.25%, Due February 2031 [Member]", "terseLabel": "5.25% Senior Notes, Due February 2031" } } }, "localname": "SeniorNotes525DueFebruary2031Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorNotes525DueJanuary2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5.25% Senior Notes Due January 2030 [Member]", "label": "Senior Notes, 5.25%, Due January 2030 [Member]", "terseLabel": "5.25% Senior Notes Due January 2030" } } }, "localname": "SeniorNotes525DueJanuary2030Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorNotes550DueMarch2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5.50% Senior Notes due March 2023 [Member]", "label": "Senior Notes, 5.50%, Due March 2023 [Member]", "verboseLabel": "5.50% Senior Notes Due March 2023" } } }, "localname": "SeniorNotes550DueMarch2023Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorNotes5875DueMay2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5.875% Senior Notes due May 2023 [Member]", "label": "Senior Notes, 5.875%, Due May 2023 [Member]", "verboseLabel": "5.875% Senior Notes Due May 2023" } } }, "localname": "SeniorNotes5875DueMay2023Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorNotes6.375PercentDueOctober2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents senior notes with an interest rate of 6.375 percent, due in October, 2020.", "label": "Senior Notes 6.375 Percent Due October 2020 [Member]", "terseLabel": "6.375% Senior Notes due in October 2020" } } }, "localname": "SeniorNotes6.375PercentDueOctober2020Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorNotes6.75PercentDueAugust2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents senior unsecured notes with an interest rate of 6.75 percent, due August, 2021.", "label": "Senior Notes 6.75 Percent Due August 2021 [Member]", "terseLabel": "6.75% Senior Notes due in August 2021" } } }, "localname": "SeniorNotes6.75PercentDueAugust2021Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorNotes6125DueApril2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "6.125% Senior Notes due April 2025 [Member]", "label": "Senior Notes, 6.125%, Due April 2025 [Member]", "terseLabel": "6.125% Senior Notes Due April 2025" } } }, "localname": "SeniorNotes6125DueApril2025Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorNotes625DueFebruary2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 6.25%, Due February 2029", "label": "Senior Notes, 6.25%, Due February 2029 [Member]", "terseLabel": "6.25% Senior Notes Due February 2029" } } }, "localname": "SeniorNotes625DueFebruary2029Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorNotes7.25PercentDueJuly2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents senior unsecured notes with an interest rate of 7.25 percent, due July, 2022.", "label": "Senior Notes 7.25 Percent Due July 2022 [Member]", "terseLabel": "7.25% Senior Notes due in July 2022" } } }, "localname": "SeniorNotes7.25PercentDueJuly2022Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorNotes7.5July2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes, 7.5%, July 2021 [Member]", "label": "Senior Notes, 7.5%, July 2021 [Member]", "terseLabel": "7.50% Senior Notes due July 2021" } } }, "localname": "SeniorNotes7.5July2021Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorNotes700DueJanuary2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 7.00 Percent Due January 2028 [Member]", "label": "Senior Notes, 7.00%, Due January 2028 [Member]", "terseLabel": "7.00 % Senior Notes Due January 2028" } } }, "localname": "SeniorNotes700DueJanuary2028Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorNotes725DueMay2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes 7.25 Percent Due May 2029 [Member]", "label": "Senior Notes, 7.25%, Due May 2029 [Member]", "terseLabel": "7.25% Senior Notes Due May 2029" } } }, "localname": "SeniorNotes725DueMay2029Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorNotes850DueJanuary2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "8.50% Senior Notes Due January 2027 [Member]", "label": "Senior Notes, 8.50%, Due January 2027 [Member]", "terseLabel": "8.50% Senior Notes Due January 2027" } } }, "localname": "SeniorNotes850DueJanuary2027Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorNotes900DueDecember2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "9.00% Senior Notes due December 2025 [Member]", "label": "Senior Notes, 9.00%, Due December 2025 [Member]", "terseLabel": "9.00% Senior Notes Due December 2025" } } }, "localname": "SeniorNotes900DueDecember2025Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorNotes925DueApril2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "9.25% Senior Notes Due April 2026 [Member]", "label": "Senior Notes, 9.25%, Due April 2026 [Member]", "verboseLabel": "9.25% Senior Notes Due April 2026" } } }, "localname": "SeniorNotes925DueApril2026Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorSecured5.50NotesDueNovember2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Secured 5.50% Notes Due November 2025 [Member]", "label": "Senior Secured 5.50% Notes Due November 2025 [Member]", "terseLabel": "5.50% Senior Notes Due November 2025" } } }, "localname": "SeniorSecured5.50NotesDueNovember2025Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorSecured5.75NotesDueAugust2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Secured 5.75% Notes Due August 2027 [Member]", "label": "Senior Secured 5.75% Notes Due August 2027 [Member]", "verboseLabel": "5.75% Senior Notes Due August 2027" } } }, "localname": "SeniorSecured5.75NotesDueAugust2027Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorSecuredCreditFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Secured Credit Facilities [Member]", "label": "Senior Secured Credit Facilities [Member]", "terseLabel": "Senior Credit Facilities" } } }, "localname": "SeniorSecuredCreditFacilitiesMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Secured Notes 6.50 Percent Due March 2022 [Member]", "label": "Senior Secured Notes 6.50 Percent Due March 2022 [Member]", "terseLabel": "6.50% Senior Notes Due March 2022" } } }, "localname": "SeniorSecuredNotes6.50PercentDueMarch2022Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Secured Notes 7.00 Percent Due March 2024 [Member]", "label": "Senior Secured Notes 7.00 Percent Due March 2024 [Member]", "terseLabel": "7.00 % Senior Notes Due March 2024" } } }, "localname": "SeniorSecuredNotes7.00PercentDueMarch2024Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Secured Notes And Senior Unsecured Notes [Member]", "label": "Senior Secured Notes And Senior Unsecured Notes [Member]", "terseLabel": "Senior Secured and Unsecured Notes" } } }, "localname": "SeniorSecuredNotesAndSeniorUnsecuredNotesMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorSecuredTermCreditFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Senior Secured Credit Facilities which includes the Revolving Credit Facility, New Term Loan A Facility, and the Delayed Draw Facility.", "label": "Senior Secured Term Credit Facilities [Member]", "terseLabel": "Senior Secured Credit Facilities" } } }, "localname": "SeniorSecuredTermCreditFacilitiesMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "bhc_SeniorUnsecuredNotesDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Unsecured Notes Due 2023 [Member]", "label": "Senior Unsecured Notes Due 2023 [Member]", "terseLabel": "Senior Unsecured Notes due 2023" } } }, "localname": "SeniorUnsecuredNotesDue2023Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "domainItemType" }, "bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sensitivity Analysis, Impact Of 1 Percent Change In Estimated Return Rate, Income (Loss) Before Tax", "label": "Sensitivity Analysis, Impact Of 1 Percent Change In Estimated Return Rate, Income (Loss) Before Tax", "terseLabel": "1% change in estimated return rates, Impact on pre-tax earnings" } } }, "localname": "SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sensitivity Analysis, Impact Of 1 Percent Change In Volume Of Product Sold Through To Medicaid Plan Participants, Income (Loss) Before Tax", "label": "Sensitivity Analysis, Impact Of 1 Percent Change In Volume Of Product Sold Through To Medicaid Plan Participants, Income (Loss) Before Tax", "terseLabel": "1% change in volume of product sold through to Medicaid plan participants, Impact on pre-tax earnings" } } }, "localname": "SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhc_SeparationCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Separation Costs", "label": "Separation Costs [Member]", "terseLabel": "Separation Costs" } } }, "localname": "SeparationCostsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_SeriesFTrancheBTermLoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series F Tranche B Term Loan Facility [Member]", "label": "Series F Tranche B Term Loan Facility [Member]", "terseLabel": "Series F Tranche B Term Loan Facility" } } }, "localname": "SeriesFTrancheBTermLoanFacilityMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the maximum number of common shares that could be issued upon vesting of outstanding awards.", "label": "Share Based Compensation, Arrangement by Share Based Payment Award, Number of Shares that could be Issued", "terseLabel": "Maximum common shares issuable upon vesting (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "sharesItemType" }, "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Share Based Compensation, Arrangement by Share Based Payment Award, Options Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "stringItemType" }, "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the total fair value of stock options vested during the period.", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options Vested in Period, Total Fair Value", "terseLabel": "Fair value of stock options vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents percentage of stock options that will vest in the future period.", "label": "Share Based Compensation, Arrangement by Share Based Payment Award, Options Vested Percentage", "terseLabel": "Percentage of stock options that will vest on each of the first, second, third and fourth anniversaries from the date of grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "percentItemType" }, "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Share Based Compensation, Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]", "terseLabel": "Weighted- Average Remaining Contractual Term (Years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "stringItemType" }, "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant", "terseLabel": "Aggregate fair market value on awards granted during any calendar year" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Share Based Compensation, Arrangement by Share Based Payment Award Options Weighted Average Exercise Price [Roll Forward]", "terseLabel": "Weighted- Average Exercise Price Per Share" } } }, "localname": "ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "stringItemType" }, "bhc_ShowertoShowerProductLiabilityLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shower to Shower Product Liability Litigation [Member]", "label": "Shower to Shower Product Liability Litigation [Member]", "terseLabel": "Shower to Shower Product Liability Litigation" } } }, "localname": "ShowertoShowerProductLiabilityLitigationMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc. [Member]", "label": "Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc. [Member]", "terseLabel": "Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc." } } }, "localname": "SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Research And Development Expense [Table Text Block]", "label": "Summary Of Research And Development Expense [Table Text Block]", "terseLabel": "Summary of research and development" } } }, "localname": "SummaryOfResearchAndDevelopmentExpenseTableTextBlock", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" ], "xbrltype": "textBlockItemType" }, "bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Valuation And Qualifying Accounts [Table Text Block]", "label": "Summary Of Valuation And Qualifying Accounts [Table Text Block]", "terseLabel": "Summary of variable consideration provisions" } } }, "localname": "SummaryOfValuationAndQualifyingAccountsTableTextBlock", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "bhc_SynergyPharmaceuticalsInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Synergy Pharmaceuticals Inc. [Member]", "label": "Synergy Pharmaceuticals Inc. [Member]", "terseLabel": "Synergy" } } }, "localname": "SynergyPharmaceuticalsInc.Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_TSRPerformanceBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TSR Performance-Based Restricted Stock Units [Member]", "label": "TSR Performance-Based Restricted Stock Units [Member]", "terseLabel": "TSR Performance-Based Restricted Stock Units" } } }, "localname": "TSRPerformanceBasedRestrictedStockUnitsMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "domainItemType" }, "bhc_TaxBenefitRecognitionMeasurementPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Benefit Recognition, Measurement Percentage", "label": "Tax Benefit Recognition, Measurement Percentage", "terseLabel": "Tax benefit recognition, measurement percentage (greater than)" } } }, "localname": "TaxBenefitRecognitionMeasurementPercentage", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "bhc_TermLoanBFacilityDueJune2025AndNovember2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan B Facility Due June 2025 And November 2025", "label": "Term Loan B Facility Due June 2025 And November 2025 [Member]", "terseLabel": "Term Loan B Facility Due June 2025 and November 2025" } } }, "localname": "TermLoanBFacilityDueJune2025AndNovember2025Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2020ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "domainItemType" }, "bhc_TermLoanBFacilityDueJune2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan B Facility Due June 2025 [Member]", "label": "Term Loan B Facility Due June 2025 [Member]", "terseLabel": "Term Loan B Facility Due June 2025", "verboseLabel": "Term Loan B Facility Due June 2025" } } }, "localname": "TermLoanBFacilityDueJune2025Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_TermLoanBFacilityDueNovember2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan B Facility Due November 2025 [Member]", "label": "Term Loan B Facility Due November 2025 [Member]", "terseLabel": "Term Loan B Facility Due November 2025" } } }, "localname": "TermLoanBFacilityDueNovember2025Member", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "bhc_ThreeLargestUSWholesalerCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the three largest U.S. wholesaler customers.", "label": "Three Largest US Wholesaler Customers [Member]", "terseLabel": "Three largest U.S. wholesaler customers" } } }, "localname": "ThreeLargestUSWholesalerCustomersMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "bhc_TimeBasedRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents stock awards in the form of time-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.", "label": "Time Based RSU [Member]", "terseLabel": "Time-Based RSUs" } } }, "localname": "TimeBasedRSUMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "domainItemType" }, "bhc_TradeReceivableNetPortionPastDue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Trade Receivable, Net, Portion Past Due", "label": "Trade Receivable, Net, Portion Past Due", "terseLabel": "Portion of net trade receivables that is past due" } } }, "localname": "TradeReceivableNetPortionPastDue", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "monetaryItemType" }, "bhc_U.S.BroadMarketMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. Broad Market [Member]", "label": "U.S. Broad Market [Member]", "terseLabel": "U.S. broad market" } } }, "localname": "U.S.BroadMarketMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "domainItemType" }, "bhc_U.S.DiversifiedProductsSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. Diversified Products Segment [Member]", "label": "U.S. Diversified Products Segment [Member]", "terseLabel": "U.S. Diversified Products" } } }, "localname": "U.S.DiversifiedProductsSegmentMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" ], "xbrltype": "domainItemType" }, "bhc_UcerisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Uceris [Member]", "label": "Uceris [Member]", "terseLabel": "Uceris" } } }, "localname": "UcerisMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of unclaimed tax credits and research and development credits.", "label": "Unclaimed Tax Credits and Research and Development Credits", "terseLabel": "Unclaimed investment tax credits and research and development credits" } } }, "localname": "UnclaimedTaxCreditsAndResearchAndDevelopmentCredits", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhc_UnitedStatesandPuertoRicoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "United States and Puerto Rico [Member]", "label": "United States and Puerto Rico [Member]", "terseLabel": "U.S. and Puerto Rico" } } }, "localname": "UnitedStatesandPuertoRicoMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" ], "xbrltype": "domainItemType" }, "bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.", "label": "Unrecognized Tax Benefits, Including Interest and Penalties", "terseLabel": "Unrecognized tax benefits including interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncludingInterestAndPenalties", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unrecognized Tax Benefits, Net Decrease Resulting From Prior Period Tax Positions", "label": "Unrecognized Tax Benefits, Net Decrease Resulting From Prior Period Tax Positions", "terseLabel": "Unrecognized tax benefits, net decrease for tax positions of prior years" } } }, "localname": "UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrecognized Tax Benefits, Net Increase Resulting from Current Period Tax Positions", "label": "Unrecognized Tax Benefits, Net Increase Resulting From Current Period Tax Positions", "terseLabel": "Unrecognized tax benefits, net increase for tax positions of current year" } } }, "localname": "UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrecognized Tax Benefits, Net Increase Resulting From Prior Period Tax Positions", "label": "Unrecognized Tax Benefits, Net Increase Resulting From Prior Period Tax Positions", "terseLabel": "Unrecognized tax benefits, net increase for tax positions of prior years" } } }, "localname": "UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhc_ValeantUSSecuritiesLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Valeant US Securities Litigation [Member]", "label": "Valeant US Securities Litigation [Member]", "terseLabel": "Valeant US Securities Litigation", "verboseLabel": "Valeant US Securities Litigation" } } }, "localname": "ValeantUSSecuritiesLitigationMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_ViolationofCanadianProvincialSecuritiesLegislationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Violation of Canadian Provincial Securities Legislation [Member]", "label": "Violation of Canadian Provincial Securities Legislation [Member]", "terseLabel": "Violation of Canadian Provincial Securities Legislation" } } }, "localname": "ViolationofCanadianProvincialSecuritiesLegislationMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhc_XifaxanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Xifaxan [Member]", "label": "Xifaxan [Member]", "terseLabel": "Xifaxan" } } }, "localname": "XifaxanMember", "nsuri": "http://www.bauschhealth.com/20201231", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "country_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CANADA", "terseLabel": "Canada", "verboseLabel": "Canada" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails", "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" ], "xbrltype": "domainItemType" }, "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "China", "verboseLabel": "China" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" ], "xbrltype": "domainItemType" }, "country_DE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GERMANY", "terseLabel": "Germany", "verboseLabel": "Germany" } } }, "localname": "DE", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" ], "xbrltype": "domainItemType" }, "country_EG": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EGYPT", "terseLabel": "Egypt" } } }, "localname": "EG", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails" ], "xbrltype": "domainItemType" }, "country_ES": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SPAIN", "terseLabel": "Spain" } } }, "localname": "ES", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails" ], "xbrltype": "domainItemType" }, "country_FR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FRANCE", "terseLabel": "France", "verboseLabel": "France" } } }, "localname": "FR", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" ], "xbrltype": "domainItemType" }, "country_GB": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED KINGDOM", "terseLabel": "United Kingdom" } } }, "localname": "GB", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails" ], "xbrltype": "domainItemType" }, "country_IE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IRELAND", "terseLabel": "Ireland" } } }, "localname": "IE", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" ], "xbrltype": "domainItemType" }, "country_IT": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ITALY", "terseLabel": "Italy" } } }, "localname": "IT", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" ], "xbrltype": "domainItemType" }, "country_JP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JAPAN", "terseLabel": "Japan" } } }, "localname": "JP", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails" ], "xbrltype": "domainItemType" }, "country_MX": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MEXICO", "terseLabel": "Mexico" } } }, "localname": "MX", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" ], "xbrltype": "domainItemType" }, "country_NL": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NETHERLANDS", "terseLabel": "Netherlands" } } }, "localname": "NL", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails" ], "xbrltype": "domainItemType" }, "country_PL": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "POLAND", "terseLabel": "Poland" } } }, "localname": "PL", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" ], "xbrltype": "domainItemType" }, "country_RS": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SERBIA", "terseLabel": "Serbia" } } }, "localname": "RS", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" ], "xbrltype": "domainItemType" }, "country_RU": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RUSSIAN FEDERATION", "terseLabel": "Russia" } } }, "localname": "RU", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFuturebenefitpaymentsforthepensionbenefitplansDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r820", "r821", "r822" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r823" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r818" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r825" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Smaller Reporting Company" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r820", "r821", "r822" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r817" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r819" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DocumentandEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r222", "r241", "r242", "r243", "r244", "r246", "r248", "r252" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r222", "r241", "r242", "r243", "r244", "r246", "r248", "r252" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r79", "r150" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r172", "r180", "r274", "r533", "r534", "r535", "r583", "r584" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r172", "r180", "r274", "r533", "r534", "r535", "r583", "r584" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r172", "r180", "r274", "r533", "r534", "r535", "r583", "r584" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails", "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails", "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r260", "r386", "r389", "r783" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Major Customers [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r484", "r490", "r725", "r726", "r727", "r728", "r729", "r730", "r732", "r780", "r784" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r484", "r490", "r725", "r726", "r727", "r728", "r729", "r730", "r732", "r780", "r784" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r260", "r386", "r389", "r783" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Name of Major Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r255", "r386", "r387", "r736", "r779", "r781" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r255", "r386", "r387", "r736", "r779", "r781" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r420", "r484", "r490", "r725", "r726", "r727", "r728", "r729", "r730", "r732", "r780", "r784" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r420", "r484", "r490", "r725", "r726", "r727", "r728", "r729", "r730", "r732", "r780", "r784" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r168", "r169", "r170", "r171", "r173", "r174", "r178", "r179", "r180", "r182", "r183", "r185", "r186", "r195" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Adjustment [Member]", "terseLabel": "Restatement Adjustment" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r168", "r169", "r170", "r171", "r173", "r174", "r178", "r179", "r180", "r182", "r183", "r184", "r185", "r186", "r195", "r275", "r276", "r536", "r584", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]", "terseLabel": "Restatement [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r168", "r169", "r170", "r171", "r173", "r174", "r178", "r179", "r180", "r182", "r183", "r184", "r185", "r186", "r195", "r275", "r276", "r536", "r584", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]", "terseLabel": "Restatement [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Scenario, Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r256", "r257", "r386", "r388", "r782", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r256", "r257", "r386", "r388", "r782", "r800", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r350", "r485", "r721" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r262", "r720" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "domainItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" ], "xbrltype": "stringItemType" }, "stpr_CA-BC": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BRITISH COLUMBIA", "terseLabel": "British Columbia" } } }, "localname": "CA-BC", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_CA-QC": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "QUEBEC", "terseLabel": "Quebec" } } }, "localname": "CA-QC", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_NJ": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW JERSEY", "terseLabel": "New Jersey" } } }, "localname": "NJ", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_OH": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OHIO", "terseLabel": "Ohio" } } }, "localname": "OH", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r173", "r174", "r175", "r176", "r271", "r272", "r273", "r274", "r275", "r276", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r583", "r584", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible List]", "terseLabel": "Accounting Standards Update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "extensibleListItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "ACCRUED AND OTHER CURRENT LIABILITIES" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r55" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Trade receivables" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r18", "r36", "r263", "r264" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Net trade receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r22", "r23", "r59" ], "calculation": { "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Employee compensation and benefit costs" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r30", "r745", "r764" ], "calculation": { "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r59" ], "calculation": { "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued and other current liabilities", "totalLabel": "Accrued and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails", "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r86", "r92", "r95", "r627" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Pension adjustment, net of tax" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r52", "r323" ], "calculation": { "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r39", "r89", "r91", "r92", "r767", "r792", "r796" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r685", "r686", "r687", "r688", "r689", "r691" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r88", "r92", "r95", "r168", "r169", "r171", "r627", "r787", "r788" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss", "verboseLabel": "AOCI Attributable to Parent" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails", "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r83", "r92", "r95", "r627", "r686", "r687", "r688", "r689", "r691" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r37" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r168", "r169", "r171", "r533", "r534", "r535" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails", "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r173", "r174", "r175", "r176", "r271", "r272", "r273", "r274", "r275", "r276", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r581", "r582", "r583", "r584", "r738", "r739", "r740", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Share-based awards tax withholding" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r492", "r494", "r539", "r540" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising Costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r543" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising expenses" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r266", "r277", "r278", "r282" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "periodEndLabel": "Balance, end of period", "periodStartLabel": "Balance, beginning of period", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": { "auth_ref": [ "r281" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.", "label": "Accounts Receivable, Allowance for Credit Loss, Recovery", "terseLabel": "Recoveries" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r280" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "negatedTerseLabel": "Write-offs" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r138", "r698" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization and write-off of debt discounts and debt issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "verboseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r138", "r318" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 6.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "negatedLabel": "Asset impairments, including loss on assets held for sale", "terseLabel": "Asset impairments, including loss on assets held for sale", "verboseLabel": "Asset impairments, including loss on assets held for sale" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r148", "r230", "r243", "r250", "r270", "r622", "r628", "r679", "r743", "r763" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Assets reclassified, held and used", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r19", "r20", "r74", "r148", "r270", "r622", "r628", "r679" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure": { "auth_ref": [ "r659" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of assets classified as held for sale.", "label": "Assets Held-for-sale, Long Lived, Fair Value Disclosure", "terseLabel": "Non-current assets held for sale" } } }, "localname": "AssetsHeldForSaleLongLivedFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r1", "r2", "r10", "r12", "r15", "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "negatedLabel": "Assets reclassified, held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]", "terseLabel": "Prepaid expenses and other current assets:" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]", "terseLabel": "Other non-current assets:" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AustralianTaxationOfficeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Australia.", "label": "Australian Taxation Office [Member]", "terseLabel": "Australia", "verboseLabel": "Australian Taxation Office" } } }, "localname": "AustralianTaxationOfficeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails", "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r496", "r527" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Buildings and improvements", "verboseLabel": "Buildings and improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r479", "r486" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r479", "r486", "r603", "r604" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r599" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Percentage interest acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r601", "r602" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Pro-forma revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r598" ], "calculation": { "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETScheduleofOtherExpenseIncomeNetDetails": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Acquisition-related costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETScheduleofOtherExpenseIncomeNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1": { "auth_ref": [ "r137", "r613" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 8.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of right to a contingent consideration asset.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset", "negatedLabel": "Acquisition-related contingent consideration", "verboseLabel": "Acquisition-related contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r610", "r611" ], "calculation": { "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details": { "order": 1.0, "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "verboseLabel": "Current portion" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r664" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Fair value, contingent consideration obligations, discount rate" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r610", "r611" ], "calculation": { "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details": { "order": 2.0, "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Non-current portion" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r600" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "terseLabel": "Revenue of acquiree since acquisition date" } } }, "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r606" ], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r606" ], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r606" ], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedTerseLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r606" ], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Product brand intangible assets (estimated useful life 7 years)" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r605", "r606" ], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r605", "r606" ], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total identifiable net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r606" ], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total fair value of consideration transferred" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r146", "r597" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Acquisitions and Acquisition-Related Contingent Consideration" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessExitCosts1": { "auth_ref": [ "r138", "r333", "r339", "r343" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Business Exit Costs", "terseLabel": "Facility closure costs" } } }, "localname": "BusinessExitCosts1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CanadaRevenueAgencyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Canada.", "label": "Canada Revenue Agency [Member]", "terseLabel": "Canada Revenue Agency" } } }, "localname": "CanadaRevenueAgencyMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r16", "r49", "r140" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents, end of year", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r26", "r141", "r146" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r132", "r140", "r143" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents and Restricted cash, end of year", "periodStartLabel": "Cash and cash equivalents and Restricted cash, beginning of year", "terseLabel": "Cash and cash equivalents and Restricted cash, end of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r132", "r684" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in Cash and cash equivalents and Restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "terseLabel": "SUPPLEMENTAL CASH FLOW DISCLOSURES" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES" ], "xbrltype": "textBlockItemType" }, "us-gaap_ChangeInAccountingEstimateByTypeAxis": { "auth_ref": [ "r181", "r197" ], "lang": { "en-us": { "role": { "documentation": "Information by type of change in accounting estimate.", "label": "Change in Accounting Estimate by Type [Axis]", "terseLabel": "Change in Accounting Estimate by Type [Axis]" } } }, "localname": "ChangeInAccountingEstimateByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInAccountingEstimateTypeDomain": { "auth_ref": [ "r181", "r197" ], "lang": { "en-us": { "role": { "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.", "label": "Change in Accounting Estimate, Type [Domain]", "terseLabel": "Change in Accounting Estimate, Type [Domain]" } } }, "localname": "ChangeInAccountingEstimateTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.", "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]", "terseLabel": "Components of the change in projected benefit obligations, change in plan assets and funded status" } } }, "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r64", "r349", "r751", "r773" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Notes\u00a020 and 21)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r346", "r347", "r348", "r359" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r146", "r362", "r801", "r802" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r168", "r169" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Shares" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r35", "r371" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "verboseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r35" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common shares, no par value, unlimited shares authorized, 355,422,347 and 352,562,636\u00a0issued and outstanding at December\u00a031, 2020 and 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r98", "r100", "r101", "r108", "r755", "r777" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss attributable to Bausch Health Companies Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r98", "r100", "r107", "r618", "r619", "r632", "r754", "r776" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "negatedTerseLabel": "Comprehensive income attributable to noncontrolling interest" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r98", "r100", "r106", "r617", "r632", "r753", "r775" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r105", "r117", "r752", "r774" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE LOSS" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r211", "r212", "r260", "r676", "r677" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r211", "r212", "r260", "r676", "r677", "r798" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r211", "r212", "r260", "r676", "r677", "r798" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r205", "r760" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentrations of Credit Risk" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r211", "r212", "r260", "r676", "r677" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r208", "r211", "r212", "r213", "r676", "r678" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r211", "r212", "r260", "r676", "r677" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "domainItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual Obligation", "terseLabel": "Capital expenditures" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualRightsMember": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements).", "label": "Contractual Rights [Member]", "terseLabel": "Product rights/patents", "verboseLabel": "Product rights/patents" } } }, "localname": "ContractualRightsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r241", "r242", "r243", "r244", "r246", "r252", "r254" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r112", "r736" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r110" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total Expenses", "verboseLabel": "Expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/SUPPLEMENTARYDATAUNAUDITEDScheduleofUnauditedQuarterlyConsolidatedFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Expenses" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_CreditConcentrationRiskMember": { "auth_ref": [ "r678" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.", "label": "Credit Concentration Risk [Member]", "terseLabel": "Credit concentration" } } }, "localname": "CreditConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2019ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2020ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2019ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2020ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrencySwapMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.", "label": "Currency Swap [Member]", "terseLabel": "Cross-currency swaps" } } }, "localname": "CurrencySwapMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r149", "r577", "r587" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "negatedTerseLabel": "Domestic" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r155", "r577" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "negatedTerseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r149", "r577", "r587", "r589" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "negatedTotalLabel": "Total" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r209", "r260" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer concentration" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "FINANCING ARRANGEMENTS" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r29", "r30", "r31", "r744", "r748", "r762" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2020ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable interest rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r31", "r365", "r748", "r762" ], "calculation": { "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Principal Amount", "totalLabel": "Total gross maturities" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r697", "r699" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Aggregate principal amount", "verboseLabel": "Aggregate principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r675" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair value of long-term debt" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate", "verboseLabel": "Stated interest rate on debt (as a percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]", "verboseLabel": "Long-term debt, net of unamortized debt discount" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2019ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2020ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2020ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r758" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r758" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "auth_ref": [ "r758" ], "lang": { "en-us": { "role": { "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period One [Member]", "terseLabel": "Debt Instrument, Redemption, Period One" } } }, "localname": "DebtInstrumentRedemptionPeriodOneMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "auth_ref": [ "r758" ], "lang": { "en-us": { "role": { "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Two [Member]", "terseLabel": "Debt Instrument, Redemption, Period Two" } } }, "localname": "DebtInstrumentRedemptionPeriodTwoMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r758" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption price percentage (as a percent)" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentRepurchasedFaceAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of the original debt instrument that was repurchased.", "label": "Debt Instrument, Repurchased Face Amount", "terseLabel": "Repurchased face amount" } } }, "localname": "DebtInstrumentRepurchasedFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r62", "r151", "r372", "r373", "r374", "r375", "r696", "r697", "r699", "r759" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2019ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2020ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r696", "r699" ], "calculation": { "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedTerseLabel": "Unamortized discounts" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of debt outstanding.", "label": "Debt, Weighted Average Interest Rate", "terseLabel": "Weighted average interest rate" } } }, "localname": "DebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "auth_ref": [ "r557" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "terseLabel": "Possible decrease in unrecognized tax benefits realized in next twelve months" } } }, "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r54", "r146" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]", "terseLabel": "Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued": { "auth_ref": [ "r508" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total fair value of shares issued during the period under a deferred compensation arrangement.", "label": "Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued", "terseLabel": "Aggregate value of long term incentive awards" } } }, "localname": "DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r149", "r578", "r587" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "negatedTerseLabel": "Domestic" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r54", "r698" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Debt issuance cost" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r149", "r578", "r587" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "negatedTerseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r550", "r551" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets, net" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r138", "r149", "r578", "r587", "r588", "r589" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "negatedTotalLabel": "Total" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r32", "r33", "r568", "r746", "r761" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "totalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r550", "r551" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities, net" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetDomain": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.", "label": "Deferred Tax Asset [Domain]", "terseLabel": "Deferred Tax Asset [Domain]" } } }, "localname": "DeferredTaxAssetDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r575", "r576" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred Tax Assets, Deferred Income", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r569" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r571" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax asset" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r571" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r575", "r576" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": { "order": 10.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r574", "r575", "r576" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r575", "r576" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Share-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "auth_ref": [ "r575", "r576" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "terseLabel": "Provisions" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r570" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less valuation allowance", "terseLabel": "Valuation allowance against deferred tax assets" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails", "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r575", "r576" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "auth_ref": [ "r575" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.", "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings", "terseLabel": "Outside basis differences" } } }, "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains": { "auth_ref": [ "r575", "r576" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on foreign currency transactions.", "label": "Deferred Tax Liabilities, Unrealized Currency Transaction Gains", "terseLabel": "Unrealized FX on U.S. dollar debt and other financing cost" } } }, "localname": "DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax": { "auth_ref": [ "r92", "r441" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax", "terseLabel": "Unrecognized actuarial losses" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax": { "auth_ref": [ "r92", "r441" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax", "negatedLabel": "Unrecognized prior service credits" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "auth_ref": [ "r410", "r470" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "terseLabel": "Actual return on plan assets" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r402" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "negatedTerseLabel": "Actuarial losses" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r396", "r436", "r464", "r470", "r471" ], "calculation": { "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedTerseLabel": "Amortization of net loss" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r396", "r437", "r465", "r470", "r471" ], "calculation": { "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "terseLabel": "Amortization of prior service credit" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]", "terseLabel": "Recognized as:" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "terseLabel": "Rate of compensation increase" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate", "terseLabel": "Interest crediting rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "auth_ref": [ "r445", "r469" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets", "terseLabel": "Percentage of expected return on plan assets", "verboseLabel": "Expected rate of return on plan assets" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "terseLabel": "Rate of compensation increase" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate", "terseLabel": "Interest crediting rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r397" ], "calculation": { "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation", "periodEndLabel": "Projected benefit obligation, end of year", "periodStartLabel": "Projected benefit obligation, beginning of year" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "auth_ref": [ "r404", "r476" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "negatedLabel": "Benefits paid" } } }, "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": { "auth_ref": [ "r401" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation.", "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant", "terseLabel": "Employee contributions" } } }, "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "auth_ref": [ "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r448", "r470" ], "lang": { "en-us": { "role": { "documentation": "Information by defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]" } } }, "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested.", "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "terseLabel": "Change in Projected Benefit Obligation" } } }, "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "terseLabel": "Change in Plan Assets" } } }, "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r412", "r421", "r423", "r468", "r470", "r471" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Company contributions" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": { "auth_ref": [ "r421", "r470" ], "lang": { "en-us": { "role": { "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.", "label": "Defined Benefit Plan, Equity Securities [Member]", "terseLabel": "Equity securities", "verboseLabel": "Equity securities:" } } }, "localname": "DefinedBenefitPlanEquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "auth_ref": [ "r430" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "terseLabel": "2026-2030" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFuturebenefitpaymentsforthepensionbenefitplansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "auth_ref": [ "r430" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "terseLabel": "2021" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFuturebenefitpaymentsforthepensionbenefitplansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "auth_ref": [ "r430" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "terseLabel": "2024" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFuturebenefitpaymentsforthepensionbenefitplansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "auth_ref": [ "r430" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "terseLabel": "2025" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFuturebenefitpaymentsforthepensionbenefitplansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "auth_ref": [ "r430" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "terseLabel": "2023" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFuturebenefitpaymentsforthepensionbenefitplansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "auth_ref": [ "r430" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "terseLabel": "2022" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFuturebenefitpaymentsforthepensionbenefitplansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": { "auth_ref": [ "r431", "r471" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year", "terseLabel": "Estimated company contributions in next fiscal year" } } }, "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r396", "r435", "r463", "r470", "r471" ], "calculation": { "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedTerseLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "auth_ref": [ "r409", "r421", "r423", "r424", "r470" ], "calculation": { "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.", "label": "Defined Benefit Plan, Plan Assets, Amount", "periodEndLabel": "Fair value of plan assets, end of year", "periodStartLabel": "Fair value of plan assets, beginning of year", "terseLabel": "Fair value of plan assets" } } }, "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "auth_ref": [ "r403" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "terseLabel": "Currency translation adjustments" } } }, "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "auth_ref": [ "r394", "r418", "r470" ], "calculation": { "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "totalLabel": "Funded status, end of year" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r396", "r400", "r434", "r462", "r470", "r471" ], "calculation": { "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r432", "r460", "r470", "r471" ], "calculation": { "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net periodic (benefit) cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanOtherCosts": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of defined benefit plan cost (credit), classified as other.", "label": "Defined Benefit Plan, Other Cost (Credit)", "terseLabel": "Other" } } }, "localname": "DefinedBenefitPlanOtherCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]", "terseLabel": "Underfunded plans having accumulated benefit obligations exceeding the fair value of plan assets" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": { "auth_ref": [ "r456", "r457", "r470" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation", "terseLabel": "Accumulated benefit obligation" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": { "auth_ref": [ "r456", "r457", "r470" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets", "terseLabel": "Fair value of plan assets" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": { "auth_ref": [ "r456" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation", "terseLabel": "Projected benefit obligation" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "auth_ref": [ "r414", "r476" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "negatedTerseLabel": "Benefits paid" } } }, "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": { "auth_ref": [ "r413" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "terseLabel": "Employee contributions" } } }, "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r411" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Currency translation adjustments" } } }, "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": { "auth_ref": [ "r420", "r470" ], "lang": { "en-us": { "role": { "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.", "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage", "terseLabel": "Defined benefit plan, percentage of actual plan asset allocations" } } }, "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r398", "r433", "r461", "r470", "r471" ], "calculation": { "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": { "auth_ref": [ "r399" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement", "negatedTerseLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanSettlementsBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "auth_ref": [ "r417" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "negatedTerseLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanSettlementsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]", "terseLabel": "For Determining Benefit Obligation" } } }, "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]", "terseLabel": "For Determining Net Periodic (Benefit) Cost" } } }, "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "auth_ref": [ "r454", "r455", "r458", "r459", "r470" ], "lang": { "en-us": { "role": { "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFuturebenefitpaymentsforthepensionbenefitplansDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFuturebenefitpaymentsforthepensionbenefitplansDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r477" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Contributions recognized" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r138", "r321" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r138", "r321" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization of intangible assets" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueGrossLiability": { "auth_ref": [ "r76", "r81", "r641" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Asset, Fair Value, Gross Liability", "terseLabel": "Fair value cross-currency swaps liability" } } }, "localname": "DerivativeAssetFairValueGrossLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r77", "r78", "r675" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Foreign currency exchange contracts" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r75", "r80", "r641", "r731" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Fair value cross-currency swaps asset" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r640", "r642", "r646", "r652" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r638", "r640", "r646" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r638", "r640", "r646", "r652", "r653", "r655", "r658" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r645", "r647" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "negatedTerseLabel": "Net change in fair value, loss" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss": { "auth_ref": [ "r645", "r647" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized loss of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Loss", "terseLabel": "Loss related to settlements during period" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r77", "r78", "r675" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative liabilities", "verboseLabel": "Fair value cross-currency swaps liability, net" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r634", "r636" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Aggregate notional amounts" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r146", "r156", "r633", "r635", "r638", "r639", "r654" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Fair Value of Derivative Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r638" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "SHARE-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).", "label": "Disclosure of Long Lived Assets Held-for-sale [Table Text Block]", "terseLabel": "Schedule of carrying amounts of assets and liabilities held for sale" } } }, "localname": "DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]", "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails", "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails", "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r12", "r316", "r329" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]", "terseLabel": "Held For Sale" } } }, "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails", "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "auth_ref": [ "r1", "r2", "r10", "r327" ], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails": { "order": 1.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "terseLabel": "Trade receivables, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": { "auth_ref": [ "r1", "r2", "r10", "r320", "r327" ], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails": { "order": 1.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets": { "auth_ref": [ "r1", "r2", "r10", "r327" ], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails": { "order": 3.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as deferred tax assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Assets", "terseLabel": "Deferred tax assets, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities": { "auth_ref": [ "r1", "r2", "r10", "r327" ], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails": { "order": 1.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities", "terseLabel": "Deferred tax liabilities, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": { "auth_ref": [ "r1", "r2", "r10", "r315", "r327" ], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails": { "order": 2.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent", "terseLabel": "Goodwill and Intangible assets, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "auth_ref": [ "r1", "r2", "r10", "r320", "r327" ], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails": { "order": 2.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Inventory, Current", "terseLabel": "Inventories, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": { "auth_ref": [ "r1", "r2", "r10", "r320", "r327" ], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current", "totalLabel": "Total Prepaid expenses and other current assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": { "auth_ref": [ "r1", "r2", "r10", "r320", "r327" ], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current", "totalLabel": "Total Accrued and other current liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": { "auth_ref": [ "r1", "r2", "r10", "r315", "r327" ], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent", "totalLabel": "Total Other non-current assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": { "auth_ref": [ "r1", "r2", "r10", "r315", "r327" ], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent", "totalLabel": "Total Other non-current liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "auth_ref": [ "r1", "r2", "r10", "r320", "r327" ], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails": { "order": 3.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": { "auth_ref": [ "r1", "r2", "r10", "r315", "r327" ], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails": { "order": 1.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r479", "r486" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails", "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "United States - Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails", "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticPlanMember": { "auth_ref": [ "r478", "r482", "r489" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Domestic Plan [Member]", "terseLabel": "Domestic Plan" } } }, "localname": "DomesticPlanMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFuturebenefitpaymentsforthepensionbenefitplansDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "negatedTerseLabel": "Decrease to earnings per share, basic and diluted (in dollars per share)", "netLabel": "Basic and Diluted (loss) earnings per share attributable to Bausch Health Companies Inc. (in dollars per share)", "terseLabel": "Basic and Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share)", "verboseLabel": "Basic and diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails", "http://www.bauschhealth.com/role/SUPPLEMENTARYDATAUNAUDITEDScheduleofUnauditedQuarterlyConsolidatedFinancialDataDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r146", "r192", "r193" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Loss Per Share Attributable to Bausch Health Companies Inc." } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r192", "r193", "r194", "r196" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "LOSS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LOSSPERSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r684" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r553", "r591" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Expected Canadian statutory rate", "verboseLabel": "Federal funds effective rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Components and classification of share-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r526" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Remaining unrecognized compensation expense related to non-vested awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EntityWideRevenueMajorCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Major Customer [Line Items]", "verboseLabel": "Segment reporting information" } } }, "localname": "EntityWideRevenueMajorCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquipmentLeasedToOtherPartyMember": { "auth_ref": [ "r719" ], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to generate rental income.", "label": "Equipment Leased to Other Party [Member]", "terseLabel": "Equipment on operating lease", "verboseLabel": "Equipment on operating lease" } } }, "localname": "EquipmentLeasedToOtherPartyMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r168", "r169", "r171", "r174", "r183", "r186", "r201", "r274", "r371", "r376", "r533", "r534", "r535", "r583", "r584", "r685", "r686", "r687", "r688", "r689", "r691", "r787", "r788", "r789" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails", "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails", "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EurodollarMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.", "label": "Eurodollar [Member]", "terseLabel": "Eurodollar" } } }, "localname": "EurodollarMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "verboseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r659", "r660", "r661", "r671" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r659", "r660" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.", "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Schedule of assets and liabilities measured at fair value on a non-recurring basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r470", "r660", "r722", "r723", "r724" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r659", "r660", "r663", "r664", "r672" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r670" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r421", "r423", "r428", "r470", "r660", "r722" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r421", "r423", "r428", "r470", "r660", "r723" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "netLabel": "Level 2", "terseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r470", "r660", "r724" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r665", "r671" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Acquisition-related contingent consideration adjustments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": { "auth_ref": [ "r667" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)", "verboseLabel": "Foreign currency translation adjustment included in other comprehensive loss" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r668" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedLabel": "Payments / Settlements" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r665" ], "calculation": { "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r470", "r722", "r723", "r724" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "auth_ref": [ "r659", "r660", "r663", "r664", "r669", "r672" ], "lang": { "en-us": { "role": { "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.", "label": "Fair Value, Nonrecurring [Member]", "terseLabel": "Non-recurring basis", "verboseLabel": "Fair Value, Nonrecurring" } } }, "localname": "FairValueMeasurementsNonrecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r670", "r672" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetAssetLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Net Asset (Liability) [Abstract]", "terseLabel": "Other non-current assets:" } } }, "localname": "FairValueNetAssetLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r146", "r673", "r674" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "auth_ref": [ "r656" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.", "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "terseLabel": "Federal Funds Effective Swap Rate" } } }, "localname": "FederalFundsEffectiveSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r701", "r716" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for charging off uncollectible financing receivables, including, but not limited to, factors and methodologies used in estimating the allowance for credit loss.", "label": "Financing Receivable, Allowance for Credit Losses, Policy for Uncollectible Amounts [Policy Text Block]", "terseLabel": "Allowance for Credit Losses" } } }, "localname": "FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Weighted- Average Remaining Useful Lives (Years)", "verboseLabel": "Estimated useful lives" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r307" ], "calculation": { "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 }, "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization and Impairments" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r308" ], "calculation": { "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "verboseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r308" ], "calculation": { "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "verboseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r308" ], "calculation": { "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "verboseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r308" ], "calculation": { "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "verboseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r308" ], "calculation": { "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "netLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r302", "r304", "r307", "r310", "r737", "r741" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Estimated aggregate amortization expense" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r307", "r741" ], "calculation": { "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "verboseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r302", "r306" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r307", "r737" ], "calculation": { "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FixedIncomeSecuritiesMember": { "auth_ref": [ "r421", "r470" ], "lang": { "en-us": { "role": { "documentation": "Investment that provides a return in the form of fixed periodic payments and eventual return of principal at maturity.", "label": "Fixed Income Securities [Member]", "terseLabel": "Fixed income securities", "verboseLabel": "Fixed income securities:" } } }, "localname": "FixedIncomeSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Ireland" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r680", "r681", "r682", "r683" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Foreign exchange and other" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r139", "r682", "r683" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Unrealized", "negatedLabel": "Foreign exchange loss (gain)" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r146", "r692" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r421", "r650" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign currency exchange contracts" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r154" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.", "label": "Foreign Income Tax Expense (Benefit), Continuing Operations", "negatedTerseLabel": "Expected benefit from income taxes at Canadian statutory rate" } } }, "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignPlanMember": { "auth_ref": [ "r478", "r482", "r489" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Foreign Plan [Member]", "terseLabel": "Foreign Plan" } } }, "localname": "ForeignPlanMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFuturebenefitpaymentsforthepensionbenefitplansDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r138", "r319", "r325" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "negatedLabel": "(Gain) loss on disposal of assets" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r138" ], "calculation": { "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETScheduleofOtherExpenseIncomeNetDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedTerseLabel": "Net (gain) loss on sales of assets", "terseLabel": "Milestone achievement, included in net gain (loss) on other sales of assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails", "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETScheduleofOtherExpenseIncomeNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r349" ], "calculation": { "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETScheduleofOtherExpenseIncomeNetDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (Loss) Related to Litigation Settlement", "negatedLabel": "Litigation and other matters", "terseLabel": "Favorable (unfavorable) adjustment, litigation and other matters" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails", "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETScheduleofOtherExpenseIncomeNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r138", "r368", "r369" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on extinguishment of debt", "terseLabel": "Loss on extinguishment of debt", "verboseLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r287", "r289", "r742" ], "calculation": { "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance at the end of the period", "periodStartLabel": "Balance at the beginning of the period", "terseLabel": "Goodwill", "verboseLabel": "Goodwill reallocated into (out of)" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r291" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "verboseLabel": "Acquisition of certain assets of Synergy" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "INTANGIBLE ASSETS AND GOODWILL" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r146", "r297" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r294" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign exchange and other" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r290", "r296" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "terseLabel": "Accumulated goodwill impairment charges to date" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r138", "r288", "r293", "r299" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "negatedTerseLabel": "Impairments", "terseLabel": "Goodwill impairments" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillOtherIncreaseDecrease": { "auth_ref": [ "r295" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Other Increase (Decrease)", "terseLabel": "Realignment of segment goodwill" } } }, "localname": "GoodwillOtherIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Change in the carrying amount of goodwill" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillTransfers": { "auth_ref": [ "r295" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers into (out of) an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Transfers", "terseLabel": "Realignment of Global Solta reporting unit goodwill" } } }, "localname": "GoodwillTransfers", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "auth_ref": [ "r292" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Written off Related to Sale of Business Unit", "negatedTerseLabel": "Goodwill reclassified to assets held for sale" } } }, "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r638", "r653" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r638" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r638" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r138", "r311" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Impairment of finite-lived intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r138", "r311" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Impairment of indefinite-lived intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r138", "r317" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "verboseLabel": "Impairment of long-lived assets" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r146", "r314", "r331" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "auth_ref": [ "r53", "r146", "r546" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.", "label": "In Process Research and Development, Policy [Policy Text Block]", "terseLabel": "IPR&D" } } }, "localname": "InProcessResearchAndDevelopmentPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r153", "r590" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r153", "r590" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r153", "r230", "r242", "r246", "r249", "r252" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "terseLabel": "Loss before benefit from income taxes", "totalLabel": "Loss before benefit from income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails", "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]", "terseLabel": "Components of loss before benefit of income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r479", "r486" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails", "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "verboseLabel": "Assets Held For Sale" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r2", "r4", "r5", "r6", "r7", "r8", "r9", "r11", "r13", "r14", "r15", "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Schedule of Significant Acquisitions and Disposals [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails", "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails", "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r559", "r565", "r567", "r580" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r554", "r566", "r573", "r585", "r592", "r594", "r595", "r596" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss": { "auth_ref": [ "r557" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated amount of loss resulting from an adverse tax position.", "label": "Income Tax Examination, Estimate of Possible Loss", "terseLabel": "Notice of tax assessment, aggregate amount of possible loss" } } }, "localname": "IncomeTaxExaminationEstimateOfPossibleLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r149", "r185", "r186", "r228", "r552", "r586", "r593", "r778" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Benefit from income taxes", "negatedTotalLabel": "(Provision for) benefit from income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails", "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]", "terseLabel": "Benefit from income taxes" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r102", "r146", "r548", "r549", "r566", "r567", "r572", "r579", "r803" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r553" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "negatedTerseLabel": "Change in valuation allowance on Canadian deferred tax assets and tax rate changes" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r553" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "negatedTerseLabel": "Foreign tax rate differences" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": { "auth_ref": [ "r553" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount", "negatedTerseLabel": "Non-deductible portion of Goodwill impairments" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r553" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount", "negatedTerseLabel": "Non-deductible amount of share-based compensation" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r553" ], "calculation": { "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": { "order": 10.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "negatedTerseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r134", "r142" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "verboseLabel": "Income taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r137" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r137" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Trade receivables" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r137" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r137" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Shareholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r303", "r309" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r309" ], "calculation": { "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Net Carrying Amount" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r303", "r309" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsAmortizationPeriodMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A revision in the estimated economic useful life of a finite-lived intangible asset (the period of time over which the asset is projected to benefit operations).", "label": "Intangible Assets, Amortization Period [Member]", "terseLabel": "Intangible Assets, Amortization Period" } } }, "localname": "IntangibleAssetsAmortizationPeriodMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r146", "r306", "r733", "r734", "r735", "r737" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "totalLabel": "Gross Carrying Amount" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r301", "r305" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Intangible Assets, Net (Excluding Goodwill)", "verboseLabel": "Carrying value of intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndDebtExpense": { "auth_ref": [ "r695" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.", "label": "Interest and Debt Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestAndDebtExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestCostsCapitalized": { "auth_ref": [ "r694" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest capitalized during the period.", "label": "Interest Costs Capitalized", "terseLabel": "Capitalized interest" } } }, "localname": "InterestCostsCapitalized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r115", "r367" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r651" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpensePolicyTextBlock": { "auth_ref": [ "r145", "r146", "r693" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs.", "label": "Interest Expense, Policy [Policy Text Block]", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpensePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r129", "r133", "r142" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "verboseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r23", "r24", "r59" ], "calculation": { "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORIES" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INVENTORIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r69" ], "calculation": { "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r17", "r72" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net", "totalLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r25", "r73", "r146", "r198", "r284", "r285", "r286" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r71" ], "calculation": { "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r70" ], "calculation": { "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r114", "r223" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandImprovementsMember": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to real estate held.", "label": "Land Improvements [Member]", "terseLabel": "Land improvements" } } }, "localname": "LandImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r715" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of lease expenses" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).", "label": "Leaseholds and Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdsAndLeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LegalCostsPolicyTextBlock": { "auth_ref": [ "r145", "r146", "r358" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.", "label": "Legal Costs, Policy [Policy Text Block]", "terseLabel": "Legal Costs" } } }, "localname": "LegalCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "LEGAL PROCEEDINGS" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGS" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r706" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Summary of operating lease future payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r716" ], "calculation": { "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r716" ], "calculation": { "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r716" ], "calculation": { "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r716" ], "calculation": { "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r716" ], "calculation": { "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r716" ], "calculation": { "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r716" ], "calculation": { "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r716" ], "calculation": { "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lease renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2020ActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r58", "r148", "r244", "r270", "r623", "r628", "r629", "r679" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r42", "r148", "r270", "r679", "r750", "r770" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r60", "r148", "r270", "r623", "r628", "r629", "r679" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]", "terseLabel": "Accrued and other current liabilities:" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]", "terseLabel": "Other non-current liabilities:" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEAssetsandLiabilitiesHeldForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": { "auth_ref": [ "r675" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of the amount outstanding under the credit facility.", "label": "Line of Credit Facility, Fair Value of Amount Outstanding", "terseLabel": "Amount outstanding" } } }, "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r56" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r56" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Remaining availability" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2020ActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Commitment fee, unutilized commitments, percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Settlement, escrow fund included in restricted cash", "verboseLabel": "Litigation, amount agreed to pay" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.", "label": "Long-lived Assets by Geographic Areas [Table Text Block]", "terseLabel": "Schedule of assets by geographic region" } } }, "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r31", "r366", "r748", "r766" ], "calculation": { "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term debt", "totalLabel": "Total long-term debt and other" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2020ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r57" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt and other", "verboseLabel": "Less: Current portion of long-term debt and other" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r158", "r363" ], "calculation": { "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": { "order": 6.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r158", "r363" ], "calculation": { "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "verboseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r158", "r363" ], "calculation": { "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r158", "r363" ], "calculation": { "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r158", "r363" ], "calculation": { "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r158", "r363" ], "calculation": { "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "verboseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r62" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Non-current portion of long-term debt", "verboseLabel": "Non-current portion of long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r62", "r364" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r349", "r350", "r351", "r353", "r354", "r355", "r357", "r360", "r361" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Legal proceedings and other matters" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r349", "r350", "r351", "r353", "r354", "r355", "r357", "r360", "r361" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyClaimsDismissedNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of claims dismissed.", "label": "Loss Contingency, Claims Dismissed, Number", "terseLabel": "Number of cases voluntarily dismissed" } } }, "localname": "LossContingencyClaimsDismissedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyClaimsSettledNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of claims settled.", "label": "Loss Contingency, Claims Settled, Number", "terseLabel": "Number of cases settled" } } }, "localname": "LossContingencyClaimsSettledNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r349", "r352", "r356" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Damages sought" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r349", "r350", "r351", "r353", "r354", "r355", "r357", "r360", "r361" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "Recent suits filed" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyPendingClaimsNumber": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Number of pending claims pertaining to a loss contingency.", "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Number of cases" } } }, "localname": "LossContingencyPendingClaimsNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r662" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Measurement Input, Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r662" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r68", "r148", "r270", "r679", "r749", "r769" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r376" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedTerseLabel": "Noncontrolling interest distributions" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "auth_ref": [ "r376", "r620", "r621" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "negatedLabel": "Acquisition of noncontrolling interest", "terseLabel": "Reduction of additional paid-in capital" } } }, "localname": "MinorityInterestDecreaseFromRedemptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails", "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r202", "r217" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "DESCRIPTION OF BUSINESS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r132" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash Flows From Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r132" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash Flows From Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r132", "r136", "r139" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Net cash provided by operating activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bauschhealth.com/role/SUPPLEMENTARYDATAUNAUDITEDScheduleofUnauditedQuarterlyConsolidatedFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash Flows From Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r96", "r99", "r185", "r186", "r625", "r631" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedTerseLabel": "Net income attributable to noncontrolling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r178", "r179", "r180", "r181", "r187", "r188", "r189", "r191", "r230", "r242", "r246", "r249", "r252" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net (loss) income attributable to Bausch Health Companies Inc.", "totalLabel": "Net loss attributable to Bausch Health Companies Inc.", "verboseLabel": "Net loss attributable to Bausch Health Companies Inc." } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails", "http://www.bauschhealth.com/role/SUPPLEMENTARYDATAUNAUDITEDScheduleofUnauditedQuarterlyConsolidatedFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r637" ], "lang": { "en-us": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedging" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r172", "r173", "r174", "r175", "r176", "r177", "r180", "r195", "r271", "r272", "r273", "r274", "r275", "r276", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r581", "r582", "r583", "r584", "r738", "r739", "r740", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Adoption of New Accounting Standards and Recently Issued Accounting Standards, Not Adopted as of December 31, 2020" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r168", "r169", "r171", "r376", "r615" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r257" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r638" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails", "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfCountriesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of countries in which the entity operates as of balance sheet date.", "label": "Number of Countries in which Entity Operates", "verboseLabel": "Number of countries in which entity operates" } } }, "localname": "NumberOfCountriesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OpenTaxYear": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Tax year that remains open to examination under enacted tax laws, in CCYY format.", "label": "Open Tax Year", "terseLabel": "Open Years" } } }, "localname": "OpenTaxYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails" ], "xbrltype": "gYearListItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r230", "r242", "r246", "r249", "r252" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating income (loss)", "totalLabel": "Operating income (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails", "http://www.bauschhealth.com/role/SUPPLEMENTARYDATAUNAUDITEDScheduleofUnauditedQuarterlyConsolidatedFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r707", "r717" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r703" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Rental expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r701" ], "calculation": { "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Lease liability", "totalLabel": "Present value of remaining lease payments" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails", "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r701" ], "calculation": { "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Less: Current portion", "verboseLabel": "Accrued and other current liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails", "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r702" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r701" ], "calculation": { "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Non-current portion", "verboseLabel": "Other non-current liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails", "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r702" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r702" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease liability.", "label": "Operating Lease, Liability, Statement of Financial Position [Extensible List]", "terseLabel": "Operating Lease, Liability, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r704", "r711" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid from operating cash flows for amounts included in the measurement of lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r700" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use asset", "verboseLabel": "Other non-current assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r714", "r717" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r713", "r717" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r241", "r242", "r243", "r244", "r246", "r252" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r22", "r23", "r24", "r59" ], "calculation": { "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r54" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax [Abstract]", "terseLabel": "Pension and postretirement benefit plan adjustments:" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r85", "r89", "r440" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax", "terseLabel": "Net actuarial loss arising during the year" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax": { "auth_ref": [ "r89", "r93", "r94", "r440" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax", "terseLabel": "Amortization of prior service credit" } } }, "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": { "auth_ref": [ "r84", "r89", "r644", "r649", "r657" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax", "terseLabel": "Gain excluded from assessment of hedge effectiveness" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r82" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r648" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Loss recognized in Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r97", "r100", "r103", "r105", "r371", "r685", "r690", "r691", "r752", "r774" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive (loss) income", "totalLabel": "Other comprehensive (loss) income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive (loss) income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r87", "r89" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedTotalLabel": "Net pension and postretirement benefit plan adjustments" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": { "auth_ref": [ "r87", "r90", "r617" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax", "terseLabel": "Income tax benefit (expense)" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDebtSecuritiesMember": { "auth_ref": [ "r269", "r283", "r421", "r670" ], "lang": { "en-us": { "role": { "documentation": "Investments in debt securities classified as other.", "label": "Other Debt Obligations [Member]", "terseLabel": "Other" } } }, "localname": "OtherDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r391", "r544" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "OTHER EXPENSE (INCOME), NET" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENET" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r63" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherMachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services.", "label": "Other Machinery and Equipment [Member]", "terseLabel": "Other equipment" } } }, "localname": "OtherMachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r139" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r116" ], "calculation": { "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETScheduleofOtherExpenseIncomeNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other expense, net", "negatedTotalLabel": "Other expense (income), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails", "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETScheduleofOtherExpenseIncomeNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 9.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "negatedTerseLabel": "Other expense (income), net", "terseLabel": "Other (expense) income, net" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r393", "r394", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r443", "r445", "r446", "r448", "r451", "r455", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r477", "r478", "r479", "r480", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "terseLabel": "Postretirement Benefit Plan", "verboseLabel": "U.S. Postretirement Benefit Plan" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFuturebenefitpaymentsforthepensionbenefitplansDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherRestructuringCosts": { "auth_ref": [ "r138", "r333", "r339", "r343" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.", "label": "Other Restructuring Costs", "verboseLabel": "Other costs" } } }, "localname": "OtherRestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Bausch Health Companies\u00a0Inc. Shareholders' Equity" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r127" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedLabel": "Payments of acquisition-related contingent consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForLegalSettlements": { "auth_ref": [ "r135" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.", "label": "Payments for Legal Settlements", "negatedLabel": "Payments of accrued legal settlements", "terseLabel": "Payments for legal settlements" } } }, "localname": "PaymentsForLegalSettlements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromHedgeInvestingActivities": { "auth_ref": [ "r157" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.", "label": "Payments for (Proceeds from) Hedge, Investing Activities", "terseLabel": "Payments or receipts in settlement of cross-currency swaps" } } }, "localname": "PaymentsForProceedsFromHedgeInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r130", "r335" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "terseLabel": "Restructuring payments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r126" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payments of financing costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtRestructuringCosts": { "auth_ref": [ "r128" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage.", "label": "Payments of Debt Restructuring Costs", "terseLabel": "Payments of debt restructuring costs" } } }, "localname": "PaymentsOfDebtRestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r124" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedLabel": "Payment of employee withholding taxes related to share-based awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r119", "r612" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash payments to acquire certain assets and assumed liabilities" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r119" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisition of businesses, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r120" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Acquisition of intangible assets and other assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r268" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedTerseLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r120" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "terseLabel": "Total capital expenditures" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r120" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PendingLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.", "label": "Pending Litigation [Member]", "terseLabel": "Pending Litigation" } } }, "localname": "PendingLitigationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r420", "r422", "r428", "r447", "r449", "r450", "r451", "r452", "r453", "r470", "r472", "r475", "r477", "r491" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r395", "r418", "r747", "r765" ], "calculation": { "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans.", "label": "Liability, Defined Benefit Plan", "negatedTerseLabel": "Other non-current liabilities" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementPlansPolicy": { "auth_ref": [ "r146", "r454", "r473", "r474", "r477", "r483" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.", "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]", "terseLabel": "Employee Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementPlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r392", "r394", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r443", "r445", "r446", "r448", "r451", "r455", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r477", "r478", "r486", "r487", "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension Benefit Plans" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFuturebenefitpaymentsforthepensionbenefitplansDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanAssetCategoriesDomain": { "auth_ref": [ "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r448", "r470" ], "lang": { "en-us": { "role": { "documentation": "Defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]" } } }, "localname": "PlanAssetCategoriesDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r496", "r527" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r19", "r47", "r48" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": { "auth_ref": [ "r118" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity.", "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested", "terseLabel": "Proceeds from sale of assets and businesses, net of costs to sell" } } }, "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r122" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Issuance of long-term debt, net of discounts", "verboseLabel": "Proceeds from issuance of long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r123", "r128", "r157" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from sale of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromShortTermDebt": { "auth_ref": [ "r122" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from Short-term Debt", "terseLabel": "Borrowings of short-term debt" } } }, "localname": "ProceedsFromShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r121", "r528" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]", "terseLabel": "Other revenues" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "domainItemType" }, "us-gaap_ProductConcentrationRiskMember": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Product Concentration Risk [Member]", "terseLabel": "Product Concentration Risk" } } }, "localname": "ProductConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product sales" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r15", "r96", "r99", "r131", "r148", "r173", "r185", "r186", "r230", "r242", "r246", "r249", "r252", "r270", "r617", "r624", "r626", "r631", "r632", "r679", "r756" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net (loss) income", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r52", "r324" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r332", "r804", "r805", "r806" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY, PLANT AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r51", "r322" ], "calculation": { "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, plant and equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r27", "r28", "r324", "r772" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r50", "r146", "r324", "r804", "r805" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r27", "r324" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r27", "r322" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "verboseLabel": "Estimated useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r109", "r279" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]", "terseLabel": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "SUPPLEMENTARY DATA (UNAUDITED)" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SUPPLEMENTARYDATAUNAUDITED" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r36", "r43", "r771", "r799" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "terseLabel": "Trade receivables, net" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r244", "r246" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of each significant reconciling item, other than profit (loss), revenues, or assets, in the reconciliation of totals of such items in reportable segments to the entity's corresponding consolidated amount.", "label": "Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]", "terseLabel": "Schedule of capital expenditures, depreciation and amortization by segment" } } }, "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r125", "r152" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "terseLabel": "Repayments of lines of credit" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2019ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2020ActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r125" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Repayments of long-term debt", "terseLabel": "Repayments of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r125" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Repayments of Short-term Debt", "negatedLabel": "Repayments of short-term debt" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReportingUnitAxis": { "auth_ref": [ "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "Information by reporting unit.", "label": "Reporting Unit [Axis]", "terseLabel": "Reporting Unit [Axis]" } } }, "localname": "ReportingUnitAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReportingUnitDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Level of reporting at which goodwill is tested for impairment.", "label": "Reporting Unit [Domain]", "terseLabel": "Reporting Unit [Domain]" } } }, "localname": "ReportingUnitDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.", "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount", "terseLabel": "Percentage of fair value in excess of carrying value" } } }, "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and Development [Abstract]", "terseLabel": "Research and Development [Abstract]" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r545" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development", "totalLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r146", "r545" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETScheduleofOtherExpenseIncomeNetDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research and Development in Process", "terseLabel": "Acquired in-process research and development costs", "verboseLabel": "Upfront payments, included in acquired in-process research and development costs" } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails", "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETScheduleofOtherExpenseIncomeNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "auth_ref": [ "r816" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.", "label": "Research, Development, and Computer Software Disclosure [Text Block]", "terseLabel": "RESEARCH AND DEVELOPMENT" } } }, "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r16", "r26", "r143" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "periodEndLabel": "Restricted cash, end of year", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]", "terseLabel": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "RESTRUCTURING, INTEGRATION AND SEPARATION COSTS" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "auth_ref": [ "r334", "r336", "r342", "r344" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.", "label": "Restructuring and Related Cost, Incurred Cost", "verboseLabel": "Restructuring costs" } } }, "localname": "RestructuringAndRelatedCostIncurredCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r138", "r333", "r339", "r343" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 7.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "negatedLabel": "Restructuring, integration and separation costs", "terseLabel": "Restructuring, integration and separation costs" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Cost-rationalization and integration initiatives" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r335", "r340" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "terseLabel": "Remaining restructuring liabilities" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r38", "r376", "r536", "r768", "r791", "r796" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r168", "r169", "r171", "r174", "r183", "r186", "r274", "r533", "r534", "r535", "r583", "r584", "r787", "r789" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r443", "r444", "r445", "r446", "r448", "r451", "r456", "r457", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r478", "r482", "r489" ], "lang": { "en-us": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFuturebenefitpaymentsforthepensionbenefitplansDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r443", "r444", "r445", "r446", "r448", "r451", "r456", "r457", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r478", "r482", "r489" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFuturebenefitpaymentsforthepensionbenefitplansDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r392", "r393", "r394", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r443", "r445", "r446", "r448", "r451", "r455", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r477", "r478", "r479", "r480", "r481", "r482", "r486", "r487", "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFuturebenefitpaymentsforthepensionbenefitplansDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r392", "r393", "r394", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r443", "r445", "r446", "r448", "r451", "r455", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r477", "r478", "r479", "r480", "r481", "r482", "r486", "r487", "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFuturebenefitpaymentsforthepensionbenefitplansDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueCommissionersIrelandMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Ireland.", "label": "Revenue Commissioners, Ireland [Member]", "terseLabel": "Revenue Commissioners, Ireland" } } }, "localname": "RevenueCommissionersIrelandMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r221", "r222", "r241", "r247", "r248", "r255", "r256", "r260", "r385", "r386", "r736" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Price appreciation credits", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails", "http://www.bauschhealth.com/role/SUPPLEMENTARYDATAUNAUDITEDScheduleofUnauditedQuarterlyConsolidatedFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r147", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r390" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues and long-lived assets by geographic region" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving credit facility", "verboseLabel": "Senior Secured Credit Facilities" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2019ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2020ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r712", "r717" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "verboseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities, upon adoption of new accounting standard" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScenarioAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Domain member used to indicate figures that are adjustments during a period or as of a point in time. This domain member would never be expected to appear in a relationship group without the \"Scenario, Previously Reported\" Member with the same parent.", "label": "Scenario, Adjustment [Member]", "terseLabel": "Scenario, Adjustment" } } }, "localname": "ScenarioAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Summary of activity in allowance for credit losses" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued and other current liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r92", "r690", "r691" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of the components of accumulated other comprehensive loss" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.", "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "terseLabel": "Actual asset allocations" } } }, "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.", "label": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of amounts recognized in accumulated other comprehensive loss" } } }, "localname": "ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "terseLabel": "Weighted-average assumptions used to determine net periodic benefit costs and benefit obligations" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r456", "r470" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]", "terseLabel": "Schedule of underfunded plans" } } }, "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r603", "r604" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of Supplemental Cash Flow Disclosures" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Summary of the components and classification of share-based compensation expense" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r579" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Components of benefit from income taxes" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of long-term debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of tax effect of major items recorded as deferred tax assets and liabilities and valuation allowance" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r454", "r455", "r458", "r459", "r470" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofnetperiodicbenefitcostDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails", "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedaverageassumptionsusedtodeterminenetperiodicbenefitcostsandbenefitobligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of calculation of loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LOSSPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Reconciliation of benefit from income taxes from the expected amount calculated by applying the Canadian statutory rate to loss before benefit of income taxes" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r494", "r525", "r538" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Schedule of revenues by product and by product category" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.", "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]", "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]" } } }, "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "terseLabel": "Future benefit payments for the pension benefit plans" } } }, "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r659", "r660" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of components and classification of financial assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r302", "r306", "r737" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r302", "r306" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of components of finite-lived intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r297", "r300" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r297", "r300" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of changes in the carrying amount of goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Components of loss before benefit from income taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r309", "r312" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r309", "r312" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of components of indefinite-lived intangible assets" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r25", "r44", "r45", "r46" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of the components of inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INVENTORIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of aggregate maturities of long-term debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Components of net periodic benefit cost" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r643" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Schedule of effect of hedging instruments on financial statements" } } }, "localname": "ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "auth_ref": [ "r508" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.", "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]", "terseLabel": "Summary of non-vested performance-based RSU activity" } } }, "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r508" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Summary of non-vested time-based RSU activity" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Schedule of other (expense) income" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r52", "r324" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule of Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Schedule of quarterly financial information" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SUPPLEMENTARYDATAUNAUDITEDTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r607" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Estimated fair values of assets acquired and liabilities assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r337", "r338", "r341" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.", "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]", "terseLabel": "Schedule of external customers that accounted for 10% or more of total revenues" } } }, "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r111", "r259" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Schedule of revenues and long-lived assets by geographic region" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r104", "r259" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r230", "r233", "r245", "r297" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r230", "r233", "r245", "r297" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of segment revenues and profit" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r496", "r527" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r501", "r513", "r516" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of weighted-average assumption as of the date of grant using the Black Scholes option-pricing model" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r565", "r580" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Reconciliation of the beginning and ending amounts of unrecognized tax benefits" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of estimated aggregate amortization expense for each of the five succeeding years" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Senior Secured Notes", "verboseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r218", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r241", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r252", "r260", "r779" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r218", "r219", "r220", "r230", "r234", "r246", "r250", "r251", "r252", "r253", "r255", "r259", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "SEGMENT INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment reporting information" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r146", "r235", "r236", "r237", "r238", "r239", "r240", "r256" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r113" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SettledLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.", "label": "Settled Litigation [Member]", "terseLabel": "Settled Litigation" } } }, "localname": "SettledLitigationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r138", "r333", "r339", "r343" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r137" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "End of the period (in shares)", "periodStartLabel": "Beginning of the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "RSUs" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "End of the period (in dollars per share)", "periodStartLabel": "Beginning of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted- Average Grant-Date Fair Value Per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r515" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Total fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Method and assumptions on valuation of stock options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected Company share volatility", "verboseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures", "terseLabel": "Number of shares canceled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Number of additional shares available for issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Total number of shares approved for grant by the Company under the share-based compensation plans (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for future grants (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Additional disclosures" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r515" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of stock options exercised in the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Expired or forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired or forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value of stock options (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r527" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding at the end of the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r503", "r527" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "End of the period (in shares)", "periodStartLabel": "Beginning of the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "End of the period (in dollars per share)", "periodStartLabel": "Beginning of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r518" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Vested and exercisable at the end of the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Vested and exercisable at the end of the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Vested and exercisable at the end of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r516" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest at the end of the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest at the end of the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest at the end of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r493", "r499" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche One [Member]", "terseLabel": "Vesting Period One" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Vesting Period Two" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r146", "r496", "r500" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Percentage of vesting rights" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r520", "r537" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Contractual term (years)", "verboseLabel": "Expected stock option life (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails", "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding at the end of the period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and exercisable at the end of the period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest at the end of the period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r708", "r717" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease expense" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r3", "r218", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r241", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r252", "r260", "r297", "r328", "r336", "r344", "r779" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails", "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails", "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r66", "r168", "r169", "r171", "r174", "r183", "r186", "r201", "r274", "r371", "r376", "r533", "r534", "r535", "r583", "r584", "r685", "r686", "r687", "r688", "r689", "r691", "r787", "r788", "r789" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails", "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails", "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r168", "r169", "r171", "r201", "r736" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-based Payment Arrangement [Member]", "verboseLabel": "Stock Compensation Plan" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r34", "r35", "r371", "r376" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Common shares issued under share-based compensation plans (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r34", "r35", "r371", "r376", "r505" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r34", "r35", "r376", "r495", "r514" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Common shares issued under share-based compensation plans" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r35", "r40", "r41", "r148", "r267", "r270", "r679" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Bausch Health Companies Inc. shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r148", "r168", "r169", "r171", "r174", "r183", "r270", "r274", "r376", "r533", "r534", "r535", "r583", "r584", "r615", "r616", "r630", "r679", "r685", "r686", "r691", "r788", "r789" ], "calculation": { "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "negatedTerseLabel": "Increase to accumulated deficit (less than)", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Accumulated other comprehensive loss", "totalLabel": "Total equity", "verboseLabel": "Cumulative-effect adjustment" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails", "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r710", "r717" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "terseLabel": "Sub-lease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "auth_ref": [ "r556", "r565", "r567" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Summary of Income Tax Contingencies [Table Text Block]", "terseLabel": "Summary of open tax years by jurisdiction" } } }, "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Supplemental Cash Flow Elements [Abstract]" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Other payments" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r574" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforward" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]", "terseLabel": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]", "terseLabel": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxYear2012Member": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Identified as tax year 2012.", "label": "Tax Year 2012 [Member]", "terseLabel": "Tax Year 2012" } } }, "localname": "TaxYear2012Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxYear2013Member": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Identified as tax year 2013.", "label": "Tax Year 2013 [Member]", "terseLabel": "Tax Year 2013" } } }, "localname": "TaxYear2013Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r608" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Corporate brands" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r608" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "B&L Trademark" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r173", "r174", "r175", "r176", "r271", "r272", "r273", "r274", "r275", "r276", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r581", "r582", "r583", "r584", "r738", "r739", "r740", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r421", "r757", "r797" ], "lang": { "en-us": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "Government bond funds" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairvalueofpensionandpostretirementbenefitplanassetsassumedinconnectionwiththeAcquisitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnfavorableRegulatoryActionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A enacted or proposed action, ruling or regulation that is likely to or possibly will have an adverse effect on the entity's financial position or results of operations, excluding tax matters.", "label": "Unfavorable Regulatory Action [Member]", "terseLabel": "Unfavorable Regulatory Action" } } }, "localname": "UnfavorableRegulatoryActionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r547", "r560" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance, end of year", "periodStartLabel": "Balance, beginning of year" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r561" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedLabel": "Reductions for tax positions of prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r555" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrued interest and penalties related to unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r555" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Net increase (decrease) recognized in interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r562" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions based on tax positions related to the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r561" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Additions for tax positions of prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r563" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedLabel": "Lapse of statute of limitations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r564" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Portion of unrecognized tax benefits, if recognized, would affect the Company's effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]", "terseLabel": "Senior Unsecured Notes", "verboseLabel": "Unsecured Debt" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilities2018ActivitiesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails", "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r203", "r204", "r206", "r207", "r214", "r215", "r216" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.", "label": "Valuation Allowance by Deferred Tax Asset [Axis]", "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]" } } }, "localname": "ValuationAllowanceByDeferredTaxAssetAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r571" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "negatedLabel": "Decrease in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.", "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset" } } }, "localname": "ValuationAllowanceOfDeferredTaxAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesAdjustments": { "auth_ref": [ "r166" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment", "negatedTerseLabel": "Reduction in variable consideration provision, adjustment" } } }, "localname": "ValuationAllowancesAndReservesAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r159", "r164" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Balance, end of year", "periodStartLabel": "Balance, beginning of year", "terseLabel": "Cooperative advertising credits included in rebates" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": { "auth_ref": [ "r162" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account", "netLabel": "Sales return provisions", "terseLabel": "Charged to other accounts", "verboseLabel": "Current period provision" } } }, "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r163" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedLabel": "Payments and credits" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r159", "r160", "r161", "r163", "r164" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired": { "auth_ref": [ "r162" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from business combination.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Business Acquired", "terseLabel": "Acquisition of Synergy" } } }, "localname": "ValuationAllowancesAndReservesReservesOfBusinessesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r159", "r160", "r161", "r163", "r164" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails", "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r709", "r717" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable operating lease costs" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Basic and diluted weighted-average common shares (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 22 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r117": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "http://asc.fasb.org/topic&trid=2134446" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(ColumnA))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r167": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e777-108305" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r200": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "b", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a,b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r286": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r313": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2510-110228" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2599-110228" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r332": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r345": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r348": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751" }, "r359": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r391": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "http://asc.fasb.org/topic&trid=49130413" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(b)(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2919-114920" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r491": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r541": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r544": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "http://asc.fasb.org/topic&trid=2122503" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r596": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998890-113959" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121607252&loc=SL5864739-113975" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r692": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=28365394&loc=d3e23770-108382" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r718": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919398-209981" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r816": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "730", "Topic": "985", "URI": "http://asc.fasb.org/subtopic&trid=2197926" }, "r817": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r818": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r819": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r820": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r821": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r822": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r823": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r824": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r825": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(dd)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" } }, "version": "2.1" } ZIP 162 0000885590-21-000011-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000885590-21-000011-xbrl.zip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�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̼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end

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